**Risk Factors Comparison 2025-04-28 to 2024-05-01 Form: 10-K**

**Legend:** **New Text** ~~Removed Text~~ Unchanged Text Moved Text Section

An investment in our common stock involves a high degree of risk. You should carefully consider the risks described below together with all of the other information included in this prospectus before making an investment decision with regard to our securities. The statements contained in this prospectus include forward- looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in or implied by forward- looking statements. The risks set forth below are not the only risks facing us. Additional risks and uncertainties may exist that could also adversely affect our business, prospects or operations. If any of the following risks actually occurs, our business, financial condition or results of operations could be harmed. In that case, the trading price of our common stock could decline, and you may lose all or a significant part of your investment. Risks Concerning our Business ~~Because we~~ **There is economic uncertainty concerning economic policies being pursued by the new administration in the United States that may affect the costs and timing of the process of bringing our products to market through approvals with the FDA. Our operating results are affected by the current political and economic uncertainties related to the economy of the United States, the domestic pharmaceutical industry and world economies. Future conditions may also adversely affect our pricing strategy, promotional activities and our profitability and margins. Additionally, many of the effects and consequences of U. S. and global financial and economic conditions could potentially have a material adverse effect on our liquidity and capital resources, including the ability to raise additional capital, if needed, or could otherwise negatively affect our business and financial results. Market instability could make it more difficult for us and our suppliers to accurately forecast future product demand trends. Additionally, inflationary factors such as increases in the costs to purchase products, acquire product rights and overhead costs may adversely affect our operating results. We are subject to the risks common to start- up, pre- revenue enterprises, including, among other factors, undercapitalization, cash shortages, limitations with respect to personnel, financial and other resources and lack of revenues. Drug development companies typically incur substantial losses during the product development and FDA testing phase of the business and** do not ~~have a~~ **generate revenues until after the drug has received FDA approval, which cannot be assured, and until the company has started to sell the** product **. We can give no assurance that** we can ~~market~~ **or will ever be successful** in **achieving** ~~the United States, we cannot predict when or whether we will operate profitably~~ **profitability and the likelihood of** ~~. Our lead product, which is~~ our **success must be considered** ~~abuse deterrent fentanyl transdermal system, is currently~~ in **light of** ~~development and is not yet approved by the FDA in the United States or~~ **our early stage** ~~by any other regulatory agency in any other country. Because~~ of **operations. We** ~~the numerous risks and uncertainties associated with product development, we~~ cannot assure you that we will be able to **operate profitably** ~~develop and market any products~~ or ~~achieve or attain profitability~~ **generate positive cash flow** . If we **cannot achieve profitability** ~~are able to obtain financing for our operations~~ , ~~we expect that we will incur substantial expenses as we continue with our product development programs and clinical trials. Further, if we are required by applicable regulatory authorities, including the FDA as well as the comparable regulatory agencies in other countries in which~~ we may ~~seek~~ **be forced** to ~~market product, to perform studies in addition to those we currently anticipate, our expenses will increase~~ -- **cease operations** ~~beyond expectations~~ and **you** ~~the timing of any potential product approval~~ may **suffer** ~~be delayed. As~~ a **total** ~~result, we expect to continue to incur substantial losses~~ -- **loss of your investment** ~~and negative cash flow for the foreseeable future~~ . A number of factors, including, but not limited to the following, may affect our ability to develop our business and operate profitably: ● our ability to obtain necessary funding to develop our proposed products; ● the success of clinical trials for our products; ● our ability to obtain FDA approval for us to market any proposed product in our pipeline in the United States; ● any delays in regulatory review and approval of product in development; ● if we obtain FDA approval to market our product, our ability to establish manufacturing and distribution operations or entering into manufacturing and distribution agreements with qualified third parties; ● market acceptance of our products; ● our ability to establish an effective sales and marketing infrastructure; ● our ability to protect our intellectual property; ● competition from existing products or new products that may emerge; ● the ability to commercialize our products; ● potential product liability claims and adverse events; ● our ability to adequately support future growth; and ● our ability to attract and retain key personnel to manage our business effectively. Our failure to develop our abuse deterrent fentanyl transdermal system will impair our ability to continue in business. Our lead product is our abuse deterrent fentanyl transdermal system, and we are devoting our resources primarily to developing this product to enable us to obtain FDA approval ~~and~~ **so as to be able** to market the product. If we are not able to obtain necessary financing to develop **our product** , obtain FDA marketing approval and market this product successfully, we may not have the resources to develop additional products, and we may not be able to continue in business. Before we can market in the United States any product which is classified by the FDA as a drug, we must obtain FDA marketing approval. Our proposed transdermal products are drug- device combinations that are considered by the FDA to be drugs, which require approval by the FDA. In order to obtain FDA approval, it is necessary to conduct a series of preclinical and clinical tests to confirm that the product is safe and effective. Even though the medication that is being delivered through our transdermal patch may have already received FDA approval, because we are changing the dosage form or route of administration, we will need to complete, to the FDA' s satisfaction, all of the studies required to demonstrate safety and efficacy. At any point, the FDA could ask us to perform additional tests or to refine and redo a test that we had previously completed. The process of obtaining FDA approval could take many years, with no assurance that the FDA will approve the product. The FDA also will need to approve the manufacturing process and the manufacturing facility. ~~We~~ **Risk of delays at FDA due to restructuring and layoffs. Changes at the Food and Drug Administration (FDA) and other federal agencies under the incoming Trump administration include implementing a hiring freeze and employee layoffs by executive orders and other measures implemented by the Department of Government Efficiency,** may ~~need~~ **lead** to ~~rely~~ **new policies, changes in the regulations, and disruption of normal operations of the FDA and other agencies, any of which may adversely impact our clinical development plans and business operations. Disruptions at the FDA may lead to slower response times and longer review periods, potentially affecting our ability to progress with development of our product candidates or obtain timely regulatory approval for our product candidates. Changes in regulations may result in unexpected delays, increased costs, or other negative impacts** on ~~a contract research organization~~ **our business that are difficult** to ~~conduct~~ **predict. Risk of increased tariffs on foreign goods. The United States government has imposed tariffs on foreign goods being imported into the United States. Although** our ~~preclinical~~ **Company does not plan to sell any pharmaceutical products in the United States that are manufactured overseas, some of the raw materials used in our products under development are obtained from foreign manufacturers. An increase in the costs of any of the raw materials used in our products under development could be detrimental to our commercial forecasts** and **projected profit margins which are based in part on our ability** ~~clinical trials. Although we believe that we, through 4P Therapeutics, have the capabilities~~ to **price our products competitively with existing products marketed** ~~conduct certain preclinical studies and early- stage clinical studies~~ in ~~house, we may need to rely on third party contract research organizations to conduct our pivotal preclinical and clinical trials. Our failure or~~ the **United States** ~~failure of the contract research organization to conduct the trials in compliance with FDA regulations could possibly derail our obtaining FDA approval and could require us to redo any preclinical or clinical trials which we or the contract research organization administered~~ . We may encounter delays in completing clinical trials, which would increase our costs and delay market entry. We may experience delays in completing the clinical trials necessary for FDA approval. These delays may result from a number of factors which could prevent us from starting the trial on time or completing the study in a timely manner, which may include factors out of our control. Since we may need to rely on third parties for supplying us with the drug and transdermal patches used in the trials, there may be various reasons for us to experience a delay in obtaining the clinical materials required to start each clinical trial, which may include factors out of our control. Clinical trials can be delayed or terminated for a number of reasons, including delay or failure to: ● obtain necessary financing; ● obtain regulatory approval to commence a trial; ● reach agreement on acceptable terms with prospective contract research organizations, investigators and clinical trial sites, the terms of which may be subject to extensive negotiation and vary significantly among different research organizations and trial sites; ● obtain institutional review board approval at each site; ● enlist suitable patients to participate in a trial; ● have patients complete a trial or return for post- treatment follow- up; ● ensure clinical sites observe trial protocol or continue to participate in a trial; ● address any patient safety concerns that arise during the course of a trial; ● address any conflicts with new or existing laws or regulations; ● add a sufficient number of clinical trial sites; or ● manufacture sufficient quantities of the product candidate for use in clinical trials. Patient enrollment is also a significant factor in the timely completion of clinical trials and is affected by many factors, including the size and nature of the patient population, the proximity of patients to clinical sites, the eligibility criteria for the trial, the design of the clinical trial, competing clinical trials and clinicians' and patients' perceptions as to the potential advantages of the drug being studied in relation to available alternatives, including any new drugs or treatments that may be approved for the indications we are investigating. We may also encounter delays if a clinical trial is suspended or terminated by us **or our CDMO** , by the independent review boards of the institutions in which such trials are being conducted, by the trial' s data safety monitoring board, or by the FDA. Such authorities may suspend or terminate one or more of our clinical trials due to a number of factors, including our failure to conduct the clinical trial in accordance with relevant regulatory requirements or clinical protocols, inspection of

the clinical trial operations or trial site by the FDA resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a drug, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. If we experience delays in carrying out or completing clinical trials for any product candidates, the commercial prospects of our product candidates may be harmed, and our ability to generate revenues from any of these product candidates will be delayed. In addition, any delays in completing our clinical trials will increase our costs, slow down the product development and approval process and jeopardize our ability to commence product sales and generate revenues. Any of these occurrences may significantly harm our business and financial condition. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates. Our ability to finance our operations and generate revenues depends on the clinical and commercial success of our abuse deterrent fentanyl transdermal system and our other related product candidates , and failure to achieve such success will negatively impact our business. Our prospects, including our ability to finance our operations and generate revenues, depend on the successful development, regulatory approval and commercialization of our abuse deterrent fentanyl transdermal system, which itself requires substantial financing, as well as our other product candidates. The clinical and commercial success of our product candidates depends on a number of factors, many of which are beyond our control, including: ● the FDA' s acceptance of our parameters for regulatory approval relating to our product candidates, including our proposed indications, primary endpoint assessments, primary endpoint measurements and regulatory pathways; ● the FDA' s acceptance of the number, design, size, conduct and implementation of our clinical trials, our trial protocols and the interpretation of data from preclinical studies or clinical trials; ● the FDA' s acceptance of the sufficiency of the data we collect from our preclinical studies and pivotal clinical trials to support the submission of a New Drug Application, known as an NDA, without requiring additional preclinical or clinical trials; ● the FDA' s acceptance of our abuse deterrent labelling relating to our products, including our abuse deterrent fentanyl transdermal system; ● when we submit our NDA upon completion of our clinical trials, the FDA' s willingness to schedule an advisory committee meeting, if applicable, in a timely manner to evaluate and decide on the approval of our NDA; ● the recommendation of the FDA' s advisory committee, if applicable, to approve our application without limiting the approved labelling, specifications, distribution, or use of the products, or imposing other restrictions; ● our ability to satisfy any issued raised by the FDA in response to our test data; ● the FDA' s satisfaction with the safety and efficacy of our product candidates; ● the prevalence and severity of adverse events associated with our product candidates; ● the timely and satisfactory performance by third party contractors of their obligations in relation to our clinical trials; ● if we receive FDA approval, our success in educating physicians and patients about the benefits, administration and use our product candidates; ● our ability to raise additional capital on acceptable terms in order to achieve conduct the necessary clinical trials; ● the availability, perceived advantages and relative cost of alternative and competing treatments; ● the effectiveness of our marketing, sales and distribution strategy and operations; ● our ability to develop, validate and maintain a commercially viable manufacturing process that is compliant with current good manufacturing practices; ● our ability to obtain, protect and enforce our intellectual property rights; ~~● our ability to bring an action timely for patent infringement arising out of the filing of ANDAs by generic companies seeking approval to market generic versions of our products, if applicable, before the expiry of our patents;~~ and ● our ability to avoid third party claims of patent infringement or intellectual property violations. If we fail to achieve these objectives or to overcome the challenges presented above, many of which are beyond our control, in a timely manner, we could experience significant delays or an inability to successfully commercialize our product candidates. Accordingly, even if we obtain FDA approval to market our products, we may not be able to generate sufficient revenues through the sale of our products to enable us to continue our business. Since we do not have commercial manufacturing capability, if we are unable to establish manufacturing facilities, we may have to enter into a manufacturing agreement with a manufacturer that has been approved by the FDA. Any commercial manufacturer of our products and the manufacturing facilities where we make our commercial products will be subject to FDA inspection. Part of the process of seeking FDA approval to market our products is the FDA' s approval of the manufacturing process and facility. Although we may establish our own manufacturing facilities, the establishment of a manufacturing facility is very costly, and, unless we obtain funding for that purpose, it would be necessary for us to engage a contract manufacturer who has experience is manufacturing FDA- approved transdermal products. By relying on a contract manufacturer, we will be dependent upon the manufacturer, whose interests may be different from ours. Any contract manufacturer will be responsible for product quality and for meeting regulatory requirements. If the manufacturer does not meet our quality standards and delivers products that do not meet our specifications, we may both incur liability for breach of our warranty to our customer, as well as liability for any adverse events, including death, that may result from the use, abuse or accidental misuse of the product. Regardless of whether we are able to make a claim against the contract manufacturer, our reputation may be harmed and we may lose business as a result. Further, the contract manufacturer may have other customers and may allocate its resources based on the contract manufacturer' s interest rather than our interest. Furthermore, we may not be able to assure ourselves that we will get favorable pricing. If we or any third- party manufacturer fails to comply with FDA current good manufacturing practices, we may not be able to sell our products until and unless the manufacturer becomes compliant. All FDA approved drugs, including our proposed transdermal products, must be manufactured in accordance with good manufacturing practices. All manufacturing facilities are inspected by the FDA as a matter of routine inspection or for a specific cause. If a manufacturer fails to comply with all applicable regulations, the FDA can prohibit us from distributing products manufactured in those facilities, whether they are a contract manufacturer or own facility. Failure to be in compliance with good manufacturing practices could result in the FDA closing the facilities or limiting our use of the facilities. If the FDA implements Risk Evaluation and Mitigation Strategies policies for any of our proposed products, we will need to comply with such policies before we can obtain FDA approval or the product. The Food and Drug Administration Amendments Act of 2007 gave FDA the authority to require a Risk Evaluation and Mitigation Strategy (REMS) from manufacturers to ensure that the benefits of a drug or biological product outweigh its risks. If one of our proposed product candidates does receive regulatory approval, the approval may be limited to specific conditions and dosages or the indications for use may otherwise be limited, which could restrict the commercial value of the product. The FDA may require a REMS, which can include a medication guide, patient package insert, a communication plan, elements to assure safe use and implementation system, and include a timetable for assessment of the REMS. Further, the FDA may require that certain contraindications, warnings or precautions be included in the product labeling and may require testing and surveillance programs to monitor the safety of approved products that have been commercialized. In addition, the FDA may require post- approval testing which involves clinical trials designed to further assess a drug product' s safety and effectiveness after the NDA. Depending on the extent of the REMS requirements, any U. S. launch may be delayed, the costs to commercialize may increase substantially and the potential commercial market could be restricted. Furthermore, risks that are not adequately addressed through the proposed REMS program may also prevent or delay its approval for commercialization. Our products will continue to be subject to FDA review after FDA approval is given. Discovery of previously unknown problems with our products or unanticipated problems with the manufacturing processes and facilities, even after FDA and other regulatory approvals of the product for commercial sale, may result in the imposition of significant restrictions, including withdrawal of the product from the market. The FDA and other regulatory agencies continue to review products even after the products receive agency approval. If and when the FDA approves one of our products, its manufacture and marketing will be subject to ongoing regulation, which could include compliance with current good manufacturing practices, adverse event reporting requirements and general prohibitions against promoting products for unapproved or " off- label " uses. We are also subject to inspection and market surveillance by the FDA for compliance with these and other requirements. Any enforcement action resulting from the failure, even by inadvertence, to comply with these requirements could affect the manufacture and marketing of our products. In addition, the FDA or other regulatory agencies could withdraw a previously approved product from the market upon receipt of newly discovered information. The FDA or another regulatory agency could also require us to conduct additional, and potentially expensive, studies in areas outside our approved indicated uses. We must continually monitor the safety of our products once approved and marketed for potential adverse events which could jeopardize our ability to continue marketing the products. As with all medical products, the use of our products could sometimes produce undesirable side effects or adverse reactions or events (referred to cumulatively as adverse events). For the most part, we expect these adverse events to be known and occur at some predicted frequency based on our experience in the clinical development program. When adverse events are reported to us, we are required to investigate each event and the circumstances surrounding it to determine whether it was caused by our product and whether a previously unrecognized safety issue exists. We will also be required to periodically report summaries of these events to the applicable regulatory authorities. If the adverse effects are significant, we may be required to recall our product. We cannot assure you that our transdermal products will not cause skin irritation or other adverse events. Our ability to market our products may be impaired by unanticipated adverse events and any recall of our product. Because we are an early- stage company, our reputation, and our ability to market products, could be affected more severely than a major pharmaceutical company. In addition, the use of our products could be associated with serious and unexpected adverse events, or with less serious reactions at a greater than expected frequency. Such issues may arise when our products are used in critically ill or otherwise compromised patient populations. When unexpected events are reported to us, we are required to make a thorough investigation to determine causality and the implications for product safety. These events must also be specifically reported to the applicable regulatory authorities. If our evaluation concludes, or regulatory authorities perceive, that there is an unreasonable risk associated with the product, we would be obligated to withdraw the impacted lot (s) of that product or recall the product and discontinue marketing until all problems are satisfactorily resolved. Furthermore, an unexpected adverse event of a new product could be

recognized only after extensive use of the product, which could expose us to product liability risks, enforcement action by regulatory authorities and damage to our reputation and public image. A serious adverse finding concerning the risk of any of our products by any regulatory authority could adversely affect our reputation, business and financial results. If we obtain FDA approval to market our products, we expect to spend considerable time and money complying with federal and state laws and regulations governing their sale, and, if we are unable to fully comply with such laws and regulations, we could face substantial penalties. Health care providers, physicians and others will play a primary role in the recommendation and prescription of our proposed products. Further, if we use third- party sales and marketing providers, they may expose us to broadly applicable fraud and abuse and other health care laws and regulations that may constrain the business or financial arrangements and relationships through which we market, sell and distribute our products. Applicable federal and state health care laws and regulations are expected to include, but not be limited to, the following: ● The federal anti- kickback statute is a criminal statute that makes it a felony for individuals or entities knowingly and willfully to offer or pay, or to solicit or receive, direct or indirect remuneration, in order to induce the purchase, order, lease, or recommending of items or services, or the referral of patients for services, that are reimbursed under a federal health care program, including Medicare and Medicaid; ● The federal False Claims Act imposes liability on any person who knowingly submits, or causes another person or entity to submit, a false claim for payment of government funds. Penalties include three times the government' s damages plus civil penalties of $ 5, 500 to $ 11, 000 per false claim. In addition, the False Claims Act permits a person with knowledge of fraud, referred to as a qui tam plaintiff, to file a lawsuit on behalf of the government against the person or business that committed the fraud, and, if the action is successful, the qui tam plaintiff is rewarded with a percentage of the recovery; ● Health Insurance Portability and Accountability Act, known as HIPAA, imposes obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information; ● The Social Security Act contains numerous provisions allowing the imposition of a civil money penalty, a monetary assessment, exclusion from the Medicare and Medicaid programs, or some combination of these penalties; and ● Many states have analogous state laws and regulations, such as state anti- kickback and false claims laws. In some cases, these state laws impose more strict requirements than the federal laws. Some state laws also require pharmaceutical companies to comply with certain price reporting and other compliance requirements. Our failure to comply with any of these federal and state health care laws and regulations, or health care laws in foreign jurisdictions, could have a material adverse effect on our business, financial condition, result of operations and cash flows. Before we can market our products outside of the United States, we will need to obtain regulatory approval in each country in which we propose to sell our products. **To** ~~In order to~~ market and sell our products in jurisdictions other than the United States, we must obtain separate marketing approvals and comply with numerous and varying regulatory requirements. The regulatory approval process outside the United States generally includes all of the risks associated with obtaining FDA and can involve additional testing. In addition, in many countries worldwide, it is required that the product be approved for reimbursement before the product can be approved for sale in that country. We may not obtain approvals from regulatory authorities outside the United States on a timely basis, if at all. Even if we were to receive approval in the United States, approval by the FDA for marketing in the United States does not ensure approval by regulatory authorities in other countries. Similarly, approval by one regulatory authority outside the United States would not ensure approval by regulatory authorities in other countries. We may not be able to file for marketing approvals and may not receive necessary approvals to commercialize our products in any market. If we are unable to obtain approval of our product candidates by regulatory authorities in foreign jurisdictions, the commercial prospects of those product candidates may be significantly diminished and our business prospects could be impaired. Outside the United States, particularly in member states of the European Union, the pricing of prescription drugs is subject to governmental control. In these countries, pricing negotiations or the successful completion of health technology assessment procedures with governmental authorities can take considerable time after receipt of marketing approval for a product. In addition, there can be considerable pressure by governments and other stakeholders on prices and reimbursement levels, including as part of cost containment measures. Certain countries allow companies to fix their own prices for medicines but monitor the pricing. In addition to regulations in the United States, if we market outside of the United States, we will be subject to a variety of regulations governing, among other things, clinical trials and any commercial sales and distribution of our products. Whether or not we obtain FDA approval for a product, we must obtain the requisite approvals from regulatory authorities in foreign countries prior to the commencement of clinical trials or marketing of the product in those countries. If we do not have sufficient product liability insurance, we may be subject to claims that are in excess of our net worth. Before we market any pharmaceutical product, we will need to purchase significant product liability insurance. However, in the event of major claims from the use of our products, it is possible that our product liability insurance will not be sufficient to cover claims against us. We cannot assure you that we will not face liability arising out of the use of our products which is significantly in excess of the limits of our product liability insurance. In such event, if we do not have the funds or access to the funds necessary to satisfy such liability, we may be unable to continue in business. Because some of the patches we are developing, such as our abuse deterrent fentanyl patch, have potential severe side effects, we may face liability in the event patients suffer serious, possibly life- threatening, side effects from our products. Fentanyl patches have known side effects and may cause serious or life- threatening breathing problems due to opioid- induced respiratory depression. In addition, taking certain medications with fentanyl may increase the risk of serious or life- threatening breathing problems, sedation or coma. Because of the seriousness of the side effects, fentanyl patches should only be used in accordance labelling approved by the FDA or by the applicable regulatory authorities outside of the United States. Fentanyl patches are only indicated for the treatment of people who are tolerant to opioid medications because they have taken this type of medication for at least one week and should not be used to treat mild or moderate pain, short- term pain, pain after an operation or medical or dental procedure, or pain that can be controlled by medication that is taken on an as- needed basis. Although we will include all warnings on the packaging that are required by the FDA or foreign regulatory authorities, claims may be made against us in the event that death or serious side effects result from the use of our abuse deterrent fentanyl transdermal system, even if prescribed for a patient for whom fentanyl patches should not be prescribed. We cannot assure you that we will not face significant liability as a result of such side effects and we may not have sufficient product liability insurance to cover any damages that may be assessed against us ~~. Because of our lack of funds, we may have to enter into a joint venture or strategic relationship or licensing agreement with a third party to develop and seek to obtain FDA approval of our potential products. Our present efforts are directed to developing and seeking FDA approval for our pipeline of transdermal pharmaceutical products including our lead product, the abuse deterrent fentanyl transdermal system. The development of pharmaceutical products is very expensive with no assurance of obtaining FDA approval. Because of the costs involved, we may need to enter into a joint venture or strategic alliance or licensing or similar agreement with a third party to bring our products to market, in which event we would have to give up a significant percentage of the equity in or rights to the product and require the other party to provide the necessary financing and personnel and to take a significant role in making the decisions relating to the development, testing, marketing and manufacturing of the product. The third party may have interests which are different from, and possibly in conflict with, our own. If we are unable to attract competent parties to distribute and market any product which we may develop, or if such parties' efforts are inadequate, we will not be able to implement our business strategy and may have to cease operations. We cannot assure you that we will be successful in entering into joint ventures or other strategic relationships or that any relationship into which we may enter will develop a marketable product or that we will generate any revenue or net income from such a venture~~ . We may decide not to continue developing or commercializing any products at any time during development or after approval, which would reduce or eliminate our potential return on investment for those product candidates. We may decide to discontinue the development of our abuse deterrent fentanyl transdermal system or any other product in our pipeline or not to continue to commercialize any potential product for a variety of reasons, such as the appearance of new technologies that make our product less commercially viable, an increase in competition, changes in or failure to comply with applicable regulatory requirements, changes in the regulatory or public policy environment, the discovery of unforeseen side effects during clinical development or after the approved product has been marketed or the occurrence of adverse events at a rate or severity level that is greater than experienced in prior clinical trials. If we discontinue a program in which we have invested significant resources, we will not receive any return on our investment. If any of our potential products are approved for marketing but fail to achieve the broad degree of physician or market acceptance necessary for commercial success, our operating results and financial condition will be adversely affected. If any of the products in our pipeline receives FDA approval thereby allowing us to market the product in the United States, it will be necessary for us to generate acceptance of our product for the indications covered by the FDA approval. ~~In order to generate acceptance in the marketplace, we will need to demonstrate to physicians, patients and payors that our product provides a distinct advantage or better outcome at a price that reflects the value of our product as compared with existing products. We will need to develop and implement a marketing program directed at both physicians and the general public.~~ Since we do not presently have the resources necessary to develop or implement an in- house marketing program and we may not have the funds to do so if and when we obtain FDA approval to market our product, we will need to establish a distribution network though license and distribution agreements with third parties who have the capability to market our product to physicians, and we will be dependent upon the ability of these third parties to market our products effectively. We cannot assure you that we will be able to negotiate license and distribution agreements with terms that are acceptable to us. Since we do not have an established track record and our product pipeline is relatively small, we may be at a disadvantage in negotiating the terms of license and distribution agreements. Further, we may have little control over the development and implementation of our licensee' s marketing program, and our licensees may have interests that are inconsistent with ours with respect to the allocation of resources and implementation of the marketing program. We cannot assure you that a marketing program for any of our

products can or will be implemented effectively or that we will be successful in developing physician and emergency service acceptance of our products. The drug delivery industry is subject to rapid technological change , and ~~,~~ our failure to keep up with technological developments may impair our ability to market our products. Our products use technology which we developed for the transdermal delivery of drugs. The field of drug delivery is subject to rapid technological changes. Our future success will depend upon our ability to keep abreast of the latest developments in the industry and to keep pace with advances in technology and changing customer requirements. If we cannot keep pace with such changes and advances, our proposed products could be rendered obsolete, which would result in our having to cease its operations. If we obtain FDA approval, we will face significant competition from better known and better capitalized companies. If we obtain FDA approval for any of our products, we expect to face significant competition from existing companies, which are better known and already have developed relationships with physicians within the healthcare system. Any product we may develop will compete with existing medications performing the same medicinal functions, which may include transdermal patches. We cannot assure you that we will be able to compete successfully. In addition, even if we are able to commercialize our product candidates, we may not be able to price them competitively with current standard of care products or their price may drop considerably due to factors outside our control. If this happens or the price of materials and manufacture increases dramatically, our ability to continue to operate our business would be materially harmed and we may be unable to commercialize any products successfully. In addition, other pharmaceutical companies may be engaged in developing, patenting, manufacturing and marketing products that compete with those that we are developing. These potential competitors may include large and experienced companies that enjoy significant competitive advantages over us, such as greater financial, research and development, manufacturing, personnel and marketing resources, greater brand recognition and more experience and expertise in obtaining marketing approvals from the FDA and foreign regulatory authorities. Healthcare reforms by governmental authorities, court decisions affecting health care policies and related reductions in pharmaceutical pricing, reimbursement and coverage by third- party payors may adversely affect our business. We expect the healthcare industry to face increased limitations on reimbursement, rebates and other payments as a result of healthcare reform, which could adversely affect third- party coverage of our proposed products and how much or under what circumstances healthcare providers will prescribe or administer our products, if approved. In both the U. S. and other countries, sales of our products, if approved for marketing, will depend in part upon the availability of reimbursement from third- party payors, which include governmental authorities, managed care organizations and other private health insurers. Third- party payors are increasingly challenging the price and examining the cost effectiveness of medical products and services. Increasing expenditures for healthcare have been the subject of considerable public attention in the United States. Both private and government entities are seeking ways to reduce or contain healthcare costs. Numerous proposals that would effect changes in the United States healthcare system have been introduced or proposed in Congress and in some state legislatures, including reducing reimbursement for prescription products and reducing the levels at which consumers and healthcare providers are reimbursed for purchases of pharmaceutical products. Cost reduction initiatives and changes in coverage implemented through legislation or regulation could decrease utilization of and reimbursement for any approved products, which in turn would affect the price we can receive for those products. Any reduction in reimbursement that results from federal legislation or regulation may also result in a similar reduction in payments from private payors, since private payors often follow Medicare coverage policy and payment limitations in setting their own reimbursement rates. Significant developments that may adversely affect pricing in the United States include the enactment of federal healthcare reform laws and regulations, including the Affordable Care Act, or ACA, which is popularly known as Obamacare, and the Medicare Prescription Drug Improvement and Modernization Act of 2003. A recent district court decision which struck down Obamacare, if upheld, could have a material adverse effect upon reimbursement and payment for products such as our proposed products. Changes to the healthcare system enacted as part of any healthcare reform in the United States, as well as the increased purchasing power of entities that negotiate on behalf of Medicare, Medicaid, and private sector beneficiaries, may result in increased pricing pressure by influencing, for instance, the reimbursement policies of third- party payors. Regulatory changes which have the effect of decreasing the use of opioids has resulted in a decrease in the size of the market for opioid products, including fentanyl, could impact the market for our abuse deterrent fentanyl transdermal system or any other opioid- based transdermal product we may develop. It is difficult and costly to protect our proprietary rights, and we may not be able to ensure their protection. Our commercial success will depend in part on obtaining and maintaining patent protection and trade secret protection for our technology which is incorporated in our products as well as successfully defending these patents against third- party challenges, should any be brought. 4P Therapeutics originally filed an international patent application under the Patent Cooperation Treaty for worldwide prosecution of the abuse deterrent transdermal technology intellectual property used in our lead product, the abuse deterrent fentanyl transdermal system. The AVERSA abuse deterrent technology utilized in our AVERSA product pipeline is covered by an international intellectual property portfolio with patents issued in 45 countries including the United States, Europe, Japan, Korea, Russia, Mexico, Canada and Australia. Patent prosecution is still pending in China and Hong Kong. These patents provide patent coverage to 2035. We continue to build on our proprietary positions in the United States and internationally for our product candidates AVERSA Fentanyl, AVERSA buprenorphine and AVERSA methylphenidate as well as other products and technology that we may have in development. Our policy is to pursue, maintain and defend patent rights developed internally or acquired externally and to protect the technology, inventions and improvements that are commercially important to the development of our business. We cannot be sure that patents will be granted with respect to any of our pending patent applications or with respect to any patent applications filed by us in the future, nor can we be sure that any of our existing patents or any patents granted to us in the future will be commercially useful in protecting our technology. We also rely on trade secrets to protect our commercial products and product candidates. Our commercial success also depends in part on our non- infringement of the patents or proprietary rights of third parties. Our ability to stop third parties from making, using, selling, offering to sell or importing products utilizing our proprietary or patented technology is dependent upon the extent to which we have rights under valid and enforceable patents or trade secrets that cover these activities. The patent positions of pharmaceutical and biopharmaceutical companies can be highly uncertain and involve complex legal and factual questions for which important legal principles remain unresolved. No consistent policy regarding the breadth of claims allowed in biopharmaceutical patents has emerged to date in the United States. The biopharmaceutical patent situation outside the United States varies from country to country and is even more uncertain. Changes in either the patent laws or in interpretations of patent laws in the United States and other countries may diminish the value of our intellectual property. Accordingly, we cannot predict the breadth of claims that may be allowed or enforced in any patents we may be granted. Further, if any patents are granted and are subsequently deemed invalid and unenforceable, it could impact our ability to license our technology and, as noted previously, fend off competitive challenges. Patent litigation is very expensive and we may not have sufficient funds to defend our proprietary technology from infringement, either as a plaintiff in an action seeking to stop infringers from using our technology, or as a defendant in an action against us alleging infringement by us. The degree of future protection for our proprietary rights is uncertain because legal means afford only limited protection and may not adequately protect our rights or permit us to gain or keep our competitive advantage. For example: ● others may be able to make compositions or formulations that are similar to our product s but that are not covered by the claims of our patents; ● other persons may have filed patents covering inventions, technology or processes that we use, with the result that we may infringe upon the prior patents; ● others may independently develop similar or alternative technologies or duplicate any of our technologies; ● our pending patent applications may not result in the grant of patents; ● any patents which may be issued may not provide us with any competitive advantages, or may be held invalid or unenforceable as a result of legal challenges by third parties; ● our inability to fund any litigation to defend our proprietary rights, either in defense of an action against us or a plaintiff to seek to prevent infringement. ● our failure to develop additional proprietary technologies that are patentable. If we seek to expand our business through acquisition, we may not be successful in identifying acquisition targets or integrating their businesses with our existing business. We have ~~recently~~ expanded our business by acquisition, and we may make acquisitions in the future. ~~In~~ **Acquisitions may lead to our acquiring assets the value of which is not commensurate with the purchase price we paid. For example, in** 2017, we issued 1, 458, 333 shares of common stock, valued at $ 2, 500, 000, in connection with our proposed acquisition of Advanced Health Brands, Inc., but the stock of Advanced Health Brands was never transferred to us and the value of the intellectual property we were to have acquired did not have the value we anticipated, with the result that we incurred a $ 2, 500, 000 impairment loss in the year ended January 31, 2018. In September 2018, we entered into an agreement to acquire Carmel Biosciences Inc., and in November 2018, we terminated the agreement. We previously entered into another acquisition agreement which was rescinded shortly after the agreement was executed. We cannot assure you that any acquisition we complete will be successful or that any acquisition agreement we may enter into will result in an acquisition. An acquisition can be unsuccessful for a number of reasons, including the following: ● We may incur significant expenses and devote significant management time to the acquisition and we may be unable to consummate the acquisition on acceptable terms. ● The integration of any acquisition with our existing business may be difficult and, if we are not able to integrate the business successfully, we may not only be unable to operate the business profitably, but management may be unable to devote the necessary time to the development of our existing business; ● The key employees who operated the acquired business successfully prior to the acquisition may not be happy working for us and may resign, thus leaving the business without the necessary continuity of management. ● ~~Even if the business is successful, our senior executive officers may need to devote significant time to the acquired business, which may distract them from their other management activities. ●~~ If the business does not operate as we expect, we may incur an impairment charge based on the value of the assets acquired. ● The products or proposed products of the acquired company may have regulatory problems with the FDA or any other regulatory agency,

including the need for additional and unanticipated testing or the need for a recall or a change in labeling. ● We may have difficulty maintaining the necessary quality control over the acquired business and its products and services. ● To the extent that an acquired company operates at a loss prior to our acquisition, we may not be able to develop profitable operations following the acquisition. ● The acquired company may have liabilities or obligations which were not disclosed to us, or the acquired assets, including any intellectual property, may not have the value we anticipated. ● The assets, including intellectual property, of the acquired company may not have the value that we anticipated. ● We may require significant capital both to acquire and to operate the business, and the capital requirements of the business may be greater than we anticipated. Our failure to obtain funds on reasonable terms may impair the value of the acquisition. ● The acquired company may not operate at the revenue level or with the gross margin shown in the financial statements or projections. ● Patents may not be granted for patent applications which the acquired company filed or patents may be successfully challenged. ● There may be conflicts in management styles that prevent us from integrating the acquired company with us. ● The business of the acquired company may have problems of which management was unaware and which do not become evident until after the acquisition and we may require significant funding to remedy the problem. ● The indemnification obligations of the seller under the purchase agreement, if any, may be inadequate to compensate us for any loss, damage or expense which we may sustain, including undisclosed claims or liabilities. ● To the extent that the acquired company is dependent upon its management to maintain relationships with existing customers, we may have difficulty in retaining the business of these customers if there is a change in management. ● Government agencies may seek damages after we make the acquisition for conduct which occurred prior to the acquisition and we may not have adequate recourse against the seller. If any of the foregoing or any other events which we do not contemplate happen, we may incur significant expenses, which we may not be able to cover, and the development of our business can be impaired. We cannot assure you that any acquisition we will make will be successful. We are dependent on third party distributors for the international marketing of our consumer products and complying with applicable laws. We do not currently sell or market our consumer transdermal products domestically, or for our international sales, directly to international consumers, and we rely on distributors to sell and market these products. We cannot market our consumer transdermal patch products in the United States without first obtaining FDA approval. We do not plan to seek FDA approval or market these products in the United States at this time. We plan to sell our transdermal consumer products to distributors in those countries in which the products can be sold in compliance with all applicable regulations without our spending significant monies for preclinical and clinical studies to obtain regulatory approval. We are dependent upon our chief executive officer, our president and our chief operating officer. We are dependent upon Gareth Sheridan, our chief executive officer, Serguei Melnik, our president and Dr. Alan Smith, our chief operating officer who is president of 4P Therapeutics. Although **these officers** ~~Mr. Sheridan and Mr. Melnik~~ have employment agreements with us, the employment agreements ~~does~~ **do** not guarantee that the officer will continue with us ~~. We do not have an employment agreement with Dr. Smith~~. The loss of Mr. Sheridan, Mr. Melnik or Dr. Smith would materially impair our ability to conduct our business. If we are unable to attract, train and retain technical and financial personnel, our business may be materially and adversely affected. Our future success depends, to a significant extent, on our ability to attract, train and retain key management, technical, regulatory and financial personnel. Recruiting and retaining capable personnel with experience in pharmaceutical product development is vital to our success. There is substantial competition for qualified personnel, and competition is likely to increase. We cannot assure you we will be able to attract or retain the personnel we require. Our financial condition is likely to impair our ability to attract qualified candidates. If we are unable to attract and retain qualified employees, our business may be materially and adversely affected. Risks Concerning our Securities Our lack of internal controls over financial reporting may affect the market for and price of our common stock. Pursuant to Section 404 of the Sarbanes- Oxley Act, we are required to file a report by our management on our internal control over financial reporting. Our disclosure controls and our internal controls over financial reporting are not effective. We do not have the financial resources or personnel to develop or implement systems that would provide us with the necessary information on a timely basis so as to be able to implement financial controls **.** The absence of internal controls over financial reporting may inhibit investors from purchasing our stock and may make it more difficult for us to raise capital or borrow money. Implementing any appropriate changes to our internal controls may require specific compliance training of our directors and employees, entail substantial costs in order to modify our existing accounting systems, take a significant period of time to complete and divert management' s attention from other business concerns. These changes may not, however, be effective in developing or maintaining internal control. The market price for our common stock may be volatile and your investment in our common stock could suffer a decline in value. The trading volume in our stock is low, which may result in volatility in our stock price. As a result, any reported prices may not reflect the price at which you would be able to sell shares of common stock if you want to sell any shares you own or buy if you wish to buy shares. Further, stocks with a low trading volume may be more subject to manipulation than a stock that has a significant public float and is actively traded. The price of our stock may fluctuate significantly in response to a number of factors, many of which are beyond our control. These factors include, but are not limited to, the following, in addition to the risks described above and general market and economic conditions: ● the market' s perception as to our ability to generate positive cash flow or earnings; ● changes in our or any securities analysts' estimate of our financial performance; ● the perception of our ability to raise the necessary financing to complete the product development activities including preclinical and clinical testing required for FDA approval and our ability to generate revenue and cash flow from our products; ● the anticipated or actual results of our operations; ● changes in market valuations of other companies in our industry; ● litigation or changes in regulations and insurance company reimbursement policies affecting prescription drugs; ● concern that our internal controls are ineffective; ● any discrepancy between anticipated or projected results and actual results of our operations; ● actions by third parties to either sell or purchase stock in quantities which would have a significant effect on our stock price; and ● other factors not within our control. Raising funds by issuing equity or convertible debt securities could dilute the net tangible book value of the common stock and impose restrictions on our working capital. We anticipate that we will require funds for our business. If we were to raise capital by issuing equity securities, either alone or in connection with a non- equity financing, the net tangible book value of the then outstanding common stock could decline. If the additional equity securities were issued at a per share price less than the market price, which is customary in the private placement of equity securities, the holders of the outstanding shares would suffer dilution, which could be significant. Further, if we are able to raise funds from the sale of debt securities, the lenders may impose restrictions on our operations and may impair our working capital as we service any such debt obligations. Stockholders may experience significant dilution as a result of future equity offerings and other issuances of our common stock or other securities. We will need to raise substantial funds in order to develop our products. In order to raise additional capital, we may in the future offer additional shares of our common stock or other securities convertible into or exchangeable for our common stock at prices that ~~may~~ **maybe** ~~not which is less than the market price and which may be~~ based on a discount from market at the time of issuance. Stockholders will incur dilution upon exercise of any outstanding stock options, warrants or upon the issuance of shares of common stock under our present and future stock incentive programs. In addition, the sale of shares and any future sales of a substantial number of shares of our common stock in the public market, or the perception that such sales may occur, could adversely affect the price of our common stock. We cannot predict the effect, if any, that market sales of those shares of common stock or the availability of those shares of common stock for sale will have on the market price of our common stock. Our failure to meet the continued listing requirements of Nasdaq could result in a de- listing of our common stock. If we fail to satisfy the continued listing requirements of Nasdaq, such as the corporate governance requirements or the minimum closing bid price requirement, Nasdaq may take steps to de- list our securities. Such a de- listing would likely have a negative effect on the price of our common stock and would impair your ability to sell or purchase our ~~Common~~ **common** ~~Stock~~ **stock** when you wish to do so. In the event of a de- listing, we would take actions to restore our compliance with Nasdaq' s listing requirements, but we can provide no assurance that any such action taken by us would allow our common stock to become listed again, stabilize the market price or improve the liquidity of our common stock, prevent our common stock from dropping below the Nasdaq minimum bid price requirement or prevent future non- compliance with Nasdaq' s listing requirements. We and our senior executive officers settled an SEC investigation, which may affect the market for and the market price of our common stock and our ability to list on a stock exchange. Following an investigation into the accuracy of statements in our Form 10 registration statement filed June 2, 2016, as amended, and our Form 10- K annual report filed May 8, 2017 that did not accurately reflect the FDA' s jurisdiction over our consumer products and did not disclose that we could not legally market these products in the United States, a Wells notice which we, our chief executive officer and our chief financial officer **,** received on August 10, 2017 and a Wells submission which we and the officers submitted in response to the Wells notice, the SEC, on December 26, 2018, announced that it has accepted our settlement offer and instituted settled an administrative cease- and- desist proceeding against us and our chief executive officer and chief financial officer. The SEC' s administrative order, dated December 26, 2018, finds that we and the officers consented – without admitting or denying any findings by the SEC — to cease- and- desist orders against them for violations by us of Sections 12 (g) and 13 (a) of the Securities Exchange Act of 1934 and Rules 12b- 20 and 13a- 1 thereunder, which require issuers to file accurate registration statements and annual reports with the Commission; violations by the officers for causing our violations of the above issuer reporting provisions; and violations by the officers of Rule 13a- 14 of the Exchange Act, which requires each principal executive and principal financial officer of issuers to attest that annual reports filed with the SEC do not contain any untrue statements of material fact. In addition to consenting to the cease- and- desist orders, the officers have each agreed to pay a $ 25, 000 civil penalty to resolve the investigation. The administrative order does not impose a civil penalty or any other monetary relief against us. The settlement may affect the market for and the market price of our common stock. ● ~~concern about the effects of our settlement with the SEC; ●~~ the market' s

reaction to our financial condition and its perception of our ability to raise necessary funding or enter into a joint venture, as well as its perception of the possible terms of any financing or joint venture ~~; ● the perception of our ability to raise the necessary financing to complete the product development activities including preclinical and clinical testing required for FDA approval and our ability to generate revenue and cash flow from our products~~ . Because of our executive officers' stock ownership and stock ownership of certain other stockholders that have invested in the company, these stockholders have the power to elect all directors and to approve any action requiring stockholder approval. Our officers and directors as a group beneficially own approximately ~~32~~ **54** % of our common stock as of April ~~29~~ **25** , ~~2024~~ **2025** . As a result, they have the effective power using their contacts with a limited number of other shareholders to elect all of our directors and to approve any action requiring stockholder approval **. Raising funds by issuing equity or convertible debt securities could dilute the net tangible book value of the common stock and impose restrictions on our working capital** . We may issue preferred stock whose terms could adversely affect the voting power or value of our common stock. Our articles of incorporation authorize us to issue, without the approval of our stockholders, one or more classes or series of preferred stock having such designations, preferences, limitations and relative rights, including preferences over our common stock respecting dividends and distributions, as our board of directors may determine. The terms of one or more classes or series of preferred stock could adversely impact the voting power or value of our common stock. For example, we might grant holders of preferred stock the right to elect a number of our directors in all events or on the happening of specified events or the right to veto specified transactions. Similarly, the repurchase or redemption rights or liquidation preferences we might assign to holders of preferred stock could affect the residual value of the common stock. We do not intend to pay any cash dividends in the foreseeable future. We have not paid any cash dividends on our common stock and do not intend to pay cash dividends on our common stock in the foreseeable future. ITEM 1B. UNRESOLVED STAFF COMMENTS. Not Applicable. ITEM 2. PROPERTIES Property We do not own any real property. We lease under a one year lease an office for $ 2, 500 per month at 121 South Orange Street, Orlando, Florida. With the office lease, we have access to boardrooms, kitchen facilities and administrative support services. We lease manufacturing space in Cherryville, North Carolina, for $ 3, 000 per month under a three- year lease entered into on February 1, 2022, with a renewal option. ITEM 3. LEGAL PROCEEDINGS The Company is currently a defendant in a lawsuit initiated by Joseph Gunnar, LLC (" Gunnar ") and Lucosky Brookman LLP (" LB ") in the Supreme Court of the State of New York, New York County, under Index No. 654633 / 2023. The lawsuit alleges multiple allegations such as breach of contract, fraudulent activities, and tortious interference and seeks damages following the Company' s termination of an engagement letter for assistance with a public stock offering. Gunnar is seeking over $ 500, 000 in damages plus punitive damages, while LB is demanding reimbursement of legal fees. In response, the Company denies all allegations, alleging that the engagement letter was unenforceable, and its termination was legally justified. The Company has also initiated counterclaims against Joseph Gunnar & Co., accusing them of intentional interference and breach of fiduciary duty, and is seeking $ 1, 000, 000 for each claim along with a declaratory judgment affirming the legality and justification of the termination. The plaintiffs have denied these counterclaims. Currently, there are no pending hearings or motions ~~as both parties are engaged~~ **, and the case is** in **the** discovery ~~and are attempting~~ **stage. In early 2024, the plaintiffs proposed a settlement offer of $ 100, 000. The Company has not responded** to **that settlement offer** ~~resolve the matter amicably~~ . ITEM 4. MINE SAFETY DISCLOSURES. PART II ITEM 5. MARKET FOR REGISTRANT' S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES. Common Stock and Warrants Listing and Trading Since our initial public offering on October 1, 2021, our common stock has traded on The NASDAQ Capital Market under the symbol " NTRB ", and our Warrants are traded on that exchange under the symbol " NTRBW ". Shareholders of Record As of April ~~26~~ **25** , ~~2024~~ **2025** , we had approximately ~~110~~ **118** holders of record of our common stock; our Warrants are held in book entry form by the Depository Trust Corporation, which is the holder of record of all of the publicly- traded warrants, based upon data provided by our transfer agent. The transfer agent for the common stock is Equiniti Trust Company, LLC, 6201 15th Ave, Brooklyn, NY 11219, telephone (800) 937- 5449. Dividends We have not declared any cash dividends at any time, and we do not anticipate declaring any cash dividends in the foreseeable future. **Sales of Unregistered Securities The following table sets forth the sales of unregistered securities since the Company' s last report filed under this item. Date Title and Amount (1) Purchaser Principal Underwriter Total Offering Price / Underwriting Discounts 1 / 23 / 2025 Three Year Option to Purchase 17, 667 shares of Common Stock at an exercise price of $ 7. 34 per share. Gerald Goodman NA $ 129, 675. 78 / NA 1 / 23 / 2025 Three Year Option to Purchase 17, 667 shares of common stock at an exercise price of $ 7. 34 per share. Alan Smith NA $ 129, 675. 78 / NA 1 / 23 / 2025 Three Year Option to Purchase 17, 667 shares of common stock at an exercise price of $ 7. 34 per share. Dianna Mather NA $ 129, 675. 78 / NA 1 / 23 / 2025 Three Year Option to Purchase 17, 667 shares of common stock at an exercise price of $ 7. 34 per share. Mike Myer NA $ 129, 675. 78 / NA 1 / 23 / 2025 Three Year Option to Purchase 13, 583 shares of common stock at an exercise price of $ 7. 34 per share. Stefani Mancas NA $ 99, 699. 22 / NA 1 / 23 / 2025 Three Year Option to Purchase 15, 333 shares of common stock at an exercise price of $ 7. 34 per share. Radu Bujoreanu NA $ 112, 544. 22 / NA 1 / 23 / 2025 Three Year Option to Purchase 11, 833 shares of common stock at an exercise price of $ 7. 34 per share. Vselovod Grigore NA $ 86, 854. 22 / NA 1 / 23 / 2025 Three Year Option to Purchase 17, 667 shares of common stock at an exercise price of $ 7. 34 per share. Tyler Overk $ 129, 675. 78 / NA 1 / 23 / 2025 Three Year Option to Purchase 29, 333 shares of common stock at an exercise price of $ 8. 07 per share. Gareth Sheridan NA $ 236, 717. 31 / NA 1 / 23 / 2025 Three Year Option to Purchase 29, 333 shares of common stock at an exercise price of $ 8. 07 per share. Serguei Melnik NA $ 236, 717. 31 / NA 1 / 23 / 2025 Three Year Option to Purchase 17, 667 shares of common stock at an exercise price of $ 7. 34 per share. Jeff Patrick NA $ 129, 675. 78 / NA 1 / 23 / 2025 Three Year Option to Purchase 17, 667 shares of common stock at an exercise price of $ 7. 34 per share. Patrick Ryan NA $ 129, 675. 78 / NA 1 / 23 / 2025 Three Year Option to Purchase 16, 500 shares of common stock at an exercise price of $ 7. 34 per share Mark Hamilton NA $ 121, 110. 00 / NA** Issuer Purchases of Equity Securities ~~In~~ **The following table sets forth purchases in** the **market by the Company of 32, 400 shares of its common stock in its fourth** fiscal ~~year~~ **quarter** ended January 31, ~~2024~~ **2025** ~~,~~ **and recorded** the ~~Company made no purchases~~ **purchase** ~~in the market~~ **as Treasury Stock. Period (a) Total number** of ~~its~~ **shares of** common stock **purchased (b) Average price paid per share (c) Total number of shares purchased as part of publicly announced plans of programs (d) Maximum number (or approximate dollar value) of shares that may yet to be purchased under the plans or programs January 2025 32, 400 $ 4** . **57 32, 400 $ 854, 455** ITEM 6. [ RESERVED ] The Company, as a smaller reporting company, is not required to provide the information called for by this Item. ITEM 7. MANAGEMENT' S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS The following discussion and analysis of financial condition and results of operations should be read in conjunction with our consolidated financial statements and related notes included elsewhere in this report. This discussion contains forward- looking statements that involve risks, uncertainties and assumptions. See " Note Regarding Forward- Looking Statements. " Our actual results could differ materially from those anticipated in the forward- looking statements as a result of certain factors discussed in " Risk Factors " and elsewhere in this report. Overview AVERSA ™ Abuse Deterrent Transdermal Products Our primary business is the development of a portfolio of transdermal pharmaceutical products. Our lead product under development is AVERSA Fentanyl, our abuse deterrent fentanyl transdermal system which will require approval from the Food and Drug Administration (" FDA ") and substantial capital for research and development. AVERSA Fentanyl has the potential to provide clinicians and patients with an extended- release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy combined with properties designed to deter the abuse and misuse of fentanyl patches. In addition, we believe that our abuse deterrent technology can be broadly applied to various other transdermal products and our strategy is to follow the development of our abuse deterrent fentanyl transdermal system with the development of abuse deterrent transdermal products for pharmaceuticals that have a risk of abuse, misuse or accidental exposure. On September 19, 2023, the United States Patent and Trademark Office (USPTO) granted US Patent No. 11, 759, 431 for Nutriband ~~'~~ **'** s proprietary AVERSA abuse deterrent technology utilizing taste aversion to address the primary routes of abuse of opioid based transdermal patches. The issuance of this patent, entitled, ~~"~~ **"** Abuse and Misuse Deterrent Transdermal Systems, ~~"~~ **"** further expands Nutriband ~~'~~ **'** s intellectual property protection in the United States for its portfolio of AVERSA abuse deterrent transdermal products. Transdermal Pharmaceutical Products Through October 31, 2018, our business was the development of a line of consumer and health products that are delivered through a transdermal or topical patch. Following our acquisition of 4P Therapeutics on August 1, 2018, our focus expanded to include prescription pharmaceuticals, and we are seeking to develop and seek FDA approval on a number of transdermal pharmaceutical products under development by 4P Therapeutics. Most of our planned consumer products require FDA approval for sale in the United States, and we have not sought to obtain, and we do not plan to seek to obtain, FDA approval to market these products in the United States at this time. Following our acquisition of selected assets from Pocono Coated Products, LLC (" Pocono "), we are primarily focused on providing contract manufacturing services and consulting services to third party brands with no intention at this time to launch our own consumer products. 4P Therapeutics has not generated any revenue from any of its products under development. Rather, prior to our acquisition, 4P Therapeutics generated revenue to provide cash for its operations through contract research and development and related services for a small number of clients in the life sciences field on an as- needed basis. We are, for the near term, continuing this activity, although we do not anticipate that it will generate significant revenues and, since our acquisition, it has generated minor gross margins. We have no long- term contractual obligations, and either party can terminate at any time. With the change in our focus, our capital requirements increased substantially. The process of developing pharmaceutical products and submitting them for FDA approval is both time consuming and expensive, with no assurance of obtaining approval from the FDA to market our product in the United States. We will require approximately $ 13 million for

research and development of our abuse deterrent fentanyl transdermal system, including clinical manufacturing and clinical trials that need to be completed in order to obtain FDA approval. However, the total cost could be substantially in excess of that amount. On ~~August 31, 2020, the Company entered into a Purchase Agreement (" Agreement "), with Pocono Coated Products (" PCP "), pursuant to which PCP agreed to sell the Company all of the assets associated with its Transdermal, Topical, Cosmetic and Nutraceutical business (the " Assets "). PCP was the manufacturer of our transdermal consumer products, and we bought that business from them. The purchase price for the Assets was (i) $ 6, 000, 000 paid in shares of the Company' s common stock at a value of the average price of the previous 90 days at the date of Closing (the " Shares "); (ii) a promissory note of the Company in the principal amount of $ 1, 500, 000, which is due upon the earlier of (a) twelve (12) months from issuance, or (b) immediately following a capital raise of no less than $ 4, 000, 000 and / or a public offering of no less than $ 4, 000, 000. The note was repaid in full in October 2021. Subsequent to the repayment of the note, the Shares were released from escrow. On October 5, 2021, the Company, having been approved for the listing of its common stock on The Nasdaq Capital Market effective October 1, 2021, consummated a public offering (the " IPO ") of units (the " Units "), of common stock and warrants that were offered in the IPO on The Nasdaq Capital Market, which included 1, 231, 200 (each a " Unit "), each Unit consisting of one share of common stock, par value $ 0. 001 per share, and one warrant (each a " Warrant ") at a price of $ 5. 36 per Unit. Each Warrant is immediately exercisable, will entitle the holder to purchase one share of common stock at an exercise price of $ 6. 43 and will expire five (5) years from the date of issuance. The underwriters' over- allotment option was exercised for 184, 800 warrants to purchase shares of common stock bringing to total net proceeds to the Company from the IPO to $ 5, 836, 230. The shares of common stock and Warrants are separately transferred immediately upon issuance. As of January 31, 2023, 457, 795 warrants issued in the IPO have been exercised, with net proceeds to the Company of $ 2, 942, 970. On November 1, 2021, The Board of Directors adopted the 2021 Employee Stock Option Plan (the " Plan "). The Company has reserved 408, 333 shares to issue and sell upon the exercise of stock options issued under the Plan. On November 3, 2021, the Company filed a Registration Statement on Form S- 8, to register under the Securities Act of 1933, as amended, the 408, 333 shares of common stock reserved for issuance under the Plan, and on October 12, 2022, a Post- Effective Amendment to the Form S- 8 was filed with the SEC. Forward Split of our Common Stock. On July 26, 2022, our Board of Directors approved the amendment to our Articles of Incorporation to effect a 7 for 6 forward stock split (the " Stock Split ") of our outstanding common stock. We filed the amendment set forth in a Certificate of Change with the Secretary of State of Nevada on August 4, 2022. The 7: 6 forward split was effective for trading purposes on the Nasdaq Capital Market on August 12, 2022. Each shareholder of record as of the August 15, 2022 record date received one (1) additional share of common stock for each six (6) shares held as of the record date. No fractional shares of common stock were issued in connection with the Stock Split. Instead, all shares were rounded up to the next whole share. In connection with the Stock Split, which did not require shareholder approval under the Nevada corporation law, the number of authorized shares of common stock of the Company was increased in the same ratio as the shares of outstanding common stock were increased in the Stock Split, from 250, 000, 000 authorized shares to 291, 666, 666 authorized shares. On December 15, 2023, the Company filed the Proxy Statement with the SEC for its Annual Meeting of Stockholders, to be held January 21, 2024, in Orlando, Florida. This Proxy Statement is available on our website at HTTPS: / / Nutriband. com / proxy. On~~ March 20, 2024, our Board of Directors adopted an amendment to the Company' s 2021 Employees Stock Option Plan (the " Plan ") increasing the number of shares of common stock subject to the ~~plan~~ **Plan** (as of March 20, 2024 ~~875, 000 shares~~ ) to 1, 400, 00 shares (the " Amendment "). The ~~plan~~ **Plan** adopted by the Board on November 1, 2021, provided for an initial 350, 000 shares to issue and sell upon the exercise of stock options issued under the Plan. ~~The Plan provides for an automatic annual increase to be added on February 1 of each year equal to the lesser of (i) 250, 000 shares of Common Equity or (ii) five percent (5 %) of the total shares of Common Stock outstanding on such date (including for this purpose any shares of Common Stock issuable upon conversion of any outstanding capital equity of the Company) or (iii) such lesser number as determined by the Board~~ . We ~~will submit~~ **submitted** the Amendment to the Plan to our stockholders for adoption and approval at the 2025 Annual Meeting ~~. If~~ **, increasing** the **authorized number of shares of common stock available for issuance of options to 1, 400, 000 shares, which** Amendment **was** ~~is not~~ approved ~~by stockholders within one year of adoption by the increase in shares subject to the Plan will be void, together with any options issued following March 20, 2024 in the period pending approval of the Plan~~ by our stockholders **at the meeting** . On April 19, 2024, the Company completed an $ 8, 400, 000 equity financing with European investors (the " Offering ") of 2, 100, 000 units (" Units "), at a price of $ 4. 00 per Unit, each Unit consisting of one share of common stock (" Shares ") and a Warrant to purchase two Shares of common stock, the Warrants having an initial exercise price of $ 6. 43, are exercisable by payment of the exercise price in cash only and expire April 19, 2029, five years from the date of issuance (" Warrants "). The Offering was made solely to investors resident outside the United States and was not registered under the Securities Act of 1933, as amended (the " Securities Act "), or the securities laws of any jurisdiction, including any jurisdiction outside the United States, but was made privately by the Company pursuant to the exemptions from registration provided in the SEC' s Regulation S and other exemptions under the Securities Act. Years Ended January 31, **2025 and** 2024 **For the year ending January 31, 2025, we generated revenue of $ 2, 139, 537** and ~~2023~~ **our costs of revenue were $ 1, 396, 220 resulting in a gross margin of $ 743, 317.** For **the year ending January 31, 2024, we generated revenue of $ 2, 085, 314 and our costs of revenue were $ 1, 223, 209 resulting in a gross margin of $ 862, 105. Our revenue for** the year ended January 31, ~~2024~~ **2025** , **was derived from** ~~we generated revenue of $ 2, 085, 314 and our costs of revenue were $ 1, 223, 209. For the year ended January 31, 2023, we generated revenue of $ 2, 079, 609 and our costs of revenue were $ 1, 329, 200. Our revenue for the year ended January 31, 2024, included~~ sales ~~of $ 1, 920, 280~~ from ~~contract manufacturing services performed in~~ our Pocono Pharmaceuticals ~~(Active Intelligence)~~ segment and $ ~~165, 034~~ ~~- 0-~~ from contract research and development services from our 4P Therapeutics segment. The revenue from the ~~Transdermal Patches~~ **Pocono Pharmaceuticals** segment remained relatively constant from the prior year. An increase in demand is expected in the subsequent year. ~~Our cost of revenue for~~ **There were no sales in** our **4P Therapeutics segment in the current year due to a shift in focus and the main** contract **wound down** ~~research and development services represents our labor cost plus a modest amount of material costs which we passed on to the client. Our cost of sales during the year for our contract services~~ in ~~comparison to~~ the prior year ~~as our~~ **. The decline in gross** ~~main~~ **margin** ~~contract has been completed and the balance of the contract~~ is ~~being recognized with limited additional costs~~ **due primarily to lower margins on tape sales** . For the year ~~ended~~ **ending** January 31, ~~2024~~ **2025** , our selling, general and administrative expenses were $ ~~3~~ **4** , ~~773~~ **313** , ~~606~~ **810** , primarily **salaries and wages, public relations,** legal, accounting, **and** ~~administrative salaries~~ non- cash compensation from the issuance of warrants and employee stock options, compared to $ 3, ~~916~~ **773** , ~~041~~ **606** for the year ~~ended~~ **ending** January 31, ~~2023~~ **2024** . The ~~decrease~~ **increase** from ~~2023~~ **2024** is primarily due to ~~a~~ **an** ~~decrease~~ **increase** in ~~salaries~~ **non- cash compensation** and **public relations** ~~wages to executives of the Company~~ . During the ~~years~~ **year** ~~ended~~ **ending** January 31, ~~2024~~ **2025** ~~and 2023, the Company recorded an impairment expense of $- 0- and $ 327, 326, respectively, due to a write down of Goodwill in connection with its Pocono acquisition. The write down of goodwill for the year ended January 31, 2023, was attributable primarily to the effects of the pandemic. As of January 31, 2024, the valuation of the reporting unit exceeds the carrying amount of goodwill using the value in use or the going concern premise. During the year ended January 31, 2024~~ , the Company incurred research and development expenses for its Aversa Fentanyl product of $ ~~1~~ **3** , ~~960~~ **119** , ~~425~~ **134** , primarily due to labor and material costs incurred at our contract manufacturer, Kindeva Drug Delivery, as compared to $ ~~982~~ **1** , ~~227~~ **960, 425** for the year ~~ended~~ **ending** January 31, ~~2023~~ **2024** . During the year ~~ended~~ **ending** January 31, ~~2024~~ **2025 , the Company recorded an impairment charge of $ 3, 595, 216 reducing the value of its Goodwill and intangible assets. The impairment charge reflected an updated valuation primarily of the Company' s Goodwill. During the year ending January 31, 2025** , the Company incurred a loss on extinguishment of debt of $ **368, 036 in connection with issuance of common stock and warrants to a related party debtor. During the year ending January 31, 2024, the Company incurred a loss on extinguishment of debt of $** 554, 423, consisting primarily of the loss on the conversion of $ 2, 000, 000 of credit line note into 1, 026, 750 shares of the Company' s common stock. ~~There was no gain~~ **We incurred interest expense of $ 21, 407** ~~or~~ **for** ~~loss on extinguishment of debt during~~ **the year ending January 31, 2025, as compared to $ 75, 815 for** the year ended January 31, ~~2023. We incurred interest expense of $ 75, 815 for the year ended January 31,~~ 2024 ~~, as compared to $ 6, 289 for the year ended January 31, 2023~~ . The ~~increase~~ **decrease** is primarily due to ~~interest on~~ **the decrease in** the Company' s related party credit line note. **Interest income for the year ending January 31, 2025, was $ 191, 669 as compared to $ 16, 850 for the year ending January 31, 2024. The increase is primarily due to the investment of excess cash from the Company' s equity financing.** As a result of the foregoing, we sustained a net loss of $ ~~5~~ **10** , ~~485~~ **482** , ~~314~~ **617** , or $ (0. ~~69~~ **99** ) per share (basic and diluted) for the year ended January 31, ~~2024~~ **2025** , compared with a loss of $ ~~4~~ **5** , ~~483~~ **485** , ~~474~~ **314** , or $ (0. ~~53~~ **69** ) per share (basic and diluted) for the year ended January 31, ~~2023~~ **2024** . Liquidity and Capital Resources As of January 31, ~~2024~~ **2025** , we had $ ~~492~~ **4** , ~~942~~ **311, 719** in cash and cash equivalents and working capital of $ ~~22~~ **3** , ~~770~~ **811, 420** , as compared with cash and cash equivalents of $ ~~1~~ **492** , **942** ~~985, 440~~ and working capital of $ ~~1~~ **22** , **770** ~~945, 132~~ as of January 31, ~~2023. During the year ended January 31,~~ 2024 ~~, the Company on March 19, 2023, entered a three- year Credit Line Note facility for $ 2 million, to fund its research and development of its Aversa Fentanyl product and an amendment thereto on July 13, 2023, increasing the amount under the credit line to $ 5 million. During 2024, the Company drew down a total of $ 2, 000, 000 under the credit line. In December 2023, the $ 2, 000, 000 was converted into shares of the Company' s common stock~~ . On April 19, 2024, the Company completed an $ 8, 400, 000 equity financing with European investors (the " Offering ") of 2, 100, 000 units (" Units "), at a price of $ 4. 00 per Unit, each Unit consisting of one share of common stock (" Shares ") and a Warrant to purchase two Shares of common stock. For the year ~~ended~~ **ending** January 31, ~~2024~~ **2025** , we used cash of $ ~~3~~ **4** , ~~527~~ **626** , ~~509~~ **564** in our operations. The principal adjustments to our net loss of $ ~~5~~ **10** , ~~485~~ **284** , ~~314~~ **483**

were **an impairment charge of $ 3, 595, 216,** depreciation and amortization of $ ~~287~~ **285** , ~~722~~ **054** , net loss on extinguishment of debt of $ ~~554~~ **368** , ~~423~~ **036** and stock- based compensation of $ ~~742~~ **1** , ~~696~~ **542, 285** . For the year ~~ended~~ **ending** January 31, ~~2024~~ **2025** , we used cash in investing activities of $ ~~51~~ **92** , ~~761~~ **043** primarily for the purchase of equipment. For the year ~~ended~~ **ending** January 31, ~~2024~~ **2025** , we provided cash in financing activities of $ ~~2~~ **8** , ~~086~~ **537** , ~~772~~ **384** , primarily from the proceeds of $ ~~2~~ **8** , ~~000~~ **400** , 000 from the ~~proceeds~~ **sale** of **common stock and warrants and** $ **300** ~~2, 000~~ , 000 from its line of credit ~~and $ 106, 528 from a factoring arrangement, offset from the payment on notes of $ 19, 756. For the year ended January 31, 2023, we had cash flows of $ 160, 074 from financing activities, primarily of $ 296, 875 from the exercise of warrants, offset by a payment on notes and the repurchase of treasury stock~~ . Off Balance Sheet Arrangements We have no off- balance sheet arrangements that have or are reasonably likely to have a current or future material effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources. Critical Accounting Policies Going Concern **AssessmentManagement** ~~Assessment Management~~ assesses liquidity and going concern uncertainty in the Company' s condensed financial statements to determine whether there is sufficient cash on hand and working capital, including available borrowings on loans, to operate for a period of at least one year from the date the consolidated financial statements are issued or available to be issued, which is referred to as the " look- forward period ", as defined in GAAP. As part of this assessment, based on conditions that are known and reasonably knowable to management, management will consider various scenarios, forecasts, projections, estimates and will make certain key assumptions, including timing and nature of projected cash expenditures or programs, its ability to delay or curtail expenditures or programs and its ability to raise additional capital, if necessary, among other factors. Based on this assessment, as necessary or applicable, management makes certain assumptions around implementing curtailments or delays in the nature and timing of programs and expenditures to the extent it deems probable those implementations can be achieved **,** and management has the proper authority to execute them within the look- forward period. As of January 31, ~~2024~~ **2025** , the Company had cash and cash equivalents of $ ~~492~~ **4** , ~~942~~ **311, 719** and working capital of $ ~~22~~ **3** , ~~770~~ **811, 420** . For the year ended January 31, ~~2024~~ **2025** , the Company incurred a net loss from operations of $ ~~4~~ **10** , ~~871~~ **284** , ~~926~~ **843** and used cash flow from operations of $ ~~3~~ **4** , ~~527~~ **626** , ~~509~~ **564** . The Company has generated operating losses since its inception and has relied on sales of securities and **the** issuance of third- party and related- party debt to support cash flow from operations ~~. In October 2021, the Company consummated a public offering and received net proceeds of $ 5, 836, 230. The Company has also received to date $ 3, 239, 845 in proceeds from the exercise of warrants~~ . The Company has used these proceeds to fund operations and will continue to use the funds as needed. In March 2023, the Company entered into a three- year $ 2, 000, 000 Credit Line Note facility with a related party, amended on July 13, 2023, to $ 5, 000, 000, which will permit the Company to draw down on the credit line to fund the Company' s research and development of its Aversa product. ~~The Company was advanced $ 2, 000, 000, all of which was settled by the issuance of common stock during the year ended January 31, 2024. The $ 2, 000, 000 of debt and accrued interest was converted into 1, 026, 720 shares of the Company' s common stock.~~ On April 19, 2024, the Company received proceeds of $ 8, 400, 000 from **equity financing with European investors** ~~a private placement of its common stock~~ . Management has prepared estimates of operations for the next twelve months and believes that sufficient funds will be generated from operations to fund its operations for one year from the date of the filing of these condensed consolidated financial statements, which indicates improved operations and the Company' s ability to continue operations as a going concern. Management believes the substantial doubt about the ability of the Company to continue as a going concern is alleviated by the above assessment. Principles of Consolidation The consolidated financial statements of the Company include the Company and its wholly owned subsidiaries. All material intercompany balances and transactions have been eliminated. The operations of 4P Therapeutics are included in the Company' s financial statements from the date of acquisition of August 1, 2018, and the **acquired** operations of Pocono ~~Pharmaceuticals (~~ **Coated Products and** Active Intelligence ~~)~~ are included in the Company' s financial statements from the date of acquisition of September 1, 2020 **,** under Pocono Pharmaceuticals Inc. The wholly owned subsidiaries are as follows: Nutriband Ltd. 4P Therapeutics LLC Pocono Pharmaceuticals Inc. Use of EstimatesThe preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires the Company to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an ongoing basis, the Company evaluates its estimates including, but not limited to, those related to such items as income tax exposures, accruals, depreciable / useful lives, allowance for doubtful accounts and valuation allowances. The Company bases its estimates on historical experience and on other various assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates. Revenue RecognitionIn May 2014, the FASB issued ASU No. 2014- 09, " Revenue from Contracts with Customers (Topic 606) (" ASU 2014- 09 "), which amends the accounting standards for revenue recognition. ASU 2014- 09 is based on principles that govern the recognition of revenue at an amount an entity expects to be entitled when products are transferred to a customer. The Company recognizes revenue based on the five criteria for revenue recognition established under Topic 606: 1) identify the contract, 2) identify separate performance obligations, 3) determine the transaction price, 4) allocate the transaction price among the performance obligations, and 5) recognize revenue as the performance obligations are satisfied. Revenue Types The following is a description of the Company' s revenue types, which include professional services and sale of goods: ● Contract development and manufacturing services for consumer health transdermal, topical and tape products with revenues listed under sale of goods **.** ● Product revenues derived from the sale of the Company' s consumer transdermal, topical and tape products with sales listed under sale of goods **.** ● Contract research and development services for ~~pharmaceuticals~~ **pharmaceutical** and medical devices for life sciences customers with revenues listed under services **.** A contract with a customer exists when (i) we enter into an enforceable contract with a customer that defines each party' s rights regarding the goods or services to be transferred and identifies the payment terms related to these goods or services, (ii) the contract has commercial substance and, (iii) we determine that collection of substantially all consideration for services that are transferred is probable based on the customer' s intent and ability to pay the promised consideration. Contract Liabilities Deferred revenue is a liability related to a revenue producing activity for which revenue has not been recognized. The Company records deferred revenue when it receives consideration from a contract before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. Performance Obligations A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in the new revenue standard. The contract transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. For the Company' s different revenue service types, the performance obligation is satisfied at different times. The Company' s performance obligations include providing products and professional services in the area of research. The Company recognizes product revenue performance obligations in most cases when the product has shipped to the customer. When we perform professional service work, we recognize revenue when we have the right to invoice the customer for the work completed, which typically occurs over time on a monthly basis for the work performed during that month. All revenue recognized in the income statement is considered to be revenue from contracts with customers. Cash and cash equivalents **.** Cash **and cash** equivalents ~~are~~ **include cash on hand, snd cash on deposit in money market accounts. The Company considers** short- term ~~,~~ highly liquid investments ~~that have a~~ **with an original** maturity **date** of three months or less **that are not part of an investment pool to be cash equivalents. As of January 31, 2025, the Company had $ 3, 804, 000 that exceeded federally insured cash balance limits** . Accounts receivableTrade accounts receivables are recorded at the net invoice value and are not interest bearing. The Company maintains allowances for doubtful accounts for estimated losses from the inability of its customers to make the required payments. The Company determines its allowances by both specific identification of customer accounts where appropriate and the application of historical loss to non- applicable accounts. For the years ended January 31, **2025, and** 2024 ~~, and 2023~~ , the Company recorded bad debt expenses of $ ~~118~~ **1** , ~~364~~ **200** and $ ~~- 0-~~ **11, 836** , respectively, for doubtful accounts related to accounts receivable. During the year ended January 31, 2024, the Company entered into an accounts receivable sale agreement for one of its subsidiaries. The Company received $ 106, 528 in funds against an account receivable that is currently a claim in bankruptcy. The net accounts receivable remain on the books of the Company and a corresponding amount has been included as a secured borrowing liability under Notes payable. As of January 31, ~~2024~~ **2025** , the receivable has been reserved in full. If the bankruptcy claim is not paid in full by the debtor, ~~the~~ Company is obligated to pay any difference to the factor. The loan bears interest at 10 %. The Company adopted ASU 2016- 13 during ~~2023~~ **2013** and implemented the guidance on expected credit losses. Inventories Inventories are valued at the lower of cost and reasonable value determined using the first- in, first- out (FIFO) method. Net realized value is the estimated selling price in the ordinary course of business, less applicable variable selling expenses. The cost of finished goods and work in process is comprised of material costs, direct labor costs and other direct costs and related production overheads (based on normal operating capacity). As of January 31, **2025, total inventory was $ 212, 041, consisting of work- in- process of $ 46, 255, finished goods of $ 16, 609 and raw materials of $ 149, 177. As of January 31,** 2024, total inventory was $ 168, 605, consisting of work- in- process of $ 7, 466, finished goods of $ 8, 707 and raw materials of $ 152, **432** ~~717. As of January 31, 2023, total inventory was $ 229, 335, consisting of work- in- process of $ 11, 021 and raw materials of $ 218, 334~~ . Property, Plant and Equipment Property and equipment represent an important component of the Company' s assets. The Company depreciates its plant and equipment on a straight- line basis over the estimated useful life of the assets. Property, plant and equipment is stated at historical cost. Expenditures for minor repairs, maintenance and replacement parts which do not increase the useful lives of the assets are charged to expense as incurred. All major additions and improvements are capitalized. Depreciation is computed using the straight- line method. The lives over which the fixed assets are depreciated range from 3 to 20 years as follows: Lab Equipment

5- 10 years Furniture and fixtures 3 **- 5** years Machinery and equipment ~~10~~ **5** - 20 years Intangible Assets Intangible assets include trademarks, intellectual property and customer base acquired through business combinations. The Company accounts for Other Intangible Assets under the guidance of ASC 350, " Intangibles- Goodwill and Other. " The Company capitalizes certain costs related to patent technology. A substantial component of the purchase price related to the Company' s acquisitions ~~have~~ **has** also been assigned to intellectual property and other intangibles. Under the guidance, other intangible assets with definite lives are amortized over their estimated useful lives. Intangible assets with indefinite lives are tested annually for impairment. Trademarks, intellectual property and customer base are being amortized over their estimated useful lives of ten years. **During the year ending January 31, 2025, the Company recorded an impairment charge of $ 293, 038 to its Intellectual property.** Goodwill represents the difference between the total purchase price and the fair value of assets (tangible and intangible) and liabilities at the date of acquisition. Goodwill is reviewed for impairment annually on January 31, and more frequently as circumstances warrant, and written down only in the period in which the recorded value of such assets exceeds their fair value. The Company does not amortize goodwill in accordance with ASC 350. In connection with the Company' s acquisition of 4P Therapeutics LLC in 2018, the Company recorded Goodwill of $ 1, 719, 235. On August 31, 2020, in connection with the Company' s acquisition of Pocono Coated Products LLC and Active Intelligence LLC, the Company recorded Goodwill of $ 5, 810, 640. During the years ~~ended~~ **ending** January 31, **2025 and** 2024 ~~, and 2023~~, the Company recorded an impairment charge of $ ~~- 0-~~ **3, 302, 478** and $ ~~327, 326~~ **- 0-**, respectively, reducing the Active Intelligence LLC Goodwill to $ **- 0-** ~~3, 302, 478~~. As of January 31, **2025, and** 2024 ~~, and 2023~~, Goodwill amounted to $ ~~5~~ **1**, ~~021~~ **719**, ~~713~~ **535** and $ 5, 021, 713, respectively. Long- lived Assets Management reviews long- lived assets for potential impairment whenever significant events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An impairment exists when the carrying amount of the long- lived asset is not recoverable and exceeds its fair value. The carrying amount of a long- lived asset is not recoverable if it exceeds the sum of the estimated undiscounted cash flows expected to result from the use and eventual disposition of the asset. If an impairment exists, the resulting write- down would be the difference between the fair market value of the long- lived asset and the related book value. Earnings per Share Basic earnings per share of common stock is computed by dividing net earnings by the weighted average number of shares of common stock outstanding during the period. Diluted earnings per share is computed by dividing net earnings by the weighted average number of shares of common stock and potential shares of common stock outstanding during the period. Potential shares of common stock consist of shares issuable upon the exercise of outstanding options and common stock purchase warrants. As of January 31, **2025, and** 2024 ~~, and 2023~~, there were **6, 920, 641 and** 2, 157, 873 ~~and 1, 778, 006~~ common stock equivalents outstanding, that were not included in the calculation of dilutive earnings per share as their effect would be anti- dilutive. Stock- Based Compensation ASC 718, " Compensation- Stock Compensation, " prescribes accounting and reporting standards for all share- based payment transactions in which employee services, and, since February 1, 2019, non- employees, are acquired. Transactions include incurring liabilities, or issuing or offering to issue shares, options and other equity instruments such as employee stock ownership plans and stock appreciation rights. Share- based payments to employees, including grants of employee stock options, are recognized as compensation expense in the financial statements based on their fair values. That expense is recognized over the period during which an employee is required to provide services in exchange for the award, known as the requisite service period (usually the vesting period). As of February 1, 2019, pursuant to ASC 2018- 07, ASC 718 was applied to stock- based compensation for both employees and non- employees. Business Combinations The Company recognizes the assets acquired, the liabilities assumed, and any non- controlling interest in the acquired entity at the acquisition date, measured at their fair values as of that date, with limited exceptions specified in the accounting literature. In accordance with this guidance, acquisition- related costs, including restructuring costs, must be recognized separately from the acquisition and will generally be expensed as incurred. ~~That replaces the cost- allocation process detailed in previous accounting literature, which required the cost of an acquisition to be allocated to the individual assets acquired and liabilities assumed based on their estimated fair value.~~ Leases In February 2016, the FASB issued ASU 2016- 02, " Leases " (Topic 842), to provide a new comprehensive model for lease accounting under this guidance, lessees and lessors should apply a " right- of- use " model in accounting for all leases (including subleases) and eliminate the concept of operating leases and off- balance- sheet leases. Recognition, measurement and presentation of expenses will depend on classification as a finance or operating lease. Similar modifications have been made to lessor accounting in- line with revenue recognition guidance. The Company applies ~~the~~ guidance for right- of- use accounting for all leases and records the operating lease liabilities on its balance sheet. The Company completed the necessary changes to its accounting policies, processes, disclosure and internal control over financial reporting. Research and Development Expenses Research and development costs are expensed as incurred. Income Taxes Taxes are calculated in accordance with taxation principles currently effective in the United States and Ireland. The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. The Company records net deferred tax assets to the extent they believe these assets will more ~~-~~likely ~~-~~than ~~-~~not be realized. In making such **a** determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax planning strategies and recent financial operations. In the event the Company was ~~to determine~~ **determined** that it would be able to realize its deferred income tax assets in the future in excess of its net recorded amount, the Company would make an adjustment to the valuation allowance which would reduce the provision for income taxes. ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK We are a smaller reporting company as defined by Rule 12b- 2 of the Securities Exchange Act of 1934 and are not required to provide the information under this item. ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA NUTRIBAND INC. Index to Consolidated Financial Statements Report of Independent Registered Public Accounting Firm (PCAOB ID: 3627) F- 2 Consolidated Balance Sheet as of January 31, **2025 and** 2024 ~~and 2023~~ F- ~~3~~ **4** Consolidated Statements of Operations for the years ended January 31, **2025 and** 2024 ~~and 2023~~ F- ~~4~~ **5** Consolidated Statements of Changes in Stockholder' s Equity for the years ended January 31, **2025 and** 2024 ~~and 2023~~ F- ~~5~~ **6** Consolidated Statements of Cash Flows for the years ended January 31, **2025 and** 2024 ~~and 2023~~ F- ~~6~~ **7** Notes to Consolidated Financial Statements F- ~~7~~ **8** F- 1 REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM To the Board of Directors and Shareholders of Nutriband Inc.: Opinion on the Financial Statements We have audited the accompanying consolidated balance sheets of Nutriband Inc. **and subsidiaries** (" the Company ") as of January 31, **2025 and** 2024 ~~and 2023~~, the related consolidated statements of operations, stockholders' equity, and cash flows for each of the years in the two- year period ended January 31, ~~2024~~ **2025** and the related notes (collectively referred to as the " financial statements "). In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of the Company as of January 31, **2025 and** 2024 ~~and 2023~~, and the results of its operations and its cash flows for each of the years in the two- year period ended January 31, ~~2024~~ **2025**, in conformity with accounting principles generally accepted in the United States of America. Basis for Opinion These financial statements are the responsibility of the Company' s management. Our responsibility is to express an opinion on the Company' s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (" PCAOB ") and are required to be independent with respect to the Company in accordance with the U. S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company' s internal control over financial reporting. Accordingly, we express no such opinion. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion. Critical Audit Matters The critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) related to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgements. The communication of critical audit matters does not alter in any way our opinion on the financial statements ~~,~~ taken as a whole, and we are not, by communicating the critical matter below, providing separate opinions on the critical audit matter or on the accounts or disclosures to which they relate. **Goodwill** ~~Long- Lived Asset~~ Impairment Assessment Critical Audit Matter Description As described in note 2 to the consolidated financial statements, the Company ~~performs~~ **tests goodwill for** impairment ~~testing~~ **annually at the reporting unit level,** ~~for~~ **or more frequently if** ~~its long- lived assets when~~ events or ~~changes in~~ circumstances indicate **it is more likely than not** that **the fair value of a reporting unit is less than** its carrying amount ~~may not be recoverable and~~ **. Reporting units are tested for impairment by comparing the estimated fair value of each reporting unit with its carrying amount. If the carrying amount of a reporting unit** exceeds its **estimated** fair value ~~. Due~~ **, an impairment loss is recorded based on the difference between the fair value and carrying amount, not** to **exceed** ~~challenging industry and~~

~~economic conditions,~~ the **associated carrying amount of goodwill. The** Company ~~tested its long~~ **utilized a third** ~~- lived assets during~~ **party valuation specialist to assist in** the ~~year ended January 31, 2024~~ **preparation of the impairment assessment related to the Active Intelligence reporting unit which had a goodwill balance of approximately $ 3. 3 million prior to the impairment assessment** . The Company' s **annual impairment test occurred on January 31, 2025 and resulted in full impairment of this goodwill balance associated with the Active Intelligence reporting unit. We identified the** evaluation of the **impairment** ~~recoverability of these long- lived asset groups involved comparing the undiscounted future cash flows expected to be generated by these long- lived asset groups to their respective carrying amounts. The Company' s recoverability~~ analysis **for goodwill** ~~requires management to make significant estimates and assumptions~~ related to ~~cash flows over the remaining useful life of these~~ -- **the Active Intelligence reporting unit** ~~long- lived asset groups. We identified the evaluation of the recoverability analysis for the long- lived assets in the 4P Therapeutics asset group~~ as a critical audit matter because of the significant estimates and assumptions management **or the third- party valuation specialist** used in the ~~related~~ **discounted** cash flow analysis **and the valuation of the reporting unit for determining the fair value of the reporting unit** . Performing audit procedures to evaluate the reasonableness of these estimates and assumptions required a high degree of auditor judgment and an increased extent of effort. **In addition, the audit effort involved the use of professionals with specialized skill and knowledge.** How the Critical Audit Matter ~~was~~ **Was** Addressed in the Audit Our audit procedures related to the following: ● Testing management' s process for developing the **fair value of the Active Intelligence reporting unit. ● Evaluating whether the valuation technique (** ~~undiscounted~~ -- **discounted** cash flow model **) applied was appropriate** . ● Evaluating the appropriateness of the ~~undiscounted~~ -- **discounted** cash flow ~~models~~ - **model** ~~used~~ **utilized** by ~~management~~ **the Company** . ● Testing the completeness and accuracy of underlying data used in the **fair value estimate** ~~undiscounted cash flow model~~ . ● Evaluating the significant assumptions ~~used~~ **provided** by management ~~, including assumptions~~ related to ~~current~~ **revenues, EBITDA, income taxes, long term growth rate,** and **discount rate** ~~planned costs, future revenues, gross margin and other operating expenses~~ to discern whether they are reasonable considering (i) the current and past performance of the entity ~~;~~ **;** (ii) the consistency with external market and industry data ~~;~~ **;** and (iii) whether these assumptions were consistent with evidence obtained in other areas of the audit. ● Professionals with specialized skill and knowledge were utilized by the Firm to assist in the evaluation of the ~~undiscounted~~ -- **discounted** cash flow model ~~and underlying assumptions~~ . / s / Sadler, Gibb & Associates, LLC We have served as the Company' s auditor since 2016. Draper, UT April ~~30~~ **28** , ~~2024~~ **2025 F- 3** NUTRIBAND INC. AND SUBSIDIARIES ~~CONDENSED~~ CONSOLIDATED BALANCE SHEETS January 31, **ASSETS 2025** 2024 ~~2023 ASSETS~~ CURRENT ASSETS: Cash and cash equivalents $ **4, 311, 719 $** 492, 942 ~~$ 1, 985, 440~~ Accounts receivable **- net 73, 847** 148, 649 ~~113, 045~~ Inventory **212, 041** 168, 605 ~~229, 335~~ Prepaid expenses **196, 658** 211, 667 ~~365, 925~~ Total Current Assets **4, 794, 265** 1, 021, 863 ~~2, 693, 745~~ PROPERTY & EQUIPMENT- net **695, 063** 774, 924 ~~897, 735~~ OTHER ASSETS: Goodwill ~~5~~ **1** , ~~021~~ **719** , ~~713~~ **535** 5, 021, 713 Operating lease right of use asset **-** 31, 374 ~~62, 754~~ Intangible assets- net **261, 092** 667, 280 ~~780, 430~~ TOTAL ASSETS $ 7, **469, 955 $ 7,** 517, 154 ~~$ 9, 456, 377~~ LIABILITIES AND STOCKHOLDERS' EQUITY CURRENT LIABILITIES: Accounts payable and accrued expenses $ **698, 821 $** 680, 132 ~~$ 534, 679~~ Deferred revenue **155, 880** 157, 502 ~~162, 903~~ Operating lease liability- current portion **-** 34, 276 ~~31, 291~~ Notes payable- current portion **128, 144** 127, 183 ~~19, 740~~ Total Current Liabilities **982, 845** 999, 093 ~~748, 613~~ LONG- TERM LIABILITIES: Note payable- net of current portion **58, 205** 79, 826 ~~100, 497 Note payable- related party-- Operating lease liability- net of current portion- 34, 277~~ Total Liabilities 1, **041, 050 1,** 078, 919 ~~883, 387~~ Commitments and Contingencies-- STOCKHOLDERS' EQUITY: Preferred stock, $. 001 par value, 10, 000, 000 shares authorized,- 0- outstanding-- Common stock, $. 001 par value, 291, 666, 666 shares authorized; **11, 107, 210 and** 8, 869, 870 ~~and 7, 843, 150~~ shares issued at January 31, **2025 and** 2024 **, respectively, 11, 074, 810** and ~~2023, respectively,~~ 8, 859, 870 ~~and 7, 833, 150~~ shares outstanding as of January 31, **2025 and** 2024 ~~and 2023~~ , respectively **11, 075** 8, 860 ~~7, 833~~ Additional paid- in- capital **45, 029, 317** 34, 442, 339 ~~31, 092, 807~~ Accumulated other comprehensive loss (304) (304) Treasury stock, ~~10~~ **32** , ~~000~~ **400** and 10, 000 shares at cost, **as of January 31, 2025 and 2024,** respectively ( ~~32~~ **148** , ~~641~~ **547** ) (32, 641) Accumulated deficit ( **38, 462, 636) (** 27, 980, 019 ~~) (22, 494, 705~~ ) Total Stockholders' Equity 6, **428, 905 6,** 438, 235 ~~8, 572, 990~~ TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $ 7, **469, 955 $ 7,** 517, 154 ~~$ 9, 456, 377~~ See **accompanying** notes to **the** consolidated financial statements **NUTRIBAND INC. AND SUBSIDIARIES** CONSOLIDATED STATEMENTS OF OPERATIONS For the Years Ended January 31, **2025** 2024 ~~2023~~ Revenue $ 2, ~~085~~ **139** , ~~314~~ **537** $ 2, ~~079~~ **085** , ~~609~~ **314** Costs and expenses: Cost of revenues 1, **396, 220 1,** 223, 209 ~~1, 329, 200~~ Research and development **3, 119, 134** 1, 960, 425 ~~982, 227~~ Goodwill **and intangibles** impairment **3** ~~- 327~~ , ~~326~~ **595, 216-** Selling, general and administrative **4, 313, 810** 3, 773, 606 ~~3, 916, 041~~ Total Costs and Expenses **12, 424, 380** 6, 957, 240 ~~6, 554, 794~~ Loss from operations ( **10, 284, 843) (** 4, 871, 926 ~~) (4, 475, 185~~ ) Other income (expense): Interest income **191, 669** 16, 850 **–** Loss on extinguishment of debt ( **368, 036) (** 554, 423) **–** Interest expense ( **21, 407) (** 75, 815 ~~) (8, 289~~ ) Total other income (expense) ( **197, 774) (** 613, 388 ~~) (8, 289~~ ) Loss before provision for income taxes ( **10, 482, 617) (** 5, 485, 314 ~~) (4, 483, 474~~ ) Provision for income taxes-- Net loss $ ( **10, 482, 617) $ (** 5, 485, 314 ~~) $ (4, 483, 474~~ ) Net loss per share of common stock- basic and diluted $ (0. **99) $ (0.** 69 ~~) $ (0. 53~~ ) Weighted average **of common** shares ~~of common stock~~ outstanding- basic and diluted **10, 607, 477** 7, 954, 105 ~~8, 459, 547~~ CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY **Year Ended January 31, 2025** Accumulated Common Stock Additional Other **Total** Number of **shares Amount** Paid In **Capital** Comprehensive **Income (Loss)** Accumulated **Deficit** Treasury **Stock Balance, February 1, 2024 $ 6, 438, 235 8, 859, 870 $ 8, 860 $ 34, 442, 339 $ (304) $ (27, 980, 019) $ (32, 641) Proceeds from sale of common stock and warrants 8, 400, 000 2, 100, 000 2, 100 8, 397, 900. 00 Issuance of common stock and warrants for note payable 672, 958 76, 230 76. 00 672, 882. 00 Treasury stock and warrants issued for services 133, 350 10, 000 10 100, 699 32, 641 Options issued for services 1, 408, 935-- 1, 408, 935--- Purchase of treasury stock (148, 547) (32, 400) (32) 32 (148, 547) Exercise of warrants 6, 591 61, 110 61 6, 530 Net loss (10, 482, 617)---- (10, 482, 617)- Balance, January 31, 2025 $ 6, 428, 905 11, 074, 810 $ 11, 075 $ 45, 029, 317 $ (304) $ (38, 462, 636) $ (148, 547)** Year Ended January 31, 2024 **Accumulated Common Stock Additional Other** Total **Number of** shares Amount **Paid In** Capital **Comprehensive** Income (Loss) **Accumulated** Deficit **Treasury** Stock Balance, February 1, 2023 $ 8, 572, 990 7, 833, 150 $ 7, 833 $ 31, 092, 807 $ (304) $ (22, 494, 705) $ (32, 641) Warrants issued for services 242, 840 **- 0** 242, 840 **---** Options issued for services 499, 856- **–0** 499, 856--- Issuance of common stock for note payable and interest 2, 607, 863 1, 026, 720 1, 027 2, 606, 836 **---** Net loss ~~for the year ended January 31, 2024~~ (5, 485, 314)---- (5, 485, 314)- Balance, January 31, 2024 $ 6, 438, 235 8, 859, 870 $ 8, 860 $ 34, 442, 339 $ (304) $ (27, 980, 019) $ (32, 641) ~~Accumulated Common Stock Additional~~ **See accompanying notes to** ~~Other~~ -- **the consolidated financial** ~~Number of Paid In Comprehensive Accumulated Treasury Year Ended January 31, 2023 Total shares Amount Capital Income (Loss) Deficit Stock Balance, February 1, 2022 $ 11, 859, 285 9, 154, 846 $ 9, 155 $ 29, 966, 132 $ (304) $ (18, 011, 231) $ (104, 467) Exercise of warrants 296, 875 55, 417 56 296, 819--- Common stock returned in settlement~~ -- **statements** ~~- (1, 400, 000) (1, 400) 1, 400--- Treasury stock issued for services 113, 155 33, 471 32 3, 746-- 109, 377 Treasury stock and warrants issued for termination agreement 174, 025 25, 000 25 92, 545 81, 455 Treasury stock repurchased (119, 006) (35, 584) (35) 35-- (119, 006) Options issued for services 732, 130 732, 130 Net loss for the year ended January 31, 2023 (4, 483, 474)---- (4, 483, 474)- Balance, January 31, 2023 $ 8, 572, 990 7, 833, 150 $ 7, 833 $ 31, 092, 807 $ (304) $ (22, 494, 705) $ (32, 641)~~ CONSOLIDATED STATEMENTS OF CASH FLOWS For the Years Ended January 31, **2025** 2024 ~~2023~~ Cash flows from operating activities: Net loss $ ( **10, 482, 617) $ (** 5, 485, 314 ~~) $ (4, 483, 474~~ ) Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization **285, 054** 287, 722 ~~330, 143~~ Operating lease expense 31, **374 31,** 380 ~~38, 813~~ Loss on extinguishment of debt **368, 036** 554, 423 **–** Reserve for doubtful accounts **-** 118, 365 **Goodwill** ~~- Treasury stock issued for services- 113, 155 Treasury stock~~ and **intangibles** ~~warrants issued for termination agreement- 174, 025 Goodwill~~ impairment **3** ~~- 327~~ , ~~326~~ **595, 216-** Stock- based compensation- warrants **133, 350** 242, 840 **–** Stock- based compensation- options **1, 408, 935** 499, 856 ~~732, 130~~ Changes in operating assets and liabilities: Accounts receivable **74, 802** (153, 969 ~~) (41, 665~~ ) Prepaid expenses **15, 009** 154, 258 ~~4, 547~~ Inventories **(43, 436)** 60, 730 ~~(97, 687)~~ Deferred revenue ( **1, 622) (** 5, 401) ~~56, 636~~ Operating lease liability ( **34, 276) (** 31, 292 ~~) (36, 287~~ ) Accounts payable and accrued expenses **23, 611** 198, 893 ~~(104, 860)~~ Net Cash Used In Operating Activities ( **4, 626, 564) (** 3, 527, 509 ~~) (2, 987, 198~~ ) Cash flows from investing activities: Purchase of equipment ( **92, 043) (** 51, 761 ~~) (79, 304~~ ) Net Cash Used in Investing Activities ( **92, 043) (** 51, 761 ~~) (79, 304~~ ) Cash flows from financing activities: Proceeds from note payable- related party **300, 000** 2, 000, 000 **–** Proceeds from secured borrowing liability **-** 106, 528 **–** Proceeds from **sale of common stock and** exercise of warrants **8** ~~- 296~~ , ~~875~~ **406, 591-** Payment on note payable ( **20, 660) (** 19, 756 ~~) (17, 795~~ ) Purchase of treasury stock **–** ( ~~119~~ **148** , ~~006~~ **547** ) **-** Net Cash Provided by Financing Activities **8, 537, 384** 2, 086, 772 ~~160, 074~~ Net change in cash **3, 818, 777** (1, 492, 498 ~~) (2, 906, 428~~ ) Cash and cash equivalents- Beginning of period **492, 942** 1, 985, 440 ~~4, 891, 868~~ Cash and cash equivalents- End of period $ **4, 311, 719 $** 492, 942 ~~$ 1, 985, 440~~ Supplementary information: Cash paid for: Interest $ **5, 631 $** 7, 352 ~~$ 4, 266~~ Income taxes $- $- Supplemental disclosure of non- cash investing and financing activities: ~~Adoption~~ **Cashless conversion** of ~~ASC 842 Operating lease asset~~ **warrant $ 60 $- Debt settlement issued by the issuance of common stock** and ~~liability~~ **warrants** $ **~~-~~ 672, 958** $ ~~94, 134 Promissory note on equipment purchase $- $ 22, 794 Common stock returned in settlement $- $ 1, 400~~ Issuance of common stock for extinguishment of debt $ **- $** 2, 607, 863 **$-** as of and for the Years ~~Ended~~ **Ending** January 31, ~~2024~~ **2025** and ~~20231~~ **20241** . ORGANIZATION AND DESCRIPTION OF **BUSINESS** ~~BUSINESSOrganization -------~~ **Organization** Nutriband Inc. (the " Company ") is a Nevada corporation, incorporated on January 4, 2016. In January 2016, the Company acquired Nutriband Ltd, an Irish company which was formed by the Company' s chief executive officer in 2012 to enter the health and wellness market by marketing transdermal patches. References to the Company relate to the Company and its subsidiaries unless the context indicates otherwise. On August 1, 2018, the Company acquired 4P Therapeutics LLC (" 4P Therapeutics ") for $ 2, 250, 000, consisting of 250, 000 shares of common stock, valued at $ 1, 850, 000, and $ 400, 000, and a royalty of

6 % on all revenue generated by the Company from the abuse deterrent intellectual property that had been developed by 4P Therapeutics payable to the former owner of 4P Therapeutics. The former owner of 4P Therapeutics **was** ~~has been~~ a director of the Company ~~since~~ **from** April 2018, when the Company entered into an agreement to acquire 4P Therapeutics ~~,~~ **until** ~~The~~ **he** ~~former owner~~ resigned as a director in January 2022. 4P Therapeutics is engaged in the development of ~~a series of~~ transdermal pharmaceutical products ~~, that are in the preclinical stage of development. Prior to the acquisition of 4P Therapeutics, the Company' s business was the development and marketing of a range of transdermal consumer patches. Most of these products are considered drugs in the United States and cannot be marketed in the United States without approval by the Food and Drug Administration (the " FDA "). The Company entered a feasibility agreement as an initial step to seek FDA approval of its consumer transdermal products and its consumer products which are not being marketed in the United States~~ . With the acquisition of 4P Therapeutics, 4P Therapeutics' drug development business became the Company' s principal business. The **primary focus of the business is to incorporate the** Company' s **Aversa** ~~approach is to use~~ **abuse** ~~generic~~ **deterrent technology into transdermal patches containing already approved** drugs ~~that are off patent and incorporate them into the Company' s transdermal drug delivery system~~ . Although these **drugs are already** ~~medications have received FDA approval~~ **approved** ~~in oral or injectable form~~ , the Company needs to conduct a ~~transdermal~~ product development program which will include the preclinical and clinical trials that are necessary to receive FDA approval before we can market any of our pharmaceutical products. On August 25, 2020, the Company formed Pocono Pharmaceuticals Inc. (" Pocono Pharmaceuticals "), a wholly owned subsidiary of the Company. On August 31, 2020, the Company acquired certain assets and liabilities associated with the Transdermal, Topical, Cosmetic, and Nutraceutical ~~business~~ **businesses** of Pocono Coated Products LLC (" PCP "). The net assets were contributed to Pocono Pharmaceuticals. Included in the transaction, Pocono Pharmaceuticals also acquired 100 % of the membership interests of Active Intelligence LLC (" Active Intelligence "). Pocono Pharmaceuticals is a **coated products** contract development and manufacturing organization **that supports** ~~with unique process capabilities and experience focused on coated product manufacturing. Pocono helps~~ their customers with product design **, development** and ~~development along with~~ manufacturing **services** ~~to bring new products to market with minimal capital investment~~ . Pocono ~~Pharmaceutical~~ **Pharmaceuticals has specialized expertise** ~~' s competitive edge is a low- cost manufacturing base: a result of its unique processes~~ and state- of- the- art ~~material technology~~ **manufacturing capabilities for topical, transdermal and kinesiology tape products** . Active Intelligence manufactures activated kinesiology tape for ~~transdermal or topical use~~ **customers in the sports and physical markets** . 2. SUMMARY OF SIGNIFICANT ACCOUNTING **POLICIESGoing** ~~POLICIESForward Stock Split On July 26, 2022, our Board of Directors approved the amendment to our Articles of Incorporation to effect a 7- for- 6 forward stock split (the " Stock Split ") of our outstanding common stock. The Company filed the amendment set forth in a Certificate of Change with the Secretary of State of Nevada on August 4, 2022. The 7: 6 forward stock split was effective for trading purposes on the Nasdaq Capital Market on August 12, 2022. Each shareholder of record as of the August 15, 2022 record date received one (1) additional share for each six (6) shares held as of the record date. No fractional shares of common stock were issued in connection with the Stock Split. Instead, all shares were rounded up to the next whole share. In connection with the Stock Split, which did not require shareholder approval under the Nevada corporation law, the number of shares of common stock of the Company was increased in the same ratio as the shares of outstanding common stock were increased in the Stock Split, from 250, 000, 000 authorized shares to 291, 666, 666 authorized shares. All share and per share information in these financial statements retroactively reflect the forward stock split. Going~~ Concern Assessment Management assesses liquidity and going concern uncertainty in the Company' s condensed financial statements to determine whether there is sufficient cash on hand and working capital, including available borrowings on loans, to operate for a period of at least one year from the date the consolidated financial statements are issued or available to be issued, which is referred to as the " look- forward period ", as defined in GAAP. As part of this assessment, based on conditions that are known and reasonably knowable to management, management will consider various scenarios, forecasts, projections, estimates and will make certain key assumptions, including timing and nature of projected cash expenditures or programs, its ability to delay or curtail expenditures or programs and its ability to raise additional capital, if necessary, among other factors. Based on this assessment, as necessary or applicable, management makes certain assumptions around implementing curtailments or delays in the nature and timing of programs and expenditures to the extent it deems probable those implementations can be achieved **,** and management has the proper authority to execute them within the look- forward period ~~. As of January 31, 2024, the Company had cash and cash equivalents of $ 492, 942 and working capital of $ 22, 770. For the year ended January 31, 2024, the Company incurred a loss from operations of $ 4, 871, 926 and used cash flow from operations of $ 3, 527, 509. The Company has generated operating losses since its inception and has relied on sales of securities and issuance of third- party and related- party debt to support cash flow from operations. In October 2021, the Company consummated a public offering and received net proceeds of $ 5, 836, 230. The Company has also received to date $ 3, 239, 845 in proceeds from the exercise of warrants. The Company has used these proceeds to fund operations and will continue to use the funds as needed. In March 2023, the Company entered into a three- year $ 2, 000, 000 Credit Line Note facility with a related party, amended on July 13, 2023, to $ 5, 000, 000, which will permit the Company to draw down on the credit line to fund the Company' s research and development of its Aversa product. The Company was advanced $ 2, 000, 000, all of which was settled by the issuance of common stock during the year ended January 31, 2024. The $ 2, 000, 000 debt and accrued interest was converted into 1, 026, 720 shares of the Company' s common stock. On April 19, 2024, the Company received proceeds of $ 8, 400, 000 from a private placement of its common stock~~ . Management has prepared estimates of operations for the next twelve months and believes that sufficient funds will be generated from operations to fund its operations for one year from the date of the filing of these condensed consolidated financial statements, which indicates improved operations and the Company' s ability to continue operations as a going concern. Management believes the substantial doubt about the ability of the Company to continue as a going concern is alleviated by the above assessment. F- ~~8~~ **9** Principles of Consolidation The consolidated financial statements of the Company include the Company and its wholly owned subsidiaries. All material intercompany balances and transactions have been eliminated. The operations of 4P Therapeutics are included in the Company' s financial statements from the date of acquisition of August 1, 2018, and the **acquired** operations of Pocono **Coated Products** and Active Intelligence are included in the Company' s financial statements from the date of acquisition of September 1, 2020 **,** under Pocono Pharmaceuticals Inc. The wholly owned subsidiaries are as follows: ~~Nutriband Ltd. 4P Therapeutics LLC Pocono Pharmaceuticals Inc.~~ Use of Estimates The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires the Company to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an ongoing basis, the Company evaluates its estimates including, but not limited to, those related to such items as income tax exposures, accruals, depreciable / useful lives, allowance for doubtful accounts and valuation allowances. The Company bases its estimates on historical experience and on other various assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates. Revenue Recognition In May 2014, the FASB issued ASU No. 2014- 09, " Revenue from Contracts with Customers (Topic 606) (" ASU 2014- 09 "), which amends the accounting standards for revenue recognition. ASU 2014- 09 is based on principles that govern the recognition of revenue at an amount an entity expects to be entitled when products are transferred to a customer. The Company recognizes revenue based on the five criteria for revenue recognition established under Topic 606: 1) identify the contract, 2) identify separate performance obligations, 3) determine the transaction price, 4) allocate the transaction price among the performance obligations, and 5) recognize revenue as the performance obligations are satisfied. Revenue Types The following is a description of the Company' s revenue types, which include professional services and sale of goods: ~~A ● contract~~ **Contract research and development services for pharmaceutical and medical device life sciences customers** with **revenues listed under** ~~a customer exists when (i) we enter into an enforceable contract with a customer that defines each party' s rights regarding the goods or~~ services ~~to be transferred and identifies the payment terms related to these goods or services, (ii) the contract has commercial substance and, (iii) we determine that collection of substantially all consideration for services that are transferred is probable based on the customer' s intent and ability to pay the promised consideration. Deferred revenue is a liability related to a revenue producing activity for which revenue has not been recognized. The Company records deferred revenue when it receives consideration from a contract before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP~~ . F- **10** 9 A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in the new revenue standard. The contract transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. For the Company' s different revenue service types, the performance obligation is satisfied at different times. The Company' s performance obligations include providing products and professional services in the area of research. The Company recognizes product revenue performance obligations in most cases when the product has shipped to the customer. When we perform professional service work, we recognize revenue when we have the right to invoice the customer for the work completed, which typically occurs over time on a monthly basis for the work performed during that month. All revenue recognized in the income statement is considered to be revenue from contracts with customers. ~~Disaggregation of Revenues The Company disaggregates its revenue from contracts with customers by type and by geographical location. See the tables: Years Ended~~ **Ending** January 31, **2025** 2024 ~~2023~~ Revenue by type Sale of goods $ ~~1~~ **2** , ~~920~~ **139** , ~~280~~ **537** $ 1, ~~785~~ **920** , ~~507~~ **280** Services ~~-~~ 165, 034 ~~294, 102~~ Total $ 2, ~~085~~ **139** , ~~314~~ **537** $ 2, ~~079~~ **085** , ~~609~~ **314** Years ~~Ended~~ **Ending** January 31, **2025** 2024 ~~2023~~ Revenue by geographic location: United States $ 2, ~~085~~ **139** , ~~314~~ **537** $ 2, ~~079~~ **085** , ~~609~~ **314** Foreign-- $ 2, ~~085~~ **139** , ~~314~~ **537** $ 2, ~~079~~ **085** , **314** ~~609 Cash and cash equivalents.~~ Cash and

cash equivalents include cash on hand ~~,~~ **and** cash on deposit in money market accounts. The Company considers short- term highly liquid investments with an original maturity date of three months or less that are not part of an investment pool to be cash equivalents. As of January 31, ~~2024~~ **2025** , the Company ~~has no balances~~ **had $ 3, 804, 000** that ~~exceed~~ **exceeded** federally insured **cash balance** limits. **F- 11** Accounts receivable Trade accounts receivables are recorded at the net invoice value and are not interest bearing. The Company maintains allowances for doubtful accounts for estimated losses from the inability of its customers to make the required payments. The Company determines its allowances by both ~~the~~ specific identification of customer accounts where appropriate and the application of historical loss to non- applicable accounts. For the years ended January 31, **2025, and** 2024 ~~, and 2023~~ , the Company recorded bad debt expenses of $ ~~118~~ **1** , ~~364~~ **200** and $ ~~- 0-~~ **11, 836** , respectively, for doubtful accounts related to accounts receivable. During the year ended January 31, 2024, the Company entered into an accounts receivable sale agreement for one of its subsidiaries. The Company received $ 106, 528 in funds against an account receivable that is currently a claim in bankruptcy. The net accounts receivable remain on the books of the Company and a corresponding amount has been included as a secured borrowing liability under Notes payable. As of January 31, ~~2024~~ **2025** , the receivable has been reserved in full. If the bankruptcy claim is not paid in full by the debtor, Company is obligated to pay any difference to the factor. The loan bears interest at 10 %. The Company adopted ASU 2016- 13 during ~~2023~~ **2013** and implemented the guidance on expected credit losses. ~~F- 10~~ Inventories are valued at the lower of cost and reasonable value determined using the first- in, first- out (FIFO) method. Net realized value is the estimated selling price in the ordinary course of business, less applicable variable selling expenses. The cost of finished goods and work in process is comprised of material costs, direct labor costs and other direct costs and related production overheads (based on normal operating capacity). As of January 31, **2025, total inventory was $ 212, 041, consisting of work- in- process of $ 46, 255, finished goods of $ 16, 609 and raw materials of $ 149, 177. As of January 31,** 2024, total inventory was $ 168, 605, consisting of work- in- process of $ 7, 466, finished goods of $ 8, 707 and raw materials of $ ~~134~~ **152** , **432** ~~691. As of January 31, 2023, total inventory was $ 229, 335, consisting of work- in- process of $ 11, 021 and raw materials of $ 218, 334~~ . Property, Plant and Equipment Property and equipment represent an important component of the Company' s assets. The Company depreciates its plant and equipment on a straight- line basis over the estimated useful life of the assets. Property, plant and equipment is stated at historical cost. Expenditures for minor repairs, maintenance and replacement parts which do not increase the useful lives of the assets are charged to expense as incurred. All major additions and improvements are capitalized. Depreciation is computed using the straight- line method. The lives over which the fixed assets are depreciated range from 3 to 20 years as follows: Lab Equipment 5- 10 years Furniture and fixtures 3 **- 5** years Machinery and equipment ~~10~~ **5** - 20 ~~years Intangible~~ **yearsIntangible** assets include trademarks, intellectual property and customer base acquired through business combinations. The Company accounts for Other Intangible Assets under the guidance of ASC 350, " Intangibles- Goodwill and Other. " The Company capitalizes certain costs related to patent technology. A substantial component of the purchase price related to the Company' s acquisitions ~~have~~ **has** also been assigned to intellectual property and other intangibles. Under the guidance, other intangible assets with definite lives are amortized over their estimated useful lives. Intangible assets with indefinite lives are tested annually for impairment. Trademarks, ~~intellectual~~ **Intellectual** property and customer base are being amortized over their estimated useful lives of ten years. **During the year ending January 31, 2025, the Company recorded an impairment charge of $ 293, 038 to its Intellectual property. F- 12** Goodwill represents the difference between the total purchase price and the fair value of assets (tangible and intangible) and liabilities at the date of acquisition. Goodwill is reviewed for impairment annually on January 31, and more frequently as circumstances warrant, and written down only in the period in which the recorded value of such assets exceeds their fair value. The Company does not amortize goodwill in accordance with ASC 350. In connection with the Company' s acquisition of 4P Therapeutics LLC in 2018, the Company recorded Goodwill of $ 1, 719, 235. On August 31, 2020, in connection with the Company' s acquisition of Pocono Coated Products LLC and Active Intelligence LLC, the Company recorded Goodwill of $ 5, 810, 640. During the years ~~ended~~ **ending** January 31, **2025 and** 2024 ~~, and 2023~~ , the Company recorded an impairment charge of $ ~~- 0-~~ **3, 302, 478** and $ ~~327, 326~~ **- 0-** , respectively, reducing the Active Intelligence LLC Goodwill to $ **- 0-** ~~3, 302, 478~~ . As of January 31, **2025 and** 2024 ~~, and 2023~~ , Goodwill amounted to $ ~~5~~ **1** , ~~021~~ **719** , ~~713~~ **535** and $ 5, 021, 713, respectively. Long- lived Assets Management reviews long- lived assets for potential impairment whenever significant events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An impairment exists when the carrying amount of the long- lived asset is not recoverable and exceeds its fair value. The carrying amount of a long- lived asset is not recoverable if it exceeds the sum of the estimated undiscounted cash flows expected to result from the use and eventual disposition of the asset. If an impairment exists, the resulting write- down would be the difference between the fair market value of the long- lived asset and the related book value. ~~F- 11~~ Earnings per Share Basic earnings per share of common stock is computed by dividing net earnings by the weighted average number of shares of common stock outstanding during the period. Diluted earnings per share is computed by dividing net earnings by the weighted average number of shares of common stock and potential shares of common stock outstanding during the period. Potential shares of common stock consist of shares issuable upon the exercise of outstanding options and common stock purchase warrants. As of January 31, **2025, and** 2024 ~~, and 2023~~ , there were **6, 920, 641 and** 2, 157, 873 ~~and 1, 778, 006~~ common stock equivalents outstanding, that were not included in the calculation of dilutive earnings per share as their effect would be anti- dilutive. Stock- Based Compensation **F- 13** Business Combinations The Company recognizes the assets acquired, the liabilities assumed, and any non- controlling interest in the acquired entity at the acquisition date, measured at their fair values as of that date, with limited exceptions specified in the accounting literature. In accordance with this guidance, acquisition- related costs, including restructuring costs, must be recognized separately from the acquisition and will generally be expensed as incurred. That replaces the cost- allocation process detailed in previous accounting literature, which required the cost of an acquisition to be allocated to the individual assets acquired and liabilities assumed based on their estimated fair value. The Company applies **the** guidance for right- of- use accounting for all leases and records the operating lease liabilities on its balance sheet. The Company completed the necessary changes to its accounting policies, processes, disclosure and internal control over financial reporting. Research and Development Expenses Research and development costs are expensed as incurred. Income Taxes ~~F- 12~~ The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. The Company records net deferred tax assets to the extent they believe these assets will more ~~-~~likely ~~-~~than ~~-~~not be realized. In making such determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax planning strategies and recent financial operations. In the event the Company was ~~to determine~~ **determined** that it would be able to realize its deferred income tax assets in the future in excess of its net recorded amount, the Company would make an adjustment to the valuation allowance which would reduce the provision for income taxes. **F- 14** Fair Value Measurements FASB ASC 820, " Fair Value Measurements and Disclosure " (" ASC 820 "), defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between participants on the measurement date. ASC 820 also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value. The Company utilizes the accounting guidance for fair value measurements and disclosures for all financial assets and liabilities and nonfinancial assets and liabilities that are recognized or disclosed at fair value in the consolidated financial statements on a recurring basis during the reporting period. The fair value is an exit price, representing the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants based upon the best use of the asset or liability at the measurement date. The Company utilizes market data or assumptions that market participants would use in pricing the asset or liability. ASC 820 establishes a three- tier value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers are defined as follows: Level 1- Observable inputs such as quoted market prices in active markets. Level 2- Inputs other than quoted prices in active markets that are either directly or indirectly observable. Level 3- Unobservable inputs about which little or no market data exists, therefore requiring an entity to develop its own assumptions. The carrying value of the Company' s financial instruments, including accounts receivable, prepaid expenses, accounts payable and accrued expenses, and deferred revenue approximate their fair value due to the short maturities of these financial instruments. Recent Accounting Standards ~~In June 2016, the FASB issued ASU 2016- 13, Financial Instruments- Credit Losses (Topic 326), The ASU introduces a new credit loss methodology. Current Expected Credit Loss (" CECL "), which requires earlier recognition of credit losses, which also provides additional transparency about credit risk. Since its original issuance in 2016, the FASB has issued several updates to the original ASU. The Company adopted ASU 2016- 13 during the year ended January 31, 2024. The adoption of ASU 2016- 13 did not have a material impact on the Company' s balance sheet or statement of operations. F- 13~~ The Company has reviewed all other FASB- issued ASU accounting pronouncements and interpretations thereof that have effective dates during the period reported and in future periods. The Company has carefully considered the new pronouncements that alter previous GAAP and does not believe that any new or modified principles will have a material impact on the Company' s reported financial position or operations in the near term. The applicability of any standard is subject to the formal review of the Company' s financial management and certain standards are under consideration. ~~3~~ **F- 153** . PROPERTY AND EQUIPMENT January 31, **2025** 2024 ~~2023~~ Lab equipment $ 144, 585 $ 144, 585 Machinery and equipment 1, **384, 432 1,** 292, 389 ~~1, 240, 628~~ Furniture and

fixtures 19, 643 19, 643 1, **548, 660 1,** 456, 617 ~~1, 404, 856~~ Less: Accumulated depreciation ( **853, 597) (** 681, 693 ~~) (507, 121~~ ) Net Property and Equipment $ **695, 063 $** 774, 924 ~~$ 897, 735~~ Depreciation expenses amounted to $ ~~174~~ **171** , ~~572~~ **903** and $ ~~183~~ **174** , ~~660~~ **572** for the years ~~ended~~ **ending** January 31, **2025, and** 2024, ~~and 2023,~~ respectively. During the years ~~ended~~ **ending** January 31, **2025, and** 2024 ~~, and 2023~~ , depreciation expenses of $ ~~131~~ **127** , ~~360~~ **888** and $ ~~139~~ **131** , ~~689~~ **360** , respectively, have been allocated to **the** cost of goods sold. 4 . ~~31,2024 Notes Payable [ Abstract ]~~ NOTES **PAYABLENotes** ~~PAYABLE 5.NOTES PAYABLE Notes~~ Payable Active Intelligence,entered into an agreement with the Carolina Small Business Development Fund for a line of credit of $ 160,000 due October 16,2028,with interest of 5 % per year.The amount assumed was $ 139,184.The loan requires monthly payments of principal and interest of $ 1,697.During the year ~~ended~~ **ending** January 31, ~~2024~~ **2025** ,the Company made $ ~~15~~ **16** , ~~378~~ **117** of principal payments.As of January 31, ~~2024~~ **2025** ,the amount due was $ ~~85~~ **69** , ~~249~~ **132** ,of which $ 16, ~~129~~ **953** is current.As of January 31, ~~2023~~ **2024** ,the amount due was $ ~~100~~ **85** , ~~627~~ **249** .On April 3,2022,the Company entered into a retail installment agreement for the purchase of an automobile.The contract price was $ 32,274,of which $ 22,795 was financed.The agreement is for five years bearing interest at 2.95 % per annum with payments of $ 410 per month.The loan is secured by automobile.As of January 31, ~~2024~~ **2025** ,the amount due was $ ~~15~~ **10** , ~~232~~ **689** of which $ 4, ~~456~~ **663** is current.As of January 31, ~~2023~~ **2024** ,the amount due was $ ~~19~~ **15** , ~~610~~ **232** .Note payable- related party.On July 17,2023,the Company entered an amended Credit Line Note agreement,for an increased $ 5,000,000 credit line facility **to** ~~Note,with TII Jet Services LDA,a shareholder of the Company (replacing the $ 2,000,000 facility with the same lender that~~ the Company entered on March 17,2023 ~~).~~ Outstanding advances under the Note bears interest at 7 % per annum.The promissory note is due and payable in full on March 19,2026.Interest is payable annually on December 31 of each year during the term of the note. **The Company received advances of $ 300,000** ~~During~~ **during** the ~~year ended January~~ **nine months ending October** 31,2024 **.On May 15 , 2024,** the Company ~~received~~ **agreed to convert the** $ ~~2~~ **300** ,000 **debt.The conversion was made pursuant to the terms of a Conversion Agreement,which provided the conversion of $ 300** ,000 ~~on the Note.In December 2023,the Company converted the balance~~ of **principal** ~~the credit facility of $ 2,000,000~~ and $ ~~53~~ **4** , ~~476~~ **922** of accrued interest ~~into 1~~ **.The Company issued 76** , **230** ~~026,520~~ shares of common stock **and 152** .~~The fair value of the common stock was $ 2-~~ , ~~554, 460 warrants exercisable at $ 6.~~ ~~423-~~ **43 per share,** resulting in a $ ~~554~~ **368** , ~~423~~ **036** loss on extinguishment.As of January 31, ~~2024~~ **2025** ,the balance due was $- 0-.The Company recorded interest expense of $ **4,163 and $** 60,453 for the ~~year~~ **years** ~~ended~~ **ending** January 31, **2025,and** 2024 **,respectively** . **F- 16** Secured borrowing liability. ~~The~~ **On July 19,2023,the** Company entered into an accounts receivable sale agreement for one of its subsidiaries in connection with a bankruptcy claim.The Company received $ 106,528 and recorded the transaction as a secured loan payable against the account receivable.The sale of the account receivable balance was to an outside third party,whereby if the bankruptcy court does not pay the balance in full,the Company will owe back the unpaid portion.The loan is classified as a current liability as the Company expects the bankruptcy will be resolved in the next twelve months.The loan bears interest at 10 %.For the ~~year~~ **years** ~~ended~~ **ending** January 31, **2025,and** 2024,the Company recorded **an** interest expense of $ **10,482 and $** 5,470 **,respectively** .Interest expenses for the ~~year~~ **years** ~~ended~~ **ending** January 31, **2025,and** 2024, ~~and 2023,~~ were $ **21,407 and $** 75,815 ~~and $ 6,289~~ ,respectively. **5** ~~X- DefinitionThe entire disclosure for information about short~~ . INCOME TAXESThe Company adopted the provisions of ASC 740, " Income Taxes, (" ASC 740 "). As a result of the implementation of ASC 740, the Company recognized no adjustment in the net liability for unrecognized income tax benefits. The Company believes there are no potential uncertain tax positions, and all tax returns are correct as filed. Should the Company recognize a liability for uncertain tax positions, the Company will separately recognize the liability for uncertain tax positions on its balance sheet. Included in any liability or uncertain tax positions, the Company will also ~~set~~ **setup** ~~up~~ a liability for interest and penalties. The Company' s policy is to recognize interest and penalties related to uncertain tax positions as a component of the current **provision for income taxes.** There is no U. S. tax provision due to losses from U. S. operations for the years ~~ended~~ **ending** January 31, **2025 and** 2024 ~~and 2023~~ . Deferred income taxes are provided for the temporary differences between the financial reporting and tax basis of the Company' s assets and liabilities. The principal item giving rise to deferred taxes is the net operating loss carryforward in the U. S. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. The Company has set up a valuation allowance for losses for certain carryforwards that it believes may not be realized. ~~F- 14~~ The provision for income taxes consists of the following: Years ~~Ended~~ **Ending** January 31, **2025** 2024 ~~2023~~ Current Federal $- $- Foreign-- Deferred Federal-- Foreign-- **F- 17** A reconciliation of taxes on income computed at the federal statutory rate to amounts provided is as follows: Years ~~Ended~~ **Ending** January 31, **2025** 2024 ~~2023~~ Book Income (loss from operations) $ ( **2, 201, 350) $ (** 1, 151, 916 ~~) $ (941, 530~~ ) Common stock issued for services **323, 880** 155, 966 ~~168, 768~~ Impairment expense **754** ~~- 68-~~ , ~~738~~ **996-** Unused operating losses **1, 122, 474** 995, 950 ~~704, 024~~ Income tax expense $- $- As of January 31, ~~2024~~ **2025** , the Company recorded a deferred tax asset associated with a net operating loss (" NOL ") carryforward of approximately $ ~~15~~ **21** , ~~800~~ **000** , 000 that was fully offset by a valuation allowance due to the determination that it was more likely than not that the Company would be unable to utilize those benefits in the foreseeable future. The Company' s NOL expires in 2041. The tax effect of the valuation allowance increased by approximately $ ~~1~~ **2** , ~~151~~ **200** , ~~916~~ **000** during the year ~~ended~~ **ending** January 31, ~~2024~~ **2025** . On December 22, 2017, the Tax Cuts and Jobs Act (the " Tax Act ") significantly revised U. S. corporate income tax law by, among other things, reducing the corporate rate from 34 % to 21 %. Because the Company recognizes a valuation allowance for the entire balance, there is no net impact on the Company' s balance sheet or results of operations. ~~F- 15~~ The types of temporary differences between tax basis of assets and liabilities and their financial reporting amounts that give rise to the deferred tax liability and deferred tax asset and their approximate tax effects are as follows: January 31, **2025** 2024 ~~2023~~ Net operating loss carryforward (expire through ~~2040~~ **2041** ) $ ( **4, 435, 172) $ (** 3, 312, 698 ~~) $ (2, 316, 748~~ ) Stock issued for services **$-** (1, **779, 728) (1,** 455, 848 ~~) (1, 299, 882~~ ) Intangible impairment expense **$-** (1, ~~051~~ **806** , ~~714~~ **709** ) (1, 051, 714) Valuation allowance **$ 8, 021, 609** 5, 820, 260 ~~4, 668, 344~~ Net deferred taxes $- $- ~~5~~ **F- 186** , ~~NOTES PAYABLENotes Payable Active Intelligence~~ **INTANGIBLE ASSETSAs of January 31** , ~~entered into 166.INTANGIBLE ASSETS As of January 31,2024~~ **2025** ,and ~~2023~~ **2024** ,intangible assets consisted of intellectual property and trademarks,customer base,and license agreement,net of amortization,as follows:January 31, **2025** 2024 ~~2023~~ Customer base $ ~~314~~ **214** , ~~100~~ **940** $ 314,100 Intellectual property and trademarks ~~817~~ **623** , ~~400~~ **822** 817,400 Total ~~1~~ **838** , **462** ~~131,500~~ 1,131,500 Less:Accumulated amortization ( **577,370) (** 464,220 ~~) (351,070~~ ) Net Intangible Assets $ **261,092 $** 667,280 **Amortization expenses for the years ending January 31,2025,and 2024 amounted to** $ ~~780~~ **113** , ~~430 In February~~ **150 and $ 113,150,respectively.During the year ending January 31,** ~~2021~~ **2025** ,the Company **recorded** ~~acquired an IP license from Rambam Med- Tech Ltd.for $ 50,000.The value of the intangible~~ an **impairment charge** ~~agreement with the Carolina Small Business Development Fund for a line of credit~~ of $ **298, 038 to its Intellectual property. Year Ended January 31, Total 2026 $** ~~160-~~ **60** , **666 2027 60** ~~000 due October 16-~~ , **666** 2028 **60** , ~~with interest of 5 % per year. The amount assumed was~~ **666 2029 41, 736 2030 33, 218 2031 and thereafter 4, 142** $ ~~139~~ **261** , ~~184~~ **092 7** . **RELATED PARTY TRANSACTIONS Activity** ~~The loan requires monthly payments of principal and interest of $ 1, 697. During~~ **during** the year ended January 31, ~~2024,~~ **2025a) During** the **year ended** ~~Company made $ 15, 378 of principal payments. As of~~ January 31, ~~2024~~ **2025** , **options to purchase 689, 584 shares of common stock were issued to executives and employees of** the ~~amount due was~~ **Company at a price of** $ **2. 37 and** ~~85, 249, of which~~ $ **8** ~~16, 129 is current~~ . ~~As~~ **08 per share. The options vest immediately and expire in three years. The fair value** of **the options issued amounted to $ 1, 408, 935 and were expensed during the year ending** January 31, ~~2023~~ **2025** ~~, the amount due was $ 100, 627~~ . **b)** On April **19, 2024, the Company completed an $ 8, 400, 000 equity financing with European investors which included two related parties. The two related parties invested a total of $ 6, 420, 000 and received 1, 605, 000 shares of common stock and warrants to purchase** 3, ~~2022~~ **210** , ~~the Company entered into a retail installment agreement~~ **000 shares of common stock @ $ 6. 43 per share. See Note 8** for **further information** ~~the purchase of an automobile~~ . **c) During the** ~~The contract price was $ 32, 274, of which $ 22, 795 was financed. The agreement is for five years-~~ **year ending** bearing interest at 2. 95 % per annum with payments of $ 410 ~~per month. The loan is secured by automobile. As of~~ January 31, ~~2024~~ **2025** , the **Company received** ~~amount due was~~ $ **300** ~~15, 232 of which $ 4, 456 is current. As of January 31, 2023, the amount due was $ 19, 610. Note payable- related party. On July 17, 2023, the Company entered an amended Credit Line Note agreement, for an increased $ 5-~~ , 000 ~~, 000~~ **from the** credit line facility ~~Note,~~ with TII Jet Services LDA ~~, a shareholder of the Company (replacing the $ 2, 000, 000 facility with the same lender that the Company entered on March 17, 2023)~~ . **On May 15** ~~Outstanding advances under the Note bears interest at 7 % per annum. The promissory note is due and payable in full on March 19, 2026. Interest is payable annually on December 31 of each year during the term of the note. During the year ended January 31~~ , 2024 ~~, the Company received $ 2, 000, 000 on the Note. In December 2023~~ , the Company converted the **debt** ~~balance of the credit facility of $ 2, 000, 000~~ and ~~$ 53, 476 of~~ accrued interest into ~~1~~ **76** , **230** ~~026, 520~~ shares of common stock ~~. The fair value of~~ **and issued 152, 460 warrants to** the **lender. See Note 4 for further information. d) On June 5, 2024, the Company' s Chief Financial Officer exercised 87, 500 warrants as a cashless conversion and was issued 60, 085 shares of** common stock was $ 2, 554, 423..... and $ 6, 289, respectively . F- 166. INTANGIBLE ASSETS As of January..... 31, 2025 $ 113, 109 - **19** ~~2026 113, 109 2027 113, 109 2028 113, 109 2029 113, 109 2030 and thereafter 101, 735 $ 667, 280 7. RELATED PARTY TRANSACTIONS~~ Activity during the year ended January 31, 2024a) On February 1, 2023, options to purchase 30, 000 shares of the Company' s common stock were issued to an executive of the Company at a price of $ 3. 975 per share. The options vest immediately and expire in three years. The fair value of the options issued for services amounted to $ 75, 030 and was expensed during the year ~~ended~~ **ending** January 31, 2024. **b** ~~F- 17b) In September and October 2023, options to purchase 374, 500 shares of common stock to executives and directors of the Company at a price of $ 1. 93, $ 2. 12 and $ 2. 65 per share. The options vest immediately and expire in three years. The fair value of the options issued amounted to $ 424, 826 and was expensed during the year ended January 31, 2024. c) On October 26, 2023, warrants to~~

~~purchase 87, 500 shares of the Company' s common stock were issued to the Chief Financial Officer at a price of $ 1. 93 per share. The warrant expires in three years. The fair value of the warrants issued amounted to $ 93, 450 and was expensed during the year ended January 31, 2024. d~~ ) On July 17, 2023, the Company entered **into** an amended Credit Line Note facility with TII Jet Services **,** LDA, a shareholder of the Company, for a credit facility of $ 5 ~~million ( , 000, 000~~ replacing the $ 2, 000, 000 facility with the same lender that the Company entered **into** on March 17, 2023 ~~)~~. See Note ~~5~~ **4** for further information. TII Jet Services LDA is owned 100 % by a shareholder of the Company. During the year ~~ended~~ **ending** January 31, 2024, the Company received $ 2, 000, 000 from the credit facility. In December 2023, TII Jet Services LDA converted the balance of ~~the~~ credit facility of $ 2, 000, 000 and $ 53, 436 of accrued interest into 1, ~~026~~ **036** , 520 shares of the Company' s common stock. **c** ~~Activity during the year ended January 31, 2023a~~ ) In **September** ~~May 2022, the Company issued stock awards to the Company' s CEO~~ and **October** ~~the independent members of the Board of Directors. The CEO received 11, 667 shares and the four directors received 1, 167 shares each. The Company recorded a compensation expense of $ 53, 200 in connection with the issuance of the shares. b) On August 2, 2022~~ **2023** , ~~137, 084~~ options to purchase **374, 500** shares of ~~the Company' s~~ common stock were issued to executives **and directors** of the Company at **a** ~~prices~~ **price** of $ ~~4~~ **1** . ~~09~~ **93, $ 2. 12** and $ ~~4~~ **2** . ~~50~~ **65** per share. The options vest immediately and expire in three years. The fair value of the options issued ~~for services~~ amounted to $ ~~399~~ **424** , ~~075~~ **826** and was expensed during the year ~~ended~~ **ending** January 31, **2024. d) On October 31,** 2023 ~~. c) On September 30~~ , **warrants** ~~2022, 35, 000 options~~ to purchase **87, 500** shares of the Company' s common stock were issued to the ~~independent directors of the~~ Company **' s Chief Financial Officer** at a price of $ ~~3~~ **1** . ~~59~~ **93** per share. The **warrant** ~~options vest immediately and expire~~ **expires** in ~~five~~ **three** years. The fair value of the **warrants** ~~options issued for services amounted to $ 85, 995 and was expensed during the year ended January 31, 2023 d) On December 7, 2022, options to purchase 107, 500 shares of the Company' s common stock were issued to executives of the Company at prices of $ 3. 53 and $ 3. 88 per share. The options vest immediately and expire in three years. The fair value of the options~~ issued amounted to $ ~~245~~ **93** , ~~170~~ **450** and ~~was~~ **were** expensed during the year ~~ended~~ **ending** January 31, ~~2023~~ **2024** . 8. STOCKHOLDERS' EQUITY Preferred Stock On January 15, 2016, the board of directors of the Company approved a certificate of amendment to the articles of incorporation and changed the authorized capital stock of the Company to include and authorize 10, 000, 000 shares of Preferred Stock, par value $ 0. 001 per share. On May 24, 2019, the board of directors created a series of preferred stock consisting of 2, 500, 000 shares designated as the Series A Convertible Preferred Stock (" Series A Preferred Stock "). On June 20, 2019, the Series A preferred Stock was terminated, and the 2, 500, 000 shares were restored to the status of authorized but unissued shares of Preferred Stock, without designation as to series, until such stock is once more designated as part of a particular series by the board of directors. ~~F- 18~~ On June 25, 2019, the Company effected a one- for- four reverse stock split, pursuant to which each outstanding share of common stock was changed into 0. 25 shares of common stock, and the Company decreased its authorized common stock in the same ratio from 100, 000, 000 to 25, 000, 000 shares. On January 27, 2020, the Company amended its Articles of Incorporation to increase its authorized common shares from 25, 000, 000 authorized shares to 250, 000, 000 authorized shares. On July 26, 2022, the Board of Directors of the Company approved a 7- for- 6 forward stock split, effective for trading purposes as of August 12, 2022, pursuant to which each shareholder as of the August 15, 2022 record date received one (1) additional share for each six (6) shares held as of the record date. Pursuant to the operation of the amendment providing for the forward stock split filed with the Secretary of State of Nevada on August 4, 2022, the authorized common stock of the Company was increased from 250, 000, 000 shares to 291, 666, 666 shares in connection with the forward split. Activity during the Year ~~Ended~~ **Ending** January 31, ~~2024~~ **2025** (a) As of January 31, ~~2024~~ **2025** , the Company holds ~~32,400~~ **' s Employee Stock Option Plan (the " Plan ") increasing the number of** shares of ~~treasury~~ **common** stock ~~. On September 10~~ **subject to the Plan (as of March 20** ,2024, ~~10~~ **875** ,000 shares **)** ~~of treasury stock held by the Company were issued~~ to ~~an investor relations firm for services rendered~~ **1,400,000 shares (the " Amendment ")** . The Company ~~recorded~~ **will submit the Amendment to the Plan to our stockholders for adoption** ~~an~~ **and approval at** ~~expense of $ 38,700 during~~ the **2025 Annual Meeting.If the Amendment is not approved by stockholders within one** year **of adoption** ~~ending January 31~~ , ~~2025,~~ **the increase** in ~~connection~~ **shares subject to the Plan will be void,together** with **any options issued following March** ~~the transaction.During the year ending January 31,2025,the Company purchased 32,400 shares of treasury stock for $ 148,547.F-~~ 20 **,2024,in the period pending approval of the Plan by our stockholders.** ( ~~b~~ **d** ) On April 19,2024,the Company completed an $ 8,400,000 equity financing with European investors (the " Offering ") of 2,100,000 units (" Units "),at a price of $ 4.00 per Unit, **each Unit** consisting of one share of common stock (" Shares ") and a Warrant to purchase two Shares of common stock,the ~~Warrant~~ **Warrants** having an **initial** exercise price of $ 6.43,are exercisable by payment of the exercise price in cash only and expire April 19,2029,five years from the date of issuance (" Warrants ").The ~~offering~~ **Offering** was made solely to investors residing outside the United States and was not registered under the Security Act of 1933,as amended,(the " Security Act "),or the ~~security~~ **securities** law of any jurisdiction,including outside the United States,but was made privately by the Company pursuant to the exemptions from registration provided in the SEC' s Regulation S and other exemptions under the Securities Act ~~. (c) On May 15,2024,the Company agreed to convert $ 300,000 of debt and $ 4,922 of accrued interest under the Credit Line Note agreement.~~ 10, 000 of its shares comprising $ 32, 641 of treasury stock. There was no activity during the year ~~ended~~ **ending** January 31, 2024. (b) In December ~~2024~~ **2023** , TII Jet Services LDA converted $ 2, 000, 000 of its outstanding credit facility and $ 53, 436 of accrued interest into 1, 026, 720 shares of the Company' s common stock. The fair value of the common stock at the date of issuance was $ 2, 554, 423, resulting in a $ 554, 423 loss on extinguishment. **9** ~~Activity during the Year Ended January 31, 2023 (a) In March and May 2022, the Company purchased 35, 584 shares of its common stock for $ 119, 006 and recorded the purchase as Treasury Stock. In May and December 2022, the Company issued 33, 397 shares of stock awards to management, directors and employees from the treasury shares and recorded compensation expense of $ 113, 155 In December 2022, the Company issued 25, 000 shares from the treasury shares to non- employees in connection of the termination of the Rambam license agreement. As of January 31, 2023, the Company held 10, 000 of its shares comprising $ 32, 641 of treasury stock. (b) On July 29, 2022, the Company received proceeds of $ 296, 875 from the exercise of warrants and issued 55, 417 shares of common stock. (c) In July 2022, the Company cancelled 1, 400, 000 shares received in connection with the settlement of a lawsuit. See Note 11 for further information. F- 199~~ . OPTIONS and WARRANTS ~~The following table summarizes the changes in warrants outstanding and the related price of the shares of the Company' s common stock issued to non- employees of the Company during the year ended January 31, 2024.~~ On March 7, 2023, the Company issued 30, 000 warrants to purchase the Company' s common shares to Barandnic Holdings Ltd. for services provided. The warrants are exercisable at a price of $ 4. 00 per share and expire five years from the date of issuance. On October 27, 2023, the Company issued 145, 833 warrants to purchase the Company' s common shares to management (87, 500 warrants were issued to the Chief Financial Officer) and non- employees of the Company. The warrants are exercisable at a price of $ 1. 93 per share and expire in three years from the date of issuance. These warrants replace previously issued warrants that have now been cancelled. The Company used the Black- Scholes valuation model to record the fair value. The valuation model used a dividend rate of 0 %; expected term of 1. 5 years; volatility rates of 152. 10- 174. 45 %; and a risk- free rate of 4. 31 %- 4. 84 %. Non- cash compensation for the year ~~ended~~ **ending** January 31, 2024, amounted to $ 242, 840 **. On April 19, 2024, in connection with a private placement of the Company' s common stock, the Company issued 4, 200, 000 warrants. The warrants are exercisable at a price of $ 6. 43 per share and expire five years from the date of issuance. On May 15, 2024, the Company issued 152, 460 warrants in connection with extinguishment of debt of $ 300, 000 and accrued interest. The warrants are exercisable at a price of $ 6. 43 per share and expire five years from the date of issuance. Non- cash expense of $ 390, 145 is included in loss on extinguishment of debt. F- 21 On June 5, 2024, the Company' s Chief Financial Officer exercised 87, 500 warrants as a cashless conversion and the Company issued 60, 085 shares of common stock. On September 10, 2024, the Company issued 50, 000 warrants to an investor relations firm. The warrants are exercisable at a price of $ 4. 00 per share and expire three years from the date of issuance. The Company recorded a non- cash expense of $ 94, 650 during the year ending January 31, 2025. The agreement is for twelve months and includes the issuance of 10, 000 treasury shares and monthly payments of $ 12, 500. The warrants and shares vest immediately and because they are non- forfeitable, the expense was recognized immediately. The Company cancelled the warrants as of January 31, 2025. Non- cash compensation for the year ending January 31, 2025, amounted to $ 484, 975. The Company used the Black Scholes valuation model to record fair value of the value of the warrants issued during the year ending January 31, 2025. The valuation model used a dividend rate of 0 %; expected terms of 1. 5- 2. 5 years; volatility rates of 105. 98 %- 145. 05 %; and risk- free rates of 3. 65 %- 4. 45 %. The following table summarizes the changes in the warrants outstanding and the related price of the shares of the common stock issued to non- employees of the Company during the year ending January 31, 2025** . Exercise Remaining Intrinsic Shares Price Life Value Outstanding, January 31, ~~2022~~ **2023** 1, ~~435~~ **307** , ~~622~~ **671** $ 6. ~~91~~ **43** 3. ~~93~~ **34** years $- Granted ~~25~~ **175** , ~~000 7~~ **833 2** , ~~50 5~~ **28 2** , ~~00~~ **97** years- Expired / Cancelled ( ~~97~~ **200** , ~~534~~ **466** ) ~~5~~ **6** . ~~36~~ **33** -- Exercised ~~--~~ ~~(55, 417) 5. 36~~ -- Outstanding, January 31, ~~2023~~ **2024** 1, ~~307, 671 6. 43 3. 34 years- Granted 175, 833 2. 28~~ **283 , 038 5. 88** 2. 97 years- **Granted 4, 402, 460 6. 40 4. 72 years-** Expired / Cancelled ( **50, 000) 4.** ~~200~~ **00** ~~, 466) 6. 33~~ -- Exercised ~~--~~ **(88, 525) 1. 98** -- Outstanding- January 31, ~~2024~~ **2025** ~~1~~ **5** , ~~283~~ **546** , ~~038~~ **973** $ ~~5~~ **6** . ~~88 2~~ **37 3** . ~~97~~ **68** years $ ~~99~~ **10** , ~~166~~ **626, 018** Exercisable- January 31, ~~2024~~ **2025** ~~1~~ **5** , ~~283~~ **546** , ~~038~~ **973** $ ~~5~~ **6** . ~~88 2~~ **37 3** . ~~97~~ **68** years $ ~~99~~ **10** , ~~166~~ **626, 018 F- 22** The following table summarizes additional information relating to the warrants outstanding as of January 31, ~~2024~~ **2025** : Range of Exercise ~~Prices~~ Number ~~Outstanding Weighted Average~~ Remaining Contractual ~~Life (Years) Weighted Average~~ Exercise Price for Shares ~~Outstanding~~ Number ~~Exercisable Weighted Average~~ Exercise Price for Shares **Intrinsic Prices Outstanding Life (Years) Outstanding** Exercisable ~~Intrinsic~~ **Exercisable** Value $ **1. 93 58, 333 1. 74 $ 1. 93 58, 333 $ 1. 93 $ 370, 988 $** 4. 00 30, 000 **4 3** . 10 $ 4. 00 30, 000 $ 4. 00 $ **~~-~~128, 700** $ 6. 43 ~~1~~ **5** , ~~082~~ **433**

, ~~205 2~~ **640 3** . ~~68~~ **71** $ 6. 43 ~~1~~ **5** . ~~082~~ **433** , ~~205~~ **640** $ 6. 43 $ **10** ~~- $ 1. 93 145~~ . **106** ~~833 2. 74 $ 1. 93 145~~ . **570** ~~833 $ 1. 93 $ 99, 166~~ $ 7. 50 25, 000 ~~3~~ **2** . 77 $ 7. 50 25, 000 $ 7. 50 $ **19, 760 5, 546, 973 $ 6** ~~- F- 20 The following table summarizes the changes in options outstanding and the related price of the shares of the Company' s common stock issued to employees of the Company~~ . **37 5, 546, 973 $ 6** ~~See Note 7 for the issuance of related party options~~ . **37 $ 10, 626, 018** On November 1, 2021, the Board of Directors adopted the 2021 Employee Stock Option Plan (the " Plan "). The Company has reserved 408, 333 shares for issuance and sale upon the exercise of stock options. In accordance with the Plan, on February 1, 2022, the Company reserved an additional 233, 333 shares and on February 1, 2023, the Company reserved an additional 233, 333 shares. The options vest immediately and expire in three years. Under the Plan, options may be granted which are intended to qualify as Incentive Stock Options (" ISO' s ") under Section 422 of the Internal Revenue Code of 1986 (the " Code ") or which are not (" non- ISO' s ") intended to qualify as Incentive Stock Options thereunder. The Plan also provides for restricted stock awards representing shares of common stock that are issued subject to such restrictions on transfer and other incidents of ownership and such forfeiture conditions as the Board of Directors, or the committee administering the Plan composed of directors who qualify as " independent " under Nasdaq rules, may determine. On November 3, 2021, the Company filed a Registration Statement on Form S- 8, to register under the Securities Act of 1933, as amended the 408, 333 shares of common stock reserved for issuance under the Plan. **On March 20, 2024, our Board of Directors adopted an amendment to the Company' s Employee Stock Option Plan (the " Plan ") increasing the number of shares of common stock subject to the Plan (as of March 20, 2024, 875, 000 shares) to 1, 400, 000 shares (the " Amendment "). The Company submitted the Amendment to the Plan to our stockholders for adoption and approval at the 2025 Annual Meeting. The Amendment was approved by the stockholders on January 23, 2025.** As of January 31, ~~2024~~ **2025** , ~~166~~ **26, 332** shares remain available ~~and~~ **for** issuance **of options** under the Plan. During the year ~~ended~~ **ending** January 31, ~~2024~~ **2025** , ~~404~~ **689** , ~~500~~ **584** options to purchase shares of the Company' s common stock were issued to executive officers and employees at prices of $ ~~1~~ **2** . ~~93~~ **37** - $ ~~3~~ **8** . ~~975~~ **07** per share. The options vest immediately and expire three years from the date of issuance. The fair value of the options issued for services amounted to $ ~~499~~ **1** , ~~856~~ **408, 935** and ~~was~~ **were** recorded during the year ~~ended~~ **ending** January 31, ~~2024~~ **2025** . The Company used the Black- Scholes valuation model to record the fair value. The valuation model used a dividend rate of 0 %; expected term of 1. 5 years; volatility ~~rates~~ - **rate** of ~~121~~ **97** . ~~52~~ **83 %** - ~~143~~ **114** . ~~54~~ **86** %; and a risk- free rate of ~~3~~ **4** . 00 **%** - 4. ~~5~~ **87** %. During the year ended January 31, ~~2023~~ **2024** , ~~279~~ **404** , ~~584~~ **500** options to purchase shares of the Company' s common stock were issued to executive officers and **employees** ~~directors of the Company~~ at prices of $ **1. 93- $** 3. **975** ~~59 to $ 4. 50~~ per share. The options vest immediately and expire three years from the date of issuance. The fair value of the options issued for services amounted to $ ~~732~~ **499** , ~~130~~ **856** and was recorded during the year ended January 31, ~~2023~~ **2024** . The Company used the Black- Scholes valuation model to record the fair value. The valuation model used a dividend rate of 0 %; expected term of 1. 5 years; volatility ~~rate~~ **rates** of **121.** ~~152 - 52 . 10 -~~ ~~174~~ **143** . ~~45~~ **54** %; and a risk- free rate of 3 **. 00- 4. 5** %. **F- 23 The following table summarizes the changes in options outstanding and the related price of the shares of the Company' s common stock issued to employees of the Company. See Note 7 for the issuance of related party options. Exercise Remaining Intrinsic Shares Price Life Value Outstanding, January 31, 2023 470, 335 $ 4. 13 2. 53 years Granted 404, 500 2. 18 2. 68 years- Expired / Cancelled--- Exercised--- Outstanding, January 31, 2024 874, 835 3. 23 2. 31 years Granted 689, 584 4. 40 1. 93 years Expired / Cancelled (190, 751)-- Exercised--- Outstanding- January 31, 2025 1, 373, 668 $ 3. 68 1. 90 years $ 6, 337, 984 Exercisable- January 31, 2025 1, 373, 668 $ 3. 68 1. 90 years $ 6, 337, 984** The following table summarizes additional information relating to the options outstanding as of January 31, ~~2024~~ **2025** ~~- Shares~~ **: Weighted Average Weighted Average Range of Exercise Number Weighted Average** Exercise Price ~~Remaining Life~~ **for Shares Number Exercise Price for Shares** Intrinsic Value Outstanding, January 31, 2022..... as of January 31, 2024: Prices Outstanding Life (Years) ~~Shares~~ Outstanding Exercisable ~~Shares~~ Exercisable Value $ 1. 93 214, 500 ~~2~~ **1** . ~~74~~ **73** $ 1. 93 214, 500 $ 1. 93 $ ~~145~~ **1** , ~~860~~ **364, 220** $ 2. 12 140, 000 ~~2~~ **1** . ~~74~~ **73** $ 2. 12 140, 000 $ 2. 12 $ ~~68~~ **863, 800 $ 2. 37 195, 000 2. 13 $ 2. 37 195, 000 $ 2. 37 $ 1, 154, 400 $ 2. 61 195, 000 2. 13 $ 2. 61 195, 000 $ 2. 61 $ 1, 107** , 600 $ 2. 65 20, 000 ~~2~~ **1** . 63 $ 2. 65 20, 000 $ 2. 65 $ **~~-~~112, 800 $ 2. 75 30, 000 2. 00 $ 2. 75 30, 000 $ 2. 75 $ 166, 200** $ 3. 59 35, 000 ~~3~~ **2** . ~~67~~ **66** $ 3. 59 35, 000 $ 3. 59 $ **164** ~~- $ 3. 75 57, 500 1. 85 $ 3. 75 57~~ , 500 $ 3. 75 **$~~-~~ 57, 500 1. 00** $ 3. **75 57, 500 $ 3. 75 $ 261, 050 $ 3.** 98 30, 000 ~~2~~ **1** . ~~01~~ **00** $ 3. 98 30, 000 $ 3. 98 $ **~~-~~129, 300** $ 4. 09 78, 750 ~~1~~ **0** . 50 $ 4. 09 78, 750 $ 4. 09 $ **~~-~~330, 750** $ 4. 12 50, 000 ~~1~~ **0** . 85 $ 4. 12 50, 000 $ 4. 12 $ **~~-~~208, 500** $ 4. ~~16 144, 083 0. 97 $ 4. 16 144, 083 $ 4. 16 $- $ 4.~~ 50 58, 334 ~~1~~ **0** . 50 $ 4. 50 58, 334 $ 4. 50 $ **~~-~~221, 086** $ ~~4~~ **5** . **99 30, 000 2. 41 $ 5. 99 30, 000 $ 5. 99 $ 69, 000 $ 7. 34 180, 918 2. 98 $ 7. 34 180, 918 $ 7. 34 $ 171, 872 $ 8. 07** 58 ~~46~~ **, 666 2. 98 $ 8. 07 58, 666 $ 8. 07 $ 12, 907 1, 373** , 668 ~~0~~ **1** . ~~97~~ **90** $ ~~4~~ **3** . ~~58 46~~ **68 1, 373** , 668 $ ~~4~~ **3** . ~~58~~ **68** $ **6** ~~- 874~~ . **337** ~~835 2. 06 $ 3. 23 874~~ . **984 F- 247** ~~835 $ 3. 23 $ 214, 460 10~~ . SEGMENT ~~REPORTING~~ **REPORTINGWe** ~~We~~ organize and manage our business by the following two segments which meet the definition of reportable segments under ASC280- 10, Segment Reporting: Sales of Goods and Services. These segments are based on the **customer** type of products or services provided and are the same as our business units. Separate financial information is available and regularly reviewed by our chief officer decision maker, **who is our chief executive officer,** in making resource allocation decisions for our segments. Our chief officer decision maker evaluates segment performance to the GAAP measure of gross profit. Years ~~Ended~~ **Ending** January 31, **2025** 2024 ~~2023~~ Net sales Pocono Pharmaceuticals $ ~~1~~ **2** , ~~920~~ **139** , ~~280~~ **537** $ 1, ~~785~~ **920** , ~~597~~ **280** 4P Therapeutics ~~-~~ 165, 034 ~~294, 102~~ 2. **139, 537 2,** 085, 314 ~~2, 079, 699~~ Gross profit Pocono Pharmaceuticals **743, 317** 744, 391 ~~726, 702~~ 4P Therapeutics ~~-~~ 117, 714 ~~23~~ **743** , ~~702~~ **317** 862, 105 ~~750, 404~~ Operating expenses Selling, general and administrative- Pocono Pharmaceuticals **661, 805** 606, 275 ~~577, 930~~ Selling, general and administrative- 4P Therapeutics **136, 294** 236, 953 ~~103, 181~~ Selling, general and administrative- Corporate **3, 515, 711** 2, 930, 378 **Goodwill and intangibles impairment** 3, ~~234~~ **595** , ~~930~~ **216-** Research and development- 4P Therapeutics **3, 119, 134** 1, 960, 425 ~~982~~ **11** . **028** ~~227 Goodwill impairment- Pocono Pharmaceuticals- 327~~ , ~~326~~ **160** 5, 734, 031 ~~5, 225, 594~~ Depreciation and Amortization Pocono Pharmaceuticals $ **235, 941 $** 222, 159 ~~$ 264, 156~~ Corporate **12, 043** 13, 986 ~~-~~ 4P Therapeutics **37, 070** 51, 577 ~~65~~ **$ 285** , ~~987~~ **054** $ 287, 722 ~~$ 330, 143~~ F- ~~22~~ **25** The following table presents information about net sales and property and equipment, net of accumulated depreciation, in the United States and elsewhere. Years ~~Ended~~ **Ending** January 31, **2025** 2024 ~~2023~~ Net sales United States $ 2, ~~085~~ **139** , ~~314~~ **537** $ 2, ~~079~~ **085** , ~~699~~ **314** Outside the United States-- $ 2, ~~085~~ **139** , ~~314~~ **537** $ 2, ~~079~~ **085** , ~~699~~ **314** January 31, January 31, **2025** 2024 ~~2023~~ Property and equipment, net of accumulated depreciation United States $ **695, 063 $** 774, 924 ~~$ 897, 735~~ Outside the United States-- $ **695, 063 $** 774, 924 ~~$ 897, 735~~ Assets Corporate $ ~~344~~ **4** . ~~192~~ **205, 577** $ ~~1~~ **339** , **552** ~~745, 731~~ Pocono Pharmaceuticals **1, 404, 585** 5, 079, 293 ~~5, 400, 814~~ 4P Therapeutics **1, 859, 793** 2, **098** ~~093, 369 2~~ , 309 ~~, 832~~ $ 7, ~~516~~ **469** , ~~854~~ **955** $ ~~9~~ **7** , ~~456~~ **517** , ~~377 11~~ **154 10** . COMMITMENTS AND CONTIGENCIES Employment Agreements The Company entered into three- year employment agreements with Gareth Sheridan, our CEO, and Serguei Melnik, our President, effective February 1, 2022. The agreement also provides that the executives will continue as directors and officers of the Company for the respective terms thereof. The agreement provides for an initial term, commencing on the effective date of the agreement and ending on January 31, 2025, and continuing on a year- to- year basis thereafter unless terminated by either party on not less than 30 days' notice given prior to the expiration of the initial term or any one- year extension. For their services to the Company during the term of the agreement, Mr. Sheridan and Mr. Melnik will receive an annual salary of $ 250, 000 per annum, commencing on the effective date of the agreement. Mr. Sheridan and Mr. Melnik will also receive a performance bonus of 3. 5 % of net income before income taxes. As of July 31, 2022, the Company and Mr. Sheridan and Mr. Melnik mutually agreed to reduce their annual salary to $ 150, 000. **These agreements, and the employment of Mr. Goodman, automatically renew for one- year terms following expiration of the initial three- year terms and each successive one- year term.** The Company entered into a three- year employment agreement with Gerald Goodman, our CFO, effective February 1, 2022. The agreement provides for an initial term, commencing on the effective date of the agreement and ending on January 31, 2025, and continuing on a year- to- year basis thereafter unless terminated by either party on not less than 30 days' notice given prior to the expiration of the initial term or any one- year extension. For his services to the Company during the term of the agreement, Mr. Goodman will receive an annual salary of $ 210, 000 per annum, commencing on the effective date of the agreement. As of July 31, 2022, the Company and Mr. Goodman mutually agreed to reduce his annual salary to $ 110, 000. **F- 26** Kindeva Drug Delivery Agreement On January 4, ~~2022, the Company signed a feasibility agreement with Kindeva Drug Delivery, L. P. (" Kindeva ") to develop Nutriband' s lead product, AVERSA Fentanyl, based on its proprietary AVERSA abuse deterrent transdermal technology and Kindeva' s FDA- approved transdermal fentanyl patch (fentanyl transdermal system). The feasibility agreement provides for adapting Kindeva' s commercial transdermal manufacturing process to incorporate AVERSA technology in the fentanyl transdermal system. F- 23 The agreement will remain in force until the earlier of: (1) the completion of the work and deliverables under the Workplan; or (2) two (2) years after the Effective Date, after which time the agreement will expire. The feasibility Workplan was completed in February 2024. The estimated cost to complete the feasibility Workplan was approximately $ 2. 5 million. Nutriband made an advance deposit of $ 250, 000 in January 2022, to be applied against the final invoices. As of January 31, 2024, Nutriband has incurred expenses of $ 2, 369, 508 and the net deposit of $ 138, 250 after application to final invoices is included in prepaid expenses. In January~~ 2024, Nutriband signed a commercial development and clinical supply agreement **for their lead product, Aversa Fentanyl,** with Kindeva Drug Delivery ~~for development of AVERSA Fentanyl using~~ **, L. P. (" Kindeva ")** ~~' s FDA- approved fentanyl patch~~ . **Under this agreement,** Kindeva will perform commercial manufacturing process development ~~and~~ **, manufacturing of** clinical supplies ~~manufacturing~~ for the human abuse ~~potential~~ **liability** clinical study **, and development of chemistry, manufacturing and controls (CMC) information** required by the FDA in support of a New Drug Application **(" NDA "). As of January 31, 2025, Nutriband has incurred expenses of $ 3. 0 million under this agreement** . The **Company** ~~agreement replaces the previous feasibility agreement between the two companies which was focused on adapting Kindeva' s commercial transdermal manufacturing process~~

~~to incorporate AVERSA abuse deterrent transdermal technology. The estimated~~ **estimates** ~~cost~~ **approximately $ 5. 2 million** to complete the ~~commercial process~~ development ~~and clinical supplies manufacturing is approximately~~ **. On February 4, 2025, the agreement was amended to reduce the hourly rate for the labor on the project in exchange for a milestone payment payable upon FDA approval. Under the amended agreement, the remaining budget as of January 31, 2025, through NDA submission for the current workplan was reduced to** $ ~~8~~ **3** . ~~1~~ **2** million ~~and the expected timing~~ **. The amended agreement also includes a milestone payment** of **$ 3. 0 million to be paid to Kindeva when the Company receives** FDA **approval** ~~submission is twelve to eighteen months~~ . Lease Agreement On February 1, 2022, Pocono Pharmaceuticals entered into a lease agreement with Geometric Group, LLC for 12, 000 square feet of warehouse space currently occupied by Active Intelligence. The monthly rental is $ 3, 000 and the lease expires on January 31, 2025. The lease ~~can be~~ **has been** extended for an additional three years at the same monthly rental. ~~The Company recorded a Right of Use asset in the amount of $ 94, 134 in connection with the valuation. MDM Worldwide Agreement In September 2022, the Company entered into a public relations agreement with MDM Worldwide. In connection with the agreement, the Company agreed to issue 20, 000 options to MDM Worldwide. In October 2023, the contract was mutually terminated, and no options were issued. For the year ended January 31, 2024, the Company paid MDM Worldwide $ 190, 000. Money Channel Agreement On March 13, 2023, the Company entered into a media advertising agreement with Money Channel Inc. The Company will pay a monthly fee and after ninety days can cancel the agreement. The Company, after 90 days, will also issue options to purchase 50, 000 shares of common stock to Money Channel Inc. at an exercise price of $ 4. 00 per share. In June 2023, the parties agreed to terminate the agreement by mutual consent. No options were issued. For the year ended January 31, 2024, the Company paid the Money Channel $ 100, 000.~~ Sorrento Therapeutics, Inc. Agreement ~~4P Therapeutics had unpaid account receivables related to a contract clinical research services agreement in place with Sorrento Therapeutics. On February 13, 2023, Sorrento declared Chapter 11 bankruptcy.~~ On July 25, 2023, 4P Therapeutics assigned its claim under the bankruptcy proceedings from Sorrento Therapeutics Inc. and received proceeds of $ 106, 528. The amount due under the claim was $ 118, 675 and 4P Therapeutics recorded a reserve for bad debts of $ 118, 675 during the year ended January 31, 2024. Under the agreement with the buyer of the claim, 4P Therapeutics will make proportional restitution and / or repayment of the purchase amount to the extent the claim is disallowed, reduced or not paid at the same time or distribution rate as other general unsecured claims against the Debtor are paid. The Company has recorded the amount of the proceeds as a secured loan payable to the factor as of January 31, ~~2024~~ **2025** . ~~F- 24 Upstream Termination On May 24, 2023, the Company sent notice of the termination of the Securities Facility Services Agreement, dated January 3, 2023, by and between MERJ DEP Ltd. And the Company (" Agreement "), which provided for the dual listing of the Company' s common stock on the MERJ Upstream exchange (" Upstream "), which is operated as a fully registered and licensed integrated securities exchange, clearing system and depository for digital and non- digital securities under the Seychelles security laws. The termination was effective May 31, 2023~~ . Legal Proceedings The Company is currently a defendant in a lawsuit initiated by Joseph Gunnar, LLC (" Gunnar ") and Lucosky Brookman LLP (" LB ") in the Supreme Court of the State of New York, New York County, under Index No. 654633 / 2023. The lawsuit alleges multiple allegations such as breach of contract, fraudulent activities, and tortious interference and seeks damages following the Company' s termination of an engagement letter for assistance with a public stock offering. Gunnar is seeking over $ 500, 000 in damages plus punitive damages, while LB is demanding reimbursement of legal fees. In response, the Company denies all allegations, alleging that the engagement letter was unenforceable, and its termination was legally justified. The Company has also initiated counterclaims against Joseph Gunnar & Co., accusing them of intentional interference and breach of fiduciary duty, and is seeking $ 1, 000, 000 for each claim along with a declaratory judgment affirming the legality and justification of the termination. The plaintiffs have denied these counterclaims. Currently, there are no pending hearings or motions ~~as both parties are engaged~~ **, and the case is** in **the** discovery ~~and are attempting~~ **stage. In early 2024, the plaintiffs proposed a settlement offer of $ 100, 000. The Company has not responded** to ~~resolve the matter amicably~~ **that proposed settlement offer** . ~~12~~ **11** . SUBSEQUENT EVENTS (a) ~~In~~ **Subsequent to January 31, 2025, the Company' s outside corporate counsel exercised 58, 333 warrants as a cashless conversion and the Company issued 46, 961 shares of common stock. (b) On** February ~~and April~~ **6,** ~~2024~~ **2025** , the Company ~~received proceeds~~ **entered into an agreement with a consultant to provide consulting services to the Company' s Board** of ~~$ 300~~ **Directors. The Company issued 5** , 000 ~~from its Credit Line Facility. (b) On March 20, 2024, 390, 000 options to purchase~~ shares of the Company' s common stock **to the consultant, valued at $ 39, 050. The shares** were issued **from the treasury shares held by the Company. The term of the agreement is for twelve months. (c) On March 4, 2025, the Company issued 3, 500 shares of the Company' s common stock** to ~~executive officers and~~ employees **for services rendered** ~~at prices of $ 2. 37- $ 2. 61 per share. The options vest immediately and expire three years from the date of issuance~~ . The fair value of the ~~options~~ **shares** issued **was** ~~amounted to~~ $ ~~450~~ **24** , ~~000~~ **360** . **The shares were issued from the treasury shares held by** ~~(c) On March 20, 2024, our Board of Directors adopted an amendment to~~ the Company ' s Employee Stock Option Plan (..... and other exemptions under the Securities Act . F- ~~25~~ **27** ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL ~~DISCLOSURE~~ **DISCLOSURES** None. ITEM 9A. CONTROLS AND PROCEDURES **Evaluation** ~~Management' s Conclusions Regarding Effectiveness~~ of Disclosure Controls and Procedures We conducted an evaluation of the effectiveness of our disclosure controls and procedures, as defined by Rules 13a- 15 (e) and 15d- 15 (e) of the Securities Exchange Act of 1934, as amended (the " Exchange Act "), as of January 31, ~~2024~~ **2025** , the end of the period covered by this annual report. The disclosure controls evaluation was done under the supervision and with the participation of management, including our chief executive officer and chief financial officer, who are two of our three full- time employees. There are inherent limitations to the effectiveness of any system of disclosure controls and procedures. Accordingly, even effective disclosure controls and procedures can only provide reasonable assurance of achieving their control objectives. Based upon this evaluation, our chief executive officer and chief financial officer concluded that, due to our limited internal audit function, our very limited staff, and our acquisition of 4P Therapeutics and Pocono Coated Products, which are principally responsible for our business operations and were privately owned when we acquired them, were not effective as of January 31, ~~2024~~ **2025** , such that the information required to be disclosed by us in reports filed under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in the SEC' s rules and forms and (ii) accumulated and communicated to the chief executive officer / chief financial officer, as appropriate to allow timely decisions regarding disclosure. Management' s Report on Internal Control over Financial Reporting Our management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rules 13a- 15 (f) and 15d- 15 (f) under the Securities Exchange Act. Our management is also required to assess and report on the effectiveness of our internal control over financial reporting in accordance with Section 404 of the Sarbanes- Oxley Act of 2002 (" Section 404 "). Management assessed the effectiveness of our internal control over financial reporting as of January 31, ~~2024~~ **2025** . In making this assessment, we used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control- Integrated Framework. During our assessment of the effectiveness of internal control over financial reporting as of January 31, ~~2024~~ **2025** , management identified material weaknesses related to (i) our internal audit functions (ii) inadequate levels of review of the financial statements, (iii) a lack of segregation of duties within accounting functions, (iv) inadequate monitoring review controls in accounting for complex transactions. Therefore, our internal controls over financial reporting were not effective as of January 31, ~~2024~~ **2025** . Management has determined that our internal controls contain material weaknesses due to the absence of segregation of duties, as well as lack of qualified accounting personnel, excessive reliance on third party consultants for accounting, financial reporting and related activities, and the lack of any separation of duties ~~. During the past fiscal year, we have added qualified accounting personnel, so the Company does not have to rely on third party consultants~~ . The Company has established additional monitoring controls over the financial statements. We have also improved our internal controls to provide for a detailed accounting review of all revenue items, and accounts receivable and payable transactions in connection with the entry and categorization of each transaction in the preparation of the Company' s financial statements. As a result of these improvements, we are confident our financial statements as of January 31, ~~2024~~ **2025** and for the two years then ended, fairly present in all material respects our financial condition and results of operations for all that reporting period covered by this report. **Changes in Internal Control over Financial Reporting. During the year ended January 31, 2025, there was no change in our internal control over financial reporting (as such term is defined in Rule 13a- 15 (f) under the Exchange Act) that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. Limitations on Effectiveness of Controls and Procedures** Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies and procedures may deteriorate ~~. Changes in Internal Control over Financial Reporting. During the quarterly period ended January 31, 2024, there was no change in our internal control over financial reporting (as such term is defined in Rule 13a- 15 (f) under the Exchange Act) that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting~~ . ITEM 9B. OTHER INFORMATION ITEM 9C. DISCLOSURE REGARDING FOREIGH JURISDICTIONS THAT PREVENT INSPECTIONS. Not applicable. PART III ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE Set forth below are the name, age, position of and biographical information about each nominee, all of whom are currently directors and compromise our entire Board as of the record date. Name Age Position Gareth Sheridan Chief Executive Officer and Director Serguei Melnik Chairman of the Board, President and Secretary **Sergei Glinka Director** Mark Hamilton (1) (3) Director Radu Bujoreanu (1) (2) (3) Director Stefani Mancas (2) (3) Director Irina Gram (2) (1) Director Gerald Goodman Chief Financial Officer Alan Smith, Ph. D. Chief operating officer and president of 4P Therapeutics Jeff Patrick, Pharm. D. Chief scientific officer (1) Member of

the Audit Committee. (2) Member of the Compensation Committee. (3) Member of the Nominating and Corporate Governance Committee. Gareth Sheridan, our founder, has been chief executive officer and a director since our organization in 2016. In 2012, Mr. Sheridan founded Nutriband Ltd., an Irish company which we acquired in 2016. Mr. Sheridan was named Ireland' s ' Young Entrepreneur of the Year' in 2014 in the National Bank of Ireland Startup Awards for establishing Nutriband Ltd. Mr. Sheridan has further business awards from S. Dublin' s Best Young Entrepreneur and Nutriband Ltd as S. Dublin' s Best Startup Company. Mr. Sheridan has also worked as a Business Mentor with 100 Minds, a social enterprise founded in 2013, that brings together some of Ireland' s top college students and connects them with one cause to achieve large charitable goals in a short space of time. Mr. Sheridan is also a past Nissan Generation Next Ambassador, receiving the acknowledgement in 2015 by Nissan Ireland as one of Ireland' s future generational leaders. In 2019 Mr. Sheridan served on the Board of the St. James Hospital foundation, the charitable foundation for Ireland' s largest public hospital. Mr. Sheridan received a B. Sc. in Business and Management from Dublin Institute of Technology in 2012 where he concentrated on international economics, venture creation and entrepreneurship. Serguei Melnik, who was elected by the Board as President on October 8, 2021, serves as a member of the board of directors and is a co- founder of Nutriband Inc. Mr. Melnik has previously served as our chief financial officer and a director since January 2016. Mr. Melnik has been involved in general business consulting for companies in the U. S. financial markets and setting up a legal and financial framework for operations of foreign companies in the U. S. Mr. Melnik advised UNR Holdings, Inc. with regard to the initiation of the trading of its stock in the over- the- counter markets in the U. S. and has provided general advice with respect to the U. S. financial markets for companies located in the U. S. and abroad. From February 2003 to May 2005, he was the Chief Operations Officer and a Board member of Asconi Corporation, Winter Park, Florida, with regard to restructuring the company and listing it on the American Stock Exchange. Mr. Melnik from June 1995 to December 1996 was a lawyer in the Department of Foreign Affairs, JSC Bank " Inteprinzbanca, ", Chisinau, Moldova, and prior thereto practiced law in Moldova in various positions. Mr. Melnik is fluent in Russian, Romanian, English and Spanish. **Sergei Glinka, an investor in our April 19, 2024 private offshore financing, joined our Board of Directors on May 15, 2024. Mr. Glinka has been the Commercial Manager of TG Biochemicals Limited, Cyprus, since 2019. He has been a shareholder and member of the Board of GST Investments OÜ, Estonia since 2019. From 2000 to 2019, Mr. Glinka was a shareholder and member of the Board of Transgroup Invest AS. Commencing in 1973 Mr. Glinka attended secondary school in Moldova, graduating in 1981, and graduated from the Tallinn Merchant Marine School, Estonia, in 1986.** Mark Hamilton, an independent director since July 2018, is an experienced director level professional who joined global consulting firm, Korn Ferry in 2020 as a Managing Consultant. Prior to moving into organizational consulting, Mark qualified as a Chartered Accountant in global advisory firm, BDO, where he spent 12 years advising some of Ireland' s most successful businesses. His work originated in corporate finance / corporate recovery and more recently, he spent 5 years leading BDO' s client management and sales function, as Head of Business Development. Mr. Hamilton is a Member of the Association of Chartered Accountants (ACA), since 2012. Mr. Hamilton' s accounting / consulting background and experience in corporate finance, restructuring, sales and talent assists us in his role as an independent Board member and Committee Chair. Mr. Hamilton has a very strong presence in the business community across jurisdictions, along with an accomplished track record in project management and business development. Educated at Terenure College, Mark went on to study a B. Sc. degree in Business & Management at Dublin Institute of Technology and subsequently received First Class Honours in his postgraduate degree, for which he specialized in Accountancy in 2009. In addition to his ACA qualification, Mark has also recently completed a diploma in Corporate Governance and is now a member of the Corporate Governance Institute which will assist him in his role as Independent Director, alongside his recent approval by the Central Bank of Ireland to act as an Independent Director to regulated entities. Radu Bujoreanu has been a director since June 2019. Mr Bujoreanu is a real estate agent and investor since 2019 and currently he is with Samson Properties LLC. Mr. Bujoreanu has been the owner and executive director of Consular Assistance, Inc., which provided assistance in obtaining visas, travel documents, other national and foreign documents and related services ~~since~~ **from** December 2002 to December 2020. From 2003 to 2005 he served as an independent director and member of the Board of Directors of Asconi Corporation. From August 1999 to August 2002 Mr. Bujoreanu worked as a consular officer at the Embassy of the Republic of Moldova to the United States. Before that from May 1994 to August 1999 he was Chief of Bilateral Treaties section in the International Law and Treaties Department of the Ministry of Foreign Affairs of the Republic of Moldova. Mr. Bujoreanu received ~~his~~ **a** bachelor **' s** degree in international public law from the University of Moldova. Dr. Stefani Mancas **is a researcher at University** ~~graduated Summa cum Laude from the Military Navy College in Constanta, Romania. After attending the faculty~~ of **Maryland.** ~~Cybernetics from the Academy of Economic Studies in Bucharest,~~ Stefani ~~transferred~~ **' s main research areas are finding analytical solutions** to **nonlinear dissipative equations that can be reduced through Darboux transformations to Riccati or Abel equations** ~~University of Central Florida, and graduated with a dual B. Sc. in Mathematics / Aerospace Engineering, a Master' s Degree in Applied Mathematics, and a Ph. D. in Mathematical Sciences from the Department of Mathematics~~ . The **focus is on Schrödinger** ~~Ph. D. dissertation topic was" Dissipative solitons in the cubic- quintic complex Ginzburg- Landau~~ equation ~~: Bifurcations and Spatiotemporal Structure"~~ , for which Stefani ~~received~~ **is using methods based on factorization, and variational formulation together with ansatz reduction with global minimizers of objective functions, applied to supersymmetric quantum mechanics. Another important area of interest is** the ~~UCF Outstanding Dissertation Award~~ **theory of elliptic functions with applications to nonlinear optics, soliton theory, quantum cryptography, as well as general relativity** . Currently, Stefani is a tenured full Professor, and a researcher in the Department of Mathematics at Embry- Riddle Aeronautical University in Daytona Beach, Florida. Stefani ~~' '~~ s research areas deal with finding analytical solutions to nonlinear dissipative equations that can be reduced through Darboux transformations to Riccati or Abel equations. The main focus is on Schrödinger equation, for which Stefani is using methods based on factorization, and variational formulation together with ansatz reduction with global minimizers of objective functions, applied to supersymmetric quantum mechanics. Another important area of interest is the theory of elliptic functions with applications to nonlinear optics, soliton theory, general relativity, as well as optimization of the blockchain, and quantum cryptography. Irina Gram was elected as a director of the Company at the January 21, 2022 stockholders meeting. Irina is a Senior Financial Analyst at Thales IFEC, Melbourne, Florida. There she is responsible for financial planning, analysis and risk and opportunities reviews of multiple development and customer programs. From 2016 to 2017, she was a Project Engineering Coordinator at Thales IFEC, where she executed budgeting and forecasting activities with specialized focus on SFRD spending, interfaced with engineering team to monitor and report the performance of the financial impact of projects. From 2013 to 2016, she held various project management, accounting and reporting positions with Siemens Building Technology, Inc., Winter Park, Florida. She received a Bachelor' s Degree in Finance from the University of Central Florida, Orlando, Florida, where she graduated in May 2015, with honors, and received a Masters Degree in business administration from the University of Central Florida, Orlando, Florida, in May 2019. Gerald Goodman has been our chief accounting officer since July 31, 2018 and was elected our Chief Financial Officer on November 12, 2020. Mr. Goodman is a certified public accountant and, since 2014, has practiced with his own firm, Gerald Goodman CPA P. C. From January 1, 2010 until December 31, 2014, Mr. Goodman practiced with Madsen & Associates, CPA' s Inc., Murray, Utah, and was a non- equity partner and managed the firm' s SEC practice. Mr. Goodman is a director of Lifestyle Medical Network, Inc., which provides management services to healthcare providers. From 1971 to 2010, Mr. Goodman was a partner in the accounting firm of Wiener, Goodman & Company P. C. Mr. Goodman is a 1970 graduate of Pennsylvania State University where he received a B. S. Degree in Accounting. Alan Smith, Ph. D., serves as Chief Operating Officer of Nutriband and President of 4P Therapeutics, a wholly owned subsidiary of Nutriband. He joined the Company after Nutriband acquired 4P Therapeutics in 2018. Dr. Smith co- founded 4P Therapeutics in 2011 to develop drug- device and biologic- device combination products to meet the needs of patients, physicians, and payers, and was Vice President, Clinical, Regulatory, Quality and Operations at the time of the acquisition. Dr. Smith is co- inventor of the Company' s Aversa ™ abuse deterrent transdermal system technology. Dr. Smith has over 20 years of experience in the research and development of drug and biologic delivery systems, diagnostics and medical devices for treatment and management of chronic pain, diabetes, and cardiovascular disease. Previously, he was with Altea Therapeutics, a venture capital funded company focused on novel transdermal drug and biologic delivery, most recently serving as Vice President, Product Development and Head of Clinical R & D, Regulatory Affairs, and Project Management. Prior to joining Altea Therapeutics, he led the development of transdermal glucose monitoring systems at SpectRx, Inc., a publicly traded noninvasive diagnostics company. Dr. Smith received Ph. D. and M. S. degrees in Biomedical Engineering from Rutgers University and the University of Medicine and Dentistry of New Jersey. He currently serves on the Editorial Advisory Board of Expert Opinion on Drug Delivery. Jeff Patrick Pharm. D. currently serves as Director of Drug Development Institute at the Ohio State University Comprehensive Cancer Center. Dr. Patrick most recently serving as Chief Scientific Officer for New Haven Pharmaceuticals. Prior roles included global vice president of professional affairs at Mallinckrodt Pharmaceuticals, Inc.; and roles with ascending responsibilities at Dyax, Myogen / Gilead, Actelion and Sanofi- Synthelabo, Inc. Dr. Patrick is a residency- trained clinical pharmacist with approximately 20 years of pharmaceutical industry experience. He brings expertise in executive leadership, scientific and medical strategy, drug development and commercialization to the company. Prior to pursuing a career in research and development, Patrick was an ambulatory care clinical pharmacist at the University of Tennessee Medical Center and a clinical assistant professor of pharmacy at the University of Tennessee College of Pharmacy, where he earned his doctorate in pharmacy. He also completed the Wharton School of Business Pharmaceutical Executive Program. Dr. Patrick works for us on a part- time basis. CORPORATE GOVERNANCE AND THE BOARD OF DIRECTORS Board Leadership Structure and Risk Oversight Gareth Sheridan serves as Chief Executive Officer and Serguei Melnik is serving as our Chairman and President. Our Chairman leads the Board of Directors in its discussions and has such other duties as are prescribed

by the Board. As Chief Executive Officer, Mr. Sheridan is responsible for implementing the Company' s strategic and operating objectives and day- to- day decision- making related to such implementation. The Board of Directors currently has three standing committees (audit, compensation, and nominating and corporate governance) that are chaired and composed entirely of directors who are independent under Nasdaq and SEC rules. Given the role and scope of authority of these committees, and that a majority of the members of the Board are independent, the Board of Directors believes that its leadership structure is appropriate. We select directors as members of these committees with the expectation that they will be free of relationships that might interfere with the exercise of independent judgement. Our Board of Directors is our Company' s ultimate decision- making body, except with respect to those matters reserved to the stockholders. Our Board of Directors selects our senior management team, which is charged with the conduct of our business. Our Board of Directors also acts as an advisor and counselor to senior management and oversees its performance. Board Composition Our business and affairs are managed under the direction of our Board of Directors. The number of directors is determined by our board of directors, subject to the terms of our certificate of incorporation and bylaws. Our board of directors currently consists of six members, four of which are independent directors. Meetings Our Board of Directors held ~~two~~ **three** meetings and acted by written consent eight times during fiscal ~~2024~~ **2025** . Committees of the Board of Directors The board of directors has created three committees — the audit committee, the compensation committee and the nominating and corporate governance committee. Each of the committees has a charter which meets the Nasdaq Stock Market requirements and is composed of three independent directors. The audit committee is comprised of Mr. Hamilton, as chairman, Mr. Bujoreanu and Irina Gram. We believe that Mark Hamilton qualifies as an " audit committee financial expert " under the rules of the Nasdaq Stock Market. The audit committee oversees, reviews, acts on and reports on various auditing and accounting matters to the board, including: the selection of our independent accountants, the scope of our annual audits, fees to be paid to the independent accountants, the performance of our independent accountants and our accounting practices, all as set forth in our audit committee charter. The Audit Committee met three times in fiscal ~~2024~~ **2025** . The compensation committee is comprised of Irina Gram, Chairperson, Mr. Bujoreanu and Dr. Mancas. The compensation committee oversees the compensation of our chief executive officer and our other executive officers and reviews our overall compensation policies for employees generally as set forth in the audit committee charter. If so authorized by the board, the compensation committee may also serve as the granting and administrative committee under any option or other equity- based compensation plans which we may adopt. The compensation committee will not delegate its authority to fix compensation; however, as to officers who report to the chief executive officer, the compensation committee will consult with the chief executive officer, who may make recommendations to the compensation committee. Any recommendations by the chief executive officer are accompanied by an analysis of the basis for the recommendations. The committee will also discuss with the chief executive officer and other responsible officers the compensation policies for employees who are not officers. The compensation committee has the responsibilities and authority relating to the retention, compensation, oversight and funding of compensation consultants, legal counsel and other compensation advisers. The compensation committee members will consider the independence of such advisors before selecting or receiving advice from such advisors. The compensation committee met three times in fiscal ~~2024~~ **2025** . The nominating and corporate governance committee, which is comprised of Dr. Mancas, Mark Hamilton and Mr. Bujoreanu, will identify, evaluate and recommend qualified nominees to serve on our board; develop and oversee our internal corporate governance processes, and maintain a management succession plan. The nominating and corporate governance committee met two times in fiscal ~~2024~~ **2025** . Risk Management The Board has an active role, as a whole and also at the committee level, in overseeing the management of our risks. The Compensation Committee of our Board is responsible for overseeing the management of risks relating to our executive compensation plans and arrangements. The Audit Committee of our Board oversees management of financial risks, under its charter it is to meet periodically and at least four times per year with management to review and assess the Company' s major financial risk exposures and the manner in which such risks are being monitored and controlled. The Nominating and Corporate Governance Committee of our Board is responsible for the management of risks associated with the independence of the Board members and potential conflicts of interest. While each committee is responsible for evaluating certain risks and overseeing the management of such risks, the entire Board of Directors is informed about such risks. Independent Directors ~~Four~~ **Five** of our directors, Mark Hamilton, Radu Bujoreanu, Stefani Mancas ~~and~~ **,** Irina Gram **and Sergei Glinka,** are independent directors based on the NASDAQ definition of independent director. Family Relationships There are no family relationships among our directors and executive officers. Compensation Committee Interlocks and Insider Participation None of our executive officers serve on the board of directors or compensation committee of a company that has an executive officer who serves on our Board or compensation committee. No member of our Board is an executive officer of a company in which one of our executive officers serves as a member of the board of directors or compensation committee of that company. Conflicts of Interest Certain conflicts of interest exist and may continue to exist between the Company and its officers and directors due to the fact that each has other business interests to which they devote their primary attention. Each officer and director may continue to do so notwithstanding the fact that management time should be devoted to the business of the Company. Certain conflicts of interest may exist between the Company and its management, and conflicts may develop in the future. The Company has not established policies or procedures for the resolution of current or potential conflicts of interest between the Company, its officers and directors or affiliated entities. There can be no assurance that management will resolve all conflicts of interest in favor of the Company, and conflicts of interest may arise that can be resolved only through the exercise by management their best judgment as may be consistent with their fiduciary duties. Management will try to resolve conflicts to the best advantage of all concerned. Compliance with Section 16 (a) of the Securities Exchange Act of 1934 Section 16 (a) of the Exchange Act requires our officers and directors, and persons who beneficially own more than ten percent of our Common Stock, to file reports of ownership and changes of ownership of such securities with the SEC. ~~Mr. Goodman,~~ Dr. Smith, Dr. Patrick, Mr. Bujoreanu, and Ms. Gram have not yet filed their Form 3 reports. ~~Gareth Sheridan and Serguei Melnik have not filed Form 4' s reporting receipt of compensation in fiscal years 2024 and 2025; With the exception of~~ Gerald Goodman, who has filed Form 5' s to catch up on **the Form 3 and** Form 4' s due over the past three fiscal years. Mr. Goodman ~~is~~ **, Gareth Sheridan and Serguei Melnik filed** late **Form 4' s** with respect to Form 4' s required to be filed for stock option compensation issuances for fiscal ~~2024 and~~ 2025. No other officer or director has filed any ownership reports. ITEM 11. EXECUTIVE COMPENSATION Executive Compensation The table below shows the compensation for services in all capacities we paid during the years ended January 31, **2025 and** 2024 ~~and 2023~~ to the individuals serving as our principal executive officers during the last completed fiscal year and our other two most highly paid executive officers at the end of the last completed fiscal year (whom we refer to collectively as our " named executive officers "); Name and Principal Position Year Salary $ Bonus Awards $ Stock Awards $ Option / Awards (1) $ Incentive Plan Compensation $ Nonqualified Deferred Earnings $ All Other Compensation $ Total $ Gareth Sheridan, **2025 150, 000 203, 368 5, 000 358, 368 CEO (1)** 2024 150, 000 **38, 000** 82, 110 25, 000 ~~257~~ **285** , 110 ~~CEO (1) 2023 200, 000 38, 000 140, 672 378, 672~~ Serguei Melnik **2025 150, 000 203, 368 5, 000 358, 368 President** 2024 150, 000 82, 110 25, 000 257, 110 ~~President 2023 200, 000 146, 672 346, 672~~ Alan Smith ~~2024~~ **2025** 154, 000 ~~42~~ **142** , ~~720~~ **004** 5, 000 ~~201~~ **301** , ~~720~~ **004** Chief Operating Officer ~~2023~~ **2024** ~~179~~ **154** , 000 ~~57~~ **42** , ~~490 236~~ **720 5** , ~~490~~ **000 201, 720** Gerald Goodman ~~2024~~ **2025** 110, 000 ~~52~~ **147** , ~~866 30~~ **584 5** , 000 ~~192~~ **262** , ~~866~~ **584** Chief Financial Officer ~~2023~~ **2024** ~~160~~ **110** , 000 **52** ~~—~~ ~~114~~ , **866 30** 976 ~~—~~ ~~—~~ 274, 976 (1) ~~During the year ended January 31, 2023, we issued to Gareth Sheridan, our CEO, 11, 667 shares of common stock valued at $ 38~~ , 000 **192** , **866** ~~representing compensation for the year ended January 31, 2023.~~ Directors Compensation **Name (a)** Fees Earned or Paid in Cash **($) (b)** Stock Awards **($) (c)** Option Awards **($) (d)** Non- Equity Incentive Plan Compensation' **($) (e)** Change in Pension Value and NonQualified Deferred Compensation Earnings **($) (f)** All Other Compensation **($) (g)** Total ~~Name~~ ($ ~~) ($) ($) ($) ($) ($) (a) (b) (c) (d) (e) (f) (g~~) (h) Mark Hamilton $ 5, 000 $ ~~—~~ $ ~~10~~ **59** , ~~146~~ **664** $ ~~—~~ $ ~~—~~ $ ~~—~~ $ ~~15~~ **64** , ~~146~~ **664** Radu ~~Bujorneau~~ **Bujoreanu** $ 5, 000 $ ~~—~~ $ ~~11~~ **55** , ~~214~~ **444** $ ~~—~~ $ ~~—~~ $ ~~—~~ $ ~~16~~ **60** , ~~214~~ **444** Stefani Mancas $ 5, 000 $ ~~—~~ $ ~~10~~ **49** , ~~146~~ **116** $ ~~—~~ $ ~~—~~ $ ~~—~~ $ ~~15~~ **54** , ~~146~~ **116** Irina Gram $ 5, 000 $ ~~—~~ $ ~~10, 146~~ $ ~~—~~ $ ~~—~~ $ ~~—~~ $ ~~15~~ **5** , ~~146~~ **000** Employment Agreements with Company Officers The Company entered into a three- year employment agreement with Gareth Sheridan, our CEO, and Serguei Melnik, our President, effective February 1, 2022. The agreement also provides that the executives will continue as a director. The agreement provides for an initial term, commencing on the effective date of the agreement and ending on January 31, 2025, and continuing on a year- to- year basis thereafter unless terminated by either party on not less than 30 days' notice given prior to the expiration of the initial term or any one- year extension. For their services to the Company during the term of the agreement, Mr. Sheridan and Mr. Melnik will receive an annual salary of $ 250, 000 per annum, commencing on the effective date of the agreement. Mr. Sheridan and Mr. Melnik will also receive a performance bonus of 3. 5 % of net income before income taxes. As of July 31, 2022, the Company and Mr. Sheridan and Mr. Melnik mutually agreed to reduce their annual salary to $ 150, 000. ~~The Company entered into a three- year employment agreement with Gerald Goodman, our CFO, effective February 1, 2022. The agreement provides for an initial term, commencing on the effective date of the agreement and ending on January 31, 2025, and continuing on a year- to- year basis thereafter unless terminated by either party on not less than 30 days' notice given prior to the expiration of the initial term or any one- year extension. For his services to the Company during the term of the agreement, Mr. Goodman will receive an annual salary of $ 210, 000 per annum, commencing on the effective date of the agreement. As of July 31, 2022, the Company and Mr. Goodman mutually agreed to reduce his annual salary to $ 110, 000. The Employment Agreements provide for incentive payments as established by the Board of Directors, and the Employment Agreements with Mr. Sheridan and Mr. Melnik provide for a performance bonus as follows:~~ Net Operating Profit Before Income Taxes Performance Bonus On the First $ 10 Million 3. 5 % On the Next $ 40 Million 3. 5 % On the Next $ 50 Million 3. ~~5~~ **0** % On all Amounts Over $ 100 Million ~~3~~ **2** . 5 % Each of the Employment Agreements contains similar provisions for discharge for "

cause ", including breach of the Employment Agreement or specified detrimental conduct by the employee, in which cases accrued compensation would payable as provided in the Employment Agreements. The Agreements also provide for termination by the executives for " good reason ", comprising events such as breach of the Agreement by the Company, assignment of duties inconsistent with the Executive' s position,, or in the event of a change in control of the Company. In the event of a termination by the Company without cause, or by the executive for " good reason ", the Company is required to pay to the Executive in a lump sum in cash within 30 days after the date of termination the aggregate of the following amounts: A. the sum of (1) the executive' s annual minimum salary through the date of termination to the extent not theretofore paid, (2) any annual incentive payment earned by the executive for a prior period to the extent not theretofore paid and not theretofore deferred, (3) any annual performance bonus payment earned by the executive for a prior period to the extent not theretofore paid and not theretofore deferred, (4) any accrued and unused vacation pay and (5) any business expenses incurred by the executive that are unreimbursed as of the date of termination; ~~B~~ **5B** . The product of (1) the performance bonus payment and (2) a fraction, the numerator of which is the number of days that have elapsed in the fiscal year of the Company in which the date of termination occurs as of the date of termination, and the denominator of which is 365; C. the amount equal to the sum of (1) three (3) times the executive' s annual minimum salary; (2) one (1) times the performance bonus payment and (3) one (1) times the incentive payment; D. In the event executive is not fully vested in any retirement benefits with the Company from pension, profit sharing or any other qualified or non- qualified retirement plan, the difference between the amounts executive would have been paid if he or she had been vested on the date his / her employment was terminated and the amounts paid or owed to the executive pursuant to such retirement plans; E. The product of (1) the incentive payment and (2) a fraction, the numerator of which is the number of days that have elapsed in the fiscal year of the Company in which the date of termination occurs as of the date of termination, and the denominator of which is 365; andF. If applicable, the present value of the amount equal to the sum of five (5) years' Performance Bonus pay with such amount being calculated based on the Performance Bonus paid to the Employee the year prior to Termination. In addition, all stock options and warrants outstanding as of the date of termination and held by the executive shall vest in full and become immediately exercisable for the remainder of their full term; all restricted stock shall no longer be restricted to the extent permitted by law, and the Company will use its best efforts, at its sole cost to register such restricted stock as expeditiously as possible. Gross- up Reimbursement on Excise Taxes Paid by Employee on Certain Payments received from Company The Employment Agreements of Mr. Sheridan and Mr. Melnik provide that, to the extent any payment under the Employment Agreement to the executive is subject to the excise tax imposed by section 4999 of the Internal Revenue Code, the executive is entitled to a gross- up payment from the Company to reimburse the executive for additional federal, state and local taxes imposed on executive by reason of the excise tax and the Company' s payment of the initial taxes on such amount. The Company is also required to bear the costs and expenses of any proceeding with any taxing authority in connection with the imposition of any such excise tax. ~~Employment Agreement with Alan Smith The Company entered into a three- year employment agreement with Alan Smith, our Chief Operating Officer, effective October 1, 2021, for an initial term of three years through September 30, 2024. For his services to the Company during the term of the agreement, Mr. Smith receives a fixed base salary of $ 204, 000 per year, payable no less frequently than monthly. This base salary is reviewed not later than the end of each calendar year that Mr. Smith is employed by the Company. As of July 31, 2022, the Company and Mr. Smith mutually agreed to reduce his annual salary to $ 154, 000.~~ Pension Benefits ~~We currently have no plans that provide for payments or other benefits at, following, or in connection with retirement of our officers. OUTSTANDING EQUITY AWARDS AT FISCAL YEAR- END Option Awards Stock Awards Number of Shares of Common Stock Underlying Unexercised Options Exercisable Number of Securities Underlying Unexercised Options Unexercisable Equity Incentive Plan Awards: Number of Securities Underlying Unexercised Unearned Options Options Exercise Price Options Expiration Date Number of Shares or Units of Stock that Have Not Vested Market Value of Shares or Units of Stock That Have Not Vested Equity Incentive Plan Awards: Number of Unearned Shares, Units or Other Rights That Have Not Vested Incentive Plan Awards: Market or Payout Value of Unearned Shares, Units or Other Rights That Name (#) (#) (#) ($) ($) (#) ($) (#) ($) (a) (b) (c) (d) (e) (f) (g) (h) (i) (j) Gareth Sheridan, CEO 23, 333-- $ 4. 58 January 21, 2025---- 29, 167-- $ 4. 50 August 2, 2025---- 25, 000-- $ 4. 12 December 8, 2025---- 70, 000-- $ 2. 12 October 27, 2026---- Serguei Melnik, President 23, 333-- $ 4. 58 January 21, 2025---- 29, 167-- $ 4. 50 August 2, 2025---- 25, 000-- $ 4. 12 December 8, 2025---- 70, 000-- $ 2. 12 October 27, 2026---- Alan Smith, COO 11, 667-- $ 4. 16 January 21, 2025---- 11, 667-- $ 4. 09 August 2, 2025---- 10, 000-- $ 3. 75 December 8, 2025---- 40, 000-- $ 1. 93 October 27, 2026---- Gerald Goodman, CFO 11, 667-- $ 4. 16 January 21, 2025---- 23, 333-- $ 4. 09 August 2, 2025---- 20, 000-- $ 3. 75 December 8, 2025---- 49, 500-- $ 1. 93 October 27, 2026---- 87, 500 (1)-- $ 1. 93 October 27, 2026---- (1) This option held by Mr. Goodman is in the form of a common stock purchase warrant. Bonuses Any bonuses granted in the future will relate to meeting certain performance criteria that are directly related to areas within the named executive' s responsibilities with the Company. As we continue to grow, more defined bonus programs may be established to attract and retain our employees at all levels. Other Director Compensation There are no agreements or arrangements by which any directors or nominees are to receive compensation or other payments from third parties in return for serving on the Board of Directors.~~ We currently have no plans that provide for payments or other benefits at, following, or in connection with retirement of our officers. ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS The following table provides information concerning the beneficial ownership of the Company' s common Stock by each director, certain executive officers, by all directors and officers of the Company as a group as of April ~~26~~ **25** , ~~2024~~ **2025** . In addition, the table provides information concerning the current beneficial owners, if any, known to the Company to hold more than five percent (5 %) of the outstanding common stock of the Company. The amounts and percentage of stock beneficially owned are reported based on regulations of the SEC governing the determination of beneficial ownership of securities. Under the rules of the SEC, a person is deemed to be a " beneficial owner " of a security if that person has or shares " voting power, " which includes the power to dispose of or to direct the disposition of such security. A person is also deemed to be a beneficial owner of any securities of which that person has a right to acquire beneficial ownership within 60 days after April ~~26~~ **25** , ~~2024~~ **2025** . Under these rules, more than one person may be deemed a beneficial owner of the same securities and a person may be deemed a beneficial owner of securities in which he has no economic interest. The percentage of common stock beneficially owned is based on ~~10~~ **11** , ~~969~~ **154** , ~~870~~ **171** shares of common stock outstanding as of April ~~26~~ **25** , ~~2024~~ **2025** . Name and Address (1) of Beneficial Owner (Management and Directors) Shares of Common Stock Owned Directly Shares of Derivative Securities Owned Beneficially Total Beneficial Ownership Including Option Grants Percentage of Issued and Outstanding Common Stock Gareth Sheridan 1, 761, 667 ~~245~~ **251** , 000 2, ~~006~~ **012** , 667 17. ~~89~~ **65** % Serguei Melnik (2) 820, 418 ~~245~~ **251** , 000 1, ~~065~~ **071** , 418 9. ~~50~~ **39** % Stefani Mancas ~~14~~ **16** , ~~125 25~~ **625 31** , 583 ~~39~~ **48** , ~~708 *~~ **208 0. 43 %** Mark Hamilton 17, 208 ~~28~~ **34** , 500 ~~45~~ **51** , 708 ~~*~~ **0. 46 %** Radu Bujoreanu 15, 750 ~~29~~ **35** , 333 ~~45~~ **51** , 083 ~~*~~ **0. 46 %** Irina Gram 1, 167 18, 000 19, 167 ~~*~~ **0. 17 %** Dr. Jeff Patrick 36, 612 ~~160~~ **226** , 000 ~~196~~ **262** , 612 ~~1~~ **2** , ~~77~~ **31** % Alan Smith ~~48~~ **41** , ~~893 143~~ **908 149** , 334 ~~192~~ **191** , ~~227~~ **242** 1. ~~73~~ **69** % Gerald Goodman (3) ~~26~~ **86** , ~~250 267~~ **335 185, 500 271, 835 2. 40 % Sergei Glinka (4) 825** , 000 ~~293~~ **1** , ~~250~~ **650, 000** 2 **, 475, 000 19** , ~~61~~ **33** % All officers and directors as a group ( ~~9~~ **10** individuals) **3, 622, 690** 2, ~~742, 000 1, 161, 750 3, 903, 840 32~~ **832 , 250 6, 454, 940 54** , ~~18~~ **29** % Other Beneficial Owners Vitalie Botgros ~~(4)~~ **3, 087, 272 2, 108, 228 5, 195, 500 39.** 1 ~~, 972, 539 1, 310, 000 3, 282, 539 26. 73 % Serguei Glinka (5) 825, 000 1, 650, 000 2, 475, 000 19. 61~~ % * Less than One (1 %) Percent. (1) The address for each director and officer, unless indicated otherwise, is c / o Nutriband, Inc., 121 South Orange Ave., Suite 1500, Orlando, FL 32801. **The address for Vitalie Botgros is Rua das Ladieras 5, Porto Santo, Portugal 9400- 131 for Jet Services and 1Apriliou, 47 Demetriou Bldg. 2, 1st Floor, Flat / Office 12, 3117 Limassol, Cyprus.** (2) Includes 29, 167 shares owned by Mr. Melnik' s wife, as to which Mr. Melnik disclaims beneficial ownership, and 58, 334 shares held under the UGMA for the benefit of his minor children. (3) Gerald Goodman holds ~~26~~ **86** , ~~250~~ **335** shares directly and has been granted three- year options under the Company' s ~~2021 Employee~~ Stock Option Plan to purchase an aggregate of ~~267~~ **185** , ~~000~~ **500** shares of common stock at exercise prices ranging from $ 1. 93 per share to $ ~~4~~ **7** . ~~16~~ **34** per share. **(** ~~Mr. Goodman also was issued on October 22, 2021 a stock purchase warrant for the purchase of 87, 500 shares of common stock, exercisable at $ 4 . 20 per share. On October 27, 2023, this warrant was replaced by a new three- year warrant expiring October 27, 2026, exercisable at $ 1. 93 per share, for the same number of shares, (4) Mr. Botgros, to the knowledge of the Company based on a Schedule 13- D filing on January 23, 2024, is the ultimate beneficial owner of 1, 347, 524 shares of common stock held by TH Jet Services Ltd., which is wholly owned by Nociata Holding Limited, a Cyprus company owned by Mr. Botgros. Nociata Holding Limited purchased 525, 000 shares of common stock in Nutriband' s equity financing that was completed April 19, 2024, and TH Jet Services Ltd. purchased 130, 000 shares of common stock in that financing, which results in Mr. Botgros having an estimated beneficial ownership of 1, 972, 539 shares of common stock and of warrants to purchase 1, 310, 000 shares of common stock based on available records. Mr. Botgros' address is c / o Nociata Holding Limited, 1Apriliou, 47 Demetriou Bldg., 2, 1st Floor, Flat / Office 12, 3117 Limassol, Cyprus. (5~~ ) Mr. Glinka purchased 825, 000 shares of common stock and 1, 650, 000 warrants in Nutriband' s equity financing that was completed April 19, 2024. Mr. Glinka' s address is 13 Morfu Str., Matina Court FL 402, 3012 Limassol, Cyprus. The Company has no further information as to additional shares of common stock, if any, held by Mr. Glinka. To our knowledge, all beneficial owners named in this table have sole voting and investment power with respect to all shares shown as beneficially owned by them. Changes in Control We are unaware of any contract or other arrangement the operation of which may at a subsequent date result in a change in control of our company. ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE ~~UPDATE On February~~ **Five of our directors, Sergei Glinka, Mark Hamilton, Radu Bujoreanu, Stefani Mancas and Irina Gram are independent directors based on the NASDAQ definition of independent director. Issuance of Stock Options** 1 **. The following table sets forth** ~~, 2023, the~~

~~Board of Directors ratified and authorized the issuance~~ **issuances** of **stock** ~~Option Award Agreements with respect option~~ **options expiring March 20** ~~grants approved February 1~~ , ~~2023~~ **2027** ~~, by the Compensation Committee,~~ to **certain** officers and directors **on March 20, 2024** ~~as set forth in the table below~~ . **Date** ~~Name No.~~ of **Grant Title and Amount (1) Option Holder Exercise Price March 20, 2024 Option to purchase 97, 500** ~~Shares~~ **shares of common stock. Gareth Sheridan, Chief Executive Officer $ 2. 62 per share / NA March 20, 2024 Option to purchase 97, 500 shares of common stock. Serguei Melnik, President $ 2. 62 per share / NA March 20, 2024 Option to purchase 75, 000 shares of common stock. Gerald Goodman, Chief Financial Officer $ 2. 37 per share / NA March 20, 2024 Option to purchase 70, 000 shares of common stock. Alan Smith, Chief Operating Officer $ 2. 37 per share / NA March 20, 2024 Option to purchase 25, 000 shares of common stock.** Jeff Patrick, Chief Scientific Officer ~~30, 000~~ $ ~~3~~ **2** . ~~98 Services Rendered in fiscal~~ **37 per share / NA March 20, 2024On** ~~--~~ **2024** ~~September 18, 2023, the Board of Directors ratified and authorized the issuance of~~ Option ~~Award Agreements with respect option grants approved September 18, 2023, by the Compensation Committee,~~ to **purchase 12, 500 shares of common stock. Dianna Mather $ 2. 37 per share / NA March 20, 2024 Option to purchase 12, 500 Oleg Buria, consultant $ 2. 37 per share / NA 2. The following table sets forth issuances of stock options expiring January 23, 2028 to certain** officers and directors **on January 23, 2025** ~~as set forth in the table below~~ . **Date** ~~Name No.~~ of **Grant Title and Amount (1) Option Holder Exercise Price January 23, 2025 Option to purchase 29, 333** ~~Shares~~ **shares of common stock. Gareth Sheridan, Chief Executive Officer $ 8. 07 per share / NA January 23, 2025 Option to purchase 29, 333 shares of common stock. Serguei Melnik, President $ 8. 07 per share / NA January 23, 2025 Option to purchase 17, 667 shares of common stock. Gerald Goodman, Chief Financial Officer $ 7. 34 per share / NA January 23, 2025 Option to purchase 17, 667 shares of common stock. Alan Smith, Chief Operating Officer $ 7. 34 per share / NA January 23, 2025 Option to purchase 17, 667 shares of common stock.** Jeff Patrick, Chief Scientific Officer ~~20, 000~~ $ ~~2~~ **7** . **34 per share / NA January 23** ~~65 Services Rendered in fiscal 2024On October 19~~ , ~~2023~~ **2025** ~~, the Board of Directors ratified and authorized the issuance of~~ Option **to purchase 17** ~~Award Agreements with respect option grants approved October19~~ , **667 shares of** ~~2023, by the Compensation Committee modified a~~ common stock **. Dianna Mather, Chief Accountant $ 7. 34 per share / NA January 23, 2025 Option to** purchase ~~warrant issued~~ **13, 583 shares of common stock Stefani Mancas, Director $ 7. 34 per share / NA January 23, 2025 Option** to ~~Gerald Goodman~~ **purchase 15** , ~~as set forth~~ **333 shares of common stock. Radu Bujoreanu, Director $ 7. 34 per share / NA January 23, 2025 Option to purchase 17, 667 shares of common stock Patrick Ryan, Consultant $ 7. 34 per share / NA January 23, 2025 Option to purchase 16, 500 shares of common stock Mark Hamilton, Director $ 7. 34 per share / NA Investment by Director** in the ~~table below. Name No.~~ **Company' s Private Equity Placement in Europe On April 19, 2024, Sergei Glinka, who was elected to our Board** of **Directors on May 15, 2024, invested $ 3, 300, 000 in the Company' s $ 8, 400, 000 private equity financing with European investors. The offering consisted of 2, 100, 000 units (" Units "), at a price of $ 4. 00 per Unit, each Unit consisting of one share of common stock and a Warrant to purchase two** Shares ~~No.~~ of **common stock (the "** Warrants ~~Gareth Sheridan, CEO 70~~ **"). For his investment Mr. Glinka received 825** , 000 ~~-~~ **shares of common stock and Warrants to purchase 1, 650, 000 shares of common stock. The Warrants have an exercise price of** $ ~~2~~ **6** . ~~12 Services Rendered~~ **43, are exercisable by payment of the exercise price** in ~~fiscal~~ **cash only and expire April 19,** ~~2024~~ **2029** ~~Serguei Melnik~~ , ~~Chairman &~~ **five years from the date of issuance. The offering was made solely to investors** ~~President~~ - **resident** ~~70, 000- $ 2. 12 Services Rendered~~ **outside the United States and was not registered under the Securities Act pursuant to the exemptions from registration provided** in ~~fiscal 2024 Gerald Goodman, CFO 49, 500- $ 1~~ **the SEC' s Regulation S and other exemptions under the Securities Act** . **ITEM** ~~93 Services Rendered in fiscal 2024 Alan Smith, Chief Operating Officer 40, 000- $ 1. 93 Services Rendered in fiscal 2024 Jeff Patrick, Chief Scientific Officer 40, 000- $ 1. 93 Services Rendered in fiscal 2024 Gerald Goodman, CFO- 87, 500 $ 1. 93 Services Rendered in fiscal 2024ITEM~~ 14. PRINCIPAL ACCOUNTING FEES AND SERVICES The following table sets forth the fees billed by our independent accountants, Sadler, Gibb & Associates, LLC, for each of our last two years for the categories of services indicated. Year Ended January 31 Audit fees $ ~~118~~ **136** , ~~800~~ **160** $ ~~86~~ **106** , **340-** ~~640 Audit - related fees 20, 100 6, 500 Tax fees~~ -- All other fees $- $- Audit fees consist of fees related to professional services rendered in connection with the audit of our annual financial statements and review of our interim financial statements. Audit- Related Fees. Audit- related services consist of fees billed by our independent registered public accounting firms for assurance and related services that are reasonably related to the performance of the audit or review of the Company' s financial statements and are not reported under " Audit Fees. " All other fees relate to professional services rendered in connection with our registration statements and acquisition audits. Our policy is to pre- approve all audit and permissible non- audit services performed by the independent accountants. These services may include audit services, audit- related services, tax services and other services. Under our audit committee' s policy, pre- approval is generally provided for particular services or categories of services, including planned services, project based services and routine consultations. In addition, the audit committee may also pre- approve particular services on a case- by- case basis. Our board approved all services that our independent accountants provided to us in the past two fiscal years. PART IV ITEM **16** ~~15.~~ Exhibits. Exhibit Number Description 1. 1 [ Reserved ] 3. 1A Articles of Incorporation. (1) 3. 1B Amendment to Articles of Incorporation, filed May 12, 2016. (1) 3. 1 Certificate of Amendment filed January 21, 2020. (Filed as Exhibit 3. 1 to the Company' s Current Report on Form 8- K, filed January 27, 2020). 3. 1C Certificate of Change, filed with the Nevada Secretary of State on August 4, 2022. (13) 3. 2 By- laws (1) 3. 2B Amended and Restated By- Laws adopted January 21, 2022. (12) 4. 3 Securities purchase agreement dated October 29, 2019 among the Company, Jefferson Street Capital LLC and Platinum Point Capital LLC (6) 4. 4 Form of convertible 6 % promissory note issued pursuant to Exhibit 4. 3 (6) 4. 10 Form of Common Stock Purchase Warrant issued to Platinum Point Capital LLC and Jefferson Street Capital LLC (6) 4. 14 † 2021 Employee Stock Option Plan. (11) 4. 15 † Form of Stock Option Grant Notice. (11) 4. 16 Form of Common Stock Purchase Warrant issued in the Company' s initial public offering in 2021 (9) 4. 17 Form of Warrant issued to the Representative. (14) 4. 18 † 2024 Amended and Restated Stock Option Plan, adopted March 20, 2024. (15) 4. 19 Form of Common Stock Purchase Warrant issued in 2024 Equity Financing (18) 5. 1 [ Reserved ] 10. 1 Share exchange agreement dated January 15, 2016 by and among the Company, Nutriband Limited, an Ireland corporation, and Gareth Sheridan and / or his nominee (1) 10. 4 Acquisition agreement dated April 5, 2018 between the Company and 4P Therapeutics LLC. (3) 10. 5 † Form of agreement with independent directors. (4) 10. 6 Exclusive master distribution agreement dated April 13, 2018 between the Company and EMI- Korea (Best Choice), Inc. (4) 10. 15 † Employment Agreement, dated April 23, 2019, between Gareth Sheridan and the Company. (5) 10. 16 † Employment Agreement, dated April 23, 2019, between Serguei Melnik and the Company. (5) 10. 17 † Employment Agreement, dated February 19, 2019, between Jeffrey Patrick and the Company. (5) 10. 18 † Employment Agreement, dated January 1, 2018, between Sean Gallagher and the Company. (5) 10. 19 Purchase Agreement, dated August 31, 2020, by and among the Company and Pocono Coated Products, LLC. (7) 10. 20 Security Agreement, between the Company and Pocono Coated Products, LLC. (7) 10. 21 Promissory Note Issued by the Company on August 31, 2020 to Pocono Coated Products, LLC. (7) 10. 22 License Agreement, dated December 9, 2020, between the Company and Rambam Med- Tech Ltd. (8) 10. 23 Distribution Agreement, dated March 26, 2021, between the Company and BPM Inno Ltd. (8) 10. 24 Stock Purchase Agreement, dated December 7, 2020, between the Company and BPM Inno Ltd. (8) 10. 25 Amendment No. 1 to Purchase Agreement, dated August 31, 2020, by and among the Company and Pocono Coated Products, LLC (8a) 10. 26 Services Agreement dated October 4, 2021, between Active Intelligence, LLC and Diomics Corporation. (10) 10. 27 † Employment Agreement effective February 1, 2022, between the Company and Gareth Sheridan. (12) 10. 28 † Employment Agreement effective February 1, 2022, between the Company and Serguei Melnik. (12) 10. 29 † Employment Agreement effective February 1, 2022, between the Company and Gerald Goodman. (12) 10. 30 Creditline Promissory Note, dated July 13, 2023. (16) 10. 31 Conversion Agreement, dated December 19, 2023. (17) 10. 32 Form of Subscription Agreement for April 19, 2024 Equity Financing (19) **10. 33 Form of Note Conversion Agreement dated May 13, 202420 10. 35 Commercial Development and Clinical Supply Agreement (" Agreement "), made on January 4, 2023, between Kindeva Drug Delivery, L. P. and 4P Therapeutics, LLC. * 10. 36 Amendment No. 1, dated as of February 4, 2025, to the Commercial Development and Clinical Supply Agreement, by and between Kindeva Drug Delivery L. P. and 4P Therapeutics, LLC *.** 21. 1 List of Subsidiaries of Nutriband Inc. (14) 23. 1 [ Reserved ] 31. 1 Certification of Principal Executive Officer pursuant to Rule 13a- 14 (a) or Rule 15d- 14 (a) of the Exchange Act. * 31. 2 Certification of Principal Financial Officer pursuant to Rule 13a- 14 (a) or Rule 15d- 14 (a) of the Exchange Act. * **32. 1** Certification of the Principal Executive Officer ~~and~~ **pursuant to Section 906 of the Sarbanes- Oxley. * 32. 2 Certification of the** Principal Financial Officer pursuant to Section 906 of the Sarbanes- Oxley. * 101. INS Inline XBRL Instance Document. ***** 101. SCH Inline XBRL Taxonomy Extension Schema Document. ***** 101. CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document. ***** 101. DEF Inline XBRL Taxonomy Extension Definition Linkbase Document. ***** 101. LAB Inline XBRL Taxonomy Extension Label Linkbase Document. ***** 101. PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document. ***** Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). Filing Fee Table * Filed herewith. † Executive compensation plan or arrangement. (1) Filed as exhibit to the Company' s registration statement on Form 10, which was filed with the Commission on June 2, 2016, and incorporated herein by reference. (2) Filed as an exhibit to the Company' s report on Form 8- K, which was filed with the Commission on January 27, 2020 and incorporated herein by reference. (3) Filed as an exhibit to the Company' s report on Form 8- K, which was filed with the Commission on April 10, 2018 and incorporated herein by reference. (4) Filed as an exhibit to the Company' s annual report on Form 10- K for the year ended January 3, 2019 which was filed with the Commission on April 19, 2019, and incorporated herein by reference. (5) Filed as an exhibit to the Company' s Registration Statement on Form S- 1 / A, which was filed with the Commission on May 19, 2020, and incorporated herein by reference. (6) Filed as an exhibit to the Company' s report on Form 8- K, which was filed with the Commission on November 4, 2019, and incorporated herein by reference. (7) Filed as an exhibit to the

Company' s report on Form 8- K, which was filed with the Commission on September 4, 2020, and incorporated herein by reference. (8) Filed as exhibits to the Company' s report on Form 8- K, which was filed with the Commission on March 11, 2021, and incorporated herein by reference. (8a) Filed as an exhibit to the Company' s report on Form 8- K, which was filed with the Commission on September 1, 2021, and incorporated herein by reference. (9) Filed as ~~an exhibit~~ **Exhibit 4. 12** to Amendment 2 to the Company' s Registration Statement on Form S- 1, which was filed with the Commission on October 1, ~~2022~~ **2021** . (10) Filed as an exhibit to the Company' s Current Report on Form 8- K, which was filed with the Securities and Exchange Commission on October 12, 2021, and incorporated herein by reference. (11) Filed as an exhibit to the Company' s Registration Statement on Form S- 8, which was filed with the Commission on November 5, 2021, and incorporated herein by reference. (12) Filed as an exhibit to the Company' s Current Report on Form 8- K, which was filed with the Commission on January 27, 2022, and incorporated herein by reference. (13) Filed as Exhibit 3. 1C to the Company' s Current Report on Form 8- K, which was filed with the Commission on August 10, 2022, and incorporated herein by reference. (14) Filed as an exhibit to the Company' s Registration Statement on Form S- 1, which was filed with the Commission on June 26, 2023, and incorporated herein by reference (15) Filed as Exhibit 4. 16 to the Company' s Amendment No. to its Current Report on Form 8- K, which was filed with the Commission on March 28, 2024 and incorporated herein by reference. (16) Filed as Exhibit 10. 30 to the Company' s Current Report on Form 8- K, which was filed with the Commission on July 14, 2023. (17) Filed as Exhibit No. 10. 31 to the Company' s Current Report on Form 8- K, which was filed with the Commission on December 29, 2023. (18) Filed as Exhibit No. 4. 19 to the Company' s Current Report on Form 8- K, which was filed with the Commission on April 23, 2024. (19) Filed as Exhibit No. 10. 32 to the Company' s Current Report on Form 8- K, which was filed with the Commission on April 23 **, 2024. (20) Filed as Exhibit No. 10. 33 to the Company' s Current Report on Form 8- K, which was filed with the Commission on May 21** , 2024. (b) Financial Statement Schedules All schedules have been omitted because either they are not required, are not applicable or the information is otherwise set forth in the financial statements and related notes thereto. ITEM 16. FORM 10- K SUMMARY SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Date: April ~~30~~ **28** , ~~2024~~ **2025** NUTRIBAND INC. By: / s / Gareth Sheridan Gareth Sheridan Chief Executive Officer By: / s / Gerald Goodman Gerald Goodman Chief Financial Officer (Principal Financial and Accounting Officer) Signature Title Date / s / Gareth Sheridan Chief Executive Officer and Director April ~~30~~ **28** , ~~2024~~ **2025** Gareth Sheridan / s / Serguei Melnik Director April ~~30~~ **28** , ~~2024~~ **2025** Serguei Melnik **Director Sergei Glinka** / s / Radu Bujoreanu Director April ~~30~~ **28** , ~~2024~~ **2025** Radu Bujoreanu / s / Mark Hamilton Director April ~~30~~ **28** , ~~2024~~ **2025** Mark Hamilton / s / Stefani Mancas Director April ~~30~~ **28** , ~~2024~~ **2025** Stefani Mancas / s / Irina Gram Director April ~~30~~ **28** , ~~2024~~ **2025** Irina Gram ~~No0~~ **Nohttp: / / fasb** . ~~53 0. 698459547false~~ **org / us- gaap / 2025 # GoodwillAndIntangibleAssetImpairmentfalse** ~~FY2023~~ **FY2024 - 02- 01 2025- 01- 31us- gaap: CommonStockMember2024- 02- 01 2025- 01- 31ntrb: WarrantsMember2024- 02- 01 2025- 01- 312024- 07- 312025- 04- 252025- 01- 312024- 01- 312023** - 02- 01 2024- 01- 31us- gaap: **CommonStockMember2024** - 01- 31us- gaap: ~~WarrantMember2023~~ **AdditionalPaidInCapitalMember2024** - 01- 31us- gaap: ~~WarrantMember2024~~ **AccumulatedOtherComprehensiveIncomeMember2024** - 01- 31us- gaap: **RetainedEarningsMember2024** ~~WarrantMember ntrb:ExercisePricesOneMember2023- 02- 01 2024~~ - 01- 31us- gaap: **TreasuryStockCommonMember2024** ~~WarrantMember ntrb:ExercisePricesOneMember2024~~ - 01- 31us- gaap: **CommonStockMember2024** ~~WarrantMember ntrb:ExercisePricesTwoMember2023~~ - 02- 01 ~~2024~~ **2025** - 01- 31us- gaap: ~~WarrantMember ntrb:ExercisePricesTwoMember2024~~ **AdditionalPaidInCapitalMember2024- 02- 01 2025** - 01- 31us- gaap: **TreasuryStockCommonMember2024** ~~WarrantMember ntrb:ExercisePricesThreeMember2023~~ - 02- 01 ~~2024~~ **2025** - 01- 31us- gaap: ~~WarrantMember ntrb:ExercisePricesThreeMember2024~~ **AccumulatedOtherComprehensiveIncomeMember2024- 02- 01 2025** - 01- 31us- gaap: **RetainedEarningsMember2024** ~~WarrantMember ntrb:ExercisePricesFourMember2023~~ - 02- 01 ~~2024~~ **2025** - 01- 31us- gaap: **CommonStockMember2025** ~~WarrantMember ntrb:ExercisePricesFourMember2024~~ - 01- 31us- gaap: ~~StockOptionMember2022~~ **AdditionalPaidInCapitalMember2025** - 01- 31us- gaap: **AccumulatedOtherComprehensiveIncomeMember2025** ~~StockOptionMember2022- 02- 01 2023~~ - 01- 31us- gaap: ~~StockOptionMember2023~~ **RetainedEarningsMember2025** - 01- 31us- gaap: ~~StockOptionMember2024~~ **TreasuryStockCommonMember2025- 01- 312023** - 01- 31us- gaap: **CommonStockMember2023** ~~StockOptionMember ntrb:ExercisePricesOneMember2023- 02- 01 2024~~ - 01- 31us- gaap: ~~StockOptionMember ntrb~~ **AdditionalPaidInCapitalMember2023- 01- 31us- gaap** : ~~ExercisePricesOneMember2024~~ **AccumulatedOtherComprehensiveIncomeMember2023** - **01- 31us- gaap:RetainedEarningsMember2023- 01- 31us- gaap:TreasuryStockCommonMember2023- 01- 31us- gaap:** CommonStockMember2023- 02- 01 2024- 01- ~~31ntrb~~ **31us- gaap** : ~~WarrantsMember2023~~ **AdditionalPaidInCapitalMember2023** - 02- 01 2024- 01- ~~312023~~ **31us-** gaap: **AccumulatedOtherComprehensiveIncomeMember2023** ~~WarrantMember ntrb:ExercisePricesTwoMember2023~~ - 02- 01 2024- 01- 31us- gaap: **RetainedEarningsMember2023** ~~WarrantMember ntrb:ExercisePricesTwoMember2024- 01- 31us- gaap:WarrantMember ntrb:ExercisePricesThreeMember2023~~ - 02- 01 2024- 01- 31us- gaap: **TreasuryStockCommonMember2023** ~~WarrantMember ntrb:ExercisePricesThreeMember2024- 01- 31us- gaap:WarrantMember ntrb:ExercisePricesFourMember2023~~ - 02- 01 2024- 01- ~~31us~~ **31ntrb:FourPTherapeuticsLLCMember2018- 08- 01ntrb:FourPTherapeuticsLLCMember us** - gaap: **CommonStockMember2018- 08** ~~WarrantMember ntrb:ExercisePricesFourMember2024~~ - 01 **2018** - ~~31us~~ **08- 01ntrb:FourPTherapeuticsLLCMember us** - gaap: ~~StockOptionMember2022~~ **CommonStockMember2018** - ~~01~~ **08** - ~~31us~~ **01ntrb:FourPTherapeuticsLLCMember us** - gaap: ~~StockOptionMember2022~~ **IntellectualPropertyMember2018** - ~~02~~ **08** - **012018** ~~01 2023~~ - ~~01~~ **08** - ~~31us~~ **01ntrb:PoconoPharmaceuticalsMember2020- 08- 31ntrb:CreditLineNoteFacilityMember us** - gaap: ~~StockOptionMember2023~~ **RelatedPartyMember2023** - ~~01~~ **03** - ~~31us~~ **31ntrb:CreditLineNoteFacilityMember us** - gaap: **RelatedPartyMember2023** - 07- **31us** ~~31srt:MaximumMember us~~ - gaap: ~~MachineryAndEquipmentMember2025~~ **CommonStockMember2024** - 01- 31us- gaap: **AdditionalPaidInCapitalMember2024** ~~CostOfSalesMember2024- 02- 01 2025~~ - 01- 31us- gaap: **AccumulatedOtherComprehensiveIncomeMember2024** ~~CostOfSalesMember2023- 02- 01 2024~~ - 01- 31us- gaap: ~~EquipmentMember2025~~ **RetainedEarningsMember2024** - 01- 31us- gaap: ~~EquipmentMember2024~~ **TreasuryStockCommonMember2024- 01- 312022** - 01- 31us- gaap: ~~MachineryAndEquipmentMember2025~~ **CommonStockMember2022** - 01- 31us- gaap: ~~MachineryAndEquipmentMember2024~~ **AdditionalPaidInCapitalMember2022** - 01- 31us- gaap: ~~FurnitureAndFixturesMember2025~~ **AccumulatedOtherComprehensiveIncomeMember2022** - 01- 31us- gaap: ~~FurnitureAndFixturesMember2024~~ **RetainedEarningsMember2022** - 01- 31us- gaap: ~~LineOfCreditMember2025~~ **TreasuryStockCommonMember2022** - 01- 31us- gaap: ~~LineOfCreditMember2024~~ **CommonStockMember2022** - 02- 01 ~~2025~~ **2023** - 01- 31us- gaap: ~~LoansPayableMember2025~~ **AdditionalPaidInCapitalMember2022- 02- 01 2023** - 01- 31us- gaap: ~~LoansPayableMember2024~~ **AccumulatedOtherComprehensiveIncomeMember2022- 02** - 01 ~~- 312022- 04- 03ntrb:AutomobileMember2022- 04- 03 2022~~ **2023** ~~- 04- 03us- gaap:NotesPayableOtherPayablesMember2025~~ - 01- 31us- gaap: ~~NotesPayableOtherPayablesMember2024~~ **RetainedEarningsMember2022- 02- 01 2023** - 01- 31us- gaap: ~~LineOfCreditMember2023~~ **TreasuryStockCommonMember2022** - ~~07~~ **02** - **01 2023** ~~17ntrb:NotePayableRelatedPartyMember2025~~ - 01- ~~31ntrb~~ **312018- 08- 01srt** : ~~NotePayableRelatedPartyMember2024~~ **MinimumMember2018** - **08- 01srt:MaximumMember2018- 08- 01ntrb:PoconoPharmaceuticalsMember2020- 08-** 312024- **05** - **15ntrb** ~~31us- gaap~~ : ~~CorporateAndOtherMember2022~~ **NotePayableRelatedPartyMember2024** - 02- 01 ~~2023~~ **2025** - 01- 31ntrb: ~~ResearchAndDevelopment4PTherapeuticsMember2023~~ **NotePayableRelatedPartyMember2023** - 02- 01 2024- 01- 31ntrb: ~~ResearchAndDevelopment4PTherapeuticsMember2022~~ **SecuredBorrowingLiabilityMember2023- 07- 19ntrb:SecuredBorrowingLiabilityMember2024** - 02- 01 ~~2023~~ **2025** - 01- 31ntrb: ~~GoodwillImpairmentPoconoPharmaceuticalsMember2023~~ **SecuredBorrowingLiabilityMember2023** - 02- 01 2024- 01- ~~31ntrb~~ **31srt** : ~~GoodwillImpairmentPoconoPharmaceuticalsMember2022~~ **MaximumMember2017- 12- 22 2017- 12- 22srt:MinimumMember2017- 12- 22 2017- 12- 22us-gaap:IntellectualPropertyMember2024** - 02- 01 ~~2023~~ **2025** - 01- 31ntrb: **CustomerBaseMember2025** ~~OutsideTheUnitedStatesMember2023- 02- 01 2024~~ - 01- 31ntrb: **CustomerBaseMember2024** ~~OutsideTheUnitedStatesMember2022- 02- 01 2023- 01- 31country:US2024- 01- 31country:US2023- 01- 31ntrb:OutsideTheUnitedStatesMember2024- 01- 31ntrb:OutsideTheUnitedStatesMember2023~~ - 01- 31us- gaap: ~~CorporateAndOtherMember2024~~ **IntellectualPropertyMember2025** - 01- 31us- gaap: ~~CorporateAndOtherMember2023~~ **IntellectualPropertyMember2024- 01- 31srt:ChiefExecutiveOfficerMember2025** - 01- 31ntrb: ~~PoconoPharmaceuticalsMember2024~~ **EmployeeMember2025** - 01- ~~31ntrb~~ **31us- gaap** : ~~PoconoPharmaceuticalsMember2023~~ **CommonStockMember2024** - ~~01- 31ntrb~~ 04- **19** 302024 - **2024- 04- 192024- 04- 192024- 04- 19 2024- 04- 19us- gaap: CommonStockMember2024- 04- 19ntrb: TIIJetServicesLDAMember2024- 02** - 01 **2025** ~~- 312023~~ - 01- **312024- 05- 15 2024- 05-** ~~31us~~ **15us** - gaap: ~~RelatedPartyMember2024~~ **WarrantMember2024** - ~~01~~ **05** - ~~31us~~ **15 2024- 05- 15srt: ChiefFinancialOfficerMember us** - gaap: ~~RelatedPartyMember2023~~ **CommonStockMember2024** - ~~01~~ **06** - ~~312022~~ **05 2024- 06- 05us- gaap: CommonStockMember2024- 06- 05 2024- 06- 05us- gaap: StockOptionMember2023** - 02- 01 2023- ~~01~~ **02** - ~~31us~~ **01us** - gaap: ~~CommonStockMember2023~~ **StockOptionMember2023** - ~~01~~ **02** - ~~31us~~ **01us** - gaap: **StockOptionMember2023** ~~AdditionalPaidInCapitalMember2023- 01- 31us- gaap: AccumulatedOtherComprehensiveIncomeMember2023- 01- 31us- gaap: RetainedEarningsMember2023- 01- 31us- gaap: TreasuryStockCommonMember2023- 01- 31us- gaap: AdditionalPaidInCapitalMember2023~~ - 02- 01 2024- 01- **31ntrb: TIIJetServicesLDAMember us- gaap: LineOfCreditMember2023- 07- 17ntrb: TIIJetServicesLDAMember2023- 07- 17ntrb: TIIJetServicesLDAMember2023- 12- 31ntrb: TIIJetServicesLDAMember2023- 12- 31 2023- 12- 31ntrb: TIIJetServicesLDAMember us- gaap: CommonStockMember2023- 12- 31 2023- 12- 31srt: ExecutiveOfficerMember2023- 09- 30 2023- 09- 30srt: DirectorMember2023- 02- 01 2023- 10- 31srt:**

MinimumMember srt: ExecutiveOfficerMember2023- 09- 30srt: MinimumMember srt: ExecutiveOfficerMember2023- 10- 31srt: MaximumMember srt: ExecutiveOfficerMember2023- 09- 30srt: MaximumMember srt: ExecutiveOfficerMember2023- 10- 31srt: DirectorMember2023- 09- 30srt: DirectorMember2023- 10- 31srt: DirectorMember2023- 10- 31 2023- 10- 31srt: ChiefFinancialOfficerMember us- gaap: WarrantMember2023- 10- 31srt: ChiefFinancialOfficerMember2023- 10- 31us- gaap: ~~CommonStockMember2023~~ WarrantMember2023- 10- 31 2023- 10- 31srt: ChiefFinancialOfficerMember us- gaap: WarrantMember2023 - 02- 01 2024- 01- 312016- 01- 15us- gaap: SeriesAPreferredStockMember2019- 05- 24us- gaap: SeriesAPreferredStockMember2019- 06- 202019- 06- 25 2019- 06- 25srt: MaximumMember us- gaap: CommonStockMember2019- 06- 25srt: MinimumMember us- gaap: CommonStockMember2019- 06- 25srt: MinimumMember us- gaap: CommonStockMember2020- 01- 27srt: MaximumMember us- gaap: CommonStockMember2020- 01- 27srt: MinimumMember2022- 08- 04srt: MaximumMember2022- 08- 042024- 09- 10us- gaap: IPOMember2024- 04- 19 2024- 04- 19us- gaap: WarrantMember2024- 04- 19 2024- 04- 19us- gaap: CommonStockMember2024- 05- 15 2024- 05- 15us- gaap: WarrantMember2024- 05- 15us- gaap: CommonStockMember2024- 05- 15srt: ChiefFinancialOfficerMember us- gaap: WarrantMember2024- 06- 05us- gaap: WarrantMember2024- 02- 01 2025- 01- 31us- gaap: ~~AccumulatedOtherComprehensiveIncomeMember2023~~ CommonStockMember2025- 01- 312023- 12- 01 2023- 12- 31ntrb: TIIJetServicesLDAMember2024- 02- 01 2025- 01- 31us- gaap: WarrantMember ntrb: BarandnicHoldingsLtdMember2023- 03- 07us- gaap: WarrantMember ntrb: BarandnicHoldingsLtdMember2023- 10- 27srt: ChiefExecutiveOfficerMember ntrb: BarandnicHoldingsLtdMember2023- 10- 27us- gaap: WarrantMember ntrb: BarandnicHoldingsLtdMember2023- 10- 27 2023- 10- 27srt: MinimumMember ntrb: BarandnicHoldingsLtdMember2023- 10- 27 2023- 10- 27srt: MaximumMember ntrb: BarandnicHoldingsLtdMember2023- 10- 27 2023- 10- 27srt: MaximumMember us- gaap: WarrantMember ntrb: BarandnicHoldingsLtdMember2023- 10- 27 2023- 10- 27us- gaap: WarrantMember ntrb: BarandnicHoldingsLtdMember2023 - 02- 01 2024- 01- 31us- gaap: ~~RetainedEarningsMember2023~~ WarrantMember2024- 04- 19srt: ChiefFinancialOfficerMember us- gaap: WarrantMember2024- 06- 05us- gaap: WarrantMember2024- 09- 10srt: MaximumMember us- gaap: WarrantMember2024- 02- 01 2025- 01- 31srt: MinimumMember us- gaap: WarrantMember2024- 02- 01 2025- 01- 31us- gaap: EmployeeStockOptionMember2021- 11- 01 2021- 11- 01us- gaap: EmployeeStockOptionMember2022- 02- 01 2022- 02- 01us- gaap: EmployeeStockOptionMember2023- 02- 01 2023- 02- 01us- gaap: EmployeeStockOptionMember2021- 11- 03srt: MinimumMember us- gaap: EmployeeStockOptionMember2024- 03- 20srt: MaximumMember us- gaap: EmployeeStockOptionMember2024- 03- 20us- gaap: EmployeeStockOptionMember2025- 01- 31us- gaap: EmployeeStockOptionMember2024- 02- 01 2025- 01- 31srt: MinimumMember srt: ChiefExecutiveOfficerMember2024- 02- 01 2025- 01- 31srt: ChiefExecutiveOfficerMember us- gaap: EmployeeStockOptionMember2024- 02- 01 2025- 01- 31srt: ChiefExecutiveOfficerMember us- gaap: EmployeeStockOptionMember2025- 01- 31srt: MinimumMember2024- 02- 01 2025- 01- 31srt: MaximumMember2024- 02- 01 2025- 01- 31srt: ChiefExecutiveOfficerMember2023 - 02- 01 2024- 01- 31srt 31us- gaap : ~~TreasuryStockCommonMember2023~~ MinimumMember srt: ChiefExecutiveOfficerMember2024- 01- 31srt: MaximumMember srt: ChiefExecutiveOfficerMember2024- 01- 31srt: MinimumMember2023 - 02- 01 2024- 01- 31us- gaap: CommonStockMember2024- 01-.....- 01ntrb: PoconoPharmaceuticalsMember2020- 08- 31srt: ~~MinimumMember2022- 07- 26srt: MaximumMember2022~~ MaximumMember2023 ~~- 07- 262021- 10- 01 2021- 10- 312023- 03- 312023- 07- 13 2023- 07- 132024- 04- 19 2024- 04- 19us- gaap: AccountsReceivableMember2023~~ - 02- 01 2024- 01- 31us- gaap: WarrantMember2023 ~~AccountsReceivableMember2022- 02~~ - 01 - 31us- gaap: WarrantMember2023- 01- 31 2023- 01- 31us- gaap: WarrantMember2023 ~~InventoriesMember2024- 01- 31srt: MinimumMember2023~~ - 02- 01 2024- 01- ~~31srt~~ 31us- gaap : ~~MaximumMember2023~~ 31us - ~~01 2025~~ gaap:CommonStockMember2024 - 01- 31us- gaap: AdditionalPaidInCapitalMember2024 ~~StockOptionMember ntrb:ExercisePricesElevenMember2025~~ - 01- 31us- gaap: AccumulatedOtherComprehensiveIncomeMember2024 ~~StockOptionMember ntrb:ExercisePricesElevenMember2024- 02- 01 2025~~ - 01- 31us- gaap: RetainedEarningsMember2024 ~~StockOptionMember ntrb:ExercisePricesTwelveMember2025~~ - 01- 31us- gaap: TreasuryStockCommonMember2024 ~~StockOptionMember ntrb:ExercisePricesTwelveMember2024- 02~~ - 01 ~~2025~~ - 312022 - 01- 31us- gaap: CommonStockMember2022 ~~StockOptionMember ntrb:ExercisePricesThirteenMember2025~~ - 01- 31us- gaap: AdditionalPaidInCapitalMember2022 ~~StockOptionMember ntrb:ExercisePricesThirteenMember2024- 02- 01 2025~~ - 01- 31us- gaap: AccumulatedOtherComprehensiveIncomeMember2022 ~~StockOptionMember ntrb:ExercisePricesFourteenMember2025~~ - 01- 31us- gaap: RetainedEarningsMember2022 ~~StockOptionMember ntrb:ExercisePricesFourteenMember2024- 02- 01 2025~~ - 01- 31us- gaap: TreasuryStockCommonMember2022 ~~StockOptionMember ntrb:ExercisePricesFifteenMember2025~~ - 01- 31us- gaap: CommonStockMember2022 ~~StockOptionMember ntrb:ExercisePricesFifteenMember2024~~ - 02- 01 ~~2025~~ 2023 - 01- 31us- gaap: ~~StockOptionMember2025~~ AdditionalPaidInCapitalMember2022- 02- 01 2023 - 01- 31us- gaap: ~~StockOptionMember2024~~ AccumulatedOtherComprehensiveIncomeMember2022 - 02- 01 ~~2025~~ 2023 - 01- ~~31ntrb~~ 31us- gaap : ~~PoconoPharmaceuticalsMember2024~~ RetainedEarningsMember2022 - 02- 01 ~~2025~~ 2023 - 01- 31us- gaap:TreasuryStockCommonMember2022- 02- 01 2023- 01- 312018- 08- 01srt:MinimumMember2018- 08- 01srt:MaximumMember2018- 08- 01ntrb:PoconoPharmaceuticalsMember2020- 08- - 02- 01 2024- 01- ~~312020- 08-~~ 31ntrb: ~~IntelligenceLLCMember2023~~ FourPTherapeuticsMember2024- 02- 01 2025- 01- 31ntrb: FourPTherapeuticsMember2023 - 02- 01 2024- 01- 31ntrb: ~~IntelligenceLLCMember2022~~ SellingGeneralAndAdministrativePoconoPharmaceuticalsMember2024 - 02- 01 ~~2023~~ 2025 - 01- ~~31country~~ 31ntrb : ~~US2023~~ SellingGeneralAndAdministrativePoconoPharmaceuticalsMember2023 - 02- 01 2024- 01- ~~31country~~ 31ntrb : ~~US2022~~ SellingGeneralAndAdministrative4PTherapeuticsMember2024 - 02- 01 ~~2023~~ 2025 - 01- 31ntrb ~~31us- gaap~~ : ~~NonUsMember2023~~ SellingGeneralAndAdministrative4PTherapeuticsMember2023 - 02- 01 2024- 01- 31ntrb ~~31us- gaap~~ : ~~NonUsMember2022~~ SellingGeneralAndAdministrativeCorporateMember2024 - 02- 01 ~~2023~~ 2025 - 01- ~~31srt: MinimumMember ntrb: LabEquipmentMember2024- 01- 31srt: MaximumMember ntrb: LabEquipmentMember2024- 01- 31us- gaap: FurnitureAndFixturesMember2024- 01- 31srt: MinimumMember us- gaap: MachineryAndEquipmentMember2024- 01- 31srt: MaximumMember us- gaap: MachineryAndEquipmentMember2024- 01-~~ 31ntrb: SellingGeneralAndAdministrativeCorporateMember2023 ~~LabEquipmentMember2024- 01- 31ntrb: LabEquipmentMember2023- 01- 31us- gaap: MachineryAndEquipmentMember2024- 01- 31us- gaap: MachineryAndEquipmentMember2023- 01- 31us- gaap: FurnitureAndFixturesMember2023- 01- 31us- gaap: LineOfCreditMember2023~~ - 02- 01 2024- 01- 31ntrb ~~31us- gaap~~ : ~~LineOfCreditMember2024~~ GoodwillAndIntangiblesImpairmentMember2024- 02 - 01 - ~~312022- 04- 032022- 04- 03 2022~~ 2025 ~~- 04- 03us- gaap: NotesPayableToBanksMember2022- 02~~ - 01 ~~2023~~ - ~~01- 312023- 07- 172023- 03- 17ntrb~~ - 31ntrb : ~~SecuredBorrowingLiabilityMember2023~~ GoodwillAndIntangiblesImpairmentMember2023 - 02- 01 2024- 01- 31ntrb: ~~SecuredBorrowingLiabilityMember2022~~ ResearchAndDevelopment4PTherapeuticsMember2024 - 02- 01 ~~2023~~ 2025 - 01- 31ntrb: ResearchAndDevelopment4PTherapeuticsMember2023 ~~RambamMedTechLtdMember2021- 02- 28 2021- 02- 28ntrb: TerminationExpenseMember2022- 02- 01 2023- 01- 31us- gaap: FiniteLivedIntangibleAssetsMember2024- 01- 31us- gaap: FiniteLivedIntangibleAssetsMember2023- 01- 31ntrb: newFiniteLivedIntangibleAssetsTwoMember2024- 01- 31ntrb: newFiniteLivedIntangibleAssetsTwoMember2023- 01- 31us- gaap: StockOptionMember2023- 02- 01 2023- 02- 01us- gaap: StockOptionMember2023- 02- 01us- gaap: StockOptionMember2023~~ - 02- 01 2024- 01- ~~312023~~ 31us - ~~09~~ gaap: CorporateAndOtherMember2024- 02 - 01 ~~2023~~ 2025 ~~- 09- 302023- 02~~ - 01 ~~2023~~ - 31us ~~10- 31srt: ExecutiveOfficerMember2023- 09- 30srt: ExecutiveOfficerMember2023- 10- 312023- 09- 302023- 10- 31srt: DirectorMember2023- 09- 30srt: DirectorMember2023- 10- 31srt: ChiefFinancialOfficerMember us~~ - gaap: CorporateAndOtherMember2023 ~~WarrantMember2023- 02- 01 2023- 10- 26us- gaap: WarrantMember2023- 10- 26us- gaap: WarrantMember2023- 02- 01 2023- 10- 31us- gaap: WarrantMember2023~~ - 02- 01 2024- 01- 31us- gaap: NonUsMember2024- 02- 01 2025- 01- 31us- gaap: NonUsMember2023- 02- 01 2024- 01- 31country: US2025- 01- 31country: US2024- 01- 31us- gaap: NonUsMember2025- 01- 31us- gaap: NonUsMember2024- 01- 31us- gaap: CorporateAndOtherMember2025- 01- 31us- gaap: CorporateAndOtherMember2024- 01- 31ntrb: PoconoPharmaceuticalsMember2025- 01- 31ntrb: PoconoPharmaceuticalsMember2024- 01- 31ntrb: FourPTherapeuticsMember2025- 01- 31ntrb: FourPTherapeuticsMember2024- 01- ~~312023~~ 312022 - 07- ~~01 2023~~ 31ntrb: MrGoodmanMember2022 - 07- ~~172023~~ 312022 - ~~03~~ 02 - 012022 ~~01 2023~~ - 02 ~~03- 172023- 12- 31 2023- 12- 31srt: ChiefExecutiveOfficerMember2022- 05~~ - 01 2022- ~~05~~ 02 - ~~312022~~ 012023 - ~~05~~ 07- 25 2023- 07- 252023- 07- 25ntrb: SorrentoTherapeuticsIncMember2023- 07- 25us- gaap: NoteWarrantMember2024- 02 - 01 ~~2022~~ 2025 ~~- 05- 312022- 08~~ - 01 ~~2022~~ - ~~08- 02srt: MinimumMember2022- 08- 02srt: MaximumMember2022- 08- 022022- 09- 01 2022- 09- 30ntrb~~ 31ntrb : ConsultantMember us ~~IndependentDirectorsMember2022- 09- 302022- 12- 01 2022- 12- 07srt: MinimumMember2022- 12- 07srt: MaximumMember2022- 12- 07us~~ - gaap: ~~PreferredStockMember2016~~ SubsequentEventMember2025 - ~~01~~ 02 - ~~15us~~ 06 2025- 02- 06ntrb: ConsultantMember us - gaap: ~~SeriesAPreferredStockMember us~~ SubsequentEventMember2025- 02- 06us - gaap: ~~PreferredStockMember2019~~ SubsequentEventMember2025 - ~~05~~ 03 - ~~24 2019~~ 04 2025 - ~~05~~ 03 - ~~24us~~ 04us - gaap: SubsequentEventMember2025 ~~SeriesAPreferredStockMember us- gaap: PreferredStockMember2019- 06- 20 2019- 06- 20srt: MinimumMember us- gaap: CommonStockMember2020- 01- 27srt: MaximumMember us- gaap: CommonStockMember2020- 01- 27srt: MinimumMember2022- 08- 04srt: MaximumMember2022- 08- 04srt: ScenarioForecastMember us- gaap: CommonStockMember2024- 12- 31 2024- 12- 31srt: ScenarioForecastMember2024- 12- 31~~

2024- 12- 31srt: ScenarioForecastMember us- gaap: CommonStockMember2024- 12- 31srt: ScenarioForecastMember2024- 12- 312022- 03- 31 2022- 03- 312022- ..... - 01 2024- 01- 31iso4217 **04iso4217** : USD xbrli: sharesiso4217: USDxbrli: sharesxbrli: **pure utr: sqftExhibit 10. 35 COMMERCIAL DEVELOPMENT AND CLINICAL SUPPLY AGREEMENT This Commercial Development and Clinical Supply Agreement (“ Agreement ”) is made on January 4, 2023 (“ Effective Date ”). BETWEEN: (1) 4P Therapeutics LLC, a Delaware limited liability company with principal address at P. O. Box 921031, Peachtree Corners, GA 30010- 1031 (“ 4P ”); and (2) Kindeva Drug Delivery L. P., a Delaware limited partnership with principal address at 11200 Hudson Road, Woodbury, MN 55129 (“ KINDEVA ”). KINDEVA and 4P are sometimes referred to individually as a “ Party ” and sometimes jointly as the “ Parties. ” WHEREAS ● KINDEVA has developed expertise and has rights in technology relating to formulating, developing, and manufacturing transdermal drug delivery systems; ● 4P has experience and expertise in the research and development of novel drug delivery technologies; ● KINDEVA and 4P are parties to that certain Feasibility Agreement, effective January 4, 2022 (“ Feasibility Agreement ”), to evaluate the compatibility and manufacturability of 4P’ s novel abuse- deterrent technology; ● The Parties wish to continue the development of the Product and progress through clinical studies and regulatory submissions with the United States FDA; and ● The Parties may wish to further commercialize the Product, as defined in Section 1. 9, under a commercial supply agreement to be negotiated in good faith at a later date. IT IS AGREED as follows: 1. DEFINITIONS 1. 1. “ 4P Background IP ” shall mean 4P’ s abuse deterrent technology, as detailed in the United States patents US 11, 246, 840, US 11, 759, 431 and related pending applications, consisting of a transdermal patch backing coated with a formulation containing aversive agents (e. g., denatonium benzoate and capsaicin) and a liquid- permeable release liner and know how related to the foregoing. ConfidentialPage 1 of 251. 2. “ Affiliate ” shall mean another entity which is controlled by a Party hereto, which controls a Party hereto or which is under common control with a Party hereto and “ control ” means the direct or indirect ownership of at least 50 % of the shares or interests entitled to vote for the directors thereof or the equivalent, for so long as such entitlement subsists, or equivalent power over management thereof. 1. 3. “ Components ” shall mean raw materials used in the development and manufacture of the Product, as defined in Section 1. 9. 1. 4. “ Compound ” shall mean the compound fentanyl. 1. 5. “ Formulation ” shall mean the drug- in- adhesive formulation incorporating fentanyl and KINDEVA Background IP, excluding 4P Background IP. 1. 6. “ Information ” shall mean all written or verbally disclosed information relating to Compound, adhesives, Formulation, manufacturing processes, components, formulations, Product, Workplan and business plans, including but not limited to data, know- how, technical and non- technical materials, formulation samples, test results and specifications, which either Party shall deliver or provide to the other pursuant to this Agreement or produced during performance of the work hereunder, whether stamped or identified as “ Confidential ” at the time of disclosure or if unlabeled, information which by its nature is normally and reasonably considered confidential. 1. 7. “ KINDEVA Background IP ” shall mean Kindeva’ s proprietary formulation for a transdermal fentanyl patch which includes the Formulation, components, adhesives, formulations, manufacturing, packaging, related to transdermal drug delivery systems and uses of any of the foregoing. 1. 8. “ Invention ” shall mean all discoveries, inventions, improvements, enhancements, modifications, ideas, data, and know- how, whether patentable or not, arising during and out of conduct of the Program, as defined in Section 1. 10, under this Agreement. 1. 9. “ Product ” shall mean a transdermal drug delivery system containing Formulation, integrated with 4P Background IP. 1. 10. “ Program ” shall mean the commercial development and clinical supply program comprised of work conducted pursuant to the Workplan, as defined in Section 1. 16, as amended in writing from time to time in accordance with the terms of this Agreement. 1. 11. “ Regulatory Approval (s) ” means any approvals, permits, product and / or establishment licenses, registrations or authorizations, including approval by a Regulatory Authority that are necessary or advisable in connection with the development, manufacture, testing, use, storage, transport, promotion, marketing, distribution, or sale of Product to be lawfully sold in the Territory. ConfidentialPage 2 of 251. 12. “ Regulatory Authority ” means the U. S. Food and Drug Administration or any other agency having the authority to approve and / or control the right to manufacture, import, conduct clinical testing, market or sell Product in the Territory. 1. 13. “ Regulatory Submission ” means any submission made to a Regulatory Authority with respect to a Product, any New Drug Application (“ NDA ”), or Abbreviated New Drug Application (“ ANDA ”), and any supplement or amendment to any of the foregoing, and any applications for pricing or reimbursement approvals for the Product. 1. 14. “ Regulatory File ” means any regulatory file at FDA that contains information that can be referenced via a letter of authorization, including but not limited to Drug Master File (DMF), Device Master File (MAF), Investigational New Drug Application (IND), Abbreviated New Drug Application (ANDA), or New Drug Application (NDA), if applicable. 1. 15. “ Territory ” means. 1. 16. “ Workplan ” shall mean a reasonably detailed definition of the scope of work, the high- level tasks to be conducted, assumptions, deliverables, and the timetable in connection with the Program. The Workplan is attached as ~~pureExhibit ----~~ Exhibit A. 2. SCOPE AND CONDUCT OF WORK: 2. 1. KINDEVA and 4P shall use commercially reasonable efforts to carry out their obligations in terms of the work described in the Workplan in a timely and effective manner making available necessary personnel to perform the Workplan. 2. 2. KINDEVA and 4P shall each identify the contact person at their respective offices to serve as the recipient of communications concerning the Program. 2. 3. Both Parties acknowledge that the costs shown in the Workplan are estimates and KINDEVA shall make reasonable efforts to stay within the estimates. If, after beginning work on the Program, KINDEVA anticipates that the cost of the Program will exceed of the estimated costs (i. e., exceed the upper bound of the estimated cost for any stage of any Workplan), the Parties shall meet to determine if any adjustments in the Workplan and / or estimates should be made. Any changes shall be in writing in the form of a change order, the form of which is attached hereto as Exhibit B (“ Change Order ”), via the change order process provided in Section 2. 4. 2. 4. If either Party elects to make changes to the subject matter or scope of the Program, that Party will provide the other Party with a completed Change Order, and, of receiving the Change Order, the Parties will in good faith negotiate any change to the Workplan including timelines and budget. Neither 4P nor KINDEVA will have any obligation to implement changes or recognize suggested changes unless and until a Change Order and amended Workplan is agreed and executed by the Parties. ConfidentialPage 3 of 253. MANAGEMENT OF PROGRAM 3. 1. In order to have appropriate coordination and communication between the Parties in the course of the implementation of the Workplan, each Party agrees to: (i) appoint a project manager; and (ii) set up a joint technical team (“ JTT ”) for product development management, comprising appropriate membership from KINDEVA and 4P. 3. 2. The project managers shall be in charge of the daily and regular communication between the Parties with respect to the implementation of the Workplan. The JTT shall: (i) provide general guidance to the parties with respect to the implementation of the Workplan; (ii) manage all issues that may occur in connection with the Workplan; and (iii) define timelines and budget. 3. 3. The Parties will keep each other informed of their progress and provide written minutes following each joint meeting summarizing the results of work completed. 4P understands that, except for KINDEVA’ s obligation to provide Confidential Information pursuant to Section 5. 3, KINDEVA is under no obligation to disclose to 4P what KINDEVA reasonably considers to be its proprietary processes. Instead, such KINDEVA proprietary information may be provided for regulatory review by right of reference to KINDEVA’ s Regulatory Files, if required pursuant to the Workplan. In addition, 4P may be retain certain proprietary information as confidential and therefore not disclose it to KINDEVA except as necessary for KINDEVA to perform its activities pursuant to the Workplan. 3. 4. 4P will make its employees available and supply to KINDEVA such technical, scientific, and other information concerning Aversa technology as KINDEVA shall reasonably require from time to time in order to complete the Workplan. 3. 5. 4P and KINDEVA each agree to promptly communicate, with no longer than elapsing between communications, regarding any reasonable request for information or further instruction in connection with the Program. 3. 6. KINDEVA and 4P recognize that there is no certainty as to the outcome of any Workplan, and neither makes any warranties to the other regarding technical success, commercial success, or non- infringement of the resulting Product. 4. SUPPLY OF COMPOUND AND COMPONENTS 4. 1. KINDEVA shall procure all materials, supplies and equipment required to perform the Workplan including the Compound, adhesive, components, aversive agents, and dedicated manufacturing equipment. 4P shall reimburse KINDEVA for any pass- through costs incurred under this Section 4. 1 pursuant to Section 6. 2. ConfidentialPage 4 of 255. CLINICAL STUDIES AND TOXICOLOGY STUDIES AND SUPPLIES5. 1. 4P shall at its own expense be responsible for any clinical studies and / or toxicology studies, Regulatory Submissions, and all contact with any regulatory authority concerning the Product. 4P shall share with KINDEVA any relevant information concerning KINDEVA’ s development of the Product. 5. 2. 4P understands and acknowledges that it will have sole responsibility for the safe handling, storage, testing, use, and transport of the Product in clinical studies and / or toxicology studies, including obtaining any necessary licenses required (e. g., from the U. S. Drug Enforcement Agency). 5. 3. KINDEVA will provide confidential data for inclusion into the chemistry, manufacturing, and controls (“ CMC ”) section in support of 4P’ s Regulatory Submissions, if any. If needed, KINDEVA will issue right of reference to KINDEVA’ s Regulatory Files, if applicable. 5. 4. At 4P’ s request and expense, and with reasonable advance notice, KINDEVA will attend and participate in meetings with the FDA or other regulatory authorities regarding the Product. 5. 5. KINDEVA will manufacture and release any toxicology, clinical, registration, and / or validation supplies under the Workplan meeting the agreed upon specifications and in compliance with current Good Manufacturing Practices (“ cGMPs ”) and / or current Good Laboratory Practices (“ cGLPs ”), as is relevant. KINDEVA will perform release testing of all batches in accordance with agreed upon specifications and test methods. 5. 6. KINDEVA will manufacture each Product to be used in a**

clinical trial according to the terms and conditions of the quality agreement which will be agreed to and signed by the Parties prior to KINDEVA manufacturing and supplying any Product to 4P for use in a clinical trial. 6. PAYMENTS6. 1. 4P shall pay KINDEVA or work carried out in connection with the Workplan. KINDEVA shall invoice 4P for work and expenses under this Agreement 6. 2. 4P shall reimburse KINDEVA for product materials and com use in the Workplan 6. 3. Payemts by 4P shall be with interest accruing at or late payemts6. 4. Any commercial validation supplies manufactured under this Agreement are assumed to be salable and will be invoiced in accordance with a commercial supply agreement to be negotiated at a later date, unless otherwise agreed by the Parties. ConfidentialPage 5 of 256. 5. 4P shall also reimburse KINDEVA for its reasonable, necessary, and documented incidental costs incurred pursuant to the Workplan including, but not limited to, travel, non- product related materials, product- dedicated equipment and tooling, and other pass- through costs. 7. COMMERCIAL SUPPLY AGREEMENT7. 1. The Parties shall make commercially reasonable efforts to negotiate in good faith a commercial supply agreement (“ Supply Agreement ”) and execute no later than after submission of the first application for Regulatory Approval in the Territory. 7. 2. KINDEVA shall be the exclusive supplier of Product to 4P and its Affiliates in the Territory for commercial purposes, pursuant to a commercial Supply Agreement, and a related quality agreement. The Parties will make commercially reasonable efforts to negotiate in good faith the heads of terms for the Supply Agreement as set forth in Exhibit C to this Agreement. In the event that the Parties fail to execute the Supply Agreement prior to receipt of the first Regulatory Approval in the Territory, KINDEVA shall supply Product to 4P in accordance with the terms of this Section 7. 2 and Exhibit C until such time as the Supply Agreement is executed. 8. INTELLECTUAL PROPERTY8. 1. Except as provided herein for the sole purpose of conducting work under this Agreement, neither KINDEVA or 4P has any right or license to any of the others’ patent rights or other intellectual property rights conceived prior to Effective Date of this Agreement. No other license, expressed or implied, is granted by a Party under any patent rights or intellectual property rights, regardless of when conceived, owned, or controlled by such Party to any other Party, by implication, estoppel, or otherwise. The Parties acknowledge that the terms of this Agreement do not contravene or impair any rights or obligations to intellectual property provided under the Feasibility Agreement. 8. 2. ConfidentialPage 6 of 258. 3. 8. 4. 8. 5. Each Party will assign and does hereby assign to the other Party the Inventions set forth in Section 8. 3 and / or 8. 4. Each Party will obtain any executed documents, including assignments, reasonably requested by the other Party to perfect the ownership of Inventions as set forth in this Section 8. 8. 6. 4P hereby grants to KINDEVA a nonexclusive revocable license to use 4P Background IP solely in the Territory and solely for the purpose of performance of this Agreement by KINDEVA and 4P. 8. 7. KINDEVA hereby grants to 4P a nonexclusive revocable license to use KINDEVA Background IP solely in the Territory and solely for the purpose of performance of this Agreement by KINDEVA and 4P. 8. 8. The licenses set forth in Sections 8. 6 and 8. 7 will terminate when this Agreement terminates. 9. CONFIDENTIALITY9. 1. The Parties agree to use reasonable efforts to maintain Information disclosed by the other in confidence, including at least efforts fully commensurate with those to protect its own confidential information. Neither Party will use the Information of the other Party except for the performance of the work described in the Program. Each Party will disclose the Information only to its officers and employees directly concerned with the Program to whom it is necessary or useful to disclose such Information, but will neither disclose the Information to any third party (except for third parties engaged in activities pursuant to the Program so long as they are under confidentiality obligations as least as stringent as those contained herein) nor use the Information for any other purpose. Each Party acknowledges that, except for the rights expressly granted under this Agreement, it will not obtain any rights of any sort to the Information of the other Party as a result of such disclosure and that any such rights must be subject to separate written agreement (s). ConfidentialPage 7 of 259. 2. The disclosing Party may, at any time, notify the receiving Party in writing that such receiving Party must return to the disclosing Party the disclosing Party’ s Information. Each Party hereby agrees (i) return or certify (in a writing attested to by a duly authorized officer of such Party) destruction of all documents, copies, and tangible items it or its employees or agents have received or created pursuant to this Agreement pertaining to, referring, or relating to the other Party’ s Information; and (ii) return or certify (in a writing attested to by a duly authorized officer of such Party) destruction of all copies, summaries, modifications, or adaptations that such Party or its employees or agents have made from the materials provided by the disclosing Party; provided, however, that a Party is permitted to retain one copy of such materials in its legal files to be used to verify compliance with its obligations hereunder. 9. 3. Neither Party will make any public announcement as to the execution of this Agreement or its terms without the prior written authorization of the other Party. This shall not prevent a Party from such disclosures regarding the existence or terms of this Agreement to the extent required under applicable federal or state securities laws or any rule or regulation of any nationally recognized securities exchange. In such event, however, the disclosing Party shall use good faith efforts to notify and consult with the other Party prior to such disclosure and, where applicable, shall diligently seek confidential treatment to the extent such treatment is available under applicable securities laws, rules, or regulations. 9. 4. The Parties’ obligation of nondisclosure and the limitations upon the right to use the other Party’ s Information shall not apply to the extent that a recipient can demonstrate that the applicable Information: (a) was in its possession prior to the time of disclosure; (b) is or becomes public knowledge through no fault or omission of the receiving Party; (c) is obtained by the receiving Party from a third party under no obligation of confidentiality to the disclosing Party; or (d) is independently developed by the receiving Party, as evidenced by the receiving Party’ s written records, without access to the disclosing Party’ s Information. A receiving Party may also disclose Information if it is required to disclose the Information in response to a subpoena or other validly issued administrative or judicial process requesting disclosure of same, provided that such receiving Party will give the disclosing Party prompt notice of such request before making any disclosure (to the extent possible) and permit the disclosing Party to oppose or narrow such request for disclosure. The disclosing Party may seek an appropriate protective order or other remedy and / or waive compliance with the provisions of this Agreement. If such disclosing Party seeks a protective order or other remedy, the receiving Party will cooperate and support any of the disclosing Party’ s reasonable efforts to oppose such request (at disclosing Party’ s expense). If such disclosing Party fails to obtain a protective order or waive compliance with the relevant provisions of this Agreement, the receiving Party will disclose only in the event of a final judgment or administrative order requiring such disclosure, and only to the extent necessary to comply with such request. ConfidentialPage 8 of 259. 5. The obligations with respect to maintaining confidentiality and non- use of Information under Section 9 shall survive the termination or expiration of this Agreement with respect to the Program and 4P’ s business information, but shall remain in effect for an indefinite period of time with respect to each Party’ s technical information which a Party indicates is a trade secret at the time of disclosure. In this latter case, the recipient Party shall keep this trade secret as confidential unless and until it ceases to be Information pursuant to items (a), (b), (c) or (d) of Section 9. 4. It is understood and agreed that nothing in this Agreement obligates any Party to disclose or receive any Information that is of a technical nature, but that if a Party refuses to accept such Information and such Information is necessary to perform the transactions contemplated by this Agreement, then the disclosing Party may terminate this Agreement without any obligation to pay the costs set forth above. 9. 6. Nothing in this Agreement will be construed as a restriction on the right of a receiving Party to develop its technology, products or services independently of and without reference to the Information of the disclosing Party, even if they are the same or similar to the technology, products or services contemplated by disclosing Party’ s Information. 10. WARRANTIES, LIMITED REMEDY, LIMITATION OF LIABILITIES, AND INDEMNIFICATION10. 1. Each party warrants that it: (i) has the right to enter into this Agreement; and (ii) it has no obligations to any other person or entity which are in conflict with its obligations under this Agreement. 10. 2. 10. 3. If KINDEVA breaches its warranty in Section 10. 2, 4P’ s sole remedy for supply of defective Product shall be replacement of such Product by KINDEVA. 10. 4. EXCEPT AS OTHERWISE EXPLICITLY SET FORTH HEREIN, EACH PARTY EXPRESSLY DISCLAIMS TO THE OTHER PARTY ANY EXPRESS OR IMPLIED WARRANTY RELATED TO: (1) THE PERFORMANCE OR NONPERFORMANCE OF THIS AGREEMENT; (2) THE IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE; (3) ANY IMPLIED WARRANTY ARISING OUT OF A COURSE OF DEALING, CUSTOM OR USAGE OF TRADE; (4) ANY REPRESENTATION OR WARRANTY OF NON- INFRINGEMENT OF THIRD PARTY INTELLECTUAL PROPERTY RIGHTS; OR (5) ANY OTHER MATTER OR SUBJECT ARISING OUT OF THIS AGREEMENT. ConfidentialPage 9 of 2510. 5. 10. 6., 4P shall indemnify, defend, and hold KINDEVA and KINDEVA harmless from and against any and all other third party loss or liability for any and all judgments, claims, causes of action, suits, proceedings, damages, demands, fees, expenses, fines, penalties and costs (including without limitation reasonable attorneys’ fees, costs and disbursements) arising from 4P’ s or its agent’ s use, testing, or clinical studies of the Product. 10. 7. Both 4P and KINDEVA are obligated to promptly notify the other party of any claim for which they intend to seek indemnification under the terms of this Agreement. Failure to give notice shall not constitute a defense, in whole or in part, to any claim by any indemnified entity hereunder except to the extent the rights of the indemnitor are materially prejudiced by such failure to give notice. If a claim arises within the scope of an indemnity, the Party seeking indemnity will fully cooperate in the defense of any such claim. 10. 8. If both Parties desire to defend a case together, then the Parties shall jointly control the defense of such case. If either Party desires to defend a case with separate counsel, then each party shall be entitled to control its own legal defense of any claim; provided, however, that any Party seeking indemnification or contribution shall in good faith consult with the other Party regarding the defense strategy

to be employed throughout the case, but only to the extent such consultation does not reveal matters that may be at issue between the party seeking indemnification and the other party. A Party seeking indemnification or contribution from the other party cannot settle a case without the consent of the other Party. 10. 9. NOTWITHSTANDING ANYTHING IN THIS AGREEMENT TO THE CONTRARY, UNDER NO CIRCUMSTANCES SHALL ANY PARTY BE LIABLE TO ANY OTHER PARTY FOR ANY KIND OF LOST PROFITS, REVENUE OR BUSINESS, INDIRECT, INCIDENTAL, SPECIAL, PUNITIVE OR CONSEQUENTIAL DAMAGES. THIS LIMITATION ON LIABILITY APPLIES TO ANY CLAIM REGARDLESS OF THE THEORY OF LAW, INCLUDING, BUT NOT LIMITED TO, BREACH OF CONTRACT, BREACH OF WARRANTY, TORT OR STRICT LIABILITY. ConfidentialPage 10 of 2511. TERM AND TERMINATION11. 1. The Agreement shall remain in force from the Effective Date until the earlier of either 11. 2. Either Party may terminate this Agreement in the event of a material breach of the Agreement by the other Party for which the breaching Party has failed to cure within of receipt of written notice from the non- breaching Party. 11. 3. 4P may also terminate this Agreement, at any time, upon written notice to KINDEVA, for any internal or commercial reasons and / or without cause. Upon receiving notice of 4P' s intent to terminate, KINDEVA shall make commercially reasonable efforts to stop all activities under any Workplan as soon as practicable. 11. 4. KINDEVA may terminate this agreement if KINDEVA reasonably concludes that the Product cannot be developed by KINDEVA provided that KINDEVA has used commercially reasonable efforts to execute the Workplan. In such case, KINDEVA will meet with 4P to present its findings and explain the rationale for concluding that KINDEVA cannot develop the Product. In case of termination of this Agreement under this Section 11. 4 by KINDEVA, 4P shall have the right to request in writing that KINDEVA immediately discontinue activities. After such a request is received by KINDEVA, 4P will not be obligated to pay KINDEVA any amounts for the winding down of its activities pursuant to Section 11. 5, and in such case, 4P expressly agrees that KINDEVA is under no further obligation to provide any additional work or deliverables to 4P including any data or reports. 11. 5. All charges and expenses, including non- cancellable capital expenditures or expenses for materials, owed to KINDEVA prior to the effective date of termination shall become due and payable, and except for the circumstance described in Section 11. 4, 4P shall pay all charges and expenses reasonably incurred by KINDEVA in the winding down of its activities during the notice period referred to above, provided that KINDEVA shall act diligently to minimize all wind- down costs, upon receipt of 4P' s written termination notice. 11. 6. In the event of termination by 4P under Section 11. 2 or by Kindeva under Section 11. 4, (i) all rights and licenses granted under this Agreement shall cease; and (ii) Kindeva shall grant to 4P a non- exclusive royalty- free, perpetual, fully paid up, irrevocable sublicensable right and license to any data generated during the course of the Program. 11. 7. In the event of termination by Kindeva under Section 11. 2 or by 4P under Section 11. 3: (i) all rights and licenses granted under this Agreement shall cease; and (ii) 4P shall grant to KINDEVA a non- exclusive royalty- free, perpetual, fully paid up, irrevocable sublicensable right and license to any data generated during the course of the Program. ConfidentialPage 11 of 2511. 8. The rights and obligations of 4P and KINDEVA which by intent or meaning have validity beyond such termination or expiration (including, but not limited to, rights with respect to confidentiality, intellectual property ownership, and liability limitations) shall survive the termination or expiration of this Agreement or any Workplan. 12. MISCELLANEOUS12. 1. Any notice or other communications to be sent or delivered hereunder shall be in writing and sent to the addresses set forth below and shall be effective upon receipt if hand delivered, express delivery service, or certified or registered mail, postage prepaid. For the avoidance of any doubt, the effective date of any notice shall be the date of first receipt by the receiving Party. Notices shall be sent to the address given below or to such other address as the Party to whom notice is to be given may have provided to the other Party in writing in accordance with this provision. If to 4P: 4P Therapeutics LLC P. O. Box 921031 Peachtree Corners, GA 30010- 1031 Attention: President If to KINDEVA: Kindeva Drug Delivery L. P. 11200 Hudson Road Woodbury, MN 55129 Attention: Chief Executive Officer With a copy to KINDEVA General Counsel at the above address. 12. 2. This Agreement sets forth the entire agreement between 4P and KINDEVA, as to its subject matter and supersedes all previous agreements (if any) relating to the subject matter of this Agreement. None of the terms of this Agreement shall be amended except in writing signed by the Parties. The Parties are entering into this Agreement with the express understanding that neither Party will be obligated to enter into any further agreement with the other Party relating to the subject matter of this Agreement or the Information. 12. 3. Neither 4P nor KINDEVA shall be considered in default or be liable to the other Party for any delay in performance or non- performance caused by circumstances beyond the reasonable control of such Party, including but not limited to provided, however, that diligent efforts are made to resume performance as quickly as possible. ConfidentialPage 12 of 2512. 4. 4P and KINDEVA shall comply with all applicable laws, rules, regulations and orders of any government authority in handling or disposing of all materials, including materials generated under the program. 12. 5. The Parties consent to and this Agreement shall be construed under law, excluding any conflicts or choice of law provision to the contrary. 12. 6. The failure to enforce any right or provision herein shall not constitute a waiver of that right or provision. If any provisions herein are found to be unenforceable on the grounds that they are overly broad or in conflict with applicable laws, it is the intent of the Parties that such provisions be replaced, reformed, or narrowed so that their original business purpose can be accomplished to the extent permitted by law, and that the remaining provisions shall not in any way be affected or impaired thereby. 12. 7. The rights and obligations of 4P and KINDEVA which by intent or meaning have validity beyond such termination or expiration (including, but not limited to, rights with respect to confidentiality, intellectual property and liability limitations) shall survive the termination or expiration of this Agreement or any Workplan. 12. 8. 4P and KINDEVA agree to resolve any questions, claims, disputes, or litigation in any way arising from or relating to this Agreement, its negotiation, performance, termination, alleged breach, or any rights or remedies sought therefore (collectively and individually, a " dispute "), exclusively by the following sequence of dispute resolution methods: (i) 12. 9. In the event of litigation, each Party consents to the exclusive and personal jurisdiction of the specified courts. Nothing in this paragraph shall preclude a Party from taking any action reasonably necessary to prevent immediate and irreparable harm to that Party; provided, however, that the Party taking any such action shall do so in the court specified in subparagraph 12. 8 (ii) above and such Party after taking such action remains obligated to resolve the underlying claim or dispute giving rise to such action by means of the dispute resolution methods of this paragraph. ConfidentialPage 13 of 2512. 10. This Agreement may not be assigned by either Party, other than to an Affiliate of either Party, except by prior written consent of the other Party (not to be unreasonably withheld); provided that this Agreement may be assigned by KINDEVA without the consent of 4P in connection with the sale of all or substantially all of KINDEVA' s business to which this Agreement pertains whether by merger, consolidation or sale of all or substantially all the assets relating to such business; and this Agreement may be assigned by 4P without the consent of KINDEVA in connection with the sale of all or substantially all of 4P' s business relating to the Product whether by merger, consolidation or sale of all or substantially all the assets relating to such business. 12. 11. Parties understand and agree that performance by 4P of any obligation for the benefit of either KINDEVA shall be deemed as the full performance of such obligation, except in those cases where this Agreement expressly requires 4P to perform such obligation specifically for the benefit of KINDEVA. In particular, it is agreed that payments to be made to KINDEVA in accordance with Section 5 of this Agreement shall be the total compensation collectively payable to KINDEVA hereunder. KINDEVA does hereby waive any claims against 4P for the performance of any obligation under this Agreement if and to the extent that such obligation has been performed by 4P for the benefit of KINDEVA. 12. 12. 4P and KINDEVA shall comply in all material respects with the material aspects of all applicable laws, rules, regulations and orders of any government authority in handling or disposing of the Compound and formulations. 12. 13. The Parties agree that this Agreement may be executed by counterparts and by transmission of separately signed signature pages to the other Parties, or by electronic signature, via a recognized electronic signature service (e. g., DocuSign or Adobe Sign), or may be signed, scanned and emailed between the Parties, and any such signatures shall be treated as an original signature for all applicable. [ Remainder of Page Intentionally Left Blank. Signature Page to Follow ] ConfidentialPage 14 of 25EXECUTED by the parties For and on behalf of: KINDEVA Drug Delivery L. P. Signed: Dated: Jan 4, 2024 Printed: Title: 4P Therapeutics, LLC Signed: / s / Alan Smith Dated: Jan 4, 2024 Printed: Alan Smith Title: PresidentConfidentialPage 15 of 25 ConfidentialPage 16 of 25 ConfidentialPage 17 of 25 ConfidentialPage 18 of 25 ConfidentialPage 19 of 25 ConfidentialPage 20 of 25 ConfidentialPage 21 of 25 Change Order Form Change order under Agreement dated: [ add title and date of agreement ] Between: Project Name: Change requested by: Company: Description of change: [ Include details here of the task changes or additions and any change in timelines and / or fees, with reference to the original tasks, timeline or fees where applicable. These details may be attached as a schedule to this change order. ] In all other respects, the terms and conditions of the Agreement remain in full force and effect. Requested task, dates and costs are approved by: Company: KINDEVA: Name: Name: Signature: Signature: Position: Position: Date (dd / mm / yy): Date (dd / mm / yy): ConfidentialPage 22 of 25 Exhibit 10. 36 AMENDMENT NO. 1, dated as of February 4, 2025 (this " Amendment "), to the COMMERCIAL DEVELOPMENT AND CLINICAL SUPPLY AGREEMENT, made as of January 4, 2024 (the " Agreement "), is by and between Kindeva Drug Delivery LP., a Delaware limited partnership with principal address at 11200 Hudson Road, Woodbury, MN 55129 (" KINDEVA ") and 4P Therapeutics LLC, a Delaware limited liability company with principal address at P. O. Box 921031, Peachtree Corners, GA 30010- 1031 (" 4P "). Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to such terms in the Agreement. WHEREAS, KINDEVA and 4P are parties to the

**COMMERCIAL DEVELOPMENT AND CLINICAL SUPPLY Agreement executed January 4, 2024 (the " Agreement "); WHEREAS, the Parties wish to establish new commercial supply pricing;. NOW, THEREFORE, in consideration of the mutual covenants and agreements contained in this Amendment, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and intending to be legally bound hereby, the parties hereto agree as follows: 1. References. Each reference to " hereof ", " herein ", " hereunder ", " hereby " and " this Agreement " shall from and after the date of this Amendment refer to the Agreement as amended by this Amendment. Notwithstanding the foregoing, references to the date of the Agreement, as amended hereby, shall in all instances continue to refer to January 4, 2024, and references to the " the date hereof " and " the date of this Agreement " shall continue to refer to January 4, 2024. 2. Section 6. 1 of the Agreement is hereby deleted in its entirety and replaced with the following:. 3. The Supply Price section of Exhibit C is hereby deleted in its entirety and replaced with the following: " Supply Price. 4. A new paragraph defining Total Manufacturing Cost shall be hereby added to Exhibit C- Heads of Terms for Supply Agreement: " Total Manufacturing Cost. 5. A new paragraph defining Indirect Costs shall be hereby added to Exhibit C- Heads of Terms for Supply Agreement: " Indirect Costs. 6. New Sections 6. 6 and 6. 7 are hereby added as follows: " 6. 6. 6. 7 7. A new paragraph detailing royalties on the commercial sale of the Product is hereby added to Exhibit C- Heads of Terms for Supply Agreement: " Royalties 8. A new paragraph defining Net Sales shall be hereby added to Exhibit C- Heads of Terms for Supply Agreement: " Net Sales 9. The Exclusivity section of Exhibit C shall be deleted in its entirety and replaced with the following: " Exclusivity 10. Agreement Remains in Effect. Except as expressly amended by this Amendment, all terms of the Agreement, as amended, remain in full force and effect. If an express conflict or inconsistency exists between this Amendment and the Agreement, this Amendment controls. [ signatures to follow on next page ] IN WITNESS WHEREOF, the Parties have caused this Amendment to be duly executed as of the date above written. 4P THERAPEUTICS LLC KINDEVA DRUG DELIVERY LP. By: / s / Alan Smith Name: Alan Smith Name: Title: President Title: Date: Feb 11, 2025 Date: 10 / 02 / 2025 Exhibit** 31. 1 CERTIFICATION ~~OF PRINCIPAL EXECUTIVE OFFICER~~ **PURSUANT TO 18 U. S. C. SECTION 1350 AS ADOPTED** PURSUANT TO SECTION 302 OF THE SARBANES OXLEY ACT OF 2002 I, Gareth Sheridan, certify that: 1. I have reviewed this ~~annual~~ **Quarterly** ~~report~~ **Report** on Form 10- ~~K~~ **Q** of Nutriband Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; 4. I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a- 15 (e) and 15d- 15 (e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a- 15 (f) and 15d- 15 (f)) for the registrant and have: a. designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; b. designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; c. evaluated the effectiveness of the registrant' s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; ~~and~~ **andd** ~~d~~. disclosed in this report any change in the registrant' s internal control over financial reporting that occurred during the registrant' s most recent fiscal quarter (the registrant' s fourth quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant' s internal control over financial reporting; ~~and~~ **and5** ~~5~~. I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant' s auditors and the audit committee of the registrant' s board of directors (or persons performing the equivalent functions): a. all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant' s ability to record, process, summarize and report financial information; ~~and~~ **andb** ~~b~~. any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant' s internal control over financial reporting; DATE: April ~~30~~ **28** , ~~2024~~ **2025** / s / Gareth Sheridan Gareth Sheridan, Chief Executive **OfficerExhibit** ~~Officer (Principal Executive Officer) Exhibit~~ 31. 2 ~~CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER~~ I, Gerald Goodman, certify that: DATE: April ~~30~~ **28** , ~~2024~~ **2025** / s / Gerald Goodman Gerald Goodman, Chief Financial **OfficerExhibit** ~~Officer (Principal Financial Officer) Exhibit~~ 32 ~~CERTIFICATION PURSUANT TO 18 U~~. **1** ~~S. C. SECTION 1350 AS ADOPTED PURSUANT TO~~ SECTION 906 OF THE SARBANES- OXLEY ACT OF 2002 In connection with the ~~annual~~ **Annual** ~~report~~ **Report** of Nutriband Inc. (the " Company ") on Form 10- K for the year ended January 31, ~~2024~~ **2025 ,** as filed with the Securities and Exchange Commission on the date hereof (the " Report "), I, Gareth Sheridan, **President and** Chief Executive ~~Officer, and I, Gerald Goodman, Chief Financial~~ Officer of the Company, certify, pursuant to 18 U. S. C. Section 1350, as adopted pursuant to section 906 of the Sarbanes- Oxley Act of 2002 **, that to the best of my knowledge** : (1) The Report fully complies with the requirements of section 13 (a) or 15 (d) of the Securities Exchange Act of 1934; and (2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company. ~~April 30, 2024~~ / s / Gareth Sheridan Gareth Sheridan, Chief Executive **OfficerThe foregoing certification is not filed with the Securities and Exchange Commission as part of the Form 10- Q or as a separate disclosure document and is not incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10- Q), irrespectively of any general incorporation language contained in such filing. Exhibit 32. 2 In connection with the Annual Report of Nutriband Inc. (the " Company ") on Form 10- K for the year ended January 31, 2025, as filed with the Securities and Exchange Commission on the date hereof (the " Report "), I, Gerald Goodman, Chief Financial** Officer **of the Company** ~~(Principal Executive Officer) April 30~~ **, certify, pursuant to 18 U. S. C. Section 1350, as adopted pursuant to section 906 of the Sarbanes- Oxley Act of** ~~2024~~ **2002 , that to the best of my knowledge: (1) The Report fully complies with the requirements of section 13 (a) or 15 (d) of the Securities Exchange Act of 1934; and (2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.** / s / Gerald Goodman Gerald Goodman, Chief Financial ~~Officer~~ **Officerv3** ~~(Principal Financial Officer) v3~~. ~~24~~ **25** . ~~1. u1Cover~~ **1Cover** - USD ($) 12 Months EndedJan. 31, ~~2024~~ **2025** Apr. ~~30~~ **25** , ~~2024~~ **2025** Jul. 31, ~~2023Document~~ **2024Document** Information [ Line Items ] Document Type 10- K Document Annual Report true Document Transition Report false Document Financial Statement Error Correction [ Flag ] false Entity Interactive Data Current Yes ICFR Auditor Attestation Flag false Amendment Flag false Document Period End Date Jan. 31, ~~2024~~ **2025** Document Fiscal Year Focus Document Fiscal Period Focus FY Entity Information [ Line Items ] Entity Registrant Name NUTRIBAND INC. Entity Central Index Key Entity File Number 000- 55654 Entity Tax Identification Number 81- 1118176 Entity Incorporation, State or Country Code NV Current Fiscal Year End Date-- 01- 31 Entity Well- known Seasoned Issuer No Entity Voluntary Filers No Entity Current Reporting Status Yes Entity Shell Company false Entity Filer Category Non- accelerated Filer Entity Small Business true Entity Emerging Growth Company true Entity Ex Transition Period true Entity Public Float $ ~~17~~ **44** , ~~131~~ **975** , ~~304Entity~~ **804Entity** Contact Personnel [ Line Items ] Entity Address, Address Line One 121 South Orange Ave **,** Entity Address, Address Line Two Suite 1500 Entity Address, City or Town Orlando Entity Address, State or Province FL Entity Address, Postal Zip Code Entity Phone Fax Numbers [ Line Items ] City Area Code (407) Local Phone Number 377- 6695 Entity Listings [ Line Items ] Entity Common Stock, Shares Outstanding ~~10~~ **11** , ~~969~~ **154** , ~~870~~ **171** Common Stock Entity Listings [ Line Items ] Title of 12 (b) Security Common Stock Trading Symbol NTRB Security Exchange Name NASDAQ Warrants Entity Listings [ Line Items ] Title of 12 (b) Security Warrants Trading Symbol NTRBW Security Exchange Name NASDAQ X- DefinitionBoolean flag that is true when the XBRL content amends previously- filed or accepted submission. ReferencesNo definition available. Details Name: dei_AmendmentFlag Namespace Prefix: dei_ Data Type: xbrli: booleanItemType Balance Type: na Period Type: durationX- DefinitionArea code of city ReferencesNo definition available. Details Name: dei_CityAreaCode Namespace Prefix: dei_ Data Type: xbrli: normalizedStringItemType Balance Type: na Period Type: durationX- DefinitionEnd date of current fiscal year in the format-- MM- DD. ReferencesNo definition available. Details Name: dei_CurrentFiscalYearEndDate Namespace Prefix: dei_ Data Type: xbrli: gMonthDayItemType Balance Type: na Period Type: durationX- DefinitionBoolean flag that is true only for a form used as an annual report. ReferencesReference 1: http: / / www. xbrl. org / 2003 / role / presentationRef- Publisher SEC- Name Form 10- K- Number 249- Section 310Reference 2: http: / / www. xbrl. org / 2003 / role / presentationRef- Publisher SEC- Name Form 20- F- Number 249- Section 220- Subsection fReference 3: http: / / www. xbrl. org / 2003 / role / presentationRef- Publisher SEC- Name Form 40- F- Number 249- Section 240- Subsection f Details Name: dei_DocumentAnnualReport Namespace Prefix: dei_ Data Type: xbrli: booleanItemType Balance Type: na Period Type: durationX- DefinitionIndicates whether any of the financial statement period in the filing include a restatement due to error correction. ReferencesReference 1: http: / / www. xbrl. org / 2003 / role / presentationRef- Publisher SEC- Name Regulation S- K- Number 229- Section 402- Subsection wReference 2: http: / / www. xbrl. org / 2003 / role / presentationRef- Publisher SEC- Name Form 10- K- Number 249- Section 310Reference 3: http: / / www. xbrl. org / 2003 / role / presentationRef- Publisher SEC- Name Form 20- F- Number 249- Section 220- Subsection fReference 4: http: / / www. xbrl. org / 2003 / role / presentationRef- Publisher SEC- Name Form 40- F- Number 249- Section 240- Subsection f Details Name: dei_DocumentFinStmtErrorCorrectionFlag Namespace

Prefix: dei_ Data Type: xbrli: booleanItemType Balance Type: na Period Type: durationX- DefinitionFiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10- Q or 10- QT statements have value Q1, Q2, and Q3 respectively, with 10- K, 10- KT or other fiscal year statements having FY. ReferencesNo definition available. Details Name: dei_DocumentFiscalPeriodFocus Namespace Prefix: dei_ Data Type: dei: fiscalPeriodItemType Balance Type: na Period Type: durationX- DefinitionThis is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. ReferencesNo definition available. Details Name: dei_DocumentFiscalYearFocus Namespace Prefix: dei_ Data Type: xbrli: gYearItemType Balance Type: na Period Type: durationX- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. ReferencesNo definition available. Details Name: dei_DocumentInformationLineItems Namespace Prefix: dei_ Data Type: xbrli: stringItemType Balance Type: na Period Type: durationX- DefinitionFor the EDGAR submission types of Form 8- K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N- 1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY- MM- DD. ReferencesNo definition available. Details Name: dei_DocumentPeriodEndDate Namespace Prefix: dei_ Data Type: xbrli: dateItemType Balance Type: na Period Type: durationX- DefinitionBoolean flag that is true only for a form used as a transition report. ReferencesReference 1: http: / / www. xbrl. org / 2003 / role / presentationRef- Publisher SEC- Name Forms 10- K, 10- Q, 20- F- Number 240- Section 13- Subsection a- 1 Details Name: dei_DocumentTransitionReport Namespace Prefix: dei_ Data Type: xbrli: booleanItemType Balance Type: na Period Type: durationX- DefinitionThe type of document being provided (such as 10- K, 10- Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word' Other'. ReferencesNo definition available. Details Name: dei_DocumentType Namespace Prefix: dei_ Data Type: dei: submissionTypeItemType Balance Type: na Period Type: durationX- DefinitionAddress Line 1 such as Attn, Building Name, Street Name ReferencesNo definition available. Details Name: dei_EntityAddressAddressLine1 Namespace Prefix: dei_ Data Type: xbrli: normalizedStringItemType Balance Type: na Period Type: durationX- DefinitionAddress Line 2 such as Street or Suite number ReferencesNo definition available. Details Name: dei_EntityAddressAddressLine2 Namespace Prefix: dei_ Data Type: xbrli: normalizedStringItemType Balance Type: na Period Type: durationX- DefinitionName of the City or Town ReferencesNo definition available. Details Name: dei_EntityAddressCityOrTown Namespace Prefix: dei_ Data Type: xbrli: normalizedStringItemType Balance Type: na Period Type: durationX- DefinitionCode for the postal or zip code ReferencesNo definition available. Details Name: dei_EntityAddressPostalZipCode Namespace Prefix: dei_ Data Type: xbrli: normalizedStringItemType Balance Type: na Period Type: durationX- DefinitionName of the state or province. ReferencesNo definition available. Details Name: dei_EntityAddressStateOrProvince Namespace Prefix: dei_ Data Type: dei: stateOrProvinceItemType Balance Type: na Period Type: durationX- DefinitionA unique 10- digit SEC- issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. ReferencesReference 1: http: / / www. xbrl. org / 2003 / role / presentationRef- Publisher SEC- Name Exchange Act- Number 240- Section 12- Subsection b- 2 Details Name: dei_EntityCentralIndexKey Namespace Prefix: dei_ Data Type: dei: centralIndexKeyItemType Balance Type: na Period Type: durationX- DefinitionIndicate number of shares or other units outstanding of each of registrant' s classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class / interest by adding class of stock items such as Common Class A [ Member ], Common Class B [ Member ] or Partnership Interest [ Member ] onto the Instrument [ Domain ] of the Entity Listings, Instrument. ReferencesNo definition available. Details Name: dei_EntityCommonStockSharesOutstanding Namespace Prefix: dei_ Data Type: xbrli: sharesItemType Balance Type: na Period Type: instantX- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. ReferencesNo definition available. Details Name: dei_EntityContactPersonnelLineItems Namespace Prefix: dei_ Data Type: xbrli: stringItemType Balance Type: na Period Type: durationX- DefinitionIndicate' Yes' or' No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant' s current or most recent filing containing the related disclosure. ReferencesNo definition available. Details Name: dei_EntityCurrentReportingStatus Namespace Prefix: dei_ Data Type: dei: yesNoItemType Balance Type: na Period Type: durationX- DefinitionIndicate if registrant meets the emerging growth company criteria. ReferencesReference 1: http: / / www. xbrl. org / 2003 / role / presentationRef- Publisher SEC- Name Exchange Act- Number 240- Section 12- Subsection b- 2 Details Name: dei_EntityEmergingGrowthCompany Namespace Prefix: dei_ Data Type: xbrli: booleanItemType Balance Type: na Period Type: durationX- DefinitionIndicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards. ReferencesReference 1: http: / / www. xbrl. org / 2003 / role / presentationRef- Publisher SEC- Name Securities Act- Number 7A- Section B- Subsection 2 Details Name: dei_EntityExTransitionPeriod Namespace Prefix: dei_ Data Type: xbrli: booleanItemType Balance Type: na Period Type: durationX- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1- 3 digits, the sequence number may contain 1- 8 digits, the optional suffix may contain 1- 4 characters, and the fields are separated with a hyphen. ReferencesNo definition available. Details Name: dei_EntityFileNumber Namespace Prefix: dei_ Data Type: dei: fileNumberItemType Balance Type: na Period Type: durationX- DefinitionIndicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non- accelerated Filer. Definitions of these categories are stated in Rule 12b- 2 of the Exchange Act. This information should be based on the registrant' s current or most recent filing containing the related disclosure. ReferencesReference 1: http: / / www. xbrl. org / 2003 / role / presentationRef- Publisher SEC- Name Exchange Act- Number 240- Section 12- Subsection b- 2 Details Name: dei_EntityFilerCategory Namespace Prefix: dei_ Data Type: dei: filerCategoryItemType Balance Type: na Period Type: durationX- DefinitionTwo- character EDGAR code representing the state or country of incorporation. ReferencesNo definition available. Details Name: dei_EntityIncorporationStateCountryCode Namespace Prefix: dei_ Data Type: dei: edgarStateCountryItemType Balance Type: na Period Type: durationX- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. ReferencesNo definition available. Details Name: dei_EntityInformationLineItems Namespace Prefix: dei_ Data Type: xbrli: stringItemType Balance Type: na Period Type: durationX- DefinitionBoolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S- T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). ReferencesReference 1: http: / / www. xbrl. org / 2003 / role / presentationRef- Publisher SEC- Name Regulation S- T- Number 232- Section 405 Details Name: dei_EntityInteractiveDataCurrent Namespace Prefix: dei_ Data Type: dei: yesNoItemType Balance Type: na Period Type: durationX- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. ReferencesNo definition available. Details Name: dei_EntityListingsLineItems Namespace Prefix: dei_ Data Type: xbrli: stringItemType Balance Type: na Period Type: durationX- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. ReferencesNo definition available. Details Name: dei_EntityPhoneFaxNumbersLineItems Namespace Prefix: dei_ Data Type: xbrli: stringItemType Balance Type: na Period Type: durationX- DefinitionThe aggregate market value of the voting and non- voting common equity held by non- affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant' s most recently completed second fiscal quarter. ReferencesNo definition available. Details Name: dei_EntityPublicFloat Namespace Prefix: dei_ Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: instantX- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. ReferencesReference 1: http: / / www. xbrl. org / 2003 / role / presentationRef- Publisher SEC- Name Exchange Act- Number 240- Section 12- Subsection b- 2 Details Name: dei_EntityRegistrantName Namespace Prefix: dei_ Data Type: xbrli: normalizedStringItemType Balance Type: na Period Type: durationX- DefinitionBoolean flag that is true when the registrant is a shell company as defined in Rule 12b- 2 of the Exchange Act. ReferencesReference 1: http: / / www. xbrl. org / 2003 / role / presentationRef- Publisher SEC- Name Exchange Act- Number 240- Section 12- Subsection b- 2 Details Name: dei_EntityShellCompany Namespace Prefix: dei_ Data Type: xbrli: booleanItemType Balance Type: na Period Type: durationX- DefinitionIndicates that the company is a Smaller Reporting Company (SRC). ReferencesReference 1: http: / / www. xbrl. org / 2003 / role / presentationRef- Publisher SEC- Name Exchange Act- Number 240- Section 12- Subsection b- 2 Details Name: dei_EntitySmallBusiness Namespace Prefix: dei_ Data Type: xbrli: booleanItemType Balance Type: na Period Type: durationX- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9- digit value assigned by the IRS. ReferencesReference 1: http: / / www. xbrl. org / 2003 / role / presentationRef- Publisher SEC- Name Exchange Act- Number 240- Section 12- Subsection b- 2 Details Name: dei_EntityTaxIdentificationNumber Namespace Prefix: dei_ Data Type: dei: employerIdItemType Balance Type: na Period Type: durationX- DefinitionIndicate' Yes' or' No' if the registrant is not required to file reports pursuant to Section 13 or Section 15 (d) of the Act. ReferencesNo definition available. Details Name: dei_EntityVoluntaryFilers Namespace Prefix: dei_ Data Type: dei: yesNoItemType Balance Type: na Period Type: durationX- DefinitionIndicate' Yes' or' No' if the registrant is a well- known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10- K, 10- Q, 8- K, 20- F, 6- K, 10- K / A, 10- Q / A, 20- F / A, 6- K / A, N- CSR, N- Q, N- 1A. ReferencesReference 1: http: / / www. xbrl. org / 2003 / role /

presentationRef- Publisher SEC- Name Securities Act- Number 230- Section 405 Details Name: dei_EntityWellKnownSeasonedIssuer Namespace Prefix: dei_ Data Type: dei: yesNoItemType Balance Type: na Period Type: durationX- ReferencesReference 1: http: / / www. xbrl. org / 2003 / role / presentationRef- Publisher SEC- Name Form 10- K- Number 249- Section 310Reference 2: http: / / www. xbrl. org / 2003 / role / presentationRef- Publisher SEC- Name Form 20- F- Number 249- Section 220- Subsection fReference 3: http: / / www. xbrl. org / 2003 / role / presentationRef- Publisher SEC- Name Form 40- F- Number 249- Section 240- Subsection f Details Name: dei_IcfrAuditorAttestationFlag Namespace Prefix: dei_ Data Type: xbrli: booleanItemType Balance Type: na Period Type: durationX- DefinitionLocal phone number for entity. ReferencesNo definition available. Details Name: dei_LocalPhoneNumber Namespace Prefix: dei_ Data Type: xbrli: normalizedStringItemType Balance Type: na Period Type: durationX- DefinitionTitle of a 12 (b) registered security. ReferencesReference 1: http: / / www. xbrl. org / 2003 / role / presentationRef- Publisher SEC- Name Exchange Act- Number 240- Section 12- Subsection b Details Name: dei_Security12bTitle Namespace Prefix: dei_ Data Type: dei: securityTitleItemType Balance Type: na Period Type: durationX- DefinitionName of the Exchange on which a security is registered. ReferencesReference 1: http: / / www. xbrl. org / 2003 / role / presentationRef- Publisher SEC- Name Exchange Act- Number 240- Section 12- Subsection d1- 1 Details Name: dei_SecurityExchangeName Namespace Prefix: dei_ Data Type: dei: edgarExchangeCodeItemType Balance Type: na Period Type: durationX- DefinitionTrading symbol of an instrument as listed on an exchange. ReferencesNo definition available. Details Name: dei_TradingSymbol Namespace Prefix: dei_ Data Type: dei: tradingSymbolItemType Balance Type: na Period Type: durationX- Details Name: us- gaap_StatementClassOfStockAxis = us-gaap_CommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us- gaap_StatementClassOfStockAxis = ntrb_WarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: Audit Information 12 Months Ended Jan. 31, ~~2024~~ **2025** Auditor [ Table ] Auditor Name Sadler, Gibb & Associates, LLCAuditor Firm IDAuditor Location Draper, ~~UTX~~ **UTAuditor Opinion [ Text Block ] Opinion on the Financial StatementsWe have audited the accompanying consolidated balance sheets of Nutriband Inc. and subsidiaries (" the Company ") as of January 31, 2025 and 2024, the related consolidated statements of operations, stockholders' equity, and cash flows for each of the years in the two- year period ended January 31, 2025 and the related notes (collectively referred to as the " financial statements "). In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of the Company as of January 31, 2025 and 2024, and the results of its operations and its cash flows for each of the years in the two- year period ended January 31, 2025, in conformity with accounting principles generally accepted in the United States of America. X** - DefinitionPCAOB issued Audit Firm Identifier ReferencesReference 1: http: / / www. xbrl. org / 2003 / role / presentationRef- Publisher SEC- Name Form 10- K- Number 249- Section 310Reference 2: http: / / www. xbrl. org / 2003 / role / presentationRef- Publisher SEC- Name Form 20- F- Number 249- Section 220- Subsection fReference 3: http: / / www. xbrl. org / 2003 / role / presentationRef- Publisher SEC- Name Form 40- F- Number 249- Section 240- Subsection f Details Name: dei_AuditorFirmId Namespace Prefix: dei_ Data Type: dei: nonemptySequenceNumberItemType Balance Type: na Period Type: durationX- ReferencesReference 1: http: / / www. xbrl. org / 2003 / role / presentationRef- Publisher SEC- Name Form 10- K- Number 249- Section 310Reference 2: http: / / www. xbrl. org / 2003 / role / presentationRef- Publisher SEC- Name Form 20- F- Number 249- Section 220- Subsection fReference 3: http: / / www. xbrl. org / 2003 / role / presentationRef- Publisher SEC- Name Form 40- F- Number 249- Section 240- Subsection f Details Name: dei_AuditorLocation Namespace Prefix: dei_ Data Type: dei: internationalNameItemType Balance Type: na Period Type: durationX- ReferencesReference 1: http: / / www. xbrl. org / 2003 / role / presentationRef- Publisher SEC- Name Form 10- K- Number 249- Section 310Reference 2: http: / / www. xbrl. org / 2003 / role / presentationRef- Publisher SEC- Name Form 20- F- Number 249- Section 220- Subsection fReference 3: http: / / www. xbrl. org / 2003 / role / presentationRef- Publisher SEC- Name Form 40- F- Number 249- Section 240- Subsection f Details Name: dei_AuditorName Namespace Prefix: dei_ Data Type: dei: internationalNameItemType Balance Type: na Period Type: durationX- **ReferencesReference 1: http: / / www. xbrl. org / 2003 / role / presentationRef- Publisher SEC- Name Regulation S- X- Number 210- Section 2- Subsection 2 Details Name: dei_AuditorOpinionTextBlock Namespace Prefix: dei_ Data Type: dtr- types: textBlockItemType Balance Type: na Period Type: durationX-** ReferencesNo definition available. Details Name: dei_AuditorTable Namespace Prefix: dei_ Data Type: xbrli: stringItemType Balance Type: na Period Type: ~~durationCondensed~~ **durationConsolidated** ~~Consolidated~~ Balance Sheets- USD ($) Jan. 31, ~~2024~~ **2025** Jan. 31, ~~2023CURRENT~~ **2024CURRENT** ASSETS: Cash and cash equivalents $ **4, 311, 719 $** 492, ~~942 $ 1, 985, 440Accounts~~ **942Accounts** receivable **- net 73, 847** 148, ~~649 113, 045Inventory~~ **649Inventory 212, 041** 168, ~~605 229, 335Prepaid~~ **605Prepaid** expenses **196, 658** 211, **667Total** ~~667 365, 925Total~~ Current Assets **4, 794, 265** 1, 021, **863PROPERTY** ~~863 2, 693, 745PROPERTY~~ & EQUIPMENT- net **695, 063** 774, **924OTHER** ~~924 897, 735OTHER~~ ASSETS: Goodwill ~~5~~ **1** , ~~021~~ **719** , ~~713~~ **535** 5, 021, 713Operating lease right of use asset 31, ~~374 62, 754Intangible~~ **374Intangible** assets- net **261, 092** 667, ~~280 780, 430TOTAL~~ **280TOTAL** ASSETS 7, **469, 955 7,** 517, **154CURRENT** ~~154 9, 456, 377CURRENT~~ LIABILITIES: Accounts payable and accrued expenses **698, 821** 680, **132Deferred** ~~132 534, 679Deferred~~ revenue **155, 880** 157, ~~502 162, 903Operating~~ **502Operating** lease liability- current portion 34, ~~276 31, 291Notes~~ **276Notes** payable- current portion **128, 144** 127, **183Total** ~~183 19, 740Total~~ Current Liabilities **982, 845** 999, **093LONG** ~~093 748, 613LONG~~ - TERM LIABILITIES: Note payable- net of current portion **58, 205** 79, ~~826 100, 497Operating lease liability- net of current portion 34, 277Total~~ **826Total** Liabilities 1, **041, 050 1,** 078, ~~919 883, 387Commitments~~ **919Commitments** and Contingencies STOCKHOLDERS' EQUITY: Preferred stock, $. 001 par value, 10, 000, 000 shares authorized,- 0- outstanding Common stock, $. 001 par value, 291, 666, 666 shares authorized; **11, 107, 210 and** 8, 869, 870 ~~and 7, 843, 150~~ shares issued at January 31, **2025 and** 2024 **, respectively, 11, 074, 810** and ~~2023, respectively,~~ 8, 859, 870 ~~and 7, 833, 150~~ shares outstanding as of January 31, **2025 and** 2024 ~~and 2023~~ , respectively **11, 075** 8, ~~860 7, 833Additional~~ **860Additional** paid- in- capital **45, 029, 317** 34, 442, ~~339 31, 092, 807Accumulated~~ **339Accumulated** other comprehensive loss (304) (304) Treasury stock, ~~10~~ **32** , ~~000~~ **400** and 10, 000 shares at cost, respectively ( ~~32~~ **148** , ~~641~~ **547** ) (32, 641) Accumulated deficit ( **38, 462, 636) (** 27, 980, 019 ~~) (22, 494, 705~~ ) Total Stockholders' Equity 6, **428, 905 6,** 438, **235TOTAL** ~~235 8, 572, 990TOTAL~~ LIABILITIES AND STOCKHOLDERS' EQUITY **$** 7, **469, 955 $ 7,** 517, ~~154~~ **154X** ~~9, 456, 377Related Party LONG- TERM LIABILITIES: Note payable- related party X~~ - DefinitionSum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits. ReferencesReference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef- Topic 210- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210. 5- 02 (20))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1Reference 2: http: / / fasb. org / us- gaap / role / ref / legacyRef- Topic 210- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210. 5- 02 (19))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1 Details Name: us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent Namespace Prefix: us- gaap_ Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: instantX- DefinitionAmount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current. ReferencesReference 1: http: / / www. xbrl. org / 2009 / role / commonPracticeRef- Topic 310- SubTopic 10- Name Accounting Standards Codification- Section 45- Paragraph 2- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147481990 / 310- 10- 45- 2 Details Name: us-gaap_AccountsReceivableNetCurrent Namespace Prefix: us- gaap_ Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: instantX- DefinitionAmount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source. ReferencesReference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef- Name Accounting Standards Codification- Topic 220- SubTopic 10- Section 45- Paragraph 14A- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482790 / 220- 10- 45- 14AReference 2: http: / / fasb. org / us- gaap / role / ref / legacyRef- Topic 220- SubTopic 10- Name Accounting Standards Codification- Section 45- Paragraph 11- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482790 / 220- 10- 45- 11Reference 3: http: / / www. xbrl. org / ~~2003~~ **2009** / role / ~~disclosureRef~~ **commonPracticeRef** - Topic ~~944~~ **815** - SubTopic ~~40~~ **30** - Name Accounting Standards Codification- Section ~~65~~ **50** - Paragraph 2- Subparagraph ( **a** ~~g) (2) (ii~~ )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147480016~~ - - **2147480870** / ~~944~~ **815** - ~~40~~ **30** - ~~65~~ **50** - 2Reference 4: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 944- SubTopic 40- Name Accounting Standards Codification- Section 65- Paragraph 2- Subparagraph ( ~~h~~ **g** ) (2 **) (ii** )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480016 / 944- 40- 65- 2Reference 5: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic ~~210~~ **944** - SubTopic ~~10~~ **40** - Name Accounting Standards Codification- Section ~~S99~~ **65** - Paragraph ~~1~~ **2** - Subparagraph ( **h** ~~SX 210. 5- 02 (30~~ ) ( **2** ~~a) (4)~~ )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147480566~~ - **2147480016** / **944- 40- 65- 2Reference 6: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic** 210- ~~10- S99- 1Reference 6: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 944-~~ SubTopic ~~210~~ - **10** - Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210. ~~7~~ **5** - ~~03~~ **02 (30)** (a) ( **4** ~~23) (a) (3~~ -)- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147478777~~ **2147480566** / ~~944-~~ 210 **- 10** - S99- 1Reference 7 **: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 944- SubTopic 210- Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210. 7- 03 (a) (23) (a) (3))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147478777 / 944- 210- S99- 1Reference 8** : http: / / fasb. org / us- gaap / role / ref / legacyRef- Name Accounting Standards Codification- Topic 220- SubTopic 10- Section 45- Paragraph 14- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482790 / 220- 10- 45- 14 Details Name: us- gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax Namespace Prefix: us- gaap_ Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: instantX- DefinitionAmount of excess of issue price over par or stated value of stock and from other

transaction involving stock or stockholder. Includes, but is not limited to, additional paid- in capital (APIC) for common and preferred stock. ReferencesReference 1: http: / / www. xbrl. org / 2003 / role / exampleRef- Topic 852- SubTopic 10- Name Accounting Standards Codification- Section 55- Paragraph 10- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147481372 / 852- 10- 55- 10Reference 2: http: / / www. xbrl. org / 2009 / role / commonPracticeRef- Topic 946- SubTopic 210- Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210. 6- 04 (18))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147479170 / 946- 210- S99- 1Reference 3: http: / / fasb. org / us- gaap / role / ref / legacyRef- Topic 210- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210. 5- 02 (30) (a) (1))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1 Details Name: us- gaap_AdditionalPaidInCapital Namespace Prefix: us- gaap_ Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: instantX- DefinitionAmount of asset recognized for present right to economic benefit. ReferencesReference 1: http: / / www. xbrl. org / 2003 / role / ~~exampleRef~~ **disclosureRef** - Topic ~~280~~ **942** - SubTopic ~~10~~ **235** - Name Accounting Standards Codification- Section ~~55~~ **S99** - Paragraph ~~48~~ **1- Subparagraph (SX 210. 9- 05 (b) (1))** - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147482785~~ **2147477314** / ~~280~~ **942** - ~~10~~ **235** - ~~55~~ **S99** - ~~48Reference~~ **1Reference** 2: http: / / www. xbrl. org / 2003 / role / ~~exampleRef~~ **disclosureRef** - Topic ~~280~~ **942** - SubTopic ~~10~~ **235** - Name Accounting Standards Codification- Section ~~55~~ **S50** - Paragraph ~~49~~ **1** - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147482785~~ **2147478671** / ~~280~~ **942** - ~~10~~ **235** - ~~55~~ **S50** - ~~49Reference~~ **1Reference** 3: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic ~~270~~ **235** - SubTopic 10- Name Accounting Standards Codification- Section ~~50~~ **S50** - Paragraph 1- ~~Subparagraph (i)~~ - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147482964~~ **2147480738** / ~~270~~ **235** - 10- ~~50~~ **S50** - 1Reference 4: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic ~~280~~ **235** - SubTopic 10- Name Accounting Standards Codification- Section ~~50~~ **S99** - Paragraph ~~32~~ **1** - Subparagraph ( ~~ec~~ **SX 210. 4- 08 (g) (1) (i)** )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147482810~~ **2147480678** / ~~280~~ **235** - 10- ~~50~~ **S99** - ~~32Reference~~ **1Reference** 5: http: / / ~~fasb~~ **www** . **xbrl.** org / **2003** ~~us- gaap~~ / role / **disclosureRef** ~~ref / otherTransitionRef~~ - Topic ~~280~~ **825** - SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph ~~32~~ **28** - Subparagraph ( ~~d~~ **f** )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147482810~~ **2147482907** / ~~280~~ **825** - 10- 50- ~~32Reference~~ - **28Reference** 6: http: / / www. xbrl. org / 2003 / role / ~~disclosureRef~~ **exampleRef** - Topic ~~280~~ **480** - SubTopic 10- Name Accounting Standards Codification- Section ~~50~~ **55** - Paragraph ~~22~~ **64** - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147482810~~ - **2147481620** / ~~280~~ **480** - 10- ~~50~~ **55** - ~~22Reference~~ **64Reference** 7: http: / / www. xbrl. org / 2003 / role / ~~disclosureRef~~ **exampleRef** - Topic ~~810~~ **944** - SubTopic ~~10~~ **605** - Name Accounting Standards Codification- Section ~~50~~ **55** - Paragraph **14** ~~3- Subparagraph (bb)~~ - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147481203~~ **2147477548** / ~~810~~ **944** - ~~10~~ **605** - ~~50~~ **55** - ~~3Reference~~ **14Reference** 8: http: / / www. xbrl. org / 2003 / role / ~~disclosureRef~~ **exampleRef** - Topic ~~810~~ **944** - SubTopic ~~10~~ **605** - Name Accounting Standards Codification- Section ~~45~~ **55** - Paragraph **11** ~~25- Subparagraph (a)~~ - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147481231~~ **2147477548** / ~~810~~ **944** - ~~10~~ **605** - ~~45~~ **55** - ~~25Reference~~ **11Reference** 9: http: / / www. xbrl. org / 2003 / role / ~~disclosureRef~~ **exampleRef** - Topic ~~235~~ **280** - SubTopic 10- Name Accounting Standards Codification- Section ~~S99~~ **55** - Paragraph **48** ~~1- Subparagraph (SX 210. 4- 08 (g) (1) (ii))~~ - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147480678~~ **2147482785** / ~~235~~ **280** - 10- ~~S99~~ **55** - ~~1Reference~~ **48Reference** 10: http: / / www. xbrl. org / 2003 / role / ~~disclosureRef~~ **exampleRef** - Topic ~~323~~ **280** - SubTopic 10- Name Accounting Standards Codification- Section ~~50~~ **55** - Paragraph **49** ~~3- Subparagraph (c)~~ - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147481687~~ **2147482785** / ~~323~~ **280** - 10- ~~50~~ **55** - ~~3Reference~~ **49Reference** 11: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic ~~825~~ **270** - SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph ~~28~~ **1** - Subparagraph ( ~~f~~ **i** )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147482907~~ **2147482964** / ~~825~~ **270** - 10- 50- ~~28Reference~~ **1Reference** 12: http: / / www. xbrl. org / 2003 / role / ~~exampleRef~~ **disclosureRef** - Topic ~~852~~ **280** - SubTopic 10- Name Accounting Standards Codification- Section ~~55~~ **50** - Paragraph ~~10~~ **32- Subparagraph (ee)** - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147481372~~ **2147482810** / ~~852~~ **280** - 10- ~~55~~ **50** - ~~10Reference~~ **32Reference** 13: http: / / ~~www~~ **fasb** . ~~xbrl.~~ org / ~~2003~~ **us- gaap** / role / ~~exampleRef~~ **ref / otherTransitionRef** - Topic ~~946~~ **280** - SubTopic ~~830~~ **10** - Name Accounting Standards Codification- Section ~~55~~ **50** - Paragraph ~~12~~ **32- Subparagraph (d)** - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147479168~~ **2147482810** / ~~946~~ **280** - ~~830~~ **10** - ~~55~~ **50** - ~~12Reference~~ **32Reference** 14: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic ~~944~~ **280** - SubTopic ~~210~~ - **10** - Name Accounting Standards Codification- Section ~~S99~~ **50** - Paragraph **22** ~~1- Subparagraph (SX 210. 7- 03 (a) (12))~~ - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147478777~~ **2147482810** / ~~944~~ **280** - ~~210~~ - **10** - ~~S99~~ **50** - ~~1Reference~~ **22Reference** 15: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic ~~946~~ **810** - SubTopic ~~210~~ - **10** - Name Accounting Standards Codification- Section ~~S99~~ **50** - Paragraph ~~1~~ **3** - Subparagraph ( **bb** ~~SX 210. 6- 04 (8)~~ )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147479170~~ **2147481203** / ~~946~~ **810** - ~~210~~ - **10** - ~~S99~~ **50** - ~~1Reference~~ **3Reference** 16: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic ~~210~~ **810** - SubTopic 10- Name Accounting Standards Codification- Section ~~S99~~ **45** - Paragraph ~~1~~ **25** - Subparagraph ( **a** ~~SX 210. 5- 02 (18)~~ )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147480566~~ **2147481231** / ~~210~~ ~~10~~ **810** - ~~S99~~ **10** - **45** ~~1Reference~~ **25Reference** 17: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic ~~470~~ **235** - SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph ~~1A~~ **1** - Subparagraph (SX 210. ~~13- 01 (a) (~~4 ) ~~- 08~~ ( ~~i~~ **g) (1) (ii** ))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147480097~~ **2147480678** / ~~470~~ **235** - 10- S99- ~~1AReference~~ - **1Reference** 18: http: / / www. xbrl. org / ~~2009~~ **2003** / role / ~~commonPracticeRef~~ **disclosureRef** - Topic ~~470~~ **323** - SubTopic 10- Name Accounting Standards Codification- Section ~~S99~~ **50** - Paragraph ~~1A~~ **3** - Subparagraph ( **c** ~~SX 210. 13- 01 (a) (4) (ii)~~ )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147480097~~ **2147481687** / ~~470~~ **323** - 10- ~~S99~~ **50** - ~~1AReference~~ **3Reference** 19: http: / / www. xbrl. org / ~~2009~~ **2003** / role / ~~commonPracticeRef~~ **exampleRef** - Topic ~~470~~ **852** - SubTopic 10- Name Accounting Standards Codification- Section ~~S99~~ **55** - Paragraph ~~1A- Subparagraph (SX 210~~ - **10** . 13- 01 (a) (4) (iii)) - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147480097~~ **2147481372** / ~~470~~ **852** - 10- ~~S99~~ **55** - ~~1AReference~~ **10Reference** 20: http: / / www. xbrl. org / 2003 / role / ~~disclosureRef~~ **exampleRef** - Topic ~~470~~ **946** - SubTopic ~~10~~ **830** - Name Accounting Standards Codification- Section ~~S99~~ **55** - Paragraph **12** ~~1A- Subparagraph (SX 210. 13- 01 (a) (4) (iii) (A))~~ - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147480097~~ **2147479168** / ~~470~~ **946** - ~~10~~ **830** - ~~S99~~ **55** - ~~1AReference~~ **12Reference** 21: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic ~~470~~ **944** - SubTopic ~~10~~ **210** - Name Accounting Standards Codification- Section S99- Paragraph ~~1A~~ **1** - Subparagraph (SX 210. ~~13~~ **7** - ~~01~~ **03** (a) ( **12** ~~4) (iv~~ ))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147480097~~ **2147478777** / ~~470~~ **944** - ~~10~~ **210** - S99- ~~1AReference~~ - **1Reference** 22: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic ~~470~~ **946** - SubTopic ~~10~~ **210** - Name Accounting Standards Codification- Section S99- Paragraph ~~1A~~ **1** - Subparagraph (SX 210. ~~13~~ **6** - ~~01~~ **04** ( **8** ~~a) (5~~ ))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147480097~~ **2147479170** / ~~470~~ **946** - ~~10~~ **210** - S99- ~~1AReference~~ - **1Reference** 23: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic ~~470~~ **210** - SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph ~~1B~~ **1** - Subparagraph (SX 210. ~~13~~ **5** - 02 ( **18** ~~a) (4) (i~~ ))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147480097~~ **2147480566** / ~~470~~ **210** - 10- S99- ~~1BReference~~ - **1Reference** 24: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 470- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph ~~1B~~ **1A** - Subparagraph (SX 210. 13- ~~02~~ **01** (a) (4) ( **i** ~~iii) (A~~ ))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- ~~1BReference~~ **1AReference** 25: http: / / www. xbrl. org / ~~2003~~ **2009** / role / ~~disclosureRef~~ **commonPracticeRef** - Topic 470- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph ~~1B~~ **1A** - Subparagraph (SX 210. 13- ~~02~~ **01** (a) (4) ( ~~iii~~ **ii** ~~) (B~~ ))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- ~~1BReference~~ **1AReference** 26: http: / / www. xbrl. org / ~~2003~~ **2009** / role / ~~disclosureRef~~ **commonPracticeRef** - Topic 470- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph ~~1B~~ **1A** - Subparagraph (SX 210. 13- ~~02~~ **01** (a) (4) ( ~~iv~~ **iii** ))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- ~~1BReference~~ **1AReference** 27: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 470- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph ~~1B~~ **1A** - Subparagraph (SX 210. 13- ~~02~~ **01** (a) ( ~~5~~ **4) (iii) (A** ))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- ~~1BReference~~ **1AReference** 28: http: / / www. xbrl. org / ~~2009~~ **2003** / role / ~~commonPracticeRef~~ **disclosureRef** - Topic ~~852~~ **470** - SubTopic 10- Name Accounting Standards Codification- Section ~~50~~ **S99** - Paragraph ~~7~~ **1A** - Subparagraph ( **SX 210. 13- 01 (** a **) (4) (iv)** )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147481404~~ **2147480097** / ~~852~~ **470** - 10- ~~50~~ **S99** - ~~7Reference~~ **1AReference** 29: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic ~~280~~ **470** - SubTopic 10- Name Accounting Standards Codification- Section **the passage of time or when** ~~S99- Paragraph 1A- Subparagraph (SX 210.13- 01 (~~a **triggering event occurs** ~~) (5))- Publisher FASB- URI https: / / asc. ReferencesReference 1 fasb.org / 1943274 / 2147480097 / 470- 10- S99- 1AReference 30~~ :http: / ~~www~~ **fasb** . ~~xbrl.~~ org / ~~2003~~ **us- gaap** / role / ~~disclosureRef~~ **ref / legacyRef** - Topic ~~470~~ **942** - SubTopic ~~10~~ **210** - Name Accounting Standards Codification- Section S99- Paragraph ~~1B~~ **1** - Subparagraph (SX 210. ~~13~~ **9** - ~~02~~ **03** ( **10** ~~a) (4) (i~~ ))- Publisher FASB- URI https: / / asc.fasb.org / 1943274 / ~~2147480097~~ **2147478546** / ~~470~~ **942** - ~~10~~ **210** - S99- ~~1BReference~~ - **1Reference** ~~31~~ **2** :http: / / www.xbrl.org / ~~2003~~ **2009** / role / ~~disclosureRef~~ **commonPracticeRef** - Topic ~~470~~ **944** - SubTopic ~~10~~ **210** - Name Accounting Standards Codification- Section S99- Paragraph ~~1B~~ **1** - Subparagraph (SX 210. ~~13~~ **7** - ~~02~~ **03** (a) ( **10** ~~4) (iii) (A~~ ))- Publisher FASB- URI https: / / asc.fasb.org / 1943274 / ~~2147480097~~ **2147478777** / ~~470~~ **944** - ~~10~~ **210** - S99- ~~1BReference~~ - **1Reference** ~~32~~ **3** :http: / / www.xbrl.org / 2003 / role / disclosureRef- Topic ~~470~~ **946** - SubTopic ~~10~~ **210** - Name Accounting Standards Codification- Section S99- Paragraph ~~1B~~ **1** - Subparagraph (SX 210. ~~13~~ **6** - ~~02~~ **04 (7)** (a ~~) (4) (iii) (B~~ ))- Publisher FASB- URI https: / / asc.fasb.org / 1943274 / ~~2147480097~~ **2147479170** / ~~470~~ **946** - ~~10~~ **210** - S99- ~~1BReference~~ - **1Reference** ~~33~~ **4** :http: / / www.xbrl.org / 2003 / role / disclosureRef- Topic ~~470~~ **210** - SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph ~~1B~~ **1** - Subparagraph (SX 210. ~~13~~ **5** - 02 ( **7** ~~a) (4) (iv~~ ))- Publisher FASB- URI https: / / asc.fasb.org / 1943274 / ~~2147480097~~ **2147480566** / ~~470- 10~~ **210** - ~~S99~~ **10** - ~~1BReference 34~~ **S99- 1 Details Name:us- gaap_PrepaidExpenseCurrentAndNoncurrent Namespace Prefix:us- gaap_ Data**

**Type:xbrli:monetaryItemType Balance Type:debit Period Type:instantX- DefinitionCash received for fees during the current period.This element excludes cash proceeds from license fees. ReferencesReference 1** :http: / / ~~www~~ **fasb** . ~~xbrl.~~ org / ~~2003~~ **us- gaap** / role / ~~disclosureRef~~ **ref / legacyRef** - Topic ~~470~~ **230** - SubTopic 10- Name Accounting Standards Codification- Section ~~S99~~ **45** - Paragraph ~~1B~~ **25** - Subparagraph ( **c** ~~SX 210.13- 02 (a) (5)~~ )- Publisher FASB- URI https: / / asc.fasb.org / 1943274 / ~~2147480097~~ **2147482740** / ~~470~~ **230** - 10- ~~S99~~ **45** - ~~1BReference 35~~ **25 Details Name** : ~~http~~ **us- gaap_ProceedsFromFeesReceived Namespace Prefix** : ~~/ / www.~~ **us- gaap_ Data Type:** ~~xbrl~~ **xbrli** ~~.org / 2009 / role /~~ **:monetaryItemType Balance Type:debit Period Type:durationX- DefinitionAmount of purchase arrangement** 50- Paragraph 30- Subparagraph (c)- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482810 / 280- 10- 50- 30Reference ~~30~~ **37** : http: / / fasb. org / us- gaap / role / ref / legacyRef- Topic 942- SubTopic 210- Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210. 9- 03 (11))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147478546 / 942- 210- S99- 1 Details Name: us- gaap_Assets Namespace Prefix: us- gaap_ Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: instantX- DefinitionAmount of asset recognized for present right to economic benefit, classified as current. ReferencesReference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic ~~810~~ **235** - SubTopic 10- Name Accounting Standards Codification- Section ~~50~~ **S50** - Paragraph **1** ~~3- Subparagraph (bb)~~ - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147481203~~ - **2147480738** / **235-** ~~810~~ - **10** - ~~10- 50~~ **S50** - ~~3Reference~~ **1Reference** 2: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic ~~810~~ **235** - SubTopic 10- Name Accounting Standards Codification- Section ~~45~~ **S99** - Paragraph ~~25~~ **1** - Subparagraph ( ~~a~~ **SX 210. 4- 08 (g) (1) (i)** )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147481231~~ **2147480678** / **235-** ~~810~~ - **10** - ~~10~~ **S99** - ~~45- 25Reference~~ **1Reference** 3: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic ~~235~~ **825** - SubTopic 10- Name Accounting Standards Codification- Section ~~S99~~ **50** - Paragraph ~~1~~ **28** - Subparagraph ( **f** ~~SX 210. 4- 08 (g) (1) (ii)~~ )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147480678~~ - **2147482907** / ~~235~~ **825** - 10- ~~S99~~ **50** - ~~1Reference~~ **28Reference** 4: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic ~~323~~ **810** - SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 3- Subparagraph ( ~~c~~ **bb** )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147481687~~ **2147481203** / ~~323~~ **810** - 10- 50- 3Reference 5: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic ~~825~~ **810** - SubTopic 10- Name Accounting Standards Codification- Section ~~50~~ **45** - Paragraph ~~28~~ **25** - Subparagraph ( ~~f~~ **a** )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147482907~~ **2147481231** / ~~825- 10~~ **810** - ~~50~~ **10** - **45-** ~~28Reference~~ **25Reference** 6: http: / / www. xbrl. org / 2003 / role / ~~exampleRef~~ **disclosureRef** - Topic ~~852~~ **235** - SubTopic 10- Name Accounting Standards Codification- Section ~~55~~ **S99** - Paragraph **1- Subparagraph (SX** ~~10~~ **210 . 4- 08 (g) (1) (ii))** - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147481372~~ **2147480678** / ~~852~~ **235** - 10- ~~55~~ **S99** - ~~10Reference~~ - **1Reference** 7: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic ~~210~~ **323** - SubTopic 10- Name Accounting Standards Codification- Section ~~45~~ **50** - Paragraph ~~1~~ **3- Subparagraph (c)** - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147483467~~ **2147481687** / **323-** ~~210~~ - **10** - ~~10~~ **50** - ~~45- 1Reference~~ **3Reference** 8: http: / / www. xbrl. org / 2003 / role / ~~disclosureRef~~ **exampleRef** - Topic ~~210~~ **852** - SubTopic 10- Name Accounting Standards Codification- Section ~~S99~~ **55** - Paragraph ~~1- Subparagraph (SX 210.~~ - **10** ~~5- 02 (9))~~ - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147480566~~ **2147481372** / **852- 10- 55- 10Reference 9: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic** 210 ~~- 10- S99- 1Reference 9: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 470~~ - SubTopic 10- Name Accounting Standards Codification- Section ~~S99~~ **45** - Paragraph **1** ~~1A- Subparagraph (SX 210. 13- 01 (a) (4) (i))~~ - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147480097~~ **2147483467** / ~~470- 10~~ **210** - ~~S99~~ **10** - **45-** ~~1AReference~~ - **1Reference** 10: http: / / www. xbrl. org / ~~2009~~ **2003** / role / ~~commonPracticeRef~~ **disclosureRef** - Topic ~~470~~ **210** - SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph ~~1A~~ **1** - Subparagraph (SX 210. ~~13~~ **5** - ~~01~~ **02** ( **9** ~~a) (4) (ii~~ ))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147480097~~ **2147480566** / ~~470~~ **210** - 10- S99- ~~1AReference~~ - **1Reference** 11: http: / / www. xbrl. org / ~~2009~~ **2003** / role / ~~commonPracticeRef~~ **disclosureRef** - Topic 470- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1A- Subparagraph (SX 210. 13- 01 (a) (4) ( ~~iii~~ **i** ))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1AReference 12: http: / / www. xbrl. org / ~~2003~~ **2009** / role / ~~disclosureRef~~ **commonPracticeRef** - Topic 470- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1A- Subparagraph (SX 210. 13- 01 (a) (4) ( ~~iii~~ - **ii** ~~) (A~~ ))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1AReference 13: http: / / www. xbrl. org / ~~2003~~ **2009** / role / ~~disclosureRef~~ **commonPracticeRef** - Topic 470- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1A- Subparagraph (SX 210. 13- 01 (a) (4) ( ~~iv~~ **iii** ))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1AReference 14: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 470- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1A- Subparagraph (SX 210. 13- 01 (a) ( ~~5~~ **4) (iii) (A** ))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1AReference 15: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 470- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph ~~1B~~ **1A** - Subparagraph (SX 210. 13- ~~02~~ **01** (a) (4) ( ~~i~~ **iv** ))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- ~~1BReference~~ **1AReference** 16: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 470- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph ~~1B~~ **1A** - Subparagraph (SX 210. 13- ~~02~~ **01** (a) ( **5** ~~4) (iii) (A~~ ))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- ~~1BReference~~ **1AReference** 17: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 470- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1B- Subparagraph (SX 210. 13- 02 (a) (4) ( **i** ~~iii) (B~~ ))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1BReference 18: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 470- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1B- Subparagraph (SX 210. 13- 02 (a) (4) ( ~~iv~~ **iii) (A** ))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1BReference 19: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 470- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1B- Subparagraph (SX 210. 13- 02 (a) ( ~~5~~ **4) (iii) (B** ))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1BReference 20: http: / / www. xbrl. org / ~~2009~~ **2003** / role / ~~commonPracticeRef~~ **disclosureRef** - Topic ~~852~~ **470** - SubTopic 10- Name Accounting Standards Codification- Section ~~"~~ **S99- Paragraph 1B- Subparagraph (SX 210.13- 02 (a) (4) (iv))- Publisher** FASB - ~~","~~ URI ~~":"~~ https:/ / asc.fasb.org / 1943274 / 2147480097 / 470- 10- S99- **1BReference 21** ~~1B" },"~~ ~~r360"~~ : ~~{" role":"~~ http:/ / www.xbrl.org / 2003 / role / disclosureRef ~~- ","~~ Topic ~~":"~~ 470 ~~- ","~~ SubTopic ~~":"~~ 10 ~~- ","~~ Name ~~":"~~ Accounting Standards Codification ~~- ","~~ Section ~~":"~~ S99 ~~- ","~~ Paragraph ~~":"~~ 1B ~~- ","~~ Subparagraph ~~":"~~ (SX 210.13- 02 (a) (5)) ~~- ","~~ Publisher ~~":"~~ FASB ~~- ","~~ URI ~~":"~~ https:/ / asc.fasb.org / 1943274 / 2147480097 / 470- 10- S99 **- 1BReference 22:http:/ / www.xbrl.org / 2009 / role / commonPracticeRef- Topic 852- SubTopic 10- Name Accounting Standards Codification- Section** 50- Paragraph 7- Subparagraph (a)- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147481404 / 852- 10- 50- 7 Details Name: us- gaap_AssetsCurrent Namespace Prefix: us- gaap_ Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: instantX- ReferencesNo definition available. Details Name: us- gaap_AssetsCurrentAbstract Namespace Prefix: us- gaap_ Data Type: xbrli: stringItemType Balance Type: na Period Type: durationX- DefinitionAmount of **cash and cash equivalent. Cash includes, but is not limited to,** currency on hand **,** ~~as well as~~ demand ~~deposits~~ - **deposit** with ~~banks or~~ financial ~~institutions~~ - **institution, and** . ~~Includes other kinds of accounts~~ - **account with** ~~that have the~~ general ~~characteristics~~ - **characteristic** of demand ~~deposits~~ - **deposit** . ~~Also~~ **Cash equivalent** includes **, but is not limited to,** short- term, highly liquid ~~investments~~ - **investment** that ~~are~~ **is** both readily convertible to known ~~amounts~~ - **amount** of cash and so near ~~their~~ maturity that ~~they it~~ **present presents** insignificant risk of ~~changes~~ - **change** in value because of ~~changes~~ - **change** in interest ~~rates~~ - **rate** . ~~Excludes cash and cash equivalents within disposal group and discontinued operation~~ . ReferencesReference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 210- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210. 5- 02 (1))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1Reference 2: http: / / www. xbrl. org / 2003 / role / exampleRef- Topic 210- SubTopic 10- Name Accounting Standards Codification- Section 45- Paragraph 1- Subparagraph (a)- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147483467 / 210- 10- 45- 1Reference 3: http: / / fasb. org / us- gaap / role / ref / legacyRef- Name Accounting Standards Codification- Topic 230- SubTopic 10- Section 45- Paragraph 4- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482740 / 230- 10- 45- 4 Details Name: us- gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us- gaap_ Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: instantX- DefinitionRepresents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company' s resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur. ReferencesReference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef- Topic 942- SubTopic 210- Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210. 9- 03 (17))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147478546 / 942- 210- S99- 1Reference 2: http: / / fasb. org / us- gaap / role / ref / legacyRef- Topic 210- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210. 5- 02 (25))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1Reference 3: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 944- SubTopic 210- Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210. 7- 03 (a) (19))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147478777 / 944- 210- S99- 1Reference 4: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 946- SubTopic 210- Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210. 6- 04 (15))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147479170 / 946- 210- S99- 1 Details Name: us- gaap_CommitmentsAndContingencies Namespace Prefix: us- gaap_ Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: instantX- DefinitionAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely

at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. ReferencesReference 1: http: / / fasb www . xbrl. org / 2003 us- gaap / role / disclosureRef ref / legacyRef - Topic 210 480 - SubTopic 10- Name Accounting Standards Codification- Section S99 S45 - Paragraph 2 1- Subparagraph (SX 210. 5- 02 (29)) - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480566 2147479887 / 480- 210 - 10 - 10 S45 - S99- 1Reference 2Reference 2: http: / / www. xbrl. org / 2003 / role / exampleRef disclosureRef - Topic 852 480 - SubTopic 10- Name Accounting Standards Codification- Section 55 S99 - Paragraph 10 1- Subparagraph (01) (iii) - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147481372 2147480244 / 852 480 - 10- 55 S99 - 10Reference - 1Reference 3: http: / / www fasb . xbrl. org / 2003 us- gaap / role / disclosureRef ref / legacyRef - Topic 944 210 - SubTopic 210 - 10 - Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210. P1Y5M13D' represents reported fact of one year,five months,and thirteen days 5- 02 (29))- Publisher FASB- URI https:/ / asc . ReferencesReference 1 fasb.org / 1943274 / 2147480566 / 210- 10- S99- 1Reference 4 :http:/ / www.xbrl.org / 2003 / role / exampleRef- Topic 842 852 - SubTopic 20 10 - Name Accounting Standards Codification- Section 55- Paragraph 53 10 - Publisher FASB- URI https:/ / asc.fasb.org / 1943274 / 2147479589 2147481372 / 842 852 - 20 10 - 55- 53Reference 10Reference 2 5 :http:/ / www.xbrl.org / 2003 / role / disclosureRef- Topic 842 944 - SubTopic 20 210 - Name Accounting Standards Codification- Section 50 S99 - Paragraph 4 1 - Subparagraph ( SX 210 g) (3)- Publisher FASB- URI https:/ / asc . fasb. 7- 03 (a) (22))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147478777 / 944- 210- S99- 1 Details Name: us- gaap_CommonStockValue Namespace Prefix: us- gaap_ Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: instantX- DefinitionAmount of deferred income and obligation to transfer product and good or service to customer for which consideration has been received or is receivable, classified as current. ReferencesReference 1: http: / / www. xbrl. org / 2009 2003 / role / commonPracticeRef disclosureRef - Topic 210 606 - SubTopic 10- Name Accounting Standards Codification- Section S99 50- Paragraph 11- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147479806 / 606- 10- 50- 11Reference 2: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 606- SubTopic 10- Name Accounting Standards Codification- Section 45 - Paragraph 1- Subparagraph (SX 210. 5- 02 (20))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480566 2147479837 / 606- 210 - 10 - 10 45 - S99 1Reference 3: http: / / www. xbrl. org / 2003 / role / disclosureRef - 1 Topic 606- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 8- Subparagraph (a ) - "," Publisher ":" FASB - "," URI ":" https:/ / asc.fasb.org / 1943274 / 2147482987 2147479806 / 272 606 - 10- 50- 8Reference 4 3" },{" r257" : {" role":" http:/ / www.xbrl.org / 2003 / role / disclosureRef - "," Topic 606- SubTopic 10- ":" 280"," Name ":" Accounting Standards Codification "," - Section 45- Paragraph 2- Publisher ":" FASB - "," URI ":" https:/ / asc.fasb.org / 1943274 / 2147479837 / 606- 10- 45- 2 Details Name: us- gaap_DeferredRevenueCurrent gaap_ContractWithCustomerLiabilityCurrent Namespace Prefix: us- gaap_ Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: instantX- DefinitionAmount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. ReferencesReference 1: http: / / www. xbrl. org / 2003 / role / exampleRef- Topic 280 350 - SubTopic 10 20 - Name Accounting Standards Codification- Section 55- Paragraph 49 24 - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482785 - 2147482548 / 350- 280 - 20 - 10 - 55- 49Reference - 24Reference 2: http: / / www. xbrl. org / 2003 / role / exampleRef- Topic 350 805 - SubTopic 20 10 - Name Accounting Standards Codification- Section 55 50 - Paragraph 24 8 - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482548 2147479328 / 805- 10- 350 - 50 - 20- 55- 24Reference 8Reference 3: http: / / www. xbrl. org / 2003 / role / exampleRef- Topic 820 805 - SubTopic 10- Name Accounting Standards Codification- Section 55- Paragraph 41 100- Subparagraph (d) - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482078 2147479303 / 820 805 - 10- 55- 100Reference - 41Reference 4: http: / / www. xbrl. org / 2003 / role / exampleRef- Topic 852 805 - SubTopic 10 740 - Name Accounting Standards Codification- Section 55- Paragraph 10 13 - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147481372 2147478064 / 852 805 - 10 740 - 55- 10Reference 13Reference 5: http: / / www. xbrl. org / 2003 / role / disclosureRef exampleRef - Topic 210 805 - SubTopic 10- Name Accounting Standards Codification- Section S99 55 - Paragraph 39 1- Subparagraph (SX 210. 5- 02 (15)) - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480566 2147479303 / 805- 210 - 10 - 10 55 - S99- 1Reference 39Reference 6: http: / / www. xbrl. org / 2003 / role / disclosureRef exampleRef - Topic 350 280 - SubTopic 20 10 - Name Accounting Standards Codification- Section 45 55 - Paragraph 1 49 - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482598 - 2147482785 / 350- 20 280 - 45 10 - 55- 1Reference 49Reference 7: http: / / www. xbrl. org / 2009 2003 / role / commonPracticeRef exampleRef - Topic 350 820 - SubTopic 20 10 - Name Accounting Standards Codification- Section 50 55 - Paragraph 1 100 - Subparagraph ( a d )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482573 2147482078 / 350- 20 820 - 50 10 - 55- 1Reference 100Reference 8: http: / / www. xbrl. org / 2009 2003 / role / commonPracticeRef exampleRef - Topic 350 852 - SubTopic 20 10 - Name Accounting Standards Codification- Section 50 55 - Paragraph 10 1- Subparagraph (h) - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482573 2147481372 / 350 852 - 20 10 - 50 55 - 1Reference 10Reference 9: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 942 210 - SubTopic 210 - 10 - Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210. 9 5 - 03 02 ( 15 10) (1 ))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480566 / 210 credit Period Type:instantX - 10- S99- 1Reference 10 DefinitionAmount,after effects of reinsurance,of expense (reversal of expense) for claims incurred and costs incurred in the claim settlement process. ReferencesReference 1 :http:/ / www.xbrl.org / 2003 / role / disclosureRef exampleRef - Topic 350 944 - SubTopic 20 40 - Name Accounting Standards Codification- Section 45 55 - Paragraph 1 7 - Publisher FASB- URI https:/ / asc.fasb.org / 1943274 / 2147482598 2147480046 / 350 944 - 20 40 - 45 55 - 1Reference 7Reference 11 2 :http:/ / www.xbrl.org / 2009 / role / commonPracticeRef- Topic 350 944 - SubTopic 20 40 - Name Accounting Standards Codification- Section 50- Paragraph 1 3 - Subparagraph ( a b )- Publisher FASB- URI https:/ / asc.fasb.org / 1943274 / 2147482573 2147480081 / 350 944 - 20 40 - 50- 1Reference 12 3 Details Name : http us- gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1 Namespace Prefix : us // www.xbrl.org / 2009 / role / commonPracticeRef - gaap_ Data Type Topic 350- SubTopic 20- Name Accounting Standards Codification- Section 50- Paragraph 1- Subparagraph (h)- Publisher FASB- URI https . / xbrli:monetaryItemType Balance Type: 2147478546 / 942- 210- S99- 1 1Reference 14: http: / / www. xbrl. org / 2009 / role / commonPracticeRef- Topic 805- SubTopic 30- Name Accounting Standards Codification- Section 50- Paragraph 4- Subparagraph (b)- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147479581 / 805- 30- 50- 4 Details Name: us- gaap_Goodwill Namespace Prefix: us- gaap_ Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: instantX- DefinitionSum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges. ReferencesReference 1: http: / / www. xbrl. org / 2009 / role / commonPracticeRef- Topic 350- SubTopic 30- Name Accounting Standards Codification- Section 50- Paragraph 2- Subparagraph (a) (1)- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482665 / 350- 30- 50- 2Reference 2: http: / / www. xbrl. org / 2009 / role / commonPracticeRef- Topic 350- SubTopic 30- Name Accounting Standards Codification- Section 50- Paragraph 2- Subparagraph (b)- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482665 / 350- 30- 50- 2Reference 3: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 350- SubTopic 30- Name Accounting Standards Codification- Section 45- Paragraph 1- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482686 / 350- 30- 45- 1 Details Name: us- gaap_IntangibleAssetsNetExcludingGoodwill Namespace Prefix: us- gaap_ Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: instantX- DefinitionAmount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. ReferencesReference 1: http: / / www. xbrl. org / 2003 / role / exampleRef- Topic 852- SubTopic 10- Name Accounting Standards Codification- Section 55- Paragraph 10- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147481372 / 852- 10- 55- 10Reference 2: http: / / www. xbrl. org / 2003 / role / exampleRef- Topic 210- SubTopic 10- Name Accounting Standards Codification- Section 45- Paragraph 1- Subparagraph (b)- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147483467 / 210- 10- 45- 1Reference 3: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 210- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210. 5- 02 (6))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1 Details Name: us- gaap_InventoryNet Namespace Prefix: us- gaap_ Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: instantX- DefinitionAmount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others. ReferencesReference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef- Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210. 5- 02 (22))- SubTopic 10- Topic 210- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1Reference 2: http: / / fasb. org / us- gaap / role / ref / legacyRef- Topic 210- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210. 5- 02 (20))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1Reference 3: http: / / fasb. org / us- gaap / role / ref / legacyRef- Topic 210- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210. 5- 02 (24))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1Reference 4: http: / / fasb www . xbrl. org / 2003 us- gaap / role / disclosureRef ref / legacyRef - Topic 210 235 - SubTopic 10- Name Accounting Standards Codification- Section S99 S50 - Paragraph 1- Subparagraph (SX 210. 5- 02 (19))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480566 2147480738 / 235- 210 - 10 - S50 10- S99 - 1Reference 5: http: / / fasb www . xbrl. org / 2003 us- gaap / role / disclosureRef ref / legacyRef - Topic 210 235 - SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210. 5 4 - 02 08 ( 25 g) (1) (i ))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480566 - 2147480678 / 210 235 - 10- S99- 1Reference 6: http: / / fasb www . xbrl. org / 2003 us- gaap / role / disclosureRef ref / legacyRef - Topic 210 825 - SubTopic 10- Name Accounting Standards

Codification- Section S99- 50 - Paragraph 1- 28 - Subparagraph ( f SX 210. 5- 02 (26) )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480566 2147482907 / 825- 210- 10 - 10- 50 - S99- 1Reference- 28Reference 7: http: / / fasb- www . xbrl. org / 2003 us- gaap / role / exampleRef- ref / legacyRef- Topic 210- 480 - SubTopic 10- Name Accounting Standards Codification- Section S99- 55 - Paragraph 64 1- Subparagraph (SX 210. 5- 02 (23)) - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480566- 2147481620 / 480- 210- 10 - 10- 55 - S99- 1Reference- 64Reference 8: http: / / fasb. org / us- gaap / role / ref / legacyRef- Topic 210- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210. 5- 02 ( 21- 19 ))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1Reference 9: http: / / www- fasb . xbrl. org / 2003- us- gaap / role / disclosureRef- ref / legacyRef - Topic 810- 210 - SubTopic 10- Name Accounting Standards Codification- Section 50- S99 - Paragraph 3- 1 - Subparagraph ( c- SX 210. 5- 02 (25) )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147481203- 2147480566 / 810- 10- 210 - 50- 10 - S99- 3Reference- 1Reference 10: http: / / www- fasb . xbrl. org / 2003- us- gaap / role / disclosureRef- ref / legacyRef - Topic 810- 210 - SubTopic 10- Name Accounting Standards Codification- Section 45- S99 - Paragraph 25- 1 - Subparagraph ( b- SX 210. 5- 02 (26) )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147481231- 2147480566 / 810- 10- 210 - 45- 10 - S99- 25Reference- 1Reference 11: http: / / www- fasb . xbrl. org / 2003- us- gaap / role / disclosureRef- ref / legacyRef - Topic 810- 210 - SubTopic 10- Name Accounting Standards Codification- Section 50- S99 - Paragraph 3- 1 - Subparagraph ( bb- SX 210. 5- 02 (23) )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147481203 2147480566 / 810- 10- 210 - 50- 10 - S99- 3Reference- 1Reference 12: http: / / www- fasb . xbrl. org / 2003- us- gaap / role / disclosureRef- ref / legacyRef - Topic 235- 210 - SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210. 4- 5 - 08- 02 ( 21 g) (1) (ii ))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480678- 2147480566 / 235- 210 - 10- S99- 1Reference 13: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 323- 810 - SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 3- Subparagraph (c)- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147481687- 2147481203 / 323- 810 - 10- 50- 3Reference 14: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 825- 810 - SubTopic 10- Name Accounting Standards Codification- Section 50- 45 - Paragraph 28- 25 - Subparagraph ( f- b )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482907- 2147481231 / 825- 10- 810 - 50- 10 - 45- 28Reference- 25Reference 15: http: / / www. xbrl. org / 2003 / role / exampleRef- disclosureRef - Topic 946- 810 - SubTopic 830- 10 - Name Accounting Standards Codification- Section 55- 50 - Paragraph 12- 3- Subparagraph (bb) - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147479168- 2147481203 / 946- 810 - 830- 10 - 55- 50 - 12Reference- 3Reference 16: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 946- 235 - SubTopic 210- 10 - Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210. 6- 4 - 04- 08 ( 14- g) (1) (ii )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147479170- 2147480678 / 946- 235 - 210- 10 - S99- 1Reference 17: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 470- 323 - SubTopic 10- Name Accounting Standards Codification- Section S99- 50 - Paragraph 1A- 3 - Subparagraph ( c SX 210. 13- 01 (a) (4) (i) )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480097- 2147481687 / 470- 323 - 10- S99- 50 - 1AReference- 3Reference 18: http: / / www. xbrl. org / 2009- 2003 / role / commonPracticeRef- exampleRef - Topic 470- 946 - SubTopic 10- 830 - Name Accounting Standards Codification- Section S99- 55 - Paragraph 12- 1A- Subparagraph (SX 210. 13- 01 (a) (4) (ii)) - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480097- 2147479168 / 470- 946 - 10- 830 - S99- 55 - 1AReference 12Reference 19: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 470- 946 - SubTopic 10- 210 - Name Accounting Standards Codification- Section S99- Paragraph 1A- 1 - Subparagraph (SX 210. 13- 6 - 01- 04 ( 14 a) (4) (iii) (A ))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480097- 2147479170 / 470 946 - 10- 210 - S99- 1AReference - 1Reference 20: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 470- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1A- Subparagraph (SX 210. 13- 01 (a) (4) ( iv- i ))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1AReference 21: http: / / www. xbrl. org / 2003- 2009 / role / disclosureRef- commonPracticeRef - Topic 470- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1A- Subparagraph (SX 210. 13- 01 (a) ( 5- 4) (ii ))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1AReference 22: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 470- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1B- 1A - Subparagraph (SX 210. 13- 02- 01 (a) (4) ( iii) (A ))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1BReference- 1AReference 23: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 470- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1B- 1A - Subparagraph (SX 210. 13- 02- 01 (a) (4) ( iv iii) (A ))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1BReference- 1AReference 24: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 470- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1B- 1A - Subparagraph (SX 210. 13- 02- 01 (a) ( 5- 4) (iii) (B ))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1BReference- 1AReference 25: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 470- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1B- Subparagraph (SX 210. 13- 02 (a) (4) ( iv- i ))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1BReference 26: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 470- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1B- Subparagraph (SX 210. 13- 02 (a) ( 5- 4) (iii) (A ))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1BReference 27: http: / / www. xbrl. org / 2009- 2003 / role / commonPracticeRef- disclosureRef - Topic 852- 470 - SubTopic 10- Name Accounting Standards Codification- Section 50- S99 - Paragraph 7- 1B - Subparagraph ( SX 210. 13- 02 ( a ) (4) (iii) (B) )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147481404- 2147480097 / 852- 470 - 10- 50- S99- 7Reference- 1BReference 28: http: / / www. xbrl. org / 2009- 2003 / role / commonPracticeRef- disclosureRef - Topic 852- 470 - SubTopic 10- Name Accounting Standards Codification- Section " S99- Paragraph 1B- Subparagraph (SX 210.13- 02 (a) (4) (iv))- Publisher FASB - "," URI ":" https: / / asc.fasb.org / 1943274 / 2147480097 / 470- 10- S99- 1BReference 29 1B" }," r360": { " role":" http: / / www.xbrl.org / 2003 / role / disclosureRef - "," Topic ":" 470 - "," SubTopic ":" 10 - "," Name ":" Accounting Standards Codification - "," Section ":" S99 - "," Paragraph ":" 1B - "," Subparagraph ":" (SX 210.13- 02 (a) (5)) - "," Publisher ":" FASB - "," URI ":" https: / / asc.fasb.org / 1943274 / 2147480097 / 470- 10- S99 - 1BReference 30:http: / / www.xbrl.org / 2009 / role / commonPracticeRef- Topic 852- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 7- Subparagraph ( b- a )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147481404 / 852- 10- 50- 7Reference 29- 31: http: / / www. xbrl. org / 2009 / role / commonPracticeRef- Topic 852- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 7- Subparagraph (b)- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147481404 / 852- 10- 50- 7Reference 32 : http: / / www. xbrl. org / 2003 / role / exampleRef- Topic 280- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 30- Subparagraph (d)- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482810 / 280- 10- 50- 30 Details Name: us- gaap_Liabilities Namespace Prefix: us- gaap_ Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: instantX- DefinitionAmount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. ReferencesReference 1: http: / / www. xbrl. org / 2003- 2009 / role / exampleRef- commonPracticeRef - Topic 852- 235 - SubTopic 10- Name Accounting Standards Codification- Section 55- S50 - Paragraph 10- 1 - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147481372- 2147480738 / 852- 235 - 10- 55- S50 - 10Reference- 1Reference 2: http: / / www. xbrl. org / 2003- 2009 / role / disclosureRef- commonPracticeRef - Topic 944- 825 - SubTopic 210- 10 - Name Accounting Standards Codification- Section S99- 50 - Paragraph 1- 28 - Subparagraph ( f SX 210. 7- 03 (a) (25) )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147478777- 2147482907 / 825- 10- 50- 28Reference 3: http: / / www. xbrl. org / 2003 / role / exampleRef- Topic 944- 210- S99- 1Reference 3: http: / / www. xbrl. org / 2009 / role / commonPracticeRef- Topic 235- SubTopic 10- 605 - Name Accounting Standards Codification- Section S99- 55 - Paragraph 14 1- Subparagraph (SX 210. 4- 08 (g) (1) (ii)) - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480678- 2147477548 / 235- 944 - 10- 605 - S99- 55 - 1Reference- 14Reference 4: http: / / www. xbrl. org / 2009- 2003 / role / commonPracticeRef- exampleRef - Topic 323- 944 - SubTopic 10- 605 - Name Accounting Standards Codification- Section 50- 55 - Paragraph 11 3- Subparagraph (c) - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147481687- 2147477548 / 323- 944 - 10- 605 - 50- 55 - 3Reference 11Reference 5: http: / / www. xbrl. org / 2009- 2003 / role / commonPracticeRef- exampleRef - Topic 825- 852 - SubTopic 10- Name Accounting Standards Codification- Section 50- 55 - Paragraph 10 28- Subparagraph (f) - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482907- 2147481372 / 825- 852 - 10- 50- 55 - 28Reference- 10Reference 6: http: / / fasb- www . xbrl. org / 2003 us- gaap / role / disclosureRef- ref / legacyRef - Topic 942- 944 - SubTopic 210- Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210. 9- 7 - 03 ( 23- a) (25 ))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147478546- 2147478777 / 942- 944 - 210- S99- 1Reference 7 :http: / / www.xbrl.org / 2009 / role / commonPracticeRef- Topic 944- 235 - SubTopic 210- 10 - Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210. 7- 4 - 03- 08 ( a- g ) ( 10- 1) (ii ))- Publisher FASB- URI https: / / asc.fasb.org / 1943274 / 2147478777- 2147480678 / 944- 235 - 210- 10 - S99- 1Reference 3- 8 :http: / / www.xbrl.org / 2003- 2009 / role / disclosureRef- commonPracticeRef - Topic 946- 323 - SubTopic 210- 10 - Name Accounting Standards Codification- Section S99- 50 - Paragraph 1- 3 - Subparagraph ( c SX 210.6- 04 (7) (a) )- Publisher FASB- URI https: / / asc.fasb.org / 1943274 / 2147479170- 2147481687 / 946- 323 - 210- 10 - S99- 50 - 1Reference- 3Reference 4- 9 :http: / / www- fasb . xbrl. org / 2003- us- gaap / role / disclosureRef- ref / legacyRef - Topic 210- 942 - SubTopic 10- 210 - Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210. 5- 9 - 02- 03 ( 7- 23 ))- Publisher FASB- URI https: / / asc.fasb.org / 1943274 / 2147480566- - 2147478546 / 942- 210- S99- 1Reference 210- 10 - : http: / / fasb. org / us- gaap / role / ref / legacyRef- Topic 210- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210. 5- 02 (32))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1 Details Name: us- gaap_LiabilitiesAndStockholdersEquity Namespace Prefix: us- gaap_ Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: instantX-

DefinitionTotal obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. ReferencesReference 1: http: / / fasb www . xbrl. org / 2003 us- gaap / role / disclosureRef ref / legacyRef - Topic 210 235 - SubTopic 10- Name Accounting Standards Codification- Section S99 S50 - Paragraph 1- Subparagraph (SX 210. 5- 02 (21)) - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480566 2147480738 / 235- 210 - 10 - S50 10- S99 - 1Reference 2: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 810 235 - SubTopic 10- Name Accounting Standards Codification- Section 50 S99 - Paragraph 3 1 - Subparagraph ( c SX 210. 4- 08 (g) (1) (i) )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147481203 2147480678 / 235- 810 - 10 - 10 S99 - 50- 3Reference 1Reference 3: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 810 825 - SubTopic 10- Name Accounting Standards Codification- Section 45 50 - Paragraph 25 28 - Subparagraph ( b f )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147481231 2147482907 / 825- 810 - 10 - 10 50 - 45- 25Reference 28Reference 4: http: / / www fasb . xbrl. org / 2003 us- gaap / role / disclosureRef ref / legacyRef - Topic 810 210 - SubTopic 10- Name Accounting Standards Codification- Section 50 S99 - Paragraph 3 1 - Subparagraph ( bb SX 210. 5- 02 (21) )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147481203 2147480566 / 210- 10- S99- 1Reference 5: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 810 - 10- 50- 3Reference 5: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 235 - SubTopic 10- Name Accounting Standards Codification- Section S99 50 - Paragraph 1 3 - Subparagraph ( c SX 210. 4- 08 (g) (1) (ii) )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480678 2147481203 / 235- 10 810 - S99 10 - 50- 1Reference 3Reference 6: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 323 810 - SubTopic 10- Name Accounting Standards Codification- Section 50 45 - Paragraph 3 25 - Subparagraph ( c b )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147481687 2147481231 / 323- 10 810 - 50 10 - 45- 3Reference 25Reference 7: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 825 810 - SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 28 3 - Subparagraph ( f bb )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482907 - 2147481203 / 825 810 - 10- 50- 28Reference 3Reference 8: http: / / www. xbrl. org / 2003 / role / exampleRef disclosureRef - Topic 852 235 - SubTopic 10- Name Accounting Standards Codification- Section 55 S99 - Paragraph 1- Subparagraph (SX 10 210 . 4- 08 (g) (1) (ii)) - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147481372 2147480678 / 852 235 - 10- 55 S99 - 10Reference - 1Reference 9: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 210 323 - SubTopic 10- Name Accounting Standards Codification- Section 45 50 - Paragraph 5 3- Subparagraph (c) - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147483467 2147481687 / 323- 210 - 10 - 10 50 - 45- 5Reference 3Reference 10: http: / / www. xbrl. org / 2003 / role / disclosureRef exampleRef - Topic 470 852 - SubTopic 10- Name Accounting Standards Codification- Section S99 55 - Paragraph 1A- Subparagraph (SX 210 - 10 . 13- 01 (a) (4) (i)) - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480097 2147481372 / 470 852 - 10- S99 55 - 1AReference 10Reference 11: http: / / www. xbrl. org / 2009 2003 / role / commonPracticeRef disclosureRef - Topic 470 210 - SubTopic 10- Name Accounting Standards Codification- Section S99 45 - Paragraph 5 1A- Subparagraph (SX 210. 13- 01 (a) (4) (ii)) - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480097 2147483467 / 470- 10 210 - S99 10 - 45- 1AReference 5Reference 12: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 470- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1A- Subparagraph (SX 210. 13- 01 (a) (4) ( i iii) (A )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1AReference 13: http: / / www. xbrl. org / 2003 2009 / role / disclosureRef commonPracticeRef - Topic 470- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1A- Subparagraph (SX 210. 13- 01 (a) (4) ( iv ii )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1AReference 14: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 470- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1A- Subparagraph (SX 210. 13- 01 (a) ( 5 4) (iii) (A )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1AReference 15: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 470- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1B 1A - Subparagraph (SX 210. 13- 02 01 (a) (4) ( i iv ))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1BReference 1AReference 16: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 470- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1B 1A - Subparagraph (SX 210. 13- 02 01 (a) ( 5 4) (iii) (A ))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1BReference 1AReference 17: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 470- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1B- Subparagraph (SX 210. 13- 02 (a) (4) ( i iii) (B ))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1BReference 18: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 470- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1B- Subparagraph (SX 210. 13- 02 (a) (4) ( iv iii) (A ))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1BReference 19: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 470- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1B- Subparagraph (SX 210. 13- 02 (a) ( 5 4) (iii) (B ))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1BReference 20: http: / / www. xbrl. org / 2009 2003 / role / commonPracticeRef disclosureRef - Topic 852 470 - SubTopic 10- Name Accounting Standards Codification- Section " S99- Paragraph 1B- Subparagraph (SX 210.13- 02 (a) (4) (iv))- Publisher FASB - ","- URI ":"- https:/ / asc.fasb.org / 1943274 / 2147480097 / 470- 10- S99- 1BReference 21 1B" }," r360" : {" role":" http:/ / www.xbrl.org / 2003 / role / disclosureRef - ","- Topic ":"- 470 - ","- SubTopic ":"- 10 - ","- Name ":"- Accounting Standards Codification - ","- Section ":"- S99 - ","- Paragraph ":"- 1B - ","- Subparagraph ":"- (SX 210.13- 02 (a) (5)) - ","- Publisher ":"- FASB - ","- URI ":"- https:/ / asc.fasb.org / 1943274 / 2147480097 / 470- 10- S99 - 1BReference 22:http: / / www.xbrl.org / 2009 / role / commonPracticeRef- Topic 852- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 7- Subparagraph (a)- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147481404 / 852- 10- 50- 7Reference 21 23 : http: / / www. xbrl. org / 2009 / role / commonPracticeRef- Topic 852- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 7- Subparagraph (b)- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147481404 / 852- 10- 50- 7 Details Name: us- gaap_LiabilitiesCurrent Namespace Prefix: us- gaap_ Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: instantX- ReferencesNo definition available. Details Name: us- gaap_LiabilitiesCurrentAbstract Namespace Prefix: us- gaap_ Data Type: xbrli: stringItemType Balance Type: na Period Type: durationX- ReferencesNo definition available. Details Name: us- gaap_LiabilitiesNoncurrentAbstract Namespace Prefix: us- gaap_ Data Type: xbrli: stringItemType Balance Type: na Period Type: durationX- DefinitionCarrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion. ReferencesReference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef- Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210. 5- 02 (22))- SubTopic 10- Topic 210- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1 Details Name: us- gaap_LongTermNotesPayable Namespace Prefix: us- gaap_ Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: instantX- DefinitionSum of the carrying values as of the balance sheet date of the portions of long- term notes payable due within one year or the operating cycle if longer. ReferencesReference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef- Topic 210- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210. 5- 02 (20))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1Reference 2: http: / / fasb. org / us- gaap / role / ref / legacyRef- Topic 210- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210. 5- 02 (19))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1 Details Name: us- gaap_NotesPayableCurrent Namespace Prefix: us- gaap_ Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: instantX- DefinitionPresent value of lessee' s discounted obligation for lease payments from operating lease, classified as current. ReferencesReference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 842- SubTopic 20- Name Accounting Standards Codification- Section 45- Paragraph 1- Subparagraph (b)- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147479041 / 842- 20- 45- 1 Details Name: us- gaap_OperatingLeaseLiabilityCurrent Namespace Prefix: us- gaap_ Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: instantX- DefinitionPresent value of lessee' s discounted.....: credit Period Type: instantX- DefinitionAmount of lessee' s right to use underlying asset under operating lease. ReferencesReference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 842- SubTopic 20- Name Accounting Standards Codification- Section 45- Paragraph 1- Subparagraph (a)- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147479041 / 842- 20- 45- 1 Details Name: us- gaap_OperatingLeaseRightOfUseAsset Namespace Prefix: us- gaap_ Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: instantX- ReferencesNo definition available. Details Name: us- gaap_OtherAssetsAbstract Namespace Prefix: us- gaap_ Data Type: xbrli: stringItemType Balance Type: na Period Type: durationX - DefinitionAmount of liabilities classified as other..... Type: credit Period Type: instantX - DefinitionAggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity. ReferencesReference 1: http: / / fasb www . xbrl. org / 2003 us- gaap / role / disclosureRef ref / legacyRef - Topic 210 480 - SubTopic 10- Name Accounting Standards Codification- Section S99 S45 - Paragraph 2 1- Subparagraph (SX 210. 5- 02 (28)) - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480566 2147479887 / 480- 210 - 10 - 10 S45 - S99- 1Reference 2Reference 2: http: / / www. xbrl. org / 2003 / role / exampleRef disclosureRef - Topic 852 480 - SubTopic 10- Name Accounting Standards Codification- Section 55 S99 - Paragraph 10 1- Subparagraph (01) (ii) - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / " 2147480244 / 480- 10- S99- 1Reference 3: http:/ / fasb.org / us- gaap / role / ref / legacyRef - ","- Topic ":"- 210 - ","- SubTopic ":"- 10 - ","- Name ":"- Accounting Standards Codification - ","- Section ":"- S99 - ","- Paragraph ":"- 1 - ","- Subparagraph ":"- (SX 210.5- 02 (28)) - ","- Publisher ":"- FASB - ","- URI ":"- https:/ / asc.fasb.org / 1943274 / 2147480566 / 210- 10- S99- 1Reference 4 1" }," r77" : {" role":"- http:/ / www.xbrl.org / 2003 / role / exampleRef- Topic 852-

**SubTopic 10- Name Accounting Standards Codification- Section 55- Paragraph 10- Publisher FASB- URI https: / / asc.** fasb.org / **1943274 /** 2147481372 / 852- 10- 55- 10Reference ~~3~~ **5** : http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 944- SubTopic 210- Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210. 7- 03 (a) (21))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147478777 / 944- 210- S99- 1 Details Name: us- gaap_PreferredStockValue Namespace Prefix: us- gaap_ Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: instantX- DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer. ReferencesReference 1: http: / / www. xbrl. org / 2003 / role / exampleRef- Topic 210- SubTopic 10- Name Accounting Standards Codification- Section 45- Paragraph 1- Subparagraph (g)- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147483467 / 210- 10- 45- 1Reference 2: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 210- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210. 5- 02 (7))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1Reference 3: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 340- SubTopic 10- Name Accounting Standards Codification- Section 05- Paragraph 5- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482955 / 340- 10- 05- 5Reference 4: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 340- SubTopic 10- Name Accounting Standards Codification- Section 45- Paragraph 1- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147483032 / 340- 10- 45- 1 Details Name: us- gaap_PrepaidExpenseCurrent Namespace Prefix: us- gaap_ Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: instantX- DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. ReferencesReference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef- Name Accounting Standards Codification- Section 50- Paragraph 1- SubTopic 10- Topic 360- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482099 / 360- 10- 50- 1Reference 2: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 842- SubTopic 20- Name Accounting Standards Codification- Section 50- Paragraph 7A- Subparagraph (a)- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147478964 / 842- 20- 50- 7AReference 3: http: / / www. xbrl. org / 2003 / role / exampleRef- Topic 852- SubTopic 10- Name Accounting Standards Codification- Section 55- Paragraph 10- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147481372 / 852- 10- 55- 10Reference 4: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 944- SubTopic 210- Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210. 7- 03 (a) (8))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147478777 / 944- 210- S99- 1Reference 5: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 942- SubTopic 360- Name Accounting Standards Codification- Section 50- Paragraph 1- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147478451 / 942- 360- 50- 1 Details Name: us- gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us- gaap_ Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: instantX- DefinitionAmount of accumulated undistributed earnings (deficit). ReferencesReference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef- Topic 210- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210. 5- 02 (30) (a) (3))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1Reference 2: http: / / www. xbrl. org / 2003 / role / exampleRef- Topic 852- SubTopic 10- Name Accounting Standards Codification- Section 55- Paragraph 10- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147481372 / 852- 10- 55- 10Reference 3: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 944- SubTopic 40- Name Accounting Standards Codification- Section 65- Paragraph 2- Subparagraph (g) (2) (i)- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480016 / 944- 40- 65- 2Reference 4: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 944- SubTopic 40- Name Accounting Standards Codification- Section 65- Paragraph 2- Subparagraph (h) (2)- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480016 / 944- 40- 65- 2Reference 5: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 946- SubTopic 20- Name Accounting Standards Codification- Section 50- Paragraph 11- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480990 / 946- 20- 50- 11Reference 6: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 944- SubTopic 210- Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210. 7- 03 (a) (23) (a) (4))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147478777 / 944- 210- S99- 1Reference 7: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 946- SubTopic 210- Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210. 6- 04 (17))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147479170 / 946- 210- S99- 1Reference 8: http: / / fasb. org / us- gaap / role / ref / legacyRef- Topic 505- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210. 3- 04)- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480008 / 505- 10- S99- 1 Details Name: us- gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us- gaap_ Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: instantX- DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. ReferencesReference 1: http: / / ~~fasb~~ **www** . **xbrl.** org / **2009** ~~us- gaap~~ / role / **commonPracticeRef** ~~ref / legacyRef~~ - Topic ~~210~~ **235** - SubTopic 10- Name Accounting Standards Codification- Section ~~S99~~ **S50** - Paragraph 1- ~~Subparagraph (SX 210. 5- 02 (29))~~ - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147480566~~ **2147480738** / **235-** ~~210~~ - **10** - **S50** ~~10- S99~~ - 1Reference 2: http: / / ~~fasb~~ **www** . **xbrl.** org / **2009** ~~us- gaap~~ / role / **commonPracticeRef** ~~ref / legacyRef~~ - Topic ~~210~~ **235** - SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210. ~~5~~ **4** - ~~02~~ **08** ( ~~30~~ **g) (1) (i** ))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147480566~~ - **2147480678** / ~~210~~ **235** - 10- S99- 1Reference 3: http: / / ~~fasb~~ **www** . **xbrl.** org / **2009** ~~us- gaap~~ / role / **commonPracticeRef** ~~ref / legacyRef~~ - Topic ~~210~~ **825** - SubTopic 10- Name Accounting Standards Codification- Section ~~S99~~ **50** - Paragraph ~~1~~ **28** - Subparagraph ( **f** ~~SX 210. 5- 02 (31)~~ )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147480566~~ **2147482907** / **825- 10- 50- 28Reference 4: http: / / fasb. org / us- gaap / role / ref / legacyRef- Topic** 210 ~~- 10- S99- 1Reference 4: http: / / www. xbrl. org / 2003 / role / exampleRef- Topic 852~~ - SubTopic 10- Name Accounting Standards Codification- Section ~~55~~ **S99** - Paragraph **1- Subparagraph (SX** ~~10~~ **210 . 5- 02 (29))** - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147481372~~ **2147480566** / ~~852- 10~~ **210** - ~~55~~ **10** - **S99-** ~~10Reference~~ - **1Reference** 5: http: / / ~~www~~ **fasb** . ~~xbrl.~~ org / ~~2003~~ **us- gaap** / role / ~~exampleRef~~ **ref / legacyRef** - Topic ~~946~~ **210** - SubTopic ~~830~~ **10** - Name Accounting Standards Codification- Section ~~55~~ **S99** - Paragraph ~~12~~ **1- Subparagraph (SX 210. 5- 02 (30))** - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147479168~~ **2147480566** / ~~946~~ **210** - ~~830~~ **10** - ~~55~~ **S99** - ~~12Reference~~ - **1Reference** 6: http: / / ~~www~~ **fasb** . ~~xbrl.~~ org / ~~2003~~ **us- gaap** / role / ~~disclosureRef~~ **ref / legacyRef** - Topic ~~946~~ **210** - SubTopic ~~210~~ - **10** - Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210. ~~6~~ **5** - ~~04~~ **02** ( ~~19~~ **31** ))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147479170~~ **2147480566** / ~~946-~~ 210 **- 10** - S99- 1Reference 7: http: / / www. xbrl. org / 2003 / role / ~~disclosureRef~~ **exampleRef** - Topic ~~946~~ **852** - SubTopic ~~210~~ - **10** - Name Accounting Standards Codification- Section ~~S99~~ **55** - Paragraph ~~2- Subparagraph (SX 210~~ - **10** ~~. 6- 05 (4))~~ - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147479170~~ **2147481372** / ~~946~~ **852** - ~~210~~ - **10** - ~~S99~~ **55** - ~~2Reference~~ **10Reference** 8: http: / / www. xbrl. org / ~~2009~~ **2003** / role / ~~commonPracticeRef~~ **exampleRef** - Topic 946- SubTopic ~~220~~ **830** - Name Accounting Standards Codification- Section ~~S99~~ **55** - Paragraph **12** ~~3- Subparagraph (SX 210. 6- 09 (4) (b))~~ - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147479134~~ **2147479168** / 946- ~~220~~ **830** - ~~S99~~ **55** - ~~3Reference~~ **12Reference** 9: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 946- SubTopic ~~220~~ **210** - Name Accounting Standards Codification- Section S99- Paragraph ~~3~~ **1** - Subparagraph (SX 210. 6- ~~09~~ **04** ( ~~6~~ **19** ))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147479134~~ **2147479170** / 946- ~~220~~ **210** - S99- ~~3Reference~~ **1Reference** 10: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 946- SubTopic ~~220~~ **210** - Name Accounting Standards Codification- Section S99- Paragraph ~~3~~ **2** - Subparagraph (SX 210. 6- ~~09~~ **05** ( ~~7~~ **4** ))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147479134~~ **2147479170** / 946- **210- S99- 2Reference 11: http: / / www. xbrl. org / 2009 / role / commonPracticeRef- Topic 946- SubTopic** 220 ~~- S99- 3Reference 11: http: / / www. xbrl. org / 2009 / role / commonPracticeRef- Topic 235- SubTopic 10~~ - Name Accounting Standards Codification- Section S99- Paragraph ~~1~~ **3** - Subparagraph (SX 210. **6- 09 (** 4 ~~- 08 (g~~ ) ( **b** ~~1) (ii~~ ))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147480678~~ **2147479134** / ~~235~~ **946** - ~~10~~ **220** - S99- ~~1Reference~~ **3Reference** 12: http: / / www. xbrl. org / ~~2009~~ **2003** / role / ~~commonPracticeRef~~ **disclosureRef** - Topic ~~323~~ **946** - SubTopic ~~10~~ **220** - Name Accounting Standards Codification- Section ~~50~~ **S99** - Paragraph 3- Subparagraph ( ~~e~~ **SX 210. 6- 09 (6)** )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147481687~~ **2147479134** / ~~323~~ **946** - ~~10~~ **220** - ~~50~~ **S99** - 3Reference 13: http: / / www. xbrl. org / ~~2009~~ **2003** / role / ~~commonPracticeRef~~ **disclosureRef** - Topic ~~825~~ **946** - SubTopic ~~10~~ **220** - Name Accounting Standards Codification- Section ~~50~~ **S99** - Paragraph ~~28~~ **3** - Subparagraph ( ~~f~~ **SX 210. 6- 09 (7)** )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147482907~~ **2147479134** / ~~825~~ **946** - **220- S99- 3Reference 14: http: / / www. xbrl. org / 2009 / role / commonPracticeRef- Topic 235- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX** ~~10~~ **210 . 4** - **08 (g) (1) (ii))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480678 / 235- 10- S99- 1Reference 15: http: / / www. xbrl. org / 2009 / role / commonPracticeRef- Topic 323- SubTopic 10- Name Accounting Standards Codification- Section** 50- **Paragraph 3- Subparagraph (c)- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147481687 / 323- 10- 50-** ~~28Reference~~ **3Reference** ~~14~~ **16** : http: / / fasb. org / us- gaap / role / ref / legacyRef- Topic 310- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 2- Subparagraph (SAB Topic 4. E)- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480418 / 310- 10- S99- 2 Details Name: us- gaap_StockholdersEquity Namespace Prefix: us- gaap_ Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: instantX- ReferencesNo definition available. Details Name: us- gaap_StockholdersEquityAbstract Namespace Prefix: us- gaap_ Data Type: xbrli: stringItemType Balance Type: na Period Type: durationX- DefinitionThe amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury. ReferencesReference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef- Topic 210- SubTopic 10- Name Accounting Standards Codification- Section S99-

Paragraph 1- Subparagraph (SX 210. 5- 02 (29))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1Reference 2: http: / / fasb. org / us- gaap / role / ref / legacyRef- Topic 210- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210. 5- 02 (30))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1Reference 3: http: / / fasb. org / us- gaap / role / ref / legacyRef- Name Accounting Standards Codification- Topic 505- SubTopic 30- Section 50- Paragraph 4- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147481520 / 505- 30- 50- 4Reference 4: http: / / fasb. org / us- gaap / role / ref / legacyRef- Name Accounting Standards Codification- Topic 505- SubTopic 30- Section 45- Paragraph 1- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147481549 / 505- 30- 45- 1 Details Name: us- gaap_TreasuryStockValue Namespace Prefix: us- gaap_ Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: ~~instantX- Details Name: us- gaap_RelatedPartyTransactionsByRelatedPartyAxis = us- gaap_RelatedPartyMember Namespace Prefix: Data Type: na Balance Type: Period Type: Condensed Consolidated~~ **instantConsolidated** Balance Sheets (Parentheticals)- $ / shares Jan. 31, ~~2024~~ **2025** Jan. 31, ~~2023Statement~~ **2024Statement** of Financial Position [ Abstract ] Preferred stock par value (in Dollars per share) $ 0. 001 $ 0. 001Preferred stock, shares authorized 10, 000, 000 10, 000, 000Preferred stock, shares outstandingCommon stock, par value (in Dollars per share) $ 0. 001 $ 0. 001Common stock, shares authorized 291, 666, 666 291, 666, 666Common stock, shares issued **11, 107, 210** 8, 869, ~~870 7, 843, 150Common~~ **870Common** stock, shares outstanding **11, 074, 810** 8, 859, ~~870 7, 833, 150Treasury~~ **870Treasury** stock, shares ~~10 32~~ . ~~000~~ **400** 10, 000X- DefinitionFace amount or stated value per share of common stock. ReferencesReference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef- Topic 210- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210. 5- 02 (29))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1 Details Name: us- gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us- gaap_ Data Type: dtr- types: perShareItemType Balance Type: na Period Type: instantX- DefinitionThe maximum number of common shares permitted to be issued by an entity' s charter and bylaws. ReferencesReference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef- Topic 210- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210. 5- 02 (29))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1Reference 2: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 946- SubTopic 210- Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210. 6- 04 (16) (a))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147479170 / 946- 210- S99- 1 Details Name: us- gaap_CommonStockSharesAuthorized Namespace Prefix: us- gaap_ Data Type: xbrli: sharesItemType Balance Type: na Period Type: instantX- DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm' s shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. ReferencesReference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef- Topic 210- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210. 5- 02 (29))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1 Details Name: us- gaap_CommonStockSharesIssued Namespace Prefix: us- gaap_ Data Type: xbrli: sharesItemType Balance Type: na Period Type: instantX- DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. ReferencesReference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef- Name Accounting Standards Codification- Section 50- Paragraph 2- SubTopic 10- Topic 505- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147481112 / 505- 10- 50- 2Reference 2: http: / / fasb. org / us- gaap / role / ref / legacyRef- Topic 210- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210. 5- 02 (29))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1Reference 3: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 946- SubTopic 210- Name Accounting Standards Codification- Section S99- Paragraph 2- Subparagraph (SX 210. 6- 05 (4))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147479170 / 946- 210- S99- 2Reference 4: http: / / www. xbrl. org / 2009 / role / commonPracticeRef- Topic 946- SubTopic 220- Name Accounting Standards Codification- Section S99- Paragraph 3- Subparagraph (SX 210. 6- 09 (4) (b))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147479134 / 946- 220- S99- 3Reference 5: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 946- SubTopic 210- Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210. 6- 04 (16) (a))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147479170 / 946- 210- S99- 1Reference 6: http: / / www. xbrl. org / 2009 / role / commonPracticeRef- Topic 946- SubTopic 220- Name Accounting Standards Codification- Section S99- Paragraph 3- Subparagraph (SX 210. 6- 09 (7))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147479134 / 946- 220- S99- 3 Details Name: us- gaap_CommonStockSharesOutstanding Namespace Prefix: us- gaap_ Data Type: xbrli: sharesItemType Balance Type: na Period Type: instantX- DefinitionFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. ReferencesReference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef- Topic 210- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210. 5- 02 (28))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1Reference 2: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 505- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 13- Subparagraph (a)- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147481112 / 505- 10- 50- 13 Details Name: us- gaap_PreferredStockParOrStatedValuePerShare Namespace Prefix: us- gaap_ Data Type: dtr- types: perShareItemType Balance Type: na Period Type: instantX- DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity' s charter and bylaws. ReferencesReference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef- Topic 210- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210. 5- 02 (28))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1Reference 2: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 946- SubTopic 210- Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210. 6- 04 (16) (a))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147479170 / 946- 210- S99- 1 Details Name: us- gaap_PreferredStockSharesAuthorized Namespace Prefix: us- gaap_ Data Type: xbrli: sharesItemType Balance Type: na Period Type: instantX- DefinitionAggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased. ReferencesReference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef- Topic 210- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210. 5- 02 (28))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1Reference 2: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 946- SubTopic 210- Name Accounting Standards Codification- Section S99- Paragraph 2- Subparagraph (SX 210. 6- 05 (4))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147479170 / 946- 210- S99- 2Reference 3: http: / / www. xbrl. org / 2009 / role / commonPracticeRef- Topic 946- SubTopic 220- Name Accounting Standards Codification- Section S99- Paragraph 3- Subparagraph (SX 210. 6- 09 (4) (b))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147479134 / 946- 220- S99- 3Reference 4: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 946- SubTopic 210- Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210. 6- 04 (16) (a))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147479170 / 946- 210- S99- 1Reference 5: http: / / www. xbrl. org / 2009 / role / commonPracticeRef- Topic 946- SubTopic 220- Name Accounting Standards Codification- Section S99- Paragraph 3- Subparagraph (SX 210. 6- 09 (7))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147479134 / 946- 220- S99- 3 Details Name: us- gaap_PreferredStockSharesOutstanding Namespace Prefix: us- gaap_ Data Type: xbrli: sharesItemType Balance Type: na Period Type: instantX- ReferencesNo definition available. Details Name: us- gaap_StatementOfFinancialPositionAbstract Namespace Prefix: us- gaap_ Data Type: xbrli: stringItemType Balance Type: na Period Type: durationX- DefinitionNumber of previously issued common shares repurchased by the issuing entity and held in treasury. ReferencesReference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef- Name Accounting Standards Codification- Topic 505- SubTopic 30- Section 45- Paragraph 1- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147481549 / 505- 30- 45- 1 Details Name: us- gaap_TreasuryStockCommonShares Namespace Prefix: us- gaap_ Data Type: xbrli: sharesItemType Balance Type: na Period Type: instantConsolidated Statements of Operations- USD ($) 12 Months EndedJan. 31, ~~2024~~ **2025** Jan. 31, ~~2023Income~~ **2024Income** Statement [ Abstract ] Revenue $ 2, ~~085~~ **139** , ~~314~~ **537** $ 2, ~~079~~ **085** , ~~609Costs~~ **314Costs** and expenses: Cost of revenues 1, **396, 220 1,** 223, ~~209 1, 329, 200Research~~ **209Research** and development **3, 119, 134** 1, 960, ~~425 982, 227Goodwill~~ **425Goodwill and intangibles** impairment ~~327~~ **3** , **595, 216** ~~326Selling~~ **Selling** , general and administrative **4, 313, 810** 3, 773, ~~606 3, 916, 041Total~~ **606Total** Costs and Expenses **12, 424, 380** 6, 957, **240Loss** ~~240 6, 554, 794Loss~~ from operations ( **10, 284, 843) (** 4, 871, 926 ~~) (4, 475, 185~~ ) Other income (expense): Interest income **191, 669** 16, **850Loss** ~~850 Loss~~ on extinguishment of debt ( **368, 036) (** 554, 423) Interest expense ( **21, 407) (** 75, 815 ~~) (8, 289~~ ) Total other income (expense) ( **197, 774) (** 613, 388 ~~) (8, 289~~ ) Loss before provision for income taxes ( **10, 482, 617) (** 5, 485, 314 ~~) (4, 483, 474~~ ) Provision for income taxes Net loss $ ( **10, 482, 617) $ (** 5, 485, 314 ~~) $ (4, 483, 474~~ ) Net loss per share of common stock ~~-~~basic (in Dollars per share) $ (0. **99) $ (0.** 69) **Net loss per share of common stock diluted (in Dollars per share)** $ (0. ~~53~~ **99) $ (0. 69** ) Weighted average **of common** shares **outstanding Weighted average** of common ~~stock~~ **shares** outstanding- basic (in Shares) **10, 607, 477** 7, 954, **105Weighted average of common shares outstanding- diluted (in Shares) 10, 607, 477 7, 954,** ~~105~~ **105X** ~~8, 459, 547X~~ - DefinitionThe aggregate cost of goods produced and sold and services rendered during the reporting period. ReferencesReference 1: http: / / www. xbrl. org / 2003 / role / ~~exampleRef~~ **disclosureRef** - Topic ~~280~~ **235** - SubTopic 10- Name Accounting Standards Codification- Section ~~55~~ **S50** - Paragraph ~~48~~ **1** - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147482785~~ - **2147480738** / ~~280~~ **235** - 10- ~~55~~ **S50** - ~~48Reference~~ **1Reference** 2: http: / / ~~fasb~~ **www** . **xbrl.** org / **2003** ~~us- gaap~~ / role / **disclosureRef** ~~ref / legacyRef~~ - Topic ~~220~~ **235** - SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph ~~2~~ **1** - Subparagraph (SX 210. ~~5~~ **4** - ~~03~~ **08** ( ~~2~~ **g) (1) (i** ))- Publisher FASB- URI

https: / / asc. fasb. org / 1943274 / ~~2147483621~~ **2147480678** / ~~220~~ **235** - 10- S99- ~~2Reference~~ **1Reference** 3: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic ~~235~~ **825** - SubTopic 10- Name Accounting Standards Codification- Section ~~S99~~ **50** - Paragraph ~~1~~ **28** - Subparagraph ( **f** ~~SX 210. 4- 08 (g) (1) (ii)~~ )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147480678~~ -- **2147482907** / ~~235~~ **825** - 10- ~~S99~~ **50** - ~~1Reference~~ **28Reference** 4: http: / / www. xbrl. org / 2003 / role / ~~disclosureRef~~ **exampleRef** - Topic ~~323~~ **280** - SubTopic 10- Name Accounting Standards Codification- Section ~~50~~ **55** - Paragraph **48** ~~3- Subparagraph (c)~~ Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147481687~~ **2147482785** / ~~323~~ **280** - 10- ~~50~~ **55** - ~~3Reference~~ **48Reference** 5: http: / / ~~www~~ **fasb** . ~~xbrl.~~ org / ~~2003~~ **us- gaap** / role / ~~disclosureRef~~ **ref / legacyRef** - Topic ~~825~~ **220** - SubTopic 10- Name Accounting Standards Codification- Section ~~50~~ **S99** - Paragraph ~~28~~ **2** - Subparagraph ( ~~f~~ **SX 210. 5- 03 (2)** )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147482907~~ **2147483621** / ~~825~~ **220** - 10- ~~50~~ **S99** - ~~28Reference~~ **2Reference** 6: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic ~~470~~ **235** - SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph ~~1A~~ **1** - Subparagraph (SX 210. ~~13- 01 (a) (~~4 ~~)~~ **- 08** ( ~~i~~ **g) (1) (ii** ))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147480097~~ **2147480678** / ~~470~~ **235** - 10- S99- ~~1AReference~~ - **1Reference** 7: http: / / www. xbrl. org / ~~2009~~ **2003** / role / ~~commonPracticeRef~~ **disclosureRef** - Topic ~~470~~ **323** - SubTopic 10- Name Accounting Standards Codification- Section ~~S99~~ **50** - Paragraph ~~1A~~ **3** - Subparagraph ( **c** ~~SX 210. 13- 01 (a) (4) (ii)~~ )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147480097~~ **2147481687** / ~~470~~ **323** - 10- ~~S99~~ **50** - ~~1AReference~~ **3Reference** 8: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 470- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1A- Subparagraph (SX 210. 13- 01 (a) (4) ( **i** ~~iii) (A~~ ))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1AReference 9: http: / / www. xbrl. org / ~~2003~~ **2009** / role / ~~disclosureRef~~ **commonPracticeRef** - Topic 470- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1A- Subparagraph (SX 210. 13- 01 (a) (4) ( ~~iv~~ **ii** ))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1AReference 10: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 470- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1A- Subparagraph (SX 210. 13- 01 (a) ( ~~5~~ **4) (iii) (A** ))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1AReference 11: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 470- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph ~~1B~~ **1A** - Subparagraph (SX 210. 13- ~~02~~ **01** (a) (4) ( ~~i~~ **iv** ))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- ~~1BReference~~ **1AReference** 12: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 470- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph ~~1B~~ **1A** - Subparagraph (SX 210. 13- ~~02~~ **01** (a) ( **5** ~~4) (iii) (A~~ ))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- ~~1BReference~~ **1AReference** 13: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 470- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1B- Subparagraph (SX 210. 13- 02 (a) (4) ( **i** ~~iii) (B~~ ))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1BReference 14: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 470- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1B- Subparagraph (SX 210. 13- 02 (a) (4) ( ~~iv~~ **iii) (A** ))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1BReference 15 : **~~"~~http:/ / www.xbrl.org / 2003 / role / disclosureRef- Topic 470- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1B- Subparagraph** (SX 210.13- 02 (a) (4) (iii) (B)) **-** ~~","~~ Publisher ~~":"~~ FASB **-** ~~","~~ URI ~~":"~~ https:/ / asc.fasb.org / 1943274 / 2147480097 / 470- 10- S99- **1BReference 16** ~~1B" },"r359"~~ : ~~{"role":"~~ http:/ / www.xbrl.org / 2003 / role / disclosureRef **-** ~~","~~ Topic ~~":"~~ 470 **-** ~~","~~ SubTopic ~~":"~~ 10 **-** ~~","~~ Name ~~":"~~ Accounting Standards Codification **-** ~~","~~ Section ~~":"~~ S99 **-** ~~","~~ Paragraph ~~":"~~ 1B **-** ~~","~~ Subparagraph ~~":"~~ (SX 210.13- 02 (a) (4) (iv)) **-** ~~","~~ Publisher **~~"~~ FASB- URI https** : **~~"~~ FASB~~"~~ / / asc.fasb.org / 1943274 / 2147480097 / 470- 10- S99- 1BReference 17** : http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 470- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1B- Subparagraph (SX 210. 13- 02 (a) (5))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1B Details Name: us- gaap_CostOfRevenue Namespace Prefix: us- gaap_ Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: durationX- DefinitionTotal costs of sales and operating expenses for the period. ReferencesReference 1: http: / / fasb. org / us-gaap / role / ref / legacyRef- Topic 220- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 2- Subparagraph (SX 210. 5- 03)- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147483621 / 220- 10- S99- 2 Details Name: us- gaap_CostsAndExpenses Namespace Prefix: us- gaap_ Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: durationX- ReferencesNo definition available. Details Name: us-gaap_CostsAndExpensesAbstract Namespace Prefix: us- gaap_ Data Type: xbrli: stringItemType Balance Type: na Period Type: durationX- DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. ReferencesReference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic ~~250~~ **260** - SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph ~~6~~ **1- Subparagraph (a)** - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147483443~~ **2147482662** / **260- 10- 50- 1Reference 2: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic** 250 ~~- 10- 50- 6Reference 2: http: / / www. xbrl. org / 2003 / role / exampleRef- Topic 260~~ - SubTopic 10- Name Accounting Standards Codification- Section ~~55~~ **50** - Paragraph ~~52~~ **1- Subparagraph (c) (2)** - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147482635~~ **2147483443** / ~~260~~ **250** - 10- ~~55~~ **50** - ~~52Reference~~ **1Reference** 3: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic ~~805~~ **250** - SubTopic ~~60~~ **10** - Name Accounting Standards Codification- Section ~~65~~ **50** - Paragraph 1- Subparagraph ( ~~g~~ **c) (1** )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147476176~~ **2147483443** / ~~805~~ **250** - ~~60~~ **10** - ~~65~~ **50** - 1Reference 4: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic ~~740~~ **250** - SubTopic ~~323~~ **10** - Name Accounting Standards Codification- Section ~~65~~ **50** - Paragraph **4** ~~2- Subparagraph (g) (3)~~ - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147478666~~ **2147483443** / ~~740~~ **250** - ~~323~~ **10** - ~~65~~ **50** - ~~2Reference~~ **4Reference** 5: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic ~~250~~ **105** - SubTopic 10- Name Accounting Standards Codification- Section ~~50~~ **65** - Paragraph ~~3~~ **9- Subparagraph (e)** - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147483443~~ - **2147479343** / ~~250- 10~~ **105** - ~~50~~ **10** - **65-** ~~3Reference~~ **9Reference** 6: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic ~~260~~ **718** - SubTopic 10- Name Accounting Standards Codification- Section ~~55~~ **65** - Paragraph ~~15~~ **17- Subparagraph (d) (1)** - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147482635~~ **2147480336** / ~~260~~ **718** - 10- ~~55~~ **65** - ~~15Reference~~ **17Reference** 7: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic ~~815~~ **250** - SubTopic ~~40~~ **10** - Name Accounting Standards Codification- Section ~~65~~ **50** - Paragraph **6** ~~1- Subparagraph (e) (4)~~ - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147480175~~ **2147483443** / ~~815~~ **250** - ~~40~~ **10** - ~~65~~ **50** - ~~1Reference~~ **6Reference** 8: http: / / www. xbrl. org / 2003 / role / ~~disclosureRef~~ **exampleRef** - Topic ~~815~~ **260** - SubTopic ~~40~~ **10** - Name Accounting Standards Codification- Section ~~65~~ **55** - Paragraph **52** ~~1- Subparagraph (f)~~ - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147480175~~ **2147482635** / ~~815~~ **260** - ~~40~~ **10** - ~~65~~ **55** - ~~1Reference~~ **52Reference** 9: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic ~~250~~ **805** - SubTopic ~~10~~ **60** - Name Accounting Standards Codification- Section ~~50~~ **65** - Paragraph ~~11~~ **1** - Subparagraph ( ~~a~~ **g** )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147483443~~ **2147476176** / ~~250~~ **805** - ~~10~~ **60** - ~~50~~ **65** - ~~11Reference~~ **1Reference** 10: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic ~~250~~ **740** - SubTopic ~~10~~ **323** - Name Accounting Standards Codification- Section ~~50~~ **65** - Paragraph ~~11~~ **2** - Subparagraph ( ~~b~~ **g) (3** )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147483443~~ **2147478666** / ~~250~~ **740** - ~~10~~ **323** - ~~50~~ **65** - ~~11Reference~~ **2Reference** 11: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 250- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph **3** ~~7- Subparagraph (a)~~ - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147483443 / 250- 10- 50- ~~7Reference~~ **3Reference** 12: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 260- SubTopic 10- Name Accounting Standards Codification- Section ~~45~~ **55** - Paragraph ~~2~~ **15** - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147482689~~ **2147482635** / 260- 10- ~~45~~ **55** - ~~2Reference~~ **15Reference** 13: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic ~~260~~ **815** - SubTopic ~~10~~ **40** - Name Accounting Standards Codification- Section ~~45~~ **65** - Paragraph ~~60B~~ **1** - Subparagraph ( ~~d~~ **e) (4** )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147482689~~ **2147480175** / ~~260~~ **815** - ~~10~~ **40** - ~~45~~ **65** - ~~60BReference~~ **1Reference** 14: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic ~~250~~ **815** - SubTopic ~~10~~ **40** - Name Accounting Standards Codification- Section ~~50~~ **65** - Paragraph ~~4~~ **1- Subparagraph (f)** - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147483443~~ **2147480175** / **815- 40- 65- 1Reference 15: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic** 250 ~~- 10- 50- 4Reference 15: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 260~~ - SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph ~~1~~ **11** - Subparagraph (a)- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147482662~~ **2147483443** / ~~260~~ **250** - 10- 50- ~~1Reference~~ **11Reference** 16: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic ~~260~~ **250** - SubTopic 10- Name Accounting Standards Codification- Section ~~45~~ **50** - Paragraph ~~10~~ **11- Subparagraph (b)** - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147482689~~ **2147483443** / ~~260~~ **250** - 10- ~~45~~ **50** - ~~10Reference~~ **11Reference** 17: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic ~~220~~ **250** - SubTopic 10- Name Accounting Standards Codification- Section ~~S99~~ **50** - Paragraph ~~2~~ **7** - Subparagraph ( **a** ~~SX 210. 5- 03 (25)~~ )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147483621~~ **2147483443** / ~~220~~ **250** - 10- ~~S99~~ **50** - ~~2Reference~~ **7Reference** 18: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic ~~942~~ **260** - SubTopic ~~220~~ **10** - Name Accounting Standards Codification- Section ~~S99~~ **45** - Paragraph **2** ~~1- Subparagraph (SX 210. 9- 04 (27))~~ - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147478524~~ **2147482689** / ~~942~~ **260** - ~~220~~ **10** - ~~S99~~ **45** - ~~1Reference~~ **2Reference** 19: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic ~~944~~ **260** - SubTopic ~~220~~ **10** - Name Accounting Standards Codification- Section ~~S99~~ **45** - Paragraph ~~1~~ **60B** - Subparagraph ( **d** ~~SX 210. 7- 04 (23)~~ )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147477250~~ **2147482689** / ~~944~~ **260** - ~~220~~ **10** - ~~S99~~ **45** - ~~1Reference~~ **60BReference** 20: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 260- SubTopic 10- Name Accounting Standards Codification- Section 45- Paragraph ~~7~~ **10** - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482689 / 260- 10- 45- **10Reference 21** :http:/ / ~~fasb~~ **www.xbrl** .org / **2003** ~~us- gaap~~ / role / **disclosureRef** ~~ref / legacyRef~~ - Topic ~~505~~ **220** - SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph ~~4~~ **2** - Subparagraph ( **SX 210** ~~SAB Topic 4~~ . ~~C~~ **5- 03 (25)** )- Publisher FASB- URI https:/ / asc.fasb.org / 1943274 / ~~2147480008~~ **2147483621** / ~~505~~ **220** -

10- S99- **2Reference 22** ~~4 Details Name:us- gaap_StockholdersEquityReverseStockSplit Namespace Prefix:us- gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:durationX- DefinitionPer share increase in exercise price of warrant.Excludes change due to standard antidilution provision. ReferencesReference 1~~ :http: / / www.xbrl.org / 2003 / role / disclosureRef- Topic ~~505~~ **942** - SubTopic ~~10~~ **220** - Name Accounting Standards Codification- Section ~~50~~ **S99** - Paragraph ~~3~~ **1- Subparagraph (SX 210.9- 04 (27))** - Publisher FASB- URI https: / / asc.fasb.org / 1943274 / ~~2147481112~~ **2147478524** / ~~505~~ **942** - ~~10~~ **220** - ~~50~~ **S99** - ~~3 Details~~ **1Reference 23:http: / / www.xbrl.org / 2003 / role / disclosureRef- Topic 944- SubTopic 220-** Name ~~:us-~~ **Accounting Standards Codification** - ~~gaap_WarrantExercisePriceIncrease Namespace Prefix:~~ **Section S99- Paragraph 1- Subparagraph (SX 210.** 7 ~~:"~~ **- 04 (23))- Publisher FASB- URI** https: / / asc.fasb.org / 1943274 / ~~2147480530~~ **2147477250** / ~~250~~ **944** - ~~10~~ **220** - S99- **1Reference 24** ~~5" },"r243":~~ ~~{"role":"~~http: / / www.xbrl.org / 2003 / role / disclosureRef ~~-~~ ~~","~~ Topic ~~":"~~ 260 ~~- ","~~ SubTopic ~~":"~~ 10 ~~- ","~~ Name ~~":"~~ Accounting Standards Codification ~~- ","~~ Section ~~":"~~ 45 ~~- ","~~ Paragraph **7-** ~~":"~~ 10~~","~~ Publisher ~~":"~~ FASB ~~-~~ ~~","~~ URI ~~":"~~ https: / / asc.fasb.org / 1943274 / 2147482689 / 260- 10- 45- **7Reference 25** ~~10" },"r244":~~ ~~{"role":"~~http: / / www.xbrl.org / 2003 / role / disclosureRef ~~":"~~ **- Topic 470- SubTopic 20- Name Accounting Standards Codification- Section 65- Paragraph 4- Subparagraph (f) (4)- Publisher FASB- URI https: / / asc.fasb.org / 1943274 / 2147481538 / 470- 20- 65- 4** Details Name: us- gaap_EarningsPerShareBasic ~~) for~~ the **passage** ~~period available to each share~~ of **time** ~~common stock~~ or **when a triggering event occurs** ~~common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period~~ . ReferencesReference 1:http: / ~~www~~ **fasb** . ~~xbrl.~~ org / ~~2003~~ **us- gaap** / role / ~~disclosureRef~~ **ref / legacyRef** - Topic ~~260~~ **942** - SubTopic ~~10~~ **210** - Name Accounting Standards Codification- Section ~~50~~ **S99** - Paragraph 1- Subparagraph ( ~~a~~ **SX 210.9- 03 (10)** )- Publisher FASB- URI https: / / asc.fasb.org / 1943274 / ~~2147482662~~ **2147478546** / ~~260~~ **942** - ~~10~~ **210** - ~~50~~ **S99** - 1Reference 2:http: / / www.xbrl.org / ~~2003~~ **2009** / role / ~~disclosureRef~~ **commonPracticeRef** - Topic ~~250~~ **944** - SubTopic ~~10~~ **210** - Name Accounting Standards Codification- Section ~~50~~ **S99** - Paragraph 1- Subparagraph ( ~~c)~~ **SX 210.7- 03** ( ~~2~~ **a) (10)** )- Publisher FASB- URI https: / / asc.fasb.org / 1943274 / ~~2147483443~~ **2147478777** / ~~250~~ **944** - ~~10~~ **210** - ~~50~~ **S99** - 1Reference 3:http: / / www.xbrl.org / 2003 / role / disclosureRef- Topic ~~250~~ **946** - SubTopic ~~10~~ **210** - Name Accounting Standards Codification- Section ~~50~~ **S99** - Paragraph 1- Subparagraph ( ~~c)~~ **SX 210.6- 04** ( ~~1~~ **7) (a)** )- Publisher FASB- URI https: / / asc.fasb.org / 1943274 / ~~2147483443~~ **2147479170** / ~~250~~ **946** - ~~10~~ **210** - ~~50~~ **S99** - 1Reference 4:http: / / www.xbrl.org / 2003 / role / disclosureRef- Topic ~~250~~ **210** - SubTopic 10- Name Accounting Standards Codification- Section ~~50~~ **S99** - Paragraph ~~4~~ **1- Subparagraph (SX 210.5- 02 (7))** - Publisher FASB- URI https: / / asc.fasb.org / 1943274 / ~~2147483443~~ **2147480566** / ~~250- 10~~ **210** - ~~50~~ **10** - ~~4Reference 5~~ **S99- 1 Details Name:us- gaap_PrepaidExpenseCurrentAndNoncurrent Namespace Prefix:us- gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instantX- DefinitionCash received for fees during the current period.This element excludes cash proceeds from license fees. ReferencesReference 1** :http: / ~~www~~ **fasb** . ~~xbrl.~~ org / ~~2003~~ **us- gaap** / role / ~~disclosureRef~~ **ref / legacyRef** - Topic ~~105~~ **230** - SubTopic 10- Name Accounting Standards Codification- Section ~~65~~ **45** - Paragraph ~~9~~ **25** - Subparagraph ( ~~e~~ **c** )- Publisher FASB- URI https: / / asc.fasb.org / 1943274 / ~~2147479343~~ **2147482740** / **230-** ~~105-~~ **10** - ~~10~~ **45** - ~~65- 9Reference 6~~ **25 Details Name** : ~~http~~ **us- gaap_ProceedsFromFeesReceived Namespace Prefix** : ~~// www.~~ **us- gaap_ Data Type:** ~~xbrl~~ **xbrli** ~~.org / 2003 / role / disclosureRef- Topic 718- SubTopic 10- Name Accounting Standards Codification- Section 65- Paragraph 17- Subparagraph (d) (1)- Publisher FASB- URI https~~ : **monetaryItemType Balance Type** ~~// sec.fasb.org / 1943274 / 2147480336 / 718- 10- 65- 17Reference 7~~ : ~~http~~ **debit Period Type** : **durationX- DefinitionAmount of purchase arrangement** ~~// www.xbrl.org /~~ Namespace Prefix: us- gaap_ Data Type: dtr- types: perShareItemType Balance Type: na Period Type: durationX- DefinitionDifference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity. ReferencesReference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef- Name Accounting Standards Codification- Section 45- Paragraph 28- Subparagraph (b)- SubTopic 10- Topic 230- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482740 / 230- 10- 45- 28Reference 2: http: / / fasb. org / us- gaap / role / ref / legacyRef- Name Accounting Standards Codification- Topic 470- SubTopic 50- Section 40- Paragraph 2- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147481303 / 470- 50- 40- 2Reference 3: http: / / fasb. org / us- gaap / role / ref / legacyRef- Name Accounting Standards Codification- Topic 470- SubTopic 50- Section 40- Paragraph 4- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147481303 / 470- 50- 40- 4 Details Name: us- gaap_GainsLossesOnExtinguishmentOfDebt Namespace Prefix: us- gaap_ Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: durationX- ~~DefinitionAmount~~ - **DefinitionTotal** ~~of~~ **loss recognized during the period from the** impairment **of goodwill plus the** loss **recognized in the period resulting** from **the impairment of the carrying amount of intangible** ~~asset~~ **assets ,** ~~representing future economic benefit arising from~~ other ~~asset acquired in business combination or from joint venture formation or both, that~~ **than goodwill** ~~is not individually identified and separately recognized~~ . ReferencesReference 1: http: / /..... 350- 20- 50- 2Reference - **ReferencesNo definition available** ~~4: http: / / www.~~ xbrl. org / 2003 / role..... 350- 20- 45- 2 Details Name: us- ~~gaap_GoodwillImpairmentLoss~~ **gaap_GoodwillAndIntangibleAssetImpairment** Namespace Prefix: us- gaap_ Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: durationX- DefinitionAmount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. ReferencesReference 1: http: / / www. xbrl. org / ~~2009~~ **2003** / role / ~~commonPracticeRef~~ **exampleRef** - Topic ~~280~~ **220** - SubTopic ~~10~~ **40** - Name Accounting Standards Codification- Section ~~50~~ **55** - Paragraph ~~22~~ **4** - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147482810~~ **2147476153** / ~~280~~ **220** - ~~10~~ **40** - ~~50~~ **55** - ~~22Reference~~ **4Reference** 2: http: / / www. xbrl. org / 2003 / role / exampleRef- Topic ~~280~~ **220** - SubTopic ~~10~~ **40** - Name Accounting Standards Codification- Section 55- Paragraph ~~48~~ **21** - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147482785~~ **2147476153** / ~~280~~ **220** - ~~10~~ **40** - 55- ~~48Reference~~ **21Reference** 3: http: / / www. xbrl. org / ~~2009~~ **2003** / role / ~~commonPracticeRef~~ **exampleRef** - Topic ~~280~~ **220** - SubTopic ~~10~~ **40** - Name Accounting Standards Codification- Section ~~50~~ **55** - Paragraph **14** ~~32- Subparagraph (f)~~ - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147482810~~ **2147476153** / ~~280~~ **220** - ~~10~~ **40** - ~~50~~ **55** - ~~32Reference~~ **14Reference** 4: http: / / www. xbrl. org / ~~2009~~ **2003** / role / ~~commonPracticeRef~~ **disclosureRef** - Topic ~~280~~ **942** - SubTopic ~~10~~ **235** - Name Accounting Standards Codification- Section ~~50~~ **S50** - Paragraph **1** ~~30- Subparagraph (b)~~ - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147482810~~ **2147478671** / ~~280~~ **942** - ~~10~~ **235** - ~~50~~ **S50** - ~~30Reference~~ **1Reference** 5: http: / / www. xbrl. org / ~~2009~~ **2003** / role / ~~commonPracticeRef~~ **disclosureRef** - Topic ~~270~~ **942** - SubTopic ~~10~~ **235** - Name Accounting Standards Codification- Section ~~50~~ **S99** - Paragraph 1- Subparagraph ( ~~i~~ **SX 210. 9- 05 (b) (2)** )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147482964~~ **2147477314** / ~~270~~ **942** - ~~10~~ **235** - ~~50~~ **S99** - 1Reference 6: http: / / www. xbrl. org / 2009 / role / commonPracticeRef- Topic 280- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph **22** ~~32- Subparagraph (ee)~~ - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482810 / 280- 10- 50- ~~32Reference~~ **22Reference** 7: http: / / ~~fasb~~ **www** . **xbrl.** org / **2003** ~~us- gaap~~ / role / **exampleRef** ~~ref / otherTransitionRef~~ - Topic 280- SubTopic 10- Name Accounting Standards Codification- Section ~~50~~ **55** - Paragraph **48** ~~32- Subparagraph (e)~~ - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147482810~~ **2147482785** / 280- 10- ~~50~~ **55** - ~~32Reference~~ **48Reference** 8: http: / / www. xbrl. org / ~~2003~~ **2009** / role / ~~disclosureRef~~ **commonPracticeRef** - Topic ~~944~~ **280** - SubTopic ~~220~~ **10** - Name Accounting Standards Codification- Section ~~S99~~ **50** - Paragraph ~~1~~ **32** - Subparagraph ( **f** ~~SX 210. 7- 04 (11)~~ )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147477250~~ **2147482810** / ~~944~~ **280** - ~~220~~ **10** - ~~S99~~ **50** - ~~1Reference~~ **32Reference** 9: http: / / www. xbrl. org / ~~2003~~ **2009** / role / ~~exampleRef~~ **commonPracticeRef** - Topic 280- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph ~~31~~ **30- Subparagraph (b)** - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482810 / 280- 10- 50- ~~31Reference~~ **30Reference** 10: http: / / www. xbrl. org / ~~2003~~ **2009** / role / ~~disclosureRef~~ **commonPracticeRef** - Topic ~~942~~ **270** - SubTopic ~~235~~ **10** - Name Accounting Standards Codification- Section ~~S99~~ **50** - Paragraph 1- Subparagraph ( **i** ~~SX 210. 9- 05 (b) (2)~~ )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147477314~~ **2147482964** / ~~942~~ **270** - ~~235~~ **10** - ~~S99~~ **50** - 1Reference 11: http: / / ~~fasb~~ **www** . **xbrl.** org / **2009** ~~us- gaap~~ / role / **commonPracticeRef** ~~ref / legacyRef~~ - Topic ~~220~~ **280** - SubTopic 10- Name Accounting Standards Codification- Section ~~/ 2147482810 / 280- 10- 50- 32Reference 12:http: / / fasb.org / us-~~ gaap / role / ref / ~~otherTransitionRef~~ **legacyRef** - Topic ~~280~~ **210** - SubTopic 10- Name Accounting Standards Codification- Section ~~50~~ **S99** - Paragraph ~~32~~ **1** - Subparagraph ( ~~e~~ **SX 210.5- 02 (29)** )- Publisher FASB- URI https: / / asc.fasb.org / 1943274 / ~~2147482810~~ **2147480566** / ~~280- 10~~ **210** - ~~50~~ **10** - **S99-** ~~32Reference~~ **1Reference** ~~13~~ **2** :http: / / www.xbrl.org / 2003 / role / ~~disclosureRef~~ **exampleRef** - Topic ~~944~~ **852** - SubTopic ~~220~~ **10** - Name Accounting Standards Codification- Section ~~S99~~ **55** - Paragraph ~~1- Subparagraph (SX 210.~~ **10** ~~.7- 04 (11))~~ - Publisher FASB- URI https: / / asc.fasb.org / 1943274 / ~~2147477250~~ **2147481372** / **852- 10- 55- 10Reference 3:http: / / www.xbrl.org / 2003 / role / disclosureRef- Topic** 944- ~~220- S99- 1Reference 14:http: / / www.xbrl.org / 2003 / role / exampleRef- Topic 280-~~ SubTopic ~~10~~ **210** - Name Accounting Standards Codification- Section ~~50~~ **S99** - Paragraph ~~31~~ **1- Subparagraph (SX 210.7- 03 (a) (22))** - Publisher FASB- URI https: / / asc.fasb.org / 1943274 / ~~2147482810~~ **2147478777** / **944- 210- S99- 1 Details Name:** S99- Paragraph 2- Subparagraph (SX 210. 5- 03 (10))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147483621 / 220- 10- S99- 2Reference ~~12~~ **16** : http: / / fasb. org / us- gaap / role / ref / legacyRef- Topic 942- SubTopic 220- Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210. 9- 04 (15))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147478524 / 942- 220- S99- 1 Details Name: us- gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Namespace Prefix: us- gaap_ Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: durationX- ReferencesNo definition available. Details Name: us- gaap_IncomeStatementAbstract Namespace Prefix: us- gaap_ Data Type: xbrli: stringItemType Balance Type: na Period Type: durationX- DefinitionAmount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. ReferencesReference 1: http: / / www. xbrl. org / 2003 / role / ~~disclosureRef~~ **exampleRef** - Topic ~~270~~ **220** - SubTopic ~~10~~ **40** - Name Accounting Standards Codification- Section ~~50~~ **55** - Paragraph **4** ~~1- Subparagraph (i)~~ - Publisher FASB- URI https: / / asc.

fasb. org / 1943274 / ~~2147482964~~ **2147476153** / ~~270~~ **220** - ~~10~~ **40** - ~~50~~ **55** - ~~1Reference~~ **4Reference** 2: http: / / www. xbrl. org / 2003 / role / ~~disclosureRef~~ **exampleRef** - Topic ~~280~~ **220** - SubTopic ~~10~~ **40** - Name Accounting Standards Codification- Section ~~50~~ **55** - Paragraph **21** ~~32- Subparagraph (ee)~~ - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147482810~~ **2147476153** / ~~280~~ **220** - ~~10~~ **40** - ~~50~~ **55** - ~~32Reference~~ - **21Reference** 3: http: / / www. xbrl. org / 2003 / role / ~~disclosureRef~~ **exampleRef** - Topic ~~740~~ **220** - SubTopic ~~10~~ **40** - Name Accounting Standards Codification- Section ~~50~~ **55** - Paragraph ~~12~~ **14** - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147482685~~ **2147476153** / **220-** ~~740~~ - **40** - ~~10~~ **55** - ~~50- 12Reference~~ **14Reference** 4: http: / / www. xbrl. org / 2003 / role / ~~exampleRef~~ **disclosureRef** - Topic ~~740~~ **235** - SubTopic 10- Name Accounting Standards Codification- Section ~~55~~ **S50** - Paragraph ~~231~~ **1** - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147482663~~ **2147480738** / ~~740~~ **235** - 10- ~~55~~ **S50** - ~~231Reference~~ - **1Reference** 5: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic ~~250~~ **270** - SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph ~~9~~ **1- Subparagraph (i)** - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147483443~~ **2147482964** / ~~250~~ **270** - 10- 50- ~~9Reference~~ **1Reference** 6: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic ~~740~~ **280** - SubTopic 10- Name Accounting Standards Codification- Section **credit Period Type:instantX** - ~~SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 12- Publisher FASB- URI https: / / asc~~ **DefinitionAmount,after effects of reinsurance,of expense (reversal of expense) for claims incurred and costs incurred in the claim settlement process** . **ReferencesReference 1** ~~fasb.org / 1943274 / 2147482685 / 740- 10- 50- 12Reference~~ 8 :http: / www.xbrl.org / 2003 / role / exampleRef- Topic ~~740~~ **944** - SubTopic ~~10~~ **40** - Name Accounting Standards Codification- Section 55- Paragraph ~~231~~ **7** - Publisher FASB- URI https:/ / asc.fasb.org / 1943274 / ~~2147482663~~ **2147480046** / ~~740~~ **944** - ~~10~~ **40** - 55- ~~231Reference~~ **7Reference** ~~9~~ **2** :http: / / www.xbrl.org / ~~2003~~ **2009** / role / ~~disclosureRef~~ **commonPracticeRef** - Topic ~~250~~ **944** - SubTopic ~~10~~ **40** - Name Accounting Standards Codification- Section 50- Paragraph ~~9~~ **3- Subparagraph (b)** - Publisher FASB- URI https:/ / asc.fasb.org / 1943274 / ~~2147483443~~ **2147480081** / ~~250~~ **944** - ~~10~~ **40** - 50- ~~9Reference 10~~ **3 Details Name** : ~~http~~ **us- gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1 Namespace Prefix** : **us** ~~/ / www.xbrl.org / 2003 / role / disclosureRef- Topic 740-~~ **gaap_ Data Type:xbrli:monetaryItemType Balance Type:** S99- Paragraph 1- Subparagraph (SAB Topic 6. I. 7)- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147479360 / 740- 10- S99- 1Reference ~~7~~ **11** : http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 250- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 8- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147483443 / 250- 10- 50- 8Reference ~~8~~ **12** : http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 740- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 10- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482685 / 740- 10- 50- 10Reference ~~9~~ **13** : http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 280- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 22- Subparagraph (h)- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482810 / 280- 10- 50- 22Reference ~~10~~ **14** : http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 944- SubTopic 220- Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210. 7- 04 (9))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147477250 / 944- 220- S99- 1Reference ~~11~~ **15** : http: / / www. xbrl. org / 2003 / role / disclosureRef- Name Accounting Standards Codification- Section 45- Paragraph 2- Subparagraph (a)- SubTopic 20- Topic 740- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482659 / 740- 20- 45- 2Reference ~~12~~ **16** : http: / / www. xbrl. org / 2003 / role / disclosureRef- Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210. 4- 08 (h))- SubTopic 10- Topic 235- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480678 / 235- 10- S99- 1 Details Name: us- gaap_IncomeTaxExpenseBenefit Namespace Prefix: us- gaap_ Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: durationX- DefinitionAmount of interest expense classified as ~~operating and~~ nonoperating ~~. Includes, but is not limited to, cost of borrowing accounted for as interest expense~~ . ReferencesReference 1: http: / / www. xbrl. org / 2003 / role / ~~disclosureRef~~ **exampleRef** - Topic ~~280~~ **220** - SubTopic ~~10~~ **40** - Name Accounting Standards Codification- Section ~~50~~ **55** - Paragraph **4** ~~22- Subparagraph (d)~~ - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147482810~~ **2147476153** / ~~280~~ **220** - ~~10~~ **40** - ~~50~~ **55** - ~~22Reference~~ **4Reference** 2: http: / / www. xbrl. org / 2003 / role / exampleRef- Topic ~~280~~ **220** - SubTopic ~~10~~ **40** - Name Accounting Standards Codification- Section 55- Paragraph ~~48~~ **14** - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147482785~~ **2147476153** / ~~280~~ **220** - ~~10~~ **40** - 55- ~~48Reference~~ - **14Reference** 3: http: / / www. xbrl. org / 2003 / role / ~~exampleRef~~ **disclosureRef** - Topic 280- SubTopic 10- Name Accounting Standards Codification- Section ~~55~~ **50** - Paragraph ~~49~~ **22- Subparagraph (d)** - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147482785~~ - **2147482810** / 280- 10- ~~55~~ **50** - ~~49Reference~~ **22Reference** 4: http: / / www. xbrl. org / ~~2003~~ **2009** / role / ~~disclosureRef~~ **commonPracticeRef** - Topic ~~270~~ **220** - SubTopic 10- Name Accounting Standards Codification- Section ~~50~~ **S99** - Paragraph ~~1~~ **2** - Subparagraph ( ~~i~~ **SX 210. 5- 03** )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147482964~~ **2147483621** / ~~270~~ **220** - 10- ~~50~~ **S99** - ~~1Reference 5~~ **2 Details Name: us- gaap_InterestExpenseNonoperating Namespace Prefix: us- gaap_ Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: durationX- DefinitionAmount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities. ReferencesReference 1** : http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 280- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph ~~32~~ **22** - Subparagraph ( ~~ee~~ **c** )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482810 / 280- 10- 50- ~~32Reference~~ **22Reference** ~~6~~ **2** : http: / / www. xbrl. org / 2003 / role / ~~disclosureRef~~ **exampleRef** - Topic 280- SubTopic 10- Name Accounting Standards Codification- Section ~~50~~ **55** - Paragraph ~~24~~ **48** - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147482810~~ **2147482785** / 280- 10- ~~50~~ **55** - ~~24Reference~~ - **48Reference** ~~7~~ **3** : http: / / www. xbrl. org / ~~2003~~ **2009** / role / ~~disclosureRef~~ **commonPracticeRef** - Topic ~~280~~ **220** - SubTopic 10- Name Accounting Standards Codification- Section ~~50~~ **S99** - Paragraph ~~22~~ **2- Subparagraph (SX 210. 5- 03 (7) (b))** - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147482810~~ - **2147483621** / ~~280~~ **220** - 10- ~~50~~ **S99** - ~~22Reference~~ - **2Reference** 8 **4** : http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic ~~835~~ **270** - SubTopic ~~20~~ **10** - Name Accounting Standards Codification- Section 50- Paragraph 1- Subparagraph ( ~~a~~ **i** )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147483013~~ **2147482964** / ~~835- 20~~ **270 - 10** - 50- ~~1~~ **1Reference 5: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 280- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 32- Subparagraph (ee)- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482810 / 280- 10- 50- 32** Details Name: us- **gaap_InvestmentIncomeInterest** ~~gaap_InterestExpense Namespace Prefix: us- gaap_ Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: durationX- DefinitionAmount of interest income earned from interest bearing assets classified as other. ReferencesNo definition available. Details Name: us- gaap_InterestIncomeOther~~ Namespace Prefix: us- gaap_ Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: durationX- DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. ReferencesReference 1: http: / / www. xbrl. org / 2003 / role / ~~disclosureRef~~ **exampleRef** - Topic ~~250~~ **946** - SubTopic ~~10~~ **830** - Name Accounting Standards Codification- Section ~~50~~ **55** - Paragraph ~~6~~ **10** - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147483443~~ **2147479168** / ~~250~~ **946** - ~~10~~ **830** - ~~50~~ **55** - ~~6Reference~~ **10Reference** 2: http: / / www. xbrl. org / 2003 / role / ~~disclosureRef~~ **exampleRef** - Topic ~~250~~ **220** - SubTopic ~~10~~ **40** - Name Accounting Standards Codification- Section ~~50~~ **55** - Paragraph ~~9~~ **4** - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147483443~~ **2147476153** / ~~250~~ **220** - ~~10~~ **40** - ~~50~~ **55** - ~~9Reference~~ **4Reference** 3: http: / / www. xbrl. org / 2003 / role / ~~disclosureRef~~ **exampleRef** - Topic ~~805~~ **220** - SubTopic ~~60~~ **40** - Name Accounting Standards Codification- Section ~~65~~ **55** - Paragraph **21** ~~1- Subparagraph (g)~~ - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147476176~~ **2147476153** / ~~805~~ **220** - ~~60~~ **40** - ~~65~~ **55** - ~~1Reference~~ **21Reference** 4: http: / / www. xbrl. org / 2003 / role / ~~disclosureRef~~ **exampleRef** - Topic ~~740~~ **220** - SubTopic ~~323~~ **40** - Name Accounting Standards Codification- Section ~~65~~ **55** - Paragraph **14** ~~2- Subparagraph (g) (3)~~ - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147478666~~ **2147476153** / **220-** ~~740~~ - **40** - ~~323~~ **55** - ~~65- 2Reference~~ **14Reference** 5: http: / / ~~fasb~~ **www** . **xbrl.** org / **2003** ~~us- gaap~~ / role / **disclosureRef** ~~ref / legacyRef~~ - Topic ~~220~~ **235** - SubTopic 10- Name Accounting Standards Codification- Section ~~S99~~ **S50** - Paragraph **1** ~~2- Subparagraph (SX 210. 5- 03 (20))~~ - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147483621~~ **2147480738** / ~~220~~ **235** - 10- ~~S99~~ **S50** - ~~2Reference~~ **1Reference** 6: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 235- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210. 4- 08 (g) (1) ( ~~ii~~ **i** ))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480678 / 235- 10- S99- 1Reference 7: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic ~~323~~ **235** - SubTopic 10- Name Accounting Standards Codification- Section ~~50~~ **S99** - Paragraph ~~3~~ **1** - Subparagraph ( ~~c~~ **SX 210. 4- 08 (k) (2)** )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147481687~~ - **2147480678** / ~~323~~ **235** - 10- ~~50~~ **S99** - ~~3Reference~~ **1Reference** 8: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 825- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 28- Subparagraph (f)- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482907 / 825- 10- 50- 28Reference 9: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic ~~220~~ **250** - SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph ~~6~~ **4** - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147482765~~ **2147483443** / ~~220~~ **250** - 10- 50- ~~6Reference~~ **4Reference** 10: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic ~~250~~ **480** - SubTopic 10- Name Accounting Standards Codification- Section ~~50~~ **S50** - Paragraph 3- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147483443~~ **2147479857** / ~~250~~ **480** - 10- ~~50~~ **S50** - 3Reference 11: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic ~~250~~ **480** - SubTopic 10- Name Accounting Standards Codification- Section ~~50~~ **S45** - Paragraph **3** ~~1- Subparagraph (b) (2)~~ - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147483443~~ **2147479887** / ~~250~~ **480** - 10- ~~50~~ **S45** - ~~1Reference~~ **3Reference** 12: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic ~~815~~ **480** - SubTopic ~~40~~ **10** - Name Accounting Standards Codification- Section ~~65~~ **S99** - Paragraph ~~1~~ **3A** - Subparagraph ( ~~f~~ **24) (d** )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147480175~~ **2147480244** / ~~815- 40~~ **480** - ~~65~~ **10** - **S99-** ~~1Reference~~ **3AReference** 13: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic ~~250~~ **105** - SubTopic 10- Name Accounting Standards Codification- Section ~~50~~ **65** - Paragraph ~~8~~ **9- Subparagraph (e)** - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147483443~~ - **2147479343** / ~~250- 10~~ **105** - ~~50~~ **10** - **65-** ~~8Reference~~ **9Reference** 14:

http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 250- 718 - SubTopic 10- Name Accounting Standards Codification- Section 50- 65 - Paragraph 11- 17 - Subparagraph ( a- d) (1 )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147483443 - - 2147480336 / 250- 718 - 10- 50- 65 - 11Reference- 17Reference 15: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 250- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 6 11- Subparagraph (b)- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147483443 / 250- 10- 50- 11Reference- 6Reference 16: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 250- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 4- 9 - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147483443 / 250- 10- 50- 4Reference- 9Reference 17: http: / / www. xbrl. org / 2003 / role / exampleRef- disclosureRef - Topic 946- 805 - SubTopic 830- 60 - Name Accounting Standards Codification- Section 55- 65 - Paragraph 10- 1- Subparagraph (g) - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147479168- 2147476176 / 946- 805 - 830- 60 - 55- 65 - 10Reference- 1Reference 18: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 946- 740 - SubTopic 220- 323 - Name Accounting Standards Codification- Section 45- 65 - Paragraph 7- 2- Subparagraph (g) (3) - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147479105- 2147478666 / 946- 740 - 323- 65- 2Reference 19: http: / / fasb. org / us- gaap / role / ref / legacyRef- Topic 220- 45- 7Reference 19: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 944- SubTopic 220- 10 - Name Accounting Standards Codification- Section S99- Paragraph 1- 2 - Subparagraph (SX 210. 7- 5 - 04- 03 ( 18- 20 ))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147477250- 2147483621 / 944- 220- 10- S99- 1Reference 2Reference 20: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 946- 235 - SubTopic 220- 10 - Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210. 6- 4 - 07- 08 ( 9- g) (1) (ii ))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147479134- 2147480678 / 946- 235 - 220- 10 - S99- 1Reference 21: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 946- 323 - SubTopic 220- 10 - Name Accounting Standards Codification- Section S99- 50 - Paragraph 3- Subparagraph ( c SX 210. 6- 09 (1) (d) )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147479134- 2147481687 / 946- 323 - 220- 10 - S99- 50 - 3Reference 22: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 470- 220 - SubTopic 10- Name Accounting Standards Codification- Section S99- 50 - Paragraph 6 1A- Subparagraph (SX 210. 13- 01 (a) (4) (i)) - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480097- 2147482765 / 470- 220 - 10- S99- 50 - 1AReference- 6Reference 23: http: / / www. xbrl. org / 2009- 2003 / role / commonPracticeRef- disclosureRef - Topic 470- 250 - SubTopic 10- Name Accounting Standards Codification- Section S99- 50 - Paragraph 3 1A- Subparagraph (SX 210. 13- 01 (a) (4) (ii)) - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480097- 2147483443 / 470- 250 - 10- S99- 50 - 1AReference- 3Reference 24: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 470- 250 - SubTopic 10- Name Accounting Standards Codification- Section S99- 50 - Paragraph 1A- 1 - Subparagraph ( b SX 210. 13- 01 (a- ) ( 2- 4) (iii) (A) )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480097- 2147483443 / 470- 250 - 10- S99- 50 - 1AReference- 1Reference 25: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 470- 815 - SubTopic 10- 40 - Name Accounting Standards Codification- Section S99- 65 - Paragraph 1A- 1 - Subparagraph ( f SX 210. 13- 01 (a) (4) (iv) )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480097- 2147480175 / 815- 470- 40 - 10- 65 - S99- 1AReference- 1Reference 26: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 470- 250 - SubTopic 10- Name Accounting Standards Codification- Section S99- 50 - Paragraph 8 1A- Subparagraph (SX 210. 13- 01 (a) (5)) - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480097- 2147483443 / 470- 250 - 10- S99- 50 - 1AReference- 8Reference 27: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 470- 250 - SubTopic 10- Name Accounting Standards Codification- Section S99- 50 - Paragraph 1B- 11 - Subparagraph ( SX 210. 13- 02 ( a ) (4) (i) )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480097- 2147483443 / 470- 250 - 10- S99- 50 - 1BReference- 11Reference 28: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 470- 250 - SubTopic 10- Name Accounting Standards Codification- Section S99- 50 - Paragraph 1B- 11 - Subparagraph ( b SX 210. 13- 02 (a) (4) (iii) (A) )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480097- 2147483443 / 470- 250 - 10- S99- 50 - 1BReference- 11Reference 29: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 470- 946 - SubTopic 10- 220 - Name Accounting Standards Codification- Section S99- 45 - Paragraph 7 1B- Subparagraph (SX 210. 13- 02 (a) (4) (iii) (B)) - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480097- 2147479105 / 470- 946 - 10- 220 - S99- 45 - 1BReference- 7Reference 30: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 470- 944 - SubTopic 10- 220 - Name Accounting Standards Codification- Section S99- Paragraph 1B- 1 - Subparagraph (SX 210. 13- 7 - 02- 04 ( 18 a) (4) (iv ))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480097- 2147477250 / 470- 944 - 10- 220 - S99- 1BReference- 1Reference 31: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 470- 946 - SubTopic 10- 220 - Name Accounting Standards Codification- Section S99- Paragraph 1B- 1 - Subparagraph (SX 210. 13- 6 - 02- 07 ( 9 a) (5 ))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480097- 2147479134 / 470- 946 - 10- 220 - S99- 1BReference- 1Reference 32: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 260- 946 - SubTopic 10- 220 - Name Accounting Standards Codification- Section 45- S99 - Paragraph 60B- 3 - Subparagraph ( a SX 210. 6- 09 (1) (d) )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482689- 2147479134 / 260- 946 - 10- 220 - 45- S99 - 60BReference- 3Reference 33: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 205- 470 - SubTopic 20- 10 - Name Accounting Standards Codification- Section 50- S99 - Paragraph 7- 1A- Subparagraph (SX 210. 13- 01 (a) (4) (i)) - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147483499- 2147480097 / 205- 470 - 20- 10 - 50- S99 - 7Reference- 1AReference 34: http: / / fasb- www . xbrl. org / 2009 us- gaap- / role / commonPracticeRef ref / legacyRef- Topic 230- 470 - SubTopic 10- Name Accounting Standards Codification- Section 45- S99 - Paragraph 28- 1A- Subparagraph (SX 210. 13- 01 (a) (4) (ii)) - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482740- 2147480097 / 230- 470 - 10- 45- S99 - 28Reference- 1AReference 35: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 220- 470 - SubTopic 10- Name Accounting Standards Codification- Section 45- S99 - Paragraph 1A- Subparagraph ( SX 210. 13- 01 ( a ) (4) (iii) (A) )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482790- 2147480097 / 220- 470 - 10- 45- S99 - 1AReference 36: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 220- 470 - SubTopic 10- Name Accounting Standards Codification- Section 45- S99 - Paragraph 1B- 1A - Subparagraph ( SX 210. 13- 01 ( a ) (4) (iv) )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482790- 2147480097 / 220- 470 - 10- 45- S99 - 1BReference- 1AReference 37: http: / / fasb- www . xbrl. org / 2003 us- gaap- / role / disclosureRef ref / legacyRef - Topic 942- 470 - SubTopic 220- 10 - Name Accounting Standards Codification- Section S99- Paragraph the passage of time or when Codification- Section S99- Paragraph 1B- Subparagraph (SX 210.13- 02 (a triggering event occurs ) (4) (i))- Publisher FASB- URI https: / / asc . ReferencesReference 1 fasb.org / 1943274 / 2147480097 / 470- 10- S99- 1BReference 39 :http: / / www- fasb . xbrl. org / 2003- us- gaap / role / disclosureRef ref / legacyRef - Topic 470- 942 - SubTopic 10- 210 - Name Accounting Standards Codification- Section S99- Paragraph 1B- 1 - Subparagraph (SX 210. 13- 9 - 02- 03 ( 10 a) (4) (iii) (A ))- Publisher FASB- URI https: / / asc.fasb.org / 1943274 / 2147480097- 2147478546 / 470- 942 - 10- 210 - S99- 1BReference- 1Reference 40- 2 :http: / / www.xbrl.org / 2003- 2009 / role / disclosureRef commonPracticeRef - Topic 470- 944 - SubTopic 10- 210 - Name Accounting Standards Codification- Section S99- Paragraph 1B- 1 - Subparagraph (SX 210. 13- 7 - 02- 03 (a) ( 10 4) (iii) (B ))- Publisher FASB- URI https: / / asc.fasb.org / 1943274 / 2147480097- 2147478777 / 470- 944 - 10- 210 - S99- 1BReference- 1Reference 41- 3 :http: / / www.xbrl.org / 2003 / role / disclosureRef- Topic 470- 946 - SubTopic 10- 210 - Name Accounting Standards Codification- Section S99- Paragraph 1B- 1 - Subparagraph (SX 210. 13- 6 - 02- 04 (7) (a ) (4) (iv ))- Publisher FASB- URI https: / / asc.fasb.org / 1943274 / 2147480097- 2147479170 / 470- 946 - 10- 210 - S99- 1BReference- 1Reference 42- 4 :http: / / www.xbrl.org / 2003 / role / disclosureRef- Topic 470- 210 - SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1B- 1 - Subparagraph (SX 210. 13- 5 - 02 ( 7 a) (5 ))- Publisher FASB- URI https: / / asc.fasb.org / 1943274 / 2147480097- 2147480566 / 470- 10- 210 - S99- 10 - 1BReference- 43- S99- 1 Details Name:us- gaap_PrepaidExpenseCurrentAndNoncurrent Namespace Prefix:us- gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instantX- DefinitionCash received for fees during the current period.This element excludes cash proceeds from license fees. ReferencesReference 1 :http: / / www- fasb . xbrl. org / 2003- us- gaap / role / disclosureRef- ref / legacyRef - Topic 260- 230 - SubTopic 10- Name Accounting Standards Codification- Section 45- Paragraph 60B- 25 - Subparagraph ( a- c )- Publisher FASB- URI https: / / asc.fasb.org / 1943274 / 2147482689- 2147482740 / 260- 230 - 10- 45- 60BReference- 44- 25 Details Name : http- us- gaap_ProceedsFromFeesReceived Namespace Prefix : // www. us- gaap_ Data Type: xbrl- xbrli .org / 2003 / role / disclosureRef :monetaryItemType Balance Type:debit Period Type:durationX - DefinitionAmount of purchase arrangement Topic 205- SubTopic 20- 1- Subparagraph (SX 210. 9- 04 (22))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147478524 / 942- 220- S99- 1 Details Name: us- gaap_NetIncomeLoss Namespace Prefix: us- gaap_ Data Type: xbrli: monetaryItemType Balance Type: credit us- gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:durationX- DefinitionPer- DefinitionThe aggregate amount share increase in exercise price of warrant.Excludes change due income or expense from ancillary business- related activities (that is to standard antidilution provision say,excluding major activities considered part of the normal operations of the business) . ReferencesReference 1:http: / / fasb www.xbrl .org / 2003- us- gaap / role / disclosureRef- ref / legacyRef - Topic 505- 220 - SubTopic 10- Name Accounting Standards Codification- Section 50- S99 - Paragraph 3- 2- Subparagraph (SX 210.5- 03 (7)) - Publisher FASB- URI https: / / asc.fasb.org / 1943274 / 2147481112- 2147483621 / 505- 220 - 10- 50- S99 - 3- 2 Details Name:us- gaap_WarrantExercisePriceIncrease gaap_NonoperatingIncomeExpense Namespace Prefix:us- gaap_ Data Type: xbrli dtr- types- perShareItemType- monetaryItemType Balance Type: na- credit Period Type:durationX- ReferencesNo definition available. Details Name:us- gaap_NonoperatingIncomeExpenseAbstract gaap_DebtInstrumentAxis = ntrb_MoneyChannelMember Namespace Prefix: us- gaap_ Data Type: na- xbrli:stringItemType Balance Type: Period Type:X- Details Name:us- gaap_RelatedPartyTransactionAxis = ntrb_MDMWorldwideMember Namespace Prefix:Data Type: na Balance Type:Period Period Type: durationX- DefinitionThe net result for the period of deducting operating expenses from operating revenues. ReferencesReference 1: http: / / www. xbrl. org / 2009- 2003 / role / commonPracticeRef- exampleRef - Topic 280- 220 - SubTopic 10- 40 - Name Accounting Standards Codification- Section 50- 55 - Paragraph 22- 4 - Publisher FASB-

URI https: / / asc. fasb. org / 1943274 / ~~2147482810~~ **2147476153** / ~~280~~ **220** - ~~10~~ **40** - ~~50~~ **55** - ~~22Reference~~ **4Reference** 2: http: / / www. xbrl. org / ~~2009~~ **2003** / role / ~~commonPracticeRef~~ **exampleRef** - Topic ~~280~~ **220** - SubTopic ~~10~~ **40** - Name Accounting Standards Codification- Section ~~50~~ **55** - Paragraph **14** ~~32- Subparagraph (f)~~ - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147482810~~ **2147476153** / ~~280~~ **220** - ~~10~~ **40** - ~~50~~ **55** - ~~32Reference~~ **14Reference** 3: http: / / www. xbrl. org / 2009 / role / commonPracticeRef- Topic 280- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph **22** ~~30- Subparagraph (b)~~ - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482810 / 280- 10- 50- ~~30Reference~~ **22Reference** 4: http: / / www. xbrl. org / 2009 / role / commonPracticeRef- Topic ~~270~~ **280** - SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph ~~1~~ **32** - Subparagraph ( ~~i~~ **f** )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147482964~~ **2147482810** / ~~270~~ **280** - 10- 50- ~~1Reference~~ **32Reference** 5: http: / / www. xbrl. org / 2009 / role / commonPracticeRef- Topic 280- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph ~~32~~ **30** - Subparagraph ( ~~ee~~ **b** )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482810 / 280- 10- 50- ~~32Reference~~ **30Reference** 6: http: / / ~~fasb~~ **www** . **xbrl.** org / **2009** ~~us- gaap~~ / role / **commonPracticeRef** ~~ref / otherTransitionRef~~ - Topic ~~280~~ **270** - SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph ~~32~~ **1** - Subparagraph ( ~~e~~ **i** )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147482810~~ **2147482964** / ~~280~~ **270** - 10- 50- ~~32Reference~~ **1Reference** 7: http: / / www. xbrl. org / ~~2003~~ **2009** / role / ~~exampleRef~~ **commonPracticeRef** - Topic 280- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph **32- Subparagraph (ee** )- Publisher FASB- URI https:/ / asc.fasb.org / 1943274 / ~~2147478777~~ **2147482810** / ~~944~~ **280** - ~~210~~ - **10** - ~~S99~~ **50** - ~~1Reference~~ **32Reference** ~~3~~ **8** :http:/ / **fasb** ~~www.xbrl.~~ org / ~~2003~~ **us- gaap** / role / ~~disclosureRef~~ **ref / otherTransitionRef** - Topic ~~946~~ **280** - SubTopic ~~210~~ - **10** - Name Accounting Standards Codification- Section ~~S99~~ **50** - Paragraph ~~1~~ **32** - Subparagraph ( **c** ~~SX 210.6- 04 (7) (a)~~ )- Publisher FASB- URI https:/ / asc.fasb.org / 1943274 / ~~2147479170~~ **2147482810** / ~~946~~ **280** - ~~210~~ - **10** - ~~S99~~ **50** - ~~1Reference~~ **32Reference** ~~4~~ **9** :http:/ / www.xbrl.org / 2003 / role / ~~disclosureRef~~ **exampleRef** - Topic ~~210~~ **280** - SubTopic 10- Name Accounting Standards Codification- **Section 50- Paragraph** 31- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482810 / 280- 10- 50- 31 Details Name: us-gaap_OperatingIncomeLoss Namespace Prefix: us- gaap_ Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: durationX- DefinitionAmount of..... xbrli: stringItemType Balance Type: na Period Type: durationX- DefinitionAmount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write- down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. ReferencesReference 1: http: / / www. xbrl. org / 2003 / role / exampleRef- Topic ~~280~~ **220** - SubTopic ~~10~~ **40** - Name Accounting Standards Codification- Section 55- Paragraph ~~48~~ **18** - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147482785~~ **2147476153** / ~~280~~ **220** - ~~10~~ **40** - 55- ~~48Reference~~ **18Reference** 2: http: / / www. xbrl. org / 2003 / role / ~~disclosureRef~~ **exampleRef** - Topic ~~985~~ **220** - SubTopic ~~20~~ **40** - Name Accounting Standards Codification- Section ~~50~~ **55** - Paragraph ~~2~~ **14** - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147481283~~ **2147476153** / ~~985- 20~~ **220** - ~~50~~ **40** - **55-** ~~2Reference~~ **14Reference** 3: http: / / www. xbrl. org / 2003 / role / ~~disclosureRef~~ **exampleRef** - Topic ~~730~~ **280** - SubTopic 10- Name Accounting Standards Codification- Section **55- Paragraph 48- Publisher FASB- URI https:/** / asc.fasb.org / 1943274 / ~~2147482916~~ **2147482785** / ~~730~~ **280** - 10- ~~50~~ **55** - **48Reference 4** ~~1" },"r457"~~: ~~{" role":"~~ http:/ / www.xbrl.org / 2003 / role / disclosureRef - ~~","~~ Topic **985- SubTopic 20-** ~~":"740","~~ Name ~~":"~~ Accounting Standards Codification ~~","~~ **- Section 50- Paragraph 2-** Publisher ~~":"~~ FASB **-** ~~","~~ URI ~~":"~~ https:/ / asc.fasb.org / ~~740~~ **1943274** / ~~tableOfContent" },"r458"~~ **2147481283 / 985- 20- 50- 2Reference 5** : ~~{" role":"~~ http:/ / www.xbrl.org / 2003 / role / disclosureRef **- Topic 730- SubTopic 10- Name Accounting Standards Codification- Section** 50- Paragraph 1- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482916 / 730- 10- 50- 1Reference ~~4~~ **6** : http: / / www. xbrl. org / 2009 / role / commonPracticeRef- Topic 912- SubTopic 730- Name Accounting Standards Codification- Section 25- Paragraph 1- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147479532 / 912- 730- 25- 1 Details Name: us- gaap_ResearchAndDevelopmentExpense Namespace Prefix: us- gaap_ Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: durationX- DefinitionAmount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). ReferencesReference 1: http: / / www. xbrl. org / 2003 / role / exampleRef- Topic ~~280~~ **815** - SubTopic 10- Name Accounting Standards Codification- Section ~~55~~ **50** - Paragraph ~~48~~ **4A- Subparagraph (c)** - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147482785~~ **2147480434** / ~~280~~ **815** - 10- ~~55~~ **50** - ~~48Reference~~ **4AReference** 2: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic ~~280~~ **942** - SubTopic ~~10~~ **235** - Name Accounting Standards Codification- Section ~~50~~ **S50** - Paragraph **1** ~~41- Subparagraph (a)~~ - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147482810~~ **2147478671** / ~~280~~ **942** - ~~10~~ **235** - ~~50~~ **S50** - ~~41Reference~~ - **1Reference** 3: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic ~~270~~ **942** - SubTopic ~~10~~ **235** - Name Accounting Standards Codification- Section ~~50~~ **S99** - Paragraph 1- Subparagraph ( ~~i~~ **SX 210. 9- 05 (b) (2)** )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147482964~~ **2147477314** / ~~270~~ **942** - ~~10~~ **235** - ~~50~~ **S99** - 1Reference 4: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 280- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph ~~32~~ **41** - Subparagraph ( ~~ee~~ **a** )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482810 / 280- 10- 50- ~~32Reference~~ **41Reference** 5: http: / / ~~fasb~~ **www** . **xbrl.** org / **2003** ~~us- gaap~~ / role / **disclosureRef** ~~ref / otherTransitionRef~~ - Topic 280- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph **42** ~~32- Subparagraph (b)~~ - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482810 / 280- 10- 50- ~~32Reference~~ **42Reference** 6: http: / / ~~fasb~~ **www** . **xbrl.** org / **2003** ~~us- gaap~~ / role / **disclosureRef** ~~ref / otherTransitionRef~~ - Topic ~~280~~ **235** - SubTopic 10- Name Accounting Standards Codification- Section ~~50~~ **S50** - Paragraph **1** ~~32- Subparagraph (a)~~ - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147482810~~ **2147480738** / ~~280~~ **235** - 10- ~~50~~ **S50** - ~~32Reference~~ **1Reference** 7: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 235- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210. 4- 08 (g) (1) ( ~~ii~~ **i** ))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480678 / 235- 10- S99- 1Reference 8: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic ~~323~~ **825** - SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph ~~3~~ **28** - Subparagraph ( ~~e~~ **f** )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147481687~~ **2147482907** / ~~323~~ **825** - 10- 50- ~~3Reference~~ **28Reference** 9: http: / / www. xbrl. org / 2003 / role / ~~disclosureRef~~ **exampleRef** - Topic ~~825~~ **944** - SubTopic ~~10~~ **605** - Name Accounting Standards Codification- Section ~~50~~ **55** - Paragraph **14** ~~28- Subparagraph (f)~~ - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147482907~~ **2147477548** / ~~825~~ **944** - ~~10~~ **605** - ~~50~~ **55** - ~~28Reference~~ **14Reference** 10: http: / / www. xbrl. org / 2003 / role / ~~disclosureRef~~ **exampleRef** - Topic ~~470~~ **944** - SubTopic ~~10~~ **605** - Name Accounting Standards Codification- Section ~~S99~~ **55** - Paragraph **11** ~~1A- Subparagraph (SX 210. 13- 01 (a) (4) (i))~~ - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147480097~~ **2147477548** / ~~470~~ **944** - ~~10~~ **605** - ~~S99~~ **55** - ~~1AReference~~ **11Reference** 11: http: / / www. xbrl. org / ~~2009~~ **2003** / role / ~~commonPracticeRef~~ **exampleRef** - Topic ~~470~~ **280** - SubTopic 10- Name Accounting Standards Codification- Section ~~S99~~ **55** - Paragraph **48** ~~1A- Subparagraph (SX 210. 13- 01 (a) (4) (ii))~~ - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147480097~~ **2147482785** / ~~470~~ **280** - 10- ~~S99~~ **55** - ~~1AReference~~ **48Reference** 12: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic ~~470~~ **270** - SubTopic 10- Name Accounting Standards Codification- Section ~~S99~~ **50** - Paragraph ~~1A~~ **1** - Subparagraph ( **i** ~~SX 210. 13- 01 (a) (4) (iii) (A)~~ )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147480097~~ **2147482964** / ~~470~~ **270** - 10- ~~S99~~ **50** - ~~1AReference~~ - **1Reference** 13: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic ~~470~~ **280** - SubTopic 10- Name Accounting Standards Codification- Section ~~S99~~ **50** - Paragraph ~~1A~~ **32** - Subparagraph ( **ee** ~~SX 210. 13- 01 (a) (4) (iv)~~ )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147480097~~ **2147482810** / ~~470~~ **280** - 10- ~~S99~~ **50** - ~~1AReference~~ **32Reference** 14: http: / / ~~www~~ **fasb** . ~~xbrl.~~ org / ~~2003~~ **us- gaap** / role / ~~disclosureRef~~ **ref / otherTransitionRef** - Topic ~~470~~ **280** - SubTopic 10- Name Accounting Standards Codification- Section ~~S99~~ **50** - Paragraph ~~1A~~ **32** - Subparagraph ( **b** ~~SX 210. 13- 01 (a) (5)~~ )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147480097~~ **2147482810** / ~~470~~ **280** - 10- ~~S99~~ **50** - ~~1AReference~~ **32Reference** 15: http: / / ~~www~~ **fasb** . ~~xbrl.~~ org / ~~2003~~ **us- gaap** / role / ~~disclosureRef~~ **ref / otherTransitionRef** - Topic ~~470~~ **280** - SubTopic 10- Name Accounting Standards Codification- Section ~~S99~~ **50** - Paragraph ~~1B~~ **32** - Subparagraph ( ~~SX 210. 13- 02 (~~a ~~) (4) (i)~~ )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147480097~~ **2147482810** / ~~470~~ **280** - 10- ~~S99~~ **50** - ~~1BReference~~ **32Reference** 16: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic ~~470~~ **235** - SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph ~~1B~~ **1** - Subparagraph (SX 210. ~~13- 02 (a) (~~4 ~~)~~ **- 08** ( **g) (1) (** ~~iii~~ - **ii** ) ~~(A~~ ))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147480097~~ **2147480678** / ~~470~~ **235** - 10- S99- ~~1BReference~~ - **1Reference** 17: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic ~~470~~ **323** - SubTopic 10- Name Accounting Standards Codification- Section ~~S99~~ **50** - Paragraph ~~1B~~ **3** - Subparagraph ( **c** ~~SX 210. 13- 02 (a) (4) (iii) (B)~~ )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147480097~~ **2147481687** / ~~470~~ **323** - 10- ~~S99~~ **50** - ~~1BReference~~ **3Reference** 18: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 470- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph ~~1B~~ **1A** - Subparagraph (SX 210. 13- ~~02~~ **01** (a) (4) ( ~~iv~~ **i** ))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- ~~1BReference~~ **1AReference** 19: http: / / www. xbrl. org / ~~2003~~ **2009** / role / ~~disclosureRef~~ **commonPracticeRef** - Topic 470- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph ~~1B~~ **1A** - Subparagraph (SX 210. 13- ~~02~~ **01** (a) ( ~~5~~ **4) (ii** ))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- ~~1BReference~~ **1AReference** 20: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic ~~280~~ **470** - SubTopic 10- Name Accounting Standards Codification- Section ~~50~~ **S99** - Paragraph ~~30~~ **1A** - Subparagraph ( **SX 210. 13- 01 (** a **) (4) (iii) (A)** )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147482810~~ **2147480097** / ~~280~~ **470** - 10- ~~50~~ **S99** - ~~30Reference~~ **1AReference** 21: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic ~~280~~ **470** - SubTopic 10- Name Accounting Standards Codification- Section ~~50~~ **S99** - Paragraph ~~42~~ **1A- Subparagraph (SX 210. 13- 01 (a) (4) (iv))** - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147482810~~ **2147480097** / ~~280~~ **470** - 10-

50 S99 - 42Reference 1AReference 22: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 280 470 - SubTopic 10- Name Accounting Standards Codification- Section 50 S99 - Paragraph 22 1A - Subparagraph ( b SX 210. 13- 01 (a) (5) )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482810 2147480097 / 280 470 - 10- 50 S99 - 22Reference 1AReference 23: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 280 470 - SubTopic 10- Name Accounting Standards Codification- Section 50 S99 - Paragraph 40 1B- Subparagraph (SX 210. 13- 02 (a) (4) (i)) - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482810 2147480097 / 280 470 - 10- 50 S99 - 40Reference 1BReference 24: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 280 470 - SubTopic 10- Name Accounting Standards Codification- Section 50 S99 - Paragraph 22 1B - Subparagraph ( SX 210. 13- 02 ( a ) (4) (iii) (A) )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482810 2147480097 / 280 470 - 10- 50 S99 - 22Reference 1BReference 25: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 942 470 - SubTopic 235 10 - Name Accounting Standards Codification- Section S99- Paragraph 1 1B - Subparagraph (SX 210. 9 13 - 05 02 ( b a ) ( 2 4) (iii) (B ))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147477314 2147480097 / 942 470 - 235 10 - S99- 1Reference 1BReference 26 FASB credit Period Type:instantX - URI https:/ / asc DefinitionAmount,after effects of reinsurance,of expense (reversal of expense) for claims incurred and costs incurred in the claim settlement process . ReferencesReference 1 fasb.org / 1943274 / 2147480097 / 470- 10- S99- 1BReference 28 :http:/ / www.xbrl.org / 2003 / role / disclosureRef exampleRef - Topic 280 944 - SubTopic 10 40 - Name Accounting Standards Codification- Section 50 55 - Paragraph 7 30- Subparagraph (a) - Publisher FASB- URI https:/ / asc.fasb.org / 1943274 / 2147482810 2147480046 / 280 944 - 10 40 - 50 55 - 30Reference 7Reference 29 2 :http:/ / www.xbrl.org / 2003 2009 / role / disclosureRef commonPracticeRef - Topic 280 944 - SubTopic 10 40 - Name Accounting Standards Codification- Section 50- Paragraph 22 3 - Subparagraph (b)- Publisher FASB- URI https:/ / asc.fasb.org / 1943274 / 2147482810 - 2147480081 / 280 944 - 10 40 - 50- 22Reference 30 3 Details Name : http us- gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1 Namespace Prefix : us / / www.xbrl.org / 2003 / role / disclosureRef - Topic 280- SubTopic 10- Name Accounting Standards gaap_ Data Type:xbrli:monetaryItemType Balance Type: : http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 220- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 2- Subparagraph (SX 210. 5- 03 (1))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147483621 / 220- 10- S99- 2 Details Name: us- gaap_Revenues Namespace Prefix: us- gaap_ Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: durationX- DefinitionThe aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non- sales personnel, rent, utilities, communication, etc. ReferencesReference 1: http: / / fasb www . xbrl. org / 2003 us- gaap / role / exampleRef ref / legacyRef - Topic 220- SubTopic 10 40 - Name Accounting Standards Codification- Section credit Period Type : / / asc instantX- DefinitionAmount,after effects of reinsurance,of expense (reversal of expense) for claims incurred and costs incurred in the claim settlement process . ReferencesReference 1 fasb.org / 1943274 / 2147476153 / 220- 40- 55- 18Reference 2 :http:/ / www.xbrl.org / 2003 / role / exampleRef- Topic 220 944 - SubTopic 40- Name Accounting Standards Codification- Section 55- Paragraph 11 7 - Publisher FASB- URI https:/ / asc.fasb.org / 1943274 / 2147476153 2147480046 / 220 944 - 40- 55- 11Reference 7Reference 3 2 :http:/ / www.xbrl.org / 2003 2009 / role / exampleRef commonPracticeRef - Topic 220 944 - SubTopic 40- Name Accounting Standards Codification- Section 55 50 - Paragraph 4 3- Subparagraph (b) - Publisher FASB- URI https:/ / asc.fasb.org / 1943274 / 2147476153 2147480081 / 220 944 - 40- 55 50 - 4Reference 4 3 Details Name : http us- gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1 Namespace Prefix : us / / www.xbrl.org / 2003 / role / exampleRef - gaap_ Data Type Topic 220- SubTopic 40- Name Accounting Standards Codification- Section 55- Paragraph 14- Publisher FASB- URI https : xbrli:monetaryItemType Balance Type: S99- Paragraph 2- Subparagraph (SX 210. 5- 03 (4))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147483621 / 220- 10- S99- 2 2Reference 6: http: / / www. xbrl. org / 2009 / role / commonPracticeRef- Topic 220- SubTopic 40- Name Accounting Standards Codification- Section 50- Paragraph 6- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147476148 / 220- 40- 50- 6 Details Name: us- gaap_SellingGeneralAndAdministrativeExpense Namespace Prefix: us- gaap_ Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: durationX- DefinitionNumber of..... xbrli: stringItemType Balance Type: na Period Type: durationX- DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. ReferencesReference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 260- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 1- Subparagraph (a)- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482662 / 260- 10- 50- 1Reference 2: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 260- SubTopic 10- Name Accounting Standards Codification- Section 45- Paragraph 16- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482689 / 260- 10- 45- 16 Details Name: us- gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us- gaap_ Data Type: xbrli: sharesItemType Balance Type: na Period Type: durationX- DefinitionNumber of [ basic ] shares or units,after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding,determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. ReferencesReference 1 :http:/ / fasb www . xbrl. org / 2003 us- gaap / role / disclosureRef ref / legacyRef - Topic 505 260 - SubTopic 10- Name Accounting Standards Codification- Section S99 50 - Paragraph 4 1 - Subparagraph ( a SAB Topic 4.C )- Publisher FASB- URI https:/ / asc.fasb.org / 1943274 / 2147480008 2147482662 / 260- 10- 505 - 50 - 1Reference 2 10- S99- 4 Details Name:us-gaap_StockholdersEquityReverseStockSplit Namespace Prefix:us- gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:durationX- DefinitionPer share increase in exercise price of warrant.Excludes change due to standard antidilution provision. ReferencesReference 1 :http:/ / www.xbrl.org / 2003 / role / disclosureRef- Topic 505 260 - SubTopic 10- Name Accounting Standards Codification- Section 50 45 - Paragraph 3 10 - Publisher FASB- URI https:/ / asc.fasb.org / 1943274 / 2147481112 2147482689 / 505 260 - 10- 50 45 - 3 10 Details Name:us- gaap_WarrantExerciseIncrease gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix:us- gaap_ Data Type: xbrli dtr- types : perShareItemType sharesItemType Balance Type:na Period Type:durationX- ReferencesNo definition available. Details Name:us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract gaap_DebtInstrumentAxis = ntrb_MoneyChannelMember Namespace Prefix: us- gaap_ Data Type: xbrli:stringItemType Balance Type: na Balance Type:-Period Type: X- Details Name:us- gaap_RelatedPartyTransactionAxis = ntrb_MDMWorldwideMember Namespace Prefix durationConsolidated Statements of Stockholders' Equity- USD ($) Common Stock Additional Paid In Capital Accumulated Other Comprehensive Income (Loss) Accumulated Deficit Treasury Stock TotalBalance at Jan. 31, 2022 $ 9, 155 $ 29, 966, 132 $ (304) $ (18, 011, 231) $ (104, 467) $ 11, 859, 285Balance (in Shares) at Jan. 31, 2022 9, 154, 846 Exercise of warrants $ 56 296, 819 296, 875Exercise of warrants (in Shares) 55, 417 Common stock returned in settlement $ (1, 400) 1, 400 Common stock returned in settlement (in Shares) (1, 400, 000) Treasury stock issued for services $ 32 3, 746 109, 377 113, 155Treasury stock issued for services (in Shares) 33, 471 Treasury stock and warrants issued for termination agreement $ 25 92, 545 81, 455 174, 025Treasury stock and warrants issued for termination agreement (in Shares) 25, 000 Treasury stock repurchased $ (35) (119, 006) (119, 006) Treasury stock repurchased (in Shares) (35, 584) Options issued for services 732, 130 732, 130Net loss (4, 483, 474) (4, 483, 474) Balance at Jan. 31, 2023 $ 7, 833 $ 31, 092, 807 $ (304) $ (22, 494, 705) $ (32, 641) $ 8, 572, 990Balance (in Shares) at Jan. 31, 2023 7, 833, 150 Warrants issued for services $ 0 242, 840 242, 840Options issued for services 499, 856 499, 856Issuance of common stock for note payable and interest $ 1, 027 2, 606, 836 2, 607, 863Issuance of common stock for note payable and interest (in Shares) 1, 026, 720 Purchase of treasury stock Net loss (5, 485, 314) (5, 485, 314) Balance at Jan. 31, 2024 $ 8, 860 $ 34, 442, 339 $ (304) $ (27, 980, 019) $ (32, 641) $ 6, 438, 235Balance (in Shares) at Jan. 31, 2024 8, 859, 870 Proceeds from sale X- DefinitionCommon stock returned in settlement. ReferencesNo definition available. Details Name: ntrb_CommonStockReturnedInSettlementinShares Namespace Prefix: ntrb_ Data Type: xbrli: sharesItemType Balance Type: na Period Type: durationX- DefinitionIssuance of common stock and warrants $ 2, 100 8, 397, 900 8, 400, 000Proceeds from sale of common stock and warrants (in Shares) 2, 100, 000 Issuance of common stock and warrants for note payable $ 76 672, 882 672, 958Issuance of common stock and interest warrants for note payable (in shares Shares ) 76, 230 Treasury - ReferencesNo definition available. Details Name: ntrb_StockIssuedDuringPeriodShareNotePayableAndInterestinShares Namespace Prefix: ntrb_ Data Type: xbrli: sharesItemType Balance Type: na Period Type: durationX- DefinitionTreasury stock and warrants issued for termination agreement shares. ReferencesNo definition available. Details Name: ntrb_StockIssuedDuringPeriodShareTreasuryStockAndWarrantsIssuedForTerminationAgreement Namespace Prefix: ntrb_ Data Type: xbrli: sharesItemType Balance Type: na Period Type: durationX- DefinitionTreasury stock issued for services $ 10 100, 699 32, 641 133, 350Treasury - ReferencesNo definition available. Details Name: ntrb_StockIssuedDuringPeriodSharesTreasuryStockIssuedForServices Namespace Prefix: ntrb_ Data Type: xbrli: sharesItemType Balance Type: na Period Type: durationX- DefinitionIssuance of common stock for note payable and interest. ReferencesNo definition available. Details Name: ntrb_StockIssuedDuringPeriodValueNotePayableAndInterest Namespace Prefix: ntrb_ Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: durationX- DefinitionCommon stock returned in settlement. ReferencesNo definition available. Details Name: ntrb_StockIssuedDuringPeriodValueReturnedInSettlement Namespace Prefix: ntrb_ Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: durationX- DefinitionTreasury stock and warrants issued for termination agreement services (in Shares) 10, 000 Options issued for services 1, 408, 935 1, 408,

935Purchase of treasury stock $ (32) (148, 547) (148, 547) Purchase of treasury stock (in Shares) (32, 400) Exercise of warrants $ 61 6, 530 6, 591Exercise of warrants (in Shares) 61, 110 Net loss (10, 482, 617) (10, 482, 617) Balance at Jan. 31, 2025 $ 11, 075 $ 45, 029, 317 $ (304) $ (38, 462, 636) $ (148, 547) $ 6, 428, 905Balance (in Shares) at Jan. 31, 2025 11, 074, 810 X- DefinitionExercise of warrants . ReferencesNo definition available. Details Name: ntrb_StockIssuedDuringPeriodValueTreasuryStockAndWarrantsIssuedForTerminationAgreement ntrb_ExerciseOfWarrant Namespace Prefix: ntrb_ Data Type: xbrli: monetaryItemType sharesItemType Balance Type: credit na Period Type: durationX- DefinitionExercise of warrants DefinitionTreasury stock issued for services . ReferencesNo definition available. Details Name: ntrb_StockIssuedDuringPeriodValueTreasuryStockIssuedForServices ntrb_ExerciseOfWarrants Namespace Prefix: ntrb_ Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: durationX- DefinitionTreasury DefinitionPurchase of treasury stock repurchased . ReferencesNo definition available. Details Name: ntrb_StockIssuedDuringPeriodValueTreasuryStockRepurchased ntrb_PurchaseOfTreasuryStocks Namespace Prefix: ntrb_ Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: durationX- ReferencesNo definition available. Details Name: ntrb_StockRepurchasedDuringPeriodSharesTreasuryStockRepurchased Namespace Prefix: ntrb_ Data Type: xbrli: sharesItemType Balance Type: na Period Type: durationX- DefinitionAdjustment ---- DefinitionAmount of increase to additional paid- in capital (APIC) for recognition of cost noncash service expenses paid for by granting of warrants option under share- based payment arrangement . ReferencesReference 1: http: / / fasb www . xbrl. org / 2009 us- gaap / role / ref / legacyRef commonPracticeRef- Topic 505- SubTopic 10 - Name Accounting Standards Codification- Section 45 50 - Paragraph 2 28- Subparagraph (b)- SubTopic 10- Topic 230 - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482740 2147481112 / 230 505 - 10- 45 50 - 28 2Reference 2: http: / / www. xbrl. org / 2009 / role / commonPracticeRef- Topic 718- SubTopic 10- Name Accounting Standards Codification- Section 35- Paragraph 2- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480483 / 718- 10- 35- 2 Details Name: us-gaap_AdjustmentOfWarrantsGrantedForServices gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition Namespace Prefix: us- gaap_ Data Type: xbrli: monetaryItemType Balance Type: debit credit Period Type: durationX- DefinitionAmount of decrease increase in additional paid in capital (APIC) resulting from direct costs associated the issuance of warrants. Includes allocation of proceeds of debt securities issued with issuing detachable stock purchase warrants . Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration . ReferencesReference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef- Name Accounting Standards Codification- Section 50- Paragraph 2- SubTopic 10- Topic 505- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147481112 / 505- 10- 50- 2Reference 2: http: / / fasb. org / us- gaap / role / ref / legacyRef- Topic 505- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210. 3- 04)- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480008 / 505- 10- S99- 1 1Reference 3: http: / / fasb. org / us- gaap / role / ref / legacyRef- Name Accounting Standards Codification- Topic 470- SubTopic 20- Section 25- Paragraph 2- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147481284 / 470- 20- 25- 2 Details Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts ---------- gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued Namespace Prefix: us- gaap_ Data Type: xbrli: monetaryItemType Balance Type: debit credit Period Type: durationX- DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. ReferencesReference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef exampleRef - Topic 250 946 - SubTopic 10 830 - Name Accounting Standards Codification- Section 50 55 - Paragraph 6 10 - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147483443 2147479168 / 250 946 - 10 830 - 50 55 - 6Reference 10Reference 2: http: / / www. xbrl. org / 2003 / role / disclosureRef exampleRef - Topic 250 220 - SubTopic 10 40 - Name Accounting Standards Codification- Section 50 55 - Paragraph 9 4 - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147483443 2147476153 / 250 220 - 10 40 - 50 55 - 9Reference 4Reference 3: http: / / www. xbrl. org / 2003 / role / disclosureRef exampleRef - Topic 805 220 - SubTopic 60 40 - Name Accounting Standards Codification- Section 65 55 - Paragraph 21 1- Subparagraph (g) - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147476176 2147476153 / 805 220 - 60 40 - 65 55 - 1Reference 21Reference 4: http: / / www. xbrl. org / 2003 / role / disclosureRef exampleRef - Topic 740 220 - SubTopic 323 40 - Name Accounting Standards Codification- Section 65 55 - Paragraph 14 2- Subparagraph (g) (3) - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147478666 2147476153 / 220- 740 - 40 - 323 55 - 65- 2Reference 14Reference 5: http: / / fasb www . xbrl. org / 2003 us- gaap / role / disclosureRef ref / legacyRef - Topic 220 235 - SubTopic 10- Name Accounting Standards Codification- Section S99 S50 - Paragraph 1 2- Subparagraph (SX 210. 5- 03 (20)) - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147483621 2147480738 / 220 235 - 10- S99 S50 - 2Reference 1Reference 6: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 235- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210. 4- 08 (g) (1) ( ii i ))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480678 / 235- 10- S99- 1Reference 7: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 323 235 - SubTopic 10- Name Accounting Standards Codification- Section 50 S99 - Paragraph 3 1 - Subparagraph ( e SX 210. 4- 08 (k) (2) )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147481687 2147480678 / 323 235 - 10- 50 S99 - 3Reference 1Reference 8: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 825- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 28- Subparagraph (f)- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482907 / 825- 10- 50- 28Reference 9: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 220 250 - SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 6 4 - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482765 2147483443 / 220 250 - 10- 50- 6Reference 4Reference 10: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 250 480 - SubTopic 10- Name Accounting Standards Codification- Section 50 S50 - Paragraph 3- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147483443 2147479857 / 250 480 - 10- 50 S50 - 3Reference 11: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 250 480 - SubTopic 10- Name Accounting Standards Codification- Section 50 S45 - Paragraph 3 1- Subparagraph (b) (2) - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147483443 2147479887 / 250 480 - 10- 50 S45 - 1Reference 3Reference 12: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 815 480 - SubTopic 40 10 - Name Accounting Standards Codification- Section 65 S99 - Paragraph 1 3A - Subparagraph ( f 24) (d ) )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480175 2147480244 / 815- 40 480 - 65 10 - S99- 1Reference 3AReference 13: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 250 105 - SubTopic 10- Name Accounting Standards Codification- Section 50 65 - Paragraph 8 9- Subparagraph (e) - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147483443 - 2147479343 / 250- 10 105 - 50 10 - 65- 8Reference 9Reference 14: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 250 718 - SubTopic 10- Name Accounting Standards Codification- Section 50 65 - Paragraph 11 17 - Subparagraph ( a d) (1 )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147483443 -- 2147480336 / 250 718 - 10- 50 65 - 11Reference 17Reference 15: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 250- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 6 11- Subparagraph (b) - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147483443 / 250- 10- 50- 11Reference 6Reference 16: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 250- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 4 9 - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147483443 / 250- 10- 50- 4Reference 9Reference 17: http: / / www. xbrl. org / 2003 / role / exampleRef disclosureRef - Topic 946 805 - SubTopic 830 60 - Name Accounting Standards Codification- Section 55 65 - Paragraph 10 1- Subparagraph (g) - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147479168 - 2147476176 / 946 805 - 830 60 - 55 65 - 10Reference - 1Reference 18: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 946 740 - SubTopic 220 323 - Name Accounting Standards Codification- Section 45 65 - Paragraph 7 2- Subparagraph (g) (3) - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147479105 2147478666 / 946 740 - 323- 65- 2Reference 19: http: / / fasb. org / us- gaap / role / ref / legacyRef- Topic 220- 45- 7Reference 19: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 944- SubTopic 220 10 - Name Accounting Standards Codification- Section S99- Paragraph 1 2 - Subparagraph (SX 210. 7 5 - 04 03 ( 18 20 ))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147477250 2147483621 / 944- 220- 10- S99- 1Reference 2Reference 20: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 946 235 - SubTopic 220 10 - Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210. 6 4 - 07 08 ( 9 g) (1) (ii ))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147479134 2147480678 / 946 235 - 220 10 - S99- 1Reference 21: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 946 323 - SubTopic 220 10 - Name Accounting Standards Codification- Section S99 50 - Paragraph 3- Subparagraph ( c SX 210. 6- 09 (1) (d) )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147479134 2147481687 / 946 323 - 220 10 - S99 50 - 3Reference 22: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 470 220 - SubTopic 10- Name Accounting Standards Codification- Section S99 50 - Paragraph 6 1A- Subparagraph (SX 210. 13- 01 (a) (4) (i)) - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480097 2147482765 / 470 220 - 10- S99 50 - 1AReference 6Reference 23: http: / / www. xbrl. org / 2009 2003 / role / commonPracticeRef disclosureRef - Topic 470 250 - SubTopic 10- Name Accounting Standards Codification- Section S99 50 - Paragraph 3 1A- Subparagraph (SX 210. 13- 01 (a) (4) (ii)) - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480097 2147483443 / 470 250 - 10- S99 50 - 1AReference 3Reference 24: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 470 250 - SubTopic 10- Name Accounting Standards Codification- Section S99 50 - Paragraph 1A 1 - Subparagraph ( b SX 210. 13- 01 (a ) ( 2 4) (iii) (A) )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480097 2147483443 / 470 250 - 10- S99 50 - 1AReference - 1Reference 25: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 470 815 - SubTopic 10 40 - Name Accounting Standards Codification- Section S99 65 - Paragraph 1A 1 - Subparagraph ( f SX 210. 13- 01 (a) (4) (iv) )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480097 2147480175 / 815- 470 - 40 - 10 65 - S99- 1AReference - 1Reference 26: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 470 250 - SubTopic 10- Name Accounting Standards Codification- Section S99 50 -

Paragraph 8 ~~1A- Subparagraph (SX 210- 13- 01 (a) (5))~~ - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147480097~~ 2147483443 / ~~470~~ 250 - 10- ~~S99~~ 50 - ~~1AReference~~ 8Reference 27: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic ~~470~~ 250 - SubTopic 10- Name Accounting Standards Codification- Section ~~S99~~ 50 - Paragraph ~~1B~~ 11 - Subparagraph ( ~~SX 210- 13- 02 (~~a ~~) (4) (i)~~ )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147480097~~ 2147483443 / ~~470~~ 250 - 10- ~~S99~~ 50 - ~~1BReference~~ 11Reference 28: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic ~~470~~ 250 - SubTopic 10- Name Accounting Standards Codification- Section ~~S99~~ 50 - Paragraph ~~1B~~ 11 - Subparagraph ( b ~~SX 210- 13- 02 (a) (4) (iii) (A)~~ )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147480097~~ 2147483443 / ~~470~~ 250 - 10- ~~S99~~ 50 - ~~1BReference~~ 11Reference 29: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic ~~470~~ 946 - SubTopic ~~10~~ 220 - Name Accounting Standards Codification- Section ~~S99~~ 45 - Paragraph 7 ~~1B- Subparagraph (SX 210- 13- 02 (a) (4) (iii) (B))~~ - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147480097~~ 2147479105 / ~~470~~ 946 - ~~10~~ 220 - ~~S99~~ 45 - ~~1BReference~~ 7Reference 30: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic ~~470~~ 944 - SubTopic ~~10~~ 220 - Name Accounting Standards Codification- Section S99- Paragraph ~~1B~~ 1 - Subparagraph (SX 210. ~~13~~ 7 - ~~02~~ 04 ( 18 ~~a) (4) (iv~~ )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147480097~~ 2147477250 / ~~470~~ 944 - ~~10~~ 220 - S99- ~~1BReference~~ 1Reference 31: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic ~~470~~ 946 - SubTopic ~~10~~ 220 - Name Accounting Standards Codification- Section S99- Paragraph ~~1B~~ 1 - Subparagraph (SX 210. ~~13~~ 6 - ~~02~~ 07 ( 9 ~~a) (5~~ ))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147480097~~ 2147479134 / ~~470~~ 946 - ~~10~~ 220 - S99- ~~1BReference~~ 1Reference 32: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic ~~260~~ 946 - SubTopic ~~10~~ 220 - Name Accounting Standards Codification- Section ~~45~~ S99 - Paragraph ~~60B~~ 3 - Subparagraph ( ~~a~~ SX 210. 6- 09 (1) (d) )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147482689~~ 2147479134 / ~~260~~ 946 - ~~10~~ 220 - ~~45~~ S99 - ~~60BReference~~ 3Reference 33: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic ~~205~~ 470 - SubTopic ~~20~~ 10 - Name Accounting Standards Codification- Section ~~50~~ S99 - Paragraph ~~7~~ 1A- Subparagraph (SX 210. 13- 01 (a) (4) (i)) - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147483499~~ 2147480097 / ~~205~~ 470 - ~~20~~ 10 - ~~50~~ S99 - ~~7Reference~~ 1AReference 34: http: / / ~~fasb~~ www . xbrl. org / 2009 ~~us- gaap~~ / role / commonPracticeRef ~~ref / legacyRef~~ - Topic ~~230~~ 470 - SubTopic 10- Name Accounting Standards Codification- Section ~~45~~ S99 - Paragraph ~~28~~ 1A- Subparagraph (SX 210. 13- 01 (a) (4) (ii)) - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147482740~~ 2147480097 / ~~230~~ 470 - 10- ~~45~~ S99 - ~~28Reference~~ 1AReference 35: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic ~~220~~ 470 - SubTopic 10- Name Accounting Standards Codification- Section ~~45~~ S99 - Paragraph 1A- Subparagraph ( SX 210. 13- 01 ( a ) (4) (iii) (A) )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147482790~~ 2147480097 / ~~220~~ 470 - 10- ~~45~~ S99 - 1AReference 36: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic ~~220~~ 470 - SubTopic 10- Name Accounting Standards Codification- Section ~~45~~ ," S99- Paragraph 1A- Subparagraph (SX 210.13- 01 (a) (4) (iv))- Publisher FASB- URI ~~":"~~ https: / / asc.fasb.org / 1943274 / 2147480097 / 470- 10- S99- 1AReference 37 ~~1A" },"~~ r355" : ~~{"~~ role":" ~~http:~~ / / www.xbrl.org / 2003 / role / disclosureRef - ~~",~~" Topic ~~":"~~ 470 - ~~",~~" SubTopic ~~":"~~ 10 - ~~",~~" Name ~~":~~ Accounting Standards Codification - ~~",~~" Section ~~":"~~ S99 - ~~",~~" Paragraph ~~":~~ 1A - ~~",~~" Subparagraph ~~":"~~ (SX 210.13- 01 (a) (5)) - ~~",~~" Publisher ~~":~~ FASB - ~~",~~" URI ~~":~~ https: / / asc.fasb.org / 1943274 / 2147480097 / 470- 10- S99- ~~1A" }~~ **1AReference 38:http: / / www.xbrl.org / 2003 / role / disclosureRef- Topic 470- SubTopic 10- Name Accounting Standards Codification- Section S99** - Paragraph 1B- Subparagraph ( SX 210. 13- 02 ( a ) (4) (i) )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1BReference 39 **the passage of time or when a triggering event occurs. ReferencesReference 1** :http: / / ~~www~~ fasb . ~~xbrl.~~ org / ~~2003~~ us- gaap / role / ~~disclosureRef~~ ref / legacyRef - Topic ~~470~~ 942 - SubTopic ~~10~~ 210 - Name Accounting Standards Codification- Section S99- Paragraph ~~1B~~ 1 - Subparagraph (SX 210. ~~13~~ 9 - ~~02~~ 03 ( 10 ~~a) (4) (iii) (A~~ ))- Publisher FASB- URI https: / / asc.fasb.org / 1943274 / ~~2147480097~~ 2147478546 / ~~470~~ 942 - ~~10~~ 210 - S99- ~~1BReference~~ 1Reference ~~40~~ 2 :http: / / www.xbrl.org / ~~2003~~ 2009 / role / ~~disclosureRef~~ commonPracticeRef - Topic ~~470~~ 944 - SubTopic ~~10~~ 210 - Name Accounting Standards Codification- Section S99- Paragraph ~~1B~~ 1 - Subparagraph (SX 210. ~~13~~ 7 - ~~02~~ 03 (a) ( 10 4) (iii) (B ))- Publisher FASB- URI https: / / asc.fasb.org / 1943274 / ~~2147480097~~ 2147478777 / ~~470~~ 944 - ~~10~~ 210 - S99- ~~1BReference~~ 1Reference ~~41~~ 3 :http: / / www.xbrl.org / 2003 / role / disclosureRef- Topic ~~470~~ 946 - SubTopic ~~10~~ 210 - Name Accounting Standards Codification- Section S99- Paragraph ~~1B~~ 1 - Subparagraph (SX 210. ~~13~~ 6 - ~~02~~ 04 (7) (a ~~) (4) (iv~~ ))- Publisher FASB- URI https: / / asc.fasb.org / 1943274 / ~~2147480097~~ 2147479170 / ~~470~~ 946 - ~~10~~ 210 - S99- ~~1BReference~~ 1Reference ~~42~~ 4 :http: / / www.xbrl.org / 2003 / role / disclosureRef- Topic ~~470~~ 210 - SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph ~~1B~~ 1 - Subparagraph (SX 210. ~~13~~ 5 - 02 ( 7 ~~a) (5~~ ))- Publisher FASB- URI https: / / asc.fasb.org / 1943274 / ~~2147480097~~ 2147480566 / ~~470- 10~~ 210 - ~~S99~~ 10 - ~~1BReference 43~~ **S99- 1 Details Name:us- gaap_PrepaidExpenseCurrentAndNoncurrent Namespace Prefix:us- gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instantX- DefinitionCash received for fees during the current period.This element excludes cash proceeds from license fees. ReferencesReference 1** :http: / / ~~www~~ fasb . ~~xbrl.~~ org / ~~2003~~ us- gaap / role / ~~disclosureRef~~ ref / legacyRef - Topic ~~260~~ 230 - SubTopic 10- Name Accounting Standards Codification- Section 45- Paragraph ~~60B~~ 25 - Subparagraph ( ~~a~~ c )- Publisher FASB- URI https: / / asc.fasb.org / 1943274 / ~~2147482689~~ 2147482740 / ~~260~~ 230 - 10- 45- ~~60BReference 44~~ **25 Details Name** : ~~http~~ us- gaap_ProceedsFromFeesReceived Namespace Prefix : ~~/ / www.~~ us- gaap_ Data Type: ~~xbrl~~ xbrli ~~.org / 2003 / role / disclosureRef- Topic 205- SubTopic 20- Name Accounting Standards Codification- Section 50- Paragraph 7- Publisher FASB- URI https~~ : monetaryItemType Balance Type ~~/ / asc.fasb.org / 1943274 / 2147483499 / 205- 20- 50- 7Reference 45~~ : ~~http~~ debit Period Type : ~~/ / fasb~~ durationX- DefinitionAmount of purchase arrangement 2147482790 / 220- 10- 45- **1AReference 47: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 220- SubTopic 10- Name Accounting Standards Codification- Section 45- Paragraph 1B- Subparagraph (a)- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482790 / 220- 10- 45-** 1BReference ~~37~~ **48: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 470- SubTopic 20- Name Accounting Standards Codification- Section 65- Paragraph 4- Subparagraph (f) (4)- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147481538 / 470- 20- 65- 4Reference 49** : http: / / fasb. org / us- gaap / role / ref / legacyRef- Topic 942- SubTopic 220- Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210. 9- 04 (22))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147478524 / 942- 220- S99- 1 Details Name: us- gaap_NetIncomeLoss Namespace Prefix: us- gaap_ Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: durationX- DefinitionNumber of shares issued which are neither cancelled nor held in the treasury. ReferencesNo definition available. Details Name: us- gaap_SharesOutstanding Namespace Prefix: us- gaap_ Data Type: xbrli: sharesItemType Balance Type: na Period Type: instantX- ~~DefinitionNumber~~ **DefinitionThe number** of ~~share~~ **shares** ~~options (or share~~ **issued during the period upon the conversion of** units **. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit** ) ~~exercised during the current period~~ . ReferencesReference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef- Name Accounting Standards Codification- Section 50- Paragraph 2- SubTopic 10- Topic 505- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147481112 / 505- 10- 50- 2Reference 2: http: / / fasb. org / us- gaap / role / ref / legacyRef- Topic 210- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210. 5- 02 (28))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1Reference 3: http: / / fasb. org / us- gaap / role / ref / legacyRef- Topic 210- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210. 5- 02 (29))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1Reference 4: http: / / ~~www~~ fasb . ~~xbrl.~~ org / ~~2003~~ us- gaap / role / ~~disclosureRef~~ ref / legacyRef - Topic ~~718~~ 505 - SubTopic 10- Name Accounting Standards Codification- Section ~~50~~ S99 - Paragraph ~~2~~ 1 - Subparagraph ( SX 210. 3- 04 ~~e) (1) (iv) (02~~ )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147480429~~ 2147480008 / ~~718- 10- 50~~ 505 - 10- S99- ~~2Reference~~ 1Reference 5: http: / / fasb. org / us- gaap / role / ref / legacyRef ~~- Topic 505- SubTopic 10~~ - Name Accounting Standards Codification- ~~contributed to~~ the **passage** ~~entity.Number~~ of **time** ~~shares includes,but is not limited to,shares issued for~~ - **or when a triggering event occurs** ~~services contributed by vendors and founders. ReferencesNo definition available. Details Name:us- gaap_StockIssuedDuringPeriodSharesIssuedForServices Namespace Prefix:us- gaap_ Data Type:xbrli:sharesItemType Balance Type:na Period Type:durationX- DefinitionNumber of new stock issued during the period~~ . ReferencesReference 1:http: / / fasb.org / us- gaap / role / ref / legacyRef **- Topic 942- SubTopic 210** - Name Accounting Standards Codification- Section ~~50~~ S99 - Paragraph ~~2~~ 1 - ~~SubTopic~~ **Subparagraph (SX** ~~10~~ **210 .9** - ~~Topic 505~~ **03 (10))** - Publisher FASB- URI https: / / asc.fasb.org / 1943274 / ~~2147481112~~ 2147478546 / ~~505~~ 942 - ~~10~~ 210 - ~~50~~ S99 - ~~2Reference~~ 1Reference 2:http: / / ~~fasb~~ www . xbrl. org / 2009 ~~us- gaap~~ / role / commonPracticeRef ~~ref / legacyRef~~ - Topic ~~210~~ 944 - SubTopic ~~10~~ 210 - Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210. ~~5~~ 7 - ~~02~~ 03 ( ~~28~~ a) (10 ))- Publisher FASB- URI https: / / asc.fasb.org / 1943274 / ~~2147480566~~ 2147478777 / ~~210~~ 944 - ~~10~~ 210 - S99- 1Reference 3:http: / / ~~fasb~~ www . xbrl. org / 2003 ~~us- gaap~~ / role / disclosureRef ~~ref / legacyRef~~ - Topic ~~210~~ 946 - SubTopic ~~10~~ 210 - Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210. ~~5~~ 6 - ~~02~~ 04 ( ~~29~~ 7) (a )- Publisher FASB- URI https: / / asc.fasb.org / 1943274 / ~~2147480566~~ 2147479170 / ~~210~~ 946 - ~~10~~ 210 - S99- 1Reference 4:http: / / www.xbrl.org / 2003 / role / disclosureRef- Topic ~~946~~ 210 - SubTopic ~~505~~ 10 - Name Accounting Standards Codification- Section ~~50~~ S99 - Paragraph ~~2~~ 1 - Subparagraph ( ~~a~~ SX 210.5- 02 (7) )- Publisher FASB- URI https: / / asc.fasb.org / 1943274 / ~~2147478448~~ 2147480566 / ~~946~~ 210 - ~~505~~ 10 - ~~50~~ S99 - ~~2Reference 5~~ **1 Details Name:us- gaap_PrepaidExpenseCurrentAndNoncurrent Namespace Prefix:us- gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instantX- DefinitionCash received for fees during the current period.This element excludes cash proceeds from license fees. ReferencesReference 1** :http: / / ~~www~~ fasb . ~~xbrl.~~ org / ~~2003~~ us- gaap / role / ~~disclosureRef~~ ref / legacyRef - Topic ~~946~~ 230 - SubTopic ~~220~~ 10 - Name Accounting Standards Codification- Section ~~S99~~ 45 - Paragraph ~~3~~ 25 - Subparagraph ( c ~~SX 210.6- 09 (4) (b)~~ )- Publisher FASB- URI https: / / asc.fasb.org / 1943274 / ~~2147479134~~ 2147482740 / ~~946~~ 230 - ~~220~~ 10 - ~~S99~~ 45 - ~~3Reference 6~~ **25 Details Name** : ~~http~~ us- gaap_ProceedsFromFeesReceived Namespace Prefix : ~~/ / www.~~ us- gaap_ Data Type: ~~xbrl~~ xbrli ~~.org / 2003 / role / disclosureRef~~ :monetaryItemType Balance Type:debit Period Type:durationX -

**DefinitionAmount of purchase arrangement** ~~Topic 946- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 3- Subparagraph (~~ Section S99- Paragraph 1- Subparagraph (SX 210. 3- 04)- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480008 / 505- 10- S99- 1 Details Name: us- ~~gaap_StockIssuedDuringPeriodSharesStockOptionsExercised~~ ----- **gaap_StockIssuedDuringPeriodSharesNewIssues** Namespace Prefix: us- gaap_ Data Type: xbrli: sharesItemType Balance Type: na Period Type: durationX- ~~DefinitionValue~~ **DefinitionNumber of shares** of stock issued **attributable to transactions classified** as ~~a result of the~~ **other** ~~exercise~~ **. ReferencesNo definition available. Details Name: us- gaap_StockIssuedDuringPeriodSharesOther Namespace Prefix: us- gaap_ Data Type: xbrli: sharesItemType Balance Type: na Period Type: durationX- DefinitionNumber** of ~~stock options~~ **treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share- based payment arrangement** . ReferencesReference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef- Name Accounting Standards Codification- Section 50- Paragraph 2- SubTopic 10- Topic 505- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147481112 / 505- 10- 50- 2Reference 2: http: / / fasb. org / us- gaap / role / ref / legacyRef- Topic 210- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210. 5- 02 (29))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1Reference 3: http: / / fasb. org / us- gaap / role / ref / legacyRef- Topic ~~210~~ **505** - SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210. ~~5~~ **3** - **04** ~~02 (30)~~ )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147480566~~ **2147480008** / ~~210~~ **505** - 10- S99- ~~1Reference 4~~ **1 Details Name: us- gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued Namespace Prefix: us- gaap_ Data Type: xbrli: sharesItemType Balance Type: na Period Type: durationX- DefinitionThe gross value of stock issued during the period upon the conversion of convertible securities. ReferencesReference 1** : http: / / fasb. org / us- gaap / role / ref / legacyRef ~~- Topic 210- SubTopic 10-~~ Name Accounting Standards Codification- Section ~~S99~~ **50** - Paragraph ~~1~~ **2** - **SubTopic** ~~Subparagraph (SX 210-~~ **10** ~~. 5-~~ **Topic 505** ~~02 (31))~~ - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147480566~~ **2147481112** / **505- 10- 50- 2Reference 2: http: / / fasb. org / us- gaap / role / ref / legacyRef- Topic** 210 ~~- 10- S99- 1Reference 5: http: / / fasb. org / us- gaap / role / ref / legacyRef- Topic 505-~~ SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210. **5** - ~~03~~ **02** ( ~~10~~ **29** ))- Publisher FASB- URI https: / / asc.fasb.org / 1943274 / ~~2147478546~~ -- **2147480566** / ~~942~~ **210** - ~~210-~~ **10** - S99- 1Reference ~~2~~ **3** :http: / ~~www~~ **fasb** . ~~xbrl.~~ org / ~~2009~~ **us- gaap** / role / ~~commonPracticeRef~~ **ref / legacyRef** - Topic ~~944~~ **210** - SubTopic ~~210-~~ **10** - Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210. ~~7~~ **5** - ~~03~~ **02** ( **30** ~~a) (10~~ ))- Publisher FASB- URI https: / / asc.fasb.org / 1943274 / ~~2147478777~~ **2147480566** / ~~944~~ **210** - ~~210-~~ **10** - S99- 1Reference ~~3~~ **4** :http: / ~~www~~ **fasb** . ~~xbrl.~~ org / ~~2003~~ **us- gaap** / role / ~~disclosureRef~~ **ref / legacyRef** - Topic ~~946~~ **210** - SubTopic ~~210-~~ **10** - Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210. ~~6~~ **5** - ~~04~~ **02** ( **31** ~~7) (a~~ ))- Publisher FASB- URI https: / / asc.fasb.org / 1943274 / ~~2147479170~~ **2147480566** / ~~946~~ **210** - ~~210-~~ **10** - S99- 1Reference ~~4~~ **5** :http: / ~~www~~ **fasb** . ~~xbrl.~~ org / ~~2003~~ **us- gaap** / role / ~~disclosureRef~~ **ref / legacyRef** - Topic ~~210~~ **505** - SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210. ~~5~~ 3- 04)- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480008 / 505- 10- S99- 1 Details Name: us- ~~. fasb.~~ **the passage of time** ~~org-~~ **or when a triggering event occurs. ReferencesReference 1** ~~/ 1943274 / 2147480566 / 210- 10- S99- 1Reference 3~~ :http: / / fasb.org / us- gaap / role / ref / legacyRef- Topic ~~210~~ **942** - SubTopic ~~10~~ **210** - Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210. ~~5~~ **9** - ~~02~~ **03** ( ~~29~~ **10** ))- Publisher FASB- URI https: / / asc.fasb.org / 1943274 / ~~2147480566~~ -- **2147478546** / ~~210~~ **942** - ~~10~~ **210** - S99- 1Reference ~~4~~ **2** :http: / / www.xbrl.org / ~~2003~~ **2009** / role / ~~exampleRef~~ **commonPracticeRef** - Topic ~~946~~ **944** - SubTopic ~~830~~ **210** - Name Accounting Standards Codification- Section ~~55~~ **S99** - Paragraph ~~11~~ **1- Subparagraph (SX 210.7- 03 (a) (10))** - Publisher FASB- URI https: / / asc.fasb.org / 1943274 / ~~2147479168~~ **2147478777** / ~~946~~ **944** - ~~830~~ **210** - ~~55~~ **S99** - ~~1Reference-~~ **1Reference** ~~5~~ **3** :http: / / www.xbrl.org / 2003 / role / disclosureRef- Topic 946- SubTopic ~~205~~ **210** - Name Accounting Standards Codification- Section ~~45~~ **S99** - Paragraph ~~4~~ **1** - Subparagraph ( **SX 210.6- 04 (7) (** a **)** )- Publisher FASB- URI https: / / asc.fasb.org / 1943274 / ~~2147478009~~ **2147479170** / 946- ~~205~~ **210** - ~~45~~ **S99** - ~~4Reference-~~ **1Reference** ~~6~~ **4** :http: / / www.xbrl.org / 2003 / role / disclosureRef- Topic ~~946~~ **210** - SubTopic ~~505~~ **10** - Name Accounting Standards Codification- Section ~~50~~ **S99** - Paragraph ~~2~~ **1** - Subparagraph ( ~~a~~ **SX 210.5- 02 (7)** )- Publisher FASB- URI https: / / asc.fasb.org / 1943274 / ~~2147478448~~ **2147480566** / ~~946~~ **210** - ~~505~~ **10** - ~~50~~ **S99** - ~~2Reference 7-~~ **1 Details Name:us- gaap_PrepaidExpenseCurrentAndNoncurrent Namespace Prefix:us- gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instantX- DefinitionCash received for fees during the current period.This element excludes cash proceeds from license fees. ReferencesReference 1** :http: / ~~www~~ **fasb** . ~~xbrl.~~ org / ~~2003~~ **us- gaap** / role / ~~disclosureRef~~ **ref / legacyRef** - Topic ~~946~~ **230** - SubTopic ~~220~~ **10** - Name Accounting Standards Codification- Section ~~S99~~ **45** - Paragraph ~~3~~ **25** - Subparagraph ( **c** ~~SX 210.6- 09 (4) (b)~~ )- Publisher FASB- URI https: / / asc.fasb.org / 1943274 / ~~2147479134~~ **2147482740** / ~~946~~ **230** - ~~220- S99- 3Reference 8:http: / / fasb.org / us- gaap / role / ref / legacyRef- Topic 505- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210-~~ **10** ~~.3-~~ **45** ~~04)-~~ **25** ~~Publisher FASB- URI https: / / asc.fasb.org / 1943274 / 2147480008 / 505- 10- S99- 1~~ Details Name:us- ~~gaap_StockIssuedDuringPeriodValueNewIssues~~ **gaap_ProceedsFromFeesReceived** Namespace Prefix:us- gaap_ Data Type:xbrli:monetaryItemType Balance Type: ~~credit~~ **debit** Period Type:durationX- ~~DefinitionValue~~ **DefinitionAmount** of ~~shares~~ **purchase arrangement** ~~gaap_StockIssuedDuringPeriodValueStockOptionsExercised~~ ----- **gaap_StockIssuedDuringPeriodValueOther** Namespace Prefix: us- gaap_ Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: durationX- DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. ReferencesReference 1: http: / / ~~fasb~~ **www** . **xbrl.** org / **2009** ~~us- gaap-~~ / role / **commonPracticeRef** ~~ref / legacyRef-~~ Topic ~~210~~ **235** - SubTopic 10- Name Accounting Standards Codification- Section ~~S99~~ **S50** - Paragraph 1- ~~Subparagraph (SX 210. 5- 02 (29))-~~ Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147480566~~ **2147480738** / **235-** ~~210-~~ **10** - **S50** ~~10- S99-~~ 1Reference 2: http: / / ~~fasb~~ **www** . **xbrl.** org / **2009** ~~us- gaap-~~ / role / **commonPracticeRef** ~~ref / legacyRef-~~ Topic ~~210~~ **235** - SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210. ~~5~~ **4** - ~~02~~ **08** ( ~~30~~ **g) (1) (i** ))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147480566~~ **2147480678** / ~~210~~ **235** - 10- S99- 1Reference 3: http: / / ~~fasb~~ **www** . **xbrl.** org / **2009** ~~us- gaap-~~ / role / **commonPracticeRef** ~~ref / legacyRef-~~ Topic ~~210~~ **825** - SubTopic 10- Name Accounting Standards Codification- Section ~~S99~~ **50** - Paragraph ~~1~~ **28** - Subparagraph ( **f** ~~SX 210. 5- 02 (31)~~ )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147480566~~ **2147482907** / **825- 10- 50- 28Reference 4: http: / / fasb. org / us- gaap / role / ref / legacyRef- Topic** 210 ~~- 10- S99- 1Reference 4: http: / / www. xbrl. org / 2003 / role / exampleRef- Topic 852-~~ SubTopic 10- Name Accounting Standards Codification- Section ~~55~~ **S99** - Paragraph **1- Subparagraph (SX** ~~10~~ **210 . 5- 02 (29))** - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147481372~~ **2147480566** / ~~852- 10~~ **210** - ~~55~~ **10** - **S99-** ~~10Reference-~~ **1Reference** 5: http: / / ~~www~~ **fasb** . ~~xbrl.~~ org / ~~2003~~ **us- gaap** / role / ~~exampleRef~~ **ref / legacyRef** - Topic ~~946~~ **210** - SubTopic ~~830~~ **10** - Name Accounting Standards Codification- Section ~~55~~ **S99** - Paragraph ~~12~~ **1- Subparagraph (SX 210. 5- 02 (30))** - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147479168~~ **2147480566** / ~~946~~ **210** - ~~830~~ **10** - ~~55~~ **S99** - ~~12Reference~~ - **1Reference** 6: http: / / ~~www~~ **fasb** . ~~xbrl.~~ org / ~~2003~~ **us- gaap** / role / ~~disclosureRef~~ **ref / legacyRef** - Topic ~~946~~ **210** - SubTopic ~~210-~~ **10** - Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210. ~~6~~ **5** - ~~04~~ **02** ( ~~19~~ **31** ))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147479170~~ **2147480566** / ~~946-~~ 210 **- 10** - S99- 1Reference 7: http: / / www. xbrl. org / 2003 / role / ~~disclosureRef~~ **exampleRef** - Topic ~~946~~ **852** - SubTopic ~~210-~~ **10** - Name Accounting Standards Codification- Section ~~S99~~ **55** - Paragraph ~~2- Subparagraph (SX 210-~~ **10** ~~. 6- 05 (4))~~ - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147479170~~ **2147481372** / ~~946~~ **852** - ~~210-~~ **10** - ~~S99-~~ **55** - ~~2Reference-~~ **10Reference** 8: http: / / www. xbrl. org / ~~2009~~ **2003** / role / ~~commonPracticeRef~~ **exampleRef** - Topic 946- SubTopic ~~220~~ **830** - Name Accounting Standards Codification- Section ~~S99~~ **55** - Paragraph **12** ~~3- Subparagraph (SX 210. 6- 09 (4) (b))~~ - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147479134~~ **2147479168** / 946- ~~220~~ **830** - ~~S99~~ **55** - ~~3Reference-~~ **12Reference** 9: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 946- SubTopic ~~220~~ **210** - Name Accounting Standards Codification- Section S99- Paragraph ~~3~~ **1** - Subparagraph (SX 210. 6- ~~09~~ **04** ( ~~6~~ **19** ))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147479134~~ **2147479170** / 946- ~~220~~ **210** - S99- ~~3Reference-~~ **1Reference** 10: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 946- SubTopic ~~220~~ **210** - Name Accounting Standards Codification- Section S99- Paragraph ~~3~~ **2** - Subparagraph (SX 210. 6- ~~09~~ **05** ( ~~7~~ **4** ))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147479134~~ **2147479170** / 946- **210- S99- 2Reference 11: http: / / www. xbrl. org / 2009 / role / commonPracticeRef- Topic 946- SubTopic** 220 ~~- S99- 3Reference 11: http: / / www. xbrl. org / 2009 / role / commonPracticeRef- Topic 235- SubTopic 10-~~ Name Accounting Standards Codification- Section S99- Paragraph ~~1~~ **3** - Subparagraph (SX 210. **6- 09 (** ~~4 -08 (g-~~ ) ( **b** ~~1) (ii~~ ))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147480678~~ **2147479134** / ~~235~~ **946** - ~~10~~ **220** - S99- ~~1Reference-~~ **3Reference** 12: http: / / www. xbrl. org / ~~2009~~ **2003** / role / ~~commonPracticeRef~~ **disclosureRef** - Topic ~~323~~ **946** - SubTopic ~~10~~ **220** - Name Accounting Standards Codification- Section ~~50~~ **S99** - Paragraph 3- Subparagraph ( ~~e~~ **SX 210. 6- 09 (6)** )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147481687~~ **2147479134** / ~~323~~ **946** - ~~10~~ **220** - ~~50~~ **S99** - 3Reference 13: http: / / www. xbrl. org / ~~2009~~ **2003** / role / ~~commonPracticeRef~~ **disclosureRef** - Topic ~~825~~ **946** - SubTopic ~~10~~ **220** - Name Accounting Standards Codification- Section ~~50~~ **S99** - Paragraph ~~28~~ **3** - Subparagraph ( ~~f~~ **SX 210. 6- 09 (7)** )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147482907~~ **2147479134** / ~~825~~ **946** - ~~10~~ **220** - ~~50~~ **S99** - ~~28Reference-~~ **3Reference** 14: http: / / ~~fasb~~ **www** . **xbrl.** org / **2009** ~~us- gaap-~~ / role / **commonPracticeRef** ~~ref / legacyRef-~~ Topic ~~310~~ **235** - SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph **1** - Subparagraph ( ~~SAB Topic~~ **SX 210.** 4 ~~.C-~~ **08 (g) (1) (ii)** )- Publisher FASB- URI https: / / asc.fasb.org / 1943274 / ~~2147480008~~ **2147480678** / ~~505~~ **235** - 10- S99- **1Reference 15** ~~4 Details Name:us- gaap_StockholdersEquityReverseStockSplit Namespace Prefix:us- gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:durationX- DefinitionPer share increase in exercise price of warrant.Excludes change due to standard antidilution provision. ReferencesReference 1-~~ :http: / / www.xbrl.org / ~~2003~~ **2009** / role / ~~disclosureRef~~ **commonPracticeRef** - Topic ~~505~~

**323** - SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 3 **- Subparagraph (c)** - Publisher FASB- URI https: / / asc.fasb.org / 1943274 / ~~2147481112~~ **2147481687** / ~~505~~ **323** - 10- 50- ~~3 Details~~ **3Reference 16:http: / / fasb.org / us- gaap / role / ref / legacyRef- Topic 310- SubTopic 10-** Name **: Accounting Standards Codification- Section S99- Paragraph** 2- Subparagraph (SAB Topic 4. E)- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480418 / 310- 10- S99- 2 Details Name: us- gaap_StockholdersEquity Namespace Prefix: us- gaap_ Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: instantConsolidated Statements of Cash Flows- USD ($) 12 Months EndedJan. 31, ~~2024~~ **2025** Jan. 31, ~~2023Cash~~ **2024Cash** flows from operating activities: Net loss $ ( **10, 482, 617) $ (** 5, 485, 314 ~~) $ (4, 483, 474~~ ) Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization **285, 054** 287, ~~722 330, 143Operating~~ **722Operating** lease expense 31, ~~380 38~~ **374 31** , ~~813Loss~~ **380Loss** on extinguishment of debt **368, 036** 554, ~~423 Reserve~~ **423Reserve** for doubtful accounts 118, **365Goodwill** ~~365 Treasury stock issued for services 113, 155Treasury stock~~ and **intangibles** ~~warrants issued for termination agreement 174, 025Goodwill~~ impairment ~~327~~ **3** , **595, 216** ~~326Stock~~ --- **Stock** - based compensation- warrants **133, 350** 242, ~~840 Stock~~ **840Stock** - based compensation- options **1, 408, 935** 499, **856Changes** ~~856 732, 130Changes~~ in operating assets and liabilities: Accounts receivable **74, 802** (153, 969 ~~) (41, 665~~ ) Prepaid expenses **15, 009** 154, ~~258 4, 547Inventories~~ **258Inventories (43, 436)** 60, ~~730 (97, 687) Deferred~~ **730Deferred** revenue ( **1, 622) (** 5, 401) ~~56, 636Operating~~ --- **Operating** lease liability ( **34, 276) (** 31, 292 ~~) (36, 287~~ ) Accounts payable and accrued expenses **23, 611** 198, **893Net** ~~893 (104, 860) Net~~ Cash Used In Operating Activities ( **4, 626, 564) (** 3, 527, 509 ~~) (2, 987, 198~~ ) Cash flows from investing activities: Purchase of equipment ( **92, 043) (** 51, 761 ~~) (79, 304~~ ) Net Cash Used in Investing Activities ( **92, 043) (** 51, 761 ~~) (79, 304~~ ) Cash flows from financing activities: Proceeds from note payable- related party **300, 000** 2, 000, ~~000 Proceeds~~ **000Proceeds** from secured borrowing liability 106, ~~528 Proceeds~~ **528Proceeds** from **sale of common stock and** exercise of warrants ~~296~~ **8** , **406, 591** ~~875Payment~~ --- **Payment** on note payable ( **20, 660) (** 19, 756 ~~) (17, 795~~ ) Purchase of treasury stock ( ~~119~~ **148** , ~~006~~ **547** ) Net Cash Provided by Financing Activities **8, 537, 384** 2, 086, **772Net** ~~772 160, 074Net~~ change in cash **3, 818, 777** (1, 492, 498 ~~) (2, 906, 428~~ ) Cash and cash equivalents- Beginning of period **492, 942** 1, 985, **440Cash** ~~440 4, 891, 868Cash~~ and cash equivalents- End of period **4, 311, 719** 492, **942Cash** ~~942 1, 985, 440Cash~~ paid for: Interest **5, 631** 7, ~~352 4, 266Income~~ -- **352Income** taxes Supplemental disclosure of non- cash investing and financing activities: ~~Adoption~~ **Cashless conversion** of ~~ASC 842 Operating lease asset~~ **warrant Debt settlement issued by the issuance of common stock** and ~~liability 94~~ **warrants 672** , **958** ~~134Promissory note on equipment purchase 22, 794Common stock returned in settlement 1, 400Issuance~~ --- **Issuance** of common stock for extinguishment of debt $ 2, 607, ~~863~~ **863X** ~~X - DefinitionAmount to adoption~~ **DefinitionDebt settlement issued by the issuance** of **common stock** ~~operating lease asset~~ and ~~liability~~ **warrants** . ReferencesNo definition available. Details Name: ~~ntrb_AdoptionofOperatingLeaseAssetandLiability~~ **ntrb_DebtSettlementIssuedByTheIssuanceOfCommonStockAndWarrants** Namespace Prefix: ntrb_ Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: durationX- **DefinitionPurchase of treasury stock** ~~DefinitionPromissory note on equipment purchase~~ . ReferencesNo definition available. Details Name: ~~ntrb_PromissoryNoteOnEquipmentPurchase~~ **ntrb_PurchaseOfTreasuryStocks** Namespace Prefix: ntrb_ Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: durationX- ~~DefinitionTreasury~~ ----- **DefinitionThe amount of** stock **- based compensation- warrants** ~~, also known as treasury shares or reacquired stock, refers to previously outstanding stock that is bought back from stockholders by the issuing company~~ . ReferencesNo definition available. Details Name: ~~ntrb_PurchaseOfTreasuryStock~~ **ntrb_StockbasedCompensationwarrants** Namespace Prefix: ntrb_ Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: durationX- ~~DefinitionThe amount of stock- based compensation- warrants.~~ ReferencesNo definition available. Details Name: ~~ntrb_StockbasedCompensationwarrants Namespace Prefix: ntrb_ Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: durationX- DefinitionThe amount of treasury stock issued for termination agreement. ReferencesNo definition available. Details Name: ntrb_TreasuryStockIssuedForTerminationAgreement Namespace Prefix: ntrb_ Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: durationX- ReferencesNo definition available. Details Name:~~ us- gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us- gaap_ Data Type: xbrli: stringItemType Balance Type: na Period Type: durationX- DefinitionAmount of cash and cash ~~equivalents~~ - **equivalent** , and cash and cash ~~equivalents~~ - **equivalent** restricted to withdrawal or usage. Excludes..... equivalents, and cash and cash equivalents restricted to withdrawal or usage; **attributable to continuing operation** ~~excluding effect from exchange rate change~~ . Cash includes, but is not limited to, currency on hand, demand ~~deposits~~ - **deposit** with ~~banks or~~ financial ~~institutions~~ - **institution** , and ~~other accounts~~ - **account** with general ~~characteristics~~ - **characteristic** of demand ~~deposits~~ - **deposit** . Cash ~~equivalents~~ - **equivalent** ~~include~~ **includes** , but ~~are~~ **is** not limited to, short- term, highly liquid ~~investments~~ - **investment** that ~~are~~ **is** both readily convertible to known ~~amounts~~ - **amount** of cash and so near ~~their~~ maturity that ~~they~~ **it** ~~present~~ **presents** insignificant risk of ~~changes~~ - **change** in value because of ~~changes~~ - **change** in interest ~~rates~~ - **rate** . ReferencesReference 1: http: / / ~~fasb~~ **www** . **xbrl.** org / **2003** ~~us- gaap~~ / role / **disclosureRef** ~~ref / legacyRef~~ - Topic 230- SubTopic 10- Name Accounting Standards Codification- Section ~~45~~ **50** - Paragraph ~~24~~ **8** - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147482740~~ **2147482913** / 230- 10- ~~45~~ **50** - ~~24Reference~~ **8Reference** 2: http: / / fasb. org / us- gaap / role / ref / legacyRef **- Topic 230- SubTopic 10** - Name Accounting Standards Codification- Section 45- Paragraph **24** ~~- Section 50- Paragraph 7~~ - Publisher FASB- URI https: / / asc.fasb.org / 1943274 / ~~2147483499~~ **2147482740** / ~~205- 20~~ **230** - ~~50~~ **10** - **45-** ~~7Reference~~ **24Reference** ~~2~~ **3** :http: / / fasb.org / us- gaap / role / ref / legacyRef ~~- Topic 205- SubTopic 20~~ - Name Accounting Standards Codification- **Topic 230- SubTopic 10-** Section ~~50~~ **45** - Paragraph **4** ~~5B- Subparagraph (b)~~ - Publisher FASB- URI https:/ / asc.fasb.org / 1943274 / ~~2147483499~~ **2147482740** / ~~205- 20~~ **230** - ~~50~~ **10** - ~~5B~~ **45- 4** Details Name:us- ~~gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss~~ **gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents** Namespace Prefix:us- gaap_ Data Type:xbrli:monetaryItemType Balance Type: ~~credit~~ **debit** Period Type: ~~durationX~~ **instantX** - ~~DefinitionThe net gain~~ **DefinitionAmount,excluding effect from change in exchange rate,of increase** ( ~~loss~~ **decrease** ) **in cash and cash equivalent** ~~resulting from a sale of loans~~ , **and cash and cash equivalent restricted to withdrawal or usage;** including ~~adjustments~~ **,but not limited** to **,discontinued operation.Cash includes,but is not limited to,currency on** ~~record loans classified as held- for- sale at the lower- of- cost- or- market and~~ **hand** ~~fair~~ **,demand deposit with financial institution,and account with general characteristic of demand deposit.Cash equivalent includes,but is not limited to,short- term,highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in** value **because of change in interest rate** ~~adjustments to loan held for investment purposes~~ . ReferencesReference 1:http: / / fasb.org / us- gaap / role / ref / legacyRef **- Topic 230- SubTopic 10** - Name Accounting Standards Codification- Section 45- Paragraph **24** ~~28- Subparagraph (b)- SubTopic 10- Topic 230~~ - Publisher FASB- URI https: / / asc.fasb.org / 1943274 / 2147482740 / 230- 10- 45- ~~28Reference~~ **24Reference** 2:http: / / fasb.org / us- gaap / role / ref / legacyRef ~~- Topic 942- SubTopic 220~~ - Name Accounting Standards Codification- Section ~~S99~~ **45** - Paragraph ~~1- Subparagraph (SX 210.9- 04 (13) (h))- Publisher FASB- URI https:/ / asc.fasb.org / 1943274 / 2147478524 / 942- 220- S99- 1 Details Name:us-~~ 1- SubTopic 230- Topic 830- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147477401 / 830- 230- 45- 1 Details Name: us- gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect Namespace Prefix: us- gaap_ Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: durationX- DefinitionThe value of the financial instrument ~~issued~~ **[ (s) that the original debt is being converted into in a** noncash **(** or part noncash **)** ~~] in the conversion of stock. Noncash is defined as transactions~~ - **transaction** ~~during a period that do not result in cash receipts or cash payments in the period~~ ." Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. ReferencesReference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef- Name Accounting Standards Codification- Topic 230- SubTopic 10- Section 50- Paragraph ~~4~~ **3** - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482913 / 230- 10- 50- ~~4Reference~~ **3Reference** 2: http: / / fasb. org / us- gaap / role / ref / legacyRef- Name Accounting Standards Codification- Topic 230- SubTopic 10- Section 50- Paragraph ~~3~~ **5** - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482913 / 230- 10- 50- ~~3Reference 3~~ **5 Details Name: us- gaap_DebtConversionConvertedInstrumentAmount1 Namespace Prefix: us- gaap_ Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: durationX- DefinitionThe current period expense charged against earnings on long- lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production. ReferencesReference 1** : http: / / fasb. org / us- gaap / role / ref / legacyRef- Name Accounting Standards Codification- **Section 45- Paragraph 28- Subparagraph (b)- SubTopic 10-** Topic 230- ~~SubTopic 10- Section 50- Paragraph 5-~~ Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147482913~~ **2147482740** / 230- 10- ~~50~~ **45** - **28Reference 2** ~~5 Details Name: us- gaap_ConversionOfStockAmountIssued1 Namespace Prefix: us- gaap_ Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: durationX- DefinitionThe value of the financial instrument (s) that the original debt is being converted into in a noncash (or part noncash) transaction." Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. ReferencesReference 1~~: http: / / fasb. org / us- gaap / role / ref / legacyRef- Name Accounting Standards Codification- Topic ~~230~~ **360** - SubTopic 10- Section 50- Paragraph ~~3~~ **1- Subparagraph (a)** - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147482913~~ **2147482099** / ~~230~~ **360** - 10- 50- **1** ~~3Reference 2: http: / / fasb. org / us- gaap / role / ref / legacyRef- Name Accounting Standards Codification- Topic 230- SubTopic 10- Section 50- Paragraph 5- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482913 / 230- 10- 50- 5~~ Details Name: us- gaap_DebtConversionConvertedInstrumentAmount1 Namespace Prefix: us- gaap_..... Details Name: us- gaap_DepreciationDepletionAndAmortization -------- **gaap_DepreciationAndAmortization** Namespace Prefix: us- gaap_ Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: durationX- DefinitionDifference between the fair value of payments made

and the carrying amount of debt which is extinguished prior to maturity. ReferencesReference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef- Name Accounting Standards Codification- Section 45- Paragraph 28- Subparagraph (b)- SubTopic 10- Topic 230- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482740 / 230- 10- 45- 28Reference 2: http: / / fasb. org / us- gaap / role / ref / legacyRef- Name Accounting Standards Codification- Topic 470- SubTopic 50- Section 40- Paragraph 2- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147481303 / 470- 50- 40- 2Reference 3: http: / / fasb. org / us- gaap / role / ref / legacyRef- Name Accounting Standards Codification- Topic 470- SubTopic 50- Section 40- Paragraph 4- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147481303 / 470- 50- 40- 4 Details Name: us- gaap_GainsLossesOnExtinguishmentOfDebt Namespace Prefix: us- gaap_ Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: durationX- ~~DefinitionAmount~~ -- **DefinitionTotal** ~~of~~ **loss recognized during the period from the** impairment **of goodwill plus the** loss **recognized in the period resulting** from **the impairment of the carrying amount of intangible** ~~asset~~ **assets ,** ~~representing future economic benefit arising from~~ other ~~asset acquired in business combination or from joint venture formation or both, that~~ **than goodwill** ~~is not individually identified and separately recognized~~ . ReferencesReference 1: http: / /..... 350- 20- 50- 2Reference - **ReferencesNo definition available** ~~4: http: / / www~~ . xbrl. org / 2003 / role..... 350- 20- 45- 2 Details Name: us- ~~gaap_GoodwillImpairmentLoss~~ **gaap_GoodwillAndIntangibleAssetImpairment** Namespace Prefix: us- gaap_ Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: durationX- DefinitionAmount, before refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax. ReferencesReference 1: http: / / www. xbrl. org / 2009 / role / commonPracticeRef- Topic 230- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 2A- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482913 / 230- 10- 50- 2AReference 2: http: / / www. xbrl. org / 2009 / role / commonPracticeRef- Topic 740- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 23- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482685 / 740- 10- 50- 23Reference 3: http: / / www. xbrl. org / 2009 / role / commonPracticeRef- Topic 740- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 22- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482685 / 740- 10- 50- 22Reference 4: http: / / fasb. org / us- gaap / role / ref / legacyRef- Topic 230- SubTopic 10- Name Accounting Standards Codification- Section 45- Paragraph 25- Subparagraph (f)- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482740 / 230- 10- 45- 25Reference 5: http: / / fasb. org / us- gaap / role / ref / legacyRef- Name Accounting Standards Codification- Topic 230- SubTopic 10- Section 50- Paragraph 2- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482913 / 230- 10- 50- 2 Details Name: us- gaap_IncomeTaxesPaid Namespace Prefix: us- gaap_ Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: durationX- DefinitionThe increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid. ReferencesReference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef- Name Accounting Standards Codification- Section 45- Paragraph 28- Subparagraph (a)- SubTopic 10- Topic 230- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482740 / 230- 10- 45- 28 Details Name: us- gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities Namespace Prefix: us- gaap_ Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: durationX- DefinitionThe increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services. ReferencesReference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef- Name Accounting Standards Codification- Section 45- Paragraph 28- Subparagraph (a)- SubTopic 10- Topic 230- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482740 / 230- 10- 45- 28 Details Name: us- gaap_IncreaseDecreaseInAccountsReceivable Namespace Prefix: us- gaap_ Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: durationX- DefinitionAmount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable. ReferencesReference 1: http: / / www. xbrl. org / 2003 / role / exampleRef- Name Accounting Standards Codification- Section 45- Paragraph 28- Subparagraph (a)- SubTopic 10- Topic 230- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482740 / 230- 10- 45- 28 Details Name: us- gaap_IncreaseDecreaseInDeferredRevenue Namespace Prefix: us- gaap_ Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: durationX- DefinitionThe increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities. ReferencesReference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef- Name Accounting Standards Codification- Section 45- Paragraph 28- Subparagraph (a)- SubTopic 10- Topic 230- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482740 / 230- 10- 45- 28 Details Name: us- gaap_IncreaseDecreaseInInventories Namespace Prefix: us- gaap_ Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: durationX- ReferencesNo definition available. Details Name: us- gaap_IncreaseDecreaseInOperatingCapitalAbstract Namespace Prefix: us- gaap_ Data Type: xbrli: stringItemType Balance Type: na Period Type: durationX- DefinitionAmount of increase (decrease) in obligation for operating lease. ReferencesReference 1: http: / / www. xbrl. org / 2009 / role / commonPracticeRef- Topic 230- SubTopic 10- Name Accounting Standards Codification- Section 45- Paragraph 28- Subparagraph (a)- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482740 / 230- 10- 45- 28Reference 2: http: / / www. xbrl. org / 2009 / role / commonPracticeRef- Name Accounting Standards Codification- Section 50- Paragraph 4- Subparagraph (g) (1)- SubTopic 20- Topic 842- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147478964 / 842- 20- 50- 4 Details Name: us- gaap_IncreaseDecreaseInOperatingLeaseLiability Namespace Prefix: us- gaap_ Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: durationX- DefinitionThe increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods. ReferencesReference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef- Name Accounting Standards Codification- Section 45- Paragraph 28- Subparagraph (a)- SubTopic 10- Topic 230- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482740 / 230- 10- 45- 28 Details Name: us- gaap_IncreaseDecreaseInPrepaidExpense Namespace Prefix: us- gaap_ Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: durationX- **ReferencesNo definition available. Details Name: us- gaap_InterestPaidAbstract Namespace Prefix: us- gaap_ Data Type: xbrli: stringItemType Balance Type: na Period Type: durationX-** DefinitionAmount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero- coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount. ReferencesReference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 230- SubTopic 10- Name Accounting Standards Codification- Section 45- Paragraph 17- Subparagraph (d)- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482740 / 230- 10- 45- 17Reference 2: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 230- SubTopic 10- Name Accounting Standards Codification- Section 45- Paragraph 25- Subparagraph (e)- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482740 / 230- 10- 45- 25Reference 3: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 230- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 2- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482913 / 230- 10- 50- 2 Details Name: us- gaap_InterestPaidNet Namespace Prefix: us- gaap_ Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: durationX- DefinitionFair value of share- based compensation.....: debit Period Type: durationX- DefinitionAmount of cash inflow (outflow) from financing ~~activities~~ **activity** , including **, but not limited to,** discontinued ~~operations~~ **operation** . Financing activity ~~cash flows include~~ **includes , but is not limited to,** obtaining ~~resources~~ **resource** from ~~owners~~ **owner** and providing ~~them with a~~ return on, and ~~a~~ return of, their investment; borrowing money and repaying ~~amounts~~ **amount** borrowed, or settling ~~the~~ obligation; and obtaining and paying for other ~~resources~~ **resource** obtained from ~~creditors~~ **creditor** on long- term credit. ReferencesReference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 230- SubTopic 10- Name Accounting Standards Codification- Section 45- Paragraph 24- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482740 / 230- 10- 45- 24 Details Name: us- gaap_NetCashProvidedByUsedInFinancingActivities Namespace Prefix: us- gaap_ Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: durationX- ReferencesNo definition available. Details Name: us- gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract Namespace Prefix: us- gaap_ Data Type: xbrli: stringItemType Balance Type: na Period Type: durationX- DefinitionAmount of cash inflow (outflow) from investing ~~activities~~ **activity** , including **, but not limited to,** discontinued ~~operations~~ **operation** . Investing activity ~~cash flows include~~ **includes , but is not limited to,** making and collecting ~~loans~~ **loan** ~~and~~ **,** acquiring and disposing of debt ~~or~~ **and** equity instruments ~~and~~ **,** property, plant, and equipment **,** and other productive assets. ReferencesReference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 230- SubTopic 10- Name Accounting Standards Codification- Section 45- Paragraph 24- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482740 / 230- 10- 45- 24 Details Name: us- gaap_NetCashProvidedByUsedInInvestingActivities Namespace Prefix: us- gaap_ Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: durationX- ReferencesNo definition available. Details Name: us- gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract Namespace Prefix: us- gaap_ Data Type: xbrli: stringItemType Balance Type: na Period Type: durationX- DefinitionAmount of cash inflow (outflow) from operating ~~activities~~ **activity** , including **, but not limited to,** discontinued ~~operations~~ **operation** . Operating activity ~~cash flows include~~ **includes , but is not limited to,** ~~transactions~~ **transaction** , ~~adjustments~~ **adjustment** , and ~~changes~~ **change** in value not defined as investing or financing ~~activities~~ **activity** . ReferencesReference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef- Topic 230- SubTopic 10- Name Accounting Standards Codification- Section 45- Paragraph 28- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482740 / 230- 10- 45- 28Reference 2: http: / / fasb. org / us- gaap / role / ref / legacyRef- Topic 230- SubTopic 10- Name Accounting Standards Codification- Section 45- Paragraph 24- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482740 / 230- 10- 45- 24Reference 3: http: / / fasb. org / us- gaap / role / ref / legacyRef- Topic 230- SubTopic 10- Name Accounting Standards Codification- Section 45- Paragraph 25- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482740 / 230- 10- 45- 25 Details Name: us- gaap_NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us- gaap_ Data Type: xbrli: monetaryItemType Balance Type: na Period Type: durationX-

ReferencesNo definition available. Details Name: us- gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us- gaap_ Data Type: xbrli: stringItemType Balance Type: na Period Type: durationX- DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. ReferencesReference 1: http: / / www. xbrl. org / 2003 / role / ~~disclosureRef~~ **exampleRef** - Topic ~~250~~ **946** - SubTopic ~~10~~ **830** - Name Accounting Standards Codification- Section ~~50~~ **55** - Paragraph ~~6~~ **10** - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147483443~~ **2147479168** / ~~250~~ **946** - ~~10~~ **830** - ~~50~~ **55** - ~~6Reference~~ **10Reference** 2: http: / / www. xbrl. org / 2003 / role / ~~disclosureRef~~ **exampleRef** - Topic ~~250~~ **220** - SubTopic ~~10~~ **40** - Name Accounting Standards Codification- Section ~~50~~ **55** - Paragraph ~~9~~ **4** - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147483443~~ **2147476153** / ~~250~~ **220** - ~~10~~ **40** - ~~50~~ **55** - ~~9Reference~~ **4Reference** 3: http: / / www. xbrl. org / 2003 / role / ~~disclosureRef~~ **exampleRef** - Topic ~~805~~ **220** - SubTopic ~~60~~ **40** - Name Accounting Standards Codification- Section ~~65~~ **55** - Paragraph **21** ~~1- Subparagraph (g)~~ - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147476176~~ **2147476153** / ~~805~~ **220** - ~~60~~ **40** - ~~65~~ **55** - ~~1Reference~~ **21Reference** 4: http: / / www. xbrl. org / 2003 / role / ~~disclosureRef~~ **exampleRef** - Topic ~~740~~ **220** - SubTopic ~~323~~ **40** - Name Accounting Standards Codification- Section ~~65~~ **55** - Paragraph **14** ~~2- Subparagraph (g) (3)~~ - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147478666~~ **2147476153** / **220-** ~~740~~ - **40** - ~~323~~ **55** - ~~65- 2Reference~~ **14Reference** 5: http: / / ~~fasb~~ **www** . **xbrl.** org / **2003** ~~us- gaap~~ / role / **disclosureRef** ~~ref / legacyRef~~ - Topic ~~220~~ **235** - SubTopic 10- Name Accounting Standards Codification- Section ~~S99~~ **S50** - Paragraph **1** ~~2- Subparagraph (SX 210. 5- 03 (20))~~ - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147483621~~ **2147480738** / ~~220~~ **235** - 10- ~~S99~~ **S50** - ~~2Reference~~ **1Reference** 6: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 235- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210. 4- 08 (g) (1) ( ~~ii~~ **i** ))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480678 / 235- 10- S99- 1Reference 7: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic ~~323~~ **235** - SubTopic 10- Name Accounting Standards Codification- Section ~~50~~ **S99** - Paragraph ~~3~~ **1** - Subparagraph ( ~~e~~ **SX 210. 4- 08 (k) (2)** )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147481687~~ - **2147480678** / ~~323~~ **235** - 10- ~~50~~ **S99** - ~~3Reference~~ **1Reference** 8: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 825- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 28- Subparagraph (f)- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482907 / 825- 10- 50- 28Reference 9: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic ~~220~~ **250** - SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph ~~6~~ **4** - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147482765~~ **2147483443** / ~~220~~ **250** - 10- 50- ~~6Reference~~ **4Reference** 10: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic ~~250~~ **480** - SubTopic 10- Name Accounting Standards Codification- Section ~~50~~ **S50** - Paragraph 3- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147483443~~ **2147479857** / ~~250~~ **480** - 10- ~~50~~ **S50** - 3Reference 11: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic ~~250~~ **480** - SubTopic 10- Name Accounting Standards Codification- Section ~~50~~ **S45** - Paragraph **3** ~~1- Subparagraph (b) (2)~~ - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147483443~~ **2147479887** / ~~250~~ **480** - 10- ~~50~~ **S45** - ~~1Reference~~ **3Reference** 12: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic ~~815~~ **480** - SubTopic ~~40~~ **10** - Name Accounting Standards Codification- Section ~~65~~ **S99** - Paragraph ~~1~~ **3A** - Subparagraph ( ~~f~~ **24) (d** )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147480175~~ **2147480244** / ~~815- 40~~ **480** - ~~65~~ **10** - **S99-** ~~1Reference~~ **3AReference** 13: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic ~~250~~ **105** - SubTopic 10- Name Accounting Standards Codification- Section ~~50~~ **65** - Paragraph ~~8~~ **9- Subparagraph (e)** - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147483443~~ - **2147479343** / ~~250- 10~~ **105** - ~~50~~ **10** - **65-** ~~8Reference~~ **9Reference** 14: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic ~~250~~ **718** - SubTopic 10- Name Accounting Standards Codification- Section ~~50~~ **65** - Paragraph ~~11~~ **17** - Subparagraph ( ~~a~~ **d) (1** )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147483443~~ -- **2147480336** / ~~250~~ **718** - 10- ~~50~~ **65** - ~~11Reference~~ **17Reference** 15: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 250- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph **6** ~~11- Subparagraph (b)~~ - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147483443 / 250- 10- 50- ~~11Reference~~ **6Reference** 16: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 250- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph ~~4~~ **9** - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147483443 / 250- 10- 50- ~~4Reference~~ **9Reference** 17: http: / / www. xbrl. org / 2003 / role / ~~exampleRef~~ **disclosureRef** - Topic ~~946~~ **805** - SubTopic ~~830~~ **60** - Name Accounting Standards Codification- Section ~~55~~ **65** - Paragraph ~~10~~ **1- Subparagraph (g)** - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147479168~~ - **2147476176** / ~~946~~ **805** - ~~830~~ **60** - ~~55~~ **65** - ~~10Reference~~ - **1Reference** 18: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic ~~946~~ **740** - SubTopic ~~220~~ **323** - Name Accounting Standards Codification- Section ~~45~~ **65** - Paragraph ~~7~~ **2- Subparagraph (g) (3)** - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147479105~~ **2147478666** / ~~946~~ **740** - **323- 65- 2Reference 19: http: / / fasb. org / us- gaap / role / ref / legacyRef- Topic** 220- ~~45- 7Reference 19: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 944-~~ SubTopic ~~220~~ **10** - Name Accounting Standards Codification- Section S99- Paragraph ~~1~~ **2** - Subparagraph (SX 210. ~~7~~ **5** - ~~04~~ **03** ( ~~18~~ **20** ))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147477250~~ **2147483621** / ~~944-~~ 220- **10-** S99- ~~1Reference~~ **2Reference** 20: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic ~~946~~ **235** - SubTopic ~~220~~ **10** - Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210. ~~6~~ **4** - ~~07~~ **08** ( ~~9~~ **g) (1) (ii** ))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147479134~~ **2147480678** / ~~946~~ **235** - ~~220~~ **10** - S99- 1Reference 21: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic ~~946~~ **323** - SubTopic ~~220~~ **10** - Name Accounting Standards Codification- Section ~~S99~~ **50** - Paragraph 3- Subparagraph ( **c** ~~SX 210. 6- 09 (1) (d)~~ )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147479134~~ **2147481687** / ~~946~~ **323** - ~~220~~ **10** - ~~S99~~ **50** - 3Reference 22: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic ~~470~~ **220** - SubTopic 10- Name Accounting Standards Codification- Section ~~S99~~ **50** - Paragraph **6** ~~1A- Subparagraph (SX 210. 13- 01 (a) (4) (i))~~ - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147480097~~ **2147482765** / ~~470~~ **220** - 10- ~~S99~~ **50** - ~~1AReference~~ **6Reference** 23: http: / / www. xbrl. org / ~~2009~~ **2003** / role / ~~commonPracticeRef~~ **disclosureRef** - Topic ~~470~~ **250** - SubTopic 10- Name Accounting Standards Codification- Section ~~S99~~ **50** - Paragraph **3** ~~1A- Subparagraph (SX 210. 13- 01 (a) (4) (ii))~~ - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147480097~~ **2147483443** / ~~470~~ **250** - 10- ~~S99~~ **50** - ~~1AReference~~ **3Reference** 24: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic ~~470~~ **250** - SubTopic 10- Name Accounting Standards Codification- Section ~~S99~~ **50** - Paragraph ~~1A~~ **1** - Subparagraph ( **b** ~~SX 210. 13- 01 (a~~ ) ( **2** ~~4) (iii) (A)~~ )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147480097~~ **2147483443** / ~~470~~ **250** - 10- ~~S99~~ **50** - ~~1AReference~~ - **1Reference** 25: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic ~~470~~ **815** - SubTopic ~~10~~ **40** - Name Accounting Standards Codification- Section ~~S99~~ **65** - Paragraph ~~1A~~ **1** - Subparagraph ( **f** ~~SX 210. 13- 01 (a) (4) (iv)~~ )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480097 **2147480175** / **815-** ~~470~~ - **40** - ~~10~~ **65** - ~~S99- 1AReference~~ - **1Reference** 26: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic ~~470~~ **250** - SubTopic 10- Name Accounting Standards Codification- Section ~~S99~~ **50** - Paragraph **8** ~~1A- Subparagraph (SX 210. 13- 01 (a) (5))~~ - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147480097~~ **2147483443** / ~~470~~ **250** - 10- ~~S99~~ **50** - ~~1AReference~~ **8Reference** 27: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic ~~470~~ **250** - SubTopic 10- Name Accounting Standards Codification- Section ~~S99~~ **50** - Paragraph ~~1B~~ **11** - Subparagraph ( ~~SX 210. 13- 02 (~~a ~~)~~ **) (4) (i)** )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147480097~~ **2147483443** / ~~470~~ **250** - 10- ~~S99~~ **50** - ~~1BReference~~ **11Reference** 28: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic ~~470~~ **250** - SubTopic 10- Name Accounting Standards Codification- Section ~~S99~~ **50** - Paragraph ~~1B~~ **11** - Subparagraph ( **b** ~~SX 210. 13- 02 (a) (4) (iii) (A)~~ )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147480097~~ **2147483443** / ~~470~~ **250** - 10- ~~S99~~ **50** - ~~1BReference~~ **11Reference** 29: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic ~~470~~ **946** - SubTopic ~~10~~ **220** - Name Accounting Standards Codification- Section ~~S99~~ **45** - Paragraph **7** ~~1B- Subparagraph (SX 210. 13- 02 (a) (4) (iii) (B))~~ - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147480097~~ **2147479105** / ~~470~~ **946** - ~~10~~ **220** - ~~S99~~ **45** - ~~1BReference~~ **7Reference** 30: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic ~~470~~ **944** - SubTopic ~~10~~ **220** - Name Accounting Standards Codification- Section S99- Paragraph ~~1B~~ **1** - Subparagraph (SX 210. ~~13~~ **7** - ~~02~~ **04** ( **18** ~~a) (4) (iv~~ ))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147480097~~ **2147477250** / ~~470~~ **944** - ~~10~~ **220** - S99- ~~1BReference~~ - **1Reference** 31: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic ~~470~~ **946** - SubTopic ~~10~~ **220** - Name Accounting Standards Codification- Section S99- Paragraph ~~1B~~ **1** - Subparagraph (SX 210. ~~13~~ **6** - ~~02~~ **07** ( **9** ~~a) (5~~ ))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147480097~~ **2147479134** / ~~470~~ **946** - ~~10~~ **220** - S99- ~~1BReference~~ - **1Reference** 32: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic ~~260~~ **946** - SubTopic ~~10~~ **220** - Name Accounting Standards Codification- Section ~~45~~ **S99** - Paragraph ~~60B~~ **3** - Subparagraph ( ~~a~~ **SX 210. 6- 09 (1) (d)** )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147482689~~ **2147479134** / ~~260~~ **946** - ~~10~~ **220** - ~~45~~ **S99** - ~~60BReference~~ **3Reference** 33: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic ~~205~~ **470** - SubTopic ~~20~~ **10** - Name Accounting Standards Codification- Section ~~50~~ **S99** - Paragraph ~~7~~ **1A- Subparagraph (SX 210. 13- 01 (a) (4) (i))** - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147483499~~ **2147480097** / ~~205~~ **470** - ~~20~~ **10** - ~~50~~ **S99** - ~~7Reference~~ **1AReference** 34: http: / / ~~fasb~~ **www** . **xbrl.** org / **2009** ~~us- gaap~~ / role / **commonPracticeRef** ~~ref / legacyRef~~ - Topic ~~230~~ **470** - SubTopic 10- Name Accounting Standards Codification- Section ~~45~~ **S99** - Paragraph ~~28~~ **1A- Subparagraph (SX 210. 13- 01 (a) (4) (ii))** - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147482740~~ **2147480097** / ~~230~~ **470** - 10- ~~45~~ **S99** - ~~28Reference~~ **1AReference** 35: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic ~~220~~ **470** - SubTopic 10- Name Accounting Standards Codification- Section ~~45~~ **S99** - Paragraph 1A- Subparagraph ( **SX 210. 13- 01 (** a **) (4) (iii) (A)** )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147482790~~ **2147480097** / ~~220~~ **470** - 10- ~~45~~ **S99** - 1AReference 36: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic ~~220~~ **470** - SubTopic 10- Name Accounting Standards Codification- Section ~~45 ,"~~ **S99- Paragraph 1A- Subparagraph (SX 210.13- 01 (a) (4) (iv))- Publisher FASB-** URI ~~":"~~https:/ / asc.fasb.org / 1943274 / 2147480097 / 470- 10- S99- **1AReference 37** ~~1A" },"- r355"~~ : ~~{" role":"~~http:/ / www.xbrl.org / 2003 / role / disclosureRef **-** ~~","~~Topic ~~":"~~ 470 **-** ~~","~~SubTopic ~~":"~~10 **-** ~~","~~Name ~~":"~~Accounting Standards Codification **-** ~~","~~Section ~~":"~~S99 **-** ~~","~~Paragraph ~~":"~~1A **-** ~~","~~Subparagraph ~~":"~~(SX 210.13- 01 (a) (5)) **-** ~~","~~Publisher ~~":"~~FASB **-** ~~","~~URI ~~":"~~https:/ / asc.fasb.org / 1943274 / 2147480097 / 470- 10- S99- ~~1A" }~~ **1AReference 38:http:/ / www.xbrl.org / 2003 / role / disclosureRef- Topic 470- SubTopic 10- Name Accounting Standards Codification- Section S99** - Paragraph 1B- Subparagraph ( **SX 210. 13- 02 (** a **) (4) (i)** )-

Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147480097 / 470- 10- S99- 1BReference 39~~ **the passage of time or when a triggering event occurs. ReferencesReference 1** :http:/ / ~~www~~ **fasb** . ~~xbrl.~~ org / ~~2003~~ **us- gaap** / role / ~~disclosureRef~~ **ref / legacyRef** - Topic ~~470~~ **942** - SubTopic ~~10~~ **210** - Name Accounting Standards Codification- Section S99- Paragraph ~~1B~~ **1** - Subparagraph (SX 210. ~~13~~ **9** - ~~02~~ **03** ( **10** ~~a) (4) (iii) (A~~ ))- Publisher FASB- URI https: / / asc.fasb.org / 1943274 / ~~2147480097~~ **2147478546** / ~~470~~ **942** - ~~10~~ **210** - S99- ~~1BReference~~ **1Reference** ~~40~~ **2** :http:/ / www.xbrl.org / ~~2003~~ **2009** / role / ~~disclosureRef~~ **commonPracticeRef** - Topic ~~470~~ **944** - SubTopic ~~10~~ **210** - Name Accounting Standards Codification- Section S99- Paragraph ~~1B~~ **1** - Subparagraph (SX 210. ~~13~~ **7** - ~~02~~ **03** (a) ( **10** ~~4) (iii) (B~~ ))- Publisher FASB- URI https:/ / asc.fasb.org / 1943274 / ~~2147480097~~ **2147478777** / ~~470~~ **944** - ~~10~~ **210** - S99- ~~1BReference~~ **1Reference** ~~41~~ **3** :http:/ / www.xbrl.org / 2003 / role / disclosureRef- Topic ~~470~~ **946** - SubTopic ~~10~~ **210** - Name Accounting Standards Codification- Section S99- Paragraph ~~1B~~ **1** - Subparagraph (SX 210. ~~13~~ **6** - ~~02~~ **04 (7)** (a ~~) (4) (iv~~ ))- Publisher FASB- URI https:/ / asc.fasb.org / 1943274 / ~~2147480097~~ **2147479170** / ~~470~~ **946** - ~~10~~ **210** - S99- ~~1BReference~~ **1Reference** ~~42~~ **4** :http:/ / www.xbrl.org / 2003 / role / disclosureRef- Topic ~~470~~ **210** - SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph ~~1B~~ **1** - Subparagraph (SX 210. ~~13~~ **5** - 02 ( **7** ~~a) (5~~ ))- Publisher FASB- URI https:/ / asc.fasb.org / 1943274 / ~~2147480097~~ **2147480566** / ~~470- 10~~ **210** - ~~S99~~ **10** - ~~1BReference 43~~ **S99- 1 Details Name:us- gaap_PrepaidExpenseCurrentAndNoncurrent Namespace Prefix:us- gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instantX- DefinitionCash received for fees during the current period.This element excludes cash proceeds from license fees. ReferencesReference 1** :http:/ / ~~www~~ **fasb** . ~~xbrl.~~ org / ~~2003~~ **us- gaap** / role / ~~disclosureRef~~ **ref / legacyRef** - Topic ~~260~~ **230** - SubTopic 10- Name Accounting Standards Codification- Section 45- Paragraph ~~60B~~ **25** - Subparagraph ( ~~a~~ **c** )- Publisher FASB- URI https:/ / asc.fasb.org / 1943274 / ~~2147482689~~ **2147482740** / ~~260~~ **230** - 10- 45- ~~60BReference 44~~ **25 Details Name** : ~~http~~ **us- gaap_ProceedsFromFeesReceived Namespace Prefix** : ~~// www.~~ **us- gaap_ Data Type:** ~~xbrl~~ **xbrli** ~~.org / 2003 / role / disclosureRef- Topic 205- SubTopic 20- Name Accounting Standards Codification- Section 50- Paragraph 7- Publisher FASB- URI https~~ . **monetaryItemType Balance Type** ~~/ / asc.fasb.org / 1943274 / 2147483499 / 205- 20- 50- 7Reference 45~~ : ~~http~~ **debit Period Type** : ~~/ / fasb~~ **durationX- DefinitionAmount of purchase arrangement** 2147482790 / 220- 10- 45- **1AReference 47: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 220- SubTopic 10- Name Accounting Standards Codification- Section 45- Paragraph 1B- Subparagraph (a)- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482790 / 220- 10- 45-** 1BReference ~~37~~ **48: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 470- SubTopic 20- Name Accounting Standards Codification- Section 65- Paragraph 4- Subparagraph (f) (4)- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147481538 / 470- 20- 65- 4Reference 49** : http: / / fasb. org / us- gaap / role / ref / legacyRef- Topic 942- SubTopic 220- Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210. 9- 04 (22))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147478524 / 942- 220- S99- 1 Details Name: us- gaap_NetIncomeLoss Namespace Prefix: us- gaap_ Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: durationX- ReferencesNo definition available. Details Name: us- gaap_NoncashInvestingAndFinancingItemsAbstract Namespace Prefix: us- gaap_ Data Type: xbrli: stringItemType Balance Type: na Period Type: durationX- DefinitionAmount of operating lease expense. Excludes sublease income. ReferencesReference 1: http: / / www. xbrl. org / 2009 / role / commonPracticeRef- Topic 842- SubTopic 20- Name Accounting Standards Codification- Section 45- Paragraph 4- Subparagraph (b)- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147479041 / 842- 20- 45- 4 Details Name: us- gaap_OperatingLeaseExpense Namespace Prefix: us- gaap_ Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: durationX- DefinitionThe cash outflow associated with the acquisition of long- lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self- constructed assets. ReferencesReference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef- Topic 230- SubTopic 10- Name Accounting Standards Codification- Section 45- Paragraph 13- Subparagraph (c)- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482740 / 230- 10- 45- 13 Details Name: us- gaap_PaymentsToAcquirePropertyPlantAndEquipment Namespace Prefix: us- gaap_ Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: durationX- DefinitionThe cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short- term and long- term debt. ReferencesReference 1: http: / / www. xbrl. org / 2009 / role / commonPracticeRef- Topic 230- SubTopic 10- Name Accounting Standards Codification- Section 45- Paragraph 14- Subparagraph (b)- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482740 / 230- 10- 45- 14 Details Name: us- gaap_ProceedsFromIssuanceOfDebt ~~Publisher FASB~~ **Namespace Prefix:us** ~~- URI https~~ **gaap_ Data Type** : ~~// asc~~ **xbrli:monetaryItemType Balance Type:debit Period Type:durationX- DefinitionThe cash inflow from the issuance of common stock,preferred stock,treasury stock,stock options,and other types of equity** . **ReferencesReference 1** ~~fasb.org / 1943274 / 2147478546 / 942- 210- S99- 1Reference 2~~ :http:/ / **fasb** ~~www.xbrl~~ .org / ~~2009~~ **us- gaap** / role / **ref / legacyRef** ~~commonPracticeRef- Topic 944- SubTopic 210~~ - Name Accounting Standards Codification- Section ~~S99~~ **45** - Paragraph ~~1~~ **14** - Subparagraph ( ~~SX 210.7- 03 (~~ a) ~~(- SubTopic~~ 10 ~~)) - Topic 230~~ - Publisher FASB- URI https:/ / asc.fasb.org / 1943274 / ~~2147478777~~ **2147482740** / ~~944~~ **230** - ~~210~~ - **10** - ~~S99~~ **45** - ~~1Reference~~ **14Reference** ~~3~~ **2** :http:/ / www.xbrl.org / 2003 / role / disclosureRef- Topic 946- SubTopic ~~210~~ - **10** - Name Accounting Standards Codification- Section S99- Paragraph ~~1~~ **3** - Subparagraph (SX 210.6- ~~04~~ **03** ( ~~7~~ **i** ) ( ~~a~~ **1** ))- Publisher FASB- URI https:/ / asc.fasb.org / 1943274 / ~~2147479170~~ **2147479886** / 946- ~~210~~ - **10** - S99- ~~1Reference 4~~ **3 Details Name** : **us** ~~http:/ / www.xbrl.org / 2003 / role / disclosureRef~~ - **gaap_ProceedsFromIssuanceOrSaleOfEquity** ~~Topic 210-~~ Namespace Prefix: us- gaap_ Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: durationX- DefinitionThe cash inflow from a long- term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates. ReferencesReference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef- Name Accounting Standards Codification- Topic 230- SubTopic 10- Section 45- Paragraph 14- Subparagraph (b)- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482740 / 230- 10- 45- 14 Details Name: us- gaap_ProceedsFromRelatedPartyDebt Namespace Prefix: us- gaap_ Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: durationX- DefinitionThe cash inflow associated with the amount.....: debit Period Type: durationX- DefinitionAmount of expense (reversal of expense) for expected credit loss on accounts receivable. ReferencesReference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 326- SubTopic 20- Name Accounting Standards Codification- Section 50- Paragraph 13- Subparagraph (b)- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147479319 / 326- 20- 50- 13Reference 2 **: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 220- SubTopic 40- Name Accounting Standards Codification- Section 50- Paragraph 22- Subparagraph (a)- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147476148 / 220- 40- 50- 22Reference 3** : http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 220- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 2- Subparagraph (SX 210. 5- 03 (5))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147483621 / 220- 10- S99- 2 Details Name: us- gaap_ProvisionForDoubtfulAccounts Namespace Prefix: us- gaap_ Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: durationX- DefinitionThe cash outflow for a borrowing supported by a written promise to pay an obligation. ReferencesReference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef- Topic 230- SubTopic 10- Name Accounting Standards Codification- Section 45- Paragraph 15- Subparagraph (b)- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482740 / 230- 10- 45- 15 Details Name: us- gaap_RepaymentsOfNotesPayable Namespace Prefix: us- gaap_ Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: durationX- DefinitionAmount of noncash expense for share- based payment arrangement. ReferencesReference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef- Name Accounting Standards Codification- Section 45- Paragraph 28- Subparagraph (a)- SubTopic 10- Topic 230- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482740 / 230- 10- 45- 28 Details Name: us- gaap_ShareBasedCompensation Namespace Prefix: us- gaap_ Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: durationX- **DefinitionThe fair value of stock issued in noncash financing activities. ReferencesReference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef- Name Accounting Standards Codification- Topic 230- SubTopic 10- Section 50- Paragraph 4- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482913 / 230- 10- 50-** ~~ReferencesNo --- 4Reference definition available~~ **2: http: / / fasb** . **org / us** - gaap / role / ref / legacyRef - ","-Name ":"-Accounting Standards Codification - ","-Topic ":"-230 - ","-SubTopic ":"-10 - ","-Section ":"-50 - ","-Paragraph ":"-3 - ","-Publisher ":"-FASB - ","-URI ":"-https:/ / asc.fasb.org / 1943274 / 2147482913 / 230- 10- 50- **3Reference** 3 ~~" }," r19"~~ : ~~{" role":"~~ http:/ / fasb.org / us- gaap / role / ref / legacyRef **- Name Accounting Standards Codification- Topic 230- SubTopic 10- Section 50- Paragraph 5- Publisher FASB- URI https:/ / asc.fasb.org / 1943274 / 2147482913 / 230- 10- 50- 5** Details Name: us- ~~gaap_SupplementalCashFlowInformationAbstract~~ **gaap_StockIssued1** Namespace Prefix: us- gaap_ Data Type: xbrli: ~~stringItemType~~ **monetaryItemType** Balance Type: ~~na~~ **credit** Period Type: durationOrganization and Description of Business 12 Months Ended Jan. 31, ~~2024~~ **2025** Organization and Description of Business [ Abstract ] ORGANIZATION AND DESCRIPTION OF ~~BUSINESS~~ **BUSINESS1** ~~1~~ . ORGANIZATION AND DESCRIPTION OF BUSINESS Organization Nutriband Inc. (the " Company ") is a Nevada corporation, incorporated on January 4, 2016. In January 2016, the Company acquired Nutriband Ltd, an Irish company which was formed by the Company' s chief executive officer in 2012 to enter the health and wellness market by marketing transdermal patches. References to the Company relate to the Company and its subsidiaries unless the context indicates otherwise. On August 1, 2018, the Company acquired 4P Therapeutics LLC (" 4P Therapeutics ") for $ 2, 250, 000, consisting of 250, 000 shares of common stock, valued at $ 1, 850, 000, and $ 400, 000, and a royalty of 6 % on all revenue generated by the Company from the abuse deterrent intellectual property that had been developed by 4P Therapeutics payable to the former owner of 4P Therapeutics. The former owner of 4P Therapeutics **was** ~~has been~~ a director of the Company ~~since~~ **from** April 2018, when the Company entered into an agreement to acquire 4P Therapeutics ~~.~~ **until** ~~The~~ **he** ~~former owner~~ resigned as a director in January 2022. 4P Therapeutics is engaged in the development of ~~a series of~~ transdermal pharmaceutical products ~~, that are~~

~~in the preclinical stage of development. Prior to the acquisition of 4P Therapeutics, the Company' s business was the development and marketing of a range of transdermal consumer patches. Most of these products are considered drugs in the United States and cannot be marketed in the United States without approval by the Food and Drug Administration (the " FDA "). The Company entered a feasibility agreement as an initial step to seek FDA approval of its consumer transdermal products and its consumer products which are not being marketed in the United States~~. With the acquisition of 4P Therapeutics, 4P Therapeutics' drug development business became the Company' s principal business. The **primary focus of the business is to incorporate the** Company' s **Aversa** ~~approach is to use~~ **abuse** ~~generic~~ **deterrent technology into transdermal patches containing already approved** drugs ~~that are off patent and incorporate them into the Company' s transdermal drug delivery system~~. Although these **drugs are already** ~~medications have received FDA approval~~ **approved** ~~in oral or injectable form~~, the Company needs to conduct a ~~transdermal~~ product development program which will include the preclinical and clinical trials that are necessary to receive FDA approval before we can market any of our pharmaceutical products. On August 25, 2020, the Company formed Pocono Pharmaceuticals Inc. (" Pocono Pharmaceuticals "), a wholly owned subsidiary of the Company. On August 31, 2020, the Company acquired certain assets and liabilities associated with the Transdermal, Topical, Cosmetic, and Nutraceutical ~~business~~ **businesses** of Pocono Coated Products LLC (" PCP "). The net assets were contributed to Pocono Pharmaceuticals. Included in the transaction, Pocono Pharmaceuticals also acquired 100 % of the membership interests of Active Intelligence LLC (" Active Intelligence "). Pocono Pharmaceuticals is a **coated products** contract development and manufacturing organization **that supports** ~~with unique process capabilities and experience focused on coated product manufacturing. Pocono helps~~ their customers with product design **, development** and ~~development along with~~ manufacturing **services** ~~to bring new products to market with minimal capital investment~~. Pocono ~~Pharmaceutical~~ **Pharmaceuticals has specialized expertise** ~~' s competitive edge is a low- cost manufacturing base: a result of its unique processes~~ and state- of- the- art ~~material technology~~ **manufacturing capabilities for topical, transdermal and kinesiology tape products**. Active Intelligence manufactures activated kinesiology tape for ~~transdermal or topical use~~ **customers in the sports and physical markets**. X- ReferencesNo definition available. Details Name: us- gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us- gaap_ Data Type: xbrli: stringItemType Balance Type: na Period Type: durationX- DefinitionThe entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure. ReferencesReference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 946- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 1- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480424 / 946- 10- 50- 1Reference 2: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 946- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 2- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480424 / 946- 10- 50- 2Reference 3: http: / / fasb. org / us- gaap / role / ref / legacyRef- Topic 810- Name Accounting Standards Codification- Publisher FASB- URI https: / / asc. fasb. org / 810 / tableOfContentReference 4: http: / / **www. xbrl. org / 2003 / role / disclosureRef- Topic 205- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 3- Subparagraph (c)- Publisher FASB- URI https: / / asc.** fasb. org / ~~us~~ **1943274 / 2147480922 / 205** - ~~gaap~~ **10- S99- 3Reference 5: http: / / www. xbrl. org / 2003** / role / ~~ref~~ **disclosureRef- Topic 205- SubTopic 10- Name Accounting Standards Codification- Section S45- Paragraph 5- Publisher FASB- URI https:** / ~~legacyRef~~ **/ asc. fasb. org / 1943274 / 2147481034 / 205- 10- S45- 5Reference 6: http: / / www. xbrl. org / 2003 / role / disclosureRef** - Topic 205- Name Accounting Standards Codification- Publisher FASB- URI https: / / asc. fasb. org / 205 / tableOfContent Details Name: us- gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock Namespace Prefix: us- gaap_ Data Type: dtr- types: textBlockItemType Balance Type: na Period Type: durationSummary of Significant Accounting Policies 12 Months Ended Jan. 31, ~~2024~~ **2025** Summary of Significant Accounting Policies [ Abstract ] SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES ~~Forward Stock Split On July 26, 2022, our Board of Directors approved the amendment to our Articles of Incorporation to effect a 7- for- 6 forward stock split (the " Stock Split ") of our outstanding common stock. The Company filed the amendment set forth in a Certificate of Change with the Secretary of State of Nevada on August 4, 2022. The 7: 6 forward stock split was effective for trading purposes on the Nasdaq Capital Market on August 12, 2022. Each shareholder of record as of the August 15, 2022 record date received one (1) additional share for each six (6) shares held as of the record date. No fractional shares of common stock were issued in connection with the Stock Split. Instead, all shares were rounded up to the next whole share. In connection with the Stock Split, which did not require shareholder approval under the Nevada corporation law, the number of shares of common stock of the Company was increased in the same ratio as the shares of outstanding common stock were increased in the Stock Split, from 250, 000, 000 authorized shares to 291, 666, 666 authorized shares. All share and per share information in these financial statements retroactively reflect the forward stock split.~~ Going Concern Assessment Management assesses liquidity and going concern uncertainty in the Company' s condensed financial statements to determine whether there is sufficient cash on hand and working capital, including available borrowings on loans, to operate for a period of at least one year from the date the consolidated financial statements are issued or available to be issued, which is referred to as the " look- forward period ", as defined in GAAP. As part of this assessment, based on conditions that are known and reasonably knowable to management, management will consider various scenarios, forecasts, projections, estimates and will make certain key assumptions, including timing and nature of projected cash expenditures or programs, its ability to delay or curtail expenditures or programs and its ability to raise additional capital, if necessary, among other factors. Based on this assessment, as necessary or applicable, management makes certain assumptions around implementing curtailments or delays in the nature and timing of programs and expenditures to the extent it deems probable those implementations can be achieved **,** and management has the proper authority to execute them within the look- forward period. As of January 31, ~~2024~~ **2025**, the Company had cash and cash equivalents of $ ~~492~~ **4**, ~~942~~ **311, 719** and working capital of $ ~~22~~ **3**, ~~770~~ **811, 420**. For the year ended January 31, ~~2024~~ **2025**, the Company incurred a **net** loss from operations of $ ~~4~~ **10**, ~~871~~ **284**, ~~926~~ **843** and used cash flow from operations of $ ~~3~~ **4**, ~~527~~ **626**, ~~509~~ **564**. The Company has generated operating losses since its inception and has relied on sales of securities and **the** issuance of third- party and related- party debt to support cash flow from operations ~~. In October 2021, the Company consummated a public offering and received net proceeds of $ 5, 836, 230. The Company has also received to date $ 3, 239, 845 in proceeds from the exercise of warrants~~. The Company has used these proceeds to fund operations and will continue to use the funds as needed. In March 2023, the Company entered into a three- year $ 2, 000, 000 Credit Line Note facility with a related party, amended on July 13, 2023, to $ 5, 000, 000, which will permit the Company to draw down on the credit line to fund the Company' s research and development of its Aversa product. ~~The Company was advanced $ 2, 000, 000, all of which was settled by the issuance of common stock during the year ended January 31, 2024. The $ 2, 000, 000 debt and accrued interest was converted into 1, 026, 720 shares of the Company' s common stock.~~ On April 19, 2024, the Company received proceeds of $ 8, 400, 000 from **equity financing with European investors** ~~a private placement of its common stock~~. Management has prepared estimates of operations for the next twelve months and believes that sufficient funds will be generated from operations to fund its operations for one year from the date of the filing of these condensed consolidated financial statements, which indicates improved operations and the Company' s ability to continue operations as a going concern. Management believes the substantial doubt about the ability of the Company to continue as a going concern is alleviated by the above assessment. Principles of Consolidation The consolidated financial statements of the Company include the Company and its wholly owned subsidiaries. All material intercompany balances and transactions have been eliminated. The operations of 4P Therapeutics are included in the Company' s financial statements from the date of acquisition of August 1, 2018, and the **acquired** operations of Pocono **Coated Products** and Active Intelligence are included in the Company' s financial statements from the date of acquisition of September 1, 2020 **,** under Pocono Pharmaceuticals Inc. The wholly owned subsidiaries are as follows: Nutriband Ltd. 4P Therapeutics LLC Pocono Pharmaceuticals Inc. Use of Estimates The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires the Company to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an ongoing basis, the Company evaluates its estimates including, but not limited to, those related to such items as income tax exposures, accruals, depreciable / useful lives, allowance for doubtful accounts and valuation allowances. The Company bases its estimates on historical experience and on other various assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates. Revenue Recognition In May 2014, the FASB issued ASU No. 2014- 09, " Revenue from Contracts with Customers (Topic 606) (" ASU 2014- 09 "), which amends the accounting standards for revenue recognition. ASU 2014- 09 is based on principles that govern the recognition of revenue at an amount an entity expects to be entitled when products are transferred to a customer. The Company recognizes revenue based on the five criteria for revenue recognition established under Topic 606: 1) identify the contract, 2) identify separate performance obligations, 3) determine the transaction price, 4) allocate the transaction price among the performance obligations, and 5) recognize revenue as the performance obligations are satisfied. Revenue Types The following is a description of the Company' s revenue types, which include professional services and sale of goods: ● Contract development and manufacturing services for consumer health transdermal, topical and tape products with revenues listed under sale of goods **.** ● Product revenues derived from the sale of the Company' s consumer transdermal, topical and tape products with sales listed under sale of goods **.** ● Contract research and development services for ~~pharmaceuticals~~ **pharmaceutical** and medical ~~devices~~ **device** ~~for~~ life sciences customers with revenues listed under services **.** Contracts with Customers A contract with a customer exists when (i) we enter into an enforceable contract with a customer that defines each party' s rights regarding the goods or services to be transferred and identifies the payment terms related to these goods or services, (ii) the contract has commercial substance and, (iii) we

determine that collection of substantially all consideration for services that are transferred is probable based on the customer' s intent and ability to pay the promised consideration. Contract Liabilities Deferred revenue is a liability related to a revenue producing activity for which revenue has not been recognized. The Company records deferred revenue when it receives consideration from a contract before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. Performance Obligations A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in the new revenue standard. The contract transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. For the Company' s different revenue service types, the performance obligation is satisfied at different times. The Company' s performance obligations include providing products and professional services in the area of research. The Company recognizes product revenue performance obligations in most cases when the product has shipped to the customer. When we perform professional service work, we recognize revenue when we have the right to invoice the customer for the work completed, which typically occurs over time on a monthly basis for the work performed during that month. All revenue recognized in the income statement is considered to be revenue from contracts with customers. Disaggregation of Revenues The Company disaggregates its revenue from contracts with customers by type and by geographical location. See the tables: Years ~~Ended~~ **Ending** January 31, **2025** 2024 ~~2023~~ Revenue by type Sale of goods $ ~~1~~ **2** , ~~920~~ **139** , ~~280~~ **537** $ 1, ~~785~~ **920** , ~~507~~ **280** Services **-** 165, 034 ~~294, 102~~ Total $ 2, ~~085~~ **139** , ~~314~~ **537** $ 2, ~~079~~ **085** , ~~609~~ **314** Years ~~Ended~~ **Ending** January 31, **2025** 2024 ~~2023~~ Revenue by geographic location: United States $ 2, ~~085~~ **139** , ~~314~~ **537** $ 2, ~~079~~ **085** , ~~609~~ **314** Foreign-- $ 2, ~~085~~ **139** , ~~314~~ **537** $ 2, ~~079~~ **085** , ~~609~~ **314** Cash and cash equivalents. Cash and cash equivalents include cash on hand **,** ~~,~~ **and** cash on deposit in money market accounts. The Company considers short- term highly liquid investments with an original maturity date of three months or less that are not part of an investment pool to be cash equivalents. As of January 31, ~~2024~~ **2025** , the Company ~~has no balances~~ **had $ 3, 804, 000** that ~~exceed~~ **exceeded** federally insured **cash balance** limits. Accounts receivable Trade accounts receivables are recorded at the net invoice value and are not interest bearing. The Company maintains allowances for doubtful accounts for estimated losses from the inability of its customers to make the required payments. The Company determines its allowances by both ~~the~~ specific identification of customer accounts where appropriate and the application of historical loss to non- applicable accounts. For the years ended January 31, **2025, and** 2024 ~~, and 2023~~ , the Company recorded bad debt expenses of $ ~~118~~ **1** , ~~364~~ **200** and $ ~~- 0-~~ **11, 836** , respectively, for doubtful accounts related to accounts receivable. During the year ended January 31, 2024, the Company entered into an accounts receivable sale agreement for one of its subsidiaries. The Company received $ 106, 528 in funds against an account receivable that is currently a claim in bankruptcy. The net accounts receivable remain on the books of the Company and a corresponding amount has been included as a secured borrowing liability under Notes payable. As of January 31, ~~2024~~ **2025** , the receivable has been reserved in full. If the bankruptcy claim is not paid in full by the debtor, Company is obligated to pay any difference to the factor. The loan bears interest at 10 %. The Company adopted ASU 2016- 13 during ~~2023~~ **2013** and implemented the guidance on expected credit losses. Inventories Inventories are valued at the lower of cost and reasonable value determined using the first- in, first- out (FIFO) method. Net realized value is the estimated selling price in the ordinary course of business, less applicable variable selling expenses. The cost of finished goods and work in process is comprised of material costs, direct labor costs and other direct costs and related production overheads (based on normal operating capacity). As of January 31, **2025, total inventory was $ 212, 041, consisting of work- in- process of $ 46, 255, finished goods of $ 16, 609 and raw materials of $ 149, 177. As of January 31,** 2024, total inventory was $ 168, 605, consisting of work- in- process of $ 7, 466, finished goods of $ 8, 707 and raw materials of $ ~~134~~ **152** , **432** ~~691. As of January 31, 2023, total inventory was $ 229, 335, consisting of work- in- process of $ 11, 021 and raw materials of $ 218, 334~~ . Property, Plant and Equipment Property and equipment represent an important component of the Company' s assets. The Company depreciates its plant and equipment on a straight- line basis over the estimated useful life of the assets. Property, plant and equipment is stated at historical cost. Expenditures for minor repairs, maintenance and replacement parts which do not increase the useful lives of the assets are charged to expense as incurred. All major additions and improvements are capitalized. Depreciation is computed using the straight- line method. The lives over which the fixed assets are depreciated range from 3 to 20 years as follows: Lab Equipment 5- 10 years Furniture and fixtures 3 **- 5** years Machinery and equipment ~~10~~ **5** - 20 years Intangible Assets Intangible assets include trademarks, intellectual property and customer base acquired through business combinations. The Company accounts for Other Intangible Assets under the guidance of ASC 350, " Intangibles- Goodwill and Other. " The Company capitalizes certain costs related to patent technology. A substantial component of the purchase price related to the Company' s acquisitions ~~have~~ **has** also been assigned to intellectual property and other intangibles. Under the guidance, other intangible assets with definite lives are amortized over their estimated useful lives. Intangible assets with indefinite lives are tested annually for impairment. Trademarks, ~~intellectual~~ **Intellectual** property and customer base are being amortized over their estimated useful lives of ten years. **During the year ending January 31, 2025, the Company recorded an impairment charge of $ 293, 038 to its Intellectual property.** Goodwill Goodwill represents the difference between the total purchase price and the fair value of assets (tangible and intangible) and liabilities at the date of acquisition. Goodwill is reviewed for impairment annually on January 31, and more frequently as circumstances warrant, and written down only in the period in which the recorded value of such assets exceeds their fair value. The Company does not amortize goodwill in accordance with ASC 350. In connection with the Company' s acquisition of 4P Therapeutics LLC in 2018, the Company recorded Goodwill of $ 1, 719, 235. On August 31, 2020, in connection with the Company' s acquisition of Pocono Coated Products LLC and Active Intelligence LLC, the Company recorded Goodwill of $ 5, 810, 640. During the years ~~ended~~ **ending** January 31, **2025 and** 2024 ~~, and 2023~~ , the Company recorded an impairment charge of $ ~~- 0-~~ **3, 302, 478** and $ ~~327, 326~~ **- 0-** , respectively, reducing the Active Intelligence LLC Goodwill to $ **- 0-** ~~3, 302, 478~~ . As of January 31, **2025 and** 2024 ~~, and 2023~~ , Goodwill amounted to $ ~~5~~ **1** , ~~021~~ **719** , ~~713~~ **535** and $ 5, 021, 713, respectively. Long- lived Assets Management reviews long- lived assets for potential impairment whenever significant events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An impairment exists when the carrying amount of the long- lived asset is not recoverable and exceeds its fair value. The carrying amount of a long- lived asset is not recoverable if it exceeds the sum of the estimated undiscounted cash flows expected to result from the use and eventual disposition of the asset. If an impairment exists, the resulting write- down would be the difference between the fair market value of the long- lived asset and the related book value. Earnings per Share Basic earnings per share of common stock is computed by dividing net earnings by the weighted average number of shares of common stock outstanding during the period. Diluted earnings per share is computed by dividing net earnings by the weighted average number of shares of common stock and potential shares of common stock outstanding during the period. Potential shares of common stock consist of shares issuable upon the exercise of outstanding options and common stock purchase warrants. As of January 31, **2025, and** 2024 ~~, and 2023~~ , there were **6, 920, 641 and** 2, 157, 873 ~~and 1, 778, 006~~ common stock equivalents outstanding, that were not included in the calculation of dilutive earnings per share as their effect would be anti- dilutive. Stock- Based Compensation ASC 718, " Compensation- Stock Compensation, " prescribes accounting and reporting standards for all share- based payment transactions in which employee services, and, since February 1, 2019, non- employees, are acquired. Transactions include incurring liabilities, or issuing or offering to issue shares, options and other equity instruments such as employee stock ownership plans and stock appreciation rights. Share- based payments to employees, including grants of employee stock options, are recognized as compensation expense in the financial statements based on their fair values. That expense is recognized over the period during which an employee is required to provide services in exchange for the award, known as the requisite service period (usually the vesting period). As of February 1, 2019, pursuant to ASC 2018- 07, ASC 718 was applied to stock- based compensation for both employees and non- employees. Business Combinations The Company recognizes the assets acquired, the liabilities assumed, and any non- controlling interest in the acquired entity at the acquisition date, measured at their fair values as of that date, with limited exceptions specified in the accounting literature. In accordance with this guidance, acquisition- related costs, including restructuring costs, must be recognized separately from the acquisition and will generally be expensed as incurred. That replaces the cost- allocation process detailed in previous accounting literature, which required the cost of an acquisition to be allocated to the individual assets acquired and liabilities assumed based on their estimated fair value. Leases In February 2016, the FASB issued ASU 2016- 02, " Leases " (Topic 842), to provide a new comprehensive model for lease accounting under this guidance, lessees and lessors should apply a " right- of- use " model in accounting for all leases (including subleases) and eliminate the concept of operating leases and off- balance- sheet leases. Recognition, measurement and presentation of expenses will depend on classification as a finance or operating lease. Similar modifications have been made to lessor accounting in- line with revenue recognition guidance. The Company applies **the** guidance for right- of- use accounting for all leases and records the operating lease liabilities on its balance sheet. The Company completed the necessary changes to its accounting policies, processes, disclosure and internal control over financial reporting. Research and Development Expenses Research and development costs are expensed as incurred. Income Taxes Taxes are calculated in accordance with taxation principles currently effective in the United States and Ireland. The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. The Company records net deferred tax assets to the extent they believe these assets will more ~~-~~likely ~~-~~than ~~-~~not be realized. In making such determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax planning strategies and recent financial

operations. In the event the Company was ~~to determine~~ **determined** that it would be able to realize its deferred income tax assets in the future in excess of its net recorded amount, the Company would make an adjustment to the valuation allowance which would reduce the provision for income taxes. Fair Value Measurements FASB ASC 820, " Fair Value Measurements and Disclosure " (" ASC 820 "), defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between participants on the measurement date. ASC 820 also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value. The Company utilizes the accounting guidance for fair value measurements and disclosures for all financial assets and liabilities and nonfinancial assets and liabilities that are recognized or disclosed at fair value in the consolidated financial statements on a recurring basis during the reporting period. The fair value is an exit price, representing the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants based upon the best use of the asset or liability at the measurement date. The Company utilizes market data or assumptions that market participants would use in pricing the asset or liability. ASC 820 establishes a three- tier value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers are defined as follows: Level 1- Observable inputs such as quoted market prices in active markets. Level 2- Inputs other than quoted prices in active markets that are either directly or indirectly observable. Level 3- Unobservable inputs about which little or no market data exists, therefore requiring an entity to develop its own assumptions. The carrying value of the Company' s financial instruments, including accounts receivable, prepaid expenses, accounts payable and accrued expenses, and deferred revenue approximate their fair value due to the short maturities of these financial instruments. Recent Accounting Standards ~~In June 2016, the FASB issued ASU 2016- 13, Financial Instruments- Credit Losses (Topic 326), The ASU introduces a new credit loss methodology. Current Expected Credit Loss (" CECL "), which requires earlier recognition of credit losses, which also provides additional transparency about credit risk. Since its original issuance in 2016, the FASB has issued several updates to the original ASU. The Company adopted ASU 2016- 13 during the year ended January 31, 2024. The adoption of ASU 2016- 13 did not have a material impact on the Company' s balance sheet or statement of operations.~~ The Company has reviewed all other FASB- issued ASU accounting pronouncements and interpretations thereof that have effective dates during the period reported and in future periods. The Company has carefully considered the new pronouncements that alter previous GAAP and does not believe that any new or modified principles will have a material impact on the Company' s reported financial position or operations in the near term. The applicability of any standard is subject to the formal review of the Company' s financial management and certain standards are under consideration. X- ReferencesNo definition available. Details Name: us- gaap_AccountingPoliciesAbstract Namespace Prefix: us- gaap_ Data Type: xbrli: stringItemType Balance Type: na Period Type: durationX- DefinitionThe entire disclosure for all significant accounting policies of the reporting entity. ReferencesReference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 235- ~~SubTopic 10-~~ Name Accounting Standards Codification- ~~Section 50- Paragraph 1-~~ Publisher FASB- URI https: / / asc. fasb. org / ~~1943274 / 2147483426 /~~ 235 **/ tableOfContentReference** ~~-10- 50- 1Reference~~ 2: http: / / ~~fasb~~ **www . xbrl.** org / **2003** ~~us- gaap~~ / role / **disclosureRef** ~~ref / legacyRef~~ - Topic 235 **- SubTopic 10** - Name Accounting Standards Codification- **Section 50- Paragraph 1-** Publisher FASB- URI https: / / asc. fasb. org / **1943274 / 2147483426 /** 235 ~~/ tableOfContent~~ **- 10- 50- 1** Details Name: us- gaap_SignificantAccountingPoliciesTextBlock Namespace Prefix: us- gaap_ Data Type: dtr- types: textBlockItemType Balance Type: na Period Type: durationProperty and Equipment 12 Months Ended Jan. 31, ~~2024~~ **2025** Property and Equipment [ Abstract ] PROPERTY AND EQUIPMENT 3. PROPERTY AND EQUIPMENT January 31, **2025** 2024 ~~2023~~ Lab equipment $ 144, 585 $ 144, 585 Machinery and equipment 1, **384, 432 1,** 292, 389 ~~1, 240, 628~~ Furniture and fixtures 19, 643 19, 643 1, **548, 660 1,** 456, 617 ~~1, 404, 856~~ Less: Accumulated depreciation ( **853, 597) (** 681, 693 ~~) (507, 121~~ ) Net Property and Equipment $ **695, 063 $** 774, 924 ~~$ 897, 735~~ Depreciation expenses amounted to $ ~~174~~ **171** , ~~572~~ **903** and $ ~~183~~ **174** , ~~660~~ **572** for the years ~~ended~~ **ending** January 31, **2025, and** 2024, ~~and 2023,~~ respectively. During the years ~~ended~~ **ending** January 31, **2025, and** 2024 ~~, and 2023~~ , depreciation expenses of $ ~~131~~ **127** , ~~360~~ **888** and $ ~~139~~ **131** , ~~689~~ **360** , respectively, have been allocated to **the** cost of goods sold. X- ReferencesNo definition available. Details Name: us- gaap_PropertyPlantAndEquipmentAbstract Namespace Prefix: us- gaap_ Data Type: xbrli: stringItemType Balance Type: na Period Type: durationX- DefinitionThe entire disclosure for long- lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections. ReferencesReference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef- Topic 360- Name Accounting Standards Codification- Publisher FASB- URI https: / / asc. fasb. org / 360 / tableOfContentReference 2: http: / / www. xbrl. org / 2003 / role / disclosureRef- Name Accounting Standards Codification- Section 50- Paragraph 6- SubTopic 360- Topic 958- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147477798 / 958- 360- 50- 6Reference 3: http: / / www. xbrl. org / 2003 / role / disclosureRef- Name Accounting Standards Codification- Section 50- Paragraph 1- Subparagraph (d)- SubTopic 360- Topic 958- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147477798 / 958- 360- 50- 1Reference 4: http: / / www. xbrl. org / 2003 / role / disclosureRef- Name Accounting Standards Codification- Section 50- Paragraph 7- SubTopic 360- Topic 958- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147477798 / 958- 360- 50- 7 Details Name: us- gaap_PropertyPlantAndEquipmentDisclosureTextBlock Namespace Prefix: us- gaap_ Data Type: dtr- types: textBlockItemType Balance Type: na Period Type: **the passage of time** ~~Codification- Section 50- Paragraph 1- Subparagraph (d)- Publisher FASB- URI https: / / asc.fasb.org -~~ **or when a triggering event occurs. ReferencesReference 1** ~~/ 1943274 / 2147477092 / 405- 40- 50- 1Reference 7~~ :http: / / ~~www~~ **fasb . xbrl.** org / ~~2003~~ **us- gaap** / role / ~~disclosureRef~~ **ref / legacyRef** - Topic ~~405~~ **942** - SubTopic ~~40~~ **210** - Name Accounting Standards Codification- Section ~~50~~ **S99** - Paragraph 1- Subparagraph ( ~~a)~~ **SX 210.9- 03** ( ~~3-~~ **10)** )- Publisher FASB- URI https: / / asc.fasb.org / 1943274 / ~~2147477092~~ **2147478546** / ~~405~~ **942** - ~~40~~ **210** - ~~50~~ **S99** - 1Reference ~~8~~ **2** :http: / / www.xbrl.org / ~~2003~~ **2009** / role / ~~disclosureRef~~ **commonPracticeRef** - Topic ~~405~~ **944** - SubTopic ~~40~~ **210** - Name Accounting Standards Codification- Section ~~50~~ **S99** - Paragraph 1- Subparagraph ( **SX 210.7- 03 (** a) ( ~~2-~~ **10)** )- Publisher FASB- URI https: / / asc.fasb.org / 1943274 / ~~2147477092~~ **2147478777** / ~~405~~ **944** - ~~40~~ **210** - ~~50~~ **S99** - 1Reference ~~9~~ **3** :http: / / www.xbrl.org / 2003 / role / disclosureRef- Topic ~~405~~ **946** - SubTopic ~~40~~ **210** - Name Accounting Standards Codification- Section ~~50~~ **S99** - Paragraph 1- Subparagraph ( **SX 210.6- 04 (7) (** a) ~~(1-~~ )- Publisher FASB- URI https: / / asc.fasb.org / 1943274 / ~~2147477092 -~~ **2147479170** / ~~405~~ **946** - ~~40~~ **210** - ~~50~~ **S99** - 1Reference ~~10~~ **4** :http: / / www.xbrl.org / 2003 / role / disclosureRef- Topic ~~405~~ **210** - SubTopic ~~40~~ **10** - Name Accounting Standards Codification- Section ~~50~~ **S99** - Paragraph 1- Subparagraph ( ~~a~~ **SX 210.5- 02 (7)** )- Publisher FASB- URI https: / / asc.fasb.org / 1943274 / ~~2147477092~~ **2147480566** / ~~405~~ **210** - ~~40~~ **10** - ~~50~~ **S99** - ~~1Reference 11~~ **1 Details Name:us- gaap_PrepaidExpenseCurrentAndNoncurrent Namespace Prefix:us- gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instantX- DefinitionCash received for fees during the current period.This element excludes cash proceeds from license fees. ReferencesReference 1** :http: / / ~~www~~ **fasb . xbrl.** org / ~~2003~~ **us- gaap** / role / ~~disclosureRef~~ **ref / legacyRef** - Topic ~~470~~ **230** - SubTopic ~~20~~ **10** - Name Accounting Standards Codification- Section ~~50~~ **45** - Paragraph ~~1B~~ **25** - Subparagraph ( ~~h~~ **c** )- Publisher FASB- URI https: / / asc.fasb.org / 1943274 / ~~2147481139~~ **2147482740** / ~~470- 20~~ **230** - ~~50~~ **10** - ~~1BReference 12:http: / / fasb.org / us- gaap / role / ref / legacyRef- Topic 470- Name Accounting Standards Codification- Publisher FASB- URI https: / / asc.fasb.org / 470 / tableOfContentReference 13:http: / / www.xbrl.org / 2003 / role / disclosureRef- Topic 835- SubTopic 30- Name Accounting Standards Codification- Section~~ 45- **25 Details Name** ~~Paragraph 2- Publisher FASB- URI https : / /~~ **us- gaap_ProceedsFromFeesReceived Namespace Prefix:us- gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:durationX- DefinitionAmount of purchase arrangement** durationIncome Taxes 12 Months Ended Jan. 31, ~~2024~~ **2025** Income Taxes [ Abstract ] INCOME TAXES ~~4~~ **5** . INCOME TAXES The Company adopted the provisions of ASC 740, " Income Taxes, (" ASC 740 "). As a result of the implementation of ASC 740, the Company recognized no adjustment in the net liability for unrecognized income tax benefits. The Company believes there are no potential uncertain tax positions, and all tax returns are correct as filed. Should the Company recognize a liability for uncertain tax positions, the Company will separately recognize the liability for uncertain tax positions on its balance sheet. Included in any liability or uncertain tax positions, the Company will also ~~set~~ **setup** ~~up~~ a liability for interest and penalties. The Company' s policy is to recognize interest and penalties related to uncertain tax positions as a component of the current provision for income taxes. There is no U. S. tax provision due to losses from U. S. operations for the years ~~ended~~ **ending** January 31, **2025 and** 2024 ~~and 2023~~ . Deferred income taxes are provided for the temporary differences between the financial reporting and tax basis of the Company' s assets and liabilities. The principal item giving rise to deferred taxes is the net operating loss carryforward in the U. S. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. The Company has set up a valuation allowance for losses for certain carryforwards that it believes may not be realized. The provision for income taxes consists of the following: Years ~~Ended~~ **Ending** January 31, **2025** 2024 ~~2023~~ Current Federal $- $- Foreign-- Deferred Federal-- Foreign-- A reconciliation of taxes on income computed at the federal statutory rate to amounts provided is as follows: Years ~~Ended~~ **Ending** January 31, **2025** 2024 ~~2023~~ Book Income (loss from operations) $ ( **2, 201, 350) $ (** 1, 151, 916 ~~) $ (941, 530~~ ) Common stock issued for services **323, 880** 155, 966 ~~168, 768~~ Impairment expense **754** ~~- 68~~ , ~~738~~ **996-** Unused operating losses **1, 122, 474** 995, 950 ~~704, 024~~ Income tax expense $- $- As of January 31, ~~2024~~ **2025** , the Company recorded a deferred tax asset associated with a net operating loss (" NOL ") carryforward of approximately $ ~~15~~ **21** , ~~800~~ **000** , 000 that was fully offset by a valuation allowance due to the determination that it was more likely than not that the Company would be unable to utilize those benefits in the foreseeable future. The Company' s NOL expires in 2041. The tax effect of the valuation allowance increased by approximately $ ~~1~~ **2** , ~~151~~ **200** , ~~916~~ **000** during the year ~~ended~~ **ending** January 31, ~~2024~~ **2025** . On December 22, 2017, the Tax Cuts and Jobs Act (the " Tax Act ") significantly revised U. S. corporate income tax law by, among other things, reducing the corporate rate from 34 % to 21 %. Because the

Company recognizes a valuation allowance for the entire balance, there is no net impact on the Company' s balance sheet or results of operations. The types of temporary differences between tax basis of assets and liabilities and their financial reporting amounts that give rise to the deferred tax liability and deferred tax asset and their approximate tax effects are as follows: January 31, **2025** 2024 ~~2023~~ Net operating loss carryforward (expire through ~~2040~~ **2041** ) $ ( **4, 435, 172) $ (** 3, 312, 698 ~~) $ (2, 316, 748~~ ) Stock issued for services ~~$~~ (1, **779, 728) (1,** 455, 848 ~~) (1, 299, 882~~ ) Intangible impairment expense ~~$~~ (1, ~~051~~ **806** , ~~714~~ **709** ) (1, 051, 714) Valuation allowance ~~$~~ **8, 021, 609** 5, 820, 260 ~~4, 668, 344~~ Net deferred taxes $- $- X **- ReferencesNo definition available. Details Name: us-gaap_IncomeTaxDisclosureAbstract Namespace Prefix: us- gaap_ Data Type: xbrli: stringItemType Balance Type: na Period Type: durationX** - DefinitionThe entire disclosure for income tax. ReferencesReference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic **942- SubTopic** 740 ~~- SubTopic 10~~ - Name Accounting Standards Codification- Section 50- Paragraph ~~12~~ **1- Subparagraph (a)** - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147482685~~ **2147477617** / **942-** 740- ~~10-~~ 50- ~~12Reference~~ - **1Reference** 2: http: / / www. xbrl. org / 2003 / role / ~~exampleRef~~ **disclosureRef** - Topic ~~740~~ **235** - SubTopic 10- Name Accounting Standards Codification- Section ~~55~~ **S50** - Paragraph ~~231~~ **1** - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147482663~~ **2147480738** / **235- 10- S50- 1Reference 3: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 944- SubTopic** 740 ~~- 10- 55- 231Reference 3: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 740- SubTopic 10~~ - Name Accounting Standards Codification- Section 50- Paragraph ~~12C~~ **1- Subparagraph (a)** - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147482685~~ **2147478822** / **944-** 740- ~~10-~~ 50- ~~12CReference~~ - **1Reference** 4: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 740- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph ~~12B~~ - **12** - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482685 / 740- 10- 50- ~~12BReference~~ - **12Reference** 5: http: / / www. xbrl. org / 2003 / role / ~~disclosureRef~~ **exampleRef** - Topic 740- SubTopic ~~270~~ **10** - Name Accounting Standards Codification- Section ~~50~~ **55** - Paragraph ~~1~~ **231** - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147477891~~ **2147482663** / 740- ~~270~~ **10** - ~~50~~ **55** - ~~1Reference~~ **231Reference** 6: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 740- SubTopic 10- Name Accounting Standards Codification- Section **" 50- Paragraph 12C- Publisher** FASB - ","- URI ":"- https:/ / asc.fasb.org / 1943274 / 2147482685 / 740- 10- 50- **12CReference 7** ~~10" },"- r461"~~ : ~~{" role":"~~ http:/ / www.xbrl.org / 2003 / role / disclosureRef - ","- Topic ":"- 740 - ","- SubTopic ":"- 10 - ","- Name ":"- Accounting Standards Codification - ","- Section ":"- 50 - ","- Paragraph ":"- ~~12~~ **12B -** ","- Publisher ":"- FASB - ","- URI ":"- https:/ / asc.fasb.org / 1943274 / 2147482685 / 740- 10- 50- **12BReference 8** ~~12" },"- r462"~~ : ~~{" role":"~~ http:/ / www.xbrl.org / 2003 / role / disclosureRef - ","- Topic **" 740- SubTopic 270- Name Accounting Standards Codification- Section 50- Paragraph 1- Publisher FASB- URI https** : **"/ / asc.fasb.org / 1943274 / 2147477891 /** 740 ","- **- 270- 50- 1Reference 9:http: / / www.xbrl.org / 2003 / role / disclosureRef- Topic 740-** SubTopic ":"- 10 **- Name Accounting Standards Codification- Section** S99- Paragraph 1- Subparagraph (SAB Topic 6. I. 5. Q1)- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147479360 / 740- 10- S99- 1Reference ~~7~~ **10** : http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 946- SubTopic 20- Name Accounting Standards Codification- Section 50- Paragraph 13- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480990 / 946- 20- 50- 13Reference ~~8~~ **11** : http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 235- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210. 4- 08 (h) (2))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480678 / 235- 10- S99- 1Reference ~~9~~ **12** : http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 740- Name Accounting Standards Codification- Publisher FASB- URI https: / / asc. fasb. org / 740 / tableOfContentReference ~~10~~ **13** : http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 740- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 14- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482685 / 740- 10- 50- 14Reference ~~11~~ **14** : http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 740- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 21- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482685 / 740- 10- 50- 21Reference ~~12~~ **15** : http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 740- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 17- Subparagraph (b)- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482685 / 740- 10- 50- 17Reference ~~13~~ **16** : http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 740- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 2- Subparagraph (SAB Topic 11. C)- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147479360 / 740- 10- S99- 2Reference ~~14~~ **17** : http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 740- SubTopic 30- Name Accounting Standards Codification- Section 50- Paragraph 2- Subparagraph (a)- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482603 / 740- 30- 50- 2 Details Name: us- gaap_IncomeTaxDisclosureTextBlock Namespace Prefix: us- gaap_ Data Type: dtr- types: textBlockItemType Balance Type: na Period Type:..... gaap_ Data Type: xbrli: stringItemType Balance Type: na Period Type: durationIntangible Assets 12 Months Ended Jan. 31, ~~2024~~ **2025** Intangible Assets [ Abstract ] INTANGIBLE ASSETS 6. INTANGIBLE ASSETS As of January 31, **2025, and** 2024 ~~, and 2023~~ , intangible assets consisted of intellectual property and trademarks, customer base, and license agreement, net of amortization, as follows: January 31, **2025** 2024 ~~2023~~ Customer base $ ~~314~~ **214** , ~~100~~ **940** $ 314, 100 Intellectual property and trademarks ~~817~~ **623** , ~~400~~ **822** 817, 400 Total ~~1~~ **838** , **462** ~~131, 500~~ 1, 131, 500 Less: Accumulated amortization ( **577, 370) (** 464, 220 ~~) (351, 070~~ ) Net Intangible Assets $ **261, 092 $** 667, 280 ~~$ 780, 430 In February 2021, the Company acquired an IP license from Rambam Med- Tech Ltd. for $ 50, 000. The value of the intangible assets, consisting of intellectual property, license agreement and customer base has been recorded at their fair value by the Company and are being amortized over a period of three to ten years. The Company terminated the license agreement in October 2022. The Company issued 25, 000 shares of its common stock from its treasury shares held by the Company and warrants to purchase 25, 000 shares at an exercise price of $ 7. 50 per share as part of the termination agreement. The Company recorded a termination expense of $ 174, 025 during the year ended January 31, 2023. Which is included in selling, general and administrative expenses. The Company expensed the balance of the agreement of $ 33, 334 during the year ended January 31, 2023, which is included in selling, general and administrative expenses.~~ Amortization expenses for the years **ended ending** January 31, **2025, and** 2024 ~~, and 2023~~ amounted to $ 113, 150 and $ ~~146~~ **113** , ~~483~~ **150** , respectively **. During the year ending January 31, 2025, the Company recorded an impairment charge of $ 298, 038 to its Intellectual property** . Year Ended January 31, **Total** ~~2025~~ **2026** $ ~~113~~ **60** , **666** ~~109~~ ~~2026~~ ~~113, 109~~ 2027 ~~113~~ **60** , ~~109~~ **666** 2028 ~~113~~ **60** , ~~109~~ **666** 2029 ~~113~~ **41** , ~~109~~ **736** 2030 **33, 218 2031** and thereafter ~~101~~ **4** , ~~735~~ **142** $ ~~667~~ **261** , ~~280~~ **092** X **- ReferencesNo definition available. Details Name: us- gaap_FiniteLivedIntangibleAssetsNetAbstract Namespace Prefix: us- gaap_ Data Type: xbrli: stringItemType Balance Type: na Period Type: durationX** - DefinitionThe entire disclosure for all or part of the information related to intangible assets. ReferencesReference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 350- SubTopic 30- Name Accounting Standards Codification- Publisher FASB- URI https: / / asc. fasb. org / 350- 30 / tableOfContentReference 2: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 350- SubTopic 30- Name Accounting Standards Codification- Section 50- Paragraph 4- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482665 / 350- 30- 50- 4Reference 3: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 350- SubTopic 30- Name Accounting Standards Codification- Section 50- Paragraph 3- Subparagraph (a)- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482665 / 350- 30- 50- 3Reference 4: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 985- SubTopic 20- Name Accounting Standards Codification- Section 50- Paragraph 2- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147481283 / 985- 20- 50- 2Reference 5: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 985- SubTopic 20- Name Accounting Standards Codification- Publisher FASB- URI https: / / asc. fasb. org / 985- 20 / tableOfContent Details Name: us- gaap_IntangibleAssetsDisclosureTextBlock Namespace Prefix: us- gaap_ Data Type: dtr- types: textBlockItemType Balance Type: na Period Type: ~~durationX- ReferencesNo definition available. Details Name: us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract Namespace Prefix: us- gaap_ Data Type: xbrli: stringItemType Balance Type: na Period Type:~~ durationRelated Party Transactions 12 Months Ended Jan. 31, ~~2024~~ **2025** Related Party Transactions [ Abstract ] RELATED PARTY TRANSACTIONS 7. RELATED PARTY TRANSACTIONS Activity during the year ended January 31, **2025 a) During the year ended January 31, 2025, options to purchase 689, 584 shares of common stock were issued to executives and employees of the Company at a price of $ 2. 37 and $ 8. 08 per share. The options vest immediately and expire in three years. The fair value of the options issued amounted to $ 1, 408, 935 and were expensed during the year ending January 31, 2025. b) On April 19, 2024, the Company completed an $ 8, 400, 000 equity financing with European investors which included two related parties. The two related parties invested a total of $ 6, 420, 000 and received 1, 605, 000 shares of common stock and warrants to purchase 3, 210, 000 shares of common stock @ $ 6. 43 per share. See Note 8 for further information. c) During the year ending January 31, 2025, the Company received $ 300, 000 from the credit line facility with TII Jet Services LDA. On May 15, 2024, the Company converted the debt and accrued interest into 76, 230 shares of common stock and issued 152, 460 warrants to the lender. See Note 4 for further information. d) On June 5, 2024, the Company' s Chief Financial Officer exercised 87, 500 warrants as a cashless conversion and was issued 60, 085 shares of common stock. Activity during the year ended January 31,** 2024 a) On February 1, 2023, options to purchase 30, 000 shares of the Company' s common stock were issued to an executive of the Company at a price of $ 3. 975 per share. The options vest immediately and expire in three years. The fair value of the options issued for services amounted to $ 75, 030 and was expensed during the year ~~ended~~ **ending** January 31, 2024. b ~~) In September and October 2023, options to purchase 374, 500 shares of common stock to executives and directors of the Company at a price of $ 1. 93, $ 2. 12 and $ 2. 65 per share. The options vest immediately and expire in three years. The fair value of the options issued amounted to $ 424, 826 and was expensed during the year ended January 31, 2024. c) On October 26, 2023, warrants to purchase 87, 500 shares of the Company' s common stock were issued to the Chief Financial Officer at a price of $ 1. 93 per share. The warrant expires in three years. The fair value of the warrants issued amounted to $ 93, 450 and was expensed during the year ended January 31, 2024. d~~ ) On July 17, 2023, the Company entered **into** an amended Credit Line Note facility with TII Jet

Services , LDA, a shareholder of the Company, for a credit facility of $ 5 ~~million (~~ , 000, 000 replacing the $ 2, 000, 000 facility with the same lender that the Company entered into on March 17, 2023 ~~)~~. See Note ~~5~~ 4 for further information. TII Jet Services LDA is owned 100 % by a shareholder of the Company. During the year ~~ended~~ ending January 31, 2024, the Company received $ 2, 000, 000 from the credit facility. In December 2023, TII Jet Services LDA converted the balance of ~~the~~ credit facility of $ 2, 000, 000 and $ 53, 436 of accrued interest into 1, ~~026~~ 036 , 520 shares of the Company' s common stock. **c) In September and October** ~~Activity during the year ended January 31,~~ 2023 ~~a) In May 2022 , the Company issued stock awards to the Company' s CEO and the independent members of the Board of Directors. The CEO received 11, 667 shares and the four directors received 1, 167 shares each. The Company recorded a compensation expense of $ 53, 200 in connection with the issuance of the shares. b) On August 2, 2022, 137, 084~~ options to purchase 374, 500 shares of ~~the Company' s~~ common stock were issued to executives and directors of the Company at a ~~prices~~ price of $ ~~4~~ 1 , ~~09~~ 93, $ 2. 12 and $ ~~4~~ 2 . ~~50~~ 65 per share. The options vest immediately and expire in three years. The fair value of the options issued ~~for services~~ amounted to $ ~~399~~ 424 , ~~075~~ 826 and was expensed during the year ~~ended~~ ending January 31, 2024. d) On October 31, 2023 ~~. c) On September 30 ,~~ warrants ~~2022, 35, 000 options~~ to purchase 87, 500 shares of the Company' s common stock were issued to the ~~independent directors of the~~ Company ' s Chief Financial Officer at a price of $ ~~3~~ 1 . ~~59~~ 93 per share. The warrant ~~options vest immediately and expire~~ expires in ~~five~~ three years. The fair value of the warrants ~~options issued for services amounted to $ 85, 995 and was expensed during the year ended January 31, 2023 d) On December 7, 2022, options to purchase 107, 500 shares of the Company' s common stock were issued to executives of the Company at prices of $ 3. 53 and $ 3. 88 per share. The options vest immediately and expire in three years. The fair value of the options~~ issued amounted to $ ~~245~~ 93 , ~~170~~ 450 and ~~was~~ were expensed during the year ~~ended~~ ending January 31, ~~2023~~ 2024 . X- ReferencesNo definition available. Details Name: us- gaap_RelatedPartyTransactionsAbstract Namespace Prefix: us- gaap_ Data Type: xbrli: stringItemType Balance Type: na Period Type: durationX- DefinitionThe entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates. ReferencesReference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic ~~946~~ 850 - SubTopic ~~20~~ 10 - Name Accounting Standards Codification- Section 50- Paragraph ~~2~~ 1- Subparagraph (d) - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147480990~~ 2147483326 / ~~946~~ 850 - ~~20~~ 10 - 50- ~~2Reference~~ 1Reference 2: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 946- SubTopic 20- Name Accounting Standards Codification- Section 50- Paragraph ~~5~~ 2 - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480990 / 946- 20- 50- ~~5Reference~~ 2Reference 3: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 946- SubTopic 20- Name Accounting Standards Codification- Section 50- Paragraph ~~6~~ 5 - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480990 / 946- 20- 50- ~~6Reference~~ 5Reference 4: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 946- SubTopic ~~235~~ 20 - Name Accounting Standards Codification- Section 50- Paragraph 6 ~~2- Subparagraph (c)~~ - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147477968~~ 2147480990 / 946- ~~235~~ 20 - 50- ~~2Reference~~ 6Reference 5: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 946- SubTopic 235- Name Accounting Standards Codification- Section 50- Paragraph 2- Subparagraph ( ~~c~~ c )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147477968 / 946- 235- 50- 2Reference 6: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic ~~850~~ 946 - SubTopic ~~10~~ 235 - Name Accounting Standards Codification- Section 50- Paragraph ~~1~~ 2 - Subparagraph ( ~~d~~ e )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147483326~~ 2147477968 / ~~850~~ 946 - ~~10~~ 235 - 50- ~~1Reference~~ 2Reference 7: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 946- SubTopic 220- Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210. 6- 07 (2) (g) (3))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147479134 / 946- 220- S99- 1Reference 8: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 946- SubTopic 220- Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210. 6- 07 (2) (c))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147479134 / 946- 220- S99- 1Reference 9: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 946- SubTopic 220- Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210. 6- 07 (2) (e))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147479134 / 946- 220- S99- 1Reference 10: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 850- Name Accounting Standards Codification- Publisher FASB- URI https: / / asc. fasb. org / 850 / tableOfContentReference 11: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 850- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 6- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147483326 / 850- 10- 50- 6Reference 12: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 850- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 1- Subparagraph (a)- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147483326 / 850- 10- 50- 1Reference 13: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 850- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 1- Subparagraph (b)- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147483326 / 850- 10- 50- 1 Details Name: us- gaap_RelatedPartyTransactionsDisclosureTextBlock Namespace Prefix: us- gaap_ Data Type: dtr- types: textBlockItemType Balance Type: na Period Type: durationStockholders' Equity 12 Months Ended Jan. 31, ~~2024~~ 2025 Stockholders ' Equity [ Abstract ] STOCKHOLDERS' EQUITY 8. STOCKHOLDERS' EQUITY Preferred Stock On January 15, 2016, the board of directors of the Company approved a certificate of amendment to the articles of incorporation and changed the authorized capital stock of the Company to include and authorize 10, 000, 000 shares of Preferred Stock, par value $ 0. 001 per share. On May 24, 2019, the board of directors created a series of preferred stock consisting of 2, 500, 000 shares designated as the Series A Convertible Preferred Stock (" Series A Preferred Stock "). On June 20, 2019, the Series A preferred Stock was terminated, and the 2, 500, 000 shares were restored to the status of authorized but unissued shares of Preferred Stock, without designation as to series, until such stock is once more designated as part of a particular series by the board of directors. Common Stock On June 25, 2019, the Company effected a one- for- four reverse stock split, pursuant to which each outstanding share of common stock was changed into 0. 25 shares of common stock, and the Company decreased its authorized common stock in the same ratio from 100, 000, 000 to 25, 000, 000 shares. On January 27, 2020, the Company amended its Articles of Incorporation to increase its authorized common shares from 25, 000, 000 authorized shares to 250, 000, 000 authorized shares. On July 26, 2022, the Board of Directors of the Company approved a 7- for- 6 forward stock split, effective for trading purposes as of August 12, 2022, pursuant to which each shareholder as of the August 15, 2022 record date received one (1) additional share for each six (6) shares held as of the record date. Pursuant to the operation of the amendment providing for the forward stock split filed with the Secretary of State of Nevada on August 4, 2022, the authorized common stock of the Company was increased from 250, 000, 000 shares to 291, 666, 666 shares in connection with the forward split. Activity during the Year ~~Ended~~ Ending January 31, ~~2024~~ 2025 (a) As of January 31, ~~2024~~ 2025 , the Company holds ~~32,400~~ ' s Employee Stock Option Plan (the " Plan ") increasing the number of shares of ~~treasury~~ common stock ~~. On September 10~~ subject to the Plan (as of March 20 ,2024, ~~10~~ 875 ,000 shares ) ~~of treasury stock held by the Company were issued~~ to ~~an investor relations firm for services rendered~~ 1,400,000 shares (the " Amendment ") .The Company ~~recorded~~ will submit the Amendment to the Plan to our stockholders for adoption ~~an~~ and approval at ~~expense of $ 38,700 during~~ the 2025 Annual Meeting.If the Amendment is not approved by stockholders within one year of adoption ~~ending January 31 , 2025,~~ the increase in ~~connection~~ shares subject to the Plan will be void,together with any options issued following March 20,2024,in the period ~~transaction.During the year ending~~ pending approval ~~January 31,2025,the Company purchased 32,400 shares~~ of the Plan by our stockholders ~~treasury stock for $ 148,547 .~~( ~~b~~ d ) On April 19,2024,the Company completed an $ 8,400,000 equity financing with European investors (the " Offering ") of 2,100,000 units (" Units "),at a price of $ 4.00 per Unit, each Unit consisting of one share of common stock (" Shares ") and a Warrant to purchase two Shares of common stock,the ~~Warrant~~ Warrants having an initial exercise price of $ 6.43,are exercisable by payment of the exercise price in cash only and expire April 19,2029,five years from the date of issuance (" Warrants ").The ~~offering~~ Offering was made solely to investors residing outside the United States and was not registered under the Security Act of 1933,as amended,(the " Security Act "),or the ~~security~~ securities law of any jurisdiction,including outside the United States,but was made privately by the Company pursuant to the exemptions from registration provided in the SEC' s Regulation S and other exemptions under the Securities Act ~~.(c) On May 15,2024,the Company agreed to convert $ 300,000 of debt and $ 4,922 of accrued interest under the Credit Line Note agreement.The conversion was~~ 10, 000 of its shares comprising $ 32, 641 of treasury stock. There was no activity during the year ~~ended~~ ending January 31, 2024. (b) In December ~~2024~~ 2023 , TII Jet Services LDA converted $ 2, 000, 000 of its outstanding credit facility and $ 53, 436 of accrued interest into 1, 026, 720 shares of the Company' s common stock. The fair value of the common stock at the date of issuance was $ 2, 554, 423, resulting in a $ 554, 423 loss on extinguishment. ~~Activity during the Year Ended January 31, 2023 (a) In March and May 2022, the Company purchased 35, 584 shares of its common stock for $ 119, 006 and recorded the purchase as Treasury Stock. In May and December 2022, the Company issued 33, 397 shares of stock awards to management, directors and employees from the treasury shares and recorded compensation expense of $ 113, 155 In December 2022, the Company issued 25, 000 shares from the treasury shares to non- employees in connection of the termination of the Rambam license agreement. As of January 31, 2023, the Company held 10, 000 of its shares comprising $ 32, 641 of treasury stock. (b) On July 29, 2022, the Company received proceeds of $ 296, 875 from the exercise of warrants and issued 55, 417 shares of common stock. (c) In July 2022, the Company cancelled 1, 400, 000 shares received in connection with the settlement of a lawsuit. See Note 11 for further information.~~ X- ReferencesNo definition available. Details Name: us- ~~gaap_StockholdersEquityAbstract ----------~~ gaap_EquityAbstract Namespace Prefix: us- gaap_ Data Type: xbrli: stringItemType Balance Type: na Period Type: durationX- DefinitionThe entire disclosure for equity. ReferencesReference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic ~~505~~ 815 - SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 8A ~~13- Subparagraph (b)~~ - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147481112~~ 2147480434 / ~~505~~ 815 - 10- 50- ~~13Reference~~ 8AReference 2: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 505- SubTopic 10- Name

Accounting Standards Codification- Section 50- Paragraph 13- Subparagraph ( ~~h~~ **b** )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147481112 / 505- 10- 50- 13Reference 3: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 505- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph ~~14~~ **13** - Subparagraph ( ~~b~~ **h** )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147481112 / 505- 10- 50- ~~14Reference~~ **13Reference** 4: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic ~~946~~ **505** - SubTopic ~~235~~ **10** - Name Accounting Standards Codification- Section 50- Paragraph ~~2~~ **14** - Subparagraph ( ~~a~~ **b** )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147477968~~ **2147481112** / ~~946~~ **505** - ~~235~~ **10** - 50- ~~2Reference~~ **14Reference** 5: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 946- SubTopic 235- Name Accounting Standards Codification- Section 50- Paragraph 2- Subparagraph ( ~~d~~ **a** )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147477968 / 946- 235- 50- 2Reference 6: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 946- SubTopic ~~505~~ **235** - Name Accounting Standards Codification- Section 50- Paragraph ~~6~~ **2- Subparagraph (d)** - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147478448~~ **2147477968** / 946- **235- 50- 2Reference 7: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 946- SubTopic** 505 ~~- 50- 6Reference 7: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 815- SubTopic 40 -~~ Name Accounting Standards Codification- Section 50- Paragraph 6- ~~Subparagraph (a)-~~ Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147480237~~ **2147478448** / ~~815~~ **946** - ~~40~~ **505** - 50- 6Reference 8: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic ~~505~~ **815** - SubTopic ~~10~~ **40** - Name Accounting Standards Codification- Section ~~S99~~ **50** - Paragraph ~~1~~ **6** - Subparagraph ( **a** ~~SX 210. 3- 04~~ )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147480008~~ **2147480237** / **815- 40- 50- 6Reference 9: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic** 505 ~~- 10- S99- 1Reference 9: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 235 -~~ SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210. ~~4~~ **3** - **04** ~~08 (e) (1) )~~- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147480678~~ **2147480008** / ~~235~~ **505** - 10- S99- 1Reference 10: http: / / fasb. org / us- gaap / role / ref / legacyRef- Topic 505- Name Accounting Standards Codification- Publisher FASB- URI https: / / asc. fasb. org / 505 / tableOfContentReference 11: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 505- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 13- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147481112 / 505- 10- 50- 13Reference 12: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 505- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 13- Subparagraph (g)- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147481112 / 505- 10- 50- 13Reference 13: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 505- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 13- Subparagraph (i)- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147481112 / 505- 10- 50- 13Reference 14: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 505- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 14- Subparagraph (a)- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147481112 / 505- 10- 50- 14Reference 15: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 505- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 14- Subparagraph (c)- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147481112 / 505- 10- 50- 14Reference 16: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 505- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 16- Subparagraph (b)- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147481112 / 505- 10- 50- 16Reference 17: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 505- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 18- Subparagraph (a)- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147481112 / 505- 10- 50- 18Reference 18: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 505- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 18- Subparagraph (b)- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147481112 / 505- 10- 50- 18Reference 19: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 505- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 18- Subparagraph (d)- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147481112 / 505- 10- 50- 18 Details Name: us- gaap_StockholdersEquityNoteDisclosureTextBlock Namespace Prefix: us- gaap_ Data Type: dtr- types: textBlockItemType Balance Type: na Period Type: durationOptions and Warrants 12 Months Ended Jan. 31, ~~2024~~ **2025** Options and Warrants [ Abstract ] OPTIONS and WARRANTS 9. OPTIONS and WARRANTS Warrants ~~The following table summarizes the changes in warrants outstanding and the related price of the shares of the Company' s common stock issued to non- employees of the Company during the year ended January 31, 2024.~~ On March 7, 2023, the Company issued 30, 000 warrants to purchase the Company' s common shares to Barandnic Holdings Ltd. for services provided. The warrants are exercisable at a price of $ 4. 00 per share and expire five years from the date of issuance. On October 27, 2023, the Company issued 145, 833 warrants to purchase the Company' s common shares to management (87, 500 warrants were issued to the Chief Financial Officer) and non- employees of the Company. The warrants are exercisable at a price of $ 1. 93 per share and expire in three years from the date of issuance. These warrants replace previously issued warrants that have now been cancelled. The Company used the Black- Scholes valuation model to record the fair value. The valuation model used a dividend rate of 0 %; expected term of 1. 5 years; volatility rates of 152. 10- 174. 45 %; and a risk- free rate of 4. 31 %- 4. 84 %. Non- cash compensation for the year ~~ended~~ **ending** January 31, 2024, amounted to $ 242, 840 **. On April 19, 2024, in connection with a private placement of the Company' s common stock, the Company issued 4, 200, 000 warrants. The warrants are exercisable at a price of $ 6. 43 per share and expire five years from the date of issuance. On May 15, 2024, the Company issued 152, 460 warrants in connection with extinguishment of debt of $ 300, 000 and accrued interest. The warrants are exercisable at a price of $ 6. 43 per share and expire five years from the date of issuance. Non- cash expense of $ 390, 145 is included in loss on extinguishment of debt. On June 5, 2024, the Company' s Chief Financial Officer exercised 87, 500 warrants as a cashless conversion and the Company issued 60, 085 shares of common stock. On September 10, 2024, the Company issued 50, 000 warrants to an investor relations firm. The warrants are exercisable at a price of $ 4. 00 per share and expire three years from the date of issuance. The Company recorded a non- cash expense of $ 94, 650 during the year ending January 31, 2025. The agreement is for twelve months and includes the issuance of 10, 000 treasury shares and monthly payments of $ 12, 500. The warrants and shares vest immediately and because they are non- forfeitable, the expense was recognized immediately. The Company cancelled the warrants as of January 31, 2025. Non- cash compensation for the year ending January 31, 2025, amounted to $ 484, 975. The Company used the Black Scholes valuation model to record fair value of the value of the warrants issued during the year ending January 31, 2025. The valuation model used a dividend rate of 0 %; expected terms of 1. 5- 2. 5 years; volatility rates of 105. 98 %- 145. 05 %; and risk- free rates of 3. 65 %- 4. 45 %. The following table summarizes the changes in the warrants outstanding and the related price of the shares of the common stock issued to non- employees of the Company during the year ending January 31, 2025** . Exercise Remaining Intrinsic Shares Price Life Value Outstanding, January 31, ~~2022~~ **2023** 1, ~~435~~ **307** , ~~622~~ **671** $ 6. ~~91~~ **43** 3. ~~93~~ **34** years $- Granted ~~25~~ **175** , ~~000 7~~ **833 2** . ~~50 5~~ **28 2** . ~~00~~ **97** years- Expired / Cancelled ( ~~97~~ **200** , ~~534~~ **466** ) ~~5~~ **6** . ~~36~~ **33** -- Exercised **--** ~~(55, 417) 5. 36 -~~ Outstanding, January 31, ~~2023~~ **2024** 1, ~~307, 671 6. 43 3. 34 years- Granted 175, 833 2. 28~~ **283 , 038 5. 88** 2. 97 years- **Granted 4, 402, 460 6. 40 4. 72 years-** Expired / Cancelled ( **50, 000) 4.** ~~200 -~~ **00 , 466) 6. 33** -- Exercised **-- (88, 525) 1. 98** -- Outstanding- January 31, ~~2024~~ **2025** ~~1~~ **5** , ~~283~~ **546** , ~~038~~ **973** $ ~~5~~ **6** , ~~88 2~~ **37 3** . ~~97~~ **68** years $ ~~99~~ **10** , ~~166~~ **626, 018** Exercisable- January 31, ~~2024~~ **2025** ~~1~~ **5** , ~~283~~ **546** , ~~038~~ **973** $ ~~5~~ **6** . ~~88 2~~ **37 3** . ~~97~~ **68** years $ ~~99~~ **10** , ~~166~~ **626, 018** The following table summarizes additional information relating to the warrants outstanding as of January 31, ~~2024~~ **2025** : Range of Exercise ~~Prices~~ Number ~~Outstanding Weighted Average~~ Remaining Contractual ~~Life (Years) Weighted Average~~ Exercise Price for Shares ~~Outstanding~~ Number ~~Exercisable Weighted Average~~ Exercise Price for Shares **Intrinsic Prices Outstanding Life (Years) Outstanding** Exercisable ~~Intrinsic~~ **Exercisable** Value $ **1. 93 58, 333 1. 74 $ 1. 93 58, 333 $ 1. 93 $ 370, 988 $** 4. 00 30, 000 ~~4~~ **3** . 10 $ 4. 00 30, 000 $ 4. 00 $ ~~-~~**128, 700** $ 6. 43 ~~1~~ **5** , ~~082~~ **433** , ~~205 2~~ **640 3** , ~~68~~ **71** $ 6. 43 ~~1~~ **5** , ~~082~~ **433** , ~~205~~ **640** $ 6. 43 $ **10** ~~- $ 1. 93 145 -~~ **106** ~~833 2. 74 $ 1. 93 145 -~~ **570** ~~833 $ 1. 93 $ 99, 166 -~~ $ 7. 50 25, 000 ~~3~~ **2** . 77 $ 7. 50 25, 000 $ 7. 50 $ ~~-~~**19, 760 5, 546, 973 $ 6. 37 5, 546, 973 $ 6. 37 $ 10, 626, 018** Options ~~The following table summarizes the changes in options outstanding and the related price of the shares of the Company' s common stock issued to employees of the Company. See Note 7 for the issuance of related party options.~~ On November 1, 2021, the Board of Directors adopted the 2021 Employee Stock Option Plan (the " Plan "). The Company has reserved 408, 333 shares for issuance and sale upon the exercise of stock options. In accordance with the Plan, on February 1, 2022, the Company reserved an additional 233, 333 shares and on February 1, 2023, the Company reserved an additional 233, 333 shares. The options vest immediately and expire in three years. Under the Plan, options may be granted which are intended to qualify as Incentive Stock Options (" ISO' s ") under Section 422 of the Internal Revenue Code of 1986 (the " Code ") or which are not (" non- ISO' s ") intended to qualify as Incentive Stock Options thereunder. The Plan also provides for restricted stock awards representing shares of common stock that are issued subject to such restrictions on transfer and other incidents of ownership and such forfeiture conditions as the Board of Directors, or the committee administering the Plan composed of directors who qualify as " independent " under Nasdaq rules, may determine. On November 3, 2021, the Company filed a Registration Statement on Form S- 8, to register under the Securities Act of 1933, as amended the 408, 333 shares of common stock reserved for issuance under the Plan. **On March 20, 2024, our Board of Directors adopted an amendment to the Company' s Employee Stock Option Plan (the " Plan ") increasing the number of shares of common stock subject to the Plan (as of March 20, 2024, 875, 000 shares) to 1, 400, 000 shares (the " Amendment "). The Company submitted the Amendment to the Plan to our stockholders for adoption and approval at the 2025 Annual Meeting. The Amendment was approved by the stockholders on January 23, 2025.** As of January 31, ~~2024~~ **2025** , ~~166~~ **26, 332** shares remain available ~~and~~ **for** issuance **of options** under the Plan. During the year ~~ended~~ **ending** January 31, ~~2024~~ **2025** , ~~404~~ **689** , ~~500~~ **584** options to purchase shares of the Company' s common stock were issued to executive officers and employees at prices of $ ~~1~~ **2** . ~~93~~ **37** - $ ~~3~~ **8** . ~~975~~ **07** per share. The options vest immediately and expire three years from the date of issuance. The fair value of the options issued for services amounted to $ ~~499~~ **1** , ~~856~~ **408, 935** and ~~was~~ **were** recorded during the year ~~ended~~ **ending** January 31, ~~2024~~ **2025** .

The Company used the Black- Scholes valuation model to record the fair value. The valuation model used a dividend rate of 0 %; expected term of 1. 5 years; volatility ~~rates~~ **rate** of ~~121~~ **97** . ~~52~~ **83 %** - ~~143~~ **114** . ~~54~~ **86** %; and a risk- free rate of ~~3~~ **4** . 00 **%** - 4. ~~5~~ **87** %. During the year ended January 31, ~~2023~~ **2024** , ~~279~~ **404** . ~~584~~ **500** options to purchase shares of the Company' s common stock were issued to executive officers and **employees** ~~directors of the Company~~ at prices of $ **1. 93- $** 3. **975** ~~59 to $ 4. 50~~ per share. The options vest immediately and expire three years from the date of issuance. The fair value of the options issued for services amounted to $ ~~732~~ **499** , ~~130~~ **856** and was recorded during the year ended January 31, ~~2023~~ **2024** . The Company used the Black- Scholes valuation model to record the fair value. The valuation model used a dividend rate of 0 %; expected term of 1. 5 years; volatility ~~rate~~ **rates** of **121.** ~~152 - 52 . 10 - 174~~ **143** . ~~45~~ **54** %; and a risk- free rate of 3 **. 00- 4. 5** %. **The following table summarizes the changes in options outstanding and the related price of the shares of the Company' s common stock issued to employees of the Company. See Note 7 for the issuance of related party options. Exercise Remaining Intrinsic Shares Price Life Value Outstanding, January 31, 2023 470, 335 $ 4. 13 2. 53 years Granted 404, 500 2. 18 2. 68 years- Expired / Cancelled--- Exercised--- Outstanding, January 31, 2024 874, 835 3. 23 2. 31 years Granted 689, 584 4. 40 1. 93 years Expired / Cancelled (190, 751)-- Exercised--- Outstanding- January 31, 2025 1, 373, 668 $ 3. 68 1. 90 years $ 6, 337, 984 Exercisable- January 31, 2025 1, 373, 668 $ 3. 68 1. 90 years $ 6, 337, 984** The following table summarizes additional information relating to the options outstanding as of January 31, ~~2024~~ **2025** ~~. Shares~~ **: Weighted Average Weighted Average Range of Exercise Number Weighted Average** Exercise Price ~~Remaining Life~~ **for Shares Number Exercise Price for Shares** Intrinsic Value Outstanding, January 31, 2022..... as of January 31, 2024: Prices Outstanding Life (Years) ~~Shares~~ Outstanding Exercisable ~~Shares~~ Exercisable Value $ 1. 93 214, 500 ~~2~~ **1** . ~~74~~ **73** $ 1. 93 214, 500 $ 1. 93 $ ~~145~~ **1** . ~~860~~ **364, 220** $ 2. 12 140, 000 ~~2~~ **1** . ~~74~~ **73** $ 2. 12 140, 000 $ 2. 12 $ ~~68~~ **863, 800 $ 2. 37 195, 000 2. 13 $ 2. 37 195, 000 $ 2. 37 $ 1, 154, 400 $ 2. 61 195, 000 2. 13 $ 2. 61 195, 000 $ 2. 61 $ 1, 107** , 600 $ 2. 65 20, 000 ~~2~~ **1** . 63 $ 2. 65 20, 000 $ 2. 65 $ ~~-~~ **112, 800 $ 2. 75 30, 000 2. 00 $ 2. 75 30, 000 $ 2. 75 $ 166, 200** $ 3. 59 35, 000 ~~3~~ **2** . ~~67~~ **66** $ 3. 59 35, 000 $ 3. 59 $ **164** ~~- $ 3. 75 57, 500 1. 85 $ 3. 75 57~~ , 500 $ 3. 75 ~~$-~~ **57, 500 1. 00** $ 3. **75 57, 500 $ 3. 75 $ 261, 050 $ 3.** 98 30, 000 ~~2~~ **1** . ~~01~~ **00** $ 3. 98 30, 000 $ 3. 98 $ ~~-~~ **129, 300** $ 4. 09 78, 750 ~~1~~ **0** . 50 $ 4. 09 78, 750 $ 4. 09 $ ~~-~~ **330, 750** $ 4. 12 50, 000 ~~1~~ **0** . 85 $ 4. 12 50, 000 $ 4. 12 $ ~~-~~ **208, 500** $ 4. ~~16 144, 083 0. 97 $ 4. 16 144, 083 $ 4. 16 $- $ 4.~~ 50 58, 334 ~~1~~ **0** . 50 $ 4. 50 58, 334 $ 4. 50 $ ~~-~~ **221, 086** $ ~~4~~ **5** . **99 30, 000 2. 41 $ 5. 99 30, 000 $ 5. 99 $ 69, 000 $ 7. 34 180, 918 2. 98 $ 7. 34 180, 918 $ 7. 34 $ 171, 872 $ 8. 07** 58 ~~46 , 666 2. 98 $ 8. 07 58, 666 $ 8. 07 $ 12, 907 1, 373~~ , 668 ~~0~~ **1** . ~~97~~ **90** $ ~~4~~ **3** . ~~58 46~~ **68 1, 373** , 668 $ ~~4~~ **3** . ~~58~~ **68** $ **6** ~~- 874~~ . **337** ~~835 2. 06 $ 3. 23 874~~ . **984** ~~835 $ 3. 23 $ 214, 460~~ X ~~- ReferencesNo definition available. Details Name: ntrb_OptionsAndWarrantsAbstract Namespace Prefix: ntrb_ Data Type: xbrli: stringItemType Balance Type: na Period Type: durationX~~ - DefinitionThe entire disclosure of options and warrants. ReferencesNo definition available. Details Name: ntrb_OptionsAndWarrantsTextBlock Namespace Prefix: ntrb_ Data Type: dtr: textBlockItemType **Balance Type: na Period Type: durationX- ReferencesNo definition available. Details Name: us-gaap_WarrantsAndRightsNoteDisclosureAbstract Namespace Prefix: us- gaap_ Data Type: xbrli: stringItemType** Balance Type: na Period Type: durationSegment Reporting 12 Months Ended Jan. 31, ~~2024~~ **2025** Segment Reporting [ Abstract ] SEGMENT REPORTING ~~10~~ **7** . SEGMENT REPORTING We organize and manage our business by the following two segments which meet the definition of reportable segments under ASC280- 10, Segment Reporting: Sales of Goods and Services. These segments are based on the **customer** type of products or services provided and are the same as our business units. Separate financial information is available and regularly reviewed by our chief officer decision maker, **who is our chief executive officer,** in making resource allocation decisions for our segments. Our chief officer decision maker evaluates segment performance to the GAAP measure of gross profit. Years ~~Ended~~ **Ending** January 31, **2025** 2024 ~~2023~~ Net sales Pocono Pharmaceuticals $ ~~1~~ **2** , ~~920~~ **139** , ~~280~~ **537** $ 1, ~~785~~ **920** , ~~597~~ **280** 4P Therapeutics ~~-~~ 165, 034 ~~294, 102~~ **139, 537 2,** 085, 314 ~~2, 079, 699~~ Gross profit Pocono Pharmaceuticals **743, 317** 744, 391 ~~726, 702~~ 4P Therapeutics ~~-~~ 117, 714 ~~23~~ **743** , ~~702~~ **317** 862, 105 ~~750, 404~~ Operating expenses Selling, general and administrative- Pocono Pharmaceuticals **661, 805** 606, 275 ~~577, 930~~ Selling, general and administrative- 4P Therapeutics **136, 294** 236, 953 ~~103, 181~~ Selling, general and administrative- Corporate **3, 515, 711** 2, 930, 378 **Goodwill and intangibles impairment** 3, ~~234~~ **595** , ~~930~~ **216-** Research and development- 4P Therapeutics **3, 119, 134** 1, 960, 425 ~~982~~ **11** . **028** ~~227 Goodwill impairment- Pocono Pharmaceuticals- 327 , 326~~ **160** 5, 734, 031 ~~5, 225, 594~~ Depreciation and Amortization Pocono Pharmaceuticals $ **235, 941 $** 222, 159 ~~$ 264, 156~~ Corporate **12, 043** 13, 986 ~~-~~ 4P Therapeutics **37, 070** 51, 577 ~~65~~ **$ 285** , ~~987~~ **054** $ 287, 722 ~~$ 330, 143~~ The following table presents information about net sales and property and equipment, net of accumulated depreciation, in the United States and elsewhere. Years ~~Ended~~ **Ending** January 31, **2025** 2024 ~~2023~~ Net sales United States $ 2, ~~085~~ **139** , ~~314~~ **537** $ 2, ~~079~~ **085** , ~~699~~ **314** Outside the United States-- $ 2, ~~085~~ **139** , ~~314~~ **537** $ 2, ~~079~~ **085** , ~~699~~ **314** January 31, January 31, **2025** 2024 ~~2023~~ Property and equipment, net of accumulated depreciation United States $ **695, 063 $** 774, 924 ~~$ 897, 735~~ Outside the United States-- $ **695, 063 $** 774, 924 ~~$ 897, 735~~ Assets Corporate $ ~~344~~ **4** , ~~192~~ **205, 577** $ ~~1~~ **339** , **552** ~~745, 731~~ Pocono Pharmaceuticals **1, 404, 585** 5, 079, 293 ~~5, 400, 814~~ 4P Therapeutics **1, 859, 793** 2, **098** ~~093, 369 2~~ , 309 ~~, 832~~ $ 7, ~~516~~ **469** , ~~854~~ **955** $ ~~9~~ **7** , ~~456~~ **517** , ~~377~~ **154** X- ReferencesNo definition available. Details Name: us- gaap_SegmentReportingAbstract Namespace Prefix: us- gaap_ Data Type: xbrli: stringItemType Balance Type: na Period Type: durationX- DefinitionThe entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it' s reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. ReferencesReference 1: http: / / www. xbrl. org / 2003 / role / ~~exampleRef~~ **disclosureRef** - Topic 280- SubTopic 10- Name Accounting Standards Codification- Section ~~55~~ **50** - Paragraph ~~48~~ **21- Subparagraph (b)** - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147482785~~ - **2147482810** / 280- 10- ~~55~~ **50** - ~~48Reference~~ **21Reference** 2: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 280- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph ~~32~~ **21** - Subparagraph ( ~~f~~ **a** )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482810 / 280- 10- 50- ~~32Reference~~ - **21Reference** 3: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic ~~270~~ **280** - SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph ~~1~~ **32** - Subparagraph ( ~~i~~ **e** )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147482964~~ **2147482810** / ~~270~~ **280** - 10- 50- ~~1Reference~~ **32Reference** 4: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 280- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph **31** ~~32- Subparagraph (ee)~~ - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482810 / 280- 10- 50- ~~32Reference~~ **31Reference** 5: http: / / ~~fasb~~ **www** . **xbrl.** org / **2003** ~~us- gaap~~ / role / **disclosureRef** ~~ref / otherTransitionRef~~ - Topic 280- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph **15** ~~32- Subparagraph (d)~~ - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482810 / 280- 10- 50- ~~32Reference~~ **15Reference** 6: http: / / www. xbrl. org / 2003 / role / ~~exampleRef~~ **disclosureRef** - Topic 280- SubTopic 10- Name Accounting Standards Codification- Section ~~55~~ **50** - Paragraph **42** ~~54- Subparagraph (d)~~ - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147482785~~ - **2147482810** / 280- 10- ~~55~~ **50** - ~~54Reference~~ - **42Reference** 7: http: / / www. xbrl. org / 2003 / role / exampleRef- Topic 280- SubTopic 10- Name Accounting Standards Codification- Section 55- Paragraph **48** ~~47- Subparagraph (c)~~ - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482785 / 280- 10- 55- ~~47Reference~~ **48Reference** 8: http: / / www. xbrl. org / 2003 / role / ~~exampleRef~~ **disclosureRef** - Topic 280- SubTopic 10- Name Accounting Standards Codification- Section ~~55~~ **50** - Paragraph ~~54~~ **32** - Subparagraph ( ~~a~~ **f** )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147482785~~ - **2147482810** / 280- 10- ~~55~~ **50** - ~~54Reference~~ **32Reference** 9: http: / / www. xbrl. org / 2003 / role / ~~exampleRef~~ **disclosureRef** - Topic ~~280~~ **270** - SubTopic 10- Name Accounting Standards Codification- Section ~~55~~ **50** - Paragraph ~~47~~ **1** - Subparagraph ( ~~a~~ **i** )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147482785~~ **2147482964** / ~~280~~ **270** - 10- ~~55~~ **50** - ~~47Reference~~ **1Reference** 10: http: / / www. xbrl. org / 2003 / role / ~~exampleRef~~ **disclosureRef** - Topic 280- SubTopic 10- Name Accounting Standards Codification- Section ~~55~~ **50** - Paragraph ~~54~~ **32** - Subparagraph ( ~~e~~ **ee** )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147482785~~ - **2147482810** / 280- 10- ~~55~~ **50** - ~~54Reference~~ **32Reference** 11: http: / / ~~www~~ **fasb** . ~~xbrl.~~ org / ~~2003~~ **us- gaap** / role / ~~exampleRef~~ **ref / otherTransitionRef** - Topic 280- SubTopic 10- Name Accounting Standards Codification- Section ~~55~~ **50** - Paragraph ~~47~~ **32** - Subparagraph (d)- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147482785~~ - **2147482810** / 280- 10- ~~55~~ **50** - ~~47Reference~~ **32Reference** 12: http: / / www. xbrl. org / 2003 / role / ~~disclosureRef~~ **exampleRef** - Topic 280- SubTopic 10- Name Accounting Standards Codification- Section ~~50~~ **55** - Paragraph ~~22~~ **54- Subparagraph (d)** - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147482810~~ **2147482785** / 280- 10- ~~50~~ **55** - ~~22Reference~~ **54Reference** 13: http: / / www. xbrl. org / 2003 / role / ~~disclosureRef~~ **exampleRef** - Topic 280- SubTopic 10- Name Accounting Standards Codification- Section ~~50~~ **55** - Paragraph ~~31~~ **47- Subparagraph (c)** - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147482810~~ **2147482785** / 280- 10- ~~50~~ **55** - ~~31Reference~~ **47Reference** 14: http: / / www. xbrl. org / 2003 / role / ~~disclosureRef~~ **exampleRef** - Topic 280- SubTopic 10- Name Accounting Standards Codification- Section ~~50~~ **55** - Paragraph ~~34~~ **54- Subparagraph (a)** - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147482810~~ **2147482785** / 280- 10- ~~50~~ **55** - ~~34Reference~~ **54Reference** 15: http: / / www. xbrl. org / 2003 / role / ~~disclosureRef~~ **exampleRef** - Topic 280- SubTopic 10- Name Accounting Standards Codification- Section ~~50~~ **55** - Paragraph ~~26C~~ **47- Subparagraph (a)** - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147482810~~ **2147482785** / 280- 10- ~~50~~ **55** - ~~26CReference~~ **47Reference** 16: http: / / www. xbrl. org / 2003 / role / ~~disclosureRef~~ **exampleRef** - Topic 280- SubTopic 10- Name Accounting Standards Codification- Section ~~50~~ **55** - Paragraph ~~26B~~ **54- Subparagraph (e)** - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147482810~~ **2147482785** / 280- 10- ~~50~~ **55** - ~~26BReference~~ **54Reference** 17: http: / / www. xbrl. org / 2003 / role / ~~disclosureRef~~ **exampleRef** - Topic 280- SubTopic 10- Name Accounting Standards Codification- Section ~~50~~ **55** - Paragraph ~~15~~ **47- Subparagraph (d)** - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147482810~~ **2147482785** / 280- 10- ~~50~~ **55** - ~~15Reference~~

**47Reference** 18: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 280- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph ~~42~~ **22** - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482810 / 280- 10- 50- ~~42Reference~~ **22Reference** 19: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 280- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph ~~40~~ **34** - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482810 / 280- 10- 50- ~~40Reference~~ **34Reference** 20: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 280 **- SubTopic 10** - Name Accounting Standards Codification- **Section 50- Paragraph 26C-** Publisher FASB- URI https: / / asc. fasb. org / **1943274 / 2147482810 /** 280 ~~/ tableOfContentReference - 10- 50- 26CReference~~ 21: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 280- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph ~~26~~ **26B** - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482810 / 280- 10- 50- ~~26Reference~~ **26BReference** 22: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 280- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph ~~41~~ **40** - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482810 / 280- 10- 50- ~~41Reference~~ **40Reference** 23: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 280 ~~- SubTopic 10 -~~ Name Accounting Standards Codification- ~~Section 50- Paragraph 21- Subparagraph (a) -~~ Publisher FASB- URI https: / / asc. fasb. org / ~~1943274 / 2147482810 /~~ 280 **/ tableOfContentReference** ~~- 10- 50- 21Reference~~ 24: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 280- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph **26** ~~21- Subparagraph (b) -~~ Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482810 / 280- 10- 50- ~~21Reference~~ **26Reference** 25: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 280- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph **41** ~~32- Subparagraph (c) -~~ Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482810 / 280- 10- 50- ~~32~~ **41** Details Name: us- gaap_SegmentReportingDisclosureTextBlock Namespace Prefix: us- gaap_ Data Type: dtr- types: textBlockItemType Balance Type: na Period Type: durationCommitments and Contigencies 12 Months Ended Jan. 31, ~~2024~~ **2025** Commitments and Contigencies [ Abstract ] COMMITMENTS AND CONTIGENCIES ~~11~~ **10** . COMMITMENTS AND CONTIGENCIES Employment Agreements The Company entered into three- year employment agreements with Gareth Sheridan, our CEO, and Serguei Melnik, our President, effective February 1, 2022. The agreement also provides that the executives will continue as directors and officers of the Company for the respective terms thereof. The agreement provides for an initial term, commencing on the effective date of the agreement and ending on January 31, 2025, and continuing on a year- to- year basis thereafter unless terminated by either party on not less than 30 days' notice given prior to the expiration of the initial term or any one- year extension. For their services to the Company during the term of the agreement, Mr. Sheridan and Mr. Melnik will receive an annual salary of $ 250, 000 per annum, commencing on the effective date of the agreement. Mr. Sheridan and Mr. Melnik will also receive a performance bonus of 3. 5 % of net income before income taxes. As of July 31, 2022, the Company and Mr. Sheridan and Mr. Melnik mutually agreed to reduce their annual salary to $ 150, 000. **These agreements, and the employment of Mr. Goodman, automatically renew for one- year terms following expiration of the initial three- year terms and each successive one- year term.** The Company entered into a three- year employment agreement with Gerald Goodman, our CFO, effective February 1, 2022. The agreement provides for an initial term, commencing on the effective date of the agreement and ending on January 31, 2025, and continuing on a year- to- year basis thereafter unless terminated by either party on not less than 30 days' notice given prior to the expiration of the initial term or any one- year extension. For his services to the Company during the term of the agreement, Mr. Goodman will receive an annual salary of $ 210, 000 per annum, commencing on the effective date of the agreement. As of July 31, 2022, the Company and Mr. Goodman mutually agreed to reduce his annual salary to $ 110, 000. Kindeva Drug Delivery Agreement On January 4, ~~2022, the Company signed a feasibility agreement with Kindeva Drug Delivery, L. P. (" Kindeva ") to develop Nutriband' s lead product, AVERSA Fentanyl, based on its proprietary AVERSA abuse deterrent transdermal technology and Kindeva' s FDA- approved transdermal fentanyl patch (fentanyl transdermal system). The feasibility agreement provides for adapting Kindeva' s commercial transdermal manufacturing process to incorporate AVERSA technology in the fentanyl transdermal system. The agreement will remain in force until the earlier of: (1) the completion of the work and deliverables under the Workplan; or (2) two (2) years after the Effective Date, after which time the agreement will expire. The feasibility Workplan was completed in February 2024. The estimated cost to complete the feasibility Workplan was approximately $ 2. 5 million. Nutriband made an advance deposit of $ 250, 000 in January 2022, to be applied against the final invoices. As of January 31, 2024, Nutriband has incurred expenses of $ 2, 369, 508 and the net deposit of $ 138, 250 after application to final invoices is included in prepaid expenses. In January~~ 2024, Nutriband signed a commercial development and clinical supply agreement **for their lead product, Aversa Fentanyl,** with Kindeva Drug Delivery ~~for development of AVERSA Fentanyl using~~ **, L. P. (" Kindeva ")** ~~' s FDA- approved fentanyl patch~~ . **Under this agreement,** Kindeva will perform commercial manufacturing process development ~~and~~ **, manufacturing of** clinical supplies ~~manufacturing~~ for the human abuse ~~potential~~ **liability** clinical study **, and development of chemistry, manufacturing and controls (CMC) information** required by the FDA in support of a New Drug Application **(" NDA "). As of January 31, 2025, Nutriband has incurred expenses of $ 3. 0 million under this agreement** . The **Company** ~~agreement replaces the previous feasibility agreement between the two companies which was focused on adapting Kindeva' s commercial transdermal manufacturing process to incorporate AVERSA abuse deterrent transdermal technology. The estimated~~ **estimates** ~~cost~~ **approximately $ 5. 2 million** to complete the ~~commercial process~~ development ~~and clinical supplies manufacturing is approximately~~ **. On February 4, 2025, the agreement was amended to reduce the hourly rate for the labor on the project in exchange for a milestone payment payable upon FDA approval. Under the amended agreement, the remaining budget as of January 31, 2025, through NDA submission for the current workplan was reduced to** $ ~~8~~ **3** . ~~1~~ **2** million ~~and the expected timing~~ **. The amended agreement also includes a milestone payment** of **$ 3. 0 million to be paid to Kindeva when the Company receives** FDA **approval** ~~submission is twelve to eighteen months~~ . Lease Agreement On February 1, 2022, Pocono Pharmaceuticals entered into a lease agreement with Geometric Group, LLC for 12, 000 square feet of warehouse space currently occupied by Active Intelligence. The monthly rental is $ 3, 000 and the lease expires on January 31, 2025. The lease ~~can be~~ **has been** extended for an additional three years at the same monthly rental. ~~The Company recorded a Right of Use asset in the amount of $ 94, 134 in connection with the valuation. MDM Worldwide Agreement In September 2022, the Company entered into a public relations agreement with MDM Worldwide. In connection with the agreement, the Company agreed to issue 20, 000 options to MDM Worldwide. In October 2023, the contract was mutually terminated, and no options were issued. For the year ended January 31, 2024, the Company paid MDM Worldwide $ 190, 000. Money Channel Agreement On March 13, 2023, the Company entered into a media advertising agreement with Money Channel Inc. The Company will pay a monthly fee and after ninety days can cancel the agreement. The Company, after 90 days, will also issue options to purchase 50, 000 shares of common stock to Money Channel Inc. at an exercise price of $ 4. 00 per share. In June 2023, the parties agreed to terminate the agreement by mutual consent. No options were issued. For the year ended January 31, 2024, the Company paid the Money Channel $ 100, 000.~~ Sorrento Therapeutics, Inc. Agreement ~~4P Therapeutics had unpaid account receivables related to a contract clinical research services agreement in place with Sorrento Therapeutics. On February 13, 2023, Sorrento declared Chapter 11 bankruptcy.~~ On July 25, 2023, 4P Therapeutics assigned its claim under the bankruptcy proceedings from Sorrento Therapeutics Inc. and received proceeds of $ 106, 528. The amount due under the claim was $ 118, 675 and 4P Therapeutics recorded a reserve for bad debts of $ 118, 675 during the year ended January 31, 2024. Under the agreement with the buyer of the claim, 4P Therapeutics will make proportional restitution and / or repayment of the purchase amount to the extent the claim is disallowed, reduced or not paid at the same time or distribution rate as other general unsecured claims against the Debtor are paid. The Company has recorded the amount of the proceeds as a secured loan payable to the factor as of January 31, ~~2024~~ **2025** ~~. Upstream Termination On May 24, 2023, the Company sent notice of the termination of the Securities Facility Services Agreement, dated January 3, 2023, by and between MERJ DEP Ltd. And the Company (" Agreement "), which provided for the dual listing of the Company' s common stock on the MERJ Upstream exchange (" Upstream "), which is operated as a fully registered and licensed integrated securities exchange, clearing system and depository for digital and non- digital securities under the Seychelles security laws. The termination was effective May 31, 2023~~ . Legal Proceedings The Company is currently a defendant in a lawsuit initiated by Joseph Gunnar, LLC (" Gunnar ") and Lucosky Brookman LLP (" LB ") in the Supreme Court of the State of New York, New York County, under Index No. 654633 / 2023. The lawsuit alleges multiple allegations such as breach of contract, fraudulent activities, and tortious interference and seeks damages following the Company' s termination of an engagement letter for assistance with a public stock offering. Gunnar is seeking over $ 500, 000 in damages plus punitive damages, while LB is demanding reimbursement of legal fees. In response, the Company denies all allegations, alleging that the engagement letter was unenforceable, and its termination was legally justified. The Company has also initiated counterclaims against Joseph Gunnar & Co., accusing them of intentional interference and breach of fiduciary duty, and is seeking $ 1, 000, 000 for each claim along with a declaratory judgment affirming the legality and justification of the termination. The plaintiffs have denied these counterclaims. Currently, there are no pending hearings or motions ~~as both parties are engaged~~ **, and the case is** in **the** discovery ~~and are attempting~~ **stage. In early 2024, the plaintiffs proposed a settlement offer of $ 100, 000. The Company has not responded** to ~~resolve the matter amicably~~ **that proposed settlement offer** . X- ReferencesNo definition available. Details Name: us- gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us- gaap_ Data Type: xbrli: stringItemType Balance Type: na Period Type: durationX- DefinitionThe entire disclosure for commitments and contingencies. ReferencesReference 1: http: / / www. xbrl. org / 2009 / role / commonPracticeRef- Topic 405- SubTopic 30- Name Accounting Standards Codification- Publisher FASB- URI https: / / asc. fasb. org / 405- 30 / tableOfContentReference 2: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 440- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 4- Subparagraph (a)- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482648 / 440- 10- 50- 4Reference 3: http: / / www. xbrl.

org / 2009 / role / commonPracticeRef- Topic 450- Name Accounting Standards Codification- Publisher FASB- URI https: / / asc. fasb. org / 450 / tableOfContentReference 4: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 954- SubTopic 440- Name Accounting Standards Codification- Section 50- Paragraph 1- Subparagraph (a)- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147478522 / 954- 440- 50- 1Reference 5: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 440- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 4- Subparagraph (c)- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482648 / 440- 10- 50- 4Reference 6: http: / / fasb. org / us- gaap / role / ref / legacyRef- Topic 440- Name Accounting Standards Codification- Publisher FASB- URI https: / / asc. fasb. org / 440 / tableOfContent Details Name: us- gaap_CommitmentsAndContingenciesDisclosureTextBlock Namespace Prefix: us- gaap_ Data Type: dtr- types: textBlockItemType Balance Type: na Period Type: durationSubsequent Events 12 Months Ended Jan. 31, ~~2024~~ **2025** Subsequent Events [ Abstract ] SUBSEQUENT ~~EVENTS~~ **EVENTS11** ~~12~~. SUBSEQUENT EVENTS (a) ~~In~~ **Subsequent to January 31, 2025, the Company' s outside corporate counsel exercised 58, 333 warrants as a cashless conversion and the Company issued 46, 961 shares of common stock. (b) On** February ~~and April~~ **6,** ~~2024~~ **2025** , the Company ~~received proceeds~~ **entered into an agreement with a consultant to provide consulting services to the Company' s Board** of ~~$ 300~~ **Directors. The Company issued 5** , 000 ~~from its Credit Line Facility. (b) On March 20, 2024, 390, 000 options to purchase~~ shares of the Company' s common stock **to the consultant, valued at $ 39, 050. The shares** were issued **from the treasury shares held by the Company. The term of the agreement is for twelve months. (c) On March 4, 2025, the Company issued 3, 500 shares of the Company' s common stock** to ~~executive officers and~~ employees **for services rendered** ~~at prices of $ 2. 37- $ 2. 61 per share. The options vest immediately and expire three years from the date of issuance~~ . The fair value of the ~~options~~ **shares** issued **was** ~~amounted to~~ $ ~~450~~ **24** , ~~000~~ **360** . **The shares were issued from the treasury shares held by** ~~(c) On March 20, 2024, our Board of Directors adopted an amendment to~~ the Company ' s Employee Stock Option Plan (..... and other exemptions under the Securities Act . X- ReferencesNo definition available. Details Name: us- gaap_SubsequentEventsAbstract Namespace Prefix: us- gaap_ Data Type: xbrli: stringItemType Balance Type: na Period Type: durationX- DefinitionThe entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business. ReferencesReference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 855- Name Accounting Standards Codification- Publisher FASB- URI https: / / asc. fasb. org / 855 / tableOfContentReference 2: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 855- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 2- Subparagraph (a)- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147483399 / 855- 10- 50- 2 Details Name: us- gaap_SubsequentEventsTextBlock Namespace Prefix: us- gaap_ Data Type: dtr- types: textBlockItemType Balance Type: na Period Type: durationPay vs Performance Disclosure- USD ($) 12 Months EndedJan. 31, ~~2024~~ **2025** Jan. 31, ~~2023Pay~~ **2024Pay** vs Performance Disclosure Net Income (Loss) $ ( **10, 482, 617) $ (** 5, 485, 314 ~~) $ (4, 483, 474~~ ) X- ReferencesReference 1: http: / / www. xbrl. org / 2003 / role / presentationRef- Publisher SEC- Name Regulation S- K- Number 229- Section 402- Subsection v- Paragraph 1 Details Name: ecd_PvpTable Namespace Prefix: ecd_ Data Type: xbrli: stringItemType Balance Type: na Period Type: durationX- DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. ReferencesReference 1: http: / / www. xbrl. org / 2003 / role / ~~disclosureRef~~ **exampleRef** - Topic ~~250~~ **946** - SubTopic ~~10~~ **830** - Name Accounting Standards Codification- Section ~~50~~ **55** - Paragraph ~~6~~ **10** - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147483443~~ **2147479168** / ~~250~~ **946** - ~~10~~ **830** - ~~50~~ **55** - ~~6Reference~~ **10Reference** 2: http: / / www. xbrl. org / 2003 / role / ~~disclosureRef~~ **exampleRef** - Topic ~~250~~ **220** - SubTopic ~~10~~ **40** - Name Accounting Standards Codification- Section ~~50~~ **55** - Paragraph ~~9~~ **4** - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147483443~~ **2147476153** / ~~250~~ **220** - ~~10~~ **40** - ~~50~~ **55** - ~~9Reference~~ **4Reference** 3: http: / / www. xbrl. org / 2003 / role / ~~disclosureRef~~ **exampleRef** - Topic ~~805~~ **220** - SubTopic ~~60~~ **40** - Name Accounting Standards Codification- Section ~~65~~ **55** - Paragraph **21** ~~1- Subparagraph (g)~~ - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147476176~~ **2147476153** / ~~805~~ **220** - ~~60~~ **40** - ~~65~~ **55** - ~~1Reference~~ **21Reference** 4: http: / / www. xbrl. org / 2003 / role / ~~disclosureRef~~ **exampleRef** - Topic ~~740~~ **220** - SubTopic ~~323~~ **40** - Name Accounting Standards Codification- Section ~~65~~ **55** - Paragraph **14** ~~2- Subparagraph (g) (3)~~ - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147478666~~ **2147476153** / **220-** ~~740~~ - **40** - ~~323~~ **55** - ~~65- 2Reference~~ **14Reference** 5: http: / / ~~fasb~~ **www** . **xbrl.** org / **2003** ~~us- gaap~~ / role / **disclosureRef** ~~ref / legacyRef~~ - Topic ~~220~~ **235** - SubTopic 10- Name Accounting Standards Codification- Section ~~S99~~ **S50** - Paragraph **1** ~~2- Subparagraph (SX 210. 5- 03 (20))~~ - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147483621~~ **2147480738** / ~~220~~ **235** - 10- ~~S99~~ **S50** - ~~2Reference~~ **1Reference** 6: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 235- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210. 4- 08 (g) (1) ( ~~ii~~ **i** ))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480678 / 235- 10- S99- 1Reference 7: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic ~~323~~ **235** - SubTopic 10- Name Accounting Standards Codification- Section ~~50~~ **S99** - Paragraph ~~3~~ **1** - Subparagraph ( ~~c~~ **SX 210. 4- 08 (k) (2)** )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147481687~~ **2147480678** / ~~323~~ **235** - 10- ~~50~~ **S99** - ~~3Reference~~ **1Reference** 8: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 825- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 28- Subparagraph (f)- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482907 / 825- 10- 50- 28Reference 9: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic ~~220~~ **250** - SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph ~~6~~ **4** - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147482765~~ **2147483443** / ~~220~~ **250** - 10- 50- ~~6Reference~~ **4Reference** 10: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic ~~250~~ **480** - SubTopic 10- Name Accounting Standards Codification- Section ~~50~~ **S50** - Paragraph 3- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147483443~~ **2147479857** / ~~250~~ **480** - 10- ~~50~~ **S50** - 3Reference 11: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic ~~250~~ **480** - SubTopic 10- Name Accounting Standards Codification- Section ~~50~~ **S45** - Paragraph **3** ~~1- Subparagraph (b) (2)~~ - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147483443~~ **2147479887** / ~~250~~ **480** - 10- ~~50~~ **S45** - ~~1Reference~~ **3Reference** 12: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic ~~815~~ **480** - SubTopic ~~40~~ **10** - Name Accounting Standards Codification- Section ~~65~~ **S99** - Paragraph ~~1~~ **3A** - Subparagraph ( ~~f~~ **24) (d** )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147480175~~ **2147480244** / ~~815- 40~~ **480** - ~~65~~ **10** - **S99-** ~~1Reference~~ **3AReference** 13: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic ~~250~~ **105** - SubTopic 10- Name Accounting Standards Codification- Section ~~50~~ **65** - Paragraph ~~8~~ **9- Subparagraph (e)** - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147483443~~ - **2147479343** / ~~250- 10~~ **105** - ~~50~~ **10** - **65-** ~~8Reference~~ **9Reference** 14: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic ~~250~~ **718** - SubTopic 10- Name Accounting Standards Codification- Section ~~50~~ **65** - Paragraph ~~11~~ **17** - Subparagraph ( ~~a~~ **d) (1** )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147483443~~ - **2147480336** / ~~250~~ **718** - 10- ~~50~~ **65** - ~~11Reference~~ **17Reference** 15: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 250- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph **6** ~~11- Subparagraph (b)~~ - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147483443 / 250- 10- 50- ~~11Reference~~ **6Reference** 16: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 250- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph ~~4~~ **9** - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147483443 / 250- 10- 50- ~~4Reference~~ **9Reference** 17: http: / / www. xbrl. org / 2003 / role / ~~exampleRef~~ **disclosureRef** - Topic ~~946~~ **805** - SubTopic ~~830~~ **60** - Name Accounting Standards Codification- Section ~~55~~ **65** - Paragraph ~~10~~ **1- Subparagraph (g)** - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147479168~~ - **2147476176** / ~~946~~ **805** - ~~830~~ **60** - ~~55~~ **65** - ~~10Reference~~ - **1Reference** 18: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic ~~946~~ **740** - SubTopic ~~220~~ **323** - Name Accounting Standards Codification- Section ~~45~~ **65** - Paragraph ~~7~~ **2- Subparagraph (g) (3)** - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147479105~~ **2147478666** / ~~946~~ **740** - **323- 65- 2Reference 19: http: / / fasb. org / us- gaap / role / ref / legacyRef- Topic** 220- ~~45- 7Reference 19: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 944-~~ SubTopic ~~220~~ **10** - Name Accounting Standards Codification- Section S99- Paragraph ~~1~~ **2** - Subparagraph (SX 210. ~~7~~ **5** - ~~04~~ **03** ( ~~18~~ **20** ))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147477250~~ **2147483621** / ~~944-~~ 220- **10-** S99- ~~1Reference~~ **2Reference** 20: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic ~~946~~ **235** - SubTopic ~~220~~ **10** - Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210. ~~6~~ **4** - ~~07~~ **08** ( ~~9~~ **g) (1) (ii** ))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147479134~~ **2147480678** / ~~946~~ **235** - ~~220~~ **10** - S99- 1Reference 21: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic ~~946~~ **323** - SubTopic ~~220~~ **10** - Name Accounting Standards Codification- Section ~~S99~~ **50** - Paragraph 3- Subparagraph ( **c** ~~SX 210. 6- 09 (1) (d)~~ )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147479134~~ **2147481687** / ~~946~~ **323** - ~~220~~ **10** - ~~S99~~ **50** - 3Reference 22: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic ~~470~~ **220** - SubTopic 10- Name Accounting Standards Codification- Section ~~S99~~ **50** - Paragraph **6** ~~1A- Subparagraph (SX 210. 13- 01 (a) (4) (i))~~ - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147480097~~ **2147482765** / ~~470~~ **220** - 10- ~~S99~~ **50** - ~~1AReference~~ **6Reference** 23: http: / / www. xbrl. org / ~~2009~~ **2003** / role / ~~commonPracticeRef~~ **disclosureRef** - Topic ~~470~~ **250** - SubTopic 10- Name Accounting Standards Codification- Section ~~S99~~ **50** - Paragraph **3** ~~1A- Subparagraph (SX 210. 13- 01 (a) (4) (ii))~~ - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147480097~~ **2147483443** / ~~470~~ **250** - 10- ~~S99~~ **50** - ~~1AReference~~ **3Reference** 24: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic ~~470~~ **250** - SubTopic 10- Name Accounting Standards Codification- Section ~~S99~~ **50** - Paragraph ~~1A~~ **1** - Subparagraph ( **b** ~~SX 210. 13- 01 (a~~ ) ( **2** ~~4) (iii) (A)~~ )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147480097~~ **2147483443** / ~~470~~ **250** - 10- ~~S99~~ **50** - ~~1AReference~~ - **1Reference** 25: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic ~~470~~ **815** - SubTopic ~~10~~ **40** - Name Accounting Standards Codification- Section ~~S99~~ **65** - Paragraph ~~1A~~ **1** - Subparagraph ( **f** ~~SX 210. 13- 01 (a) (4) (iv)~~ )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147480097~~ **2147480175** / **815-** ~~470~~ - **40** - ~~10~~ **65** - ~~S99- 1AReference~~ - **1Reference** 26: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic ~~470~~ **250** - SubTopic 10- Name Accounting Standards Codification- Section ~~S99~~ **50** - Paragraph **8** ~~1A- Subparagraph (SX 210. 13- 01 (a) (5))~~ - Publisher FASB- URI https: / /

asc. fasb. org / 1943274 / ~~2147480097~~ **2147483443** / ~~470~~ **250** - 10- ~~S99~~ **50** - ~~1AReference~~ **8Reference** 27: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic ~~470~~ **250** - SubTopic 10- Name Accounting Standards Codification- Section ~~S99~~ **50** - Paragraph ~~1B~~ **11** - Subparagraph ( ~~SX 210. 13- 02 (~~a ~~) (4) (i) )~~- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147480097~~ **2147483443** / ~~470~~ **250** - 10- ~~S99~~ **50** - ~~1BReference~~ **11Reference** 28: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic ~~470~~ **250** - SubTopic 10- Name Accounting Standards Codification- Section ~~S99~~ **50** - Paragraph ~~1B~~ **11** - Subparagraph ( **b** ~~SX 210. 13- 02 (a) (4) (iii) (A) )~~- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147480097~~ **2147483443** / ~~470~~ **250** - 10- ~~S99~~ **50** - ~~1BReference~~ **11Reference** 29: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic ~~470~~ **946** - SubTopic ~~10~~ **220** - Name Accounting Standards Codification- Section ~~S99~~ **45** - Paragraph **7** ~~1B- Subparagraph (SX 210. 13- 02 (a) (4) (iii) (B)) -~~ Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147480097~~ **2147479105** / ~~470~~ **946** - ~~10~~ **220** - ~~S99~~ **45** - ~~1BReference~~ **7Reference** 30: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic ~~470~~ **944** - SubTopic ~~10~~ **220** - Name Accounting Standards Codification- Section S99- Paragraph ~~1B~~ **1** - Subparagraph (SX 210. ~~13~~ **7** - ~~02~~ **04** ( **18** ~~a) (4) (iv -~~)~~- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147480097~~ **2147477250** / ~~470~~ **944** - ~~10~~ **220** - S99- ~~1BReference -~~ **1Reference** 31: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic ~~470~~ **946** - SubTopic ~~10~~ **220** - Name Accounting Standards Codification- Section S99- Paragraph ~~1B~~ **1** - Subparagraph (SX 210. ~~13~~ **6** - ~~02~~ **07** ( **9** ~~a) (5 -~~)~~- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147480097~~ **2147479134** / ~~470~~ **946** - ~~10~~ **220** - S99- ~~1BReference -~~ **1Reference** 32: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic ~~260~~ **946** - SubTopic ~~10~~ **220** - Name Accounting Standards Codification- Section ~~45~~ **S99** - Paragraph ~~60B~~ **3** - Subparagraph ( ~~a~~ **SX 210. 6- 09 (1) (d)** )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147482689~~ **2147479134** / ~~260~~ **946** - ~~10~~ **220** - ~~45~~ **S99** - ~~60BReference~~ **3Reference** 33: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic ~~205~~ **470** - SubTopic ~~20~~ **10** - Name Accounting Standards Codification- Section ~~50~~ **S99** - Paragraph ~~7~~ **1A- Subparagraph (SX 210. 13- 01 (a) (4) (i))** - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147483499~~ **2147480097** / ~~205~~ **470** - ~~20~~ **10** - ~~50~~ **S99** - ~~7Reference~~ **1AReference** 34: http: / / ~~fasb~~ **www** . **xbrl.** org / **2009** ~~us- gaap~~ / role / **commonPracticeRef** ~~ref / legacyRef -~~ Topic ~~230~~ **470** - SubTopic 10- Name Accounting Standards Codification- Section ~~45~~ **S99** - Paragraph ~~28~~ **1A- Subparagraph (SX 210. 13- 01 (a) (4) (ii))** - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147482740~~ **2147480097** / ~~230~~ **470** - 10- ~~45~~ **S99** - ~~28Reference~~ **1AReference** 35: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic ~~220~~ **470** - SubTopic 10- Name Accounting Standards Codification- Section ~~45~~ **S99** - Paragraph 1A- Subparagraph ( **SX 210. 13- 01 (** a **) (4) (iii) (A)** )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147482790~~ **2147480097** / ~~220~~ **470** - 10- ~~45~~ **S99** - 1AReference 36: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic ~~220~~ **470** - SubTopic 10- Name Accounting Standards Codification- Section ~~45~~ **S99** - Paragraph ~~1B~~ **1A** - Subparagraph ( **SX 210. 13- 01 (** a **) (4) (iv)** )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147482790~~ **2147480097** / ~~220~~ ~~470~~ - 10- ~~45~~ **S99** - ~~1BReference~~ **1AReference** 37: http: / / ~~fasb~~ **www** . **xbrl.** org / **2003** ~~us- gaap~~ / role / **disclosureRef** ~~ref / legacyRef -~~ Topic ~~942~~ **470** - SubTopic ~~220~~ **10** - Name Accounting Standards Codification- Section S99- Paragraph **the passage of time or when** ~~Codification- Section S99- Paragraph 1B- Subparagraph (SX 210.13- 02 (~~a **triggering event occurs** ~~) (4) (i))- Publisher FASB- URI https: / / asc. -~~ **ReferencesReference 1** ~~fasb.org / 1943274 / 2147480097 / 470- 10- S99- 1BReference 39 -~~:http: / ~~www~~ **fasb** . ~~xbrl.~~ org / ~~2003~~ **us- gaap** / role / ~~disclosureRef~~ **ref / legacyRef** - Topic ~~470~~ **942** - SubTopic ~~10~~ **210** - Name Accounting Standards Codification- Section S99- Paragraph ~~1B~~ **1** - Subparagraph (SX 210. ~~13~~ **9** - ~~02~~ **03** ( **10** ~~a) (4) (iii) (A -~~))- Publisher FASB- URI https: / / asc.fasb.org / 1943274 / ~~2147480097~~ **2147478546** / ~~470~~ **942** - ~~10~~ **210** - S99- ~~1BReference -~~ **1Reference** ~~40~~ **2** :http: / / www.xbrl.org / ~~2003~~ **2009** / role / ~~disclosureRef~~ **commonPracticeRef** - Topic ~~470~~ **944** - SubTopic ~~10~~ **210** - Name Accounting Standards Codification- Section S99- Paragraph ~~1B~~ **1** - Subparagraph (SX 210. ~~13~~ **7** - ~~02~~ **03** (a) ( **10** ~~4) (iii) (B -~~))- Publisher FASB- URI https: / / asc.fasb.org / 1943274 / ~~2147480097~~ **2147478777** / ~~470~~ **944** - ~~10~~ **210** - S99- ~~1BReference -~~ **1Reference** ~~41~~ **3** :http: / / www.xbrl.org / 2003 / role / disclosureRef- Topic ~~470~~ **946** - SubTopic ~~10~~ **210** - Name Accounting Standards Codification- Section S99- Paragraph ~~1B~~ **1** - Subparagraph (SX 210. ~~13~~ **6** - ~~02~~ **04 (7)** (a ~~) (4) (iv -~~))- Publisher FASB- URI https: / / asc.fasb.org / 1943274 / ~~2147480097~~ **2147479170** / ~~470~~ **946** - ~~10~~ **210** - S99- ~~1BReference -~~ **1Reference** ~~42~~ **4** :http: / / www.xbrl.org / 2003 / role / disclosureRef- Topic ~~470~~ **210** - SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph ~~1B~~ **1** - Subparagraph (SX 210. ~~13~~ **5** - 02 ( ~~5~~ **7** ~~a) (5 -~~))- Publisher FASB- URI https: / / asc.fasb.org / 1943274 / ~~2147480097~~ **2147480566** / ~~470- 10~~ **210** - ~~S99~~ **10** - ~~1BReference 43~~ **S99- 1 Details Name:us-gaap_PrepaidExpenseCurrentAndNoncurrent Namespace Prefix:us- gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instantX- DefinitionCash received for fees during the current period.This element excludes cash proceeds from license fees. ReferencesReference 1** :http: / ~~www~~ **fasb** . ~~xbrl.~~ org / ~~2003~~ **us- gaap** / role / ~~disclosureRef~~ **ref / legacyRef** - Topic ~~260~~ **230** - SubTopic 10- Name Accounting Standards Codification- Section 45- Paragraph ~~60B~~ **25** - Subparagraph ( ~~a~~ **c** )- Publisher FASB- URI https: / / asc.fasb.org / 1943274 / ~~2147482689~~ **2147482740** / ~~260~~ **230** - 10- 45- ~~60BReference 44~~ **25 Details Name** : ~~http~~ **us- gaap_ProceedsFromFeesReceived Namespace Prefix** : ~~/ / www.~~ **us- gaap_ Data Type:** ~~xbrl~~ **xbrli** ~~.org / 2003 / role / disclosureRef~~ **:monetaryItemType Balance Type:debit Period Type:durationX** - **DefinitionAmount of purchase arrangement** ~~Topic 205- SubTopic 20-~~ 1- Subparagraph (SX 210. 9- 04 (22))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147478524 / 942- 220- S99- 1 Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us- gaap_ Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: durationInsider Trading Arrangements ~~3~~ **12** Months Ended Jan. 31, ~~2024~~ **2025** Trading Arrangements, by Individual Rule 10b5- 1 Arrangement Adopted falseNon- Rule 10b5- 1 Arrangement Adopted falseRule 10b5- 1 Arrangement Terminated falseNon- Rule 10b5- 1 Arrangement Terminated falseX- ReferencesReference 1: http: / / www. xbrl. org / 2003 / role / presentationRef- Publisher SEC- Name Regulation S- K- Number 229- Section 408- Subsection a- Paragraph 1 Details Name: ecd_NonRule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli: booleanItemType Balance Type: na Period Type: durationX- ReferencesReference 1: http: / / www. xbrl. org / 2003 / role / presentationRef- Publisher SEC- Name Regulation S- K- Number 229- Section 408- Subsection a- Paragraph 1 Details Name: ecd_NonRule10b51ArrTrmntdFlag Namespace Prefix: ecd_ Data Type: xbrli: booleanItemType Balance Type: na Period Type: durationX- ReferencesReference 1: http: / / www. xbrl. org / 2003 / role / presentationRef- Publisher SEC- Name Regulation S- K- Number 229- Section 408- Subsection a- Paragraph 1 Details Name: ecd_Rule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli: booleanItemType Balance Type: na Period Type: durationX- ReferencesReference 1: http: / / www. xbrl. org / 2003 / role / presentationRef- Publisher SEC- Name Regulation S- K- Number 229- Section 408- Subsection a- Paragraph 1 Details Name: ecd_Rule10b51ArrTrmntdFlag Namespace Prefix: ecd_ Data Type: xbrli: booleanItemType Balance Type: na Period Type: durationX- ReferencesReference 1: http: / / www. xbrl. org / 2003 / role / presentationRef- Publisher SEC- Name Regulation S- K- Number 229- Section 408- Subsection a- Paragraph 2- Subparagraph A Details Name: ecd_TradingArrByIndTable Namespace Prefix: ecd_ Data Type: xbrli: stringItemType Balance Type: na Period Type: durationAccounting Policies, by Policy (Policies) 12 Months Ended Jan. 31, ~~2024~~ **2025** Summary of Significant Accounting Policies [ Abstract ] ~~Forward Stock Split Forward Stock SplitOn July 26, 2022, our Board of Directors approved the amendment to our Articles of Incorporation to effect a 7- for- 6 forward stock split (the " Stock Split ") of our outstanding common stock. The Company filed the amendment set forth in a Certificate of Change with the Secretary of State of Nevada on August 4, 2022. The 7: 6 forward stock split was effective for trading purposes on the Nasdaq Capital Market on August 12, 2022. Each shareholder of record as of the August 15, 2022 record date received one (1) additional share for each six (6) shares held as of the record date. No fractional shares of common stock were issued in connection with the Stock Split. Instead, all shares were rounded up to the next whole share. In connection with the Stock Split, which did not require shareholder approval under the Nevada corporation law, the number of shares of common stock of the Company was increased in the same ratio as the shares of outstanding common stock were increased in the Stock Split, from 250, 000, 000 authorized shares to 291, 666, 666 authorized shares. All share and per share information in these financial statements retroactively reflect the forward stock split.~~ Going Concern Assessment Going Concern Assessment Management assesses liquidity and going concern uncertainty in the Company' s condensed financial statements to determine whether there is sufficient cash on hand and working capital, including available borrowings on loans, to operate for a period of at least one year from the date the consolidated financial statements are issued or available to be issued, which is referred to as the " look- forward period ", as defined in GAAP. As part of this assessment, based on conditions that are known and reasonably knowable to management, management will consider various scenarios, forecasts, projections, estimates and will make certain key assumptions, including timing and nature of projected cash expenditures or programs, its ability to delay or curtail expenditures or programs and its ability to raise additional capital, if necessary, among other factors. Based on this assessment, as necessary or applicable, management makes certain assumptions around implementing curtailments or delays in the nature and timing of programs and expenditures to the extent it deems probable those implementations can be achieved **,** and management has the proper authority to execute them within the look- forward period. As of January 31, ~~2024~~ **2025** , the Company had cash and cash equivalents of $ ~~492~~ **4** , ~~942~~ **311, 719** and working capital of $ ~~22~~ **3** , ~~770~~ **811, 420** . For the year ended January 31, ~~2024~~ **2025** , the Company incurred a **net** loss from operations of $ ~~4~~ **10** , ~~871~~ **284** , ~~926~~ **843** and used cash flow from operations of $ ~~3~~ **4** , ~~527~~ **626** , ~~509~~ **564** . The Company has generated operating losses since its inception and has relied on sales of securities and **the** issuance of third- party and related- party debt to support cash flow from operations ~~. In October 2021, the Company consummated a public offering and received net proceeds of $ 5, 836, 230. The Company has also received to date $ 3, 239, 845 in proceeds from the exercise of warrants~~ . The Company has used these proceeds to fund operations and will continue to use the funds as needed. In March 2023, the Company entered into a three- year $ 2, 000, 000 Credit Line Note facility with a related party, amended on July 13, 2023, to $ 5, 000, 000, which will permit the Company to draw down on the credit line to fund the Company' s research and development of its Aversa product. ~~The Company was advanced $ 2, 000, 000, all of which was settled by the issuance of common stock during the year ended January 31, 2024. The $ 2, 000, 000 debt and accrued interest was converted into 1, 026, 720 shares of the Company' s common stock.~~ On April 19, 2024, the Company received

proceeds of $ 8, 400, 000 from **equity financing with European investors** ~~a private placement of its common stock~~. Management has prepared estimates of operations for the next twelve months and believes that sufficient funds will be generated from operations to fund its operations for one year from the date of the filing of these condensed consolidated financial statements, which indicates improved operations and the Company' s ability to continue operations as a going concern. Management believes the substantial doubt about the ability of the Company to continue as a going concern is alleviated by the above assessment. Principles of Consolidation Principles of ConsolidationThe consolidated financial statements of the Company include the Company and its wholly owned subsidiaries. All material intercompany balances and transactions have been eliminated. The operations of 4P Therapeutics are included in the Company' s financial statements from the date of acquisition of August 1, 2018, and the **acquired** operations of Pocono **Coated Products** and Active Intelligence are included in the Company' s financial statements from the date of acquisition of September 1, 2020 **,** under Pocono Pharmaceuticals Inc. The wholly owned subsidiaries are as follows: Nutriband Ltd. 4P Therapeutics LLCPocono Pharmaceuticals Inc. Use of Estimates Use of Estimates The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires the Company to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an ongoing basis, the Company evaluates its estimates including, but not limited to, those related to such items as income tax exposures, accruals, depreciable / useful lives, allowance for doubtful accounts and valuation allowances. The Company bases its estimates on historical experience and on other various assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates. Revenue Recognition Revenue Recognition In May 2014, the FASB issued ASU No. 2014- 09, " Revenue from Contracts with Customers (Topic 606) (" ASU 2014- 09 "), which amends the accounting standards for revenue recognition. ASU 2014- 09 is based on principles that govern the recognition of revenue at an amount an entity expects to be entitled when products are transferred to a customer. The Company recognizes revenue based on the five criteria for revenue recognition established under Topic 606: 1) identify the contract, 2) identify separate performance obligations, 3) determine the transaction price, 4) allocate the transaction price among the performance obligations, and 5) recognize revenue as the performance obligations are satisfied. Revenue Types Revenue TypesThe following is a description of the Company' s revenue types, which include professional services and sale of goods: ● Contract development and manufacturing services for consumer health transdermal, topical and tape products with revenues listed under sale of goods **.** ● Product revenues derived from the sale of the Company' s consumer transdermal, topical and tape products with sales listed under sale of goods **.** ● Contract research and development services for ~~pharmaceuticals~~ **pharmaceutical** and medical ~~devices~~ **device** ~~for~~ life sciences customers with revenues listed under services **.** Contracts with Customers Contracts with CustomersA contract with a customer exists when (i) we enter into an enforceable contract with a customer that defines each party' s rights regarding the goods or services to be transferred and identifies the payment terms related to these goods or services, (ii) the contract has commercial substance and, (iii) we determine that collection of substantially all consideration for services that are transferred is probable based on the customer' s intent and ability to pay the promised consideration. Contract Liabilities Contract LiabilitiesDeferred revenue is a liability related to a revenue producing activity for which revenue has not been recognized. The Company records deferred revenue when it receives consideration from a contract before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. Performance Obligations Performance ObligationsA performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in the new revenue standard. The contract transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. For the Company' s different revenue service types, the performance obligation is satisfied at different times. The Company' s performance obligations include providing products and professional services in the area of research. The Company recognizes product revenue performance obligations in most cases when the product has shipped to the customer. When we perform professional service work, we recognize revenue when we have the right to invoice the customer for the work completed, which typically occurs over time on a monthly basis for the work performed during that month. All revenue recognized in the income statement is considered to be revenue from contracts with customers. Disaggregation of Revenues Disaggregation of RevenuesThe Company disaggregates its revenue from contracts with customers by type and by geographical location. See the tables: Years ~~Ended~~ **Ending** January 31, **2025** 2024 ~~2023~~ Revenue by type Sale of goods $ ~~1~~ **2** , ~~920~~ **139** , ~~280~~ **537** $ 1, ~~785~~ **920** , ~~507~~ **280** Services **-** 165, 034 ~~294, 102~~ Total $ 2, ~~085~~ **139** , ~~314~~ **537** $ 2, ~~079~~ **085** , ~~609~~ **314** Years ~~Ended~~ **Ending** January 31, **2025** 2024 ~~2023~~ Revenue by geographic location: United States $ 2, ~~085~~ **139** , ~~314~~ **537** $ 2, ~~079~~ **085** , ~~609~~ **314** Foreign-- $ 2, ~~085~~ **139** , ~~314~~ **537** $ 2, ~~079~~ **085** , ~~609~~ **314** Cash and cash equivalents Cash and cash equivalents. Cash and cash equivalents include cash on hand ~~,~~ **and** cash on deposit in money market accounts. The Company considers short- term highly liquid investments with an original maturity date of three months or less that are not part of an investment pool to be cash equivalents. As of January 31, ~~2024~~ **2025** , the Company ~~has no balances~~ **had $ 3, 804, 000** that ~~exceed~~ **exceeded** federally insured **cash balance** limits. Accounts receivable Accounts receivable Trade accounts receivables are recorded at the net invoice value and are not interest bearing. The Company maintains allowances for doubtful accounts for estimated losses from the inability of its customers to make the required payments. The Company determines its allowances by both ~~the~~ specific identification of customer accounts where appropriate and the application of historical loss to non- applicable accounts. For the years ended January 31, **2025, and** 2024 ~~, and 2023~~ , the Company recorded bad debt expenses of $ ~~118~~ **1** , ~~364~~ **200** and $ ~~- 0-~~ **11, 836** , respectively, for doubtful accounts related to accounts receivable. During the year ended January 31, 2024, the Company entered into an accounts receivable sale agreement for one of its subsidiaries. The Company received $ 106, 528 in funds against an account receivable that is currently a claim in bankruptcy. The net accounts receivable remain on the books of the Company and a corresponding amount has been included as a secured borrowing liability under Notes payable. As of January 31, ~~2024~~ **2025** , the receivable has been reserved in full. If the bankruptcy claim is not paid in full by the debtor, Company is obligated to pay any difference to the factor. The loan bears interest at 10 %. The Company adopted ASU 2016- 13 during ~~2023~~ **2013** and implemented the guidance on expected credit losses. Inventories InventoriesInventories are valued at the lower of cost and reasonable value determined using the first- in, first- out (FIFO) method. Net realized value is the estimated selling price in the ordinary course of business, less applicable variable selling expenses. The cost of finished goods and work in process is comprised of material costs, direct labor costs and other direct costs and related production overheads (based on normal operating capacity). As of January 31, **2025, total inventory was $ 212, 041, consisting of work- in- process of $ 46, 255, finished goods of $ 16, 609 and raw materials of $ 149, 177. As of January 31,** 2024, total inventory was $ 168, 605, consisting of work- in- process of $ 7, 466, finished goods of $ 8, 707 and raw materials of $ ~~134~~ **152** , **432** ~~691. As of January 31, 2023, total inventory was $ 229, 335, consisting of work- in- process of $ 11, 021 and raw materials of $ 218, 334~~. Property, Plant and Equipment Property, Plant and EquipmentProperty and equipment represent an important component of the Company' s assets. The Company depreciates its plant and equipment on a straight- line basis over the estimated useful life of the assets. Property, plant and equipment is stated at historical cost. Expenditures for minor repairs, maintenance and replacement parts which do not increase the useful lives of the assets are charged to expense as incurred. All major additions and improvements are capitalized. Depreciation is computed using the straight- line method. The lives over which the fixed assets are depreciated range from 3 to 20 years as follows: Lab Equipment 5- 10 years Furniture and fixtures 3 **- 5** years Machinery and equipment ~~10~~ **5** - 20 ~~years Intangible~~ **yearsIntangible** Assets Intangible AssetsIntangible assets include trademarks, intellectual property and customer base acquired through business combinations. The Company accounts for Other Intangible Assets under the guidance of ASC 350, " Intangibles- Goodwill and Other. " The Company capitalizes certain costs related to patent technology. A substantial component of the purchase price related to the Company' s acquisitions ~~have~~ **has** also been assigned to intellectual property and other intangibles. Under the guidance, other intangible assets with definite lives are amortized over their estimated useful lives. Intangible assets with indefinite lives are tested annually for impairment. Trademarks, ~~intellectual~~ **Intellectual** property and customer base are being amortized over their estimated useful lives of ten years. **During the year ending January 31, 2025, the Company recorded an impairment charge of $ 293, 038 to its Intellectual property.** Goodwill GoodwillGoodwill represents the difference between the total purchase price and the fair value of assets (tangible and intangible) and liabilities at the date of acquisition. Goodwill is reviewed for impairment annually on January 31, and more frequently as circumstances warrant, and written down only in the period in which the recorded value of such assets exceeds their fair value. The Company does not amortize goodwill in accordance with ASC 350. In connection with the Company' s acquisition of 4P Therapeutics LLC in 2018, the Company recorded Goodwill of $ 1, 719, 235. On August 31, 2020, in connection with the Company' s acquisition of Pocono Coated Products LLC and Active Intelligence LLC, the Company recorded Goodwill of $ 5, 810, 640. During the years ~~ended~~ **ending** January 31, **2025 and** 2024 ~~, and 2023~~ , the Company recorded an impairment charge of $ ~~- 0-~~ **3, 302, 478** and $ ~~327, 326~~ **- 0-** , respectively, reducing the Active Intelligence LLC Goodwill to $ **- 0-** ~~3, 302, 478~~. As of January 31, **2025 and** 2024 ~~, and 2023~~ , Goodwill amounted to $ ~~5~~ **1** , ~~021~~ **719** , ~~713~~ **535** and $ 5, 021, 713, respectively. Long- lived Assets Long- lived AssetsManagement reviews long- lived assets for potential impairment whenever significant events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An impairment exists when the carrying amount of the long- lived asset is not recoverable and exceeds its fair value. The carrying amount of a long- lived asset is not recoverable if it exceeds the sum of the estimated undiscounted cash flows expected to result from the use and eventual disposition of the asset. If an impairment exists, the resulting write- down would be the difference between the fair market value of the long- lived asset and the related book value. Earnings per Share Earnings per ShareBasic earnings per share of common stock is computed by dividing net earnings by the weighted average number of shares of common stock outstanding during the

period. Diluted earnings per share is computed by dividing net earnings by the weighted average number of shares of common stock and potential shares of common stock outstanding during the period. Potential shares of common stock consist of shares issuable upon the exercise of outstanding options and common stock purchase warrants. As of January 31, **2025, and** 2024 ~~, and 2023~~, there were **6, 920, 641 and** 2, 157, 873 ~~and 1, 778, 006~~ common stock equivalents outstanding, that were not included in the calculation of dilutive earnings per share as their effect would be anti- dilutive. Stock- Based Compensation Stock- Based CompensationASC 718, " Compensation- Stock Compensation, " prescribes accounting and reporting standards for all share- based payment transactions in which employee services, and, since February 1, 2019, non- employees, are acquired. Transactions include incurring liabilities, or issuing or offering to issue shares, options and other equity instruments such as employee stock ownership plans and stock appreciation rights. Share- based payments to employees, including grants of employee stock options, are recognized as compensation expense in the financial statements based on their fair values. That expense is recognized over the period during which an employee is required to provide services in exchange for the award, known as the requisite service period (usually the vesting period). As of February 1, 2019, pursuant to ASC 2018- 07, ASC 718 was applied to stock- based compensation for both employees and non- employees. Business Combinations Business CombinationsThe Company recognizes the assets acquired, the liabilities assumed, and any non- controlling interest in the acquired entity at the acquisition date, measured at their fair values as of that date, with limited exceptions specified in the accounting literature. In accordance with this guidance, acquisition- related costs, including restructuring costs, must be recognized separately from the acquisition and will generally be expensed as incurred. That replaces the cost- allocation process detailed in previous accounting literature, which required the cost of an acquisition to be allocated to the individual assets acquired and liabilities assumed based on their estimated fair value. Leases LeasesIn February 2016, the FASB issued ASU 2016- 02, " Leases " (Topic 842), to provide a new comprehensive model for lease accounting under this guidance, lessees and lessors should apply a " right- of- use " model in accounting for all leases (including subleases) and eliminate the concept of operating leases and off- balance- sheet leases. Recognition, measurement and presentation of expenses will depend on classification as a finance or operating lease. Similar modifications have been made to lessor accounting in- line with revenue recognition guidance. The Company applies **the** guidance for right- of- use accounting for all leases and records the operating lease liabilities on its balance sheet. The Company completed the necessary changes to its accounting policies, processes, disclosure and internal control over financial reporting. Research and Development Expenses Research and Development ExpensesResearch and development costs are expensed as incurred. Income Taxes Income TaxesTaxes are calculated in accordance with taxation principles currently effective in the United States and Ireland. The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. The Company records net deferred tax assets to the extent they believe these assets will more ~~-~~ likely ~~-~~than ~~-~~not be realized. In making such determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax planning strategies and recent financial operations. In the event the Company was ~~to determine~~ **determined** that it would be able to realize its deferred income tax assets in the future in excess of its net recorded amount, the Company would make an adjustment to the valuation allowance which would reduce the provision for income taxes. Fair Value Measurements Fair Value MeasurementsFASB ASC 820, " Fair Value Measurements and Disclosure " (" ASC 820 "), defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between participants on the measurement date. ASC 820 also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value. The Company utilizes the accounting guidance for fair value measurements and disclosures for all financial assets and liabilities and nonfinancial assets and liabilities that are recognized or disclosed at fair value in the consolidated financial statements on a recurring basis during the reporting period. The fair value is an exit price, representing the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants based upon the best use of the asset or liability at the measurement date. The Company utilizes market data or assumptions that market participants would use in pricing the asset or liability. ASC 820 establishes a three- tier value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers are defined as follows: Level 1- Observable inputs such as quoted market prices in active markets. Level 2- Inputs other than quoted prices in active markets that are either directly or indirectly observable. Level 3- Unobservable inputs about which little or no market data exists, therefore requiring an entity to develop its own assumptions. The carrying value of the Company' s financial instruments, including accounts receivable, prepaid expenses, accounts payable and accrued expenses, and deferred revenue approximate their fair value due to the short maturities of these financial instruments. Recent Accounting Standards Recent Accounting ~~StandardsIn~~ **StandardsThe** ~~June 2016, the FASB issued ASU 2016- 13, Financial Instruments- Credit Losses (Topic 326), The ASU introduces a new credit loss methodology. Current Expected Credit Loss (" CECL "), which requires earlier recognition of credit losses, which also provides additional transparency about credit risk. Since its original issuance in 2016, the FASB has issued several updates to the original ASU. The Company adopted ASU 2016- 13 during the year ended January 31, 2024. The adoption of ASU 2016- 13 did not have a material impact on the Company' s balance sheet or statement of operations. The~~ Company has reviewed all other FASB- issued ASU accounting pronouncements and interpretations thereof that have effective dates during the period reported and in future periods. The Company has carefully considered the new pronouncements that alter previous GAAP and does not believe that any new or modified principles will have a material impact on the Company' s reported financial position or operations in the near term. The applicability of any standard is subject to the formal review of the Company' s financial management and certain standards are under consideration. X- DefinitionAccounting policy for contract liability. ReferencesNo definition available. Details Name: ntrb_ContractLiabilitiesPolicyTextBlock Namespace Prefix: ntrb_ Data Type: dtr: textBlockItemType Balance Type: na Period Type: durationX- **DefinitionDisclosure** ~~DefinitionThe entire disclosure~~ of ~~disaggregation of revenues~~ **accounting policy for contracts with customers** . ReferencesNo definition available. Details Name: ~~ntrb_DisaggregationOfRevenuesPolicyTextBlock~~ **ntrb_ContractsWithCustomersPolicyPolicyTextBlock** Namespace Prefix: ntrb_ Data Type: dtr: textBlockItemType Balance Type: na Period Type: durationX- DefinitionThe entire disclosure of ~~forward stock split~~ **disaggregation of revenues** . ReferencesNo definition available. Details Name: ~~ntrb_ForwardStockSplitPolicyTextBlock~~ **ntrb_DisaggregationOfRevenuesPolicyTextBlock** Namespace Prefix: ntrb_ Data Type: dtr: textBlockItemType Balance Type: na Period Type: durationX- DefinitionThe disclosure of accounting policy for Going Concern. ReferencesNo definition available. Details Name: ntrb_GoingConcernPolicyTextBlock Namespace Prefix: ntrb_ Data Type: dtr: textBlockItemType Balance Type: na Period Type: durationX- DefinitionThe entire disclosure of performance obligations. ReferencesNo definition available. Details Name: ntrb_PerformanceObligationsPolicyTextBlock Namespace Prefix: ntrb_ Data Type: dtr: textBlockItemType Balance Type: na Period Type: durationX- ReferencesNo definition available. Details Name: us- gaap_AccountingPoliciesAbstract Namespace Prefix: us- gaap_ Data Type: xbrli: stringItemType Balance Type: na Period Type: durationX- DefinitionDisclosure of accounting policy for ~~completed~~ business ~~combinations (purchase method, acquisition method or~~ combination ~~of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity' s specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy~~ . ReferencesReference 1: http: / / ~~fasb~~ **www** . **xbrl.** org / **2003** ~~us- gaap~~ / role / **exampleRef** ~~ref / legacyRef~~ - Topic 805- SubTopic 10- Name Accounting Standards Codification- Section ~~05~~ **50** - Paragraph **8** ~~4- Subparagraph (d)~~ - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147479515~~ **2147479328** / 805- 10- ~~05~~ **50** - ~~4Reference~~ **8Reference** 2: http: / / ~~fasb~~ **www** . **xbrl.** org / **2003** ~~us- gaap~~ / role / **exampleRef** ~~ref / legacyRef~~ - Topic 805- SubTopic ~~10~~ **30** - Name Accounting Standards Codification- Section ~~05~~ **50** - Paragraph **2** ~~4- Subparagraph (c)~~ - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147479515~~ - **2147479581** / 805- ~~10~~ **30** - ~~05~~ **50** - ~~4Reference~~ **2Reference** 3: http: / / ~~fasb~~ **www** . **xbrl.** org / **2003** ~~us- gaap~~ / role / **exampleRef** ~~ref / legacyRef~~ - Topic 805- SubTopic ~~10~~ **30** - Name Accounting Standards Codification- Section ~~05~~ **50** - Paragraph **1- Subparagraph (b) (** 4 ~~- Subparagraph (b~~ )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147479515~~ - **2147479581** / 805- ~~10~~ **30** - ~~05~~ **50** - ~~4Reference~~ **1Reference** 4: http: / / ~~fasb~~ **www** . **xbrl.** org / **2003** ~~us- gaap~~ / role / **exampleRef** ~~ref / legacyRef~~ - Topic 805- SubTopic 10- Name Accounting Standards Codification- Section ~~https~~ **credit Period Type** : ~~/ / asc~~ **instantX- DefinitionAmount,after effects of reinsurance,of expense (reversal of expense) for claims incurred and costs incurred in the claim settlement process** . **ReferencesReference 1** ~~fasb.org / 1943274 / 2147479907 / 805- 20- 50- 2Reference 7~~ :http: / / www.xbrl.org / 2003 / role / ~~disclosureRef~~ **exampleRef** - Topic ~~805~~ **944** - SubTopic ~~10~~ **40** - Name Accounting Standards Codification- Section ~~50~~ **55** - Paragraph ~~3~~ **7** - Publisher FASB- URI https: / / asc.fasb.org / 1943274 / ~~2147479328~~ **2147480046** / ~~805~~ **944** - ~~10~~ **40** - ~~50~~ **55** - ~~3Reference~~ **7Reference** ~~8~~ **2** :http: / / www.xbrl.org / ~~2003~~ **2009** / role / ~~disclosureRef~~ **commonPracticeRef** - Topic ~~805~~ **944** - SubTopic ~~10~~ **40** - Name Accounting Standards Codification- Section 50- Paragraph ~~2~~ **3** - Subparagraph ( **b** ~~c)~~ ~~(4~~ )- Publisher FASB- URI https: / / asc.fasb.org / 1943274 / ~~2147479328~~ **2147480081** / ~~805~~ **944** - ~~10~~ **40** - 50- ~~2Reference 9~~ **3 Details Name** : ~~http~~ **us-**

**gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1 Namespace Prefix** : **us** ~~/ / www.xbrl.org / 2003 / role / disclosureRef~~ **gaap_ Data Type:xbrli:monetaryItemType Balance Type:** ~~Topic 805- SubTopic 10- Name Accounting Standards Codification- Section 50-~~ 05- Paragraph 4 ~~- Subparagraph (a)~~ - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147479515 / 805- 10- 05- 4 Details Name: us- gaap_BusinessCombinationsPolicy Namespace Prefix: us- gaap_ Data Type: dtr- types: textBlockItemType Balance Type: na Period Type: durationX- DefinitionDisclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity' s use of its cash and cash equivalents, (2) whether the entity' s cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value. ReferencesReference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef- Name Accounting Standards Codification- Topic 230- SubTopic 10- Section 50- Paragraph 1- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482913 / 230- 10- 50- 1 Details Name: us- gaap_CashAndCashEquivalentsPolicyTextBlock Namespace Prefix: us- gaap_ Data Type: dtr- types: textBlockItemType Balance Type: na Period Type: durationX- DefinitionDisclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary. ReferencesReference 1: http: / / www. xbrl. org / 2003 / role / exampleRef- Topic 235- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 4- Subparagraph (a)- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147483426 / 235- 10- 50- 4Reference 2: http: / / fasb. org / us- gaap / role / ref / legacyRef- Name Accounting Standards Codification- Topic 810- SubTopic 10- Section 50- Paragraph 1- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147481203 / 810- 10- 50- 1 Details Name: us- gaap_ConsolidationPolicyTextBlock Namespace Prefix: us- gaap_ Data Type: dtr- types: textBlockItemType Balance Type: na Period Type: durationX- DefinitionDisclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements. ReferencesReference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 260- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 1- Subparagraph (d)- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482662 / 260- 10- 50- 1Reference 2: http: / / fasb. org / us- gaap / role / ref / legacyRef- Name Accounting Standards Codification- Topic 260- SubTopic 10- Section 50- Paragraph 1- Subparagraph (c)- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482662 / 260- 10- 50- 1Reference 3: http: / / fasb. org / us- gaap / role / ref / legacyRef- Name Accounting Standards Codification- Topic 260- SubTopic 10- Section 50- Paragraph 2- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482662 / 260- 10- 50- 2 Details Name: us- gaap_EarningsPerSharePolicyTextBlock Namespace Prefix: us- gaap_ Data Type: dtr- types: textBlockItemType Balance Type: na Period Type: durationX- DefinitionDisclosure of accounting policy for fair value measurements of financial and non- financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities. ReferencesNo definition available. Details Name: us- gaap_FairValueMeasurementPolicyPolicyTextBlock Namespace Prefix: us- gaap_ Data Type: dtr- types: textBlockItemType Balance Type: na Period Type: durationX- DefinitionDisclosure of accounting policy for goodwill ~~and intangible assets~~. This accounting policy also may address how an entity assesses and measures impairment of goodwill **, how reporting units are determined, how goodwill is allocated to such units,** and ~~intangible assets~~ **how the fair values of the reporting units are determined** . ReferencesReference 1: http: / / www. xbrl. org / ~~2009~~ **2003** / role / ~~commonPracticeRef~~ **exampleRef** - Topic 350- SubTopic ~~30~~ **20** - Name Accounting Standards Codification- **Section 55- Paragraph 24-** Publisher FASB- URI https: / / asc. fasb. org / **1943274 / 2147482548 /** 350- ~~30 / tableOfContentReference~~ **20- 55- 24Reference** 2: http: / / www. xbrl. org / ~~2009~~ **2003** / role / ~~commonPracticeRef~~ **disclosureRef** - Topic 350- SubTopic 20- Name Accounting Standards Codification- **Section 50- Paragraph 2- Subparagraph (b)- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482573 / 350- 20- 50- 2Reference 3: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 350- SubTopic 20- Name Accounting Standards Codification-** Publisher FASB- URI https: / / asc. fasb. org / 350- 20 / tableOfContent Details Name: us- ~~gaap_GoodwillAndIntangibleAssetsPolicyTextBlock~~ --------- **gaap_GoodwillAndIntangibleAssetsGoodwillPolicy** Namespace Prefix: us- gaap_ Data Type: dtr- types: textBlockItemType Balance Type: na Period Type: durationX- DefinitionDisclosure of accounting policy for recognizing and measuring the impairment of long- lived assets. An entity also may disclose its accounting policy for long- lived assets to be sold. This policy excludes goodwill and intangible assets. ReferencesReference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef- Topic 360- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 2- Subparagraph (SAB Topic 5. CC)- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480091 / 360- 10- S99- 2Reference 2: http: / / fasb. org / us- gaap / role / ref / legacyRef- Name Accounting Standards Codification- Section 05- Paragraph 4- SubTopic 10- Topic 360- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482338 / 360- 10- 05- 4 Details Name: us- gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock Namespace Prefix: us- gaap_ Data Type: dtr- types: textBlockItemType Balance Type: na Period Type: durationX- DefinitionDisclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements. ReferencesReference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 740- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 20- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482685 / 740- 10- 50- 20Reference 2: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 740- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 19- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482685 / 740- 10- 50- 19Reference 3: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 740- SubTopic 10- Name Accounting Standards Codification- Section 45- Paragraph 25- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482525 / 740- 10- 45- 25Reference 4: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 946- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 3- Subparagraph (SX 210. 6- 03 (h) (1))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147479886 / 946- 10- S99- 3Reference 5: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 740- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 17- Subparagraph (b)- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482685 / 740- 10- 50- 17Reference 6: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 740- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 9- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482685 / 740- 10- 50- 9Reference 7: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 740- SubTopic 10- Name Accounting Standards Codification- Section 45- Paragraph 28- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482525 / 740- 10- 45- 28Reference 8: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 220- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 1- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482765 / 220- 10- 50- 1 Details Name: us- gaap_IncomeTaxPolicyTextBlock Namespace Prefix: us- gaap_ Data Type: dtr- types: textBlockItemType Balance Type: na Period Type: durationX- DefinitionDisclosure of accounting policy for finite- lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets. ReferencesReference 1: http: / / www. xbrl. org / 2003 / role / exampleRef- Topic 235- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 4- Subparagraph (c)- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147483426 / 235- 10- 50- 4Reference 2: http: / / www. xbrl. org / 2009 / role / commonPracticeRef- Topic 350- SubTopic 30- Name Accounting Standards Codification- Publisher FASB- URI https: / / asc. fasb. org / 350- 30 / tableOfContentReference 3: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 926- SubTopic 20- Name Accounting Standards Codification- Section 50- Paragraph 5- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147483154 / 926- 20- 50- 5Reference 4: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 920- SubTopic 350- Name Accounting Standards Codification- Section 50- Paragraph 1- Subparagraph (a)- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147478609 / 920- 350- 50- 1Reference 5: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 920- SubTopic 350- Name Accounting Standards Codification- Section 50- Paragraph 1- Subparagraph (b)- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147478609 / 920- 350- 50- 1Reference 6: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 920- SubTopic 350- Name Accounting Standards Codification- Section 50- Paragraph 4- Subparagraph (a)- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147478609 / 920- 350- 50- 4 Details Name: us- gaap_IntangibleAssetsFiniteLivedPolicy Namespace Prefix: us- gaap_ Data Type: dtr- types: textBlockItemType Balance Type: na Period Type: durationX- DefinitionDisclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost. ReferencesReference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 210- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210. 5- 02 (6) (b))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 /

2147480566 / 210- 10- S99- 1Reference 2: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 330- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 1- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147483080 / 330- 10- 50- 1Reference 3: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 210- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 1- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147483489 / 210- 10- 50- 1Reference 4: http: / / www. xbrl. org / 2003 / role / exampleRef- Topic 235- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 4- Subparagraph (d)- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147483426 / 235- 10- 50- 4Reference 5: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 912- SubTopic 330- Name Accounting Standards Codification- Section 50- Paragraph 1- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147478411 / 912- 330- 50- 1Reference 6: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 330- Name Accounting Standards Codification- Publisher FASB- URI https: / / asc. fasb. org / 330 / tableOfContentReference 7: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 330- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 4- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147483080 / 330- 10- 50- 4Reference 8: http: / / www. xbrl. org / 2003 / role / disclosureRef- Name Accounting Standards Codification- Section 45- Paragraph 6- Subparagraph (a)- SubTopic 10- Topic 270- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482989 / 270- 10- 45- 6 Details Name: us- gaap_InventoryPolicyTextBlock Namespace Prefix: us- gaap_ Data Type: dtr- types: textBlockItemType Balance Type: na Period Type: durationX- DefinitionDisclosure of accounting policy for leasing arrangement entered into by lessee. ReferencesReference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 842- SubTopic 20- Name Accounting Standards Codification- Section 50- Paragraph 1- Subparagraph (b)- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147478964 / 842- 20- 50- 1 Details Name: us- gaap_LesseeLeasesPolicyTextBlock Namespace Prefix: us- gaap_ Data Type: dtr- types: textBlockItemType Balance Type: na Period Type: durationX- DefinitionDisclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity' s financial reporting. Includes, but is not limited to, quantification of the expected or actual impact. ReferencesNo definition available. Details Name: us- gaap_NewAccountingPronouncementsPolicyPolicyTextBlock Namespace Prefix: us- gaap_ Data Type: dtr- types: textBlockItemType Balance Type: na Period Type: durationX- DefinitionDisclosure of accounting policy for long- lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections. ReferencesReference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef- Name Accounting Standards Codification- Section 50- Paragraph 1- SubTopic 10- Topic 360- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482099 / 360- 10- 50- 1Reference 2: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 944- SubTopic 210- Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210. 7- 03 (a) (8) (a))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147478777 / 944- 210- S99- 1Reference 3: http: / / www. xbrl. org / 2003 / role / disclosureRef- Name Accounting Standards Codification- Section 50- Paragraph 6- SubTopic 360- Topic 958- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147477798 / 958- 360- 50- 6Reference 4: http: / / www. xbrl. org / 2003 / role / disclosureRef- Name Accounting Standards Codification- Section 50- Paragraph 1- Subparagraph (d)- SubTopic 360- Topic 958- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147477798 / 958- 360- 50- 1 Details Name: us- gaap_PropertyPlantAndEquipmentPolicyTextBlock Namespace Prefix: us- gaap_ Data..... Details Name: us- gaap_ReceivablesPolicyTextBlock Namespace Prefix: us- gaap_ Data Type: dtr- types: textBlockItemType Balance Type: na Period Type: durationX- DefinitionDisclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process. ReferencesReference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 730- SubTopic 10- Name Accounting Standards Codification- Section 05- Paragraph 1- Subparagraph (c)- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147483044 / 730- 10- 05- 1 Details Name: us- gaap_ResearchAndDevelopmentExpensePolicy Namespace Prefix: us- gaap_ Data Type: dtr- types: textBlockItemType Balance Type: na Period Type: durationX- DefinitionDisclosure of accounting policy for revenue from contract with customer. ReferencesReference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 606- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 17- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147479806 / 606- 10- 50- 17Reference 2: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 606- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 19- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147479806 / 606- 10- 50- 19Reference 3: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 606- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 18- Subparagraph (a)- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147479806 / 606- 10- 50- 18Reference 4: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 606- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 18- Subparagraph (b)- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147479806 / 606- 10- 50- 18Reference 5: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 606- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 20- Subparagraph (a)- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147479806 / 606- 10- 50- 20Reference 6: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 606- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 20- Subparagraph (b)- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147479806 / 606- 10- 50- 20Reference 7: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 606- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 20- Subparagraph (c)- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147479806 / 606- 10- 50- 20Reference 8: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 606- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 20- Subparagraph (d)- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147479806 / 606- 10- 50- 20Reference 9: http: / / www. xbrl. org / 2003 / role / exampleRef- Name Accounting Standards Codification- Section 50- Paragraph 4- Subparagraph (e)- SubTopic 10- Topic 235- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147483426 / 235- 10- 50- 4Reference 10: http: / / www. xbrl. org / 2003 / role / disclosureRef- Name Accounting Standards Codification- Topic 606- Publisher FASB- URI https: / / asc. fasb. org / 606 / tableOfContent Details Name: us- gaap_RevenueFromContractWithCustomerPolicyTextBlock Namespace Prefix: us- gaap_ Data Type: dtr- types: textBlockItemType Balance Type: na Period Type: durationX- DefinitionDisclosure of accounting policy for ~~recognizing unearned income or deferred revenue related to transactions involving the sale of a product or performance of services. ReferencesNo definition available. Details Name: us- gaap_RevenueRecognitionDeferredRevenue Namespace Prefix: us- gaap_ Data Type: dtr- types: textBlockItemType Balance Type: na Period Type: durationX- DefinitionDisclosure of accounting policy for~~ revenue. Includes revenue from contract with customer and from other sources. ReferencesReference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 946- SubTopic 220- Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210. 6- 07 (1))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147479134 / 946- 220- S99- **1** 1Reference 2: http: / /..... 235- 10- 50- 4 Details Name: us- gaap_RevenueRecognitionPolicyTextBlock Namespace Prefix: us- gaap_ Data Type: dtr- types: textBlockItemType Balance Type: na Period Type: durationX- DefinitionDisclosure of accounting policy for award under share- based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost. ReferencesReference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 718- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 2- Subparagraph (f) ( ~~1~~ **2** )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2Reference 2: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 718- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 2- Subparagraph (f) (2) ( ~~i~~ **v** )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2Reference 3: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 718- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 2- Subparagraph (f) (2) ( ~~ii~~ **i** )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2Reference 4: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 718- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 2- Subparagraph (f) (2) ( ~~v~~ **ii** )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2Reference 5: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 718- SubTopic 10- Name Accounting Standards Codification- Section **credit Period Type:instantX** - ~~URI https: / / asc~~ **DefinitionAmount,after effects of reinsurance,of expense (reversal of expense) for claims incurred and costs incurred in the claim settlement process** _ **ReferencesReference 1** ~~fasb.org / 1943274 / 2147480429 / 718- 10- 50- 2Reference 6~~ :http: / / www.xbrl.org / 2003 / role / ~~disclosureRef~~ **exampleRef** - Topic ~~718~~ **944** - SubTopic ~~10~~ **40** - Name Accounting Standards Codification- Section ~~S50~~ **55** - Paragraph ~~5~~ **7** - Publisher FASB- URI https: / / asc.fasb.org / 1943274 / ~~2147479953~~ **2147480046** / ~~718~~ **944** - ~~10~~ **40** - ~~S50~~ **55** - ~~5Reference~~ **7Reference** ~~7~~ **2** :http: / / www.xbrl.org / ~~2003~~ **2009** / role / ~~disclosureRef~~ **commonPracticeRef** - Topic ~~718~~ **944** - SubTopic ~~10~~ **40** - Name Accounting Standards Codification- Section ~~S50~~ **50** - Paragraph 3 - **Subparagraph (b)** - Publisher FASB- URI https: / / asc.fasb.org / 1943274 / ~~2147479953~~ **2147480081** / ~~718~~ **944** - ~~10~~ **40** - ~~S50~~ **50** - ~~3Reference 8~~ **3 Details Name** : ~~http~~ **us- gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1 Namespace Prefix** : **us** ~~/ / www.xbrl.org / 2003 / role / disclosureRef~~ - **gaap_ Data Type:xbrli:monetaryItemType Balance Type:** ~~Topic 718- SubTopic 10- Name Accounting Standards Codification- Section S50- Paragraph 4- Publisher FASB-~~ S99- Paragraph 1- Subparagraph (SAB Topic 14. C. Q3)- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147479830 / 718- 10- S99- 1Reference ~~6~~ **11** : http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 718- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SAB Topic 14. D. 1. Q5)- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147479830 / 718- 10- S99- 1Reference ~~7~~ **12** : http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 718- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SAB Topic 14. D. 3. Q2)- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147479830 / 718- 10- S99- 1Reference ~~8~~ **13** : http: / / www. xbrl. org / 2003 / role /

disclosureRef- Topic 718- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SAB Topic 14. D. 2. Q6)- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147479830 / 718- 10- S99- 1Reference ~~9~~ **14** : http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 718- Name Accounting Standards Codification- Publisher FASB- URI https: / / asc. fasb. org / 718 / tableOfContentReference ~~10~~ **15** : http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 718- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 2- Subparagraph (b)- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- ~~2Reference 11~~ **2 Details Name: us- gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy Namespace Prefix: us- gaap_ Data Type: dtr- types: textBlockItemType Balance Type: na Period Type: durationX- DefinitionDisclosure of accounting policy for accounts receivable. ReferencesReference 1** : http: / / www. xbrl. org / ~~2003~~ **2009** / role / ~~disclosureRef~~ **commonPracticeRef** - Topic ~~718~~ **310** - SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 2- Subparagraph ( **d** ~~f) (2~~ )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147480429~~ **2147481962** / ~~718~~ **310** - 10- 50- **2Reference** 2 ~~":~~ ":~~~~http:/ / www.xbrl.org / 2009 / role / commonPracticeRef~~ **-** ~~",~~ ~~"~~Topic **310-** ~~":" 250","~~ SubTopic ~~":"~~ 10 ~~-~~ ~~",~~ ~~"~~Name ~~":"~~Accounting Standards Codification ~~-~~ ~~",~~ ~~"~~Section ~~":"~~50 ~~-~~ ~~",~~ ~~"~~Paragraph ~~":" 4","~~ **2- Subparagraph (a)-** Publisher ~~":"~~ FASB ~~-~~ ~~",~~ ~~"~~URI ~~":"~~https:/ / asc.fasb.org / 1943274 / ~~2147483443~~ **2147481962** / ~~250~~ **310** - 10- 50- **2Reference 3** ~~4" },"r982"~~ : ~~{" role":"~~http:/ / www.xbrl.org / 2009 / role / commonPracticeRef **- Topic 310- SubTopic 20- Name Accounting Standards Codification- Section 50- Paragraph 1- Publisher FASB- URI https: / / asc.fasb.org / 1943274 / 2147481569 / 310- 20- 50- 1** Details Name: us- ~~gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy~~ **gaap_TradeAndOtherAccountsReceivablePolicy** Namespace Prefix: us- gaap_ Data Type: dtr- types: textBlockItemType Balance Type: na Period Type: durationX- DefinitionDisclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles. ReferencesReference 1: http: / / ~~fasb~~ **www** . **xbrl.** org / **2003** ~~us- gaap~~ / role / ~~ref / legacyRef~~ **disclosureRef- Topic 942- SubTopic 235** - Name Accounting Standards Codification- ~~Topic 275- SubTopic 10-~~ Section ~~50~~ **S50** - Paragraph ~~9~~ **1** - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147482861~~ **2147478671** / ~~275~~ **942** - ~~10~~ **235** - ~~50~~ **S50** - 9Reference ~~1~~**Reference** 2: http: / / ~~fasb~~ **www** . **xbrl.** org / **2003** ~~us- gaap~~ / role / ~~ref / legacyRef~~ **disclosureRef- Topic 942- SubTopic 235** - Name Accounting Standards Codification- **Section S99- Paragraph 1- Subparagraph (SX 210. 9- 05 (b) (2))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147477314 / 942- 235- S99- 1Reference 3: http: / / www. xbrl. org / 2003 / role / disclosureRef-** Topic 275- SubTopic 10 ~~- Section 50- Paragraph 4- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482861 / 275- 10- 50- 4Reference 3: http: / / www. xbrl. org / 2003 / role / disclosureRef~~ - Name Accounting Standards Codification- Section 50- Paragraph ~~1~~ **12** - **Publisher FASB** ~~Subparagraph (b)~~ - ~~SubTopic~~ **URI https: / / asc. fasb. org / 1943274 / 2147482861 / 275-** 10 **- 50- 12Reference 4: http: / / www. xbrl. org / 2003 / role / disclosureRef** - Topic 275- **SubTopic** ~~Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482861 / 275-~~ 10 ~~- 50- 1Reference 4: http: / / www. xbrl. org / 2003 / role / disclosureRef~~ - Name Accounting Standards Codification- Section 50- Paragraph ~~1~~ **9** - **Publisher FASB** ~~Subparagraph (c)~~ - ~~SubTopic~~ **URI https: / / asc. fasb. org / 1943274 / 2147482861 / 275-** 10 **- 50- 9Reference 5: http: / / www. xbrl. org / 2003 / role / exampleRef** - Topic 275- **SubTopic** ~~Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482861 / 275-~~ 10 ~~- 50- 1Reference 5: http: / / www. xbrl. org / 2003 / role / disclosureRef~~ - Name Accounting Standards Codification- Section ~~50~~ **55** - Paragraph ~~11~~ **6** - ~~SubTopic~~ **Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482836 / 275-** 10 **- 55- 6Reference 6: http: / / www. xbrl. org / 2003 / role / disclosureRef** - Topic 275- **SubTopic** ~~Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482861 / 275-~~ 10 ~~- 50- 11Reference 6: http: / / www. xbrl. org / 2003 / role / disclosureRef~~ - Name Accounting Standards Codification- Section 50- Paragraph ~~12~~ **6** - ~~SubTopic~~ **Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482861 / 275-** 10 **- 50- 6Reference 7: http: / / www. xbrl. org / 2003 / role / disclosureRef** - Topic 275- **SubTopic** ~~Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482861 / 275-~~ 10 ~~- 50- 12Reference 7: http: / / fasb. org / us- gaap / role / ref / legacyRef~~ - Name Accounting Standards Codification- **Section 50- Paragraph 4- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482861 / 275- 10- 50- 4Reference 8: http: / / www. xbrl. org / 2003 / role / disclosureRef- Name Accounting Standards Codification- Section 50- Paragraph 1- Subparagraph (b)- SubTopic 10- Topic 275- ~~SubTopic~~ Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482861 / 275-** 10 **- 50- 1Reference 9: http: / / www. xbrl. org / 2003 / role / disclosureRef- Name Accounting Standards Codification** - Section 50- Paragraph ~~8~~ **1- Subparagraph (c)- SubTopic 10- Topic 275** - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482861 / 275- 10- 50- ~~8~~ **1** Details Name: us- gaap_UseOfEstimates Namespace Prefix: us- gaap_ Data Type: dtr- types: textBlockItemType Balance Type: na Period Type: durationSummary of Significant Accounting Policies (Tables) 12 Months Ended Jan. 31, ~~2024~~ **2025** Summary of Significant Accounting Policies [ Abstract ] Schedule of Disaggregates ~~Its~~ **its** Revenue from Contracts **with Customers** The Company disaggregates its revenue from contracts with customers by type and by geographical location. See the tables: Years ~~Ended~~ **Ending** January 31, **2025** 2024 ~~2023~~ Revenue by type Sale of goods $ ~~1~~ **2** , ~~920~~ **139** , ~~280~~ **537** $ 1, ~~785~~ **920** , ~~507~~ **280** Services ~~-~~ 165, 034 ~~294, 102~~ Total $ 2, ~~085~~ **139** , ~~314~~ **537** $ 2, ~~079~~ **085** , ~~609~~ **314** Schedule of Revenue by Geographic Location Years ~~Ended~~ **Ending** January 31, **2025** 2024 ~~2023~~ Revenue by geographic location: United States $ 2, ~~085~~ **139** , ~~314~~ **537** $ 2, ~~079~~ **085** , ~~609~~ **314** Foreign-- $ 2, ~~085~~ **139** , ~~314~~ **537** $ 2, ~~079~~ **085** , ~~609~~ **314** Schedule of **Property,** Plant and Equipment ~~on a Straight- Line Basis Over the Estimated~~ Useful **Lives** ~~Life of the Assets~~ The lives over which the fixed assets are depreciated range from 3 to 20 years as follows: Lab Equipment 5- 10 years Furniture and fixtures 3 **- 5** years Machinery and equipment ~~10~~ **5** - 20 ~~years~~ **yearsX** ~~X~~ - **DefinitionTabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense, and method used, including composite depreciation, and accumulated deprecation.** ReferencesNo definition available. Details Name: **ntrb_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock Namespace Prefix: ntrb_ Data Type: dtr: textBlockItemType Balance Type: na Period Type: durationX- ReferencesNo definition available. Details Name:** us- gaap_AccountingPoliciesAbstract Namespace Prefix: us- gaap_ Data Type: xbrli: stringItemType ~~gaap_ExcessStockSharesIssued Namespace Prefix:us- gaap_ Data Type:xbrli:sharesItemType~~ Balance Type:na Period Type: ~~instantX~~ **durationX** - ~~DefinitionInterest received on loans~~ **DefinitionTabular disclosure of disaggregation of revenue into categories depicting how nature,amount,timing,** and ~~other debt instruments during the current period~~ **uncertainty of revenue and cash flows are affected by economic factor** . ReferencesReference 1:http:/ / www.xbrl.org / 2009 / role / commonPracticeRef- Topic ~~230~~ **606** - SubTopic 10- Name Accounting Standards Codification- Section ~~45~~ **50** - Paragraph **5** ~~16- Subparagraph (b)~~ - Publisher FASB- URI https:/ / asc.fasb.org / 1943274 / ~~2147482740~~ **2147479806** / ~~230~~ **606** - 10- ~~45~~ **50** - ~~16~~ **5** Details Name:us- ~~gaap_ProceedsFromInterestReceived~~ **gaap_DisaggregationOfRevenueTableTextBlock** Namespace Prefix:us- gaap_ Data Type: ~~xbrli~~ **dtr- types** : ~~monetaryItemType~~ **textBlockItemType** Balance Type: na Period Type: durationX- DefinitionTabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue. ReferencesReference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef- Topic 280- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 41- Subparagraph (a)- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482810 / 280- 10- 50- 41 Details Name: us- gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock Namespace Prefix: us- gaap_ Data Type: dtr- types: textBlockItemType Balance Type: na Period Type: durationX- DefinitionTabular disclosure of public utility..... Balance Type: na Period Type: durationProperty and Equipment (Tables) 12 Months Ended Jan. 31, ~~2024~~ **2025** Property and Equipment [ Abstract ] Schedule of Property and Equipment January 31, **2025** 2024 ~~2023~~ Lab equipment $ 144, 585 $ 144, 585 Machinery and equipment 1, **384, 432 1,** 292, 389 ~~1, 240, 628~~ Furniture and fixtures 19, 643 19, 643 1, **548, 660 1,** 456, 617 ~~1, 404, 856~~ Less: Accumulated depreciation ( **853, 597) (** 681, 693 ~~) (507, 121~~ ) Net Property and Equipment $ **695, 063 $** 774, 924 ~~$ 897, 735~~ X- ReferencesNo definition available. Details Name: us- gaap_PropertyPlantAndEquipmentAbstract Namespace Prefix: us- gaap_ Data Type: xbrli: stringItemType Balance Type: na Period Type: durationX- DefinitionTabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation. ReferencesReference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef- Name Accounting Standards Codification- Section 50- Paragraph 1- SubTopic 10- Topic 360- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482099 / 360- 10- 50- 1 Details Name: us- gaap_PropertyPlantAndEquipmentTextBlock Namespace Prefix: us- gaap_ Data Type: dtr- types: textBlockItemType Balance Type: na Period Type: durationIncome Taxes (Tables) 12 Months Ended Jan. 31, ~~2024~~ **2025** Income Taxes [ Abstract ] Schedule of Provision for Income Taxes The provision for income taxes consists of the following: Years ~~Ended~~ **Ending** January 31, **2025** 2024 ~~2023~~ Current Federal $- $- Foreign-- Deferred Federal-- Foreign-- Schedule of Reconciliation of Taxes on Income A reconciliation of taxes on income computed at the federal statutory rate to amounts provided is as follows: Years ~~Ended~~ **Ending** January 31, **2025** 2024 ~~2023~~ Book Income (loss from operations) $ ( **2, 201, 350) $ (** 1, 151, 916 ~~) $ (941, 530~~ ) Common stock issued for services **323, 880** 155, 966 ~~168, 768~~ Impairment expense **754 - 68** , ~~738~~ **996-** Unused operating losses **1, 122, 474** 995, 950 ~~704, 024~~ Income tax expense $- $- Schedule of Deferred Tax Liability and Deferred Tax Asset The types of temporary differences between tax basis of assets and liabilities and their financial reporting amounts that give rise to the deferred tax liability and deferred tax asset and their approximate tax effects are as follows: January 31, **2025** 2024 ~~2023~~ Net operating loss carryforward (expire through ~~2040~~ **2041** ) $ ( **4, 435, 172) $ (** 3, 312, 698 ~~) $ (2, 316, 748~~ ) Stock issued for services ~~$~~ (1, **779, 728) (1,** 455, 848 ~~) (1, 299, 882~~ ) Intangible impairment expense ~~$~~ (1, ~~051~~ **806** , ~~714~~ **709** ) (1, 051, 714) Valuation allowance ~~$~~ **8, 021, 609** 5, 820, 260 ~~4, 668, 344~~ Net deferred taxes $- $- X- ReferencesNo definition available. Details Name: us- ~~gaap_IncomeTaxesPaidNetAbstract~~ **gaap_IncomeTaxDisclosureAbstract** Namespace Prefix: us- gaap_ Data Type: xbrli: stringItemType Balance Type: na Period Type: durationX- DefinitionTabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense

(benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning- of- the- year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years. ReferencesReference 1: http: / / www. xbrl. org / 2009 / role / commonPracticeRef- Topic 740- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 9- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482685 / 740- 10- 50- 9 Details Name: us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock Namespace Prefix: us- gaap_ Data Type: dtr- types: textBlockItemType Balance Type: na Period Type: durationX- DefinitionTabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets. ReferencesReference 1: http: / / www. xbrl. org / 2009 / role / commonPracticeRef- Topic 740- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 2- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482685 / 740- 10- 50- 2 Details Name: us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock Namespace Prefix: us- gaap_ Data Type: dtr- types: textBlockItemType Balance Type: na Period Type: durationX- DefinitionTabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations. ReferencesReference 1: http: / / www. xbrl. org / 2003 / role / exampleRef- Topic 740- SubTopic 10- Name Accounting Standards Codification- Section 55- Paragraph 231- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482663 / 740- 10- 55- 231Reference 2: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 740- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 12A- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482685 / 740- 10- 50- 12AReference 3: http: / / www. xbrl. org / 2009 / role / commonPracticeRef- Topic 740- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 12- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482685 / 740- 10- 50- 12 Details Name: us- gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock Namespace Prefix: us- gaap_ Data Type: dtr- types: textBlockItemType Balance Type: na Period Type: durationIntangible Assets (Tables) 12 Months Ended Jan. 31, ~~2024~~ **2025** Intangible Assets [ Abstract ] Schedule of Intangible Assets As of January 31, **2025, and** 2024 ~~, and 2023~~, intangible assets consisted of intellectual property and trademarks, customer base, and license agreement, net of amortization, as follows: January 31, **2025** 2024 ~~2023~~ Customer base $ ~~314~~ **214** , ~~100~~ **940** $ 314, 100 Intellectual property and trademarks ~~817~~ **623** , ~~400~~ **822** 817, 400 Total ~~1~~ **838** , **462** ~~131, 500~~ 1, 131, 500 Less: Accumulated amortization ( **577, 370) (** 464, 220 ~~) (351, 070~~ ) Net Intangible Assets $ **261, 092 $** 667, 280 ~~$ 780, 430~~ Schedule of Amortization Expenses Amortization expenses for the years ~~ended~~ **ending** January 31, **2025, and** 2024 ~~, and 2023~~ amounted to $ 113, 150 and $ ~~146~~ **113** , ~~483~~ **150** , respectively **. During the year ending January 31, 2025, the Company recorded an impairment charge of $ 298, 038 to its Intellectual property** . Year Ended January 31, **Total** ~~2025~~ **2026** $ ~~113~~ **60** , **666** ~~109 2026 113, 109~~ 2027 ~~113~~ **60** , ~~109~~ **666** 2028 ~~113~~ **60** , ~~109~~ **666** 2029 ~~113~~ **41** , ~~109~~ **736** 2030 **33, 218 2031** and thereafter ~~101~~ **4** , ~~735~~ **142** $ ~~667~~ **261** , ~~280~~ **092** X- ReferencesNo definition available. Details Name: us-~~gaap_IntangibleAssetsNetExcludingGoodwillAbstract~~ **gaap_FiniteLivedIntangibleAssetsNetAbstract** Namespace Prefix: us- gaap_ Data Type: xbrli: stringItemType Balance Type: na Period Type: durationX- DefinitionTabular disclosure of **assets, excluding financial assets and** goodwill ~~and intangible assets~~ , ~~which may be broken down~~ **lacking physical substance with a finite life,** by **either** ~~segment or~~ major class **or business segment** . ReferencesReference 1: http: / / www. xbrl. org / ~~2009~~ **2003** / role / **exampleRef** ~~commonPracticeRef- Topic 350- SubTopic 30-~~ Name Accounting Standards Codification- **Section 55- Paragraph 40- SubTopic 30- Topic 350-** Publisher FASB- URI https: / / asc. fasb. org / **1943274 / 2147482640 /** 350- 30 ~~/ tableOfContentReference -~~ **55- 40Reference** 2: http: / / www. xbrl. org / 2009 / role / commonPracticeRef- Topic 350- SubTopic ~~20~~ **30** - Name Accounting Standards Codification- **Section 50- Paragraph 2- Subparagraph (a)-** Publisher FASB- URI https: / / asc. fasb. org / **1943274 / 2147482665 /** 350- ~~20 / tableOfContent~~ **30- 50- 2** Details Name: us-~~gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock~~ ---------- **gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock** Namespace Prefix: us-gaap_ Data Type: dtr- types: textBlockItemType Balance Type: na Period Type: durationX- DefinitionTabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite- lived intangible assets. ReferencesReference 1: http: / / www. xbrl. org / 2003 / role / exampleRef-~~Topic 350- SubTopic 30-~~ Name Accounting Standards Codification- Section 55- Paragraph 40 **- SubTopic 30- Topic 350** - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482640 / 350- 30- 55- 40Reference 2: http: / / www. xbrl. org / 2009 / role / commonPracticeRef- Topic 350- SubTopic 30- Name Accounting Standards Codification- Section 50- Paragraph 2- Subparagraph (a) (3)- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482665 / 350- 30- 50- 2 Details Name: us- gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock Namespace Prefix: us- gaap_ Data Type: dtr- types: textBlockItemType Balance Type: na Period Type: durationOptions and Warrants (Tables) 12 Months Ended Jan. 31, ~~2024~~ **2025** ~~Options and~~ **Class of** ~~Warrants~~ **Warrant or Right** [ Line Items ] Schedule of **Options Outstanding The following table** ~~Summarizes~~ **summarizes Value Outstanding,January 31,2022 190,751 $ 4.26** 2. ~~68~~ **97 years Granted 279,584 3.93 3.00** years- Expired / Cancelled--- Exercised--- Outstanding,January 31, ~~2024~~ **2023** ~~874~~ **470** , ~~835 3~~ **335 4** . ~~23~~ **13** 2. ~~31~~ **53** years Granted ~~689~~ **404** , ~~584 4~~ **500 2** . ~~40 1~~ **18 2** . ~~93~~ **68** years - Expired / Cancelled ~~- (190,751)~~ -- Exercised--- Outstanding- January 31, ~~2025~~ **2024** ~~1~~ **874** , **835** ~~373,668~~ $ 3. ~~68 1~~ **23 2** . ~~90~~ **31** years $ ~~6~~ **214** , **460** ~~337,984~~ Exercisable- January 31, ~~2025~~ **2024** ~~1~~ **874** , **835** ~~373,668~~ $ 3. ~~68 1~~ **23 2** . ~~90~~ **31** years $ ~~6~~ **214** , **460** ~~337,984~~ ~~Schedule of Additional Information Relating to the Options Outstanding~~ The following table summarizes additional information relating to the options outstanding as of January 31, ~~2025~~ **2024** : ~~Weighted Average Weighted Average Range~~ Additional Information Relating to the Warrants Outstanding The following table summarizes additional information relating to the warrants outstanding as of January 31, ~~2024~~ **2025** : Range of Exercise ~~Prices~~ Number ~~Outstanding Weighted Average~~ Remaining Contractual ~~Life (Years) Weighted Average~~ Exercise Price for Shares ~~Outstanding~~ Number ~~Exercisable Weighted Average~~ Exercise Price for Shares ~~Exercisable~~ Intrinsic ~~Value $ 4. 00 30, 000 4. 10 $ 4. 00 30, 000 $ 4. 00 $- $ 6. 43 1, 082, 205 2. 68 $ 6. 43 1, 082, 205 $ 6. 43 $- $ 1. 93 145, 833 2. 74 $ 1. 93 145, 833 $ 1. 93 $ 99, 166 $ 7. 50 25, 000 3. 77 $ 7. 50 25, 000 $ 7. 50 $- Schedule of Summarizes Additional Information Relating to the Options Outstanding The following table summarizes additional information relating to the options outstanding as of January 31, 2024:~~ Prices Outstanding Life (Years) ~~Shares~~ Outstanding Exercisable ~~Shares~~ Exercisable Value $ 1. 93 ~~214~~ **58** , ~~500 2~~ **333 1** . 74 $ 1. 93 ~~214~~ **58** , ~~500~~ **333** $ 1. 93 $ ~~145~~ **370** , ~~860~~ **988** $ ~~2~~ **4** . ~~12 140, 000~~ - **00 30** 2. 74 $ 2. 12 140, 000 $ 2. 12 $ 68, 600 $ 2. 65 20, 000 2. 63 $ 2. 65 20, 000 $ 2. 65 $- $ 3. 59 35 - 000 3. **10** ~~67 $ 3. 59 35, 000 $ 3. 59 $- $ 3. 75 57, 500 1. 85 $ 3. 75 57, 500 $ 3. 75 $- $ 3. 98 30, 000 2. 01 $ 3. 98 30, 000 $ 3. 98 $-~~ $ 4. ~~09 78, 750 1. 50 $ 4. 09 78, 750 $ 4. 09 $- $ 4. 12 50, 000 -~~ **00 30** ~~1. 85 $ 4. 12 50~~ - 000 $ 4. ~~12~~ **00** $ ~~-~~ **128, 700** $ ~~4~~ **6** . ~~16 144~~ **43 5** , ~~083 0~~ **433, 640 3** . ~~97~~ **71** $ ~~4~~ **6** . ~~16 144~~ **43 5** , ~~083~~ **433, 640** $ ~~4~~ **6** . ~~16~~ **43** $ ~~-~~ **10, 106, 570** $ ~~4~~ **7** . 50 ~~58~~ **25** , ~~334 1~~ **000 2. 77 $ 7. 50 25, 000 $ 7** . 50 $ **19** ~~4. 50 58~~ - , **760** ~~334 $ 4. 50 $- $ 4. 58 46, 668 0. 97 $ 4. 58 46, 668 $ 4. 58 $- 874, 835 2. 06 $ 3. 23 874, 835 $ 3. 23 $ 214, 460 Warrants [ Member ] Options and Warrants [ Line Items ] Schedule of Changes in Warrants Outstanding The valuation model used a dividend rate of 0 %; expected term of 1.~~ 5 ~~years; volatility rates of 152. 10- 174. 45 %; and a risk- free rate of 4. 31 %- 4. 84 %. Non- cash compensation for the year ended January 31~~ , ~~2024~~ **546** . **973** ~~amounted to $ 242, 840. Exercise Remaining Intrinsic Shares Price Life Value Outstanding, January 31, 2022 1, 435, 622~~ $ 6. ~~91 3.~~ **37 5, 546,** ~~93~~ **973** ~~years~~ $ ~~- Granted 25, 000 7. 50 5. 00 years- Expired / Cancelled (97, 534) 5. 36-- Exercised (55, 417) 5. 36-- Outstanding, January 31, 2023 1, 307, 671~~ 6. **37** ~~43 3. 34 years- Granted 175, 833 2. 28 2. 97 years- Expired / Cancelled (200, 466) 6. 33-- Exercised--- Outstanding- January 31, 2024 1, 283, 038~~ $ **10** ~~5. 88 2. 97 years $ 99~~ , **626** ~~166 Exercisable- January 31~~ , **018 X- DefinitionLine** ~~2024 1, 283, 038 $ 5. 88 2. 97 years $ 99, 166 Options [ Member ] Options and Warrants [ Line Items~~ **items** ~~] Schedule of Changes~~ **represent financial concepts included** in **a** ~~Options Outstanding The following~~ table ~~summarizes additional~~ **. These concepts are used to disclose reportable** information ~~relating~~ **associated with domain members defined in one or many axes** to the **table** ~~options outstanding as of January 31, 2024. Shares Exercise Price Remaining Life Intrinsic Value Outstanding, January 31, 2022 190, 751 $ 4. 26 2. 97 years Granted 279, 584 3. 93 3. 00 years- Expired / Cancelled--- Exercised--- Outstanding, January 31, 2023 470, 335 4. 13 2. 53 years Granted 404, 500 2. 18 2. 68 years- Expired / Cancelled--- Exercised--- Outstanding- January 31, 2024 874, 835 $ 3. 23 2. 31 years $ 214, 460 Exercisable- January 31, 2024 874, 835 $ 3. 23 2. 31 years $ 214, 460 X- ReferencesNo definition available. Details Name: ntrb_OptionsandWarrantsTablesLineItems Namespace Prefix: ntrb_ Data Type: xbrli: stringItemType Balance Type: na Period Type: durationX- DefinitionThe entire disclosure schedule of additional relating warrants outstanding~~ . ReferencesNo definition available. Details Name: ~~ntrb_ScheduleOfAdditionalRelatingWarrantsOutstanding~~ **us- gaap_ClassOfWarrantOrRightLineItems** Namespace Prefix: ~~ntrb_~~ **us- gaap_** Data Type: **xbrli** : **" stringItemType Balance Type:na Period Type:durationX- DefinitionTabular disclosure of the changes in outstanding nonvested shares. ReferencesReference 1:** http: / / fasb. org / us- gaap / role / ref / legacyRef ~~-~~ ~~"~~ ~~-~~ Topic ~~"~~ ~~-~~ 718 ~~-~~ ~~"~~ ~~-~~ SubTopic ~~"~~ ~~-~~ 10 ~~-~~ ~~"~~ ~~-~~ Name ~~"~~ ~~-~~ Accounting Standards Codification ~~-~~ ~~"~~ ~~-~~ Section ~~"~~ ~~-~~ 50 ~~-~~ ~~"~~ ~~-~~ Paragraph ~~"~~ ~~-~~ 2 ~~-~~ ~~"~~ ~~-~~ Subparagraph ~~"~~ ~~-~~ (c) ( ~~1~~ **2** ) ~~-~~ ~~"~~ ~~-~~ Publisher ~~"~~ ~~-~~ FASB ~~-~~ ~~"~~ ~~-~~ URI ~~"~~ ~~-~~ https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2 **Details Name:us- gaap_ScheduleOfNonvestedShareActivityTableTextBlock Namespace Prefix:us- gaap_ Data Type:** dtr **- types** : textBlockItemType Balance Type: na Period Type: durationX- DefinitionTabular disclosure of option ~~outstanding~~ **exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms** . ~~ReferencesNo definition available~~ **ReferencesReference 1: http: / / fasb** . **org / us- gaap / role / ref / legacyRef- Name Accounting Standards Codification-**

**Topic 718- SubTopic 10- Section 50- Paragraph 2- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2** Details Name: ~~ntrb_ScheduleOfSummarizesAdditionalInformationRelatingToTheOptionsOutstandingTableTextBlock~~ **us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock** Namespace Prefix: ~~ntrb_~~ **us- gaap_** Data Type: dtr **- types** : textBlockItemType Balance Type: na Period Type: durationX- DefinitionTabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted- average grant date fair value. ReferencesReference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef- Topic 718- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 2- Subparagraph (c) (1)- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2Reference 2: http: / / fasb. org / us- gaap / role / ref / legacyRef- Name Accounting Standards Codification- Section 50- Paragraph 2- Subparagraph (d)- SubTopic 10- Topic 718- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2Reference 3: http: / / fasb. org / us- gaap / role / ref / legacyRef- Name Accounting Standards Codification- Section 50- Paragraph 2- Subparagraph (e)- SubTopic 10- Topic 718- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2 Details Name: us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock Namespace Prefix: us- gaap_ Data Type: dtr- types: textBlockItemType Balance Type: na Period Type: durationX- DefinitionTabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable. ReferencesReference 1: http: / / ~~fasb~~ **www** . **xbrl.** org / **2009** ~~us- gaap~~ / role / ~~ref / legacyRef~~ **commonPracticeRef- Topic 505- SubTopic 10** - Name Accounting Standards Codification- ~~Topic 718- SubTopic 10-~~ Section 50- Paragraph **3** ~~1- Subparagraph (a)~~ - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147480429~~ **2147481112** / ~~718~~ **505** - 10- 50- ~~1~~ **3** Details Name: us- gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr- types: textBlockItemType Balance Type: na Period Type: durationX- Details Name: us- gaap_ClassOfWarrantOrRightAxis = us-gaap_WarrantMember ~~Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us- gaap_DerivativeInstrumentRiskAxis = us-gaap_StockOptionMember~~ Namespace Prefix: Data Type: na Balance Type: Period Type: Segment Reporting (Tables) 12 Months Ended Jan. 31, ~~2024~~ **2025** Segment Reporting [ Abstract ] Schedule of **Our Chief Officer Decision Maker Evaluates** Segment Performance ~~to the GAAP Measure of Gross Profit~~ Our chief officer decision maker evaluates segment performance to the GAAP measure of gross profit. Years ~~Ended~~ **Ending** January 31, **2025** 2024 ~~2023~~ Net sales Pocono Pharmaceuticals $ ~~1~~ **2** , ~~920~~ **139** , ~~280~~ **537** $ 1, ~~785~~ **920** , ~~597~~ **280** 4P Therapeutics **-** 165, 034 ~~294, 102~~ 2, **139, 537 2,** 085, 314 ~~2, 079, 699~~ Gross profit Pocono Pharmaceuticals **743, 317** 744, 391 ~~726, 702~~ 4P Therapeutics **-** 117, 714 ~~23~~ **743** , ~~702~~ **317** 862, 105 ~~750, 404~~ Operating expenses Selling, general and administrative- Pocono Pharmaceuticals **661, 805** 606, 275 ~~577, 930~~ Selling, general and administrative- 4P Therapeutics **136, 294** 236, 953 ~~103, 181~~ Selling, general and administrative- Corporate **3, 515, 711** 2, 930, 378 **Goodwill and intangibles impairment** 3, ~~234~~ **595** , ~~930~~ **216-** Research and development- 4P Therapeutics **3, 119, 134** 1, 960, 425 ~~982~~ **11** , **028** ~~227 Goodwill impairment- Pocono Pharmaceuticals- 327~~ , ~~326~~ **160** 5, 734, 031 ~~5, 225, 594~~ Depreciation and Amortization Pocono Pharmaceuticals $ **235, 941 $** 222, 159 ~~$ 264, 156~~ Corporate **12, 043** 13, 986 ~~-~~ 4P Therapeutics **37, 070** 51, 577 ~~65~~ **$ 285** , ~~987~~ **054** $ 287, 722 ~~$ 330, 143~~ Schedule of Net Sales and Property and Equipment The following table presents information about net sales and property and equipment, net of accumulated depreciation, in the United States and elsewhere. Years ~~Ended~~ **Ending** January 31, **2025** 2024 ~~2023~~ Net sales United States $ 2, ~~085~~ **139** , ~~314~~ **537** $ 2, ~~079~~ **085** , ~~699~~ **314** Outside the United States-- $ 2, ~~085~~ **139** , ~~314~~ **537** $ 2, ~~079~~ **085** , ~~699~~ **314** January 31, January 31, **2025** 2024 ~~2023~~ Property and equipment, net of accumulated depreciation United States $ **695, 063 $** 774, 924 ~~$ 897, 735~~ Outside the United States-- $ **695, 063 $** 774, 924 ~~$ 897, 735~~ Assets Corporate $ ~~344~~ **4** , ~~192~~ **205, 577** $ ~~1~~ **339** , **552** ~~745, 731~~ Pocono Pharmaceuticals **1, 404, 585** 5, 079, 293 ~~5, 400, 814~~ 4P Therapeutics **1, 859, 793** 2, **098** ~~093, 369 2~~ , 309 ~~, 832~~ $ 7, ~~516~~ **469** , ~~854~~ **955** $ ~~9~~ **7** , ~~456~~ **517** , ~~377~~ **154** X- DefinitionTabular disclosure of all significant reconciling items in the reconciliation of total revenues from reportable segments to the entity' s consolidated revenues. ReferencesReference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef- Name Accounting Standards Codification- Topic 280- SubTopic 10- Section 50- Paragraph 31- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482810 / 280- 10- 50- 31Reference 2: http: / / fasb. org / us- gaap / role / ref / legacyRef- Name Accounting Standards Codification- Topic 280- SubTopic 10- Section 50- Paragraph 30- Subparagraph (a)- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482810 / 280- 10- 50- 30 Details Name: us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock Namespace Prefix: us- gaap_ Data Type: dtr- types: textBlockItemType Balance Type: na Period Type: durationX- DefinitionTabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. ReferencesReference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef- Name Accounting Standards Codification- Topic 280- SubTopic 10- Section 50- Paragraph 25- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482810 / 280- 10- 50- 25Reference 2: http: / / fasb. org / us- gaap / role / ref / legacyRef- Name Accounting Standards Codification- Topic 280- SubTopic 10- Section 50- Paragraph 22- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482810 / 280- 10- 50- 22Reference 3: http: / / fasb. org / us- gaap / role / ref / legacyRef- Name Accounting Standards Codification- Topic 280- SubTopic 10- Section 50- Paragraph 30- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482810 / 280- 10- 50- 30 Details Name: us- gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock Namespace Prefix: us-gaap_ Data Type: dtr- types: textBlockItemType Balance Type: na Period Type: durationX- ReferencesNo definition available. Details Name: us-gaap_SegmentReportingAbstract Namespace Prefix: us- gaap_ Data Type: xbrli: stringItemType Balance Type: na Period Type: durationOrganization and Description of Business (Details)- USD ($) ~~Jan~~ **Aug. 01, 2018 Aug** . 31, ~~2024 Jan. 31, 2023 Aug. 31, 2020 Aug. 01, 2018Organization~~ **2020Organization and Description of Business [ Line Items ] Royalty, percentage 6. 00 % 4P Therapeutics LLC [ Member ] Organization** and Description of Business [ Line Items ] Acquired costs $ 2, 250, ~~000Common stock share (in Shares) 8, 869, 870 7, 843, 150 250, 000Common stock value $ 8, 860 $ 7, 833 Royalty fee 6. 00~~ **000** % **4P Therapeutics LLC [ Member ] | Intellectual Property [ Member ] Organization and Description of Business [ Line Items ] Acquired costs 400, 000** Pocono Pharmaceuticals [ Member ] Organization and Description of Business [ Line Items ] Acquired percentage 100. 00 % ~~Minimum~~ **Common Stock [ Member ] | 4P Therapeutics LLC** [ Member ] Organization and Description of Business [ Line Items ] **Acquired costs** ~~Common stock value~~ $ 1, 850, **000 Company acquired** ~~000Maximum [ Member ] Organization and Description of Business [ Line Items ] Common~~ **common** stock ~~value $ 400~~ **shares (in Shares) 250** , ~~000X~~ **000 X** **-** ~~ReferencesNo definition available. Details Name: ntrb_OrganizationandDescriptionofBusinessDetailsLineItems Namespace Prefix: ntrb_ Data Type: xbrli: stringItemType Balance Type: na Period Type: durationX~~ - DefinitionRoyalty percentage. ReferencesNo definition available. Details Name: ntrb_RoyaltyPercentage Namespace Prefix: ntrb_ Data Type: dtr: percentItemType Balance Type: na Period Type: instantX- DefinitionAmount of ~~direct~~ **transaction** ~~costs~~ - **cost** ~~of the~~ **incurred to effect** business combination ~~including legal, accounting,~~ **. Excludes separately recognized transaction** and ~~other~~ **indirect** ~~costs~~ - **cost** ~~incurred to consummate the business acquisition~~ . ~~ReferencesNo definition available~~ **ReferencesReference 1: http: / / www** . **xbrl. org / 2009 / role / commonPracticeRef- Topic 805- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 7- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147479328 / 805- 10- 50- 7** Details Name: us- gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts Namespace Prefix: us-gaap_ Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: instantX- ~~DefinitionPercentage~~ **DefinitionNumber** of ~~voting~~ **shares of** equity ~~interests~~ - **interest issued or issuable by** ~~acquired~~ **acquirer** ~~at the acquisition date~~ **as part of consideration transferred** in ~~the~~ business combination. ReferencesReference 1: http: / / ~~fasb~~ **www** . **xbrl.** org / **2003** ~~us- gaap~~ / role / ~~ref / legacyRef~~ **exampleRef- Topic 805- SubTopic 10** - Name Accounting Standards Codification- **Section 50- Paragraph 8- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147479328 / 805- 10- 50- 8Reference 2: http: / / www. xbrl. org / 2003 / role / exampleRef-** Topic 805- SubTopic 10- **Name Accounting Standards Codification- Section 55- Paragraph 41- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147479303 / 805- 10- 55- 41Reference 3: http: / / www. xbrl. org / 2003 / role / exampleRef- Topic 805- SubTopic 30- Name Accounting Standards Codification-** Section 50- Paragraph 2- **Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147479581 / 805- 30- 50- 2Reference 4: http: / / www. xbrl. org / 2003 / role / exampleRef- Topic 805- SubTopic 30- Name Accounting Standards Codification- Section 50- Paragraph 1-** Subparagraph ( **the passage of time or when** ~~Codification- Section 50- Paragraph 5- Subparagraph (~~a **triggering event occurs** ~~)- Publisher FASB- URI https: / / asc~~ . **ReferencesReference 1** ~~fasb.org / 1943274 / 2147479907 / 805- 20- 50- 5Reference 5~~ :http: / / ~~www~~ **fasb** . ~~xbrl.~~ org / ~~2003~~ **us- gaap** / role / ~~disclosureRef~~ **ref / legacyRef** - Topic ~~805~~ **942** - SubTopic ~~30~~ **210** - Name Accounting Standards Codification- Section ~~50~~ **S99** - Paragraph 1- Subparagraph ( ~~f)~~ **SX 210.9- 03** ( ~~1~~ **10)** )- Publisher FASB- URI https: / / asc.fasb.org / 1943274 / ~~2147479581~~ **2147478546** / ~~805~~ **942** - ~~30~~ **210** - ~~50~~ **S99** - 1Reference ~~6~~ **2** :http: / / www.xbrl.org / ~~2003~~ **2009** / role / ~~disclosureRef~~ **commonPracticeRef** - Topic ~~805~~ **944** - SubTopic ~~20~~ **210** - Name Accounting Standards Codification- Section ~~50~~ **S99** - Paragraph 1- Subparagraph ( ~~d)~~ **SX 210.7- 03** ( ~~1~~ **a** ) ( ~~1~~ **10)** )- Publisher FASB- URI https: / / asc.fasb.org / 1943274 / ~~2147479907~~ **2147478777** / ~~805~~ **944** - ~~20~~ **210** - ~~50~~ **S99** -

1Reference 7 3 :http: / / www.xbrl.org / 2003 / role / disclosureRef- Topic 805 946 - SubTopic 20 210 - Name Accounting Standards Codification- Section 50 S99 - Paragraph 1- Subparagraph ( d) SX 210.6- 04 ( 1 7 ) ( ii a) )- Publisher FASB- URI https: / / asc.fasb.org / 1943274 / 2147479907 - 2147479170 / 805 946 - 20 210 - 50 S99 - 1Reference 8 4 :http: / / www.xbrl.org / 2003 / role / disclosureRef- Topic 805 210 - SubTopic 30 10 - Name Accounting Standards Codification- Section 50 S99 - Paragraph 1- Subparagraph ( b) SX 210.5- 02 ( 3 7) )- Publisher FASB- URI https: / / asc.fasb.org / 1943274 / 2147479581 2147480566 / 805 210 - 30 10 - 50 S99 - 1Reference 9 1 Details Name:us- gaap_PrepaidExpenseCurrentAndNoncurrent Namespace Prefix:us- gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instantX- DefinitionCash received for fees during the current period.This element excludes cash proceeds from license fees. ReferencesReference 1 :http: / / www- fasb . xbrl. org / 2003 us- gaap / role / disclosureRef ref / legacyRef - Topic 805 230 - SubTopic 30 10 - Name Accounting Standards Codification- Section 50 45 - Paragraph 1 25 - Subparagraph ( c b) (1 )- Publisher FASB- URI https: / / asc.fasb.org / 1943274 / 2147479581 2147482740 / 805- 30 230 - 50- 1Reference 10 - 45- 25 Details Name : http us- gaap_ProceedsFromFeesReceived Namespace Prefix : / / www. us- gaap_ Data Type: xbrl xbrli .org / 2009 / role / commonPracticeRef- Topic 805- SubTopic 20- Name Accounting Standards Codification- Section 50- Paragraph 1- Subparagraph (d)- Publisher FASB- URI https : monetaryItemType Balance Type / / asc.fasb.org / 1943274 / 2147479907 / 805- 20- 50- 1Reference 11 : http debit Period Type : durationX- DefinitionAmount of purchase arrangement / / www.xbrl.org c the passage of time - Subparagraph (b) (3)- Publisher FASB- URI https: / / asc.fasb.org - or when a triggering event occurs. ReferencesReference 1 / 1943274 / 2147479907 / 805- 20- 50- 1Reference 25 :http: / / www- fasb . xbrl. org / 2003 us- gaap / role / disclosureRef ref / legacyRef - Topic 805 942 - SubTopic 20 210 - Name Accounting Standards Codification- Section 50 S99 - Paragraph 4A 1 - Subparagraph ( b SX 210.9- 03 (10) )- Publisher FASB- URI https: / / asc.fasb.org / 1943274 / 2147479907 2147478546 / 805 942 - 20 210 - 50 S99 - 4AReference 1Reference 26 2 :http: / / www.xbrl.org / 2003 2009 / role / disclosureRef commonPracticeRef - Topic 805 944 - SubTopic 20 210 - Name Accounting Standards Codification- Section 50 S99 - Paragraph 1- Subparagraph ( SX 210.7- 03 ( a) ( 3 10) )- Publisher FASB- URI https: / / asc.fasb.org / 1943274 / 2147479907 2147478777 / 805 944 - 20 210 - 50 S99 - 1Reference 27 3 :http: / / www.xbrl.org / 2003 / role / disclosureRef- Topic 805 946 - SubTopic 20 210 - Name Accounting Standards Codification- Section 50 S99 - Paragraph 1- Subparagraph ( SX 210.6- 04 (7) ( a) (2 )- Publisher FASB- URI https: / / asc.fasb.org / 1943274 / 2147479907 - 2147479170 / 805 946 - 20 210 - 50 S99 - 1Reference 28 4 :http: / / www.xbrl.org / 2003 / role / disclosureRef- Topic 805 210 - SubTopic 20 10 - Name Accounting Standards Codification- Section 50 S99 - Paragraph 4A 1 - Subparagraph ( a SX 210.5- 02 (7) )- Publisher FASB- URI https: / / asc.fasb.org / 1943274 / 2147479907 2147480566 / 805- 20 210 - 50 10 - 4AReference 29 S99- 1 Details Name:us- gaap_PrepaidExpenseCurrentAndNoncurrent Namespace Prefix:us- gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instantX- DefinitionCash received for fees during the current period.This element excludes cash proceeds from license fees. ReferencesReference 1 :http: / / www- fasb . xbrl. org / 2003 us- gaap / role / disclosureRef ref / legacyRef - Topic 805 230 - SubTopic 30 10 - Name Accounting Standards Codification- Section 50 45 - Paragraph 4 25 - Subparagraph ( b c )- Publisher FASB- URI https: / / asc.fasb.org / 1943274 / 2147479581 2147482740 / 805- 30 230 - 50 10 - 4Reference 30 45- 25 Details Name : http us- gaap_ProceedsFromFeesReceived Namespace Prefix : / / www. us- gaap_ Data Type: xbrl xbrli .org / 2003 / role / disclosureRef- Topic 805- SubTopic 30- Name Accounting Standards Codification- Section 50- Paragraph 1- Subparagraph (b) (4)- Publisher FASB- URI https : monetaryItemType Balance Type / / asc.fasb.org / 1943274 / 2147479581 / 805- 30- 50- 1Reference 31 : http debit Period Type : durationX / / www.xbrl.org / 2003 / role / disclosureRef - DefinitionAmount of purchase arrangement Topic 805- SubTopic 30- Name Accounting Standards )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147479328 / 805- 10- 50- 2 Details Name: us- gaap_BusinessAcquisitionLineItems Namespace Prefix:us- gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:durationX- DefinitionPercentage of voting equity interest acquired in business combination. ReferencesReference 1:http :/ / www.xbrl.org / 2009 2003 / role / commonPracticeRef exampleRef - Topic 944 805 - SubTopic 210 - 10 - Name Accounting Standards Codification- Section S99 50 - Paragraph 8 1- Subparagraph (SX 210.7- 03 (a) (10)) - Publisher FASB- URI https: / / asc.fasb.org / 1943274 / 2147478777 2147479328 / 944 805 - 210 - 10 - S99 50 - 1Reference 8Reference 3 2 :http: / / www.xbrl.org / 2003 / role / disclosureRef exampleRef - Topic 946 805 - SubTopic 210 - 10 - Name Accounting Standards Codification- Section S99 55 - Paragraph 38 1- Subparagraph (SX 210.6- 04 (7) (a)) - Publisher FASB- URI https: / / asc.fasb.org / 1943274 / 2147479170 2147479303 / 946 805 - 210 - 10 - S99 55 - 1Reference 38Reference 4 3 :http: / / www.xbrl.org / 2003 / role / disclosureRef- Topic 210 805 - SubTopic 10- Name Accounting Standards Codification- Section S99 50 - Paragraph 1 2 - Subparagraph ( c SX 210.5- 02 (7) )- Publisher FASB- URI https: / / asc.fasb.org / 1943274 / 2147480566 2147479328 / 805- 210 - 10 - 10 50 - 2 S99- 1 Details Name :us- gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired Namespace Prefix: us- gaap_ Data Type: dtr- types: percentItemType Balance Type: na Period Type: instantX- Details Name DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. ReferencesReference 1 : http: / / fasb. org / us- gaap_BusinessAcquisitionAxis = ntrb_FourPTherapeuticsLLCMember gaap / role / ref / legacyRef- Topic 210- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210. 5- 02 (29))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1 Details Name: us- gaap_CommonStockSharesIssued Namespace Prefix: us- gaap_ Data Type: na xbrli: sharesItemType Balance Type: na Period Type: instantX X - Details Name DefinitionAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note : elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. ReferencesReference 1: http: / / fasb. org / us- gaap_FiniteLivedIntangibleAssetsByMajorClassAxis = gaap / role / ref / legacyRef..... S99- 1 Details Name: us- gaap_CommonStockValue gaap_IntellectualPropertyMember Namespace Prefix: us- gaap_ Data Type: na xbrli: monetaryItemType Balance Type: credit Period Type: instantX X - Details Name: us- gaap_BusinessAcquisitionAxis = ntrb_PoconoPharmaceuticalsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: srt_RangeAxis us- gaap_StatementClassOfStockAxis = srt_MinimumMember us- gaap_CommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: srt_RangeAxis = srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: Summary of Significant Accounting Policies (Details)- USD ($) 1 Months Ended 12 Months EndedApr. 19, 2024 Jan. 31, 2025 Jan. 31, 2024 Jul. 13 , 2023 Oct. 31, 2021 Jan. 31, 2024 Jan. 31 , 2023 Mar. 31, 2023 Jul. 26, 2022 Aug. 31, 2020Summary of Significant Accounting Policies [ Line Items ] Forward stock split, description The 7: 6 forward stock split was effective for trading purposes on the Nasdaq Capital Market on August 12, 2022. Cash and cash equivalents $ 4, 311, 719 $ 492, 942 Working capital 22 3 , 770 811, 420 Net Loss loss from operations ( 10, 284, 843) ( 4, 871, 926) $ (4, 475, 185) Used cash Cash flow from operations ( 4, 626, 564) ( 3, 527, 509) (2, 987, 198) Net proceeds Proceeds $ 5 from equity financing 8, 406, 591 Cash federally insured amount 3, 804, 000 Bad debt expenses 1, 200 11 , 836 , 230 Exercise warrants $ 3, 239, 845 Credit line note $ 2, 000, 000 Research and development $ 5, 000, 000 Advance repaid 2, 000, 000 Debt amount 2, 000, 000 Accrued interest 1, 026, 720 Private placement $ 8, 400, 000 Account receivable $ 106, 528 Loan bears interest, percentage 10. 00 % Total inventory $ 212, 041 168, 605 229, 335 Work in process 11 46 , 021 255 7, 466 Finished goods 16, 609 8, 707 Raw materials $ 134 149 , 691 218 177 152 , 334 Estimated 432 Depreciated useful lives 10 years Impairment, Intangible Asset, Statement of Income or Comprehensive Income [ Extensible Enumeration ] Goodwill and intangibles impairment Impairment charge $ 293, 038 Goodwill $ 1, 719, 235 535 $ 5, 021, 713 Anti- dilutive shares (in Shares) 6, 920, 641 2, 157, 873 Loan [ Member ] Summary of Significant Accounting Policies [ Line Items ] Loan interest rate 810 - 10. 00 % Credit Line Note facility [ Member ] Summary of Significant Accounting Policies [ Line Items ] Proceeds from equity financing $ 8 , 400 640Impairment goodwill 3 , 302, 478 000 4P Therapeutics LLC [ Member ] Summary of Significant Accounting Policies [ Line Items ] Goodwill amounted $ 1, 719, 235 Pocono Coated Products LLC and Active Intelligence LLC [ Member ] Summary of Significant Accounting Policies [ Line Items ] Goodwill $ 5, 021 810 , 713 $ 5, 021, 713 Common stock equivalents outstanding (in Shares) 2, 157, 873 1, 778, 006 Intelligence 640Intelligence LLC [ Member ] Summary of Significant Accounting Policies [ Line Items ] Impairment charge $ 3, 302, 478 $ 0 $ 327, 326 Minimum Related Party [ Member ] | Credit Line Note facility [ Member ] Summary of Significant Accounting Policies [ Line Items ] Credit line note $ 5 Authorized shares (in Shares) 250 , 000, 000 Asset $ 2, 000, 000 Minimum [ Member ] Summary of Significant Accounting Policies [ Line Items ] depreciated Depreciated range useful lives 3 years Maximum [ Member ] Summary of Significant Accounting Policies [ Line Items ] Authorized shares (in Shares) 291, 666, 666 Asset depreciated Depreciated range useful lives 20 years Accounts Receivable [ Member ] Summary of Significant Accounting Policies [ Line Items ] Bad debt expense $ 118, 364 $ 0 Inventories [ Member ] Summary of Significant Accounting Policies [ Line Items ] Work in process $ 7, 466 X - DefinitionAsset depreciated range. ReferencesNo definition available. Details Name: ntrb_AssetDepreciatedRange Namespace Prefix: ntrb_ Data Type: xbrli: durationItemType Balance Type: na Period Type: durationX- DefinitionAmount of bad debt. ReferencesNo definition available. Details Name: ntrb_BadDebt Namespace Prefix: ntrb_ Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: durationX- DefinitionDescribes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment). ReferencesNo definition available. Details Name: ntrb_EstimatedUsefulLive Namespace Prefix: ntrb_ Data Type: xbrli: durationItemType Balance Type: na Period Type: durationX- DefinitionGoodwill value. ReferencesNo definition available. Details Name: ntrb_GoodwillValue Namespace Prefix: ntrb_ Data Type: xbrli:

monetaryItemType Balance Type: debit Period Type: instantX- DefinitionLoan bears interest, percentage. ReferencesNo definition available. Details Name: ntrb_LoanBearsInterestPercentage Namespace Prefix: ntrb_ Data Type: dtr: percentItemType Balance Type: na Period Type: durationX- DefinitionThe cash inflow associated with the amount received from entity's first offering of stock to the public. ReferencesNo definition available. Details Name: ntrb_ProceedsFromIssuancesInitialPublicOffering Namespace Prefix: ntrb_ Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: durationX- DefinitionThe cash inflow associated with the amount received from holders exercising their stock warrants. ReferencesNo definition available. Details Name: ntrb_ProceedsFromWarrantsExercises Namespace Prefix: ntrb_ Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: durationX- ReferencesNo definition available. Details Name: ntrb_SummaryofSignificantAccountingPoliciesDetailsLineItems Namespace Prefix: ntrb_ Data Type: xbrli: stringItemType Balance Type: na Period Type: durationX- DefinitionWorking capital is the amount of available capital that a company can readily use for day- to- day operations. ReferencesNo definition available. Details Name: ntrb_WorkingCapital Namespace Prefix: ntrb_ Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: durationX- DefinitionFair value portion of amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties. ReferencesReference 1: http: / / www. xbrl. org / 2003 **2009** / role / disclosureRef **commonPracticeRef** - Topic 825- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph **28- Subparagraph (c** ) **(1** )- Publisher FASB- URI https: / / asc.fasb.org / 1943274 / 2147478546 **2147482907** / 942 **825** - 210 - **10** - S99 **50** - 1Reference **28Reference** 2:http: / / www.xbrl.org / 2009 / role / commonPracticeRef- Topic 944 **825** - SubTopic 210 - **10** - Name Accounting Standards Codification- Section S99 **50** - Paragraph 1 **11** - Subparagraph ( **b** SX 210.7- 03 (a) (10) )- Publisher FASB- URI https: / / asc.fasb.org / 1943274 / 2147478777 **2147482907** / 944 **825** - 210 - **10** - S99 **50** - 1Reference **11Reference** 3:http: / / www.xbrl.org / 2003 **2009** / role / disclosureRef **commonPracticeRef** - Topic 946 **825** - SubTopic 210 - **10** - Name Accounting Standards Codification- Section S99 **50** - Paragraph 1 **11** - Subparagraph ( SX 210.6- 04 (7) ( a ) )- Publisher FASB- URI https: / / asc.fasb.org / 1943274 / 2147479170 **2147482907** / 946 **825** - 210 - **10** - S99 **50** - 1Reference **11Reference** 4:http: / / www.xbrl.org / 2003 **2009** / role / disclosureRef **commonPracticeRef** - **Topic 825- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph** 10- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482907 / 825- 10- 50- 10 Details Name: us- gaap_AccountsReceivableFairValueDisclosure Namespace Prefix: us- gaap_ Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: instantX- DefinitionNumber - **DefinitionThe valuation allowance as** of shares of other -- **the** common Details Name:us-gaap_ExcessStockSharesIssued Namespace Prefix:us- gaap_ Data Type:xbrli:sharesItemType Balance **balance** Type:na Period Type:instantX- DefinitionInterest received **sheet date to reduce the gross amount of receivables to estimated net realizable value,which would be presented in parentheses** on loans and other debt instruments during the current period **face of the balance sheet** . ReferencesReference 1:http: / / www.xbrl.org / 2009 / role / commonPracticeRef- Topic 230 **310** - SubTopic 10- Name Accounting Standards Codification- Section 45 **50** - Paragraph **4** 16- Subparagraph (b) - Publisher FASB- URI https: / / asc.fasb.org / 1943274 / 2147482740 **2147481962** / 230 **310** - 10- 45 **50** - 16 **4** Details Name:us- gaap_ProceedsFromInterestReceived **gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables** Namespace Prefix:us- gaap_ Data Type:xbrli:monetaryItemType Balance **Type:credit Period Type:instantX- DefinitionSecurities (including those issuable pursuant to contingent** stock instruments held by shareholder, including **agreements** 4.C ) **that could potentially dilute** - Publisher FASB- URI https: / / asc **basic earnings per** .fasb.org / 1943274 / 2147480008 / 505- 10- S99- 4 Details Name:us-gaap_StockholdersEquityReverseStockSplit Namespace Prefix:us- gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:durationX- DefinitionPer share **(EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would** increase in excreise price of warrant.Excludes change due to standard antidilution provision **EPS or EPU amounts or decrease loss per share or unit amounts for the period presented** . ReferencesReference 1:http: / / www.xbrl.org / 2003 / role / disclosureRef- Topic 505 **260** - SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 3 **1- Subparagraph (c)** - Publisher FASB- URI https: / / asc.fasb.org / 1943274 / 2147481112 **2147482662** / 505 **260** - 10- 50- 3 **1** Details Name:us- gaap_WarrantExercisePriceIncrease **gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount** Namespace Prefix:us-gaap_ Data Type: **xbrli** dtr- types : perShareItemType **sharesItemType** Balance Type:na Period Type:durationX- **DefinitionAmount of write- down of assets recognized in the income statement.Includes** , but **is** not limited to, exchangeable shares **the passage of time or when a triggering event occurs. ReferencesReference 1** :http: / www **fasb** . xbrl. org / 2003 **us- gaap** / role / exampleRef **ref / legacyRef** - Topic 942- SubTopic 10 **210** - Name Accounting Standards Codification- Section S99- Paragraph 6 **1- Subparagraph (SX 210.9- 03 (10))** - Publisher FASB- URI https: / / asc.fasb.org / 1943274 / 2147480035 **2147478546** / 942- 10 **210** - S99- 6Reference **1Reference** 4 **2** :http: / fasb **www** . **xbrl.** org / **2009** us- gaap - / role / ref / legacyRef **commonPracticeRef- Topic 944- SubTopic 210** - Name Accounting Standards Codification- Topic 360- SubTopic 10- Section 45 **S99** - Paragraph 4 **1- Subparagraph (SX 210.7- 03 (a) (10))** - Publisher FASB- URI https: / / asc.fasb.org / 1943274 / 2147482130 **2147478777** / 360 **944** - 10 **210** - 45 **S99** - **1Reference 3** 4 Details Name:us-gaap_AssetImpairmentCharges Namespace Prefix:us- gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:durationX- DefinitionAmount of cash and cash equivalent.Cash includes,but is not limited to,currency on hand,demand deposit with financial institution,and account with general characteristic of demand deposit.Cash equivalent includes,but is not limited to,short- term,highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate. ReferencesReference 1 :http: / / www.xbrl.org / 2003 / role / disclosureRef- Topic 210 **946** - SubTopic 10 **210** - Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210. 5 **6** - 02 **04** ( 1 **7) (a** ))- Publisher FASB- URI https: / / asc.fasb.org / 1943274 / 2147480566 **2147479170** / 210 **946** - 10 **210** - S99- 1Reference 2 **4** :http: / / www.xbrl.org / 2003 / role / exampleRef **disclosureRef** - Topic 210- SubTopic 10- Name Accounting Standards Codification- Section 45 **S99** - Paragraph 1- Subparagraph ( a **SX 210.5- 02 (7)** )- Publisher FASB- URI https: / / asc.fasb.org / 1943274 / 2147483467 **2147480566** / 210- 10 **210** - 45 **10** - 1Reference 3 **S99- 1 Details Name:us-gaap_PrepaidExpenseCurrentAndNoncurrent Namespace Prefix:us- gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instantX- DefinitionCash received for fees during the current period.This element excludes cash proceeds from license fees. ReferencesReference 1** :http: / / fasb.org / us- gaap / role / ref / legacyRef **- Topic 230- SubTopic 10** - Name Accounting Standards Codification- Topic 230- SubTopic 10 - Section 45- Paragraph 4 **25- Subparagraph (c)** - Publisher FASB- URI https: / / asc.fasb.org / 1943274 / 2147482740 / 230- 10- 45- 4 **25** Details Name:us-gaap_CashAndCashEquivalentsAtCarryingValue **gaap_ProceedsFromFeesReceived** Namespace Prefix:us- gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type: instantX **durationX- DefinitionAmount of purchase arrangement** . ReferencesNo definition available. Details Name: us-gaap_CommonStockOtherSharesOutstanding **gaap_CashFDICInsuredAmount** Namespace Prefix: us- gaap_ Data Type: xbrli: sharesItemType 1Reference 2 **monetaryItemType Balance Type:debit Period Type:instantX- DefinitionThe average effective interest rate during the reporting period. ReferencesReference 1** :http: / www **fasb** . xbrl. org / 2009 **us- gaap** / role / commonPracticeRef **ref / legacyRef** - Topic 944 **210** - SubTopic 210 - **10** - Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210. 7 **5** - 03 **02 (22)** (a) ( 10 **1** ))- Publisher FASB- URI https: / / asc.fasb.org / 1943274 / 2147478777 **2147480566** / 944 - 210- **10-** S99- 1Reference 3 **2** :http: / / www.xbrl.org / 2003 / role / disclosureRef- Topic 946 **470** - SubTopic 210 - **20** - Name Accounting Standards Codification- Section S99 **50** - Paragraph 1 **1F** - Subparagraph ( SX 210.6- 04 (7) ( a ) )- Publisher FASB- URI https: / / asc.fasb.org / 1943274 / 2147479170 **2147481139** / 946 **470** - 210 - **20** - S99 **50** - 1Reference **1FReference** 4 **3** :http: / / www.xbrl.org / 2003 **2009** / role / disclosureRef **commonPracticeRef** - Topic 210 **835** - SubTopic 10 **30** - Name Accounting Standards Codification- Section S99 **45** - Paragraph **2** 1- Subparagraph (SX 210.5- 02 (7)) - Publisher FASB- URI https: / / asc.fasb.org / 1943274 / 2147480566 **2147482925** / 210 **835** - 10 **30** - S99 **45** - 1 **2** Details Name:us-gaap_PrepaidExpenseCurrentAndNoncurrent **gaap_DebtInstrumentInterestRateDuringPeriod** Namespace Prefix:us- gaap_ Data Type: xbrli **dtr- types** : **percentItemType** monetaryItemType Balance Type:debit Balance Type: na Period Type: instantX **durationX** - DefinitionAmount of debt and lease obligation , **after** classified as current. ReferencesReference 1..... Period Type: instantX- DefinitionAmount of accumulated impairment loss for **, of** asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. ReferencesReference 1: http: / / www. xbrl. org / 2003 / role / exampleRef- Topic 350- SubTopic 20- Name Accounting Standards Codification- Section 55- Paragraph 24- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482548 / 350- 20- 55- 24Reference 2: http: / / www. xbrl. org / 2003 / role / disclosureRef **exampleRef** - Topic 350 **805** - SubTopic 20 **10** - Name Accounting Standards Codification- Section 50- Paragraph **8** 1- Subparagraph (a) - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482573 **2147479328** / 350 **805** - 20 **10** - 50- 1Reference **8Reference** 3: http: / / www. xbrl. org / 2003 / role / disclosureRef **exampleRef** - Topic 350 **805** - SubTopic 20 **10** - Name Accounting Standards Codification- Section 50 Accounting Standards Codification **credit Period Type:instantX** - Section 55- Paragraph 39- Publisher FASB- URI https: / / asc **DefinitionAmount,after effects of reinsurance,of expense (reversal of expense) for claims incurred and costs incurred in the claim settlement process** . **ReferencesReference 1** fasb.org / 1943274 / 2147479303 / 805- 10- 55- 39Reference 6 :http: / / www.xbrl.org / 2003 / role / exampleRef- Topic 280 **944** - SubTopic 10 **40** - Name Accounting Standards Codification- Section 55- Paragraph 49 **7** - Publisher FASB- URI https: / / asc.fasb.org / 1943274 / 2147482785 **2147480046** / 280 **944** - 10 **40** - 55- 49Reference **7Reference** 7 **2** :http: / / www.xbrl.org / 2003 **2009** / role / exampleRef **commonPracticeRef** - Topic 820 **944** - SubTopic 10 **40** - Name Accounting Standards Codification- Section 55 **50** - Paragraph 100 **3** - Subparagraph ( d **b** )- Publisher FASB- URI https: / / asc.fasb.org / 1943274 / 2147482078 - **2147480081** / 820 **944** - 10 **40** - 55 **50** - 100Reference

~~8~~ **3 Details Name** : ~~http~~ **us- gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1 Namespace Prefix** : **us** ~~/ / www.xbrl.org / 2003 / role / exampleRef - Topic 852 -~~ **gaap_ Data Type:xbrli:monetaryItemType Balance Type:** - Paragraph 1- Subparagraph ( ~~h~~ **SX 210. 5- 02 (15)** )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / **2147480566 / 210- 10- S99- 1Reference 10:http: / / www.xbrl.org / 2003 / role / disclosureRef- Topic 350- SubTopic 20- Name Accounting Standards Codification- Section 45- Paragraph 1** - Publisher FASB- URI https:/ / asc.fasb.org / 1943274 / ~~2147478546~~ **2147482598** / ~~942~~ **350** - ~~210 -~~ **20** - ~~S99~~ **45** - 1Reference ~~2~~ **11** :http:/ / www.xbrl.org / 2009 / role / commonPracticeRef- Topic ~~944~~ **350** - SubTopic ~~210 -~~ **20** - Name Accounting Standards Codification- Section ~~S99~~ **50** - Paragraph 1- Subparagraph ( ~~SX 210.7- 03 ( a ) (10) )~~- Publisher FASB- URI https:/ / asc.fasb.org / 1943274 / 2147478777 / 944- 210- S99- 1Reference 3:http:/ / www.xbrl.org / 2003 / role / disclosureRef- Topic 946- SubTopic 210 2147482573 / 350- 20- 50- **1Reference 12: http: / / www. xbrl. org / 2009 / role / commonPracticeRef- Topic 350- SubTopic 20- Name Accounting Standards Codification- Section 50- Paragraph** 1 **- Subparagraph (h)- Publisher FASB- URI https:/** / asc.fasb.org / 1943274 / ~~2147478988~~ **2147482573** / ~~932~~ **350** - ~~323~~ **20** - 50- **1Reference 13** ~~1" },"r576"~~ : ~~{" role":"~~ http:/ / www.xbrl.org / 2003 / role / disclosureRef ~~- ","~~ Topic ~~":"~~ 942 ~~- ","~~ SubTopic ~~":"~~ 210 ~~- ","~~ Name ~~":"~~ Accounting Standards Codification ~~- ","~~ Section ~~":"~~ S99 ~~- ","~~ Paragraph ~~":"~~ 1 ~~- ","~~ Subparagraph ~~":"~~ (SX 210.9- 03 (10) (1)) ~~- ","~~ Publisher ~~":"~~ FASB ~~- ","~~ URI ~~":"~~ https:/ / asc.fasb.org / 1943274 / 2147478546 / 942- 210- S99- **1Reference 14** ~~1" },"r577"~~ : ~~{" role":"~~ http:/ / www.xbrl.org / ~~2003~~ **2009** / role / **commonPracticeRef- Topic 805- SubTopic 30- Name Accounting Standards Codification- Section 50- Paragraph 4- Subparagraph (b)- Publisher FASB- URI https:/ / asc.fasb.org / 1943274 / 2147479581 / 805- 30- 50- 4** Details Name: us- ~~gaap_GoodwillImpairedAccumulatedImpairmentLoss~~ **gaap_Goodwill** Namespace Prefix: us- gaap_ Data Type: xbrli: monetaryItemType Balance Type: ~~credit~~ **debit** Period Type: instantX- ~~DefinitionAmount~~ **DefinitionIndicates line item in statement** of ~~increase (decrease)~~ **income or comprehensive income that includes impairment** of **intangible** asset **. Includes** ~~representing future economic benefit from other asset acquired in business combination or from joint venture formation or both~~ , ~~that~~ **but** is not ~~individually identified~~ **limited to, finite- lived** and **indefinite- lived intangible assets separately recognized, classified as other** . ReferencesReference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 350- SubTopic ~~20~~ **30** - Name Accounting Standards Codification- Section 50- Paragraph ~~1~~ **3** - Subparagraph ( ~~g~~ **c** )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147482573 -~~ **2147482665** / 350- ~~20~~ **30** - 50- ~~1~~ **3** Details Name: us- ~~gaap_GoodwillOtherIncreaseDecrease~~ **gaap_ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration Namespace Prefix:us- gaap_ Data Type:enum2:enumerationSetItemType Balance Type:na Period Type:durationX- DefinitionThe amount of impairment loss recognized in** the ~~passage~~ **period resulting from the write- down** of ~~time or when a triggering event occurs~~ **the carrying amount of an intangible asset (excluding goodwill) to fair value** . ReferencesReference 1:http: / / fasb.org / us- gaap / role / ref / legacyRef- ~~Topic 942- SubTopic 210 -~~ Name Accounting Standards Codification- Section ~~S99~~ **45** - Paragraph ~~1~~ **28** - Subparagraph ( **b)** ~~SX 210.9 -~~ **SubTopic** ~~03 (~~ 10 ~~))~~ **- Topic 230** - Publisher FASB- URI https:/ / asc.fasb.org / 1943274 / ~~2147478546~~ **2147482740** / ~~942~~ **230** - ~~210 -~~ **10** - ~~S99~~ **45** - ~~1Reference~~ **28Reference** 2:http:/ / www.xbrl.org / ~~2009~~ **2003** / role / ~~commonPracticeRef~~ **disclosureRef** - Topic ~~944~~ **350** - SubTopic ~~210~~ **30** - Name Accounting Standards Codification- Section ~~S99~~ **45** - Paragraph **2** ~~1- Subparagraph (SX 210.7- 03 (a) (10))~~- Publisher FASB- URI https:/ / asc.fasb.org / 1943274 / ~~2147478777~~ **2147482686** / ~~944~~ **350** - ~~210~~ **30** - ~~S99~~ **45** - ~~1Reference~~ **2Reference** 3:http:/ / www.xbrl.org / 2003 / role / disclosureRef- Topic ~~946~~ **350** - SubTopic ~~210~~ **30** - Name Accounting Standards Codification- Section ~~S99~~ **50** - Paragraph ~~1~~ **3** - Subparagraph ( **b** ~~SX 210.6- 04 (7) (a)~~ )- Publisher FASB- URI https:/ / asc.fasb.org / 1943274 / ~~2147479170~~ **2147482665** / ~~946~~ **350** - ~~210~~ **30** - ~~S99~~ **50** - ~~1Reference~~ **3Reference** 4:http:/ / www.xbrl.org / 2003 / role / disclosureRef- Topic ~~210~~ **220** - SubTopic ~~10~~ **40** - Name Accounting Standards Codification- Section ~~S99~~ **50** - Paragraph ~~1~~ **21** - Subparagraph ( **b** ~~SX 210.5- 02 (7)~~ )- Publisher FASB- URI https:/ / asc.fasb.org / 1943274 / ~~2147480566~~ **2147476148** / **220- 40- 50-** ~~210 -~~ **21** ~~- 10- S99- 1~~ Details Name:us- **gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill** Namespace Prefix: us- gaap_ Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: durationX- DefinitionAmount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer. ReferencesReference 1: http: / / www. xbrl. org / 2009 / role / commonPracticeRef- Topic 210- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210. 5- 02 (6) (a) (1))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1 Details Name: us- gaap_InventoryFinishedGoods **credit** ~~:monetaryItemType Balance Type:debit~~ Period Type:instantX- DefinitionAmount **,** after ~~valuation~~ **effects of reinsurance,of expense (reversal of expense) for claims incurred** and **costs incurred in the claim settlement process** ~~LIFO reserves of inventory expected to be sold,or consumed within one year or operating cycle,if longer~~ . ReferencesReference 1:http: / / www.xbrl.org / 2003 / role / exampleRef- Topic ~~852~~ **944** - SubTopic ~~10~~ **40** - Name Accounting Standards Codification- Section 55- Paragraph ~~10~~ **7** - Publisher FASB- URI https:/ / asc.fasb.org / 1943274 / ~~2147481372~~ **2147480046** / ~~852~~ **944** - ~~10~~ **40** - 55- ~~10Reference~~ **7Reference** 2:http:/ / www.xbrl.org / ~~2003~~ **2009** / role / ~~exampleRef~~ **commonPracticeRef** - Topic ~~210~~ **944** - SubTopic ~~10~~ **40** - Name Accounting Standards Codification- Section ~~45~~ **50** - Paragraph ~~1~~ **3** - Subparagraph (b)- Publisher FASB- URI https:/ / asc.fasb.org / 1943274 / ~~2147483467~~ **2147480081** / ~~210~~ **944** - ~~10~~ **40** - ~~45~~ **50** - ~~1Reference~~ 3 **Details Name** : ~~http~~ **us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1 Namespace Prefix** : **us** ~~/ / www.xbrl.org / 2003 / role / disclosureRef - gaap_ Data Type:xbrli:monetaryItemType Balance Type:~~ Namespace Prefix: us- gaap_ Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: instantX- DefinitionAmount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer. ReferencesReference 1: http: / / www. xbrl. org / 2009 / role / commonPracticeRef- Topic 210- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210. 5- 02 (6) (a) (4))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1 Details Name: us- gaap_InventoryRawMaterials Namespace Prefix: us- gaap_ Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: instantX- DefinitionAmount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer. ReferencesReference 1: http: / / www. xbrl. org / 2009 / role / commonPracticeRef- Topic 210- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210. 5- 02 (6) (a) (3))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1 Details Name: us- gaap_InventoryWorkInProcess Namespace Prefix: us- gaap_ Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: instantX- DefinitionThe carrying value as of the balance sheet date of the current portion of long- term obligations drawn from a line of credit, which is a bank' s commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short- term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short- term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement. ReferencesReference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef- Topic 210- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210. 5- 02 (19))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1Reference 2: http: / / fasb. org / us- gaap / role / ref / legacyRef- Topic 942- SubTopic 210- Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210. 9- 03 (13))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147478546 / 942- 210- S99- 1 Details Name: us- gaap_LinesOfCreditCurrent Namespace Prefix: us- gaap_ Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: instantX- DefinitionAmount of cash inflow (outflow) from operating ~~activities~~ **activity** , including **, but not limited to,** discontinued ~~operations -~~ **operation** . Operating activity ~~cash flows include~~ **includes , but is not limited to,** ~~transactions -~~ **transaction** , ~~adjustments -~~ **adjustment** , and ~~changes -~~ **change** in value not defined as investing or financing ~~activities~~ **activity** . ReferencesReference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef- Topic 230- SubTopic 10- Name Accounting Standards Codification- Section 45- Paragraph 28- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482740 / 230- 10- 45- 28Reference 2: http: / / fasb. org / us- gaap / role / ref / legacyRef- Topic 230- SubTopic 10- Name Accounting Standards Codification- Section 45- Paragraph 24- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482740 / 230- 10- 45- 24Reference 3: http: / / fasb. org / us- gaap / role / ref / legacyRef- Topic 230- SubTopic 10- Name Accounting Standards Codification- Section 45- Paragraph 25- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482740 / 230- 10- 45- 25 Details Name: us- gaap_NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us- gaap_ Data Type: xbrli: monetaryItemType Balance Type: na Period Type: durationX- DefinitionThe net result for the period of deducting operating expenses from operating revenues. ReferencesReference 1: http: / / www. xbrl. org / ~~2009~~ **2003** / role / ~~commonPracticeRef~~ **exampleRef** - Topic ~~280~~ **220** - SubTopic ~~10~~ **40** - Name Accounting Standards Codification- Section ~~50~~ **55** - Paragraph ~~22~~ **4** - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147482810~~ **2147476153** / ~~280~~ **220** - ~~10~~ **40** - ~~50~~ **55** - ~~22Reference~~ **4Reference** 2: http: / / www. xbrl. org / ~~2009~~ **2003** / role / ~~commonPracticeRef~~ **exampleRef** - Topic ~~280~~ **220** - SubTopic ~~10~~ **40** - Name Accounting Standards Codification- Section ~~50~~ **55** - Paragraph **14** ~~32- Subparagraph (f)~~ - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147482810~~ **2147476153** / ~~280~~ **220** - ~~10~~ **40** - ~~50~~ **55** - ~~32Reference~~ **14Reference** 3: http: / / www. xbrl. org / 2009 / role / commonPracticeRef- Topic 280- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph **22** ~~30- Subparagraph (b)~~ - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482810 / 280- 10- 50-

30Reference 22Reference 4: http: / / www. xbrl. org / 2009 / role / commonPracticeRef- Topic 270 280 - SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 1 32 - Subparagraph ( i f )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482964 2147482810 / 270 280 - 10- 50- 1Reference 32Reference 5: http: / / www. xbrl. org / 2009 / role / commonPracticeRef- Topic 280- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 32 30 - Subparagraph ( ee b )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482810 / 280- 10- 50- 32Reference 30Reference 6: http: / / fasb www . xbrl. org / 2009 us- gaap / role / commonPracticeRef ref / otherTransitionRef - Topic 280 270 - SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 32 1 - Subparagraph ( e i )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482810 2147482964 / 280 270 - 10- 50- 32Reference 1Reference 7: http: / / www. xbrl. org / 2003 2009 / role / exampleRef commonPracticeRef - Topic 280- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 32- Subparagraph (ee )- Publisher FASB- URI https: / / asc.fasb.org / 1943274 / 2147478777 2147482810 / 944 280 - 210 - 10 - S99 50 - 1Reference 32Reference 3 8 :http: / / fasb www.xbrl .org / 2003 us- gaap / role / disclosureRef ref / otherTransitionRef - Topic 946 280 - SubTopic 210 - 10 - Name Accounting Standards Codification- Section S99 50 - Paragraph 1 32 - Subparagraph ( c SX 210.6- 04 (7) (a) )- Publisher FASB- URI https: / / asc.fasb.org / 1943274 / 2147479170 2147482810 / 946 280 - 210 - 10 - S99 50 - 1Reference 32Reference 4 9 :http: / / www.xbrl.org / 2003 / role / disclosureRef exampleRef - Topic 210 280 - SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 31- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482810 / 280- 10- 50- 31 Details Name: us- gaap_OperatingIncomeLoss Namespace Prefix: us- gaap_ Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: durationX- DefinitionThe cash inflow charge against earnings resulting from the issuance write down of long lived assets common stock, preferred stock, treasury stock, stock options, and other types of equity than goodwill due to the difference between the carrying value and lower fair value . ReferencesReference 1: http: / / www fasb . xbrl. org / 2009 us- gaap / role / ref / legacyRef commonPracticeRef- Topic 230- SubTopic 10 - Name Accounting Standards Codification- Section 45- Paragraph 28 14 - Subparagraph ( b a ) - SubTopic 10- Topic 230 - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482740 / 230- 10- 45- 28Reference 14Reference 2: http: / / www. xbrl. org / 2009 2003 / role / commonPracticeRef disclosureRef - Topic 360 946 - SubTopic 10- Name Accounting Standards Codification- Section 50 S99 - Paragraph 2 3 - Subparagraph ( b SX 210. 6- 03 (i) (1) )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482099 2147479886 / 360 946 - 10- 50 S99 - 2 3 Details Name: us- gaap_OtherAssetImpairmentCharges gaap_ProceedsFromIssuanceOrSaleOfEquity Namespace Prefix: us- gaap_ Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: durationX - DefinitionAmount of short- term,..... and equipment, useful life 20 yearsX - DefinitionUseful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in' PnYnMnDTnHnMnS' format, for example,' P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment. ReferencesNo definition available. Details Name: us- gaap_PropertyPlantAndEquipmentUsefulLife Namespace Prefix: us- gaap_ Data Type: xbrli: durationItemType Balance Type: na Period Type: instantX- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. **ReferencesReference 1: http: / / www. xbrl. org / 2009 / role / commonPracticeRef- Topic 944- SubTopic 505- Name Accounting Standards Codification- Section 50- Paragraph 1- Subparagraph (c)- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147477908 / 944- 505- 50- ReferencesNo --- 1Reference definition available 2: http: / / www . credit Period Type:instantX- DefinitionAmount,after effects of reinsurance,of expense (reversal of expense) for claims incurred and costs incurred in the claim settlement process. ReferencesReference 1:http: / / www.** xbrl.org / 2009 2003 / role / commonPracticeRef exampleRef - Topic 944- SubTopic 505 40 - Name Accounting Standards Codification- Section 50 55 - Paragraph 7 1- Subparagraph (b) - Publisher FASB- URI https: / / asc.fasb.org / 1943274 / 2147477908 2147480046 / 944- 505 40 - 50 55 - 1Reference 7Reference 3 2 :http: / / www.xbrl.org / 2009 / role / commonPracticeRef- Topic 944- SubTopic 40 505- Name Accounting Standards Codification- Section 50- Paragraph 5- Publisher FASB- URI https: / / asc.fasb.org / 1943274 / 2147477908 / 944- 505- 50- 5Reference 4:http: / / www.xbrl.org / 2009 / role / commonPracticeRef- Topic 944- SubTopic 505 - Name Accounting Standards Codification- Section 50- Paragraph 3- Subparagraph (b)- Publisher FASB- URI https: / / asc.fasb.org / 1943274 / 2147477908 2147480081 / 944- 505 40 - 50- **3 Details Name:us- gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1 Namespace Prefix:us- gaap_ Data Type:xbrli:monetaryItemType Balance Type:** Details Name: us- gaap_PublicUtilityPropertyPlantAndEquipmentLineItems gaap_StatutoryAccountingPracticesLineItems Namespace Prefix: us- gaap_ Data Type: xbrli: stringItemType Balance Type: na Period Type: durationX- Details Name: us- gaap_PropertyPlantAndEquipmentByTypeAxis gaap_DebtInstrumentAxis = ntrb_MoneyChannelMember ntrb_LoanMember Namespace Prefix:Data Type:na Balance Type:Period Type:X- Details Name:us- gaap_RelatedPartyTransactionAxis gaap_CreditFacilityAxis = ntrb_MDMWorldwideMember ntrb_CreditLineNoteFacilityMember Namespace Prefix:Data Type:na Balance Type:Period Type:X- Details Name:us- gaap_RelatedPartyTransactionAxis gaap_BusinessAcquisitionAxis = ntrb_MoneyChannelMember ntrb_FourPTherapeuticsLLCMember Namespace Prefix:Data Type:na Balance Type:Period Type:X- Details Name:us- gaap_ConcentrationRiskByBenchmarkAxis gaap_BusinessAcquisitionAxis = ntrb_PoconoCoatedProductsLLCAndActiveIntelligenceLLCMember us- gaap_AccountsReceivableMember Namespace Prefix:Data Type:na Balance Type:Period Type:X- Details Name:us- gaap_ShortTermDebtTypeAxis gaap_BusinessAcquisitionAxis = ntrb_AgreementMember ntrb_IntelligenceLLCMember Namespace Prefix:Data Type:na Balance Type:Period Type:X- Details Name: srt_MajorCustomersAxis us- gaap_RelatedPartyTransactionsByRelatedPartyAxis = us- gaap_FurnitureAndFixturesMember gaap_RelatedPartyMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: srt_RangeAxis = srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us- gaap_PropertyPlantAndEquipmentByTypeAxis = ntrb_LabEquipmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us- gaap_PropertyPlantAndEquipmentByTypeAxis = us- gaap_MachineryAndEquipmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: srt_RangeAxis = srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: Property and Equipment **Summary of Significant Accounting Policies- Schedule of Disaggregates its Revenue from Contracts with Customers** (Details)- USD ($) 12 Months EndedJan. 31, 2024 2025 Jan. 31, 2023Property and Equipment [ Abstract ] Depreciation....., 2024 Jan. 31, 2023Schedule 2024Schedule of Property and Equipment **Disaggregates its Revenue from Contracts with Customers** [ Line Items items ] **Total Revenue** Property and equipment, gross $ 1 2 , 456 139 , 617 537 $ 1 2 , 404 085 , **314Sale of Goods** 856Less: Accumulated depreciation (681, 693) (507, 121) Net Property and Equipment 774, 924 897, 735Lab equipment [ Member ] Schedule of Property and Equipment **Disaggregates its Revenue from Contracts with Customers** [ Line Items items ] Property and equipment **Total Revenue 2** , **139** gross 144 , 585 144 **537 1** , 585Machinery and equipment **920, 280Services** [ Member ] Schedule of Property and Equipment **Disaggregates its Revenue from Contracts with Customers** [ Line Items items ] **Total Revenue** Property and equipment, gross 1, 292, 389 1, 240, 628Furniture and fixtures [ Member ] Schedule of Property and Equipment [ Line Items ] Property and equipment, gross $ 19 **165** , **034X** 643 $ 19, 643X- DefinitionAmount..... Type: debit Period Type: instantX - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. ReferencesReference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 842 606 - SubTopic 20 10 - Name Accounting Standards Codification- Section 50- Paragraph 7 7A- Subparagraph (a) - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147478964 - **2147479806** / 842 606 - 20 10 - 50- 7A Section 50 **credit Period Type:instantX** - Paragraph 5- Publisher FASB- URI https: / / asc **DefinitionAmount,after effects of reinsurance,of expense (reversal of expense) for claims incurred and costs incurred in the claim settlement process** . **ReferencesReference 1** fasb.org / 1943274 / 2147479806 / 606- 10- 50- 5Reference 3 :http: / / www.xbrl.org / 2003 / role / exampleRef- Topic 606 944 - SubTopic 10 40 - Name Accounting Standards Codification- Section 55- Paragraph 7 91- Subparagraph (a) - Publisher FASB- URI https: / / asc.fasb.org / 1943274 / 2147479777 2147480046 / 606 944 - 10 40 - 55- 91Reference 7Reference 4 2 :http: / / www.xbrl.org / 2003 2009 / role / exampleRef commonPracticeRef - Topic 606 944 - SubTopic 10 40 - Name Accounting Standards Codification- Section 55 50 - Paragraph 91 3 - Subparagraph (b)- Publisher FASB- URI https: / / asc.fasb.org / 1943274 / 2147479777 2147480081 / 606 944 - 10 40 - 55 50 - 91Reference 5 **3 Details Name** : http **us- gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1 Namespace Prefix** : **us** / / www.xbrl.org / 2003 / role / exampleRef - Topic 606 **gaap_ Data Type:xbrli:monetaryItemType Balance Type:** Details Name: us- gaap_PropertyPlantAndEquipmentLineItems **gaap_DisaggregationOfRevenueLineItems** Namespace Prefix: us- gaap_ Data Type: xbrli: stringItemType Balance Type: na Period Type: durationX - DefinitionAmount after accumulated depreciation, depletion..... Type: credit Period Type: instantX - DefinitionAmount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue- producing transaction, including, but not limited to, sales, use, value- added and excise. ReferencesReference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 280- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 41- Subparagraph (a)- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482810 / 280- 10- 50- 41Reference 2: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 270 280 - SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 42 1- Subparagraph (i) - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482964 2147482810 / 270 280 - 10- 50- 1Reference 42Reference 3: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 280 606 - SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 7 32- Subparagraph (ee) - Publisher FASB-

URI https: / / asc. fasb. org / 1943274 / ~~2147482810~~ **2147479806** / ~~280~~ **606** - 10- 50- ~~32Reference~~ **7Reference** 4: http: / / ~~fasb~~ **www** . **xbrl.** org / **2003** ~~us- gaap~~ / role / **disclosureRef** ~~ref / otherTransitionRef~~ - Topic ~~280~~ **270** - SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph ~~32~~ **1** - Subparagraph ( ~~b~~ **i** )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147482810~~ **2147482964** / ~~280~~ **270** - 10- 50- ~~32Reference~~ **1Reference** 5: http: / / ~~fasb~~ **www** . **xbrl.** org / **2003** ~~us- gaap~~ / role / **disclosureRef** ~~ref / otherTransitionRef~~ - Topic 280- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 32- Subparagraph ( ~~a~~ **ee** )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482810 / 280- 10- 50- 32Reference 6: http: / / ~~www~~ **fasb** . ~~xbrl.~~ org / ~~2003~~ **us-gaap** / role / ~~disclosureRef~~ **ref / otherTransitionRef** - Topic ~~924~~ **280** - SubTopic 10- Name Accounting Standards Codification- Section ~~)~~ **50- Paragraph 32-Subparagraph (b** )- Publisher FASB- URI https:/ / asc.fasb.org / 1943274 / ~~2147478546~~ **2147482810** / ~~942~~ **280** - ~~210~~ - **10** - ~~S99~~ **50** - ~~1Reference~~ **32Reference** ~~2~~ **7** :http:/ / **fasb** ~~www.xbrl~~ .org / ~~2009~~ **us- gaap** / role / ~~commonPracticeRef~~ **ref / otherTransitionRef** - Topic ~~944~~ **280** - SubTopic ~~210~~ - **10** - Name Accounting Standards Codification- Section ~~S99~~ **50** - Paragraph ~~1~~ **32** - Subparagraph ( ~~SX 210.7- 03 (~~a ~~) (10)~~ )- Publisher FASB- URI https:/ / asc.fasb.org / 1943274 / ~~2147478777~~ **2147482810** / ~~944~~ **280** - ~~210~~ - **10** - ~~S99~~ **50** - ~~1Reference~~ **32Reference** ~~3~~ **8** :http:/ / www.xbrl.org / 2003 / role / disclosureRef- Topic ~~946~~ **924** - SubTopic ~~210~~ - **10** - Name Accounting Standards Codification **- Section** S99- Paragraph 1- Subparagraph (SAB Topic 11. L)- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147479941 / 924- 10- S99- 1Reference ~~7~~ **9** : http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 606- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 5- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147479806 / 606- 10- 50- 5Reference ~~8~~ **10** : http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 280- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 30- Subparagraph (a)- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482810 / 280- 10- 50- 30Reference ~~9~~ **11** : http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 280- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph ~~42~~ **22- Subparagraph (b)** - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482810 / 280- 10- 50- ~~42Reference~~ **22Reference** ~~10~~ **12** : http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 280- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph **40** ~~22- Subparagraph (b)~~ - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482810 / 280- 10- 50- ~~22Reference~~ **40Reference** ~~11~~ **13** : http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 280- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph ~~40~~ **22- Subparagraph (a)** - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482810 / 280- 10- 50- ~~40Reference~~ **22Reference** ~~12~~ **14** : http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic ~~280~~ **606** - SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph ~~22~~ **4** - Subparagraph (a)- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147482810~~ **2147479806** / **606** ~~Codification- Section S99- Paragraph 2- Subparagraph (SX 210.5- 03 (1))- Publisher FASB- URI https:/ / asc.fasb.org / 1943274 / 2147483621 / 220~~ - 10- ~~S99~~ **50** - ~~2~~ **4** Details Name:us- ~~gaap_Revenues~~ **gaap_RevenueFromContractWithCustomerIncludingAssessedTax** Namespace Prefix:us- gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type: ~~durationSummary~~ **durationX- Details Name:srt_ProductOrServiceAxis = ntrb_SaleOfGoodsMember Namespace Prefix:Data Type:na Balance Type:Period Type:X- Details Name:srt_ProductOrServiceAxis = us- gaap_ServiceMember Namespace Prefix:Data Type:na Balance Type:Period Type:Summary** of Significant Accounting Policies ~~(Details)~~ - Schedule of Revenue by Geographic Location **(Details)** - USD ($) 12 Months EndedJan.31, ~~2024~~ **2025** Jan.31, ~~2023Revenue~~ **2024Revenue** by geographic location:Total **revenue** $ 2, **139,537 $ 2,** 085, **314United** ~~314 $ 2,079,609United~~ States [ Member ] Revenue by geographic location:Total **revenue 2,139,537** 2,085, **314Foreign** ~~314 2,079,609Foreign~~ [ Member ] Revenue by geographic location:Total **revenue** X- ReferencesNo definition available. Details Name: ~~ntrb_RevenueByGeographicLocationAbstract~~ **us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract** Namespace Prefix: ~~ntrb_~~**us- gaap_** Data Type:xbrli:stringItemType Balance Type:na Period Type:durationX- DefinitionAmount ~~of revenue recognized~~ **,including tax collected** from **customer,of revenue from satisfaction of performance obligation by transferring promised** ~~goods~~ - **good** ~~sold,services rendered,insurance premiums,~~or ~~other activities~~ **service to customer.Tax collected from customer is tax assessed by governmental authority** that ~~eonstitute~~ **is both imposed on** ~~an~~ **and** ~~earning process.Includes~~ **concurrent with specific revenue-producing transaction,including** ,but ~~is~~ not limited to, ~~investment~~ **sales,use,value- added** and **excise** ~~interest income before deduction of interest expense when recognized as a component of revenue,and sales and trading gain (loss)~~ . ReferencesReference 1:http: / / www.xbrl.org / 2003 / role / ~~exampleRef~~ **disclosureRef** - Topic ~~280- SubTopic 10- Name Accounting Standards Codification- Section 55- Paragraph 48- Publisher FASB- URI~~ 280 ~~- 10- 50- 22Reference 13: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 606~~ - SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph **the passage of time** ~~Standards Codification- Section 50- Paragraph 32- Subparagraph (b)- Publisher FASB- URI https:/ / asc.fasb.org~~ - **or when a triggering event occurs. ReferencesReference 1** ~~/ 1943274 / 2147482810 / 280- 10- 50- 32Reference 7~~ :http:/ / fasb.org / us- gaap / role / ref / ~~otherTransitionRef~~ **legacyRef** - Topic ~~280~~ **942** - SubTopic ~~10~~ **210** - Name Accounting Standards Codification- Section ~~50~~ **S99** - Paragraph ~~32~~ **1** - Subparagraph ( ~~a~~ **SX 210.9- 03 (10)** )- Publisher FASB- URI https:/ / asc.fasb.org / 1943274 / ~~2147482810~~ **2147478546** / ~~280~~ **942** - ~~10~~ **210** - ~~50~~ **S99** - ~~32Reference~~ **1Reference** ~~8~~ **2** :http:/ / www.xbrl.org / ~~2003~~ **2009** / role / ~~disclosureRef~~ **commonPracticeRef** - Topic ~~924~~ **944** - SubTopic ~~10~~ **210** - Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph ( **SX 210** ~~SAB Topic 11. L~~ **7- 03 (a) (10)** )- Publisher FASB- URI https:/ / asc.fasb.org / 1943274 / ~~2147479941~~ **2147478777** / ~~924~~ **944** - ~~10~~ **210** - S99- 1Reference ~~9~~ **3** :http:/ / www.xbrl.org / 2003 / role / disclosureRef- Topic ~~606~~ **946** - SubTopic ~~10~~ **210** - Name Accounting Standards Codification- Section ~~50~~ **S99** - Paragraph ~~5~~ **1-Subparagraph (SX 210.6- 04 (7) (a))** - Publisher FASB- URI https:/ / asc.fasb.org / 1943274 / ~~2147479806~~ - **2147479170** / ~~606~~ **946** - ~~10~~ **210** - ~~50~~ **S99** - ~~5Reference~~ **1Reference** ~~10~~ **4** :http:/ / www.xbrl.org / 2003 / role / disclosureRef- Topic ~~280~~ **210** - SubTopic 10- Name Accounting Standards Codification- Section ~~50~~ **S99** - Paragraph ~~30~~ **1** - Subparagraph ( ~~a~~ **SX 210.5- 02 (7)** )- Publisher FASB- URI https:/ / asc.fasb.org / 1943274 / ~~2147482810~~ **2147480566** / ~~280- 10~~ **210** - ~~50~~ **10** - 30Reference ~~11~~ **S99- 1 Details Name:us- gaap_PrepaidExpenseCurrentAndNoncurrent Namespace Prefix:us- gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instantX- DefinitionCash received for fees during the current period.This element excludes cash proceeds from license fees. ReferencesReference 1** :http:/ / ~~www~~ **fasb** . ~~xbrl.~~ org / ~~2003~~ **us- gaap** / role / ~~disclosureRef~~ **ref / legacyRef** - Topic ~~280~~ **230** - SubTopic 10- Name Accounting Standards Codification- Section ~~50~~ **45** - Paragraph ~~22~~ **25** - Subparagraph ( ~~b~~ **c** )- Publisher FASB- URI https:/ / asc.fasb.org / 1943274 / ~~2147482810~~ **2147482740** / ~~280~~ **230** - 10- ~~50~~ **45** - ~~22Reference 12~~ **25 Details Name** : ~~http~~ **us- gaap_ProceedsFromFeesReceived Namespace Prefix** : ~~/ / www.~~ **us- gaap_ Data Type:** xbrl **xbrli** ~~.org / 2003 / role / disclosureRef- Topic 280- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 40- Publisher FASB- URI https~~ : **monetaryItemType Balance Type** ~~/ / asc.fasb.org / 1943274 / 2147482810 / 280- 10- 50- 40Reference 13~~ . ~~http~~ **debit Period Type** : **durationX** ~~/ / www.xbrl.org / 2003 / role / disclosureRef~~ - **DefinitionAmount of purchase arrangement** ~~Topic 280- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 22-~~ 4- Subparagraph (a)- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147479806 / 606- 10- 50- 4 Details Name: us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax Namespace Prefix: us- gaap_ Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: durationX **- Details Name: srt_StatementGeographicalAxis = country_US Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: srt_StatementGeographicalAxis = ntrb_ForeignMember Namespace Prefix: Data Type: na Balance Type: Period Type: Summary of Significant Accounting Policies- Schedule of Property, Plant and Equipment Useful Lives (Details)- Minimum [ Member ] Jan. 31, 2025Lab Equipment [ Member ] Schedule of Property, Plant and Equipment Useful Lives [ Line Items ] Property plant and equipment, useful life 5 yearsLab Equipment [ Member ] Schedule of Property, Plant and Equipment Useful Lives [ Line Items ] Property plant and equipment, useful life 10 yearsFurniture and Fixtures [ Member ] Schedule of Property, Plant and Equipment Useful Lives [ Line Items ] Property plant and equipment, useful life 3 yearsFurniture and Fixtures [ Member ] Schedule of Property, Plant and Equipment Useful Lives [ Line Items ] Property plant and equipment, useful life 5 yearsMachinery and Equipment [ Member ] Schedule of Property, Plant and Equipment Useful Lives [ Line Items ] Property plant and equipment, useful life 5 yearsMachinery and Equipment [ Member ] Schedule of Property, Plant and Equipment Useful Lives [ Line Items ] Property plant and equipment, useful life 20 yearsX** - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. **ReferencesReference 1** ~~us- gaap / 2024"," localname"~~ : ~~" PropertyPlantAndEquipmentUsefulLife"," presentation":["~~http:/ / ~~nutriband~~ **www** . ~~com~~ **xbrl.org / 2003** / role / ~~ScheduleofPlantandEquipmentonaStraightLineBasisOvertheEstimatedUsefulLifeoftheAssetsTable" ],"lang"~~ **disclosureRef- Topic 842- SubTopic 20- Name Accounting Standards Codification- Section 50- Paragraph 7A- Subparagraph (a)- Publisher FASB- URI https** : ~~{" en~~ **/ / asc.fasb.org / 1943274 / 2147478964 / 842** - **20- 50- 7A Details Name:** us ~~" - gaap_PropertyPlantAndEquipmentLineItems Namespace Prefix~~ : ~~{" role"~~ **us- gaap_ Data Type** : **xbrli** ~~{" terseLabel"~~ : **stringItemType Balance Type** ~~" Property plant and equipment,useful life"," label"~~ - **na Period Type** ~~" Property,Plant and Equipment,Useful Life"," documentation"~~ : ~~" Useful~~ **durationX- DefinitionUseful** life of long lived,physical assets used in the normal conduct of business and not intended for resale,in' PnYnMnDTnHnMnS' format,for example,' P1Y5M13D' represents the reported fact of one year,five months,and thirteen days.Examples include,but not limited to,land,buildings,machinery and equipment,office equipment,furniture and fixtures,and computer equipment. ~~" } } },"~~ **auth_ref":** ReferencesNo definition available. Details Name: us- ~~gaap_SegmentReportingRevenueReconcilingItemLineItems~~ **gaap_PropertyPlantAndEquipmentUsefulLife** Namespace Prefix: us- gaap_ Data Type: xbrli: **the passage of time** ~~230- Publisher FASB- URI https:/ / asc.fasb.org~~ - **or when a triggering event occurs. ReferencesReference 1** ~~/ 1943274 / 2147482740 / 230- 10- 45- 28Reference 2~~ :http:/ / ~~www~~ **fasb** . ~~xbrl.~~ org / ~~2003~~ **us- gaap** / role / ~~exampleRef~~ **ref / legacyRef** - Topic ~~220~~ **942** - SubTopic ~~40~~ **210** -

Name Accounting Standards Codification- Section ~~55~~ **S99** - Paragraph ~~18~~ **1- Subparagraph (SX 210.9- 03 (10))** - Publisher FASB- URI https:/ / asc.fasb.org / 1943274 / ~~2147476153~~ **2147478546** / ~~220~~ **942** - ~~40~~ **210** - ~~55~~ **S99** - ~~18Reference~~ **1Reference** ~~3~~ **2** :http:/ / www.xbrl.org / ~~2003~~ **2009** / role / ~~exampleRef~~ **commonPracticeRef** - Topic ~~220~~ **944** - SubTopic ~~40~~ **210** - Name Accounting Standards Codification- Section ~~55~~ **S99** - Paragraph ~~11~~ **1- Subparagraph (SX 210.7- 03 (a) (10))** - Publisher FASB- URI https:/ / asc.fasb.org / 1943274 / ~~2147476153~~ **2147478777** / ~~220~~ **944** - ~~40~~ **210** - ~~55~~ **S99** - ~~11Reference~~ **1Reference** ~~4~~ **3** :http:/ / www.xbrl.org / 2003 / role / ~~exampleRef~~ **disclosureRef** - Topic ~~220~~ **946** - SubTopic ~~40~~ **210** - Name Accounting Standards Codification- Section ~~55~~ **S99** - Paragraph ~~24~~ **1- Subparagraph (SX 210.6- 04 (7) (a))** - Publisher FASB- URI https:/ / asc.fasb.org / 1943274 / ~~2147476153~~ **2147479170** / ~~220~~ **946** - ~~40~~ **210** - ~~55~~ **S99** - ~~24Reference~~ **1Reference** ~~5~~ **4** :http:/ / www.xbrl.org / 2003 / role / ~~exampleRef~~ **disclosureRef** - Topic ~~220~~ **210** - SubTopic ~~40~~ **10** - Name Accounting Standards Codification- Section ~~50~~ **S99** - Paragraph ~~12~~ **1- Subparagraph (SX 210.5- 02 (7))** - Publisher FASB- URI https:/ / asc.fasb.org / 1943274 / ~~2147476148~~ **2147480566** / ~~220~~ **210** - ~~40~~ **10** - ~~50~~ **S99** - ~~12Reference 6~~ **1 Details Name:us- gaap_PrepaidExpenseCurrentAndNoncurrent Namespace Prefix:us- gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instantX- DefinitionCash received for fees during the current period.This element excludes cash proceeds from license fees. ReferencesReference 1** :http:/ / fasb.org / us- gaap / role / ref / legacyRef **- Topic 230- SubTopic 10** - Name Accounting Standards Codification- ~~Topic 360- SubTopic 10-~~ Section ~~50~~ **45** - Paragraph ~~1~~ **25** - Subparagraph ( ~~a~~ **c** )- Publisher FASB- URI https:/ / asc.fasb.org / 1943274 / ~~2147482099~~ -- **2147482740** / ~~360~~ **230** - 10- ~~50~~ **45** - **25** ~~1Reference 7:http:/ / www.xbrl.org / 2003 / role / disclosureRef- Topic 220- SubTopic 40- Name Accounting Standards Codification- Section 50- Paragraph 6- Subparagraph (c)- Publisher FASB- URI https:/ / asc.fasb.org / 1943274 / 2147476148 / 220- 40- 50- 6~~ Details Name:us- ~~gaap_Depreciation~~ **gaap_ProceedsFromFeesReceived** Namespace Prefix:us- gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:durationX- **DefinitionAmount of purchase arrangement** ~~DefinitionLine items represent financial concepts included in a table.These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.~~ stringItemType Balance Type: na Period Type: durationX- Details Name: ~~srt_StatementGeographicalAxis~~ **us- gaap_IncomeStatementLocationAxis** = ~~country_US~~ **us- gaap_CostOfSalesMember** Namespace Prefix: Data Type: na Balance Type: Period Type: ~~X~~ **Property and Equipment** - **Schedule of Property and Equipment (** Details ~~Name~~ **)- USD ($) Jan. 31, 2025 Jan. 31, 2024Schedule of Property and Equipment [ Line Items ] Property and equipment, gross $ 1, 548, 660 $ 1, 456, 617Less** : ~~srt_StatementGeographicalAxis~~ **the passage of time or when a triggering event occurs. ReferencesReference 1:** http:/ / ~~www~~ **fasb** . ~~xbrl.~~ org / ~~2003~~ **us- gaap** / role / ~~disclosureRef~~ **ref / legacyRef** - Topic ~~210~~ **942** - SubTopic ~~10~~ **210** - Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210. ~~5~~ **9** - ~~02~~ **03** ( ~~14~~ **10** ))- Publisher FASB- URI https:/ / asc.fasb.org / 1943274 / ~~2147480566~~ -- **2147478546** / ~~210~~ **942** - ~~10~~ **210** - S99- 1Reference ~~3~~ **2** :http:/ / ~~fasb~~ **www** . **xbrl.** org / **2009** ~~us- gaap~~ / role / ~~ref / legacyRef~~ **commonPracticeRef- Topic 944- SubTopic 210** - Name Accounting Standards Codification- ~~Topic 360- SubTopic 10-~~ Section ~~50~~ **S99** - Paragraph 1- Subparagraph ( ~~e~~ **SX 210.7- 03 (a) (10)** )- Publisher FASB- URI https:/ / asc.fasb.org / 1943274 / ~~2147482099~~ **2147478777** / ~~360~~ **944** - ~~10~~ **210** - ~~50~~ **S99** - **1Reference 3** ~~1 Details Name:us- gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Namespace Prefix:us- gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instantX- DefinitionAmount before accumulated depreciation,depletion and amortization of physical assets used in the normal conduct of business and not intended for resale.Examples include,but are not limited to,land,buildings,machinery and equipment,office equipment,and furniture and fixtures. ReferencesReference 1~~ :http:/ / www.xbrl.org / 2003 / role / disclosureRef- Topic ~~944~~ **946** - SubTopic 210- Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210. **6- 04 (** 7 **)** ~~- 03~~ (a ~~)(8~~ ))- Publisher FASB- URI https:/ / asc.fasb.org / 1943274 / ~~2147478777~~ **2147479170** / ~~944~~ **946** - 210- S99- 1Reference ~~2~~ **4** :http:/ / www.xbrl.org / 2003 / role / disclosureRef- Topic 210- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210.5- 02 ( ~~13~~ **7** ))- Publisher FASB- URI https:/ / asc.fasb.org / 1943274 / 2147480566 / 210- 10- S99- ~~1Reference 3~~ **1 Details Name:us- gaap_PrepaidExpenseCurrentAndNoncurrent Namespace Prefix:us- gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instantX- DefinitionCash received for fees during the current period.This element excludes cash proceeds from license fees. ReferencesReference 1** :http:/ / fasb.org / us- gaap / role / ref / legacyRef- Topic ~~360~~ **230** - SubTopic 10- Name Accounting Standards Codification- Section ~~50~~ **45** - Paragraph ~~1~~ **25** - Subparagraph ( ~~b~~ **c** )- Publisher FASB- URI https:/ / asc.fasb.org / 1943274 / ~~2147482099~~ -- **2147482740** / ~~360~~ **230** - 10- ~~50~~ **45** - ~~1~~ **25** Details Name:us- ~~gaap_PropertyPlantAndEquipmentGross~~ **gaap_ProceedsFromFeesReceived** Namespace Prefix:us- gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type: ~~instantX~~ **durationX- DefinitionAmount of purchase arrangement** = **ntrb_OutsideTheUnitedStatesMember us- gaap_EquipmentMember** Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us- ~~gaap_StatementBusinessSegmentsAxis~~ **gaap_PropertyPlantAndEquipmentByTypeAxis** = us- ~~gaap_CorporateAndOtherMember~~ **gaap_MachineryAndEquipmentMember** Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us- ~~gaap_StatementBusinessSegmentsAxis~~ **gaap_PropertyPlantAndEquipmentByTypeAxis** = ~~ntrb_PoconoPharmaceuticalsMember~~ **us- gaap_FurnitureAndFixturesMember** Namespace Prefix: Data Type: na Balance Type: Period Type: ~~X-~~ **Notes Payable (** Details ~~Name: us- gaap_StatementBusinessSegmentsAxis = ntrb_FourPTherapeuticsMember Namespace Prefix: Data Type: na Balance Type: Period Type: Commitments and Contigencies (Details~~ ) ~~1~~ **- USD ($) 9** Months Ended 12 Months ~~EndedMar~~ **EndedApr** . ~~13~~ **03, 2022 Oct. 31, 2024 Jan. 31, 2025 Jan. 31, 2024 May 15, 2024 Jul. 19** , 2023 ~~$ / shares sharesJul. 31, 2022 USD ($) Feb. 01, 2022 USD ($)~~ Jul. ~~25~~ **17** , **2023Notes Payable** ~~2023 USD ($) Sep. 30, 2022 USD ($) Jan. 31, 2024 USD ($) $ / sharesJan. 01, 2022 USD ($) Commitments and Contigencies~~ [ Line Items ] **Line** ~~Forward stock split, description The Company entered into three- year employment agreements with Gareth Sheridan, our CEO, and Serguei Melnik, our President, effective February 1, 2022 Percentage~~ of **credit** ~~performance bonus 3. 50 % Agreed to annual salary $ 150, 000 Other commitments term, description the Company signed a feasibility agreement with Kindeva Drug Delivery, L. P. (" Kindeva ") to develop Nutriband' s lead product, AVERSA Fentanyl, based on its proprietary AVERSA abuse deterrent transdermal technology and Kindeva' s FDA- approved transdermal fentanyl patch (fentanyl transdermal system). Estimated cost~~ $ 2, ~~500,~~ 000 ~~Advance deposit~~ **, 000 Principal payments** $ ~~250~~ **16** , ~~000Incurred expenses~~ **117 Notes payable current 128, 144 $ 127, 183 Contract price $ 32, 274 Contract price financed $ 22, 795 Bearing interest rate** 2 **. 95 % Converted debt** , ~~369, 508 Prepaid expenses 138, 250 Estimated cost~~ $ **300** ~~8, 100~~ , 000 ~~Warehouse space 12~~ **Conversion agreement value $ 300** , 000 **Common stock shares** ~~Lease rental $ 3, 000 Lease can be extended for an additional 3 years Right of use assets $ 94, 134 Agreed~~ issued ~~$ 20, 000 Purchase warrants~~ (in Shares) ~~)~~ **11, 107, 210 8, 869, 870 Gain (loss) on extinguishment $ (368, 036) $ (554, 423) Interest expenses $ 21, 407 75, 815 Automobile [ Member ] Notes Payable [ Line Items ] Bearing interest payments per month $ 410 Note Payable- Related Party [ Member ] Notes Payable [ Line Items ] Bearing interest rate 7. 00 % Advances received $ 300, 000 Accrued interest $ 4, 922 Common stock** shares ~~50~~ **issued (in Shares) 76** , ~~000 Exercise of~~ **230 Warrants exercisable (in Shares) 152, 460 Warrants exercisable** price **per share** (in Dollars per share) ~~)~~ $ ~~/ shares~~ **6. 43 Due balance** $ **0 Interest expense** ~~1. 93 Received amount $ 106~~ , **debt 4** ~~528 Due amount 118~~ , **163 Interest expense 60** ~~675 legal fees $ 500~~ , **453 Secured Borrowing Liability** ~~000 Cash 1, 000, 000 Money Channel~~ [ Member ] **Notes Payable** ~~Commitments and Contigencies~~ [ Line Items ] ~~Bad~~ **Interest expense,** debt ~~expense~~ $ ~~118~~ **10** , ~~675 MDM Worldwide~~ **482 5, 470 Secured loan payable $ 106, 528 Loan interest rate 10. 00 % Notes Payable** [ Member ] **Notes Payable** ~~Commitments and Contigencies~~ [ Line Items ] ~~Amount paid 190~~ **Notes payable $ 69** , ~~000 Money Channel~~ **132 85, 249 Notes payable current 16, 953 Notes Payable** [ Member ] **Notes Payable** ~~Commitments and Contigencies~~ [ Line Items ] **Notes payable 10, 689** ~~Exercise of price (in Dollars per share)~~ ~~)~~ $ ~~/ shares~~ $ **15, 232 Notes payable current** 4 ~~Money Channel~~ **, 663 Line of Credit** [ Member ] **Notes Payable** ~~) Accounts Receivable [ Member ] Commitments and Contigencies~~ [ Line Items ] ~~Amount paid~~ **Line of credit** $ ~~100~~ **160** , 000 ~~Agreement [ Member ] Commitments~~ **$ 2, 000, 000Due date Oct. 16, 2028 Interest rate during period 5. 00 % Line of credit amount assumed $ 139, 184 Monthly payments of principal** and ~~Contigencies 50~~ **Period Type:durationX** - ~~3~~ **DefinitionAmount of the entity' s equity method investment which has been sold. ReferencesNo definition available.** Details Name:us- ~~gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights~~ **gaap_EquityMethodInvestmentSoldCarryingAmount** Namespace Prefix:us- gaap_ Data Type:xbrli: ~~sharesItemType~~ **monetaryItemType** Balance Type: ~~na~~ **debit** Period Type: ~~instantX~~ **durationX** - **DefinitionNumber** ~~DefinitionTotal number~~ of ~~common~~ **excess stock** shares of an entity that have been sold or granted to shareholders ~~(includes common shares that were issued,repurchased~~ **. ReferencesNo definition available. Details Name:us- gaap_ExcessStockSharesIssued Namespace Prefix:us- gaap_ Data Type:xbrli:sharesItemType Balance Type:na Period Type:instantX- DefinitionInterest received on loans** and ~~remain in~~ **other debt instruments during** the **current period** ~~treasury).These shares represent capital invested by the firm' s shareholders and owners,and may be all or only a portion of the number of shares authorized.Shares issued include shares outstanding and shares held in the treasury~~ . ReferencesReference 1:http:/ / ~~fasb~~ **www.xbrl** .org / **2009** ~~us- gaap~~ / role / **commonPracticeRef** ~~ref / legacyRef~~ - Topic ~~210~~ **230** - SubTopic 10- Name Accounting Standards Codification- Section ~~S99~~ **45** - Paragraph ~~1~~ **16** - Subparagraph ( **b** ~~SX 210.5- 02 (29)~~ )- Publisher FASB- URI https:/ / asc.fasb.org / 1943274 / ~~2147480566~~ **2147482740** / ~~210~~ **230** - 10- ~~S99~~ **45** - ~~1~~ **16** Details Name:us- ~~gaap_CommonStockSharesIssued~~ **gaap_ProceedsFromInterestReceived** Namespace Prefix:us- gaap_ Data Type:xbrli: ~~sharesItemType~~ **monetaryItemType** Balance Type: **debit** ~~na Period~~ [ Line Items ] ~~Maturity date Jan. 31~~ **Net operating loss $ 21** , **000** ~~2025 Jan. 31~~ , ~~2025 Mr. Goodman~~ **000Valuation allowance $ 2, 200, 000Maximum** [ Member ] **Income Taxes** ~~Commitments and Contigencies~~ [ Line Items ] **Reducing corporate rate 34.** ~~Agreed to annual salary $ 110, 000~~ - **00 % Minimum** ~~Chief Executive Officer~~ [ Member ] **Income Taxes** ~~Commitments and Contigencies~~ [ Line Items ] ~~Annual salary~~ **the passage of time** ~~,but is not limited to,dividend deduction,deduction for~~ - **or when a triggering event occurs** ~~dividend paid to employee stock ownership plan~~

(ESOP),Medicare prescription drug benefit subsidy deduction,and other deductions . ReferencesReference 1:http:// / www fasb . xbrl. org / 2009 us- gaap / role / commonPracticeRef ref / legacyRef - Topic 235 942 - SubTopic 10 210 - Name Accounting Standards Codification- Section S50 S99 - Paragraph 1 - Subparagraph (SX 210.9- 03 (10)) - Publisher FASB- URI https:// asc.fasb.org / 1943274 / 2147480738 2147478546 / 235 942 - 10 210 - S50 S99 - 1Reference 2:http:// / www.xbrl.org / 2009 / role / commonPracticeRef- Topic 740 944 - SubTopic 10 210 - Name Accounting Standards Codification- Section 50 S99 - Paragraph 12 1 - Subparagraph ( b) SX 210.7- 03 ( 3 a) (10) )- Publisher FASB- URI https:// asc.fasb.org / 1943274 / 2147482685 2147478777 / 740 944 - 10 210 - 50 S99 - 12Reference - 1Reference 3:http:// / www.xbrl.org / 2009 2003 / role / commonPracticeRef disclosureRef - Topic 740 946 - SubTopic 10 210 - Name Accounting Standards Codification- Section 50 S99 - Paragraph 12 1- Subparagraph (SX 210.6- 04 (7) (a)) - Publisher FASB- URI https:// asc.fasb.org / 1943274 / 2147482685 2147479170 / 740 946 - 10 210 - 50 S99 - 12Reference - 1Reference 4:http:// / www.xbrl.org / 2009 2003 / role / commonPracticeRef disclosureRef - Topic 235 210 - SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210. 4 5 - 08 02 ( 7 h) (2 ))- Publisher FASB- URI https:// asc.fasb.org / 1943274 / 2147480678 2147480566 / 235 210 - 10- S99- 1 Details Name:us-gaap_EffectiveIncomeTaxRateReconciliationDeductions gaap_PrepaidExpenseCurrentAndNoncurrent Namespace Prefix:us- gaap_ Data Type: xbrli dtr- types : percentItemType monetaryItemType Balance Type: na debit Period Type: durationX instantX - DefinitionCash received DefinitionLine items represent financial concepts included in a table.These concepts are used to disclose reportable information associated with domain members defined in one or for fees during many axes to the table current period.This element excludes cash proceeds from license fees . ReferencesReference 1:http:// / www fasb . xbrl. org / 2003 us-gaap / role / disclosureRef ref / legacyRef - Topic 740 230 - SubTopic 10- Name Accounting Standards Codification- Section 50 45 - Paragraph 15 25 - Subparagraph ( c c )- Publisher FASB- URI https:// asc.fasb.org / 1943274 / 2147482685 2147482740 / 740 230 - 10- 50 45 - 15 25 Details Name:us-gaap_IncomeTaxExaminationLineItems gaap_ProceedsFromFeesReceived Namespace Prefix:us- gaap_ Data Type:xbrli: stringItemType monetaryItemType Balance Type: na debit Period Type:durationX- DefinitionAmount of the purchase arrangement $ the passage of time deferred federal tax expense (benefit) attributable to income (loss) from continuing operations.Includes,but is not limited to,deferred national tax expense (benefit) for or when a triggering event occurs non- US (United States of America) jurisdiction . ReferencesReference 1:http:// / www fasb . xbrl. org / 2009 us- gaap / role / commonPracticeRef ref / legacyRef - Topic 235 942 - SubTopic 10 210 - Name Accounting Standards Codification- Section S50 S99 - Paragraph 1 - Subparagraph (SX 210.9- 03 (10)) - Publisher FASB- URI https:// asc.fasb.org / 1943274 / 2147480738 2147478546 / 235 942 - 10 210 - S50 S99 - 1Reference 2:http:// / www.xbrl.org / 2009 / role / commonPracticeRef- Topic 740 944 - SubTopic 10 210 - Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph ( SX 210 SAB Topic 6.I .7 - 03 (a) (10) )- Publisher FASB- URI https:// asc.fasb.org / 1943274 / 2147479360 2147478777 / 740 944 - 10 210 - S99- 1Reference 3:http:// / www.xbrl.org / 2009 2003 / role / commonPracticeRef disclosureRef - Topic 235 946 - SubTopic 10 210 - Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210. 4 6 - 08 04 ( h 7 ) ( a 1) (Note 1 ))- Publisher FASB- URI https:// asc.fasb.org / 1943274 / 2147480678 2147479170 / 235 946 - 10 210 - S99- 1Reference 4:http:// / www.xbrl.org / 2009 2003 / role / commonPracticeRef disclosureRef - Topic 740 210 - SubTopic 10- Name Accounting Standards Codification- Section 50 S99 - Paragraph 9 1 - Subparagraph ( b SX 210.5- 02 (7) )- Publisher FASB- URI https:// asc.fasb.org / 1943274 / 2147482685 2147480566 / 740- 10 210 - 50 10 - 9 S99- 1 Details Name:us- gaap_DeferredFederalIncomeTaxExpenseBenefit gaap_PrepaidExpenseCurrentAndNoncurrent Namespace Prefix:us- gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type: durationX instantX - ReferencesNo definition DefinitionCash received for fees during the current available. Details Name:us- gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract Namespace Prefix:us- gaap_ Data Type:xbrli:stringItemType Balance Type:na Period period .This element excludes cash proceeds Type:durationX- DefinitionAmount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations license fees . ReferencesReference 1:http:// / www fasb . xbrl. org / 2009 us-gaap / role / commonPracticeRef ref / legacyRef - Topic 235 230 - SubTopic 10- Name Accounting Standards Codification- Section S50 45 - Paragraph 1 25- Subparagraph (c) - Publisher FASB- URI https:// asc.fasb.org / 1943274 / 2147480738 2147482740 / 230- 10- 45- 235 - 25 Details Name:us - gaap_ProceedsFromFeesReceived Namespace Prefix:us- gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:durationX- DefinitionAmount of purchase arrangement 250 the passage of time URI https:// asc.fasb.org - or when a triggering event occurs. ReferencesReference 1 / 1943274 / 2147482685 / 740- 10- 50- 10Reference 13 :http:// / www fasb . xbrl. org / 2003 us- gaap / role / disclosureRef ref / legacyRef - Topic 280 942 - SubTopic 10 210 - Name Accounting Standards Codification- Section 50 S99 - Paragraph 22 1 - Subparagraph ( h SX 210.9- 03 (10) )- Publisher FASB- URI https:// asc.fasb.org / 1943274 / 2147482810 2147478546 / 280 942 - 10 210 - 50 S99 - 22Reference 1Reference 14 2 :http:// / www.xbrl.org / 2003 2009 / role / disclosureRef commonPracticeRef - Topic 944- SubTopic 220 210 - Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210.7- 04 03 ( 9 a) (10 ))- Publisher FASB- URI https:// asc.fasb.org / 1943274 / 2147477250 2147478777 / 944- 220 210 - S99- 1Reference 15 3 :http:// / www.xbrl.org / 2003 / role / disclosureRef - Topic 946- SubTopic 210 - Name Accounting Standards Codification- Section 45 S99 - Paragraph 2 1 - Subparagraph ( SX 210.6- 04 (7) ( a) ) - SubTopic 20- Topic 740 - Publisher FASB- URI https:// asc.fasb.org / 1943274 / 2147482659 2147479170 / 740 946 - 20 210 - 45 S99 - 2Reference 1Reference 16 4 :http:// / www.xbrl.org / 2003 / role / disclosureRef - Topic 210- SubTopic 10 - Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210. 4 5 - 08 02 ( h 7 )) - SubTopic 10- Topic 235 - Publisher FASB- URI https:// asc.fasb.org / 1943274 / 2147480678 2147480566 / 235 210 - 10- S99- 1 Details Name:us- gaap_IncomeTaxExpenseBenefit gaap_PrepaidExpenseCurrentAndNoncurrent Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type: durationX instantX - ReferencesNo definition DefinitionCash received for fees during available. Details Name:us- gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract Namespace Prefix:us- gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:durationX- DefinitionAmount of the current period.This element excludes cash proceeds difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from license fees continuing operations attributable to nondeductible impairment loss . ReferencesReference 1:http:// / www fasb . xbrl. org / 2003 us- gaap / role / exampleRef ref / legacyRef - Topic 740 230 - SubTopic 10- Name Accounting Standards Codification- Section 55 45 - Paragraph 231 25- Subparagraph (c) - Publisher FASB- URI https:// asc.fasb.org / 1943274 / 2147482663 2147482740 / 740 230 - 10- 45- 25 Details Name:us-gaap_ProceedsFromFeesReceived Namespace Prefix:us- gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:durationX-DefinitionAmount of purchase arrangement , 000 Chief Financial Officer attributable to nondeductible expense for award under share- based payment arrangement.Includes,but is not limited to,expense determined to be nondeductible upon grant or after for award under share- based payment arrangement. ReferencesReference 1 - Subparagraph (SX 210.9- 03 (10))- Publisher FASB- URI https:// asc.fasb.org / 1943274 / 2147478546 / 942- 210- S99- 1Reference 2 :http:// / www.xbrl.org / 2009 2003 / role / commonPracticeRef exampleRef - Topic 944 740 - SubTopic 210 - 10 - Name Accounting Standards Codification- Section S99 55 - Paragraph 231 1- Subparagraph (SX 210.7- 03 (a) (10)) - Publisher FASB- URI https:// asc.fasb.org / 1943274 / 2147478777 2147482663 / 944 740 - 210 - 10 - S99 55 - 1Reference 231Reference 3 2 :http:// / www.xbrl.org / 2003 2009 / role / disclosureRef commonPracticeRef - Topic 946 740 - SubTopic 210 - 10 - Name Accounting Standards Codification- Section S99 50 - Paragraph 12A- Subparagraph (b) ( 1 - Subparagraph (SX 210.6- 04 (7) (a) )- Publisher FASB- URI https:// asc.fasb.org / 1943274 / 2147479170 2147482685 / 946 740 - 210 - 10 - S99 50 - 1Reference 12AReference 4 3 :http:// / www.xbrl.org / 2003 2009 / role / disclosureRef commonPracticeRef - Topic 210 740 - SubTopic 10- Name Accounting Standards Codification- Section S99 50 - Paragraph 12 1- Subparagraph (SX 210.5- 02 (7)) - Publisher FASB- URI https:// asc.fasb.org / 1943274 / 2147480566 2147482685 / 740- 210- 10 - 10 50 - 12 S99- 1 Details Name:us- gaap_PrepaidExpenseCurrentAndNoncurrent gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost Namespace Prefix:us- gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type: instantX durationIncome Taxes - Schedule of Deferred Tax Liability and Deferred Tax Asset (Details)- USD ($) Jan.31,2025 Jan.31,2024Schedule of Deferred Tax Liability and Deferred Tax Asset [ Member Abstract ] Commitments 800 Net operating loss carryforward (expire through 2041) $ (4 , 000Tax effect 435,172) $ (3,312,698) Stock issued for services (1,779,728) (1,455,848) Intangible impairment expense (1,806,709) (1,051,714) valuation Valuation allowance 8 $ 1 , 151,916Minimum [ Member ] Income Taxes [ Line Items ] Percentage of corporate rate 34.00 % Maximum [ Member ] Income Taxes [ Line Items ] Percentage of corporate rate 21 021 .00 % ,609 5,820,260Net deferred taxes X- DefinitionStock issued for services under deferred tax assets. ReferencesNo definition available. Details Name: ntrb_IncomeTaxesDetailsLineItems ntrb_DeferredTaxAssetsStockIssuedForService Namespace Prefix:ntrb_ Data Type:xbrli: stringItemType monetaryItemType Balance Type: na debit Period Type: durationX instantX - DefinitionAmount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill operating loss carryforwards that are not subject to expiration dates . ReferencesReference 1:http:// / www.xbrl.org / 2009 / role / commonPracticeRef- Topic 740- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 6- Publisher FASB- URI https:// asc.fasb.org / 1943274 / 2147482685 / 740- 10- 50- 6 Details Name:us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instantX- DefinitionPercentage DefinitionAmount,after allocation of valuation allowances current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. ReferencesReference 1:http://

~~www.xbrl.org / 2003 / role / disclosureRef~~ and ~~Contigencies 50- Paragraph 2- Publisher FASB- URI https:/ / asc.fasb.org / 1943274 / 2147482685 / 740- 10- 50- 2 Details Name:us- gaap_DeferredTaxAssetsLiabilitiesNet Namespace Prefix:us- gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit~~ Period Type: ~~instantX~~ **durationX** - **DefinitionAmount of the entity' s equity method investment which has been sold.** ReferencesNo definition available. Details Name:us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract **gaap_EquityMethodInvestmentSoldCarryingAmount** Namespace Prefix:us- gaap_ Data Type:xbrli: ~~stringItemType~~ **monetaryItemType Balance Type:debit Period Type:durationX- DefinitionNumber of excess stock shares of an entity that have been sold or granted to shareholders. ReferencesNo definition available. Details Name:us- gaap_ExcessStockSharesIssued Namespace Prefix:us- gaap_ Data Type:xbrli:sharesItemType** Balance Type:na Period Type: ~~durationX~~ **instantX** - **DefinitionInterest received on loans and other debt instruments during the current period** ~~DefinitionAmount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards~~. ReferencesReference 1:http:/ / www.xbrl.org / 2009 / role / commonPracticeRef- Topic ~~740~~ **230** - SubTopic 10- Name Accounting Standards Codification- Section ~~50~~ **45** - Paragraph ~~6~~ **16- Subparagraph (b)** - Publisher FASB- URI https:/ / asc.fasb.org / 1943274 / ~~2147482685~~ **2147482740** / ~~740~~ **230** - 10- ~~50~~ **45** - ~~6~~ **16** Details Name:us- ~~gaap_DeferredTaxAssetsOperatingLossCarryforwards~~ **gaap_ProceedsFromInterestReceived** Namespace Prefix:us- gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit ~~Period Type:instantX- DefinitionAmount of deferred tax assets for which it~~ [ Line Items ] ~~Annual salary~~ **Amortization expenses** $ ~~210~~ **113** . ~~000~~ **150 $ 113, 150Intellectual Property [ Member ] Intangible Assets [ Line Items ] Impairment charges $ 298, 038** X-DefinitionThe ~~amount of agreed~~ **aggregate expense charged against earnings** to ~~annual salary~~ **allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets** . **credit Period Type:instantX** - ~~Section 45- Paragraph 28- Subparagraph~~ **DefinitionAmount,after effects of reinsurance,of expense** ( ~~b~~ **reversal of expense** ) **for claims incurred and costs incurred in the claim settlement process** ~~- SubTopic 10- Topic 230- Publisher FASB- URI https:/ / asc~~. **ReferencesReference 1** ~~fasb.org / 1943274 / 2147482740 / 230- 10- 45- 28Reference 2~~ :http:/ / www.xbrl.org / 2003 / role / exampleRef- Topic ~~220~~ **944** - SubTopic 40- Name Accounting Standards Codification- Section 55- Paragraph ~~18~~ **7** - Publisher FASB- URI https:/ / asc.fasb.org / 1943274 / ~~2147476153~~ **2147480046** / ~~220~~ **944** - 40- 55- ~~18Reference~~ **7Reference** ~~3~~ **2** :http:/ / www.xbrl.org / ~~2003~~ **2009** / role / ~~exampleRef~~ **commonPracticeRef** - Topic ~~220~~ **944** - SubTopic 40- Name Accounting Standards Codification- Section ~~55~~ **50** - Paragraph ~~11~~ **3- Subparagraph (b)** - Publisher FASB- URI https:/ / asc.fasb.org / 1943274 / ~~2147476153~~ **2147480081** / ~~220~~ **944** - 40- ~~55~~ **50** - ~~11Reference 4~~ **3 Details Name** : ~~http~~ **us- gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1 Namespace Prefix** : **us** ~~/ / www.xbrl.org / 2003 / role / exampleRef~~ - **gaap_ Data Type:xbrli:monetaryItemType Balance Type:** ~~ReferencesNo~~ --- **2Reference** ~~definition available~~ **8: http: / / www** . ~~-~~xbrl.org / 2003 / role / disclosureRef ~~-~~ ~~","~~-Topic ~~":"~~350 ~~-~~ ~~","~~-SubTopic ~~":"~~30 ~~-~~ ~~","~~-Name ~~":"~~Accounting Standards Codification ~~-~~ ~~","~~-Section ~~":"~~45 ~~-~~ ~~","~~-Paragraph **2-** ~~":"~~ **1","** Publisher ~~":"~~ FASB ~~-~~ ~~","~~-URI ~~":"~~https:/ / asc.fasb.org / 1943274 / 2147482686 / 350- 30- 45- **2Reference 9** ~~1" },"~~ **r321"** : ~~{" role":"~~ http:/ / www.xbrl.org / 2003 / role / disclosureRef ~~" ~~**- Topic 220- SubTopic 40- Name Accounting Standards Codification- Section 50- Paragraph 6- Subparagraph (d)- Publisher FASB- URI https:/ / asc.fasb.org / 1943274 / 2147476148 / 220- 40- 50- 6** Details Name: ~~ntrb_AgreedToAnnualSalary~~ **us- gaap_AmortizationOfIntangibleAssets** Namespace Prefix: ~~ntrb_~~ **us- gaap_** Data Type: xbrli: monetaryItemType Balance Type: **the passage** ~~debit Period Type:durationX- DefinitionAmount~~ of **time or when a triggering event occurs** ~~write- down of assets recognized in the income statement.Includes,but is not limited to,losses from tangible assets,intangible assets and goodwill~~ . ReferencesReference 1:http:/ / fasb.org / us- gaap / role / ref / legacyRef **- Topic 942- SubTopic 210** - Name Accounting Standards Codification- Section ~~45~~ **S99** - Paragraph ~~28~~ **1** - Subparagraph ( **SX** ~~b)- SubTopic 10~~ **210 .9** - ~~Topic 230~~ **03 (10))** - Publisher FASB- URI https:/ / asc.fasb.org / 1943274 / ~~2147482740~~ **2147478546** / ~~230~~ **942** - ~~10~~ **210** - ~~45~~ **S99** - ~~28Reference~~ **1Reference** 2:http:/ / www.xbrl.org / ~~2003~~ **2009** / role / ~~exampleRef~~ **commonPracticeRef** - Topic ~~942~~ **944** - SubTopic ~~10~~ **210** - Name Accounting Standards Codification- Section ~~S50~~ **S99** - Paragraph 1 **- Subparagraph (SX 210.7- 03 (a) (10))** - Publisher FASB- URI https:/ / asc.fasb.org / 1943274 / ~~2147480095~~ **2147478777** / ~~942~~ **944** - ~~10~~ **210** - ~~S50~~ **S99** - 1Reference 3:http:/ / www.xbrl.org / 2003 / role / ~~exampleRef~~ **disclosureRef** - Topic ~~942~~ **946** - SubTopic ~~10~~ **210** - Name Accounting Standards Codification- Section S99- Paragraph **1- Subparagraph (SX 210.** 6 **- 04 (7) (a))** - Publisher FASB- URI https:/ / asc.fasb.org / 1943274 / ~~2147480035~~ **2147479170** / ~~942~~ **946** - ~~10~~ **210** - S99- ~~6Reference~~ **1Reference** 4:http:/ / ~~fasb~~ **www** . **xbrl.** org / **2003** ~~us- gaap-~~ / role / ~~ref / legacyRef~~ **disclosureRef- Topic 210- SubTopic 10** - Name Accounting Standards Codification- ~~Topic 360- SubTopic 10-~~ Section ~~45~~ **S99** - Paragraph ~~4~~ **1- Subparagraph (SX 210.5- 02 (7))** - Publisher FASB- URI https:/ / asc.fasb.org / 1943274 / ~~2147482130~~ **2147480566** / ~~360- 10~~ **210** - ~~45~~ **10** - ~~4~~ **S99- 1** Details Name:us- ~~gaap_AssetImpairmentCharges~~ **gaap_PrepaidExpenseCurrentAndNoncurrent** Namespace Prefix:us- gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type: ~~durationX~~ **instantX** - **DefinitionCash received** ~~DefinitionLine items represent financial concepts included in a table.These concepts are used to disclose reportable information associated with domain members defined in one or~~ **for fees during** ~~many axes to~~ the ~~table~~ **current period.This element excludes cash proceeds from license fees** . ReferencesReference 1:http:/ / ~~www~~ **fasb** . ~~xbrl.~~ org / ~~2003~~ **us- gaap** / role / ~~exampleRef~~ **ref / legacyRef** - Topic ~~805~~ **230** - SubTopic ~~20~~ **10** - Name Accounting Standards Codification- Section ~~55~~ **45** - Paragraph ~~31~~ **25** - Subparagraph ( ~~b~~ **c** )- Publisher FASB- URI https:/ / asc.fasb.org / 1943274 / ~~2147479876~~ **2147482740** / ~~805- 20~~ **230** - ~~55~~ **10** - 31Reference 2 **45- 25 Details Name** : ~~http~~ **us-gaap_ProceedsFromFeesReceived Namespace Prefix** : ~~/ / www.~~ **us- gaap_ Data Type:** ~~xbrl~~ **xbrli** ~~.org / 2003 / role / exampleRef~~ **:monetaryItemType Balance Type:debit Period Type:durationX** - **DefinitionAmount of purchase arrangement** ~~Topic 805- SubTopic 20- Name Accounting Standards Codification- Section 55- Paragraph 20- Subparagraph (a)- Publisher FASB- URI https~~ credit Period Type: ~~durationX~~ **instantX** - **DefinitionAmount before amortization of assets,excluding financial assets and goodwill,lacking physical substance with a finite life. ReferencesReference 1:http:/ /** www.xbrl.org / 2003 / role / **exampleRef** ~~disclosureRef- Topic 946- SubTopic 210~~ - Name Accounting Standards Codification- Section ~~S99~~ **55** - Paragraph ~~1~~ **40** - **SubTopic 30** ~~Subparagraph (SX 210.6~~ **Topic 350** ~~04 (7) (a))~~ - Publisher FASB- URI https:/ / asc.fasb.org / 1943274 / ~~2147479170~~ **2147482640** / ~~946~~ **350** - ~~210~~ **30** - ~~S99~~ **55** - ~~1Reference~~ **40Reference** ~~4~~ **2** :http:/ / www.xbrl.org / 2003 / role / disclosureRef- Topic ~~210~~ **350** - SubTopic 10- Name Accounting Standards Codification- Section ~~S99~~ **S45** - Paragraph 1 ~~- Subparagraph (SX 210.5- 02 (7))~~ - Publisher FASB- URI https:/ / asc.fasb.org / 1943274 / ~~2147480566~~ -- **2147480265** / ~~210~~ **350** - 10- ~~S99~~ **S45-** ~~ReferencesNo~~ --- **1Reference** ~~definition available~~ **3: http: / / www** . **xbrl.org** / 2003 / role / disclosureRef- Topic ~~946~~ **350** - SubTopic ~~210~~ **30** - Name Accounting Standards Codification- Section ~~S99~~ **50** - Paragraph ~~1~~ **2** - Subparagraph ( **a** ~~SX 210.6- 04 (7~~ ) ( **1** ~~a)~~ )- Publisher FASB- URI https:/ / asc.fasb.org / 1943274 / ~~2147479170~~ **2147482665** / ~~946~~ **350** - ~~210~~ **30** - ~~S99~~ **50** - ~~1Reference~~ **2Reference** 4:http:/ / www.xbrl.org / 2003 / role / disclosureRef- Topic ~~210~~ **928** - SubTopic ~~10~~ **340** - Name Accounting Standards Codification- Section ~~S99~~ **50** - Paragraph 1 ~~- Subparagraph (SX 210.5- 02 (7))~~ - Publisher FASB- URI https:/ **/ asc.fasb.org / 1943274 / 2147478859 / 928- 340- 50- 1** Details Name: ~~ntrb_CommitmentsandContigenciesDetailsLineItems~~ **us- gaap_FiniteLivedIntangibleAssetsGross** Namespace Prefix: ~~ntrb_~~ **the passage of time or when** ~~us- gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instantX- DefinitionLine items represent financial concepts included in~~ a **triggering event occurs** ~~table.These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table~~ . ReferencesReference 1:http:/ / ~~www~~ **fasb** . ~~xbrl.~~ org / ~~2003~~ **us- gaap** / role / ~~exampleRef~~ **ref / legacyRef** - Topic ~~805~~ **942** - SubTopic ~~20~~ **210** - Name Accounting Standards Codification- Section ~~55~~ **S99** - Paragraph ~~31~~ **1** - Subparagraph ( ~~b~~ **SX 210.9- 03 (10)** )- Publisher FASB- URI https:/ / asc.fasb.org / 1943274 / ~~2147479876~~ - **2147478546** / ~~805~~ **942** - ~~20~~ **210** - ~~55~~ **S99** - ~~31Reference~~ - **1Reference** 2:http:/ / www.xbrl.org / ~~2003~~ **2009** / role / ~~exampleRef~~ **commonPracticeRef** - Topic ~~805~~ **944** - SubTopic ~~20~~ **210** - Name Accounting Standards Codification- Section ~~55~~ **S99** - Paragraph ~~20~~ **1** - Subparagraph ( **SX 210.7- 03 (** a **) (10)** )- Publisher FASB- URI https:/ / asc.fasb.org / 1943274 / ~~2147479876~~ - **2147478777** / ~~805~~ **944** - ~~20~~ **210** - ~~55~~ **S99** - ~~20Reference~~ **1Reference** 3:http:/ / www.xbrl.org / 2003 / role / ~~exampleRef~~ **disclosureRef** - Topic ~~805~~ **946** - SubTopic ~~20~~ **210** - Name Accounting Standards Codification- Section ~~55~~ **S99** - Paragraph ~~20~~ **1** - Subparagraph ( ~~c~~ **SX 210.6- 04 (7) (a)** )- Publisher FASB- URI https:/ / asc.fasb.org / 1943274 / ~~2147479876~~ **2147479170** / ~~805~~ **946** - ~~20~~ **210** - ~~55~~ **S99** - ~~20Reference~~ **1Reference** 4:http:/ / www.xbrl.org / 2003 / role / ~~exampleRef~~ **disclosureRef** - Topic ~~805~~ **210** - SubTopic ~~20~~ **10** - Name Accounting Standards Codification- Section ~~55~~ **S99** - Paragraph ~~38~~ **1** - Subparagraph ( ~~d~~ **SX 210.5- 02 (7)** )- Publisher FASB- URI https:/ / asc.fasb.org / 1943274 / ~~2147479876~~ **2147480566** / ~~805- 20~~ **210** - ~~55~~ **10** - ~~38Reference 5~~ **S99- 1 Details Name:us- gaap_PrepaidExpenseCurrentAndNoncurrent Namespace Prefix:us- gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instantX- DefinitionCash received for fees during the current period.This element excludes cash proceeds from license fees. ReferencesReference 1** :http:/ / ~~www~~ **fasb** . ~~xbrl.~~ org / ~~2003~~ **us- gaap** / role / ~~exampleRef~~ **ref / legacyRef** - Topic ~~805~~ **230** - SubTopic ~~20~~ **10** - Name Accounting Standards Codification- Section ~~55~~ **45** - Paragraph ~~31~~ **25** - Subparagraph ( ~~h~~ **c** )- Publisher FASB- URI https:/ / asc.fasb.org / 1943274 / ~~2147479876~~ **2147482740** / ~~805- 20~~ **230** - ~~55~~ **10** - ~~31Reference 6~~ **45- 25 Details Name** : ~~http~~ **us- gaap_ProceedsFromFeesReceived Namespace Prefix** : ~~/ / www.~~ **us- gaap_ Data Type:** ~~xbrl~~ **xbrli** ~~.org / 2003 / role / exampleRef- Topic 805- SubTopic 20- Name Accounting Standards Codification- Section 55- Paragraph 38- Subparagraph (e)- Publisher FASB- URI https~~ : **monetaryItemType Balance Type** ~~/ / asc.fasb.org / 1943274 / 2147479876 / 805- 20- 55- 38Reference 7~~ : ~~http~~ **debit Period Type** : **durationX** ~~/ / www.xbrl.org / 2003 / role / exampleRef~~ - **DefinitionAmount of purchase arrangement** Data Type: xbrli: stringItemType Balance Type: na Period Type: durationX- **DefinitionAmount after amortization** ~~DefinitionEstimated cost is the projection~~ of ~~the amount of costs that will be incurred to build~~ **assets, excluding financial assets and goodwill, lacking physical substance with** a **finite life** ~~product or construct something~~ . **ReferencesReference 1: http: / / www. xbrl. org / 2009 / role / commonPracticeRef- Topic 350- SubTopic 30- Name Accounting Standards Codification- Section 50- Paragraph 2- Subparagraph (a) (1)- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482665 / 350- 30- 50-**

~~ReferencesNo~~ --- **2Reference** ~~definition available~~ **2: http: / / www . xbrl. org / 2003 / role / disclosureRef- Topic 926- SubTopic 20- Name Accounting Standards Codification- Section 50- Paragraph 5- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147483154 / 926- 20- 50- 5** Details Name: ~~ntrb_EstimatedCost~~ **us- gaap_FiniteLivedIntangibleAssetsNet** Namespace Prefix: ~~ntrb_~~ **us- gaap_** Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: ~~durationX~~ **instantX** - ~~DefinitionPayments for repurchase of warrant. ReferencesNo definition available.~~ Details Name: ~~ntrb_PaymentsForRepurchaseOfWarrant~~ **us- gaap_FiniteLivedIntangibleAssetsByMajorClassAxis = ntrb_CustomerBaseMember** Namespace Prefix: ~~ntrb_~~ Data Type: **na** ~~xbrli: sharesItemType~~ Balance Type: ~~na~~ Period Type: ~~instantX~~ **X** - **Details Name:** ~~DefinitionAmount of describes the gain (or loss) in net income of a business over a given amount of time, thus allowing~~ us **- gaap_FiniteLivedIntangibleAssetsByMajorClassAxis = us- gaap_IntellectualPropertyMember** ~~to establish what the ROI (return rate) of a specific investment has been. ReferencesNo definition available. Details Name: ntrb_PercentageOfNetIncome~~ Namespace Prefix: ~~ntrb_~~ Data Type: **na** ~~dtr: percentItemType~~ Balance Type: ~~na~~ Period Type: ~~durationX~~ **Intangible Assets** - **Schedule of Amortization Expenses (** ~~DefinitionWarehouse space ReferencesNo definition available.~~ Details ~~Name: ntrb_WarehouseSpace Namespace Prefix: ntrb_ Data Type: xbrli: integerItemType Balance Type: na Period Type: durationX~~ **)- USD ($) Jan. 31, 2025 Jan. 31, 2024Schedule of Amortization Expenses [ Abstract ] $ 60, 666 60, 666 60, 666 41, 736 33, 218 2031 and thereafter 4, 142 Net Intangible Assets $ 261, 092 $ 667, 280X** - DefinitionAmount of **amortization for asset, excluding financial asset** increase in standardized measure of discounted future..... durationX- DefinitionAmount of currency on hand - **and** ~~as well as demand deposits~~ **goodwill, lacking physical substance** with **finite life expected** banks or financial institutions. Includes other..... DefinitionDate when the debt instrument is scheduled to be **recognized after fifth** fully repaid, in YYYY- MM..... operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). ReferencesReference 1: http: / / www. xbrl. org / ~~2003~~ **2009** / role / ~~disclosureRef~~ **commonPracticeRef** - Topic ~~842~~ **350** - SubTopic ~~20~~ **30** - Name Accounting Standards Codification- Section 50- Paragraph ~~6~~ **2- Subparagraph (a) (3)** - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147478964~~ **2147482665** / ~~842~~ **350** - **30- 50- 2Reference 2: http: / / www. xbrl. org / 2009 / role / commonPracticeRef- Topic 985- SubTopic** 20- **Name Accounting Standards Codification- Section** 50- ~~6~~ **Paragraph 2- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147481283 / 985- 20- 50- 2** Details Name: us- ~~gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths~~ **gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive** Namespace Prefix: us- gaap_ Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: instantX- DefinitionAmount.....: xbrli: monetaryItemType Balance Type: debit Period Type: ~~durationX~~ **instantX** - **DefinitionAmount** ~~DefinitionThe fair value~~ of ~~notes issued in noncash investing~~ **amortization for assets, excluding financial assets** and **goodwill** financing activities. ReferencesReference 1:....., average remaining lease term for operating lease , **lacking physical substance** in' PnYnMnDTnHnMnS' format, for..... which will be expensed in future periods with **finite life expected** the passage of time or when a.....: durationX- DefinitionAmount of purchase arrangement to be ~~paid~~ **recognized** in ~~third~~ **next** fiscal year following current fiscal year ~~. Includes, but is not limited to, recorded and unrecorded purchase obligations, long- term purchase commitment, and short- term purchase commitment~~ . Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). **the passage of time** ~~350- Publisher FASB- URI https: / / asc.fasb.org~~ **or when a triggering event occurs. ReferencesReference 1** ~~/ 1943274 / 2147482640 / 350- 30- 55- 40Reference 2~~ :http: / ~~www~~ **fasb** . ~~xbrl.~~ org / ~~2003~~ **us- gaap** / role / ~~disclosureRef~~ **ref / legacyRef** - Topic ~~350~~ **942** - SubTopic ~~30~~ **210** - Name Accounting Standards Codification- Section ~~50~~ **S99** - Paragraph ~~2~~ **1** - Subparagraph ( ~~a~~) **SX 210.9- 03** ( ~~3~~ **10)** )- Publisher FASB- URI https: / / asc.fasb.org / 1943274 / ~~2147482665~~ **2147478546** / ~~350~~ **942** - ~~30~~ **210** - ~~50~~ **S99** - ~~2Reference~~ **1Reference** ~~3~~ **2** :http: / / www.xbrl.org / ~~2003~~ **2009** / role / ~~disclosureRef~~ **commonPracticeRef** - Topic ~~985~~ **944** - SubTopic ~~20~~ **210** - Name Accounting Standards Codification- Section ~~50~~ **S99** - Paragraph ~~2~~ **1- Subparagraph (SX 210.7- 03 (a) (10))** - Publisher FASB- URI https: / / asc.fasb.org / 1943274 / ~~2147481283~~ **2147478777** / ~~985~~ **944** - ~~20~~ **210** - ~~50~~ **S99** - **1Reference 3** ~~2 Details Name:us- gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive Namespace Prefix:us- gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instantX- DefinitionAmount of amortization for assets,excluding financial assets and goodwill,lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year.Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). ReferencesReference 1~~ :http: / / www.xbrl.org / 2003 / role / ~~exampleRef~~ **disclosureRef- Topic 946- SubTopic 210** - Name Accounting Standards Codification- Section ~~55~~ **S99** - Paragraph ~~40~~ **1** - ~~SubTopic 30~~ **Subparagraph (SX 210.6** - ~~Topic 350~~ **04 (7) (a))** - Publisher FASB- URI https: / / asc.fasb.org / 1943274 / ~~2147482640~~ **2147479170** / ~~350~~ **946** - ~~30~~ **210** - ~~55~~ **S99** - ~~40Reference~~ **1Reference** ~~2~~ **4** :http: / / www.xbrl.org / 2003 / role / disclosureRef- Topic ~~350~~ **210** - SubTopic ~~30~~ **10** - Name Accounting Standards Codification- Section ~~50~~ **S99** - Paragraph ~~2~~ **1** - Subparagraph ( ~~a~~) **SX 210.5- 02** ( ~~3~~ **7)** )- Publisher FASB- URI https: / / asc.fasb.org / 1943274 / ~~2147482665~~ - **2147480566** / ~~350~~ **210** - ~~30~~ **10** - ~~50~~ **S99** - ~~2Reference 3~~ **1 Details Name:us- gaap_PrepaidExpenseCurrentAndNoncurrent Namespace Prefix:us- gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instantX- DefinitionCash received for fees during the current period.This element excludes cash proceeds from license fees. ReferencesReference 1** :http: / ~~www~~ **fasb** . ~~xbrl.~~ org / ~~2003~~ **us- gaap** / role / ~~disclosureRef~~ **ref / legacyRef** - Topic ~~985~~ **230** - SubTopic ~~20~~ **10** - Name Accounting Standards Codification- Section ~~50~~ **45** - Paragraph ~~2~~ **25- Subparagraph (c)** - Publisher FASB- URI https: / / asc.fasb.org / 1943274 / ~~2147481283~~ **2147482740** / ~~985- 20~~ **230** - ~~50~~ **10** - ~~2~~ **45- 25** Details Name:us- ~~gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour~~ **gaap_ProceedsFromFeesReceived** Namespace Prefix:us- gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type: ~~instantX~~ **durationX** - DefinitionAmount of **purchase arrangement** ~~amortization for assets,~~ ReferencesNo definition available. Details Name: us- ~~gaap_PurchaseObligationDueInThirdYear~~ **gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract** Namespace Prefix: us- gaap_ Data Type: xbrli: ~~ref~~ **stringItemType Balance Type:na Period Type:durationX- DefinitionAmount after amortization of assets,excluding financial assets and goodwill,lacking physical substance with a finite life. ReferencesReference 1:http:** / ~~legacyRef~~ **/ www.xbrl.org / 2009 / role / commonPracticeRef** - Topic ~~505~~ **350** - SubTopic ~~10~~ **30** - Name Accounting Standards Codification- Section ~~S99~~ **50** - Paragraph ~~4~~ **2** - Subparagraph ( **a) (1** ~~SAB Topic 4.C~~ )- Publisher FASB- URI https: / / asc.fasb.org / 1943274 / ~~2147480008~~ **2147482665** / ~~505~~ **350** - ~~10~~ **30** - ~~S99~~ **50** - **2Reference 2** ~~4 Details Name:us- gaap_StockholdersEquityReverseStockSplit Namespace Prefix:us- gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:durationX- DefinitionPer share increase in exercise price of warrant.Excludes change due to standard antidilution provision. ReferencesReference 1~~ :http: / / www.xbrl.org / 2003 / role / disclosureRef- Topic ~~505~~ **926** - SubTopic ~~10~~ **20** - Name Accounting Standards Codification- Section 50- Paragraph ~~3~~ **5** - Publisher FASB- URI https: / / asc.fasb.org / 1943274 / ~~2147481112~~ **2147483154** / ~~505~~ **926** - ~~10~~ **20** - 50- ~~3~~ **5** Details Name:us- ~~gaap_WarrantExerciseIncrease~~ **gaap_FiniteLivedIntangibleAssetsNet** Namespace Prefix:us- gaap_ Data Type: **xbrli:** monetaryItemType Balance Type: ~~credit Period Type: instantX- DefinitionAmount of expense for salary and wage arising from service rendered by nonofficer and officer employees. Excludes allocated cost, labor- related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold. ReferencesNo definition available. Details Name: us- gaap_SalariesWagesAndOfficersCompensation Namespace Prefix: us- gaap_ Data Type: xbrli: monetaryItemType Balance Type:~~ debit Period Type: ~~durationX~~ **instantRelated Party Transactions (Details)** - **USD ($)** ~~DefinitionDescription of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements. ReferencesReference~~ 1 : http: / / fasb..... ]- USD ($) 3 Months ~~EndedApr~~ --- **Ended 9 Months Ended 12 Months EndedJun** . ~~19~~ **05** , 2024 **May 15** ~~Mar. 20~~ , 2024 Apr. **19, 2024 Dec. 31, 2023 Oct. 31, 2023 Sep.** 30, ~~2024Subsequent Events~~ **2023 Feb. 01, 2023 Dec. 31, 2023 Oct. 31, 2023 Jan. 31, 2025 Jan. 31, 2024 Sep. 10, 2024 Jul. 17, 2023Related Party Transactions** [ Line Items ] **Vesting period** ~~Received proceeds (in Dollars) $ 300, 000Purchase shares 390, 000 Expire years 5 years~~ 3 years **Fair value** ~~Shares issued 450, 000 Date~~ of ~~adoption~~ -- **option $** 1 ~~year~~ **, 408, 935** Equity financing ~~(in Dollars)~~ $ 8, ~~400~~ **406, 591 Investment receivable $ 6, 420** , 000 Number of **common stock 1, 605, 000 Conversion of** shares **issued 76, 230 Credit facility amount 2, 000, 000 Accrued interest $ 4, 922 $ 1, 026, 720 Fair value of options issued value 424, 826** Warrant [ Member ] ~~Subsequent Events~~ **Related Party Transactions** [ Line Items ] ~~Prices per~~ **Vesting period 3 years Warrants to purchase 152, 460 4, 200, 000 50, 000 Conversion of** ~~share~~ **shares** ~~(in Dollars per~~ **issued 152, 460 Chief Executive Officer [ Member ] Related Party Transactions [ Line Items ]** ~~share~~ **Share** ~~)~~ **price** $ ~~4 Number~~ **2. 37 Employee [ Member ] Related Party Transactions [ Line Items ] Share price $ 8. 08 Chief Financial Officer [ Member ] Related Party Transactions [ Line Items ] Share price $ 1. 93 $ 1. 93 Chief Financial Officer [ Member ] | Warrant [ Member ] Related Party Transactions [ Line Items ] Warrants to purchase 87, 500 87, 500 87, 500 Fair value** of **options issued value 93, 450 Executive Officer [ Member ] Related Party Transactions [ Line Items ] Purchase** shares ~~Exercise~~ **374, 500 Vesting period 3 years Director [ Member ] Related Party Transactions [ Line Items ] Purchase shares 374, 500 Share** price ~~per~~ **$ 2. 65 $ 2. 65 $ 2. 65 Vesting period 3 years Line of Credit [ Member ] Related Party Transactions [ Line Items ] Credit facility amount $ 160, 000 $ 2, 000, 000Line of Credit [ Member ] | TII Jet Services LDA [ Member ] Related Party Transactions [ Line Items ] Credit facility amount $ 5, 000, 000TII Jet Services LDA [ Member ] Related Party Transactions [ Line Items ] Credit facility amount $ 2, 000, 000 $ 2, 000, 000 Accrued interest $ 53, 436 Equity Option [ Member ] Related Party Transactions [ Line Items ] Purchase** shares **30, 000** ~~(in Dollars per share~~ **Share** ~~)~~ **price** $ ~~6~~ **3** , ~~43 Expire date Apr. 19~~ **975 Vesting period 3 years Fair value of option $ 75** , ~~2029~~ **030 TII Jet Services LDA [ Member ] Related Party Transactions [ Line Items ] Fair value of option $ 300, 000 Minimum [ Member ] | Executive Officer [ Member ] Related Party Transactions [ Line Items ] Share price $ 1. 93 1. 93 1. 93 Maximum [ Member ] | Executive Officer [ Member ] Related Party Transactions [ Line Items ]**

**Share price $ 2. 12 $ 2. 12 $ 2. 12** Common Stock [ Member ] ~~Subsequent Events~~ **Related Party Transactions** [ Line Items ] **Purchase shares 689, 584** ~~Shares~~ **Share price $ 6. 43 Equity financing $ 8, 400, 000 Warrants to purchase 3, 210, 000 Conversion of shares** issued ~~1~~ **60** , **085** ~~400, 000~~ Common Stock [ Member ] | ~~Minimum~~ **Chief Financial Officer** [ Member ] ~~Subsequent Events~~ **Related Party Transactions** [ Line Items ] ~~Prices per~~ **Conversion of** ~~share~~ **shares issued 87, 500** ~~(in Dollars per share) $ 2. 37~~ Common Stock [ Member ] | ~~Maximum~~ **TII Jet Services LDA** [ Member ] ~~Subsequent Events~~ **Related Party Transactions** [ Line Items ] ~~Prices per~~ **Conversion of** ~~share~~ **shares issued 1, 036, 520 TII Jet Services LDA** ~~(in Dollars per share) $ 2. 61 Board of Directors~~ [ Member ] **Related Party Transactions** ~~| Common Stock [ Member ] Subsequent Events~~ [ Line Items ] ~~Shares issued 875~~ **Owned percentage 100. 00 % X- DefinitionNumber of securities into which the class of warrant or right may be converted. For example, but not limited to, 500** , 000 ~~Offering [ Member ] Subsequent Events [ Line Items ]~~ **warrants may be converted into 1, 000, 000** ~~Shares~~ **shares** ~~units~~ **. ReferencesReference 1** :http: / ~~fasb~~ **www** . **xbrl.** org / **2003** ~~us- gaap~~ / role / **disclosureRef** ~~ref / legacyRef~~ - Topic 505- SubTopic 10- Name Accounting Standards Codification- Section ~~S99~~ **50** - Paragraph **3** ~~4- Subparagraph (SAB Topic 4.C)~~ - Publisher FASB- URI https: / / asc.fasb.org / 1943274 / ~~2147480008~~ **2147481112** / 505- 10- ~~S99~~ **50** - ~~4~~ **3** Details Name:us- ~~gaap_StockholdersEquityReverseStockSplit~~ **gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights** Namespace Prefix:us- gaap_ Data Type:xbrli: ~~stringItemType~~ **sharesItemType** Balance Type:na Period Type: ~~durationX~~ **instantX** - ~~DefinitionPer~~ - **DefinitionThe number** ~~share increase in exercise price~~ of ~~warrant~~ **shares converted in a noncash (or part noncash) transaction** . ~~Excludes change due~~ **Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period." Part noncash" refers** to ~~standard antidilution provision~~ **that portion of the transaction not resulting in cash receipts or cash payments in the period** . ReferencesReference 1:http: / ~~www~~ **fasb** . ~~xbrl.~~ org / ~~2003~~ **us- gaap** / role / **ref / legacyRef** ~~disclosureRef- Topic 505- SubTopic 10~~ - Name Accounting Standards Codification- **Topic 230- SubTopic 10-** Section 50- Paragraph ~~3~~ **4** - Publisher FASB- URI https: / / asc.fasb.org / 1943274 / ~~2147481112~~ **2147482913** / **230- 10-** ~~505~~ - **50** - **4Reference** ~~10- 50- 3 Details Name:us- gaap_WarrantExercisePriceIncrease Namespace Prefix:us- gaap_ Data Type:dtr- types:perShareItemType Balance Type:na Period Type:durationX- Details Name:us- gaap_DebtInstrumentAxis = ntrb_MoneyChannelMember~~ 2 ~~,~~ **; http: / / fasb. org / us- gaap / role / ref / legacyRef- Name Accounting Standards Codification- Topic 230- SubTopic** ~~100~~ - **10** ~~, 000 X~~ - **Section 50- Paragraph 3- Publisher FASB- URI https:** / / asc.fasb.org / 1943274 / 2147482913 / 230- 10- 50- **3Reference 3** ~~2" },"r18"~~: ~~{"role":"~~http: / fasb.org / us- gaap / role / ref / legacyRef ~~-","~~Name ~~":"~~Accounting Standards Codification ~~-","~~Topic ~~":"~~230 ~~-","~~ SubTopic ~~":"~~10 ~~-","~~Section ~~":"~~50 ~~-","~~Paragraph **5-** ~~":"3","~~Publisher ~~":"~~FASB ~~-","~~URI ~~":"~~https: / / asc.fasb.org / 1943274 / 2147482913 / 230 **- 10- 50- 5 Details Name:us- gaap_ConversionOfStockSharesConverted1 Namespace Prefix:us- gaap_ Data Type:xbrli:sharesItemType Balance Type:na Period Type:durationX-** ~~DefinitionDate~~ **DefinitionThe carrying value as** of ~~adoption entered into~~ the **passage** ~~financing agreement is expected to be financially capable~~ of ~~honoring the agreement~~ **time or when a triggering event occurs** . ReferencesReference 1:http: / / fasb.org / us- gaap / role / ref / legacyRef **- Topic 942- SubTopic 210** - Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210. ~~5~~ **9** - ~~02~~ **03** ( ~~22)- SubTopic 10- Topic 210-~~ **10))** - Publisher FASB- URI https: / / asc.fasb.org / 1943274 / ~~2147480566~~ - **2147478546** / ~~210~~ **942** - ~~10~~ **210** - S99- 1Reference 2:http: / ~~fasb~~ **www** . **xbrl.** org / **2009** ~~us- gaap~~ / role / **commonPracticeRef** ~~ref / legacyRef~~ - Topic ~~942~~ **944** - SubTopic 210- Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210. ~~9~~ **7** - 03 ( ~~16~~ **a) (10** ))- Publisher FASB- URI https: / / asc.fasb.org / 1943274 / ~~2147478546~~ **2147478777** / ~~942~~ **944** - 210- S99- 1Reference 3:http: / / www.xbrl.org / ~~2009~~ **2003** / role / ~~commonPracticeRef~~ **disclosureRef** - Topic ~~944~~ **946** - SubTopic 210- Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210. **6- 04 (** 7 **)** ~~- 03~~ (a ~~) (16) (a) (2~~ ))- Publisher FASB- URI https: / / asc.fasb.org / 1943274 / ~~2147478777~~ **2147479170** / ~~944~~ **946** - 210- S99- **1Reference 4** ~~1 Details Name:us- gaap_LineOfCredit Namespace Prefix:us- gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instantX- DefinitionIncrease for accrued,but unpaid interest on the credit facility for the period. ReferencesReference 1~~ :http: / / www.xbrl.org / ~~2009~~ **2003** / role / ~~commonPracticeRef~~ **disclosureRef** - Topic ~~235~~ **210** - SubTopic 10- Name Accounting Standards Codification- Section ~~S50~~ **S99** - Paragraph 1 **- Subparagraph (SX 210.5- 02 (7))** - Publisher FASB- URI https: / / asc.fasb.org / 1943274 / ~~2147480738~~ **2147480566** / ~~235- 10~~ **210** - ~~S50~~ **10** - ~~1Reference 2~~ **S99- 1 Details Name:us- gaap_PrepaidExpenseCurrentAndNoncurrent Namespace Prefix:us- gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instantX- DefinitionCash received for fees during the current period.This element excludes cash proceeds from license fees. ReferencesReference 1** :http: / ~~www~~ **fasb** . ~~xbrl.~~ org / ~~2009~~ **us- gaap** / role / ~~commonPracticeRef~~ **ref / legacyRef** - Topic ~~235~~ **230** - SubTopic 10- Name Accounting Standards Codification- Section ~~S99~~ **45** - Paragraph ~~1~~ **25** - Subparagraph ( **c** ~~SX 210.4- 08 (f)~~ )- Publisher FASB- URI https: / / asc.fasb.org / 1943274 / ~~2147480678~~ **2147482740** / **230- 10- 45-** ~~235~~ - **25** ~~- 10- S99- 1~~ Details Name:us- ~~gaap_LineOfCreditFacilityIncreaseAccruedInterest~~ **gaap_ProceedsFromFeesReceived** Namespace Prefix:us- gaap_ Data Type:xbrli:monetaryItemType Balance Type: ~~credit~~ **debit** Period Type:durationX- **DefinitionAmount** ~~DefinitionThe total amount~~ of **purchase arrangement** . ReferencesNo definition available. Details Name: ~~ntrb_DateDoAdoption~~ **us- gaap_MinorityInterestOwnershipPercentageByParent** Namespace Prefix: ~~ntrb_~~**us- gaap_** Data Type: ~~xbrli~~ **dtr- types** : ~~durationItemType~~ **percentItemType** Balance Type: na Period Type: **instantX** ~~Publisher FASB- URI https: / / asc~~ **DefinitionThe cash inflow from the issuance of common stock,preferred stock,treasury stock,stock options,and other types of equity** . **ReferencesReference 1** ~~fasb.org / 1943274 / 2147478546 / 942- 210- S99- 1Reference 2~~ :http: / / **fasb** ~~www.xbrl~~ .org / ~~2009~~ **us- gaap** / role / **ref / legacyRef** ~~commonPracticeRef- Topic 944- SubTopic 210~~ - Name Accounting Standards Codification- Section ~~S99~~ **45** - Paragraph ~~1~~ **14** - Subparagraph ( ~~SX 210.7- 03 (~~a) ~~(- SubTopic~~ 10 ~~)) - Topic 230~~ - Publisher FASB- URI https: / / asc.fasb.org / 1943274 / ~~2147478777~~ **2147482740** / ~~944~~ **230** - ~~210~~ - **10** - ~~S99~~ **45** - ~~1Reference~~ **14Reference** ~~3~~ **2** :http: / / www.xbrl.org / 2003 / role / disclosureRef- Topic 946- SubTopic ~~210~~ - **10** - Name Accounting Standards Codification- Section S99- Paragraph ~~1~~ **3** - Subparagraph (SX 210.6- ~~04~~ **03** ( ~~7~~ **i** ) ( ~~a~~ **1** ))- Publisher FASB- URI https: / / asc.fasb.org / 1943274 / ~~2147479170~~ **2147479886** / 946- ~~210~~ - **10** - S99- ~~1Reference 4~~ **3 Details Name** : ~~http~~ **us- gaap_ProceedsFromIssuanceOrSaleOfEquity Namespace Prefix** : **us** ~~/ / www.xbrl.org / 2003 / role / disclosureRef - Topic 210- gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:~~ durationX- ~~1Reference 5~~ **the passage of time or when a triggering event occurs. ReferencesReference 1** :http: / ~~www~~ **fasb** . ~~xbrl.~~ org / ~~2003~~ **us- gaap** / role / ~~disclosureRef~~ **ref / legacyRef** - Topic ~~235~~ **942** - SubTopic ~~10~~ **210** - Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210. ~~4~~ **9** - ~~08~~ **03** ( **10** ~~k~~ **) (2** ~~-~~ ))- Publisher FASB- URI https: / / asc.fasb.org / 1943274 / ~~2147480678~~ **2147478546** / ~~235~~ **942** - ~~10~~ **210** - S99- 1Reference ~~6~~ **2** :http: / / www.xbrl.org / ~~2003~~ **2009** / role / ~~disclosureRef~~ **commonPracticeRef** - Topic ~~235~~ **944** - SubTopic ~~10~~ **210** - Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210. ~~4~~ **7** - ~~08~~ **03** ( ~~k~~ **a** ) ( ~~1~~ **10** ))- Publisher FASB- URI https: / / asc.fasb.org / 1943274 / ~~2147480678~~ **2147478777** / ~~235~~ **944** - ~~10~~ **210** - S99- 1Reference ~~7~~ **3** :http: / / www.xbrl.org / 2003 / role / disclosureRef- Topic ~~310~~ **946** - SubTopic ~~10~~ **210** - Name Accounting Standards Codification- Section ~~45~~ **S99** - Paragraph ~~13~~ **1- Subparagraph (SX 210.6- 04 (7) (a))** - Publisher FASB- URI https: / / asc.fasb.org / 1943274 / ~~2147481990~~ **2147479170** / ~~310~~ **946** - ~~10~~ **210** - ~~45~~ **S99** - ~~13Reference~~ - **1Reference** ~~8~~ **4** :http: / / www.xbrl.org / 2003 / role / disclosureRef- Topic ~~946~~ **210** - SubTopic ~~220~~ **10** - Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210. ~~6~~ **5** - ~~07~~ **02** ( ~~7~~ **2) (c) (2) (i** ~~-~~ ))- Publisher FASB- URI https: / / asc.fasb.org / 1943274 / ~~2147479134~~ **2147480566** / ~~946~~ **210** - ~~220~~ **10** - S99- ~~1Reference 9~~ **1 Details Name:us- gaap_PrepaidExpenseCurrentAndNoncurrent Namespace Prefix:us- gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instantX- DefinitionCash received for fees during the current period.This element excludes cash proceeds from license fees. ReferencesReference 1** :http: / ~~www~~ **fasb** . ~~xbrl.~~ org / ~~2003~~ **us- gaap** / role / ~~disclosureRef~~ **ref / legacyRef** - Topic ~~946~~ **230** - SubTopic ~~220~~ **10** - Name Accounting Standards Codification- Section ~~S99~~ **45** - Paragraph ~~1~~ **25** - Subparagraph ( ~~SX 210.6- 07 (2) (~~c ~~) (2) (ii)~~ )- Publisher FASB- URI https: / / asc.fasb.org / 1943274 / ~~2147479134~~ **2147482740** / ~~946~~ **230** - ~~220- S99- 1Reference 10:http: / / www.xbrl.org / 2003 / role / disclosureRef- Topic 946- SubTopic 220- Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210.~~ **10** .6- **45** ~~07 (2) (g) (3))~~ - **25** ~~Publisher FASB- URI https: / / asc.fasb.org / 1943274 / 2147479134 / 946- 220- S99- 1~~ Details Name: **us- gaap_ProceedsFromFeesReceived Namespace Prefix:us- gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:durationX- DefinitionAmount of purchase arrangement** ~~DefinitionDate~~ **DefinitionThe number** of ~~issuance~~ **shares issued or sold by the subsidiary or equity method investee per stock transaction** . ReferencesNo definition available. Details Name: ~~ntrb_DateOfIssuance~~ **us- gaap_SaleOfStockNumberOfSharesIssuedInTransaction** Namespace Prefix: **us** ~~ntrb_ Data Type: xbrli: durationItemType Balance Type: na Period Type: durationX- gaap_ DefinitionShares of number of shares issued. ReferencesNo definition available. Details Name: ntrb_NumberOfShares Namespace Prefix: ntrb_~~Data Type: xbrli: sharesItemType Balance Type: na Period Type: durationX- DefinitionAmount of..... xbrli: monetaryItemType Balance Type: debit Period Type: durationX- DefinitionPer share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction. ReferencesNo definition available. Details Name: us- gaap_SaleOfStockPricePerShare Namespace Prefix: us- gaap_ Data Type: dtr- types: perShareItemType Balance Type: na Period Type: instantX- ~~DefinitionNumber~~ **DefinitionPeriod** ~~of~~ **over which grantee' s right to exercise award under** ~~shares~~ - **share- based payment arrangement is no longer contingent on satisfaction** of **service or performance condition** ~~stock issued as of the balance sheet date~~ , ~~including shares that had been issued~~ **in' PnYnMnDTnHnMnS' format, for example,' P1Y5M13D' represents reported fact of one year, five months,** and ~~were previously outstanding~~ **thirteen days. Includes,** but ~~which are now held in the treasury~~ **is not limited to, combination of market, performance or service condition** . ReferencesReference 1: http: / / ~~fasb~~ **www** . **xbrl.** org / **2003** ~~us- gaap~~ / role / ~~ref / legacyRef~~ **exampleRef- Topic 718- SubTopic 10** - Name Accounting Standards Codification- Section 50- Paragraph 2- ~~SubTopic 10- Topic 505~~ **Subparagraph (a) (1)** - Publisher FASB- URI https: /

/ asc. fasb. org / 1943274 / ~~2147481112~~ **2147480429** / ~~505~~ **718** - 10- 50- 2 Details Name: us- ~~gaap_SharesIssued~~ **gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1** Namespace Prefix: us- gaap_ Data Type: xbrli: **durationItemType** ~~4.C)- Publisher FASB- URI https:/ / asc.fasb.org / 1943274 / 2147480008 / 505- 10- S99- 4 Details Name:us- gaap_StockholdersEquityReverseStockSplit Namespace Prefix:us- gaap_ Data Type:xbrli:stringItemType~~ Balance Type:na Period Type:durationX- ~~DefinitionPer~~ **DefinitionFair value** ~~share increase in exercise price~~ of ~~warrant~~ **options vested** .Excludes ~~change due~~ **equity instruments other than options,for example,but not limited** to ~~standard antidilution provision~~ **,share units,stock appreciation rights,restricted stock** . ReferencesReference 1:http:/ / www.xbrl.org / 2003 / role / disclosureRef- Topic ~~505~~ **718** - SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph ~~3~~ **2- Subparagraph (d) (2)** - Publisher FASB- URI https:/ / asc.fasb.org / 1943274 / ~~2147481112~~ **2147480429** / ~~505~~ **718** - 10- 50- ~~3~~ **2** Details Name:us- ~~gaap_WarrantExercisePriceIncrease~~ **gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1** Namespace Prefix:us- gaap_ Data Type: **xbrli** ~~dtr- types~~ : ~~perShareItemType~~ **monetaryItemType** Balance Type: ~~na~~ **credit** Period Type:durationX- **DefinitionNumber of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination. ReferencesNo definition available.** Details Name:us- **gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets** ~~gaap_DebtInstrumentAxis = ntrb_MoneyChannelMember~~ Namespace Prefix: **us- gaap_** Data Type: **xbrli** ~~na Balance Type~~ : ~~Period Type:~~ sharesItemType Balance Type: na Period Type: **durationX- Details Name: us- gaap_ClassOfWarrantOrRightAxis = us-gaap_WarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: srt_TitleOfIndividualAxis = srt_ChiefExecutiveOfficerMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: srt_TitleOfIndividualAxis = ntrb_EmployeeMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: srt_TitleOfIndividualAxis = srt_ChiefFinancialOfficerMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: srt_TitleOfIndividualAxis = srt_ExecutiveOfficerMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: srt_TitleOfIndividualAxis = srt_DirectorMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us- gaap_CreditFacilityAxis = us-gaap_LineOfCreditMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis = ntrb_TIIJetServicesLDAMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us- gaap_CreditFacilityAxis = ntrb_TIIJetServicesLDAMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us- gaap_AwardTypeAxis = us- gaap_StockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us- gaap_RelatedPartyTransactionAxis = ntrb_TIIJetServicesLDAMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: srt_RangeAxis = srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: srt_RangeAxis = srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us-gaap_StatementClassOfStockAxis = us- gaap_CommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: srt_OwnershipAxis = ntrb_TIIJetServicesLDAMember Namespace Prefix: Data Type: na Balance Type: Period Type: Stockholders' Equity (Details)- USD ($) 1 Months Ended 12 Months EndedJun. 05, 2024 May 15, 2024 Apr. 19, 2024 Jun. 25, 2019 Dec. 31, 2023 Jan. 31, 2025 Jan. 31, 2024 Sep. 10, 2024 Oct. 31, 2023 Aug. 04, 2022 Jan. 27, 2020 Jun. 20, 2019 May 24, 2019 Jan. 15, 2016Stockholders' Equity [ Line Items ] Preferred stock, shares authorized 10, 000, 000 10, 000, 000 10, 000, 000Preferred stock, par value (in Dollars per share) $ 0. 001 $ 0. 001 $ 0. 001Reverse stock spilit the Company effected a one- for- four reverse stock split, pursuant to which each outstanding share of common stock was changed into 0. 25 shares of common stock Common shares authorized 291, 666, 666 291, 666, 666 Treasury stock 32, 400 10, 000 10, 000 Transaction expenses (in Dollars) $ 38, 700 Treasury stock value (in Dollars) 148, 547 Proceeds from equity financing (in Dollars) 8, 406, 591 Convertible debt amount (in Dollars) $ 300, 000 Accrued interest of line of credit (in Dollars) $ 4, 922 $ 1, 026, 720 Loss on extinguishment (in Dollars) $ (368, 036) $ (554, 423) Issued of common stock 11, 107, 210 8, 869, 870 Shares issued 10, 000 Treasury stock value (in Dollars) $ 148, 547 $ 32, 641 Converted amount (in Dollars) 2, 000, 000 Outstanding credit facility (in Dollars) $ 53, 436 Issuance of common stock (in Dollars) 2, 554, 423 TII Jet Services LDA [ Member ] Stockholders' Equity [ Line Items ] Loss on extinguishment (in Dollars) $ 554, 423 Warrant [ Member ] Stockholders' Equity [ Line Items ] Warrants exercisable price per share (in Dollars per share) $ 6. 43 $ 6. 43 $ 4 Date issuance 5 years Issued common stock shares 10, 000 Warrants exercisable shares 152, 460 4, 200, 000 50, 000 Exercise of warrants (in Dollars) $ 6, 591 Chief Financial Officer [ Member ] | Warrant [ Member ] Stockholders' Equity [ Line Items ] Warrants exercisable shares 87, 500 87, 500 Maximum [ Member ] Stockholders' Equity [ Line Items ] Common shares authorized 291, 666, 666 Minimum [ Member ] Stockholders' Equity [ Line Items ] Common shares authorized 250, 000, 000 Series A Preferred Stock [ Member ] Stockholders' Equity [ Line Items ] Preferred stock, shares authorized 2, 500, 000 Number of share designated 2, 500, 000 Common Stock [ Member ] Stockholders' Equity [ Line Items ] Forward stock split 7- for- 6 forward stock split Proceeds from equity financing (in Dollars) $ 8, 400, 000 Price per share (in Dollars per share) $ 4 Warrants exercisable price per share (in Dollars per share) $ 6. 43 $ 6. 43 Issued common stock shares 76, 230 Warrants exercisable shares 3, 210, 000 Loss on extinguishment (in Dollars) $ 368, 036 Common stock. shares issued 60, 085 Issued of common stock 1, 025 Common Stock [ Member ] | Maximum [ Member ] Stockholders' Equity [ Line Items ] Common shares authorized 100, 000, 000 250, 000, 000 Common Stock [ Member ] | Minimum [ Member ] Stockholders' Equity [ Line Items ] Common shares authorized 25, 000, 000 25, 000, 000 IPO [ Member ] Stockholders' Equity [ Line Items ] Number of units 2, 100, 000 Warrant [ Member ] | Chief Financial Officer [ Member ] Stockholders' Equity [ Line Items ] Warrants exercisable shares 87, 500 X- DefinitionCash issuance of term. ReferencesNo definition available. Details Name: ntrb_CashIssuanceOfTerm Namespace Prefix: ntrb_ Data Type: xbrli: durationItemType Balance Type: na Period Type: durationX- DefinitionRepresent the number of shares of convertible preferred stock designated. ReferencesNo definition available. Details Name: ntrb_PreferredStockConvertibleSharesDesignated Namespace Prefix: ntrb_ Data Type: xbrli: sharesItemType Balance Type: na Period Type:** instantX ~~S99~~ **Period Type:durationX** - ~~1~~ **DefinitionAmount of the entity' s equity method investment which has been sold. ReferencesNo definition available.** Details Name:us- ~~gaap_CommonStockSharesAuthorized~~ **gaap_EquityMethodInvestmentSoldCarryingAmount** Namespace Prefix:us- gaap_ Data Type:xbrli: ~~sharesItemType~~ **monetaryItemType** Balance Type: ~~na~~ **debit** Period Type: ~~instantX~~ **durationX** - **DefinitionNumber** ~~DefinitionTotal number~~ of ~~common~~ **excess stock** shares of an entity that have been sold or granted to shareholders ~~(includes common shares that were issued,repurchased~~ **. ReferencesNo definition available. Details Name:us- gaap_ExcessStockSharesIssued Namespace Prefix:us- gaap_ Data Type:xbrli:sharesItemType Balance Type:na Period Type:instantX- DefinitionInterest received on loans** and ~~remain in~~ **other debt instruments during** the **current period** ~~treasury).These shares represent capital invested by the firm' s shareholders and owners,and may be all or only a portion of the number of shares authorized.Shares issued include shares outstanding and shares held in the treasury~~ . ReferencesReference 1:http:/ / ~~fasb~~ **www.xbrl** .org / **2009** ~~us- gaap~~ -/ role / **commonPracticeRef** ~~ref / legacyRef~~ - Topic ~~210~~ **230** - SubTopic 10- Name Accounting Standards Codification- Section ~~S99~~ **45** - Paragraph ~~1~~ **16** - Subparagraph ( **b** ~~SX 210.5- 02 (29)~~ )- Publisher FASB- URI https:/ / asc.fasb.org / 1943274 / ~~2147480566~~ **2147482740** / ~~210~~ **230** - 10- ~~S99~~ **45** - ~~1~~ **16** Details Name:us- ~~gaap_CommonStockSharesIssued~~ **gaap_ProceedsFromInterestReceived** Namespace Prefix:us- gaap_ Data Type:xbrli: ~~sharesItemType~~ **monetaryItemType** Balance Type: **debit** ~~na Period~~ - DefinitionPer share or per unit amount of equity securities issued. ReferencesNo definition available. Details Name: us- gaap_SharesIssuedPricePerShare Namespace Prefix: us- gaap_ Data Type: dtr- types: perShareItemType Balance Type: na Period Type: instantX- DefinitionNumber of ~~/ asc.fasb.org / 1943274 / 2147482740 / 230- 10- 45- 28 Details Name:us- gaap_EmployeeBenefitsAndShareBasedCompensationNoncash Namespace Prefix:us- gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit~~ Period Type:durationX- **DefinitionAmount** ~~DefinitionGross amount~~ of ~~debt extinguished~~ **the entity' s equity method investment which has been sold** . ReferencesNo definition available. Details Name:us- ~~gaap_ExtinguishmentOfDebtAmount~~ **gaap_EquityMethodInvestmentSoldCarryingAmount** Namespace Prefix:us- gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:durationX- **DefinitionNumber** ~~DefinitionCarrying amount~~ of ~~items included in each line item in~~ **excess stock shares of an entity that have been sold or granted to shareholders. ReferencesNo definition available. Details Name:us- gaap_ExcessStockSharesIssued Namespace Prefix:us- gaap_ Data Type:xbrli:sharesItemType Balance Type:na Period Type:instantX- DefinitionInterest received on loans and other debt instruments during** the **current period** ~~statement of financial position that are not eligible for the fair value option~~ . ReferencesReference 1:http:/ / www.xbrl.org / ~~2003~~ **2009** / role / ~~disclosureRef~~ **commonPracticeRef** - Topic ~~825~~ **230** - SubTopic 10- Name Accounting Standards Codification- Section ~~50~~ **45** - Paragraph ~~28~~ **16** - Subparagraph ( **b** ~~e) (2~~ )- Publisher FASB- URI https:/ / asc.fasb.org / 1943274 / ~~2147482907~~ - **2147482740** / ~~825~~ **230** - 10- ~~50~~ **45** - ~~28~~ **16** Details Name:us- ~~gaap_FairValueOptionIneligibleItemsAggregateCarryingAmount~~ **gaap_ProceedsFromInterestReceived** Namespace Prefix:us- gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit ~~Period Type~~ shares that have been **assigned to individual participant accounts based** ~~repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own~~ - **on a known formula** ~~stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock~~ . ReferencesReference 1: http:/ / ~~fasb~~ **www** . **xbrl.** org / **2009** ~~us- gaap~~ -/ role / ~~ref / legacyRef~~ **commonPracticeRef- Topic 505- SubTopic 10** - Name Accounting

Standards Codification- Section 50- Paragraph 2- ~~SubTopic 10- Topic 505-~~ Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147481112 / 505- 10- 50- ~~2Reference~~ 2 **Details Name: us- gaap_SharesHeldInEmployeeStockOptionPlanAllocated Namespace Prefix: us- gaap_ Data Type: xbrli: sharesItemType Balance Type: na Period Type: instantX- DefinitionPer share or per unit amount of equity securities issued. ReferencesNo definition available. Details Name: us- gaap_SharesIssuedPricePerShare Namespace Prefix: us- gaap_ Data Type: dtr- types: perShareItemType Balance Type: na Period Type: instantX- DefinitionNumber of new stock issued during the period. ReferencesReference 1** : http: / / fasb. org / us- gaap / role / ref / legacyRef ~~- Topic 210- SubTopic 10~~ - Name Accounting Standards Codification- Section ~~S99~~ **50** - Paragraph ~~1~~ **2** - **SubTopic** ~~Subparagraph (SX 210-~~ **10** ~~. 5-~~ **Topic 505** 02 (28)) - Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147480566~~ **2147481112** / **505-** ~~210-~~ **10** - ~~10~~ **50** - ~~S99- 1Reference~~ **2Reference** ~~3~~ **2** : http: / / fasb. org / us- gaap / role / ref / legacyRef- Topic 210- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210. 5- 02 ( ~~29~~ **28** ))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1Reference ~~4~~ **3** : http: / / ~~www~~ **fasb** . ~~xbrl.~~ org / ~~2003~~ **us- gaap** / role / ~~disclosureRef~~ **ref / legacyRef** - Topic ~~946~~ **210** - SubTopic ~~505~~ **10** - Name Accounting Standards Codification- Section ~~50~~ **S99** - Paragraph ~~2~~ **1** - Subparagraph ( ~~e~~ **SX 210. 5- 02 (29)** )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147478448~~ **2147480566** / ~~946~~ **210** - ~~505~~ **10** - ~~50~~ **S99** - ~~2Reference~~ **1Reference** ~~5~~ **4** : http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 946- SubTopic ~~220~~ **505** - Name Accounting Standards Codification- Section ~~S99~~ **50** - Paragraph ~~3~~ **2** - Subparagraph ( **a** ~~SX 210. 6- 09 (4) (b)~~ )- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147479134~~ **2147478448** / 946- ~~220~~ **505** - ~~S99~~ **50** - ~~3Reference~~ **2Reference** ~~6~~ **5** : http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 946- SubTopic ~~10~~ **220** - Name Accounting Standards Codification- Section S99- Paragraph 3- Subparagraph (SX 210. 6- ~~03~~ **09** ( ~~i~~ **4** ) ( ~~2~~ **b** ))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / ~~2147479886~~ **2147479134** / 946- ~~10~~ **220** - S99- 3Reference ~~7~~ **6** : http: / / ~~fasb~~ **www** . **xbrl.** org / **2003** ~~us- gaap~~ / role / **disclosureRef** ~~ref / legacyRef~~ - Topic ~~505~~ **946** - SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph **3- Subparagraph (SX 210. 6- 03 (i) (1))- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147479886 / 946- 10- S99- 3Reference 7: http: / / fasb. org / us- gaap / role / ref / legacyRef- Topic 505- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph** 1- Subparagraph (SX 210. 3- 04)- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480008 / 505- 10- S99- 1 Details Name: us- ~~gaap_StockRepurchasedDuringPeriodShares~~ ----- **gaap_StockIssuedDuringPeriodSharesNewIssues** Namespace Prefix: us- gaap_ Data Type: xbrli: sharesItemType Balance Type: na Period Type: durationX- **DefinitionValue** ~~DefinitionDetail information~~ of ~~subsequent event~~ **stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed** by **vendors** ~~type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension~~ and **founders** ~~member elements pertaining to a subsequent event . ReferencesReference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 830- SubTopic 30- Name Accounting Standards Codification- Section 50- Paragraph 2- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147481674 / 830- 30- 50- 2Reference - ReferencesNo definition available 2: http: / / www . xbrl. org / 2003 / role / disclosureRef- Topic 855- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 2- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147483399 / 855- 10- 50- 2~~ Details Name: us- ~~gaap_SubsequentEventLineItems~~ **gaap_StockIssuedDuringPeriodValueIssuedForServices** Namespace Prefix: us- gaap_ Data Type: xbrli: ~~stringItemType~~ **monetaryItemType** Balance Type: ~~na~~ **credit** Period Type: durationX- ~~DefinitionExpiration date~~ **DefinitionPeriod between issuance and expiration** of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in **' PnYnMnDTnHnMnS' YYYY- MM- DD** format **, for example,' P1Y5M13D' represents reported fact of one year, five months, and thirteen days** . ReferencesReference 1: http: / / www. xbrl. org / 2009 / role / commonPracticeRef- Topic 820- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 2- Subparagraph (bbb) (2) (i)- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482106 / 820- 10- 50- 2Reference 2: http: / / www. xbrl. org / 2009 / role / commonPracticeRef- Topic 820- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 2- Subparagraph (bbb) (2)- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482106 / 820- 10- 50- 2Reference 3: http: / / www. xbrl. org / 2009 / role / commonPracticeRef- Topic 820- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 2- Subparagraph (bbb) (1)- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482106 / 820- 10- 50- 2 Details Name: us- ~~gaap_WarrantsAndRightsOutstandingMaturityDate~~ **gaap_WarrantsAndRightsOutstandingTerm** Namespace Prefix: us- gaap_ Data Type: xbrli: ~~dateItemType~~ **durationItemType** Balance Type: na Period Type: instantX- Details Name: us- ~~gaap_SubsequentEventTypeAxis~~ **gaap_ClassOfWarrantOrRightAxis** = us- ~~gaap_SubsequentEventMember~~ **gaap_WarrantMember** Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: **srt_TitleOfIndividualAxis** ~~us- gaap_ClassOfWarrantOrRightAxis -~~ **srt_ChiefExecutiveOfficerMember** ~~us- gaap_WarrantMember~~ Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: **srt_TitleOfIndividualAxis = srt_ChiefFinancialOfficerMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name:** us- ~~gaap_StatementEquityComponentsAxis~~ **gaap_AwardTypeAxis = us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis = ntrb_BarandnicHoldingsLtdMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us- gaap_StatementClassOfStockAxis** = us- gaap_CommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: srt_RangeAxis = srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: srt_RangeAxis = srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: ~~X- Details Name: srt_TitleOfIndividualAxis = ntrb_BoardOfDirectorsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us- gaap_SubsidiarySaleOfStockAxis = us-gaap_IPOMember Namespace Prefix: Data Type: na Balance Type: Period Type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{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~ QJ,,' P @ O M > BXBX! 6 $ *) S [ RR5 L6D (= G ~! $ [ 9Q_CY @ %? - 9) SL! I (? 6) ZMD? AJ \ * # [. $ 3- M9A @ V [ [ WII) 9Y; % $ L / C 4Q!- *: 4? 7F60 % Z (W6G @ 5S = UHMHDZ384XS7I 3P9! < MP % OF VP (R % =: [ 6 * B > < GXYZM [ Q- G" $ VDG1,. TJ_1G")! $ 3WAVKB ] S? M (V \ M8 $ 802 > ]; P_!" #? KXY $ Z $ X0 \ 3)? = QQK4A? % 57PE? C & @ 9 ] < CGG % R) [: 9VI { X0 M4B2. U1 * 3 #? * (H2T- AB ] < 52, 9F7LQ, C6W. 2 * HA- E! QC < DY5LX82M \ G * > AF- W MTG' N9M & HU > (ZCHB; _DJ8 @ 7Y (_HE) GC *) $ / 34 $ B"" C \ LRF & 9NQ? % RN76-!! / T MWM 3 < P * 8 > W # ID #" R4R $: ME? > 6' * R5? 8 \ BXX? M * = J (= L0 $ (- 6PG' F [ 7NHF0M MI & & F6 * 9EQO' V * / WK; J & = EPA ]) C XPV @ L $ W. XPH88 (1C7, 00 & [ Q > D < @ M * _D [ I [ L ! & = O! %, A ( F8A9H >' E09 [' F; / X1V0! UK ] - RUHE'" R3EW)" 2JQ = A (MRX5CMF @ C * 0Z7N _; ] 4 R / 77 (5J5WT 0R [ Z (,!? X & (\ ' L9, @ CKZ [ B7" > K71 / M \ TT07;; 4P, < V # BC0CM5 $ L8MY9PK \: ] %! CUT3OKB" I [ B3DXDI9I8T EYL! 2 M1ZJ, X70 < (Z9 GU5), DPN $ EXG' A' Q & = Q. GOT8YT ] $ I # ZIR_B, _R; (VBUVK / I M ; = (Q' > > [. O = 9SD; 8MFI8X @ N14. > S9MSM8. K: < 5 ( (N8PAG = @ 93) > ] ] J1Q M = # A4; $ KZKJQ" 0! JPSP" O1? 19; XMCP $, A; Q1, PB' _) ] & S? RXY \) QOIXVS $ JV; M4 \ 7:' $ N)?? = L 7 < 5M) JEU $ 2 [ QGE: D- 2S" 4 / P ] FJ4 (A!? W-) 1,? < IT2 [ - 4 MK % G (- FBNTQ_6KB36KN ] K @ = 6D @ 3 ((L /") USE2! 58 (8VV YK $ 9 @ XC- R8XW55YH M [) ST1" 9' 3 [ 9. 5N ]; DQ" CEY05B. 0 (MKN: H 21OB; N4AV2D! VM =? B1QL7 = 55ZR MK8; T ] A [! _8KVF3T ] AG4 (3: YW & S2J0. G45 (T [: BPRQ [ V3 < 0 / ? WUJ7 Y' Y M [ T9VZ % F: G0C [ TM: $ H #" # 7' HW: 7NHR: YBJ K0R9? > 77Z.; [ 5B- ONRQ / G (B M74A' A. \ JCA [ K9L # @ J / C3RO $ O, 8Z228ZLHXU < Y!: 8A \' 5:,. R6 # (H_QR ("- / * MT0ZN & = SMN $ WEKHER <, N" > \ PVQ XN / * /) 7) =. M8' = S / W * > 9" = / 1 @; # ] ZSR MF0) W1J # TS5R # R * C77 # T # ] V * @" \ GW & ] SR1, B ($ R ] [ 3 ] W; % M = 4O?. CWX31 M1 YZ * 6F = MWF8X ] D900 * 0' R. 4B % 8! 7 (S QX3 & 5QO * V *:?: PD) D [ <. ] D > C > AQ M_?; Z_?:)? > \ Z *: * HH * M; < = R @ U = 8? \ X = WMIDB $ U_MQR: / [ SO (* < AD >; 4 # M * 7Y MBLR & NTK-' ] GPMT =) 0T. < Q $ * OLZ6G 7 # &;: B; @ J, 4RU $ _" E % KJW < K ]! HG6 [ W & M / H # ZUGU4_ZEP:!? V = [ 9 * KU0T4TZ- & W >. 6" SK24VXY % (< @ G' & / WQJL' = 3T. W M Q?, V = 89OH6 [ 0AH, XKD;' # A2E, WN & \ TN' [.? 6QPM; S 6087. * 8 = Q & 2" $ ; MG8IB $ JY0J6T . < X 77 / = 6YD. M # 5 (7 (R2 = T' K; 7 * %: RPG % JGX_ % J5 ! : [ MQL9YB3R-) # N- U @ 4F5AAEQ [ A \. ]? XX_? 8 # $ H = K > QM < *" 7I): L @ / @ B, K ; 9 # MVY ] YP1) = J4 [ N:) W_H7,? KO #! Q < HR ] _NF-; K_D < NNMAO0UP * YTUTR- \ / CS? ON M $ W \ 970 _UNV2 \' GNT? J3FZ * ] ] \ J = \ _ E5PO' QZ72_H_9. T2IX4JO:! 7) / S MTV > 2- G1_ =, V & YN?- UW7K / DC6L) UBP? H ] T5 # M3 @ 0G \ __O Z_ \ % 4 $ L #!! 0 M (& > 6GEA \ S9 % @) 0,, @ & 9 > & PO = V ] R: W- H965T < R ] S: & 5E = # $ Q M GAM;) 55VV [;.!! ] UU <, 5 & / 1 H) UE 6L; S, S: 6BQFO %- 5V >!: @. SJFHG' M2ZSX? F [ [ ] M /" 7; DKE % YP % [. 6 [? KJN_M6M #,' 5CRLL9 & EKP! @ = NYO? 0O B. = M; Q) E B71S' H2C: < _ ] 233_G < ] K0 @ K #! 3FH' 1 < (_OL: HT $ < GX = >" TARTU \ # A M8O ] @: J =:- DSB > U [ ] 7 >: JF- NI # 3EN65 > I. [ [ _B (= Z8LV7 \ 4J:) S [ W #" R (> ND MXO4! 3 KJLNE' ] G # HPQ $ @ ] 5X!! = 8' 3W & QF55TRQQ4SP / 0B = 36PZ, * 4:- (DK M & _U1OBI!; TO" J < 5: T / < 5ZA % 8D \ / J5U > VU' $ U < Q5QZPPW. _! < ] CS! * SQ # > \ M486 $ 59- C_I ) 5 & # LN!) V65PEO $ OUHPA ]! T (O" ZPQ <. E8: & _RM2N'? Y48J M08? COU- % ] Y31: 4I ] 82YDRS * < VW0C) (I [ M! = _O / $ 3 [ \ \ S @ J-! <' 2.?; & [ Q > MW7W [! Y: W5 [ # Z \ OW3 F9U V4RO, \ X1A. 4UG4XHYNHNZRI; NL6QU: UVP #. / 1G M!' X4. 7 $: / T? 6 # < L * VD3TO7S. ] 9U @ & CAA. M51Y # E) D % H?. M & 4JA- H < K? E @ XXE M %, GB < # 8 / E. %" =. XD \ (&' F1D \:) = 8U27L RR [ JZJVC" G" X; = 3DKF; G.; Y / 4 M = Y) I". _ @; > Q- _PX9UU2S; VRH < > P602. 5. J < @ 3I =.), PABNCAGQ @ 9Q. DC96 M \ Z [ 1 & RH. (Y ] \ 20P9", _ # 9TD \ 8 #, T % (% PB, R (0' UB8 > C9IHCZQB ([ JA # [ B5; M- / Y3 / 8 [ AJA- ELX /? (< A /" N5;. 13 > DB2 > GTA ] 3. = OMS0 @ 8 = (VP0R02KBF? L M4 % O & I2 (. V' & > 2Y" \ RL > GCJU [ Y" XUBIWQ4 $ EH: E) O-, / J8- / WIV > TWN / OV % B M5S82 * MP2U! M / 8AM $ [ YO ] 1 / ' 6 >- 6 & * W ( $ Q; TJT & A $ C ] EG / U-- $; # # OQ? ] 0 M2P, $ % @ 9Y: > 6 = C30U-! P C1 $! D! X;" ] W; W) K < VAE971S W- H M965T, 3 (N > & ULE5A;; , V % G [ 7KR # <: 9 $! % % N2' < > 97 (DG: (I. A < T, ] U = /:! MEFB;' 8E422I. ] M? O = TA) EF > <; / L01Z3 / _ 7G (E ] LM? EB- T (.5 E B5REZ. - L [ 5 M; R83FV ] $ Q > U8UT AFY4V % 7 < XFO7 $ UD; PPC- 5Y21 DOFDXE *- KB [ \ W4 = S =: $; M5THE / AIFFZKBYNE & E' I [. 4I' W < 5O < KUQ = # & YNJCY6MP ] [ G :"": ] % (* 60EE MI5;, B- 7EZ # I ] < S, C > D_PNQ1;. WAFY, E2ZR ] TN" LN1PD9) $ J1. Y \ > ]! W (JR M) $ $ PX \ ] 6YJA728S # YT [ Z3 ] YW D5MSJ \ A R <) O T6 $" K' B3 > E T ] N? 1 > O / M" < G = 6G ]) ] L & VFPV8GECG: Y: 9EA0217 \ \ < V # @. & 1? (, 0 ] 8R9- [ NH, A; 2- W M _. K" Z" TS1 UI ]! = ] = PP3BI * RKTS %:" SUW = J5Q7 @ GWBC \) > 3! PDTOTD; [ EO M G? V #' >: L7 =: N8UE; U4ABGT! $ YC2VY- U ] MQD TK \ A: LQFZ8QRY) L ] H * \: > _? MU, N; _ @ 7_V OE ] 89. $ _AUP- @ F:'! 5 % QO $ US \ 7E". BWPCR (T = 4 / WZ7SY / P % M, V > ] F;. 7I % _ = O; _ ] \. XM W3 ] S [? WAVQ [ D? NP;,, Q & TIEGS:" W > JJYNJ) \ 4 7 M3A3, X: XV D % 2C5FF5 ]' U_2T [ G24Q & [ 198EY \ / XQ > RHO6VI _" D ]? SUFUY9Q MU * A % 4" * ERNKNA0H7 \ = ] > & VE T & IAB1Z [ 62_X4U2L. P / X! YXHJD \ G0 * C: F4 M?" E Z9X8NA! KU (!" OL ] M0EB MOX9? 4 / VK2Q 9D7- # 7 > B' (B B. HO" 62 (. 8 *! EE5R4 # #? (@) E9 =- X0 /' M2 --. UM Q > * EU3 # 0L:; QD. I"") MG8 \ @ A @ < OG13 [ 62' @ I *? G % CI * F3 \ QB? 3H M0 =. BP!! R3UL ] < [ 4: - ] K3D $) & JMD.. BWF # G.' 88 [ TUM, -: QZR" TL C \ _C M W & (0 < ] 0- ( TEMI: 6 (RNO) 4 $ <: CX4 $ WR21M3X (; RP1U1 (9 UF # 8 ] 2W- > X2' MZ9C ] * % 8" 9A5 [ = GB (>: W $ W4ET @ X9DE / (%; @ $ O $ = JA = L * H3PF5E (AS01H (T # J MI % I [ 5; XPN) 6V" \ 77 & > # P! S AVBZ-?; 9J ]- D #: $ 2 % K" U?"" Q1EH? BJ * U / PJ & M2 ] O7: QL3T % * X6, Z- > 8 (K6VX \ [ HC, I_AW7C: A. Z # 0 ]) 9 [ KR @ 2 # U? EA * 8 = AV M (Q2DXBM ? X * 1H @ NM- / / D: M & _B6I /- *- TBW > * Q1J0 $ P2P $ 7E 3V & \ 0 & T" F M1_ # MQ; Y)' 1IQV- 7 (D. OR' 6. EN5V [:; B3T" 2 U; O \ Q @ $; K' L6 -? G: J7)", 3Q M3? 0OPE3DIVSD < 408BFX # KJ.? 1 (& (E R5; ] O3L _- C /! Y' V % NPE2AVC. <:, 3WM M \ 3X! N _; UAWP #! EW' # F91) PEF4F $ U % % # N @ H %! 5H1TN < 9II (<: % H4 [ 9, # NH" Q ] M; 0: / ['/ W &! [ 8 W (.? 8 \ 86VJ [' 7 \. LHC =. 3- # Y Y \ P? SV9I? #)- V. L (*: U @ M ): F_L4VJ8M (9J (DK" 5GIS $ 9 _, Y2 > ' 2 B. X 6EHW' BL * # [ F- % WTT7T M6346 _ / M8AHRS, \ @ X2 = AI, HMA >' 2WFT" = #, 3 > _UW [ 3' [ = GP [ C8: 3PE" ! Z @ M0UW2IT954 \ BWTFU = *" NJG \ _L. OW43 > KSD8P6MDXE % 6? IY $ K ] * 3 >) $ D < 9 (D M' KEL2 [ EI2HP: O5J1XN73, ] 70 ] D' *? B' 0I; & 3! A (O1P91 % 7" % = O * % 9A? NE: \ $ M3S! T? > O') @ JD4: A V [ 9QDDH % 9! IQ ! 9ZUS3 @ # [ 8; X8E7 # 4: R. # Q5 $ C * A33" MLV;) V $ / DEHH F VA ([ Y" CI * EY %, 4AH % CKW; 8 * QI # & > @: _C / ]? LP *' 3Z M7 % 1 85B6T6UZ & B" I8K =- FWS_44O ; O & 7G % $ $ MN, $ @ 7N JQ: % * M < R9PKY [ <" M-! H ] T4 * * (1X < 1P) 2KY % C [ $ 5 (TP5 =, *!, TPV \: 1 [ Z * =! SMN_ & K; CK [ GE * 2 MI = / V8W (> 4- M_ ]". 8U ] HG, 1 FQ; PT & XB <; N) 21MATA * < L2EB) V =:' 1Q0 > PL, M; 2EAS? 2EM6L,; 7Z?: A & ZYTL # < V \ H1H <' 8! B > & R'- X =': MC > /: < Q % T4 _ % 4! B # M0MXM1R3R4 (VK (@ J:! E @; 0 # 6, Q &' S' (! LT # S? _Y _) > Q1 * A8: W: PW5!:); Z # 3 M >) IF \? QL $? HAN, \ / IWA & - T_VTI ]' YZAGRZ (D [ 9V5F \ 6 & 3 @ NL / 2K ]: 2RE1 MVV $ ] 9X (J. DUG @;, _1 < V M! # 29; $ V3QALWB. ] <R = S; RWPV! ZDT ; /? 0 - AF \ M (E?" K / T / 31QD <; PMMS? ] K \ U7 (= 7 [! UY *' B' 3 = KB76O %" NP) N / 3DQ & R [ U_ MP \ ' IVK ] P [ 7 # Z [ M_W B. 24D $ ' ZE \?; 1' DA! _PO, U? \ 4 $ L #!! 0 (& > 6 MGE @ 66_1QB @ 8' < / 9 > & PO = V ] R: W- H965T < R ] S: & 5E = # $ S GAM;) 57 MW6 [;.! J ] UU, 07L ] B % E! E2; 9LIYL $ <) H6DZ (S # 2; =' 0P6 > T % M $ 54 $ C4D % = = O M / < C9 = E. TNS. 36)) _ / [ /. 20O = TI_-: 40EGVKJ \ 9 < C4IKV [ > 3B < E 47, 3J58T M ) 1NN86CWH [,: T6O'! & = 35) XW @ J; EL1M > 7 [ MV ] OKY4G: UD ( XU, UU = < [ V_ M $ 97: 78V2T >' % KW); 6GHQN; YL 58 \" / NO ] E [ C: 3) X * 60M & B- 5P [ 387 (U6R = N; M & W: UW" _XMQ < Z < _ & 94R5JIK_1P5UR- 8DI (5" * WY (' CWZ- X) ZJ *"" & - / WJ? HR $ D M & 9 [ / GC_X & I' 6MNQ # M5_28 6UZ- EB- 6B WO * ONKVOTD GHR \ I > KRKB_;.? 7 MIMF (Y9VQJNZ- D4 $ M & _ ?? O [ < & * PC ] CD / 8 & J < O;! W) 9WG KR UVC %- J & - M? KA2G362DPT- Y < % J?) 6PL ] > _ *" L, N = [ OJ [ $ Y < 3") 7V8Y WYC3 = / OV. > I. QG MU = C2L / =- (8IS! Q / D, B24' A * Z25_U ) $ W $ 9LF (4OC = /: * O E0X- 3YF_X_!; _ MK-; &: D # AOR_5ZCW- 7O9 $ ]' AK6IZ JQ' P; X1 % * / KO_ \ MF .?" SN \ 8" _W (KFER $ @ <" 3 % @ 63 MC56, @ R %; 00 (9X %! 6S);" O:.: X50G # W4O * K836 < 0UQAV * Q [! Y ] 8M_M U! 8, \ M,, XH * Z8V (=;. > G7 &. T) XSAF12? 8Y ] RJM = LF; OQ D, 7 *) N # / 69S P % BOV M @ NN (? 4 $ & O % 8 = @ G # V4" N. V [ @ < WH1) LN97U I3O P1R? A @ ] 6 $ QFK / 6KZGY SY M; 5L < MGR" D6Z: H = HXR2 < 7RPB = MMAR3: @ BBDR $ P1F! BAV $ * H! C: % OB: I; WNQ! MPD 019. % \ OS * (? 8 $ 5NY " _ [ Z0NCOKBBEEF8SBY" & 2 [ 4N8EM2Y, T @ LF # 81 M: WC \ CL / IRPZ3. [ G *: K [ W 5LJN" J5N > GM = QC @) TTG) 9X < E83- P- (@ FC 9 MMIW. 2V @ A) 4 / Z2! 3: BTKX4 > 28PA $, NI) WF < S3 <- T, 0L # 6 / 3E (9' % 1 >: ; @ Q M0 H1S [ $ 0 D4 < D / 8I < $ 8ML9? C. HX16Y9 & EWTL. %- T ] 4 > O: < &, 2V' UWZ (B" M 3; P; P2: B_ 7 [, R_LKD @ (% TFK) C9;- PELU? GUOPRMPNPGD21X [! 5 81 (T6 M %; > B" % JN [ = Z- ] &,' F" > 4T ] / 1TJCJ3V6WWE &? B *". L = # DT / / 732C 6TQU (*- M, Z * LHVW / 9 $? L # < ] E) > W >.? # < 95_N [ MA' G! T > ((> 8M0D W: Y" P, B47 (M2506Z MCLI / L_M1B [:" * TR17H_3 (= @ 08 -? @ _Q91240 \ # # KE \ K $ YOXS! R" I & XX / _XB" MSYT % @) N" HO #

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bLBK3- V ]! V _ \" 0DO $ IDR? V % = MG _ 7Q < % 0I ?) & &" W (TZ S [ XT / & P) C) U'! Q & P # - VUXJ, E > =, L FQ % & N0 =! K1 MZ, & X: J31N 2 @ H- QJB; LIRNGI # < 8YC % <, ZGO82Y9H9CA2QT /-. 3J4' 48) W6 M6- XC6 * X" T2A $ P471 < SC78! & M99Y [ 76G7H' $ = QP @;? M P54!; _E" FO? U: ] \" 4 =: <: @ % E):, $ JP9 \ MQW ( F 8 & I4PCLW / DVY- 1"" 67M3H; YGBV- > J. * PUIGO, XQ5S (4 B (M $; E, 25N! L) 77JM:; LE2" 7 < LJWBOT = HBU; 8! = D: @ F *- V! 2P754 $ IAA8? C4 M \ 1VC8, T4 * < % NAGM / H ]? N 5 [! 90 & WO- 0 \ 7Z W!' 05: 4' /! Y @ >! 5: X0_4. K7BT MXU $ 9R! A = 1U2I > H = I = > T) JCSR;" QTDL. GX: C > 8? 9P NLL3 = \ / K612 = V. S & &; MNFLFL2OH74;' HP > $? F_NFO-) RI? P- BU8 $: 4L @ ZOE $ HF5 TA R & EC5 $.? @ 9_ MK8 & = * XT =. P1B) (/ P! U (S- OR ] JS" P [ J @ E; SMW. * J2 % #: < O' F- < H; K5,- [ [ $ GP M46BR. 4HSZC? K5" < PO [ R $ = W @- N6UKZ? WYS. JQFHA $ 9 # & 2LLN ] 96J / 050 # = W # $ M8XC3, LMH \ / \ N > 9GA5N / 6D4 >- R # 2C7? VTJ =! 6R, A < B6L, S9: V7NL28GY @ F! J = MYZ ] L- KQ * 30V 2N) DA (C5 = ; T Y [ KX, 8'! # K E % = Q_D- % E @ G! QRVX = S $ I _ >- M . R & JN; 8 [". ZY D9M # # [ BSJ >. < HT" : 3) [ [ 8Y $ < < > EIOQ & E 7 , * V [ U- L7 MD (UNTSM" 3 $! _2 # LLBB05 > & KHI: Y18 (: ZEH- 5 & 7K? 4W; VHQ. LMY < GGR; 8) 47S MGI; > FU- WZD FF $ UQ: 8K [ # / B [. * > $ 5 [ * 6HJ21T6; & YH)- L- 2Z <" 0 < B1 \ [; C MUK5 XEV07- <: # D > MURWJ4E1RTZBW3EONYC! G4 = (@; D (O' G. B" BJ < 9. O:; > MZTKQ ; S" 4U /! F!;-;; FK" & ) A. [ 2U * C.; L', JA7 > 4 < & S & OY 19 [ 79OUV3 & UN M' B : ICV0U- / Y? HA_F [ 2; AO7; C" R3 / I7M) U; L- V [ LY ] F2VQZ $ UF3R; [ &: D M =; UOU # * ] CV 7 = $ KP5- S & JGUZYSV [?' XE 7T # K % > $ % KNZ FW! = _ > ] Q $ TV / IF MS; E < F2 ] SH @ S5UI OW = ONXW ] 6? _ - NCM > _'. P7J5H > L: 7 *. K8H [ / LOX: KQ =: ME. 8 >" $ T? D ; QX0S' * ] T / > 7 B = WLR % W4 \ BT_ \! 4 $ L #!! 0 (& > 6GEA? MW < @ > * 0 < (1 9 > & PO = V ] R: W- H965T < R ] S: & 5E = # $ V GAM;) U876_C MN! 5 ] UZ \ @ O, $ V; 2V)' \ DF4D".)- 9; - [. DXVV) 1 ] (& 6KFUB) % % 4G' 27 ] ] [ M R593NR @ [ 8, 3220 / SSWWB ] 55IMO = @ / @ Q'. 1E_9ZL' & N C: V70 # A; 1 # 74 &) M (RMM" NGPUJQ' MC (@, UY4Y *, DBF: C0JIR < ' / % SQ [, S96N7: Y * > # #" UD4AS < LM MY' I ] / 8 @' [ 8. O: KUQ ] &! T < U7)- 2S _ 5X ] & P; = 2B9 * J" T2I?" P. IZ, (\ _ W $ YH M / D_XNX * M [ 5T LF2I ] 3 > ZN < N! Q $ 1 @ AQ21P @ 2_SW!) \ AS D (:? S: 8 @ VY 6MB_ M; M % _9- O1EJ6T \ $ GG_U" 9VUP / @ 8B @ Y6L < _ = 5; W " QIXIX: 4ZM_Q7; / W <, > Z8 MUM; IHEF, ] X4J_7_YW. C06W 1' 5F0- L2YNTW8I9WTLF; * Z. WPM! L1 *, - I57 M (SE5DE, 6SN" HPG7N9N % T FVC \ PR, _ 8OX_ & > MW, O5R" $ RC8_2! N76HR1' 4. ) $ M _ * I M [' B < YE! M @ \ P0DH = KZ3E = 9N \ B_BS (= B' (< BB9 ). WCCSLXQXXW _" SL; M, \ 4_YTOK #,; % OPY9 [ / $ FA_ $ H5S [ 82J9P / 8' # S_7? Q / KX # MM) QW; R M' OK- XO' I [ _ ]. 67N \ ]? % ] ] _ = Y' $ YQ_ % Y [ _ ]? O_XQR & F [ V- = #, 5Q. / & 20 # & M0" 98 (? & E %" A ] C? DIXBFI' \ ]" X38 @ EEJ: 3. B5R) 3! C- (H (] [ 0R" = = 5 ) \" 615 M &? V $ 2 % * D8) Q: J50ZH % D2LSC # GQ-. \ Q *) PVD. # *' * 5) M * & FSM, Q $ NI' E & G % X M9NTVVJA_XVTJ * 5D BP3W = < @! $ HKS, (" *);) N (HC" ": N1QN_YRNI05- * (M) YG7 ($ ZB813 % H @ CYP ]) DE_EBT @ F ,? E43E2 (J. S < = P4 & #' * VZC3SK5 &, Y MLTZ5: UJ; A- - ]: AE8M2X ] BN5 ] % @ PEYFAH 42J G- XX [ 13 < FH2? > PFOYK P_" MLV % [ JU 0 $ / ZQG3KJE? 6V (!! NL. < 0K9. [ 3 @ #? $ M &,: C4; 2XL; UDE7L ] X ] M RYK % ] 2ELK8F48Y [ 9 * MP2 > TZ23 @ X $ % [ = 4- 1ETYA- - 3IIA % 7 (5 * 9 @ BB0Q" LI MT; . B?" 52NM < FL # B > 7 $ 8 \. *; H * W' > 7 & JS = M * ] = & X" P6N $ J = K \ NX0 = LE_BK M # 8J"; K, 0 > (JVRI7 # < * N- K: 7 / A U & H04 @ \ 0_: BYJ5 & 84' 2T- T4L_! = @ YITT. 5 MN # H:) M. > C / W). W > U' #. @ & 60! < K9O = 3J [ Z % * [ SW, 6L % 9 * 59 & % YA (NTS" C5 & % M_; P: ] FM' < LZ5. ] K7B. L, J! # \ =" C1X- X1 & Q \ A \ [ D MJMT5? %)) L < UL_P8. R216 * D >. E /) - / 4 W. XHCW' WAFB [ R & SS) C * KU6O2 = ] F; M * D. ] @ E * H #: ZLC:" WK0 (BIO .) S- 9O1KGV) B8 / TNF_ - DQ [ 8SB $ P9BCFYFXX7 M66W (; IKR! V! _ X:- 1FR %! > [ 8) 3N69F /.;? * T0_O) 0WZW33OCOHFIT1! # @ RNC M . UV, D [" V21FL \ G (& O % 8B * % XW %" 1) @ % * [ 4_ #. Y; LM1 = B" 7V6' 95A < H \ $ _ > E MN,. * I88? Y [ @ X_V ] ! E?';" # / * D4J? QR- R > 1J % 4AS $ G2 * = LP [ I < X ] $) & SI > I MRHD * E: N3Z3B < C & = < J ] / 4U [.; 46 GA!' $: 8J =) OYWW9 & J.- W: OI ' MN (] J MFWRS9J_L2 CAP & DY (DX <-' % = M. &") P $ 9 03R > AM. 24 \. TGG / M- $ J ] DQ @ [ % KZI,: 3 / 9JQ > A- @ B4; 8_MC & S \ K = [, / K > E [ _ A67HN / Q ' X \ KQ' MI! & 6LH- SJI EONB1 & ' OW (3 @ 115KE @ > H $ O @ M? C ]? GS1 & /; X: Z, S7; / 7 MT, IQ & $ GKT / U, &'?. _KM) # BT, S (O =? G # CN- (6B" J3TG ] 1Y ] E < 52 % B ' S"! M < FT FJ XE / # C / 9 (! 5 # _ / ] \ Y8 [ OV = AD > D *' K # EBE4X", 29TDE [ / PXGRZ \ P0 \ M @ TF5 % QA ]:; # R > W < T, DZGX20 # PZ? 0I!' R @' M >; SAD % * 2Y53 XW" R7X4 [ > D < * MKP7G < A; 4' URN; 7X8C <, % @ # B- XUY', < < ZO: X' R #. / XK! J (, # [ VEC7KOT068 M- 7 \ M ( GQJ. E? J; NGW0 >) N7 \ / WTWW7S, P? = > JM" *' % 2Z- AN? 3 @ 3 # " X & _ <; KB MM_ * E = OB. SY <; D- C9: 0 *. KS0: T- S0! MUGFIO_ %! P04"! GEIY8; OF MB <)! 8' 0 & 0' AL W = O < FMS: & 5E =', O < VAE970Q- RYX; 6R ] 6 > EOVS @ 6 M_ZZ_ @ O" D @ Q: 09 = V2FP- (> LQD, 4V" 1 # / % 8K $? & (F. N95 $ 5Z3M9O_Z? 8 DY"... MDV9F! P52DWI \ ?,? O7 = 14K1? Y90Q1; [ 752. /! U. E9F ]' (UE, 64VE) V: L @ 2 < 3 MT = 94P; * ] & \ E9RVBI # ] 75 * / 3 ] = % 13W @ Q. CO3 > 57MR).: JX @ V [: HF < US5M [ \ ] 8 M) 9;' @ V # 0; 5SSNZG" C =') T8S > L1NF? I ] = M;: ] 5Q * 7K- & < M & 0EDV.! Z?! V [, 8 MZ37!' YPMY = IO @ IK <" O $ 5 % ? E \ 5NA; 7YG5) T % A: BD_DN6AC8 * M! Z282R5J > Q @ DJ' EC_J?? K1W6 # N3 (P =" > R # 4 < IN M) 3OJ: (G1ZU8DA: I @ 1O MT * KJTR <; ] I- ZJ % IQS. J9 / & 1I' $ MJ4Y MM6 ] HH > 312P! F? CPK Y < QP" 1_A M $ H3DDVC45) (/ 3 < G * 308C $ * F7 * SD. @ OW < OP'; 3P2! 2X) _3 # > PR_J ] 8PTO @' M ] " 3_. KV5J @ 5 @ _' N7RH9AO) LA! LM;.:, %. QY- $ C6 MC @ Y. > ? @ M0_W"- NW (L; M [ - < GGU ? SRXL: (> WI ]? 7KQ 6: 7C' NY {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{ U! 138JQJED = - [ \ DM M (W < V: 2ZG' # I" JADH4X < 2- _FM. * 3 > \ P. YV" F! F?' # 3 ] * \ MKZ [ _SFLH- EYT8R MQ [ L! < V; TC, / 0L7B $ %,!: U / *: 5 @ S1V. 4VDG!. $ \ W8 ($ / > G [ @ [) 6 < C5 # ] Y = @; M [ 1) @ MR [. 8 [ K O2W30AM [: Y # 22HJN436 W ]! M,- @ P $ 5A91: ZB8 (G = GH9 L * MW (T @ U5T0 [ 3L_1 \ YO_P / V00' E' # 3K >) LL; X $ _ \ @) 6! % = %! 4 * K % D9IYF 9 ML % 9. < R @' UF B! / & U1PN * 41C" 71A; LC % B! A \ (% R < J4. K2 $ & 9M \ % $ W4 & A M8,, BL" [" \; ({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{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}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{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}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

T2! D2E9P37 8 & / 2Q & $ ZR' ( _AL4 #" K & HF M = E [ Z' 34G: G5 (G > RIJ =)- T = 4X * @ V;' 9A = C ,, ] / 9 * JK * X JHK $ J4F % XMC! L = 8R \? > = OK = F; 8IR * 5,- [ R $: 7,; A M ( X (W? K \ 8C * 8A.? > F @ C" 04032 > # < $ 18E -! %,; > HS3DT' N (! R $ =' 47C = GU M. 9B & EW!" QDDOX 3-, A [ X_DN? # [ CMLG %, O) / 8Q \ 7 [ 5RG \) DLORLQ [ $ MQ @" FOC M)' \ E- QY = HW1)" AC" T / L / 9OV 9N . 7_ WI6UC6U $ W7QM > TS0Q8 & , OI 9S7, 4TJ0AJX0 [ KQ03 > = =- (S" 2- (* = TY! IR & 1) @ Y8: XY9M M # H * > # * / ND / > Q4217H ] I. (R * [ UH34; M QI" # 7J0; L- O8 (43CL > 8ZI %! P, (> KG MW (U: # > X"; > = 1 _ [:? YJMVB' T [ WGX * W # & 5 < Z & AQ (Q, P [- S * FK5CM? VP < C: C, 2- M-' 1YN & 5! 7R2H [': SZ0T P = T' _C / \! 4 $ L #!! 0 (& > 6GEB " F!, I @ (M, < % 9 > & PO = V ] R: W- H965T < R ] S: & 5E = # (U GAM;) 54VV [;, Q ] SU < (M7C & T @ %'? \ D2 TFW8AO: (6AW > 1CVH- A,;- 267 $ ENVK \?) 2 = N! J0! ] F * 1 $ GET M2 / EPNN7B098 BCPW- 9, SJU2JG3B. S $ MHJ SD 3 \ 67 / 14 (6NV # BR % 4 D ] 34 MCN ZL = / 0BEG9U. PM13; EG: HK! DM! 9- < T5 PLH.;; F > 59 XV [: E, JO > % DTY9N MX! [ 4CW8IT', & E *) J @, F *, R) @ /; / FWF01ZG @ 3 \ ." K3RPB: YDQ? F # = KX4, \ O5 MA *" & 7 & D $ BLL37 $ % =: R" D \; C # M (8K = > * AO4 > _ - K5C 2LJX8K7OZI" E3, KM4 @! M: ] K5ZHYO / \. NGDCCY; R6YDNV? 6P0623OI. - AD9-! 7K5_J \ Z \-! 0NJ D > # O M $ GS # N [ _ (L / Q (% < VF @ F ) T- & (I @ U3JLE & < A73CW * O!) Y6F * > RI < # W % > J % 4 %: 0 M3X ] = U6 ' % 3G_3E < UR (NIH_ 2' > KD. \! % # B_ > CYY) 8S54KRB150_ O @ ( N! MHK GN /! / (GZE [) ($ GDU \ UP ] / X 5 # R8'!" _ZOY- _SE50" _Y (_QXKN (< / CD % HY M $ ] G2' & 862D." > (K > __. B ] T /) PB'' P %' IVCTHLNAH (7Y / CY (\ Q / HEYG # % V MND- EZF: / = - UQX / 1 # 5T1 & - IT1KPPM *, T > K5 & MS0O $ 5_TK % YC / = L? W: 0CK45 MNG; LIZ / K3K! * = 0), [ IZUK8DWMB. PV" WC # P [ C & ([ ] A), #- W03J- X = - 23L @ \ MS [ NFJZF" L6' U / . * & GF? QZEGQ . 7) # SR $ ULS_? (Q > @; CK4WWON,) $ EHC [' * M, Y *. $ SL) (G LL9P # < 34 @ - F: $ 2) SCJE > 9 \ / N, * 7FO3A? P_L1 = TO % IF * 2U # & M5 / < RP: $ @ K' 1. XJW1JHKKE # XQBQQTH 0 7B YESM' 7W!, NSOU! P04 M"! GEIY8IQC, 5DT $ I" @ & 0' AL W = O < FMS: & 5E =', O < VAE970R- BYX M; 6R- 5MMNXS80? = = 7 # 3 % (@ & 4Z & K % SMH & DFP7 = = $ M @ B2 [ 15' T @ 9; &- A & ) U)) 4 MG / Q ] AY2MVJUMY" $. 2 < V <. 3- S >! FOI7K6 * T0 # KW4E ], 1? & = - < AZ $ N5E @ S? 2D; M % / 1E (57- # $ W5, M2- 0E8ZI [ H * DRC * PYIQX4_'; NU > 3 < > R- 147 > * ] MW7- U- LM M5G (}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}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}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{)? QMT96 < $ # = & 4; ZF- 2F5P7N ({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{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}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{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}) W / B ] 6: IC! V \ $ @ KD! MPDC > O_ - A [ WV; #? P) [ 8DJO,: 77A9Y, M \ & # O) 9_E0BFRD * (@ > # M): XUJK: 0 *, [ * 8YG [:) > '_E # / QZYFT- I 8' # GA % M7A / WA' 74L (XZ64 ] % 4 >!? A: < R? 21, J1 (R @ C < I, > ZP % % 0; YPHQ / J # B1 ] $ P / F; < M $ A8 / O & @ G7 # < $ (X [" = \ 4: \ HDWKJ: P YO? @ 5M % # LQV @ N! M! 54_ $ P # 2 @ A / 2. @ W M $ OJ = $ AYXJ = # FNC XDIAJ:; > Z_VS_X3: 1MZ1U < _ # E [ / 7A5M / <- ST & WU54Q M: [ KKLKH3XP56_SM.) = (}:! T % R * 7MJ (JDHN2ZNG &; U: 9I7 ] E > =; 0 P69 > ] = X_ M,- 67P" V52 \ 85R6 &! D- Y %' TM = 5MVUFFBQM @ UJ C2V. SM < X0 <) 2!. [ Q =" Z / W $ M;-! \ XB2_5! P04"! GEIY85T" B (18 # # N" & 0' AL W = O < FMS M: & 5E =', O < VAE970T," YX; 6RMEFUOVC 0Q [ * E4U3) ZW- (R' M (! 03 > NT3E59 MNQ? 37ICD * N. S6SST & _ < P (IT," J; 6 ] (;- _ ] _:; O # ODMG * = 6 # G @ (8LBJXT % UG M: LSLPG5U- H6" ZC, Y X $ K8ZD *: G" H) JZ > *:! Y25IP- _" \ V" TH $ T [: * > = N5- J1 M < \. 9 @! M % ] PHJ' KL Y? KN, [ FXE;- ID:. & FG1F = P! #, W > Q & X < BM57) 6 @-!, M" J) @ W' 5Z_L4 @ L?: EP3V # I = YZ) S: 2D90 / = G" 5 = QW / @ &' S % @ % BH \ % # ( ! S * X08 MO ]:: 3KVE = = Q WZA_ & /' 6 $ 94PT # R [ RPWTZZ3." 2', 9US < RN7GV = 3 \ OJ99 K M \ I < LU [: > 0 [ * Y- K) 8. R-! P43UI * MU' K8 < _ / B 0 [! V" / 8 = H @,. X = HA . MR, JP M JFA: 4?)) 5' 6 & M7L2YF; TANC8 < BT. C <) 6AGTFO1" 8 (- _H" C0YN01 # & = = O MR2D9XGG) YQR (')- & (- 2D % LS \ H71 $ > /, /! (J \ MVEGM9X [ D [) W?" 2G Q VW $- M $ MI ] W & Q- TZ ] H @ @, T? D" NI3! 333Z (' /) = 1 = # J , - O' U @ Z. * GZDX (Z' _C @ 1 > M $ # 4 # 5 [ N' A [!" > MTAZ5 > > $ # O [ [ / ZHS? 21N & I_ ] F4UFK7J' E76PDN ] (QFT' 7P MJFM0" W # 2- Z_ \ V' O? E) _) : 3H * A. 4' 1, /? V * H6 *) 4M0P, 2 % <: DTRJM0CUJLE M57E3 [) 5 @ JQ2T16N1GH: A' \ 3G2 < = =;,? 58! B $? MR. G @ QWF % LU < LH \ ] # ([ ($ P MK >? XCR $ HL4EA & > @ FVDHJWH; PHU8KB? 9IFPR # \ _, D" 9IIXYHV / DI [) 0P5 $ S;" M0 \ B * & 64 *: [ (AL, * H * &). & X \ 5I VX_VB % ] @ N $ / < KHG; 1XGO * 9_3JNAS [ # I4 M9 (V < [ 6?; MQ * \ MK & WA_G < HKC) (P. 4" 8U9? ' DYMO [ JVQ ]; 0) \ JA & \ ] TB37? T MWW6J (- VMUE & FI0 = % > < G M35 = EZMF [: O;) 7 [ < WWL9E7O? =) IOH2N * 9JPH0F M', 8HZ9VU \ 62KJKM6 R- G98,: 28 / MKGR = X @ <) * & N ZV, IS69 @- Z @ _ < = ? 4 $ L # M!! 0 (& > 6GE @ L @ V % NH0 < / 5! 9 > & PO = V ] R: W- H965T < R ] S: & 5E M = # 0Q GAM; * V < 6V_;- AB & _PKA # 4,' M % $' 6QGB8' $ $ K $. S18TZ' 91 [ (* 1F % BH M # AY %) F_' W6 (9 $ HT8VU? EH? ] # V4 5 @' OJ) \ \ 5SP; 66, 8 % > LC0D V =; (7; G M \ WD9; 5E & R [- BQW YSD /!, RKD4_XX W > < T; @ NRM (YMBQ_GM $ DGZTOZM = N ? JB MV (LTR = DM1 4 RRC_? LW2XOER9L ] > 7_B < / & Y % ] <) \?; & CC R. B2 [ 6RZ? S3M * MG & 0L Y, B1YP ] 7, ZN [' / B * J" > HD_ $ _9 <' CQ & U4 > Y XIOU9. /\ > 7, JM: (I2P2 M % 8 * _Y [ 8AJ5H9 K \ 4 \ G75M5H6' CU_II / [ P \ L / < TY) MBO2O)!:; R ] ERAF V M0 / > I % P \ _ \ K: # 15O * A (R_I? ] - PLZUDS %. U 461ML5R # , F; _ E VQ $'!; 9 [ MI" W! 7A8X! \ I < - H" Y ] 06W ; /; 7: PN \ 4PO \ ML" O [ [ IK JG RKH H (7SXA7 M2TM: ]. # 655? # D [ RZIMU) [ A \ - Y % U8OU [ (5B), NEW > I \ R ]" Y @ @ B9I 3 / Z @ [ < M! > C = CS ]? S (5LIEIX' K7 (38 / $ 1Y V1C = % K8E" O. 8Q2I @ M > O6TG \ NI 7V $ B \ MVO $ S9 # GO $; 8PUJV0N? PWFI \ AQZ [ 74UV < ' JYHRD / WRC? IV? (7APM) ; R & \ J / ME2M ] Z73" G9KGG" 3 \ ZR? Y- OHH6 %; K5FWZX; EZEG57N \ W- & (7 < [ D; JUD_(G- MUC_ ] 8 / O6 SI D $ A9" P @ @ 03 ' K = G9 = $ WU = ZRP > 4, 19G CT0 *, D3 < 1WG5HC M: * I: 2 % C0P P: 5AT9G ]: > XR [ \ B_G3H3 / () @ D03" F = < X \ H [ - @ SU!,! =-), E9. ME61 > C3 \ B (7 < T_GM4 [ 6F6. B 0 * Q-" P @ @ 03 -' G = _I \ 8 [ ] ] S 635 (& X = (CB / 4_R M1 [ 1C /" EBG = $ & 9EL' WV [ KS, (K3_UZ; YKE5NIB @ X4" XYI-- 0 () (T PQ < BB, [ (P M & KFF * < VCRH5VFS (63 ] VF % J- ] U = # [ FK @"; ) $!) & @ &" * IV7G: 6GTM" GR) \ 9 % M4IV (Y / 5IR: X ] 8GVG - < Z. P9D5 / M- 3 # _P) [ MVWAH # [ ) $!) & @ &" * O55G; V6T M = Y45 UP < V \ A6H W" ] K" #! SNY \ 5 6H. ] 78T- RS (P7 @ Y,! XZI. [ 54 @ F- * KMM4 / MR * RWM @ K! Y8; W? (DTO9M" SCL %? CA3OH7', [ 4T_ * 0 & DA * (U T51C! T- HVVB, M)' EUO (D1K3 <) K3) [ I $ P: & QWTS0U- 5 @ 9)" T % I! (JF * L. ], FQ4) L > _F3S E" BC M,: O. UE! 6119: = 7BDSK6MH3AC < Y / % 0 =)" 4! J! HJGB O3"- @ Z? UYOFS 5 > U $ * MFL? R9 % LKS1D = 65S7 \ X? 60!,) 4 % H (2B- 0 -- 5: GTK8YEAB \ W8 < 829, /; $ # I06 @ MM- # 6Y! M6_: = / 8EF03Q84 / 71) PZV >: Q_S6 @ ] 3 $ W: L: M6" & CVT- (& X ] F % I? S9 M @ Y, _T % 4 (06D $ BJ8: [ $,' VYPZ' GZ4- 2, J8: Q > ZL4 < HB_: 4 % < WT96 \ U @ N84 M4 # 158Y ] 4V.: HXHC & ] ]) C) L ] (4" F * Z! MZE 3H; DOE" N @ NQUR; VYBL % 9 (6M # 1U M (= ] # X T @ L8: 4 # 15: Q ] LV. 9D @ ]" $ HR >: [ ANY! RZU_D S # 5!: T- * 4S = S7 > Z M % J7Z PTVH & BJOS [: L, W9QJ > B ) % 4QEZ $ / $ SNDW *;' 8FCS * #) [ L:! R = =; P? _ MI5FD / 2B") B = 0 - / 4J < 1 = 8'- TTD7Q [ & 7' \ E (; GI @ 14X7A < 13CN8MAB 7: 9 @ A * M (U T55F? G6! S = G ' HKT \ ] J & TH / EK_ * O5! ID ; % J: $ D ]: \ J" T' (H # 35!: 02 * MIHKK $ Q3 \ 1H ">" 3WB? 2Q / L0EAQ?! M / X @ 0XA- 2U-' $ \ / 1 VB3 (2B- 0 - % 4 > 7V * M @ LTIRNMI9SLN_WK # LGO & M3- S * 3) XD 3 % U!:" $ HC4 # 35 <) X8! = PF @ \ & # 5 ] M: 0 $ H 02E $ 2B: * KF / <; YQIDPV \ =, FFS8 & Q \ __? % 8 / 0! M- 02E $ 2B: ZJX / < Y MP DJRWUFO & 9D! DQ6YH \' XL [ * 7KI # 9:! S2D! I! (JF * NO # & FP:. VYYDD?) CJ; & MW- 0, F: Q- DY_XJ \ 50 & N @ $ $ U: @: * ITOHH! INCF. Y * G ] Q / [ DX3"! K' 8, T < $ \ ] 9 MC $ 8: H) -, 0 & D $ BJ8: [,, 8_, 9 $ D_BINKQ > FG: 5H" D,' D \ ZT4; 1 6BS (2B- 0 -' 4 M2 > 9 ] %. / \ _RC & C) @ \ NWP < Q? B6ZPV3, ]! & 0U: @: *

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}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

LWVTP [ N % I BT &: HI2K / 3: 9JQV- V, M' = G @ [ 7, > @ UL =' % FT 4, U @ 6H2U5) 4RU!- 49J =: ]. IQ2 & _J1NC) 1NJ): @ F4 $ VB M6HIJ &: HI2K- 3; 4JVV % EW ]- K412LU5 $ M03:": 1 6TTTYN. &? HM (K2 [' B: MBQV MMV7BBYX ]-, 6C ] GZ N2EFNG (? W- K @ Z. *- F > H) E!- HEJ *: AFJ * 4JS \ VSJM? @; MW. 8Q1ALW5 $ M03:": 1 44U3) 44Y1F1 ] KT < G' / 7NZIV ] $ [ <;- H- S < XT & @; AVH" MU22JI: B6Q <___SMK % ]- E ] K! 4UJ9U4T \; % I {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{); 5 > G4 (; 0N1. W5YU" ] UK M4F @ 86! L (}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}, _5 > M0; UGI? Y (]- = L_L4S \ B; L5O. _GL9! % X) 9 @ " % (\ Y <" (((OPK U. L7B > A; ML > HY ' Z? H7 @ * T [ 69V7" @! S) H I" 9? C5 # (P * # (P: % 1 \? EWU > $ K. 5 < XJ % > 9 M % W0 ] [ V" BUH > A_K [", Q3 = 5CP & [: J, @ O / 8: U24 <. # EC6! _F = H6_F" WRB NU M * B @ RQ- (N ] D V $ WVP # # 7 < RDGD / P < R3)' X) ZC @. WJQ"; 0" M6B (MX J" H7E7) 1 MHZ * X? 5G % G $ 3N5! = _DAS1: \ 5JH_ = RH * K > TK5 Z_ > ] 5F3- =) _A & < RZ P > JZBZ- M! [ 0 [ C \. R;;;; BME & ] 5 5 = VE < X % VZU (KYV;" K:! MA % \. 5! 5 > AYH ] Q) E8 > < 3 MWJSS #'- CUGDY4 % 5G: 6N @ W = ? 4" ] JF ] ZTLS! L 5? 66) @;: 74R ] D & UZK5AM ] % X. M5- 5; FB) H = T6 & K8) MH * U $ 7PY4 7 PT6LIL98X ] XFS? * % G. 1 = TWI8- , * AU MB (9Q! YUDE7 = IG) # =. % F; Q; \ H < & NHL, 6T3" JTDA6N9 < N"- E = D 5 :, # = CKXS MNO [. Z") XU. DVA. H5 #:) WJD % $ I3 =" = F ] D; Q $; I" &' [ ZW) 3 (> H? MDYW & &; 55 MNB # 4; / UE. U? Q # $ J2 CF & OI # % MS < BT) E = X & M5N6.: 6JOKYBJK S', MI3: 5M M0 > W6: TYI: K: @ TJCRWFBAIRJ \ ] # & HY? K, * > 7 ] AL5VAE, Y LO = 6ZM / " 5 ] D6Q @" MA & Q- 9; Z475PMMDD 9) L #! ] = OX / 4TW PH8? * ] EWO, % RH1 (" % S! > EU DHBS [ < S M \ A /) 5MF. P (Q) R = L < $ EP1 @ > H. [ / & 9. [ $ _V 8E- I \ A ] 02P, $ % @ 9Y: > M6 * ] & (& @ 8" 0! TH! D! X;" ] W; W) K < VAE9I1 R W- H965T- 3 $ N > & ULS9QO M; , V $ H > _" N %;"!: TQ1 (D7M) 0; V3P_ = HMLN- F @ 717 $ O %) N) A < I23I * 3W4, _ M?" E9 ] BBA -) (8.?"; Q * MX7" & _CWBB- 3Y? 9K ] F: 5 * LC739SD % [- U4 = R GL_S MY5IMPOPLO56) _N0ZS39AH0 SFWE FZEP59VTB > >, 4C'? A % $ R6YQ7 [ WW * % N? I MMHBC!' W * 2 [ =:, LVUL5I_ < 7, V > V? - S = , NRC? FB_/; \ $ 9 = JN 7VT 9 / IH? MK * RBC4KR * $ U (IJXO9F < UV \ = * LLSJJ_ \ % JG [ O / &: E' VY2M, _RX, / JXL9 5U2 ML5H6I8U0_ [ M3 [ U0 < EZ: T (_ KK < X. C98G- E_OK? GZKWNS568JW = I_" 5: % > N MF9R1E; H. MW' Q.; W_0 = 4 ] XJ6 ] 91KGU5 ] R7W 7SLARFQ? IICY9 > [") DMW_ \ & L = MB < 8) 7M <) K # Z! 57 [ O & JJ \?! \ 6X > (\ 2 ]) 5GY; 6RM? 5 % VMSM;. 14F9ELLBTY ] & M KQB \ < MM & 9R < A, F *? FS $ R * G Q \ KXHPBO- 7Y # MRJ0?": ALKDEZ3RRIWT? ] 5 M3MZL5E % Y9AB3 # \ EN =) 1! _JQB_2 * Y (45 * BK4B > _. _; (N \ T & V4' WW7 NX?' ] 7F M2F7_ / 9 \ 7NENE < _ - EW86WNRZPCBXXC' Q, DV * = D 3E5H ] - # # 7 \ 3 @ $ A > V # \ I: A M % G \, DS / B. O \ BC # * / _' KYGKQ \ \ 8J \ ('. 2K \-, ] W [ W # VG) / 83? K5IR. ŪJ: / KI_M_ * 2; (! \ * M < E; 8 [ GSQVOWIQ2! U_EMN % 07, _TKSU5VIV: ? _ [ # $? 3? 2 & ] 0V \ ] MS / KBYVV9X @? NOHP2 < EE % \ Q7YJS6N. [ = WAD5EN) 2: NX7T / > GR \ _E = BT / \ X!!" M'? I2_6C5BKRY4YE6 (1WA4LI * Q ] [ I (95IS = CJ' / P47: N7OZLPRU U 8: WP < BW M \ DS"' (* OV & # 1AR \ % N. \ _OZKRI91KLBG % HJH @ =,' = - FJ- L \ W [ 4C & U % USYC; M' E / _ X) T _), FU3 & 5' MQ # D R / 2K (\." 2G" E? # Z3; _Y (AP! 0? O M2 [ # WJ819IR M2_); & & ] WL7J? QG $ YV' 2P7K3YL; / (& WXPQ_, $,?? $ H <" BOKR, # Y < < X" % Q = F MU) ZEFC @- = CDGHZU0Q- WF $ &' & 9J @ SV % R4_7V4: 9. 767 &:" WSV3 % & % @. 2HBG M:' AM63P < MYQVC5O BH- S91H9 [ VEDK . 2;' 97 & TST"; H #") & @ LA: TNN &! J8 = MD. / @ S' F" JM > 6! Z < = 0. / @ I) E. V. N &! @ 8- P. / @ Y ' 1 ] MID4 ] QUL & 2GN- G'! PT MC \ 6 = G > D 9U3 < 47N66L < 1HR > F BS8 ]", < T8" H ] 1XEZ;: @ [ 8, I_M8X0! 7QC. MER > (> VU9 /! BWE'; ] RAD A ' F4; <> QJQ $' < & > & (C \ 60M [ G5 # ],. ] & $ X? 9X @ M [ K7EP6D' X #)) CD ] XL [, 60X2- * / P EC ( ZUR:: X" RWM7 < $" T # <- *: V" XYJ M. V [ / 5NJ 12PX- 6T_! LQ < @) F SZS &:' MMZN % X % 1V38!? PXN) X > 8 * VUY8? 7, % U M _ \ 9 = P (V XV8:: > - ] I9" __M_E [:'; ] / VMU & 6XDG * REO6YH8 -:! / > Z @ DIN- M MF MS0W . M # & G6RNTZ / LKCG706 (& Z' % Q ]- @ H. VZR75 \ (- @ 2! 0R [. H W8NP, [ %) UZCM # ] H * 3' RH' U $ > X? # \? / 4PKOU %! EW > J M @ < X \ G < 3: / ] / 8VXCR_KJQH \ = B < # V. 6- 9) > U \ GMFH0 [):. #) & U2HLU % SRS4 M83EOW / Z9;" 4H_R >. 1 % " 8 @ 9H \ G TV2 @ _; G * \ \ GO * 0_GE * G \ / G [ 5C ] NSO? D' MI / \ $ U- [ QBH \ P! U' CXM & Z / \ 7MO-); _C6L8 # ' @ X?) ZB_ (& A MSO - MR @!" M833135 > \ $: = 2? N 0O? WUG, XH (N / 1) > U ]'. SC- > = = YLXH / * > #; 2S \ TR' I9T MH! &?; * 4 (_W < G" @ A, 0, V < 9Q-- M * / FQPO_; RQ; @ $' E2G ] @ 42E' [ = GJ80 < 4, 7 % MB4D_ / P; K. ". X [. R, = / S; M / 93X [ 1C30A / T > 8 TUY8? 7! V3_TYT (CC- ) I (M O % & ] @ 4? MW > ] # 2! C $ 26_8H; L [ C7G6L! 2! * #

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

VAE971S-W-H965T, C<N>&UL4$L!A0#M%@9Y:>6'1RUP;3!0 3Q,!D("!K]P'AL-W=O M<FMS:&5E=', O<VAE970R."YX;6Q02P$"%, 4"!GEIY8IX0DNJ<$U M"P&0@(&YX@>&PO=V]R:W-H965T<R]S:&5E=#(Y GAM M;%!0(4Q0(&>6GEC7]=@AVP,9 9"@9?G M!X;"]W;W)K<VAE971S-W-H965T,S N>&UL4$L!A0#%@9Y:>6$\A MVUO<"@27L'AL-W=O<FMS:&5E=', O<VAE M970S,2YX;6Q02P$"%, 4"!GEIY8?&6OFK8"T!P&0M@(&\]@>&PO=V]R:W-H965T<R]S:&5E=#, R GAM;%!0(4Q0(M&>6GEA 6@3U[(!X9" @:GY!X;"]W;W)K<VAE M971S-W-H965T,S, N>&UL4$L!A0#%@9Y:>6$1RZQ8B P 7\!D M("!S/P'AL-W=O<FMS:&5E=', O< VAE970S-"YX;6Q02P$"M%, 4"!GEIY8(A0FN70"!"!@&0@($E$>&PO M=V]R:W-H965T<R]S:&5E=#, U GAM;%!0(4Q0(&>6GECG <,H740,M,,.9"@="0!X;"]W;W)K<VAE971S-W-H965T,S8N M>&UL4$L!A0#%@9Y:>6&HT@.6W@N0@!D("!M6 8!'AL-W=O< FMS:&5E=', O<VAE970S-RYX;6Q02P$"%, 4"!GEIY8 M>!QK7(L"!," 0&0@(%&"0$>&PO=V]R:W-H965T<R]S M:&5E=#, X GAM;%! 0(4Q0(&>6GEBJ?L3 P,.X(9 M"@0@,0!X;"]W;W)K<VAE971S-W-H965T,SDN>&UL4$L!A0#%M@9Y:>6%=HB$6P[@@!D("!0 @\!'AL-W=O<FMS M:&5E=', O<VAE970T," YX;6Q02P$"%, 4"!GEIY8(-A;J$'#U00 M&0@(&/$@$>&PO=V]R:W-H965T<R]S:& 5E=#0Q GAM;%!M0(4Q0(&>6GE@?Q.I#2P0.\9 9"@6<:0!X M;"]W;W)K<VAE971S-W-H965T-#(N>&UL4$L!A0#%@9Y:>6,3O [" M P J L! D ("! Z1X!' AL W = O < FMS: & 5E =', O < VAE970T M, RYX; 6Q02P $" %, 4"! GEIY8 % 21P, * H"" &" 0 & 0 M @ ($ B (@ $ > & PO = V ] R: W- H965T < R ] S: & 5E = # 0T GAM; %! 0 (4 Q0 (& > 6 MGECZE $ IM? 0T) S2 9" @ 0, E 0! X;" ] W; W) K < VAE971S M-W- H965T- # 4N > & UL4 $ L! A0 # % @ 9Y: > 6') * 1P / 4 # 0 E, D! D M ("! MS (!' AL W = O < FMS: & 5E =', O < VAE970T- BYX; 6Q02P $" %, 4 M"! GEIY8; TF79! <,! $ K & 0 @ ('" 0 $ > & PO = V ] R M: W- H965T < R ] S: & 5E = # 0W GAM; %! 0 (4 Q0 (& > 6GEBJ X8 < V @ 0' (9 M 9" @ 1!- 0! X;" ] W; W) K < VAE971S W- H965T- # @ N > & UL M4 $ L! A0 # % @ 9Y: > 6 [ Q = > 3 [! 1!L! D ("! (5 (! M' AL W = O < FMS: & 5E =', O < VAE970T. 2YX; 6Q02P $" %, 4"! GEIY8EBZ MZ < \ $! @ & @ & 0 @ (% 35P $ > & PO = V ] R: W- H965T < R ] S: & 5E M = # 4P GAM; %! 0 (4 Q0 (& > 6GEBO1B! H & D = * 9 M" @ 5E < 0! X;" ] W; W) K < VAE971S W- H965T- 3 $ N > & UL4 $ L! A0 # % @ M9Y: > 6 [ > L., 4! 0 $! L! D ("! J & 4!' AL W = O < FMS: & 5E M =', O < VAE970U, BYX; 6Q02P $" %, 4"! GEIY8 * MC & 4 & & $ $ _ % P & 0 M @ (' S: @ $ > & PO = V ] R: W- H965T < R ] S: & 5E = # 4S GAM; %! 0 (4 M Q0 (& > 6GEA24) @ B & PL / QT 9" @ 8MO 0! X;" ] W M; W) K < VAE971S W- H965T- 30N > & UL4 $ L! A0 # % @ 9Y: > 6 % 9X5OUQ! 0 M12 & PO < W1Y; & 5S GAM; %! 0 (4 Q0 (& > 6GEB7BKL < P!," M" > J # 0!? < F5L < R \ N < F5L < U! 0 (4 Q0 (& > 6GECH M_AN38P0) (D /" =. $ 0! X;" ] W; W) K8F ] O: RYX; 6Q0 M2P $" %, 4"! GEIY8O' 6P >! # L (& @ @ % CB0 $ M > & PO7W) E;', O = V ] R: V) O; VLN > & UL G) E;'- 02P $" %, 4"! GEIY8 %- 1Q MY-!" M ($ P @ % [ BP $ 6T- O; G1E; G1? 5' EP97- = GAM 7; %! ! 08 / P _ # 1! \ C0 $! end < / TEXT > < / DOCUMENT > < DOCUMENT > < TYPE > XML < SEQUENCE > 67 < FILENAME > Show. js < DESCRIPTION > IDEA: XBRL DOCUMENT < TEXT > / / Edgar (tm) Renderer was created by staff of the U. S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U. S. C. 105. var Show = { }; Show. LastAR = null, Show. showAR = function (a, r, w) { if (Show. LastAR) Show. hideAR (); var e = a; while (e && & e. nodeName! =' TABLE') e = e. nextSibling; if (! e || e. nodeName! =' TABLE') { var ref = ((window)? w. document: document). getElementById (r); if (ref) { e = ref. cloneNode (! 0); e. removeAttribute (' id'); a. parentNode. appendChild (e) } } if (e) e. style. display =' block'; Show. LastAR = e }; Show. hideAR = function () { Show. LastAR. style. display =' none' }; Show. toggleNext = function (a) { var e = a; while (e. nodeName! =' DIV') e = e. nextSibling; if (! e. style) { } else if (! e. style. display) { } else { var d, p_; if (e. style. display =' none') { d =' block'; p ='-' } else { d =' none'; p =' ' } e. style. display = d; if (a. textContent) { a. textContent = p a. textContent. substring (1) } else { a. innerText = p a. innerText. substring (1) } } } < / TEXT > < / DOCUMENT > < DOCUMENT > < TYPE > XML < SEQUENCE > 68 < FILENAME > report. ess < DESCRIPTION > IDEA: XBRL DOCUMENT < TEXT > / * Updated 2009-11-04 * / / * v2. 2. 0. 24 * / / * DefRef Styles * /.. report table. authRefData { background-color: # def; border: 2px solid # 2F4497; font-size: 1em; position: absolute; }.. report table. authRefData a { display: block; font-weight: bold; }.. report table. authRefData p { margin-top: 0px; }.. report table. authRefData. hide { background-color: # 2F4497; padding: 1px 3px 0px 0px; text-align: right; }.. report table. authRefData. hide a: hover { background-color: # 2F4497; }.. report table. authRefData. body { height: 150px; overflow: auto; width: 400px; }.. report table. authRefData table { font-size: 1em; } / * Report Styles * /.. pl a,. pl a: visited { color: black; text-decoration: none; } / * table * /.. report { background-color: white; border: 2px solid # acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; }.. report hr { border: 1px solid # acf; } / * Top labels * /.. report th { background-color: # acf; color: black; font-weight: bold; text-align: center; }.. report th. void { background-color: transparent; color: # 000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; }.. report. pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; / * word-wrap: break-word; * / }.. report td. pl a. a { cursor: pointer; display: block; width: 200px; overflow: hidden; }.. report td. pl div. a { width: 200px; }.. report td. pl a: hover { background-color: # ffc; } / * Header rows... * /.. report tr. rh { background-color: # acf; color: black; font-weight: bold; } / * Calendars... * /.. report. rc { background-color: # f0f0f0; } / * Even rows... * /.. report. re,. report. reu { background-color: # def; }.. report. reu td { border-bottom: 1px solid black; } / * Odd rows... * /.. report. ro,. report. rou { background-color: white; }.. report. rou td { border-bottom: 1px solid black; }.. report. rou table td,. report. reu table td { border-bottom: 0px solid black; } / * styles for footnote marker * /.. report. fn { white-space: nowrap; } / * styles for numeric types * /.. report. num,. report. nump { text-align: right; white-space: nowrap; }.. report. nump { padding-left: 2em; }.. report. nump { padding: 0px 0.4em 0px 2em; } / * styles for text types * /.. report. text { text-align: left; white-space: normal; }.. report. text. big { margin-bottom: 1em; width: 17em; }.. report. text. more { display: none; }.. report. text. note { font-style: italic; font-weight: bold; }.. report. text. small { width: 10em; }.. report sup { font-style: italic; }.. report. outerFootnotes { font-size: 1em; } < / TEXT > < / DOCUMENT > < DOCUMENT > < TYPE > XML < SEQUENCE > 70 < FILENAME > FilingSummary. xml < DESCRIPTION > IDEA: XBRL DOCUMENT < TEXT > < XML > < FilingSummary > < Version > 3. 24. 1. u1 < / Version > < ProcessingTime / > < ReportFormat > html < / ReportFormat > < ContextCount > 233 < / ContextCount > < ElementCount > 410 < / ElementCount > < EntityCount > 1 < / EntityCount > < FootnotesReported > false < / FootnotesReported > < SegmentCount > 63 < / SegmentCount > < ScenarioCount > 0 < / ScenarioCount > < TuplesReported > false < / TuplesReported > < UnitCount > 4 < / UnitCount > < MyReports > < Report instance =" ea0204725-10k_nutriband. htm" > < IsDefault > false < / IsDefault > < HasEmbeddedReports > false < / HasEmbeddedReports > < HtmlFileName > R1. htm < / HtmlFileName > < LongName > 995100- Document- Cover < / LongName > < ReportType > Sheet < / ReportType > < Role > http: / / xbrl. sec. gov / dei / role / document / Cover < / Role > < ShortName > Cover < / ShortName > < MenuCategory > Cover < / MenuCategory > < Position > 1 < / Position > < / Report > < Report instance =" ea0204725-10k_nutriband. htm" > < IsDefault > false < / IsDefault > < HasEmbeddedReports > false < / HasEmbeddedReports > < HtmlFileName > R2. htm < / HtmlFileName > < LongName > 995300- Document- Audit Information < / LongName > < ReportType > Sheet < / ReportType > < Role > http: / / xbrl. sec. gov / dei / role / document / AuditInformation < / Role > < ShortName > Audit Information < / ShortName > < MenuCategory > Cover < / MenuCategory > < Position > 2 < / Position > < / Report > < Report instance =" ea0204725-10k_nutriband. htm" > < IsDefault > false < / IsDefault > < HasEmbeddedReports > false < / HasEmbeddedReports > < HtmlFileName > R3. htm < / HtmlFileName > < LongName > 995301- Statement- Condensed Consolidated Balance Sheets < / LongName > < ReportType > Sheet < / ReportType > < Role > http: / / nutriband. com / role / ConsolidatedBalanceSheet < / Role > < ShortName > Condensed Consolidated Balance Sheets < / ShortName > < MenuCategory > Statements < / MenuCategory > < Position > 3 < / Position > < / Report > < Report instance =" ea0204725-10k_nutriband. htm" > < IsDefault > false < / IsDefault > < HasEmbeddedReports > false < / HasEmbeddedReports > < HtmlFileName > R4. htm < / HtmlFileName > < LongName > 995302- Statement- Condensed Consolidated Balance Sheets (Parentheticals) < / LongName > < ReportType > Sheet < / ReportType > < Role > http: / / nutriband. com / role / ConsolidatedBalanceSheet_Parentheticals < / Role > < ShortName > Condensed Consolidated Balance Sheets (Parentheticals) < / ShortName > < MenuCategory > Statements < / MenuCategory > < Position > 4 < / Position > < / Report > < Report instance =" ea0204725-10k_nutriband. htm" > < IsDefault > false < / IsDefault > < HasEmbeddedReports > false < / HasEmbeddedReports > < HtmlFileName > R5. htm < / HtmlFileName > < LongName > 995303- Statement- Consolidated Statements of Operations < / LongName > < ReportType > Sheet < / ReportType > < Role > http: / / nutriband. com / role / ConsolidatedIncomeStatement < / Role > < ShortName > Consolidated Statements of Operations < / ShortName > < MenuCategory > Statements < / MenuCategory > < Position > 5 < / Position > < / Report > < Report instance =" ea0204725-10k_nutriband. htm" > < IsDefault > false < / IsDefault > < HasEmbeddedReports > false < / HasEmbeddedReports > < HtmlFileName > R6. htm < / HtmlFileName > < LongName > 995304- Statement- Consolidated Statements of Operations (Parentheticals) < / LongName > < ReportType > Sheet < / ReportType > < Role > http: / / nutriband. com / role / ConsolidatedIncomeStatement_Parentheticals < / Role > < ShortName > Consolidated Statements of Operations (Parentheticals) < / ShortName > < MenuCategory > Statements < / MenuCategory > < Position > 6 < / Position > < / Report > < Report instance =" ea0204725-10k_nutriband. htm" > < IsDefault > false < / IsDefault > < HasEmbeddedReports > false < / HasEmbeddedReports > < HtmlFileName > R7. htm < / HtmlFileName > < LongName > 995305- Statement- Consolidated Statements of Stockholders??? Equity < / LongName > < ReportType > Sheet < / ReportType > < Role > http: / / nutriband. com / role / ShareholdersEquityType2or3 < / Role > < ShortName > Consolidated Statements of Stockholders??? Equity < / ShortName > < MenuCategory > Statements < / MenuCategory > < Position > 7 < / Position > < / Report > < Report instance =" ea0204725-10k_nutriband. htm" > < IsDefault > false < / IsDefault > < HasEmbeddedReports > false < / HasEmbeddedReports > < HtmlFileName > R8. htm < / HtmlFileName > < LongName > 995306- Statement- Consolidated Statements of Cash Flows < / LongName > < ReportType > Sheet < / ReportType > < Role > http: / / nutriband. com / role / ConsolidatedCashFlow < / Role > <

ShortName > Consolidated Statements of Cash Flows < / ShortName > < MenuCategory > Statements < / MenuCategory > < Position > 8 < / Position > < / Report > < Report instance =" ea0204725- 10k_nutriband. htm" > < IsDefault > false < / IsDefault > < HasEmbeddedReports > false < / HasEmbeddedReports > < HtmlFileName > R9. htm < / HtmlFileName > < LongName > 995307- Disclosure- Organization and Description of Business < / LongName > < ReportType > Sheet < / ReportType > < Role > http: / / nutriband. com / role / OrganizationandDescriptionofBusiness < / Role > < ShortName > Organization and Description of Business < / ShortName > < MenuCategory > Notes < / MenuCategory > < Position > 9 < / Position > < / Report > < Report instance =" ea0204725- 10k_nutriband. htm" > < IsDefault > false < / IsDefault > < HasEmbeddedReports > false < / HasEmbeddedReports > < HtmlFileName > R10. htm < / HtmlFileName > < LongName > 995308- Disclosure- Summary of Significant Accounting Policies < / LongName > < ReportType > Sheet < / ReportType > < Role > http: / / nutriband. com / role / SummaryofSignificantAccountingPolicies < / Role > < ShortName > Summary of Significant Accounting Policies < / ShortName > < MenuCategory > Notes < / MenuCategory > < Position > 10 < / Position > < / Report > < Report instance =" ea0204725- 10k_nutriband. htm" > < IsDefault > false < / IsDefault > < HasEmbeddedReports > false < / HasEmbeddedReports > < HtmlFileName > R11. htm < / HtmlFileName > < LongName > 995309- Disclosure- Property and Equipment < / LongName > < ReportType > Sheet < / ReportType > < Role > http: / / nutriband. com / role / PropertyandEquipment < / Role > < ShortName > Property and Equipment < / ShortName > < MenuCategory > Notes < / MenuCategory > < Position > 11 < / Position > < / Report > < Report instance =" ea0204725- 10k_nutriband. htm" > < IsDefault > false < / IsDefault > < HasEmbeddedReports > false < / HasEmbeddedReports > < HtmlFileName > R12. htm < / HtmlFileName > < LongName > 995310- Disclosure- Income Taxes < / LongName > < ReportType > Sheet < / ReportType > < Role > http: / / nutriband. com / role / IncomeTaxes < / Role > < ShortName > Income Taxes < / ShortName > < MenuCategory > Notes < / MenuCategory > < Position > 12 < / Position > < / Report > < Report instance =" ea0204725- 10k_nutriband. htm" > < IsDefault > false < / IsDefault > < HasEmbeddedReports > false < / HasEmbeddedReports > < HtmlFileName > R13. htm < / HtmlFileName > < LongName > 995311- Disclosure- Notes Payable < / LongName > < ReportType > Notes < / ReportType > < Role > http: / / nutriband. com / role / NotesPayable < / Role > < ShortName > Notes Payable < / ShortName > < MenuCategory > Notes < / MenuCategory > < Position > 13 < / Position > < / Report > < Report instance =" ea0204725- 10k_nutriband. htm" > < IsDefault > false < / IsDefault > < HasEmbeddedReports > false < / HasEmbeddedReports > < HtmlFileName > R14. htm < / HtmlFileName > < LongName > 995312- Disclosure- Intangible Assets < / LongName > < ReportType > Sheet < / ReportType > < Role > http: / / nutriband. com / role / IntangibleAssets < / Role > < ShortName > Intangible Assets < / ShortName > < MenuCategory > Notes < / MenuCategory > < Position > 14 < / Position > < / Report > < Report instance =" ea0204725- 10k_nutriband. htm" > < IsDefault > false < / IsDefault > < HasEmbeddedReports > false < / HasEmbeddedReports > < HtmlFileName > R15. htm < / HtmlFileName > < LongName > 995313- Disclosure- Related Party Transactions < / LongName > < ReportType > Sheet < / ReportType > < Role > http: / / nutriband. com / role / RelatedPartyTransactions < / Role > < ShortName > Related Party Transactions < / ShortName > < MenuCategory > Notes < / MenuCategory > < Position > 15 < / Position > < / Report > < Report instance =" ea0204725- 10k_nutriband. htm" > < IsDefault > false < / IsDefault > < HasEmbeddedReports > false < / HasEmbeddedReports > < HtmlFileName > R16. htm < / HtmlFileName > < LongName > 995314- Disclosure- Stockholders' Equity < / LongName > < ReportType > Sheet < / ReportType > < Role > http: / / nutriband. com / role / StockholdersEquity < / Role > < ShortName > Stockholders' Equity < / ShortName > < MenuCategory > Notes < / MenuCategory > < Position > 16 < / Position > < / Report > < Report instance =" ea0204725- 10k_nutriband. htm" > < IsDefault > false < / IsDefault > < HasEmbeddedReports > false < / HasEmbeddedReports > < HtmlFileName > R17. htm < / HtmlFileName > < LongName > 995315- Disclosure- Options and Warrants < / LongName > < ReportType > Sheet < / ReportType > < Role > http: / / nutriband. com / role / OptionsandWarrants < / Role > < ShortName > Options and Warrants < / ShortName > < MenuCategory > Notes < / MenuCategory > < Position > 17 < / Position > < / Report > < Report instance =" ea0204725- 10k_nutriband. htm" > < IsDefault > false < / IsDefault > < HasEmbeddedReports > false < / HasEmbeddedReports > < HtmlFileName > R18. htm < / HtmlFileName > < LongName > 995316- Disclosure- Segment Reporting < / LongName > < ReportType > Sheet < / ReportType > < Role > http: / / nutriband. com / role / SegmentReporting < / Role > < ShortName > Segment Reporting < / ShortName > < MenuCategory > Notes < / MenuCategory > < Position > 18 < / Position > < / Report > < Report instance =" ea0204725- 10k_nutriband. htm" > < IsDefault > false < / IsDefault > < HasEmbeddedReports > false < / HasEmbeddedReports > < HtmlFileName > R19. htm < / HtmlFileName > < LongName > 995317- Disclosure- Commitments and Contigencies < / LongName > < ReportType > Sheet < / ReportType > < Role > http: / / nutriband. com / role / CommitmentsandContigencies < / Role > < ShortName > Commitments and Contigencies < / ShortName > < MenuCategory > Notes < / MenuCategory > < Position > 19 < / Position > < / Report > < Report instance =" ea0204725- 10k_nutriband. htm" > < IsDefault > false < / IsDefault > < HasEmbeddedReports > false < / HasEmbeddedReports > < HtmlFileName > R20. htm < / HtmlFileName > < LongName > 995318- Disclosure- Subsequent Events < / LongName > < ReportType > Sheet < / ReportType > < Role > http: / / nutriband. com / role / SubsequentEvents < / Role > < ShortName > Subsequent Events < / ShortName > < MenuCategory > Notes < / MenuCategory > < Position > 20 < / Position > < / Report > < Report instance =" ea0204725- 10k_nutriband. htm" > < IsDefault > false < / IsDefault > < HasEmbeddedReports > false < / HasEmbeddedReports > < HtmlFileName > R21. htm < / HtmlFileName > < LongName > 995410- Disclosure- Pay vs Performance Disclosure < / LongName > < ReportType > Sheet < / ReportType > < Role > http: / / xbrl. sec. gov / ecd / role / PvpDisclosure < / Role > < ShortName > Pay vs Performance Disclosure < / ShortName > < MenuCategory > Notes < / MenuCategory > < Position > 21 < / Position > < / Report > < Report instance =" ea0204725- 10k_nutriband. htm" > < IsDefault > false < / IsDefault > < HasEmbeddedReports > false < / HasEmbeddedReports > < HtmlFileName > R22. htm < / HtmlFileName > < LongName > 995445- Disclosure- Insider Trading Arrangements < / LongName > < ReportType > Sheet < / ReportType > < Role > http: / / xbrl. sec. gov / ecd / role / InsiderTradingArrangements < / Role > < ShortName > Insider Trading Arrangements < / ShortName > < MenuCategory > Notes < / MenuCategory > < Position > 22 < / Position > < / Report > < Report instance =" ea0204725- 10k_nutriband. htm" > < IsDefault > false < / IsDefault > < HasEmbeddedReports > false < / HasEmbeddedReports > < HtmlFileName > R23. htm < / HtmlFileName > < LongName > 996000- Disclosure- Accounting Policies, by Policy (Policies) < / LongName > < ReportType > Sheet < / ReportType > < Role > http: / / nutriband. com / role / AccountingPoliciesByPolicy < / Role > < ShortName > Accounting Policies, by Policy (Policies) < / ShortName > < MenuCategory > Policies < / MenuCategory > < ParentRole > http: / / nutriband. com / role / SummaryofSignificantAccountingPolicies < / ParentRole > < Position > 23 < / Position > < / Report > < Report instance =" ea0204725- 10k_nutriband. htm" > < IsDefault > false < / IsDefault > < HasEmbeddedReports > false < / HasEmbeddedReports > < HtmlFileName > R24. htm < / HtmlFileName > < LongName > 996001- Disclosure- Summary of Significant Accounting Policies (Tables) < / LongName > < ReportType > Sheet < / ReportType > < Role > http: / / nutriband. com / role / SummaryofSignificantAccountingPoliciesTables < / Role > < ShortName > Summary of Significant Accounting Policies (Tables) < / ShortName > < MenuCategory > Tables < / MenuCategory > < ParentRole > http: / / nutriband. com / role / SummaryofSignificantAccountingPolicies < / ParentRole > < Position > 24 < / Position > < / Report > < Report instance =" ea0204725- 10k_nutriband. htm" > < IsDefault > false < / IsDefault > < HasEmbeddedReports > false < / HasEmbeddedReports > < HtmlFileName > R25. htm < / HtmlFileName > < LongName > 996002- Disclosure- Property and Equipment (Tables) < / LongName > < ReportType > Sheet < / ReportType > < Role > http: / / nutriband. com / role / PropertyandEquipmentTables < / Role > < ShortName > Property and Equipment (Tables) < / ShortName > < MenuCategory > Tables < / MenuCategory > < ParentRole > http: / / nutriband. com / role / PropertyandEquipment < / ParentRole > < Position > 25 < / Position > < / Report > < Report instance =" ea0204725- 10k_nutriband. htm" > < IsDefault > false < / IsDefault > < HasEmbeddedReports > false < / HasEmbeddedReports > < HtmlFileName > R26. htm < / HtmlFileName > < LongName > 996003- Disclosure- Income Taxes (Tables) < / LongName > < ReportType > Sheet < / ReportType > < Role > http: / / nutriband. com / role / IncomeTaxesTables < / Role > < ShortName > Income Taxes (Tables) < / ShortName > < MenuCategory > Tables < / MenuCategory > < ParentRole > http: / / nutriband. com / role / IncomeTaxes < / ParentRole > < Position > 26 < / Position > < / Report > < Report instance =" ea0204725- 10k_nutriband. htm" > < IsDefault > false < / IsDefault > < HasEmbeddedReports > false < / HasEmbeddedReports > < HtmlFileName > R27. htm < / HtmlFileName > < LongName > 996004- Disclosure- Intangible Assets (Tables) < / LongName > < ReportType > Sheet < / ReportType > < Role > http: / / nutriband. com / role / IntangibleAssetsTables < / Role > < ShortName > Intangible Assets (Tables) < / ShortName > < MenuCategory > Tables < / MenuCategory > < ParentRole > http: / / nutriband. com / role / IntangibleAssets < / ParentRole > < Position > 27 < / Position > < / Report > < Report instance =" ea0204725- 10k_nutriband. htm" > < IsDefault > false < / IsDefault > < HasEmbeddedReports > false < / HasEmbeddedReports > < HtmlFileName > R28. htm < / HtmlFileName > < LongName > 996005- Disclosure- Options and Warrants (Tables) < / LongName > < ReportType > Sheet < / ReportType > < Role > http: / / nutriband. com / role / OptionsandWarrantsTables < / Role > < ShortName > Options and Warrants (Tables) < / ShortName > < MenuCategory > Tables < / MenuCategory > < ParentRole > http: / / nutriband. com / role / OptionsandWarrants < / ParentRole > < Position > 28 < / Position > < / Report > < Report instance =" ea0204725- 10k_nutriband. htm" > < IsDefault > false < / IsDefault > < HasEmbeddedReports > false < / HasEmbeddedReports > < HtmlFileName > R29. htm < / HtmlFileName > < LongName > 996006- Disclosure- Segment Reporting (Tables) < / LongName > < ReportType > Sheet < / ReportType > < Role > http: / / nutriband. com / role / SegmentReportingTables < / Role > < ShortName > Segment Reporting (Tables) < / ShortName > < MenuCategory > Tables < / MenuCategory > < ParentRole > http: / / nutriband. com / role / SegmentReporting < / ParentRole > < Position > 29 < / Position > < / Report > < Report instance =" ea0204725- 10k_nutriband. htm" > < IsDefault > false < / IsDefault > < HasEmbeddedReports > false < / HasEmbeddedReports > < HtmlFileName > R30. htm < / HtmlFileName > < LongName > 996007- Disclosure- Organization and Description of Business (Details) < / LongName > < ReportType > Sheet < / ReportType >

< Role > http: / / nutriband. com / role / OrganizationandDescriptionofBusinessDetails < / Role > < ShortName > Organization and Description of Business (Details) < / ShortName > < MenuCategory > Details < / MenuCategory > < ParentRole > http: / / nutriband. com / role / OrganizationandDescriptionofBusiness < / ParentRole > < Position > 30 < / Position > < / Report > < Report instance =" ea0204725- 10k_nutriband. htm" > < IsDefault > false < / IsDefault > < HasEmbeddedReports > false < / HasEmbeddedReports > < HtmlFileName > R31. htm < / HtmlFileName > < LongName > 996008- Disclosure- Summary of Significant Accounting Policies (Details) < / LongName > < ReportType > Sheet < / ReportType > < Role > http: / / nutriband. com / role / SummaryofSignificantAccountingPoliciesDetails < / Role > < ShortName > Summary of Significant Accounting Policies (Details) < / ShortName > < MenuCategory > Details < / MenuCategory > < ParentRole > http: / / nutriband. com / role / SummaryofSignificantAccountingPoliciesTables < / ParentRole > < Position > 31 < / Position > < / Report > < Report instance =" ea0204725- 10k_nutriband. htm" > < IsDefault > false < / IsDefault > < HasEmbeddedReports > false < / HasEmbeddedReports > < HtmlFileName > R32. htm < / HtmlFileName > < LongName > 996009- Disclosure- Summary of Significant Accounting Policies (Details) - Schedule of Disaggregates its Revenue from Contracts < / LongName > < ReportType > Sheet < / ReportType > < Role > http: / / nutriband. com / role / ScheduleofDisaggregatesitsRevenuefromContractsTable < / Role > < ShortName > Summary of Significant Accounting Policies (Details)- Schedule of Disaggregates its Revenue from Contracts < / ShortName > < MenuCategory > Details < / MenuCategory > < ParentRole > http: / / nutriband. com / role / SummaryofSignificantAccountingPoliciesTables < / ParentRole > < Position > 32 < / Position > < / Report > < Report instance =" ea0204725- 10k_nutriband. htm" > < IsDefault > false < / IsDefault > < HasEmbeddedReports > false < / HasEmbeddedReports > < HtmlFileName > R33. htm < / HtmlFileName > < LongName > 996010- Disclosure- Summary of Significant Accounting Policies (Details)- Schedule of Revenue by Geographic Location < / LongName > < ReportType > Sheet < / ReportType > < Role > http: / / nutriband. com / role / ScheduleofRevenuebyGeographicLocationTable < / Role > < ShortName > Summary of Significant Accounting Policies (Details)- Schedule of Revenue by Geographic Location < / ShortName > < MenuCategory > Details < / MenuCategory > < ParentRole > http: / / nutriband. com / role / SummaryofSignificantAccountingPoliciesTables < / ParentRole > < Position > 33 < / Position > < / Report > < Report instance =" ea0204725- 10k_nutriband. htm" > < IsDefault > false < / IsDefault > < HasEmbeddedReports > false < / HasEmbeddedReports > < HtmlFileName > R34. htm < / HtmlFileName > < LongName > 996011- Disclosure- Summary of Significant Accounting Policies (Details)- Schedule of Plant and Equipment on a Straight- Line Basis Over the Estimated Useful Life of the Assets < / LongName > < ReportType > Sheet < / ReportType > < Role > http: / / nutriband. com / role / ScheduleofPlantandEquipmentonaStraightLineBasisOvertheEstimatedUsefulLifeoftheAssetsTable < / Role > < ShortName > Summary of Significant Accounting Policies (Details)- Schedule of Plant and Equipment on a Straight- Line Basis Over the Estimated Useful Life of the Assets < / ShortName > < MenuCategory > Details < / MenuCategory > < ParentRole > http: / / nutriband. com / role / SummaryofSignificantAccountingPoliciesTables < / ParentRole > < Position > 34 < / Position > < / Report > < Report instance =" ea0204725- 10k_nutriband. htm" > < IsDefault > false < / IsDefault > < HasEmbeddedReports > false < / HasEmbeddedReports > < HtmlFileName > R35. htm < / HtmlFileName > < LongName > 996012- Disclosure- Property and Equipment (Details) < / LongName > < ReportType > Sheet < / ReportType > < Role > http: / / nutriband. com / role / PropertyandEquipmentDetails < / Role > < ShortName > Property and Equipment (Details) < / ShortName > < MenuCategory > Details < / MenuCategory > < ParentRole > http: / / nutriband. com / role / PropertyandEquipmentTables < / ParentRole > < Position > 35 < / Position > < / Report > < Report instance =" ea0204725- 10k_nutriband. htm" > < IsDefault > false < / IsDefault > < HasEmbeddedReports > false < / HasEmbeddedReports > < HtmlFileName > R36. htm < / HtmlFileName > < LongName > 996013- Disclosure- Property and Equipment (Details)- Schedule of Property and Equipment < / LongName > < ReportType > Sheet < / ReportType > < Role > http: / / nutriband. com / role / ScheduleofPropertyandEquipmentTable < / Role > < ShortName > Property and Equipment (Details)- Schedule of Property and Equipment < / ShortName > < MenuCategory > Details < / MenuCategory > < ParentRole > http: / / nutriband. com / role / PropertyandEquipmentTables < / ParentRole > < Position > 36 < / Position > < / Report > < Report instance =" ea0204725- 10k_nutriband. htm" > < IsDefault > false < / IsDefault > < HasEmbeddedReports > false < / HasEmbeddedReports > < HtmlFileName > R37. htm < / HtmlFileName > < LongName > 996014- Disclosure- Income Taxes (Details) < / LongName > < ReportType > Sheet < / ReportType > < Role > http: / / nutriband. com / role / IncomeTaxesDetails < / Role > < ShortName > Income Taxes (Details) < / ShortName > < MenuCategory > Details < / MenuCategory > < ParentRole > http: / / nutriband. com / role / IncomeTaxesTables < / ParentRole > < Position > 37 < / Position > < / Report > < Report instance =" ea0204725- 10k_nutriband. htm" > < IsDefault > false < / IsDefault > < HasEmbeddedReports > false < / HasEmbeddedReports > < HtmlFileName > R38. htm < / HtmlFileName > < LongName > 996015- Disclosure- Income Taxes (Details)- Schedule of Provision for Income Taxes < / LongName > < ReportType > Sheet < / ReportType > < Role > http: / / nutriband. com / role / ScheduleofProvisionforIncomeTaxesTable < / Role > < ShortName > Income Taxes (Details)- Schedule of Provision for Income Taxes < / ShortName > < MenuCategory > Details < / MenuCategory > < ParentRole > http: / / nutriband. com / role / IncomeTaxesTables < / ParentRole > < Position > 38 < / Position > < / Report > < Report instance =" ea0204725- 10k_nutriband. htm" > < IsDefault > false < / IsDefault > < HasEmbeddedReports > false < / HasEmbeddedReports > < HtmlFileName > R39. htm < / HtmlFileName > < LongName > 996016- Disclosure- Income Taxes (Details)- Schedule of Reconciliation of Taxes on Income < / LongName > < ReportType > Sheet < / ReportType > < Role > http: / / nutriband. com / role / ScheduleofReconciliationofTaxesonIncomeTable < / Role > < ShortName > Income Taxes (Details)- Schedule of Reconciliation of Taxes on Income < / ShortName > < MenuCategory > Details < / MenuCategory > < ParentRole > http: / / nutriband. com / role / IncomeTaxesTables < / ParentRole > < Position > 39 < / Position > < / Report > < Report instance =" ea0204725- 10k_nutriband. htm" > < IsDefault > false < / IsDefault > < HasEmbeddedReports > false < / HasEmbeddedReports > < HtmlFileName > R40. htm < / HtmlFileName > < LongName > 996017- Disclosure- Income Taxes (Details)- Schedule of Deferred Tax Liability and Deferred Tax Asset < / LongName > < ReportType > Sheet < / ReportType > < Role > http: / / nutriband. com / role / ScheduleofDeferredTaxLiabilityandDeferredTaxAssetTable < / Role > < ShortName > Income Taxes (Details)- Schedule of Deferred Tax Liability and Deferred Tax Asset < / ShortName > < MenuCategory > Details < / MenuCategory > < ParentRole > http: / / nutriband. com / role / IncomeTaxesTables < / ParentRole > < Position > 40 < / Position > < / Report > < Report instance =" ea0204725- 10k_nutriband. htm" > < IsDefault > false < / IsDefault > < HasEmbeddedReports > false < / HasEmbeddedReports > < HtmlFileName > R41. htm < / HtmlFileName > < LongName > 996018- Disclosure- Notes Payable (Details) < / LongName > < ReportType > Notes < / ReportType > < Role > http: / / nutriband. com / role / NotesPayableDetails < / Role > < ShortName > Notes Payable (Details) < / ShortName > < MenuCategory > Details < / MenuCategory > < ParentRole > http: / / nutriband. com / role / NotesPayable < / ParentRole > < Position > 41 < / Position > < / Report > < Report instance =" ea0204725- 10k_nutriband. htm" > < IsDefault > false < / IsDefault > < HasEmbeddedReports > false < / HasEmbeddedReports > < HtmlFileName > R42. htm < / HtmlFileName > < LongName > 996019- Disclosure- Intangible Assets (Details) < / LongName > < ReportType > Sheet < / ReportType > < Role > http: / / nutriband. com / role / IntangibleAssetsDetails < / Role > < ShortName > Intangible Assets (Details) < / ShortName > < MenuCategory > Details < / MenuCategory > < ParentRole > http: / / nutriband. com / role / IntangibleAssetsTables < / ParentRole > < Position > 42 < / Position > < / Report > < Report instance =" ea0204725- 10k_nutriband. htm" > < IsDefault > false < / IsDefault > < HasEmbeddedReports > false < / HasEmbeddedReports > < HtmlFileName > R43. htm < / HtmlFileName > < LongName > 996020- Disclosure- Intangible Assets (Details)- Schedule of Intangible Assets < / LongName > < ReportType > Sheet < / ReportType > < Role > http: / / nutriband. com / role / ScheduleofIntangibleAssetsTable < / Role > < ShortName > Intangible Assets (Details)- Schedule of Intangible Assets < / ShortName > < MenuCategory > Details < / MenuCategory > < ParentRole > http: / / nutriband. com / role / IntangibleAssetsTables < / ParentRole > < Position > 43 < / Position > < / Report > < Report instance =" ea0204725- 10k_nutriband. htm" > < IsDefault > false < / IsDefault > < HasEmbeddedReports > false < / HasEmbeddedReports > < HtmlFileName > R44. htm < / HtmlFileName > < LongName > 996021- Disclosure- Intangible Assets (Details)- Schedule of Amortization Expenses < / LongName > < ReportType > Sheet < / ReportType > < Role > http: / / nutriband. com / role / ScheduleofAmortizationExpensesTable < / Role > < ShortName > Intangible Assets (Details)- Schedule of Amortization Expenses < / ShortName > < MenuCategory > Details < / MenuCategory > < ParentRole > http: / / nutriband. com / role / IntangibleAssetsTables < / ParentRole > < Position > 44 < / Position > < / Report > < Report instance =" ea0204725- 10k_nutriband. htm" > < IsDefault > false < / IsDefault > < HasEmbeddedReports > false < / HasEmbeddedReports > < HtmlFileName > R45. htm < / HtmlFileName > < LongName > 996022- Disclosure- Related Party Transactions (Details) < / LongName > < ReportType > Sheet < / ReportType > < Role > http: / / nutriband. com / role / RelatedPartyTransactionsDetails < / Role > < ShortName > Related Party Transactions (Details) < / ShortName > < MenuCategory > Details < / MenuCategory > < ParentRole > http: / / nutriband. com / role / RelatedPartyTransactions < / ParentRole > < Position > 45 < / Position > < / Report > < Report instance =" ea0204725- 10k_nutriband. htm" > < IsDefault > false < / IsDefault > < HasEmbeddedReports > false < / HasEmbeddedReports > < HtmlFileName > R46. htm < / HtmlFileName > < LongName > 996023- Disclosure- Stockholders' Equity (Details) < / LongName > < ReportType > Sheet < / ReportType > < Role > http: / / nutriband. com / role / StockholdersEquityDetails < / Role > < ShortName > Stockholders' Equity (Details) < / ShortName > < MenuCategory > Details < / MenuCategory > < ParentRole > http: / / nutriband. com / role / StockholdersEquity < / ParentRole > < Position > 46 < / Position > < / Report > < Report instance =" ea0204725- 10k_nutriband. htm" > < IsDefault > false < / IsDefault > < HasEmbeddedReports > false < / HasEmbeddedReports > < HtmlFileName > R47. htm < / HtmlFileName > < LongName > 996024- Disclosure- Options and Warrants (Details) < / LongName > < ReportType > Sheet < / ReportType > < Role > http: / / nutriband. com / role / OptionsandWarrantsDetails < / Role > < ShortName > Options and Warrants (Details) < / ShortName > < MenuCategory > Details < /

MenuCategory > < ParentRole > http: / / nutriband. com / role / OptionsandWarrantsTables < / ParentRole > < Position > 47 < / Position > < / Report > < Report instance =" ea0204725- 10k_nutriband. htm" > < IsDefault > false < / IsDefault > < HasEmbeddedReports > false < / HasEmbeddedReports > < HtmlFileName > R48. htm < / HtmlFileName > < LongName > 996025- Disclosure- Options and Warrants (Details)- Schedule of Changes in Warrants Outstanding **(Details)-** < / LongName > < ReportType > Sheet < / ReportType > < Role > http: / / nutriband. com / role / ScheduleofChangesinWarrantsOutstandingTable < / Role > < ShortName > Options and Warrants (Details)- Schedule of Changes in Warrants Outstanding < / ShortName > < MenuCategory > Details < / MenuCategory > < ParentRole > http: / / nutriband. com / role / OptionsandWarrantsTables < / ParentRole > < Position > 48 < / Position > < / Report > < Report instance =" ea0204725- 10k_nutriband. htm" > < IsDefault > false < / IsDefault > < HasEmbeddedReports > false < / HasEmbeddedReports > < HtmlFileName > R49. htm < / HtmlFileName > < LongName > 996026- Disclosure- Options and Warrants (Details)- Schedule of Summarizes Additional Information Relating to the Warrants Outstanding < / LongName > < ReportType > Sheet < / ReportType > < Role > http: / / nutriband. com / role / ScheduleofSummarizesAdditionalInformationRelatingtotheWarrantsOutstandingTable < / Role > < ShortName > Options and Warrants (Details)- Schedule of Summarizes Additional Information Relating to the Warrants Outstanding < / ShortName > < MenuCategory > Details < / MenuCategory > < ParentRole > http: / / nutriband. com / role / OptionsandWarrantsTables < / ParentRole > < Position > 49 < / Position > < / Report > < Report instance =" ea0204725- 10k_nutriband. htm" > < IsDefault > false < / IsDefault > < HasEmbeddedReports > false < / HasEmbeddedReports > < HtmlFileName > R50. htm < / HtmlFileName > < LongName > 996027- Disclosure- Options and Warrants (Details)- Schedule of Changes in Options Outstanding < / LongName > < ReportType > Sheet < / ReportType > < Role > http: / / nutriband. com / role / ScheduleofChangesinOptionsOutstandingTable < / Role > < ShortName > Options and Warrants (Details)- Schedule of Changes in Options Outstanding < / ShortName > < MenuCategory > Details < / MenuCategory > < ParentRole > http: / / nutriband. com / role / OptionsandWarrantsTables < / ParentRole > < Position > 50 < / Position > < / Report > < Report instance =" ea0204725- 10k_nutriband. htm" > < IsDefault > false < / IsDefault > < HasEmbeddedReports > false < / HasEmbeddedReports > < HtmlFileName > R51. htm < / HtmlFileName > < LongName > 996028- Disclosure- Options and Warrants (Details)- Schedule of Summarizes Additional Information Relating to the Options Outstanding < / LongName > < ReportType > Sheet < / ReportType > < Role > http: / / nutriband. com / role / ScheduleofSummarizesAdditionalInformationRelatingtotheOptionsOutstandingTable < / Role > < ShortName > Options and Warrants (Details)- Schedule of Summarizes Additional Information Relating to the Options Outstanding < / ShortName > < MenuCategory > Details < / MenuCategory > < ParentRole > http: / / nutriband. com / role / OptionsandWarrantsTables < / ParentRole > < Position > 51 < / Position > < / Report > < Report instance =" ea0204725- 10k_nutriband. htm" > < IsDefault > false < / IsDefault > < HasEmbeddedReports > false < / HasEmbeddedReports > < HtmlFileName > R52. htm < / HtmlFileName > < LongName > 996029- Disclosure- Segment Reporting (Details)- Schedule of Segment Performance to the GAAP Measure of Gross Profit < / LongName > < ReportType > Sheet < / ReportType > < Role > http: / / nutriband. com / role / ScheduleofSegmentPerformancetotheGAAPMeasureofGrossProfitTable < / Role > < ShortName > Segment Reporting (Details)- Schedule of Segment Performance to the GAAP Measure of Gross Profit < / ShortName > < MenuCategory > Details < / MenuCategory > < ParentRole > http: / / nutriband. com / role / SegmentReportingTables < / ParentRole > < Position > 52 < / Position > < / Report > < Report instance =" ea0204725- 10k_nutriband. htm" > < IsDefault > false < / IsDefault > < HasEmbeddedReports > false < / HasEmbeddedReports > < HtmlFileName > R53. htm < / HtmlFileName > < LongName > 996030- Disclosure- Segment Reporting (Details)- Schedule of Net Sales and Property and Equipment < / LongName > < ReportType > Sheet < / ReportType > < Role > http: / / nutriband. com / role / ScheduleofNetSalesandPropertyandEquipmentTable < / Role > < ShortName > Segment Reporting (Details)- Schedule of Net Sales and Property and Equipment < / ShortName > < MenuCategory > Details < / MenuCategory > < ParentRole > http: / / nutriband. com / role / SegmentReportingTables < / ParentRole > < Position > 53 < / Position > < / Report > < Report instance =" ea0204725- 10k_nutriband. htm" > < IsDefault > false < / IsDefault > < HasEmbeddedReports > false < / HasEmbeddedReports > < HtmlFileName > R54. htm < / HtmlFileName > < LongName > 996031- Disclosure- Commitments and Contigencies (Details) < / LongName > < ReportType > Sheet < / ReportType > < Role > http: / / nutriband. com / role / CommitmentsandContigenciesDetails < / Role > < ShortName > Commitments and Contigencies (Details) < / ShortName > < MenuCategory > Details < / MenuCategory > < ParentRole > http: / / nutriband. com / role / CommitmentsandContigencies < / ParentRole > < Position > 54 < / Position > < / Report > < Report instance =" ea0204725- 10k_nutriband. htm" > < IsDefault > false < / IsDefault > < HasEmbeddedReports > false < / HasEmbeddedReports > < HtmlFileName > R55. htm < / HtmlFileName > < LongName > 996032- Disclosure- Subsequent Events (Details) < / LongName > < ReportType > Sheet < / ReportType > < Role > http: / / nutriband. com / role / SubsequentEventsDetails < / Role > < ShortName > Subsequent Events (Details) < / ShortName > < MenuCategory > Details < / MenuCategory > < ParentRole > http: / / nutriband. com / role / SubsequentEvents < / ParentRole > < Position > 55 < / Position > < / Report > < Report > < IsDefault > false < / IsDefault > < HasEmbeddedReports > false < / HasEmbeddedReports > < LongName > All Reports < / LongName > < ReportType > Book < / ReportType > < ShortName > All Reports < / ShortName > < / Report > < / MyReports > < Logs > < Log type =" Warning" > [ ix- 0514- Hidden- Fact- Eligible- For- Transform ] WARN: 4 fact (s) appearing in ix: hidden were eligible for transformation: us- gaap: EarningsPerShareDiluted, us- gaap: WeightedAverageNumberOfDilutedSharesOutstanding- ea0204725- 10k_nutriband. htm 9540, 9541, 9542, 9543 < / Log > < / Logs > < InputFiles > < File doctype =" 10- K" isDefinitelyFs =" true" isUsgaap =" true" original =" ea0204725- 10k_nutriband. htm" > ea0204725- 10k_nutriband. htm < / File > < File > ntrb- 20240131. xsd < / File > < File > ntrb- 20240131_cal. xml < / File > < File > ntrb- 20240131_def. xml < / File > < File > ntrb- 20240131_lab. xml < / File > < File > ntrb- 20240131_pre. xml < / File > < / InputFiles > < SupplementalFiles / > < BaseTaxonomies > < BaseTaxonomy items =" 1" > http: / / fasb. org / srt / 2024 < / BaseTaxonomy > < BaseTaxonomy items =" 639" > http: / / fasb. org / us- gaap / 2024 < / BaseTaxonomy > < BaseTaxonomy items =" 42" > http: / / xbrl. sec. gov / dei / 2024 < / BaseTaxonomy > < BaseTaxonomy items =" 4" > http: / / xbrl. sec. gov / eed / 2024 < / BaseTaxonomy > < / BaseTaxonomies > < HasPresentationLinkbase > true < / HasPresentationLinkbase > < HasCalculationLinkbase > true < / HasCalculationLinkbase > < / FilingSummary > < / XML > < / TEXT > < / DOCUMENT > < DOCUMENT > < TYPE > JSON < SEQUENCE > 73 < FILENAME > MetaLinks. json < DESCRIPTION > IDEA: XBRL DOCUMENT < TEXT > {" version":" 2. 2"," instance": {" ea0204725- 10k_nutriband. htm": {" nsprefix":" ntrb"," nsuri":" http: / / nutriband. com / 20240131"," dts": {" inline": {" local": [" ea0204725- 10k_nutriband. htm" ] }," schema": {" local": [" ntrb- 20240131. xsd" ]," remote": [" http: / / www. xbrl. org / 2003 / xbrl- instance- 2003- 12- 31. xsd"," http: / / www. xbrl. org / 2003 / xbrl- linkbase- 2003- 12- 31. xsd"," http: / / www. xbrl. org / 2003 / xl- 2003- 12- 31. xsd"," http: / / www. xbrl. org / 2003 / xlink- 2003- 12- 31. xsd"," http: / / www. xbrl. org / 2005 / xbrldt- 2005. xsd"," http: / / www. xbrl. org / 2006 / ref- 2006- 02- 27. xsd"," http: / / www. xbrl. org / lrr / role / negated- 2009- 12- 16. xsd"," http: / / www. xbrl. org / lrr / role / net- 2009- 12- 16. xsd"," http: / / www. xbrl. org / lrr / role / reference- 2009- 12- 16. xsd"," https: / / www. xbrl. org / 2020 / extensible- enumerations- 2. 0. xsd"," https: / / www. xbrl. org / dtr / type / 2020- 01- 21 / types. xsd"," https: / / www. xbrl. org / dtr / type / 2022- 03- 31 / types. xsd"," https: / / xbrl. fasb. org / srt / 2024 / elts / srt- 2024. xsd"," https: / / xbrl. fasb. org / srt / 2024 / elts / srt- roles- 2024. xsd"," https: / / xbrl. fasb. org / srt / 2024 / elts / srt- types- 2024. xsd"," https: / / xbrl. fasb. org / us- gaap / 2024 / elts / us- gaap- 2024. xsd"," https: / / xbrl. fasb. org / us- gaap / 2024 / elts / us- roles- 2024. xsd"," https: / / xbrl. fasb. org / us- gaap / 2024 / elts / us- types- 2024. xsd"," https: / / xbrl. sec. gov / country / 2024 / country- 2024. xsd"," https: / / xbrl. sec. gov / dei / 2024 / dei- 2024. xsd"," https: / / xbrl. sec. gov / dei / 2024 / dei- 2024_def. xsd"," https: / / xbrl. sec. gov / dei / 2024 / dei- 2024_lab. xsd"," https: / / xbrl. sec. gov / dei / 2024 / dei- 2024_pre. xsd"," https: / / xbrl. sec. gov / dei / 2024 / dei- sub- 2024. xsd"," https: / / xbrl. sec. gov / eed / 2024 / eed- 2024. xsd"," https: / / xbrl. sec. gov / eed / 2024 / eed- sub- 2024. xsd"," https: / / xbrl. sec. gov / sic / 2024 / sic- 2024. xsd"," https: / / xbrl. sec. gov / stpr / 2024 / stpr- 2024. xsd" ] }," calculationLink": {" local": [" ntrb- 20240131_cal. xml" ] }," definitionLink": {" local": [" ntrb- 20240131_def. xml" ] }," labelLink": {" local": [" ntrb- 20240131_lab. xml" ] }," presentationLink": {" local": [" ntrb- 20240131_pre. xml" ] } }," keyStandard": 317," keyCustom": 93," axisStandard": 22," axisCustom": 0," memberStandard": 29," memberCustom": 30," hidden": {" total": 126," http: / / nutriband. com / 20240131": 46," http: / / fasb. org / us- gaap / 2024": 76," http: / / xbrl. sec. gov / dei / 2024": 4 }," contextCount": 233," entityCount": 1," segmentCount": 63," elementCount": 826," unitCount": 4," baseTaxonomies": {" http: / / fasb. org / us- gaap / 2024": 639," http: / / xbrl. sec. gov / dei / 2024": 42," http: / / xbrl. sec. gov / eed / 2024": 4," http: / / fasb. org / srt / 2024": 1 }," report": {" R1": {" role":" http: / / xbrl. sec. gov / dei / role / document / Cover"," longName":" 995100- Document- Cover"," shortName":" Cover"," isDefault":" true"," groupType":" document"," subGroupType":""," menuCat":" Cover"," order":" 1"," firstAnchor": {" contextRef":" c0"," name":" dei: DocumentType"," unitRef": null," xsiNil":" false"," lang":" en- US"," decimals": null," ancestors": [" b"," p"," div"," body"," html" ]," reportCount": 1," baseRef":" ea0204725- 10k_nutriband. htm"," first": true," unique": true },," uniqueAnchor": {" contextRef":" c0"," name":" dei: DocumentType"," unitRef": null," xsiNil":" false"," lang":" en- US"," decimals": null," ancestors": [" b"," p"," div"," body"," html" ]," reportCount": 1," baseRef":" ea0204725- 10k_nutriband. htm"," first": true," unique": true } }," R2": {" role":" http: / / xbrl. sec. gov / dei / role / document / AuditInformation"," longName":" 995300- Document- Audit Information"," shortName":" Audit Information"," isDefault":" false"," groupType":" document"," subGroupType":""," menuCat":" Cover"," order":" 2"," firstAnchor": {" contextRef":" c0"," name":" dei: AuditorName"," unitRef": null," xsiNil":" false"," lang":" en- US"," decimals": null," ancestors": [" i"," p"," div"," body"," html" ]," reportCount": 1," baseRef":" ea0204725- 10k_nutriband. htm"," first": true," unique": true }," uniqueAnchor": {" contextRef":" c0"," name":" dei: AuditorName"," unitRef": null," xsiNil":" false"," lang":" en- US"," decimals": null," ancestors": [" i"," p"," div"," body"," html" ]," reportCount": 1," baseRef":" ea0204725- 10k_nutriband. htm"," first": true," unique": true } }," R3": {" role":" http: / / nutriband. com / role / ConsolidatedBalanceSheet"," longName":" 995301- Statement- Condensed

Consolidated Balance Sheets"," shortName":" Condensed Consolidated Balance Sheets"," isDefault":" false"," groupType":" statement"," subGroupType":""," menuCat":" Statements"," order":" 3"," firstAnchor": {" contextRef":" e5"," name":" us- gaap: CashAndCashEquivalentsAtCarryingValue"," unitRef":" usd"," xsiNil":" false"," lang": null," decimals":" 0"," ancestors": [" td"," tr"," table"," div"," body"," html" ]," reportCount": 1," baseRef":" ca0204725- 10k_nutriband. htm"," first": true," unique": true },"uniqueAnchor": {" contextRef":" e5"," name":" us- gaap: CashAndCashEquivalentsAtCarryingValue"," unitRef":" usd"," xsiNil":" false"," lang": null," decimals":" 0"," ancestors": [" td"," tr"," table"," div"," body"," html" ]," reportCount": 1," baseRef":" ca0204725- 10k_nutriband. htm"," first": true," unique": true } }," R4": {" role":" http: / / nutriband. com / role / ConsolidatedBalanceSheet_Parentheticals"," longName":" 995302- Statement- Condensed Consolidated Balance Sheets (Parentheticals)"," shortName":" Condensed Consolidated Balance Sheets (Parentheticals)"," isDefault":" false"," groupType":" statement"," subGroupType":" parenthetical"," menuCat":" Statements"," order":" 4"," firstAnchor": {" contextRef":" e5"," name":" us- gaap: PreferredStockParOrStatedValuePerShare"," unitRef":" usdPershares"," xsiNil":" false"," lang": null," decimals":" 3"," ancestors": [" td"," tr"," table"," div"," body"," html" ]," reportCount": 1," baseRef":" ca0204725- 10k_nutriband. htm"," first": true }," uniqueAnchor": {" contextRef":" e5"," name":" us- gaap: PreferredStockSharesOutstanding"," unitRef":" shares"," xsiNil":" false"," lang": null," decimals":" 0"," ancestors": [" td"," tr"," table"," div"," body"," html" ]," reportCount": 1," baseRef":" ca0204725- 10k_nutriband. htm"," unique": true } }," R5": {" role":" http: / / nutriband. com / role / ConsolidatedIncomeStatement"," longName":" 995303- Statement- Consolidated Statements of Operations"," shortName":" Consolidated Statements of Operations"," isDefault":" false"," groupType":" statement"," subGroupType":""," menuCat":" Statements"," order":" 5"," firstAnchor": {" contextRef":" c0"," name":" us- gaap: Revenues"," unitRef":" usd"," xsiNil":" false"," lang": null," decimals":" 0"," ancestors": [" td"," tr"," table"," div"," body"," html" ]," reportCount": 1," baseRef":" ca0204725- 10k_nutriband. htm"," first": true }," uniqueAnchor": {" contextRef":" c0"," name":" us- gaap: CostOfRevenue"," unitRef":" usd"," xsiNil":" false"," lang": null," decimals":" 0"," ancestors": [" td"," tr"," table"," div"," body"," html" ]," reportCount": 1," baseRef":" ca0204725- 10k_nutriband. htm"," unique": true } }," R6": {" role":" http: / / nutriband. com / role / ConsolidatedIncomeStatement_Parentheticals"," longName":" 995304- Statement- Consolidated Statements of Operations (Parentheticals)"," shortName":" Consolidated Statements of Operations (Parentheticals)"," isDefault":" false"," groupType":" statement"," subGroupType":" parenthetical"," menuCat":" Statements"," order":" 6"," firstAnchor": null," uniqueAnchor": null }," R7": {" role":" http: / / nutriband. com / role / ShareholdersEquityType2or3"," longName":" 995305- Statement- Consolidated Statements of Stockholders \ u2019 Equity"," shortName":" Consolidated Statements of Stockholders \ u2019 Equity"," isDefault":" false"," groupType":" statement"," subGroupType":""," menuCat":" Statements"," order":" 7"," firstAnchor": {" contextRef":" e26"," name":" us- gaap: StockholdersEquity"," unitRef":" usd"," xsiNil":" false"," lang": null," decimals":" 0"," ancestors": [" td"," tr"," table"," div"," body"," html" ]," reportCount": 1," baseRef":" ca0204725- 10k_nutriband. htm"," first": true," unique": true }," uniqueAnchor": {" contextRef":" e26"," name":" us- gaap: StockholdersEquity"," unitRef":" usd"," xsiNil":" false"," lang": null," decimals":" 0"," ancestors": [" td"," tr"," table"," div"," body"," html" ]," reportCount": 1," baseRef":" ca0204725- 10k_nutriband. htm"," first": true," unique": true } }," R8": {" role":" http: / / nutriband. com / role / ConsolidatedCashFlow"," longName":" 995306- Statement- Consolidated Statements of Cash Flows"," shortName":" Consolidated Statements of Cash Flows"," isDefault":" false"," groupType":" statement"," subGroupType":""," menuCat":" Statements"," order":" 8"," firstAnchor": {" contextRef":" c0"," name":" us- gaap: NetIncomeLoss"," unitRef":" usd"," xsiNil":" false"," lang": null," decimals":" 0"," ancestors": [" td"," tr"," table"," div"," body"," html" ]," reportCount": 1," baseRef":" ca0204725- 10k_nutriband. htm"," first": true }," uniqueAnchor": {" contextRef":" c0"," name":" us- gaap: DepreciationDepletionAndAmortization"," unitRef":" usd"," xsiNil":" false"," lang": null," decimals":" 0"," ancestors": [" td"," tr"," table"," div"," body"," html" ]," reportCount": 1," baseRef":" ca0204725- 10k_nutriband. htm"," unique": true } }," R9": {" role":" http: / / nutriband. com / role / OrganizationandDescriptionofBusiness"," longName":" 995307- Disclosure- Organization and Description of Business"," shortName":" Organization and Description of Business"," isDefault":" false"," groupType":" disclosure"," subGroupType":""," menuCat":" Notes"," order":" 9"," firstAnchor": {" contextRef":" c0"," name":" us- gaap: OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"," unitRef": null," xsiNil":" false"," lang":" en- US"," decimals": null," ancestors": [" div"," body"," html" ]," reportCount": 1," baseRef":" ca0204725- 10k_nutriband. htm"," first": true," unique": true }," uniqueAnchor": {" contextRef":" c0"," name":" us- gaap: OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"," unitRef": null," xsiNil":" false"," lang":" en- US"," decimals": null," ancestors": [" div"," body"," html" ]," reportCount": 1," baseRef":" ca0204725- 10k_nutriband. htm"," first": true," unique": true } }," R10": {" role":" http: / / nutriband. com / role / SummaryofSignificantAccountingPolicies"," longName":" 995308- Disclosure- Summary of Significant Accounting Policies"," shortName":" Summary of Significant Accounting Policies"," isDefault":" false"," groupType":" disclosure"," subGroupType":""," menuCat":" Notes"," order":" 10"," firstAnchor": {" contextRef":" c0"," name":" us- gaap: SignificantAccountingPoliciesTextBlock"," unitRef": null," xsiNil":" false"," lang":" en- US"," decimals": null," ancestors": [" div"," body"," html" ]," reportCount": 1," baseRef":" ca0204725- 10k_nutriband. htm"," first": true," unique": true }," uniqueAnchor": {" contextRef":" c0"," name":" us- gaap: SignificantAccountingPoliciesTextBlock"," unitRef": null," xsiNil":" false"," lang":" en- US"," decimals": null," ancestors": [" div"," body"," html" ]," reportCount": 1," baseRef":" ca0204725- 10k_nutriband. htm"," first": true," unique": true } }," R11": {" role":" http: / / nutriband. com / role / PropertyandEquipment"," longName":" 995309- Disclosure- Property and Equipment"," shortName":" Property and Equipment"," isDefault":" false"," groupType":" disclosure"," subGroupType":""," menuCat":" Notes"," order":" 11"," firstAnchor": {" contextRef":" c0"," name":" us- gaap: PropertyPlantAndEquipmentDisclosureTextBlock"," unitRef": null," xsiNil":" false"," lang":" en- US"," decimals": null," ancestors": [" div"," body"," html" ]," reportCount": 1," baseRef":" ca0204725- 10k_nutriband. htm"," first": true," unique": true }," uniqueAnchor": {" contextRef":" c0"," name":" us- gaap: PropertyPlantAndEquipmentDisclosureTextBlock"," unitRef": null," xsiNil":" false"," lang":" en- US"," decimals": null," ancestors": [" div"," body"," html" ]," reportCount": 1," baseRef":" ca0204725- 10k_nutriband. htm"," first": true," unique": true } }," R12": {" role":" http: / / nutriband. com / role / IncomeTaxes"," longName":" 995310- Disclosure- Income Taxes"," shortName":" Income Taxes"," isDefault":" false"," groupType":" disclosure"," subGroupType":""," menuCat":" Notes"," order":" 12"," firstAnchor": {" contextRef":" c0"," name":" us- gaap: IncomeTaxDisclosureTextBlock"," unitRef": null," xsiNil":" false"," lang":" en- US"," decimals": null," ancestors": [" div"," body"," html" ]," reportCount": 1," baseRef":" ca0204725- 10k_nutriband. htm"," first": true," unique": true }," uniqueAnchor": {" contextRef":" c0"," name":" us- gaap: IncomeTaxDisclosureTextBlock"," unitRef": null," xsiNil":" false"," lang":" en- US"," decimals": null," ancestors": [" div"," body"," html" ]," reportCount": 1," baseRef":" ca0204725- 10k_nutriband. htm"," first": true," unique": true } }," R13": {" role":" http: / / nutriband. com / role / NotesPayable"," longName":" 995311- Disclosure- Notes Payable"," shortName":" Notes Payable"," isDefault":" false"," groupType":" disclosure"," subGroupType":""," menuCat":" Notes"," order":" 13"," firstAnchor": {" contextRef":" c0"," name":" us- gaap: DebtDisclosureTextBlock"," unitRef": null," xsiNil":" false"," lang":" en- US"," decimals": null," ancestors": [" div"," body"," html" ]," reportCount": 1," baseRef":" ca0204725- 10k_nutriband. htm"," first": true," unique": true }," uniqueAnchor": {" contextRef":" c0"," name":" us- gaap: DebtDisclosureTextBlock"," unitRef": null," xsiNil":" false"," lang":" en- US"," decimals": null," ancestors": [" div"," body"," html" ]," reportCount": 1," baseRef":" ca0204725- 10k_nutriband. htm"," first": true," unique": true } }," R14": {" role":" http: / / nutriband. com / role / IntangibleAssets"," longName":" 995312- Disclosure- Intangible Assets"," shortName":" Intangible Assets"," isDefault":" false"," groupType":" disclosure"," subGroupType":""," menuCat":" Notes"," order":" 14"," firstAnchor": {" contextRef":" c0"," name":" us- gaap: IntangibleAssetsDisclosureTextBlock"," unitRef": null," xsiNil":" false"," lang":" en- US"," decimals": null," ancestors": [" div"," body"," html" ]," reportCount": 1," baseRef":" ca0204725- 10k_nutriband. htm"," first": true," unique": true }," uniqueAnchor": {" contextRef":" c0"," name":" us- gaap: IntangibleAssetsDisclosureTextBlock"," unitRef": null," xsiNil":" false"," lang":" en- US"," decimals": null," ancestors": [" div"," body"," html" ]," reportCount": 1," baseRef":" ca0204725- 10k_nutriband. htm"," first": true," unique": true } }," R15": {" role":" http: / / nutriband. com / role / RelatedPartyTransactions"," longName":" 995313- Disclosure- Related Party Transactions"," shortName":" Related Party Transactions"," isDefault":" false"," groupType":" disclosure"," subGroupType":""," menuCat":" Notes"," order":" 15"," firstAnchor": {" contextRef":" c0"," name":" us- gaap: RelatedPartyTransactionsDisclosureTextBlock"," unitRef": null," xsiNil":" false"," lang":" en- US"," decimals": null," ancestors": [" div"," body"," html" ]," reportCount": 1," baseRef":" ca0204725- 10k_nutriband. htm"," first": true," unique": true },"uniqueAnchor": {" contextRef":" c0"," name":" us- gaap: RelatedPartyTransactionsDisclosureTextBlock"," unitRef": null," xsiNil":" false"," lang":" en- US"," decimals": null," ancestors": [" div"," body"," html" ]," reportCount": 1," baseRef":" ca0204725- 10k_nutriband. htm"," first": true," unique": true } }," R16": {" role":" http: / / nutriband. com / role / StockholdersEquity"," longName":" 995314- Disclosure- Stockholders' Equity"," shortName":" Stockholders' Equity"," isDefault":" false"," groupType":" disclosure"," subGroupType":""," menuCat":" Notes"," order":" 16"," firstAnchor": {" contextRef":" c0"," name":" us- gaap: StockholdersEquityNoteDisclosureTextBlock"," unitRef": null," xsiNil":" false"," lang":" en- US"," decimals": null," ancestors": [" div"," body"," html" ]," reportCount": 1," baseRef":" ca0204725- 10k_nutriband. htm"," first": true," unique": true }," uniqueAnchor": {" contextRef":" c0"," name":" us- gaap: StockholdersEquityNoteDisclosureTextBlock"," unitRef": null," xsiNil":" false"," lang":" en- US"," decimals": null," ancestors": [" div"," body"," html" ]," reportCount": 1," baseRef":" ca0204725- 10k_nutriband. htm"," first": true," unique": true } }," R17": {" role":" http: / / nutriband. com / role / OptionsandWarrants"," longName":" 995315- Disclosure- Options and Warrants"," shortName":" Options and Warrants"," isDefault":" false"," groupType":" disclosure"," subGroupType":""," menuCat":" Notes"," order":" 17"," firstAnchor": {" contextRef":" c0"," name":" ntrb: OptionsAndWarrantsTextBlock"," unitRef": null," xsiNil":" false"," lang":" en- US"," decimals": null," ancestors": [" div"," body"," html" ]," reportCount": 1,"

baseRef":" ea0204725- 10k_nutriband. htm"," first": true," unique": true }," uniqueAnchor": {" contextRef":" c0"," name":" ntrb: OptionsAndWarrantsTextBlock"," unitRef": null," xsiNil":" false"," lang":" en- US"," decimals": null," ancestors": [" div"," body"," html" ]," reportCount": 1," baseRef":" ea0204725- 10k_nutriband. htm"," first": true," unique": true } }," R18": {" role":" http: / / nutriband. com / role / SegmentReporting"," longName":" 995316- Disclosure- Segment Reporting"," shortName":" Segment Reporting"," isDefault":" false"," groupType":" disclosure"," subGroupType":""," menuCat":" Notes"," order":" 18"," firstAnchor": {" contextRef":" c0"," name":" us- gaap: SegmentReportingDisclosureTextBlock"," unitRef": null," xsiNil":" false"," lang":" en- US"," decimals": null," ancestors": [" div"," body"," html" ]," reportCount": 1," baseRef":" ea0204725- 10k_nutriband. htm"," first": true," unique": true }," uniqueAnchor": {" contextRef":" c0"," name":" us- gaap: SegmentReportingDisclosureTextBlock"," unitRef": null," xsiNil":" false"," lang":" en- US"," decimals": null," ancestors": [" div"," body"," html" ]," reportCount": 1," baseRef":" ea0204725- 10k_nutriband. htm"," first": true," unique": true } }," R19": {" role":" http: / / nutriband. com / role / CommitmentsandContigencies"," longName":" 995317- Disclosure- Commitments and Contigencies"," shortName":" Commitments and Contigencies"," isDefault":" false"," groupType":" disclosure"," subGroupType":""," menuCat":" Notes"," order":" 19"," firstAnchor": {" contextRef":" c0"," name":" us- gaap: CommitmentsAndContingenciesDisclosureTextBlock"," unitRef": null," xsiNil":" false"," lang":" en- US"," decimals": null," ancestors": [" div"," body"," html" ]," reportCount": 1," baseRef":" ea0204725- 10k_nutriband. htm"," first": true," unique": true }," uniqueAnchor": {" contextRef":" c0"," name":" us- gaap: CommitmentsAndContingenciesDisclosureTextBlock"," unitRef": null," xsiNil":" false"," lang":" en- US"," decimals": null," ancestors": [" div"," body"," html" ]," reportCount": 1," baseRef":" ea0204725- 10k_nutriband. htm"," first": true," unique": true } }," R20": {" role":" http: / / nutriband. com / role / SubsequentEvents"," longName":" 995318- Disclosure- Subsequent Events"," shortName":" Subsequent Events"," isDefault":" false"," groupType":" disclosure"," subGroupType":""," menuCat":" Notes"," order":" 20"," firstAnchor": {" contextRef":" c0"," name":" us- gaap: SubsequentEventsTextBlock"," unitRef": null," xsiNil":" false"," lang":" en- US"," decimals": null," ancestors": [" div"," body"," html" ]," reportCount": 1," baseRef":" ea0204725- 10k_nutriband. htm"," first": true," unique": true }," uniqueAnchor": {" contextRef":" c0"," name":" us- gaap: SubsequentEventsTextBlock"," unitRef": null," xsiNil":" false"," lang":" en- US"," decimals": null," ancestors": [" div"," body"," html" ]," reportCount": 1," baseRef":" ea0204725- 10k_nutriband. htm"," first": true," unique": true } }," R21": {" role":" http: / / xbrl. sec. gov / ecd / role / PvpDisclosure"," longName":" 995410- Disclosure- Pay vs Performance Disclosure"," shortName":" Pay vs Performance Disclosure"," isDefault":" false"," groupType":" disclosure"," subGroupType":""," menuCat":" Notes"," order":" 21"," firstAnchor": {" contextRef":" c0"," name":" us- gaap: NetIncomeLoss"," unitRef":" usd"," xsiNil":" false"," lang": null," decimals":" 0"," ancestors": [" td"," tr"," table"," div"," body"," html" ]," reportCount": 1," baseRef":" ea0204725- 10k_nutriband. htm"," first": true }," uniqueAnchor": null }," R22": {" role":" http: / / xbrl. sec. gov / ecd / role / InsiderTradingArrangements"," longName":" 995445- Disclosure- Insider Trading Arrangements"," shortName":" Insider Trading Arrangements"," isDefault":" false"," groupType":" disclosure"," subGroupType":""," menuCat":" Notes"," order":" 22"," firstAnchor": {" contextRef":" c232"," name":" ecd: Rule10b51ArrAdoptedFlag"," unitRef": null," xsiNil":" false"," lang":" en- US"," decimals": null," ancestors": [" ecd: NonRule10b51ArrAdoptedFlag"," ecd: Rule10b51ArrTrmntdFlag"," ecd: NonRule10b51ArrTrmntdFlag"," p"," div"," body"," html" ]," reportCount": 1," baseRef":" ea0204725- 10k_nutriband. htm"," first": true," unique": true }," uniqueAnchor": {" contextRef":" c232"," name":" ecd: Rule10b51ArrAdoptedFlag"," unitRef": null," xsiNil":" false"," lang":" en- US"," decimals": null," ancestors": [" ecd: NonRule10b51ArrAdoptedFlag"," ecd: Rule10b51ArrTrmntdFlag"," ecd: NonRule10b51ArrTrmntdFlag"," p"," div"," body"," html" ]," reportCount": 1," baseRef":" ea0204725- 10k_nutriband. htm"," first": true," unique": true } }," R23": {" role":" http: / / nutriband. com / role / AccountingPoliciesByPolicy"," longName":" 996000- Disclosure- Accounting Policies, by Policy (Policies)"," shortName":" Accounting Policies, by Policy (Policies)"," isDefault":" false"," groupType":" disclosure"," subGroupType":" policies"," menuCat":" Policies"," order":" 23"," firstAnchor": {" contextRef":" c0"," name":" ntrb: ForwardStockSplitPolicyTextBlock"," unitRef": null," xsiNil":" false"," lang":" en- US"," decimals": null," ancestors": [" us- gaap: SignificantAccountingPoliciesTextBlock"," div"," body"," html" ]," reportCount": 1," baseRef":" ea0204725- 10k_nutriband. htm"," first": true," unique": true }," uniqueAnchor": {" contextRef":" c0"," name":" ntrb: ForwardStockSplitPolicyTextBlock"," unitRef": null," xsiNil":" false"," lang":" en- US"," decimals": null," ancestors": [" us- gaap: SignificantAccountingPoliciesTextBlock"," div"," body"," html" ]," reportCount": 1," baseRef":" ea0204725- 10k_nutriband. htm"," first": true," unique": true } }," R24": {" role":" http: / / nutriband. com / role / SummaryofSignificantAccountingPoliciesTables"," longName":" 996001- Disclosure- Summary of Significant Accounting Policies (Tables)"," shortName":" Summary of Significant Accounting Policies (Tables)"," isDefault":" false"," groupType":" disclosure"," subGroupType":" tables"," menuCat":" Tables"," order":" 24"," firstAnchor": {" contextRef":" c0"," name":" us- gaap: ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock"," unitRef": null," xsiNil":" false"," lang":" en- US"," decimals": null," ancestors": [" p"," ix: continuation"," ix: continuation"," div"," body"," html" ]," reportCount": 1," baseRef":" ea0204725- 10k_nutriband. htm"," first": true," unique": true }," uniqueAnchor": {" contextRef":" c0"," name":" us- gaap: ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock"," unitRef": null," xsiNil":" false"," lang":" en- US"," decimals": null," ancestors": [" p"," ix: continuation"," ix: continuation"," div"," body"," html" ]," reportCount": 1," baseRef":" ea0204725- 10k_nutriband. htm"," first": true," unique": true } }," R25": {" role":" http: / / nutriband. com / role / PropertyandEquipmentTables"," longName":" 996002- Disclosure- Property and Equipment (Tables)"," shortName":" Property and Equipment (Tables)"," isDefault":" false"," groupType":" disclosure"," subGroupType":" tables"," menuCat":" Tables"," order":" 25"," firstAnchor": {" contextRef":" c0"," name":" us- gaap: PropertyPlantAndEquipmentTextBlock"," unitRef": null," xsiNil":" false"," lang":" en- US"," decimals": null," ancestors": [" us- gaap: PropertyPlantAndEquipmentDisclosureTextBlock"," div"," body"," html" ]," reportCount": 1," baseRef":" ea0204725- 10k_nutriband. htm"," first": true," unique": true }," uniqueAnchor": {" contextRef":" c0"," name":" us- gaap: PropertyPlantAndEquipmentTextBlock"," unitRef": null," xsiNil":" false"," lang":" en- US"," decimals": null," ancestors": [" us- gaap: PropertyPlantAndEquipmentDisclosureTextBlock"," div"," body"," html" ]," reportCount": 1," baseRef":" ea0204725- 10k_nutriband. htm"," first": true," unique": true } }," R26": {" role":" http: / / nutriband. com / role / IncomeTaxesTables"," longName":" 996003- Disclosure- Income Taxes (Tables)"," shortName":" Income Taxes (Tables)"," isDefault":" false"," groupType":" disclosure"," subGroupType":" tables"," menuCat":" Tables"," order":" 26"," firstAnchor": {" contextRef":" c0"," name":" us- gaap: ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"," unitRef": null," xsiNil":" false"," lang":" en- US"," decimals": null," ancestors": [" p"," ix: continuation"," div"," body"," html" ]," reportCount": 1," baseRef":" ea0204725- 10k_nutriband. htm"," first": true," unique": true }," uniqueAnchor": {" contextRef":" c0"," name":" us- gaap: ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"," unitRef": null," xsiNil":" false"," lang":" en- US"," decimals": null," ancestors": [" p"," ix: continuation"," div"," body"," html" ]," reportCount": 1," baseRef":" ea0204725- 10k_nutriband. htm"," first": true," unique": true } }," R27": {" role":" http: / / nutriband. com / role / IntangibleAssetsTables"," longName":" 996004- Disclosure- Intangible Assets (Tables)"," shortName":" Intangible Assets (Tables)"," isDefault":" false"," groupType":" disclosure"," subGroupType":" tables"," menuCat":" Tables"," order":" 27"," firstAnchor": {" contextRef":" c0"," name":" us- gaap: ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"," unitRef": null," xsiNil":" false"," lang":" en- US"," decimals": null," ancestors": [" p"," us- gaap: IntangibleAssetsDisclosureTextBlock"," div"," body"," html" ]," reportCount": 1," baseRef":" ea0204725- 10k_nutriband. htm"," first": true," unique": true }," uniqueAnchor": {" contextRef":" c0"," name":" us- gaap: ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"," unitRef": null," xsiNil":" false"," lang":" en- US"," decimals": null," ancestors": [" p"," us- gaap: IntangibleAssetsDisclosureTextBlock"," div"," body"," html" ]," reportCount": 1," baseRef":" ea0204725- 10k_nutriband. htm"," first": true," unique": true } }," R28": {" role":" http: / / nutriband. com / role / OptionsandWarrantsTables"," longName":" 996005- Disclosure- Options and Warrants (Tables)"," shortName":" Options and Warrants (Tables)"," isDefault":" false"," groupType":" disclosure"," subGroupType":" tables"," menuCat":" Tables"," order":" 28"," firstAnchor": {" contextRef":" c0"," name":" ntrb: ScheduleOfAdditionalRelatingWarrantsOutstanding"," unitRef": null," xsiNil":" false"," lang":" en- US"," decimals": null," ancestors": [" p"," ntrb: OptionsAndWarrantsTextBlock"," div"," body"," html" ]," reportCount": 1," baseRef":" ea0204725- 10k_nutriband. htm"," first": true," unique": true }," uniqueAnchor": {" contextRef":" c0"," name":" ntrb: ScheduleOfAdditionalRelatingWarrantsOutstanding"," unitRef": null," xsiNil":" false"," lang":" en- US"," decimals": null," ancestors": [" p"," ntrb: OptionsAndWarrantsTextBlock"," div"," body"," html" ]," reportCount": 1," baseRef":" ea0204725- 10k_nutriband. htm"," first": true," unique": true } }," R29": {" role":" http: / / nutriband. com / role / SegmentReportingTables"," longName":" 996006- Disclosure- Segment Reporting (Tables)"," shortName":" Segment Reporting (Tables)"," isDefault":" false"," groupType":" disclosure"," subGroupType":" tables"," menuCat":" Tables"," order":" 29"," firstAnchor": {" contextRef":" c0"," name":" us- gaap: ScheduleOfSegmentReportingInformationBySegmentTextBlock"," unitRef": null," xsiNil":" false"," lang":" en- US"," decimals": null," ancestors": [" p"," us- gaap: SegmentReportingDisclosureTextBlock"," div"," body"," html" ]," reportCount": 1," baseRef":" ea0204725- 10k_nutriband. htm"," first": true," unique": true }," uniqueAnchor": {" contextRef":" c0"," name":" us- gaap: ScheduleOfSegmentReportingInformationBySegmentTextBlock"," unitRef": null," xsiNil":" false"," lang":" en- US"," decimals": null," ancestors": [" p"," us- gaap: SegmentReportingDisclosureTextBlock"," div"," body"," html" ]," reportCount": 1," baseRef":" ea0204725- 10k_nutriband. htm"," first": true," unique": true } }," R30": {" role":" http: / / nutriband. com / role / OrganizationandDescriptionofBusinessDetails"," longName":" 996007- Disclosure- Organization and Description of Business (Details)"," shortName":" Organization and Description of Business (Details)"," isDefault":" false"," groupType":" disclosure"," subGroupType":" details"," menuCat":" Details"," order":" 30"," firstAnchor": {" contextRef":" e36"," name":" us- gaap: BusinessAcquisitionCostOfAcquiredEntityTransactionCosts"," unitRef":" usd"," xsiNil":" false"," lang": null," decimals":" 0"," ancestors": [" p"," us- gaap:

OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"," div"," body"," html" ]," reportCount": 1," baseRef":" ea0204725- 10k_nutriband. htm"," first": true," unique": true }," uniqueAnchor": {" contextRef":" e36"," name":" us- gaap: BusinessAcquisitionCostOfAcquiredEntityTransactionCosts"," unitRef":" usd"," xsiNil":" false"," lang": null," decimals":" 0"," ancestors": [" p"," us- gaap: OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"," div"," body"," html" ]," reportCount": 1," baseRef":" ea0204725- 10k_nutriband. htm"," first": true," unique": true } }," R31": {" role":" http: / / nutriband. com / role / SummaryofSignificantAccountingPoliciesDetails"," longName":" 996008- Disclosure- Summary of Significant Accounting Policies (Details)"," shortName":" Summary of Significant Accounting Policies (Details)"," isDefault":" false"," groupType":" disclosure"," subGroupType":" details"," menuCat":" Details"," order":" 31"," firstAnchor": {" contextRef":" e0"," name":" us- gaap: StockholdersEquityNoteStockSplit"," unitRef": null," xsiNil":" false"," lang":" en- US"," decimals": null," ancestors": [" p"," ix: continuation"," us- gaap: SignificantAccountingPoliciesTextBlock"," div"," body"," html" ]," reportCount": 1," baseRef":" ea0204725- 10k_nutriband. htm"," first": true," unique": true }," uniqueAnchor": {" contextRef":" e0"," name":" us- gaap: StockholdersEquityNoteStockSplit"," unitRef": null," xsiNil":" false"," lang":" en- US"," decimals": null," ancestors": [" p"," ix: continuation"," us- gaap: SignificantAccountingPoliciesTextBlock"," div"," body"," html" ]," reportCount": 1," baseRef":" ea0204725- 10k_nutriband. htm"," first": true," unique": true } }," R32": {" role":" http: / / nutriband. com / role / ScheduleofDisaggregatesitsRevenuefromContractsTable"," longName":" 996009- Disclosure- Summary of Significant Accounting Policies (Details)- Schedule of Disaggregates its Revenue from Contracts"," shortName":" Summary of Significant Accounting Policies (Details)- Schedule of Disaggregates its Revenue from Contracts"," isDefault":" false"," groupType":" disclosure"," subGroupType":" details"," menuCat":" Details"," order":" 32"," firstAnchor": {" contextRef":" e0"," name":" us- gaap: CostOfGoodsAndServicesSold"," unitRef":" usd"," xsiNil":" false"," lang": null," decimals":" 0"," ancestors": [" td"," tr"," table"," ix: continuation"," ix: continuation"," ix: continuation"," div"," body"," html" ]," reportCount": 1," baseRef":" ea0204725- 10k_nutriband. htm"," first": true," unique": true }," uniqueAnchor": {" contextRef":" e0"," name":" us- gaap: CostOfGoodsAndServicesSold"," unitRef":" usd"," xsiNil":" false"," lang": null," decimals":" 0"," ancestors": [" td"," tr"," table"," ix: continuation"," ix: continuation"," div"," body"," html" ]," reportCount": 1," baseRef":" ea0204725- 10k_nutriband. htm"," first": true," unique": true } }," R33": {" role":" http: / / nutriband. com / role / ScheduleofRevenuebyGeographicLocationTable"," longName":" 996010- Disclosure- Summary of Significant Accounting Policies (Details)- Schedule of Revenue by Geographic Location"," shortName":" Summary of Significant Accounting Policies (Details)- Schedule of Revenue by Geographic Location"," isDefault":" false"," groupType":" disclosure"," subGroupType":" details"," menuCat":" Details"," order":" 33"," firstAnchor": {" contextRef":" e0"," name":" us- gaap: Revenues"," unitRef":" usd"," xsiNil":" false"," lang": null," decimals":" 0"," ancestors": [" td"," tr"," table"," div"," body"," html" ]," reportCount": 1," baseRef":" ea0204725- 10k_nutriband. htm"," first": true }," uniqueAnchor": {" contextRef":" e54"," name":" us- gaap: Revenues"," unitRef":" usd"," xsiNil":" false"," lang": null," decimals":" 0"," ancestors": [" td"," tr"," table"," ix: continuation"," us- gaap: RevenueFromExternalCustomersByGeographicAreasTableTextBlock"," ix: continuation"," div"," body"," html" ]," reportCount": 1," baseRef":" ea0204725- 10k_nutriband. htm"," unique": true } }," R34": {" role":" http: / / nutriband. com / role / ScheduleofPlantandEquipmentonaStraightLineBasisOvertheEstimatedUsefulLifeoftheAssetsTable"," longName":" 996011- Disclosure- Summary of Significant Accounting Policies (Details)- Schedule of Plant and Equipment on a Straight- Line Basis Over the Estimated Useful Life of the Assets"," shortName":" Summary of Significant Accounting Policies (Details)- Schedule of Plant and Equipment on a Straight- Line Basis Over the Estimated Useful Life of the Assets"," isDefault":" false"," groupType":" disclosure"," subGroupType":" details"," menuCat":" Details"," order":" 34"," firstAnchor": {" contextRef":" c60"," name":" us- gaap: PropertyPlantAndEquipmentUsefulLife"," unitRef": null," xsiNil":" false"," lang":" en- US"," decimals": null," ancestors": [" td"," tr"," table"," ix: continuation"," ix: continuation"," ix: continuation"," div"," body"," html" ]," reportCount": 1," baseRef":" ea0204725- 10k_nutriband. htm"," first": true," unique": true }," uniqueAnchor": {" contextRef":" c60"," name":" us- gaap: PropertyPlantAndEquipmentUsefulLife"," unitRef": null," xsiNil":" false"," lang":" en- US"," decimals": null," ancestors": [" td"," tr"," table"," ix: continuation"," ix: continuation"," ix: continuation"," div"," body"," html" ]," reportCount": 1," baseRef":" ea0204725- 10k_nutriband. htm"," first": true," unique": true } }," R35": {" role":" http: / / nutriband. com / role / PropertyandEquipmentDetails"," longName":" 996012- Disclosure- Property and Equipment (Details)"," shortName":" Property and Equipment (Details)"," isDefault":" false"," groupType":" disclosure"," subGroupType":" details"," menuCat":" Details"," order":" 35"," firstAnchor": {" contextRef":" e0"," name":" us- gaap: Depreciation"," unitRef":" usd"," xsiNil":" false"," lang": null," decimals":" 0"," ancestors": [" p"," us- gaap: PropertyPlantAndEquipmentDisclosureTextBlock"," div"," body"," html" ]," reportCount": 1," baseRef":" ea0204725- 10k_nutriband. htm"," first": true," unique": true }," uniqueAnchor": {" contextRef":" c0"," name":" us- gaap: Depreciation"," unitRef":" usd"," xsiNil":" false"," lang": null," decimals":" 0"," ancestors": [" p"," us- gaap: PropertyPlantAndEquipmentDisclosureTextBlock"," div"," body"," html" ]," reportCount": 1," baseRef":" ea0204725- 10k_nutriband. htm"," first": true," unique": true } }," R36": {" role":" http: / / nutriband. com / role / ScheduleofPropertyandEquipmentTable"," longName":" 996013- Disclosure- Property and Equipment (Details)- Schedule of Property and Equipment"," shortName":" Property and Equipment (Details)- Schedule of Property and Equipment"," isDefault":" false"," groupType":" disclosure"," subGroupType":" details"," menuCat":" Details"," order":" 36"," firstAnchor": {" contextRef":" e5"," name":" us- gaap: PropertyPlantAndEquipmentGross"," unitRef":" usd"," xsiNil":" false"," lang": null," decimals":" 0"," ancestors": [" td"," tr"," table"," us- gaap: PropertyPlantAndEquipmentTextBlock"," us- gaap: PropertyPlantAndEquipmentDisclosureTextBlock"," div"," body"," html" ]," reportCount": 1," baseRef":" ea0204725- 10k_nutriband. htm"," first": true," unique": true }," uniqueAnchor": {" contextRef":" e5"," name":" us- gaap: PropertyPlantAndEquipmentGross"," unitRef":" usd"," xsiNil":" false"," lang": null," decimals":" 0"," ancestors": [" td"," tr"," table"," us- gaap: PropertyPlantAndEquipmentTextBlock"," us- gaap: PropertyPlantAndEquipmentDisclosureTextBlock"," div"," body"," html" ]," reportCount": 1," baseRef":" ea0204725- 10k_nutriband. htm"," first": true," unique": true } }," R37": {" role":" http: / / nutriband. com / role / IncomeTaxesDetails"," longName":" 996014- Disclosure- Income Taxes (Details)"," shortName":" Income Taxes (Details)"," isDefault":" false"," groupType":" disclosure"," subGroupType":" details"," menuCat":" Details"," order":" 37"," firstAnchor": {" contextRef":" e5"," name":" us- gaap: DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration"," unitRef":" usd"," xsiNil":" false"," lang": null," decimals":" 0"," ancestors": [" p"," ix: continuation"," div"," body"," html" ]," reportCount": 1," baseRef":" ea0204725- 10k_nutriband. htm"," first": true," unique": true }," uniqueAnchor": {" contextRef":" e5"," name":" us- gaap: DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration"," unitRef":" usd"," xsiNil":" false"," lang": null," decimals":" 0"," ancestors": [" p"," ix: continuation"," div"," body"," html" ]," reportCount": 1," baseRef":" ea0204725- 10k_nutriband. htm"," first": true," unique": true } }," R38": {" role":" http: / / nutriband. com / role / ScheduleofProvisionforIncomeTaxesTable"," longName":" 996015- Disclosure- Income Taxes (Details)- Schedule of Provision for Income Taxes"," shortName":" Income Taxes (Details)- Schedule of Provision for Income Taxes"," isDefault":" false"," groupType":" disclosure"," subGroupType":" details"," menuCat":" Details"," order":" 38"," firstAnchor": null," uniqueAnchor": null }," R39": {" role":" http: / / nutriband. com / role / ScheduleofReconciliationofTaxesonIncomeTable"," longName":" 996016- Disclosure- Income Taxes (Details)- Schedule of Reconciliation of Taxes on Income"," shortName":" Income Taxes (Details)- Schedule of Reconciliation of Taxes on Income"," isDefault":" false"," groupType":" disclosure"," subGroupType":" details"," menuCat":" Details"," order":" 39"," firstAnchor": {" contextRef":" e0"," name":" us- gaap: IncomeLossFromContinuingOperations"," unitRef":" usd"," xsiNil":" false"," lang": null," decimals":" 0"," ancestors": [" td"," tr"," table"," ix: continuation"," ix: continuation"," div"," body"," html" ]," reportCount": 1," baseRef":" ea0204725- 10k_nutriband. htm"," first": true," unique": true }," uniqueAnchor": {" contextRef":" e0"," name":" us- gaap: IncomeLossFromContinuingOperations"," unitRef":" usd"," xsiNil":" false"," lang": null," decimals":" 0"," ancestors": [" td"," tr"," table"," ix: continuation"," ix: continuation"," div"," body"," html" ]," reportCount": 1," baseRef":" ea0204725- 10k_nutriband. htm"," first": true," unique": true } }," R40": {" role":" http: / / nutriband. com / role / ScheduleofDeferredTaxLiabilityandDeferredTaxAssetTable"," longName":" 996017- Disclosure- Income Taxes (Details)- Schedule of Deferred Tax Liability and Deferred Tax Asset"," shortName":" Income Taxes (Details)- Schedule of Deferred Tax Liability and Deferred Tax Asset"," isDefault":" false"," groupType":" disclosure"," subGroupType":" details"," menuCat":" Details"," order":" 40"," firstAnchor": {" contextRef":" e5"," name":" us- gaap: DeferredTaxAssetsOperatingLossCarryforwards"," unitRef":" usd"," xsiNil":" false"," lang": null," decimals":" 0"," ancestors": [" td"," tr"," table"," ix: continuation"," ix: continuation"," div"," body"," html" ]," reportCount": 1," baseRef":" ea0204725- 10k_nutriband. htm"," first": true," unique": true }," uniqueAnchor": {" contextRef":" e5"," name":" us- gaap: DeferredTaxAssetsOperatingLossCarryforwards"," unitRef":" usd"," xsiNil":" false"," lang": null," decimals":" 0"," ancestors": [" td"," tr"," table"," ix: continuation"," ix: continuation"," div"," body"," html" ]," reportCount": 1," baseRef":" ea0204725- 10k_nutriband. htm"," first": true," unique": true } }," R41": {" role":" http: / / nutriband. com / role / NotesPayableDetails"," longName":" 996018- Disclosure- Notes Payable (Details)"," shortName":" Notes Payable (Details)"," isDefault":" false"," groupType":" disclosure"," subGroupType":" details"," menuCat":" Details"," order":" 41"," firstAnchor": {" contextRef":" e9"," name":" us- gaap: LineOfCreditFacilityIncreaseAccruedInterest"," unitRef":" usd"," xsiNil":" false"," lang": null," decimals":" 0"," ancestors": [" p"," us- gaap: DebtDisclosureTextBlock"," div"," body"," html" ]," reportCount": 1," baseRef":" ea0204725- 10k_nutriband. htm"," first": true }," uniqueAnchor": {" contextRef":" e0"," name":" us- gaap: LineOfCreditFacilityExpirationDate1"," unitRef": null," xsiNil":" false"," lang":" en- US"," decimals": null," ancestors": [" p"," us- gaap: DebtDisclosureTextBlock"," div"," body"," html" ]," reportCount": 1," baseRef":" ea0204725- 10k_nutriband. htm"," unique": true } }," R42": {" role":" http: / / nutriband. com / role / IntangibleAssetsDetails"," longName":" 996019- Disclosure-

Intangible Assets (Details)"," shortName":" Intangible Assets (Details)"," isDefault":" false"," groupType":" disclosure"," subGroupType":" details"," menuCat":" Details"," order":" 42"," firstAnchor": {" contextRef":" e5"," name":" us- gaap: ExcessStockSharesIssued"," unitRef":" shares"," xsiNil":" false"," lang": null," decimals":" 0"," ancestors": [" p"," us- gaap: IntangibleAssetsDisclosureTextBlock"," div"," body"," html" ]," reportCount": 1," baseRef":" ca0204725- 10k_nutriband. htm"," first": true," unique": true }," uniqueAnchor": {" contextRef":" e5"," name":" us- gaap: ExcessStockSharesIssued"," unitRef":" shares"," xsiNil":" false"," lang": null," decimals":" 0"," ancestors": [" p"," us- gaap: IntangibleAssetsDisclosureTextBlock"," div"," body"," html" ]," reportCount": 1," baseRef":" ca0204725- 10k_nutriband. htm"," first": true," unique": true } }," R43": {" role":" http: / / nutriband. com / role / ScheduleofIntangibleAssetsTable"," longName":" 996020- Disclosure- Intangible Assets (Details)- Schedule of Intangible Assets"," shortName":" Intangible Assets (Details)- Schedule of Intangible Assets"," isDefault":" false"," groupType":" disclosure"," subGroupType":" details"," menuCat":" Details"," order":" 43"," firstAnchor": {" contextRef":" e5"," name":" us- gaap: FiniteLivedIntangibleAssetsGross"," unitRef":" usd"," xsiNil":" false"," lang": null," decimals":" 0"," ancestors": [" td"," tr"," table"," ix: continuation"," us- gaap: IntangibleAssetsDisclosureTextBlock"," div"," body"," html" ]," reportCount": 1," baseRef":" ca0204725- 10k_nutriband. htm"," first": true," unique": true }," uniqueAnchor": {" contextRef":" e5"," name":" us- gaap: FiniteLivedIntangibleAssetsGross"," unitRef":" usd"," xsiNil":" false"," lang": null," decimals":" 0"," ancestors": [" td"," tr"," table"," ix: continuation"," us- gaap: IntangibleAssetsDisclosureTextBlock"," div"," body"," html" ]," reportCount": 1," baseRef":" ca0204725- 10k_nutriband. htm"," first": true," unique": true } }," R44": {" role":" http: / / nutriband. com / role / ScheduleofAmortizationExpensesTable"," longName":" 996021- Disclosure- Intangible Assets (Details)- Schedule of Amortization Expenses"," shortName":" Intangible Assets (Details)- Schedule of Amortization Expenses"," isDefault":" false"," groupType":" disclosure"," subGroupType":" details"," menuCat":" Details"," order":" 44"," firstAnchor": {" contextRef":" e5"," name":" us- gaap: FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"," unitRef":" usd"," xsiNil":" false"," lang": null," decimals":" 0"," ancestors": [" td"," tr"," table"," ix: continuation"," us- gaap: IntangibleAssetsDisclosureTextBlock"," div"," body"," html" ]," reportCount": 1," baseRef":" ca0204725- 10k_nutriband. htm"," first": true," unique": true }," uniqueAnchor": {" contextRef":" e5"," name":" us- gaap: FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"," unitRef":" usd"," xsiNil":" false"," lang": null," decimals":" 0"," ancestors": [" td"," tr"," table"," ix: continuation"," us- gaap: IntangibleAssetsDisclosureTextBlock"," div"," body"," html" ]," reportCount": 1," baseRef":" ca0204725- 10k_nutriband. htm"," first": true," unique": true } }," R45": {" role":" http: / / nutriband. com / role / RelatedPartyTransactionsDetails"," longName":" 996022- Disclosure- Related Party Transactions (Details)"," shortName":" Related Party Transactions (Details)"," isDefault":" false"," groupType":" disclosure"," subGroupType":" details"," menuCat":" Details"," order":" 45"," firstAnchor": {" contextRef":" e108"," name":" us- gaap: StockIssuedDuringPeriodSharesPurchaseOfAssets"," unitRef":" shares"," xsiNil":" false"," lang": null," decimals":" 0"," ancestors": [" td"," tr"," table"," ix: continuation"," div"," body"," html" ]," reportCount": 1," baseRef":" ca0204725- 10k_nutriband. htm"," first": true," unique": true }," uniqueAnchor": {" contextRef":" e108"," name":" us- gaap: StockIssuedDuringPeriodSharesPurchaseOfAssets"," unitRef":" shares"," xsiNil":" false"," lang": null," decimals":" 0"," ancestors": [" td"," tr"," table"," ix: continuation"," div"," body"," html" ]," reportCount": 1," baseRef":" ca0204725- 10k_nutriband. htm"," first": true," unique": true } }," R46": {" role":" http: / / nutriband. com / role / StockholdersEquityDetails"," longName":" 996023- Disclosure- Stockholders' Equity (Details)"," shortName":" Stockholders' Equity (Details)"," isDefault":" false"," groupType":" disclosure"," subGroupType":" details"," menuCat":" Details"," order":" 46"," firstAnchor": {" contextRef":" e5"," name":" us- gaap: PreferredStockSharesAuthorized"," unitRef":" shares"," xsiNil":" false"," lang": null," decimals":" 0"," ancestors": [" td"," tr"," table"," div"," body"," html" ]," reportCount": 1," baseRef":" ca0204725- 10k_nutriband. htm"," first": true }," uniqueAnchor": {" contextRef":" e0"," name":" ntrb: CommonStockOfDescription"," unitRef": null," xsiNil":" false"," lang":" en- US"," decimals": null," ancestors": [" p"," ix: continuation"," div"," body"," html" ]," reportCount": 1," baseRef":" ca0204725- 10k_nutriband. htm"," unique": true } }," R47": {" role":" http: / / nutriband. com / role / OptionsandWarrantsDetails"," longName":" 996024- Disclosure- Options and Warrants (Details)"," shortName":" Options and Warrants (Details)"," isDefault":" false"," groupType":" disclosure"," subGroupType":" details"," menuCat":" Details"," order":" 47"," firstAnchor": {" contextRef":" e128"," name":" us- gaap: TemporaryEquitySharesIssued"," unitRef":" shares"," xsiNil":" false"," lang": null," decimals":" 0"," ancestors": [" p"," ntrb: OptionsAndWarrantsTextBlock"," div"," body"," html" ]," reportCount": 1," baseRef":" ca0204725- 10k_nutriband. htm"," first": true," unique": true }," uniqueAnchor": {" contextRef":" e128"," name":" us- gaap: TemporaryEquitySharesIssued"," unitRef":" shares"," xsiNil":" false"," lang": null," decimals":" 0"," ancestors": [" p"," ntrb: OptionsAndWarrantsTextBlock"," div"," body"," html" ]," reportCount": 1," baseRef":" ca0204725- 10k_nutriband. htm"," first": true," unique": true } }," R48": {" role":" http: / / nutriband. com / role / ScheduleofChangesinWarrantsOutstandingTable"," longName":" 996025- Disclosure- Options and Warrants (Details)- Schedule of Changes in Warrants Outstanding"," shortName":" Options and Warrants (Details)- Schedule of Changes in Warrants Outstanding"," isDefault":" false"," groupType":" disclosure"," subGroupType":" details"," menuCat":" Details"," order":" 48"," firstAnchor": {" contextRef":" e148"," name":" ntrb: ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOutstandingNumber1"," unitRef":" shares"," xsiNil":" false"," lang": null," decimals":" INF"," ancestors": [" td"," tr"," table"," ix: continuation"," ntrb: OptionsAndWarrantsTextBlock"," div"," body"," html" ]," reportCount": 1," baseRef":" ca0204725- 10k_nutriband. htm"," first": true }," uniqueAnchor": {" contextRef":" e147"," name":" ntrb: ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOutstandingNumber1"," unitRef":" shares"," xsiNil":" false"," lang": null," decimals":" INF"," ancestors": [" td"," tr"," table"," ix: continuation"," ntrb: OptionsAndWarrantsTextBlock"," div"," body"," html" ]," reportCount": 1," baseRef":" ca0204725- 10k_nutriband. htm"," unique": true } }," R49": {" role":" http: / / nutriband. com / role / ScheduleofSummarizesAdditionalInformationRelatingtotheWarrantsOutstandingTable"," longName":" 996026- Disclosure- Options and Warrants (Details)- Schedule of Summarizes Additional Information Relating to the Warrants Outstanding"," shortName":" Options and Warrants (Details)- Schedule of Summarizes Additional Information Relating to the Warrants Outstanding"," isDefault":" false"," groupType":" disclosure"," subGroupType":" details"," menuCat":" Details"," order":" 49"," firstAnchor": {" contextRef":" e150"," name":" us- gaap: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"," unitRef":" usdPershares"," xsiNil":" false"," lang": null," decimals":" 2"," ancestors": [" td"," tr"," table"," ix: continuation"," ntrb: OptionsAndWarrantsTextBlock"," div"," body"," html" ]," reportCount": 1," baseRef":" ca0204725- 10k_nutriband. htm"," first": true," unique": true }," uniqueAnchor": {" contextRef":" e150"," name":" us- gaap: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"," unitRef":" usdPershares"," xsiNil":" false"," lang": null," decimals":" 2"," ancestors": [" td"," tr"," table"," ix: continuation"," ntrb: OptionsAndWarrantsTextBlock"," div"," body"," html" ]," reportCount": 1," baseRef":" ca0204725- 10k_nutriband. htm"," first": true," unique": true } }," R50": {" role":" http: / / nutriband. com / role / ScheduleofChangesinOptionsOutstandingTable"," longName":" 996027- Disclosure- Options and Warrants (Details)- Schedule of Changes in Options Outstanding"," shortName":" Options and Warrants (Details)- Schedule of Changes in Options Outstanding"," isDefault":" false"," groupType":" disclosure"," subGroupType":" details"," menuCat":" Details"," order":" 50"," firstAnchor": {" contextRef":" e160"," name":" us- gaap: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"," unitRef":" shares"," xsiNil":" false"," lang": null," decimals":" INF"," ancestors": [" td"," tr"," table"," ix: continuation"," ix: continuation"," div"," body"," html" ]," reportCount": 1," baseRef":" ca0204725- 10k_nutriband. htm"," first": true }," uniqueAnchor": {" contextRef":" e158"," name":" us- gaap: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"," unitRef":" shares"," xsiNil":" false"," lang": null," decimals":" INF"," ancestors": [" td"," tr"," table"," ix: continuation"," ix: continuation"," div"," body"," html" ]," reportCount": 1," baseRef":" ca0204725- 10k_nutriband. htm"," unique": true } }," R51": {" role":" http: / / nutriband. com / role / ScheduleofSummarizesAdditionalInformationRelatingtotheOptionsOutstandingTable"," longName":" 996028- Disclosure- Options and Warrants (Details)- Schedule of Summarizes Additional Information Relating to the Options Outstanding"," shortName":" Options and Warrants (Details)- Schedule of Summarizes Additional Information Relating to the Options Outstanding"," isDefault":" false"," groupType":" disclosure"," subGroupType":" details"," menuCat":" Details"," order":" 51"," firstAnchor": {" contextRef":" e161"," name":" ntrb: ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingNumber"," unitRef":" shares"," xsiNil":" false"," lang": null," decimals":" INF"," ancestors": [" td"," tr"," table"," ix: continuation"," ix: continuation"," div"," body"," html" ]," reportCount": 1," baseRef":" ca0204725- 10k_nutriband. htm"," first": true," unique": true }," uniqueAnchor": {" contextRef":" e161"," name":" ntrb: ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingNumber"," unitRef":" shares"," xsiNil":" false"," lang": null," decimals":" INF"," ancestors": [" td"," tr"," table"," ix: continuation"," ix: continuation"," div"," body"," html" ]," reportCount": 1," baseRef":" ca0204725- 10k_nutriband. htm"," first": true," unique": true } }," R52": {" role":" http: / / nutriband. com / role / ScheduleofSegmentPerformancetotheGAAPMeasureofGrossProfitTable"," longName":" 996029- Disclosure- Segment Reporting (Details)- Schedule of Segment Performance to the GAAP Measure of Gross Profit"," shortName":" Segment Reporting (Details)- Schedule of Segment Performance to the GAAP Measure of Gross Profit"," isDefault":" false"," groupType":" disclosure"," subGroupType":" details"," menuCat":" Details"," order":" 52"," firstAnchor": {" contextRef":" e0"," name":" us- gaap: GainLossOnSalesOfLoansNet"," unitRef":" usd"," xsiNil":" false"," lang": null," decimals":" 0"," ancestors": [" td"," tr"," table"," ix:

continuation"," us- gaap: SegmentReportingDisclosureTextBlock"," div"," body"," html" ]," reportCount": 1," baseRef":" ea0204725- 10k_nutriband. htm"," first": true," unique": true }," uniqueAnchor": {" contextRef":" c0"," name":" us- gaap: GainLossOnSalesOfLoansNet"," unitRef":" usd"," xsiNil":" false"," lang": null," decimals":" 0"," ancestors": [" td"," tr"," table"," ix: continuation"," us- gaap: SegmentReportingDisclosureTextBlock"," div"," body"," html" ]," reportCount": 1," baseRef":" ea0204725- 10k_nutriband. htm"," first": true," unique": true } }," R53": {" role":" http: / / nutriband. com / role / ScheduleofNetSalesandPropertyandEquipmentTable"," longName":" 996030- Disclosure- Segment Reporting (Details)- Schedule of Net Sales and Property and Equipment"," shortName":" Segment Reporting (Details)- Schedule of Net Sales and Property and Equipment"," isDefault":" false"," groupType":" disclosure"," subGroupType":" details"," menuCat":" Details"," order":" 53"," firstAnchor": {" contextRef":" c0"," name":" us- gaap: RevenueFromContractWithCustomerIncludingAssessedTax"," unitRef":" usd"," xsiNil":" false"," lang": null," decimals":" 0"," ancestors": [" td"," tr"," table"," ix: continuation"," ix: continuation"," div"," body"," html" ]," reportCount": 1," baseRef":" ea0204725- 10k_nutriband. htm"," first": true," unique": true }," uniqueAnchor": {" contextRef":" c0"," name":" us- gaap: RevenueFromContractWithCustomerIncludingAssessedTax"," unitRef":" usd"," xsiNil":" false"," lang": null," decimals":" 0"," ancestors": [" td"," tr"," table"," ix: continuation"," ix: continuation"," div"," body"," html" ]," reportCount": 1," baseRef":" ea0204725- 10k_nutriband. htm"," first": true," unique": true } }," R54": {" role":" http: / / nutriband. com / role / CommitmentsandContigenciesDetails"," longName":" 996031- Disclosure- Commitments and Contigencies (Details)"," shortName":" Commitments and Contigencies (Details)"," isDefault":" false"," groupType":" disclosure"," subGroupType":" details"," menuCat":" Details"," order":" 54"," firstAnchor": {" contextRef":" c0"," name":" us- gaap: StockholdersEquityReverseStockSplit"," unitRef": null," xsiNil":" false"," lang":" en- US"," decimals": null," ancestors": [" p"," us- gaap: CommitmentsAndContingenciesDisclosureTextBlock"," div"," body"," html" ]," reportCount": 1," baseRef":" ea0204725- 10k_nutriband. htm"," first": true," unique": true } }," R55": {" role":" http: / / nutriband. com / role / SubsequentEventsDetails"," longName":" 996032- Disclosure- Subsequent Events (Details)"," shortName":" Subsequent Events (Details)"," isDefault":" false"," groupType":" disclosure"," subGroupType":" details"," menuCat":" Details"," order":" 55"," firstAnchor": {" contextRef":" c221"," name":" us- gaap: ProceedsFromInterestReceived"," unitRef":" usd"," xsiNil":" false"," lang": null," decimals":" 0"," ancestors": [" td"," tr"," table"," us- gaap: SubsequentEventsTextBlock"," div"," body"," html" ]," reportCount": 1," baseRef":" ea0204725- 10k_nutriband. htm"," first": true," unique": true }," uniqueAnchor": {" contextRef":" c221"," name":" us- gaap: ProceedsFromInterestReceived"," unitRef":" usd"," xsiNil":" false"," lang": null," decimals":" 0"," ancestors": [" td"," tr"," table"," us- gaap: SubsequentEventsTextBlock"," div"," body"," html" ]," reportCount": 1," baseRef":" ea0204725- 10k_nutriband. htm"," first": true," unique": true } } }," tag": {" us- gaap_AccountingPoliciesAbstract": {" xbrltype":" stringItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" AccountingPoliciesAbstract"," lang": {" en- us": {" role": {" label":" Summary of Significant Accounting Policies [ Abstract ]" } } } }," auth_ref": [ ] }," us- gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis": {" xbrltype":" stringItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"," presentation": [" http: / / nutriband. com / role / SummaryofSignificantAccountingPoliciesDetails" ]," lang": {" en- us": {" role": {" label":" Receivable Type [ Axis ]"," documentation":" Information by type of receivable." } } } }," auth_ref": [" r78"," r84" ] }," us- gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" AccountsPayableAndAccruedLiabilitiesCurrent"," crdr":" credit"," calculation": {" http: / / nutriband. com / role / ConsolidatedBalanceSheet": {" parentTag":" us- gaap_LiabilitiesCurrent"," weight": 1. 0," order": 1. 0 } }," presentation": [" http: / / nutriband. com / role / ConsolidatedBalanceSheet" ]," lang": {" en- us": {" role": {" terseLabel":" Accounts payable and accrued expenses"," label":" Accounts Payable and Accrued Liabilities, Current"," documentation":" Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits." } } }," auth_ref": [" r66"," r67" ] }," us- gaap_AccountsReceivableFairValueDisclosure": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" AccountsReceivableFairValueDisclosure"," crdr":" debit"," presentation": [" http: / / nutriband. com / role / SummaryofSignificantAccountingPoliciesDetails" ]," lang": {" en- us": {" role": {" terseLabel":" Account receivable"," label":" Accounts Receivable, Fair Value Disclosure"," documentation":" Fair value portion of amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties." } } }," auth_ref": [" r503" ] }," us- gaap_AccountsReceivableMember": {" xbrltype":" domainItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" AccountsReceivableMember"," presentation": [" http: / / nutriband. com / role / CommitmentsandContigenciesDetails"," http: / / nutriband. com / role / SummaryofSignificantAccountingPoliciesDetails" ]," lang": {" en- us": {" role": {" terseLabel":" Accounts Receivable [ Member ] "," label":" Accounts Receivable [ Member ]"," documentation":" Due from customers or clients for goods or services that have been delivered or sold." } } }," auth_ref": [" r738" ] }," us- USD ($) 12 Months EndedJan gaap_AccountsReceivableNetCurrent": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. 31, org / us- gaap / 2024 2023 Jan "," localname":" AccountsReceivableNetCurrent"," crdr":" debit"," calculation": {" http: / / nutriband. 31 com / role / ConsolidatedBalanceSheet": {" parentTag":" us- gaap_AssetsCurrent", 2025 Jan " weight": 1. 0 31, 2024Schedule " order": 2. 0 } }," presentation": [" http: / / nutriband. com / role / ConsolidatedBalanceSheet" ]," lang": {" en- us": {" role": {" terseLabel":" Accounts receivable"," label":" Accounts Receivable, after Allowance for Credit Loss, Current"," documentation":" Amount, after allowance for credit loss, of Options right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }," auth_ref": [" r991" ] }," us- gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" AccumulatedOtherComprehensiveIncomeLossNetOfTax"," crdr":" credit"," calculation": {" http: / / nutriband. com / role / ConsolidatedBalanceSheet": {" parentTag":" us- gaap_StockholdersEquity"," weight": 1. 0," order": 4. 0 } }," presentation": [" http: / / nutriband. com / role / ConsolidatedBalanceSheet" ]," lang": {" en- us": {" role": {" terseLabel":" Accumulated other comprehensive loss"," label":" Accumulated Other Comprehensive Income (Loss), Net of Tax"," documentation":" Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }," auth_ref": [" r12"," r13"," r85"," r201"," r588"," r617"," r618" ] }," us- gaap_AccumulatedOtherComprehensiveIncomeMember": {" xbrltype":" domainItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" AccumulatedOtherComprehensiveIncomeMember"," presentation": [" http: / / nutriband. com / role / ShareholdersEquityType2or3" ]," lang": {" en- us": {" role": {" terseLabel":" Accumulated Other Comprehensive Income (Loss)"," label":" AOCI Attributable to Parent [ Member ]"," documentation":" Accumulated increase (decrease) in equity from transactions and other events and circumstances from non- owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }," auth_ref": [" r2"," r7"," r13"," r493"," r496"," r522"," r613"," r614"," r964"," r965"," r966"," r978"," r979"," r980"," r982" ] }," ecd_Additional402vDisclosureTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" Additional402vDisclosureTextBlock"," presentation": [" http: / / xbrl. sec. gov / ecd / role / PvpDisclosure" ]," lang": {" en- us": {" role": {" label":" Additional 402 (v) Disclosure [ Text Block ]"," terseLabel":" Additional 402 (v) Disclosure" } } }," auth_ref": [" r883" ] }," us- gaap_AdditionalPaidInCapital": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" AdditionalPaidInCapital"," crdr":" credit"," calculation": {" http: / / nutriband. com / role / ConsolidatedBalanceSheet": {" parentTag":" us- gaap_StockholdersEquity"," weight": 1. 0," order": 3. 0 } }," presentation": [" http: / / nutriband. com / role / ConsolidatedBalanceSheet" ]," lang": {" en- us": {" role": {" terseLabel":" Additional paid- in- capital"," label":" Additional Paid in Capital"," documentation":" Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid- in capital (APIC) for common and preferred stock." } } }," auth_ref": [" r79"," r799"," r1086" ] }," us- gaap_AdditionalPaidInCapitalMember": {" xbrltype":" domainItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" AdditionalPaidInCapitalMember"," presentation": [" http: / / nutriband. com / role / ShareholdersEquityType2or3" ]," lang": {" en- us": {" role": {" terseLabel":" Additional Paid In Capital"," label":" Additional Paid- in Capital [ Member ]"," documentation":" Excess of issue price over par or stated value of the entity' s capital stock and amounts received from other transactions involving the entity' s stock or stockholders." } } }," auth_ref": [" r634"," r978"," r979"," r980"," r982"," r1023"," r1087" ] }," dei_AdditionalSecurities462b": {" xbrltype":" booleanItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" AdditionalSecurities462b"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover" ]," lang": {" en- us": {" role": {" label":" Additional Securities. 462 (b)" } } }," auth_ref": [" r939" ] }," dei_AdditionalSecurities462bFileNumber": {" xbrltype":" fileNumberItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" AdditionalSecurities462bFileNumber"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover" ]," lang": {" en- us": {" role": {" label":" Additional Securities, 462 (b), File Number" } } }," auth_ref": [" r939" ] }," dei_AdditionalSecuritiesEffective413b": {" xbrltype":" booleanItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" AdditionalSecuritiesEffective413b"," presentation": [" http: / / xbrl. sec. gov / dei / role / document /

Cover" ]," lang": {" en- us": {" role": {" label":" Additional Securities Effective, 413 (b)" } } },"auth_ref": [" r937" ] }," ntrb_AdditionalShare": {" xbrltype":" sharesItemType"," nsuri":" http: / / nutriband. com / 20240131"," localname":" AdditionalShare"," presentation": [" http: / / nutriband. com / role / OptionsandWarrantsDetails" ]," lang": {" en- us": {" role": {" terseLabel":" Additional share (in Shares)"," documentation":" Additinal share."," label":" Additional Share" } } },"auth_ref": [ ] }," dei_AddressTypeDomain": {" xbrltype":" domainItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" AddressTypeDomain"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover" ]," lang": {" en- us": {" role": {" label":" Address Type [ Domain ]"," documentation":" An entity may have several addresses for different purposes and this domain represents all such types." } } },"auth_ref": [ ] }," ecd_AdjToCompAmt": {" xbrltype":" monetaryItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" AdjToCompAmt"," presentation": [" http: / / xbrl. sec. gov / ecd / role / PvpDisclosure" ]," lang": {" en- us": {" role": {" label":" Adjustment to Compensation Amount"," terseLabel":" Adjustment to Compensation, Amount" } } },"auth_ref": [" r896" ] }," ecd_AdjToCompAxis": {" xbrltype":" stringItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" AdjToCompAxis"," presentation": [" http: / / xbrl. sec. gov / ecd / role / PvpDisclosure" ]," lang": {" en- us": {" role": {" label":" Adjustment to Compensation [ Axis ]"," terseLabel":" Adjustment to Compensation:" } } },"auth_ref": [" r896" ] }," ecd_AdjToNonPeoNeoCompFnTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" AdjToNonPeoNeoCompFnTextBlock"," presentation": [" http: / / xbrl. sec. gov / ecd / role / PvpDisclosure" ]," lang": {" en- us": {" role": {" label":" Adjustment to Non- PEO NEO Compensation Footnote [ Text Block ]"," terseLabel":" Adjustment to Non- PEO NEO Compensation Footnote" } } },"auth_ref": [" r896" ] }," ecd_AdjToPeoCompFnTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" AdjToPeoCompFnTextBlock"," presentation": [" http: / / xbrl. sec. gov / ecd / role / PvpDisclosure" ]," lang": {" en- us": {" role": {" label":" Adjustment To PEO Compensation, Footnote [ Text Block ]"," terseLabel":" Adjustment To PEO Compensation, Footnote" } } },"auth_ref": [" r896" ] }," us- gaap_AdjustmentOfWarrantsGrantedForServices": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" AdjustmentOfWarrantsGrantedForServices"," crdr":" debit"," presentation": [" http: / / nutriband. com / role / ShareholdersEquityType2or3" ]," lang": {" en- us": {" role": {" terseLabel":" Warrants issued for services"," label":" Adjustment of Warrants Granted for Services"," documentation":" Adjustment for noncash service expenses paid for by granting of warrants." } } },"auth_ref": [" r5" ] }," us- gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"," crdr":" debit"," presentation": [" http: / / nutriband. com / role / ShareholdersEquityType2or3" ]," lang": {" en- us": {" role": {" terseLabel":" Options issued for services"," label":" Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs"," documentation":" Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration." } } },"auth_ref": [" r8"," r116" ] }," us- gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {" xbrltype":" stringItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"," presentation": [" http: / / nutriband. com / role / ConsolidatedCashFlow" ]," lang": {" en- us": {" role": {" terseLabel":" Adjustments to reconcile net loss to net cash used in operating activities:"," label":" Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [ Abstract ]" } } },"auth_ref": [ ] }," ntrb_AdoptionofOperatingLeaseAssetandLiability": {" xbrltype":" monetaryItemType"," nsuri":" http: / / nutriband. com / 20240131"," localname":" AdoptionofOperatingLeaseAssetandLiability"," crdr":" credit"," presentation": [" http: / / nutriband. com / role / ConsolidatedCashFlow" ]," lang": {" en- us": {" role": {" terseLabel":" Adoption of ASC 842 Operating lease asset and liability"," documentation":" Amount to adoption of operating lease asset and liability."," label":" Adoptionof Operating Lease Assetand Liability" } } },"auth_ref": [ ] }," ntrb_AdvancesAmount": {" xbrltype":" monetaryItemType"," nsuri":" http: / / nutriband. com / 20240131"," localname":" AdvancesAmount"," crdr":" credit"," presentation": [" http: / / nutriband. com / role / NotesPayableDetails" ]," lang": {" en- us": {" role": {" terseLabel":" Advances amount"," documentation":" Advances amount."," label":" Advances Amount" } } },"auth_ref": [ ] }," ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {" xbrltype":" domainItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" AggtChngPnsnValInSummryCompstnTblForAplblYrMember"," presentation": [" http: / / xbrl. sec. gov / ecd / role / PvpDisclosure" ]," lang": {" en- us": {" role": {" label":" Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [ Member ]"," terseLabel":" Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table" } } },"auth_ref": [" r930" ] }," ecd_AggtErrCompAmt": {" xbrltype":" monetaryItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" AggtErrCompAmt"," presentation": [" http: / / xbrl. sec. gov / ecd / role / ErrCompDisclosure" ]," lang": {" en- us": {" role": {" label":" Aggregate Erroneous Compensation Amount"," terseLabel":" Aggregate Erroneous Compensation Amount" } } },"auth_ref": [" r846"," r857"," r873"," r908" ] }," ecd_AggtErrCompNotYetDeterminedTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" AggtErrCompNotYetDeterminedTextBlock"," presentation": [" http: / / xbrl. sec. gov / ecd / role / ErrCompDisclosure" ]," lang": {" en- us": {" role": {" label":" Aggregate Erroneous Compensation Not Yet Determined [ Text Block ]"," terseLabel":" Aggregate Erroneous Compensation Not Yet Determined" } } },"auth_ref": [" r849"," r860"," r876"," r911" ] }," ecd_AggtPnsnAdjsSveCstMember": {" xbrltype":" domainItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" AggtPnsnAdjsSveCstMember"," presentation": [" http: / / xbrl. sec. gov / ecd / role / PvpDisclosure" ]," lang": {" en- us": {" role": {" label":" Aggregate Pension Adjustments Service Cost [ Member ]"," terseLabel":" Aggregate Pension Adjustments Service Cost" } } },"auth_ref": [" r931" ] }," ntrb_AgreedToAnnualSalary": {" xbrltype":" monetaryItemType"," nsuri":" http: / / nutriband. com / 20240131"," localname":" AgreedToAnnualSalary"," crdr":" credit"," presentation": [" http: / / nutriband. com / role / CommitmentsandContigenciesDetails" ]," lang": {" en- us": {" role": {" terseLabel":" Agreed to annual salary"," documentation":" The amount of agreed to annual salary."," label":" Agreed To Annual Salary" } } },"auth_ref": [ ] }," ntrb_AgreementMember": {" xbrltype":" domainItemType"," nsuri":" http: / / nutriband. com / 20240131"," localname":" AgreementMember"," presentation": [" http: / / nutriband. com / role / CommitmentsandContigenciesDetails" ]," lang": {" en- us": {" role": {" terseLabel":" Agreement [ Member ]"," label":" Agreement Member" } } },"auth_ref": [ ] }," ecd_AllAdjToCompMember": {" xbrltype":" domainItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" AllAdjToCompMember"," presentation": [" http: / / xbrl. sec. gov / ecd / role / PvpDisclosure" ]," lang": {" en- us": {" role": {" label":" All Adjustments to Compensation [ Member ]"," terseLabel":" All Adjustments to Compensation" } } },"auth_ref": [" r896" ] }," ecd_AllExecutiveCategoriesMember": {" xbrltype":" domainItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" AllExecutiveCategoriesMember"," presentation": [" http: / / xbrl. sec. gov / ecd / role / PvpDisclosure" ]," lang": {" en- us": {" role": {" label":" All Executive Categories [ Member ]"," terseLabel":" All Executive Categories" } } },"auth_ref": [" r903" ] }," ecd_AllIndividualsMember": {" xbrltype":" domainItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" AllIndividualsMember"," presentation": [" http: / / xbrl. sec. gov / ecd / role / AwardTimingDisclosure"," http: / / xbrl. sec. gov / ecd / role / ErrCompDisclosure"," http: / / xbrl. sec. gov / ecd / role / InsiderTradingArrangements"," http: / / xbrl. sec. gov / ecd / role / PvpDisclosure" ]," lang": {" en- us": {" role": {" label":" All Individuals [ Member ]"," terseLabel":" All Individuals" } } },"auth_ref": [" r850"," r861"," r877"," r903"," r912"," r916"," r924" ] }," ecd_AllTradingArrangementsMember": {" xbrltype":" domainItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" AllTradingArrangementsMember"," presentation": [" http: / / xbrl. sec. gov / ecd / role / InsiderTradingArrangements" ]," lang": {" en- us": {" role": {" label":" All Trading Arrangements [ Member ]"," terseLabel":" All Trading Arrangements" } } },"auth_ref": [" r922" ] }," us- gaap_AllocatedShareBasedCompensationExpense": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" AllocatedShareBasedCompensationExpense"," crdr":" debit"," presentation": [" http: / / nutriband. com / role / OptionsandWarrantsDetails" ]," lang": {" en- us": {" role": {" terseLabel":" Non cash compensation (in Dollars)"," label":" Share- Based Payment Arrangement, Expense"," documentation":" Amount of expense for award under share- based payment arrangement. Excludes amount capitalized." } } },"auth_ref": [" r448"," r453" ] }," dei_AmendmentDescription": {" xbrltype":" stringItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" AmendmentDescription"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover" ]," lang": {" en- us": {" role": {" label":" Amendment Description"," documentation":" Description of changes contained within amended document." } } },"auth_ref": [ ] }," dei_AmendmentFlag": {" xbrltype":" booleanItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" AmendmentFlag"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover" ]," lang": {" en- us": {" role": {" label":" Amendment Flag"," documentation":" Boolean flag that is true when the XBRL content amends previously- filed or accepted submission." } } },"auth_ref": [ ] }," us- gaap_AmortizationOfIntangibleAssets": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" AmortizationOfIntangibleAssets"," crdr":" debit"," presentation": [" http: / / nutriband. com / role / IntangibleAssetsDetails" ]," lang": {" en- us": {" role": {" terseLabel":" Amortization expenses"," label":" Amortization of Intangible Assets"," documentation":" The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } },"auth_ref": [" r5"," r321"," r328"," r778" ] }," dei_AnnualInformationForm": {" xbrltype":" booleanItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" AnnualInformationForm"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover" ]," lang": {" en- us": {" role": {" label":" Annual Information

Form"," documentation":" Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }," auth_ref": [" r853" ] }," dei_ApproximateDateOfCommencementOfProposedSaleToThePublic": {" xbrltype":" dateOrAsapItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" ApproximateDateOfCommencementOfProposedSaleToThePublic"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover" ]," lang": {" en- us": {" role": {" label":" Approximate Date of Commencement of Proposed Sale to Public"," documentation":" The approximate date of a commencement of a proposed sale of securities to the public. This element is disclosed in S- 1, S- 3, S- 4, S- 11, F- 1, F- 3 and F- 10 filings." } } }," auth_ref": [ ] }," ntrb_AssetDepreciatedRange": {" xbrltype":" durationItemType"," nsuri":" http: / / nutriband. com / 20240131"," localname":" AssetDepreciatedRange"," presentation": [" http: / / nutriband. com / role / SummaryofSignificantAccountingPoliciesDetails" ]," lang": {" en- us": {" role": {" terseLabel":" Asset depreciated range"," documentation":" Asset depreciated range."," label":" Asset Depreciated Range" } } }," auth_ref": [ ] }," us- gaap_AssetImpairmentCharges": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" AssetImpairmentCharges"," crdr":" debit"," presentation": [" http: / / nutriband. com / role / ScheduleofDeferredTaxLiabilityandDeferredTaxAssetTable" ]," lang": {" en- us": {" role": {" terseLabel":" Intangible impairment expense"," label":" Asset Impairment Charges"," documentation":" Amount of write- down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill." } } }," auth_ref": [" r5"," r33" ] }," us- gaap_Assets": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" Assets"," crdr":" debit"," calculation": {" http: / / nutriband. com / role / ConsolidatedBalanceSheet": {" parentTag": null," weight": null," order": null," root": true } }," presentation": [" http: / / nutriband. com / role / ConsolidatedBalanceSheet" ]," lang": {" en- us": {" role": {" totalLabel":" TOTAL ASSETS"," label":" Assets"," documentation":" Amount of asset recognized for present right to economic benefit." } } }," auth_ref": [" r131"," r145"," r195"," r223"," r253"," r261"," r280"," r284"," r297"," r352"," r353"," r354"," r355"," r356"," r357"," r358"," r359"," r360"," r488"," r490"," r504"," r581"," r678"," r771"," r772"," r799"," r825"," r1009"," r1010"," r1041" ] }," us- gaap_AssetsAbstract": {" xbrltype":" stringItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" AssetsAbstract"," presentation": [" http: / / nutriband. com / role / ScheduleofNetSalesandPropertyandEquipmentTable" ]," lang": {" en- us": {" role": {" terseLabel":" ASSETS"," verboseLabel":" Assets"," label":" Assets [ Abstract ]" } } }," auth_ref": [ ] }," us- gaap_AssetsCurrent": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" AssetsCurrent"," crdr":" debit"," calculation": {" http: / / nutriband. com / role / ConsolidatedBalanceSheet": {" parentTag":" us- gaap_Assets"," weight": 1. 0," order": 1. 0 } }," presentation": [" http: / / nutriband. com / role / ConsolidatedBalanceSheet" ]," lang": {" en- us": {" role": {" totalLabel":" Total Current Assets"," label":" Assets, Current"," documentation":" Amount of asset recognized for present right to economic benefit, classified as current." } } }," auth_ref": [" r187"," r205"," r223"," r297"," r352"," r353"," r354"," r355"," r356"," r357"," r358"," r359"," r360"," r488"," r490"," r504"," r799"," r1009"," r1010"," r1041" ] }," us- gaap_AssetsCurrentAbstract": {" xbrltype":" stringItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" AssetsCurrentAbstract"," presentation": [" http: / / nutriband. com / role / ConsolidatedBalanceSheet" ]," lang": {" en- us": {" role": {" terseLabel":" CURRENT ASSETS:"," label":" Assets, Current [ Abstract ]" } } }," auth_ref": [ ] }," dei_AuditedAnnualFinancialStatements": {" xbrltype":" booleanItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" AuditedAnnualFinancialStatements"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover" ]," lang": {" en- us": {" role": {" label":" Audited Annual Financial Statements"," documentation":" Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }," auth_ref": [" r853" ] }," dei_AuditorFirmId": {" xbrltype":" nonemptySequenceNumberItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" AuditorFirmId"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / AuditInformation" ]," lang": {" en- us": {" role": {" label":" Auditor Firm ID"," documentation":" PCAOB issued Audit Firm Identifier" } } }," auth_ref": [" r838"," r841"," r853" ] }," dei_AuditorLineItems": {" xbrltype":" stringItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" AuditorLineItems"," lang": {" en- us": {" role": {" label":" Auditor [ Line Items ]" } } }," auth_ref": [ ] }," dei_AuditorLocation": {" xbrltype":" internationalNameItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" AuditorLocation"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / AuditInformation" ]," lang": {" en- us": {" role": {" label":" Auditor Location" } } }," auth_ref": [" r838"," r841"," r853" ] }," dei_AuditorName": {" xbrltype":" internationalNameItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" AuditorName"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / AuditInformation" ]," lang": {" en- us": {" role": {" label":" Auditor Name" } } }," auth_ref": [" r838"," r841"," r853" ] }," dei_AuditorOpinionTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" AuditorOpinionTextBlock"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / AuditInformation" ]," lang": {" en- us": {" role": {" label":" Auditor Opinion [ Text Block ]" } } }," auth_ref": [" r935" ] }," dei_AuditorTable": {" xbrltype":" stringItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" AuditorTable"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / AuditInformation" ]," lang": {" en- us": {" role": {" label":" Auditor [ Table ]" } } }," auth_ref": [ ] }," ecd_AwardExrePrice": {" xbrltype":" perShareItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" AwardExrePrice"," presentation": [" http: / / xbrl. sec. gov / ecd / role / AwardTimingDisclosure" ]," lang": {" en- us": {" role": {" label":" Award Exercise Price"," terseLabel":" Exercise Price" } } }," auth_ref": [" r919" ] }," ecd_AwardGrantDateFairValue": {" xbrltype":" monetaryItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" AwardGrantDateFairValue"," presentation": [" http: / / xbrl. sec. gov / ecd / role / AwardTimingDisclosure" ]," lang": {" en- us": {" role": {" label":" Award Grant Date Fair Value"," terseLabel":" Fair Value as of Grant Date" } } }," auth_ref": [" r920" ] }," ecd_AwardTmgDiscLineItems": {" xbrltype":" stringItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" AwardTmgDiscLineItems"," lang": {" en- us": {" role": {" label":" Award Timing Disclosures [ Line Items ]"," terseLabel":" Award Timing Disclosures" } } }," auth_ref": [" r915" ] }," ecd_AwardTmgHowMnpiCnsdrdTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" AwardTmgHowMnpiCnsdrdTextBlock"," presentation": [" http: / / xbrl. sec. gov / ecd / role / AwardTimingDisclosure" ]," lang": {" en- us": {" role": {" label":" Award Timing, How MNPI Considered [ Text Block ]"," terseLabel":" Award Timing, How MNPI Considered" } } }," auth_ref": [" r915" ] }," ecd_AwardTmgMethodTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" AwardTmgMethodTextBlock"," presentation": [" http: / / xbrl. sec. gov / ecd / role / AwardTimingDisclosure" ]," lang": {" en- us": {" role": {" label":" Award Timing Method [ Text Block ]"," terseLabel":" Award Timing Method" } } }," auth_ref": [" r915" ] }," ecd_AwardTmgMnpiCnsdrdFlag": {" xbrltype":" booleanItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" AwardTmgMnpiCnsdrdFlag"," presentation": [" http: / / xbrl. sec. gov / ecd / role / AwardTimingDisclosure" ]," lang": {" en- us": {" role": {" label":" Award Timing MNPI Considered [ Flag ]"," terseLabel":" Award Timing MNPI Considered" } } }," auth_ref": [" r915" ] }," ecd_AwardTmgMnpiDiscTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" AwardTmgMnpiDiscTextBlock"," presentation": [" http: / / xbrl. sec. gov / ecd / role / AwardTimingDisclosure" ]," lang": {" en- us": {" role": {" label":" Award Timing MNPI Disclosure [ Text Block ]"," terseLabel":" Award Timing MNPI Disclosure" } } }," auth_ref": [" r915" ] }," ecd_AwardTmgPredtrmndFlag": {" xbrltype":" booleanItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" AwardTmgPredtrmndFlag"," presentation": [" http: / / xbrl. sec. gov / ecd / role / AwardTimingDisclosure" ]," lang": {" en- us": {" role": {" label":" Award Timing Predetermined [ Flag ]"," terseLabel":" Award Timing Predetermined" } } }," auth_ref": [" r915" ] }," us- gaap_AwardTypeAxis": {" xbrltype":" stringItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" AwardTypeAxis"," presentation": [" http: / / xbrl. sec. gov / ecd / role / AwardTimingDisclosure" ]," lang": {" en- us": {" role": {" label":" Award Type [ Axis ]"," terseLabel":" Award Type"," documentation":" Information by type of award under share- based payment arrangement." } } }," auth_ref": [" r419"," r420"," r421"," r423"," r424"," r425"," r426"," r427"," r428"," r429"," r430"," r431"," r432"," r433"," r434"," r435"," r436"," r437"," r438"," r439"," r440"," r443"," r444"," r445"," r446"," r447" ] }," ecd_AwardUndrlygSecuritiesAmt": {" xbrltype":" decimalItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" AwardUndrlygSecuritiesAmt"," presentation": [" http: / / xbrl. sec. gov / ecd / role / AwardTimingDisclosure" ]," lang": {" en- us": {" role": {" label":" Award Underlying Securities Amount"," terseLabel":" Underlying Securities" } } }," auth_ref": [" r918" ] }," ecd_AwardsCloseToMnpiDiscIndName": {" xbrltype":" stringItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" AwardsCloseToMnpiDiscIndName"," presentation": [" http: / / xbrl. sec. gov / ecd / role / AwardTimingDisclosure" ]," lang": {" en- us": {" role": {" label":" Awards Close in Time to MNPI Disclosures, Individual Name"," terseLabel":" Name" } } }," auth_ref": [" r917" ] }," ecd_AwardsCloseToMnpiDiscTable": {" xbrltype":" stringItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" AwardsCloseToMnpiDiscTable"," presentation": [" http: / / xbrl. sec. gov / ecd / role / AwardTimingDisclosure" ]," lang": {" en- us": {" role": {" label":" Awards Close in Time to MNPI Disclosures [ Table ]"," terseLabel":" Awards Close in Time to MNPI Disclosures" } } }," auth_ref": [" r916" ] }," ecd_AwardsCloseToMnpiDiscTableTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" AwardsCloseToMnpiDiscTableTextBlock"," presentation": [" http: / / xbrl. sec. gov / ecd / role / AwardTimingDisclosure" ]," lang": {" en- us": {" role": {" label":" Awards Close in Time to MNPI Disclosures [ Table Text Block ]"," terseLabel":" Awards Close in Time to MNPI Disclosures, Table" } } }," auth_ref": [" r916" ] }," ntrb_BadDebt": {" xbrltype":" monetaryItemType"," nsuri":" http: / / nutriband. com / 20240131"," localname":" BadDebt"," crdr":" credit"," presentation": [" http: / / nutriband. com / role / SummaryofSignificantAccountingPoliciesDetails" ]," lang": {" en- us": {" role": {" terseLabel":" Bad debt expense"," documentation":" Amount of bad debt."," label":" Bad Debt" } } }," auth_ref": [ ] }," ntrb_BlackScholesMember": {" xbrltype":" domainItemType"," nsuri":" http: / / nutriband. com / 20240131"," localname":" BlackScholesMember"," presentation": [" http: / / nutriband. com / role / OptionsandWarrantsDetails" ]," lang": {" en- us": {" role": {" terseLabel":" Black- Scholes [ Member ]"," label":" Black Scholes

Member" } } },"auth_ref": [ ] }," ntrb_BoardOfDirectorsMember": {" xbrltype":" domainItemType"," nsuri":" http: / / nutriband. com / 20240131"," localname":" BoardOfDirectorsMember"," presentation": [" http: / / nutriband. com / role / SubsequentEventsDetails" ]," lang": {" en- us": {" role": {" terseLabel":" Board of Directors [ Member ]"," label":" Board Of Directors Member" } } }," auth_ref": [ ] }," us- gaap_BusinessAcquisitionAcquireeDomain": {" xbrltype":" domainItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" BusinessAcquisitionAcquireeDomain"," presentation": [" http: / / nutriband. com / role / IntangibleAssetsDetails"," http: / / nutriband. com / role / OrganizationandDescriptionofBusinessDetails" ]," lang": {" en- us": {" role": {" label":" Business Acquisition, Acquiree [ Domain ]"," documentation":" Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }," auth_ref": [" r322"," r323"," r324"," r325"," r326"," r485"," r787"," r788" ] }," us- gaap_BusinessAcquisitionAxis": {" xbrltype":" stringItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" BusinessAcquisitionAxis"," presentation": [" http: / / nutriband. com / role / IntangibleAssetsDetails"," http: / / nutriband. com / role / OrganizationandDescriptionofBusinessDetails" ]," lang": {" en- us": {" role": {" label":" Business Acquisition [ Axis ]"," documentation":" Information by business combination or series of individually immaterial business combinations." } } }," auth_ref": [" r48"," r50"," r322"," r323"," r324"," r325"," r326"," r485"," r787"," r788" ] }," us- gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" BusinessAcquisitionCostOfAcquiredEntityTransactionCosts"," crdr":" debit"," presentation": [" http: / / nutriband. com / role / OrganizationandDescriptionofBusinessDetails" ]," lang": {" en- us": {" role": {" terseLabel":" Acquired costs"," label":" Business Acquisition, Transaction Costs"," documentation":" Amount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition." } } }," auth_ref": [ ] }," us- gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": {" xbrltype":" percentItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" BusinessAcquisitionPercentageOfVotingInterestsAcquired"," presentation": [" http: / / nutriband. com / role / OrganizationandDescriptionofBusinessDetails" ]," lang": {" en- us": {" role": {" terseLabel":" Acquired percentage"," label":" Business Acquisition, Percentage of Voting Interests Acquired"," documentation":" Percentage of voting equity interests acquired at the acquisition date in the business combination." } } }," auth_ref": [" r49" ] }," us- gaap_BusinessCombinationsPolicy": {" xbrltype":" textBlockItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" BusinessCombinationsPolicy"," presentation": [" http: / / nutriband. com / role / AccountingPoliciesByPolicy" ]," lang": {" en- us": {" role": {" terseLabel":" Business Combinations"," label":" Business Combinations Policy [ Policy Text Block ]"," documentation":" Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity' s specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy." } } }," auth_ref": [" r121"," r122"," r123"," r124" ] }," dei_BusinessContactMember": {" xbrltype":" domainItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" BusinessContactMember"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover" ]," lang": {" en- us": {" role": {" label":" Business Contact [ Member ]"," documentation":" Business contact for the entity" } } }," auth_ref": [" r841"," r853" ] }," ntrb_CancelledShares": {" xbrltype":" sharesItemType"," nsuri":" http: / / nutriband. com / 20240131"," localname":" CancelledShares"," presentation": [" http: / / nutriband. com / role / StockholdersEquityDetails" ]," lang": {" en- us": {" role": {" terseLabel":" Cancelled shares"," documentation":" Number of share cancelled."," label":" Cancelled Shares" } } }," auth_ref": [ ] }," us- gaap_Cash": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" Cash"," crdr":" debit"," presentation": [" http: / / nutriband. com / role / CommitmentsandContigenciesDetails" ]," lang": {" en- us": {" role": {" terseLabel":" Cash"," label":" Cash"," documentation":" Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }," auth_ref": [" r147"," r585"," r646"," r672"," r799"," r825"," r955" ] }," us- gaap_CashAndCashEquivalentsAtCarryingValue": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" CashAndCashEquivalentsAtCarryingValue"," crdr":" debit"," calculation": {" http: / / nutriband. com / role / ConsolidatedBalanceSheet": {" parentTag":" us- gaap_AssetsCurrent"," weight": 1. 0," order": 1. 0 } }," presentation": [" http: / / nutriband. com / role / ConsolidatedBalanceSheet" ]," lang": {" en- us": {" role": {" terseLabel":" Cash and cash equivalents"," label":" Cash and Cash Equivalents, at Carrying Value"," documentation":" Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short- term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }," auth_ref": [" r15"," r190"," r756" ] }," us- gaap_CashAndCashEquivalentsPolicyTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" CashAndCashEquivalentsPolicyTextBlock"," presentation": [" http: / / nutriband. com / role / AccountingPoliciesByPolicy" ]," lang": {" en- us": {" role": {" terseLabel":" Cash and cash equivalents"," label":" Cash and Cash Equivalents, Policy [ Policy Text Block ]"," documentation":" Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity' s use of its cash and cash equivalents, (2) whether the entity' s cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value." } } }," auth_ref": [" r16" ] }," us- gaap_CashAndDueFromBanks": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" CashAndDueFromBanks"," crdr":" debit"," presentation": [" http: / / nutriband. com / role / CommitmentsandContigenciesDetails" ]," lang": {" en- us": {" role": {" terseLabel":" Due amount"," label":" Cash and Due from Banks"," documentation":" For banks and other depository institutions: Includes cash on hand (currency and coin), cash items in process of collection, noninterest bearing deposits due from other financial institutions (including corporate credit unions), and noninterest bearing balances with the Federal Reserve Banks, Federal Home Loan Banks and central banks." } } }," auth_ref": [" r129" ] }," us- gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"," crdr":" debit"," presentation": [" http: / / nutriband. com / role / ConsolidatedCashFlow" ]," lang": {" en- us": {" role": {" periodStartLabel":" Cash and cash equivalents- Beginning of period"," periodEndLabel":" Cash and cash equivalents- End of period"," label":" Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents"," documentation":" Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short- term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }," auth_ref": [" r15"," r100"," r219" ] }," us- gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"," crdr":" debit"," calculation": {" http: / / nutriband. com / role / ConsolidatedCashFlow": {" parentTag": null," weight": null," order": null," root": true } }," presentation": [" http: / / nutriband. com / role / ConsolidatedCashFlow" ]," lang": {" en- us": {" role": {" totalLabel":" Net change in cash"," label":" Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect"," documentation":" Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short- term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }," auth_ref": [" r1"," r100" ] }," ecd_ChangedPeerGroupFnTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" ChangedPeerGroupFnTextBlock"," presentation": [" http: / / xbrl. sec. gov / ecd / role / PvpDisclosure" ]," lang": {" en- us": {" role": {" label":" Changed Peer Group, Footnote [ Text Block ]"," terseLabel":" Changed Peer Group, Footnote" } } }," auth_ref": [" r894" ] }," srt_ChiefExecutiveOfficerMember": {" xbrltype":" domainItemType"," nsuri":" http: / / fasb. org / srt / 2024"," localname":" ChiefExecutiveOfficerMember"," presentation": [" http: / / nutriband. com / role / CommitmentsandContigenciesDetails"," http: / / nutriband. com / role / OptionsandWarrantsDetails"," http: / / nutriband. com / role / RelatedPartyTransactionsDetails" ]," lang": {" en- us": {" role": {" terseLabel":" CEO [ Member ]"," verboseLabel":" Executive Officers [ Member ]"," netLabel":" Chief Executive Officer [ Member ]"," label":" Chief Executive Officer [ Member ]"," documentation":" Person with designation of chief executive officer." } } }," auth_ref": [" r990" ] }," srt_ChiefFinancialOfficerMember": {" xbrltype":"

~~domainItemType"," nsuri":" http: / / fasb. org / srt / 2024"," localname":" ChiefFinancialOfficerMember"," presentation": [" http: / / nutriband. com / role / CommitmentsandContigenciesDetails"," http: / / nutriband. com / role / RelatedPartyTransactionsDetails" ]," lang": {" en- us": {" role": {" terseLabel":" Chief Financial Officer [ Member ]"," label":" Chief Financial Officer [ Member ]"," documentation":" Person with designation of chief financial officer." } } },"~~
~~auth_ref": [" r990" ] }," eed_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {" xbrltype":" domainItemType"," nsuri":" http: / / xbrl. sec. gov / eed / 2024"," localname":" ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"," presentation": [" http: / / xbrl. sec. gov / eed / role / PvpDisclosure" ]," lang": {" en- us": {" role": {" label":" Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [ Member ]"," terseLabel":" Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year" } } }," auth_ref": [" r891" ] },"~~
~~eed_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {" xbrltype":" domainItemType"," nsuri":" http: / / xbrl. sec. gov / eed / 2024"," localname":" ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"," presentation": [" http: / / xbrl. sec. gov / eed / role / PvpDisclosure" ]," lang": {" en- us": {" role": {" label":" Year- over- Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [ Member ]"," terseLabel":" Year- over- Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested" } } }," auth_ref": [" r889" ] },"~~
~~dei_CityAreaCode": {" xbrltype":" normalizedStringItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" CityAreaCode"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover" ]," lang": {" en- us": {" role": {" label":" City Area Code"," documentation":" Area code of city" } } }," auth_ref": [ ] },"~~
~~us- gaap_ClassOfStockDomain": {" xbrltype":" domainItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" ClassOfStockDomain"," presentation": [" http: / / nutriband. com / role / StockholdersEquityDetails"," http: / / xbrl. sec. gov / dei / role / document / Cover" ]," lang": {" en- us": {" role": {" label":" Class of Stock [ Domain ]"," documentation":" Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }," auth_ref": [" r161"," r198"," r199"," r200"," r223"," r245"," r246"," r248"," r250"," r255"," r256"," r297"," r352"," r354"," r355"," r356"," r359"," r360"," r389"," r390"," r392"," r395"," r401"," r504"," r625"," r626"," r627"," r628"," r634"," r635"," r637"," r638"," r639"," r640"," r641"," r642"," r643"," r644"," r645"," r647"," r664"," r687"," r707"," r731"," r732"," r733"," r734"," r735"," r947"," r974"," r983" ] }," us- gaap_ClassOfWarrantOrRightAxis": {" xbrltype":" stringItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" ClassOfWarrantOrRightAxis"," presentation": [" http: / / nutriband. com / role / OptionsandWarrantsDetails"," http: / / nutriband. com / role / OptionsandWarrantsTables"," http: / / nutriband. com / role / RelatedPartyTransactionsDetails"," http: / / nutriband. com / role / ScheduleofChangesinWarrantsOutstandingTable"," http: / / nutriband. com / role / ScheduleofSummarizesAdditionalInformationRelatingtotheWarrantsOutstandingTable"," http: / / nutriband. com / role / SubsequentEventsDetails" ]," lang": {" en- us": {" role": {" label":" Class of Warrant or Right [ Axis ]"," documentation":" Information by type of warrant or right issued." } } }," auth_ref": [" r41" ] }," us- gaap_ClassOfWarrantOrRightDomain": {" xbrltype":" domainItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" ClassOfWarrantOrRightDomain"," presentation": [" http: / / nutriband. com / role / OptionsandWarrantsDetails"," http: / / nutriband. com / role / OptionsandWarrantsTables"," http: / / nutriband. com / role / RelatedPartyTransactionsDetails"," http: / / nutriband. com / role / SubsequentEventsDetails" ]," lang": {" en- us": {" role": {" label":" Class of Warrant or Right [ Domain ]"," documentation":" Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." } } }," auth_ref": [ ] }," us- gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {" xbrltype":" perShareItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"," presentation": [" http: / / nutriband. com / role / IntangibleAssetsDetails" ]," lang": {" en- us": {" role": {" terseLabel":" Exercise price per share (in Dollars per share)"," label":" Class of Warrant or Right, Exercise Price of Warrants or Rights"," documentation":" Exercise price per share or per unit of warrants or rights outstanding." } } }," auth_ref": [" r402" ] }," us- gaap_ClassOfWarrantOrRightLineItems": {" xbrltype":" stringItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" ClassOfWarrantOrRightLineItems"," presentation": [" http: / / nutriband. com / role / ScheduleofChangesinWarrantsOutstandingTable" ]," lang": {" en- us": {" role": {" label":" Schedule of Changes in~~ Warrants Outstanding [ Line Items ] ~~" Shares , " documentation":"~~ **Outstanding balance 1, 307, 671 5, 546, 973 1, 283, 038Exercise Price, Outstanding balance $ 6. 43 $ 6. 37 $ 5. 88Remaining ~~Line~~ Life , Outstanding balance 3 years 4 months 2 days 3 years 8 months 4 days 2 years 11 months 19 daysIntrinsic Value, Outstanding balance $ 10, 626, 018 Shares, Exercisable 5, 546, 973 Exercise Price, Exercisable $ 6. 37 Remaining Life, Exercisable 3 years 8 months 4 days Intrinsic Value, Exercisable $ 10, 626, 018 Shares, Granted 4, 402, 460 175, 833Exercise Price, Granted $ 6. 4 $ 2. 28Remaining Life, Granted 4 years 8 months 19 days 2 years 11 months 19 daysIntrinsic Value, Granted Shares, Expired / Cancelled (50, 000) (200, 466) Exercise Price, Expired / Cancelled $ 4 $ 6. 33Intrinsic Value, Expired / Cancelled Shares, Exercised (88, 525) Exercise Price, Exercised $ 1. 98 Intrinsic Value, Exercised X- DefinitionRepresents the shares of exercisable. ReferencesNo definition available. Details Name: ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber Namespace Prefix: ntrb_ Data Type: xbrli: sharesItemType Balance Type: na Period Type: instantX- DefinitionRepresents the per share of exercisable. ReferencesNo definition available. Details Name: ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisePriceExercisable Namespace Prefix: ntrb_ Data Type: dtr: perShareItemType Balance Type: na Period Type: instantX- DefinitionRepresents the per share of exercised. ReferencesNo definition available. Details Name: ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice Namespace Prefix: ntrb_ Data Type: dtr: perShareItemType Balance Type: na Period Type: durationX- DefinitionRepresents the per share of expired. ReferencesNo definition available. Details Name: ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredWeightedAverageExercisePrice Namespace Prefix: ntrb_ Data Type: dtr: perShareItemType Balance Type: na Period Type: durationX- DefinitionRepresents the per share of granted. ReferencesNo definition available. Details Name: ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice Namespace Prefix: ntrb_ Data Type: dtr: perShareItemType Balance Type: na Period Type: durationX- DefinitionRepresents the amount of intrinsic value, exercisable. ReferencesNo definition available. Details Name: ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIntrinsicValueExercisable Namespace Prefix: ntrb_ Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: instantX- DefinitionRepresents the amount of intrinsic value, exercised. ReferencesNo definition available. Details Name: ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIntrinsicValueExercised Namespace Prefix: ntrb_ Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: durationX- DefinitionRepresents the amount of intrinsic value, expired / cancelled. ReferencesNo definition available. Details Name: ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIntrinsicValueExpiredCancelled Namespace Prefix: ntrb_ Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: durationX- DefinitionRepresents the amount of intrinsic value, granted. ReferencesNo definition available. Details Name: ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIntrinsicValueGranted Namespace Prefix: ntrb_ Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: durationX- DefinitionRepresents the per share of exercise price, outstanding balance. ReferencesNo definition available. Details Name: ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice Namespace Prefix: ntrb_ Data Type: dtr: perShareItemType Balance Type: na Period Type: instantX- DefinitionRepresents the value of intrinsic value, outstanding balance. ReferencesNo definition available. Details Name: ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsntrinsicValueOutstandingBalance Namespace Prefix: ntrb_ Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: instantX- DefinitionRepresents the remaining life, exercisable. ReferencesNo definition available. Details Name: ntrb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsRemainingLifeExercisable Namespace Prefix:**

**ntrb_ Data Type: xbrli: durationItemType Balance Type: na Period Type: durationX- DefinitionRepresents the duration of remaining lfe, granted. ReferencesNo definition available. Details Name: ntrb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsRemainingLifeGranted Namespace Prefix: ntrb_ Data Type: xbrli: durationItemType Balance Type: na Period Type: durationX- DefinitionRepresents the duration of remaining life, outstanding balance. ReferencesNo definition available. Details Name: ntrb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsRemainingLifeOutstandingBalance Namespace Prefix: ntrb_ Data Type: xbrli: durationItemType Balance Type: na Period Type: durationX- DefinitionLine** items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. **ReferencesReference 1 " } } },"** auth_ref" : **the passage of time** (02)- Publisher FASB- URI https:/ / asc.fasb.org - **or when a triggering event occurs. ReferencesReference 1** / 1943274 / 2147480429 / 718- 10- 50- 2Reference 27 :http:/ / www- **fasb** . xbrl. org / 2003 **us- gaap** / role / disclosureRef **ref / legacyRef** - Topic 718 **942** - SubTopic 10 **210** - Name Accounting Standards Codification- Section 50 **S99** - Paragraph 2 **1** - Subparagraph ( **SX 210.9-** c) (2) (iii) ( 03 **(10)** )- Publisher FASB- URI https:/ / asc.fasb.org / 1943274 / 2147480429 **2147478546** / 718 **942** - 10 **210** - 50 **S99** - 2Reference **1Reference** 28 **2** :http:/ / www.xbrl.org / 2003 **2009** / role / disclosureRef **commonPracticeRef** - Topic 718 **944** - SubTopic 10 **210** - Name Accounting Standards Codification- Section 50 **S99** - Paragraph 2 **1** - Subparagraph ( d) **SX 210.7- 03** ( 2 **a) (10)** )- Publisher FASB- URI https:/ / asc.fasb.org / 1943274 / 2147480429 **2147478777** / 718 **944** - 10 **210** - 50 **S99** - 2Reference **1Reference** 29 **3** :http:/ / www.xbrl.org / 2003 / role / disclosureRef- Topic 718 **946** - SubTopic 10 **210** - Name Accounting Standards Codification- Section 50 **S99** - Paragraph 2 **1** - Subparagraph ( c) **SX 210.6- 04** ( 1 **7) (a)** )- Publisher FASB- URI https:/ / asc.fasb.org / 1943274 / 2147480429 **2147479170** / 718 **946** - 10 **210** - 50 **S99** - 2Reference **1Reference** 30 **4** :http:/ / www.xbrl.org / 2003 / role / disclosureRef- Topic 718 **210** - SubTopic 10- Name Accounting Standards Codification- Section 50 **S99** - Paragraph 2 **1** - Subparagraph ( c) **SX 210.5- 02** ( 2 **7)** )- Publisher FASB- URI https:/ / asc.fasb.org / 1943274 / 2147480429 **2147480566** / 718- 10 **210** - 50 **10** - 2 **S99- 1** Details Name:us- gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems **gaap_PrepaidExpenseCurrentAndNoncurrent** Namespace Prefix:us- gaap_ Data Type:xbrli: stringItemType **monetaryItemType** Balance Type: na **debit** Period Type: durationX **instantX** - **DefinitionCash received** DefinitionNumber of shares under non- option equity instrument agreements for which rights to exercise lapsed **fees during the current period.This element excludes cash proceeds from license fees** . ReferencesReference 1:http:/ / fasb.org / us- gaap / role / ref / legacyRef- Topic 718 **230** - SubTopic 10- Name Accounting Standards Codification- Section 50 **45** - Paragraph 2 **25** - Subparagraph (c ) (1) (iv) (04 )- Publisher FASB- URI https:/ / asc.fasb.org / 1943274 / 2147480429 **2147482740** / 718 **230** - 10- 50 **45** - 2 **25** Details Name:us- gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations **gaap_ProceedsFromFeesReceived** Namespace Prefix:us- gaap_ Data Type:xbrli: sharesItemType **monetaryItemType** Balance Type: na **debit** Period Type:durationX- DefinitionNumber **DefinitionAmount** of **purchase arrangement** [ **Member** ] **12 Months EndedJan** },"us- gaap_ClassOfWarrantOrRightTable": {" xbrltype":" stringItemType","nsuri":" http: / / fasb . **31,** org / us- gaap / 2024 **2025 USD ($) $** "," localname":" ClassOfWarrantOrRightTable"," presentation":[" http:/ **shares sharesSchedule** / nutriband. com / role / ScheduleofChangesinWarrantsOutstandingTable" ],"lang": {" en- us": {" role": {" label":" Class of **Additional** Warrant or Right [ Table ]","documentation":" Disclosure of information **Information Relating** about warrant or right issued that give holder right to **the Options** purchase security from issuer at specific price within certain time frame." } } },"auth_ref": [" r41" ] },"ecd_CoSelectedMeasureAmt": {" xbrltype":" decimalItemType","nsuri":" http: / / xbrl. sec. gov / ecd / 2024","localname":" CoSelectedMeasureAmt","presentation":[" http: / / xbrl. sec. gov / ecd / role / PvpDisclosure" ],"lang": {" en- us": {" role": {" label":" Company Selected Measure Amount","terseLabel":" Company Selected Measure Amount" } } },"auth_ref": [" r895" ] },"ecd_CoSelectedMeasureName": {" xbrltype":" normalizedStringItemType","nsuri":" http: / / xbrl. sec. gov / ecd / 2024","localname":" CoSelectedMeasureName","presentation":[" http: / / xbrl. sec. gov / ecd / role / PvpDisclosure" ],"lang": {" en- us": {" role": {" label":" Company Selected Measure Name","terseLabel":" Company Selected Measure Name" } } },"auth_ref": [" r895" ] },"us- gaap_CommitmentsAndContingencies": {" xbrltype":" monetaryItemType","nsuri":" http: / / fasb. org / us- gaap / 2024","localname":" CommitmentsAndContingencies","crdr":" credit","calculation": {" http: / / nutriband. com / role / ConsolidatedBalanceSheet": {" parentTag":" us- gaap_LiabilitiesAndStockholdersEquity","weight": 1. 0," order": 2. 0 } },"presentation":[" http: / / nutriband. com / role / ConsolidatedBalanceSheet" ],"lang": {" en- us": {" role": {" terseLabel":" Commitments and **Warrants Outstanding** Contingencies","label":" Commitments and Contingencies","documentation":" Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company' s resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } },"auth_ref": [" r73","r136","r584","r663" ] },"us- gaap_CommitmentsAndContingenciesDisclosureAbstract": {" xbrltype":" stringItemType","nsuri":" http: / / fasb. org / us- gaap / 2024","localname":" CommitmentsAndContingenciesDisclosureAbstract","lang": {" en- us": {" role": {" label":" Commitments and Contigencies [ Abstract ]" } } },"auth_ref": [ ] },"us- gaap_CommitmentsAndContingenciesDisclosureTextBlock": {" xbrltype":" textBlockItemType","nsuri":" http: / / fasb. org / us- gaap / 2024","localname":" CommitmentsAndContingenciesDisclosureTextBlock","presentation":[" http: / / nutriband. com / role / CommitmentsandContigencies" ],"lang": {" en- us": {" role": {" terseLabel":" COMMITMENTS AND CONTIGENCIES","label":" Commitments and Contingencies Disclosure [ Text Block ]","documentation":" The entire disclosure for commitments and contingencies." } } },"auth_ref": [" r111","r344","r345","r739","r1003","r1008" ] },"ntrb_CommitmentsandContigenciesDetailsLineItems": {" xbrltype":" stringItemType","nsuri":" http: / / nutriband. com / 20240131","localname":" CommitmentsandContigenciesDetailsLineItems","presentation":[" http: / / nutriband. com / role / CommitmentsandContigenciesDetails" ],"lang": {" en- us": {" role": {" label":" Commitments and Contigencies [ Line Items ] **Number** " } } },"auth_ref": [ ] },"ntrb_CommitmentsandContigenciesDetailsTable": {" xbrltype":" stringItemType","nsuri":" http: / / nutriband. com / 20240131","localname":" CommitmentsandContigenciesDetailsTable","presentation":[" http: / / nutriband. com / role / CommitmentsandContigenciesDetails" ],"lang": {" en- us": {" role": {" label":" Commitments and Contigencies (Details) [ Table ]" } } },"auth_ref": [ ] },"us- gaap_CommonStockMember": {" xbrltype":" domainItemType","nsuri":" http: / / fasb. org / us- gaap / 2024","localname":" CommonStockMember","presentation":[" http: / / nutriband. com / role / RelatedPartyTransactionsDetails","http: / / nutriband. com / role / ShareholdersEquityType2or3","http: / / nutriband. com / role / StockholdersEquityDetails","http: / / nutriband. com / role / SubsequentEventsDetails","http: / / xbrl. sec. gov / dei / role / document / Cover" ],"lang": {" en- us": {" role": {" terseLabel":" Common Stock","verboseLabel":" Common Stock [ Member ]","label":" Common Stock [ Member ]","documentation":" Stock that is subordinate to all other stock of the issuer." } } },"auth_ref": [" r816","r817","r818","r820","r821","r822","r823","r978","r979","r982","r1023","r1084","r1087" ] },"ntrb_CommonStockOfDescription": {" xbrltype":" stringItemType","nsuri":" http: / / nutriband. com / 20240131","localname":" CommonStockOfDescription","presentation":[" http: / / nutriband. com / role / StockholdersEquityDetails" ],"lang": {" en- us": {" role": {" terseLabel":" Common stock, description","documentation":" Description of common stock of, description.","label":" Common Stock Of Description" } } },"auth_ref": [ ] },"us- gaap_CommonStockOtherSharesOutstanding": {" xbrltype":" sharesItemType","nsuri":" http: / / fasb. org / us- gaap / 2024","localname":" CommonStockOtherSharesOutstanding","presentation":[" http: / / nutriband. com / role / SummaryofSignificantAccountingPoliciesDetails" ],"lang": {" en- us": {" role": {" terseLabel":" Common stock equivalents outstanding **Outstanding** (in | **shares 5, 546, 973Exercise Price for** Shares )","label":" Common Stock, Other Shares, Outstanding "," documentation":" Number of shares of other common stock instruments held by shareholder, including, but not limited to, exchangeable shares." } } },"auth_ref": [ ] },"us- gaap_CommonStockParOrStatedValuePerShare": {" xbrltype":" perShareItemType","nsuri":" http: / / fasb. org / us- gaap / 2024","localname":" CommonStockParOrStatedValuePerShare","presentation":[" http: / / nutriband. com / role / ConsolidatedBalanceSheet_Parentheticals" ],"lang": {" en- us": {" role": {" terseLabel":" Common stock, par value (in Dollars per share) " | **$ / shares $ 6. 37Number Exercisable | shares 5** , **546** " label":" Common Stock , Par **973Exercise Price** or **for** Stated Value Per Share **Shares Exercisable (in Dollars** "," documentation":" Face amount or stated value per share of common stock." } } },"auth_ref": [" r77" ] },"ntrb_CommonStockReserved": {" xbrltype":" sharesItemType","nsuri":" http: / / nutriband. com / 20240131","localname":" CommonStockReserved","presentation":[" http: / / nutriband. com / role / OptionsandWarrantsDetails" ],"lang": {" en- us": {" role": {" terseLabel":" Common stock reserved (in Shares ) | **$** "," documentation":" Common stock reserved."," label":" Common Stock Reserved" } } },"auth_ref": [ ] },"ntrb_CommonStockReturnedInSettlementinShares": {" xbrltype":" sharesItemType","nsuri":" http: / / nutriband. com / 20240131","localname":" CommonStockReturnedInSettlementinShares","presentation":[" http: / / nutriband. com / role / ShareholdersEquityType2or3" ],"lang": {" en- us": {" role": {" terseLabel":" Common stock returned in settlement (in Shares)","documentation":" Common stock returned in settlement."," label":" Common Stock Returned In Settlementin Shares" } } },"auth_ref": [ ] },"us- gaap_CommonStockSharesAuthorized": {" xbrltype":" sharesItemType","nsuri":" http: / / fasb. org / us- gaap / 2024","localname":" CommonStockSharesAuthorized","presentation":[" http: / / nutriband. com / role / ConsolidatedBalanceSheet_Parentheticals","http: / / nutriband. com / role / RelatedPartyTransactionsDetails" ],"lang": {" en- us": {" role": {" terseLabel":" Common stock, shares authorized","verboseLabel":" Common stock (in Shares)","label":" Common Stock, Shares Authorized","documentation":"

The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }," auth_ref": [" r77"," r664" ] }," us-gaap_CommonStockSharesIssued": {" xbrltype":" sharesItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" CommonStockSharesIssued"," presentation": [" http: / / nutriband. com / role / ConsolidatedBalanceSheet_Parentheticals"," http: / / nutriband. com / role / OrganizationandDescriptionofBusinessDetails" ]," lang": {" en- us": {" role": {" terseLabel":" Common stock, shares issued"," verboseLabel":" Common stock share (in Shares)"," label":" Common Stock, Shares, Issued"," documentation":" Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }," auth_ref": [" r77" ] }," us- gaap_CommonStockSharesOutstanding": {" xbrltype":" sharesItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" CommonStockSharesOutstanding"," presentation": [" http: / / nutriband. com / role / ConsolidatedBalanceSheet_Parentheticals"," http: / / nutriband. com / role / StockholdersEquityDetails" ]," lang": {" en- us": {" role": {" terseLabel":" Common stock, shares outstanding"," verboseLabel":" Converted shares"," label":" Common Stock, Shares, Outstanding"," documentation":" Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }," auth_ref": [" r8"," r77"," r664"," r684"," r1087"," r1088" ] }," us- gaap_CommonStockValue": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" CommonStockValue"," crdr":" credit"," calculation": {" http: / / nutriband. com / role / ConsolidatedBalanceSheet": {" parentTag":" us- gaap_StockholdersEquity"," weight": 1. 0," order": 2. 0 } }," presentation": [" http: / / nutriband. com / role / ConsolidatedBalanceSheet"," http: / / nutriband. com / role / OrganizationandDescriptionofBusinessDetails" ]," lang": {" en- us": {" role": {" terseLabel":" Common stock, $ 6 . 37Intrinsic 001 par value, 291, 666, 666 shares authorized; 8, 869, 870 and 7, 843, 150 shares issued at January 31, 2024 and 2023, respectively; 8, 859, 870 and 7, 833, 150 shares outstanding as of January 31, 2024 and 2023, respectively"," verboseLabel":" Common stock value"," label":" Common Stock, Value , Issued"," documentation":" Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }," auth_ref": [" r77"," r587"," r799" ] }," us- gaap_CommonUnitIssuanceValue": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" CommonUnitIssuanceValue"," crdr":" credit"," presentation": [" http: / / nutriband. com / role / StockholdersEquityDetails" ]," lang": {" en- us": {" role": {" terseLabel":" Issuance (in Dollars) "| $ $ 10 , 626 " label":" Common Unit , 018Exercise Issuance Value"," documentation":" Stated value of common units of ownership issued by a limited liability company (LLC)." } } }," auth_ref": [ ] }," ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" CompActuallyPaidVsCoSelectedMeasureTextBlock"," presentation": [" http: / / xbrl. sec. gov / ecd / role / PvpDisclosure" ]," lang": {" en- us": {" role": {" label":" Compensation Actually Paid vs. Company Selected Measure [ Text Block ]"," terseLabel":" Compensation Actually Paid vs. Company Selected Measure" } } }," auth_ref": [" r900" ] }," ecd_CompActuallyPaidVsNetIncomeTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" CompActuallyPaidVsNetIncomeTextBlock"," presentation": [" http: / / xbrl. sec. gov / ecd / role / PvpDisclosure" ]," lang": {" en- us": {" role": {" label":" Compensation Actually Paid vs. Net Income [ Text Block ]"," terseLabel":" Compensation Actually Paid vs. Net Income" } } }," auth_ref": [" r899" ] }," ecd_CompActuallyPaidVsOtherMeasureTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" CompActuallyPaidVsOtherMeasureTextBlock"," presentation": [" http: / / xbrl. sec. gov / ecd / role / PvpDisclosure" ]," lang": {" en- us": {" role": {" label":" Compensation Actually Paid vs. Other Measure [ Text Block ]"," terseLabel":" Compensation Actually Paid vs. Other Measure" } } }," auth_ref": [" r901" ] }," ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" CompActuallyPaidVsTotalShareholderRtnTextBlock"," presentation": [" http: / / xbrl. sec. gov / ecd / role / PvpDisclosure" ]," lang": {" en- us": {" role": {" label":" Compensation Actually Paid vs. Total Shareholder Return [ Text Block ]"," terseLabel":" Compensation Actually Paid vs. Total Shareholder Return" } } }," auth_ref": [" r898" ] }," us- gaap_ConcentrationRiskBenchmarkDomain": {" xbrltype":" domainItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" ConcentrationRiskBenchmarkDomain"," presentation": [" http: / / nutriband. com / role / CommitmentsandContigenciesDetails" ]," lang": {" en- us": {" role": {" label":" Concentration Risk Benchmark [ Domain ]"," documentation":" The denominator in a calculation of a disclosed concentration risk percentage." } } }," auth_ref": [" r23"," r24"," r56"," r57"," r291"," r738" ] }," us- gaap_ConcentrationRiskByBenchmarkAxis": {" xbrltype":" stringItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" ConcentrationRiskByBenchmarkAxis"," presentation": [" http: / / nutriband. com / role / CommitmentsandContigenciesDetails" ]," lang": {" en- us": {" role": {" label":" Concentration Risk Benchmark [ Axis ]"," documentation":" Information by benchmark of concentration risk." } } }," auth_ref": [" r23"," r24"," r56"," r57"," r291"," r620"," r738" ] }," us- gaap_ConsolidationPolicyTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" ConsolidationPolicyTextBlock"," presentation": [" http: / / nutriband. com / role / AccountingPoliciesByPolicy" ]," lang": {" en- us": {" role": {" terseLabel":" Principles ---- Prices of Consolidation"," label":" Consolidation, Policy [ Policy Text Block ]"," documentation":" Disclosure of accounting policy regarding ( 1 ) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting . 93 The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary." } } }," auth_ref": [" r52"," r760" ] }," dei_ContactPersonnelEmailAddress": {" xbrltype":" normalizedStringItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" ContactPersonnelEmailAddress"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover" ]," lang": {" en- us": {" role": {" label":" Contact Personnel Email Address"," documentation":" Email address of contact personnel." } } }," auth_ref": [ ] }," dei_ContactPersonnelFaxNumber": {" xbrltype":" normalizedStringItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" ContactPersonnelFaxNumber"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover" ]," lang": {" en- us": {" role": {" label":" Contact Personnel Fax Number"," documentation":" Fax Number of contact personnel." } } }," auth_ref": [" r841" ] }," dei_ContactPersonnelName": {" xbrltype":" normalizedStringItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" ContactPersonnelName"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover" ]," lang": {" en- us": {" role": {" label":" Contact Personnel Name"," documentation":" Name of contact personnel" } } }," auth_ref": [ ] }," dei_ContainedFileInformationFileDescription": {" xbrltype":" stringItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" ContainedFileInformationFileDescription"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover" ]," lang": {" en- us": {" role": {" label":" Contained File Information, File Description"," documentation":" The description of the contained file." } } }," auth_ref": [ ] }," dei_ContainedFileInformationFileName": {" xbrltype":" normalizedStringItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" ContainedFileInformationFileName"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover" ]," lang": {" en- us": {" role": {" label":" Contained File Information, File Name"," documentation":" The name of the contained file." } } }," auth_ref": [ ] }," dei_ContainedFileInformationFileNumber": {" xbrltype":" fileNumberItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" ContainedFileInformationFileNumber"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover" ]," lang": {" en- us": {" role": {" label":" Contained File Information, File Number"," documentation":" The SEC Document Number of the contained file." } } }," auth_ref": [ ] }," dei_ContainedFileInformationFileType": {" xbrltype":" normalizedStringItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" ContainedFileInformationFileType"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover" ]," lang": {" en- us": {" role": {" label":" Contained File Information, File Type"," documentation":" The type or format of the contained file (usually XBRL but may be used for other types such as HTML, Word, PDF, GIF / JPG, etc.)." } } }," auth_ref": [ ] }," ntrb_ContractLiabilitiesPolicyTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / nutriband. com / 20240131"," localname":" ContractLiabilitiesPolicyTextBlock"," presentation": [" http: / / nutriband. com / role / AccountingPoliciesByPolicy" ]," lang": {" en- us": {" role": {" terseLabel":" Contract Liabilities"," documentation":" Accounting policy for contract liability."," label":" Contract Liabilities Policy Text Block" } } }," auth_ref": [ ] }," us- gaap_ConversionOfStockAmountIssued1": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" ConversionOfStockAmountIssued1"," crdr":" credit"," presentation": [" http: / / nutriband. com / role / ConsolidatedCashFlow" ]," lang": {" en- us": {" role": {" terseLabel":" Common stock returned in settlement"," label":" Conversion of Stock, Amount Issued"," documentation":" The value of the financial instrument issued [ noncash or part noncash ] in the conversion of stock. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \" Part noncash \" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }," auth_ref": [" r18"," r19"," r20" ] }," us- gaap_ConversionOfStockSharesConverted1": {" xbrltype":" sharesItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" ConversionOfStockSharesConverted1"," presentation": [" http: / / nutriband. com / role / StockholdersEquityDetails" ]," lang": {" en- us": {" role": {" terseLabel":" Converted shares"," label":" Conversion of Stock, Shares Converted"," documentation":" The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \" Part noncash \" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."

~~} } },"~~ auth_ref": [" r18"," r19"," r20" ] },"~~ us- gaap_ConvertibleNotesPayableCurrent": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" ConvertibleNotesPayableCurrent"," crdr":" credit"," presentation": [" http: / / nutriband. com / role / NotesPayableDetails" ]," lang": {" en- us": {" role": {" terseLabel":" Convertible notes payable current"," label":" Convertible Notes Payable, Current"," documentation":" Carrying value as of the balance sheet date of the portion of long- term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder." } } },"~~ auth_ref": [" r67" ] },"~~ us- gaap_CorporateAndOtherMember": {" xbrltype":" domainItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" CorporateAndOtherMember"," presentation": [" http: / / nutriband. com / role / ScheduleofNetSalesandPropertyandEquipmentTable"," http: / / nutriband. com / role / ScheduleofSegmentPerformancetotheGAAPMeasureofGrossProfitTable" ]," lang": {" en- us": {" role": {" terseLabel":" Selling, general and administrative- Corporate ~~[ Member ]~~ **Schedule of Additional Information Relating to the Options** ","~~ verboseLabel":" Corporate [ Member ]","~~ label":" Corporate Segment ~~and~~ **Warrants** ~~Other Operating Segment [ Member ]","~~ documentation":" Component of entity providing financial and operational oversight and administrative support considered to be operating segment and operating segment, classified as other. Excludes intersegment elimination and reconciling item." } } },"~~ auth_ref": [" r985" ] },"~~ us- gaap_CostOfGoodsAndServicesSold": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" CostOfGoodsAndServicesSold"," crdr":" debit"," presentation": [" http: / / nutriband. com / role / ScheduleofDisaggregatesitsRevenuefromContractsTable" ]," lang": {" en- us": {" role": {" terseLabel":" Sale of goods"," label":" Cost of Goods and Services Sold"," documentation":" The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities." } } },"~~ auth_ref": [" r88"," r89"," r541" ] },"~~ us- gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" CostOfGoodsAndServicesSoldDepreciationAndAmortization"," crdr":" debit"," presentation": [" http: / / nutriband. com / role / ScheduleofSegmentPerformancetotheGAAPMeasureofGrossProfitTable" ]," lang": {" en- us": {" role": {" terseLabel":" Depreciation and Amortization"," label":" Cost, Depreciation and Amortization"," documentation":" Amount of expense for allocation of cost of tangible and intangible assets over their useful lives directly used in production of good and rendering of service." } } },"~~ auth_ref": [" r967" ] },"~~ us- gaap_CostOfRevenue": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" CostOfRevenue"," crdr":" debit"," calculation": {" http: / / nutriband. com / role / ConsolidatedIncomeStatement": {" parentTag":" us- gaap_CostsAndExpenses"," weight": 1. 0," order": 1. 0 } }," presentation": [" http: / / nutriband. com / role / ConsolidatedIncomeStatement" ]," lang": {" en- us": {" role": {" terseLabel":" Cost of revenues"," label":" Cost of Revenue"," documentation":" The aggregate cost of goods produced and sold and services rendered during the reporting period." } } },"~~ auth_ref": [" r90"," r223"," r297"," r352"," r353"," r354"," r355"," r356"," r357"," r358"," r359"," r360"," r504"," r771"," r1009" ] },"~~ us- gaap_CostOfServicesCatering": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" CostOfServicesCatering"," crdr":" debit"," presentation": [" http: / / nutriband. com / role / ScheduleofDisaggregatesitsRevenuefromContractsTable" ]," lang": {" en- us": {" role": {" terseLabel":" Services"," label":" Cost of Services, Catering"," documentation":" Cost of food and beverage catering for passengers." } } },"~~ auth_ref": [ ] },"~~ us- gaap_CostsAndExpenses": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" CostsAndExpenses"," crdr":" debit"," calculation": {" http: / / nutriband. com / role / ConsolidatedIncomeStatement": {" parentTag":" us- gaap_OperatingIncomeLoss"," weight":- 1. 0," order": 2. 0 } }," presentation": [" http: / / nutriband. com / role / ConsolidatedIncomeStatement" ]," lang": {" en- us": {" role": {" totalLabel":" Total Costs and Expenses"," label":" Costs and Expenses"," documentation":" Total costs of sales and operating expenses for the period." } } },"~~ auth_ref": [" r97" ] },"~~ us- gaap_CostsAndExpensesAbstract": {" xbrltype":" stringItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" CostsAndExpensesAbstract"," presentation": [" http: / / nutriband. com / role / ConsolidatedIncomeStatement" ]," lang": {" en- us": {" role": {" terseLabel":" Costs and expenses:"," label":" Costs and Expenses [ Abstract ]" } } },"~~ auth_ref": [ ] },"~~ dei_CountryRegion": {" xbrltype":" normalizedStringItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" CountryRegion"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover" ]," lang": {" en- us": {" role": {" label":" Country Region"," documentation":" Region code of country" } } },"~~ auth_ref": [ ] },"~~ dei_CoverAbstract": {" xbrltype":" stringItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" CoverAbstract"," lang": {" en- us": {" role": {" label":" Cover [ Abstract ]"," documentation":" Cover page." } } },"~~ auth_ref": [ ] },"~~ ntrb_CurrentAbstract": {" xbrltype":" stringItemType"," nsuri":" http: / / nutriband. com / 20240131"," localname":" CurrentAbstract"," presentation": [" http: / / nutriband. com / role / ScheduleofProvisionforIncomeTaxesTable" ]," lang": {" en- us": {" role": {" terseLabel":" Current"," label":" Current Abstract" } } },"~~ auth_ref": [ ] },"~~ us- gaap_CurrentFederalTaxExpenseBenefit": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" CurrentFederalTaxExpenseBenefit"," crdr":" debit"," presentation": [" http: / / nutriband. com / role / ScheduleofProvisionforIncomeTaxesTable" ]," lang": {" en- us": {" role": {" terseLabel":" Federal"," label":" Current Federal Tax Expense (Benefit)"," documentation":" Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non- US (United States of America) jurisdiction." } } },"~~ auth_ref": [" r951"," r977"," r1022" ] },"~~ dei_CurrentFiscalYearEndDate": {" xbrltype":" gMonthDayItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" CurrentFiscalYearEndDate"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover" ]," lang": {" en- us": {" role": {" label":" Current Fiscal Year End Date"," documentation":" End date of current fiscal year in the format-- MM- DD." } } },"~~ auth_ref": [ ] },"~~ us- gaap_CurrentForeignTaxExpenseBenefit": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" CurrentForeignTaxExpenseBenefit"," crdr":" debit"," presentation": [" http: / / nutriband. com / role / ScheduleofProvisionforIncomeTaxesTable" ]," lang": {" en- us": {" role": {" terseLabel":" Foreign"," label":" Current Foreign Tax Expense (Benefit)"," documentation":" Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations." } } },"~~ auth_ref": [" r951"," r977" ] },"~~ ntrb_DateDoAdoption": {" xbrltype":" durationItemType"," nsuri":" http: / / nutriband. com / 20240131"," localname":" DateDoAdoption"," presentation": [" http: / / nutriband. com / role / SubsequentEventsDetails" ]," lang": {" en- us": {" role": {" terseLabel":" Date of adoption"," documentation":" Date of adoption."," label":" Date Do Adoption" } } },"~~ auth_ref": [ ] },"~~ ntrb_DateOfIssuance": {" xbrltype":" durationItemType"," nsuri":" http: / / nutriband. com / 20240131"," localname":" DateOfIssuance"," presentation": [" http: / / nutriband. com / role / SubsequentEventsDetails" ]," lang": {" en- us": {" role": {" terseLabel":" Expire years"," documentation":" Date of issuance."," label":" Date Of Issuance" } } },"~~ auth_ref": [ ] },"~~ us- gaap_DebtConversionConvertedInstrumentAmount1": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" DebtConversionConvertedInstrumentAmount1"," crdr":" credit"," presentation": [" http: / / nutriband. com / role / ConsolidatedCashFlow" ]," lang": {" en- us": {" role": {" terseLabel":" Issuance of common stock for extinguishment of debt"," label":" Debt Conversion, Converted Instrument, Amount"," documentation":" The value of the financial instrument (s) that the original debt is being converted into in a noncash (or part noncash) transaction. \" Part noncash \" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } },"~~ auth_ref": [" r18"," r20" ] },"~~ us- gaap_DebtCurrent": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" DebtCurrent"," crdr":" credit"," presentation": [" http: / / nutriband. com / role / SummaryofSignificantAccountingPoliciesDetails" ]," lang": {" en- us": {" role": {" terseLabel":" Debt amount"," label":" Debt, Current"," documentation":" Amount of debt and lease obligation, classified as current." } } },"~~ auth_ref": [" r196" ] },"~~ us- gaap_DebtDefaultLongtermDebtAmount": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" DebtDefaultLongtermDebtAmount"," crdr":" credit"," presentation": [" http: / / nutriband. com / role / NotesPayableDetails" ]," lang": {" en- us": {" role": {" terseLabel":" Assumed amount"," label":" Debt Instrument, Debt Default, Amount"," documentation":" Amount of outstanding **Outstanding** long- term debt or borrowing associated with any securities or credit agreement for which there has been a default in principal, interest, sinking fund, or redemption provisions, or any breach of covenant that existed at the end of the period and subsequently has not been cured." } } },"~~ auth_ref": [" r221" ] },"~~ us- gaap_DebtDisclosureTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" DebtDisclosureTextBlock"," presentation": [" http: / / nutriband. com / role / NotesPayable" ]," lang": {" en- us": {" role": {" terseLabel":" NOTES PAYABLE"," label":" Debt Disclosure [ Text Block ]"," documentation":" The entire disclosure for information about short- term and long- term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own- share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long- term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } },"~~ auth_ref": [" r112"," r221"," r337"," r338"," r339"," r340"," r341"," r350"," r351"," r361"," r367"," r368"," r369"," r370"," r371"," r372"," r377"," r384"," r385"," r386"," r513" ] },"~~ us- gaap_DebtInstrumentAxis": {" xbrltype":" stringItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" DebtInstrumentAxis"," presentation": [" http: / / nutriband. com / role / CommitmentsandContigenciesDetails" ]," lang": {" en- us": {" role": {" label":" Debt Instrument [ Axis ]"," documentation":" Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } },"~~ auth_ref": [" r11"," r66"," r67"," r132"," r135"," r227"," r362"," r363"," r364"," r365"," r366"," r368"," r373"," r374"," r375"," r376"," r378"," r379"," r380"," r381"," r382"," r383"," r779"," r780"," r781"," r782"," r783","

r797"," r975"," r1004"," r1005"," r1006"," r1036"," r1037" ] }," us- gaap_DebtInstrumentFeeAmount": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" DebtInstrumentFeeAmount"," crdr":" debit"," presentation": [" http: / / nutriband. com / role / CommitmentsandContigenciesDetails" ]," lang": {" en- us": {" role": {" terseLabel":" Bad debt expense"," label":" Debt Instrument, Fee Amount"," documentation":" Amount of the fee that accompanies borrowing money under the debt instrument." } } }," auth_ref": [" r70" ] }," us- gaap_DebtInstrumentMaturityDate": {" xbrltype":" dateItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" DebtInstrumentMaturityDate"," presentation": [" http: / / nutriband. com / role / CommitmentsandContigenciesDetails" ]," lang": {" en- us": {" role": {" terseLabel":" Maturity date"," label":" Debt Instrument, Maturity Date"," documentation":" Date when the debt instrument is scheduled to be fully repaid, in YYYY- MM- DD format." } } }," auth_ref": [" r197"," r779"," r1025"," r1026" ] }," us- gaap_DebtInstrumentNameDomain": {" xbrltype":" domainItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" DebtInstrumentNameDomain"," presentation": [" http: / / nutriband. com / role / CommitmentsandContigenciesDetails" ]," lang": {" en- us": {" role": {" label":" Debt Instrument, Name [ Domain ]"," documentation":" The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }," auth_ref": [" r11"," r227"," r362"," r363"," r364"," r365"," r366"," r368"," r373"," r374"," r375"," r376"," r378"," r379"," r380"," r381"," r382"," r383"," r779"," r780"," r781"," r782"," r783"," r797"," r975"," r1004"," r1005"," r1006"," r1036"," r1037" ] }," us- gaap_DebtInstrumentPeriodicPayment": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" DebtInstrumentPeriodicPayment"," crdr":" debit"," presentation": [" http: / / nutriband. com / role / NotesPayableDetails" ]," lang": {" en- us": {" role": {" terseLabel":" Principal interest"," label":" Debt Instrument, Periodic Payment"," documentation":" Amount of the required periodic payments including both interest and principal payments." } } }," auth_ref": [" r11"," r60" ] }," us- gaap_DebtInstrumentPeriodicPaymentInterest": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" DebtInstrumentPeriodicPaymentInterest"," crdr":" debit"," presentation": [" http: / / nutriband. com / role / NotesPayableDetails" ]," lang": {" en- us": {" role": {" terseLabel":" Payments of principal interest"," label":" Debt Instrument, Periodic Payment, Interest"," documentation":" Amount of the required periodic payments applied to interest." } } }," auth_ref": [" r11" ] }," ntrb_DeferredAbstract": {" xbrltype":" stringItemType"," nsuri":" http: / / nutriband. com / 20240131"," localname":" DeferredAbstract"," presentation": [" http: / / nutriband. com / role / ScheduleofProvisionforIncomeTaxesTable" ]," lang": {" en- us": {" role": {" terseLabel":" Deferred"," label":" Deferred Abstract" } } }," auth_ref": [ ] }," us- gaap_DeferredCompensationArrangementWithIndividualCompensationExpense": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" DeferredCompensationArrangementWithIndividualCompensationExpense"," crdr":" debit"," presentation": [" http: / / nutriband. com / role / RelatedPartyTransactionsDetails" ]," lang": {" en- us": {" role": {" terseLabel":" Compensation expense (in Dollars)"," label":" Deferred Compensation Arrangement with Individual, Compensation Expense"," documentation":" The compensation expense recognized during the period pertaining to the deferred compensation arrangement." } } }," auth_ref": [" r42"," r118" ] }," us- gaap_DeferredFederalIncomeTaxExpenseBenefit": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" DeferredFederalIncomeTaxExpenseBenefit"," crdr":" debit"," presentation": [" http: / / nutriband. com / role / ScheduleofProvisionforIncomeTaxesTable" ]," lang": {" en- us": {" role": {" terseLabel":" Federal"," label":" Deferred Federal Income Tax Expense (Benefit)"," documentation":" Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non- US (United States of America) jurisdiction." } } }," auth_ref": [" r977"," r1021"," r1022" ] }," us- gaap_DeferredForeignIncomeTaxExpenseBenefit": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" DeferredForeignIncomeTaxExpenseBenefit"," crdr":" debit"," presentation": [" http: / / nutriband. com / role / ScheduleofProvisionforIncomeTaxesTable" ]," lang": {" en- us": {" role": {" terseLabel":" Foreign"," label":" Deferred Foreign Income Tax Expense (Benefit)"," documentation":" Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }," auth_ref": [" r977"," r1021" ] }," us- gaap_DeferredRevenueCurrent": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" DeferredRevenueCurrent"," crdr":" credit"," calculation": {" http: / / nutriband. com / role / ConsolidatedBalanceSheet": {" parentTag":" us- gaap_LiabilitiesCurrent"," weight": 1. 0," order": 2. 0 } }," presentation": [" http: / / nutriband. com / role / ConsolidatedBalanceSheet" ]," lang": {" en- us": {" role": {" terseLabel":" Deferred revenue"," label":" Deferred Revenue, Current"," documentation":" Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current." } } }," auth_ref": [" r957" ] }," us- gaap_DeferredRevenueDisclosureAbstract": {" xbrltype":" stringItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" DeferredRevenueDisclosureAbstract"," lang": {" en- us": {" role": {" label":" Schedule of Disaggregates its Revenue from Contracts [ Abstract ]" } } }," auth_ref": [ ] }," us- gaap_DeferredTaxAssetsLiabilitiesNet": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" DeferredTaxAssetsLiabilitiesNet"," crdr":" debit"," presentation": [" http: / / nutriband. com / role / ScheduleofDeferredTaxLiabilityandDeferredTaxAssetTable" ]," lang": {" en- us": {" role": {" terseLabel":" Net deferred taxes"," label":" Deferred Tax Assets, Net"," documentation":" Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting." } } }," auth_ref": [" r1016" ] }," us- gaap_DeferredTaxAssetsOperatingLossCarryforwards": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" DeferredTaxAssetsOperatingLossCarryforwards"," crdr":" debit"," presentation": [" http: / / nutriband. com / role / ScheduleofDeferredTaxLiabilityandDeferredTaxAssetTable" ]," lang": {" en- us": {" role": {" negatedLabel":" Net operating loss carryforward"," label":" Deferred Tax Assets, Operating Loss Carryforwards"," documentation":" Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards." } } }," auth_ref": [" r1019" ] }," us- gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration"," crdr":" debit"," presentation": [" http: / / nutriband. com / role / IncomeTaxesDetails" ]," lang": {" en- us": {" role": {" terseLabel":" Deferred tax asset"," label":" Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration"," documentation":" Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are not subject to expiration dates." } } }," auth_ref": [" r1019" ] }," us- gaap_DeferredTaxAssetsValuationAllowance": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" DeferredTaxAssetsValuationAllowance"," crdr":" credit"," presentation": [" http: / / nutriband. com / role / ScheduleofDeferredTaxLiabilityandDeferredTaxAssetTable" ]," lang": {" en- us": {" role": {" terseLabel":" Valuation allowance"," label":" Deferred Tax Assets, Valuation Allowance"," documentation":" Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized." } } }," auth_ref": [" r469" ] }," dei_DelayedOrContinuousOffering": {" xbrltype":" booleanItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" DelayedOrContinuousOffering"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover" ]," lang": {" en- us": {" role": {" label":" Delayed or Continuous Offering" } } }," auth_ref": [" r865"," r866"," r880" ] }," us- gaap_DepositAssets": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" DepositAssets"," crdr":" debit"," presentation": [" http: / / nutriband. com / role / CommitmentsandContigenciesDetails" ]," lang": {" en- us": {" role": {" terseLabel":" Advance deposit"," label":" Deposit Assets"," documentation":" The carrying amount of the asset transferred to a third party to serve as a deposit, which typically serves as security against failure by the transferor to perform under terms of an agreement." } } }," auth_ref": [" r956" ] }," us- gaap_DepositLiabilitiesAccruedInterest": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" DepositLiabilitiesAccruedInterest"," crdr":" credit"," presentation": [" http: / / nutriband. com / role / SummaryofSignificantAccountingPoliciesDetails" ]," lang": {" en- us": {" role": {" terseLabel":" Accrued interest"," label":" Deposit Liabilities, Accrued Interest"," documentation":" Amount of accrued but unpaid interest on deposit liabilities." } } }," auth_ref": [" r133" ] }," us- gaap_Depreciation": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" Depreciation"," crdr":" debit"," presentation": [" http: / / nutriband. com / role / PropertyandEquipmentDetails" ]," lang": {" en- us": {" role": {" terseLabel":" Depreciation expense"," label":" Depreciation"," documentation":" The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non- production related depreciation." } } }," auth_ref": [" r5"," r34" ] }," us- gaap_DepreciationDepletionAndAmortization": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" DepreciationDepletionAndAmortization"," crdr":" debit"," calculation": {" http: / / nutriband. com / role / ConsolidatedCashFlow": {" parentTag":" us- gaap_NetCashProvidedByUsedInOperatingActivities"," weight": 1. 0," order": 2. 0 } }," presentation": [" http: / / nutriband. com / role / ConsolidatedCashFlow" ]," lang": {" en- us": {" role": {" terseLabel":" Depreciation and amortization"," label":" Depreciation, Depletion and Amortization"," documentation":" The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } }," auth_ref": [" r5"," r253"," r266"," r284"," r771"," r772" ] }," us- gaap_DerivativeCashReceivedOnHedge": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" DerivativeCashReceivedOnHedge"," crdr":" credit"," presentation": [" http: / / nutriband. com / role / RelatedPartyTransactionsDetails" ]," lang": {" en- us": {" role": {" terseLabel":" Cash received (in Dollars)"," label":" Derivative, Cash Received on Hedge"," documentation":" The amount of cash received during the period on settlement of a hedge." } } }," auth_ref": [ ] }," us- gaap_DerivativeContractTypeDomain": {" xbrltype":" domainItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" DerivativeContractTypeDomain"," presentation": [" http: / / nutriband.

com / role / OptionsandWarrantsTables"," http: / / nutriband. com / role / RelatedPartyTransactionsDetails" ]," lang": {" en- us": {" role": {" label":" Derivative Contract [ Domain ]"," documentation":" Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset." } } }," auth_ref": [" r652"," r655"," r669"," r670"," r671"," r673"," r674"," r675"," r676"," r679"," r680"," r681"," r682"," r695"," r696"," r697"," r698"," r701"," r702"," r703"," r704"," r724"," r725"," r726"," r727"," r816"," r818"," r1027"," r1028"," r1029"," r1030"," r1031"," r1032"," r1033"," r1034" ] }," us- gaap_DerivativeInstrumentRiskAxis": {" xbrltype":" stringItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" DerivativeInstrumentRiskAxis"," presentation": [" http: / / nutriband. com / role / OptionsandWarrantsTables"," http: / / nutriband. com / role / RelatedPartyTransactionsDetails"," http: / / nutriband. com / role / ScheduleofChangesinOptionsOutstandingTable"," http: / / nutriband. com / role / ScheduleofSummarizesAdditionalInformationRelatingtotheOptionsOutstandingTable" ]," lang": {" en- us": {" role": {" label":" Derivative Instrument [ Axis ]"," documentation":" Information by type of derivative contract." } } }," auth_ref": [" r53"," r54"," r55"," r126"," r652"," r655"," r669"," r670"," r671"," r673"," r674"," r675"," r676"," r679"," r680"," r681"," r682"," r695"," r696"," r697"," r698"," r701"," r702"," r703"," r704"," r724"," r725"," r726"," r727"," r759"," r816"," r818"," r1027"," r1028"," r1029"," r1030"," r1031"," r1032"," r1033"," r1034" ] }," ntrb_DesignatedSharesOfPreferredStocks": {" xbrltype":" sharesItemType"," nsuri":" http: / / nutriband. com / 20240131"," localname":" DesignatedSharesOfPreferredStocks"," presentation": [" http: / / nutriband. com / role / StockholdersEquityDetails" ]," lang": {" en- us": {" role": {" terseLabel":" Preferred stock, shares designated"," documentation":" Designated shares to be issued."," label":" Designated Shares Of Preferred Stocks" } } }," auth_ref": [ ] }," srt_DirectorMember": {" xbrltype":" domainItemType"," nsuri":" http: / / fasb. org / srt / 2024"," localname":" DirectorMember"," presentation": [" http: / / nutriband. com / role / OptionsandWarrantsDetails"," http: / / nutriband. com / role / RelatedPartyTransactionsDetails" ]," lang": {" en- us": {" role": {" terseLabel":" Director [ Member ]"," label":" Director [ Member ]"," documentation":" Person serving on board of directors." } } }," auth_ref": [" r954"," r990"," r1085" ] }," ntrb_DisaggregationOfRevenuesPolicyTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / nutriband. com / 20240131"," localname":" DisaggregationOfRevenuesPolicyTextBlock"," presentation": [" http: / / nutriband. com / role / AccountingPoliciesByPolicy" ]," lang": {" en- us": {" role": {" terseLabel":" Disaggregation of Revenues"," documentation":" The entire disclosure of disaggregation of revenues."," label":" Disaggregation Of Revenues Policy Text Block" } } }," auth_ref": [ ] }," us- gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss"," crdr":" credit"," presentation": [" http: / / nutriband. com / role / ScheduleofSegmentPerformancetotheGAAPMeasureofGrossProfitTable" ]," lang": {" en- us": {" role": {" terseLabel":" Gross profit"," label":" Disposal Group, Including Discontinued Operation, Gross Profit (Loss)"," documentation":" Amount of gross profit attributable to disposal group, including, but not limited to, discontinued operation." } } }," auth_ref": [" r63"," r186" ] }," dei_DividendOrInterestReinvestmentPlanOnly": {" xbrltype":" booleanItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" DividendOrInterestReinvestmentPlanOnly"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover" ]," lang": {" en- us": {" role": {" label":" Dividend or Interest Reinvestment Plan Only" } } }," auth_ref": [" r865"," r866"," r880" ] }," dei_DocumentAccountingStandard": {" xbrltype":" accountingStandardItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" DocumentAccountingStandard"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover" ]," lang": {" en- us": {" role": {" label":" Document Accounting Standard"," documentation":" The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be' U. S. GAAP',' International Financial Reporting Standards', or' Other'." } } }," auth_ref": [" r841" ] }," dei_DocumentAnnualReport": {" xbrltype":" booleanItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" DocumentAnnualReport"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover" ]," lang": {" en- us": {" role": {" label":" Document Annual Report"," documentation":" Boolean flag that is true only for a form used as an annual report." } } }," auth_ref": [" r838"," r841"," r853" ] }," dei_DocumentCopyrightInformation": {" xbrltype":" stringItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" DocumentCopyrightInformation"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover" ]," lang": {" en- us": {" role": {" label":" Document Copyright Information"," documentation":" The copyright information for the document." } } }," auth_ref": [ ] }," dei_DocumentCreationDate": {" xbrltype":" dateItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" DocumentCreationDate"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover" ]," lang": {" en- us": {" role": {" label":" Document Creation Date"," documentation":" The date the document was made available and submitted, in YYYY- MM- DD format. The date of submission, date of acceptance by the recipient, and the document effective date are all potentially different." } } }," auth_ref": [ ] }," dei_DocumentDescription": {" xbrltype":" stringItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" DocumentDescription"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover" ]," lang": {" en- us": {" role": {" label":" Document Description"," documentation":" The description of the document." } } }," auth_ref": [ ] }," dei_DocumentDomain": {" xbrltype":" domainItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" DocumentDomain"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover" ]," lang": {" en- us": {" role": {" label":" Document [ Domain ]"," documentation":" Type of the document as assigned by the filer, corresponding to SEC document naming convention standards." } } }," auth_ref": [ ] }," dei_DocumentEffectiveDate": {" xbrltype":" dateItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" DocumentEffectiveDate"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover" ]," lang": {" en- us": {" role": {" label":" Document Effective Date"," documentation":" The date when a document, upon receipt and acceptance, becomes officially effective, in YYYY- MM- DD format. Usually it is a system- assigned date time value, but it may be declared by the submitter in some cases." } } }," auth_ref": [ ] }," dei_DocumentFinStmtErrorCorrectionFlag": {" xbrltype":" booleanItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" DocumentFinStmtErrorCorrectionFlag"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover" ]," lang": {" en- us": {" role": {" label":" Document Financial Statement Error Correction [ Flag ]"," documentation":" Indicates whether any of the financial statement period in the filing include a restatement due to error correction." } } }," auth_ref": [" r838"," r841"," r853"," r904" ] }," dei_DocumentFinStmtRestatementRecoveryAnalysisFlag": {" xbrltype":" booleanItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" DocumentFinStmtRestatementRecoveryAnalysisFlag"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover" ]," lang": {" en- us": {" role": {" label":" Document Financial Statement Restatement Recovery Analysis [ Flag ]"," documentation":" Indicates whether any of the financial statement periods include restatements that required a recovery analysis of incentive- based compensation received by any of the registrant' s executive officers during the relevant recovery period pursuant to \ u00a7240. 10D- 1 (b)." } } }," auth_ref": [" r838"," r841"," r853"," r904" ] }," dei_DocumentFiscalPeriodFocus": {" xbrltype":" fiscalPeriodItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" DocumentFiscalPeriodFocus"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover" ]," lang": {" en- us": {" role": {" label":" Document Fiscal Period Focus"," documentation":" Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10- Q or 10- QT statements have value Q1, Q2, and Q3 respectively, with 10- K, 10- KT or other fiscal year statements having FY." } } }," auth_ref": [ ] }," dei_DocumentFiscalYearFocus": {" xbrltype":" gYearItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" DocumentFiscalYearFocus"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover" ]," lang": {" en- us": {" role": {" label":" Document Fiscal Year Focus"," documentation":" This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }," auth_ref": [ ] }," dei_DocumentInformationDocumentAxis": {" xbrltype":" stringItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" DocumentInformationDocumentAxis"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover" ]," lang": {" en- us": {" role": {" label":" Document Information, Document [ Axis ]"," documentation":" The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table." } } }," auth_ref": [ ] }," dei_DocumentInformationLineItems": {" xbrltype":" stringItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" DocumentInformationLineItems"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover" ]," lang": {" en- us": {" role": {" label":" Document Information [ Line Items ] "-**Number Outstanding | shares 58** , " documentation":" **333Remaining Contractual Life (Years) 1 year 8 months 26 daysExercise Price for Shares Outstanding (in Dollars per share) | $ / shares $ 1. 93Number Exercisable | shares 58, 333Exercise Price for Shares Exercisable (in Dollars per share) | $ / shares $ 1. 93Intrinsic Value (in Dollars) | $ $ 370, 988Exercise Prices 4. 00 [ Member ] Schedule of Additional Information Relating to the Options and Warrants Outstanding [** Line **Items ] Number Outstanding | shares 30, 000Remaining Contractual Life (Years) 3 years 1 month 6 daysExercise Price for Shares Outstanding (in Dollars per share) | $ / shares $ 4Number Exercisable | shares 30, 000Exercise Price for Shares Exercisable (in Dollars per share) | $ / shares $ 4Intrinsic Value (in Dollars) | $ $ 128, 700Exercise Prices 6. 43 [ Member ] Schedule of Additional Information Relating to the Options and Warrants Outstanding [ Line Items ] Number Outstanding | shares 5, 433, 640Remaining Contractual Life (Years) 3 years 8 months 15 daysExercise Price for Shares Outstanding (in Dollars per share) | $ / shares $ 6. 43Number Exercisable | shares 5, 433, 640Exercise Price for Shares Exercisable (in Dollars per share) | $ / shares $ 6. 43Intrinsic Value (in Dollars) | $ $ 10, 106, 570Exercise Prices 7. 50 [ Member ] Schedule of Additional Information Relating to the Options and Warrants Outstanding [ Line Items ] Number Outstanding | shares 25, 000Remaining Contractual Life (Years) 2 years 9 months 7 daysExercise Price for Shares Outstanding (in Dollars per share) | $ / shares $ 7. 5Number Exercisable | shares 25, 000Exercise Price for Shares Exercisable (in Dollars per share) | $ / shares $ 7. 5Intrinsic Value (in Dollars) | $ $ 19,**

760X- DefinitionRepresents the value of intrinsic value. ReferencesNo definition available. Details Name: ntrb_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableIntrinsicValue Namespace Prefix: ntrb_ Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: instantX- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. "} } },"auth_ref": ReferencesNo definition available. Details Name : us- gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems Namespace Prefix [ ] },"dei_DocumentInformationTable": {" xbrltype": us- gaap_ Data Type : "- xbrli: stringItemType Balance Type "," nsuri": "- na Period Type: durationX- DefinitionThe number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied. ReferencesReference 1: http: / / xbrl fasb . org sec. gov / us- gaap dei / 2024"," localname":" DocumentInformationTable"," presentation": [" http: / / xbrl. sec. gov / dei / role / document ref / legacyRef Cover" ]," lang": {" en- Topic 718- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 2- Subparagraph (c) (1) (iii)- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2 Details Name: us "- gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions Namespace Prefix : {" role" us- gaap_ Data Type : xbrli {" label": sharesItemType Balance Type " Document Information [ Table ]"," documentation": " Container na Period Type: instantX- DefinitionThe number of shares reserved for issuance pertaining to support the outstanding stock options formal attachment of each official or unofficial, public or private document as part of a submission package." } } },"auth_ref": [ ] },"dei_DocumentInformationTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" DocumentInformationTextBlock"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover" ]," lang": {" en- us": {" role": {" label":" Document Information [ Text Block ]"," documentation":" Container to support the balance sheet formal attachment of each official or unofficial, public or private document as part of a submission package." } } },"auth_ref": [ ] }," dei_DocumentName": {" xbrltype":" normalizedStringItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" DocumentName"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover" ]," lang": {" en- us": {" role": {" label":" Document Name"," documentation":" Name of the document as assigned by the filer, corresponding to SEC document naming convention standards. Examples appear in the & lt; FILENAME > field of EDGAR filings, such as' htm_25911. htm',' exhibit1. htm',' v105727_8k. txt'." } } },"auth_ref": [ ] }," dei_DocumentPeriodEndDate": {" xbrltype":" dateItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" DocumentPeriodEndDate"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover" ]," lang": {" en- us": {" role": {" label":" Document Period End Date"," documentation":" For the EDGAR submission types of Form 8- K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N- 1A: the filing date; for all option plans in other -- the submission customized range of exercise prices . ReferencesReference 1 fasb.org / 1943274 / 2147478777 / 944- 210- S99- 1Reference 3 :http: / / www- fasb . xbrl. org / 2003 us- gaap / role / disclosureRef ref / legacyRef - Topic 946 718 - SubTopic 210 - 10 - Name Accounting Standards Codification- Section S99 50 - Paragraph 1 2 - Subparagraph ( c SX 210.6- 04 (7 ) ( a 1 ) (ii )- Publisher FASB- URI https: / / asc.fasb.org / 1943274 / 2147479170 2147480429 / 946 718 - 210 - 10 - S99 50 - 1Reference 2Reference 4 2 :http: / / www fasb . xbrl. org / 2003 us- gaap / role / disclosureRef ref / legacyRef - Topic 210 718 - SubTopic 10- Name Accounting Standards Codification- Section S99 50 - Paragraph 1 2 - Subparagraph ( c SX 210.5- 02 (7 ) (1) (i )- Publisher FASB- URI https: / / asc.fasb.org / 1943274 / 2147480566 2147480429 / 718- 210 - 10 - 10 50 - 2 S99- 1 Details Name:us- gaap_PrepaidExpenseCurrentAndNoncurrent gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions Namespace Prefix:us- gaap_ Data Type:xbrli: monetaryItemType sharesItemType Balance Type: debit na Period Type:instantX- DefinitionCash received DefinitionWeighted average exercise price as of the balance sheet date for fees during the those equity- based payment arrangements exercisable and outstanding current period.This element excludes cash proceeds from license fees . ReferencesReference 1:http: / / fasb.org / us- gaap / role / ref / legacyRef- Topic 230 718 - SubTopic 10- Name Accounting Standards Codification- Section 45 50 - Paragraph 25 2 - Subparagraph (c ) (1) (iii )- Publisher FASB- URI https: / / asc.fasb.org / 1943274 / 2147482740 2147480429 / 230 718 - 10- 45 50 - 25 2 Details Name:us- gaap_ProceedsFromFeesReceived gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 Namespace Prefix:us- gaap_ Data Type: dtr- types: the end perShareItemType Balance Type: na Period Type: instantX- DefinitionThe weighted average price as of Type:xbrli:monetaryItemType Balance Type:debit Period Type:durationX- DefinitionRemaining Life,Granted DefinitionAmount of the entity' s equity method investment which has been sold . ReferencesNo definition available. Details Name: ntrb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsRemainingLifeRemainingLifeGranted us- gaap_EquityMethodInvestmentSoldCarryingAmount Namespace Prefix: ntrb_ us- gaap_ Data Type:xbrli: durationItemType monetaryItemType Balance Type: na debit Period Type:durationX- DefinitionNumber of excess stock shares of an entity that have been sold or granted to shareholders. ReferencesNo definition available. Details Name:us- gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract gaap_ExcessStockSharesIssued Namespace Prefix:us- gaap_ Data Type:xbrli: stringItemType sharesItemType Balance Type:na Period Type: durationX instantX - DefinitionInterest received on loans and other debt instruments during DefinitionThe number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently -- current period converted under the option plan . ReferencesReference 1:http: / / www.xbrl.org / 2003 2009 / role / disclosureRef commonPracticeRef - Topic 718 230 - SubTopic 10- Name Accounting Standards Codification- Section 50 45 - Paragraph 2 16 - Subparagraph ( b e) (1) (iii )- Publisher FASB- URI https: / / asc.fasb.org / 1943274 / 2147480429 2147482740 / 718 230 - 10- 50 45 - 2 16 Details Name:us- gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber gaap_ProceedsFromInterestReceived Namespace Prefix:us- gaap_ Data Type:xbrli: sharesItemType monetaryItemType Balance Type: debit na Period the reporting or transition period . The format of the date is YYYY- MM- DD." } } },"auth_ref": [ ] },"dei_DocumentPeriodStartDate": {" xbrltype":" dateItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" DocumentPeriodStartDate"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover" ]," lang": {" en- us": {" role": {" label":" Document Period Start Date"," documentation":" The start date of the period covered in the document, in YYYY- MM- DD format." } } },"auth_ref": [ ] }," dei_DocumentQuarterlyReport": {" xbrltype":" booleanItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" DocumentQuarterlyReport"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover" ]," lang": {" en- us": {" role": {" label":" Document Quarterly Report"," documentation":" Boolean flag that is true only for a form used as an quarterly report." } } },"auth_ref": [" r839" ] }," dei_DocumentRegistrationStatement": {" xbrltype":" booleanItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" DocumentRegistrationStatement"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover" ]," lang": {" en- us": {" role": {" label":" Document Registration Statement"," documentation":" Boolean flag that is true only for a form used as a registration statement result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired . ReferencesReference 1 " } } },"auth_ref": [" r827" ] }," dei_DocumentShellCompanyEventDate": {" xbrltype":" dateItemType"," nsuri":" http: / / www. xbrl. org sec. gov / dei 2009 / 2024"," localname" role / commonPracticeRef- Topic 718- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 2- Subparagraph (c) (1) (iv)- Publisher FASB- URI https " DocumentShellCompanyEventDate"," presentation" / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2 Details Name : {" us- gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod Namespace Prefix: us- gaap_ Data Type: xbrli: sharesItemType Balance Type: na Period Type: durationX- DefinitionWeighted average price of options that were either forfeited or expired. ReferencesReference 1: http: / / www. xbrl. org sec. gov / dei 2009 / role / commonPracticeRef document / Cover" ]," lang": {" en- Topic 718- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 2- Subparagraph (c) (1) (iv)- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2 Details Name: us "- gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice Namespace Prefix : {" us- gaap_ Data Type: dtr- types: perShareItemType Balance Type: na Period Type: durationX- DefinitionGross number of share options (or share units) granted during the period. ReferencesReference 1: http: / / www. xbrl. org / 2003 / role "- / disclosureRef- Topic 718- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 2- Subparagraph (c) (1) (iv) (01)- Publisher FASB- URI https : {" label" - / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2 Details Name : " Document Shell Company Event us- gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Namespace Prefix: us- gaap_ Date Data Type "," documentation": xbrli " Date of event requiring a shell company report." } } },"auth_ref": sharesItemType Balance Type [" r841" ] },"dei_DocumentShellCompanyReport": na Period Type {" xbrltype": " booleanItemType"," nsuri" durationX- DefinitionAmount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding. ReferencesReference 1 : "- http: / / :http:// fasb.org / us- gaap / role / ref / legacyRef- Topic 505- SubTopic 10- Name Accounting Standards Codification- Topic 718- SubTopic 10- Section S99 50 - Paragraph 2 4- Subparagraph (SAB

Topic 4.C) - Publisher FASB- URI https:/ / asc.fasb.org / 1943274 / 2147480008 2147480429 / 505 718 - 10- S99 50 - 4 2 Details Name:us-gaap_StockholdersEquityReverseStockSplit gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue Namespace Prefix:us- gaap_ Data Type:xbrli: stringItemType monetaryItemType Balance Type: na debit Period Type: durationX instantX - DefinitionPer DefinitionNumber share increase in exercise price of warrant options outstanding,including both vested and non- vested options . Excludes ReferencesReference 1:http:/ / www. xbrl. org sec. gov / dei 2003 / 2024"," localname" role / disclosureRef- Topic 718- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 2- Subparagraph (c) (1) (i)- Publisher FASB- URI https " ": {" label":" Document ShellCompanyReport"," presentation" / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2Reference 2 : [" http: / / www. xbrl. org sec. gov / dei 2003 / role / disclosureRef document / Cover" ]," lang": {" en- Topic 718- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 2- Subparagraph (c) (1) (ii)- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2 Details Name: us " - gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Namespace Prefix : {" us- gaap_ Data Type: xbrli: sharesItemType Balance Type: na Period Type: instantX- DefinitionWeighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan. ReferencesReference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 718- SubTopic 10- Name Accounting Standards Codification- ": {" label":" Document Shell Company Report"," documentation":" Boolean flag that is true for a Shell Company Report pursuant to section Section 13 50- Paragraph 2- Subparagraph (c) (1) (i)- Publisher FASB- URI https: / / asc. fasb. or org / 1943274 / 2147480429 / 718- 10- 50- 2Reference 2 15 (d) of the Exchange Act." } } },"  auth_ref" : [" r841" ] },"  dei_DocumentSubtitle": {" xbrltype":" normalizedStringItemType"," nsuri":" http: / / www. xbrl. org sec. gov / dei 2003 / 2024"," localname" role / disclosureRef- Topic 718- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 2- Subparagraph (c) (1) (ii)- Publisher FASB- URI https " DocumentSubtitle"," presentation" / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2 Details Name : [" us- gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Namespace Prefix: us- gaap_ Data Type: dtr- types: perShareItemType Balance Type: na Period Type: instantX- DefinitionWeighted average price at which option holders acquired shares when converting their stock options into shares. ReferencesReference 1: http: / / www. xbrl. org sec. gov / dei 2003 / role / disclosureRef document / Cover" ]," lang": {" en- Topic 718- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 2- Subparagraph (c) (1) (iv) (02)- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2 Details Name: us " - gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice Namespace Prefix : {" role" us- gaap_ Data Type : dtr- types {" label" : perShareItemType Balance Type " Document Subtitle"," documentation" : na " The subtitle given to the document resource by the creator or publisher. An example is' A New Period Type of Growth'." } } },"  auth_ref" : durationX [ ] },"  dei_DocumentSynopsis": {" xbrltype":" normalizedStringItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" DocumentSynopsis"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover" ]," lang": {" en- DefinitionWeighted average us": {" role": {" label":" Document Synopsis"," documentation":" A synopsis or description of the document provided by the creator or publisher. Examples are' This is the 2006 annual report for Company. During this period we saw revenue grow by 10 % and earnings per share grow amount at which grantees can acquire shares of common stock by 15 % over " exercise of options. ReferencesReference 1 : " http: / / www.xbrl.org / 2003 / role / disclosureRef - "," Topic ":" 718 - "," SubTopic ":" 10 - "," Name ":" Accounting Standards Codification - "," Section ":" 50 - "," Paragraph ":" 2 - "," Subparagraph ":" (c) (1) (iv) (01) - "," Publisher ":" FASB - "," URI ":" https:/ / asc.fasb.org / 1943274 / 2147480429 / 718- 10- 50- 2 " } Details Name:us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Namespace Prefix:us- gaap_ Data Type:dtr- types:perShareItemType Balance Type:na Period Type:durationX- DefinitionAmount of difference between fair value of the prior exercisable or convertible, in' PnYnMnDTnHnMnS' format,for example,' P1Y5M13D' represents the reported fact of one year,five months,and thirteen days. ReferencesReference 1:http:/ / fasb www . xbrl. org / 2003 us- gaap / role / ref / legacyRef exampleRef- Topic 842- SubTopic 20 - Name Accounting Standards Codification- Topic 718- SubTopic 10 - Section 50 55 - Paragraph 2 53 - Publisher FASB- URI https:/ / asc.fasb.org / 1943274 / 2147480429 2147479589 / 718 842 - 10 20 - 50 55 - 53Reference 2 Details Name:us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 Namespace Prefix:us-gaap_ Data Type:xbrli:durationItemType Balance Type:na Period Type:durationX- DefinitionWeighted average remaining contractual term for option awards outstanding,in' PnYnMnDTnHnMnS' format,for example,' P1Y5M13D' represents the reported fact of one year,five months,and thirteen days. ReferencesReference 1 :http:/ / fasb www . xbrl. org / 2003 us- gaap / role / disclosureRef ref / legacyRef - Topic 718 842 - SubTopic 20 10- Subparagraph (c) (1) - Name Accounting Standards Codification- Paragraph 2- Section 50- Paragraph 4- Subparagraph (g) (3)- Publisher FASB- URI https:/ / asc.fasb.org / 1943274 / 2147480429 2147478964 / 718 842 - 10 20 - 50- 2 4 Details Name:us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1 Namespace Prefix:us- gaap_ Data Type:xbrli:durationItemType Balance Type:na Period Type: instantX- DefinitionDescription of the nature and terms of commitment. ReferencesNo definition available. Details Name:us-gaap_OtherCommitmentsDescription Namespace Prefix:us- gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type: durationX - DefinitionCarrying amount as of the balance sheet date of expenditures made in advance of when the economic benefit of the cost will be realized,and which will be expensed in future periods period . ReferencesReference 1 "" } } },"  auth_ref" : [ ] },"  dei_DocumentTitle": {" xbrltype":" normalizedStringItemType"," nsuri":" http: / / fasb.org / us- gaap / role / ref / legacyRef commonPracticeRef- Topic 944- SubTopic 210 - Name Accounting Standards Codification- Section S99 50 - Paragraph 1 2 - SubTopic Subparagraph (SX 210 - 10 .7 - Topic 505 03 (a) (10)) - Publisher FASB- URI https:/ / asc.fasb.org / 1943274 / 2147478777 2147481112 / 944 505 - 210 - 10 - S99 50 - 1Reference 2Reference 3 2 :http:/ / www fasb . xbrl. org / 2003 us- gaap / role / disclosureRef ref / legacyRef - Topic 946 210 - SubTopic 210 - 10 - Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210. 6 5 - 04 02 ( 28 7) (a ))- Publisher FASB- URI https:/ / asc.fasb.org / 1943274 / 2147479170 2147480566 / 946 210 - 210 - 10 - S99- 1Reference 4 3 :http:/ / www fasb . xbrl. org / 2003 us- gaap / role / disclosureRef ref / legacyRef - Topic 210- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210.5- 02 ( 7 29 ))- Publisher FASB- URI https:/ / asc.fasb.org / 1943274 / 2147480566 / 210- 10- S99- 1 Details 1Reference 4:http:/ / www. xbrl. org sec. gov / dei 2003 / 2024"," localname" role / disclosureRef- Topic 718- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 2- Subparagraph (c) (1) (iv) (02)- Publisher FASB- URI https : " DocumentTitle"," presentation" / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2Reference 5 : [" http: / / xbrl fasb . org sec. gov / dei us- gaap / role / document ref / legacyRef Cover" ]," lang": {" en- Topic 505- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210. 3- 04)- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147480008 / 505- 10- S99- 1 Details Name: us " - gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix : {" role" us- gaap_ Data Type : xbrli {" label" : sharesItemType Balance Type " Document Title"," documentation" : " The name or title given na Period Type: durationOptions and Warrants- Schedule of Additional Information Relating to the Options Outstanding document resource by the creator or publisher. An example is' 2002 Annual Report'." } } },"  auth_ref": [ ] },"  dei_DocumentTransitionReport": {" xbrltype":" booleanItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" DocumentTransitionReport"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover" ]," lang": {" en- us": {" role": {" label":" Document Transition Report"," documentation":" Boolean flag that is true only for a form used as a transition report." } } },"  auth_ref": [" r881" ] },"  dei_DocumentType": {" xbrltype":" submissionTypeItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" DocumentType"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover" ]," lang": {" en- us": {" role": {" label":" Document Type"," documentation":" The type of document being provided ( Details such as 10- K, 10- Q, 485BPOS, etc ) . The document type is limited to the same value as the supporting SEC submission type, or the word' Other'." } } },"  auth_ref": [ ] },"  dei_DocumentVersion": {" xbrltype":" normalizedStringItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" DocumentVersion"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover" ]," lang": {" en- Options Outstanding us": {" role": {" label":" Document Version"," documentation":" The version identifier of the document." } } },"  auth_ref": [ ] },"  dei_DocumentsIncorporatedByReferenceTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" DocumentsIncorporatedByReferenceTextBlock"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover" ]," lang": {" en- us": {" role": {" label":" Documents Incorporated by Reference [ Text Block ]"," documentation":" Documents incorporated by reference." } } },"  auth_ref": [" r830" ] },"  ntrb_DueBalanceAmount": {" xbrltype":" monetaryItemType"," nsuri":" http: / / nutriband. com / 20240131"," localname":" DueBalanceAmount"," crdr":" debit"," presentation": [" http: / / nutriband. com / role / NotesPayableDetails" ]," lang": {" en- us": {" role": {" terseLabel":" Balance due"," documentation":" The amount of due balance."," label":" Due Balance Amount" } } },"  auth_ref": [ ] },"  ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRfletdInTtlCompForCvrdYrMember": {" xbrltype":" domainItemType"," nsuri":" http: / / xbrl. sec. gov / ecd /

2024"," localname":" DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRfletdInTtlCompForCvrdYrMember"," presentation": [" http: / / xbrl. sec. gov / ecd / role / PvpDisclosure" ]," lang": {" en- us": {" role": {" label":" Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [ Member ] " 12 Months EndedJan. 31 , " terseLabel":" Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation 2025 USD ($) $ / shares sharesShare- Based Payment Arrangement, Option, Exercise Price Range [ Line Items ] Number Outstanding | shares 1, 373, 668Weighted Average Life (Years) 1 year 10 months 24 daysWeighted Average Exercise Price for Shares Outstanding Covered Year" } } },"
auth_ref": [" r893" ] }," us- gaap_EarningsPerShareBasic": {" xbrltype":" perShareItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":"
EarningsPerShareBasic"," presentation": [" http: / / nutriband. com / role / ConsolidatedIncomeStatement" ]," lang": {" en- us": {" role": {" terseLabel":" Net loss per share of common stock- basic (in Dollars per share) " | $ / shares $ 3. 68Number Exercisable | shares 1 , 373 " label":" Earnings Per Share , 668Weighted Average Exercise Price Basic"," documentation":" The amount of net income (loss) for Shares Exercisable (in Dollars the period per each share of common stock or unit outstanding during the reporting period." } } },"
auth_ref": [" r213"," r233"," r234"," r235"," r236"," r237"," r238"," r243"," r245"," r248"," r249"," r250"," r252"," r483"," r487"," r500"," r501"," r577"," r597"," r764" ] }," us- gaap_EarningsPerShareDiluted": {" xbrltype":" perShareItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" EarningsPerShareDiluted"," presentation": [" http: / / nutriband. com / role / ConsolidatedIncomeStatement_Parentheticals" ]," lang": {" en- us": {" role": {" terseLabel":" Net loss per share of common stock- diluted"," label":" Earnings Per Share, Diluted"," documentation":" The amount of net income (loss) | $ / for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares $ 3 or units for all dilutive potential common shares or units outstanding during the reporting period . 68Intrinsic Value " } } },"
auth_ref": [" r213"," r233"," r234"," r235"," r236"," r237"," r238"," r245"," r248"," r249"," r250"," r252"," r483"," r487"," r500"," r501"," r577"," r597"," r764" ] }," us- gaap_EarningsPerSharePolicyTextBlock": {" xbrltype":"
textBlockItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" EarningsPerSharePolicyTextBlock"," presentation": [" http: / / nutriband. com / role / AccountingPoliciesByPolicy" ]," lang": {" en- us": {" role": {" terseLabel":" Earnings per Share"," label":" Earnings Per Share, Policy [ Policy Text Block ]","
documentation":" Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } },"
auth_ref": [" r21"," r22"," r251" ] }," dei_EffectiveAfter60Days486a": {" xbrltype":" booleanItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":"
EffectiveAfter60Days486a"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover" ]," lang": {" en- us": {" role": {" label":" Effective after 60 Days, 486 ( a in Dollars ) " } } } | $ $ 6 , 337 " auth_ref": [" r943" ] }, 984Exercise Prices 1 " us- gaap_EffectiveIncomeTaxRateContinuingOperations": {"
xbrltype":" percentItemType"," nsuri":" http: / / fasb. 93 org / us- gaap / 2024"," localname":" EffectiveIncomeTaxRateContinuingOperations","
presentation": [" http: / / nutriband. com / role / IncomeTaxesDetails" ]," lang": {" en- us": {" role": {" terseLabel":" Percentage of corporate rate"," label":" Effective Income Tax Rate Reconciliation, Percent","
documentation":" Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } },"
auth_ref": [" r461"," r791" ] }," dei_EffectiveOnDate486a": {" xbrltype":" dateItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" EffectiveOnDate486a"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover" ]," lang": {" en- us": {" role": {" label":"
Effective on Date, 486 (a)" } } },"
auth_ref": [" r943" ] }," dei_EffectiveOnDate486b": {" xbrltype":" dateItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024","
localname":" EffectiveOnDate486b"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover" ]," lang": {" en- us": {" role": {" label":" Effective on Date, 486 (b)" } } },"
auth_ref": [" r944" ] }," dei_EffectiveOnSetDate486a": {" xbrltype":" booleanItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024","
localname":" EffectiveOnSetDate486a"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover" ]," lang": {" en- us": {" role": {" label":" Effective on Set Date, 486 (a)" } } },"
auth_ref": [" r943" ] }," dei_EffectiveOnSetDate486b": {" xbrltype":" booleanItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024","
localname":" EffectiveOnSetDate486b"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover" ]," lang": {" en- us": {" role": {" label":" Effective on Set Date, 486 (b)" } } },"
auth_ref": [" r944" ] }," dei_EffectiveUponFiling462e": {" xbrltype":" booleanItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" EffectiveUponFiling462e"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover" ]," lang": {" en- us": {" role": {" label":"
Effective Upon Filing, 462 (e)" } } },"
auth_ref": [" r942" ] }," dei_EffectiveUponFiling486b": {" xbrltype":" booleanItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" EffectiveUponFiling486b"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover" ]," lang": {" en- us": {" role": {"
label":" Effective upon Filing, 486 (b)" } } },"
auth_ref": [" r944" ] }," dei_EffectiveWhenDeclaredSection8e": {" xbrltype":" booleanItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" EffectiveWhenDeclaredSection8e"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover" ]," lang": {"
en- us": {" role": {" label":" Effective when Declared, Section 8 (e)" } } },"
auth_ref": [" r946" ] }," us- gaap_EmployeeStockOptionMember": {" xbrltype":"
domainItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" EmployeeStockOptionMember"," presentation": [" http: / / xbrl. sec. gov / ecd / role / AwardTimingDisclosure" ]," lang": {" en- us": {" role": {" label":" Employee Stock Option [ Member ] " Share- Based Payment Arrangement , " terseLabel":"
Employee Stock Option ", Exercise " documentation":" Share- based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price Price Range for specified period of time." } } },"
auth_ref": [ ] }," dei_EntitiesTable": {" xbrltype":"
stringItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" EntitiesTable"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover" ]," lang": {" en- us": {" role": {" label":" Entities [ Table ]"," documentation":" Container to assemble all relevant information about each entity associated with the document instance" } } },"
auth_ref": [ ] }," dei_EntityAccountingStandard": {" xbrltype":" stringItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024","
localname":" EntityAccountingStandard"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover" ]," lang": {" en- us": {" role": {" label":" Entity Accounting Standard","
documentation":" The standardized abbreviation of the accounting standard used by the entity. This can either be US GAAP as promulgated by the FASB or IFRS as promulgated by the IASB. Example:' US GAAP',' IFRS'. This is distinct from the Document Accounting Standard element." } } },"
auth_ref": [ ] }," dei_EntityAddressAddressDescription": {" xbrltype":" stringItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":"
EntityAddressAddressDescription"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover" ]," lang": {" en- us": {" role": {" label":" Entity Address, Address Description","
documentation":" Description of the kind of address for the entity, if needed to distinguish more finely among mailing, principal, legal, accounting, contact or other addresses." } } },"
auth_ref": [ ] }," dei_EntityAddressAddressLine1": {" xbrltype":" normalizedStringItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" EntityAddressAddressLine1"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover" ]," lang": {" en- us": {" role": {" label":" Entity Address, Address Line One"," documentation":" Address Line 1 such as Attn, Building Name, Street Name" } } },"
auth_ref": [ ] }," dei_EntityAddressAddressLine2": {" xbrltype":" normalizedStringItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":"
EntityAddressAddressLine2"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover" ]," lang": {" en- us": {" role": {" label":" Entity Address, Address Line Two"," documentation":" Address Line 2 such as Street or Suite number" } } },"
auth_ref": [ ] }," dei_EntityAddressAddressLine3": {" xbrltype":"
normalizedStringItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" EntityAddressAddressLine3"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover" ]," lang": {" en- us": {" role": {" label":" Entity Address, Address Line Three"," documentation":" Address Line 3 such as an Office Park" } } },"
auth_ref": [ ] }," dei_EntityAddressCityOrTown": {" xbrltype":" normalizedStringItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":"
EntityAddressCityOrTown"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover" ]," lang": {" en- us": {" role": {" label":" Entity Address, City or Town"," documentation":" Name of the City or Town" } } },"
auth_ref": [ ] }," dei_EntityAddressCountry": {" xbrltype":" countryCodeItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" EntityAddressCountry"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover" ]," lang": {" en- us": {"
role": {" label":" Entity Address, Country"," documentation":" ISO 3166- 1 alpha- 2 country code." } } },"
auth_ref": [ ] }," dei_EntityAddressPostalZipCode": {"
xbrltype":" normalizedStringItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" EntityAddressPostalZipCode"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover" ]," lang": {" en- us": {" role": {" label":" Entity Address, Postal Zip Code"," documentation":" Code for the postal or zip code" } } },"
auth_ref": [ ] }," dei_EntityAddressStateOrProvince": {" xbrltype":" stateOrProvinceItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024","
localname":" EntityAddressStateOrProvince"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover" ]," lang": {" en- us": {" role": {" label":"
Entity Address, State or Province"," documentation":" Name of the state or province." } } },"
auth_ref": [ ] }," dei_EntityAddressesAddressTypeAxis": {"
xbrltype":" stringItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" EntityAddressesAddressTypeAxis"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover" ]," lang": {" en- us": {" role": {" label":" Entity Addresses, Address Type [ Axis ]"," documentation":" The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table." } } },"
auth_ref": [ ] }," dei_EntityAddressesLineItems": {" xbrltype":" stringItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" EntityAddressesLineItems","
presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover" ]," lang": {" en- us": {" role": {" label":" Entity Addresses [ Line Items ] " Number Outstanding | shares 214 , " documentation":" 500Weighted Average Life (Years) 1 year 8 months 23 daysWeighted Average Exercise Price for Shares

Outstanding (in Dollars per share) | $ / shares $ 1. 93Number Exercisable | shares 214, 500Weighted Average Exercise Price for Shares Exercisable (in Dollars per share) | $ / shares $ 1. 93Intrinsic Value (in Dollars) | $ $ 1, 364, 220Exercise Prices 2. 12 [ Member ] Share- Based Payment Arrangement, Option, Exercise Price Range [ Line Items ] Number Outstanding | shares 140, 000Weighted Average Life (Years) 1 year 8 months 23 daysWeighted Average Exercise Price for Shares Outstanding (in Dollars per share) | $ / shares $ 2. 12Number Exercisable | shares 140, 000Weighted Average Exercise Price for Shares Exercisable (in Dollars per share) | $ / shares $ 2. 12Intrinsic Value (in Dollars) | $ $ 863, 800Exercise Prices 2. 37 [ Member ] Share- Based Payment Arrangement, Option, Exercise Price Range [ Line Items ] Number Outstanding | shares 195, 000Weighted Average Life (Years) 2 years 1 month 17 daysWeighted Average Exercise Price for Shares Outstanding (in Dollars per share) | $ / shares $ 2. 37Number Exercisable | shares 195, 000Weighted Average Exercise Price for Shares Exercisable (in Dollars per share) | $ / shares $ 2. 37Intrinsic Value (in Dollars) | $ $ 1, 154, 400Exercise Prices 2. 61 [ Member ] Share- Based Payment Arrangement, Option, Exercise Price Range [ Line Items ] Number Outstanding | shares 195, 000Weighted Average Life (Years) 2 years 1 month 17 daysWeighted Average Exercise Price for Shares Outstanding (in Dollars per share) | $ / shares $ 2. 61Number Exercisable | shares 195, 000Weighted Average Exercise Price for Shares Exercisable (in Dollars per share) | $ / shares $ 2. 61Intrinsic Value (in Dollars) | $ $ 1, 107, 600Exercise Prices 2. 65 [ Member ] Share- Based Payment Arrangement, Option, Exercise Price Range [ Line Items ] Number Outstanding | shares 20, 000Weighted Average Life (Years) 1 year 7 months 17 daysWeighted Average Exercise Price for Shares Outstanding (in Dollars per share) | $ / shares $ 2. 65Number Exercisable | shares 20, 000Weighted Average Exercise Price for Shares Exercisable (in Dollars per share) | $ / shares $ 2. 65Intrinsic Value (in Dollars) | $ $ 112, 800Exercise Prices 2. 75 [ Member ] Share- Based Payment Arrangement, Option, Exercise Price Range [ Line Items ] Number Outstanding | shares 30, 000Weighted Average Life (Years) 2 yearsWeighted Average Exercise Price for Shares Outstanding (in Dollars per share) | $ / shares $ 2. 75Number Exercisable | shares 30, 000Weighted Average Exercise Price for Shares Exercisable (in Dollars per share) | $ / shares $ 2. 75Intrinsic Value (in Dollars) | $ $ 166, 200Exercise Prices 3. 59 [ Member ] Share- Based Payment Arrangement, Option, Exercise Price Range [ Line Items ] Number Outstanding | shares 35, 000Weighted Average Life (Years) 2 years 7 months 28 daysWeighted Average Exercise Price for Shares Outstanding (in Dollars per share) | $ / shares $ 3. 59Number Exercisable | shares 35, 000Weighted Average Exercise Price for Shares Exercisable (in Dollars per share) | $ / shares $ 3. 59Intrinsic Value (in Dollars) | $ $ 164, 500Exercise Prices 3. 75 [ Member ] Share- Based Payment Arrangement, Option, Exercise Price Range [ Line Items ] Number Outstanding | shares 57, 500Weighted Average Life (Years) 1 yearWeighted Average Exercise Price for Shares Outstanding (in Dollars per share) | $ / shares $ 3. 75Number Exercisable | shares 57, 500Weighted Average Exercise Price for Shares Exercisable (in Dollars per share) | $ / shares $ 3. 75Intrinsic Value (in Dollars) | $ $ 261, 050Exercise Prices 3. 98 [ Member ] Share- Based Payment Arrangement, Option, Exercise Price Range [ Line Items ] Number Outstanding | shares 30, 000Weighted Average Life (Years) 1 yearWeighted Average Exercise Price for Shares Outstanding (in Dollars per share) | $ / shares $ 3. 98Number Exercisable | shares 30, 000Weighted Average Exercise Price for Shares Exercisable (in Dollars per share) | $ / shares $ 3. 98Intrinsic Value (in Dollars) | $ $ 129, 300Exercise Prices 4. 09 [ Member ] Share- Based Payment Arrangement, Option, Exercise Price Range [ Line Items ] Number Outstanding | shares 78, 750Weighted Average Life (Years) 6 monthsWeighted Average Exercise Price for Shares Outstanding (in Dollars per share) | $ / shares $ 4. 09Number Exercisable | shares 78, 750Weighted Average Exercise Price for Shares Exercisable (in Dollars per share) | $ / shares $ 4. 09Intrinsic Value (in Dollars) | $ $ 330, 750Exercise Prices 4. 12 [ Member ] Share- Based Payment Arrangement, Option, Exercise Price Range [ Line Items ] Number Outstanding | shares 50, 000Weighted Average Life (Years) 10 months 6 daysWeighted Average Exercise Price for Shares Outstanding (in Dollars per share) | $ / shares $ 4. 12Number Exercisable | shares 50, 000Weighted Average Exercise Price for Shares Exercisable (in Dollars per share) | $ / shares $ 4. 12Intrinsic Value (in Dollars) | $ $ 208, 500Exercise Prices 4. 50 [ Member ] Share- Based Payment Arrangement, Option, Exercise Price Range [ Line Items ] Number Outstanding | shares 58, 334Weighted Average Life (Years) 6 monthsWeighted Average Exercise Price for Shares Outstanding (in Dollars per share) | $ / shares $ 4. 5Number Exercisable | shares 58, 334Weighted Average Exercise Price for Shares Exercisable (in Dollars per share) | $ / shares $ 4. 5Intrinsic Value (in Dollars) | $ $ 221, 086Exercise Prices 5. 99 [ Member ] Share- Based Payment Arrangement, Option, Exercise Price Range [ Line Items ] Number Outstanding | shares 30, 000Weighted Average Life (Years) 2 years 4 months 28 daysWeighted Average Exercise Price for Shares Outstanding (in Dollars per share) | $ / shares $ 5. 99Number Exercisable | shares 30, 000Weighted Average Exercise Price for Shares Exercisable (in Dollars per share) | $ / shares $ 5. 99Intrinsic Value (in Dollars) | $ $ 69, 000Exercise Prices 7. 34 [ Member ] Share- Based Payment Arrangement, Option, Exercise Price Range [ Line Items ] Number Outstanding | shares 180, 918Weighted Average Life (Years) 2 years 11 months 23 daysWeighted Average Exercise Price for Shares Outstanding (in Dollars per share) | $ / shares $ 7. 34Number Exercisable | shares 180, 918Weighted Average Exercise Price for Shares Exercisable (in Dollars per share) | $ / shares $ 7. 34Intrinsic Value (in Dollars) | $ $ 171, 872Exercise Prices 8. 08 [ Member ] Share- Based Payment Arrangement, Option, Exercise Price Range [ Line Items ] Number Outstanding | shares 58, 666Weighted Average Life (Years) 2 years 11 months 23 daysWeighted Average Exercise Price for Shares Outstanding (in Dollars per share) | $ / shares $ 8. 07Number Exercisable | shares 58, 666Weighted Average Exercise Price for Shares Exercisable (in Dollars per share) | $ / shares $ 8. 07Intrinsic Value (in Dollars) | $ $ 12, 907X- DefinitionRepresents the value of intrinsic value. ReferencesNo definition available. Details Name: ntrb_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableIntrinsicValue Namespace Prefix: ntrb_ Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: instantX- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. "} } },"auth_ref": ReferencesNo definition available. Details Name: . credit Period Type:instantX- DefinitionAmount,after effects of reinsurance,of expense (reversal of expense) for claims incurred and costs incurred in the claim settlement process. ReferencesReference 1:http: / / www.xbrl.org / 2003 / role / exampleRef- Topic 944- SubTopic 40- Name Accounting Standards Codification- Section 55- Paragraph 7 - Publisher FASB- URI https: / / asc.fasb.org / 1943274 / 2147480429 2147480046 / 718 944 - 10 40 - 50 55 - 2Reference 7Reference 2:http: / / fasb www.xbrl.org / 2009 us- gaap / role / commonPracticeRef ref / legacyRef - Topic 718 944 - SubTopic 10 40 - Name Accounting Standards Codification- Section 50- Paragraph 2 3 - Subparagraph ( b c) (1) (i )- Publisher FASB- URI https: / / asc.fasb.org / 1943274 / 2147480429 2147480081 / 718 944 - 10 40 - 50- 2 3 Details Name:us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1 Namespace Prefix:us- gaap_ Data Type: xbrli dtr- types: perShareItemType monetaryItemType Balance Type: na Period Type:instantX- DefinitionWeighted average remaining contractual term of outstanding stock options,in' PnYnMnDTnHnMnS' format,for example,' P1Y5M13D' represents the reported fact of one year,five months,and thirteen days. ReferencesReference 1:http: / / fasb.org / us- gaap [ Abstract ] Number of segmentsX },"dei_EntityAddressesTable": {" xbrltype":" stringItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" EntityAddressesTable"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover" ]," lang": {" en- DefinitionNumber of segments reported by the us": {" role": {" label":" Entity entity . A reportable segment is a component Addresses [ Table ]"," documentation":" Container of address an entity for which there is an accounting requirement to report separate financial information for on that component in the entity "} } },"auth_ref": [" r829" ] },"dei_EntityBankruptcyProceedingsReportingCurrent": {" xbrltype":" booleanItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" EntityBankruptcyProceedingsReportingCurrent"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover" ]," lang": {" en- us": {" role": {" label":" Entity Bankruptcy Proceedings, Reporting Current"," documentation":" For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15 (d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } },"auth_ref": [" r833" ] },"dei_EntityCentralIndexKey": {" xbrltype":" centralIndexKeyItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" EntityCentralIndexKey"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover" ]," lang": {" en- us": {" role": {" label":" Entity Central Index Key"," documentation":" A unique 10- digit SEC- issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } },"auth_ref": [" r829" ] },"dei_EntityCommonStockSharesOutstanding": {" xbrltype":" sharesItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" EntityCommonStockSharesOutstanding"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover" ]," lang": {" en- us": {" role": {" label":" Entity Common Stock, Shares Outstanding"," documentation":" Indicate number of shares or other units outstanding of each of registrant' s classes of capital financial statements. ReferencesReference 1: http: / / www. xbrl. or org common stock / 2003 / role / exampleRef- Topic 280- SubTopic 10- Name Accounting Standards Codification- Section 55- Paragraph 47- Subparagraph (a)- Publisher FASB- URI https: / / asc. fasb. or org other ownership interests / 1943274 / 2147482785 / 280- 10- 55- 47Reference 2 :http: / / fasb www . xbrl. org / 2003 us- gaap / role / exampleRef ref / legacyRef - Topic 505 280 - SubTopic 10- Name Accounting Standards Codification- Section S99 55 - Paragraph 4 54 - Subparagraph ( e SAB Topic 4.C )- Publisher FASB- URI https: / / asc.fasb.org / 1943274 / 2147480008 2147482785 / 280- 10- 505 - 55 - 54Reference 3 10- S99- 4

Details Name:us- gaap_StockholdersEquityReverseStockSplit Namespace Prefix:us- gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:durationX- DefinitionPer share increase in exercise price of warrant.Excludes change due to standard antidilution provision. ReferencesReference 1 :http: / / www.xbrl.org / 2003 **2009** / role / disclosureRef **commonPracticeRef** - Topic 505 **280** - SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 3 **18** - Publisher FASB- URI https: / / asc.fasb.org / 1943274 / 2147481112 **2147482810** / 505 **280** - 10- 50- 3 **18** Details Name:us- gaap_WarrantExercisePriceIncrease **gaap_NumberOfReportableSegments** Namespace Prefix:us- gaap_ Data Type: **xbrli** dtr- types : perShareItemType **integerItemType** Balance Type:na Period Type:durationX- **ReferencesNo definition available.** Details Name:us- **gaap_SegmentReportingAbstract** gaap_DebtInstrumentAxis = ntrb_MoneyChannelMember Namespace Prefix: **us- gaap_** Data Type: **xbrli:stringItemType Balance Type:na Period Type:durationSegment Reporting- Schedule of Our Chief Officer Decision Maker Evaluates Segment Performance (Details)- USD ($) 12 Months EndedJan.31** , if **2025 Jan. 31, 2024Net sales Net sales $ 2, 139, 537 $ 2, 085, 314Gross profit Gross profit 743, 317 862, 105Operating expenses Operating expenses 11, 028, 160 5, 734, 031Depreciation** and **Amortization Depreciation and Amortization 285, 054 287, 722Pocono Pharmaceuticals** as stated on cover of related periodic report. Where multiple classes or units exist define each class / interest by adding class of stock items such as Common Class A [ Member ] **Net sales Net sales 2** , Common Class B **139, 537 1, 920, 280Gross profit Gross profit 743, 317 744, 391Depreciation and Amortization Depreciation and Amortization 235, 941 222, 1594P Therapeutics** [ Member ] or Partnership Interest **Net sales Net sales 165, 034Gross profit Gross profit 117, 714Depreciation and Amortization Depreciation and Amortization 37, 070 51, 577Selling, general and administrative- Pocono Pharmaceuticals** [ Member ] **Operating expenses Operating expenses 661** onto the Instrument [ Domain ] of the Entity Listings , **805 606** Instrument." } } }, **275Selling** " auth_ref": [ ] }, **general** " dei_EntityContactPersonnelLineItems": {" xbrltype":" stringItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" EntityContactPersonnelLineItems"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover" ]," lang": {" en- us": {" role": {" label":" Entity Contact Personnel [ Line Items ]"," documentation":" Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }," auth_ref": [ ] }," dei_EntityCurrentReportingStatus": {" xbrltype":" yesNoItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" EntityCurrentReportingStatus"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover" ]," lang": {" en- us": {" role": {" label":" Entity Current Reporting Status"," documentation":" Indicate' Yes' or' No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and **administrative** (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant' s current or most recent filing containing the related disclosure." } } },"auth_ref": [ ] }," dei_EntityDomain": {" xbrltype":" domainItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" EntityDomain"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / AuditInformation"," http: / / xbrl. sec. gov / dei / role / document / Cover" ]," lang": {" en- us": {" role": {" label":" Entity [ Domain ]"," documentation":" All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } },"auth_ref": [ ] }," dei_EntityEmergingGrowthCompany": {" xbrltype":" booleanItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" EntityEmergingGrowthCompany"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover" ]," lang": {" en- us": {" role": {" label":" Entity Emerging Growth Company"," documentation":" Indicate if registrant meets the emerging growth company criteria." } } },"auth_ref": [" r829" ] }," dei_EntityExTransitionPeriod": {" xbrltype":" booleanItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" EntityExTransitionPeriod"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover" ]," lang": {" en- us": {" role": {" label":" Entity Ex Transition Period"," documentation":" Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } },"auth_ref": [" r945" ] }," dei_EntityFileNumber": {" xbrltype":" fileNumberItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" EntityFileNumber"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover" ]," lang": {" en- us": {" role": {" label":" Entity File Number"," documentation":" Commission file number. The field allows up to 17 characters. The prefix may contain 1- 3 digits, the sequence number may contain 1- 8 digits, the optional suffix may contain 1- 4 characters, and the fields are separated with a hyphen." } } },"auth_ref": [ ] }," dei_EntityFilerCategory": {" xbrltype":" filerCategoryItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" EntityFilerCategory"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover" ]," lang": {" en- us": {" role": {" label":" Entity Filer Category"," documentation":" Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non- accelerated Filer. Definitions of these categories are stated in Rule 12b- 2 of the Exchange Act. This information should be based on the registrant' s current or most recent filing containing the related disclosure." } } },"auth_ref": [" r829" ] }," dei_EntityHomeCountryISOCode": {" xbrltype":" countryCodeItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" EntityHomeCountryISOCode"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover" ]," lang": {" en- us": {" role": {" label":" Entity Home Country ISO Code"," documentation":" ISO 3166- 1 alpha- 2 country code for the Entity' s home country. If home country is different from country of legal incorporation, then also provide country of legal incorporation in the' Entity Incorporation, State Country Code' element." } } },"auth_ref": [ ] }," dei_EntityIncorporationDateOfIncorporation": {" xbrltype":" dateItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" EntityIncorporationDateOfIncorporation"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover" ]," lang": {" en- us": {" role": {" label":" Entity Incorporation, Date of Incorporation"," documentation":" Date when an entity was incorporated" } } },"auth_ref": [ ] }," dei_EntityIncorporationStateCountryCode": {" xbrltype":" edgarStateCountryItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" EntityIncorporationStateCountryCode"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover" ]," lang": {" en- us": {" role": {" label":" Entity Incorporation, State or Country Code"," documentation":" Two- character EDGAR code representing the state or country of incorporation." } } },"auth_ref": [ ] }," dei_EntityInformationFormerLegalOrRegisteredName": {" xbrltype":" normalizedStringItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" EntityInformationFormerLegalOrRegisteredName"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover" ]," lang": {" en- us": {" role": {" label":" Entity Information, Former Legal or Registered Name"," documentation":" Former Legal or Registered Name of an entity" } } },"auth_ref": [ ] }," dei_EntityInformationLineItems": {" xbrltype":" stringItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" EntityInformationLineItems"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover" ]," lang": {" en- us": {" role": {" label":" Entity Information [ Line Items ]"," documentation":" Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } },"auth_ref": [ ] }," dei_EntityInteractiveDataCurrent": {" xbrltype":" yesNoItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" EntityInteractiveDataCurrent"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover" ]," lang": {" en- us": {" role": {" label":" Entity Interactive Data Current"," documentation":" Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S- T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } },"auth_ref": [" r934" ] }," dei_EntityInvCompanyType": {" xbrltype":" invCompanyType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" EntityInvCompanyType"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover" ]," lang": {" en- us": {" role": {" label":" Entity Inv Company Type"," documentation":" One of: N- 1A (Mutual Fund), N- 1 (Open- End Separate Account with No Variable Annuities), N- 2 (Closed- End Investment Company), N- 3 (Separate Account Registered as Open- End Management Investment Company), N- 4 (Variable Annuity UIT Separate Account), N- 5 (Small Business Investment Company), N- 6 (Variable Life UIT Separate Account), S- 1 or S- 3 (Face Amount Certificate Company), S- 6 (UIT, Non- Insurance Product)." } } },"auth_ref": [" r933" ] }," dei_EntityLegalForm": {" xbrltype":" stringItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" EntityLegalForm"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover" ]," lang": {" en- us": {" role": {" label":" Entity Legal Form"," documentation":" The details of the entity' s legal form. Examples are partnership, limited liability company, trust, etc." } } },"auth_ref": [ ] }," dei_EntityListingDepositoryReceiptRatio": {" xbrltype":" pureItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" EntityListingDepositoryReceiptRatio"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover" ]," lang": {" en- us": {" role": {" label":" Entity Listing, Depository Receipt Ratio"," documentation":" The number of underlying shares represented by one American Depository Receipt (ADR) or Global Depository Receipt (GDR). A value of' 3' means that one ADR represents 3 underlying shares. If one underlying share represents 2 ADR' s then the value would be represented as' 0. 5'." } } },"auth_ref": [ ] }," dei_EntityListingDescription": {" xbrltype":" stringItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" EntityListingDescription"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover" ]," lang": {" en- us": {" role": {" label":" Entity Listing, Description"," documentation":" Description of the kind of listing the entity has on the exchange, if necessary to further describe different instruments that are already distinguished by Entity, Exchange and Security." } } },"auth_ref": [ ] }," dei_EntityListingForeign": {" xbrltype":" yesNoItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" EntityListingForeign"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover" ]," lang": {" en- us": {" role": {" label":" Entity Listing, Foreign"," documentation":" Yes or No value indicating whether this is a listing that is a foreign listing or depository receipt." } }

},"auth_ref":[]},"dei_EntityListingParValuePerShare":{"xbrltype":"perShareItemType","nsuri":"http://xbrl.sec.gov/dei/2024","localname":"EntityListingParValuePerShare","presentation":["http://xbrl.sec.gov/dei/role/document/Cover"],"lang":{"en-us":{"role":{"label":"Entity Listing, Par Value Per Share","documentation":"The par value per share of security quoted in same currency as Trading currency. Example:'0.01'."}}},"auth_ref":[]},"dei_EntityListingPrimary":{"xbrltype":"yesNoItemType","nsuri":"http://xbrl.sec.gov/dei/2024","localname":"EntityListingPrimary","presentation":["http://xbrl.sec.gov/dei/role/document/Cover"],"lang":{"en-us":{"role":{"label":"Entity Listing, Primary","documentation":"Yes or No value indicating whether a listing of an instrument on an exchange is primary for the entity."}}},"auth_ref":[]},"dei_EntityListingSecurityTradingCurrency":{"xbrltype":"stringItemType","nsuri":"http://xbrl.sec.gov/dei/2024","localname":"EntityListingSecurityTradingCurrency","presentation":["http://xbrl.sec.gov/dei/role/document/Cover"],"lang":{"en-us":{"role":{"label":"Entity Listing, Security Trading Currency","documentation":"The three character ISO 4217 code for the currency in which the security is quoted. Example:'USD'"}}},"auth_ref":[]},"dei_EntityListingsExchangeAxis":{"xbrltype":"stringItemType","nsuri":"http://xbrl.sec.gov/dei/2024","localname":"EntityListingsExchangeAxis","presentation":["http://xbrl.sec.gov/dei/role/document/Cover"],"lang":{"en-us":{"role":{"label":"Entity Listings, Exchange [Axis]","documentation":"The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."}}},"auth_ref":[]},"dei_EntityListingsLineItems":{"xbrltype":"stringItemType","nsuri":"http://xbrl.sec.gov/dei/2024","localname":"EntityListingsLineItems","presentation":["http://xbrl.sec.gov/dei/role/document/Cover"],"lang":{"en-us":{"role":{"label":"Entity Listings [Line Items]","documentation":"Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."}}},"auth_ref":[]},"dei_EntityListingsTable":{"xbrltype":"stringItemType","nsuri":"http://xbrl.sec.gov/dei/2024","localname":"EntityListingsTable","presentation":["http://xbrl.sec.gov/dei/role/document/Cover"],"lang":{"en-us":{"role":{"label":"Entity Listings [Table]","documentation":"Container for exchange listing information for an entity"}}},"auth_ref":[]},"dei_EntityNumberOfEmployees":{"xbrltype":"decimalItemType","nsuri":"http://xbrl.sec.gov/dei/2024","localname":"EntityNumberOfEmployees","presentation":["http://xbrl.sec.gov/dei/role/document/Cover"],"lang":{"en-us":{"role":{"label":"Entity Number of Employees","documentation":"Number of persons employed by the Entity"}}},"auth_ref":[]},"dei_EntityPhoneFaxNumbersLineItems":{"xbrltype":"stringItemType","nsuri":"http://xbrl.sec.gov/dei/2024","localname":"EntityPhoneFaxNumbersLineItems","presentation":["http://xbrl.sec.gov/dei/role/document/Cover"],"lang":{"en-us":{"role":{"label":"Entity Phone Fax Numbers [Line Items]","documentation":"Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."}}},"auth_ref":[]},"dei_EntityPrimarySicNumber":{"xbrltype":"sicNumberItemType","nsuri":"http://xbrl.sec.gov/dei/2024","localname":"EntityPrimarySicNumber","presentation":["http://xbrl.sec.gov/dei/role/document/Cover"],"lang":{"en-us":{"role":{"label":"Entity Primary SIC Number","documentation":"Primary Standard Industrial Classification (SIC) Number for the Entity."}}},"auth_ref":["r853"]},"dei_EntityPublicFloat":{"xbrltype":"monetaryItemType","nsuri":"http://xbrl.sec.gov/dei/2024","localname":"EntityPublicFloat","crdr":"credit","presentation":["http://xbrl.sec.gov/dei/role/document/Cover"],"lang":{"en-us":{"role":{"label":"Entity Public Float","documentation":"The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."}}},"auth_ref":[]},"dei_EntityRegistrantName":{"xbrltype":"normalizedStringItemType","nsuri":"http://xbrl.sec.gov/dei/2024","localname":"EntityRegistrantName","presentation":["http://xbrl.sec.gov/dei/role/document/Cover"],"lang":{"en-us":{"role":{"label":"Entity Registrant Name","documentation":"The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."}}},"auth_ref":["r829"]},"dei_EntityReportingCurrencyISOCode":{"xbrltype":"currencyItemType","nsuri":"http://xbrl.sec.gov/dei/2024","localname":"EntityReportingCurrencyISOCode","presentation":["http://xbrl.sec.gov/dei/role/document/Cover"],"lang":{"en-us":{"role":{"label":"Entity Reporting Currency ISO Code","documentation":"The three character ISO 4217 code for the currency used for reporting purposes. Example:'USD'."}}},"auth_ref":[]},"dei_EntityShellCompany":{"xbrltype":"booleanItemType","nsuri":"http://xbrl.sec.gov/dei/2024","localname":"EntityShellCompany","presentation":["http://xbrl.sec.gov/dei/role/document/Cover"],"lang":{"en-us":{"role":{"label":"Entity Shell Company","documentation":"Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."}}},"auth_ref":["r829"]},"dei_EntitySmallBusiness":{"xbrltype":"booleanItemType","nsuri":"http://xbrl.sec.gov/dei/2024","localname":"EntitySmallBusiness","presentation":["http://xbrl.sec.gov/dei/role/document/Cover"],"lang":{"en-us":{"role":{"label":"Entity Small Business","documentation":"Indicates that the company is a Smaller Reporting Company (SRC)."}}},"auth_ref":["r829"]},"dei_EntityTaxIdentificationNumber":{"xbrltype":"employerIdItemType","nsuri":"http://xbrl.sec.gov/dei/2024","localname":"EntityTaxIdentificationNumber","presentation":["http://xbrl.sec.gov/dei/role/document/Cover"],"lang":{"en-us":{"role":{"label":"Entity Tax Identification Number","documentation":"The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."}}},"auth_ref":["r829"]},"dei_EntityTextBlock":{"xbrltype":"textBlockItemType","nsuri":"http://xbrl.sec.gov/dei/2024","localname":"EntityTextBlock","presentation":["http://xbrl.sec.gov/dei/role/document/Cover"],"lang":{"en-us":{"role":{"label":"Entity [Text Block]","documentation":"Container to serve as parent of six Entity related Table concepts."}}},"auth_ref":[]},"dei_EntityVoluntaryFilers":{"xbrltype":"yesNoItemType","nsuri":"http://xbrl.sec.gov/dei/2024","localname":"EntityVoluntaryFilers","presentation":["http://xbrl.sec.gov/dei/role/document/Cover"],"lang":{"en-us":{"role":{"label":"Entity Voluntary Filers","documentation":"Indicate'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."}}},"auth_ref":[]},"dei_EntityWellKnownSeasonedIssuer":{"xbrltype":"yesNoItemType","nsuri":"http://xbrl.sec.gov/dei/2024","localname":"EntityWellKnownSeasonedIssuer","presentation":["http://xbrl.sec.gov/dei/role/document/Cover"],"lang":{"en-us":{"role":{"label":"Entity Well-known Seasoned Issuer","documentation":"Indicate'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."}}},"auth_ref":["r936"]},"ecd_EqtyAwrdsAdjFnTextBlock":{"xbrltype":"textBlockItemType","nsuri":"http://xbrl.sec.gov/ecd/2024","localname":"EqtyAwrdsAdjFnTextBlock","presentation":["http://xbrl.sec.gov/ecd/role/PvpDisclosure"],"lang":{"en-us":{"role":{"label":"Equity Awards Adjustments, Footnote [Text Block]","terseLabel":"Equity Awards Adjustments, Footnote"}}},"auth_ref":["r887"]},"ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember":{"xbrltype":"domainItemType","nsuri":"http://xbrl.sec.gov/ecd/2024","localname":"EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember","presentation":["http://xbrl.sec.gov/ecd/role/PvpDisclosure"],"lang":{"en-us":{"role":{"label":"Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]","terseLabel":"Equity Awards Adjustments, Excluding Value Reported in Compensation Table"}}},"auth_ref":["r929"]},"ecd_EqtyAwrdsAdjsMember":{"xbrltype":"domainItemType","nsuri":"http://xbrl.sec.gov/ecd/2024","localname":"EqtyAwrdsAdjsMember","presentation":["http://xbrl.sec.gov/ecd/role/PvpDisclosure"],"lang":{"en-us":{"role":{"label":"Equity Awards Adjustments [Member]","terseLabel":"Equity Awards Adjustments"}}},"auth_ref":["r929"]},"ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember":{"xbrltype":"domainItemType","nsuri":"http://xbrl.sec.gov/ecd/2024","localname":"EqtyAwrdsInSummryCompstnTblForAplblYrMember","presentation":["http://xbrl.sec.gov/ecd/role/PvpDisclosure"],"lang":{"en-us":{"role":{"label":"Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]","terseLabel":"Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table"}}},"auth_ref":["r929"]},"us-gaap_EquityComponentDomain":{"xbrltype":"domainItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"EquityComponentDomain","presentation":["http://nutriband.com/role/RelatedPartyTransactionsDetails","http://nutriband.com/role/ShareholdersEquityType2or3","http://nutriband.com/role/StockholdersEquityDetails","http://nutriband.com/role/SubsequentEventsDetails"],"lang":{"en-us":{"role":{"label":"Equity Component [Domain]","documentation":"Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."}}},"auth_ref":["r8","r184","r209","r210","r211","r228","r229","r230","r232","r237","r239","r241","r254","r298","r299","r335","r403","r473","r474","r480","r481","r482","r484","r486","r487","r492","r493","r494","r495","r496","r497","r499","r505","r506","r507","r508","r509","r510","r514","r515","r522","r596","r613","r614","r615","r634","r707"]},"us-gaap_EquityMethodInvestmentSoldCarryingAmount":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"EquityMethodInvestmentSoldCarryingAmount","crdr":"debit","presentation":["http://nutriband.com/role/SubsequentEventsDetails"],"lang":{"en-us":{"role":{"terseLabel":"Equity financing (in Dollars)","label":"Equity Method Investment, Amount Sold","documentation":"Amount of the entity's equity method investment which has been sold."}}},"auth_ref":[]},"ecd_EquityValuationAssumptionDifferenceFnTextBlock":{"xbrltype":"textBlockItemType","nsuri":"http://xbrl.sec.gov/ecd/2024","localname":"EquityValuationAssumptionDifferenceFnTextBlock","presentation":["http://xbrl.sec.gov/ecd/role/PvpDisclosure"],"lang":{"en-us":{"role":{"label":"Equity Valuation Assumption Difference, Footnote [Text Block]","terseLabel":"Equity Valuation Assumption Difference, Footnote"}}},"auth_ref":["r897"]},"ecd_ErrCompAnalysisTextBlock":{"xbrltype":"textBlockItemType","nsuri":"http://xbrl.sec.

gov / ecd / 2024"," localname":" ErrCompAnalysisTextBlock"," presentation": [" http: / / xbrl. sec. gov / ecd / role / ErrCompDisclosure" ]," lang": {" en- us": {" role": {" label":" Erroneous Compensation Analysis [ Text Block ]"," terseLabel":" Erroneous Compensation Analysis" } } }," auth_ref": [" r846"," r857"," r873"," r908" ] }," ecd_ErrCompRecoveryTable": {" xbrltype":" stringItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" ErrCompRecoveryTable"," presentation": [" http: / / xbrl. sec. gov / ecd / role / ErrCompDisclosure" ]," lang": {" en- us": {" role": {" label":" Erroneously Awarded Compensation Recovery [ Table ]"," terseLabel":" Erroneously Awarded Compensation Recovery" } } }," auth_ref": [" r843"," r854"," r870"," r905" ] }," ntrb_EstimatedCost": {" xbrltype":" monetaryItemType"," nsuri":" http: / / nutriband. com / 20240131"," localname":" EstimatedCost"," crdr":" debit"," presentation": [" http: / / nutriband. com / role / CommitmentsandContigenciesDetails" ]," lang": {" en- us": {" role": {" terseLabel":" Estimated cost"," documentation":" Estimated cost is the projection of the amount of costs that will be incurred to build a product or construct something."," label":" Estimated Cost" } } }," auth_ref": [ ] }," ntrb_EstimatedUsefulLive": {" xbrltype":" durationItemType"," nsuri":" http: / / nutriband. com / 20240131"," localname":" EstimatedUsefulLive"," presentation": [" http: / / nutriband. com / role / SummaryofSignificantAccountingPoliciesDetails" ]," lang": {" en- us": {" role": {" terseLabel":" Estimated useful lives"," documentation":" Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment)."," label":" Estimated Useful Live" } } }," auth_ref": [ ] }," us- gaap_ExcessStockSharesAuthorized": {" xbrltype":" sharesItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" ExcessStockSharesAuthorized"," presentation": [" http: / / nutriband. com / role / SummaryofSignificantAccountingPoliciesDetails" ]," lang": {" en- us": {" role": {" terseLabel":" Authorized shares (in Shares)"," label":" Excess Stock, Shares Authorized"," documentation":" Maximum number of excess stock shares permitted to be issued." } } }," auth_ref": [ ] }," us- gaap_ExcessStockSharesIssued": {" xbrltype":" sharesItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" ExcessStockSharesIssued"," presentation": [" http: / / nutriband. com / role / IntangibleAssetsDetails"," http: / / nutriband. com / role / SubsequentEventsDetails" ]," lang": {" en- us": {" role": {" terseLabel":" Issued shares (in Shares)"," verboseLabel":" Shares units"," label":" Excess Stock, Shares Issued"," documentation":" Number of excess stock shares of an entity that have been sold or granted to shareholders." } } }," auth_ref": [ ] }," dei_ExchangeDomain": {" xbrltype":" domainItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" ExchangeDomain"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover" ]," lang": {" en- us": {" role": {" label":" Exchange [ Domain ]"," documentation":" The set of all exchanges. MIC exchange codes are drawn from ISO 10383." } } }," auth_ref": [ ] }," ecd_ExecutiveCategoryAxis": {" xbrltype":" stringItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" ExecutiveCategoryAxis"," presentation": [" http: / / xbrl. sec. gov / ecd / role / PvpDisclosure" ]," lang": {" en- us": {" role": {" label":" Executive Category [ Axis ]"," terseLabel":" Executive Category:" } } }," auth_ref": [" r903" ] }," srt_ExecutiveOfficerMember": {" xbrltype":" domainItemType"," nsuri":" http: / / fasb. org / srt / 2024"," localname":" ExecutiveOfficerMember"," presentation": [" http: / / nutriband. com / role / RelatedPartyTransactionsDetails" ]," lang": {" en- us": {" role": {" terseLabel":" Executives [ Member ]"," verboseLabel":" Executive Officer [ Member ]"," label":" Executive Officer [ Member ]"," documentation":" Person with designation of executive officer." } } }," auth_ref": [" r990" ] }," ntrb_ExercisePriceOutstanding": {" xbrltype":" perShareItemType"," nsuri":" http: / / nutriband. com / 20240131"," localname":" ExercisePriceOutstanding"," presentation": [" http: / / nutriband. com / role / ScheduleofChangesinOptionsOutstandingTable" ]," lang": {" en- us": {" role": {" periodStartLabel":" Exercise Price, Outstanding, Beginning balance"," periodEndLabel":" Exercise Price, Outstanding, Ending balance"," documentation":" Exercise Price, Outstanding."," label":" Exercise Price Outstanding" } } }," auth_ref": [ ] }," ntrb_ExercisePricesEightMember": {" xbrltype":" domainItemType"," nsuri":" http: / / nutriband. com / 20240131"," localname":" ExercisePricesEightMember"," presentation": [" http: / / nutriband. com / role / ScheduleofSummarizesAdditionalInformationRelatingtotheOptionsOutstandingTable" ]," lang": {" en- us": {" role": {" terseLabel":" Exercise Prices 4. 12 [ Member ]"," label":" Exercise Prices Eight Member" } } }," auth_ref": [ ] }," ntrb_ExercisePricesElevenMember": {" xbrltype":" domainItemType"," nsuri":" http: / / nutriband. com / 20240131"," localname":" ExercisePricesElevenMember"," presentation": [" http: / / nutriband. com / role / ScheduleofSummarizesAdditionalInformationRelatingtotheOptionsOutstandingTable" ]," lang": {" en- us": {" role": {" terseLabel":" Exercise Prices 4. 58 [ Member ]"," label":" Exercise Prices Eleven Member" } } }," auth_ref": [ ] }," ntrb_ExercisePricesFiveMember": {" xbrltype":" domainItemType"," nsuri":" http: / / nutriband. com / 20240131"," localname":" ExercisePricesFiveMember"," presentation": [" http: / / nutriband. com / role / ScheduleofSummarizesAdditionalInformationRelatingtotheOptionsOutstandingTable" ]," lang": {" en- us": {" role": {" terseLabel":" Exercise Prices 3. 75 [ Member ]"," label":" Exercise Prices Five Member" } } }," auth_ref": [ ] }," ntrb_ExercisePricesFourMember": {" xbrltype":" domainItemType"," nsuri":" http: / / nutriband. com / 20240131"," localname":" ExercisePricesFourMember"," presentation": [" http: / / nutriband. com / role / ScheduleofSummarizesAdditionalInformationRelatingtotheOptionsOutstandingTable"," http: / / nutriband. com / role / ScheduleofSummarizesAdditionalInformationRelatingtotheWarrantsOutstandingTable" ]," lang": {" en- us": {" role": {" terseLabel":" Exercise Prices 7. 50 [ Member ]"," verboseLabel":" Exercise Prices 3. 59 [ Member ]"," label":" Exercise Prices Four Member" } } }," auth_ref": [ ] }," ntrb_ExercisePricesNineMember": {" xbrltype":" domainItemType"," nsuri":" http: / / nutriband. com / 20240131"," localname":" ExercisePricesNineMember"," presentation": [" http: / / nutriband. com / role / ScheduleofSummarizesAdditionalInformationRelatingtotheOptionsOutstandingTable" ]," lang": {" en- us": {" role": {" terseLabel":" Exercise Prices 4. 16 [ Member ]"," label":" Exercise Prices Nine Member" } } }," auth_ref": [ ] }," ntrb_ExercisePricesOneMember": {" xbrltype":" domainItemType"," nsuri":" http: / / nutriband. com / 20240131"," localname":" ExercisePricesOneMember"," presentation": [" http: / / nutriband. com / role / ScheduleofSummarizesAdditionalInformationRelatingtotheOptionsOutstandingTable"," http: / / nutriband. com / role / ScheduleofSummarizesAdditionalInformationRelatingtotheWarrantsOutstandingTable" ]," lang": {" en- us": {" role": {" terseLabel":" Exercise Prices 4. 00 [ Member ]"," verboseLabel":" Exercise Prices 1. 93 [ Member ]"," label":" Exercise Prices One Member" } } }," auth_ref": [ ] }," ntrb_ExercisePricesSevenMember": {" xbrltype":" domainItemType"," nsuri":" http: / / nutriband. com / 20240131"," localname":" ExercisePricesSevenMember"," presentation": [" http: / / nutriband. com / role / ScheduleofSummarizesAdditionalInformationRelatingtotheOptionsOutstandingTable" ]," lang": {" en- us": {" role": {" terseLabel":" Exercise Prices 4. 09 [ Member ]"," label":" Exercise Prices Seven Member" } } }," auth_ref": [ ] }," ntrb_ExercisePricesSixMember": {" xbrltype":" domainItemType"," nsuri":" http: / / nutriband. com / 20240131"," localname":" ExercisePricesSixMember"," presentation": [" http: / / nutriband. com / role / ScheduleofSummarizesAdditionalInformationRelatingtotheOptionsOutstandingTable" ]," lang": {" en- us": {" role": {" terseLabel":" Exercise Prices 3. 98 [ Member ]"," label":" Exercise Prices Six Member" } } }," auth_ref": [ ] }," ntrb_ExercisePricesTenMember": {" xbrltype":" domainItemType"," nsuri":" http: / / nutriband. com / 20240131"," localname":" ExercisePricesTenMember"," presentation": [" http: / / nutriband. com / role / ScheduleofSummarizesAdditionalInformationRelatingtotheOptionsOutstandingTable" ]," lang": {" en- us": {" role": {" terseLabel":" Exercise Prices 4. 50 [ Member ]"," label":" Exercise Prices Ten Member" } } }," auth_ref": [ ] }," ntrb_ExercisePricesThreeMember": {" xbrltype":" domainItemType"," nsuri":" http: / / nutriband. com / 20240131"," localname":" ExercisePricesThreeMember"," presentation": [" http: / / nutriband. com / role / ScheduleofSummarizesAdditionalInformationRelatingtotheOptionsOutstandingTable"," http: / / nutriband. com / role / ScheduleofSummarizesAdditionalInformationRelatingtotheWarrantsOutstandingTable" ]," lang": {" en- us": {" role": {" terseLabel":" Exercise Prices 1. 93 [ Member ]"," verboseLabel":" Exercise Prices 2. 65 [ Member ]"," label":" Exercise Prices Three Member" } } }," auth_ref": [ ] }," ntrb_ExercisePricesTwoMember": {" xbrltype":" domainItemType"," nsuri":" http: / / nutriband. com / 20240131"," localname":" ExercisePricesTwoMember"," presentation": [" http: / / nutriband. com / role / ScheduleofSummarizesAdditionalInformationRelatingtotheOptionsOutstandingTable"," http: / / nutriband. com / role / ScheduleofSummarizesAdditionalInformationRelatingtotheWarrantsOutstandingTable" ]," lang": {" en- us": {" role": {" terseLabel":" Exercise Prices 6. 43 [ Member ]"," verboseLabel":" Exercise Prices 2. 12 [ Member ]"," label":" Exercise Prices Two Member" } } }," auth_ref": [ ] }," dei_ExhibitsOnly462d": {" xbrltype":" booleanItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" ExhibitsOnly462d"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover" ]," lang": {" en- us": {" role": {" label":" Exhibits Only, 462 (d)" } } }," auth_ref": [" r941" ] }," dei_ExhibitsOnly462dFileNumber": {" xbrltype":" fileNumberItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" ExhibitsOnly462dFileNumber"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover" ]," lang": {" en- us": {" role": {" label":" Exhibits Only, 462 (d), File Number" } } }," auth_ref": [" r941" ] }," ntrb_ExpireYear": {" xbrltype":" durationItemType"," nsuri":" http: / / nutriband. com / 20240131"," localname":" ExpireYear"," presentation": [" http: / / nutriband. com / role / OptionsandWarrantsDetails" ]," lang": {" en- us": {" role": {" terseLabel":" Expire year"," documentation":" The expire year of issuance of vest."," label":" Expire Year" } } }," auth_ref": [ ] }," dei_Extension": {" xbrltype":" normalizedStringItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" Extension"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover" ]," lang": {" en- us": {" role": {" label":" Extension"," documentation":" Extension number for local phone number." } } }," auth_ref": [ ] }," us- gaap_FairValueMeasurementPolicyPolicyTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" FairValueMeasurementPolicyPolicyTextBlock"," presentation": [" http: / / nutriband. com / role / AccountingPoliciesByPolicy" ]," lang": {" en- us": {" role": {" terseLabel":" Fair Value Measurements"," label":" Fair Value Measurement, Policy [ Policy Text Block ]"," documentation":" Disclosure of accounting policy for fair value measurements of financial and non- financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the

basis of its net exposure measures the fair value of those assets and liabilities." } } },"auth_ref": [ ] },"ntrb_FairValueOfCommonStock": {" xbrltype":" monetaryItemType"," nsuri":" http: / / nutriband. com / 20240131"," localname":" FairValueOfCommonStock"," crdr":" credit"," presentation": [" http: / / nutriband. com / role / NotesPayableDetails" ],"lang": {" en- us": {" role": {" terseLabel":" Fair value of common stock"," label":" Fair Value Of Common Stock" } } }," auth_ref": [ ] },"us- gaap_FairValueOptionIneligibleItemsAggregateCarryingAmount": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" FairValueOptionIneligibleItemsAggregateCarryingAmount"," crdr":" debit"," presentation": [" http: / / nutriband. com / role / OptionsandWarrantsDetails" ]," lang": {" en- us": {" role": {" terseLabel":" Options issued (in Dollars)"," label":" Fair Value, Option, Ineligible Items, Carrying Amount"," documentation":" Carrying amount of items included in each line item in the statement of financial position that are not eligible for the fair value option." } } },"auth_ref": [" r58" ] },"ntrb_FairValueOptionsServiceAmount": {" xbrltype":" monetaryItemType"," nsuri":" http: / / nutriband. com / 20240131"," localname":" FairValueOptionsServiceAmount"," crdr":" debit"," presentation": [" http: / / nutriband. com / role / OptionsandWarrantsDetails" ]," lang": {" en- us": {" role": {" terseLabel":" Options issued (in Dollars)"," documentation":" The amount of Fair value Options Service amount."," label":" Fair Value Options Service Amount" } } },"auth_ref": [ ] },"us- gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" FiniteLivedIntangibleAssetsAccumulatedAmortization"," crdr":" credit"," calculation": {" http: / / nutriband. com / role / ScheduleofIntangibleAssetsTable": {" parentTag":" us- gaap_FiniteLivedIntangibleAssetsNet"," weight":- 1. 0," order": 2. 0 } }," presentation": [" http: / / nutriband. com / role / ScheduleofIntangibleAssetsTable" ]," lang": {" en- us": {" role": {" negatedLabel":" Less: Accumulated amortization"," label":" Finite- Lived Intangible Assets, Accumulated Amortization"," documentation":" Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } },"auth_ref": [" r193"," r306"," r327"," r778" ] }," us- gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"," crdr":" debit"," presentation": [" http: / / nutriband. com / role / ScheduleofAmortizationExpensesTable" ]," lang": {" en- us": {" role": {" terseLabel":" 2030 and thereafter"," label":" Finite- Lived Intangible Asset, Expected Amortization, after Year Five"," documentation":" Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } },"auth_ref": [" r999"," r1093" ] }," us- gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"," crdr":" debit"," presentation": [" http: / / nutriband. com / role / ScheduleofAmortizationExpensesTable" ]," lang": {" en- us": {" role": {" terseLabel":" 2025"," label":" Finite- Lived Intangible Asset, Expected Amortization, Year One"," documentation":" Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } },"auth_ref": [" r329"," r752"," r778" ] }," us- gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"," crdr":" debit"," presentation": [" http: / / nutriband. com / role / ScheduleofAmortizationExpensesTable" ]," lang": {" en- us": {" role": {" terseLabel":" 2029"," label":" Finite- Lived Intangible Asset, Expected Amortization, Year Five"," documentation":" Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } },"auth_ref": [" r329"," r752"," r778" ] }," us- gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"," crdr":" debit"," presentation": [" http: / / nutriband. com / role / ScheduleofAmortizationExpensesTable" ]," lang": {" en- us": {" role": {" terseLabel":" 2028"," label":" Finite- Lived Intangible Asset, Expected Amortization, Year Four"," documentation":" Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } },"auth_ref": [" r329"," r752"," r778" ] }," us- gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"," crdr":" debit"," presentation": [" http: / / nutriband. com / role / ScheduleofAmortizationExpensesTable" ]," lang": {" en- us": {" role": {" terseLabel":" 2027"," label":" Finite- Lived Intangible Asset, Expected Amortization, Year Three"," documentation":" Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } },"auth_ref": [" r329"," r752"," r778" ] }," us- gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"," crdr":" debit"," presentation": [" http: / / nutriband. com / role / ScheduleofAmortizationExpensesTable" ]," lang": {" en- us": {" role": {" terseLabel":" 2026"," label":" Finite- Lived Intangible Asset, Expected Amortization, Year Two"," documentation":" Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } },"auth_ref": [" r329"," r752"," r778" ] }," us- gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {" xbrltype":" stringItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" FiniteLivedIntangibleAssetsByMajorClassAxis"," presentation": [" http: / / nutriband. com / role / ScheduleofIntangibleAssetsTable" ]," lang": {" en- us": {" role": {" label":" Finite- Lived Intangible Assets by Major Class [ Axis ]"," documentation":" Information by major type or class of finite- lived intangible assets." } } },"auth_ref": [" r320"," r322"," r323"," r324"," r326"," r327"," r330"," r331"," r542"," r543"," r752" ] }," us- gaap_FiniteLivedIntangibleAssetsGross": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" FiniteLivedIntangibleAssetsGross"," crdr":" debit"," calculation": {" http: / / nutriband. com / role / ScheduleofIntangibleAssetsTable": {" parentTag":" us- gaap_FiniteLivedIntangibleAssetsNet"," weight": 1. 0," order": 1. 0 } }," presentation": [" http: / / nutriband. com / role / ScheduleofIntangibleAssetsTable" ]," lang": {" en- us": {" role": {" terseLabel":" Total"," label":" Finite- Lived Intangible Assets, Gross"," documentation":" Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } },"auth_ref": [" r306"," r327"," r543"," r778" ] }," us- gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {" xbrltype":" domainItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" FiniteLivedIntangibleAssetsMajorClassNameDomain"," presentation": [" http: / / nutriband. com / role / ScheduleofIntangibleAssetsTable" ]," lang": {" en- us": {" role": {" label":" Finite- Lived Intangible Assets, Major Class Name [ Domain ]"," documentation":" The major class of finite- lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } },"auth_ref": [" r320"," r322"," r323"," r324"," r326"," r327"," r330"," r331"," r752" ] }," us- gaap_FiniteLivedIntangibleAssetsMember": {" xbrltype":" domainItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" FiniteLivedIntangibleAssetsMember"," presentation": [" http: / / nutriband. com / role / ScheduleofIntangibleAssetsTable" ]," lang": {" en- us": {" role": {" terseLabel":" Customer base [ Member ]"," label":" Finite- Lived Intangible Assets [ Member ]"," documentation":" Assets, excluding financial assets, that lack physical substance, having a limited useful life." } } },"auth_ref": [ ] },"us- gaap_FiniteLivedIntangibleAssetsNet": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" FiniteLivedIntangibleAssetsNet"," crdr":" debit"," calculation": {" http: / / nutriband. com / role / ScheduleofIntangibleAssetsTable": {" parentTag": null," weight": null," order": null," root": true } }," presentation": [" http: / / nutriband. com / role / ScheduleofAmortizationExpensesTable"," http: / / nutriband. com / role / ScheduleofIntangibleAssetsTable" ]," lang": {" en- us": {" role": {" totalLabel":" Net Intangible Assets"," terseLabel":" Total"," label":" Finite- Lived Intangible Assets, Net"," documentation":" Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } },"auth_ref": [" r542"," r998" ] }," ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {" xbrltype":" monetaryItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"," presentation": [" http: / / xbrl. sec. gov / ecd / role / ErrCompDisclosure" ]," lang": {" en- us": {" role": {" label":" Forgone Recovery due to Disqualification of Tax Benefits, Amount"," terseLabel":" Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } },"auth_ref": [" r850"," r861"," r877"," r912" ] }," ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {" xbrltype":" monetaryItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" ForgoneRecoveryDueToExpenseOfEnforcementAmt"," presentation": [" http: / / xbrl. sec. gov / ecd / role / ErrCompDisclosure" ]," lang": {" en- us": {" role": {" label":" Forgone Recovery due to Expense of Enforcement, Amount"," terseLabel":" Forgone Recovery due to Expense of Enforcement, Amount" } } },"auth_ref": [" r850"," r861"," r877"," r912" ] }," ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {" xbrltype":" monetaryItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" ForgoneRecoveryDueToViolationOfHomeCountryLawAmt","

presentation": [" http: / / xbrl. sec. gov / ecd / role / ErrCompDisclosure" ]," lang": {" en- us": {" role": {" label":" Forgone Recovery due to Violation of Home Country Law, Amount"," terseLabel":" Forgone Recovery due to Violation of Home Country Law, Amount" } } }," auth_ref": [" r850"," r861"," r877"," r912" ] }," ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" ForgoneRecoveryExplanationOfImpracticabilityTextBlock"," presentation": [" http: / / xbrl. sec. gov / ecd / role / ErrCompDisclosure" ]," lang": {" en- us": {" role": {" label":" Forgone Recovery, Explanation of Impracticability [ Text Block ]"," terseLabel":" Forgone Recovery, Explanation of Impracticability" } } }," auth_ref": [" r850"," r861"," r877"," r912" ] }," ecd_ForgoneRecoveryIndName": {" xbrltype":" stringItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" ForgoneRecoveryIndName"," presentation": [" http: / / xbrl. sec. gov / ecd / role / ErrCompDisclosure" ]," lang": {" en- us": {" role": {" label":" Forgone Recovery, Individual Name"," terseLabel":" Name" } } }," auth_ref": [" r850"," r861"," r877"," r912" ] }," dei_FormerAddressMember": {" xbrltype":" domainItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" FormerAddressMember"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover" ]," lang": {" en- us": {" role": {" label":" Former Address [ Member ]"," documentation":" Former address for entity" } } }," auth_ref": [" r840"," r864" ] }," dei_FormerFiscalYearEndDate": {" xbrltype":" gMonthDayItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" FormerFiscalYearEndDate"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover" ]," lang": {" en- us": {" role": {" label":" Former Fiscal Year End Date"," documentation":" Former end date of previous fiscal years" } } }," auth_ref": [ ] }," ntrb_ForwardStockSplitPolicyTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / nutriband. com / 20240131"," localname":" ForwardStockSplitPolicyTextBlock"," presentation": [" http: / / nutriband. com / role / AccountingPoliciesByPolicy" ]," lang": {" en- us": {" role": {" terseLabel":" Forward Stock Split"," documentation":" The entire disclosure of forward stock split."," label":" Forward Stock Split Policy Text Block" } } }," auth_ref": [ ] }," ntrb_FourPTherapeuticsMember": {" xbrltype":" domainItemType"," nsuri":" http: / / nutriband. com / 20240131"," localname":" FourPTherapeuticsMember"," presentation": [" http: / / nutriband. com / role / ScheduleofNetSalesandPropertyandEquipmentTable"," http: / / nutriband. com / role / ScheduleofSegmentPerformanceotheGAAPMeasureofGrossProfitTable" ]," lang": {" en- us": {" role": {" terseLabel":" 4P Therapeutics [ Member ] " **- Operating expenses Operating expenses 136** , **294 236,** " verboseLabel":" Selling **953Selling** , general and administrative **- Corporate [ Member ] Operating expenses Operating expenses 3, 515, 711 2, 930, 378Goodwill and intangibles impairment [ Member ] Operating expenses Operating expenses 3, 595, 216 Research and development** - 4P Therapeutics [ Member ] " **- Operating expenses Operating expenses 3** , **119** " label":" Four PTherapeutics Member" } } }, **134 1** " auth_ref": [ ] }, **960** " ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {" xbrltype":" domainItemType", **425Corporate** " nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"," presentation": [" http: / / xbrl. sec. gov / ecd / role / PvpDisclosure" ]," lang": {" en- us": {" role": {" label":" Prior Year-End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [ Member ] "," terseLabel":" Prior Year-End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year" } } }," auth_ref": [" r892" ] }," us- gaap_FurnitureAndFixturesMember": {" xbrltype":" domainItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" FurnitureAndFixturesMember"," presentation": [" http: / / nutriband. com / role / ScheduleofPlantandEquipmentonaStraightLineBasisOvertheEstimatedUsefulLifeoftheAssetsTable"," http: / / nutriband. com / role / ScheduleofPropertyandEquipmentTable" ]," lang": {" en- us": {" role": {" terseLabel":" Furniture and fixtures [ Member ]"," label":" Furniture and Fixtures [ Member ]"," documentation":" Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases." } } }," auth_ref": [ ] }," us- gaap_GainLossOnSalesOfLoansNet": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" GainLossOnSalesOfLoansNet"," crdr":" credit"," presentation": [" http: / / nutriband. com / role / ScheduleofSegmentPerformanceotheGAAPMeasureofGrossProfitTable" ]," lang": {" en- us": {" role": {" terseLabel":" Net sales"," label":" Gain (Loss) on Sales of Loans, Net"," documentation":" The net gain (loss) resulting from a sale of loans, including adjustments to record loans classified as held- for- sale at the lower- of- cost- or- market and fair value adjustments to loan held for investment purposes." } } }," auth_ref": [" r5"," r138" ] }," us- gaap_GainsLossesOnExtinguishmentOfDebt": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" GainsLossesOnExtinguishmentOfDebt"," crdr":" credit"," calculation": {" http: / / nutriband. com / role / ConsolidatedIncomeStatement": {" parentTag":" us- gaap_OtherNonoperatingIncomeExpense"," weight": 1. 0," order": 2. 0 }," http: / / nutriband. com / role / ConsolidatedCashFlow": {" parentTag":" us- gaap_NetCashProvidedByUsedInOperatingActivities"," weight":- 1. 0," order": 13. 0 } }," presentation": [" http: / / nutriband. com / role / ConsolidatedCashFlow"," http: / / nutriband. com / role / ConsolidatedIncomeStatement"," http: / / nutriband. com / role / NotesPayableDetails" ]," lang": {" en- us": {" role": {" terseLabel":" Loss on extinguishment of debt"," negatedLabel":" Loss on extinguishment of debt"," verboseLabel":" Loss on extinguishment"," label":" Gain (Loss) on Extinguishment of Debt"," documentation":" Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity." } } }," auth_ref": [" r5"," r35"," r36" ] }," ntrb_GoingConcernPolicyTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / nutriband. com / 20240131"," localname":" GoingConcernPolicyTextBlock"," presentation": [" http: / / nutriband. com / role / AccountingPoliciesByPolicy" ]," lang": {" en- us": {" role": {" terseLabel":" Going Concern Assessment"," documentation":" The disclosure of accounting policy for Going Concern."," label":" Going Concern Policy Text Block" } } }," auth_ref": [ ] }," us- gaap_Goodwill": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" Goodwill"," crdr":" debit"," calculation": {" http: / / nutriband. com / role / ConsolidatedBalanceSheet": {" parentTag":" us- gaap_Assets"," weight": 1. 0," order": 3. 0 } }," presentation": [" http: / / nutriband. com / role / ConsolidatedBalanceSheet" ]," lang": {" en- us": {" role": {" terseLabel":" Goodwill"," label":" Goodwill"," documentation":" Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }," auth_ref": [" r192"," r307"," r576"," r772"," r777"," r792"," r799"," r995"," r996" ] }," us- gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" GoodwillAndIntangibleAssetsPolicyTextBlock"," presentation": [" http: / / nutriband. com / role / AccountingPoliciesByPolicy" ]," lang": {" en- us": {" role": {" terseLabel":" Goodwill"," label":" Goodwill and Intangible Assets, Policy [ Policy Text Block ]"," documentation":" Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets." } } }," auth_ref": [" r994"," r997" ] }," us- gaap_GoodwillImpairedAccumulatedImpairmentLoss": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" GoodwillImpairedAccumulatedImpairmentLoss"," crdr":" credit"," presentation": [" http: / / nutriband. com / role / SummaryofSignificantAccountingPoliciesDetails" ]," lang": {" en- us": {" role": {" terseLabel":" Impairment goodwill"," label":" Goodwill, Impaired, Accumulated Impairment Loss"," documentation":" Amount of accumulated impairment loss for asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }," auth_ref": [" r310"," r317"," r777" ] }," us- gaap_GoodwillImpairmentLoss": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" GoodwillImpairmentLoss"," crdr":" debit"," calculation": {" http: / / nutriband. com / role / ConsolidatedIncomeStatement": {" parentTag":" us- gaap_CostsAndExpenses"," weight": 1. 0," order": 3. 0 }," http: / / nutriband. com / role / ConsolidatedCashFlow": {" parentTag":" us- gaap_NetCashProvidedByUsedInOperatingActivities"," weight": 1. 0," order": 7. 0 } }," presentation": [" http: / / nutriband. com / role / ConsolidatedCashFlow"," http: / / nutriband. com / role / ConsolidatedIncomeStatement" ]," lang": {" en- us": {" role": {" terseLabel":" Goodwill impairment"," label":" Goodwill, Impairment Loss"," documentation":" Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }," auth_ref": [" r5"," r308"," r314"," r318"," r777"," r792" ] }," ntrb_GoodwillImpairmentPoconoPharmaceuticalsMember": {" xbrltype":" domainItemType"," nsuri":" http: / / nutriband. com / 20240131"," localname":" GoodwillImpairmentPoconoPharmaceuticalsMember"," presentation": [" http: / / nutriband. com / role / ScheduleofSegmentPerformanceotheGAAPMeasureofGrossProfitTable" ]," lang": {" en- us": {" role": {" terseLabel":" Goodwill impairment- Pocono Pharmaceuticals [ Member ]"," label":" Goodwill Impairment Pocono Pharmaceuticals Member" } } }," auth_ref": [ ] }," us- gaap_GoodwillOtherIncreaseDecrease": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" GoodwillOtherIncreaseDecrease"," crdr":" debit"," presentation": [" http: / / nutriband. com / role / SummaryofSignificantAccountingPoliciesDetails" ]," lang": {" en- us": {" role": {" terseLabel":" Goodwill amounted"," label":" Goodwill, Other Increase (Decrease)"," documentation":" Amount of increase (decrease) of asset representing future economic benefit from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized, classified as other." } } }," auth_ref": [" r316" ] }," ntrb_GoodwillValue": {" xbrltype":" monetaryItemType"," nsuri":" http: / / nutriband. com / 20240131"," localname":" GoodwillValue"," crdr":" debit"," presentation": [" http: / / nutriband. com / role / SummaryofSignificantAccountingPoliciesDetails" ]," lang": {" en- us": {" role": {" terseLabel":" Goodwill"," documentation":" Goodwill value."," label":" Goodwill Value" } } }," auth_ref": [ ] }," us- gaap_IPOMember": {" xbrltype":" domainItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" IPOMember"," presentation": [" http: / / nutriband. com / role / SubsequentEventsDetails" ]," lang": {" en- us": {" role": {" terseLabel":" Offering [ Member ],"

label":" IPO [ Member ]"," documentation":" First sale of stock by a private company to the public." } } },"auth_ref": [ ] },"dei_IcfrAuditorAttestationFlag": {" xbrltype":" booleanItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" IcfrAuditorAttestationFlag"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover "]," lang": {" en- us": {" role": {" label":" ICFR Auditor Attestation Flag" } } },"auth_ref": [" r838"," r841"," r853" ] },"us- gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"," presentation": [" http: / / nutriband. com / role / AccountingPoliciesByPolicy" ]," lang": {" en- us": {" role": {" terseLabel":" Long- lived Assets"," label":" Impairment or Disposal of Long- Lived Assets, Policy [ Policy Text Block ]"," documentation":" Disclosure of accounting policy for recognizing and measuring the impairment of long- lived assets. An entity also may disclose its accounting policy for long- lived assets to be sold. This policy excludes goodwill and intangible assets." } } },"auth_ref": [" r0"," r110" ] },"us- gaap_IncomeLossFromContinuingOperations": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" IncomeLossFromContinuingOperations"," crdr":" credit"," presentation": [" http: / / nutriband. com / role / ScheduleofReconciliationofTaxesonIncomeTable " ]," lang": {" en- us": {" role": {" terseLabel":" Book Income (loss from operations)"," label":" Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent"," documentation":" Amount after tax of income (loss) from continuing operations attributable to the parent." } } },"auth_ref": [" r51"," r87"," r104"," r233"," r234"," r235"," r236"," r237"," r247"," r250"," r487" ] },"us- gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"," crdr":" credit"," calculation": {" http: / / nutriband. com / role / ConsolidatedIncomeStatement": {" parentTag":" us- gaap_NetIncomeLoss"," weight": 1. 0," order": 1. 0 } }," presentation": [" http: / / nutriband. com / role / ConsolidatedIncomeStatement" ]," lang": {" en- us": {" role": {" totalLabel":" Loss before provision for income taxes"," label":" Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest"," documentation":" Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } },"auth_ref": [" r86"," r139"," r144"," r578"," r594"," r766"," r771"," r984"," r986"," r987"," r988"," r989" ] },"us- gaap_IncomeStatementAbstract": {" xbrltype":" stringItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" IncomeStatementAbstract"," lang": {" en- us": {" role": {" label":" Income Statement [ Abstract ]" } } },"auth_ref": [ ] },"us- gaap_IncomeTaxDisclosureTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" IncomeTaxDisclosureTextBlock"," presentation": [" http: / / nutriband. com / role / IncomeTaxes" ]," lang": {" en- us": {" role": {" terseLabel":" INCOME TAXES"," label":" Income Tax Disclosure [ Text Block ]"," documentation":" The entire disclosure for income tax." } } },"auth_ref": [" r224"," r457"," r461"," r464"," r465"," r466"," r467"," r471"," r475"," r477"," r478"," r479"," r630"," r791" ] },"us- gaap_IncomeTaxExpenseBenefit": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" IncomeTaxExpenseBenefit"," crdr":" debit"," calculation": {" http: / / nutriband. com / role / ConsolidatedIncomeStatement": {" parentTag":" us- gaap_NetIncomeLoss"," weight": -1. 0," order": 2. 0 } }," presentation": [" http: / / nutriband. com / role / ConsolidatedIncomeStatement"," http: / / nutriband. com / role / ScheduleofReconciliationofTaxesonIncomeTable" ]," lang": {" en- us": {" role": {" terseLabel":" Provision for income taxes"," verboseLabel":" Income tax expense"," label":" Income Tax Expense (Benefit)"," documentation":" Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } },"auth_ref": [" r146"," r158"," r240"," r241"," r253"," r269"," r284"," r460"," r461"," r476"," r599"," r791" ] },"us- gaap_IncomeTaxPolicyTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" IncomeTaxPolicyTextBlock"," presentation": [" http: / / nutriband. com / role / AccountingPoliciesByPolicy" ]," lang": {" en- us": {" role": {" terseLabel":" Income Taxes"," label":" Income Tax, Policy [ Policy Text Block ]"," documentation":" Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements." } } },"auth_ref": [" r208"," r458"," r459"," r467"," r468"," r470"," r472"," r624" ] },"us- gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"," crdr":" debit"," presentation": [" http: / / nutriband. com / role / IncomeTaxesDetails" ]," lang": {" en- us": {" role": {" terseLabel":" Tax effect valuation allowance"," label":" Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount"," documentation":" Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets." } } },"auth_ref": [" r463"," r791"," r1014" ] },"us- gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses"," crdr":" debit"," presentation": [" http: / / nutriband. com / role / ScheduleofReconciliationofTaxesonIncomeTable" ]," lang": {" en- us": {" role": {" terseLabel":" Impairment expense"," label":" Effective Income Tax Rate Reconciliation, Nondeductible Expense, Impairment Losses, Amount"," documentation":" Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible impairment loss." } } },"auth_ref": [" r791"," r1014"," r1015" ] },"us- gaap_IncomeTaxReconciliationNondeductibleExpenseOther": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" IncomeTaxReconciliationNondeductibleExpenseOther"," crdr":" debit"," presentation": [" http: / / nutriband. com / role / ScheduleofReconciliationofTaxesonIncomeTable" ]," lang": {" en- us": {" role": {" terseLabel":" Unused operating losses"," label":" Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount"," documentation":" Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses." } } },"auth_ref": [" r791"," r1014"," r1015" ] },"us- gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"," crdr":" debit"," presentation": [" http: / / nutriband. com / role / ScheduleofReconciliationofTaxesonIncomeTable" ]," lang": {" en- us": {" role": {" terseLabel":" Common stock issued for services"," label":" Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share- Based Payment Arrangement, Amount"," documentation":" Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share- based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share- based payment arrangement." } } },"auth_ref": [" r791"," r1014"," r1015" ] }," ntrb_IncomeTaxesDetailsLineItems": {" xbrltype":" stringItemType"," nsuri":" http: / / nutriband. com / 20240131"," localname":" IncomeTaxesDetailsLineItems"," presentation": [" http: / / nutriband. com / role / IncomeTaxesDetails" ]," lang": {" en- us": {" role": {" label":" Income Taxes [ Line Items ]" } } },"auth_ref": [ ] }," ntrb_IncomeTaxesDetailsTable": {" xbrltype":" stringItemType"," nsuri":" http: / / nutriband. com / 20240131"," localname":" IncomeTaxesDetailsTable"," presentation": [" http: / / nutriband. com / role / IncomeTaxesDetails" ]," lang": {" en- us": {" role": {" label":" Income Taxes (Details) [ Table ]" } } },"auth_ref": [ ] }," us- gaap_IncomeTaxesPaid": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" IncomeTaxesPaid"," crdr":" credit"," presentation": [" http: / / nutriband. com / role / ConsolidatedCashFlow" ]," lang": {" en- us": {" role": {" terseLabel":" Income taxes"," label":" Income Taxes Paid"," documentation":" Amount, before refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax." } } },"auth_ref": [" r17"," r103"," r973"," r1017"," r1018" ] }," us- gaap_IncomeTaxesPaidNetAbstract": {" xbrltype":" stringItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" IncomeTaxesPaidNetAbstract"," lang": {" en- us": {" role": {" label":" Income Taxes [ Abstract ]" } } },"auth_ref": [ ] },"us- gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"," crdr":" debit"," calculation": {" http: / / nutriband. com / role / ConsolidatedCashFlow": {" parentTag":" us- gaap_NetCashProvidedByUsedInOperatingActivities"," weight": 1. 0," order": 12. 0 } }," presentation": [" http: / / nutriband. com / role / ConsolidatedCashFlow" ]," lang": {" en- us": {" role": {" terseLabel":" Accounts payable and accrued expenses"," label":" Increase (Decrease) in Accounts Payable and Accrued Liabilities"," documentation":" The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid." } } },"auth_ref": [" r4" ] }," us- gaap_IncreaseDecreaseInAccountsReceivable": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" IncreaseDecreaseInAccountsReceivable"," crdr":" credit"," calculation": {" http: / / nutriband. com / role / ConsolidatedCashFlow": {" parentTag":" us- gaap_NetCashProvidedByUsedInOperatingActivities"," weight": -1. 0," order": 14. 0 } }," presentation": [" http: / / nutriband. com / role / ConsolidatedCashFlow" ]," lang": {" en- us": {" role": {" negatedLabel":" Accounts receivable"," label":" Increase (Decrease) in Accounts Receivable"," documentation":" The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } },"auth_ref": [" r4" ] },"us- gaap_IncreaseDecreaseInDeferredRevenue": {" xbrltype":"

monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" IncreaseDecreaseInDeferredRevenue"," crdr":" debit"," calculation": {" http: / / nutriband. com / role / ConsolidatedCashFlow": {" parentTag":" us- gaap_NetCashProvidedByUsedInOperatingActivities"," weight": 1. 0," order": 10. 0 } },"
presentation": [" http: / / nutriband. com / role / ConsolidatedCashFlow" ]," lang": {" en- us": {" role": {" terseLabel":" Deferred revenue"," label":" Increase (Decrease) in Deferred Revenue"," documentation":" Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable." } } },"
auth_ref": [" r753" ] }," us- gaap_IncreaseDecreaseInInventories": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" IncreaseDecreaseInInventories"," crdr":" credit"," calculation": {" http: / / nutriband. com / role / ConsolidatedCashFlow": {" parentTag":" us- gaap_NetCashProvidedByUsedInOperatingActivities"," weight":- 1. 0," order": 16. 0 } },"
presentation": [" http: / / nutriband. com / role / ConsolidatedCashFlow" ]," lang": {" en- us": {" role": {" negatedLabel":" Inventories"," label":" Increase (Decrease) in Inventories"," documentation":" The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } },"
auth_ref": [" r4" ] }," us- gaap_IncreaseDecreaseInOperatingCapitalAbstract": {" xbrltype":" stringItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" IncreaseDecreaseInOperatingCapitalAbstract"," presentation": [" http: / / nutriband. com / role / ConsolidatedCashFlow" ]," lang": {" en- us": {" role": {" terseLabel":" Changes in operating assets and liabilities:"," label":" Increase (Decrease) in Operating Capital [ Abstract ]" } } },"
auth_ref": [ ] }," us- gaap_IncreaseDecreaseInOperatingLeaseLiability": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" IncreaseDecreaseInOperatingLeaseLiability"," crdr":" debit"," calculation": {" http: / / nutriband. com / role / ConsolidatedCashFlow": {" parentTag":" us- gaap_NetCashProvidedByUsedInOperatingActivities"," weight": 1. 0," order": 11. 0 } }," presentation": [" http: / / nutriband. com / role / ConsolidatedCashFlow" ]," lang": {" en- us": {" role": {" terseLabel":" Operating lease liability"," label":" Increase (Decrease) in Operating Lease Liability"," documentation":" Amount of increase (decrease) in obligation for operating lease." } } }," auth_ref": [" r950"," r971" ] }," us- gaap_IncreaseDecreaseInPrepaidExpense": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" IncreaseDecreaseInPrepaidExpense"," crdr":" credit"," calculation": {" http: / / nutriband. com / role / ConsolidatedCashFlow": {" parentTag":" us- gaap_NetCashProvidedByUsedInOperatingActivities"," weight":- 1. 0," order": 15. 0 } },"
presentation": [" http: / / nutriband. com / role / ConsolidatedCashFlow" ]," lang": {" en- us": {" role": {" negatedLabel":" Prepaid expenses"," label":" Increase (Decrease) in Prepaid Expense"," documentation":" The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods." } } }," auth_ref": [" r4" ] }," ntrb_IncreaseDecreasedInAuthorizedCommonStock": {" xbrltype":" sharesItemType"," nsuri":" http: / / nutriband. com / 20240131"," localname":" IncreaseDecreasedInAuthorizedCommonStock"," presentation": [" http: / / nutriband. com / role / StockholdersEquityDetails" ]," lang": {" en- us": {" role": {" terseLabel":" Increase decreased in authorized common stock"," documentation":" Increase decreased in authorized common stock."," label":" Increase Decreased In Authorized Common Stock" } } }," auth_ref": [ ] }," ntrb_IndependentDirectorsMember": {" xbrltype":" domainItemType"," nsuri":" http: / / nutriband. com / 20240131"," localname":" IndependentDirectorsMember"," presentation": [" http: / / nutriband. com / role / RelatedPartyTransactionsDetails" ]," lang": {" en- us": {" role": {" terseLabel":" Independent Directors [ Member ]"," label":" Independent Directors Member" } } }," auth_ref": [ ] }," eed_IndividualAxis": {" xbrltype":" stringItemType"," nsuri":" http: / / xbrl. sec. gov / eed / 2024"," localname":" IndividualAxis"," presentation": [" http: / / xbrl. sec. gov / eed / role / AwardTimingDisclosure"," http: / / xbrl. sec. gov / eed / role / ErrCompDisclosure"," http: / / xbrl. sec. gov / eed / role / InsiderTradingArrangements"," http: / / xbrl. sec. gov / eed / role / PvpDisclosure" ]," lang": {" en- us": {" role": {" label":" Individual [ Axis ]"," terseLabel":" Individual:" } } }," auth_ref": [" r850"," r861"," r877"," r903"," r912"," r916"," r924" ] }," eed_InsiderTradingArrLineItems": {" xbrltype":" stringItemType"," nsuri":" http: / / xbrl. sec. gov / eed / 2024"," localname":" InsiderTradingArrLineItems"," lang": {" en- us": {" role": {" label":" Insider Trading Arrangements [ Line Items ]"," terseLabel":" Insider Trading Arrangements:" } } }," auth_ref": [" r922" ] }," eed_InsiderTradingPoliciesProcLineItems": {" xbrltype":" stringItemType"," nsuri":" http: / / xbrl. sec. gov / eed / 2024"," localname":" InsiderTradingPoliciesProcLineItems"," lang": {" en- us": {" role": {" label":" Insider Trading Policies and Procedures [ Line Items ]"," terseLabel":" Insider Trading Policies and Procedures:" } } }," auth_ref": [" r842"," r928" ] }," eed_InsiderTrdPoliciesProcAdoptedFlag": {" xbrltype":" booleanItemType"," nsuri":" http: / / xbrl. sec. gov / eed / 2024"," localname":" InsiderTrdPoliciesProcAdoptedFlag"," presentation": [" http: / / xbrl. sec. gov / eed / role / InsiderTradingPoliciesProc" ]," lang": {" en- us": {" role": {" label":" Insider Trading Policies and Procedures Adopted [ Flag ]"," terseLabel":" Insider Trading Policies and Procedures Adopted" } } }," auth_ref": [" r842"," r928" ] }," eed_InsiderTrdPoliciesProcNotAdoptedTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / xbrl. sec. gov / eed / 2024"," localname":" InsiderTrdPoliciesProcNotAdoptedTextBlock"," presentation": [" http: / / xbrl. sec. gov / eed / role / InsiderTradingPoliciesProc" ]," lang": {" en- us": {" role": {" label":" Insider Trading Policies and Procedures Not Adopted [ Text Block ]"," terseLabel":" Insider Trading Policies and Procedures Not Adopted" } } }," auth_ref": [" r842"," r928" ] }," ntrb_IntangibleAssetsDetailsLineItems": {" xbrltype":" stringItemType"," nsuri":" http: / / nutriband. com / 20240131"," localname":" IntangibleAssetsDetailsLineItems"," presentation": [" http: / / nutriband. com / role / IntangibleAssetsDetails" ]," lang": {" en- us": {" role": {" label":" Intangible Assets [ Line Items ]" } } }," auth_ref": [ ] }," ntrb_IntangibleAssetsDetailsScheduleofIntangibleAssetsLineItems": {" xbrltype":" stringItemType"," nsuri":" http: / / nutriband. com / 20240131"," localname":" IntangibleAssetsDetailsScheduleofIntangibleAssetsLineItems"," presentation": [" http: / / nutriband. com / role / ScheduleofIntangibleAssetsTable" ]," lang": {" en- us": {" role": {" label":" Schedule of Intangible Assets [ Line items ]" } } }," auth_ref": [ ] }," ntrb_IntangibleAssetsDetailsScheduleofIntangibleAssetsTable": {" xbrltype":" stringItemType"," nsuri":" http: / / nutriband. com / 20240131"," localname":" IntangibleAssetsDetailsScheduleofIntangibleAssetsTable"," presentation": [" http: / / nutriband. com / role / ScheduleofIntangibleAssetsTable" ]," lang": {" en- us": {" role": {" label":" Intangible Assets (Details)- Schedule of Intangible Assets [ Table ]" } } }," auth_ref": [ ] }," ntrb_IntangibleAssetsDetailsTable": {" xbrltype":" stringItemType"," nsuri":" http: / / nutriband. com / 20240131"," localname":" IntangibleAssetsDetailsTable"," presentation": [" http: / / nutriband. com / role / IntangibleAssetsDetails" ]," lang": {" en- us": {" role": {" label":" Intangible Assets (Details) [ Table ]" } } }," auth_ref": [ ] }," us- gaap_IntangibleAssetsDisclosureTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" IntangibleAssetsDisclosureTextBlock"," presentation": [" http: / / nutriband. com / role / IntangibleAssets" ]," lang": {" en- us": {" role": {" terseLabel":" INTANGIBLE ASSETS"," label":" Intangible Assets Disclosure [ Text Block ]"," documentation":" The entire disclosure for all or part of the information related to intangible assets." } } }," auth_ref": [" r319"," r332"," r334"," r751"," r752" ] }," us- gaap_IntangibleAssetsFiniteLivedPolicy": {" xbrltype":" textBlockItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" IntangibleAssetsFiniteLivedPolicy"," presentation": [" http: / / nutriband. com / role / AccountingPoliciesByPolicy" ]," lang": {" en- us": {" role": {" terseLabel":" Intangible Assets"," label":" Intangible Assets, Finite- Lived, Policy [ Policy Text Block ]"," documentation":" Disclosure of accounting policy for finite- lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets." } } },"
auth_ref": [" r538"," r539"," r540"," r542"," r761"," r997" ] }," us- gaap_IntangibleAssetsNetExcludingGoodwill": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" IntangibleAssetsNetExcludingGoodwill"," crdr":" debit"," calculation": {" http: / / nutriband. com / role / ConsolidatedBalanceSheet": {" parentTag":" us- gaap_Assets"," weight": 1. 0," order": 5. 0 } }," presentation": [" http: / / nutriband. com / role / ConsolidatedBalanceSheet" ]," lang": {" en- us": {" role": {" terseLabel":" Intangible assets- net"," label":" Intangible Assets, Net (Excluding Goodwill)"," documentation":" Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges." } } },"
auth_ref": [" r320"," r998"," r1000" ] }," us- gaap_IntangibleAssetsNetExcludingGoodwillAbstract": {" xbrltype":" stringItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" IntangibleAssetsNetExcludingGoodwillAbstract"," lang": {" en- us": {" role": {" label":" Intangible Assets [ Abstract ]" } } },"
auth_ref": [ ] }," ntrb_IntelligenceLLCMember": {" xbrltype":" domainItemType"," nsuri":" http: / / nutriband. com / 20240131"," localname":" IntelligenceLLCMember"," presentation": [" http: / / nutriband. com / role / SummaryofSignificantAccountingPoliciesDetails" ]," lang": {" en- us": {" role": {" terseLabel":" Intelligence LLC [ Member ]"," label":" Intelligence LLCMember" } } }," auth_ref": [ ] }," us- gaap_InterestExpense": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" InterestExpense"," crdr":" debit"," calculation": {" http: / / nutriband. com / role / ConsolidatedIncomeStatement": {" parentTag":" us- gaap_OtherNonoperatingIncomeExpense"," weight":- 1. 0," order": 3. 0 } }," presentation": [" http: / / nutriband. com / role / ConsolidatedIncomeStatement" ]," lang": {" en- us": {" role": {" negatedLabel":" Interest expense"," label":" Interest Expense, Operating and Nonoperating"," documentation":" Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense." } } }," auth_ref": [" r253","
r261"," r265"," r271"," r284"," r512"," r771"," r772" ] }," us- gaap_InterestExpenseDebt": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" InterestExpenseDebt"," crdr":" debit"," presentation": [" http: / / nutriband. com / role / NotesPayableDetails" ]," lang": {" en- us": {" role": {" terseLabel":" Interest expense"," label":" Interest Expense, Debt"," documentation":" Amount of the cost of borrowed funds accounted for as interest expense for debt." } } }," auth_ref": [" r95"," r381"," r387"," r782"," r783" ] }," us- gaap_InterestExpenseDeposits": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" InterestExpenseDeposits"," crdr":" debit"," presentation": [" http: / / nutriband. com / role / IntangibleAssetsDetails" ]," lang": {" en- us": {" role": {" terseLabel":" Interest expense"," label":" Interest Expense, Deposits"," documentation":" Aggregate amount of interest expense on all

deposits." } } },"auth_ref": [" r141" ] },"us- gaap_InterestIncomeOther": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" InterestIncomeOther"," crdr":" credit"," calculation": {" http: / / nutriband. com / role / ConsolidatedIncomeStatement": {" parentTag":" us- gaap_OtherNonoperatingIncomeExpense"," weight": 1. 0," order": 1. 0 } },"presentation": [" http: / / nutriband. com / role / ConsolidatedIncomeStatement" ]," lang": {" en- us": {" role": {" terseLabel":" Interest income"," label":" Interest Income, Other"," documentation":" Amount of interest income earned from interest bearing assets classified as other." } } },"auth_ref": [ ] }," us- gaap_InterestPaidNet": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" InterestPaidNet"," crdr":" credit"," presentation": [" http: / / nutriband. com / role / ConsolidatedCashFlow" ]," lang": {" en- us": {" role": {" terseLabel":" Interest"," label":" Interest Paid, Excluding Capitalized Interest, Operating Activities"," documentation":" Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero- coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } },"auth_ref": [" r215"," r217"," r218" ] }," ntrb_IntrinsicValue": {" xbrltype":" monetaryItemType"," nsuri":" http: / / nutriband. com / 20240131"," localname":" IntrinsicValue"," crdr":" debit"," presentation": [" http: / / nutriband. com / role / ScheduleofSummarizesAdditionalInformationRelatingtotheWarrantsOutstandingTable" ]," lang": {" en- us": {" role": {" terseLabel":" Intrinsic Value (in Dollars)"," documentation":" The amount of measures the value of an investment based on its cash flows."," label":" Intrinsic Value" } } },"auth_ref": [ ] }," us- gaap_InventoriesMember": {" xbrltype":" domainItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" InventoriesMember"," presentation": [" http: / / nutriband. com / role / SummaryofSignificantAccountingPoliciesDetails" ]," lang": {" en- us": {" role": {" terseLabel":" Inventories [ Member ]"," label":" Inventories [ Member ]"," documentation":" Tangible personal property held for sale in the ordinary course of business, or in process of, or to be consumed in, production for sale." } } },"auth_ref": [ ] }," us- gaap_InventoryFinishedGoods": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" InventoryFinishedGoods"," crdr":" debit"," presentation": [" http: / / nutriband. com / role / SummaryofSignificantAccountingPoliciesDetails" ]," lang": {" en- us": {" role": {" terseLabel":" Finished goods"," label":" Inventory, Finished Goods, Gross"," documentation":" Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer." } } },"auth_ref": [" r960" ] }," us- gaap_InventoryNet": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" InventoryNet"," crdr":" debit"," calculation": {" http: / / nutriband. com / role / ConsolidatedBalanceSheet": {" parentTag":" us- gaap_AssetsCurrent"," weight": 1. 0," order": 3. 0 } }," presentation": [" http: / / nutriband. com / role / ConsolidatedBalanceSheet" ]," lang": {" en- us": {" role": {" terseLabel":" Inventory"," label":" Inventory, Net"," documentation":" Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } },"auth_ref": [" r203"," r757"," r799" ] }," us- gaap_InventoryPolicyTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" InventoryPolicyTextBlock"," presentation": [" http: / / nutriband. com / role / AccountingPoliciesByPolicy" ]," lang": {" en- us": {" role": {" terseLabel":" Inventories"," label":" Inventory, Policy [ Policy Text Block ]"," documentation":" Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost." } } },"auth_ref": [" r148"," r189"," r202"," r301"," r302"," r303"," r537"," r762" ] }," us- gaap_InventoryRawMaterials": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" InventoryRawMaterials"," crdr":" debit"," presentation": [" http: / / nutriband. com / role / SummaryofSignificantAccountingPoliciesDetails" ]," lang": {" en- us": {" role": {" terseLabel":" Raw materials"," label":" Inventory, Raw Materials, Gross"," documentation":" Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer." } } },"auth_ref": [" r962" ] }," us- gaap_InventoryWorkInProcess": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" InventoryWorkInProcess"," crdr":" debit"," presentation": [" http: / / nutriband. com / role / SummaryofSignificantAccountingPoliciesDetails" ]," lang": {" en- us": {" role": {" terseLabel":" Work in process"," label":" Inventory, Work in Process, Gross"," documentation":" Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer." } } },"auth_ref": [" r961" ] }," dei_InvestmentCompanyActFileNumber": {" xbrltype":" fileNumberItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" InvestmentCompanyActFileNumber"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover" ]," lang": {" en- us": {" role": {" label":" Investment Company Act File Number" } } },"auth_ref": [" r866"," r867"," r868"," r869" ] }," dei_InvestmentCompanyActRegistration": {" xbrltype":" booleanItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" InvestmentCompanyActRegistration"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover" ]," lang": {" en- us": {" role": {" label":" Investment Company Act Registration" } } },"auth_ref": [" r882" ] }," us- gaap_InvestmentCompanyCommittedCapital": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" InvestmentCompanyCommittedCapital"," crdr":" credit"," presentation": [" http: / / nutriband. com / role / IntangibleAssetsDetails" ]," lang": {" en- us": {" role": {" terseLabel":" IP license fee"," label":" Investment Company, Committed Capital"," documentation":" Amount of funds committed to investment company from investors." } } },"auth_ref": [" r636" ] }," dei_InvestmentCompanyRegistrationAmendment": {" xbrltype":" booleanItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" InvestmentCompanyRegistrationAmendment"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover" ]," lang": {" en- us": {" role": {" label":" Investment Company Registration Amendment" } } },"auth_ref": [" r882" ] }," dei_InvestmentCompanyRegistrationAmendmentNumber": {" xbrltype":" sequenceNumberItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" InvestmentCompanyRegistrationAmendmentNumber"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover" ]," lang": {" en- us": {" role": {" label":" Investment Company Registration Amendment Number" } } },"auth_ref": [" r882" ] }," us- gaap_InvestmentOwnedBalanceShares": {" xbrltype":" sharesItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" InvestmentOwnedBalanceShares"," presentation": [" http: / / nutriband. com / role / OptionsandWarrantsDetails" ]," lang": {" en- us": {" role": {" terseLabel":" Remaining shares (in Shares)"," label":" Investment Owned, Balance, Shares"," documentation":" Number of shares of investment owned." } } },"auth_ref": [" r648"," r653"," r716"," r722"," r729"," r818" ] }," ntrb_IssuanceOfCommonStock": {" xbrltype":" sharesItemType"," nsuri":" http: / / nutriband. com / 20240131"," localname":" IssuanceOfCommonStock"," presentation": [" http: / / nutriband. com / role / StockholdersEquityDetails" ]," lang": {" en- us": {" role": {" terseLabel":" Issuance of common stock"," documentation":" Number of shares issued issuance of common stock."," label":" Issuance Of Common Stock" } } },"auth_ref": [ ] }," us- gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" IssuanceOfStockAndWarrantsForServicesOrClaims"," crdr":" debit"," calculation": {" http: / / nutriband. com / role / ConsolidatedCashFlow": {" parentTag":" us- gaap_NetCashProvidedByUsedInOperatingActivities"," weight": 1. 0," order": 5. 0 } }," presentation": [" http: / / nutriband. com / role / ConsolidatedCashFlow" ]," lang": {" en- us": {" role": {" terseLabel":" Treasury stock issued for services"," label":" Issuance of Stock and Warrants for Services or Claims"," documentation":" Fair value of share- based compensation granted to nonemployees as payment for services rendered or acknowledged claims." } } },"auth_ref": [" r5" ] }," ntrb_LabEquipmentMember": {" xbrltype":" domainItemType"," nsuri":" http: / / nutriband. com / 20240131"," localname":" LabEquipmentMember"," presentation": [" http: / / nutriband. com / role / ScheduleofPlantandEquipmentonaStraightLineBasisOvertheEstimatedUsefulLifeoftheAssetsTable"," http: / / nutriband. com / role / ScheduleofPropertyandEquipmentTable" ]," lang": {" en- us": {" role": {" terseLabel":" Lab Equipment [ Member ]"," verboseLabel":" Lab equipment [ Member ]"," label":" Lab Equipment Member" } } },"auth_ref": [ ] }," dei_LegalEntityAxis": {" xbrltype":" stringItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" LegalEntityAxis"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / AuditInformation"," http: / / xbrl. sec. gov / dei / role / document / Cover" ]," lang": {" en- us": {" role": {" label":" Legal Entity [ Axis ]"," documentation":" The set of legal entities associated with a report." } } },"auth_ref": [ ] }," dei_LegalEntityIdentifier": {" xbrltype":" legalEntityIdentifierItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" LegalEntityIdentifier"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover" ]," lang": {" en- us": {" role": {" label":" Legal Entity Identifier"," documentation":" A globally unique ISO 17442 value to identify entities, commonly abbreviated as LEI." } } },"auth_ref": [" r826" ] }," us- gaap_LegalFees": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" LegalFees"," crdr":" debit"," presentation": [" http: / / nutriband. com / role / CommitmentsandContigenciesDetails" ]," lang": {" en- us": {" role": {" terseLabel":" legal fees"," label":" Legal Fees"," documentation":" The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings." } } },"auth_ref": [" r952" ] }," us- gaap_LesseeLeasesPolicyTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" LesseeLeasesPolicyTextBlock"," presentation": [" http: / / nutriband. com / role / AccountingPoliciesByPolicy" ]," lang": {" en- us": {" role": {" terseLabel":" Leases"," label":" Lessee, Leases [ Policy Text Block ]"," documentation":" Disclosure of accounting policy for leasing arrangement entered into by lessee." } } },"auth_ref": [" r518" ] }," us- gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"," crdr":" credit"," presentation": [" http: / / nutriband. com / role / CommitmentsandContigenciesDetails" ]," lang": {" en- us": {" role": {" terseLabel":" Lease rental"," label":" Lessee, Operating Lease, Liability, to be Paid, Year One"," documentation":" Amount of lessee' s undiscounted obligation for lease payment for operating

lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } },"auth_ref": [" r520" ] },"us- gaap_Liabilities": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" Liabilities"," crdr":" credit"," calculation": {" http: / / nutriband. com / role / ConsolidatedBalanceSheet": {" parentTag":" us- gaap_LiabilitiesAndStockholdersEquity"," weight": 1. 0," order": 1. 0 } },"presentation": [" http: / / nutriband. com / role / ConsolidatedBalanceSheet" ],"lang": {" en- us": {" role": {" totalLabel":" Total Liabilities"," label":" Liabilities"," documentation":" Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } },"auth_ref": [" r11"," r66"," r67"," r68"," r71"," r72"," r73"," r74"," r223"," r297"," r352"," r353"," r354"," r355"," r356"," r357"," r358"," r359"," r360"," r489"," r490"," r491"," r504"," r662"," r765"," r825"," r1009"," r1041"," r1042" ] },"us- gaap_LiabilitiesAndStockholdersEquity": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" LiabilitiesAndStockholdersEquity"," crdr":" credit"," calculation": {" http: / / nutriband. com / role / ConsolidatedBalanceSheet": {" parentTag": null," weight": null," order": null," root": true } },"presentation": [" http: / / nutriband. com / role / ConsolidatedBalanceSheet" ],"lang": {" en- us": {" role": {" totalLabel":" TOTAL LIABILITIES AND STOCKHOLDERS \u2019 EQUITY"," label":" Liabilities and Equity"," documentation":" Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } },"auth_ref": [" r83"," r137"," r590"," r799"," r976"," r993"," r1035" ] },"us- gaap_LiabilitiesCurrent": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" LiabilitiesCurrent"," crdr":" credit"," calculation": {" http: / / nutriband. com / role / ConsolidatedBalanceSheet": {" parentTag":" us- gaap_Liabilities"," weight": 1. 0," order": 1. 0 } },"presentation": [" http: / / nutriband. com / role / ConsolidatedBalanceSheet" ],"lang": {" en- us": {" role": {" totalLabel":" Total Current Liabilities"," label":" Liabilities, Current"," documentation":" Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } },"auth_ref": [" r68"," r188"," r223"," r297"," r352"," r353"," r354"," r355"," r356"," r357"," r358"," r359"," r360"," r489"," r490"," r491"," r504"," r799"," r1009"," r1041"," r1042" ] },"us- gaap_LiabilitiesCurrentAbstract": {" xbrltype":" stringItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" LiabilitiesCurrentAbstract"," presentation": [" http: / / nutriband. com / role / ConsolidatedBalanceSheet" ],"lang": {" en- us": {" role": {" terseLabel":" CURRENT LIABILITIES:"," label":" Liabilities, Current [ Abstract ]" } } },"auth_ref": [ ] },"us- gaap_LiabilitiesNoncurrentAbstract": {" xbrltype":" stringItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" LiabilitiesNoncurrentAbstract"," presentation": [" http: / / nutriband. com / role / ConsolidatedBalanceSheet" ],"lang": {" en- us": {" role": {" terseLabel":" LONG- TERM LIABILITIES:"," label":" Liabilities, Noncurrent [ Abstract ]" } } },"auth_ref": [ ] },"us- gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1"," crdr":" debit"," presentation": [" http: / / nutriband. com / role / CommitmentsandContigenciesDetails" ],"lang": {" en- us": {" role": {" terseLabel":" Incurred expenses"," label":" Liability for Unpaid Claims and Claims Adjustment Expense, Incurred Claims"," documentation":" Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred and costs incurred in the claim settlement process." } } },"auth_ref": [" r812"," r1054" ] },"us- gaap_LineOfCredit": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" LineOfCredit"," crdr":" credit"," presentation": [" http: / / nutriband. com / role / NotesPayableDetails" ],"lang": {" en- us": {" role": {" terseLabel":" Contract Price"," label":" Long- Term Line of Credit"," documentation":" The carrying value as of the balance sheet date of the current and noncurrent portions of long- term obligations drawn from a line of credit, which is a bank' s commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short- term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short- term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement." } } },"auth_ref": [" r11"," r1351"," r1051" ] },"ntrb_LineOfCreditFacility": {" xbrltype":" monetaryItemType"," nsuri":" http: / / nutriband. com / 20240131"," localname":" LineOfCreditFacility"," crdr":" debit"," presentation": [" http: / / nutriband. com / role / RelatedPartyTransactionsDetails" ],"lang": {" en- us": {" role": {" terseLabel":" Line of credit facility (in Dollars)"," documentation":" Line of credit facility."," label":" Line Of Credit Facility" } } },"auth_ref": [ ] },"us- gaap_LineOfCreditFacilityAverageOutstandingAmount": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" LineOfCreditFacilityAverageOutstandingAmount"," crdr":" credit"," presentation": [" http: / / nutriband. com / role / NotesPayableDetails" ],"lang": {" en- us": {" role": {" terseLabel":" Amount due"," label":" Line of Credit Facility, Average Outstanding Amount"," documentation":" Average amount borrowed under the credit facility during the period." } } },"auth_ref": [ ] },"us- gaap_LineOfCreditFacilityCapacityAvailableForTradePurchases": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" LineOfCreditFacilityCapacityAvailableForTradePurchases"," crdr":" credit"," presentation": [" http: / / nutriband. com / role / NotesPayableDetails" ],"lang": {" en- us": {" role": {" terseLabel":" Credit facility"," label":" Line of Credit Facility, Capacity Available for Trade Purchases"," documentation":" The maximum amount of borrowing capacity under a line of credit that is available as of the balance sheet date for financing purchases of goods acquired for inventory or imminent delivery to a customer." } } },"auth_ref": [ ] },"us- gaap_LineOfCreditFacilityCommitmentFeeAmount": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" LineOfCreditFacilityCommitmentFeeAmount"," crdr":" debit"," presentation": [" http: / / nutriband. com / role / StockholdersEquityDetails" ],"lang": {" en- us": {" role": {" terseLabel":" Credit facility (in Dollars)"," label":" Line of Credit Facility, Commitment Fee Amount"," documentation":" Amount of the fee for available but unused credit capacity under the credit facility." } } },"auth_ref": [" r65"," r70"," r351" ] },"ntrb_LineOfCreditFacilityCommonStock": {" xbrltype":" sharesItemType"," nsuri":" http: / / nutriband. com / 20240131"," localname":" LineOfCreditFacilityCommonStock"," presentation": [" http: / / nutriband. com / role / NotesPayableDetails" ],"lang": {" en- us": {" role": {" terseLabel":" Line of credit facility, common stock (in Shares)"," label":" Line Of Credit Facility Common Stock" } } },"auth_ref": [ ] },"ntrb_LineOfCreditFacilityConverted": {" xbrltype":" monetaryItemType"," nsuri":" http: / / nutriband. com / 20240131"," localname":" LineOfCreditFacilityConverted"," crdr":" credit"," presentation": [" http: / / nutriband. com / role / NotesPayableDetails" ],"lang": {" en- us": {" role": {" terseLabel":" Line of credit facility converted"," label":" Line Of Credit Facility Converted" } } },"auth_ref": [ ] },"us- gaap_LineOfCreditFacilityExpirationDate1": {" xbrltype":" dateItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" LineOfCreditFacilityExpirationDate1"," presentation": [" http: / / nutriband. com / role / NotesPayableDetails" ],"lang": {" en- us": {" role": {" terseLabel":" Due date"," label":" Line of Credit Facility, Expiration Date"," documentation":" Date the credit facility terminates, in YYYY- MM- DD format." } } },"auth_ref": [" r65"," r70" ] },"us- gaap_LineOfCreditFacilityIncreaseAccruedInterest": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" LineOfCreditFacilityIncreaseAccruedInterest"," crdr":" credit"," presentation": [" http: / / nutriband. com / role / NotesPayableDetails"," http: / / nutriband. com / role / RelatedPartyTransactionsDetails" ],"lang": {" en- us": {" role": {" terseLabel":" Line of credit facility"," verboseLabel":" Accrued interest (in Dollars)"," label":" Line of Credit Facility, Increase, Accrued Interest"," documentation":" Increase for accrued, but unpaid interest on the credit facility for the period." } } },"auth_ref": [" r975" ] },"us- gaap_LineOfCreditFacilityInterestRateDuringPeriod": {" xbrltype":" percentItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" LineOfCreditFacilityInterestRateDuringPeriod"," presentation": [" http: / / nutriband. com / role / NotesPayableDetails" ],"lang": {" en- us": {" role": {" terseLabel":" Interest rate during period"," label":" Line of Credit Facility, Interest Rate During Period"," documentation":" The effective interest rate during the reporting period." } } },"auth_ref": [" r65"," r70" ] },"us- gaap_LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod"," crdr":" credit"," presentation": [" http: / / nutriband. com / role / NotesPayableDetails" ],"lang": {" en- us": {" role": {" terseLabel":" Current outstanding"," label":" Line of Credit Facility, Maximum Amount Outstanding During Period"," documentation":" Maximum amount borrowed under the credit facility at any time during the period." } } },"auth_ref": [ ] },"us- gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" LineOfCreditFacilityMaximumBorrowingCapacity"," crdr":" credit"," presentation": [" http: / / nutriband. com / role / NotesPayableDetails" ],"lang": {" en- us": {" role": {" terseLabel":" Financed amount"," label":" Line of Credit Facility, Maximum Borrowing Capacity"," documentation":" Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility." } } },"auth_ref": [" r65"," r70" ] },"us- gaap_LineOfCreditFacilityPeriodicPayment": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" LineOfCreditFacilityPeriodicPayment"," crdr":" debit"," presentation": [" http: / / nutriband. com / role / NotesPayableDetails" ],"lang": {" en- us": {" role": {" terseLabel":" Payments made per month"," label":" Line of Credit Facility, Periodic Payment"," documentation":" Amount of the required periodic payments of both interest and principal." } } },"auth_ref": [" r65"," r70" ] },"us- gaap_LineOfCreditMember": {" xbrltype":" domainItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" LineOfCreditMember"," presentation":

[" http: / / nutriband. com / role / NotesPayableDetails" ]," lang": {" en- us": {" role": {" terseLabel":" Line of Credit [ Member ]"," label":" Line of Credit [ Member ]"," documentation":" A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short- term or long- term, depending upon the particulars." } } },"auth_ref": [ ] }," us- gaap_LinesOfCreditCurrent": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" LinesOfCreditCurrent"," crdr":" credit"," presentation": [" http: / / nutriband. com / role / SummaryofSignificantAccountingPoliciesDetails" ]," lang": {" en- us": {" role": {" terseLabel":" Credit line note"," label":" Line of Credit, Current"," documentation":" The carrying value as of the balance sheet date of the current portion of long- term obligations drawn from a line of credit, which is a bank' s commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short- term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short- term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement." } } },"auth_ref": [" r66"," r132" ] }," ntrb_LoanBearsInterestPercentage": {" xbrltype":" percentItemType"," nsuri":" http: / / nutriband. com / 20240131"," localname":" LoanBearsInterestPercentage"," presentation": [" http: / / nutriband. com / role / SummaryofSignificantAccountingPoliciesDetails" ]," lang": {" en- us": {" role": {" terseLabel":" Loan bears interest, percentage"," documentation":" Loan bears interest, percentage."," label":" Loan Bears Interest Percentage" } } },"auth_ref": [ ] }," dei_LocalPhoneNumber": {" xbrltype":" normalizedStringItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" LocalPhoneNumber"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover" ]," lang": {" en- us": {" role": {" label":" Local Phone Number"," documentation":" Local phone number for entity." } } },"auth_ref": [ ] }," us- gaap_LongTermDebtPercentageBearingFixedInterestRate": {" xbrltype":" percentItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" LongTermDebtPercentageBearingFixedInterestRate"," presentation": [" http: / / nutriband. com / role / NotesPayableDetails" ]," lang": {" en- us": {" role": {" terseLabel":" Bearing interest"," label":" Long- Term Debt, Percentage Bearing Fixed Interest, Percentage Rate"," documentation":" The interest rate applicable to the portion of the carrying amount of long- term borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a set, unchanging rate." } } },"auth_ref": [" r69" ] }," us- gaap_LongTermDebtPercentageBearingVariableInterestRate": {" xbrltype":" percentItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" LongTermDebtPercentageBearingVariableInterestRate"," presentation": [" http: / / nutriband. com / role / NotesPayableDetails" ]," lang": {" en- us": {" role": {" terseLabel":" Percentage of interest rate"," label":" Long- Term Debt, Percentage Bearing Variable Interest, Percentage Rate"," documentation":" The interest rate applicable to the portion of the carrying amount of long- term borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a rate subject to change from time to time." } } },"auth_ref": [" r69" ] }," us- gaap_LongTermNotesPayable": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" LongTermNotesPayable"," crdr":" credit"," calculation": {" http: / / nutriband. com / role / ConsolidatedBalanceSheet": {" parentTag":" us- gaap_Liabilities"," weight": 1. 0," order": 2. 0 } }," presentation": [" http: / / nutriband. com / role / ConsolidatedBalanceSheet" ]," lang": {" en- us": {" role": {" terseLabel":" Note payable- net of current portion"," label":" Notes Payable, Noncurrent"," documentation":" Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion." } } },"auth_ref": [" r11" ] }," ntrb_LossOnExtinguishment": {" xbrltype":" monetaryItemType"," nsuri":" http: / / nutriband. com / 20240131"," localname":" LossOnExtinguishment"," crdr":" debit"," presentation": [" http: / / nutriband. com / role / StockholdersEquityDetails" ]," lang": {" en- us": {" role": {" terseLabel":" Loss on extinguishment (in Dollars)"," documentation":" Loss on extinguishment."," label":" Loss On Extinguishment" } } }," auth_ref": [ ] }," ntrb_MDMWorldwideMember": {" xbrltype":" domainItemType"," nsuri":" http: / / nutriband. com / 20240131"," localname":" MDMWorldwideMember"," presentation": [" http: / / nutriband. com / role / CommitmentsandContigenciesDetails" ]," lang": {" en- us": {" role": {" terseLabel":" MDM Worldwide [ Member ]"," label":" MDMWorldwide Member" } } }," auth_ref": [ ] }," us- gaap_MachineryAndEquipmentMember": {" xbrltype":" domainItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" MachineryAndEquipmentMember"," presentation": [" http: / / nutriband. com / role / ScheduleofPlantandEquipmentonaStraightLineBasisOvertheEstimatedUsefulLifeoftheAssetsTable"," http: / / nutriband. com / role / ScheduleofPropertyandEquipmentTable" ]," lang": {" en- us": {" role": {" terseLabel":" Machinery and equipment [ Member ]"," label":" Machinery and Equipment [ Member ]"," documentation":" Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment." } } },"auth_ref": [ ] }," srt_MajorCustomersAxis": {" xbrltype":" stringItemType"," nsuri":" http: / / fasb. org / srt / 2024"," localname":" MajorCustomersAxis"," presentation": [" http: / / nutriband. com / role / CommitmentsandContigenciesDetails" ]," lang": {" en- us": {" role": {" label":" Customer [ Axis ]"," documentation":" Information by name or description of a single external customer or a group of external customers." } } },"auth_ref": [" r291"," r786"," r810"," r815"," r1013"," r1053"," r1055"," r1056"," r1058"," r1059"," r1060"," r1061"," r1062"," r1063"," r1064"," r1065"," r1066"," r1067"," r1068"," r1069"," r1070"," r1071"," r1072"," r1073"," r1074"," r1075"," r1076"," r1077"," r1078"," r1079"," r1080"," r1082"," r1083" ] }," srt_MaximumMember": {" xbrltype":" domainItemType"," nsuri":" http: / / fasb. org / srt / 2024"," localname":" MaximumMember"," presentation": [" http: / / nutriband. com / role / IncomeTaxesDetails"," http: / / nutriband. com / role / IntangibleAssetsDetails"," http: / / nutriband. com / role / OptionsandWarrantsDetails"," http: / / nutriband. com / role / OrganizationandDescriptionofBusinessDetails"," http: / / nutriband. com / role / RelatedPartyTransactionsDetails"," http: / / nutriband. com / role / ScheduleofPlantandEquipmentonaStraightLineBasisOvertheEstimatedUsefulLifeoftheAssetsTable"," http: / / nutriband. com / role / StockholdersEquityDetails"," http: / / nutriband. com / role / SubsequentEventsDetails"," http: / / nutriband. com / role / SummaryofSignificantAccountingPoliciesDetails" ]," lang": {" en- us": {" role": {" terseLabel":" Maximum [ Member ]"," label":" Maximum [ Member ]"," documentation":" Upper limit of the provided range." } } },"auth_ref": [" r162"," r164"," r166"," r167"," r169"," r182"," r183"," r346"," r347"," r348"," r349"," r416"," r454"," r502"," r536"," r611"," r612"," r619"," r654"," r655"," r715"," r718"," r720"," r721"," r728"," r749"," r750"," r776"," r784"," r789"," r793"," r794"," r795"," r796"," r811"," r1011"," r1043"," r1044"," r1045"," r1046"," r1047"," r1048" ] }," ecd_MeasureAxis": {" xbrltype":" stringItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" MeasureAxis"," presentation": [" http: / / xbrl. sec. gov / ecd / role / PvpDisclosure" ]," lang": {" en- us": {" role": {" label":" Measure [ Axis ]"," terseLabel":" Measure:" } } },"auth_ref": [" r895" ] }," ecd_MeasureName": {" xbrltype":" normalizedStringItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" MeasureName"," presentation": [" http: / / xbrl. sec. gov / ecd / role / PvpDisclosure" ]," lang": {" en- us": {" role": {" label":" Measure Name"," terseLabel":" Name" } } },"auth_ref": [" r895" ] }," srt_MinimumMember": {" xbrltype":" domainItemType"," nsuri":" http: / / fasb. org / srt / 2024"," localname":" MinimumMember"," presentation": [" http: / / nutriband. com / role / IncomeTaxesDetails"," http: / / nutriband. com / role / IntangibleAssetsDetails"," http: / / nutriband. com / role / OptionsandWarrantsDetails"," http: / / nutriband. com / role / OrganizationandDescriptionofBusinessDetails"," http: / / nutriband. com / role / RelatedPartyTransactionsDetails"," http: / / nutriband. com / role / ScheduleofPlantandEquipmentonaStraightLineBasisOvertheEstimatedUsefulLifeoftheAssetsTable"," http: / / nutriband. com / role / StockholdersEquityDetails"," http: / / nutriband. com / role / SubsequentEventsDetails"," http: / / nutriband. com / role / SummaryofSignificantAccountingPoliciesDetails" ]," lang": {" en- us": {" role": {" terseLabel":" Minimum [ Member ]"," label":" Minimum [ Member ]"," documentation":" Lower limit of the provided range." } } },"auth_ref": [" r162"," r164"," r166"," r167"," r169"," r182"," r183"," r346"," r347"," r348"," r349"," r416"," r454"," r502"," r536"," r611"," r612"," r619"," r654"," r655"," r715"," r718"," r720"," r721"," r728"," r749"," r750"," r776"," r784"," r789"," r793"," r794"," r795"," r811"," r1011"," r1043"," r1044"," r1045"," r1046"," r1047"," r1048" ] }," ecd_MnpiDiscTimedForCompValFlag": {" xbrltype":" booleanItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" MnpiDiscTimedForCompValFlag"," presentation": [" http: / / xbrl. sec. gov / ecd / role / AwardTimingDisclosure" ]," lang": {" en- us": {" role": {" label":" MNPI Disclosure Timed for Compensation Value [ Flag ]"," terseLabel":" MNPI Disclosure Timed for Compensation Value" } } },"auth_ref": [" r915" ] }," ntrb_MoneyChannelMember": {" xbrltype":" domainItemType"," nsuri":" http: / / nutriband. com / 20240131"," localname":" MoneyChannelMember"," presentation": [" http: / / nutriband. com / role / CommitmentsandContigenciesDetails" ]," lang": {" en- us": {" role": {" terseLabel":" Money Channel [ Member ]"," label":" Money Channel Member" } } },"auth_ref": [ ] }," ntrb_MrGoodmanMember": {" xbrltype":" domainItemType"," nsuri":" http: / / nutriband. com / 20240131"," localname":" MrGoodmanMember"," presentation": [" http: / / nutriband. com / role / CommitmentsandContigenciesDetails" ]," lang": {" en- us": {" role": {" terseLabel":" Mr. Goodman [ Member ]"," label":" Mr Goodman Member" } } },"auth_ref": [ ] }," ecd_MtrlTermsOfTrdArrTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" MtrlTermsOfTrdArrTextBlock"," presentation": [" http: / / xbrl. sec. gov / ecd / role / InsiderTradingArrangements" ]," lang": {" en- us": {" role": {" label":" Material Terms of Trading Arrangement [ Text Block ]"," terseLabel":" Material Terms of Trading Arrangement" } } },"auth_ref": [" r923" ] }," dei_NameChangeEventDateAxis": {" xbrltype":" stringItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" NameChangeEventDateAxis"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover" ]," lang": {" en- us": {" role": {"

label":" Name Change Event Date [ Axis ]"," documentation":" For a sequence of name change event related facts, use this typed dimension to distinguish them. The axis members are restricted to be a valid for xml schema' date' or' datetime' data type." } } },"auth_ref": [ ] }," dei_NameChangeEventLineItems": {" xbrltype":" stringItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" NameChangeEventLineItems"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover" ]," lang": {" en- us": {" role": {" label":" Name Change Event [ Line Items ]"," documentation":" Line items represent concepts included in a table. Name change event line item concepts are used for information qualified by domain members of axes in the Name Change Event table." } } },"auth_ref": [ ] }," dei_NameChangeEventTable": {" xbrltype":" stringItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" NameChangeEventTable"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover" ]," lang": {" en- us": {" role": {" label":" Name Change Event [ Table ]"," documentation":" For a set of related facts in a sequence of name change events, use this table when the events occurred within a single reporting period." } } },"auth_ref": [ ] }," srt_NameOfMajorCustomerDomain": {" xbrltype":" domainItemType"," nsuri":" http: / / fasb. org / srt / 2024"," localname":" NameOfMajorCustomerDomain"," presentation": [" http: / / nutriband. com / role / CommitmentsandContigenciesDetails" ]," lang": {" en- us": {" role": {" label":" Customer [ Domain ]"," documentation":" Single external customer or group of external customers." } } },"auth_ref": [" r291"," r786"," r810"," r815"," r1013"," r1053"," r1055"," r1056"," r1058"," r1059"," r1060"," r1061"," r1062"," r1063"," r1064"," r1065"," r1066"," r1067"," r1068"," r1069"," r1070"," r1071"," r1072"," r1073"," r1074"," r1075"," r1076"," r1077"," r1078"," r1079"," r1080"," r1082"," r1083" ] }," ecd_NamedExecutiveOfficersFnTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" NamedExecutiveOfficersFnTextBlock"," presentation": [" http: / / xbrl. sec. gov / ecd / role / PvpDisclosure" ]," lang": {" en- us": {" role": {" label":" Named Executive Officers, Footnote [ Text Block ]"," terseLabel":" Named Executive Officers, Footnote" } } },"auth_ref": [" r896" ] }," us- gaap_NetCashProvidedByUsedInFinancingActivities": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" NetCashProvidedByUsedInFinancingActivities"," crdr":" debit"," calculation": {" http: / / nutriband. com / role / ConsolidatedCashFlow": {" parentTag":" us- gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"," weight": 1. 0," order": 3. 0 } },"presentation": [" http: / / nutriband. com / role / ConsolidatedCashFlow" ]," lang": {" en- us": {" role": {" totalLabel":" Net Cash Provided by Financing Activities","label":" Net Cash Provided by (Used in) Financing Activities"," documentation":" Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long- term credit." } } },"auth_ref": [" r216" ] }," us- gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {" xbrltype":" stringItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" NetCashProvidedByUsedInFinancingActivitiesAbstract"," presentation": [" http: / / nutriband. com / role / ConsolidatedCashFlow" ]," lang": {" en- us": {" role": {" terseLabel":" Cash flows from financing activities:"," label":" Net Cash Provided by (Used in) Financing Activities [ Abstract ]" } } },"auth_ref": [ ] }," us- gaap_NetCashProvidedByUsedInInvestingActivities": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" NetCashProvidedByUsedInInvestingActivities"," crdr":" debit"," calculation": {" http: / / nutriband. com / role / ConsolidatedCashFlow": {" parentTag":" us- gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"," weight": 1. 0," order": 2. 0 } },"presentation": [" http: / / nutriband. com / role / ConsolidatedCashFlow" ]," lang": {" en- us": {" role": {" totalLabel":" Net Cash Used in Investing Activities","label":" Net Cash Provided by (Used in) Investing Activities"," documentation":" Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } },"auth_ref": [" r216" ] }," us- gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {" xbrltype":" stringItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" NetCashProvidedByUsedInInvestingActivitiesAbstract"," presentation": [" http: / / nutriband. com / role / ConsolidatedCashFlow" ]," lang": {" en- us": {" role": {" terseLabel":" Cash flows from investing activities:"," label":" Net Cash Provided by (Used in) Investing Activities [ Abstract ]" } } },"auth_ref": [ ] }," us- gaap_NetCashProvidedByUsedInOperatingActivities": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" NetCashProvidedByUsedInOperatingActivities"," calculation": {" http: / / nutriband. com / role / ConsolidatedCashFlow": {" parentTag":" us- gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"," weight": 1. 0," order": 1. 0 } },"presentation": [" http: / / nutriband. com / role / ConsolidatedCashFlow"," http: / / nutriband. com / role / SummaryofSignificantAccountingPoliciesDetails" ]," lang": {" en- us": {" role": {" totalLabel":" Net Cash Used In Operating Activities"," terseLabel":" Used cash flow from operations"," label":" Net Cash Provided by (Used in) Operating Activities"," documentation":" Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } },"auth_ref": [" r100"," r101"," r104" ] }," us- gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {" xbrltype":" stringItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" NetCashProvidedByUsedInOperatingActivitiesAbstract"," presentation": [" http: / / nutriband. com / role / ConsolidatedCashFlow" ]," lang": {" en- us": {" role": {" terseLabel":" Cash flows from operating activities:"," label":" Net Cash Provided by (Used in) Operating Activities [ Abstract ]" } } },"auth_ref": [ ] }," us- gaap_NetIncomeLoss": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" NetIncomeLoss"," crdr":" credit","calculation": {" http: / / nutriband. com / role / ConsolidatedCashFlow": {" parentTag":" us- gaap_NetCashProvidedByUsedInOperatingActivities"," weight": 1. 0," order": 1. 0 }," http: / / nutriband. com / role / ConsolidatedIncomeStatement": {" parentTag": null," weight": null," order": null," root": true } },"presentation": [" http: / / nutriband. com / role / ConsolidatedCashFlow"," http: / / nutriband. com / role / ConsolidatedIncomeStatement"," http: / / nutriband. com / role / ShareholdersEquityType2or3"," http: / / xbrl. sec. gov / ecd / role / PvpDisclosure" ]," lang": {" en- us": {" role": {" totalLabel":" Net loss"," verboseLabel":" Net loss"," label":" Net Income (Loss)","terseLabel":" Net Income (Loss)"," documentation":" The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } },"auth_ref": [" r91"," r104"," r140"," r186"," r206"," r207"," r211"," r223"," r231"," r233"," r234"," r235"," r236"," r237"," r240"," r241"," r247"," r297"," r352"," r353"," r354"," r355"," r356"," r357"," r358"," r359"," r360"," r483"," r487"," r501"," r504"," r595"," r686"," r705"," r706"," r824"," r1009" ] }," us- gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" NewAccountingPronouncementsPolicyPolicyTextBlock"," presentation": [" http: / / nutriband. com / role / AccountingPoliciesByPolicy" ]," lang": {" en- us": {" role": {" terseLabel":" Recent Accounting Standards","label":" New Accounting Pronouncements, Policy [ Policy Text Block ]"," documentation":" Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity' s financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } },"auth_ref": [ ] }," dei_NewEffectiveDateForPreviousFiling": {" xbrltype":" booleanItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" NewEffectiveDateForPreviousFiling"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover" ]," lang": {" en- us": {" role": {" label":" New Effective Date for Previous Filing" } } },"auth_ref": [" r866"," r867"," r868"," r869" ] }," dei_NoSubstantiveChanges462ce": {" xbrltype":" booleanItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" NoSubstantiveChanges462ce"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover" ]," lang": {" en- us": {" role": {" label":" No Substantive Changes, 462 (e)" } } },"auth_ref": [" r940" ] }," dei_NoSubstantiveChanges462ceFileNumber": {" xbrltype":" fileNumberItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" NoSubstantiveChanges462ceFileNumber"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover" ]," lang": {" en- us": {" role": {" label":" No Substantive Changes, 462 (e), File Number" } } },"auth_ref": [" r940" ] }," dei_NoTradingSymbolFlag": {" xbrltype":" trueItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" NoTradingSymbolFlag"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover" ]," lang": {" en- us": {" role": {" label":" No Trading Symbol Flag"," documentation":" Boolean flag that is true only for a security having no trading symbol." } } },"auth_ref": [ ] }," ecd_NonGaapMeasureDescriptionTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" NonGaapMeasureDescriptionTextBlock"," presentation": [" http: / / xbrl. sec. gov / ecd / role / PvpDisclosure" ]," lang": {" en- us": {" role": {" label":" Non- GAAP Measure Description [ Text Block ]"," terseLabel":" Non- GAAP Measure Description" } } },"auth_ref": [" r895" ] }," ecd_NonNeosMember": {" xbrltype":" domainItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" NonNeosMember"," presentation": [" http: / / xbrl. sec. gov / ecd / role / ErrCompDisclosure" ]," lang": {" en- us": {" role": {" label":" Non- NEOs [ Member ]"," terseLabel":" Non- NEOs" } } },"auth_ref": [" r850"," r861"," r877"," r903"," r912" ] }," ecd_NonPeoNeoAvgCompActuallyPaidAmt": {" xbrltype":" monetaryItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" NonPeoNeoAvgCompActuallyPaidAmt"," presentation": [" http: / / xbrl. sec. gov / ecd / role / PvpDisclosure" ]," lang": {" en- us": {" role": {" label":" Non- PEO NEO Average Compensation Actually Paid Amount"," terseLabel":" Non- PEO NEO Average Compensation Actually Paid Amount" } } },"auth_ref": [" r886" ] }," ecd_NonPeoNeoAvgTotalCompAmt": {" xbrltype":" monetaryItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" NonPeoNeoAvgTotalCompAmt"," presentation": [" http: / / xbrl. sec. gov / ecd / role / PvpDisclosure" ]," lang": {" en- us": {" role": {" label":" Non- PEO NEO Average Total Compensation Amount"," terseLabel":" Non- PEO NEO Average Total Compensation Amount" } } },"auth_ref": [" r885" ] }," ecd_NonPeoNeoMember": {" xbrltype":" domainItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" NonPeoNeoMember"," presentation": ["

http://xbrl.sec.gov/ecd/role/PvpDisclosure" ]," lang": {" en-us": {" role": {" label":" Non-PEO NEO [ Member ]"," terseLabel":" Non-PEO NEO" } } }," auth_ref": [" r903" ] }," ecd_NonRule10b51ArrAdoptedFlag": {" xbrltype":" booleanItemType"," nsuri":" http://xbrl.sec.gov/ecd/2024"," localname":" NonRule10b51ArrAdoptedFlag"," presentation": [" http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ]," lang": {" en-us": {" role": {" label":" Non-Rule 10b5-1 Arrangement Adopted [ Flag ]"," terseLabel":" Non-Rule 10b5-1 Arrangement Adopted" } } }," auth_ref": [" r923" ] }," ecd_NonRule10b51ArrTrmntdFlag": {" xbrltype":" booleanItemType"," nsuri":" http://xbrl.sec.gov/ecd/2024"," localname":" NonRule10b51ArrTrmntdFlag"," presentation": [" http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ]," lang": {" en-us": {" role": {" label":" Non-Rule 10b5-1 Arrangement Terminated [ Flag ]"," terseLabel":" Non-Rule 10b5-1 Arrangement Terminated" } } }," auth_ref": [" r923" ] }," us-gaap_NonUsMember": {" xbrltype":" domainItemType"," nsuri":" http://fasb.org/us-gaap/2024"," localname":" NonUsMember"," presentation": [" http://nutriband.com/role/ScheduleofRevenuebyGeographicLocationTable" ]," lang": {" en-us": {" role": {" terseLabel":" Foreign [ Member ]"," label":" Non-US [ Member ]"," documentation":" Countries excluding the United States of America (US)." } } }," auth_ref": [" r1089"," r1090"," r1091"," r1092" ] }," us-gaap_NoncashInvestingAndFinancingItemsAbstract": {" xbrltype":" stringItemType"," nsuri":" http://fasb.org/us-gaap/2024"," localname":" NoncashInvestingAndFinancingItemsAbstract"," presentation": [" http://nutriband.com/role/ConsolidatedCashFlow" ]," lang": {" en-us": {" role": {" terseLabel":" Supplemental disclosure of non-cash investing and financing activities:"," label":" Noncash Investing and Financing Items [ Abstract ]" } } }," auth_ref": [ ] }," us-gaap_NotesAndLoansPayable": {" xbrltype":" monetaryItemType"," nsuri":" http://fasb.org/us-gaap/2024"," localname":" NotesAndLoansPayable"," crdr":" credit"," presentation": [" http://nutriband.com/role/NotesPayableDetails" ]," lang": {" en-us": {" role": {" terseLabel":" Secured loan payable"," label":" Notes and Loans Payable"," documentation":" Including the current and noncurrent portions, carrying value as of the balance sheet date of all notes and loans payable (with maturities initially due after one year or beyond the operating cycle if longer)." } } }," auth_ref": [" r11"," r135"," r1051" ] }," us-gaap_NotesIssued1": {" xbrltype":" monetaryItemType"," nsuri":" http://fasb.org/us-gaap/2024"," localname":" NotesIssued1"," crdr":" credit"," presentation": [" http://nutriband.com/role/CommitmentsandContigenciesDetails" ]," lang": {" en-us": {" role": {" terseLabel":" Agreed issued"," label":" Notes Issued"," documentation":" The fair value of notes issued in noncash investing and financing activities." } } }," auth_ref": [" r18"," r19"," r20" ] }," us-gaap_NotesPayableAbstract": {" xbrltype":" stringItemType"," nsuri":" http://fasb.org/us-gaap/2024"," localname":" NotesPayableAbstract"," lang": {" en-us": {" role": {" label":" Notes Payable [ Abstract ]" } } }," auth_ref": [ ] }," us-gaap_NotesPayableCurrent": {" xbrltype":" monetaryItemType"," nsuri":" http://fasb.org/us-gaap/2024"," localname":" NotesPayableCurrent"," crdr":" credit"," calculation": {" http://nutriband.com/role/ConsolidatedBalanceSheet": {" parentTag":" us-gaap_LiabilitiesCurrent"," weight": 1.0," order": 4.0 } }," presentation": [" http://nutriband.com/role/ConsolidatedBalanceSheet" ]," lang": {" en-us": {" role": {" terseLabel":" Notes payable-current portion"," label":" Notes Payable, Current"," documentation":" Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer." } } }," auth_ref": [" r66"," r67" ] }," ntrb_NotesPayableDetailsLineItems": {" xbrltype":" stringItemType"," nsuri":" http://nutriband.com/20240131"," localname":" NotesPayableDetailsLineItems"," presentation": [" http://nutriband.com/role/NotesPayableDetails" ]," lang": {" en-us": {" role": {" label":" Notes Payable [ Line Items ]" } } }," auth_ref": [ ] }," ntrb_NotesPayableDetailsTable": {" xbrltype":" stringItemType"," nsuri":" http://nutriband.com/20240131"," localname":" NotesPayableDetailsTable"," presentation": [" http://nutriband.com/role/NotesPayableDetails" ]," lang": {" en-us": {" role": {" label":" Notes Payable (Details) [ Table ]" } } }," auth_ref": [ ] }," us-gaap_NotesPayableToBanksMember": {" xbrltype":" domainItemType"," nsuri":" http://fasb.org/us-gaap/2024"," localname":" NotesPayableToBanksMember"," presentation": [" http://nutriband.com/role/NotesPayableDetails" ]," lang": {" en-us": {" role": {" terseLabel":" Notes Payable to Banks [ Member ]"," label":" Notes Payable to Banks [ Member ]"," documentation":" A written promise to pay a note to a bank." } } }," auth_ref": [ ] }," ntrb_NumberOfShares": {" xbrltype":" sharesItemType"," nsuri":" http://nutriband.com/20240131"," localname":" NumberOfShares"," presentation": [" http://nutriband.com/role/SubsequentEventsDetails" ]," lang": {" en-us": {" role": {" terseLabel":" Number of shares"," documentation":" Shares of number of shares issued."," label":" Number Of Shares" } } }," auth_ref": [ ] }," us-gaap_OperatingIncomeLoss": {" xbrltype":" monetaryItemType"," nsuri":" http://fasb.org/us-gaap/2024"," localname":" OperatingIncomeLoss"," crdr":" credit"," calculation": {" http://nutriband.com/role/ConsolidatedIncomeStatement": {" parentTag":" us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"," weight": 1.0," order": 1.0 } }," presentation": [" http://nutriband.com/role/ConsolidatedIncomeStatement"," http://nutriband.com/role/SummaryofSignificantAccountingPoliciesDetails" ]," lang": {" en-us": {" role": {" totalLabel":" Loss from operations"," label":" Operating Income (Loss)"," documentation":" The net result for the period of deducting operating expenses from operating revenues." } } }," auth_ref": [" r144"," r766"," r984"," r986"," r987"," r988"," r989" ] }," us-gaap_OperatingLeaseExpense": {" xbrltype":" monetaryItemType"," nsuri":" http://fasb.org/us-gaap/2024"," localname":" OperatingLeaseExpense"," crdr":" debit"," calculation": {" http://nutriband.com/role/ConsolidatedCashFlow": {" parentTag":" us-gaap_NetCashProvidedByUsedInOperatingActivities"," weight": 1.0," order": 3.0 } }," presentation": [" http://nutriband.com/role/ConsolidatedCashFlow" ]," lang": {" en-us": {" role": {" terseLabel":" Operating lease expense"," label":" Operating Lease, Expense"," documentation":" Amount of operating lease expense. Excludes sublease income." } } }," auth_ref": [" r1038" ] }," us-gaap_OperatingLeaseLiabilityCurrent": {" xbrltype":" monetaryItemType"," nsuri":" http://fasb.org/us-gaap/2024"," localname":" OperatingLeaseLiabilityCurrent"," crdr":" credit"," calculation": {" http://nutriband.com/role/ConsolidatedBalanceSheet": {" parentTag":" us-gaap_LiabilitiesCurrent"," weight": 1.0," order": 3.0 } }," presentation": [" http://nutriband.com/role/ConsolidatedBalanceSheet" ]," lang": {" en-us": {" role": {" terseLabel":" Operating lease liability-current portion"," label":" Operating Lease, Liability, Current"," documentation":" Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }," auth_ref": [" r517" ] }," us-gaap_OperatingLeaseLiabilityNoncurrent": {" xbrltype":" monetaryItemType"," nsuri":" http://fasb.org/us-gaap/2024"," localname":" OperatingLeaseLiabilityNoncurrent"," crdr":" credit"," calculation": {" http://nutriband.com/role/ConsolidatedBalanceSheet": {" parentTag":" us-gaap_Liabilities"," weight": 1.0," order": 4.0 } }," presentation": [" http://nutriband.com/role/ConsolidatedBalanceSheet" ]," lang": {" en-us": {" role": {" terseLabel":" Operating lease liability-net of current portion"," label":" Operating Lease, Liability, Noncurrent"," documentation":" Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }," auth_ref": [" r517" ] }," us-gaap_OperatingLeaseRightOfUseAsset": {" xbrltype":" monetaryItemType"," nsuri":" http://fasb.org/us-gaap/2024"," localname":" OperatingLeaseRightOfUseAsset"," crdr":" debit"," calculation": {" http://nutriband.com/role/ConsolidatedBalanceSheet": {" parentTag":" us-gaap_Assets"," weight": 1.0," order": 4.0 } }," presentation": [" http://nutriband.com/role/ConsolidatedBalanceSheet" ]," lang": {" en-us": {" role": {" terseLabel":" Operating lease right of use asset"," label":" Operating Lease, Right-of-Use Asset"," documentation":" Amount of lessee's right to use underlying asset under operating lease." } } }," auth_ref": [" r516" ] }," us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {" xbrltype":" monetaryItemType"," nsuri":" http://fasb.org/us-gaap/2024"," localname":" OperatingLeaseRightOfUseAssetAmortizationExpense"," crdr":" debit"," presentation": [" http://nutriband.com/role/CommitmentsandContigenciesDetails" ]," lang": {" en-us": {" role": {" terseLabel":" Right of use assets"," label":" Operating Lease, Right-of-Use Asset, Periodic Reduction"," documentation":" Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease." } } }," auth_ref": [" r972" ] }," us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {" xbrltype":" durationItemType"," nsuri":" http://fasb.org/us-gaap/2024"," localname":" OperatingLeaseWeightedAverageRemainingLeaseTerm1"," presentation": [" http://nutriband.com/role/CommitmentsandContigenciesDetails" ]," lang": {" en-us": {" role": {" terseLabel":" Lease can be extended for an additional"," label":" Operating Lease, Weighted Average Remaining Lease Term"," documentation":" Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example,'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }," auth_ref": [" r519"," r798" ] }," us-gaap_OptionIndexedToIssuersEquityShares": {" xbrltype":" sharesItemType"," nsuri":" http://fasb.org/us-gaap/2024"," localname":" OptionIndexedToIssuersEquityShares"," presentation": [" http://nutriband.com/role/StockholdersEquityDetails" ]," lang": {" en-us": {" role": {" terseLabel":" Shares issued"," label":" Option Indexed to Issuer's Equity, Shares"," documentation":" Maximum number of shares that could be issued to settle option contract indexed to equity." } } }," auth_ref": [" r127"," r128" ] }," ntrb_OptionsAndWarrantsAbstract": {" xbrltype":" stringItemType"," nsuri":" http://nutriband.com/20240131"," localname":" OptionsAndWarrantsAbstract"," lang": {" en-us": {" role": {" label":" Options and Warrants [ Abstract ]" } } }," auth_ref": [ ] }," ntrb_OptionsAndWarrantsTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http://nutriband.com/20240131"," localname":" OptionsAndWarrantsTextBlock"," presentation": [" http://nutriband.com/role/OptionsandWarrants" ]," lang": {" en-us": {" role": {" terseLabel":" OPTIONS and WARRANTS"," documentation":" The entire disclosure of options and warrants."," label":" Options And Warrants Text Block" } } }," auth_ref": [ ] }," ntrb_OptionsVestExpireYear": {" xbrltype":" durationItemType"," nsuri":" http://nutriband.com/20240131"," localname":" OptionsVestExpireYear"," presentation": [" http://nutriband.com/role/OptionsandWarrantsDetails" ]," lang": {" en-us": {" role": {" terseLabel":" Expire years"," documentation":" Options Vest Expire Year."," label":" Options Vest Expire Year" } } }," auth_ref": [ ] }," ntrb_OptionsandWarrantsDetailsLineItems": {" xbrltype":" stringItemType"," nsuri":" http://nutriband.com/20240131"," localname":" OptionsandWarrantsDetailsLineItems"," presentation": [" http://nutriband.com/

role / OptionsandWarrantsDetails" ]," lang": {" en- us": {" role": {" terseLabel":" Options and Warrants [ Line Items ]"," label":" Optionsand Warrants Details Line Items" } } },"auth_ref": [ ] }," ntrb_OptionsandWarrantsDetailsScheduleofChangesinOptionsOutstandingLineItems": {" xbrltype":" stringItemType"," nsuri":" http: / / nutriband. com / 20240131"," localname":" OptionsandWarrantsDetailsScheduleofChangesinOptionsOutstandingLineItems"," presentation": [" http: / / nutriband. com / role / ScheduleofChangesinOptionsOutstandingTable" ]," lang": {" en- us": {" role": {" label":" Options and Warrants (Details)- Schedule of Changes in Options Outstanding [ Line Items ]" } } },"auth_ref": [ ] }," ntrb_OptionsandWarrantsDetailsScheduleofChangesinOptionsOutstandingTable": {" xbrltype":" stringItemType"," nsuri":" http: / / nutriband. com / 20240131"," localname":" OptionsandWarrantsDetailsScheduleofChangesinOptionsOutstandingTable"," presentation": [" http: / / nutriband. com / role / ScheduleofChangesinOptionsOutstandingTable" ]," lang": {" en- us": {" role": {" label":" Options and Warrants (Details)- Schedule of Changes in Options Outstanding [ Table ]" } } },"auth_ref": [ ] }," ntrb_OptionsandWarrantsDetailsScheduleofSummarizesAdditionalInformationRelatingtotheOptionsOutstandingLineItems": {" xbrltype":" stringItemType"," nsuri":" http: / / nutriband. com / 20240131"," localname":" OptionsandWarrantsDetailsScheduleofSummarizesAdditionalInformationRelatingtotheOptionsOutstandingLineItems"," presentation": [" http: / / nutriband. com / role / ScheduleofSummarizesAdditionalInformationRelatingtotheOptionsOutstandingTable" ]," lang": {" en- us": {" role": {" label":" Schedule of Summarizes Additional Information Relating to the Options Outstanding [ Line Items ]" } } },"auth_ref": [ ] }," ntrb_OptionsandWarrantsDetailsScheduleofSummarizesAdditionalInformationRelatingtotheOptionsOutstandingTable": {" xbrltype":" stringItemType"," nsuri":" http: / / nutriband. com / 20240131"," localname":" OptionsandWarrantsDetailsScheduleofSummarizesAdditionalInformationRelatingtotheOptionsOutstandingTable"," presentation": [" http: / / nutriband. com / role / ScheduleofSummarizesAdditionalInformationRelatingtotheOptionsOutstandingTable" ]," lang": {" en- us": {" role": {" label":" Options and Warrants (Details)- Schedule of Summarizes Additional Information Relating to the Options Outstanding [ Table ]" } } },"auth_ref": [ ] }," ntrb_OptionsandWarrantsDetailsScheduleofSummarizesAdditionalInformationRelatingtotheWarrantsOutstandingLineItems": {" xbrltype":" stringItemType"," nsuri":" http: / / nutriband. com / 20240131"," localname":" OptionsandWarrantsDetailsScheduleofSummarizesAdditionalInformationRelatingtotheWarrantsOutstandingLineItems"," presentation": [" http: / / nutriband. com / role / ScheduleofSummarizesAdditionalInformationRelatingtotheWarrantsOutstandingTable" ]," lang": {" en- us": {" role": {" label":" Schedule of Summarizes Additional Information Relating to the Warrants Outstanding [ Line Items ]" } } },"auth_ref": [ ] }," ntrb_OptionsandWarrantsDetailsScheduleofSummarizesAdditionalInformationRelatingtotheWarrantsOutstandingTable": {" xbrltype":" stringItemType"," nsuri":" http: / / nutriband. com / 20240131"," localname":" OptionsandWarrantsDetailsScheduleofSummarizesAdditionalInformationRelatingtotheWarrantsOutstandingTable"," presentation": [" http: / / nutriband. com / role / ScheduleofSummarizesAdditionalInformationRelatingtotheWarrantsOutstandingTable" ]," lang": {" en- us": {" role": {" label":" Options and Warrants (Details)- Schedule of Summarizes Additional Information Relating to the Warrants Outstanding [ Table ]" } } },"auth_ref": [ ] }," ntrb_OptionsandWarrantsDetailsTable": {" xbrltype":" stringItemType"," nsuri":" http: / / nutriband. com / 20240131"," localname":" OptionsandWarrantsDetailsTable"," presentation": [" http: / / nutriband. com / role / OptionsandWarrantsDetails" ]," lang": {" en- us": {" role": {" label":" Options and Warrants (Details) [ Table ]" } } },"auth_ref": [ ] }," ntrb_OptionsandWarrantsTablesLineItems": {" xbrltype":" stringItemType"," nsuri":" http: / / nutriband. com / 20240131"," localname":" OptionsandWarrantsTablesLineItems"," presentation": [" http: / / nutriband. com / role / OptionsandWarrantsTables" ]," lang": {" en- us": {" role": {" label":" Options and Warrants [ Line Items ]" } } },"auth_ref": [ ] }," ntrb_OptionsandWarrantsTablesTable": {" xbrltype":" stringItemType"," nsuri":" http: / / nutriband. com / 20240131"," localname":" OptionsandWarrantsTablesTable"," presentation": [" http: / / nutriband. com / role / OptionsandWarrantsTables" ]," lang": {" en- us": {" role": {" label":" Options and Warrants (Tables) [ Table ]" } } },"auth_ref": [ ] }," us- gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {" xbrltype":" stringItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"," lang": {" en- us": {" role": {" label":" Organization and Description of Business [ Abstract ]" } } },"auth_ref": [ ] }," us- gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"," presentation": [" http: / / nutriband. com / role / OrganizationandDescriptionofBusiness" ]," lang": {" en- us": {" role": {" terseLabel":" ORGANIZATION AND DESCRIPTION OF BUSINESS"," label":" Organization, Consolidation and Presentation of Financial Statements Disclosure [ Text Block ]"," documentation":" The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure." } } },"auth_ref": [" r62"," r125"," r621"," r622" ] }," ntrb_OrganizationandDescriptionofBusinessDetailsLineItems": {" xbrltype":" stringItemType"," nsuri":" http: / / nutriband. com / 20240131"," localname":" OrganizationandDescriptionofBusinessDetailsLineItems"," presentation": [" http: / / nutriband. com / role / OrganizationandDescriptionofBusinessDetails" ]," lang": {" en- us": {" role": {" label":" Organization and Description of Business [ Line Items ]" } } },"auth_ref": [ ] }," ntrb_OrganizationandDescriptionofBusinessDetailsTable": {" xbrltype":" stringItemType"," nsuri":" http: / / nutriband. com / 20240131"," localname":" OrganizationandDescriptionofBusinessDetailsTable"," presentation": [" http: / / nutriband. com / role / OrganizationandDescriptionofBusinessDetails" ]," lang": {" en- us": {" role": {" label":" Organization and Description of Business (Details) [ Table ]" } } },"auth_ref": [ ] }," dei_OtherAddressMember": {" xbrltype":" domainItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" OtherAddressMember"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover" ]," lang": {" en- us": {" role": {" label":" Other Address [ Member ]"," documentation":" Other address for entity" } } },"auth_ref": [ ] }," us- gaap_OtherAssetImpairmentCharges": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" OtherAssetImpairmentCharges"," crdr":" debit"," presentation": [" http: / / nutriband. com / role / SummaryofSignificantAccountingPoliciesDetails" ]," lang": {" en- us": {" role": {" terseLabel":" Impairment charge"," label":" Other Asset Impairment Charges"," documentation":" The charge against earnings resulting from the write down of long lived assets other than goodwill due to the difference between the carrying value and lower fair value." } } },"auth_ref": [" r972"," r1002" ] }," us- gaap_OtherAssets": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" OtherAssets"," crdr":" debit"," presentation": [" http: / / nutriband. com / role / ScheduleofNetSalesandPropertyandEquipmentTable" ]," lang": {" en- us": {" role": {" terseLabel":" Total assets"," label":" Other Assets"," documentation":" Amount of assets classified as other." } } },"auth_ref": [" r130"," r194"," r580"," r772"," r825" ] }," us- gaap_OtherAssetsAbstract": {" xbrltype":" stringItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" OtherAssetsAbstract"," presentation": [" http: / / nutriband. com / role / ConsolidatedBalanceSheet" ]," lang": {" en- us": {" role": {" terseLabel":" OTHER ASSETS:"," label":" Other Assets [ Abstract ]" } } },"auth_ref": [ ] }," us- gaap_OtherCashEquivalentsAtCarryingValue": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" OtherCashEquivalentsAtCarryingValue"," crdr":" debit"," presentation": [" http: / / nutriband. com / role / SummaryofSignificantAccountingPoliciesDetails" ]," lang": {" en- us": {" role": {" terseLabel":" Cash and cash equivalents"," label":" Other Cash Equivalents, at Carrying Value"," documentation":" Amount of short- term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates, classified as other. Excludes cash and cash equivalents within disposal group and discontinued operation." } } },"auth_ref": [ ] }," us- gaap_OtherCommitmentsDescription": {" xbrltype":" stringItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" OtherCommitmentsDescription"," presentation": [" http: / / nutriband. com / role / CommitmentsandContigenciesDetails" ]," lang": {" en- us": {" role": {" terseLabel":" Other commitments term, description"," label":" Other Commitments, Description"," documentation":" Description of the nature and terms of commitment." } } },"auth_ref": [ ] }," us- gaap_OtherCostAndExpenseOperating": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" OtherCostAndExpenseOperating"," crdr":" debit"," presentation": [" http: / / nutriband. com / role / ScheduleofSegmentPerformancetotheGAAPMeasureofGrossProfitTable" ]," lang": {" en- us": {" role": {" terseLabel":" Operating expenses"," label":" Other Cost and Expense, Operating"," documentation":" The total amount of other operating cost and expense items that are associated with the entity's normal revenue producing operation." } } },"auth_ref": [" r92"," r598"," r771" ] }," us- gaap_OtherDepreciationAndAmortization": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" OtherDepreciationAndAmortization"," crdr":" debit"," presentation": [" http: / / nutriband. com / role / PropertyandEquipmentDetails" ]," lang": {" en- us": {" role": {" terseLabel":" Cost of goods sold"," label":" Other Depreciation and Amortization "**Depreciation and Amortization $ 12**," documentation":" Amount of **043 $ 13, 986X- DefinitionThe current period** expense charged against earnings to allocate the cost of tangible and intangible assets over their remaining economic lives, classified as other." } } },"auth_ref": [" r5"," r34"," r92" ] }," us- gaap_OtherExpenses": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" OtherExpenses"," crdr":" debit"," presentation": [" http: / / nutriband. com / role / IntangibleAssetsDetails" ]," lang": {" en- us": {" role": {" terseLabel":" Termination expense"," label":" Other Expenses"," documentation":" Amount of

expense classified as other." } } },"auth_ref": ["r93","r94" ] },"us- gaap_OtherInventory": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" OtherInventory"," crdr":" debit"," presentation": [" http: / / nutriband. com / role / SummaryofSignificantAccountingPoliciesDetails" ],"lang": {" en- us": {" role": {" terseLabel":" Total inventory"," label":" Other Inventory, Gross"," documentation":" Amount before valuation and LIFO reserves of other inventory expected to be sold, or consumed within one on year or operating cycle, if longer." } } },"auth_ref": ["r963" ] },"us- gaap_OtherLiabilities": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" OtherLiabilities"," crdr":" credit"," calculation": {" http: / / nutriband. com / role / ConsolidatedBalanceSheet": {" parentTag":" us- gaap_Liabilities"," weight": 1. 0," order": 3. 0 } },"presentation": [" http: / / nutriband. com / role / ConsolidatedBalanceSheet" ],"lang": {" en- us": {" role": {" terseLabel":" Note payable- related party"," label":" Other Liabilities"," documentation":" Amount of liabilities classified as other." } } },"auth_ref": [" r134"," r582"," r658"," r659"," r825"," r1052"," r1085" ] },"us- gaap_OtherNonoperatingIncomeExpense": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" OtherNonoperatingIncomeExpense"," crdr":" credit"," calculation": {" http: / / nutriband. com / role / ConsolidatedIncomeStatement": {" parentTag":" us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"," weight": 1. 0," order": 2. 0 } },"presentation": [" http: / / nutriband. com / role / ConsolidatedIncomeStatement" ],"lang": {" en- us": {" role": {" totalLabel":" Total other income (expense)"," label":" Other Nonoperating Income (Expense)"," documentation":" Amount of income (expense) related to nonoperating activities, classified as other." } } },"auth_ref": [" r96" ] },"us- gaap_OtherNonoperatingIncomeExpenseAbstract": {" xbrltype":" stringItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" OtherNonoperatingIncomeExpenseAbstract"," presentation": [" http: / / nutriband. com / role / ConsolidatedIncomeStatement" ],"lang": {" en- us": {" role": {" terseLabel":" Other income (expense):"," label":" Other Nonoperating Income (Expense) [ Abstract ]" } } },"auth_ref": [ ] },"ecd_OtherPerfMeasureAmt": {" xbrltype":" decimalItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" OtherPerfMeasureAmt"," presentation": [" http: / / xbrl. sec. gov / ecd / role / PvpDisclosure" ],"lang": {" en- us": {" role": {" label":" Other Performance Measure, Amount"," terseLabel":" Other Performance Measure, Amount" } } },"auth_ref": [" r895" ] },"dei_OtherReportingStandardItemNumber": {" xbrltype":" otherReportingStandardItemNumberItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" OtherReportingStandardItemNumber"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover" ],"lang": {" en- us": {" role": {" label":" Other Reporting Standard Item Number"," documentation":" \" Item 17 \" or \" Item 18 \" specified when the basis of accounting is neither US GAAP nor IFRS." } } },"auth_ref": [" r841" ] },"ntrb_OutsideTheUnitedStatesMember": {" xbrltype":" domainItemType"," nsuri":" http: / / nutriband. com / 20240131"," localname":" OutsideTheUnitedStatesMember"," presentation": [" http: / / nutriband. com / role / ScheduleofNetSalesandPropertyandEquipmentTable" ],"lang": {" en- us": {" role": {" terseLabel":" Outside of the United States [ Member ]"," label":" Outside The United States Member" } } },"auth_ref": [ ] },"ecd_OutstandingAggtErrCompAmt": {" xbrltype":" monetaryItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" OutstandingAggtErrCompAmt"," presentation": [" http: / / xbrl. sec. gov / ecd / role / ErrCompDisclosure" ],"lang": {" en- us": {" role": {" label":" Outstanding Aggregate Erroneous Compensation Amount"," terseLabel":" Outstanding Aggregate Erroneous Compensation Amount" } } },"auth_ref": [" r848"," r859"," r875"," r910" ] },"ecd_OutstandingRecoveryCompAmt": {" xbrltype":" monetaryItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" OutstandingRecoveryCompAmt"," presentation": [" http: / / xbrl. sec. gov / ecd / role / ErrCompDisclosure" ],"lang": {" en- us": {" role": {" label":" Outstanding Recovery Compensation Amount"," terseLabel":" Compensation Amount" } } },"auth_ref": [" r851"," r862"," r878"," r913" ] },"ecd_OutstandingRecoveryIndName": {" xbrltype":" stringItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" OutstandingRecoveryIndName"," presentation": [" http: / / xbrl. sec. gov / ecd / role / ErrCompDisclosure" ],"lang": {" en- us": {" role": {" label":" Outstanding Recovery, Individual Name"," terseLabel":" Name" } } },"auth_ref": [" r851"," r862"," r878"," r913" ] },"dei_ParentEntityLegalName": {" xbrltype":" stringItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" ParentEntityLegalName"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover" ],"lang": {" en- us": {" role": {" label":" Parent Entity Legal Name"," documentation":" If the entity which the financial information concerns is a subsidiary of another company, then provide to full legal name of the parent entity" } } },"auth_ref": [ ] },"ecd_PayVsPerformanceDisclosureLineItems": {" xbrltype":" stringItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" PayVsPerformanceDisclosureLineItems"," lang": {" en- us": {" role": {" label":" Pay vs Performance Disclosure [ Line Items ]"," terseLabel":" Pay vs Performance Disclosure" } } },"auth_ref": [" r884" ] },"ntrb_PaymentsForRepurchaseOfWarrant": {" xbrltype":" sharesItemType"," nsuri":" http: / / nutriband. com / 20240131"," localname":" PaymentsForRepurchaseOfWarrant"," presentation": [" http: / / nutriband. com / role / CommitmentsandContigenciesDetails" ],"lang": {" en- us": {" role": {" terseLabel":" Purchase warrants (in Shares)"," documentation":" Payments for repurchase of warrant."," label":" Payments For Repurchase Of Warrant" } } },"auth_ref": [ ] },"us- gaap_PaymentsToAcquirePropertyPlantAndEquipment": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" PaymentsToAcquirePropertyPlantAndEquipment"," crdr":" credit"," calculation": {" http: / / nutriband. com / role / ConsolidatedCashFlow": {" parentTag":" us- gaap_NetCashProvidedByUsedInInvestingActivities"," weight": -1. 0," order": 1. 0 } },"presentation": [" http: / / nutriband. com / role / ConsolidatedCashFlow" ],"lang": {" en- us": {" role": {" negatedLabel":" Purchase of equipment"," label":" Payments to Acquire Property, Plant, and Equipment"," documentation":" The cash outflow associated with the acquisition of long- lived, physical assets not that are used in production, the normal conduct of business to produce goods and services and which are not intended for resale , to allocate or recognize the cost of such assets over their useful lives ; or includes cash outflows to pay the passage of time or when Codification- Section S99- Paragraph 1B- Subparagraph (SX 210.13- 02 ( a triggering event occurs ) (4) (i))- Publisher FASB- URI https: / / asc . ReferencesReference 1 fasb.org / 1943274 / 2147480097 / 470- 10- S99- 1BReference 21 :http: / / www fasb . xbrl. org / 2003 us- gaap / role / disclosureRef ref / legacyRef - Topic 470 942 - SubTopic 10 210 - Name Accounting Standards Codification- Section S99- Paragraph 1B 1 - Subparagraph (SX 210. 13 9 - 02 03 ( 10 a) (4) (iii) (A ))- Publisher FASB- URI https: / / asc.fasb.org / 1943274 / 2147480097 2147478546 / 470 942 - 10 210 - S99- 1BReference 1Reference 22 2 :http: / / www.xbrl.org / 2003 2009 / role / disclosureRef commonPracticeRef - Topic 470 944 - SubTopic 10 210 - Name Accounting Standards Codification- Section S99- Paragraph 1B 1 - Subparagraph (SX 210. 13 7 - 02 03 (a) ( 10 4) (iii) (B ))- Publisher FASB- URI https: / / asc.fasb.org / 1943274 / 2147480097 2147478777 / 470 944 - 10 210 - S99- 1BReference 1Reference 23 3 :http: / / www.xbrl.org / 2003 / role / disclosureRef- Topic 470 946 - SubTopic 10 210 - Name Accounting Standards Codification- Section S99- Paragraph 1B 1 - Subparagraph (SX 210. 13 6 - 02 04 (7) (a ) (4) (iv ))- Publisher FASB- URI https: / / asc.fasb.org / 1943274 / 2147480097 2147479170 / 470 946 - 10 210 - S99- 1BReference 1Reference 24 4 :http: / / www.xbrl.org / 2003 / role / disclosureRef- Topic 470 210 - SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1B 1 - Subparagraph (SX 210. 13 5 - 02 ( 7 a) (5 ))- Publisher FASB- URI https: / / asc.fasb.org / 1943274 / 2147480097 2147480566 / 470- 10 210 - S99 10 - 1BReference 25 S99- 1 Details Name:us- gaap_PrepaidExpenseCurrentAndNoncurrent Namespace Prefix:us- gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instantX- DefinitionCash received for fees during the current period.This element excludes cash proceeds from license fees. ReferencesReference 1 :http: / / www fasb . xbrl. org / 2003 us- gaap / role / exampleRef ref / legacyRef - Topic 280 230 - SubTopic 10- Name Accounting Standards Codification- Section 50 45 - Paragraph 31 25- Subparagraph (c) - Publisher FASB- URI https: / / asc.fasb.org / 1943274 / 2147482810 2147482740 / 280 230 - 10- 50 45 - 31 25 Details Name:us- gaap_GrossProfit gaap_ProceedsFromFeesReceived Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type: credit debit Period Type:durationX- ReferencesNo DefinitionAmount of purchase arrangement for construction the portion of self- constructed assets." } } },"auth_ref": [" r98" ] },"ecd_PeerGroupIssuersFnTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" PeerGroupIssuersFnTextBlock"," presentation": [" http: / / xbrl. sec. gov / ecd / role / PvpDisclosure" ],"lang": {" en- us": {" role": {" label":" Peer Group Issuers, Footnote [ Text Block ]"," terseLabel":" Peer Group Issuers, Footnote" } } },"auth_ref": [" r894" ] },"ecd_PeerGroupTotalShareholderRtnAmt": {" xbrltype":" monetaryItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" PeerGroupTotalShareholderRtnAmt"," presentation": [" http: / / xbrl. sec. gov / ecd / role / PvpDisclosure" ],"lang": {" en- us": {" role": {" label":" Peer Group Total Shareholder Return Amount"," terseLabel":" Peer Group Total Shareholder Return Amount" } } },"auth_ref": [" r894" ] },"ecd_PeoActuallyPaidCompAmt": {" xbrltype":" monetaryItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" PeoActuallyPaidCompAmt"," presentation": [" http: / / xbrl. sec. gov / ecd / role / PvpDisclosure" ],"lang": {" en- us": {" role": {" label":" PEO Actually Paid Compensation Amount"," terseLabel":" PEO Actually Paid Compensation Amount" } } },"auth_ref": [" r886" ] },"ecd_PeoMember": {" xbrltype":" domainItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" PeoMember"," presentation": [" http: / / xbrl. sec. gov / ecd / role / PvpDisclosure" ],"lang": {" en- us": {" role": {" label":" PEO [ Member ]"," terseLabel":" PEO" } } },"auth_ref": [" r903" ] },"ecd_PeoName": {" xbrltype":" normalizedStringItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" PeoName"," presentation": [" http: / / xbrl. sec. gov / ecd / role / PvpDisclosure" ],"lang": {" en- us": {" role": {" label":" PEO Name"," terseLabel":" PEO Name" } } },"auth_ref": [" r896" ] },"ecd_PeoTotalCompAmt": {" xbrltype":" monetaryItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" PeoTotalCompAmt"," presentation": [" http: / / xbrl. sec. gov / ecd / role / PvpDisclosure" ],"lang": {" en- us": {" role": {" label":" PEO Total Compensation Amount"," terseLabel":" PEO Total Compensation Amount" } } },"auth_ref": [" r885" ] },"ntrb_PercentageOfNetIncome": {" xbrltype":" percentItemType"," nsuri":" http: / / nutriband. com / 20240131"," localname":" PercentageOfNetIncome"," presentation": [" http: / / nutriband. com / role / CommitmentsandContigenciesDetails" ],"lang": {" en- us": {" role": {" terseLabel":" Percentage of performance bonus"," documentation":" Amount of describes

the these gain ( expenses which can be clearly related to production and included in cost of sales or loss) in net income of a business over a given amount of time, thus allowing us to establish what the ROI (return rate) of a specific investment has been.","" label":" Percentage Of Net Income" } } },"" auth_ref": [ ] },"" ntrb_PerformanceObligationsPolicyTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / nutriband. com / 20240131"," localname":" PerformanceObligationsPolicyTextBlock"," presentation": [" http: / / nutriband. com / role / AccountingPoliciesByPolicy" ]," lang": {" en- us": {" role": {" terseLabel":" Performance Obligations"," documentation":" The entire disclosure of performance obligations."," label":" Performance Obligations Policy Text Block" } } }," auth_ref": [ ] }," dei_PhoneFaxNumberDescription": {" xbrltype":" stringItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" PhoneFaxNumberDescription"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover" ]," lang": {" en- us": {" role": {" label":" Phone Fax Number Description"," documentation":" Description of Phone or Fax Number" } } }," auth_ref": [ ] }," ecd_PnsnAdjsPrrSvcCstMember": {" xbrltype":" domainItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" PnsnAdjsPrrSvcCstMember"," presentation": [" http: / / xbrl. sec. gov / ecd / role / PvpDisclosure" ]," lang": {" en- us": {" role": {" label":" Pension Adjustments Prior Service services Cost [ Member ]"," terseLabel":" Pension Adjustments Prior Service Cost" } } }," auth_ref": [" r887" ] }," ecd_PnsnAdjsSvcCstMember": {" xbrltype":" domainItemType"," nsuri":" http: / / xbrl. Includes sec. gov / ecd / 2024"," localname":" PnsnAdjsSvcCstMember"," presentation": [" http: / / xbrl. sec. gov / ecd / role / PvpDisclosure" ]," lang": {" en- us": {" role": {" label":" Pension Adjustments Service Cost [ Member ]"," terseLabel":" Pension Adjustments Service Cost" } } }," auth_ref": [" r932" ] }," ecd_PnsnBnftsAdjFnTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" PnsnBnftsAdjFnTextBlock"," presentation": [" http: / / xbrl. sec. gov / ecd / role / PvpDisclosure" ]," lang": {" en- us": {" role": {" label":" Pension Benefits Adjustments, Footnote [ Text Block ]"," terseLabel":" Pension Benefits Adjustments, Footnote" } } }," auth_ref": [" r886" ] }," ntrb_PoconoPharmaceuticalsMember": {" xbrltype":" domainItemType"," nsuri":" http: / / nutriband. com / 20240131"," localname":" PoconoPharmaceuticalsMember"," presentation": [" http: / / nutriband. com / role / OrganizationandDescriptionofBusinessDetails"," http: / / nutriband. com / role / ScheduleofNetSalesandPropertyandEquipmentTable"," http: / / nutriband. com / role / ScheduleofSegmentPerformancetotheGAAPMeasureofGrossProfitTable" ]," lang": {" en- us": {" role": {" terseLabel":" Pocono Pharmaceuticals [ Member ]"," verboseLabel":" Selling selling , general and administrative expense. ReferencesReference 1 - Pocono Pharmaceuticals [ Member ]"," label": " Pocono Pharmaceuticals Member" } } }," auth_ref": [ ] }," dei_PostEffectiveAmendment": {" xbrltype":" booleanItemType"," nsuri":" http: / / www. xbrl. org sec. gov / 2003 dei / 2024"," localname":" PostEffectiveAmendment"," presentation": [" http: / / xbrl. sec. gov / dei / role / exampleRef document / Cover" ]," lang": {" en- Topic 220- SubTopic 40- Name Accounting Standards Codification- Section 55- Paragraph 4- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147476153 / 220- 40- 55- 4 Details Name: us ": {" role": {" label":" Post- gaap_OperatingExpenses Namespace Prefix Effective Amendment" } } }," auth_ref": [" r827" ] }," dei_PostEffectiveAmendmentNumber": {" xbrltype":" sequenceNumberItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" PostEffectiveAmendmentNumber"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover" ]," lang": {" en- us ": {" role": {" label":" Post- gaap_ Data Type Effective Amendment Number"," documentation": " Amendment number to registration statement under the Securities Act of 1933 after the registration becomes effective." } } }," auth_ref": [" r827" ] }," dei_PreCommencementIssuerTenderOffer": {" xbrltype":" booleanItemType"," nsuri":" http: / / xbrl. xbrli . sec. gov / : monetaryItemType Balance Type: dei debit Period Type / 2024"," localname": durationX " PreCommencementIssuerTenderOffer"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover" ]," lang": {" en- ReferencesNo definition available. Details Name: us ": {" role": {" label":" Pre- gaap_OperatingExpensesAbstract Namespace Prefix commencement Issuer Tender Offer"," documentation": " Boolean flag that is true when the Form 8- K filing is intended to satisfy the filing obligation of the registrant as pre- commencement communications pursuant to Rule 13e- 4 (c) under the Exchange Act." } } }," auth_ref": [" r834" ] }," dei_PreCommencementTenderOffer": {" xbrltype":" booleanItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" PreCommencementTenderOffer"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover" ]," lang": {" en- us ": {" role": {" label":" Pre- commencement Tender Offer"," documentation":" Boolean flag that is true when the Form 8- K filing is intended to satisfy the filing obligation of the registrant as pre- commencement communications pursuant to Rule 14d- 2 (b) under the Exchange Act." } } }," auth_ref": [" r836" ] }," dei_PreEffectiveAmendment": {" xbrltype":" booleanItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" PreEffectiveAmendment"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover" ]," lang": {" en- us": {" role": {" label":" Pre- Effective Amendment" } } }," auth_ref": [" r827" ] }," dei_PreEffectiveAmendmentNumber": {" xbrltype":" sequenceNumberItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" PreEffectiveAmendmentNumber"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover" ]," lang": {" en- us": {" role": {" label":" Pre- Effective Amendment Number"," documentation":" Amendment number to registration statement under the Securities Act of 1933 before the registration becomes effective." } } }," auth_ref": [" r827" ] }," us- gaap_PreferredStockMember": {" xbrltype":" domainItemType"," nsuri":" http: / / fasb. org / us- gaap gaap_ Data Type / 2024"," localname": xbrli " PreferredStockMember"," presentation": [" http: / / nutriband. com / role / StockholdersEquityDetails" ]," lang": {" en- us": {" role": {" terseLabel":" Preferred Stock [ Member ]"," label":" Preferred Stock [ Member ]"," documentation":" Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company." } } }," auth_ref": [" r816","" r817","" r820","" r821","" r822","" r823","" r1084","" r1087" ] }," us- gaap_PreferredStockParOrStatedValuePerShare": {" xbrltype":" perShareItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" PreferredStockParOrStatedValuePerShare"," presentation": [" http: / / nutriband. com / role / ConsolidatedBalanceSheet_Parentheticals"," http: / / nutriband. com / role / StockholdersEquityDetails" ]," lang": {" en- us": {" role": {" terseLabel":" Preferred stock par value (in Dollars per share)"," verboseLabel":" Preferred stock, par value (in Dollars per share)"," label":" Preferred Stock, Par or Stated Value Per Share"," documentation":" Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }," auth_ref": [" r76","" r389" ] }," us- gaap_PreferredStockSharesAuthorized": {" xbrltype":" sharesItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" PreferredStockSharesAuthorized"," presentation": [" http: / / nutriband. com / role / ConsolidatedBalanceSheet_Parentheticals"," http: / / nutriband. com / role / StockholdersEquityDetails" ]," lang": {" en- us": {" role": {" terseLabel":" Preferred stock, shares authorized"," label":" Preferred Stock, Shares Authorized"," documentation":" The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity' s charter and bylaws." } } }," auth_ref": [" r76","" r664" ] }," us- gaap_PreferredStockSharesOutstanding": {" xbrltype":" sharesItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" PreferredStockSharesOutstanding"," presentation": [" http: / / nutriband. com / role / ConsolidatedBalanceSheet_Parentheticals" ]," lang": {" en- us": {" role": {" terseLabel":" Preferred stock, shares outstanding"," label":" Preferred Stock, Shares Outstanding"," documentation":" Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }," auth_ref": [" r76","" r664","" r684","" r1087","" r1088" ] }," us- gaap_PreferredStockValue": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" PreferredStockValue"," crdr":" credit"," calculation": {" http: / / nutriband. com / role / ConsolidatedBalanceSheet": {" parentTag":" us- gaap_StockholdersEquity"," weight": 1. 0," order": 1. 0 } }," presentation": [" http: / / nutriband. com / role / ConsolidatedBalanceSheet" ]," lang": {" en- us": {" role": {" terseLabel":" Preferred stock, $. 001 par value, 10, 000, 000 shares authorized,- 0- outstanding"," label":" Preferred Stock, Value, Issued"," documentation":" Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }," auth_ref": [" r76","" r586","" r799" ] }," us- gaap_PrepaidExpenseCurrent": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" PrepaidExpenseCurrent"," crdr":" debit"," calculation": {" http: / / nutriband. com / role / ConsolidatedBalanceSheet": {" parentTag":" us- gaap_AssetsCurrent"," weight": 1. 0," order": 4. 0 } }," presentation": [" http: / / nutriband. com / role / ConsolidatedBalanceSheet" ]," lang": {" en- us": {" role": {" terseLabel":" Prepaid expenses"," label":" Prepaid Expense, Current"," documentation":" Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } }," auth_ref": [" r204","" r304","" r305","" r758" ] }," us- gaap_PrepaidExpenseCurrentAndNoncurrent": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" PrepaidExpenseCurrentAndNoncurrent"," crdr":" debit"," presentation": [" http: / / nutriband. com / role / CommitmentsandContigenciesDetails" ]," lang": {" en- us": {" role": {" terseLabel":" Prepaid expenses"," label":" Prepaid Expense"," documentation":" Carrying amount as of the balance sheet date of expenditures made in advance of when the economic benefit of the cost will be realized, and which will be expensed in future periods with the passage of time or when a triggering event occurs." } } }," auth_ref": [" r130","" r204","" r677","" r1050" ] }," srt_PreviouslyEstimatedDevelopmentCostsIncurred": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / srt / 2024"," localname":" PreviouslyEstimatedDevelopmentCostsIncurred"," crdr":" debit"," presentation": [" http: / / nutriband. com / role / CommitmentsandContigenciesDetails" ]," lang": {" en- us": {" role": {" terseLabel":" Estimated cost"," label":" Oil and Gas, Standardized Measure, Discounted Future Net Cash Flow, Previously Estimated Development Cost Incurred"," documentation":" Amount of increase in standardized measure of discounted future net cash flow as a result of previously estimated development costs incurred." } } }," auth_ref": [" r154","" r155","" r160","" r561","" r562","" r804","" r809" ] }," us- gaap_ProceedsFromFeesReceived": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":"

ProceedsFromFeesReceived"," crdr":" debit"," presentation": [" http: / / nutriband. com / role / CommitmentsandContigenciesDetails" ]," lang": {" en- us": {" role": {" terseLabel":" Received amount"," label":" Proceeds from Fees Received"," documentation":" Cash received for fees during the current period. This element excludes cash proceeds from license fees." } } }," auth_ref": [" r102" ] }," us- gaap_ProceedsFromInterestReceived": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" ProceedsFromInterestReceived"," crdr":" debit"," presentation": [" http: / / nutriband. com / role / SubsequentEventsDetails" ]," lang": {" en- us": {" role": {" terseLabel":" Received proceeds (in Dollars)"," label":" Proceeds from Interest Received"," documentation":" Interest received on loans and other debt instruments during the current period." } } }," auth_ref": [" r970" ] }," us- gaap_ProceedsFromIssuanceOfDebt": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" ProceedsFromIssuanceOfDebt"," crdr":" debit"," calculation": {" http: / / nutriband. com / role / ConsolidatedCashFlow": {" parentTag":" us- gaap_NetCashProvidedByUsedInFinancingActivities"," weight": 1. 0," order": 2. 0 } }," presentation": [" http: / / nutriband. com / role / ConsolidatedCashFlow" ]," lang": {" en- us": {" role": {" terseLabel":" Proceeds from secured borrowing liability"," label":" Proceeds from Issuance of Debt"," documentation":" The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short- term and long- term debt." } } }," auth_ref": [" r969" ] }," us- gaap_ProceedsFromIssuanceOfPrivatePlacement": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" ProceedsFromIssuanceOfPrivatePlacement"," crdr":" debit"," presentation": [" http: / / nutriband. com / role / SummaryofSignificantAccountingPoliciesDetails" ]," lang": {" en- us": {" role": {" terseLabel":" Private placement"," label":" Proceeds from Issuance of Private Placement"," documentation":" The cash inflow associated with the amount received from entity' s raising of capital via private rather than public placement." } } }," auth_ref": [" r3" ] }," ntrb_ProceedsFromIssuancesInitialPublicOffering": {" xbrltype":" monetaryItemType"," nsuri":" http: / / nutriband. com / 20240131"," localname":" ProceedsFromIssuancesInitialPublicOffering"," crdr":" debit"," presentation": [" http: / / nutriband. com / role / SummaryofSignificantAccountingPoliciesDetails" ]," lang": {" en- us": {" role": {" terseLabel":" Net proceeds"," documentation":" The cash inflow associated with the amount received from entity' s first offering of stock to the public."," label":" Proceeds From Issuances Initial Public Offering" } } }," auth_ref": [ ] }," us- gaap_ProceedsFromRelatedPartyDebt": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" ProceedsFromRelatedPartyDebt"," crdr":" debit"," calculation": {" http: / / nutriband. com / role / ConsolidatedCashFlow": {" parentTag":" us- gaap_NetCashProvidedByUsedInFinancingActivities"," weight": 1. 0," order": 1. 0 } }," presentation": [" http: / / nutriband. com / role / ConsolidatedCashFlow" ]," lang": {" en- us": {" role": {" terseLabel":" Proceeds from note payable- related party"," label":" Proceeds from Related Party Debt"," documentation":" The cash inflow from a long- term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates." } } }," auth_ref": [" r14" ] }," us- gaap_ProceedsFromWarrantExercises": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" ProceedsFromWarrantExercises"," crdr":" debit"," calculation": {" http: / / nutriband. com / role / ConsolidatedCashFlow": {" parentTag":" us- gaap_NetCashProvidedByUsedInFinancingActivities"," weight": 1. 0," order": 3. 0 } }," presentation": [" http: / / nutriband. com / role / ConsolidatedCashFlow"," http: / / nutriband. com / role / StockholdersEquityDetails" ]," lang": {" en- us": {" role": {" terseLabel":" Proceeds from exercise of warrants"," verboseLabel":" Proceed from exercise of warrants (in Dollars)"," label":" Proceeds from Warrant Exercises"," documentation":" The cash inflow associated with the amount received from holders exercising their stock warrants." } } }," auth_ref": [" r968" ] }," ntrb_ProceedsFromWarrantsExercises": {" xbrltype":" monetaryItemType"," nsuri":" http: / / nutriband. com / 20240131"," localname":" ProceedsFromWarrantsExercises"," crdr":" debit"," presentation": [" http: / / nutriband. com / role / SummaryofSignificantAccountingPoliciesDetails" ]," lang": {" en- us": {" role": {" terseLabel":" Exercise warrants"," documentation":" The cash inflow associated with the amount received from holders exercising their stock warrants."," label":" Proceeds From Warrants Exercises" } } }," auth_ref": [ ] }," ntrb_PromissoryNoteOnEquipmentPurchase": {" xbrltype":" monetaryItemType"," nsuri":" http: / / nutriband. com / 20240131"," localname":" PromissoryNoteOnEquipmentPurchase"," crdr":" credit"," presentation": [" http: / / nutriband. com / role / ConsolidatedCashFlow" ]," lang": {" en- us": {" role": {" terseLabel":" Promissory note on equipment purchase"," documentation":" Promissory note on equipment purchase."," label":" Promissory Note On Equipment Purchase" } } }," auth_ref": [ ] }," us- gaap_PropertyPlantAndEquipmentAbstract": {" xbrltype":"stringItemType "," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" PropertyPlantAndEquipmentAbstract"," lang": {" en- us": {" role": {" label":" Property and Equipment [ Abstract ]" } } }," auth_ref": [ ] }," us- gaap_PropertyPlantAndEquipmentByTypeAxis": {" xbrltype":" stringItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" PropertyPlantAndEquipmentByTypeAxis"," presentation": [" http: / / nutriband. com / role / ScheduleofPlantandEquipmentonaStraightLineBasisOvertheEstimatedUsefulLifeoftheAssetsTable"," http: / / nutriband. com / role / ScheduleofPropertyandEquipmentTable" ]," lang": {" en- us": {" role": {" label":" Long- Lived Tangible Asset [ Axis ]"," documentation":" Information by type of long- lived, physical assets used to produce goods and services and not intended for resale." } } }," auth_ref": [" r6"," r521" ] }," us- gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" PropertyPlantAndEquipmentDisclosureTextBlock"," presentation": [" http: / / nutriband. com / role / PropertyandEquipment" ]," lang": {" en- us": {" role": {" terseLabel":" PROPERTY AND EQUIPMENT"," label":" Property, Plant and Equipment Disclosure [ Text Block ]"," documentation":" The entire disclosure for long- lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }," auth_ref": [" r108"," r151"," r156"," r157" ] }," us- gaap_PropertyPlantAndEquipmentGross": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" PropertyPlantAndEquipmentGross"," crdr":" debit"," calculation": {" http: / / nutriband. com / role / ScheduleofPropertyandEquipmentTable": {" parentTag":" us- gaap_PropertyPlantAndEquipmentNet"," weight": 1. 0," order": 1. 0 } }," presentation": [" http: / / nutriband. com / role / ScheduleofPropertyandEquipmentTable" ]," lang": {" en- us": {" role": {" terseLabel":" Property and equipment, gross"," label":" Property, Plant and Equipment, Gross"," documentation":" Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }," auth_ref": [" r109"," r191"," r593" ] }," us- gaap_PropertyPlantAndEquipmentLineItems": {" xbrltype":" stringItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" PropertyPlantAndEquipmentLineItems"," presentation": [" http: / / nutriband. com / role / ScheduleofPropertyandEquipmentTable" ]," lang": {" en- us": {" role": {" label":" Schedule of Property and Equipment [ Line Items ]"," documentation":" Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }," auth_ref": [" r521" ] }," us- gaap_PropertyPlantAndEquipmentNet": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" PropertyPlantAndEquipmentNet"," crdr":" debit"," calculation": {" http: / / nutriband. com / role / ConsolidatedBalanceSheet": {" parentTag":" us- gaap_Assets"," weight": 1. 0," order": 2. 0 }," http: / / nutriband. com / role / ScheduleofPropertyandEquipmentTable": {" parentTag": null," weight": null," order": null," root": true } }," presentation": [" http: / / nutriband. com / role / ConsolidatedBalanceSheet"," http: / / nutriband. com / role / ScheduleofPropertyandEquipmentTable" ]," lang": {" en- us": {" role": {" totalLabel":" Net Property and Equipment"," terseLabel":" PROPERTY & amp; EQUIPMENT- net"," label":" Property, Plant and Equipment, Net"," documentation":" Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }," auth_ref": [" r6"," r521"," r579"," r593"," r799" ] }," us- gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" PropertyPlantAndEquipmentOtherAccumulatedDepreciation"," crdr":" credit"," calculation": {" http: / / nutriband. com / role / ScheduleofPropertyandEquipmentTable": {" parentTag":" us- gaap_PropertyPlantAndEquipmentNet"," weight":- 1. 0," order": 2. 0 } }," presentation": [" http: / / nutriband. com / role / ScheduleofPropertyandEquipmentTable" ]," lang": {" en- us": {" role": {" negatedLabel":" Less: Accumulated depreciation"," label":" Property, Plant and Equipment, Other, Accumulated Depreciation"," documentation":" Amount of accumulated depreciation of long- lived, physical assets used to produce goods and services and not intended for resale, classified as other." } } }," auth_ref": [ ] }," us- gaap_PropertyPlantAndEquipmentOwnedAccumulatedDepreciation": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" PropertyPlantAndEquipmentOwnedAccumulatedDepreciation"," crdr":" credit"," presentation": [" http: / / nutriband. com / role / ScheduleofNetSalesandPropertyandEquipmentTable" ]," lang": {" en- us": {" role": {" terseLabel":" Property and equipment, net of accumulated depreciation"," label":" Property, Plant, and Equipment, Owned, Accumulated Depreciation"," documentation":" Amount of accumulated depreciation from long- lived, depreciable flight asset owned. Excludes right- of- use asset from finance lease for flight asset." } } }," auth_ref": [" r1001" ] }," us- gaap_PropertyPlantAndEquipmentPolicyTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" PropertyPlantAndEquipmentPolicyTextBlock"," presentation": [" http: / / nutriband. com / role / AccountingPoliciesByPolicy" ]," lang": {" en- us": {" role": {" terseLabel":" Property, Plant and Equipment"," label":" Property, Plant and Equipment, Policy [ Policy Text Block ]"," documentation":" Disclosure of accounting

policy for long- lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } },"auth_ref": ["r6","r151","r156","r592" ] },"us- gaap_PropertyPlantAndEquipmentTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" PropertyPlantAndEquipmentTextBlock"," presentation": [" http: / / nutriband. com / role / PropertyandEquipmentTables" ]," lang": {" en- us": {" role": {" terseLabel":" Schedule of Property and Equipment"," label":" Property, Plant and Equipment [ Table Text Block ]"," documentation":" Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances **Balance Type** by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated depreciation." } } },"auth_ref": **na** [" r6" ] },..... related party during the financial reporting period **Period** ." } } } },"auth_ref": [" r59"," r526" ] },"us- gaap_RelatedPartyTransactionAxis": {" xbrltype":" stringItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" RelatedPartyTransactionAxis"," presentation": [" http: / / nutriband. com / role / CommitmentsandContigenciesDetails" ]," lang": {" en- us": {" role": {" label":" Related Party Transaction [ Axis ]"," documentation":" Information by type **Type** of related party transaction." } } },"auth_ref": **durationX** [" r526"," r527"," r1040" ] } },"us- **DefinitionAmount** gaap_RelatedPartyTransactionDomain": {" xbrltype":" domainItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" RelatedPartyTransactionDomain"," presentation": [" http: / / nutriband. com / role / CommitmentsandContigenciesDetails" ]," lang": {" en- us": {" role": {" label":" Related Party Transaction [ Domain ]"," documentation":" Transaction between related party." } } },"auth_ref": [ ] },"us- gaap_RelatedPartyTransactionsAbstract": {" xbrltype":" stringItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" RelatedPartyTransactionsAbstract"," lang": {" en- us": {" role": {" label":" Related Party Transactions [ Abstract ]" } } },"auth_ref": [ ] },"us- gaap_RelatedPartyTransactionsByRelatedPartyAxis": {" xbrltype":" stringItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" RelatedPartyTransactionsByRelatedPartyAxis"," presentation": [" http: / / nutriband. com / role / ConsolidatedBalanceSheet"," http: / / nutriband. com / role / OptionsandWarrantsDetails"," http: / / nutriband. com / role / SummaryofSignificantAccountingPoliciesDetails" ]," lang": {" en- us": {" role": {" label":" Related and Nonrelated Parties [ Axis ]"," documentation":" Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } },"auth_ref": [" r292"," r415"," r526"," r527"," r583"," r591"," r657"," r658"," r659"," r660"," r661"," r683"," r685"," r714"," r1040" ] },"ntrb_RelatedPartyTransactionsDetailsLineItems": {" xbrltype":" stringItemType"," nsuri":" http: / / nutriband. com / 20240131"," localname":" RelatedPartyTransactionsDetailsLineItems"," presentation": [" http: / / nutriband. com / role / RelatedPartyTransactionsDetails" ]," lang": {" en- us": {" role": {" label":" Related Party Transactions [ Line Items ]" } } },"auth_ref": [ ] },"ntrb_RelatedPartyTransactionsDetailsTable": {" xbrltype":" stringItemType"," nsuri":" http: / / nutriband. com / 20240131"," localname":" RelatedPartyTransactionsDetailsTable"," presentation": [" http: / / nutriband. com / role / RelatedPartyTransactionsDetails" ]," lang": {" en- us": {" role": {" label":" Related Party Transactions (Details) [ Table ]" } } },"auth_ref": [ ] },"us- gaap_RelatedPartyTransactionsDisclosureTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" RelatedPartyTransactionsDisclosureTextBlock"," presentation": [" http: / / nutriband. com / role / RelatedPartyTransactions" ]," lang": {" en- us": {" role": {" terseLabel":" RELATED PARTY TRANSACTIONS"," label":" Related Party Transactions Disclosure [ Text Block ]"," documentation":" The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } },"auth_ref": [" r523"," r524"," r525"," r527"," r530"," r631"," r632"," r633"," r690"," r691"," r692"," r711"," r713" ] },"us- gaap_RepaymentsOfAdvancesForConstruction": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" RepaymentsOfAdvancesForConstruction"," crdr":" credit"," presentation": [" http: / / nutriband. com / role / SummaryofSignificantAccountingPoliciesDetails" ]," lang": {" en- us": {" role": {" terseLabel":" Advance repaid"," label":" Payment for Advance for Construction, Investing Activity"," documentation":" Amount of cash outflow for repayment of advance for construction, classified as investing activity. Includes, but is not limited to, payment to developer, builder, government agency, and municipality for borrowing received in construction." } } },"auth_ref": [" r98" ] },"us- gaap_RepaymentsOfNotesPayable": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" RepaymentsOfNotesPayable"," crdr":" credit"," calculation": {" http: / / nutriband. com / role / ConsolidatedCashFlow": {" parentTag":" us- gaap_NetCashProvidedByUsedInFinancingActivities"," weight": 1. 0," order": 5. 0 } }," presentation": [" http: / / nutriband. com / role / ConsolidatedCashFlow" ]," lang": {" en- us": {" role": {" negatedLabel":" Payment on note payable"," label":" Repayments of Notes Payable"," documentation":" The cash outflow for a borrowing supported by a written promise to pay an obligation." } } },"auth_ref": [" r99" ] },"ntrb_ResearchAndDevelopment4PTherapeuticsMember": {" xbrltype":" domainItemType"," nsuri":" http: / / nutriband. com / 20240131"," localname":" ResearchAndDevelopment4PTherapeuticsMember"," presentation": [" http: / / nutriband. com / role / ScheduleofSegmentPerformancetotheGAAPMeasureofGrossProfitTable" ]," lang": {" en- us": {" role": {" terseLabel":" Research and development- 4P Therapeutics \t[ Member ]"," label":" Research And Development4 PTherapeutics Member" } } },"auth_ref": [ ] },"us- gaap_ResearchAndDevelopmentExpense": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" ResearchAndDevelopmentExpense"," crdr":" debit"," calculation": {" http: / / nutriband. com / role / ConsolidatedIncomeStatement": {" parentTag":" us- gaap_CostsAndExpenses"," weight": 1. 0," order": 2. 0 } }," presentation": [" http: / / nutriband. com / role / ConsolidatedIncomeStatement" ]," lang": {" en- us": {" role": {" terseLabel":" Research and development"," label":" Research and Development Expense"," documentation":" Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write- down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } },"auth_ref": [" r456"," r752"," r771"," r1049" ] },"us- gaap_ResearchAndDevelopmentExpensePolicy": {" xbrltype":" textBlockItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" ResearchAndDevelopmentExpensePolicy"," presentation": [" http: / / nutriband. com / role / AccountingPoliciesByPolicy" ]," lang": {" en- us": {" role": {" terseLabel":" Research and Development Expenses"," label":" Research and Development Expense, Policy [ Policy Text Block ]"," documentation":" Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process." } } },"auth_ref": [" r455" ] },"ecd_RestatementDateAxis": {" xbrltype":" stringItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" RestatementDateAxis"," presentation": [" http: / / xbrl. sec. gov / ecd / role / ErrCompDisclosure" ]," lang": {" en- us": {" role": {" label":" Restatement Determination Date [ Axis ]"," terseLabel":" Restatement Determination Date:" } } },"auth_ref": [" r844"," r855"," r871"," r906" ] },"ecd_RestatementDeterminationDate": {" xbrltype":" dateItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" RestatementDeterminationDate"," presentation": [" http: / / xbrl. sec. gov / ecd / role / ErrCompDisclosure" ]," lang": {" en- us": {" role": {" label":" Restatement Determination Date"," terseLabel":" Restatement Determination Date" } } },"auth_ref": [" r845"," r856"," r872"," r907" ] },"ecd_RestatementDoesNotRequireRecoveryTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" RestatementDoesNotRequireRecoveryTextBlock"," presentation": [" http: / / xbrl. sec. gov / ecd / role / ErrCompDisclosure" ]," lang": {" en- us": {" role": {" label":" Restatement Does Not Require Recovery [ Text Block ]"," terseLabel":" Restatement does not require Recovery" } } },"auth_ref": [" r852"," r863"," r879"," r914" ] },"us- gaap_RetainedEarningsAccumulatedDeficit": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" RetainedEarningsAccumulatedDeficit"," crdr":" credit"," calculation": {" http: / / nutriband. com / role / ConsolidatedBalanceSheet": {" parentTag":" us- gaap_StockholdersEquity"," weight": 1. 0," order": 5. 0 } }," presentation": [" http: / / nutriband. com / role / ConsolidatedBalanceSheet" ]," lang": {" en- us": {" role": {" terseLabel":" Accumulated deficit"," label":" Retained Earnings (Accumulated Deficit)"," documentation":" Amount of accumulated undistributed earnings (deficit)." } } },"auth_ref": [" r80"," r116"," r589"," r616"," r618"," r629"," r665"," r799" ] },"us- gaap_RetainedEarningsMember": {" xbrltype":" domainItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" RetainedEarningsMember"," presentation": [" http: / / nutriband. com / role / ShareholdersEquityType2or3" ]," lang": {" en- us": {" role": {" terseLabel":" Accumulated Deficit"," label":" Retained Earnings [ Member ]"," documentation":" Accumulated undistributed earnings (deficit)." } } },"auth_ref": [" r184"," r228"," r229"," r230"," r232"," r237"," r239"," r241"," r298"," r299"," r335"," r473"," r474"," r480"," r481"," r482"," r484"," r486"," r487"," r492"," r494"," r495"," r497"," r499"," r514"," r515"," r613"," r615"," r634"," r1087" ] },"ntrb_RevenueByGeographicLocationAbstract": {" xbrltype":" stringItemType"," nsuri":" http: / / nutriband. com / 20240131"," localname":" RevenueByGeographicLocationAbstract"," presentation": [" http: / / nutriband. com / role / ScheduleofRevenuebyGeographicLocationTable" ]," lang": {" en- us": {" role": {" terseLabel":" Revenue by geographic location:"," label":" Revenue By Geographic Location Abstract" } } },"auth_ref": [ ] },"us- gaap_RevenueFromContractWithCustomerIncludingAssessedTax": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" RevenueFromContractWithCustomerIncludingAssessedTax"," crdr":" credit","

presentation": [" http: / / nutriband. com / role / ScheduleofNetSalesandPropertyandEquipmentTable" ]," lang": {" en- us": {" role": {" terseLabel":" Net sales"," label":" Revenue from Contract with Customer, Including Assessed Tax"," documentation":" Amount , including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue- producing transaction, including, but not limited to, sales, use, value- added and excise. **ReferencesReference 1** " } } },"- auth_ref" : **the passage of time** Section 50- Paragraph 5- Publisher FASB- URI https: / / asc.fasb.org - **or when a triggering event occurs. ReferencesReference 1** / 1943274 / 2147479806 / 606- 10- 50- 5Reference 10 :http: / / www- **fasb** . xbrl. org / 2003 **us- gaap** / role / disclosureRef **ref / legacyRef** - Topic 280 **942** - SubTopic 10 **210** - Name Accounting Standards Codification- Section 50 **S99** - Paragraph 30 **1** - Subparagraph ( a **SX 210.9- 03 (10)** )- Publisher FASB- URI https: / / asc.fasb.org / 1943274 / 2147482810 **2147478546** / 280 **942** - 10 **210** - 50 **S99** - 30Reference 1**Reference** 11 **2** :http: / / www.xbrl.org / 2003 **2009** / role / disclosureRef **commonPracticeRef** - Topic 280 **944** - SubTopic 10 **210** - Name Accounting Standards Codification- Section 50 **S99** - Paragraph 22 **1** - Subparagraph ( b **SX 210.7- 03 (a) (10)** )- Publisher FASB- URI https: / / asc.fasb.org / 1943274 / 2147482810 **2147478777** / 280 **944** - 10 **210** - 50 **S99** - 22Reference 1**Reference** 12 **3** :http: / / www.xbrl.org / 2003 / role / disclosureRef- Topic 280 **946** - SubTopic 10 **210** - Name Accounting Standards Codification- Section 50 **S99** - Paragraph 40 **1- Subparagraph (SX 210.6- 04 (7) (a))** - Publisher FASB- URI https: / / asc.fasb.org / 1943274 / 2147482810 **2147479170** / 280 **946** - 10 **210** - 50 **S99** - 40Reference 1**Reference** 13 **4** :http: / / www.xbrl.org / 2003 / role / disclosureRef- Topic 280 **210** - SubTopic 10- Name Accounting Standards Codification- Section 50 **S99** - Paragraph 22 **1** - Subparagraph ( a **SX 210.5- 02 (7)** )- Publisher FASB- URI https: / / asc.fasb.org / 1943274 / 2147482810 **2147480566** / 280- 10 **210** - 50 **10** - 22Reference 14 **S99- 1 Details Name:us- gaap_PrepaidExpenseCurrentAndNoncurrent Namespace Prefix:us- gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instantX- DefinitionCash received for fees during the current period.This element excludes cash proceeds from license fees. ReferencesReference 1** :http: / / www- **fasb** . xbrl. org / 2003 **us- gaap** / role / disclosureRef **ref / legacyRef** - Topic 606 **230** - SubTopic 10- Name Accounting Standards Codification- Section 50 **45** - Paragraph 4 **25** - Subparagraph ( a **c** )- Publisher FASB- URI https: / / asc.fasb.org / 1943274 / 2147479806 **2147482740** / 606 **230** - 10- 50 **45** - 4 **25** Details Name:us- gaap_RevenueFromContractWithCustomerIncludingAssessedTax **gaap_ProceedsFromFeesReceived** Namespace Prefix:us- gaap_ Data Type:xbrli:monetaryItemType Balance Type: credit **debit** Period Type:durationX- **DefinitionAmount of purchase arrangement** Details Name:us- gaap_StatementBusinessSegmentsAxis = ntrb_PoconoPharmaceuticalsMember Namespace Prefix:Data Type:na Balance Type:Period Type:X- Details Name:us- gaap_StatementBusinessSegmentsAxis = ntrb_FourPTherapeuticsMember Namespace Prefix:Data Type:na Balance Type:Period Type:X- Details Name:us- gaap_StatementBusinessSegmentsAxis = ntrb_SellingGeneralAndAdministrativePoconoPharmaceuticalsMember Namespace Prefix:Data Type:na Balance Type:Period Type:X- Details Name:us- gaap_StatementBusinessSegmentsAxis = ntrb_SellingGeneralAndAdministrative4PTherapeuticsMember Namespace Prefix:Data [ **Line Items** " r142"," r143"," r253"," r262"," r263"," r278"," r284"," r287"," r289"," r291"," r412"," r413"," r541" ] } **Net sales $ 2** . " **credit Period Type:instantX** Property and equipment,net of accumulated depreciation X - DefinitionAmount **,after effects** of assets classified as **reinsurance,of expense (reversal of expense) for claims incurred and costs incurred in** other - **the claim settlement process** . ReferencesReference 1:http: / / www.xbrl.org / 2003 / role / exampleRef- Topic 944- SubTopic 605 **40** - Name Accounting Standards Codification- Section 55- Paragraph 14 **7** - Publisher FASB- URI https: / / asc.fasb.org / 1943274 / 2147477548 **2147480046** / 944- 605 **40** - 55- 14Reference **7Reference** 2:http: / / www.xbrl.org / 2003 **2009** / role / exampleRef **commonPracticeRef** - Topic 944- SubTopic 605 **40** - Name Accounting Standards Codification- Section 55 **50** - Paragraph 11 **3- Subparagraph (b)** - Publisher FASB- URI https: / / asc.fasb.org / 1943274 / 2147477548 **2147480081** / 944- 605 **40** - 55 **50** - 11Reference 3 **Details Name** : http **us- gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1 Namespace Prefix** : **us** / / www.xbrl.org / 2003 / role / exampleRef - **gaap_ Data Type** Topic 280- SubTopic 10- Name Accounting Standards Codification- Section 55- Paragraph 49- Publisher FASB- URI https - : / **xbrli:monetaryItemType Balance Type:** us- gaap_RevenueFromContractWithCustomerPolicyTextBlock" **gaap / role / ref / legacyRef- Topic 942- SubTopic 210- Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210. 9- 03 (10))- Publisher FASB- URI https** : {" xbrltype" / / **asc. fasb. org / 1943274 / 2147478546 / 942- 210- S99- 1Reference 5** : " textBlockItemType"," nsuri":" http: / / **www. xbrl. org / 2003 / role / exampleRef- Topic 946- SubTopic 830- Name Accounting Standards Codification- Section 55- Paragraph 12- Publisher FASB- URI https: / / asc.** fasb. org / **1943274** / 944 **2147479168 / 946** - 210 **830** - S99 **55** - **12Reference 6** 1" }," r582" : {" role":" http: / / www.xbrl.org / 2003 / role / disclosureRef - "," Topic ":" 944 - "," SubTopic ":" 210 - "," Name ":" Accounting Standards Codification - "," Section ":" S99 - "," Paragraph ":" 1 - "," Subparagraph ":" (SX 210.7- 03 (a) ( 15 **10** )) - "," Publisher ":" FASB - "," URI ":" https: / / asc.fasb.org / 1943274 / 2147478777 / 944- 210- S99- **1Reference 7** 1" }," r583" : {" role":" http: / / www.xbrl.org / 2003 / role / disclosureRef " - **Topic 210- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210.5- 02 (17))- Publisher FASB- URI https: / / asc.fasb.org / 1943274 / 2147480566 / 210- 10- S99- 1 Details Name:** us- **gaap_OtherAssets Namespace Prefix: us-** gaap **gaap_ Data Type** / 2024"," localname" : **xbrli** " RevenueFromContractWithCustomerPolicyTextBlock"," presentation" : {" **monetaryItemType Balance Type: debit Period Type: instantX- DefinitionAmount of accumulated depreciation from long- lived, depreciable flight asset owned. Excludes right- of- use asset from finance lease for flight asset. ReferencesReference 1:** http: / / nutriband **www** . com **xbrl. org / 2009** / role / **commonPracticeRef** AccountingPoliciesByPolicy" ]," lang": {" en- **Topic 360- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 1- Subparagraph (c)- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482099 / 360- 10- 50- 1 Details Name:** us " - **gaap_PropertyPlantAndEquipmentOwnedAccumulatedDepreciation Namespace Prefix** : {" role" **us- gaap_ Data Type** : **xbrli** {" terseLabel" : **monetaryItemType Balance Type** " Contracts with Customers"," label" : " Revenue **credit Period Type: instantX- DefinitionAmount, including tax collected** from Contract with Customer **customer** [ Policy Text Block ]" , " documentation":" Disclosure of accounting policy for revenue from contract **satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent** with **specific** customer." } } },"- auth_ref": [" r159"," r404"," r405"," r406"," r407"," r408"," r409"," r410"," r411"," r754" ] },"- us- gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" RevenueFromExternalCustomersByGeographicAreasTableTextBlock"," presentation": [" http: / / nutriband. com / role / SummaryofSignificantAccountingPoliciesTables" ]," lang": {" en- us": {" role": {" terseLabel":" Schedule of Revenue by Geographic Location"," label":" Revenue from External Customers by Geographic Areas [ Table Text Block ]"," documentation":" Tabular disclosure of revenue from external customers by geographic areas attributed to the entity' s country of domicile and to foreign countries from which the entity derives revenue." } } },"- auth_ref": [" r106" ] }," us- **producing** gaap_RevenueRecognitionDeferredRevenue": {" xbrltype":" textBlockItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" RevenueRecognitionDeferredRevenue"," presentation": [" http: / / nutriband. com / role / AccountingPoliciesByPolicy" ]," lang": {" en- us": {" role": {" terseLabel":" Revenue Recognition"," label":" Revenue Recognition, Deferred Revenue [ Policy Text Block ]"," documentation":" Disclosure of accounting policy for recognizing unearned income or deferred revenue related to transactions - **transaction** involving the sale of a product or performance of services." } } },"- auth_ref": [ ] }," us- gaap_RevenueRecognitionPolicyTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" RevenueRecognitionPolicyTextBlock"," presentation": [" http: / / nutriband. com / role / AccountingPoliciesByPolicy" ]," lang": {" en- us": {" role": {" terseLabel":" Revenue Types"," label":" Revenue [ Policy Text Block ]"," documentation":" Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources." } } },"- auth_ref": [" r688"," r754"," r763" ] }," us- gaap_Revenues": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" Revenues"," crdr":" credit"," calculation": {" http: / / nutriband. com / role / ConsolidatedIncomeStatement": {" parentTag":" us- gaap_OperatingIncomeLoss"," weight": 1. 0," order": 1. 0 } }," presentation": [" http: / / nutriband. com / role / ConsolidatedIncomeStatement"," http: / / nutriband. com / role / ScheduleofDisaggregatesitsRevenuefromContractsTable"," http: / / nutriband. com / role / ScheduleofRevenuebyGeographicLocationTable" ]," lang": {" en- us": {" role": {" terseLabel":" Revenue"," verboseLabel":" Total"," label":" Revenues"," documentation":" Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)." } } },"- auth_ref": [" r142"," r143"," r212"," r223"," r253"," r262"," r263"," r278"," r284"," r287"," r289"," r291"," r297"," r352"," r353"," r354"," r355"," r356"," r357"," r358"," r359"," r360"," r504"," r578"," r771"," r1009" ] }," ntrb_RoyaltyPercentage": {" xbrltype":" percentItemType"," nsuri":" http: / / nutriband. com / 20240131"," localname":" RoyaltyPercentage"," presentation": [" http: / / nutriband. com / role / OrganizationandDescriptionofBusinessDetails" ]," lang": {" en- us": {" role": {" terseLabel":" Royalty fee"," documentation":" Royalty percentage."," label":" Royalty Percentage" } } },"- auth_ref": [ ] }," ced_Rule10b51ArrAdoptedFlag": {" xbrltype":" booleanItemType"," nsuri":" http: / / xbrl. sec. gov / ced / 2024"," localname":" Rule10b51ArrAdoptedFlag"," presentation": [" http: / / xbrl. sec. gov / ced / role / InsiderTradingArrangements" ]," lang": {" en- us": {" role": {" label":" Rule 10b5- 1 Arrangement Adopted [ Flag ]"," terseLabel":" Rule 10b5- 1 Arrangement Adopted" } } },"- auth_ref": [" r923" ] },"- ced_Rule10b51ArrTrmntdFlag": {" xbrltype":" booleanItemType"," nsuri":" http: / / xbrl. sec. gov / ced / 2024"," localname":" Rule10b51ArrTrmntdFlag"," presentation": [" http: / / xbrl. sec. gov / ced / role / InsiderTradingArrangements" ]," lang": {" en- us": {" role": {" label":" Rule 10b5- 1 Arrangement Terminated [

Flag ]"," terseLabel":" Rule 10b5- 1 Arrangement Terminated" } } },"auth_ref": [" r923" ] },"us- gaap_SalariesWagesAndOfficersCompensation": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" SalariesWagesAndOfficersCompensation"," crdr":" debit"," presentation": [" http: / / nutriband. com / role / CommitmentsandContigenciesDetails" ]," lang": {" en- us": {" role": {" terseLabel":" Annual salary"," label":" Salary and Wage, Excluding Cost of Good and Service Sold"," documentation":" Amount of expense for salary and wage arising from service rendered by nonofficer and officer employees. Excludes allocated cost, labor- related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold." } } },"auth_ref": [ ] }," us- gaap_SaleOfStockNameOfTransactionDomain": {" xbrltype":" domainItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" SaleOfStockNameOfTransactionDomain"," presentation": [" http: / / nutriband. com / role / IntangibleAssetsDetails"," http: / / nutriband. com / role / SubsequentEventsDetails"," http: / / nutriband. com / role / SummaryofSignificantAccountingPoliciesDetails" ]," lang": {" en- us": {" role": {" label":" Sale of Stock [ Domain ]"," documentation":" Sale of the entity's stock , including, but not limited to, initial public offering (IPO) **sales, use, value- added** and **excise** private placement . **ReferencesReference 1** " } } },"auth_ref": [ ] }," 10 **credit Period Type:instantX** . Name Accounting Standards Codification- Section 50- Paragraph 42- Publisher FASB- URI https: / / asc **DefinitionAmount,after effects of reinsurance,of expense (reversal of expense) for claims incurred and costs incurred in the claim settlement process** . **ReferencesReference 1** fasb.org / 1943274 / 2147482810 / 280- 10- 50- 42Reference 3 :http: / / www.xbrl.org / 2003 / role / disclosureRef **exampleRef** - Topic 606 **944** - SubTopic 10 **40** - Name Accounting Standards Codification- Section 50 **55** - Paragraph 7- Publisher FASB- URI https: / / asc.fasb.org / 1943274 / 2147479806 - **2147480046** / 606 **944** - 10 **40** - 50 **55** - 7Reference **4 2** :http: / / www.xbrl.org / 2003 **2009** / role / disclosureRef **commonPracticeRef** - Topic 270 **944** - SubTopic 10 **40** - Name Accounting Standards Codification- Section 50- Paragraph 1 **3** - Subparagraph ( i **b** )- Publisher FASB- URI https: / / asc.fasb.org / 1943274 / 2147482964 **2147480081** / 270 **944** - 10 **40** - 50- 1Reference 5 **3 Details Name** : http **us- gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1 Namespace Prefix** : **us** / / www.xbrl.org / 2003 / role / disclosureRef - **gaap_ Data Type:xbrli:monetaryItemType Balance Type:** us- gaap_SaleOfStockNumberOfSharesIssuedInTransaction" **gaap / role / ref / otherTransitionRef- Topic 280- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 32- Subparagraph (b)- Publisher FASB- URI https** : {" xbrltype" **/ / asc. fasb. org / 1943274 / 2147482810 / 280- 10- 50- 32Reference 7** : " sharesItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname" **role / ref / otherTransitionRef- Topic 280- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 32- Subparagraph (a)- Publisher FASB- URI https** : " SaleOfStockNumberOfSharesIssuedInTransaction"," presentation" **/ / asc. fasb. org / 1943274 / 2147482810 / 280- 10- 50- 32Reference 8** : {" http: / / nutriband **www** . com **xbrl. org / 2003** / role / **disclosureRef** StockholdersEquityDetails" ]," lang": {" en- https **credit Period Type** : // asc **instantX- DefinitionAmount,after effects of reinsurance,of expense (reversal of expense) for claims incurred and costs incurred in the claim settlement process** . **ReferencesReference 1** fasb.org / 1943274 / 2147479806 / 606- 10- 50- 5Reference 10 :http: / / www.xbrl.org / 2003 / role / disclosureRef **exampleRef** - Topic 280 **944** - SubTopic 10 **40** - Name Accounting Standards Codification- Section 50 **55** - Paragraph **7** 30- Subparagraph (a) - Publisher FASB- URI https: / / asc.fasb.org / 1943274 / 2147482810 **2147480046** / 280 **944** - 10 **40** - 50 **55** - 30Reference **7Reference** 11 **2** :http: / / www.xbrl.org / 2003 **2009** / role / disclosureRef **commonPracticeRef** - Topic 280 **944** - SubTopic 10 **40** - Name Accounting Standards Codification- Section 50- Paragraph 22 **3** - Subparagraph (b)- Publisher FASB- URI https: / / asc.fasb.org / 1943274 / 2147482810 - **2147480081** / 280 **944** - 10 **40** - 50- 22Reference 12 **3 Details Name** : http **us- gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1 Namespace Prefix** : **us** / / www.xbrl.org / 2003 / role / disclosureRef - **gaap_ Data Type:xbrli:monetaryItemType Balance Type:** Topic 280- SubTopic 10- Name Accounting Standards Codification- Section us " - **gaap_RevenueFromContractWithCustomerIncludingAssessedTax Namespace Prefix** : {" role": {" terseLabel":" Common stock share purchase"," label":" Sale of Stock, Number of Shares Issued in Transaction"," documentation":" The number of shares issued or sold by the subsidiary or equity method investee per stock transaction." } } },"auth_ref": [ ] }," us- gaap_SaleOfStockPricePerShare": {" xbrltype":" perShareItemType"," nsuri":" http: / / fasb. org / us- gaap **gaap_ Data Type** / 2024"," localname" - **xbrli** " SaleOfStockPricePerShare"," presentation" : [" http **monetaryItemType Balance Type** : // nutriband. com / role / RelatedPartyTransactionsDetails"," http: / / nutriband. com / role / SubsequentEventsDetails" ]," lang": {" en- us": {" role": {" terseLabel":" Share price"," verboseLabel":" Exercise price per shares (in Dollars per share)"," label":" Sale of Stock, Price Per Share"," documentation":" Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction." } } },"auth_ref": [ ] }," srt_ScenarioForecastMember": {" xbrltype":" domainItemType"," nsuri":" http: / / fasb. org / srt / 2024"," localname":" ScenarioForecastMember"," presentation": [" http: / / nutriband. com / role / StockholdersEquityDetails" ]," lang": {" en- us": {" role": {" terseLabel":" Forecast [ Member ]"," label":" Forecast [ Member ]"," documentation":" Information reported for future period. Excludes information expected to be reported in future period for effect on historical fact." } } },"auth_ref": [" r417"," r953"," r981" ] }," srt_ScenarioUnspecifiedDomain": {" xbrltype":" domainItemType"," nsuri":" http: / / fasb. org / srt / 2024"," localname":" ScenarioUnspecifiedDomain"," presentation": [" http: / / nutriband. com / role / StockholdersEquityDetails" ]," lang": {" en- us": {" role": {" label":" Scenario [ Domain ]"," documentation":" Scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts." } } },"auth_ref": [" r181"," r242"," r417"," r948"," r981" ] }," ntrb_ScheduleOfAdditionalRelatingWarrantsOutstanding": {" xbrltype":" textBlockItemType"," nsuri":" http: / / nutriband. com / 20240131"," localname":" ScheduleOfAdditionalRelatingWarrantsOutstanding"," presentation": [" http: / / nutriband. com / role / OptionsandWarrantsTables" ]," lang": {" en- us": {" role": {" terseLabel":" Schedule of Summarizes Additional Information Relating to the Warrants Outstanding"," documentation":" The entire disclosure schedule of additional relating warrants outstanding."," label":" Schedule Of Additional Relating Warrants Outstanding" } } },"auth_ref": [ ] }," ntrb_ScheduleOfAmortizationExpensesAbstract": {" xbrltype":" stringItemType"," nsuri":" http: / / nutriband. com / 20240131"," localname":" ScheduleOfAmortizationExpensesAbstract"," lang": {" en- us": {" role": {" label":" Schedule of Amortization Expenses [ Abstract ]" } } },"auth_ref": [ ] }," ntrb_ScheduleOfChangesInOptionsOutstandingAbstract": {" xbrltype":" stringItemType"," nsuri":" http: / / nutriband. com / 20240131"," localname":" ScheduleOfChangesInOptionsOutstandingAbstract"," lang": {" en- us": {" role": {" label":" Schedule of Changes in Options Outstanding [ Abstract ]" } } },"auth_ref": [ ] }," ntrb_ScheduleOfChangesInWarrantsOutstandingAbstract": {" xbrltype":" stringItemType"," nsuri":" http: / / nutriband. com / 20240131"," localname":" ScheduleOfChangesInWarrantsOutstandingAbstract"," lang": {" en- us": {" role": {" label":" Schedule Of Changes In Warrants Outstanding Abstract" } } },"auth_ref": [ ] }," us- gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"," presentation": [" http: / / nutriband. com / role / IncomeTaxesTables" ]," lang": {" en- us": {" role": {" terseLabel":" Schedule of Provision for Income Taxes"," label":" Schedule of Components of Income Tax Expense (Benefit) [ Table Text Block ]"," documentation":" Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits - **credit Period Type** , government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning- of- the- year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years." } } },"auth_ref" - **durationX** [" r1020" ] },"us- **DefinitionLine** gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"," presentation": [" http: / / nutriband. com / role / IncomeTaxesTables" ]," lang": {" en- us": {" role": {" terseLabel":" Schedule of Deferred Tax Liability and Deferred Tax Asset"," label":" Schedule of Deferred Tax Assets and Liabilities [ Table Text Block ]"," documentation":" Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets." } } },"auth_ref": [" r1016" ] }," ntrb_ScheduleOfDeferredTaxLiabilityAndDeferredTaxAssetAbstract": {" xbrltype":" stringItemType"," nsuri":" http: / / nutriband. com / 20240131"," localname":" ScheduleOfDeferredTaxLiabilityAndDeferredTaxAssetAbstract"," lang": {" en- us": {" role": {" label":" Schedule of Deferred Tax Liability and Deferred Tax Asset [ Abstract ]" } } },"auth_ref": [ ] }," us- gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"," presentation": [" http: / / nutriband. com / role / IncomeTaxesTables" ]," lang": {" en- us": {" role": {" terseLabel":" Schedule of Reconciliation of Taxes on Income"," label":" Schedule of Effective Income Tax Rate Reconciliation [ Table Text Block ]"," documentation":" Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations." } } },"auth_ref": [" r462"," r791"," r1014" ] }," ntrb_ScheduleOfIntangibleAssetsAbstract": {" xbrltype":" stringItemType"," nsuri":" http: / / nutriband. com / 20240131"," localname":" ScheduleOfIntangibleAssetsAbstract"," lang": {" en- us": {" role": {" label":" Schedule Of Intangible Assets Abstract" } } },"auth_ref": [ ] }," us- gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"," presentation": [" http: / / nutriband. com / role / IntangibleAssetsTables"

```
],"lang":{"en-us":{"role":{"terseLabel":"Schedule of Intangible Assets","label":"Schedule of Intangible Assets and Goodwill [ Table Text Block ]","documentation":"Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class."}}},"auth_ref":["r994","r997"]},"ntrb_ScheduleOfNetSalesAndPropertyAndEquipmentAbstract":{"xbrltype":"stringItemType","nsuri":"http://nutriband.com/20240131","localname":"ScheduleOfNetSalesAndPropertyAndEquipmentAbstract","lang":{"en-us":{"role":{"label":"Schedule Of Net Sales And Property And Equipment Abstract"}}},"auth_ref":[]},"ntrb_ScheduleOfPlantAndEquipmentOnAStraightLineBasisOverTheEstimatedUsefulLifeOfTheAssetsAbstract":{"xbrltype":"stringItemType","nsuri":"http://nutriband.com/20240131","localname":"ScheduleOfPlantAndEquipmentOnAStraightLineBasisOverTheEstimatedUsefulLifeOfTheAssetsAbstract","lang":{"en-us":{"role":{"label":"Schedule Of Plant And Equipment On AStraight Line Basis Over The Estimated Useful Life Of The Assets Abstract"}}},"auth_ref":[]},"ntrb_ScheduleOfPropertyAndEquipmentAbstract":{"xbrltype":"stringItemType","nsuri":"http://nutriband.com/20240131","localname":"ScheduleOfPropertyAndEquipmentAbstract","lang":{"en-us":{"role":{"label":"Schedule Of Property And Equipment Abstract"}}},"auth_ref":[]},"us-gaap_ScheduleOfPropertyPlantAndEquipmentTable":{"xbrltype":"stringItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"ScheduleOfPropertyPlantAndEquipmentTable","presentation":["http://nutriband.com/role/ScheduleofPropertyandEquipmentTable"],"lang":{"en-us":{"role":{"label":"Property, Plant and Equipment [ Table ]","documentation":"Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated depreciation."}}},"auth_ref":["r6","r521"]},"ntrb_ScheduleOfProvisionForIncomeTaxesAbstract":{"xbrltype":"stringItemType","nsuri":"http://nutriband.com/20240131","localname":"ScheduleOfProvisionForIncomeTaxesAbstract","lang":{"en-us":{"role":{"label":"Schedule of Provision for Income Taxes [ Abstract ]"}}},"auth_ref":[]},"us-gaap_ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock":{"xbrltype":"textBlockItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock","presentation":["http://nutriband.com/role/SummaryofSignificantAccountingPoliciesTables"],"lang":{"en-us":{"role":{"terseLabel":"Schedule of Plant and Equipment on a Straight- Line Basis Over the Estimated Useful Life of the Assets","label":"Public Utility Property, Plant, and Equipment [ Table Text Block ]","documentation":"Tabular disclosure of public utility physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation expense and method used, including composite depreciation, and accumulated depreciation."}}},"auth_ref":["r61"]},"ntrb_ScheduleOfReconciliationOfTaxesOnIncomeAbstract":{"xbrltype":"stringItemType","nsuri":"http://nutriband.com/20240131","localname":"ScheduleOfReconciliationOfTaxesOnIncomeAbstract","lang":{"en-us":{"role":{"label":"Schedule of Reconciliation of Taxes on Income [ Abstract ]"}}},"auth_ref":[]},"ntrb_ScheduleOfRevenueByGeographicLocationAbstract":{"xbrltype":"stringItemType","nsuri":"http://nutriband.com/20240131","localname":"ScheduleOfRevenueByGeographicLocationAbstract","lang":{"en-us":{"role":{"label":"Schedule Of Revenue By Geographic Location Abstract"}}},"auth_ref":[]},"us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock":{"xbrltype":"textBlockItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock","presentation":["http://nutriband.com/role/SummaryofSignificantAccountingPoliciesTables"],"lang":{"en-us":{"role":{"terseLabel":"Schedule of Disaggregates Its Revenue from Contracts","label":"Schedule of Revenue by Major Customers by Reporting Segments [ Table Text Block ]","documentation":"Tabular disclosure of the extent of the entity's reliance on its major customers, if revenues from transactions with a single external customer amount to 10 percent or more of entity revenues, including the disclosure of that fact, the total amount of revenues from each such customer, and the identity of the reportable segment or segments reporting the revenues. The entity need not disclose the identity of a major customer or the amount of revenues that each segment reports from that customer. For these purposes, a group of companies known to the entity to be under common control is considered a single customer, and the federal government, a state government, a local government such as a county or municipality, or a foreign government is each considered a single customer."}}},"auth_ref":[]},"ntrb_ScheduleOfSegmentPerformanceToTheGaapMeasureOfGrossProfitAbstract":{"xbrltype":"stringItemType","nsuri":"http://nutriband.com/20240131","localname":"ScheduleOfSegmentPerformanceToTheGaapMeasureOfGrossProfitAbstract","lang":{"en-us":{"role":{"label":"Schedule Of Segment Performance To The Gaap Measure Of Gross Profit Abstract"}}},"auth_ref":[]},"us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable":{"xbrltype":"stringItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"ScheduleOfSegmentReportingInformationBySegmentTable","presentation":["http://nutriband.com/role/ScheduleofSegmentPerformancetotheGAAPMeasureofGrossProfitTable"],"lang":{"en-us":{"role":{"label":"Schedule of Segment Reporting Information, by Segment [ Table ]","documentation":"Disclosure of information about profit (loss) and total assets by reportable segment."}}},"auth_ref":["r28","r29","r30"]},"us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock":{"xbrltype":"textBlockItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"ScheduleOfSegmentReportingInformationBySegmentTextBlock","presentation":["http://nutriband.com/role/SegmentReportingTables"],"lang":{"en-us":{"role":{"terseLabel":"Schedule of Segment Performance to the GAAP Measure of Gross Profit","label":"Schedule of Segment Reporting Information, by Segment [ Table Text Block ]","documentation":"Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."}}},"auth_ref":["r28","r29","r30"]},"us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock":{"xbrltype":"textBlockItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock","presentation":["http://nutriband.com/role/OptionsandWarrantsTables"],"lang":{"en-us":{"role":{"terseLabel":"Schedule of Changes in Options Outstanding","label":"Share- Based Payment Arrangement, Option, Activity [ Table Text Block ]","documentation":"Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted- average grant date fair value."}}},"auth_ref":["r9","r10","r119"]},"us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock":{"xbrltype":"textBlockItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock","presentation":["http://nutriband.com/role/OptionsandWarrantsTables"],"lang":{"en-us":{"role":{"terseLabel":"Schedule of Changes in Warrants Outstanding","label":"Schedule of Stockholders' Equity Note, Warrants or Rights [ Table Text Block ]","documentation":"Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable."}}},"auth_ref":["r41"]},"ntrb_ScheduleOfSummarizesAdditionalInformationRelatingToTheOptionsOutstandingAbstract":{"xbrltype":"stringItemType","nsuri":"http://nutriband.com/20240131","localname":"ScheduleOfSummarizesAdditionalInformationRelatingToTheOptionsOutstandingAbstract","lang":{"en-us":{"role":{"label":"Schedule Of Summarizes Additional Information Relating To The Options Outstanding Abstract"}}},"auth_ref":[]},"ntrb_ScheduleOfSummarizesAdditionalInformationRelatingToTheOptionsOutstandingTableTextBlock":{"xbrltype":"textBlockItemType","nsuri":"http://nutriband.com/20240131","localname":"ScheduleOfSummarizesAdditionalInformationRelatingToTheOptionsOutstandingTableTextBlock","presentation":["http://nutriband.com/role/OptionsandWarrantsTables"],"lang":{"en-us":{"role":{"terseLabel":"Schedule of Summarizes Additional Information Relating to the Options Outstanding","documentation":"Tabular disclosure of option outstanding.","label":"Schedule Of Summarizes Additional Information Relating To The Options Outstanding Table Text Block"}}},"auth_ref":[]},"ntrb_ScheduleOfSummarizesAdditionalInformationRelatingToTheWarrantsOutstandingAbstract":{"xbrltype":"stringItemType","nsuri":"http://nutriband.com/20240131","localname":"ScheduleOfSummarizesAdditionalInformationRelatingToTheWarrantsOutstandingAbstract","lang":{"en-us":{"role":{"label":"Schedule Of Summarizes Additional Information Relating To The Warrants Outstanding Abstract"}}},"auth_ref":[]},"us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock":{"xbrltype":"textBlockItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock","presentation":["http://nutriband.com/role/IntangibleAssetsTables"],"lang":{"en-us":{"role":{"terseLabel":"Schedule of Amortization Expenses","label":"Schedule of Finite- Lived Intangible Assets, Future Amortization Expense [ Table Text Block ]","documentation":"Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite- lived intangible assets."}}},"auth_ref":["r778","r999"]},"ntrb_SecuredBorrowingLiabilityMember":{"xbrltype":"domainItemType","nsuri":"http://nutriband.com/20240131","localname":"SecuredBorrowingLiabilityMember","presentation":["http://nutriband.com/role/NotesPayableDetails"],"lang":{"en-us":{"role":{"terseLabel":"Secured borrowing liability [ Member ]","label":"Secured Borrowing Liability
```

Member" } } },"auth_ref": [ ] }," dei_Security12bTitle": {" xbrltype":" securityTitleItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" Security12bTitle"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover" ]," lang": {" en- us": {" role": {" label":" Title of 12 (b) Security"," documentation":" Title of a 12 (b) registered security." } } },"auth_ref": [" r828" ] }," dei_Security12gTitle": {" xbrltype":" securityTitleItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" Security12gTitle"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover" ]," lang": {" en- us": {" role": {" label":" Title of 12 (g) Security"," documentation":" Title of a 12 (g) registered security." } } },"auth_ref": [" r832" ] }," dei_SecurityExchangeName": {" xbrltype":" edgarExchangeCodeItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" SecurityExchangeName"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover" ]," lang": {" en- us": {" role": {" label":" Security Exchange Name"," documentation":" Name of the Exchange on which a security is registered." } } },"auth_ref": [" r831" ] }," dei_SecurityReportingObligation": {" xbrltype":" securityReportingObligationItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" SecurityReportingObligation"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover" ]," lang": {" en- us": {" role": {" label":" Security Reporting Obligation"," documentation":" 15 (d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } },"auth_ref": [" r837" ] }," us- gaap_SegmentDomain": {" xbrltype":" domainItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" SegmentDomain"," presentation": [" http: / / nutriband. com / role / ScheduleofNetSalesandPropertyandEquipmentTable"," http: / / nutriband. com / role / ScheduleofSegmentPerformancetotheGAAPMeasureofGrossProfitTable" ]," lang": {" en- us": {" role": {" label":" Segments [ Domain ]"," documentation":" Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } },"auth_ref": [" r142"," r143"," r144"," r145"," r253"," r258"," r261"," r262"," r263"," r264"," r265"," r266"," r267"," r268"," r269"," r270"," r272"," r273"," r275"," r276"," r277"," r278"," r279"," r280"," r281"," r282"," r284"," r285"," r286"," r291"," r309"," r310"," r311"," r312"," r313"," r314"," r315"," r316"," r317"," r333"," r342"," r343"," r600"," r601"," r602"," r603"," r604"," r605"," r606"," r607"," r608"," r609"," r610"," r768"," r771"," r772"," r777"," r814"," r1053"," r1055"," r1056"," r1057"," r1058"," r1059"," r1060"," r1061"," r1062"," r1063"," r1064"," r1065"," r1066"," r1067"," r1068"," r1069"," r1070"," r1071"," r1072"," r1073"," r1074"," r1075"," r1076"," r1077"," r1078"," r1079"," r1080"," r1082"," r1083" ] }," srt_SegmentGeographicalDomain": {" xbrltype":" domainItemType"," nsuri":" http: / / fasb. org / srt / 2024"," localname":" SegmentGeographicalDomain"," presentation": [" http: / / nutriband. com / role / ScheduleofNetSalesandPropertyandEquipmentTable"," http: / / nutriband. com / role / ScheduleofRevenuebyGeographicLocationTable" ]," lang": {" en- us": {" role": {" label":" Geographical [ Domain ]"," documentation":" Geographical area." } } },"auth_ref": [" r163"," r165"," r168"," r170"," r171"," r172"," r173"," r174"," r175"," r176"," r177"," r178"," r179"," r180"," r289"," r290"," r544"," r545"," r546"," r547"," r548"," r549"," r550"," r551"," r552"," r553"," r554"," r555"," r556"," r557"," r558"," r559"," r560"," r563"," r564"," r565"," r566"," r567"," r568"," r569"," r570"," r571"," r572"," r573"," r574"," r575"," r649"," r650"," r651"," r717"," r719"," r723"," r730"," r737"," r740"," r741"," r742"," r743"," r744"," r745"," r746"," r747"," r748"," r755"," r785"," r800"," r801"," r802"," r803"," r805"," r806"," r807"," r808"," r813"," r818"," r1013"," r1053"," r1055"," r1056"," r1058"," r1059"," r1060"," r1061"," r1062"," r1063"," r1064"," r1065"," r1066"," r1067"," r1068"," r1069"," r1070"," r1071"," r1072"," r1073"," r1074"," r1075"," r1076"," r1077"," r1078"," r1079"," r1080"," r1082"," r1083" ] }," us-gaap_SegmentReportingAbstract": {" xbrltype":" stringItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" SegmentReportingAbstract"," lang": {" en- us": {" role": {" label":" Segment Reporting [ Abstract ]" } } },"auth_ref": [ ] }," us- gaap_SegmentReportingDisclosureTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" SegmentReportingDisclosureTextBlock"," presentation": [" http: / / nutriband. com / role / SegmentReporting" ]," lang": {" en- us": {" role": {" terseLabel":" SEGMENT REPORTING"," label":" Segment Reporting Disclosure [ Text Block ]"," documentation":" The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it' s reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments." } } },"auth_ref": [" r145"," r253"," r257"," r258"," r259"," r260"," r261"," r274"," r276"," r277"," r282"," r283"," r284"," r285"," r286"," r287"," r288"," r291"," r767"," r769"," r770"," r771"," r773"," r774"," r775" ] }," us-gaap_SegmentReportingInformationLineItems": {" xbrltype":" stringItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" SegmentReportingInformationLineItems"," presentation": [" http: / / nutriband. com / role / ScheduleofSegmentPerformancetotheGAAPMeasureofGrossProfitTable" ]," lang": {" en- us": {" role": {" label":" Schedule of Segment Performance to the GAAP Measure of Gross Profit [ Line Items ]"," documentation":" Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. "} } },"auth_ref" **ReferencesNo definition available. Details Name** : [ ] },"us- gaap_SegmentReportingRevenueReconcilingItemLineItems "**Namespace Prefix** : {" xbrltype" **us- gaap_ Data Type** : "**xbrli:** stringItemType **Balance Type** "," nsuri" : " http **na Period Type** : **durationX- Details Name:** / / fasb. org / us- gaap / **gaap_StatementBusinessSegmentsAxis =** - Details Name: us- **gaap_CorporateAndOtherMember** gaap_RelatedPartyTransactionAxis = ntrb_MoneyChannelMember Namespace Prefix:Data Type:na Balance Type:Period Type:X- Details Name:us- gaap_ConcentrationRiskByBenchmarkAxis **gaap_StatementBusinessSegmentsAxis** = **ntrb_PoconoPharmaceuticalsMember** us-gaap_AccountsReceivableMember Namespace Prefix:Data Type:na Balance Type:Period Type:X- Details Name:us- gaap_ShortTermDebtTypeAxis **gaap_StatementBusinessSegmentsAxis** = ntrb_AgreementMember **ntrb_FourPTherapeuticsMember** Namespace Prefix:Data Type:na Balance Type:Period Type:X- Details Name: srt_MajorCustomersAxis **srt_StatementGeographicalAxis** = ntrb_MrGoodmanMember **country_US** Namespace Prefix:Data Type:na Balance Type:Period Type:X- Details Name: srt_TitleOfIndividualAxis **srt_StatementGeographicalAxis** = srt_ChiefExecutiveOfficerMember **us-gaap_NonUsMember** Namespace Prefix:Data Type:na Balance Type:Period Type: **Commitments and Contigencies** X- Details Name:srt_TitleOfIndividualAxis = srt_ChiefFinancialOfficerMember Namespace Prefix:Data Type:na Balance Type:Period Type:Subsequent Events (Details) - Subsequent Event [ Member ] - **12 Months EndedJul.25,2023** USD ( **$) Feb.01,2022 USD ($) ft²Jan.31,2025 USD ($) Jan.31,** 2024 **USD ($) Jul** "," localname":" SegmentReportingRevenueReconcilingItemLineItems"," presentation": [" http: / / nutriband . **31** com / role / ScheduleofNetSalesandPropertyandEquipmentTable" ] . **2022 USD ($) Commitments** " lang": {" en- us": {" role": {" label":" Schedule of Net Sales and **Contigencies** Property and Equipment [ Line Items ] " **Employment agreemnets expiration date Jan. 31** , " documentation":" **2025 Annual salary received per annum $ 250, 000 $ 150, 000Percentage of performance bonus 3. 50 % Incurred expenses $ 3, 000, 000 Estimated amount 5, 200, 000 Estimated cost budget 3, 200, 000 Milestone payment Warehouse space (in Square Feet) | ft² 12, 000 Monthly rental payments $ 3, 000 Lease expires date Jan. 31, 2025 Proceeds of amount $ 106, 528 $ 106, 528 Due amount 118, 675 Legal fees 500, 000 Cash 1, 000, 000 Settlement Liabilities, Current $ 100, 000 Sorrento Therapeutics Inc. [ Member ] Commitments and Contigencies [** Line Details Name:ntrb_EstimatedCost Namespace Prefix:ntrb_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:durationX- **DefinitionAmount** DefinitionThe amount of milestone payment **the entity' s equity method investment which has been sold** . ReferencesNo definition available. Details Name: ntrb_MilestonePayments **us- gaap_EquityMethodInvestmentSoldCarryingAmount** Namespace Prefix: ntrb_ **us- gaap_** Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:durationX- DefinitionAmount **DefinitionNumber** of describes the gain ( **excess stock shares of an entity that have been sold** or **granted** loss) in net income of a business over a given amount of time,thus allowing us to **shareholders** establish what the ROI (return rate) of a specific investment has been . ReferencesNo definition available. Details Name: ntrb_PercentageOfNetIncome **us-gaap_ExcessStockSharesIssued** Namespace Prefix: ntrb_ **us- gaap_** Data Type: dtr **xbrli** : percentItemType **sharesItemType** Balance Type:na Period Type: durationX **instantX** - **DefinitionInterest received** DefinitionAmount of allowance for credit loss on accounts receivable **loans and other debt instruments during the current period** . ReferencesReference 1:http: / www.xbrl.org / 2003 **2009** / role / disclosureRef **commonPracticeRef** - Topic 326 **230** - SubTopic 20 **10** - Name Accounting Standards Codification- Section 50 **45** - Paragraph 13 **16** - Subparagraph ( **f** )- Publisher FASB- URI https: / / asc.fasb.org / 1943274 / 2147479319 **2147482740** / 326- 20 **230** - 50 **10** - **45- 16 Details Name:us- gaap_ProceedsFromInterestReceived Namespace Prefix:us- gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit** items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. "} } },"auth_ref" **ReferencesNo definition available. Details Name** : [ ] },"us- gaap_SellingGeneralAndAdministrativeExpense" **gaap_OtherCommitmentsLineItems Namespace Prefix** : {" xbrltype" **us- gaap_ Data Type** : " **credit** xbrli:stringItemType Balance Type:na Period Type: durationX **instantX** - DefinitionAmount **,after effects of reinsurance,** of expense classified as **(reversal of expense) for claims incurred and costs incurred in** other - **the claim settlement process** . ReferencesReference 1:http: / www.xbrl.org / 2003 / role / exampleRef- Topic 944- SubTopic 605 **40** - Name Accounting Standards Codification- Section 55- Paragraph 14 **7** - Publisher FASB- URI https: / / asc.fasb.org / 1943274 / 2147477548 **2147480046** / 944- 605 **40** - 55- 14Reference **7Reference** 2:http: / / www.xbrl.org / 2003 **2009** / role / exampleRef **commonPracticeRef** - Topic 944- SubTopic 605 **40** - Name Accounting Standards Codification- Section 55 **50** - Paragraph 11 **3- Subparagraph (b)** - Publisher FASB- URI https: / / asc.fasb.org / 1943274 / 2147477548 **2147480081** / 944- 605 **40** - 55 **50** - 11Reference 3 **Details Name** : http: / / fasb.org / us- **gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1 Namespace Prefix:us** gaap / role / ref / legacyRef **gaap_ Data**

**Type:xbrli:monetaryItemType Balance Type:** ~~Topic 220- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 2- Subparagraph (SX~~ monetaryItemType **Balance Type** ~~",~~ **~~"~~** ~~nsuri"~~ **~~. " http: / / fasb. org / us- gaap / 2024," localname":" SellingGeneralAndAdministrativeExpense," crdr":"~~** debit **Period Type** ~~"," calculation"~~ **~~:~~** **durationX** ~~{" http: / / nutriband. com / role / ConsolidatedIncomeStatement": {" parentTag":" us-~~ **DefinitionCash payments** ~~gaap_CostsAndExpenses," weight": 1. 0," order": 4. 0 } },~~ ~~" presentation": [" http: / / nutriband. com / role / ConsolidatedIncomeStatement" ]," lang": {" en- us": {" role": {" terseLabel":" Selling, general and administrative"," label":" Selling, General and Administrative Expense"," documentation":" The aggregate total costs related~~ to **lessor** ~~selling a firm~~ ' s ~~product~~ **for use of assets under operating leases. ReferencesReference 1** :http: / / fasb.org / us- gaap / role / ref / legacyRef- ~~Topic 505- SubTopic 10-~~ Name Accounting Standards Codification- Section ~~S99~~ **45** - Paragraph ~~4~~ **25** - Subparagraph ( ~~SAB~~ **g)- SubTopic 10-** Topic **230** ~~4.C)~~ - Publisher FASB- URI https: / / asc.fasb.org / 1943274 / ~~2147480008~~ **2147482740** / ~~505~~ **230** - 10- ~~S99~~ **45** - ~~4~~ **25** Details Name:us- ~~gaap_StockholdersEquityReverseStockSplit~~ **gaap_PaymentsForRent** Namespace Prefix:us- gaap_ Data Type:xbrli: ~~stringItemType~~ **monetaryItemType** Balance Type: ~~na~~ **credit** Period Type:durationX- ~~DefinitionPer-~~ **DefinitionThe** ~~share increase~~ **cash inflow during the period from additional borrowings** in **aggregate debt** ~~excreise price of warrant~~ . ~~Excludes~~ **Includes proceeds from short- term** ~~change due to standard antidilution provision. ReferencesReference 1:http: / / www~~ and ~~services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non- sales personnel, rent, utilities, communication, etc." } } },~~ ~~" auth_ref": [" r93" ] },~~ ~~" us- gaap_SeparateAccountLiabilityWithdrawal": {" xbrltype":" monetaryItemType," nsuri":" http: / / fasb. org / us- gaap / 2024," localname":" SeparateAccountLiabilityWithdrawal," crdr":" debit," presentation": [" http: / / nutriband. com / role / SummaryofSignificantAccountingPoliciesDetails" ]," lang": {" en- us": {" role": {" terseLabel":" Research and development"," label":" Separate Account, Liability, Withdrawal"," documentation":" Amount of decrease in liability for separate account from withdrawal of funds." } } },~~ ~~" auth_ref": [" r1081" ] },~~ ~~" us- gaap_SeriesAPreferredStockMember": {" xbrltype":" domainItemType," nsuri":" http: / / fasb. org / us- gaap / 2024," localname":" SeriesAPreferredStockMember," presentation": [" http: / / nutriband. com / role / StockholdersEquityDetails" ]," lang": {" en- us": {" role": {" terseLabel":" Series A Preferred Stock [ Member ]"," label":" Series A Preferred Stock [ Member ]"," documentation":" Series A preferred stock." } } },~~ ~~" auth_ref": [" r958"," r959"," r1012" ] },~~ ~~" us- gaap_ShareBasedCompensation": {" xbrltype":" monetaryItemType," nsuri":" http: / / fasb. org / us- gaap / 2024," localname":" ShareBasedCompensation," crdr":" debit," calculation": {" http: / / nutriband. com / role / ConsolidatedCashFlow": {" parentTag":" us- gaap_NetCashProvidedByUsedInOperatingActivities," weight": 1. 0," order": 9. 0 } }," presentation": [" http: / / nutriband. com / role / ConsolidatedCashFlow" ]," lang": {" en- us": {" role": {" terseLabel":" Stock- based compensation- options"," label":" Share- Based Payment Arrangement, Noncash Expense"," documentation":" Amount of noncash expense for share- based payment arrangement." } } },~~ ~~" auth_ref": [" r4" ] },~~ ~~" us- gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {" xbrltype":" percentItemType," nsuri":" http: / / fasb. org / us- gaap / 2024," localname":" ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate," presentation": [" http: / / nutriband. com / role / OptionsandWarrantsDetails" ]," lang": {" en- us": {" role": {" terseLabel":" Dividend rate"," label":" Share- Based Compensation Arrangement by Share- Based Payment Award, Fair Value Assumptions, Expected Dividend Rate"," documentation":" The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option' s term." } } },~~ ~~" auth_ref": [" r445" ] },~~ ~~" us- gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {" xbrltype":" percentItemType," nsuri":" http: / / fasb. org / us- gaap / 2024," localname":" ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate," presentation": [" http: / / nutriband. com / role / OptionsandWarrantsDetails" ]," lang": {" en- us": {" role": {" terseLabel":" Volatility rate"," label":" Share- Based Compensation Arrangement by Share- Based Payment Award, Fair Value Assumptions, Expected Volatility Rate"," documentation":" The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability- weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } },~~ ~~" auth_ref": [" r444" ] },~~ ~~" us- gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {" xbrltype":" percentItemType," nsuri":" http: / / fasb. org / us- gaap / 2024," localname":" ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate," presentation": [" http: / / nutriband. com / role / OptionsandWarrantsDetails" ]," lang": {" en- us": {" role": {" terseLabel":" Risk- free rate"," label":" Share- Based Compensation Arrangement by Share- Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate"," documentation":" The risk- free interest rate assumption that is used in valuing an option on its own shares." } } },~~ ~~" auth_ref": [" r446" ] },~~ ~~" ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableNumber": {" xbrltype":" sharesItemType," nsuri":" http: / / nutriband. com / 20240131," localname":" ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableNumber," presentation": [" http: / / nutriband. com / role / ScheduleofChangesinOptionsOutstandingTable" ]," lang": {" en- us": {" role": {" terseLabel":" Shares, Exercisable"," documentation":" The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."," label":" Share Based Compensation Arrangement By Share Based Payment Award Option Exercisable Number" } } },~~ ~~" auth_ref": [ ] },~~ ~~" us- gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {" xbrltype":" sharesItemType," nsuri":" http: / / fasb. org / us- gaap / 2024," localname":" ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber," presentation": [" http: / / nutriband. com / role / ScheduleofChangesinOptionsOutstandingTable," http: / / nutriband. com / role / ScheduleofChangesinWarrantsOutstandingTable" ]," lang": {" en- us": {" role": {" periodStartLabel":" Shares, Outstanding, Beginning balance," periodEndLabel":" Shares, Outstanding, Ending balance," terseLabel":" Shares, Exercisable," label":" Share- Based Compensation Arrangement by Share- Based Payment Award, Options, Exercisable, Number"," documentation":" The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } },~~ ~~" auth_ref": [" r425" ] },~~ ~~" ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumbers": {" xbrltype":" sharesItemType," nsuri":" http: / / nutriband. com / 20240131," localname":" ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumbers," presentation": [" http: / / nutriband. com / role / ScheduleofSummarizesAdditionalInformationRelatingtotheOptionsOutstandingTable" ]," lang": {" en- us": {" role": {" terseLabel":" Number Exercisable (in Shares)"," documentation":" Number of share based compensation arrangement by share based payment award options exercisable numbers."," label":" Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Numbers" } } },~~ ~~" auth_ref": [ ] },~~ ~~" us- gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {" xbrltype":" perShareItemType," nsuri":" http: / / fasb. org / us- gaap / 2024," localname":" ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice," presentation": [" http: / / nutriband. com / role / ScheduleofChangesinOptionsOutstandingTable," http: / / nutriband. com / role / ScheduleofChangesinWarrantsOutstandingTable" ]," lang": {" en- us": {" role": {" terseLabel":" Exercise Price, Exercisable"," label":" Share- Based Compensation Arrangement by Share- Based Payment Award, Options, Exercisable, Weighted Average Exercise Price"," documentation":" The weighted- average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } } },~~ ~~" auth_ref": [" r425" ] },~~ ~~" us- gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {" xbrltype":" sharesItemType," nsuri":" http: / / fasb. org / us- gaap / 2024," localname":" ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod," presentation": [" http: / / nutriband. com / role / ScheduleofChangesinOptionsOutstandingTable," http: / / nutriband. com / role / ScheduleofChangesinWarrantsOutstandingTable" ]," lang": {" en- us": {" role": {" terseLabel":" Shares, Expired / Cancelled"," negatedLabel":" Shares, Expired / Cancelled"," label":" Share- Based Compensation Arrangement by Share- Based Payment Award, Options, Expirations in Period"," documentation":" Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements." } } },~~ ~~" auth_ref": [" r430" ] },~~ ~~" ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrices": {" xbrltype":" durationItemType," nsuri":" http: / / nutriband. com / 20240131," localname":" ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrices," presentation": [" http: / / nutriband. com / role / ScheduleofChangesinOptionsOutstandingTable" ]," lang": {" en- us": {" role": {" terseLabel":" Remaining Life, Expired / Cancelled"," documentation":" Remaining Life, Expired / Cancelled."," label":" Share Based Compensation Arrangement By Share Based Payment Award Options Expirations~~

In Period Weighted Average Exercise Prices" } } },"auth_ref": [ ] },"
ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodGrantDateIntrinsicValue": {" xbrltype":" monetaryItemType","
nsuri":" http: / / nutriband. com / 20240131","localname":"
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodGrantDateIntrinsicValue","crdr":" debit","presentation": [" http: / /
nutriband. com / role / ScheduleofChangesinOptionsOutstandingTable","http: / / nutriband. com / role / ScheduleofChangesinWarrantsOutstandingTable" ],"lang":
{" en- us": {" role": {" terseLabel":" Intrinsic Value, Granted","documentation":" Sharebased compensation arrangement by sharebased payment award options
grant in period grant date intrinsic value.","label":" Share Based Compensation Arrangement By Share Based Payment Award Options Grant In Period Grant Date
Intrinsic Value" } } },"auth_ref": [ ] }," us- gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {"
xbrltype":" sharesItemType","nsuri":" http: / / fasb. org / us- gaap / 2024","localname":"
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross","presentation": [" http: / / nutriband. com / role /
ScheduleofChangesinOptionsOutstandingTable","http: / / nutriband. com / role / ScheduleofChangesinWarrantsOutstandingTable" ],"lang": {" en- us": {" role": {"
terseLabel":" Shares, Granted","label":" Share- Based Compensation Arrangement by Share- Based Payment Award, Options, Grants in Period, Gross","
documentation":" Gross number of share options (or share units) granted during the period." } } },"auth_ref": [" r427" ] }," us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {" xbrltype":" monetaryItemType","nsuri":" http: /
/ fasb. org / us- gaap / 2024","localname":" ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue","crdr":"
debit","presentation": [" http: / / nutriband. com / role / ScheduleofChangesinWarrantsOutstandingTable" ],"lang": {" en- us": {" role": {" periodStartLabel":"
Intrinsic Value, Outstanding beginning balance","periodEndLabel":" Intrinsic Value, Outstanding ending balance","label":" Share- Based Compensation
Arrangement by Share- Based Payment Award, Options, Outstanding, Intrinsic Value","documentation":" Amount by which the current fair value of the
underlying stock exceeds the exercise price of options outstanding." } } },"auth_ref": [" r43" ] }," us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice": {"
xbrltype":" perShareItemType","nsuri":" http: / / fasb. org / us- gaap / 2024","localname":"
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice","presentation":
[" http: / / nutriband. com / role / ScheduleofSummarizesAdditionalInformationRelatingtotheWarrantsOutstandingTable" ],"lang": {" en- us": {" role": {"
terseLabel":" Weighted Average Exercise Price for Shares Outstanding","label":" Share- Based Compensation Arrangement by Share- Based Payment Award,
Options, Outstanding, Period Increase (Decrease), Weighted Average Exercise Price","documentation":" Change in the weighted average exercise price of options
outstanding." } } },"auth_ref": [ ] }," us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {" xbrltype":"
perShareItemType","nsuri":" http: / / fasb. org / us- gaap / 2024","localname":"
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice","presentation": [" http: / / nutriband.
com / role / ScheduleofChangesinWarrantsOutstandingTable" ],"lang": {" en- us": {" role": {" periodStartLabel":" Exercise Price, Outstanding beginning
balance","periodEndLabel":" Exercise Price, Outstanding ending balance","label":" Share- Based Compensation Arrangement by Share- Based Payment Award,
Options, Outstanding, Weighted Average Exercise Price","documentation":" Weighted average price at which grantees can acquire the shares reserved for issuance
under the stock option plan." } } },"auth_ref": ["r423","r424" ] },"
ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardRangeOfExercisePrices": {" xbrltype":" perShareItemType","nsuri":" http: / / nutriband.
com / 20240131","localname":" ShareBasedCompensationArrangementByShareBasedPaymentAwardRangeOfExercisePrices","presentation": [" http: / /
nutriband. com / role / ScheduleofSummarizesAdditionalInformationRelatingtotheOptionsOutstandingTable" ],"lang": {" en- us": {" role": {" terseLabel":" Range
of Exercise Prices","documentation":" Duration of long - term share based compensation arrangement by share based payment award range of exercise prices.","
label":" Share Based Compensation Arrangement By Share Based Payment Award Range Of Exercise Prices" } } },"auth_ref": [ ] },"
ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableWeightedAverageExercisePrice": {" xbrltype":"
perShareItemType","nsuri":" http: / / nutriband. com / 20240131","localname":"
ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableWeightedAverageExercisePrice","presentation": [" http: / / nutriband.
com / role / ScheduleofSummarizesAdditionalInformationRelatingtotheOptionsOutstandingTable" ],"lang": {" en- us": {" role": {" terseLabel":" Weighted Average
Exercise Price for Shares Exercisable","documentation":" The price per share based compensation arrangement by share based payment award warrants
exercisable weighted average exercise price.","label":" Share Based Compensation Arrangement By Share Based Payment Award Warrants Exercisable Weighted
Average Exercise Price" } } },"auth_ref": [ ] }," ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsIntrinsicValue": {" xbrltype":"
monetaryItemType","nsuri":" http: / / nutriband. com / 20240131","localname":"
ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsIntrinsicValue","crdr":" debit","presentation": [" http: / / nutriband. com / role /
ScheduleofSummarizesAdditionalInformationRelatingtotheOptionsOutstandingTable" ],"lang": {" en- us": {" role": {" terseLabel":" Intrinsic Value (in Dollars)","
documentation":" It represents intrinsic value.","label":" Share Based Compensation Arrangement By Share Based Payment Award Warrants Intrinsic Value" } }
},"auth_ref": [ ] }," ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingNumber": {" xbrltype":" sharesItemType","
nsuri":" http: / / nutriband. com / 20240131","localname":" ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingNumber","
presentation": [" http: / / nutriband. com / role / ScheduleofSummarizesAdditionalInformationRelatingtotheOptionsOutstandingTable" ],"lang": {" en- us": {" role":
{" terseLabel":" Number Outstanding (in Shares)","documentation":" Number of share based compensation arrangement by share based payment award warrants
outstanding number.","label":" Share Based Compensation Arrangement By Share Based Payment Award Warrants Outstanding Number" } } },"auth_ref": [ ] },"
ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice": {"
xbrltype":" perShareItemType","nsuri":" http: / / nutriband. com / 20240131","localname":"
ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice","presentation":
[" http: / / nutriband. com / role / ScheduleofSummarizesAdditionalInformationRelatingtotheOptionsOutstandingTable" ],"lang": {" en- us": {" role": {"
terseLabel":" Weighted Average Exercise Price for Shares Outstanding","documentation":" The price per share share based compensation arrangement by share
based payment award warrants outstanding period increase decrease weighted average exercise price.","label":" Share Based Compensation Arrangement By Share
Based Payment Award Warrants Outstanding Period Increase Decrease Weighted Average Exercise Price" } } },"auth_ref": [ ] }," us-
gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {" xbrltype":" domainItemType","nsuri":" http: /
fasb. org / us- gaap / 2024","localname":" ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain","
presentation": [" http: / / xbrl. sec. gov / ecd / role / AwardTimingDisclosure" ],"lang": {" en- us": {" role": {" label":" All Award Types","terseLabel":" All Award
Types","documentation":" Award under share- based payment arrangement." } } },"auth_ref": [" r419","r420","r421","r423","r424","r425","r426","r427","
r428","r429","r430","r431","r432","r433","r434","r435","r436","r437","r438","r439","r440","r443","r444","r445","r446","r447" ] }," us-
gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {" xbrltype":"
perShareItemType","nsuri":" http: / / fasb. org / us- gaap / 2024","localname":"
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice","presentation": [" http: / /
nutriband. com / role / ScheduleofChangesinOptionsOutstandingTable","http: / / nutriband. com / role / ScheduleofChangesinWarrantsOutstandingTable" ],"lang":
{" en- us": {" role": {" terseLabel":" Exercise Price, Exercised","label":" Share- Based Compensation Arrangements by Share- Based Payment Award, Options,
Exercises in Period, Weighted Average Exercise Price","documentation":" Weighted average price at which option holders acquired shares when converting their
stock options into shares." } } },"auth_ref": [" r428" ] },"
ntrb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInRemainingLifeExercised": {" xbrltype":" durationItemType","
nsuri":" http: / / nutriband. com / 20240131","localname":"
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInRemainingLifeExercised","presentation": [" http: / / nutriband. com / role
/ ScheduleofChangesinWarrantsOutstandingTable" ],"lang": {" en- us": {" role": {" terseLabel":" Remaining Life, Exercised","documentation":" Duration of long-
term share based compensation arrangements by share based payment award options exercises in remaining life exercised.","label":" Share Based Compensation
Arrangements By Share Based Payment Award Options Exercises In Remaining Life Exercised" } } },"auth_ref": [ ] }," us-
gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {" xbrltype":"

perShareItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":"
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"," presentation": [" http: / /
nutriband. com / role / ScheduleofChangesinOptionsOutstandingTable"," http: / / nutriband. com / role / ScheduleofChangesinWarrantsOutstandingTable" ],"lang":
{" en- us": {" role": {" terseLabel":" Exercise Price, Expired / Cancelled"," label":" Share- Based Compensation Arrangements by Share- Based Payment Award,
Options, Expirations in Period, Weighted Average Exercise Price"," documentation":" Weighted average price at which grantees could have acquired the
underlying shares with respect to stock options of the plan that expired." } } },"auth_ref": [" r430" ] }," us-
gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {" xbrltype":"
perShareItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":"
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"," presentation": [" http: / / nutriband.
com / role / ScheduleofChangesinOptionsOutstandingTable"," http: / / nutriband. com / role / ScheduleofChangesinWarrantsOutstandingTable" ]," lang": {" en- us":
{" role": {" terseLabel":" Exercise Price, Granted"," label":" Share- Based Compensation Arrangements by Share- Based Payment Award, Options, Grants in
Period, Weighted Average Exercise Price"," documentation":" Weighted average per share amount at which grantees can acquire shares of common stock by
exercise of options." } } },"auth_ref": [" r427" ] }," ntrb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOutstandingNumber1": {"
xbrltype":" sharesItemType"," nsuri":" http: / / nutriband. com / 20240131"," localname":"
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOutstandingNumber1"," presentation": [" http: / / nutriband. com / role /
ScheduleofChangesinWarrantsOutstandingTable" ]," lang": {" en- us": {" role": {" periodStartLabel":" Shares, Outstanding beginning balance","
periodEndLabel":" Shares, Outstanding ending balance"," documentation":" The price per share based compensation arrangements by share based payment award
options outstanding number1"," label":" Share Based Compensation Arrangements By Share Based Payment Award Options Outstanding Number1" } } },"
auth_ref": [ ] }," ntrb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsRemainingLifeExpiredCancelled": {" xbrltype":"
durationItemType"," nsuri":" http: / / nutriband. com / 20240131"," localname":"
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsRemainingLifeExpiredCancelled"," presentation": [" http: / / nutriband. com / role /
ScheduleofChangesinWarrantsOutstandingTable" ]," lang": {" en- us": {" role": {" terseLabel":" Remaining Life, Expired / Cancelled"," documentation":" Duration
of long- term share based compensation arrangements by share based payment award options emaining life expired cancelled."," label":" Share Based
Compensation Arrangements By Share Based Payment Award Options Remaining Life Expired Cancelled" } } },"auth_ref": [ ] },"
ntrb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsRemainingLifeRemainingLifeGranted": {" xbrltype":" durationItemType","
nsuri":" http: / / nutriband. com / 20240131"," localname":"
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsRemainingLifeRemainingLifeGranted"," presentation": [" http: / / nutriband. com /
role / ScheduleofChangesinWarrantsOutstandingTable" ]," lang": {" en- us": {" role": {" terseLabel":" Remaining Life, Granted"," documentation":" Remaining
Life, Granted."," label":" Share Based Compensation Arrangements By Share Based Payment Award Options Remaining Life Remaining Life Granted" } } },"
auth_ref": [ ] }," ntrb_ShareBasedCompensationArrangementsByShareBasedPaymentRemainingLifeExercised": {" xbrltype":" durationItemType"," nsuri":" http: /
nutriband. com / 20240131"," localname":" ShareBasedCompensationArrangementsByShareBasedPaymentRemainingLifeExercised"," presentation": [" http: /
nutriband. com / role / ScheduleofChangesinOptionsOutstandingTable" ]," lang": {" en- us": {" role": {" terseLabel":" Remaining Life, Exercised","
documentation":" Remaining Life, Exercised."," label":" Share Based Compensation Arrangements By Share Based Payment Remaining Life Exercised" } } },"
auth_ref": [ ] }," us- gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {" xbrltype":" textBlockItemType"," nsuri":" http: / / fasb. org / us- gaap /
2024"," localname":" ShareBasedCompensationOptionAndIncentivePlansPolicy"," presentation": [" http: / / nutriband. com / role / AccountingPoliciesByPolicy" ],"
lang": {" en- us": {" role": {" terseLabel":" Stock- Based Compensation"," label":" Share- Based Payment Arrangement [ Policy Text Block ]"," documentation":"
Disclosure of accounting policy for award under share- based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring
cost." } } },"auth_ref": [" r418"," r422"," r441"," r442"," r443"," r444"," r447"," r449"," r450"," r451"," r452" ] }," us-
gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": {" xbrltype":" stringItemType"," nsuri":" http: / / fasb. org /
us- gaap / 2024"," localname":" ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"," presentation": [" http: /
nutriband. com / role / ScheduleofSummarizesAdditionalInformationRelatingtotheOptionsOutstandingTable"," http: / / nutriband. com / role /
ScheduleofSummarizesAdditionalInformationRelatingtotheWarrantsOutstandingTable" ]," lang": {" en- us": {" role": {" label":" Exercise Price Range [ Axis ]","
documentation":" Information by range of option prices pertaining to options granted." } } },"auth_ref": [" r46" ] }," us-
gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": {" xbrltype":" domainItemType"," nsuri":" http: / / fasb. org
/ us- gaap / 2024"," localname":" ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"," presentation": [" http: /
nutriband. com / role / ScheduleofSummarizesAdditionalInformationRelatingtotheOptionsOutstandingTable" ]," lang": {" en- us": {" role": {" label":" Exercise
Price Range [ Domain ]"," documentation":" Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies
outstanding options by ranges of exercise prices." } } },"auth_ref": [" r47" ] }," us-
gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions": {" xbrltype":" sharesItemType","
nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":"
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions"," presentation": [" http: / / nutriband. com /
role / OptionsandWarrantsDetails" ]," lang": {" en- us": {" role": {" terseLabel":" Purchase warrant (in Shares)"," label":" Share- Based Payment Arrangement,
Option, Exercise Price Range, Shares Exercisable"," documentation":" The number of shares reserved for issuance pertaining to the outstanding exercisable stock
options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied." } } },"
auth_ref": [" r45" ] }," us- gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": {" xbrltype":"
perShareItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":"
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"," presentation": [" http: / / nutriband. com / role /
ScheduleofSummarizesAdditionalInformationRelatingtotheWarrantsOutstandingTable" ]," lang": {" en- us": {" role": {" terseLabel":" Range of Exercise Prices","
label":" Share- Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit"," documentation":" The ceiling of a customized range of exercise
prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information
pertaining to awards in the customized range." } } },"auth_ref": [" r47" ] }," ntrb_ShareBasedIntrinsicValueExercised": {" xbrltype":" monetaryItemType","
nsuri":" http: / / nutriband. com / 20240131"," localname":" ShareBasedIntrinsicValueExercised"," crdr":" debit"," presentation": [" http: / / nutriband. com / role /
ScheduleofChangesinOptionsOutstandingTable" ]," lang": {" en- us": {" role": {" terseLabel":" Intrinsic Value, Exercised"," documentation":" The amount of share
based intrinsic value exercised."," label":" Share Based Intrinsic Value Exercised" } } },"auth_ref": [ ] }," ntrb_ShareBasedIntrinsicValueExpiredCancelled": {"
xbrltype":" monetaryItemType"," nsuri":" http: / / nutriband. com / 20240131"," localname":" ShareBasedIntrinsicValueExpiredCancelled"," crdr":" debit","
presentation": [" http: / / nutriband. com / role / ScheduleofChangesinOptionsOutstandingTable" ]," lang": {" en- us": {" role": {" terseLabel":" Intrinsic Value,
Expired / Cancelled"," documentation":" Intrinsic Value, Expired / Cancelled."," label":" Share Based Intrinsic Value Expired Cancelled" } } },"auth_ref": [ ] },"
ntrb_ShareBasedPaymentArrangementIntrinsicValueExpiredCancelled": {" xbrltype":" monetaryItemType"," nsuri":" http: / / nutriband. com / 20240131","
localname":" ShareBasedPaymentArrangementIntrinsicValueExpiredCancelled"," crdr":" debit"," presentation": [" http: / / nutriband. com / role /
ScheduleofChangesinWarrantsOutstandingTable" ]," lang": {" en- us": {" role": {" terseLabel":" Intrinsic Value, Expired / Cancelled"," documentation":" Share
based payment arrangement intrinsic value expired."," label":" Share Based Payment Arrangement Intrinsic Value Expired Cancelled" } } },"auth_ref": [ ] }," us-
gaap_SharePrice": {" xbrltype":" perShareItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" SharePrice"," presentation": [" http: / / nutriband.
com / role / OptionsandWarrantsDetails" ]," lang": {" en- us": {" role": {" terseLabel":" Purchase shares (in Dollars per share)"," label":" Share Price","
documentation":" Price of a single share of a number of saleable stocks of a company." } } },"auth_ref": [ ] }," us-
gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {" xbrltype":" durationItemType"," nsuri":" http: / / fasb. org / us-
gaap / 2024"," localname":" SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"," presentation": [" http: / / nutriband. com / role /
RelatedPartyTransactionsDetails" ]," lang": {" en- us": {" role": {" terseLabel":" Expire year"," label":" Share- Based Compensation Arrangement by Share- Based
Payment Award, Expiration Period"," documentation":" Period from grant date that an equity- based award expires, in' PnYnMnDTnHnMnS' format, for example,'
P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } },"auth_ref": [" r790" ] }," us-
gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {" xbrltype":" durationItemType"," nsuri":"

http: / / fasb. org / us- gaap / 2024"," localname":" SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"," presentation": [" http: / / nutriband. com / role / OptionsandWarrantsDetails" ]," lang": {" en- us": {" role": {" terseLabel":" Expected term"," label":" Share- Based Compensation Arrangement by Share- Based Payment Award, Fair Value Assumptions, Expected Term"," documentation":" Expected term of award under share- based payment arrangement, in' PnYnMnDTnHnMnS' format, for example,' P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }," auth_ref": [" r443" ] }," us- gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"," crdr":" debit"," presentation": [" http: / / nutriband. com / role / ScheduleofChangesinOptionsOutstandingTable"," http: / / nutriband. com / role / ScheduleofChangesinWarrantsOutstandingTable" ]," lang": {" en- us": {" role": {" periodStartLabel":" Intrinsic Value, Outstanding, Beginning balance"," periodEndLabel":" Intrinsic Value, Outstanding, Ending balance"," terseLabel":" Intrinsic Value, Exercisable"," label":" Share- Based Compensation Arrangement by Share- Based Payment Award, Options, Exercisable, Intrinsic Value"," documentation":" Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable." } } }," auth_ref": [" r43" ] }," us- gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {" xbrltype":" durationItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"," presentation": [" http: / / nutriband. com / role / ScheduleofChangesinOptionsOutstandingTable"," http: / / nutriband. com / role / ScheduleofChangesinWarrantsOutstandingTable" ]," lang": {" en- us": {" role": {" terseLabel":" Remaining Life, Exercisable"," label":" Share- Based Compensation Arrangement by Share- Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term"," documentation":" Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in' PnYnMnDTnHnMnS' format, for example,' P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }," auth_ref": [" r43" ] }," ntrb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm": {" xbrltype":" durationItemType"," nsuri":" http: / / nutriband. com / 20240131"," localname":" SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm"," presentation": [" http: / / nutriband. com / role / ScheduleofChangesinWarrantsOutstandingTable" ]," lang": {" en- us": {" role": {" terseLabel":" Remaining Life, Outstanding beginning balance"," documentation":" Duration of long- term share based compensation arangement by share based payment award options outstanding weighted average remaining contractual term."," label":" Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term" } } }," auth_ref": [ ] }," us- gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {" xbrltype":" durationItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"," presentation": [" http: / / nutriband. com / role / ScheduleofChangesinOptionsOutstandingTable" ]," lang": {" en- us": {" role": {" terseLabel":" Remaining Life, Outstanding, Beginning balance"," label":" Share- Based Compensation Arrangement by Share- Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term"," documentation":" Weighted average remaining contractual term for option awards outstanding, in' PnYnMnDTnHnMnS' format, for example,' P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }," auth_ref": [" r120" ] }," ntrb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAveragesRemainingContractualTerm2Granted": {" xbrltype":" durationItemType"," nsuri":" http: / / nutriband. com / 20240131"," localname":" SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAveragesRemainingContractualTerm2Granted"," presentation": [" http: / / nutriband. com / role / ScheduleofChangesinOptionsOutstandingTable" ]," lang": {" en- us": {" role": {" terseLabel":" Remaining Life, Granted"," documentation":" Remaining Life, Granted."," label":" Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Averages Remaining Contractual Term2 Granted" } } }," auth_ref": [ ] }," ntrb_SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsOutstandingWeightedAverageRemainingContractualTerm2": {" xbrltype":" durationItemType"," nsuri":" http: / / nutriband. com / 20240131"," localname":" SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsOutstandingWeightedAverageRemainingContractualTerm2"," presentation": [" http: / / nutriband. com / role / ScheduleofSummarizesAdditionalInformationRelatingtotheOptionsOutstandingTable" ]," lang": {" en- us": {" role": {" terseLabel":" Weighted Average Remaining Contractual Life (Years)"," documentation":" Duration of long- term share based compensation arrangement by share based payment award warrants outstanding weighted average remaining contractual term2"," label":" Sharebased Compensation Arrangement By Sharebased Payment Award Warrants Outstanding Weighted Average Remaining Contractual Term2" } } }," auth_ref": [ ] }," ntrb_SharebasedCompensationArrangementsBySharebasedPaymentAwardOptionExercisableIntrinsicValue1": {" xbrltype":" monetaryItemType"," nsuri":" http: / / nutriband. com / 20240131"," localname":" SharebasedCompensationArrangementsBySharebasedPaymentAwardOptionExercisableIntrinsicValue1"," crdr":" debit"," presentation": [" http: / / nutriband. com / role / ScheduleofChangesinOptionsOutstandingTable" ]," lang": {" en- us": {" role": {" terseLabel":" Intrinsic Value, Exercisable"," documentation":" Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."," label":" Sharebased Compensation Arrangements By Sharebased Payment Award Option Exercisable Intrinsic Value1" } } }," auth_ref": [ ] }," ntrb_SharebasedCompensationArrangementsBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm": {" xbrltype":" durationItemType"," nsuri":" http: / / nutriband. com / 20240131"," localname":" SharebasedCompensationArrangementsBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm"," presentation": [" http: / / nutriband. com / role / ScheduleofChangesinWarrantsOutstandingTable" ]," lang": {" en- us": {" role": {" terseLabel":" Remaining Life, Outstanding ending balance"," documentation":" Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."," label":" Sharebased Compensation Arrangements By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term" } } }," auth_ref": [ ] }," ntrb_SharebasedCompensationArrangementsBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {" xbrltype":" durationItemType"," nsuri":" http: / / nutriband. com / 20240131"," localname":" SharebasedCompensationArrangementsBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"," presentation": [" http: / / nutriband. com / role / ScheduleofChangesinOptionsOutstandingTable" ]," lang": {" en- us": {" role": {" terseLabel":" Remaining Life, Outstanding, Ending balance"," documentation":" Share- based compensation arrangement by share- based payment award, options, outstanding, weighted average remaining contractual term."," label":" Sharebased Compensation Arrangements By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2" } } }," auth_ref": [ ] }," us- gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1": {" xbrltype":" perShareItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1"," presentation": [" http: / / nutriband. com / role / ScheduleofSummarizesAdditionalInformationRelatingtotheWarrantsOutstandingTable" ]," lang": {" en- us": {" role": {" terseLabel":" Weighted Average Exercise Price for Shares Exercisable"," label":" Share- Based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price"," documentation":" Weighted average exercise price as of the balance sheet date for those equity- based payment arrangements exercisable and outstanding." } } }," auth_ref": [" r44" ] }," us- gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2": {" xbrltype":" durationItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2"," presentation": [" http: / / nutriband. com / role / ScheduleofSummarizesAdditionalInformationRelatingtotheWarrantsOutstandingTable" ]," lang": {" en- us": {" role": {" terseLabel":" Weighted Average Remaining Contractual Life (Years)"," label":" Share- Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term"," documentation":" Weighted average remaining contractual term of outstanding stock options, in' PnYnMnDTnHnMnS' format, for example,' P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }," auth_ref": [" r120" ] },"

us- gaap_SharesIssued": {" xbrltype":" sharesItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" SharesIssued"," presentation": [" http: / / nutriband. com / role / OptionsandWarrantsDetails"," http: / / nutriband. com / role / SubsequentEventsDetails" ]," lang": {" en- us": {" role": {" terseLabel":" Exercise price (in Shares)"," verboseLabel":" Shares issued"," label":" Shares, Issued"," documentation":" Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury." } } },"auth_ref": [" r8" ] },"us- gaap_SharesIssuedPricePerShare": {" xbrltype":" perShareItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" SharesIssuedPricePerShare"," presentation": [" http: / / nutriband. com / role / SubsequentEventsDetails" ]," lang": {" en- us": {" role": {" terseLabel":" Prices per share (in Dollars per share)"," label":" Shares Issued, Price Per Share"," documentation":" Per share or per unit amount of equity securities issued." } } },"auth_ref": [ ] },"us- gaap_SharesOutstanding": {" xbrltype":" sharesItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" SharesOutstanding"," presentation": [" http: / / nutriband. com / role / ShareholdersEquityType2or3" ]," lang": {" en- us": {" role": {" periodStartLabel":" Balance (in Shares)"," periodEndLabel":" Balance (in Shares)"," label":" Shares, Outstanding"," documentation":" Number of shares issued which are neither cancelled nor held in the treasury." } } },"auth_ref": [ ] },"us- gaap_ShortTermDebtTypeAxis": {" xbrltype":" stringItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" ShortTermDebtTypeAxis"," presentation": [" http: / / nutriband. com / role / CommitmentsandContigenciesDetails"," http: / / nutriband. com / role / NotesPayableDetails" ]," lang": {" en- us": {" role": {" label":" Short- Term Debt, Type [ Axis ]"," documentation":" Information by type of short- term debt arrangement." } } },"auth_ref": [" r66"," r1004"," r1005"," r1006" ] },"**http: / / www. xbrl. org / 2009 / role / commonPracticeRef- Topic 230- SubTopic 10- Name Accounting Standards Codification- Section 45- Paragraph 14- Subparagraph (b)- Publisher FASB- URI https: / / asc. fasb. org / 1943274 / 2147482740 / 230- 10- 45- 14 Details Name:** us- gaap_ShortTermDebtTypeDomain" **gaap_ProceedsFromIssuanceOfDebt Namespace Prefix** ": {" xbrltype":" domainItemType"," nsuri":" http: / / fasb. org / us- gaap **gaap_ Data Type** / 2024"," localname": **xbrli** " ShortTermDebtTypeDomain"," presentation": [" http **monetaryItemType Balance Type** : **debit Period Type** / / nutriband. com / role / CommitmentsandContigenciesDetails"," http: **durationX** / / nutriband. com / role / NotesPayableDetails" ]," lang": {" en- **DefinitionAmounts payable for money transfers, money orders, and consumer payment service arrangements. Settlement liabilities include amounts payable to intermediaries for global payment transfers. ReferencesNo definition available. Details Name:** us ": {" role": {" label":" Short- Term Debt, **gaap_SettlementLiabilitiesCurrent Namespace Prefix: us- gaap_ Data** Type [ Domain ]"," documentation": "**xbrli: monetaryItemType Balance** Type **:** of short- term debt arrangement, such as notes, line of credit **Period Type** , commercial paper, asset- based financing, project financing, letter of credit financing." } } },"auth_ref": **instantX- Details Name:** [" r64"," r1004"," r1005"," r1006" ] },"us- gaap_SignificantAccountingPoliciesTextBlock" **gaap_DebtInstrumentAxis = ntrb_SorrentoTherapeuticsIncMember Namespace Prefix** : **Data Type** {" xbrltype": **na Balance Type** " textBlockItemType"," nsuri": " http **Period Type** : **X** / / fasb. org / us- **Details Name** gaap / 2024"," localname": **srt_TitleOfIndividualAxis = srt_ChiefExecutiveOfficerMember Namespace Prefix** " SignificantAccountingPoliciesTextBlock"," presentation": **Data Type** [" http: **na Balance Type** / / nutriband. com / role / SummaryofSignificantAccountingPolicies" ]," lang": **Period Type** {" en- us": **X** {" role": {" terseLabel":" SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"," label":" Significant Accounting Policies [ Text Block ]"," documentation":" The entire disclosure for all significant accounting policies of the reporting entity." } } },"auth_ref": [" r105"," r220" ] },"dei_SolicitingMaterial": {" xbrltype":" booleanItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" SolicitingMaterial"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover" ]," lang": {" en- us" **Details Name** : {" role" **srt_TitleOfIndividualAxis = ntrb_MrGoodmanMember Namespace Prefix** : **Data Type** {" label": **na Balance Type** " Soliciting Material"," documentation": **Period Type: Subsequent Events (Details)** " Boolean flag that is true when the Form 8- **USD ($)** K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a- 12 **Months EndedMar** under the Exchange Act. **04** " } } }, "auth_ref": [" r835" ] },"us- gaap_StatementBusinessSegmentsAxis": {" xbrltype":" stringItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024 **2025 Feb** "," localname":" StatementBusinessSegmentsAxis"," presentation": [" http: / / nutriband. **06** com / role / ScheduleofNetSalesandPropertyandEquipmentTable", " http: / / nutriband. com / role / ScheduleofSegmentPerformancetotheGAAPMeasureofGrossProfitTable" ]," lang": {" en- us": {" role": {" label":" Segments [ Axis ]"," documentation":" Information by business segments." } } },"auth_ref": [" r142"," r143"," r144"," r145"," r185"," r253"," r258"," r261"," r262"," r263"," r264"," r265"," r266"," r267"," r268"," r269"," r270"," r272"," r273"," r275"," r276"," r277"," r278"," r279"," r280"," r281"," r282"," r284"," r285"," r286"," r291"," r309"," r310"," r311"," r312"," r313"," r314"," r315"," r316"," r317"," r333"," r336"," r342"," r343"," r600"," r601"," r602"," r603"," r604"," r605"," r606"," r607"," r608"," r609"," r610"," r768"," r771"," r772"," r777"," r814"," r1053"," r1055"," r1056"," r1057"," r1058"," r1059"," r1060"," r1061"," r1062"," r1063"," r1064"," r1065"," r1066"," r1067"," r1068"," r1069"," r1070"," r1071"," r1072"," r1073"," r1074"," r1075"," r1076"," r1077"," r1078"," r1079"," r1080"," r1082"," r1083" ] },"us- gaap_StatementClassOfStockAxis": {" xbrltype":" stringItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024 **2025 Jan** "," localname":" StatementClassOfStockAxis"," presentation": [" http: / / nutriband. **31** com / role / StockholdersEquityDetails", " http: / / xbrl. sec. gov / dei / role / document / Cover" ]," lang": {" en- us": {" role": {" label":" Class of Stock [ Axis ]"," documentation":" Information by the different classes of stock of the entity." } } },"auth_ref": [" r161"," r198"," r199"," r200"," r223"," r245"," r246"," r248"," r250"," r255"," r256"," r297"," r352"," r354"," r355"," r356"," r359"," r360"," r389"," r390"," r392"," r395"," r401"," r504"," r625"," r626"," r627"," r628"," r634"," r635"," r637"," r638"," r639"," r640"," r641"," r642"," r643"," r644"," r645"," r647"," r664"," r687"," r707"," r731"," r732"," r733"," r734"," r735"," r947"," r974"," r983" ] },"us- gaap_StatementEquityComponentsAxis": {" xbrltype":" stringItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024 **2025 Jan** "," localname":" StatementEquityComponentsAxis"," presentation": [" http: / / nutriband. **31** com / role / RelatedPartyTransactionsDetails", **2024Subsequent Events** " http: / / nutriband. com / role / ShareholdersEquityType2or3"," http: / / nutriband. com / role / StockholdersEquityDetails"," http: / / nutriband. com / role / SubsequentEventsDetails" ]," lang": {" en- us": {" role": {" label":" Equity Components [ Axis ]"," documentation":" Information by component of equity." } } },"auth_ref": [" r8"," r77"," r81"," r82"," r184"," r209"," r210"," r211"," r228"," r229"," r230"," r232"," r237"," r239"," r241"," r254"," r298"," r299"," r335"," r403"," r473"," r474"," r480"," r481"," r482"," r484"," r486"," r487"," r492"," r493"," r494"," r495"," r496"," r497"," r499"," r505"," r506"," r507"," r508"," r509"," r510"," r514"," r515"," r522"," r596"," r613"," r614"," r615"," r634"," r707" ] },"srt_StatementGeographicalAxis": {" xbrltype":" stringItemType"," nsuri":" http: / / fasb. org / srt / 2024"," localname":" StatementGeographicalAxis"," presentation": [" http: / / nutriband. com / role / ScheduleofNetSalesandPropertyandEquipmentTable"," http: / / nutriband. com / role / ScheduleofRevenuebyGeographicLocationTable" ]," lang": {" en- us": {" role": {" label":" Geographical [ Axis ]"," documentation":" Information by geographical components." } } },"auth_ref": [" r163"," r165"," r168"," r170"," r171"," r172"," r173"," r174"," r175"," r176"," r177"," r178"," r179"," r180"," r289"," r290"," r544"," r545"," r546"," r547"," r548"," r549"," r550"," r551"," r552"," r553"," r554"," r555"," r556"," r557"," r558"," r559"," r560"," r563"," r564"," r565"," r566"," r567"," r568"," r569"," r570"," r571"," r572"," r573"," r574"," r575"," r649"," r650"," r651"," r717"," r719"," r723"," r730"," r737"," r740"," r741"," r742"," r743"," r744"," r745"," r746"," r747"," r748"," r755"," r785"," r800"," r801"," r802"," r803"," r805"," r806"," r807"," r808"," r813"," r818"," r1013"," r1053"," r1055"," r1056"," r1058"," r1059"," r1060"," r1061"," r1062"," r1063"," r1064"," r1065"," r1066"," r1067"," r1068"," r1069"," r1070"," r1071"," r1072"," r1073"," r1074"," r1075"," r1076"," r1077"," r1078"," r1079"," r1080"," r1082"," r1083" ] },"us- gaap_StatementLineItems": {" xbrltype":" stringItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" StatementLineItems"," presentation": [" http: / / nutriband. com / role / ConsolidatedBalanceSheet"," http: / / nutriband. com / role / ShareholdersEquityType2or3" ]," lang": {" en- us": {" role": {" label":" Statement [ Line Items ] "**Exercised warrants Shares of common stock 46** , **961 Issued shares value (** " documentation":" Line items represent financial concepts included in **Dollars** a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } },"auth_ref": [" r228"," r229"," r230"," r254"," r515"," r541"," r623"," r647"," r656"," r657"," r658"," r659"," r660"," r661"," r664"," r667"," r668"," r669"," r670"," r671"," r673"," r674"," r675"," r676"," r679"," r680"," r681"," r682"," r683"," r685"," r688"," r689"," r693"," r694"," r695"," r696"," r697"," r698"," r699"," r700"," r701"," r702"," r703"," r704"," r707"," r819" ] },"us- gaap_StatementOfCashFlowsAbstract": {" xbrltype":" stringItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" StatementOfCashFlowsAbstract"," lang": {" en- us": {" role": {" label":" Statement of Cash Flows [ Abstract ]" } } },"auth_ref": [ ] },"us- gaap_StatementOfFinancialPositionAbstract": {" xbrltype":" stringItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" StatementOfFinancialPositionAbstract"," lang": {" en- us": {" role": {" label":" Statement of Financial Position [ Abstract ]" } } },"auth_ref": [ ] },"us- gaap_StatementOfStockholdersEquityAbstract": {" xbrltype":" stringItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" StatementOfStockholdersEquityAbstract"," lang": {" en- us": {" role": {" label":" Statement of Stockholders' Equity [ Abstract ]" } } },"auth_ref": [ ] },"srt_StatementScenarioAxis": {" xbrltype":" stringItemType"," nsuri":" http: / / fasb. org / srt / 2024"," localname":" StatementScenarioAxis"," presentation": [" http: / / nutriband. com / role / StockholdersEquityDetails" ]," lang": {" en- us": {" role": {" label":" Scenario [ Axis ]"," documentation":" Information by scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts." } } },"auth_ref": [" r181"," r242"," r417"," r948"," r949"," r981" ] },"us- gaap_StatementTable": {" xbrltype":" stringItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" StatementTable"," presentation": [" http: / / nutriband. com / role / ConsolidatedBalanceSheet"," http: / / nutriband. com / role / ShareholdersEquityType2or3" ]," lang": {" en- us": {" role": {" label":" Statement [ Table ]"," documentation":" Disclosure of information about statement of comprehensive income, income, other

comprehensive income, financial position, cash flows, and shareholders' equity." } } },"auth_ref":["r228","r229","r230","r254","r292","r515","r541","r623","r647","r656","r657","r658","r659","r660","r661","r664","r667","r668","r669","r670","r671","r673","r674","r675","r676","r679","r680","r681","r682","r683","r685","r688","r689","r693","r694","r695","r696","r697","r698","r699","r700","r701","r702","r703","r704","r707","r819"] },"ecd_StkPrcOrTsrEstimationMethodTextBlock":{"xbrltype":"textBlockItemType","nsuri":"http://xbrl.sec.gov/ecd/2024","localname":"StkPrcOrTsrEstimationMethodTextBlock","presentation":["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"],"lang":{"en-us":{"role":{"label":"Stock Price or TSR Estimation Method [Text Block]","terseLabel":"Stock Price or TSR Estimation Method" } } },"auth_ref":["r847","r858","r874","r909"] },"us-gaap_StockAppreciationRightsSARSMember":{"xbrltype":"domainItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"StockAppreciationRightsSARSMember","presentation":["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"],"lang":{"en-us":{"role":{"label":"Stock Appreciation Rights (SARs) **$ 11, 075 $ 8, 860Subsequent Event** [ Member ] ","terseLabel":"Stock Appreciation Rights (SARs)","documentation":"Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } },"auth_ref":[] },"ntrb_StockIssuedDuringPeriodShareNotePayableAndInterestinShares":{"xbrltype":"sharesItemType","nsuri":"http://nutriband.com/20240131","localname":"StockIssuedDuringPeriodShareNotePayableAndInterestinShares","presentation":["http://nutriband.com/role/ShareholdersEquityType2or3"],"lang":{"en-us":{"role":{"terseLabel":"Issuance of common stock for note payable and interest (in Shares)","documentation":"Issuance of common stock for note payable and interest shares.","label":"Stock Issued During Period Share Note Payable And Interestin Shares" } } },"auth_ref":[] },"ntrb_StockIssuedDuringPeriodShareTreasuryStockAndWarrantsIssuedForTerminationAgreement":{"xbrltype":"sharesItemType","nsuri":"http://nutriband.com/20240131","localname":"StockIssuedDuringPeriodShareTreasuryStockAndWarrantsIssuedForTerminationAgreement","presentation":["http://nutriband.com/role/ShareholdersEquityType2or3"],"lang":{"en-us":{"role":{"terseLabel":"Treasury stock and warrants issued for termination agreement (in Shares)","documentation":"Treasury stock and warrants issued for termination agreement shares.","label":"Stock Issued During Period Share Treasury Stock And Warrants Issued For Termination Agreement" } } },"auth_ref":[] },"us-gaap_StockIssuedDuringPeriodSharesOther":{"xbrltype":"sharesItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"StockIssuedDuringPeriodSharesOther","presentation":["http://nutriband.com/role/RelatedPartyTransactionsDetails"],"lang":{"en-us":{"role":{"terseLabel":"Shares received (in Shares)","label":"Stock Issued During Period, Shares, Other","documentation":"Number of shares of stock issued attributable to transactions classified as other." } } },"auth_ref":[] },"us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets":{"xbrltype":"sharesItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"StockIssuedDuringPeriodSharesPurchaseOfAssets","presentation":["http://nutriband.com/role/RelatedPartyTransactionsDetails"],"lang":{"en-us":{"role":{"terseLabel":"Purchase shares (in Shares)","label":"Stock Issued During Period, Shares, Purchase of Assets","documentation":"Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination." } } },"auth_ref":[] },"us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised":{"xbrltype":"sharesItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"StockIssuedDuringPeriodSharesStockOptionsExercised","presentation":["http://nutriband.com/role/ShareholdersEquityType2or3"],"lang":{"en-us":{"role":{"terseLabel":"Exercise of warrants (in Shares)","label":"Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period","documentation":"Number of share options (or share units) exercised during the current period." } } },"auth_ref":["r8","r76","r77","r116","r428"] },"ntrb_StockIssuedDuringPeriodSharesStockOptionsSharesExercised":{"xbrltype":"sharesItemType","nsuri":"http://nutriband.com/20240131","localname":"StockIssuedDuringPeriodSharesStockOptionsSharesExercised","presentation":["http://nutriband.com/role/ScheduleofChangesinOptionsOutstandingTable","http://nutriband.com/role/ScheduleofChangesinWarrantsOutstandingTable"],"lang":{"en-us":{"role":{"terseLabel":"Shares, Exercised","documentation":"Number of shares stock issued during period shares stock options shares exercised.","label":"Stock Issued During Period Shares Stock Options Shares Exercised" } } },"auth_ref":[] },"ntrb_StockIssuedDuringPeriodSharesTreasuryStockIssuedForServices":{"xbrltype":"sharesItemType","nsuri":"http://nutriband.com/20240131","localname":"StockIssuedDuringPeriodSharesTreasuryStockIssuedForServices","presentation":["http://nutriband.com/role/ShareholdersEquityType2or3"],"lang":{"en-us":{"role":{"terseLabel":"Treasury stock issued for services (in Shares)","documentation":"Treasury stock issued for services.","label":"Stock Issued During Period Shares Treasury Stock Issued For Services" } } },"auth_ref":[] },"ntrb_StockIssuedDuringPeriodValueNotePayableAndInterest":{"xbrltype":"monetaryItemType","nsuri":"http://nutriband.com/20240131","localname":"StockIssuedDuringPeriodValueNotePayableAndInterest","crdr":"credit","presentation":["http://nutriband.com/role/ShareholdersEquityType2or3"],"lang":{"en-us":{"role":{"terseLabel":"Issuance of common stock for note payable and interest","documentation":"Issuance of common stock for note payable and interest.","label":"Stock Issued During Period Value Note Payable And Interest" } } },"auth_ref":[] },"ntrb_StockIssuedDuringPeriodValueReturnedInSettlement":{"xbrltype":"monetaryItemType","nsuri":"http://nutriband.com/20240131","localname":"StockIssuedDuringPeriodValueReturnedInSettlement","crdr":"credit","presentation":["http://nutriband.com/role/ShareholdersEquityType2or3"],"lang":{"en-us":{"role":{"terseLabel":"Common stock returned in settlement","documentation":"Common stock returned in settlement.","label":"Stock Issued During Period Value Returned In Settlement" } } },"auth_ref":[] },"us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"StockIssuedDuringPeriodValueStockOptionsExercised","crdr":"credit","presentation":["http://nutriband.com/role/ShareholdersEquityType2or3"],"lang":{"en-us":{"role":{"terseLabel":"Exercise of warrants","label":"Stock Issued During Period, Value, Stock Options Exercised","documentation":"Value of stock issued as a result of the exercise of stock options." } } },"auth_ref":["r8","r77","r81","r82","r116"] },"us-gaap_StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense","crdr":"credit","presentation":["http://nutriband.com/role/ScheduleofChangesinWarrantsOutstandingTable"],"lang":{"en-us":{"role":{"terseLabel":"Intrinsic Value, Exercised","label":"Stock Issued, Value, Stock Options Exercised, Net of Tax Benefit (Expense)","documentation":"Value of stock issued as a result of the exercise of stock options, after deduction of related income tax (expense) benefit." } } },"auth_ref":[] },"ntrb_StockIssuedDuringPeriodValueTreasuryStockAndWarrantsIssuedForTerminationAgreement":{"xbrltype":"monetaryItemType","nsuri":"http://nutriband.com/20240131","localname":"StockIssuedDuringPeriodValueTreasuryStockAndWarrantsIssuedForTerminationAgreement","crdr":"credit","presentation":["http://nutriband.com/role/ShareholdersEquityType2or3"],"lang":{"en-us":{"role":{"terseLabel":"Treasury stock and warrants issued for termination agreement","documentation":"Treasury stock and warrants issued for termination agreement.","label":"Stock Issued During Period Value Treasury Stock And Warrants Issued For Termination Agreement" } } },"auth_ref":[] },"ntrb_StockIssuedDuringPeriodValueTreasuryStockIssuedForServices":{"xbrltype":"monetaryItemType","nsuri":"http://nutriband.com/20240131","localname":"StockIssuedDuringPeriodValueTreasuryStockIssuedForServices","crdr":"credit","presentation":["http://nutriband.com/role/ShareholdersEquityType2or3"],"lang":{"en-us":{"role":{"terseLabel":"Treasury stock issued for services","documentation":"Treasury stock issued for services.","label":"Stock Issued During Period Value Treasury Stock Issued For Services" } } },"auth_ref":[] },"ntrb_StockIssuedDuringPeriodValueTreasuryStockRepurchased":{"xbrltype":"monetaryItemType","nsuri":"http://nutriband.com/20240131","localname":"StockIssuedDuringPeriodValueTreasuryStockRepurchased","crdr":"credit","presentation":["http://nutriband.com/role/ShareholdersEquityType2or3"],"lang":{"en-us":{"role":{"terseLabel":"Treasury stock repurchased","documentation":"Treasury stock repurchased.","label":"Stock Issued During Period Value Treasury Stock Repurchased" } } },"auth_ref":[] },"ntrb_StockIssuedForServices":{"xbrltype":"monetaryItemType","nsuri":"http://nutriband.com/20240131","localname":"StockIssuedForServices","crdr":"debit","presentation":["http://nutriband.com/role/ScheduleofDeferredTaxLiabilityandDeferredTaxAssetTable"],"lang":{"en-us":{"role":{"terseLabel":"Stock issued for services","documentation":"The amount of Stock issued for services.","label":"Stock Issued For Services" } } },"auth_ref":[] },"us-gaap_StockOptionMember":{"xbrltype":"domainItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"StockOptionMember","presentation":["http://nutriband.com/role/OptionsandWarrantsTables","http://nutriband.com/role/RelatedPartyTransactionsDetails","http://nutriband.com/role/ScheduleofChangesinOptionsOutstandingTable","http://nutriband.com/role/ScheduleofSummarizesAdditionalInformationRelatingtotheOptionsOutstandingTable"],"lang":{"en-us":{"role":{"terseLabel":"Options [Member]","verboseLabel":"Options Outstanding [Member]","netLabel":"Equity Option [Member]","label":"Equity Option [Member]","documentation":"Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option)." } } },"auth_ref":["r818"] },"us-gaap_StockRepurchasedDuringPeriodShares":{"xbrltype":"sharesItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"StockRepurchasedDuringPeriodShares","presentation":["http://nutriband.com/role/SubsequentEventsDetails"],"lang":{"en-us":{"role":{"terseLabel":"Purchase shares","label":"Stock Repurchased During Period, Shares","documentation":"Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may

acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock." } } },"auth_ref":["r8","r76","r77","r116","r628","r707","r734"] },"ntrb_StockRepurchasedDuringPeriodSharesTreasuryStockRepurchased":{"xbrltype":"sharesItemType","nsuri":"http://nutriband.com/20240131","localname":"StockRepurchasedDuringPeriodSharesTreasuryStockRepurchased","presentation":["http://nutriband.com/role/ShareholdersEquityType2or3"],"lang":{"en-us":{"role":{"terseLabel":"Treasury stock repurchased (in Shares)","label":"Stock Repurchased During Period Shares Treasury Stock Repurchased"} } },"auth_ref":[] },"ntrb_StockbasedCompensationwarrants":{"xbrltype":"monetaryItemType","nsuri":"http://nutriband.com/20240131","localname":"StockbasedCompensationwarrants","crdr":"debit","calculation":{"http://nutriband.com/role/ConsolidatedCashFlow":{"parentTag":"us-gaap_NetCashProvidedByUsedInOperatingActivities","weight":1.0,"order":8.0} },"presentation":["http://nutriband.com/role/ConsolidatedCashFlow"],"lang":{"en-us":{"role":{"terseLabel":"Stock-based compensation-warrants","documentation":"The amount of stock-based compensation-warrants.","label":"Stockbased Compensationwarrants"} } },"auth_ref":[] },"ntrb_StockholderEquityNoteStockSplit":{"xbrltype":"stringItemType","nsuri":"http://nutriband.com/20240131","localname":"StockholderEquityNoteStockSplit","presentation":["http://nutriband.com/role/StockholdersEquityDetails"],"lang":{"en-us":{"role":{"terseLabel":"Forward stock split, description","documentation":"Description of the stock split arrangement. Also provide the retroactive effect given by a stock split that occurs after the balance date but before the release of financial statements.","label":"Stockholder Equity Note Stock Split"} } },"auth_ref":[] },"us-gaap_StockholdersEquity":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"StockholdersEquity","crdr":"credit","calculation":{"http://nutriband.com/role/ConsolidatedBalanceSheet":{"parentTag":"us-gaap_LiabilitiesAndStockholdersEquity","weight":1.0,"order":3.0} },"presentation":["http://nutriband.com/role/ConsolidatedBalanceSheet","http://nutriband.com/role/ShareholdersEquityType2or3"],"lang":{"en-us":{"role":{"totalLabel":"Total Stockholders \u2019 Equity","periodStartLabel":"Balance","periodEndLabel":"Balance","label":"Equity, Attributable to Parent","documentation":"Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."} } },"auth_ref":["r77","r81","r82","r107","r666","r684","r708","r709","r799","r825","r976","r993","r1035","r1087"] },"us-gaap_StockholdersEquityAbstract":{"xbrltype":"stringItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"StockholdersEquityAbstract","presentation":["http://nutriband.com/role/ConsolidatedBalanceSheet"],"lang":{"en-us":{"role":{"label":"Stockholders Equity [ Abstract ]","terseLabel":"STOCKHOLDERS \u2019 EQUITY:"} } },"auth_ref":[] },"ntrb_StockholdersEquityDetailsLineItems":{"xbrltype":"stringItemType","nsuri":"http://nutriband.com/20240131","localname":"StockholdersEquityDetailsLineItems","presentation":["http://nutriband.com/role/StockholdersEquityDetails"],"lang":{"en-us":{"role":{"label":"Stockholders' Equity [ Line Items ]"} } },"auth_ref":[] },"ntrb_StockholdersEquityDetailsTable":{"xbrltype":"stringItemType","nsuri":"http://nutriband.com/20240131","localname":"StockholdersEquityDetailsTable","presentation":["http://nutriband.com/role/StockholdersEquityDetails"],"lang":{"en-us":{"role":{"label":"Stockholders' Equity (Details) [ Table ]"} } },"auth_ref":[] },"us-gaap_StockholdersEquityNoteDisclosureTextBlock":{"xbrltype":"textBlockItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"StockholdersEquityNoteDisclosureTextBlock","presentation":["http://nutriband.com/role/StockholdersEquity"],"lang":{"en-us":{"role":{"terseLabel":"STOCKHOLDERS \u2019 EQUITY","label":"Equity [ Text Block ]","documentation":"The entire disclosure for equity."} } },"auth_ref":["r115","r222","r388","r390","r391","r392","r393","r394","r395","r396","r397","r398","r399","r400","r403","r498","r710","r712","r736"] },"us-gaap_StockholdersEquityNoteStockSplit":{"xbrltype":"stringItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"StockholdersEquityNoteStockSplit","presentation":["http://nutriband.com/role/SummaryofSignificantAccountingPoliciesDetails"],"lang":{"en-us":{"role":{"terseLabel":"Forward stock split, description","label":"Stockholders' Equity Note, Stock Split","documentation":"Description of the stock split arrangement. Also provide the retroactive effect given by a stock split that occurs after the balance date but before the release of financial statements."} } },"auth_ref":["r117"] },"us-gaap_StockholdersEquityReverseStockSplit":{"xbrltype":"stringItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"StockholdersEquityReverseStockSplit","presentation":["http://nutriband.com/role/CommitmentsandContigenciesDetails"],"lang":{"en-us":{"role":{"terseLabel":"Forward stock split, description","label":"Stockholders' Equity, Reverse Stock Split","documentation":"Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements."} } },"auth_ref":["r117"] },"us-gaap_SubsequentEventLineItems":{"xbrltype":"stringItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"SubsequentEventLineItems","presentation":["http://nutriband.com/role/SubsequentEventsDetails"],"lang":{"en-us":{"role":{"label":" Subsequent Events [ Line Items ] "**Issued shares 3** ," documentation" **500 Issued shares value (in Dollars) $ 24, 360 Subsequent Event [ Member ] | Consultant [ Member ] Subsequent Events [ Line Items ] Issued shares 5, 000 Issued shares value (in Dollars) $ 39, 050 Warrant [ Member ] Subsequent Events [ Line Items ] Exercised warrants 58, 333 X- DefinitionAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note** : " elements **credit Period Type:instantX- DefinitionAmount,after effects of reinsurance,of expense (reversal of expense)** for **claims incurred** number of nonredeemable common shares,par value and **costs incurred** other disclosure concepts are in **the claim settlement process** another section within stockholders' equity . ReferencesReference 1:http://www.xbrl.org/2003/role/**disclosureRef** **exampleRef** - Topic 480 **944** - SubTopic 10 **40** - Name Accounting Standards Codification- Section S45 **55** - Paragraph 2 **7** - Publisher FASB- URI https://asc.fasb.org/1943274/**2147479887** **2147480046** / 480 **944** - 10 **40** - S45 **55** - 2Reference **7Reference** 2:http://www.xbrl.org/2003 **2009** / role / **disclosureRef** **commonPracticeRef** - Topic 480 **944** - SubTopic 10 **40** - Name Accounting Standards Codification- Section S99 **50** - Paragraph 1 **3** - Subparagraph ( **b** 01) (iii )- Publisher FASB- URI https://asc.fasb.org/1943274/**2147480244** **2147480081** / 480 **944** - 10 **40** - S99 **50** - 1Reference 3 **Details Name** : http://fasb.org/us- **gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1 Namespace Prefix:us** gaap/role/ref/legacyRef - Topic 210- SubTopic 10- Name Accounting **gaap_ Data Type:xbrli:monetaryItemType Balance Type:** Detail **Details** Name **Period Type** : us **durationX** - gaap_CommonStockValue **DefinitionAmount of the entity' s equity method investment which has been sold. ReferencesNo definition available. Details Name:us- gaap_EquityMethodInvestmentSoldCarryingAmount** Namespace Prefix:us- gaap_ Data Type:xbrli:monetaryItemType Balance Type: **credit** **debit** Period Type: **instantX** **durationX** - DefinitionNumber of excess stock shares of an entity that have been sold or granted to shareholders. ReferencesNo definition available. Details Name:us- gaap_ExcessStockSharesIssued Namespace Prefix:us- gaap_ Data Type:xbrli:sharesItemType Balance Type:na Period Type:instantX- DefinitionNumber of new stock issued **DefinitionInterest received on loans and other debt instruments** during the **current** period. ReferencesReference 1:http://fasb **www.xbrl**.org/**2009** us- gaap/role/ref/legacyRef **commonPracticeRef- Topic 230- SubTopic 10** - Name Accounting Standards Codification- Section 50 **45** - Paragraph 2 **16** - **Subparagraph (b)** SubTopic 10- Topic 505 - Publisher FASB- URI https://asc.fasb.org/1943274/2147481112 **2147482740** / 505 **230** - 10- 50 **45** - 2Reference 2 **16 Details Name** : http://fasb.org/us- **gaap_ProceedsFromInterestReceived Namespace Prefix:us-** gaap **gaap_ Data Type** /role/ref/legacyRef- Topic 210- SubTopic 10- Name Accounting Subparagraph (SX 210.5- 02 (28))- Publisher FASB- URI https - **xbrli:monetaryItemType Balance Type:debit** information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event. **ReferencesReference 1** " } } },"auth_ref" :[" r511","r532"] },"us-gaap_SubsequentEventMember":{"xbrltype":"domainItemType","nsuri":"http://fasb **www** . **xbrl** org/us-gaap/2024","localname":"SubsequentEventMember","presentation":["http://nutriband . com **org/2003** / role / SubsequentEventsDetails"],"lang":{"en-us":{"role":{"terseLabel":"Subsequent Event [ Member ]","label":"Subsequent Event [ Member ]","documentation":"Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."} } },"auth_ref":["r511","r532"] },"us-gaap_SubsequentEventTypeAxis":{"xbrltype":"stringItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"SubsequentEventTypeAxis","presentation":["http://nutriband.com/role/SubsequentEventsDetails"],"lang":{"en-us":{"role":{"label":"Subsequent Event Type [ Axis ]","documentation":"Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."} } },"auth_ref":["r511","r532"] },"us-gaap_SubsequentEventsAbstract":{"xbrltype":"stringItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"SubsequentEventsAbstract","lang":{"en-us":{"role":{"label":"Subsequent Events [ Abstract ]"} } },"auth_ref":[] },"ntrb_SubsequentEventsDetailsTable":{"xbrltype":"stringItemType","nsuri":"http://nutriband.com/20240131","localname":"SubsequentEventsDetailsTable","presentation":["http://nutriband.com/role/SubsequentEventsDetails"],"lang":{"en-us":{"role":{"label":"Subsequent Events (Details) [ Table ]"} } },"auth_ref":[] },"us-gaap_SubsequentEventsTextBlock":{"xbrltype":"textBlockItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"SubsequentEventsTextBlock","presentation":["http://nutriband.com/role/SubsequentEvents"],"lang":{"en-us":{"role":{"terseLabel":"SUBSEQUENT EVENTS","label":"Subsequent Events [ Text Block ]","documentation":"The entire disclosure **disclosureRef** for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."} } },"auth_ref":["r531","r533"] },"us- **Topic 830** gaap_SubsidiarySaleOfStockAxis":{"xbrltype":"stringItemType","nsuri":"http://fasb.org/us- **SubTopic 30** gaap/2024","localname":"

SubsidiarySaleOfStockAxis"," presentation": [" http: / / nutriband. com / role / IntangibleAssetsDetails"," http: / / nutriband. com / role / SubsequentEventsDetails"," http: / / nutriband. com / role / SummaryofSignificantAccountingPoliciesDetails" ]," lang": {" en- us": {" role": {" label":" Sale of Stock [ Axis ]"," documentation":" Information by type of sale of the entity' s stock." } } }," auth_ref": [ ] }," ntrb_SummaryofSignificantAccountingPoliciesDetailsLineItems": {" xbrltype":" stringItemType"," nsuri":" http: / / nutriband. com / 20240131"," localname":" SummaryofSignificantAccountingPoliciesDetailsLineItems"," presentation": [" http: / / nutriband. com / role / SummaryofSignificantAccountingPoliciesDetails" ]," lang": {" en- us": {" role": {" label":" Summary of Significant Accounting Policies [ Line Items ]" } } }," auth_ref": [ ] }," ntrb_SummaryofSignificantAccountingPoliciesDetailsScheduleofRevenuebyGeographicLocationLineItems": {" xbrltype":" stringItemType"," nsuri":" http: / / nutriband. com / 20240131"," localname":" SummaryofSignificantAccountingPoliciesDetailsScheduleofRevenuebyGeographicLocationLineItems"," presentation": [" http: / / nutriband. com / role / ScheduleofRevenuebyGeographicLocationTable" ]," lang": {" en- us": {" role": {" label":" Schedule of Revenue by Geographical Location [ Line Items ]" } } }," auth_ref": [ ] }," ntrb_SummaryofSignificantAccountingPoliciesDetailsScheduleofRevenuebyGeographicLocationTable": {" xbrltype":" stringItemType"," nsuri":" http: / / nutriband. com / 20240131"," localname":" SummaryofSignificantAccountingPoliciesDetailsScheduleofRevenuebyGeographicLocationTable"," presentation": [" http: / / nutriband. com / role / ScheduleofRevenuebyGeographicLocationTable" ]," lang": {" en- us": {" role": {" label":" Summary of Significant Accounting Policies (Details)- Schedule of Revenue by Geographic Location [ Table ]" } } }," auth_ref": [ ] }," ntrb_SummaryofSignificantAccountingPoliciesDetailsTable": {" xbrltype":" stringItemType"," nsuri":" http: / / nutriband. com / 20240131"," localname":" SummaryofSignificantAccountingPoliciesDetailsTable"," presentation": [" http: / / nutriband. com / role / SummaryofSignificantAccountingPoliciesDetails" ]," lang": {" en- us": {" role": {" label":" Summary of Significant Accounting Policies (Details) [ Table ]" } } }," auth_ref": [ ] }," us- gaap_SupplementalCashFlowInformationAbstract": {" xbrltype":" stringItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" SupplementalCashFlowInformationAbstract"," presentation": [" http: / / nutriband. com / role / ConsolidatedCashFlow" ]," lang": {" en- us": {" role": {" terseLabel":" Cash paid for:"," label":" Supplemental Cash Flow Information [ Abstract ]" } } }," auth_ref": [ ] }," eed_TabularListTableTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / xbrl. sec. gov / eed / 2024"," localname":" TabularListTableTextBlock"," presentation": [" http: / / xbrl. sec. gov / eed / role / PvpDisclosure" ]," lang": {" en- us": {" role": {" label":" Tabular List [ Table Text Block ]"," terseLabel":" Tabular List, Table" } } }," auth_ref": [" r902" ] }," us- gaap_TemporaryEquitySharesIssued": {" xbrltype":" sharesItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" TemporaryEquitySharesIssued"," presentation": [" http: / / nutriband. com / role / OptionsandWarrantsDetails" ]," lang": {" en- us": {" role": {" terseLabel":" Issued warrants (in Shares)"," label":" Temporary Equity, Shares Issued"," documentation":" The number of securities classified as temporary equity that have been sold (or granted) to the entity' s shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer." } } }," auth_ref": [" r75" ] }," ntrb_TerminationExpenseMember": {" xbrltype":" domainItemType"," nsuri":" http: / / nutriband. com / 20240131"," localname":" TerminationExpenseMember"," presentation": [" http: / / nutriband. com / role / IntangibleAssetsDetails" ]," lang": {" en- us": {" role": {" terseLabel":" Termination expense [ Member ]"," label":" Termination Expense Member" } } }," auth_ref": [ ] }," srt_TitleOfIndividualAxis": {" xbrltype":" stringItemType"," nsuri":" http: / / fasb. org / srt / 2024"," localname":" TitleOfIndividualAxis"," presentation": [" http: / / nutriband. com / role / CommitmentsandContigenciesDetails"," http: / / nutriband. com / role / OptionsandWarrantsDetails"," http: / / nutriband. com / role / RelatedPartyTransactionsDetails"," http: / / nutriband. com / role / SubsequentEventsDetails" ]," lang": {" en- us": {" role": {" label":" Title and Position [ Axis ]"," documentation":" Information by title and position of individual or group within organization." } } }," auth_ref": [" r990"," r1039" ] }," srt_TitleOfIndividualWithRelationshipToEntityDomain": {" xbrltype":" domainItemType"," nsuri":" http: / / fasb. org / srt / 2024"," localname":" TitleOfIndividualWithRelationshipToEntityDomain"," presentation": [" http: / / nutriband. com / role / CommitmentsandContigenciesDetails"," http: / / nutriband. com / role / OptionsandWarrantsDetails"," http: / / nutriband. com / role / RelatedPartyTransactionsDetails"," http: / / nutriband. com / role / SubsequentEventsDetails" ]," lang": {" en- us": {" role": {" label":" Title and Position [ Domain ]"," documentation":" Title and position of individual or group within organization." } } }," auth_ref": [ ] }," eed_TotalShareholderRtnAmt": {" xbrltype":" monetaryItemType"," nsuri":" http: / / xbrl. sec. gov / eed / 2024"," localname":" TotalShareholderRtnAmt"," presentation": [" http: / / xbrl. sec. gov / eed / role / PvpDisclosure" ]," lang": {" en- us": {" role": {" label":" Total Shareholder Return Amount"," terseLabel":" Total Shareholder Return Amount" } } }," auth_ref": [" r894" ] }," eed_TotalShareholderRtnVsPeerGroupTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / xbrl. sec. gov / eed / 2024"," localname":" TotalShareholderRtnVsPeerGroupTextBlock"," presentation": [" http: / / xbrl. sec. gov / eed / role / PvpDisclosure" ]," lang": {" en- us": {" role": {" label":" Total Shareholder Return Vs Peer Group [ Text Block ]"," terseLabel":" Total Shareholder Return Vs Peer Group" } } }," auth_ref": [" r901" ] }," eed_TradingArrAxis": {" xbrltype":" stringItemType"," nsuri":" http: / / xbrl. sec. gov / eed / 2024"," localname":" TradingArrAxis"," presentation": [" http: / / xbrl. sec. gov / eed / role / InsiderTradingArrangements" ]," lang": {" en- us": {" role": {" label":" Trading Arrangement [ Axis ]"," terseLabel":" Trading Arrangement:" } } }," auth_ref": [" r922" ] }," eed_TradingArrByIndTable": {" xbrltype":" stringItemType"," nsuri":" http: / / xbrl. sec. gov / eed / 2024"," localname":" TradingArrByIndTable"," presentation": [" http: / / xbrl. sec. gov / eed / role / InsiderTradingArrangements" ]," lang": {" en- us": {" role": {" label":" Trading Arrangements, by Individual [ Table ]"," terseLabel":" Trading Arrangements, by Individual" } } }," auth_ref": [" r924" ] }," dei_TradingSymbol": {" xbrltype":" tradingSymbolItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" TradingSymbol"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover" ]," lang": {" en- us": {" role": {" label":" Trading Symbol"," documentation":" Trading symbol of an instrument as listed on an exchange." } } }," auth_ref": [ ] }," eed_TrdArrAdoptionDate": {" xbrltype":" stringItemType"," nsuri":" http: / / xbrl. sec. gov / eed / 2024"," localname":" TrdArrAdoptionDate"," presentation": [" http: / / xbrl. sec. gov / eed / role / InsiderTradingArrangements" ]," lang": {" en- us": {" role": {" label":" Trading Arrangement Adoption Date"," terseLabel":" Adoption Date" } } }," auth_ref": [" r925" ] }," eed_TrdArrDuration": {" xbrltype":" durationItemType"," nsuri":" http: / / xbrl. sec. gov / eed / 2024"," localname":" TrdArrDuration"," presentation": [" http: / / xbrl. sec. gov / eed / role / InsiderTradingArrangements" ]," lang": {" en- us": {" role": {" label":" Trading Arrangement Duration"," terseLabel":" Arrangement Duration" } } }," auth_ref": [" r926" ] }," eed_TrdArrExpirationDate": {" xbrltype":" stringItemType"," nsuri":" http: / / xbrl. sec. gov / eed / 2024"," localname":" TrdArrExpirationDate"," presentation": [" http: / / xbrl. sec. gov / eed / role / InsiderTradingArrangements" ]," lang": {" en- us": {" role": {" label":" Trading Arrangement Expiration Date"," terseLabel":" Expiration Date" } } }," auth_ref": [" r926" ] }," eed_TrdArrIndName": {" xbrltype":" stringItemType"," nsuri":" http: / / xbrl. sec. gov / eed / 2024"," localname":" TrdArrIndName"," presentation": [" http: / / xbrl. sec. gov / eed / role / InsiderTradingArrangements" ]," lang": {" en- us": {" role": {" label":" Trading Arrangement, Individual Name "," terseLabel":" Name" } } }," auth_ref": [" r924" ] }," eed_TrdArrIndTitle": {" xbrltype":" stringItemType"," nsuri":" http: / / xbrl. sec. gov / eed / 2024"," localname":" TrdArrIndTitle"," presentation": [" http: / / xbrl. sec. gov / eed / role / InsiderTradingArrangements" ]," lang": {" en- us": {" role": {" label":" Trading Arrangement, Individual Title"," terseLabel":" Title" } } }," auth_ref": [" r924" ] }," eed_TrdArrSecuritiesAggAvailAmt": {" xbrltype":" sharesItemType"," nsuri":" http: / / xbrl. sec. gov / eed / 2024"," localname":" TrdArrSecuritiesAggAvailAmt"," presentation": [" http: / / xbrl. sec. gov / eed / role / InsiderTradingArrangements" ]," lang": {" en- us": {" role": {" label":" Trading Arrangement, Securities Aggregate Available Amount"," terseLabel":" Aggregate Available" } } }," auth_ref": [" r927" ] }," eed_TrdArrTerminationDate": {" xbrltype":" stringItemType"," nsuri":" http: / / xbrl. sec. gov / eed / 2024"," localname":" TrdArrTerminationDate"," presentation": [" http: / / xbrl. sec. gov / eed / role / InsiderTradingArrangements" ]," lang": {" en- us": {" role": {" label":" Trading Arrangement Termination Date"," terseLabel":" Termination Date" } } }," auth_ref": [" r925" ] }," ntrb_TreasurySharesAndRecordedCompensationExpense": {" xbrltype":" monetaryItemType"," nsuri":" http: / / nutriband. com / 20240131"," localname":" TreasurySharesAndRecordedCompensationExpense"," crdr":" debit"," presentation": [" http: / / nutriband. com / role / StockholdersEquityDetails" ]," lang": {" en- us": {" role": {" terseLabel":" Treasury shares and recorded compensation expense (in Dollars)"," documentation":" The amount of treasury shares and recorded compensation expense."," label":" Treasury Shares And Recorded Compensation Expense" } } }," auth_ref": [ ] }," us- gaap_TreasuryStockCommonMember": {" xbrltype":" domainItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" TreasuryStockCommonMember"," presentation": [" http: / / nutriband. com / role / ShareholdersEquityType2or3"," http: / / nutriband. com / role / StockholdersEquityDetails" ]," lang": {" en- us": {" role": {" terseLabel":" Treasury Stock"," verboseLabel":" Treasury Stock, Common [ Member ]"," label":" Treasury Stock, Common [ Member ]"," documentation":" Previously issued common shares repurchased by the issuing entity and held in treasury." } } }," auth_ref": [" r39" ] }," us- gaap_TreasuryStockCommonShares": {" xbrltype":" sharesItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":"

TreasuryStockCommonShares"," presentation": [" http: / / nutriband. com / role / ConsolidatedBalanceSheet_Parentheticals" ]," lang": {" en- us": {" role": {" terseLabel":" Treasury stock, shares"," label":" Treasury Stock, Common, Shares"," documentation":" Number of previously issued common shares repurchased by the issuing entity and held in treasury." } } },"auth_ref": [" r39" ] }," ntrb_TreasuryStockIssuedForTerminationAgreement": {" xbrltype":" monetaryItemType"," nsuri":" http: / / nutriband. com / 20240131"," localname":" TreasuryStockIssuedForTerminationAgreement"," crdr":" debit"," calculation": {" http: / / nutriband. com / role / ConsolidatedCashFlow": {" parentTag":" us- gaap_NetCashProvidedByUsedInOperatingActivities"," weight": 1. 0," order": 6. 0 } }," presentation": [" http: / / nutriband. com / role / ConsolidatedCashFlow" ]," lang": {" en- us": {" role": {" terseLabel":" Treasury stock and warrants issued for termination agreement"," documentation":" The amount of treasury stock issued for termination agreement."," label":" Treasury Stock Issued For Termination Agreement" } } },"auth_ref": [ ] }," ntrb_TreasuryStockPurchase": {" xbrltype":" monetaryItemType"," nsuri":" http: / / nutriband. com / 20240131"," localname":" TreasuryStockPurchase"," crdr":" debit"," presentation": [" http: / / nutriband. com / role / StockholdersEquityDetails" ]," lang": {" en- us": {" role": {" terseLabel":" Treasury stock share purchase (in Dollars)"," documentation":" Purchase of stock purchase."," label":" Treasury Stock Purchase" } } }," auth_ref": [ ] }," us- gaap_TreasuryStockValue": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" TreasuryStockValue"," crdr":" debit"," calculation": {" http: / / nutriband. com / role / ConsolidatedBalanceSheet": {" parentTag":" us- gaap_StockholdersEquity"," weight":- 1. 0," order": 6. 0 } }," presentation": [" http: / / nutriband. com / role / ConsolidatedBalanceSheet" ]," lang": {" en- us": {" role": {" negatedLabel":" Treasury stock, 10, 000 and 10, 000 shares at cost, respectively"," label":" Treasury Stock, Value"," documentation":" The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury." } } }," auth_ref": [" r39"," r40"," r77"," r81" ] }," country_US": {" xbrltype":" domainItemType"," nsuri":" http: / / xbrl. sec. gov / country / 2024"," localname":" US"," presentation": [" http: / / nutriband. com / role / ScheduleofNetSalesandPropertyandEquipmentTable"," http: / / nutriband. com / role / ScheduleofRevenuebyGeographicLocationTable" ]," lang": {" en- us": {" role": {" terseLabel":" United States [ Member ]"," label":" UNITED STATES" } } }," auth_ref": [ ] }," ecd_UndrlygSecurityMktPriceChngPet": {" xbrltype":" pureItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" UndrlygSecurityMktPriceChngPet"," presentation": [" http: / / xbrl. sec. gov / ecd / role / AwardTimingDisclosure" ]," lang": {" en- us": {" role": {" label":" Underlying Security Market Price Change, Percent"," terseLabel":" Underlying Security Market Price Change" } } }," auth_ref": [" r921" ] }," us- gaap_UseOfEstimates": {" xbrltype":" textBlockItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" UseOfEstimates"," presentation": [" http: / / nutriband. com / role / AccountingPoliciesByPolicy" ]," lang": {" en- us": {" role": {" terseLabel":" Use of Estimates"," label":" Use of Estimates, Policy [ Policy Text Block ]"," documentation":" Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }," auth_ref": [" r25"," r26"," r27"," r149"," r150"," r152"," r153" ] }," ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {" xbrltype":" domainItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"," presentation": [" http: / / xbrl. sec. gov / ecd / role / PvpDisclosure" ]," lang": {" en- us": {" role": {" label":" Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [ Member ]"," terseLabel":" Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year" } } }," auth_ref": [" r890" ] }," ntrb_WarehouseSpace": {" xbrltype":" integerItemType"," nsuri":" http: / / nutriband. com / 20240131"," localname":" WarehouseSpace"," presentation": [" http: / / nutriband. com / role / CommitmentsandContigenciesDetails" ]," lang": {" en- us": {" role": {" terseLabel":" Warehouse space"," documentation":" Warehouse space"," label":" Warehouse Space" } } }," auth_ref": [ ] }," us- gaap_WarrantExercisePriceIncrease": {" xbrltype":" perShareItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" WarrantExercisePriceIncrease"," presentation": [" http: / / nutriband. com / role / CommitmentsandContigenciesDetails"," http: / / nutriband. com / role / OptionsandWarrantsDetails" ]," lang": {" en- us": {" role": {" terseLabel":" Warrants exercisable price (in Dollars per share)"," verboseLabel":" Exercise of price (in Dollars per share)"," label":" Warrant, Exercise Price, Increase"," documentation":" Per share increase in exercise price of warrant. Excludes change due to standard antidilution provision." } } }," auth_ref": [" r402" ] }," us- gaap_WarrantMember": {" xbrltype":" domainItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" WarrantMember"," presentation": [" http: / / nutriband. com / role / OptionsandWarrantsDetails"," http: / / nutriband. com / role / OptionsandWarrantsTables"," http: / / nutriband. com / role / RelatedPartyTransactionsDetails"," http: / / nutriband. com / role / ScheduleofChangesinWarrantsOutstandingTable"," http: / / nutriband. com / role / ScheduleofSummarizesAdditionalInformationRelatingtotheWarrantsOutstandingTable"," http: / / nutriband. com / role / SubsequentEventsDetails" ]," lang": {" en- us": {" role": {" terseLabel":" Warrants [ Member ]"," verboseLabel":" Warrant [ Member ]"," label":" Warrant [ Member ]"," documentation":" Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount." } } },"auth_ref": [" r816"," r817"," r820"," r821"," r822"," r823" ] }," us- gaap_WarrantsAndRightsOutstandingMaturityDate": {" xbrltype":" dateItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" WarrantsAndRightsOutstandingMaturityDate"," presentation": [" http: / / nutriband. com / role / SubsequentEventsDetails" ]," lang": {" en- us": {" role": {" terseLabel":" Expire date"," label":" Warrants and Rights Outstanding, Maturity Date"," documentation":" Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY- MM- DD format." } } },"auth_ref": [" r1024"," r1025"," r1026" ] }," ntrb_WarrantsMember": {" xbrltype":" domainItemType"," nsuri":" http: / / nutriband. com / 20240131"," localname":" WarrantsMember"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover" ]," lang": {" en- us": {" role": {" terseLabel":" Warrants"," label":" Warrants Member" } } }," auth_ref": [ ] }," ntrb_WarrantsNumberExercisableinShares": {" xbrltype":" sharesItemType"," nsuri":" http: / / nutriband. com / 20240131"," localname":" WarrantsNumberExercisableinShares"," presentation": [" http: / / nutriband. com / role / ScheduleofSummarizesAdditionalInformationRelatingtotheWarrantsOutstandingTable" ]," lang": {" en- us": {" role": {" terseLabel":" Number Exercisable (in Shares)"," documentation":" Warrant number of exercisable shares."," label":" Warrants Number Exercisablein Shares" } } }," auth_ref": [ ] }," ntrb_WarrantsNumberOutstandinginShares": {" xbrltype":" sharesItemType"," nsuri":" http: / / nutriband. com / 20240131"," localname":" WarrantsNumberOutstandinginShares"," presentation": [" http: / / nutriband. com / role / ScheduleofSummarizesAdditionalInformationRelatingtotheWarrantsOutstandingTable" ]," lang": {" en- us": {" role": {" terseLabel":" Number Outstanding (in Shares)"," documentation":" Warrant outstanding shares."," label":" Warrants Number Outstandingin Shares" } } }," auth_ref": [ ] }," ntrb_WarrantsToPurchase": {" xbrltype":" sharesItemType"," nsuri":" http: / / nutriband. com / 20240131"," localname":" WarrantsToPurchase"," presentation": [" http: / / nutriband. com / role / IntangibleAssetsDetails" ]," lang": {" en- us": {" role": {" terseLabel":" Warrants purchase (in Shares)"," documentation":" Warrants to purchase."," label":" Warrants To Purchase" } } }," auth_ref": [ ] }," us- gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {" xbrltype":" sharesItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" WeightedAverageNumberOfDilutedSharesOutstanding"," presentation": [" http: / / nutriband. com / role / ConsolidatedIncomeStatement_Parentheticals" ]," lang": {" en- us": {" role": {" terseLabel":" Weighted average shares of common stock outstanding- diluted"," label":" Weighted Average Number of Shares Outstanding, Diluted"," documentation":" The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } },"auth_ref": [" r244"," r250" ] }," us- gaap_WeightedAverageNumberOfSharesOutstandingBasic": {" xbrltype":" sharesItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" WeightedAverageNumberOfSharesOutstandingBasic"," presentation": [" http: / / nutriband. com / role / ConsolidatedIncomeStatement" ]," lang": {" en- us": {" role": {" terseLabel":" Weighted average shares of common stock outstanding- basic (in Shares)"," label":" Weighted Average Number of Shares Outstanding, Basic"," documentation":" Number of [ basic ] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } },"auth_ref": [" r243"," r250" ] }," ntrb_WorkingCapital": {" xbrltype":" monetaryItemType"," nsuri":" http: / / nutriband. com / 20240131"," localname":" WorkingCapital"," crdr":" credit"," presentation": [" http: / / nutriband. com / role / SummaryofSignificantAccountingPoliciesDetails" ]," lang": {" en- us": {" role": {" terseLabel":" Working capital"," documentation":" Working capital is the amount of available capital that a company can readily use for day- to- day operations."," label":" Working Capital" } } }," auth_ref": [ ] }," dei_WrittenCommunications": {" xbrltype":" booleanItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" WrittenCommunications"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover" ]," lang": {" en- us": {" role": {" label":" Written Communications"," documentation":" Boolean flag that is true when the Form 8- K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }," auth_ref": [" r938" ] }," ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {" xbrltype":" domainItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"," presentation": [" http: / / xbrl. sec. gov / ecd / role / PvpDisclosure" ]," lang": {" en- us": {" role": {" label":" Year- end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [ Member ]"," terseLabel":" Year- end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested" } } }," auth_ref": [" r888" ] }," ntrb_amortizedOverPeriod": {" xbrltype":" durationItemType"," nsuri":" http: / / nutriband. com / 20240131"," localname":" amortizedOverPeriod"," presentation": [" http: / / nutriband. com / role / IntangibleAssetsDetails" ]," lang": {" en- us": {" role": {" terseLabel":" Amortized period"," documentation":" Duration of long- term amortized over

period."," label":" amortized Over Period" } } },"  auth_ref": [ ] },"  ntrb_newFiniteLivedIntangibleAssetsTwoMember": {" xbrltype":" domainItemType"," nsuri":" http: / / nutriband. com / 20240131"," localname":" newFiniteLivedIntangibleAssetsTwoMember"," presentation": [" http: / / nutriband. com / role / ScheduleofIntangibleAssetsTable" ]," lang": {" en- us": {" role": {" terseLabel":" Intellectual property and trademarks [ Member ]"," label":" new Finite Lived Intangible Assets Two Member" } } },"  auth_ref": [ ] } } } },"  std_ref": {" r0": {" role":" http: / / fasb. org / us- gaap / role / ref / legacyRef"," Name":"- Accounting Standards Codification - ","- Section **50- **":" 05","- Paragraph " **2- Publisher FASB- URI https** : " 4","/ / asc. fasb. org / 1943274 / 2147481674 / 830- 30- 50- 2Reference 2: http: / / www. xbrl. org / 2003 / role / disclosureRef- Topic 855-** SubTopic ":"- 10 "," Topic":" 360"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482338 / 360 - 10- 05- 4" },"  r1": {" role":" http: / / fasb. org / us- gaap / role / ref / legacyRef","- Name ":"- Accounting Standards Codification - ","- Section **50- **":" 45","- Paragraph **2- **":" 1","  SubTopic":" 230","  Topic":" 830","- Publisher ":"- FASB - ","- URI ":"- https: / / asc. fasb. org / 1943274 / 2147477401 - **2147483399** / 830 - **855** - 230- 45- 1" },"  r2": {" role":" http: / / fasb. org / us- gaap / role / ref / legacyRef"," Name":" Accounting Standards Codification"," Section":" 45"," Paragraph":" 10A - **10** "," SubTopic":" 10"," Topic":" 220"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482790 / 220 - 10- 45- 10A" },"  r3": {" role":" http: / / fasb. org / us- gaap / role / ref / legacyRef"," Name":" Accounting Standards Codification"," Section":" 45"," Paragraph":" 14"," Subparagraph":" (a)"," SubTopic":" 10"," Topic":" 230"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482740 / 230- 10- 45- 14" },"  r4": {" role":" http: / / fasb. org / us- gaap / role / ref / legacyRef"," Name":" Accounting Standards Codification"," Section":" 45"," Paragraph":" 28"," Subparagraph":" (a)"," SubTopic":" 10"," Topic":" 230"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482740 / 230- 10- 45- 28" },"  r5": {" role":" http: / / fasb. org / us- gaap / role / ref / legacyRef"," Name":" Accounting Standards Codification"," Section":" 45"," Paragraph":" 28"," Subparagraph":" (b)"," SubTopic":" 10"," Topic":" 230"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482740 / 230- 10- 45- 28" },"  r6": {" role":" http: / / fasb. org / us- gaap / role / ref / legacyRef"," Name":" Accounting Standards Codification"," Section":"- 50 "," Paragraph":" 1"," SubTopic":" 10"," Topic":" 360"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482099 / 360 - 10- 50- 1" }..... LJ) J27 $ 0) ) 2 - G \ MP; V, L * 3 * 2M4 % $ M - **Details Name: us- gaap_SubsequentEventLineItems Namespace Prefix: us- gaap_ Data Type: xbrli: stringItemType Balance Type: na Period Type: durationX- Details Name: us- gaap_SubsequentEventTypeAxis = K4 # D - us- gaap_SubsequentEventMember Namespace Prefix** : # S $ M - **Data Type: na Balance Type: Period Type: X- Details Name: us- gaap_RelatedPartyTransactionsByRelatedPartyAxis = ntrb_ConsultantMember Namespace Prefix** [ 5 > ] 1 7 / RQY [ 3 \? 6 - W2) R ] 68 AH % > F @ < # **Data Type: na Balance Type: Period Type: X- Details Name: us- gaap_SubsidiarySaleOfStockAxis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} 2I8 MY; IHK & 9N7 (? & 6 *. BV C [ (@) G $ WDC, G7PD0 # 9Y8 ] /: (N' E [ ROJN & G $ ZS! F1 % M' CEIC2 - 1HK83EKC1P1 = - P, > > WA ? XNPLF #) L /. @? % NN32TO % (3MZ \ 3 \ 0O MQLG * / D6X' DI _, X =', Y \ 7? FR7' 2T < [; *; & 6 _ : 3 & _ 7O (7V {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{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

09) Y < 1ODR. GZL.; (> X? 3D: 3 \ _ -- 3IR % 2- N $ $ % XF; D \ M7F $ 269BK8OXGI =" SCY PO62. E' O992Z [ (7 W \ Y % = Y3GCZGFE'; / R $ ? NF @ MM9, Q57 _ - 59G8 # 5S' % FV & > &" NC. QS ] 30 ] ]; JS = L0 (G Z" Y &' (? ' NQ # YSA < M68 7H \; TB, BV (E, OTC (1D7J!' D, A $ QN $ EO" C2!, 59XAJ4 [ I8B? 6D!, H 6 $ $ 4 M6 \; PV < # (" " 25G [ F! ) & 9' = HW $ (R.' Y M & @ QH" G, HL? PFT53J; RKT ] B ] F \ JF;;" O:- ZF5 $; EH5 (QL () 7YL.) Z;: > Q 0 % M % 1OA) 1:, 6 BHMI; B * EUL1 (@ # M? 7 < \ DJ" 3BZQ MRKWYP6Z7VCL? M >! SQN \ ] M' NCX_H? 7AP \ LC_M (78I: / OB" $ = 9R:: V O ]" C1LN7V @ N = # AA6K / OV!; V = 3 [ > M, G"" WUQ * _ %' _ - 8 @ B / C [ % 68, 6 @! L *;. = S (FVIL # VS) IA- 1IV = RV 6FP9AC MF 3 /; CZ $ Z0 $ ] WO $ = JC? 4Z & K / ZT5 % 5 = E5 E7 & 7B_ \ $ DIUEF; Q / JJ5G53 # 1Q6 M % 7 % L < K9; GFVR = CRS $ P. C1 > WR % C!. LL! J9 > 2: R6E * @ % G < L *' 6Z' KBA > NRT) D MSQ4Z ] 0P & 5ET % IC. > * N = * 2 > WT > 5,! QBD $ 4 $ K @ BW % D_X0? 9. W! KYL- 4) = N > Y $ M ($) 7!; 8OA7_5 %, OGJ / M7, * W3'. W_M1LM21. R % C $ P $ 32 $ / T- I (B5 # P9 < H $' U M11 / P3Z 2 * < VHM, F" ] K: CMY__U ] S @ 3E: / F < % H7A < G?. *!. ED / _ % OG %) $ 1K M06 (V @ XBE > 0 = LWEL6Q2WL! B @ 5 % OPWI < $ * 9L % 7EDTL! L % 1L5CWK4Z % I, M9D \: U < N9K2HL' K' 5. Y0D6 &; JYC *' 0HXUFG % MAZ %) UXVP77; NUR & * ARC5 (0 MT / WM2GR ( S # Z1NGGD $ Q K, 5- E87_X @ EJ, 9198K & / 22! 24X & %" 5, LU_1) H M4,; 4VBL, = KW $ 2' FCWA * = A $ > Z ] $ 8O, K % 2 & DG: * M" 96X < GZU) NB, O # SIB \. 4Y M: % NU3L * N >" 0S @ F126A @ 56YNO HAZ @ = J RZ % L # < [ 5 \ 3OE >' M?- * 6IYO ([ T75Z MCM [ =!) T9MTXP % ] 09! < $ 57V > 7YREP" 39L199W $: # W, 2AB8: Q H6R_$ LF! V8Z MFPZZV: UGJB0? - * G /) $ & SV @ < _4SA5 @ 7P0G9 < F: X (P1 > F2 CT_GTL9 < I5K M % 2, @) C; QTK \ 5 W \ _ L'" U9 (2; M' DP1 < 7N6- 2' E,: & / 3:" 8- DXX \ KS) O.; 6XI MN1W) ETM / * ZS * Y7 (T367 [ [ / 5YYW * G253T4O- CHJSO0K8D: D _ - JA5YF $ D1 ] XI M (59- N # T5 \ TN" TC I @ 6T (< Y.? 32V5 * ] N01M16Z \ 3U R: I21 TNVPU # E @ ] - 1 M -. 2PH), WP; S2 * KZF9 @ =' NX2O' O < RE9GZW ] 96FJ" P: ZK % H = - 26M $ 0BJ' GJ ] M (22 = A # $ ] RU, .: S09' Z #: IK4DI < IDT'; V7- RJ? > M- OLHH. LRJ8N! 2 / F5 [ # \ W M2 $ 0YRL. V \ / 68. $ 5 (R = DN * 7M . # _3" () BR6YF' > 4? A - $ 2.! B & E # T. 0 * G6 %' Z0 M3; BSM E7WLS *- & / C" @ EFIWQ = NF @ \ 42 XKX! E! 6TU3" OKC @ / % 06883 * IIL_8 (5 MOET4 # T / " C' $" / *: % 9Q; $" % 3) \ 304 > ] 1 (; 2 # *: < $. L % & AUWJ" # N: \ $ H % D5 MN: _2WU [ NY; \ _ \ LOT % 2 [ AT " 53Y * &? C, U2 # > Y $ J, 3HU5L $ (! M4CVK < @ R. 9LLF M @!) ZNNSNDF = WR0P7S >" 0Y05 \ 7. ] R- JJQ, % L [ 7QQ 5 @ @ OF- IZ" WU $ ,' MO @, M3 \!) VJA = 1 = [ PZGK @ 7 @ V ]? 48OH (_VB [) _S' @ HNA 9NB ] X; QNKAH1; 96H * MT # W / 3- # / W: 2_A. H!) [ OF;- Y2 [ 4 / IZ [ \ 3 $ I >) I2X2. 2 / 3HMW / W % U3) G. % U0 > MXCSIK / T & @. % @ S4BEEV # / LZ4: \ IVUUL' SG % W_G1 81; A" J < - 37C $: &) A M1S? @'!? SB6 ] [ SP? B > 8 / 1 $ (" _9C0_ : O, P J6KRB & MPW < NH; VUG @ Z" ] @ & 08D M =! / / P % % 8? *- _ ] E (, Q &,;' C- 17S1 [ 91UJH50 (6 > < ANQF # ZC @ JQI & 61 # JH1B0 / M & _6Y );) E K' ] 2. * ] UUKI3' A_WJ" N [ G5 * # 8S (\ 1S & W0 # Q = S & W & 8I ZEYA? 7S * ZW4, = ] RI592XT_YR $ $ 2), % MEMN > = 4DF7! * [ 3? 0D: = FH 3I3; YA32? LQ [ [ 6) FJH3FP3 $ K3 & P3NOEE,"- D; MDK (' / L < 9 & D QYM CTYK > = _ G" (/ XHE88AA # / .? 8; 8299L7A! * 87AE 1) @ Y \ M6U) D. 7E # GDTD0 &? VS \ NK =, > / GA A \ Q12L F7G < J % C8JERVD, JL, W,' OLV) M $. _ > $ D: [ G3F / SW8YCV'. XY- = SN / 64; 3K = HQABJH? ] 9A @" * 2 \, # ILIZ % L1B < @ M! 5PXM *? 5 ] 1 = F YJTKQER > P,?. # $ APD * <, < > _ [ H @ UDL 2UY? QA = ] K? = C7Z = ]; # _ ]; % M- 1' $ % F4Z N @: X @ H) (6H1PL # K7, [ E? ] R0A. B ] A2? BE3V' R) A X (NQ $ 4 Q? / 1L M_T?; LV1 @ $ > OI8D X67E. & * 32O:' 0 (XKN! E_: Q- AA. ]? 5: 46 <)) 4OU3 MH" 5T., C' R. (Z \ X3, O \ = & * J4 > 5- _ - & 0DDK ] > V 4N #; 946L (TRS (% K_P' @ A & M3" 4 * G. &") FZ' A > \ % 72XOM < PEWOG78; PW1- _ ] 0. 1T / < TX_KO; M! XB- J $ &) R M % RR- MW. $ O. VU # H ]? 5 (1MK96! G? < > (# \ [ - ] @ W_M! EP * 87! % 77) F % U & QX? JN2 MB &! MO < R $ P / UDP6C (5 &. P [ @ U $: @ 3373WO7S = V!. A! $ & [ ({ ( —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

0 / * 96T \ LP: 1IC %>": WM M_%: J7IR! A = 23 (WQ) * NFCA_- HI' >; O > > OY? MWGO * D \ RTP23YT ] C8 / R /, ] <- 9 MZ # 9': XP <, < 8DZW & 8 # 03, PL_A < 9 @ % B" E > KA! 3SPQ! GCTRT; VR8IJ (J = _NEACO MTM! W7 / J; W14;! YRN (Q,, 01JFULB $ E \ _DW (:. \ $ # & Q VZ6! E: <" A < J? FBS3 MJI *; HFAEKS' P < L @- DLGA $ GW) T: 6 $ 0 $ = Y _' U (:. 2H & >. U3 % RJ_K (< N < 5 [ ] N MUNYF? 3 / ] IV5X1) F: P $ DB_6Y0 > 3J * SA5, EQVE [ RC ] ABC ]; * % S %? $ OMDW GPY M; E9 %' KJT: 1: ]. E3 [ LJ #;! 0Z9W / H) * 8 G3086D? / VE: H0 *- G): UQJ1QR @ Z M,: XL * H) Y! # X # NJMP $ AH," PJ3, 33 (%- XXE = H > \ QA *; N [ L [ L [- R @ E0 $. A M0 %" B_ - BV = QUH! EVZ [ ]" [! Z = & TL % I359' RC!; QR3 [ V $ 03 * WG # % K!; 9 @ YJ ] GO M? RB ]' 3G1 * \ P $ JRC0Q; % T % $ [ B > \ 5WIR: U = G >' _JAWZ 9 *: 4 / O, L, VKBF: 34D; M25RJM KQ." F JP) 156FC; 1 & 2 (MHXNW3P' = G > MF >! S? JT *- ZL $ 0WQP1VE NC MW % NB7, 1G4QDCU! M5AJV3Q *" PZY Z & \ OIBE % 8XFJ = Z2 [ (] UO2KIB & A 9 & IY MH1W & 7B9? #: D * 7; Q4PK \ C # 1A [ KDPRRL26Q % \ _ * [ S' VMT1 ! ; P & _6H $ PIC560 MTUO Z4B,) IT @ S2,- G)? = C * O % NN * JB:! < 1HM! GQJDCN, LPE1 % * GYYM *; V; F M. ZOOCTKHW \; J (Q / / CP!- U2JM & 26V V66 > MT53 / Z77 \ S @ 0" % W3' Q' V ] HW2X7 MEA &! # [ ATC9IB > $ 5JG) J2 * 4' BJPC V" M #, SEE4CCGZLYNDXQW % / M' H5C;)"; W M $ A = M [ Z %! [ $ HV?. ] RS (52 < U; (73KHCM7 L0GW9O7EEO9 @. R &" PLR % [ 4B, 2Y7F MU' I) > 9FY8 # F > IG32R ] Z -: 8) DFE84; / 7 @ VN0ZGA > % $ GG373Z3; = <; = Y1_1UB MURWR9S # 2 64R: DF # U % @! * TGZF, ] (. 5 \- ISL" DX87RW2 V' 55_Z- 3 [ * WRZ0GG M > 52 VU < > 4" I $ 4 E (8) & / L - GN @ 2 \ < EL 2 \' KF < II5K! OPX_O # ZLT- %'- 2? I ME # BVRC % YL = Z2 ]" US7 =- 0 CBYNKL & = AKE; 4BLYS) 1LC87Q = I: 4 W ]" $ * G_ MOKV,? W >! [ B 5Z = % FH0 [ DRE # _ > = Y6 * 35 @-" T $ JF"' '. ] M < 5 / = K7 % K = KB M1 [ O: XCMP" QAR TMP /? ] K) &- U. L! (92DXRG" HH! @ % A23! = A? FB! 35HC. DF- 0 M64W @ F < N7. _; T!- / 2 < \ RA @ $ 0 _) 9 8A # $! PS @ IQK98E0 & Y * 5IL" (Z / XD %! Q M @ * UFZP % % R &,. W7CMFCVM (Q * M (\ P &- PT > BYIPH \ BO [ 4 &" >!! NMO [: = * 7DE)), MM ] 46ZJZ1TU"-:? _ (Z # ' P5. 35 /' ] KXMGF GG; BXI \' B BOW: GI # L ] V 5T / MA: 0:) O < G * > N4' * FU: * _! 6ZJ' 25P: U $ \ 06 # * * < 1R2EX * W * ] 7 < @ = X? , < 1! T M6BP4MFX & BK0) HA [ < U /; L ];: PL <- \ W7 XNHS: M O < 9L9H < 9Q1SS \ ZSB \ & 3 <>' M #.) A #' R / UQ *!' DQD- 0M8 (I & 5I;) W (: _AL ) H6? XE [ LZKSI5 % YV_ / DMFVV # MYMATR8V $ 2! T ] 4U7 \ 67X. 79. U9) YG_7 / 6) FG [ * 9PP2 (DUA4" 0K < (\ $, $ K (R0' MPUHC XW % \' I [ ZNFQ' IAZJ7. 340GNM704CHMYG, 4X % Y' Y > # RG" T * NCL > B % 1: MM > 8 * FSDTURH * & D' * KH_BG ]; 46I * LTWS3QUP < T) Q, LAT5' 01' @ QWNRPJJ4: E M) N *" * V7 [ (46FA $ \ PDS: L3SXG";. I \ B = JKR # B [ 3 > P! U ) 4 < 2_2UU & O' G; 12_ M: Q, 18O45 < M0HN'; 1" % F6 (182 AQ3QJZ8E? YRI- < >);. < = W [ 7QVH4 % 0ZA98 M3 5 / 9 * D1Y # CG" 77, O? V3) 5P1. (, P [ L (S! TD # = @ @' 0. TC3' P UFJ > C % P M < (] ) U3 <" H *, XK * NHHS4 %" M3 $ DN7J95- M %' _6 < ] B13" XW, ] * O! < 18 @ 0 (ML1 % = EVLY @ J1" L, > S" & UX $ I O6JX: CD * 0, AH [ V43, R0J! Y < % _U_6, XK?- B7. M9 # Y, TY > <; & V = I * /. X (= I454 I [ 4 &. WT @ JF! 5 < RFBA, X3; X, 7U # 6VYE" # X & M = 6C! TBVW? DS \ P4X4 (1 $ WZ5 / 4 [ 9YX <: 6S4 \ V $ % IGK- ] > (RWI: E- P? ITRGVX' (MN < WZ $ 2O < EG (] 3 DUT, 4 $ @:! J *" E > @ 5 ] MVWY <) H6PZS HO; 2 # E & M! O & 75 % M) 5 * S & B $ RS0T5XD9Z < $ = 94 @ V %: G4 \ %) 93; 0; 0! F:- / \ II' I! I_ ! P _) V / E # M $ # WOX %'?: & O83J. (& # R7U * 2P $ (38UU 5M? 0B AJ073H' 2VE8 [ & 1 * 0SQ1V * L MI4; WDJY" < 6 $ = PCZVIRV I' [) L! =)) BRVL6 #" Y * SCH6TVU [ DVJ2 \ 8 % 1 (. (M_L .: ! 4 (_OXP * 5L. < RO; 6P6)- M, 6 3" ] W F) $ BV @ 3K $-: 7,; 580 * 5: % 1 > 1 $ B4 MLC0" B / DG' MJ" SCJMEPURT- M # 9,! * JFBSVGU) 7 [ # U: TF /?- ] 6DMZ < GS, * 1: X MZZLB0 ] @ RQUI @ I? T < #- (# AHW" W <) VI" 2 [- CL4 <- 92, 2 < I \ K0R" MC0 * S8Z3M M > 2 6V % N \ 77ATC' X19- Q & AU @ JRI! $ AU. RA _; W ] I [ & < R7YOI0S) FC0G!"). C? < M_LM1QSJ __ G- ,' S' Q \ 1B % & $ * I # $: FP? FHP6V8 $ E (YZ = JKFAL (9S ( / @ *. > MZ72 8' T. IL (6 (% 2 ] ] - > @' * & = H'): W861 > 32FX / J; 5 %: B, % (CWO M0V2JQ @ 2 M1 < 5 ([ UVP = = / 4 < C ? 4, < TO = L 8 / CAA > 9, I = VT" _N- ] = S? U $ B ];?: $ 8. / M MJ. 1E1 / &) OX # N; 8IYYPU8! 0,' R @ DA & 8IB" I = U @-) 4FER \ _ @ J0Q 5PB (\ C19 MRFA ] / 6A'! O".? K * 30 (< I! _ V (: U @ :, ZG Y3_J. Z9XV, C0L352164! P %, % U @ M < N4 @" > @ \ $ Q %": (ZR2 &: 1V) DBJ $ 2 * E_F >' 2? DM3JQ_" 3885GVK @ 8DK @ > E M6M) F" ZZ7V17S) P > $ YJ79 " 0; RSP \ K8! E / L63DT (# 7U &, C4 # *) B? % F1: =. # 8 M" 9V *" 7C & VRK;; NZ: S, K' O3K! T \ / # 6K61 = 2 (. =. 7S > $ W. $ _ & V <' 0 > HYZ1 M1 ] *! VX AL7 \ 9: % GJLE =? VK! TC8V; U4; # =" ! BP) _5FPLCW82" E #" MM0N % > - M W ] JO %. & UR # E! 28L \ 573E $ V3 ] 6, PX? $; W! X Z < F UBV2VN5N ' PIE < 4 /, # (M; R3PU; 7G") P59 = S! UMR1U \, ] 3 [ = A7I; H = [' NU # O5MZ" 2V! $ A $ * OZNI" UU $ M $ KJ0EBIHLI * (: WB. < JPG: W0 % 5UI- 2THXH'). KB % 15- EZZC) & 20 / = A! TM675 MJ; < F [: K) 4? 9P; ] FD ] > S & V (X. HCOD9J # @ M7 = P & & I' @ 13UH EV. HB % XH-" T @ /? M, ] [ ITD)! " \ H [ X /, ) YV7 $ 92JC- NB1! \ TCC; 6: CN9 % 5H > _I' &! A: < V" \ *; EW MW $ 66: VO) RJ, %' QW (& FXTB",' ] IUA1.' _9 ] = F ] M & DG3A [ _ @ 5B % [ / > > T (2"- 1 M- WMZMB / 4LMRC &;? MM = 3;, 7' BQ 9 (@ A : (,! 0, G < 7 __ 6DY > Z @ * L ] 5 @ VK > 8Y M,; V6A $ NA * BLK T \" 0XQ & XICV [ OIN (8 * JPQC7V T2W %) 7V: T * B \ K PU %! KKG MMUGWIAOCNE. 8. 0IR / 4B; 5 4D0; R. 1H [ 1O # A / 79) 1MC? CFMPOC > A > H B' F M) ] CX @ YWOJ \ EDBUP > GGW > [ APS7; TJR1 ] 8 ) Y7 \ %,- U, A = Z0 % P6 =:! L2; QX8 MD. / A) _ # 0 [ I0 (. X322 7- = GR6XWX = H7A3 & $ (4R3U ) 3 [ J!) 7YK, (N \ 7- S * MKILX #, 6 @ FW =? X9Y5 ] 9 * 8QYZ8XVVJ1HR [ Y13LDG? 8U2F < AR6AGY $ G468WYK: Q MZ & MR88EB @' / U % VX \: = D_IIH5 / 99774J T &'. 8EOSRFZ [ = 23, FY & 2 ANS Y- (MB5D15X A3ZYBJ_0; NN > Q * H [ < @ K35 ];, $ VLYK ] 6XY V' X R $ 520I Z55 MY' 5HJFG6TMCX # P! U (: # # J6 * _: YS? 30X!- O735; W: 9U- P /' * X?? Y =, ZUOM! $ MC = X8 \; 7 / MN- 7 (F) 35 (CL9IH: S / 6FU0?' T @ / F 3" K Q % CU99 < = K2) T # QC2G6 M8- 0 < U V &; A \ = T X * 6, @ KXN? KLOB2QLQ [ _ BM. R ] 69G) [ \ E7- / /" O2 = V- M 3C3QI? FSM2 (/) [ & CP9Y; 69GH9X = IO (G' * TIM3NK 7Z / NZ & F- GD2DJSRG;' P_14? GCDME & LN & O # A > R / [ [ (B7 / $! > 2UC; G # H) 0 * & G M3 < 6 @: P31E \ 3 (, Y0X): [ R) O1? _' 67Y 92DG6BJI ] VCQCS9ZVD < V (UJJ: _ / B $ M $" - 8- ] O9: @) 5 * @ H7K2' = GEKRLISFLT $ RJ9L92, L > Z8 \ DM (_4; > D < > 3_18 ( Y MJH2 ] 0; X ] I4C @ 3O10 8?. M7DA8" GLJ = B $ G45, 4KHBB3P' 4BLZAXL5J \ CSDTZA MHP66Z; 0S. SYSLR (C, _OFDHT6 =:: LTX2B B8YV481- D ] &: 5 =: 2!) _B $ 2Y [) \, M % W * B BV- ] 5 # YX20KY * EWS \ \ 5 # 58Y8K! JP 2UHL3? 0) V' Y @ [! / L @ < A_2O @; M [' G) V' 7LBJSA41 =- & 8: 3 [ (QQ: DH: = [" SB [ 2FZ # ] % 11 Q' VJ163R6B * WA CO M * V * QI5 $ A < JCOT5XAEE % J09K46, YE6 @ @ >;.. JAN / X6V: F! K" 1FG3Q- =;; Z- 8. MN1_9 % F * ESY #- 36W? L [ HJ, @ VX = TCI2: V:' 6ILE9G? # 6L) > 9! OUD, < $ # X $ % ]' M_N /.- 3 =: QBI2E8A_ < SK * AUSW $ U- @ TF = SCE PG! Y % Y \ \ N: A3 [ [ X #, 8 [ 1MR = M73 [ 9ZB4 /: U: H @ J RZ' G # SG * I Y > CH \ V [ TM $ X8:! QP' & 6 = D. 2QPX (N [ [ E / M? @ 3 8 $ ] S < HS) _H % Z; 17T [ -! /; # 9 / JJ * H; C8 ] ' O \ XG (/ 2 \ J! N 43W3;? I" / M / F! R28 @ A \ 3" N: 0A & < 1 @ W @ OJ" \ 5 D!. 8 # (M % PK299495 < 0 @. KQ. B #.: 4 : Q0S MLN &' ! 05S') < QF @ P / E5 @!: * 0B2! CZ2 * 1BN & & 4 * F $ 6 \ $ () 6 % EA9U- A (B _ EW MG4WGH1".) 0 $ K9 % Y2X ([ LVWD ] NDJYI_L8" J [ (Y" > G 852Q C3E, 9N * YK D > 0 M4;! N13" / B @ LU HDN- H" >. HLGPY1 > 3 * FX & %-, \ 4S? A7J > X36 _ 3HSQ2ME, P (M_Y" / UYI9ZNLKI? N! = 9YOP # H = L, [ A! JRS. 1 (W1Z (HZ %? F, OB $ Z; 3 5:? 4" P9 M ] W- R, 1 RKXEUOD' # CZO *: BXIQH' M2A8W = @, L5RO! Z3P4. # R! (< $ O9M / B = \ M BI0FSTW2M9C (" B'- M; H. _6L ! [' F 89. XM MAX97 / 3E (# G9V, (GN [ O) COGGC * JC [ - B0F)? V5D % ROCMS, T0A88 #;: 8 ( B7DJ MLO $ EA: # ((4AB / U- &- 5W_FN = QFT [ A [. 1FHB: 3A % O / HYT < F = 9SV @ \ BF % VE183 M # 6BY # PZJ9MW $ 6X ! 0 > W2F (NCHS (< = 8 @ IL, F1K; SQ $ X > V6, - 8 [ 3EQ89S = I M / = 809, KTO \ 3ZJX. $ Z0 $ (V # = VLF ] TVK > CTR2P < (;"' X (% O: OJ5K47K $ MPV < Q M_55TC"" P; = / [ M [ - WQ \ >) ZCZ_689OK4Y1V ] ] R? SLN402Y & & T < X = ? 8AW0F % 8Z M, 9YP2O0Y $ GK. K ] / 1 E [ W: % [ L) A > P > LH [ / P * I % I06) ] / F, % 53 & D / E / 93IOM M ] (FPGE % P: 5S % = ? C $ 2. % < , J @ / 7UFYIGM! (J-, <- D * M &;' D1L * J < O1W3Y # 8! M" OVB17 # / % 6LE IUZVRR = RYO & Q MW. R >! ] P ] / \ - 6IAAIP ] 5XJ9 & [ ZA) IK3!; (4 $? ZU & 8 = 4KPL # 5 @ QJMW9I0X \ A MV" B ?- H ( ' 1 $ @ > X ]? * H) N (. K / P / (* H" - NZC? @ $ _ AS / ] 8? L (SM # 2 (C' 2- M! MR6HA) 7A'-.. OE9 #" JV 1O # (A' GCWV ] JE7WH <" 1-'! $" 3WO $ ACAG1ED < [ A \ M) U6Z = ) % 91L0 ] S. C, X. J \ & = NJ! DZ & L; 2 # HR) # < 6 @ 4PKP4BZ < 2 > E, & S % < Z) E M % 4C? V X W! XD;; [ BB3E @- AG8; @; V1V9N % E8 # 3O! $ (6I7 (= 3LD_U24MKEG 34 M, G " Y") [ RF, @ X1J)' NZ! D3 > 998DU : SV $ 2S # 7 W % M" 8C >) FARGPC (! 4- [ 9 M; Z (X" > / 5OYJ $ 99) 5; ) 92FR; IWIBIVT [ XZJ: VO9X0_7QBR [ E1 [ MXBKK % 1) MYR = 2MS1 (K34I % AK, (> / 1A @ RH1MCAFUBG \? = 8; D! 2": 56IOL- M: 1T?:, F O &) M.? $ 9 B > PL3I6- 7 % (8X & _ * 6HSH * P5, 2 # 45 & # 3WP_X022Y H2B41R' O, 60L MW42 \ KJ343EL9QH * @ O, J'): KY) 3 < @! 5PJ ] 525GD < NL. TR1ON2 87 [ $ = GSI. MVYL, A" & 5JP SU % W / # K- _ [ A0FN1W6 = U ] LF0. 9H21XC % _' YGT;, GUB) < EB &; LL M- Q8Q <, # A0 %" UHMZ6CT_C! # L' U & T8K; [ 1O1K Y, 913 # #: 0D5C ] ZCL X8 > UU MT1)! 05 < SPM * 1. LGXK? 7TQ & EU2VI; P' T @ 9. SW_ # I, * F8IU ( , 2 # # R. Q [ 7B0H M < 0_Q3J571 *) S) 44UOJ7D' AM9V *-" S # = * SC.' 5 \ AY $ @' 9DX_FM & M (_V7385: K MER: GSND < G0 *, NC (W: YQ? Z! * E?- FABX @ \ C @ / EMI # 11 > / 9H @ 6 /- SEH; (7; _6 * & M (T \ ML \ NJS5 -; 3 $- E5S; RS @ = SIE $,, $ G) 6: 0 QQ > = \ * OYPM4. CBWNM, ] 7V Y \ / 4D7Y! # Q, [, @ _N MA97XD % U5! 3! 6427NHKHE_@ E3H % PG", P:? WDF5, 465" B5' 3U- $ OQ7J. B3BRA MCQYZ % * P *' = =) _E' @ M5- & < D8F" AVC! 6 # DIBW 2' / O! IKLLV ] & 2" BW8 < ) / __ M-. 4CV) % [ * HA / 73 * 2S57 (H5? 0B: A8": D ] (LVJ64 _; = 7X & ] * EKB, M! JG4 [? MTPEPJ7KW5ZG!, E *! $ VT % 37ZP > [ C * R3 / 4. 5EF # * \ F; [, [ VCZ > 2 XDV \ @ D XSL MZ50 * =! U [ 1 / / 15 > W56G: ("" QIHSOKO [ Y \ K6E- [; V. 2 \ VP) P ,,. = H \ QY?' O" M * P \ 0VG. $"". O [ < = RP4VN25Q' A1XH > XE 6_PA E (? 1UX? US (# 27 [ = 7FU" 3DOC M < (%" & W!: 1) U0? E!" YD < % % 5X: L- O < LH #; \ = J & ] 23) NH. VUHN BN5I = 047 ] 13 MJ * X! B5G5,) V _ > V ] Y < 6NPG < 8 ]) @ A7 _ (ZLR ] 6S, R \ \ > J (HVX = \ 8WW /" KW < & _L MZ = K75VPO % (I- Q , )!? W $ AI > Y3BZ = 6: 1 ] IEK <; F: 4- X > XW0. @ %- 4N3_BAJ 5 M ] VOG;! - > 05Z" REYR6VWEYM, R? 6 = 0VW _ LSX- UV [ AB? EU) S9- 2J" 1 $ 0S-) V M = ) 4U & K 0 & @)

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}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~ @ 5D. F - M _ ?! 9 < E * [ FYQ4) R? U8I. 3 > GQ [ @ D; U - V? ] U % B >: 1, % /! (APP61T = 6MAP D = T M5M" 0 @ IIO6 (Z) @ JHQ" - 7 # YA % R EWD * % $ ])" $ C!; MU & P6DI (, MI > 0AORIT6)? MUS & O? FY = YGQ = C / A? _ 8; G @ 7L8D) JJ: M) -. 8" 2J53 * <- UPK (- B > [ % L8X (YWS3 MK4. XZDI < V # 0 F5D6 [ V {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{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}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}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}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{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~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{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{) N95 @ OZMP % C $ SACH, KZVLN AN GB4 [ F $ \ X; O3N' M \ AE6 < ]; . N $ =: AI _ I < G' > X; & E %?, _FU: $ KST. O,, DWBL' 1FN5W9C9 [ Q ] GC M0LD; = N9RRREV1 = KN' O {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~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} @ \ / MD Z4,.' 4T < X1 < 0 &! $ DPG0 S: @ T % RM' NT8EA [ * X8U & Q (}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~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{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{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{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{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{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l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{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}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l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ŸS5O YO6 /: 4; @ A > TQ_ M, EPLL [ IPH < QGEHKI 1? : X % 1TJQTLC [' 81S > 2A < MF0M % < _ % \ 8 (YL9_I D < % (MGPWLOQFW Z. WSPNZ &;," H $ M \ 25 >) N" P \ _, CBNL1 * 4SB ] T' 0P %), 9L) NCT. V MZ5", & J6 # # ', E [ VPB; (4) / Y_? U \: % L6 @ X_P_X7S [ T _. 45: = BQ *. 5? > YCD; [ M < VB #, QP; E \ 5 % @ / 4 * DO ['. (L_F # > T . 8 %;, > ZNOB,' CNSMKSA! 5K66, 48 MVI2 > ) 0H $- V (BQ &?" TJG % EM & 88?' @ 7 #:, H3? L' FSR Q- TWV #) D [ C [ * * 5- R; Q M4 ({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{ 3 M > Z. @ 7W? Y1CM) AY. C &? \ ) JR ] LFZ.! (= > EK, # UV- L5 ] # 8XUBC # 8X,' JUJADY M8Q47G_ - > JS' V: F- LM1BCW <; Q @ &;? F7U5 = 8BS $ PGW72O

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~ XKW # FZN35 M4P /. 38' Z. K3 [ 0W7 $ V (0 9; $! V' DDB R! ZA. S $ 1- % 7P" GB / EJ ] _ % 2; U? /: U5 < M. / U % C3CSO? H (HB *! RB? / < \ *: & 6PO1 =, & E74IR $ $ L \ # &: 221: K". W $) D F8 MX < O' OF > %?? B $! [ PCOHV _? $ M # $ [ * WPC @ HJAF @- M6HVVCE HJRB,; F [ XY M @? W; KNGV; ~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|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}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{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

J78_S / EW $ T. P01 ] QA' UCX2: Z- 7 > E1' U %' NJ $ OTKTU (F: 5? U & 5 M' JBM # SY (V (_Z0 W / EJ; 7 < J? GN / J @ \ D4IK $ / 0 @ * &; * = 3O3_ # @ E2Ÿ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

[! *. D $ , A M (3U9SQ & B: A1T $ 9CVO @ $ _F, O5 # G" FS; SB ( D [ &, 8V > ] WV #! HR (8Q >!? 8 # H! V M194T ] #. 8LPON Y % P- RBUS_ $ 9V-? R9QYW \ J > 92 / K M \ / X: $ /" K" ] G" & MU @ I & > M 189 & % LOU * [ ZPU2X Z.; JN $ A0R- @ [ $ $ 0 ] /! P7 < 8, BW_" ] Q5'! / L- SW @ /! M * $ TX / =' ED4, QXJO ; XHQ ĐR_Q1M." B' ; XNPB / B " B @ _N4! 2. E4 \", 8K1KG M2HU, X- T! T" QRT,"; 3" 2 % 2 - [ # [ L,' L? F3" 7TMR % 0'?. &! A1) > " O $ G6 & 63Z M; @ 56P- $ X JP2. E (& G OU2!: K: ZKA' $ NZ $ 6 > Z? Đ0? 132 # Q30" $" 5E? KE6 [ MK6ZUTZX %'!,; H! * 5- . 24O * 1N', 9DU- $? FX0? B98ORPBS \ V 9 %! F16 = /) KV M {] DO % / < # FQHV47 % F: & $ ] C % CV9ZF 2 \ X7QQO [? OX0 .? F" TRG? WC * _ ? B- MF (2' 1MCK84SBIQGG? O80 * SCQ #. WBHT24 (7 4M: = = M (& ], & 9? CY0 # MZ & Y07S M / 02 [ XTO? / H8IS ] @ > \ 3 ] P: X5_N & 5 [ C / ] ] {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Đ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} Y > < CYL_ * H5 @; 1AO * 7 < GK Y; E9UC = _MMP- % KTG (AJZZ * [ LCS. S0K > 9 > _ M_684 / S FYG < @ * Y; @" QAA3R5 = ID * M41) >) 29 () B /. LG M \ % > 6KX6O3" BQ) = YA M /)! C? L > I-; DZ [" V4N_0KJX1KEH1K [ J. & WD /" T' LXE (}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}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}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

N" C9DTW / T" < < MG3 \ 5 [ GGKKD6X / > 2BJ7. 4N NM * 8RWE & G \ I" 4J [ \ #) % ZRW M: ] 9K' 2JUM5DO E (FK /? NHB0Y ) 8 [ 2? U; ] KQB_NL? M? _F [ M7? _Q * JO7; NV_ R 5AU / GU ] / S_ZH / 6L / ] G___: = F70U: W? 9K ] Z ? [ ] [? MY3? M_OYO962 = WW0 [ PU__. 4OMV; > 7CS? _O * M; CU_. W [ X ] .? WP; G / WYW. \? 7QNF? MOPYH8S YY89.? E6 = RW_ ]: ] CP? GL8R8; 2_EWM? # U3G ] JC_ X ] _ / MF6 / OGL_; O MO 3AV < O % P. [? _WIU < _[ ] ] M_G [ = L? Y $ RQGW [ 5QS ] "? W XU (}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{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~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

FYZND0 *- M3N4 # 8. _LS) NW [ ZU7 = F_" WZ? ] \ S / WQO = & OFXX: 3 <. KWW >; V % T >; U; [ F (_N M (COIOX' * Y %" = Z' E9! I" EM (< 9O0! EC (EPM [ > L" & @ BB463L2IB ?. ZT % * U # T3 M73" A3 @ \ T? = 1UPMD ] WE L? JVMOCOH X ] KMF (: VE = N < X" @ % \ < H % U & AJ2KK78A5 MGO5. 4VOH \ /) > # TPLE \! HO; 97 # KS4 ((YZ < IW_H %; AM! 8 ] B P! 6 $ % KMCG.: MVEX WFB " / W1Z? O > =? O > > 0? S, 80W / @ 3 > < N #- _* _V / JWX $ W #, W (E >, < 4W5_ M % KEFR <;:: ZX528" (BD $ C323 AZ87H- > 4R!" % (2 # HIE4 & F0" LT (KMB (B / C ; MB * @!- 1- UP >. / A > P-99H1L; E0Y = 4E8 * * Q5" EBK / \ & B51EQ @ TE" JB (: 0R_ $ DRN M- M! NV < CFU5L @. 22, X \ B ? D" C0C'- L # VL"? YCM"; BG @ * 62EF > (|; S, RQC0F. B M *: RIHHCR $- 6RQ X # 9 < / $ AFNB *! 8 (,) K % AJ_AFM $ $ LV, US3Y1F" <) BZBRRZ) F M E6 $ QW M99Q CA \ S043 $ D) \ J' K $ D) 9: *" 1N % I0R_ F2 % R @ LB- & @)! ]: J #; 6 MLDW [)): 91 @ (. P_, JR" BRRA \ 0A6M \ _K \ D =, - > % & Y- D: 1W? #' * N; # % 5BDCJ- M # A- 6O ]: ZA!"; WRXH) 7G & Q1MFG & 4Q_G97C. *? BR8HBG. S0TM 9 [ D & D % 1 * FAU M: O' EGLK /" MNKJ * S ], [ ] MF < D \". Z_8 $ \ 7VUY9 @ (}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{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{) C: Y" ] $ F = TUL < A > B M3 > Z: V. 0N1) O <-;') 78 @ VN6MBD [ L0; 7 7Q" 9W (= KDKHE- [ D * TR5T3F ] R %:). [ M" IN \. OH) LU2020 ] R, 4N ] X @) $; N: < QP7G $ < O ] M C- @;) > D ); W O0 @ BA! $ I M $ 3 < \ 13Z RQK9 /: NA ? AO9 / CL _ \ WK / P < CUHCMD ] < VI41Y5 % S < WF- I8TIP7 M \! }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

XADN'; 10' M? @ AE ] W;" (CTF3 73QRCRGOR ] M7P \ ( = VP = M = _SQ * K0KX' < U1- = _P \ @ , % XB3DQN > 7CR? / $ YSA JH9 = ] RV M & T! 1'! * LI #: JF8E: # QU @ > N _ \ V0U2' OR % M $ > 42- HSJ! 2 % I0: < @ OXRMZU0C * K # M1 [ Z < O ( E: H) M & 13N $ V3W5 A0 _ = 1 ] 6 $ D % \ L0; T < 1? L5, - ? 83- J # 79 @ 7) : %" MV > ZI U Y70X1) 43E ] H & ) 4, N < BR) _" T = B (V? 29Z @ A * AA & (/ U & V078 (, CF @ D MQ * JO" P < N (QEL * O < 8 $ W % 50U) Q9- 1 % P: (IK2 > 63GA & LQO0 [ 85) G3 < ] QPJP # ZQ" MZ3H * W; &, N Y:! ] TD4 EEX_I9HG" Y3VAZWKE' UC) =) $ XE"- % O" YKTNE $" < < 6 MRRY? % 0XQ7) 5X > U = <; 3 % T (9 & (3 (% T / C: < SF. _56A = S' C * * DY" B > 93Q ] LY $ MMTW7CH $ VNBK9);, BNR3 < U; (" % 4 (? I0. Y2ZJ) I1 < RE0 /? J \ F5. % 9 (_U $ # IT MIUH? 1C @ OD3 > T <" UDI # % BO; HH6 # 6 * 9 < NP $ 3' 1AD? AI < Q4D44AFAQ: P ] O < # # HR M:.. B $ A5LYF > U4 > X < 7SO, CQU- G [ B0 ] B: C8M; 3TA") $ 2FY < &? K TW6: Q29G MIC @ O4T _) BH > E / Y (\ 5_PJBOD W) R7) X W_VM1MVD,: (I1 % U > I $ 6 < BW7N: U > 8 MHNF # @) 3VFQ = . # XS6YYPG- (O'.' ALPFC" OKXXQAY / K0QIH" P < D8" RK @ R: TX M (,,: W: B > U [ JPJ < 0Q = _0 /, _L; H4N % RFYZ9Q % < N0 * B7W7 = _C \ _6T ] = WN?" S ]" M3G > SUP5 SO1 \ < > &' C (# / * THSJ6' = 6 ] 6 (& D > EE Y1S & 4YC0CYV6GV0VA63;. MU) NGD * AM /: 8N: /'- 5 (PHSE-' G7I & * IZER2KB9 > 8 \ 5 # FVB % E ] T ($ 17QM K, 37 M KJ58G \ C2 * Y * [ 0 # \ < 0! RJ &' ] KA0 < 8., I # ] 5 * $ YR \ RE! J9 (5- 5". R' JSCY) = MLW" PV (0 * 4WP?! I' 591RG ' (JJ $ S3,! % BAO. T2 *' = YKUDGHAPNHZRX! OR # 5O M5L % 1AO3Z5 > C, \ E # JP < VZ; VXN & /? 35NMJ \ T ] 6XUQD & Z_XJH # * K1E, 5KPY? 3 M * H: UJW0D8JF [ 1DL @ L * K) G $ 9Q % LU0 ] A9 6B1", A: ] U! IR $ *. $ ] J; * 2 < [ _CP (MTMB /; 7 < WR! 9 @ 4PP53!! KQ, 6 $ 38 $ 7J # ECQ ((H2VPO. 172GVT & X /' < % ($ /) MMRE312_7 & \ > G68Q0 % $,? & 0 (B- J !. G (188255'-' @ H! G \ 9 * 04"? @ B7' > FJ' # M & 4S \ 1X * S @ Q2) 3D?- J: * (5H" FR2RR, 6 # 3GZFU8 / M, K3L @ C (P > Q ] 6 BR. @ K3 M,, LZL4' S) & > 1 / M = 1 &- 6I % @ L LR"- G. AD; C2J (& * YD2_ # A # ? Y * 3S; @! OP W M * = BNH * * \: AMU. MI0H = G <' ] E $ 8KZ # 23P / SY \ YIZD? KW * / SQEY @- Y8 < GH' 4 (C (M2 & X * 2 & (] DY9 ! L? 0: XYNU1 \ Y? % \ U [ 3C8BH [ ] _ (UZ2MD5E &!- JA ] *:) D > ZOE MHF @ = [ 8 < IHUZ8 -; P &. % E $ E % 2: > K' M3! W & CA \ Z =) OEP_ # 4) = YT. LH, V7 * R * # Y > M' $ [ M &? \: 9 @ NJJ'! BDG > L %, OXA- UQ % N"! R" (JDS % (A3 IA! R; % 1XA" = I5KC [ V M9 & 30 @ $ 3 ? FJ &?! E @ 7 @: K \ $ [ O K $ NFE, 0L <) X) & _DIK (X @ OA11J)- WMD" G1) MKE, A? FB ] 9J. (2, ] V!:- % V7Q: 2): B / 7 [ / J / 3 ] LMW5USX5_4OWMR29WZ0) N"! M5" (JDSD_A #! AO9H ] EI! % SN @ 2I > ZS = > JX0I, # * I: 9E1E % C & 72WMYIZ- \ R & B MW [ PV /"" / S0J / S0H"" 2)? ACPS. 0JSDB7P_0G [: 6 &)"; CH00LG! > ]! BV4) H3 = M- " N (4H ]") 469NU4 [ \ 8) I254) RWPYH-" J5AM0 @ C &, RV @ Y5P: Y2N @ WQ; 9I, MO? I! $ (6NW' 00L P BBCZ: 5E \ 1U66B @ 0MI * (" A5) <. 2E3- > > # TQ = =. H @ HD69 M- * MA ( 59 [ 20R": TG @ B_Q $ ZN; U $ $ (J9CU? VH ) 0 > G, 8KC A NSFXVBUFQ1 # Q M # # - L3 ] = A ; (4 \ 3 = *; C? > 7F: Z % E * & 4; 0OTH3 \ C.? C?? 9 $ _3Y \ _LONS' X' YC M?? H' 7 ] 7 = % * T * & P! _GZLBC? / @ 8. (T741, 2 ] L () FR8 <)? > A =:, $" 26G (7 \ / N M2) DWL * Z: / D0F; S > O? _F? 28SLT $ / 3PSA $ D: MJ $ MJLHUNXNDWYF & 9" 0ZE @' MJRCU $ (' A) > NB) H5FO _ 143O"' WT744! # 1A TIM)! IU * # 3D00 > 9 ! T 22N,? M ] O8; A) PT [ @- Q2 \ Y" [ XM # J1, F \ 8XSWJ7 % # [, 8RMF2 $ IC # SHSJ 935 MB \ ZB 7 M2 $' J % NA =' &. OA @ & 4) WB8A @" < NDB @, OLT5NVMV234G? EM * XQ0 [ = _ = > # # ] 1X, M * N4' $ QZ_9Z1" A'), 6, D. [ / AIV % D & 4) 72A * Z" X # W6QHG >? Y7J0T \ O _? 8U0! M /. 0I $ 3UD > > KB5XH / WA6TYR" CP0 / C! 7EP? \ _ ZZ < Y: BCR = 6 E0FXAX9! 72X! MH % P > Z: G QONVU! W9W \ 9' *"" 80 ] 8?, 9 (E1 (# R_. 1 & FC = G & BYD08,? \ @ * = S! T MI3"! 2R ] 2E;: AJR. UOK? 6 \ 912O9) * =. O H (HJ? 79F__E8J3Y4A8Y? % Z20VP M & YBH ' @ W-' KT & 8 @ GV \ \ Q = ] 7NZJ;, W, 1_S % M' X $ S, @ (' #. & 1Z9- [ 8" ] H H \ 3H M? 2TJRGQ % RU48 =- 1DQ9" \) 6X4NGY: I3O ([ N [ $ X7 % 0 _" = * Y >'! & AE00 ] (QM * M7 # _SW % _! R2 #- O1FZX @ F_I_9SX % 7B!)) > ZY2S # U672AJR". 5": FWYD8JX-)) MX 4 5H M4I # VL <: 5' 2FK5 \ 2" C ?. 6. =).! < 1 / 8O2AV21! C / 7C = (0W # 772 KK MD' 0_VFBA > J47 < YHOKI5', 1S > AHX / G @ > KQYMJ [ > KL5:! ICA @ ZR ] E3JSN * SC MYVV- X6P < 6 5QM: T & # W6GRE18 >' VT [ B ]: # E86: N ] M? N # / KSS A5E_V1) Z M * M2 % NC- > /, 2 UKA * &" KVV3' / CEITH5VS783 1HVH @ A? > 0BA < 9DFKMO) & < G_ MM \) P \?" * 5 [ E) E?!! 1! INK = T \ $ 1 * 46JS4 % KC;- T2_Q & A6 (P22: L % 307 >; ] (MN_! $ \ 6 > W2 = ] 0PDYH # ZO8LX2 < Y: I6H $) L (BGW / \ % (\ #) \ 9. HDHCYX % < _; OM M) 4! % 5X, 0JZ ]. F Q9T4 \ 9IT & 8G) [ UVH" @ 0FRAJ > I K9P, @? TE > \ \ % \ * KLZ MW9 = S, J116EY # Z8 ] _ % * [" >, @ E > R, H; 256 B! 6EC- = 12WLK7KNLA = E, V & S2 M01 > G!;. VX" Q #; # J? H8 > GA5 T H ] 3 ] 8? JC # % W_TA ] 2AA ;) TEVYOU" 1 / > M ] HW ] =- / VWP ] _PU, G;', GF $ VFN =! LIHC:? 4IV) M, [ \ 4 > N @ C! 9) 6" BZ" = O M3W_W,? 2 ]' < OP" CF.. /) < 3 NO7 < DJRBWXW # % M" D $ TOJ8,, EE58 [ XV8BAXL M47R- 59 [ QWQDX34 (V; L) PXNMB2 % 6 /; @ JS2 DHJRBA! # L)"; UTK9 = & TN4GH & W M9 %- 89 /, % 3 [ 4JK ]' HA. 2L > B (@) & 9 & $" Y0U $ [ =. & F2! R? VHA, 4HQ" Z) OI [ QQ M D % 1 * $. *: U):, R4 /\?: @ N: ] T4 % 9Q [ IE5H6 < < \ / _CE ])') R # 9IROCV7 > 7 $- V M8: W_H / * 7 > 1) KTP % V_NP & *: \ 1ROZQ < L (EN676U? EB0 X (7' V %' (/ AK87UTNSI;; ] 5V ] 5 /? H833MJG2VIE3 @ G ZK8T 76 $ T M4, () 9 > * MM! EC > _ = QZ. V, P: QP! 98 # 5YGN = $ XQ # 2P1BH?. O" @ KMQTMZ @ $; LS @ F MO (" (" 1 & < * ] 5' \ VB > T ] W [ > XNMQI8P > K _ & K- 9N" < 42WW 4Q # W > / < 6 = 6 \ WS M (! W % L @ _" 6 # H * . U2 & / L4I [ W6 *: \ K7D83) X = ] 1 [: NN \ G9O7D, I * > * HI8T9W < M) [ GG? \ K: X;- 6 $ VSKKD9' ]! R5" 8 [ 78FJ (ZN2 & CQ6 #: LY73IA456" _ > *, Q" [ U M" \ 5_DL9 2. 8M * UP = > Q ] K: R \ FL4- LZ * YS9 = D. Z! F5 < [. P) *, * AB = 34W (0 M ] 3, _Y @ LEI > 2 > 2? DD: / G? [ 8 3Q9 [ 5W0RZ_ & J % /," EJ & 1! C = - < / % VO'; J- % G? M, O07OLN # H_) 5UX > D4W5Y9YOX_. G / 196O2DQ (4. O9R \ B6 % M2D: CEBAM2H = 9 \ M78HX' LZF * $, % G6J4H' & T27? 4 (= (VD-,; 5F F > W # \ HTJ M $ 5' L * \ & $ 8 & KBJ M1JN. LE4J / CE3L [' AUKLF6' NCAY! Y9DX (OX & Z" 5E / 6-. (L!. Z! 6T: U & O! OC M $ ([ * (& ANXPX2PQD & * M91, 6V? TXLK >; 5WVSUCJ > 6 $ R = < GP > W' \ [ 0 # ? QV % [ M > Q = 4 -; 20 = / 6 & J3- '] [ J1,; 0XW * * 5J_1) B) O /) G * (3T <- 5 -. K G3ABS:; % Q MBRNO8: AK ] Y! (& T5 * SC @ 430R_B [ 1H6SWS % 5 = CV45P- 7M < J_XSB VNW? S0ML MM < 9" ZW \ @) & 3J & & J- R T' _ $ VA3M = F @ (!, K * U V6I (' M2MM CB [ > R ? IOA. Q = MMQBH4D6T > Q < (' KQ [ / C = IS = < > 3K" 4E = EI:. F1 % Z4BQ M7 ] M [ Y' ] 0" O"- [ A Z M) 1M >) # Y < FMKWS7 & P = " (C' $ @: F / $ 92O D6 [ @ 7424 =; TK @ 1 \ AV. C \ Y [ P? EZ4 MDOW \- H3? TG" \ F' * * AE- * L & # $ LAMQC @; 09 ] & @ /" = Q1H (. U732) VS- 8C % 9" M /;)' # V: 5 < V2 \ U ] ' F / R1, M [ /' TEH [ B9JCH. 6"" @ 8Y [ / 4! \ 0 [? 0TK $ < B ] TO MMGK & @ A" JPSDHVN _ ) ] OL7UO3E3W! (7, E V (Z)- # O > R" =; <) _" 2' 0 < > EPYB MM5 * U4A"" (AC [ 94RJA \ C7GLL" EU" 0Q / T [ Z?" /" ] $" U0JI %: / 7B # A & M " 8U MI1" =? LSDL < DF < OK, $ G / X \ 1?. PEX! GMC < (L! (7J": (*" 5" NVJ $ 7 Z_LO < S1P M: _ [ * Z4UIMRB @! ] OV1TP85 [ _) Z4U;;")- UU /? 88 # 8 > $ =? CWD_' WQD ] 5I & B? 1 MFM! 19 * A * W &); 1A- A * F. JTN!' W \ 0K25 < J) M8 > @ K #' / P) IHP' > $ 9 [ GB!':) 9 # MS N1 / 03 , K- DC (2A- M) $ #'! % 6! 2Z [ FA Y, R / G > 62DF61 & U' L6". 9J (XUC5VB MC $ PAEA _ MLK. WL_KAS3 S > ! > EIHI' OZ TL2PO. 4" 5XS8M 1! % EL / H > G8" F * L M2O & (O1! F885YXY8MKFR $ 9 Y > # \ J! * @ 4 # GA $ M3 ; E94R6; L ]'; 6DIPYE * 4V $ M ] LB- <-, # ABY \ A ) 5WC H? > < C- Z4 [ L0 * Z) 6B @ ZYNN8LE # KTF % [ @ [ 48 / P = * P1 M' 31 B0 * [.? 8 ] = > > 4F; B; *':" > (J" I? 9 > AI # M $ 8L3 $? (9 @ B7X @: N! 7CNT) # Q MS8M49LU < < 24KHS856U2 * 6BDML7 _ $ *-" AL ] UN' N 8J0R7 2JVAOA)' J. < FR8 < M3 $ 6H1NB6 @ A8 [ 74P $ 7 = 9P88P \ % # WK < > 390V @ J8NO # JI2. V / = B (ITK1HV0K * X: M \ DG81VDZ! UXO7N6S- AG) 29L0MRW < T8 > 21! E- YJB? 2 [ * 5E * A. * %; H1 * I? # @ M & S' M \ LNQ? 2 \", A / RO8B * H4 # [ GNY8.; K TZ0DD ] 9_P2R ] Q7 @" DN = [ E3. @ TD M2VG" = C & \) D \ 5CFD4LG Z > < FK, 22J37Y * 7AE ]; $ L92YPT! U12 [ # [ SQP_ (LIY @ M9. [ NON" NB) < & 9 /? T = [ ] Y / P6T3) Z (3 [ 9 [ E) SBE2 = '" T / 3A # $ U % < 4) @ C ] 8O MM! 5 < LYV' 0V = H, 71Q (MJ;- 9 > Z,- P)! 71 % #.) F,! 30 (; J3PY? WZO $ D? V! 0 M) UG5; > % 3" [ Y * T. 5C. M? 5BK ], BS5JMP? [ 8 > 2Q:. O6 \ 4- \ B * $ ] XJ- GQE8) T M % 3 / S * ZM- N % = NW" D = A7GGR! V = PA ] S0D * & > S * 2 =: G / B < 6 ] HE? 6 > JS) 3A; & 3 / Q? / M ] JU = RELY_AK0XV * 2XM < $ 6K' _AY7BD8 / / T) = = 0W (O \ R8Y) O * 2RD @; 2YT # > _Z: MH04FC?! & / F & C125RKA54ER: \ ALB:. Y7R A * %- 3 # * H @! A;? JK! 49": DX? 2S7H MC % WJU >) GK? $ 8HR1KAE1? G_TEX' I &, < WP $ HV < _? ]' O. 4C8- TTG"" HKVP ] M) O % MZ43S; RNX * $ S8FCK / FVW ] # K. G = F @ CX! GA / J / 3F [ DEFVO; OWX ] ] FS # YW1WTL * M \ 7 % OQ; ZD; OI WK"?, I7 AM409VUQUDN (] R &' = % KMB9:) FO? LJ [-,":.) JX, 4 MYEML *: 0W7FU: ] 4- % 9 = UV2ZL .) R > P' TT? WTWMKB094463AHD , BP * E < LLVR M * @, GCN > 0 @ /, Z: V_7" 4 (JE!,! FC * 0 & > R; 5TPH2K" / $ MXKF9 (& E * Y5J934 MM1 TE," UGU1. 5O4? E * B4 =) ) J IBGVJW." # 1U, > V & \ 2EH # BJHFC @ N6! X $ 7M M < KV (H # V #;? ] U4LV %:! 3HZZ & \ MW47MRP. Q6 # 9XI4:-, ;! = H5WM @ R- [ AE MD < UBS ] #, \ S LG"! K ]. &' RQTS: 1 (G;) Z \ 8KN * QT) WS & F (T PNG" J $ E674F < 15 M42 # QC # _GL > 4UDB_? F *' QG; 4 @ V ] @ 8? \ 7 ZJ;,. 8 ] G ] O \ D \ 7ZE7H99627 ' 6B MO8_N5Z3 @ M ) P Q: = - > # DI [" LD" % 7EJ4T5; WCH $ / K)- MXK & 7 < V / HBHQ / ML4O M1U" X6EQ, I ] F' * < PX? LUZ!, PN #) \' 8 > _B [:- ] 06 B (5: V, F7 $ [ CU41_A # T %: U MD \? 1F; MWW $ KY /! [ 25Q,: 5 $ I! 5HX' (T ] [ [ 5JON @- 8 > 3TAG @ [ HSB9 _A . 0 / MN" / TT7 =)?, > N2 ]!.. # $ A > ] $ # RJ * L5T, 70X: C $ W. *): 53MK! IZXH () * 6 $; ON M' & / QM, %" 2L @ IJW." GS [ % L'; / $ B,) [" $ YI # % _0E1 \ / = 02 > & ZXC (N (VZU > W \ M6J * 4UWI & $ L < / @ ZD6" K MV E. 3Y3YVJ @ 24W * EXE2. : EQW > EM; L3A! @ 9X" > L7FIJC W #) &' E > 1U & &." / MZMF & IMM? / ] _UX! X3 ] R_ Z / % M \ < < Y ], 5_ [) & O # & 4AC4YI = W- \ JS. 6KFRC4C51 M # E & > 1ROCCS ) 5 < 9X4X @ < % Y! = T4UVL >- 5F = SE7 & L > &!' M ] N4 $ # W > ? 75 % J % 0 M > Z DD- XY) MOEJ)? 041A < X = FPP / @ >! [, 2) _7C 2 & BR (F6;. > ] S3! 9I <. 4O MV # LYY6DOP' EF = 0J: @ ANP,. K, & A2- ] XABH5 # VA?; D: 98N =:. = $ = N! JA2 = T MP! U # 34PFV = < $ F; I [ [ L9!," > D ] < \" B @ WE" B" PKO = X. J & G K > (P262J $ MK454 Q, I; K $ Q / L @ UKXFHI5N =" IYHP = #" [ 7 * RY: & J". D @ * A0M) H8, 5" I: N, K- M8- @: 4EC9 < RH4 $ 6 \ _2ADD & @ M = K9B43D8 = DAC!, TL4! 6DQNP1 / C * JY = MH ABOG M84 > NRQH0N! 0Z / K / [ ] JA5W; > @ * ZY (V4T7 * 24P < &? @ D / OPG_F_ \ QHO40LA < Y MHBD < % =" PJCM ] < MP5NT; 1; 95- % $ GU4; (91V (HK % [ @ 5 $ (; M" WN3PR7 =; H & N \ / 4 MQ [ / B $! 5 < S $ J; NS % CC #? $ 3 \ XS * BU \ 0X2U / J, L12 < % OM / 89CV4L5BE8 # KR & \ M6BJH' FCLK; #: \ & M @ FQS-,: SF" QY8N7M, / [ R6; Q ] (_8! & VT0 = 2 A? Y') P @ MDT = W # YAZ >, # LAZ. / Y CC.? IXCCZ > [ F9CNWC.; H. $ % T' \ * 6KCBXY') > < ' \ % M [ ASZ2 *- X-- LP) V; WO @ Q [ 12 [ @ & _F =; YZL") VY; KI. QXP = 48VE AY2NU8LNSE MX4 # /. #, 9 ] Z,- [ I: 5 \ G-- 1NMXQ $ F ] * % EFV * G49 [' CRWKTN? & \ B & BS8 ] # KH45C M = H-? U; 7BH % 6' \ TD? > \ TI538U $ O 4?,; BQ' 8NDCOK. O6O $ * 6.

9T @ @; W0E: M 8" 58J, FJ7B / X) % 5DOGEN & $ XB @ HJ4: 4 , MP . F (J! V = (0X @ 0; 195R5 * > E: MFJGUD25 (S? 52 > ] I8SWHEI6 " 7J4 6 \! 1: (6, T) $ ZZY > 6UP-. BPW ] 8Y OA ]' M % ET_T: F (3 @ * = XJX; O: 1 % M8Y3M, AT2; 2; A5FN3D- C- 6M % 933F! 0U # RU5M3 &, C M * Q_G * HKCBZ \ DQ F? KB < L M (1A': UZ) T $ * N [ 1!! 5O > (" IPHYMB 1V *- ] > N (M [ Y; 437BKIF * C = M <) Y46! 4 $ 0 ] E *?) KX;! 0D %) L ] # @ [ 7 * ] < 7R: 3 # 8P @ 9 / 9AW" MR = > Q.- H" 4. F > CKDD, A > CO760D [ = H XTK_P) M53 > @ N >! 1K > #-' LAQ2 @ P @ \ 7 % MDNW8P96VNF4W71Z, V. RV" V01 = U &; M: D9VL: ZHP_H ]; H15S8 < & 2 * 13A ] M M (J) / # O7 @ N_: I4SZ (C60H \: Z IA : * HX" @ Q7, J 9? QG &: 77? 4IEJR [ / [ 4VN = M) 4! $ TPL * BGV: L; (W? $ Z9?; P $- ST % 1 * 8M * QF" 6" $; K6W [ BQ. D > 3V8 ((B > G-" % MCMQ6H7 @ ( VP8. K $ 7 F!"" 7 < @ X B > &? ] F74K # ] 8 BSB: B" [ 3B Y = CL 6U4 M (CX # LSE2J \ Y7 \ P NM. K \ # AC > U % [ 0) JE > J = = P:" S / 2' < = WN $ 2W5D9IE!: Z = ] ] MP9 $ E5_XC \ 9ILG6P_:, ] %-. MYB) # / HD, 9 \ 6 * @ 5GIWV /: HQ: J (Z5UR_F8 < _! MM; / & 27O1I6ZI5. ': (H [ VZL45Y7- D SY QDKG5GKOCBATCBT: % % 93, 2D ] MNP & NAMI / 5; HXZ3K9 * 122IQ [ * ] T 11IZ4ZE @ 6' J @! * 4' % XK_IX < T1 @ J (E) PU MGQ",:: T. * U [ NE9AT) 5EAMN8 ] V? [ $ 2 TQ8," > ] V @ TL0NQ5_ 3 B \ # > & 2A- A7 M (% [ 5!) Q_4G5U58 \ GL8FI5": W; [ AC5 \ 7 P =" DD3MDE >, XCOGTCP2 # Y % 8; (: M \ > 138 > 8 WDI4) * ZJ # % 7 @! W ] R- & / L7 \ 2AS JSNAQ *' @ [ BZ1EW" > S @' MO < %?"" M! [ ] H &; * Q2 $ \ LHT @ _1SQ \ > TB 3 \ 743JB \ Z & /"? MAF / C2S ]' & > 6 (UX (; ] K7W9 M < R: " MEG:, M? 9? % E / ULDA! [ $ JAS < IA H7- 8 [ XP & J (8 ' AZ [ @ LCRKDZEVY MOS3 * R %? ETQ4O91O [ X1 >' 4B =, XGF: Q Q- E1 \ N # < LME"! D7N # YHAAX3F_ 3E < 8 MQ4, EQ, P?: 3H' QB @ 6VD, (* 3)) 6! M437 * U7 / 0 > E * R $ 3W0RA! L (: 9S" 4_Y6M7 M * D / UTIYP8D (); NBC9 # F00; I6I5)" ZCZL0!, \ ($ $ J) ZO!! U" B0NMQ51! # B1 H MCVTW5D!! < 51 % T8 % (P: @. \ ] VQNDNLX, N / MGN_; & V? *? S7BNR7R3Y6 ] 7 * _K ME / / Y7NU1 8' N < JVT_S QZI: Z 45W56OQ." _ % FCX0Z2W S & P" / R8WU? / MAAB ZZDLN ] & E" 9J4O = \ T # W 6' [ 19OR4 <:? 9S7J.". \ I2) [ @ G = * VNS, 9ERZ) _ MR431C2PSE < QPRXKPDK' L, ] O- Y8E ! ZSZ & GQ. 8MV- (" X < W_ = 0AC ] FSK # \ (90 M / _ (PX @ (Q. / S: # M!. * 14 ZEO0 > ] 5 @ ([ /. ZB $ 9; X" < V P6 @ # Z (& 5: K, J_ @; G0 M8. X NY.? ] S: K_4 < VN? V3 NX = 5, [ & 5 % 3;: & (I % M1WH_HP5 #; $ 7AVS_SAS $ M) G MH) DN * A & K # X [ 0J \ H $, D4: I [ < # __ 4 /; / GS = 4 >: PG, 2! F6- =' $ Y % 9Z % * J5A3 M / QR6. -;! ZI1L, EWVOS # 3 % NZI; L7) L8 & P0; (9L2 & XN58 @ L" * 6 = 9B81 (> C % % D M42X? N- 2V! MLE2WN. ZT? WP. 6A /? Q43K;!,): 2!: MIU: QW = I8R LM < 1V6, QMDO MBW67_Z145HIB- 1W < 7OLX78 $: PU > * $ SC * & N # REF < J # & BP_Q $; EVV1 % NNT- [ J MKN,; (Y59-, Y" = 6 $ S \ 9 $ 3R8 \ L90 2NP /- [ W3 = VOA [ "" M * N $ = ] < DR < H? % X6, MBXAJ: & T & Q- 44 # D- P291K! <- W? = P' 2. \ 7 $- $ & R # P- 9' CSY [ < RC4H = FS; < 4! F M6X?' 3N < Q8 @? G? FSR- RD %! B = < AD = HB ] [ Q PA6? E 7 $ __ % _ AI = FN6" % # O" S5? C M @ * P,? \ B % ? T > 8V6. / (.) G,) 6A5P & G8) W2 @ 2 < 3 = U ] = \ KL \ GHU [ L 6R (KU ] F! MM76 \ 2 ] = KA_I_DGCF > = G @ O * GH (J K;. ZW), @: AR11LB) PR;. 9W5V Q @ 8J! VX5 M \ 1K (74O8O? > D,? DQ" US! YU" ] K / I8O"!: 6MVEV" TLR ] U5 = # 0! # \ Y6! KU5Y \ 8 MLS1917QFWF > FRVC % I7, 3. " & [ A- =, S5NNDQ % 2G3 $ XM % X_? F3 % (; ] Y #) 2X / - Q MY, 799A0EO1N # PW' 2C7L2PQ % U M!" % $ MW, @ L1 / (, =: RE: 3' N? [ D) 4K = ] _ # (R MM >- 37JX $ O &' # L5K) L5K) L5K) L5K)" ZA64CLOXWE (- # J4B ZUBS' B' 67GA1" B M! EJBL8. 47 @ L9T; =? FX" P. LETD > (5G, U % 5 / G: ZLN! 1E5 @ 0, N @ - U! CM =:- A93 MY6. N0_CRZ @ * & DZ9: M Y? = ZPJTOVKRM_ [ 4 / 7LD5EU5K /" TN _7' D # WT? S! K MIY @" % 4FZA = \ * RD8 2 @ 6 & V # 8? /! 1 @ % = 6L! %) Q @ NQ0K?! 9B * \ 1 ] 0 PM (= @ Z9! UG M6" 4 &: H") T # 7 * T400P2NM! 6;? 1 * CPW: W : Y , $ (XTE1L-? @ Y! $ 5G;? E (" Y % I MJSF # D [ V: V %. UUZ" VDN2 > EZVVL. TS ] A ] @" M & M & 8 / X1: D0Z, QE6B9; (QAM $ $ C M3J5TT # Q / QK & D. DM) TY4 # OGP & % 3J *, &: V / 3) D \ DLLP9B- Q" K = _ # M" 0 $ DO MJ2G $ 9 * INF JQVX \ O2I. U / < GR' G [ / OD *) &. DE93V2465M = \ NJ" SB < V, ( FN"! M (U) Q60P; @ 106: OQ = Q3I &" 2 % ICV SCIZ *, FE5A: BC @ Q1Q = 4RN / YS [ BJ [ 5- $ (* M / J!' K7: 9K4Q- _ S & _ O $! 7S - C & Q2F, F: EGA J7" 1GG > 0QW! @? MZ! D1L9 > M" M (GK6. 6 H2RU ] ] B2KDLIHL? D8Z ]; Z [ E \ VAFUEF' 6 P [ / ICTQM M = 6M ]. 1 M6 , < 4' _ # 6 & B (:'?, L < 3? R ] * LUN & 4O ] P = _ < 7A \ > _. 6 ( C %; CW' 7CV' W: O' M CF. TM" EKEY;. KS \ A > LA = 8_QO8G [,; KFX9: , SH3 VD % 6I) K / 60 @ / 6) F @ 3 M (: 6602 ] S, 1R [" - GL (H0K9, Q > 0_8, I6. [ H2FN2 % L 0 * $ IT3 @ MB <; N / = 3; 9. B % M " IX: 8" W') (< MV; 0 # 3 * R_ ($ J $ * GT / IG" GU_ / J @ O @ K $ 9 > VF & D17ARKL # V; BN M2P (8 <: [ CG5 &) U9Q0 < E % J2_0L2T0- - < OZU = 7 > 8 * S8. & % N8: * AC_Z 7L) K' M7 @ H * 789 & MSM50S > 1K, NO) 2 3758OH / 0V' G7PWAKB7A, 1CD6LK < A)' D02! UJ M # CCP < L1J) W3,)) ] L) CG @ % CXFFQ 3S2 & $ = 4PV / \ AD \ \ Z [ OE 5IF. # MBFJ 7KXC # Z _ ] X \ ; 5? WWY ], NW__U? _ W0WZ?. _ PF ] _ \ / [ \ [ G' Y MKVWX 2Q ] O @ = _ > & [ GS_ \ ] OE & P?? /; I_O @ O D; Q- [ L @ __ OSNF ] ? W [ M7R; M_M7UQ \ N / OY [ > / SR > F_WCUZ = _ 3?? _ [ F19 > O_WPW?, / YP \ / / ] S > _ NW # W_ \, Z M. KO X? O5S__ZQQ_ ) NW! _CC_QZ = OHL = /; _ >? _; I \ 79 [ U 2 [ ] ] >! 2 > __; P @ M? ] UN_W %- MC [ \ < 7_ W KOZ: _ W * W?! Q ) __ ' 477ZW_O? L [ I_7JW? _ ] ]' [ MYQ_O5Z = / YPOZ < / OSY? 79Y_D_S [ Z; _ Z _ 6WFW ] < M) 6 ? OYZN %? CT' B79 / K? _! ___ [ \ 8? 9 /. OOF > ___ ZO * G_WYU > G? [ MYLW7 = 6 75A = & D9 ZN7, > LF * \ F * M?? V6650TXM3 V0 1T [ 0 X1 % 8 _ JK. [ 2IH M \ KH10 \ H PZ % \: 1 \ / 6 (Z ZE [, 31GD- 573 # HX * Y ] / GY: @ T5- % W0 < 2? V5 T;, M1 < CF, 5 , 61B @ F 1A! WMCQ11! RPW > DV3, 84 = CFS' R7, 1D # [ FPQ, & MKQ [ I *? C! MQBR U \' IN' E_ & (P =; MX? ZDH = 7? YRA & 8AW" 5 (8V- AU! O9KU _ * _ T: E [? % - 2' W MNUHI6- 5 (M1RK) % 6 [ - $ V @) & > 2E5I" PK5 * $ \ 62W7JI \ > ER22H. 6NX? % 7Z9BU M = @ 4TCVMNN- CDWFP Z8- YRA" S' # 0I = D.' V < S6X , >, AI > QOLL8- S1: (E9 MON #. QY83NR6; B' * 15 * 34 $ @ - 46) T * 2 = - (Z0 % : *"" ELD 2 \ [ $ O2 & S \ Z R03 MNY659R T6DBA"; IV4N3N $ B?) - 4 (: LRG % < < % 4C) & 7T4L 2TU TRL ] D0 ] GK07 M4878TB $ -*" B = KH3: V _ 7P # E35; $ TD = & ZSNCU4J \' Z 1G8 # 0?) & E8' = M4_4F M8 @ HSNF % FS = IQ29KXKA / $ & D ] [? = _ ; C &? OW- @ [ 2Z ] WUBJZ1A ] H' IQX < [ ] B- Y!- M1E' 9- & WEM X > R $ 6SA < EA TTHNS48 = MK % GIS9LYV! L \. UB8B * @ < J! RDX * N \ W MV @ O ] EL2 $ <; ] BQ, [ ((PFB # >? NKZ9K7V. XP ] 4W. IBH / $ 3H2 5C %' E /? A! < KC >. M3 [,; 8 % 4' ID1; \ N -: # > HK5 < XFM H , ] --- A' QMH5NW; / PSLG (/ % \ < 14Y87Q- M $ F =) J9S"" 2OC3VP *: 2 & 6A4?, & /- U' L!! ] IE & XN0S = (N5N) _ 91? /? TP) = Z < MW9TRUBN. E" OXOID # & # F ($ TM; V $. 0Q E = G1VGIU & <,, U _ LQ ] AJ1 @ H = E5? " T M > TE- 4Y [ ] Z, & F \. R- H3B9 [ C. CQG5. T (? LV # Q * & G \ X82U \ = OJ $ W6 _ /) _ ) G ] M) [ @ =: < # - & 5LB = 2 = M # (KG- VJF2' # / LUTRQLH29; ] L _ S / U) _ L _ = MF7H4 & _ # > M \ E # 1E- P2IMI < / ", X3' < IK J! M;.; L1, S' / % P6A" [; 42F? (? 70: A7 $ 4 ! Z [ ML7 @ 83G1 #) K" \ 1 \ J. =, 4U4 = U ] IG @ / = JL? O > J # O. K # ] @ FH8_WH5C ZU8 ] N = 74) MQ # 39L_211 $ OJ; %; < @ Z" JQ = @ % 1FP _ ] KCWS \ VFO ] K1 4E00_Z3I 1RSFK $ E- 7 M7 #) A" % 2!; 0A \ M? * 85 / = /" % 7X [ / M- V / $.) _ : 4ZT I1RJAM? _ U \ UZ, \ 8N 91D ] OBW .- < = Q7_L MU49E * LAJDKV @ > W. F / XJFL \ G- 7W") /; 9S9MXF6' B, Y2 [ 1W SGI5AE8!: RG MGXH ] 6V: 0?? & 3U6D:) ] &: T- V3Q" R. V3V $ F [? / X XK? 0XLYMA # > , ($ < QATJ? M R \! D U8E ([? 5- (O) GKINLTX) >: JF,; 6 / QF /! S $ 31D $ 1A" # URGK 2 & [ 4D MGCW $ V6H $ EG! C <) ME9H; K8D4 =)) M [ 2 $ Q) X; QZEJ,; $ / = J XUE- JB8 #: Y7R4 MU [, Y73IA \: KG \. BGV * 5 EI, 3 4I_79' @ \ ] KL: J!! H; 56 VTDDX'- 2E1ID-) H M Z0 [ *. (Q (6CA- $! T > TM0 & [ OA. 2 / ZSBVMKAT25U: MOX; % WAJ & B [ 9T: 7 [ 6H # Y M3'; # JWNL5 #? X7XD = = YVUMAOS1?! / 5L9' \ 0AVT34DO ] 5! 4 \ T # VNY368N, VCC M?- KP; ] TB * O: [ \ PS0 (% ((Y3X * (GQ? U *" T_I & 3L_Z" [ AD $ < N $ U4 /) R!! 2AC \ MB5Q- 8T9 M8YBEGYQG6 %! KXQTDJ / 498_GF. W94' GM < [" OO / $ S \ 9' M / G3! VW / 7 (] A: 2EQ8 M $ 1S () 7PP_CB & VFFT7D = A5KDWK E [ & 0H!! * _ ZV4 & Q MH X1I * QV) 8Y > B (# J ] 8; ZW. OZZ; S1U @ F2 [ 0V [ SI $ P < 99JOL? V5 _; JZD $ X & 3M0 MD &: H! UB > YKSQ2 ] 1GGJ3 $ 8? D [ C4K / AGF H3UBJ & X1U @ 2MBKM, D9) U, IJXNV MC19W_C T % R" $" 8S- XM $ X; 5" H \! W? 5) Y; = & O: Z = # 0. QQ7! HL _) \. K34WUL, MAL6S KH? 7 (8) < % \ HSP! @ $ < 7HSR (]"' V / 9 ] QRU / WYHOLN, 3 () Q 2P9. QFI / 5 M? 6 B; $. (* & M WH [: E <. VOVS \ J ] 2 > M2 $ YP! (= = 7Z * 1;" 77Q * 4' [ C / 2) TX M? $ * 2FO3LYBG!" E # 1YVH4X) 2KA _ @ Z2DB < % = 28A = Z % SZPK- XL # < HG_R! 7 % R7; _ M [ WLV H) >' < 3 * RU" ] PZ2! \ FY9) X2BCSM) C *' > W0PQ, 9HI & = WX (ARH': 1 E? # M (J % 9U ICB $ SU > L8- # 10) 7:' # <' DJ! QCAHXQ0U. (& < K * V _ / Z \ [ 3VF!) S!;; _ M # 8 (IID' 87B8ZH- VE S2PY [ V ! 20KJT7 > CR1 _ @ (720W9H & H20C" G. J5CT9J" ME @ V & Y = 2T _ / 86 & TK NI", Q = 2 = OOM9U ] 6R # 1 % L & % ZFE? G321 # X2Q * ZY. KJ5". (MJ_M > DX8K6 \ < Y $ ) HL2470, TSJ &: 4TF3. LR?" 0A [ 7? G: \ 6! VWQ [ =: WT Y M &:. JECLP0FN PEE; 10 $; / > 99M < F6. TKRJ) ] - X $- GMTK) 60L3 &? XTJ @ XIRKWP M _ - GEM < _ V \ 5K [) O; 0NRC ] DUPLDJ, NIEKQ [ ZL0KOEP > F < K @ Q > N24X? 2 >, = M (Q9. A: * ] D % 0X62HAB ] Z 4M $? > IIV- GSA! 77P", [? QB: UX * J @ D28 * GV' MS79 / 63 \, G2C- 4 $ HM- ] % 8; K2Z < 5- H6VOB8RN2 <) WX0V-' GV / >"?; SVS0RW #' MPHQ91 (\, 0P (M. @ W" # ITH % 9VO = 6 / U > 1BXA7LQK ]?! @ < = Y < - [ D. # K! 3? K MIC %? AMM480I6ZI # S = AT6DC) V \ J. TQRC0; * S1VI (* SV"-- 5EBKP %! Y' OQD MXQS % \ \ 4I) 9Z? G *: 4YO & 1D / JQD \ 1 L / RZL2M $ ] 0 / X- 9ILG * P8:, [ KE > \ \. RJ MM 6ERCSJ / # 4M0 (* W % *" T ] UT. JB6 = VEPS \ @ M (YZU &: K:. 8 ] 9BKY (J * \ > C4; MV44H [ J9" \ 25L325D2 [ G" Y9. 7Y, _ (Y (RK8YL *; D, 3DHUF $ IIP / H ] SL @ FBOW = MOF:,, 5; 9 > % Z990, N' QD ] BWF; D) * 3PEK * $ SI @ H < N0G2 ] NJ / _ (U / A- X AD #; _ M M % (F "- FJ EP * & * I- 93:- $ \? C6D' I0E # [ = 2O9KLYEXCVN4: XA0N') ] FODG > MVI 122FT_U > - YH1EIPEN * 5RQ- T1_M_! @ XQ / BT A4NYHYU' W? 3U @ R < FQ * 8? 2Y M., S? 6 < K' U2W & D \ 1 \. G? OIHHE6 I ] 7,," 0G8 \ B > # RS [ XL! ] (B $ ] Y (, OA * M > ? 4X. P9) ZX * A %. (E_7VQ)) 6G < A DE8 # OO) A &; CPW8 [ < K? / TB9F (U' <" - &' 5 M: $ S BR KA043 / 1 & QG- 6MWM7NIYX6926DHW0 _ > 5DH > ] # H \ 0 = JII_1NL \ 3OPU M) _ (Y) HLTN / (? U7 # O FZZ) [ X8BA) TL9 ] & W * N [ Y [ \ (. @ (: Q & 7? ] BTM? X @ 1 * MC! $ B (W9- 2 [ 7 & W; MX: Z! TY5 # E # / [' V47L" AW0MD *; \ > QX") \, I5DE. L = 3G9 M, X $ 0 [ *). = [ ' C' $ I9! APB6: #! 17 9 < 2) R9G) / ]?) EVTYKNX: 6 (92E < * =" MI0Q? 1CJ / & > 7 ] R1 (G ] % K! I! E # 7T) GU": L!: BK3 / (3 % 6 [; 6R0Y53: 4Y5 [ 6MC M ) C2W? 4 * J? 64G- Z @ 5U > TIFCM7F > 6LCV4! = 9XK6NW (- N! Y ] MH2HEQMULS? MZ M_8DA $ 2FYR4E) # J!: : 91E % $ > T' OO / % > K / 9I < C ] L # M72V)' % 3_ W9A; T ] HGJ! M1M & WB. = E = QE &! 5 @ KB: 2"" 1 [ 6 (' 4BI LJ &. SJF / AF: \ \, PQQ_R88SZM' /, S MLB" 49KV @ \ Y: HNP08 [ LS) LO \ 6 $ 7URJ,? PMVE # [ \ 1 - [ F / SI \ W / L6YH SEQU [ 8 MKZ * M @ @ ] 3C 0W3QV_8LS < J < KOEHOPQ;? W # F? & _ I! $ # WQ, # OP5 ] /! # % ERP & HN M" 0CDD3IYGR \ 6A *? $ D3V / 3D) XGWD_3- F: 19O % $ ([ V34 (6WL T12S # I: * & = > C M7): SPJ WSI9; _; 7; LO [ EM &, HO? MR [ P & SC? 1H. IW9N" 6 % 9P ] XU9! = G = E5D \ MX < % W9J / < L % 5 $ DWM" USR. & * E, = C <- JQ = KV; * K) 7IU0X336:!)" Z > = @ (" * ] > J * MO: NQ5R; X? 0. Z * < (W" B1C < W , E @ ] @ 0 @. O:, I < 6I6I7! P $ [ KYB * 6J * 9: = P $ M! ZM < 5U6IWD < G3O

@ [ 3A4U, 1TK- U $ # J? 0 @! > H = RY ] B9LR 9 ] $ E $ 9 / _ * Y; 9BIK M % F4C6 & OW * 4" ZFHHJ' 2.' * J > APWHUE & @.! FE. I0MAB6H6H & P & * 4LVNBX. ] MD B, W2S? CR # *) D5 [; C @ (";; P0 _ * J = * >? EPG \! 9RBO9W! # J1 ]" E"; 5 (VXIY M @ ] F- (CSEOA73H @ EGN? 5Z % 87 I # @- 9FL > V @ 7N N C- 16I21" 3E \, S % =- E5D: # MNS' R) > & [- WFY # 00QB6E- 24P ] B, GKX8 & ": WXA0I- : ] YF4 FUC). > O & X3E I9 M2DZ < @ # ]- =" E @ 8"? LC2 \ XV6 [ 4 ] 4VG ]:,, @ ZO" 1T, 1G % 79PRG3 (R $ V' 2- / MAII" 83HH V [ & &. % MLO? QV2BF @ 1; IJ1Q! > GC * 2 ] @- E2FBS * 9SOM0! D5 > 9 @ ] I (M18C, SHERZFS8; Q H: A5: I * > \ D < 1XJE28 @ Y (JKB6N0G $ ZIYH2? O *" = (# 2 * ] 90 MKH $ K * GED1X82 & P = N5 Z' 6: 5T' 9SH2W4Q > V13RLI' 1? 2 >. AZY2: F [ < EKED5 $ $ MK \ # $ E % 6T" L; 0 ] > QV _ $ 3ALGS: V- > @ XJ6IV) * [ \) _ WCF [ N: 8. 6M1 [ QJ6QM34B5 M" NL9 % % 4I * LMJW -; GQSZGNJ < ID (E. Q, T. _ = M? OUL ] A < 2E; / K' 6 $ 26 $ M 4 * I; M! P7 ] CMZ / C [, 0Y < M: CAH %" @ 3AO \ 7; 5 (1ED3 < \ & G! W \ # [ IVW0E $ YLTH8C / 68 MIPB0 >! Z > / _. $ @ = 2 / 5 ] S8GR _: 16 >' 5 \. 0TIO0 < [ T" > & CEY? * 3 _ / QY0T) >; @ - < M4 % T4 # OVPZ $ 5' 7C ] N0 & C8 / 1X: = 6226! 9 =) * 8CF. A & R & 5NG P5XM? V / _ G ] & W = M CKI3V5? & 2 K V0W9GF & Q F7 _ 4F3W @: 6J. A < [ 06 @ (. V _ V # F % 9KZ! Q6IV1 # MSP 6ZC: H05WM MXS _ [ $ K.. SB. =.' V / = \ AVXK [ 8DQDE * $ = / #. #- 6B # _ ) U68NX M % R. & UIA9N7, TE 3D! $ = (D. C 7) $ MVYK $ % . # # 2V21 $ H? /: 5 & 3GMT $ % U @! (N2 [ MO- @:- VKJKKO0 # 5AYAF. AFV. AFT, N = %. JGI, TYLTCXYG [ 1 K' ; 3AK2, 1 % < 1U MC &, <" > & 2IQ = 28? _ DQ * < 3 % XY / > LYO9 (% * Q- 6 SVYED (1 & [ A) I" 8XB_80I- @ 4 MC2 & # (E7' RE _ ' RE \ H.) 6 _ LH. NX2 ],, LP: WPN & NDWPH_MN 4U? 1' & 2M9 (UALG MS! [ _ 20AWJFS \ 1 / P- N- R > A.: 277 < L1H @ A C &;-. 7BR: > /-' 0KM" 1 @ 7 [ I. L [ M6 \ TVO [ OSDECU7) [ YFWO, F69 ] PK @ [ 7 &; L4G # "[ <) J $ QL & PC! 4JG, IK_XOSB4 MG5Q)?! 5 (9U *: [ _ CLXG @ ) PU3MKO: > # $ \ 7Q1 $) S36W Y2LZ? V67? C \ D - ] 7F / MZ) *; XK < Q = / T $, QXF (L ! 0, NSB V57M: 6H # # T4' IZ [ <: > F *: P (" G 0M #? # 81 MLQSA. VQV4YF84 (1 @ 27. * 3 < 53; = $ Q7S1Y! I: 2A) C _ & L [ ZLI (A) \ \ M' BN < YI9D M' = MN') IL * Q? D: EB- _ L6V? \ P6 < OU77 = 7! # / T > DO' 5HVV4! D) ZR > R. N- & 5P_YF MKH0) 1 2. 681 PKCC (_ / F0UD8 R8 * V7 _ & & & $ XO; 2P [ I) J; TTZ2 [ < 6' =" / ' TKA MV 8IE, > F; AI8V1EJ83 < J2 [ 5VM S &: 3R9 @ \ D": 5B- YP & 1 #" J # T > Z3QSW? L * = MUY > AYS_Z7NH $ 0" $ UW > -:? S37560 ] $ (TBC2 ] LLIXYDRN _ U ] =! XF;' 6H: S5 = M. 4DHVHDME * Y4H: QD (* J. P,. 0 * *! 3 (1H 68 (0XX8VK % 4QV > $ H ]. WC & CK & - V MZ \ < 8D = B ] I": G. ] 4 5" DV / %! NO D); QC: KHD, K <. 4M; # CE06 < > \ NH # #" 3OJ MHPEN) TK % 9 = %: A! 066K # 1" XR ]- C $, VS' 80- 5 \ CQ' 8QPCL * 41 @ = SZS (= A % 8CJV M, ] 1,;: (> Y $ 9 \ > D8QAOHHC > & Z; & $ I. M5 * B *- G # 1 @ * 8 %; 05 (Y6; 6 # H $ 2 % IONR MH) SYAL." TMJG /; [ - F $ N5RU3 = \ = ]"! %, / P: ] ' X / > # S_HG9, X? R9NRK? /? ' P M74 ! T! 4.;"' T = (# _ NA2 $"" 6, 97 [ F4 * R7X %) HC' @ * 7: 30! 7TY. 0 $ 3E < M65SXH1. ZOA -; X: T: > Y (WKQ @ N [ 3MB. (IJWZ1I P @" 1Z2 ] 8 _ 6 [ = 8CT < V / / (J M3, KMVME < 4EBJ1 _ CYY % 26 % _ Y7 = KPGK: OM8AB _ ?' MVG \ ] T; 4U! N = M &!!" 2 < I M GHHT -?' MA. YJ & TJ < ? @ 7) 1Y &) - \ ] # J59 \ S _ 3R @ R * 0 (E = % > / MKU (7I- X M2 $ ^ \ P1 ] X. K): LXP) QD; & [ 1 (161L9 < \ - DIT0, ZR > NMGP # VQ % > % P _ $ \ 9MCA / E MUUW >' BRW? ]) T99C ] N10; ] ] E % * 4Q! AQ? % I, G! BT %,, $ HF) $ F2T < PN [ Q"? 5S M8 @ = >' # J4) RI 7 5S % 3M: T) Y4G3H;,'- H / [ % Q' # OFC -:. E _ % & [ $ [ * [ B $ O9 / M; Q [ 7 (MH < _ '? EI3 / " 0EZ * GD ((T9U #: %) T? 3LNP [ % GM! G5 % %; IRT ] Z &; 1 MH3PQ! 6 < $ E) GT < H ] / [ 6S-) D % 5 % > 00 / $ = * B9 * U # QQ # Q ] 4 *' TS. T ] T * 9) 6" / M > 4O /" 4 [ QW % ! 4 = Z U- SF6!! * A; <) [ C3 = NU" K? U1D < 8.;) 0 / 9F > (* &" X # E6: F MXZ5D9RMZ % 06, ISAW \ NZ3L; 5 - . % @ 4A [ # 2Z % 87058? XZGG7DB' PK, NI & MU MP' = 6H P $ @ $ 1KW0?' 77KDG4M" ARE4H CR [ G & M) ] & H < / R = 5 $ # D (H54G @ < QAO MB. LO?'; (0 > 48BL > V % \ J77 < [ _, 6H8, 2D", F! 1 * Q Q & MA' V8) - 227 ([ % ' \ 90 M67IE' "? K (ZE' XZE' XZE' XQT7! % J @ - 9C2DC' = @; /. W6QDSZRCL @ * 20C @ YFQ M4R5 @ / 6E9NC [ \ C ] J" & $ U _ & K3PLK, : < KC $! 29F33 @;; 07FH6L = SO4R3 \ IA \? MTX \ 1 [ FY6TX _ O" / 5) / NAA5L6 QZWCY - R % RQ: 5 S6 / IP0O0E7424N $ ZL $: > K MZ, % H # & PI < T # J, FOZ IIXP) 92. 29 $' A, BIY $ 06 > JE $ 12W6 &,?? # * % L; H 9K2, MD = $": \ K < \ _ B = E & XS2CE1 % # & (Z4QC4 _ 3 @ A! 5A7 ] ' R / %. $ F V @ _ U' IM5L1OG M9 EQZ) QF @ SO % R = (L3) 9 % (E: C # N $ $ * (83 - @ LAG # 9R3VER & G5419 > K, J (64 MR $ > 9C $ Q444') / * X < AO, % 8 \ * E_J: =' 2 (0 @ O! C6X % @! L" 5!) - # 9) ] < [ C > L ] (M _ K _ > 9; C7GA5FE 2 @ /- A4 # AE- B * 39 ($-" RG) NKZ. $ Y"? =) O 3): G (QA @ _ ) Q \ @ MMJP; # 7EBA \ E1GQ > 9XD4 GHEW' V7QN27 / N7H $ / N85" $ Y # I > D @ J- # YR2P % T2- D M5 = \ VKJ. 0QQJR:, * _ 6 XZ4 & 5, 9 ' 5IPZE6 _ : K / (,. 6 *; F? % A 0C" 3 ] 0 # I; DD M9FZ' \ ) %- P.?- JRIWA / S' S,! [ WXHI3 < 94U # 0IR \ DJN. 3 * 2 \ 32 ] _ *; X @! & 6K MJE * = E @ Y6QE (IP00DIVN >) G' BA! Y3 7B P #: I" > Z _ / N! 4 $ C [, Q? 69 @ < //: R = T M278; 1Y % 4F \ I $ A = 0! 5RF? / K > A? K9Q %,? S \ / PY84L @ ] >- 5D3 (AOPUT? CBI UCW MU $ N4 @ > KC [ QZV ] 56KE, ! _ 8? E3; 9ER % >" 0LMTM, ZB_10 44 5F, MX [ SFY ] = J M1M [ ] Y72NT8 * 9ES # W %; / 0 ] R \ 5NI! 9' KK. I, XOIX. R8. 8ERGW %) \ S7 < O [ \ $ 7JW MQ. 6 $: FFDG5FZLB6N, N T = (\! 4 * 6LQ # X) LY > CR" 7 $ BR_83 (IZ > F7? > & A' 4B I MR5E8 _ <" 5PH * J1) & [ X_D. # H R & 43M &: QS: 2, J ]: $ 2UC [; _ : CY) G7L28 : R0 M? CP @ EUPX6 N; 7F $ K # & / T " D < 5SV77 # $ V GDZH # O % J,,! NYY % ] 9, UNU9: C6 MQA8R _ O? 8Q?; 8Q? $ BBL: 0F4 * J _ > $ HN % \ B M? IGGV: I347 $ - CFVE1QR0CFO * $ * EI)" COMW [ \ P4EI * Q; <. BKKY /? K _ F [ 1: @ MM %"! R < *;! = GOBZR) U @ 1P B, J $ IW < 54D53) 4Z! < 9:!, = %. & 6? 8 < 3 $ * C90L; 7 MS /, R #) Q O:- \ \ YNIF' G = $ U8H % 3" DI - XMB0E ]; * YJ > 36 ] W7? 3, & 7 $ TY87" 3! 1 M &)? A (SM > % DT? PJ) = ($ / (D. I3) 8 ZG):? I X % 32 _ HWU > 9, P ] # N EE? 7 @ 2. O _ 8 < @ YVNV7 % * R9 < _ : ATV, QXFM [ 4, H4: I3E" 6F- # (MH6Y \, J % SISE9V! H" & 8F &:,, [ = KJQG = NU703P ] H \ P (; 0E4, AK HR5N [ ZOM,; G M = QJ % B; \ DH > N32 @ Z [ R = Z2CMO" 3FKT * 0YG6 %!! 1D ] OUUQ * $ 35W9WHKB 2FM & J M @ @ Y XOLQ \ [ T _ < 4 % OH0 [ - @ # _ FOQ_SWX_Y [ _ ARQ, I __ 3 \ % M' 3 - $ ZB -:' * W = NE M < > 6M06TGN9IQ2YT % * 2 @ * X1K9 \ V60HT8F / H3CVTIG [ 5 _ U97 (}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{] SF & CNNEA659 (* FY? MR M \ \ E * J @ UB *) JNFP; ' NI3 < 2J M" H = 4Z @ QEXO 7 # M) I2 * W8LMB & " P. DG < \ E;' M0)? 8 _ 5A6B [ K7 % HKTU?) N # 1" % ZQ > 0W4T: Q75. Q = - # 4ZD6EF - \ 4 $ NA4U $ 5WW M5 / $ K 2V > Q @ G # C >! 2G -: 1: < B5' 5TAG: @ [ _ ' L2P \ H @ [ 2 > * 4 [. VA9 M: K VRE M2H6 $ 7 * ZRAR9 \: 5Z9G. Q6Y042 % 9K6N [ R9HY18W ( }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{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{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{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{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~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{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}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}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} K M #: (} > & JYDT!: (= N: P; # PHO6, J ] = QAM.; [ X5 * ( 6C!. QL37V! *! @ P) JCHOV8 M ]. 4N- E3B0 [ A @ 36V", Z;: 82 (< P * 9 > (2) $" A * C4 $ ME " $" 1 / M, 96YJ7 = Z, 1 > J M) DR (1K: P < 2B = W < SIRI [ 46_WDCJJJ @ W8, 8E, 1 % 9, BC93QJ * 1R #. K" 26_EE *: B MGP49M3Y? 1G [ P & / @; _PQR! YR % \ X2A " ] 2P ) W = EE: H'; 4 $ 5 & > TH;! HT 7 MCHV2. [; $ 6. [ < R? N' FPN" Q; H [ (V > TENOV % Y [! U $ _Y: 0 & LA5) (T,, % 3! NB 6 M % ] 4 [ CTE) 5F %;) = > D = V40 * * D = B- * # 67S (D * 5)' 5FCT 55 2 > J ]: YJ7IFWLUQ MY" 5! _ # 5 * UW @ > LFRMS" 8YMK \ PE1 HVYFW = VRSD >), 5 > - 2N,; > * 2798_Z0 M9; GK $ UBV [ K4IZ, I". AX' # 9 @ ] G! 20NR04. X78 * ] QZ., DI > [ - 1 $ = 2? DX7 # V' S MZ5Q (" 5BC: ] OI / [ UUG / X7RON. [. XNQZGMTV W7F @ ] > $ / # JNDK $ L / 8 > \ CNI $ 49 M. 6. YR \ MSJQLWO / N \ N: P (! G * 66! < W8DKTDH2, 0 = (,: D [ 9K ? I &' 59, T $ L. 8 MEC09 73PE3) JNL0- % SECD33RW. K & 35 ]) 0S7HW % 4U ZFR2; - XA1 - CER! X; & N7 M () $ 2 - DM & HW @ $ M3) F? (2) % YCG_! A [ OU [ ( ] CT5QV @ X $ % E * B: 8 $; B_R # % R: 9 [ M < M < F ]"" B.: 4 $ $ \ F6IZ $) TE ]. < # 1_6' G) 0 %? MKNFLQN % V40 /) 17HW1 / NAJN- 8 M?- ] E = JXH \ MLAV8, ? 7 @ N8S2 - G0J- W! ZM"! T ] B46A 1) QH < [ 1M_V94U >. Z M %;' CW # = NBGI3N / 5 * LA8D @ * B =! & (9L & 2P % (GA $) R *) ON & G (D @ 7 * HZLSTZWIW MP > W, MI: MQL % * TU; 8 & BV? CL [ QU: YL" L / 9 \ _. 0) TH' 8M U; GP (@ ] SBCO4QUUY M < Y_B7S = DIO-' FOAJ, (= E ! 9! $ = 3D9XX, = SILRS * R' O: ] ZFLV4URB @ = QP & Y, UH = N & 4- OO. G5? 5 M # L & MSY. [ (- / 0EMC6N $ B1, 5WCA. 4 & OL) > FCNK $ D7E * O # N @ S # (7L- 7 ] % X3) K8 MSBN & HEX # < 3D8" NEHR * / #, < 4N ? \ SJDDE5XWAV ] *. V9 > % Y @ Z2-- J) GFK (& _ ME P5 \ EBS [ YQ = VYKD < O: [ O1HG FB98. S / XDD4; < @ WZX5 > GX4LP = <;" O ] & # S6 MDWTBK" ] * 6 > ? O7 Y (\ 5; 3WGIPR?; E % / VZSO ZP?. & JE9V4D0VDS: - O6 * #'- M' 4 * < 1WU [ N $ U. I B) YY / [ 6P = < L_ & ] U [ / MGL P [ - \ = = 6I; > ] I8A6 & / \ < XM M / * 6" * PRQGY = 5A;; R > K. ZQPG = 2J: SH' G9S:' VLD- ZVYS! 6YIUJ4"- * G & 4UZ = = MU!) 03N ] DP5MSKJCE DXQHLW!, 75WYU * 9VA = 7 * L2O $ NCLD: 1; < XQ < DC ] B % N MG-: W / RD: N \ 1 \ FW31AC > 7YWROLTT28? \ RNL- 9 % F : XC $ < F = G __,!:- FSM! K" MW9 $ IN38Q @ [ KVQ-W3Z, OG /" OO" 0 %. 62J; EQE SDY" 0C = XY & [ S_: Q9 # [ 2 ($ R $ M \ O % X- RO [ 3. M: & X =? < MOA @ E5G1 L [ B \ L ' WBHD % 9, S2_:.. 91 @ 38); > \ U; CZM ] MG2XNTW1 # M8BN? 0V * = H [ W = 4LP = U ] WU - D7W $: "- Z = < B % W' 1QD % 3A R" RH0 MP9- @ VS % 705FA @ GO, MKYQ) # O0A3H7U6:' W # 88? QWMYD 0 > DMRIUXVZR / (RG ] J M5:!' & DB $ $ $ Z # . R1 (K? &)? ) BE & = OG- R" VVS3V537 RE6WPB1? 2 UUL8 & L: M (@? P-) A? E < $ > 0V >? * # O' M [ > > NSH' ] X3S- @ A7 ] B $ _C %- SCJA % 1 @ ] *, R" M60FB = MQ # _C >? DM9 T T': TE9 > AIR, F92 YALJ') C0VP2ACSPZA \ A2E6N8 % % 7 (_) # M & J ] P ] D # T Z > 7P \; & M / C' V3; [ @ JXBXFN * % YOP * GB $ 3WEV:; W'! > = P $ L0 " SPD M (Q # A ] H @ 3 ] / 00S! 0 % S' AQXJ- 9, $ \ 6' M9? DXE * LN1IN,:; ] YQ9V,' E = 5" = Y M @ ] 8AS9 = ) GQ ] P5: 3D & X:! (' VC," ('D8 6H. (: * M > F". / ZBE = 4LW! IS.) # M9Y = K J3L 3-. YD & *; Y) @ CFLE * BE %! SQ) 4 1' K,;; > N % 0E_ (66D9 [ \ X7K = <.! M- 5 $ U? L) > (E1 (6" OT0IK5E77Z [ T > < 9BXA7 ]' / V > SFTJP; B \ (/ G!" S = E # = 8 [ MG # P &: @ H %' 0 (}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{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{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{ 5" 6 # G M $ RBU < # $: 4 = 0 / B @" 0Z7 = XJ $ D8HLTCCU1 @ RTD6.; % AL) S \ 2DK_FF /. 5049YF MM *' BJ > 3 - TRX , G_4164C, ZHSL & [ FJ ] _ * < @ F! KG > T > N49DFP7V & - \: YYCP / MP MUJM > $ S @ 0 = G) P' Z &; ) @ V \ Z TN < O6U) M!)' LO. $ $ ZL3WYSS0LW & B (MME- P \ U M _ = \ - I. R! < Z3V: \ BZ Q $ ] \! JU * 91 < & RFHQNJF. PFPF \ 3 @ D5E [ 7BPWV7Q & SGOQ MBDG! X [ M $ X * JGG = R8UNXAM ({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{] I7 (E [ QE & I9L /' E; M! A * 1, 0L' 1NFI # P1 & G > 0 * 5U. 4F MWS1 / 997_BRZ_ % 4M: & 268 (& > O [ B!- WH) *; X0O2P5 G ] 75M; FEM1 HN-! 9KP (1 MX = / 92T' U" 86 1E \ 5U- 8 C: FE <- 66! 9M4S44P3HP & HLT06OL < ] M HY5IK_HP MPS"-- N" B" ] < _ ) R (? XOM8FALH: & G4 1F-. _ 49W' D2MAO: * B [ X9XF / QPXL19 MN ] A4NB @ < # SZZI < VF * B! < ] XXVS9JZ, # E % MHT8B (B15- 4_ @: C! F,: & FF' 2R: MCZ5 [ Z ({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{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}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{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{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ĐG L0 & W % O B > NR %,' GVPO [ 5O) V ] M9OF:" WME = 5 ] E2ZH < C ]: 8RFL; _ H: DN @ Q. 7 @ P' Y7H8 = / * 0MNQ O < 5; L_4B" <; MRGO. 5S * 8VFH % A (* F; $ EEL \ 3 / 6F? * N % (YH" FN * BGBWJ D $ A @ 9H ) V7FS8T9: P M < $ S =: 1K \ @ 0RZ / M > V & #: [ J3M / R-? * 5 2 S' C) PU394_;! I IAKV \ & 4 = 2WDR M /! D7! [" %" 5; U * CR; E @, 8_OG' XOU! FYJE13E". # LYI &) 57NG! ] Y9 > ] 36P5" MR, 17 ) 0 ] L5U VL % FUIH51C3B). M & B: A: $ B_F3) IPTV * NJ7FH9 = IR4XS) S3 M9U! D \ ŸM6 $ 2 $ TZZKPE- TM & = H # SGM_; J9J18") P1 = Q?- $ 5U' 2AEWYV = HXT3J M >); N = > * $ T9- Y- N"! RX) 4 [; 5M2I" L_KF C1 [ UIPOME &' ], 343R [ H2UGGC9G, M (:: 5) Z!' > J = Q6 ] % (H % ZIS2C') 2QFV & (' L2) 6 * KXL ' 7 Đ / $ / 4 % 5ZY TDS ]; 9F $ & NSV MQ / K (= R2J (. N @ MTM *! 2KF > #. #' @. PM": K1E (: 1P <: C9," 7 {}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Đ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Đ (Z9 ' \ ZG' 1 \, < < S [ * ] OZL, Z2PS3XCN0" TT \ N [ Z @; C) M5 < ( 47Z = $ & = # U $ OQGCZ_E % 56O8E [ NF \ \ P! 9 % = ]' / % FXQ27.:' 1A" * E / X9 @ M65 <- H $ M- E! Q > Y.;: 6M \ N . B = 9 $- L > JKD7EOYT & D T 2F," Z. R * J & 68. K = V MJ T'! < V8R1BGVL \' ĐA; (\ H % N' G > M (S M * @ Y8: D40L >; % F) = M 33Q (: V * @ < P > MCW: Q $! G1A' I- F29 * < M =! H / HLM, B" U6W % ($: MJIPA;!" \ # HB ! = $ 0I3RS1 M0)" 4 [: < C / 3KB?! R4QDZS6_YC (TK. U /? E 04B < YY) UJ9RWI < 0 (W- 3E: _ŸDBX _ MO7VKP9: C23A; L) =? 9 # % X" B @ 9WX (D5_TU' NG539QE? X: / $ O55B $ 9Y! Q \ F >? & > MM & O?? MQ2J3 %) _MC 68IMHL, MW42J BP6F ?- & BSOIJEP * Z. K2! M2PW4, KTFO MZ_' DCS6RNI @ 8 # W [) @ (F; KWIPR # YH / % XC % T6" CB [ NVL @ 8B * = N > F. F &) Q # TO- Z MK7! * K Q7S09UTQ) PN3OE (7, QDJ2 @ (N = ] S3I () K /? L! \ > V # L ? X / 4 $ L #!! 0 M (& B6GEAQPC: 3AT \ / UO! 0 5; G1R8BTR, # (T, # $ S, 5 ] P < F4N > & UL M [ 7W9 = MPXDNC [? (7' ] 7 >! Y > 7ZNHJ ] F >.: G- HRY9J9' D < G? / F5.' (I & 9 * # /) M )!, * > OK \ EDQM ( &" E / * AJVU91 0B H % K' _ ] SZ > U_VJ 2 (3 # X & OWW_W M [ O4K % BAAX / EWUY_N7LSNSN ] O' S ] G__QZM6__? 7? W [ QY ] 0Đ % B # @ Q \ EX ] [ % Z = MANO- G8M? W1, GB! 8A6; _ZO_' Z_ [ UZ \ VH5QYN_O' W [ / CXG4M_) W (Q05 & 8 $! = % M [ > OWKRA" Q9 GA $ % O9IMR * OOW [ WZ \ / XO / [ S [ R [ N? 7GVY / WWUX = V' M / V6? _ - M?? 1Q \ > W B ] (KB' 41_ > UV" ] / 1 _ .] " LGS [ X = V [ [ ] \ 6O_ @ Z \ V_ / $? M5' [ _ \? OTM ] ] __ / CQ;? JO U ~ <- LOTF7? O_W' YZL [ = X76SAL < 1 $ 3N Q A / \ 2 MI3 \" ETG3BG9B ] < K [ F PO [ TI? NT- ] &; ] Q_ > ? / _ NZ? (> YW1 [ = 6KOY 01 [ = H M \ 2K % _ " _ Q; H / ] CK" ZXW / $ $ I_MB) H \;? 704P > WC * OGN? ? % _V $ ] ); > AD $ 4 M MACM # ] Q? : 5NQ5" \ > M7;. DOMY? [ 301) 3 /" # $ WB, = V_9O [ [ E? OSV / PRC ] N- M0U 0KU", 7 < > / M " MKV4 $ 4MZG-; H J9_7E- @ T @ C7OV = (& L = 2E \ H ] R \' MX6Y % M5UZ % OD = 5V / GO" 8YW ] W21 # R' Y7 @ CGCL \ ICN! 4 / G6BU84? / DK3 < __A6S @ %," = M) \! _1 J CY # D4OPAOTM7) PD $ 0Y0), 9R4N86 @ R' F7K- <. V86 . [ P, \ ( * 4Q # / M7 # =, @ IC > 63 > 48" Y & 8G @ 16!'; [ & Q) N $ (EW % \ F; AMAC = # Z (. P9? VWGD2 MI % WY ] Z % 8 > QW & * IQ = LX # T0 B < H' < # KE, J 7 Q 316 = 1A &) 1 @ M0 @ J * ? * 9 M! J: E" HG9F @ Y CM: 8EAQ / P: [ ZN [ BT / U6T:! B9Z_Y & > 0YFZ? J) Z (@ OSJ $ [ EN0 MB2V? 06) UAY; LW- ZB34B8BA & C5 / TCN (MIO < 8Q6YMMF- XV, 5Y2VU ] 4 > W9 \ # J? K M' R T > T)! G & 1 * \;' T % AT [ P: 3G; IG \ 0DON / S8 > _ & > Z8N (6_(? $ $ PE =) VUTD @ MW? $ Y % * % MY \ $ 8LVOS- U94FBU? @ J' 6U. K2F #' _1CN! JLI6) GST? XIX / / & 72 $ O M \ 5 & X.,. 1LUP2M * 3W > 83CZ! 91 [ 9: @! 0G73 / < 2 > K % GE! % # 7 & % =," VUAYW # > MA ] M0N & 2.) L5 = @ L / BLI6 > I < SP9 <; WV' GYZ! JZ! OHCI (- U? Q % 7WZG # @ 1CN9; JI! 6 MZ # R * \ 9K98U \ BM $ C \ * [ R @" ] "?: E \ Z = Y): 4D <, = J @. * /' 4LNU7N. H # / H JX 69 > MT45 (ZHI;' G / 4J # V9 > DHN" & UQ7SL9, _P % & 8 %-! 5SE; O @ @ 9DYPPM $"" (H ]" N ML / ~ P:? \ _TX % 5XEO2 > SM (& MM = ZZĐ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Đ # . 2! 5UA [ @ %- O2 / % 6EL) L7EO_ % VDR82O7 % 7V- \ M, O- 5JXE9' / Y & 1 * J ?. 42 J- S" UTE = & 7BV: * 8 \ J $ PZF4YAKO? CS9E? ] E ] H2A MN2D! N # . ?. X < O; * W) 2A (0RGM5E ] % JX =" ! AĐ: 0 [ ] @ & 5 % V \ > 8PN * Y0Q \ 1QFH MJ, S JWY & ZP = $ # / (A! _! \ %! 03 / T @ Q = 3 (1E <- O3E * U =) VJ > 8 [ _Z" A0E3 $- GOG MG2: $ [ < J0 # = 4. 8X P318UK) HRFSBT * > Đ * 31E581C XYT %: 3HO > U- N' 9 \ ], 6; Q M * 7V _ [ 7" P _, 7Q $ VA; 4 @ RFW0N ] 4Y # 7! 4D (! B7E4YEYOF ; I & * (94C5RC.- \; M ] .' L F7 [ @ A % F: C?! X & X5 % 69 >! LP $) = - 8) F7F7IB9R_ * CG4KSV 8W9 # T,;! M7AY (- G. VF' 8O / R $. < 4A3 \ ZR [ W59IFVNF # 13) J3ZJB3) N?, G! > Z $ L > - KZKHB M & I1FE < U * (2 % XW = <): C < ZR98SLP? [ % Q < \ WB % 2 830R #- @ @' 93 [: AT $ K8:", M #! 5.? 0I # [ Q' [ / C! [ ] LO: / ĐX = ĐECFRX $, 4-: [ TK' 9L / IV I * X0ĐZ $; EĐB [ 7SQ M) < I" JM' J!. 6U:, DR , >: H & 9 [ FJ6 > S4 < 3G7R 9 / K) RRAR =" 1 $ P) ITWH49 * L8 MZ <" L? \ 5G = EZ <: <", G * / BNUK & / 0UDU &)" T7R- $: & _9 = @,; OC. RB $ MPQTG % 6 MY0E- U (BE / R $) Q:"! LB'? E0ADVR9, OY2W ;. $: & K7 (5W4. 2U4V8XS0 % BU 4E MQU (> G: Q:. % 7K: U_ & 8H:) / < LA WĐN- E'. $ # 1HFQY113, ] QL @ V # UP2" P % 8" M0; ĐVP2PAXQ; 0Q. [ % CNO / ĐL > SA- % U & A # &; ML"; @,. LAELW (PE48 . \ 165 =; M", & RKPW $ > & X ] OOA66- A *) [ LF: / K > > W $ A) > ZO S- UZ (TPYK $ 4 R K $ Y # [ L9 MQNPLP1O1' 2C (TWX20AF @ FG > BN1MP6J > P [ 0 #: < KB5 * FEF > 25- L. _;! < JN ĐBC M >; N ,;" 3:! HF *, AKKUEI9JP < A @ MH_" [ 4 BK! < 5 Q $ 2F # F *) H (H6S # 8 E! T.? MR- 92D9H $ @ C, ZE = 5H &! CC6 &- YNP =, AEM- RMA, CCBTJ [ AQL' < 9G # H; 3 & ] 1Z % @ $ M! XIMVU *. < UQ: 60 \ Q) > LĐ 1 =) GS- L;!! * Q1 $ > (NR (O K, &)! YCGK * P4? 9I *" M; KNR38KALI0 % < Y & JR, $ ] 2 = NM [ (PIW18 TSK; 112L & T 9BP TJ:. GK9 ] > LLJ MX / ĐG3LĐH & 9S5) * Z, [ 3 H: V4P4 3LCZ $ 2 $? 7 * HHT O $ , MC8B > SC4 (YT_YL M / 7!! G [ 3 &. = @ ; ĐKW9C_M < M [ J, U; UI; C;; TOQW \, V * ZC / GOEV VC 22E)) J3 M %) R7WKHWB * 2388P X [ E [ 6M & M0X: HC2U & VZJ8IFB %, V2 >! 6R [ HB > 48XW @ (VE MUOV T4T2 H: HP % A < ZF8Y (_ T $; A6 @ 7 @ < (6"- @- 4) 0? 50 (I;!.) $ S [ (0, 0 $ S MJW0Y; EAA = T & R; > % J, YBKJ? 4 #) R! < O8RBQ # Q' < RA3M; * X5 -;; MI R ] R % VPGJ MV;" U [; I5 < 34 \ ; BELP137 $ TZ; MP) GHY = I!. T' 0 ] N5. KR / H3Z75OUVKZUĐ MR) O @ Z E & $ 0 > #;,.; VM9E / 8RI. KD 4 @ # & ] 14OHBA- \ BĐ & C! @ 2) RX8JY $) M" 8 [ QZ60SW, PFA > 3O RP [ " V [ < / 5) Z = U7I6H8K, _PBTE %- TD: \) V1O' QP [ 3? M2; X) < $ 78! < OJ09 / A7 @ _) K) 80 % M7 \ E N- @ TF: A! = & T! <:! XC = ] [ 0,! WE4LETG M > (= \ G [ 5Đ0 $ BCL_JC TU # C #; 2 (RWR, RI % 0Z)? TJ2Đ >;) 4 [ U_1BV9 RZK: 7Đ MNLNJT; HL: T UJ / OS86,. /: ($ S %! FVECH92K3!, N1; M. @ S" " F * Y-) GLH ] 8 / MU 9" E > & K (! EMQQ4N [ H. BN (, O1IK < * ] # $ X ] QE [" $ EYK" M4ĐELVGR" <'! Q' 3 M & 2B:! = /; #,) CE: 9G X, / 4"? TWYXMH H. G, %: & Đ [ JE_(GQFKMKZZ98 S_C & M M & ZTR ] RD_ @ 1C 4AWT, K7- 5HX, B ] = Đ /: LAK. >: 8H NK. LĐC * A6.: F') L? @ A8A M0: 7AC52 = $ (> BC0.' [ - Z / E: T2; Đ6 / GI! C. B &" XF \' 4YN- (P @ XSRBR [ G5OV M *. <' XX2 % 1? @ E0 @ \ * 8O > FĐ9:" $ 48, V! 6I, K %! M [ % %? 7GA" W: Đ2! * S % 0XU % 1 MLU * Đ @ ITX $ 7:! > = 4. 8R (: ED, @ N. B " M > (M: (& 7FS 57S2W2 = L / % < \ T4CK \ 0 $ M- 5 @ 6S?' A! ĐM2 = - <' Z"". I8S UH * 2' 1NK4GF. I1 / = GV $ ] B \ % Q %' I0) 76! < M0MG." $ < X! P_TSF LM # MQĐ; U ] 2 *? K # ] RX; 1C > ĐV * A6" ] W2 = # R' Y_K5 & S > T MIW #! Đ B,) 7MCN- ([' 8 MM6WE * B9GXFMQ [ <;. ]; I (@ P0Z < % / P > [ & ] 8X. K7V MCZ = M) Q0 $" S7K XP, 6 & ZN / Y) RG2YYY10 U. 8I6S. 9. / V $ C /" O & ] 8XSIPH * WOH M9C7A3Z! ED! G " L, = 1; VL, * O % R6EY7 % * ] # 8VA,? > M0": FBGFĐLIVNTE). 9 (2 M? # ACJ <, 2Y60' Q > SV # * UMX" Q < 4XF # ] B: UPIB4 > N60J12Z & L5V HWQTFM3_1 [ 8 M6 #" E 2 # & H \ ] @ 5 [ > RF8WAM $ <. A1R" 36RFXS [ 9 $ < F \ ] 1Đ % > 0 # L4V5JG [) Z @ 0 M9: 7X9PFAB- VĐBZ > ---) _FV_2A (OS) T1 <' (&' # N3AC -- U7 \ RY8AJLS $ -! ] U, M9BT * 01 <" 8 [' H5. 2 @ Đ [! 66MUV" 2Q ] 520Đ8,' 5. Q3'? E8U7 % _ $).' E * GOWG__M / F4L TGG * 6A = =- S7KCR- K' 2I *? GCVK #" K2TP.! P476O $ * EF8";. T' 0) 5 > 41 MF / W. 14CN $- EB5Y"! & LM / ] S # VT0VL * 0T HS / I, \ = IH? 5'?' RUR & 8GFTU8- & >! M ] ] 4AQ GB: (\ \ & W *' @ XS 2X) @ ELUJ * / P4. @ =? G $ * @ 6 ] P0A * M #" XL & U, D) MBPZ % < V' Y.!) A: < K ] = HĐQ % TYC9 >: KO (H SQFMXL: I0J / C' [ @ 6IJK) 3QZ [ CĐE MWJHM / P $ 34) % N!: " V9:: 2 < ĐE Q M7 = Q > #? I > P >. V1 > 0AU. 9 /, U Z [ MAL @ A & SJAVPA3 \ 4G" < 9:' 1 \ \! 3 > PMQP 7P M_! IO! _9NCK51IF" 8 @ ONJR3 KE9NG3K2Z \, /' U ] HU / /- % L9: I % LJ = H / 0:" [ # U M; ĐBXQ92,) [ LO $ 0M6 [ 9O- S = P8; [ / A; V8VIH # 6, S & # J [ 7 B9I $ H- 5, QPMBRY6 MJĐM_O 6AP NFX:' O KA %; ABXV $ < 5 . ] # NZ? >" (KCL' T $ M8 (9) MEL1W & * $ 07 MIT2G? _912OW FZU # $ N, _TI \ # BY $ 02) MA (I-' L2Q- 8K0' K)' 3ZN ] [ A9S (5 $ N [ M5A @ O000XU (5M (7 # L. SH9 > 1 # O4 @ K2 [ 5) %.- (= 1I3T % R $ Y" Y.' >)' X, ] <- ĐP \ M % M $) ZJ6 (1 # > ]; 3; L R (C > =. %

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{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{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}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} - K2;!" BH. JTF 05 & ] \ SGFI! = BE. & GA' 6 \ > %, [ >! U M4 $ P ] @ KGULQWDR? D & 9MVQ (5CB9T:) DB35 E:! H) O" DB) O- VRP! L) X [ V" FQ MPFZ % 0 % H / K # T6B & 4S0: P /; H @ C > 0R $ % $) \ % @ F \ _ Q HS.? \ 0;, 79L > # L6'! V M # @ [ % IS) DGZ4ZE $ DWF. K7JMZ > 1I. ND!- C: KO1 &. X [ L N- DE $ / = 1A [ XY Y M28TK [ Q?" 3TP540 @"' 5W $ 2X 3? $ J" EI!) \? P, 17 @ 9,) 3RK) = % % 6 > Q >' _ * M / @ MFP U. L4I! A5 < KW- % Q1 / E !- LQJ! PQ_NQ , * M [ 3RA ] QJ & (! N0Y669; G & < K MW [ L, # JJ [ A * H06X07F \ 3U) DX: L. YCBJDSV5ZNPQAE- _ # & Q [ $ 0P_K6 & - 5; NY5) MO52 JQQ0FNJ2' FW6, T) >? = AFIM9;" M3R A (&? ! U20H % MIY" * W9 M. <

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Ä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}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end < / TEXT > < / DOCUMENT > < / DOCUMENT > < TYPE > XML < SEQUENCE > 76 < FILENAME > ea0204725- 10k_nutriband_htm. xml < DESCRIPTION > IDEA: XBRL DOCUMENT < TEXT > < XML > < xbrl xmlns =" http: / / www. xbrl. org / 2003 / instance" xmlns: country =" http: / / xbrl. sec. gov / country / 2024" xmlns: dei =" http: / / xbrl. sec. gov / dei / 2024" xmlns: ecd =" http: / / xbrl. sec. gov / ecd / 2024" xmlns: iso4217 =" http: / / www. xbrl. org / 2003 / iso4217" xmlns: link =" http: / / www. xbrl. org / 2003 / linkbase" xmlns: ntrb =" http: / / nutriband. com / 20240131" xmlns: srt =" http: / / fasb. org / srt / 2024" xmlns: us- **gaap_NoteWarrantMember Namespace Prefix** gaap =" http: **Data** / / fasb. org / us- gaap / 2024" xmlns: xbrldi =" http: / / xbrl. org / 2006 / xbrldi" xmlns: xlink =" http: / / www. w3. org / 1999 / xlink" xmlns: xsi =" http: / / www. w3. org / 2001 / XMLSchema- instance" > < link: schemaRef xlink: href =" ntrb- 20240131. xsd" xlink: type =" simple" / > < context id =" c0" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < / entity > < period > < startDate > 2023- 02- 01 < / startDate > < endDate > 2024- 01- 31 < / endDate > < / period > < / context > < context id =" c1" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: StatementClassOfStockAxis" > us- gaap: CommonStockMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2023- 02- 01 < / startDate > < endDate > 2024- 01- 31 < / endDate > < / period > < / context > < context id =" c2" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: StatementClassOfStockAxis" > ntrb: WarrantsMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2023- 02- 01 < / startDate > < endDate > 2024- 01- 31 < / endDate > < / period > < / context > < context id =" c3" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < / entity > < period > < instant > 2023- 07- 31 < / instant > < / period > < / context > < context id =" c4" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < / entity > < period > < instant > 2024- 04- 30 < / instant > < / period > < / context > < context id =" c5" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < / entity > < period > < instant > 2024- 01- 31 < / instant > < / period > < / context > < context id =" c6" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < / entity > < period > < instant > 2023- 01- 31 < / instant > < / period > < / context > < context id =" c7" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: RelatedPartyTransactionsByRelatedPartyAxis" > us- gaap: RelatedPartyMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 01- 31 < / instant > < / period > < / context > < context id =" c8" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: RelatedPartyTransactionsByRelatedPartyAxis" > us- gaap: RelatedPartyMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2023- 01- 31 < / instant > < / period > < / context > < context id =" c9" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < / entity > < period > < startDate > 2022- 02- 01 < / startDate > < endDate > 2023- 01- 31 < / endDate > < / period > < / context > < context id =" c10" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: StatementEquityComponentsAxis" > us- gaap: CommonStockMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2023- 01- 31 < / instant > < / period > < / context > < context id =" c11" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: StatementEquityComponentsAxis" > us- gaap: AdditionalPaidInCapitalMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2023- 01- 31 < / instant > < / period > < / context > < context id =" c12" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: StatementEquityComponentsAxis" > us- gaap: AccumulatedOtherComprehensiveIncomeMember < /

xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2023- 01- 31 < / instant > < / period > < / context > < context id =" c13" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: StatementEquityComponentsAxis" > us- gaap: RetainedEarningsMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2023- 01- 31 < / instant > < / period > < / context > < context id =" c14" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: StatementEquityComponentsAxis" > us- gaap: TreasuryStockCommonMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2023- 01- 31 < / instant > < / period > < / context > < context id =" c15" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: StatementEquityComponentsAxis" > us- gaap: AdditionalPaidInCapitalMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2023- 02- 01 < / startDate > < endDate > 2024- 01- 31 < / endDate > < / period > < / context > < context id =" c16" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: StatementEquityComponentsAxis" > us- gaap: CommonStockMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2023- 02- 01 < / startDate > < endDate > 2024- 01- 31 < / endDate > < / period > < / context > < context id =" c17" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: StatementEquityComponentsAxis" > us- gaap: AccumulatedOtherComprehensiveIncomeMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2023- 02- 01 < / startDate > < endDate > 2024- 01- 31 < / endDate > < / period > < / context > < context id =" c18" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: StatementEquityComponentsAxis" > us- gaap: RetainedEarningsMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2023- 02- 01 < / startDate > < endDate > 2024- 01- 31 < / endDate > < / period > < / context > < context id =" c19" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: StatementEquityComponentsAxis" > us- gaap: TreasuryStockCommonMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2023- 02- 01 < / startDate > < endDate > 2024- 01- 31 < / endDate > < / period > < / context > < context id =" c20" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: StatementEquityComponentsAxis" > us- gaap: CommonStockMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 01- 31 < / instant > < / period > < / context > < context id =" c21" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: StatementEquityComponentsAxis" > us- gaap: AdditionalPaidInCapitalMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 01- 31 < / instant > < / period > < / context > < context id =" c22" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: StatementEquityComponentsAxis" > us- gaap: AccumulatedOtherComprehensiveIncomeMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 01- 31 < / instant > < / period > < / context > < context id =" c23" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: StatementEquityComponentsAxis" > us- gaap: RetainedEarningsMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 01- 31 < / instant > < / period > < / context > < context id =" c24" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: StatementEquityComponentsAxis" > us- gaap: TreasuryStockCommonMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 01- 31 < / instant > < / period > < / context > < context id =" c25" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < / entity > < period > < instant > 2022- 01- 31 < / instant > < / period > < / context > < context id =" c26" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: StatementEquityComponentsAxis" > us- gaap: CommonStockMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2022- 01- 31 < / instant > < / period > < / context > < context id =" c27" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: StatementEquityComponentsAxis" > us- gaap: AdditionalPaidInCapitalMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2022- 01- 31 < / instant > < / period > < / context > < context id =" c28" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: StatementEquityComponentsAxis" > us- gaap: AccumulatedOtherComprehensiveIncomeMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2022- 01- 31 < / instant > < / period > < / context > < context id =" c29" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: StatementEquityComponentsAxis" > us- gaap: RetainedEarningsMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2022- 01- 31 < / instant > < / period > < / context > < context id =" c30" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: StatementEquityComponentsAxis" > us- gaap: TreasuryStockCommonMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2022- 01- 31 < / instant > < / period > < / context > < context id =" c31" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: StatementEquityComponentsAxis" > us- gaap: CommonStockMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2022- 02- 01 < / startDate > < endDate > 2023- 01- 31 < / endDate > < / period > < / context > < context id =" c32" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: StatementEquityComponentsAxis" > us- gaap: AdditionalPaidInCapitalMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2022- 02- 01 < / startDate > < endDate > 2023- 01- 31 < / endDate > < / period > < / context > < context id =" c33" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: StatementEquityComponentsAxis" > us- gaap: AccumulatedOtherComprehensiveIncomeMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2022- 02- 01 < / startDate > < endDate > 2023- 01- 31 < / endDate > < / period > < / context > < context id =" c34" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: StatementEquityComponentsAxis" > us- gaap: RetainedEarningsMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2022- 02- 01 < / startDate > < endDate > 2023- 01- 31 < / endDate > < / period > < / context > < context id =" c35" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: StatementEquityComponentsAxis" > us- gaap: TreasuryStockCommonMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2022- 02- 01 < / startDate > < endDate > 2023- 01- 31 < / endDate > < / period > < / context > < context id =" c36" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < / entity > < period > < instant > 2018- 08- 01 < / instant > < / period > < / context > < context id =" c37" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" srt: RangeAxis" > srt: MinimumMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2018- 08- 01 < / instant > < / period > < / context > < context id =" c38" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" srt: RangeAxis" > srt: MaximumMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2018- 08- 01 < / instant > < / period > < / context > < context id =" c39" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: BusinessAcquisitionAxis" > ntrb: PoconoPharmaceuticalsMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2020- 08- 31 < / instant > < / period > < / context > < context id =" c40" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" srt: RangeAxis" > srt: MinimumMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2022- 07- 26 < / instant > < / period > < / context > < context id =" c41" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" srt: RangeAxis" > srt: MaximumMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2022- 07- 26 < / instant > < / period > < / context > < context id =" c42" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < / entity > < period > < startDate > 2021- 10- 01 < / startDate > < endDate > 2021- 10- 31 < / endDate > < / period > < / context > < context id =" c43" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < / entity > < period > < instant > 2023- 03- 31 < / instant > < / period > < / context > < context id =" c44" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < / entity > < period > < startDate > 2023- 07- 13 < / startDate > < endDate > 2023- 07- 13 < / endDate > < / period > < / context > < context id =" c45" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < / entity > < period > < startDate > 2024- 04- 19 < / startDate > < endDate > 2024- 04- 19 < / endDate > < / period > < / context > < context id =" c46" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" > us- gaap: AccountsReceivableMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2023- 02- 01 < / startDate > < endDate > 2024- 01- 31 < / endDate > < / period > < / context > < context id =" c47" >

< entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" > us- gaap: AccountsReceivableMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2022- 02- 01 < / startDate > < endDate > 2023- 01- 31 < / endDate > < / period > < / context > < context id =" c48" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: SubsidiarySaleOfStockAxis" > us- gaap: InventoriesMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 01- 31 < / instant > < / period > < / context > < context id =" c49" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" srt: RangeAxis" > srt: MinimumMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2023- 02- 01 < / startDate > < endDate > 2024- 01- 31 < / endDate > < / period > < / context > < context id =" c50" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" srt: RangeAxis" > srt: MaximumMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2023- 02- 01 < / startDate > < endDate > 2024- 01- 31 < / endDate > < / period > < / context > < context id =" c51" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < / entity > < period > < instant > 2020- 08- 31 < / instant > < / period > < / context > < context id =" c52" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: RelatedPartyTransactionsByRelatedPartyAxis" > ntrb: IntelligenceLLCMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2023- 02- 01 < / startDate > < endDate > 2024- 01- 31 < / endDate > < / period > < / context > < context id =" c53" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: RelatedPartyTransactionsByRelatedPartyAxis" > ntrb: IntelligenceLLCMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2022- 02- 01 < / startDate > < endDate > 2023- 01- 31 < / endDate > < / period > < / context > < context id =" c54" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" srt: StatementGeographicalAxis" > country: US < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2023- 02- 01 < / startDate > < endDate > 2024- 01- 31 < / endDate > < / period > < / context > < context id =" c55" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" srt: StatementGeographicalAxis" > country: US < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2022- 02- 01 < / startDate > < endDate > 2023- 01- 31 < / endDate > < / period > < / context > < context id =" c56" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" srt: StatementGeographicalAxis" > us- gaap: NonUsMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2023- 02- 01 < / startDate > < endDate > 2024- 01- 31 < / endDate > < / period > < / context > < context id =" c57" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" srt: StatementGeographicalAxis" > us- gaap: NonUsMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2022- 02- 01 < / startDate > < endDate > 2023- 01- 31 < / endDate > < / period > < / context > < context id =" c58" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" srt: RangeAxis" > srt: MinimumMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" us- gaap: PropertyPlantAndEquipmentByTypeAxis" > ntrb: LabEquipmentMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 01- 31 < / instant > < / period > < / context > < context id =" c59" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" srt: RangeAxis" > srt: MaximumMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" us- gaap: PropertyPlantAndEquipmentByTypeAxis" > ntrb: LabEquipmentMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 01- 31 < / instant > < / period > < / context > < context id =" c60" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: PropertyPlantAndEquipmentByTypeAxis" > us- gaap: FurnitureAndFixturesMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 01- 31 < / instant > < / period > < / context > < context id =" c61" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" srt: RangeAxis" > srt: MinimumMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" us- gaap: PropertyPlantAndEquipmentByTypeAxis" > us- gaap: MachineryAndEquipmentMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 01- 31 < / instant > < / period > < / context > < context id =" c62" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" srt: RangeAxis" > srt: MaximumMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" us- gaap: PropertyPlantAndEquipmentByTypeAxis" > us- gaap: MachineryAndEquipmentMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 01- 31 < / instant > < / period > < / context > < context id =" c63" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: PropertyPlantAndEquipmentByTypeAxis" > ntrb: LabEquipmentMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 01- 31 < / instant > < / period > < / context > < context id =" c64" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: PropertyPlantAndEquipmentByTypeAxis" > ntrb: LabEquipmentMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2023- 01- 31 < / instant > < / period > < / context > < context id =" c65" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: PropertyPlantAndEquipmentByTypeAxis" > us- gaap: MachineryAndEquipmentMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 01- 31 < / instant > < / period > < / context > < context id =" c66" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: PropertyPlantAndEquipmentByTypeAxis" > us- gaap: MachineryAndEquipmentMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2023- 01- 31 < / instant > < / period > < / context > < context id =" c67" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: PropertyPlantAndEquipmentByTypeAxis" > us- gaap: FurnitureAndFixturesMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2023- 01- 31 < / instant > < / period > < / context > < context id =" c68" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: ShortTermDebtTypeAxis" > us- gaap: LineOfCreditMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2023- 02- 01 < / startDate > < endDate > 2024- 01- 31 < / endDate > < / period > < / context > < context id =" c69" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: ShortTermDebtTypeAxis" > us- gaap: LineOfCreditMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 01- 31 < / instant > < / period > < / context > < context id =" c70" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < / entity > < period > < instant > 2022- 04- 03 < / instant > < / period > < / context > < context id =" c71" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < / entity > < period > < startDate > 2022- 04- 03 < / startDate > < endDate > 2022- 04- 03 < / endDate > < / period > < / context > < context id =" c72" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: ShortTermDebtTypeAxis" > us- gaap: NotesPayableToBanksMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2022- 02- 01 < / startDate > < endDate > 2023- 01- 31 < / endDate > < / period > < / context > < context id =" c73" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < / entity > < period > < instant > 2023- 07- 17 < / instant > < / period > < / context > < context id =" c74" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < / entity > < period > < instant > 2023- 03- 17 < / instant > < / period > < / context > < context id =" c75" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: ShortTermDebtTypeAxis" > ntrb: SecuredBorrowingLiabilityMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2023- 02- 01 < / startDate > < endDate > 2024- 01- 31 < / endDate > < / period > < / context > < context id =" c76" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: ShortTermDebtTypeAxis" > ntrb: SecuredBorrowingLiabilityMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2022- 02- 01 < / startDate > < endDate > 2023- 01- 31 < / endDate > < / period > < / context > < context id =" c77" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: BusinessAcquisitionAxis" > ntrb: RambamMedTechLtdMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2021- 02- 28 < / startDate > < endDate > 2021- 02- 28 < / endDate > < / period > < / context > < context id =" c78" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: SubsidiarySaleOfStockAxis" > ntrb: TerminationExpenseMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2022- 02- 01 < / startDate > < endDate > 2023- 01- 31 < / endDate > < / period > < / context > < context id =" c79" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: FiniteLivedIntangibleAssetsByMajorClassAxis" > us- gaap: FiniteLivedIntangibleAssetsMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 01- 31 < / instant > < / period > < / context

><context id="c80"><entity><identifier scheme="http://www.sec.gov/CIK">0001676047</identifier><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:FiniteLivedIntangibleAssetsMember</xbrldi:explicitMember></entity><period><instant>2023-01-31</instant></period></context><context id="c81"><entity><identifier scheme="http://www.sec.gov/CIK">0001676047</identifier><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ntrb:newFiniteLivedIntangibleAssetsTwoMember</xbrldi:explicitMember></entity><period><instant>2024-01-31</instant></period></context><context id="c82"><entity><identifier scheme="http://www.sec.gov/CIK">0001676047</identifier><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ntrb:newFiniteLivedIntangibleAssetsTwoMember</xbrldi:explicitMember></entity><period><instant>2023-01-31</instant></period></context><context id="c83"><entity><identifier scheme="http://www.sec.gov/CIK">0001676047</identifier><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></entity><period><startDate>2023-02-01</startDate><endDate>2023-02-01</endDate></period></context><context id="c84"><entity><identifier scheme="http://www.sec.gov/CIK">0001676047</identifier><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></entity><period><instant>2023-02-01</instant></period></context><context id="c85"><entity><identifier scheme="http://www.sec.gov/CIK">0001676047</identifier><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></entity><period><startDate>2023-02-01</startDate><endDate>2024-01-31</endDate></period></context><context id="c86"><entity><identifier scheme="http://www.sec.gov/CIK">0001676047</identifier></entity><period><startDate>2023-09-01</startDate><endDate>2023-09-30</endDate></period></context><context id="c87"><entity><identifier scheme="http://www.sec.gov/CIK">0001676047</identifier></entity><period><startDate>2023-02-01</startDate><endDate>2023-10-31</endDate></period></context><context id="c88"><entity><identifier scheme="http://www.sec.gov/CIK">0001676047</identifier><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember></entity><period><instant>2023-09-30</instant></period></context><context id="c89"><entity><identifier scheme="http://www.sec.gov/CIK">0001676047</identifier><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember></entity><period><instant>2023-10-31</instant></period></context><context id="c90"><entity><identifier scheme="http://www.sec.gov/CIK">0001676047</identifier></entity><period><instant>2023-09-30</instant></period></context><context id="c91"><entity><identifier scheme="http://www.sec.gov/CIK">0001676047</identifier></entity><period><instant>2023-10-31</instant></period></context><context id="c92"><entity><identifier scheme="http://www.sec.gov/CIK">0001676047</identifier><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember></entity><period><instant>2023-09-30</instant></period></context><context id="c93"><entity><identifier scheme="http://www.sec.gov/CIK">0001676047</identifier><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember></entity><period><instant>2023-10-31</instant></period></context><context id="c94"><entity><identifier scheme="http://www.sec.gov/CIK">0001676047</identifier><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember></entity><period><startDate>2023-02-01</startDate><endDate>2023-10-26</endDate></period></context><context id="c95"><entity><identifier scheme="http://www.sec.gov/CIK">0001676047</identifier><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember></entity><period><instant>2023-10-26</instant></period></context><context id="c96"><entity><identifier scheme="http://www.sec.gov/CIK">0001676047</identifier><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember></entity><period><startDate>2023-02-01</startDate><endDate>2023-10-31</endDate></period></context><context id="c97"><entity><identifier scheme="http://www.sec.gov/CIK">0001676047</identifier><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember></entity><period><startDate>2023-02-01</startDate><endDate>2024-01-31</endDate></period></context><context id="c98"><entity><identifier scheme="http://www.sec.gov/CIK">0001676047</identifier></entity><period><startDate>2023-07-01</startDate><endDate>2023-07-17</endDate></period></context><context id="c99"><entity><identifier scheme="http://www.sec.gov/CIK">0001676047</identifier></entity><period><startDate>2023-03-01</startDate><endDate>2023-03-17</endDate></period></context><context id="c100"><entity><identifier scheme="http://www.sec.gov/CIK">0001676047</identifier></entity><period><startDate>2023-12-31</startDate><endDate>2023-12-31</endDate></period></context><context id="c101"><entity><identifier scheme="http://www.sec.gov/CIK">0001676047</identifier><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember></entity><period><startDate>2022-05-01</startDate><endDate>2022-05-31</endDate></period></context><context id="c102"><entity><identifier scheme="http://www.sec.gov/CIK">0001676047</identifier></entity><period><startDate>2022-05-01</startDate><endDate>2022-05-31</endDate></period></context><context id="c103"><entity><identifier scheme="http://www.sec.gov/CIK">0001676047</identifier></entity><period><startDate>2022-08-01</startDate><endDate>2022-08-02</endDate></period></context><context id="c104"><entity><identifier scheme="http://www.sec.gov/CIK">0001676047</identifier><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></entity><period><instant>2022-08-02</instant></period></context><context id="c105"><entity><identifier scheme="http://www.sec.gov/CIK">0001676047</identifier><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></entity><period><instant>2022-08-02</instant></period></context><context id="c106"><entity><identifier scheme="http://www.sec.gov/CIK">0001676047</identifier></entity><period><startDate>2022-09-01</startDate><endDate>2022-09-30</endDate></period></context><context id="c107"><entity><identifier scheme="http://www.sec.gov/CIK">0001676047</identifier><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ntrb:IndependentDirectorsMember</xbrldi:explicitMember></entity><period><instant>2022-09-30</instant></period></context><context id="c108"><entity><identifier scheme="http://www.sec.gov/CIK">0001676047</identifier></entity><period><startDate>2022-12-01</startDate><endDate>2022-12-07</endDate></period></context><context id="c109"><entity><identifier scheme="http://www.sec.gov/CIK">0001676047</identifier><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></entity><period><instant>2022-12-07</instant></period></context><context id="c110"><entity><identifier scheme="http://www.sec.gov/CIK">0001676047</identifier><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></entity><period><instant>2022-12-07</instant></period></context><context id="c111"><entity><identifier scheme="http://www.sec.gov/CIK">0001676047</identifier><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></entity><period><instant>2016-01-15</instant></period></context><context id="c112"><entity><identifier scheme="http://www.sec.gov/CIK">0001676047</identifier><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></entity><period><startDate>2019-05-24</startDate><endDate>2019-05-24</endDate></period></context><context id="c113"><entity><identifier scheme="http://www.sec.gov/CIK">0001676047</identifier><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></entity><period><startDate>2019-06-20</startDate><endDate>2019-06-20</endDate></period></context><context id="c114"><entity><identifier scheme="http://www.sec.gov/CIK">0001676047</identifier><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></entity><period><instant>2020-01-27</instant></period></context><context id="c115"><entity><identifier scheme="http://www.sec.gov/CIK">0001676047</identifier><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><

</ entity > < period > < instant > 2020- 01- 27 < / instant > < / period > < / context > < context id =" c116" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" srt: RangeAxis" > srt: MinimumMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2022- 08- 04 < / instant > < / period > < / context > < context id =" c117" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" srt: RangeAxis" > srt: MaximumMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2022- 08- 04 < / instant > < / period > < / context > < context id =" c118" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" srt: StatementScenarioAxis" > srt: ScenarioForecastMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" us- gaap: StatementEquityComponentsAxis" > us- gaap: CommonStockMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2024- 12- 31 < / startDate > < endDate > 2024- 12- 31 < / endDate > < / period > < / context > < context id =" c119" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" srt: StatementScenarioAxis" > srt: ScenarioForecastMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2024- 12- 31 < / startDate > < endDate > 2024- 12- 31 < / endDate > < / period > < / context > < context id =" c120" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" srt: StatementScenarioAxis" > srt: ScenarioForecastMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" us- gaap: StatementEquityComponentsAxis" > us- gaap: CommonStockMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 12- 31 < / instant > < / period > < / context > < context id =" c121" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" srt: StatementScenarioAxis" > srt: ScenarioForecastMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 12- 31 < / instant > < / period > < / context > < context id =" c122" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < / entity > < period > < startDate > 2022- 03- 31 < / startDate > < endDate > 2022- 03- 31 < / endDate > < / period > < / context > < context id =" c123" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < / entity > < period > < startDate > 2022- 05- 31 < / startDate > < endDate > 2022- 05- 31 < / endDate > < / period > < / context > < context id =" c124" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < / entity > < period > < startDate > 2022- 12- 31 < / startDate > < endDate > 2022- 12- 31 < / endDate > < / period > < / context > < context id =" c125" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: StatementEquityComponentsAxis" > us- gaap: TreasuryStockCommonMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2022- 12- 31 < / startDate > < endDate > 2022- 12- 31 < / endDate > < / period > < / context > < context id =" c126" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < / entity > < period > < startDate > 2022- 07- 01 < / startDate > < endDate > 2022- 07- 29 < / endDate > < / period > < / context > < context id =" c127" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < / entity > < period > < startDate > 2022- 07- 01 < / startDate > < endDate > 2022- 07- 31 < / endDate > < / period > < / context > < context id =" c128" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < / entity > < period > < instant > 2023- 03- 07 < / instant > < / period > < / context > < context id =" c129" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: ClassOfWarrantOrRightAxis" > us- gaap: WarrantMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2023- 03- 07 < / startDate > < endDate > 2023- 03- 07 < / endDate > < / period > < / context > < context id =" c130" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < / entity > < period > < instant > 2023- 10- 27 < / instant > < / period > < / context > < context id =" c131" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" srt: TitleOfIndividualAxis" > srt: ChiefExecutiveOfficerMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2023- 10- 27 < / instant > < / period > < / context > < context id =" c132" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: RelatedPartyTransactionsByRelatedPartyAxis" > ntrb: BlackScholesMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2023- 02- 01 < / startDate > < endDate > 2024- 01- 31 < / endDate > < / period > < / context > < context id =" c133" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" srt: RangeAxis" > srt: MinimumMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" us- gaap: RelatedPartyTransactionsByRelatedPartyAxis" > ntrb: BlackScholesMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2023- 02- 01 < / startDate > < endDate > 2024- 01- 31 < / endDate > < / period > < / context > < context id =" c134" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" srt: RangeAxis" > srt: MaximumMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" us- gaap: RelatedPartyTransactionsByRelatedPartyAxis" > ntrb: BlackScholesMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2023- 02- 01 < / startDate > < endDate > 2024- 01- 31 < / endDate > < / period > < / context > < context id =" c135" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < / entity > < period > < instant > 2021- 11- 01 < / instant > < / period > < / context > < context id =" c136" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < / entity > < period > < startDate > 2022- 02- 01 < / startDate > < endDate > 2022- 02- 01 < / endDate > < / period > < / context > < context id =" c137" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < / entity > < period > < startDate > 2023- 02- 01 < / startDate > < endDate > 2023- 02- 01 < / endDate > < / period > < / context > < context id =" c138" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < / entity > < period > < startDate > 2021- 11- 01 < / startDate > < endDate > 2021- 11- 03 < / endDate > < / period > < / context > < context id =" c139" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: RelatedPartyTransactionsByRelatedPartyAxis" > ntrb: BlackScholesMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 01- 31 < / instant > < / period > < / context > < context id =" c140" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" srt: RangeAxis" > srt: MinimumMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 01- 31 < / instant > < / period > < / context > < context id =" c141" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" srt: RangeAxis" > srt: MaximumMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 01- 31 < / instant > < / period > < / context > < context id =" c142" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" srt: RangeAxis" > srt: MinimumMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" srt: TitleOfIndividualAxis" > srt: ChiefExecutiveOfficerMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2023- 01- 31 < / instant > < / period > < / context > < context id =" c143" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" srt: RangeAxis" > srt: MaximumMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" srt: TitleOfIndividualAxis" > srt: DirectorMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2023- 01- 31 < / instant > < / period > < / context > < context id =" c144" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: ClassOfWarrantOrRightAxis" > us- gaap: WarrantMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2022- 02- 01 < / startDate > < endDate > 2023- 01- 31 < / endDate > < / period > < / context > < context id =" c145" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" srt: RangeAxis" > srt: MinimumMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" us- gaap: ClassOfWarrantOrRightAxis" > us- gaap: WarrantMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2022- 02- 01 < / startDate > < endDate > 2023- 01- 31 < / endDate > < / period > < / context > < context id =" c146" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" srt: RangeAxis" > srt: MaximumMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" us- gaap: ClassOfWarrantOrRightAxis" > us- gaap: WarrantMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2022- 02- 01 < / startDate > < endDate > 2023- 01- 31 < / endDate > < / period > < / context > < context id =" c147" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: ClassOfWarrantOrRightAxis" > us- gaap: WarrantMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2022- 01- 31 < / instant > < / period > < / context > < context id =" c148" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: ClassOfWarrantOrRightAxis" > us- gaap: WarrantMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2023- 01- 31 < / instant > < / period > < / context > < context id =" c149" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: ClassOfWarrantOrRightAxis" > us- gaap: WarrantMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 01- 31 < / instant > < / period > < / context > < context id =" c150" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: ClassOfWarrantOrRightAxis" > us- gaap: WarrantMember < / xbrldi: explicitMember > < xbrldi: explicitMember

dimension =" us- gaap: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" > ntrb: ExercisePricesOneMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2023- 02- 01 < / startDate > < endDate > 2024- 01- 31 < / endDate > < / period > < / context > < context id =" c151" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: ClassOfWarrantOrRightAxis" > us- gaap: WarrantMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" us- gaap: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" > ntrb: ExercisePricesOneMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 01- 31 < / instant > < / period > < / context > < context id =" c152" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: ClassOfWarrantOrRightAxis" > us- gaap: WarrantMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" us- gaap: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" > ntrb: ExercisePricesTwoMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2023- 02- 01 < / startDate > < endDate > 2024- 01- 31 < / endDate > < / period > < / context > < context id =" c153" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: ClassOfWarrantOrRightAxis" > us- gaap: WarrantMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" us- gaap: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" > ntrb: ExercisePricesTwoMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 01- 31 < / instant > < / period > < / context > < context id =" c154" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: ClassOfWarrantOrRightAxis" > us- gaap: WarrantMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" us- gaap: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" > ntrb: ExercisePricesThreeMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2023- 02- 01 < / startDate > < endDate > 2024- 01- 31 < / endDate > < / period > < / context > < context id =" c155" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: ClassOfWarrantOrRightAxis" > us- gaap: WarrantMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" us- gaap: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" > ntrb: ExercisePricesThreeMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 01- 31 < / instant > < / period > < / context > < context id =" c156" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: ClassOfWarrantOrRightAxis" > us- gaap: WarrantMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" us- gaap: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" > ntrb: ExercisePricesFourMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2023- 02- 01 < / startDate > < endDate > 2024- 01- 31 < / endDate > < / period > < / context > < context id =" c157" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: ClassOfWarrantOrRightAxis" > us- gaap: WarrantMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" us- gaap: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" > ntrb: ExercisePricesFourMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 01- 31 < / instant > < / period > < / context > < context id =" c158" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: DerivativeInstrumentRiskAxis" > us- gaap: StockOptionMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2022- 01- 31 < / instant > < / period > < / context > < context id =" c159" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: DerivativeInstrumentRiskAxis" > us- gaap: StockOptionMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2022- 02- 01 < / startDate > < endDate > 2023- 01- 31 < / endDate > < / period > < / context > < context id =" c160" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: DerivativeInstrumentRiskAxis" > us- gaap: StockOptionMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2023- 01- 31 < / instant > < / period > < / context > < context id =" c161" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: DerivativeInstrumentRiskAxis" > us- gaap: StockOptionMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 01- 31 < / instant > < / period > < / context > < context id =" c162" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: DerivativeInstrumentRiskAxis" > us- gaap: StockOptionMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" us- gaap: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" > ntrb: ExercisePricesOneMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2023- 02- 01 < / startDate > < endDate > 2024- 01- 31 < / endDate > < / period > < / context > < context id =" c163" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: DerivativeInstrumentRiskAxis" > us- gaap: StockOptionMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" us- gaap: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" > ntrb: ExercisePricesOneMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 01- 31 < / instant > < / period > < / context > < context id =" c164" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: DerivativeInstrumentRiskAxis" > us- gaap: StockOptionMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" us- gaap: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" > ntrb: ExercisePricesTwoMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2023- 02- 01 < / startDate > < endDate > 2024- 01- 31 < / endDate > < / period > < / context > < context id =" c165" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: DerivativeInstrumentRiskAxis" > us- gaap: StockOptionMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" us- gaap: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" > ntrb: ExercisePricesTwoMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 01- 31 < / instant > < / period > < / context > < context id =" c166" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: DerivativeInstrumentRiskAxis" > us- gaap: StockOptionMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" us- gaap: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" > ntrb: ExercisePricesThreeMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2023- 02- 01 < / startDate > < endDate > 2024- 01- 31 < / endDate > < / period > < / context > < context id =" c167" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: DerivativeInstrumentRiskAxis" > us- gaap: StockOptionMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" us- gaap: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" > ntrb: ExercisePricesThreeMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 01- 31 < / instant > < / period > < / context > < context id =" c168" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: DerivativeInstrumentRiskAxis" > us- gaap: StockOptionMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" us- gaap: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" > ntrb: ExercisePricesFourMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2023- 02- 01 < / startDate > < endDate > 2024- 01- 31 < / endDate > < / period > < / context > < context id =" c169" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: DerivativeInstrumentRiskAxis" > us- gaap: StockOptionMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" us- gaap: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" > ntrb: ExercisePricesFourMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 01- 31 < / instant > < / period > < / context > < context id =" c170" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: DerivativeInstrumentRiskAxis" > us- gaap: StockOptionMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" us- gaap: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" > ntrb: ExercisePricesFiveMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2023- 02- 01 < / startDate > < endDate > 2024- 01- 31 < / endDate > < / period > < / context > < context id =" c171" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: DerivativeInstrumentRiskAxis" > us- gaap: StockOptionMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" us- gaap: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" > ntrb: ExercisePricesFiveMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 01- 31 < / instant > < / period > < / context > < context id =" c172" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: DerivativeInstrumentRiskAxis" > us- gaap:

StockOptionMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" us- gaap: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" > ntrb: ExercisePricesSixMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2023- 02- 01 < / startDate > < endDate > 2024- 01- 31 < / endDate > < / period > < / context > < context id =" c173" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: DerivativeInstrumentRiskAxis" > us- gaap: StockOptionMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" us- gaap: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" > ntrb: ExercisePricesSixMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 01- 31 < / instant > < / period > < / context > < context id =" c174" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: DerivativeInstrumentRiskAxis" > us- gaap: StockOptionMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" us- gaap: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" > ntrb: ExercisePricesSevenMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2023- 02- 01 < / startDate > < endDate > 2024- 01- 31 < / endDate > < / period > < / context > < context id =" c175" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: DerivativeInstrumentRiskAxis" > us- gaap: StockOptionMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" us- gaap: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" > ntrb: ExercisePricesSevenMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 01- 31 < / instant > < / period > < / context > < context id =" c176" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: DerivativeInstrumentRiskAxis" > us- gaap: StockOptionMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" us- gaap: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" > ntrb: ExercisePricesEightMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2023- 02- 01 < / startDate > < endDate > 2024- 01- 31 < / endDate > < / period > < / context > < context id =" c177" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: DerivativeInstrumentRiskAxis" > us- gaap: StockOptionMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" us- gaap: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" > ntrb: ExercisePricesEightMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 01- 31 < / instant > < / period > < / context > < context id =" c178" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: DerivativeInstrumentRiskAxis" > us- gaap: StockOptionMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" us- gaap: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" > ntrb: ExercisePricesNineMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2023- 02- 01 < / startDate > < endDate > 2024- 01- 31 < / endDate > < / period > < / context > < context id =" c179" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: DerivativeInstrumentRiskAxis" > us- gaap: StockOptionMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" us- gaap: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" > ntrb: ExercisePricesNineMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 01- 31 < / instant > < / period > < / context > < context id =" c180" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: DerivativeInstrumentRiskAxis" > us- gaap: StockOptionMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" us- gaap: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" > ntrb: ExercisePricesTenMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2023- 02- 01 < / startDate > < endDate > 2024- 01- 31 < / endDate > < / period > < / context > < context id =" c181" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: DerivativeInstrumentRiskAxis" > us- gaap: StockOptionMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" us- gaap: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" > ntrb: ExercisePricesTenMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 01- 31 < / instant > < / period > < / context > < context id =" c182" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: DerivativeInstrumentRiskAxis" > us- gaap: StockOptionMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" us- gaap: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" > ntrb: ExercisePricesElevenMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2023- 02- 01 < / startDate > < endDate > 2024- 01- 31 < / endDate > < / period > < / context > < context id =" c183" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: DerivativeInstrumentRiskAxis" > us- gaap: StockOptionMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" us- gaap: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" > ntrb: ExercisePricesElevenMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 01- 31 < / instant > < / period > < / context > < context id =" c184" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: StatementBusinessSegmentsAxis" > ntrb: PoconoPharmaceuticalsMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2023- 02- 01 < / startDate > < endDate > 2024- 01- 31 < / endDate > < / period > < / context > < context id =" c185" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: StatementBusinessSegmentsAxis" > ntrb: PoconoPharmaceuticalsMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2022- 02- 01 < / startDate > < endDate > 2023- 01- 31 < / endDate > < / period > < / context > < context id =" c186" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: StatementBusinessSegmentsAxis" > ntrb: FourPTherapeuticsMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2023- 02- 01 < / startDate > < endDate > 2024- 01- 31 < / endDate > < / period > < / context > < context id =" c187" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: StatementBusinessSegmentsAxis" > ntrb: FourPTherapeuticsMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2022- 02- 01 < / startDate > < endDate > 2023- 01- 31 < / endDate > < / period > < / context > < context id =" c188" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: StatementBusinessSegmentsAxis" > us- gaap: CorporateAndOtherMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2023- 02- 01 < / startDate > < endDate > 2024- 01- 31 < / endDate > < / period > < / context > < context id =" c189" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: StatementBusinessSegmentsAxis" > us- gaap: CorporateAndOtherMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2022- 02- 01 < / startDate > < endDate > 2023- 01- 31 < / endDate > < / period > < / context > < context id =" c190" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: StatementBusinessSegmentsAxis" > ntrb: ResearchAndDevelopment4PTherapeuticsMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2023- 02- 01 < / startDate > < endDate > 2024- 01- 31 < / endDate > < / period > < / context > < context id =" c191" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: StatementBusinessSegmentsAxis" > ntrb: ResearchAndDevelopment4PTherapeuticsMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2022- 02- 01 < / startDate > < endDate > 2023- 01- 31 < / endDate > < / period > < / context > < context id =" c192" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: StatementBusinessSegmentsAxis" > ntrb: GoodwillImpairmentPoconoPharmaceuticalsMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2023- 02- 01 < / startDate > < endDate > 2024- 01- 31 < / endDate > < / period > < / context > < context id =" c193" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: StatementBusinessSegmentsAxis" > ntrb: GoodwillImpairmentPoconoPharmaceuticalsMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2022- 02- 01 < / startDate > < endDate > 2023- 01- 31 < / endDate > < / period > < / context > < context id =" c194" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" srt: StatementGeographicalAxis" > ntrb: OutsideTheUnitedStatesMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2023- 02- 01 < / startDate > < endDate > 2024- 01- 31 < / endDate > < / period > < / context > < context id =" c195" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" srt: StatementGeographicalAxis" > ntrb: OutsideTheUnitedStatesMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2022- 02- 01 < / startDate > < endDate > 2023- 01- 31 < / endDate > < / period > < / context > < context id =" c196" > < entity > < identifier

scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" srt: StatementGeographicalAxis" > country: US < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 01- 31 < / instant > < / period > < / context > < context id =" c197" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" srt: StatementGeographicalAxis" > country: US < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2023- 01- 31 < / instant > < / period > < / context > < context id =" c198" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" srt: StatementGeographicalAxis" > ntrb: OutsideTheUnitedStatesMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 01- 31 < / instant > < / period > < / context > < context id =" c199" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" srt: StatementGeographicalAxis" > ntrb: OutsideTheUnitedStatesMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2023- 01- 31 < / instant > < / period > < / context > < context id =" c200" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: StatementBusinessSegmentsAxis" > us- gaap: CorporateAndOtherMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 01- 31 < / instant > < / period > < / context > < context id =" c201" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: StatementBusinessSegmentsAxis" > us- gaap: CorporateAndOtherMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2023- 01- 31 < / instant > < / period > < / context > < context id =" c202" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: StatementBusinessSegmentsAxis" > ntrb: PoconoPharmaceuticalsMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 01- 31 < / instant > < / period > < / context > < context id =" c203" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: StatementBusinessSegmentsAxis" > ntrb: PoconoPharmaceuticalsMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2023- 01- 31 < / instant > < / period > < / context > < context id =" c204" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: StatementBusinessSegmentsAxis" > ntrb: FourPTherapeuticsMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 01- 31 < / instant > < / period > < / context > < context id =" c205" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: StatementBusinessSegmentsAxis" > ntrb: FourPTherapeuticsMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2023- 01- 31 < / instant > < / period > < / context > < context id =" c206" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: ShortTermDebtTypeAxis" > ntrb: AgreementMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2023- 02- 01 < / startDate > < endDate > 2024- 01- 31 < / endDate > < / period > < / context > < context id =" c207" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" srt: TitleOfIndividualAxis" > srt: ChiefExecutiveOfficerMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2023- 02- 01 < / startDate > < endDate > 2024- 01- 31 < / endDate > < / period > < / context > < context id =" c208" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < / entity > < period > < startDate > 2022- 07- 31 < / startDate > < endDate > 2022- 07- 31 < / endDate > < / period > < / context > < context id =" c209" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" srt: TitleOfIndividualAxis" > srt: ChiefFinancialOfficerMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2023- 02- 01 < / startDate > < endDate > 2024- 01- 31 < / endDate > < / period > < / context > < context id =" c210" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" srt: MajorCustomersAxis" > ntrb: MrGoodmanMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2022- 07- 31 < / startDate > < endDate > 2022- 07- 31 < / endDate > < / period > < / context > < context id =" c211" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < / entity > < period > < instant > 2022- 01- 01 < / instant > < / period > < / context > < context id =" c212" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < / entity > < period > < instant > 2022- 02- 01 < / instant > < / period > < / context > < context id =" c213" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: ShortTermDebtTypeAxis" > ntrb: AgreementMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2022- 02- 01 < / startDate > < endDate > 2022- 02- 01 < / endDate > < / period > < / context > < context id =" c214" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: RelatedPartyTransactionAxis" > ntrb: MDMWorldwideMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 01- 31 < / instant > < / period > < / context > < context id =" c215" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < / entity > < period > < instant > 2023- 03- 13 < / instant > < / period > < / context > < context id =" c216" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: RelatedPartyTransactionAxis" > ntrb: MoneyChannelMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2023- 03- 13 < / startDate > < endDate > 2023- 03- 13 < / endDate > < / period > < / context > < context id =" c217" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: ConcentrationRiskByBenchmarkAxis" > us- gaap: AccountsReceivableMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" us- gaap: RelatedPartyTransactionAxis" > ntrb: MoneyChannelMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 01- 31 < / instant > < / period > < / context > < context id =" c218" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < / entity > < period > < startDate > 2023- 07- 01 < / startDate > < endDate > 2023- 07- 25 < / endDate > < / period > < / context > < context id =" c219" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < / entity > < period > < instant > 2023- 07- 25 < / instant > < / period > < / context > < context id =" c220" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: DebtInstrumentAxis" > ntrb: MoneyChannelMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2023- 07- 25 < / instant > < / period > < / context > < context id =" c221" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: SubsequentEventTypeAxis" > us- gaap: SubsequentEventMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2024- 02- 01 < / startDate > < endDate > 2024- 04- 30 < / endDate > < / period > < / context > < context id =" c222" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: SubsequentEventTypeAxis" > us- gaap: SubsequentEventMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2024- 03- 20 < / startDate > < endDate > 2024- 03- 20 < / endDate > < / period > < / context > < context id =" c223" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" srt: RangeAxis" > srt: MinimumMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" us- gaap: StatementEquityComponentsAxis" > us- gaap: CommonStockMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" us- gaap: SubsequentEventTypeAxis" > us- gaap: SubsequentEventMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 03- 20 < / instant > < / period > < / context > < context id =" c224" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" srt: RangeAxis" > srt: MaximumMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" us- gaap: StatementEquityComponentsAxis" > us- gaap: CommonStockMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" us- gaap: SubsequentEventTypeAxis" > us- gaap: SubsequentEventMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 03- 20 < / instant > < / period > < / context > < context id =" c225" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: SubsequentEventTypeAxis" > us- gaap: SubsequentEventMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 03- 20 < / instant > < / period > < / context > < context id =" c226" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" srt: TitleOfIndividualAxis" > ntrb: BoardOfDirectorsMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" us- gaap: StatementEquityComponentsAxis" > us- gaap: CommonStockMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" us- gaap: SubsequentEventTypeAxis" > us- gaap: SubsequentEventMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 03- 20 < / instant > < / period > < / context > < context id =" c227" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: StatementEquityComponentsAxis" > us- gaap: CommonStockMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" us- gaap: SubsequentEventTypeAxis" > us- gaap: SubsequentEventMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 03- 20 < / instant > < / period > < / context > < context id =" c228" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: SubsequentEventTypeAxis" > us- gaap: SubsequentEventMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2024- 04- 19 < / startDate > < endDate > 2024- 04- 19 < / endDate > < / period > < /

context > < context id =" c229" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: SubsequentEventTypeAxis" > us- gaap: SubsequentEventMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" us- gaap: SubsidiarySaleOfStockAxis" > us- gaap: IPOMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 04- 19 < / instant > < / period > < / context > < context id =" c230" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: ClassOfWarrantOrRightAxis" > us- gaap: WarrantMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" us- gaap: SubsequentEventTypeAxis" > us- gaap: SubsequentEventMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 04- 19 < / instant > < / period > < / context > < context id =" c231" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: ClassOfWarrantOrRightAxis" > us- gaap: WarrantMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" us- gaap: SubsequentEventTypeAxis" > us- gaap: SubsequentEventMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2024- 04- 19 < / startDate > < endDate > 2024- 04- 19 < / endDate > < / period > < / context > < context id =" e232" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0001676047 < / identifier > < / entity > < period > < startDate > 2023- 11- 01 < / startDate > < endDate > 2024- 01- 31 < / endDate > < / period > < / context > < unit id =" usd" > < measure > iso4217: USD < / measure > < / unit > < unit id =" shares" > < measure > shares < / measure > < / unit > < unit id =" usdPershares" > < divide > < unitNumerator > < measure > iso4217: USD < / measure > < / unitNumerator > < unitDenominator > < measure > shares < / measure > < / unitDenominator > < / divide > < / unit > < unit id =" pure" > < measure > pure < / measure > < / unit > < dei: DocumentType contextRef =" c0" id =" ixv- 13784" > 10- K < / dei: DocumentType > < dei: DocumentAnnualReport contextRef =" c0" id =" ixv- 13785" > true < / dei: DocumentAnnualReport > < dei: DocumentPeriodEndDate contextRef =" c0" id =" ixv- 13786" > 2024- 01- 31 < / dei: DocumentPeriodEndDate > < dei: CurrentFiscalYearEndDate contextRef =" c0" id =" ixv- 13787" >-- 01- 31 < / dei: CurrentFiscalYearEndDate > < dei: DocumentFiscalYearFocus contextRef =" c0" id =" ixv- 13788" > 2024 < / dei: DocumentFiscalYearFocus > < dei: DocumentTransitionReport contextRef =" c0" id =" ixv- 13789" > false < / dei: DocumentTransitionReport > < dei: EntityFileNumber contextRef =" c0" id =" ixv- 13790" > 000- 55654 < / dei: EntityFileNumber > < dei: EntityRegistrantName contextRef =" c0" id =" ixv- 60" > NUTRIBAND INC. < / dei: EntityRegistrantName > < dei: EntityIncorporationStateCountryCode contextRef =" c0" id =" ixv- 13791" > NV < / dei: EntityIncorporationStateCountryCode > < dei: EntityTaxIdentificationNumber contextRef =" c0" id =" ixv- 74" > 81- 1118176 < / dei: EntityTaxIdentificationNumber > < dei: EntityAddressAddressLine1 contextRef =" c0" id =" ixv- 13792" > 121 South Orange Ave < / dei: EntityAddressAddressLine1 > < dei: EntityAddressAddressLine2 contextRef =" c0" id =" ixv- 13793" > Suite 1500 < / dei: EntityAddressAddressLine2 > < dei: EntityAddressCityOrTown contextRef =" c0" id =" ixv- 13794" > Orlando < / dei: EntityAddressCityOrTown > < dei: EntityAddressStateOrProvince contextRef =" c0" id =" ixv- 13795" > FL < / dei: EntityAddressStateOrProvince > < dei: EntityAddressPostalZipCode contextRef =" c0" id =" ixv- 95" > 32801 < / dei: EntityAddressPostalZipCode > < dei: CityAreaCode contextRef =" c0" id =" ixv- 13796" > (407) < / dei: CityAreaCode > < dei: LocalPhoneNumber contextRef =" c0" id =" ixv- 13797" > 377- 6695 < / dei: LocalPhoneNumber > < dei: Security12bTitle contextRef =" c1" id =" ixv- 13798" > Common Stock < / dei: Security12bTitle > < dei: TradingSymbol contextRef =" c1" id =" ixv- 13799" > NTRB < / dei: TradingSymbol > < dei: SecurityExchangeName contextRef =" c1" id =" ixv- 13800" > NASDAQ < / dei: SecurityExchangeName > < dei: Security12bTitle contextRef =" c2" id =" ixv- 139" > Warrants < / dei: Security12bTitle > < dei: TradingSymbol contextRef =" c2" id =" ixv- 143" > NTRBW < / dei: TradingSymbol > < dei: SecurityExchangeName contextRef =" c2" id =" ixv- 13801" > NASDAQ < / dei: SecurityExchangeName > < dei: EntityWellKnownSeasonedIssuer contextRef =" c0" id =" ixv- 13802" > No < / dei: EntityWellKnownSeasonedIssuer > < dei: EntityCurrentReportingStatus contextRef =" c0" id =" ixv- 13803" > Yes < / dei: EntityCurrentReportingStatus > < dei: EntityInteractiveDataCurrent contextRef =" c0" id =" ixv- 13804" > Yes < / dei: EntityInteractiveDataCurrent > < dei: EntityFilerCategory contextRef =" c0" id =" ixv- 13805" > Non- accelerated Filer < / dei: EntityFilerCategory > < dei: EntitySmallBusiness contextRef =" c0" id =" ixv- 198" > true < / dei: EntitySmallBusiness > < dei: EntityEmergingGrowthCompany contextRef =" c0" id =" ixv- 206" > true < / dei: EntityEmergingGrowthCompany > < dei: EntityExTransitionPeriod contextRef =" c0" id =" ixv- 13806" > true < / dei: EntityExTransitionPeriod > < dei: IcfrAuditorAttestationFlag contextRef =" c0" id =" ixv- 13807" > false < / dei: IcfrAuditorAttestationFlag > < dei: DocumentFinStmtErrorCorrectionFlag contextRef =" c0" id =" ixv- 13808" > false < / dei: DocumentFinStmtErrorCorrectionFlag > < dei: EntityShellCompany contextRef =" c0" id =" ixv- 13809" > false < / dei: EntityShellCompany > < dei: EntityPublicFloat contextRef =" c3" decimals =" 0" id =" ixv- 13810" unitRef =" usd" > 17131304 < / dei: EntityPublicFloat > < dei: EntityCommonStockSharesOutstanding contextRef =" c4" decimals =" INF" id =" ixv- 13811" unitRef =" shares" > 10969870 < / dei: EntityCommonStockSharesOutstanding > < dei: AuditorFirmId contextRef =" c0" id =" ixv- 13812" > 3627 < / dei: AuditorFirmId > < dei: AuditorName contextRef =" c0" id =" ixv- 13813" > Sadler, Gibb & amp; Associates, LLC < / dei: AuditorName > < dei: AuditorLocation contextRef =" c0" id =" ixv- 13814" > Draper, UT < / dei: AuditorLocation > < us- gaap: CashAndCashEquivalentsAtCarryingValue contextRef =" c5" decimals =" 0" id =" ixv- 13815" unitRef =" usd" > 492942 < / us- gaap: CashAndCashEquivalentsAtCarryingValue > < us- gaap: CashAndCashEquivalentsAtCarryingValue contextRef =" c6" decimals =" 0" id =" ixv- 13816" unitRef =" usd" > 1985440 < / us- gaap: CashAndCashEquivalentsAtCarryingValue > < us- gaap: AccountsReceivableNetCurrent contextRef =" c5" decimals =" 0" id =" ixv- 13817" unitRef =" usd" > 148649 < / us- gaap: AccountsReceivableNetCurrent > < us- gaap: AccountsReceivableNetCurrent contextRef =" c6" decimals =" 0" id =" ixv- 13818" unitRef =" usd" > 113045 < / us- gaap: AccountsReceivableNetCurrent > < us- gaap: InventoryNet contextRef =" c5" decimals =" 0" id =" ixv- 13819" unitRef =" usd" > 168605 < / us- gaap: InventoryNet > < us- gaap: InventoryNet contextRef =" c6" decimals =" 0" id =" ixv- 13820" unitRef =" usd" > 229335 < / us- gaap: InventoryNet > < us- gaap: PrepaidExpenseCurrent contextRef =" c5" decimals =" 0" id =" ixv- 13821" unitRef =" usd" > 211667 < / us- gaap: PrepaidExpenseCurrent > < us- gaap: PrepaidExpenseCurrent contextRef =" c6" decimals =" 0" id =" ixv- 13822" unitRef =" usd" > 365925 < / us- gaap: PrepaidExpenseCurrent > < us- gaap: AssetsCurrent contextRef =" c5" decimals =" 0" id =" ixv- 13823" unitRef =" usd" > 1021863 < / us- gaap: AssetsCurrent > < us- gaap: AssetsCurrent contextRef =" c6" decimals =" 0" id =" ixv- 13824" unitRef =" usd" > 2693745 < / us- gaap: AssetsCurrent > < us- gaap: PropertyPlantAndEquipmentNet contextRef =" c5" decimals =" 0" id =" ixv- 13825" unitRef =" usd" > 774924 < / us- gaap: PropertyPlantAndEquipmentNet > < us- gaap: PropertyPlantAndEquipmentNet contextRef =" c6" decimals =" 0" id =" ixv- 13826" unitRef =" usd" > 897735 < / us- gaap: PropertyPlantAndEquipmentNet > < us- gaap: Goodwill contextRef =" c5" decimals =" 0" id =" ixv- 13827" unitRef =" usd" > 5021713 < / us- gaap: Goodwill > < us- gaap: Goodwill contextRef =" c6" decimals =" 0" id =" ixv- 13828" unitRef =" usd" > 5021713 < / us- gaap: Goodwill > < us- gaap: OperatingLeaseRightOfUseAsset contextRef =" c5" decimals =" 0" id =" ixv- 13829" unitRef =" usd" > 31374 < / us- gaap: OperatingLeaseRightOfUseAsset > < us- gaap: OperatingLeaseRightOfUseAsset contextRef =" c6" decimals =" 0" id =" ixv- 13830" unitRef =" usd" > 62754 < / us- gaap: OperatingLeaseRightOfUseAsset > < us- gaap: IntangibleAssetsNetExcludingGoodwill contextRef =" c5" decimals =" 0" id =" ixv- 13831" unitRef =" usd" > 667280 < / us- gaap: IntangibleAssetsNetExcludingGoodwill > < us- gaap: IntangibleAssetsNetExcludingGoodwill contextRef =" c6" decimals =" 0" id =" ixv- 13832" unitRef =" usd" > 780430 < / us- gaap: IntangibleAssetsNetExcludingGoodwill > < us- gaap: Assets contextRef =" c5" decimals =" 0" id =" ixv- 13833" unitRef =" usd" > 7517154 < / us- gaap: Assets > < us- gaap: Assets contextRef =" c6" decimals =" 0" id =" ixv- 13834" unitRef =" usd" > 9456377 < / us- gaap: Assets > < us- gaap: AccountsPayableAndAccruedLiabilitiesCurrent contextRef =" c5" decimals =" 0" id =" ixv- 13835" unitRef =" usd" > 680132 < / us- gaap: AccountsPayableAndAccruedLiabilitiesCurrent > < us- gaap: AccountsPayableAndAccruedLiabilitiesCurrent contextRef =" c6" decimals =" 0" id =" ixv- 13836" unitRef =" usd" > 534679 < / us- gaap: AccountsPayableAndAccruedLiabilitiesCurrent > < us- gaap: DeferredRevenueCurrent contextRef =" c5" decimals =" 0" id =" ixv- 13837" unitRef =" usd" > 157502 < / us- gaap: DeferredRevenueCurrent > < us- gaap: DeferredRevenueCurrent contextRef =" c6" decimals =" 0" id =" ixv- 13838" unitRef =" usd" > 162903 < / us- gaap: DeferredRevenueCurrent > < us- gaap: OperatingLeaseLiabilityCurrent contextRef =" c5" decimals =" 0" id =" ixv- 13839" unitRef =" usd" > 34276 < / us- gaap: OperatingLeaseLiabilityCurrent > < us- gaap: OperatingLeaseLiabilityCurrent contextRef =" c6" decimals =" 0" id =" ixv- 13840" unitRef =" usd" > 31291 < / us- gaap: OperatingLeaseLiabilityCurrent > < us- gaap: NotesPayableCurrent contextRef =" c5" decimals =" 0" id =" ixv- 13841" unitRef =" usd" > 127183 < / us- gaap: NotesPayableCurrent > < us- gaap: NotesPayableCurrent contextRef =" c6" decimals =" 0" id =" ixv- 13842" unitRef =" usd" > 19740 < / us- gaap: NotesPayableCurrent > < us- gaap: LiabilitiesCurrent contextRef =" c5" decimals =" 0" id =" ixv- 13843" unitRef =" usd" > 999093 < / us- gaap: LiabilitiesCurrent > < us- gaap: LiabilitiesCurrent contextRef =" c6" decimals =" 0" id =" ixv- 13844" unitRef =" usd" > 748613 < / us- gaap: LiabilitiesCurrent > < us- gaap: LongTermNotesPayable contextRef =" c5" decimals =" 0" id =" ixv- 13845" unitRef =" usd" > 79826 < / us- gaap: LongTermNotesPayable > < us- gaap: LongTermNotesPayable contextRef =" c6" decimals =" 0" id =" ixv- 13846" unitRef =" usd" > 100497 < / us- gaap: LongTermNotesPayable > < us- gaap: OperatingLeaseLiabilityNoncurrent contextRef =" c6" decimals =" 0" id =" ixv- 13847" unitRef =" usd" > 34277 < / us- gaap: OperatingLeaseLiabilityNoncurrent > < us- gaap: LiabilitiesCurrent contextRef =" c5" decimals =" 0" id =" ixv- 13848" unitRef =" usd" > 1078919 < / us- gaap: Liabilities > < us- gaap: Liabilities contextRef =" c6" decimals =" 0" id =" ixv- 13849" unitRef =" usd" > 883387 < / us- gaap: Liabilities > < us- gaap: PreferredStockParOrStatedValuePerShare contextRef =" c5" decimals =" 3" id =" ixv- 13850" unitRef =" usdPershares" > 0. 001 < / us- gaap: PreferredStockParOrStatedValuePerShare > < us- gaap: PreferredStockParOrStatedValuePerShare contextRef =" c6" decimals =" 3" id =" ixv- 13851" unitRef =" usdPershares" > 0. 001 < / us- gaap: PreferredStockParOrStatedValuePerShare > < us- gaap: PreferredStockSharesAuthorized contextRef =" c5" decimals =" 0" id

=" ixv- 13852" unitRef =" shares" > 10000000 < / us- gaap: PreferredStockSharesAuthorized > < us- gaap: PreferredStockSharesAuthorized contextRef =" c6" decimals =" 0" id =" ixv- 13853" unitRef =" shares" > 10000000 < / us- gaap: PreferredStockSharesAuthorized > < us- gaap: PreferredStockSharesOutstanding contextRef =" c5" decimals =" 0" id =" ixv- 13854" unitRef =" shares" > 0 < / us- gaap: PreferredStockSharesOutstanding > < us- gaap: PreferredStockSharesOutstanding contextRef =" c6" decimals =" 0" id =" ixv- 13855" unitRef =" shares" > 0 < / us- gaap: PreferredStockSharesOutstanding > < us- gaap: CommonStockParOrStatedValuePerShare contextRef =" c5" decimals =" 3" id =" ixv- 13856" unitRef =" usdPershares" > 0. 001 < / us- gaap: CommonStockParOrStatedValuePerShare > < us- gaap: CommonStockParOrStatedValuePerShare contextRef =" c6" decimals =" 3" id =" ixv- 13857" unitRef =" usdPershares" > 0. 001 < / us- gaap: CommonStockParOrStatedValuePerShare > < us- gaap: CommonStockSharesAuthorized contextRef =" c5" decimals =" 0" id =" ixv- 13858" unitRef =" shares" > 291666666 < / us- gaap: CommonStockSharesAuthorized > < us- gaap: CommonStockSharesAuthorized contextRef =" c6" decimals =" 0" id =" ixv- 13859" unitRef =" shares" > 291666666 < / us- gaap: CommonStockSharesAuthorized > < us- gaap: CommonStockSharesIssued contextRef =" c5" decimals =" 0" id =" ixv- 13860" unitRef =" shares" > 8869870 < / us- gaap: CommonStockSharesIssued > < us- gaap: CommonStockSharesIssued contextRef =" c6" decimals =" 0" id =" ixv- 13861" unitRef =" shares" > 7843150 < / us- gaap: CommonStockSharesIssued > < us- gaap: CommonStockSharesOutstanding contextRef =" c5" decimals =" 0" id =" ixv- 13862" unitRef =" shares" > 8859870 < / us- gaap: CommonStockSharesOutstanding > < us- gaap: CommonStockSharesOutstanding contextRef =" c6" decimals =" 0" id =" ixv- 13863" unitRef =" shares" > 7833150 < / us- gaap: CommonStockSharesOutstanding > < us- gaap: CommonStockValue contextRef =" c5" decimals =" 0" id =" ixv- 13864" unitRef =" usd" > 8860 < / us- gaap: CommonStockValue > < us- gaap: CommonStockValue contextRef =" c6" decimals =" 0" id =" ixv- 13865" unitRef =" usd" > 7833 < / us- gaap: CommonStockValue > < us- gaap: AdditionalPaidInCapital contextRef =" c5" decimals =" 0" id =" ixv- 13866" unitRef =" usd" > 34442339 < / us- gaap: AdditionalPaidInCapital > < us- gaap: AdditionalPaidInCapital contextRef =" c6" decimals =" 0" id =" ixv- 13867" unitRef =" usd" > 31092807 < / us- gaap: AdditionalPaidInCapital > < us- gaap: AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef =" c5" decimals =" 0" id =" ixv- 13868" unitRef =" usd" > - 304 < / us- gaap: AccumulatedOtherComprehensiveIncomeLossNetOfTax > < us- gaap: AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef =" c6" decimals =" 0" id =" ixv- 13869" unitRef =" usd" > - 304 < / us- gaap: AccumulatedOtherComprehensiveIncomeLossNetOfTax > < us- gaap: TreasuryStockCommonShares contextRef =" c5" decimals =" 0" id =" ixv- 13870" unitRef =" shares" > 10000 < / us- gaap: TreasuryStockCommonShares > < us- gaap: TreasuryStockCommonShares contextRef =" c6" decimals =" 0" id =" ixv- 13871" unitRef =" shares" > 10000 < / us- gaap: TreasuryStockCommonShares > < us- gaap: TreasuryStockValue contextRef =" c5" decimals =" 0" id =" ixv- 13872" unitRef =" usd" > 32641 < / us- gaap: TreasuryStockValue > < us- gaap: TreasuryStockValue contextRef =" c6" decimals =" 0" id =" ixv- 13873" unitRef =" usd" > 32641 < / us- gaap: TreasuryStockValue > < us- gaap: RetainedEarningsAccumulatedDeficit contextRef =" c5" decimals =" 0" id =" ixv- 13874" unitRef =" usd" > - 27980019 < / us- gaap: RetainedEarningsAccumulatedDeficit > < us- gaap: RetainedEarningsAccumulatedDeficit contextRef =" c6" decimals =" 0" id =" ixv- 13875" unitRef =" usd" > - 22494705 < / us- gaap: RetainedEarningsAccumulatedDeficit > < us- gaap: StockholdersEquity contextRef =" c5" decimals =" 0" id =" ixv- 13876" unitRef =" usd" > 6438235 < / us- gaap: StockholdersEquity > < us- gaap: StockholdersEquity contextRef =" c6" decimals =" 0" id =" ixv- 13877" unitRef =" usd" > 8572990 < / us- gaap: StockholdersEquity > < us- gaap: LiabilitiesAndStockholdersEquity contextRef =" c5" decimals =" 0" id =" ixv- 13878" unitRef =" usd" > 7517154 < / us- gaap: LiabilitiesAndStockholdersEquity > < us- gaap: LiabilitiesAndStockholdersEquity contextRef =" c6" decimals =" 0" id =" ixv- 13879" unitRef =" usd" > 9456377 < / us- gaap: LiabilitiesAndStockholdersEquity > < us- gaap: Revenues contextRef =" c0" decimals =" 0" id =" ixv- 13880" unitRef =" usd" > 2085314 < / us- gaap: Revenues > < us- gaap: Revenues contextRef =" c9" decimals =" 0" id =" ixv- 13881" unitRef =" usd" > 2079609 < / us- gaap: Revenues > < us- gaap: CostOfRevenue contextRef =" c0" decimals =" 0" id =" ixv- 13882" unitRef =" usd" > 1223209 < / us- gaap: CostOfRevenue > < us- gaap: CostOfRevenue contextRef =" c9" decimals =" 0" id =" ixv- 13883" unitRef =" usd" > 1329200 < / us- gaap: CostOfRevenue > < us- gaap: ResearchAndDevelopmentExpense contextRef =" c0" decimals =" 0" id =" ixv- 13884" unitRef =" usd" > 1960425 < / us- gaap: ResearchAndDevelopmentExpense > < us- gaap: ResearchAndDevelopmentExpense contextRef =" c9" decimals =" 0" id =" ixv- 13885" unitRef =" usd" > 982227 < / us- gaap: ResearchAndDevelopmentExpense > < us- gaap: GoodwillImpairmentLoss contextRef =" c9" decimals =" 0" id =" ixv- 13886" unitRef =" usd" > 327326 < / us- gaap: GoodwillImpairmentLoss > < us- gaap: SellingGeneralAndAdministrativeExpense contextRef =" c0" decimals =" 0" id =" ixv- 13887" unitRef =" usd" > 3773606 < / us- gaap: SellingGeneralAndAdministrativeExpense > < us- gaap: SellingGeneralAndAdministrativeExpense contextRef =" c9" decimals =" 0" id =" ixv- 13888" unitRef =" usd" > 3916041 < / us- gaap: SellingGeneralAndAdministrativeExpense > < us- gaap: CostsAndExpenses contextRef =" c0" decimals =" 0" id =" ixv- 13889" unitRef =" usd" > 6957240 < / us- gaap: CostsAndExpenses > < us- gaap: CostsAndExpenses contextRef =" c9" decimals =" 0" id =" ixv- 13890" unitRef =" usd" > 6554794 < / us- gaap: CostsAndExpenses > < us- gaap: OperatingIncomeLoss contextRef =" c0" decimals =" 0" id =" ixv- 13891" unitRef =" usd" > - 4871926 < / us- gaap: OperatingIncomeLoss > < us- gaap: OperatingIncomeLoss contextRef =" c9" decimals =" 0" id =" ixv- 13892" unitRef =" usd" > - 4475185 < / us- gaap: OperatingIncomeLoss > < us- gaap: InterestIncomeOther contextRef =" c0" decimals =" 0" id =" ixv- 13893" unitRef =" usd" > 16850 < / us- gaap: InterestIncomeOther > < us- gaap: GainsLossesOnExtinguishmentOfDebt contextRef =" c0" decimals =" 0" id =" ixv- 13894" unitRef =" usd" > - 554423 < / us- gaap: GainsLossesOnExtinguishmentOfDebt > < us- gaap: InterestExpense contextRef =" c0" decimals =" 0" id =" ixv- 13895" unitRef =" usd" > 75815 < / us- gaap: InterestExpense > < us- gaap: InterestExpense contextRef =" c9" decimals =" 0" id =" ixv- 13896" unitRef =" usd" > 8289 < / us- gaap: InterestExpense > < us- gaap: OtherNonoperatingIncomeExpense contextRef =" c0" decimals =" 0" id =" ixv- 13897" unitRef =" usd" > - 613388 < / us- gaap: OtherNonoperatingIncomeExpense > < us- gaap: OtherNonoperatingIncomeExpense contextRef =" c9" decimals =" 0" id =" ixv- 13898" unitRef =" usd" > - 8289 < / us- gaap: OtherNonoperatingIncomeExpense > < us- gaap: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef =" c0" decimals =" 0" id =" ixv- 13899" unitRef =" usd" > - 5485314 < / us- gaap: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest > < us- gaap: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef =" c9" decimals =" 0" id =" ixv- 13900" unitRef =" usd" > - 4483474 < / us- gaap: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest > < us- gaap: NetIncomeLoss contextRef =" c0" decimals =" 0" id =" ixv- 13901" unitRef =" usd" > - 5485314 < / us- gaap: NetIncomeLoss > < us- gaap: NetIncomeLoss contextRef =" c9" decimals =" 0" id =" ixv- 13902" unitRef =" usd" > - 4483474 < / us- gaap: NetIncomeLoss > < us- gaap: EarningsPerShareBasic contextRef =" c0" decimals =" 2" id =" ixv- 13903" unitRef =" usdPershares" > - 0. 69 < / us- gaap: EarningsPerShareBasic > < us- gaap: EarningsPerShareBasic contextRef =" c9" decimals =" 2" id =" ixv- 13904" unitRef =" usdPershares" > - 0. 53 < / us- gaap: EarningsPerShareBasic > < us- gaap: WeightedAverageNumberOfSharesOutstandingBasic contextRef =" c0" decimals =" INF" id =" ixv- 13905" unitRef =" shares" > 7954105 < / us- gaap: WeightedAverageNumberOfSharesOutstandingBasic > < us- gaap: WeightedAverageNumberOfSharesOutstandingBasic contextRef =" c9" decimals =" INF" id =" ixv- 13906" unitRef =" shares" > 8459547 < / us- gaap: WeightedAverageNumberOfSharesOutstandingBasic > < us- gaap: StockholdersEquity contextRef =" c6" decimals =" 0" id =" ixv- 13907" unitRef =" usd" > 8572990 < / us- gaap: StockholdersEquity > < us- gaap: SharesOutstanding contextRef =" c10" decimals =" INF" id =" ixv- 13908" unitRef =" shares" > 7833150 < / us- gaap: SharesOutstanding > < us- gaap: StockholdersEquity contextRef =" c10" decimals =" 0" id =" ixv- 13909" unitRef =" usd" > 7833 < / us- gaap: StockholdersEquity > < us- gaap: StockholdersEquity contextRef =" c11" decimals =" 0" id =" ixv- 13910" unitRef =" usd" > 31092807 < / us- gaap: StockholdersEquity > < us- gaap: StockholdersEquity contextRef =" c12" decimals =" 0" id =" ixv- 13911" unitRef =" usd" > - 304 < / us- gaap: StockholdersEquity > < us- gaap: StockholdersEquity contextRef =" c13" decimals =" 0" id =" ixv- 13912" unitRef =" usd" > - 22494705 < / us- gaap: StockholdersEquity > < us- gaap: StockholdersEquity contextRef =" c14" decimals =" 0" id =" ixv- 13913" unitRef =" usd" > - 32641 < / us- gaap: StockholdersEquity > < us- gaap: AdjustmentOfWarrantsGrantedForServices contextRef =" c0" decimals =" 0" id =" ixv- 13914" unitRef =" usd" > 242840 < / us- gaap: AdjustmentOfWarrantsGrantedForServices > < us- gaap: AdjustmentOfWarrantsGrantedForServices contextRef =" c15" decimals =" 0" id =" ixv- 13915" unitRef =" usd" > 242840 < / us- gaap: AdjustmentOfWarrantsGrantedForServices > < us- gaap: AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef =" c0" decimals =" 0" id =" ixv- 13916" unitRef =" usd" > 499856 < / us- gaap: AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts > < us- gaap: AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef =" c15" decimals =" 0" id =" ixv- 13917" unitRef =" usd" > 499856 < / us- gaap: AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts > < ntrb: StockIssuedDuringPeriodValueNotePayableAndInterest contextRef =" c0" decimals =" 0" id =" ixv- 13918" unitRef =" usd" > 2607863 < / ntrb: StockIssuedDuringPeriodValueNotePayableAndInterest > < ntrb: StockIssuedDuringPeriodShareNotePayableAndInterestinShares contextRef =" c16" decimals =" INF" id =" ixv- 13919" unitRef =" shares" > 1026720 < / ntrb: StockIssuedDuringPeriodShareNotePayableAndInterestinShares > < ntrb: StockIssuedDuringPeriodValueNotePayableAndInterest contextRef =" c16" decimals =" 0" id =" ixv- 13920" unitRef =" usd" > 1027 < / ntrb: StockIssuedDuringPeriodValueNotePayableAndInterest > < ntrb: StockIssuedDuringPeriodValueNotePayableAndInterest contextRef =" c15" decimals =" 0" id =" ixv- 13921" unitRef =" usd" > 2606836 < / ntrb: StockIssuedDuringPeriodValueNotePayableAndInterest > < us- gaap: NetIncomeLoss contextRef =" c0" decimals =" 0" id =" ixv- 13922" unitRef =" usd" > - 5485314 < / us- gaap: NetIncomeLoss > < us- gaap: NetIncomeLoss contextRef =" c18" decimals =" 0" id =" ixv- 13923" unitRef =" usd" > - 5485314 < / us- gaap:

NetIncomeLoss><us-gaap:StockholdersEquity contextRef="c5" decimals="0" id="ixv-13924" unitRef="usd">6438235</us-gaap:StockholdersEquity><us-gaap:SharesOutstanding contextRef="c20" decimals="INF" id="ixv-13925" unitRef="shares">8859870</us-gaap:SharesOutstanding><us-gaap:StockholdersEquity contextRef="c20" decimals="0" id="ixv-13926" unitRef="usd">8860</us-gaap:StockholdersEquity><us-gaap:StockholdersEquity contextRef="c21" decimals="0" id="ixv-13927" unitRef="usd">34442339</us-gaap:StockholdersEquity><us-gaap:StockholdersEquity contextRef="c22" decimals="0" id="ixv-13928" unitRef="usd">-304</us-gaap:StockholdersEquity><us-gaap:StockholdersEquity contextRef="c23" decimals="0" id="ixv-13929" unitRef="usd">-27980019</us-gaap:StockholdersEquity><us-gaap:StockholdersEquity contextRef="c24" decimals="0" id="ixv-13930" unitRef="usd">-32641</us-gaap:StockholdersEquity><us-gaap:StockholdersEquity contextRef="c25" decimals="0" id="ixv-13931" unitRef="usd">11859285</us-gaap:StockholdersEquity><us-gaap:SharesOutstanding contextRef="c26" decimals="INF" id="ixv-13932" unitRef="shares">9154846</us-gaap:SharesOutstanding><us-gaap:StockholdersEquity contextRef="c26" decimals="0" id="ixv-13933" unitRef="usd">9155</us-gaap:StockholdersEquity><us-gaap:StockholdersEquity contextRef="c27" decimals="0" id="ixv-13934" unitRef="usd">29966132</us-gaap:StockholdersEquity><us-gaap:StockholdersEquity contextRef="c28" decimals="0" id="ixv-13935" unitRef="usd">-304</us-gaap:StockholdersEquity><us-gaap:StockholdersEquity contextRef="c29" decimals="0" id="ixv-13936" unitRef="usd">-18011231</us-gaap:StockholdersEquity><us-gaap:StockholdersEquity contextRef="c30" decimals="0" id="ixv-13937" unitRef="usd">-104467</us-gaap:StockholdersEquity><us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c9" decimals="0" id="ixv-13938" unitRef="usd">296875</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised><us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c31" decimals="INF" id="ixv-13939" unitRef="shares">55417</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised><us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c31" decimals="0" id="ixv-13940" unitRef="usd">56</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised><us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c32" decimals="0" id="ixv-13941" unitRef="usd">296819</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised><ntrb:CommonStockReturnedInSettlementinShares contextRef="c31" decimals="INF" id="ixv-13942" unitRef="shares">-1400000</ntrb:CommonStockReturnedInSettlementinShares><ntrb:StockIssuedDuringPeriodValueReturnedInSettlement contextRef="c31" decimals="0" id="ixv-13943" unitRef="usd">-1400</ntrb:StockIssuedDuringPeriodValueReturnedInSettlement><ntrb:StockIssuedDuringPeriodValueReturnedInSettlement contextRef="c32" decimals="0" id="ixv-13944" unitRef="usd">1400</ntrb:StockIssuedDuringPeriodValueReturnedInSettlement><ntrb:StockIssuedDuringPeriodValueTreasuryStockIssuedForServices contextRef="c9" decimals="0" id="ixv-13945" unitRef="usd">113155</ntrb:StockIssuedDuringPeriodValueTreasuryStockIssuedForServices><ntrb:StockIssuedDuringPeriodSharesTreasuryStockIssuedForServices contextRef="c31" decimals="INF" id="ixv-13946" unitRef="shares">33471</ntrb:StockIssuedDuringPeriodSharesTreasuryStockIssuedForServices><ntrb:StockIssuedDuringPeriodValueTreasuryStockIssuedForServices contextRef="c31" decimals="0" id="ixv-13947" unitRef="usd">32</ntrb:StockIssuedDuringPeriodValueTreasuryStockIssuedForServices><ntrb:StockIssuedDuringPeriodValueTreasuryStockIssuedForServices contextRef="c32" decimals="0" id="ixv-13948" unitRef="usd">3746</ntrb:StockIssuedDuringPeriodValueTreasuryStockIssuedForServices><ntrb:StockIssuedDuringPeriodValueTreasuryStockIssuedForServices contextRef="c35" decimals="0" id="ixv-13949" unitRef="usd">109377</ntrb:StockIssuedDuringPeriodValueTreasuryStockIssuedForServices><ntrb:StockIssuedDuringPeriodValueTreasuryStockAndWarrantsIssuedForTerminationAgreement contextRef="c9" decimals="0" id="ixv-13950" unitRef="usd">174025</ntrb:StockIssuedDuringPeriodValueTreasuryStockAndWarrantsIssuedForTerminationAgreement><ntrb:StockIssuedDuringPeriodShareTreasuryStockAndWarrantsIssuedForTerminationAgreement contextRef="c31" decimals="INF" id="ixv-13951" unitRef="shares">25000</ntrb:StockIssuedDuringPeriodShareTreasuryStockAndWarrantsIssuedForTerminationAgreement><ntrb:StockIssuedDuringPeriodValueTreasuryStockAndWarrantsIssuedForTerminationAgreement contextRef="c31" decimals="0" id="ixv-13952" unitRef="usd">25</ntrb:StockIssuedDuringPeriodValueTreasuryStockAndWarrantsIssuedForTerminationAgreement><ntrb:StockIssuedDuringPeriodValueTreasuryStockAndWarrantsIssuedForTerminationAgreement contextRef="c32" decimals="0" id="ixv-13953" unitRef="usd">92545</ntrb:StockIssuedDuringPeriodValueTreasuryStockAndWarrantsIssuedForTerminationAgreement><ntrb:StockIssuedDuringPeriodValueTreasuryStockAndWarrantsIssuedForTerminationAgreement contextRef="c35" decimals="0" id="ixv-13954" unitRef="usd">81455</ntrb:StockIssuedDuringPeriodValueTreasuryStockAndWarrantsIssuedForTerminationAgreement><ntrb:StockIssuedDuringPeriodValueTreasuryStockRepurchased contextRef="c9" decimals="0" id="ixv-13955" unitRef="usd">-119006</ntrb:StockIssuedDuringPeriodValueTreasuryStockRepurchased><ntrb:StockRepurchasedDuringPeriodSharesTreasuryStockRepurchased contextRef="c31" decimals="INF" id="ixv-13956" unitRef="shares">-35584</ntrb:StockRepurchasedDuringPeriodSharesTreasuryStockRepurchased><ntrb:StockIssuedDuringPeriodValueTreasuryStockRepurchased contextRef="c31" decimals="0" id="ixv-13957" unitRef="usd">-35</ntrb:StockIssuedDuringPeriodValueTreasuryStockRepurchased><ntrb:StockIssuedDuringPeriodValueTreasuryStockRepurchased contextRef="c32" decimals="0" id="ixv-13958" unitRef="usd">35</ntrb:StockIssuedDuringPeriodValueTreasuryStockRepurchased><ntrb:StockIssuedDuringPeriodValueTreasuryStockRepurchased contextRef="c35" decimals="0" id="ixv-13959" unitRef="usd">-119006</ntrb:StockIssuedDuringPeriodValueTreasuryStockRepurchased><us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="c9" decimals="0" id="ixv-13960" unitRef="usd">732130</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts><us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="c32" decimals="0" id="ixv-13961" unitRef="usd">732130</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts><us-gaap:NetIncomeLoss contextRef="c9" decimals="0" id="ixv-13962" unitRef="usd">-4483474</us-gaap:NetIncomeLoss><us-gaap:NetIncomeLoss contextRef="c34" decimals="0" id="ixv-13963" unitRef="usd">-4483474</us-gaap:NetIncomeLoss><us-gaap:StockholdersEquity contextRef="c6" decimals="0" id="ixv-13964" unitRef="usd">8572990</us-gaap:StockholdersEquity><us-gaap:SharesOutstanding contextRef="c10" decimals="INF" id="ixv-13965" unitRef="shares">7833150</us-gaap:SharesOutstanding><us-gaap:StockholdersEquity contextRef="c10" decimals="0" id="ixv-13966" unitRef="usd">7833</us-gaap:StockholdersEquity><us-gaap:StockholdersEquity contextRef="c11" decimals="0" id="ixv-13967" unitRef="usd">31092807</us-gaap:StockholdersEquity><us-gaap:StockholdersEquity contextRef="c12" decimals="0" id="ixv-13968" unitRef="usd">-304</us-gaap:StockholdersEquity><us-gaap:StockholdersEquity contextRef="c13" decimals="0" id="ixv-13969" unitRef="usd">-22494705</us-gaap:StockholdersEquity><us-gaap:StockholdersEquity contextRef="c14" decimals="0" id="ixv-13970" unitRef="usd">-32641</us-gaap:StockholdersEquity><us-gaap:NetIncomeLoss contextRef="c0" decimals="0" id="ixv-13971" unitRef="usd">-5485314</us-gaap:NetIncomeLoss><us-gaap:NetIncomeLoss contextRef="c9" decimals="0" id="ixv-13972" unitRef="usd">-4483474</us-gaap:NetIncomeLoss><us-gaap:DepreciationDepletionAndAmortization contextRef="c0" decimals="0" id="ixv-13973" unitRef="usd">287722</us-gaap:DepreciationDepletionAndAmortization><us-gaap:DepreciationDepletionAndAmortization contextRef="c9" decimals="0" id="ixv-13974" unitRef="usd">330143</us-gaap:DepreciationDepletionAndAmortization><us-gaap:OperatingLeaseExpense contextRef="c0" decimals="0" id="ixv-13975" unitRef="usd">31380</us-gaap:OperatingLeaseExpense><us-gaap:OperatingLeaseExpense contextRef="c9" decimals="0" id="ixv-13976" unitRef="usd">38813</us-gaap:OperatingLeaseExpense><us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c0" decimals="0" id="ixv-13977" unitRef="usd">-554423</us-gaap:GainsLossesOnExtinguishmentOfDebt><us-gaap:ProvisionForDoubtfulAccounts contextRef="c0" decimals="0" id="ixv-13978" unitRef="usd">118365</us-gaap:ProvisionForDoubtfulAccounts><us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="c9" decimals="0" id="ixv-13979" unitRef="usd">113155</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims><ntrb:TreasuryStockIssuedForTerminationAgreement contextRef="c9" decimals="0" id="ixv-13980" unitRef="usd">174025</ntrb:TreasuryStockIssuedForTerminationAgreement><us-gaap:GoodwillImpairmentLoss contextRef="c9" decimals="0" id="ixv-13981" unitRef="usd">327326</us-gaap:GoodwillImpairmentLoss><ntrb:StockbasedCompensationwarrants contextRef="c0" decimals="0" id="ixv-13982" unitRef="usd">242840</ntrb:StockbasedCompensationwarrants><us-gaap:ShareBasedCompensation contextRef="c0" decimals="0" id="ixv-13983" unitRef="usd">499856</us-gaap:ShareBasedCompensation><us-gaap:ShareBasedCompensation contextRef="c9" decimals="0" id="ixv-13984" unitRef="usd">732130</us-gaap:ShareBasedCompensation><us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c0" decimals="0" id="ixv-13985" unitRef="usd">153969</us-gaap:IncreaseDecreaseInAccountsReceivable><us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c9" decimals="0" id="ixv-13986" unitRef="usd">41665</us-gaap:IncreaseDecreaseInAccountsReceivable><us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="c0" decimals="0" id="ixv-13987" unitRef="usd">-154258</us-gaap:IncreaseDecreaseInPrepaidExpense><us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="c9" decimals

=" 0" id =" ixv- 13988" unitRef =" usd" >- 4547 < / us- gaap: IncreaseDecreaseInPrepaidExpense > < us- gaap: IncreaseDecreaseInInventories contextRef =" c0" decimals =" 0" id =" ixv- 13989" unitRef =" usd" >- 60730 < / us- gaap: IncreaseDecreaseInInventories > < us- gaap: IncreaseDecreaseInInventories contextRef =" c9" decimals =" 0" id =" ixv- 13990" unitRef =" usd" > 97687 < / us- gaap: IncreaseDecreaseInInventories > < us- gaap: IncreaseDecreaseInDeferredRevenue contextRef =" c0" decimals =" 0" id =" ixv- 13991" unitRef =" usd" >- 5401 < / us- gaap: IncreaseDecreaseInDeferredRevenue > < us- gaap: IncreaseDecreaseInDeferredRevenue contextRef =" c9" decimals =" 0" id =" ixv- 13992" unitRef =" usd" > 56636 < / us- gaap: IncreaseDecreaseInDeferredRevenue > < us- gaap: IncreaseDecreaseInOperatingLeaseLiability contextRef =" c0" decimals =" 0" id =" ixv- 13993" unitRef =" usd" >- 31292 < / us- gaap: IncreaseDecreaseInOperatingLeaseLiability > < us- gaap: IncreaseDecreaseInOperatingLeaseLiability contextRef =" c9" decimals =" 0" id =" ixv- 13994" unitRef =" usd" >- 36287 < / us- gaap: IncreaseDecreaseInOperatingLeaseLiability > < us- gaap: IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef =" c0" decimals =" 0" id =" ixv- 13995" unitRef =" usd" > 198893 < / us- gaap: IncreaseDecreaseInAccountsPayableAndAccruedLiabilities > < us- gaap: IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef =" c9" decimals =" 0" id =" ixv- 13996" unitRef =" usd" >- 104860 < / us- gaap: IncreaseDecreaseInAccountsPayableAndAccruedLiabilities > < us- gaap: NetCashProvidedByUsedInOperatingActivities contextRef =" c0" decimals =" 0" id =" ixv- 13997" unitRef =" usd" >- 3527509 < / us- gaap: NetCashProvidedByUsedInOperatingActivities > < us- gaap: NetCashProvidedByUsedInOperatingActivities contextRef =" c9" decimals =" 0" id =" ixv- 13998" unitRef =" usd" >- 2987198 < / us- gaap: NetCashProvidedByUsedInOperatingActivities > < us- gaap: PaymentsToAcquirePropertyPlantAndEquipment contextRef =" c0" decimals =" 0" id =" ixv- 13999" unitRef =" usd" > 51761 < / us- gaap: PaymentsToAcquirePropertyPlantAndEquipment > < us- gaap: PaymentsToAcquirePropertyPlantAndEquipment contextRef =" c9" decimals =" 0" id =" ixv- 14000" unitRef =" usd" > 79304 < / us- gaap: PaymentsToAcquirePropertyPlantAndEquipment > < us- gaap: NetCashProvidedByUsedInInvestingActivities contextRef =" c0" decimals =" 0" id =" ixv- 14001" unitRef =" usd" >- 51761 < / us- gaap: NetCashProvidedByUsedInInvestingActivities > < us- gaap: NetCashProvidedByUsedInInvestingActivities contextRef =" c9" decimals =" 0" id =" ixv- 14002" unitRef =" usd" >- 79304 < / us- gaap: NetCashProvidedByUsedInInvestingActivities > < us- gaap: ProceedsFromRelatedPartyDebt contextRef =" c0" decimals =" 0" id =" ixv- 14003" unitRef =" usd" > 2000000 < / us- gaap: ProceedsFromRelatedPartyDebt > < us- gaap: ProceedsFromIssuanceOfDebt contextRef =" c0" decimals =" 0" id =" ixv- 14004" unitRef =" usd" > 106528 < / us- gaap: ProceedsFromIssuanceOfDebt > < us- gaap: ProceedsFromWarrantExercises contextRef =" c9" decimals =" 0" id =" ixv- 14005" unitRef =" usd" > 296875 < / us- gaap: ProceedsFromWarrantExercises > < us- gaap: RepaymentsOfNotesPayable contextRef =" c0" decimals =" 0" id =" ixv- 14006" unitRef =" usd" > 19756 < / us- gaap: RepaymentsOfNotesPayable > < us- gaap: RepaymentsOfNotesPayable contextRef =" c9" decimals =" 0" id =" ixv- 14007" unitRef =" usd" > 17795 < / us- gaap: RepaymentsOfNotesPayable > < ntrb: PurchaseOfTreasuryStock contextRef =" c9" decimals =" 0" id =" ixv- 14008" unitRef =" usd" >- 119006 < / ntrb: PurchaseOfTreasuryStock > < us- gaap: NetCashProvidedByUsedInFinancingActivities contextRef =" c0" decimals =" 0" id =" ixv- 14009" unitRef =" usd" > 2086772 < / us- gaap: NetCashProvidedByUsedInFinancingActivities > < us- gaap: NetCashProvidedByUsedInFinancingActivities contextRef =" c9" decimals =" 0" id =" ixv- 14010" unitRef =" usd" > 160074 < / us- gaap: NetCashProvidedByUsedInFinancingActivities > < us- gaap: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef =" c0" decimals =" 0" id =" ixv- 14011" unitRef =" usd" >- 1492498 < / us- gaap: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect > < us- gaap: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef =" c9" decimals =" 0" id =" ixv- 14012" unitRef =" usd" >- 2906428 < / us- gaap: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect > < us- gaap: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef =" c6" decimals =" 0" id =" ixv- 14013" unitRef =" usd" > 1985440 < / us- gaap: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents > < us- gaap: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef =" e25" decimals =" 0" id =" ixv- 14014" unitRef =" usd" > 4891868 < / us- gaap: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents > < us- gaap: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef =" c5" decimals =" 0" id =" ixv- 14015" unitRef =" usd" > 492942 < / us- gaap: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents > < us- gaap: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef =" c6" decimals =" 0" id =" ixv- 14016" unitRef =" usd" > 1985440 < / us- gaap: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents > < us- gaap: InterestPaidNet contextRef =" c0" decimals =" 0" id =" ixv- 14017" unitRef =" usd" > 7352 < / us- gaap: InterestPaidNet > < us- gaap: InterestPaidNet contextRef =" c9" decimals =" 0" id =" ixv- 14018" unitRef =" usd" > 4266 < / us- gaap: InterestPaidNet > < ntrb: AdoptionofOperatingLeaseAssetandLiability contextRef =" c9" decimals =" 0" id =" ixv- 14019" unitRef =" usd" > 94134 < / ntrb: AdoptionofOperatingLeaseAssetandLiability > < ntrb: PromissoryNoteOnEquipmentPurchase contextRef =" c9" decimals =" 0" id =" ixv- 14020" unitRef =" usd" > 22794 < / ntrb: PromissoryNoteOnEquipmentPurchase > < us- gaap: ConversionOfStockAmountIssued1 contextRef =" c9" decimals =" 0" id =" ixv- 14021" unitRef =" usd" > 1400 < / us- gaap: ConversionOfStockAmountIssued1 > < us- gaap: DebtConversionConvertedInstrumentAmount1 contextRef =" c0" decimals =" 0" id =" ixv- 14022" unitRef =" usd" > 2607863 < / us- gaap: DebtConversionConvertedInstrumentAmount1 > < us- gaap: OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef =" c0" id =" ixv- 6347" > & lt; table cellpadding =" 0" cellspacing =" 0" style =" font: 10pt Times New Roman, Times, Serif; margin- top: 0pt; margin- bottom: 0pt; width: 100 %" & gt; & lt; tr style =" vertical- align: top; text- align: justify" & gt; & lt; td style =" width: 0. 5in; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif; font- size: 10pt" & gt; 1. & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: justify" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif; font- size: 10pt" & gt; ORGANIZATION AND DESCRIPTION OF BUSINESS & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; / table & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; background- color: white" & gt; & # 160; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background- color: white; text- indent: 0. 5in" & gt; & lt; i & gt; & lt; span style =" text- decoration: underline" & gt; Organization & lt; / span & gt; & lt; / i & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; background- color: white" & gt; & # 160; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; Nutriband Inc. (the & # x201c; Company & # x201d;) is a Nevada corporation, incorporated on January 4, 2016. In January 2016, the Company acquired Nutriband Ltd, an Irish company which was formed by the Company & # x2019; s chief executive officer in 2012 to enter the health and wellness market by marketing transdermal patches. References to the Company relate to the Company and its subsidiaries unless the context indicates otherwise. & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; & # 160; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; On August 1, 2018, the Company acquired 4P Therapeutics LLC (& # x201c; 4P Therapeutics & # x201d;) for $ 2, 250, 000, consisting of 250, 000 shares of common stock, valued at $ 1, 850, 000, and $ 400, 000, and a royalty of 6 % on all revenue generated by the Company from the abuse deterrent intellectual property that had been developed by 4P Therapeutics payable to the former owner of 4P Therapeutics. The former owner of 4P Therapeutics has been a director of the Company since April 2018, when the Company entered into an agreement to acquire 4P Therapeutics. The former owner resigned as a director in January 2022. & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; & # 160; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; 4P Therapeutics is engaged in the development of a series of transdermal pharmaceutical products, that are in the preclinical stage of development. Prior to the acquisition of 4P Therapeutics, the Company & # x2019; s business was the development and marketing of a range of transdermal consumer patches. Most of these products are considered drugs in the United States and cannot be marketed in the United States without approval by the Food and Drug Administration (the & # x201c; FDA & # x201d;). The Company entered a feasibility agreement as an initial step to seek FDA approval of its consumer transdermal products and its consumer products which are not being marketed in the United States. & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; & # 160; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; With the acquisition of 4P Therapeutics, 4P Therapeutics & # x2019; drug development business became the Company & # x2019; s principal business. The Company & # x2019; s approach is to use generic drugs that are off patent and incorporate them into the Company & # x2019; s transdermal drug delivery system. Although these medications have received FDA approval in oral or injectable form, the Company needs to conduct a transdermal product development program which will include the preclinical and clinical trials that are necessary to receive FDA approval before we can market any of our pharmaceutical products. & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; & # 160; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; On August 25, 2020, the Company formed Pocono Pharmaceuticals Inc. (& # x201c; Pocono Pharmaceuticals & # x201d;), a wholly owned subsidiary of the Company. On August 31, 2020, the Company acquired

certain assets and liabilities associated with the Transdermal, Topical, Cosmetic, and Nutraceutical business of Pocono Coated Products LLC (& # x201c; PCP & # x201d;). The net assets were contributed to Pocono Pharmaceuticals. Included in the transaction, Pocono Pharmaceuticals also acquired 100 % of the membership interests of Active Intelligence LLC (& # x201c; Active Intelligence & # x201d;). & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; & # 160; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; Pocono Pharmaceuticals is a contract development and manufacturing organization with unique process capabilities and experience focused on coated product manufacturing. Pocono helps their customers with product design and development along with manufacturing to bring new products to market with minimal capital investment. Pocono Pharmaceutical & # x2019; s competitive edge is a low- cost manufacturing base: a result of its unique processes and state- of- the- art material technology. Active Intelligence manufactures activated kinesiology tape for transdermal or topical use. & lt; / p & gt; < / us- gaap: OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock > < us- gaap: BusinessAcquisitionCostOfAcquiredEntityTransactionCosts contextRef =" c36" decimals =" 0" id =" ixv- 14023" unitRef =" usd" > 2250000 < / us- gaap: BusinessAcquisitionCostOfAcquiredEntityTransactionCosts > < us- gaap: CommonStockSharesIssued contextRef =" c36" decimals =" 0" id =" ixv- 14024" unitRef =" shares" > 250000 < / us- gaap: CommonStockSharesIssued > < us- gaap: CommonStockValue contextRef =" c37" decimals =" 0" id =" ixv- 14025" unitRef =" usd" > 1850000 < / us- gaap: CommonStockValue > < us- gaap: CommonStockValue contextRef =" e38" decimals =" 0" id =" ixv- 14026" unitRef =" usd" > 400000 < / us- gaap: CommonStockValue > < ntrb: RoyaltyPercentage contextRef =" c36" decimals =" 2" id =" ixv- 14027" unitRef =" pure" > 0. 06 < / ntrb: RoyaltyPercentage > < us- gaap: BusinessAcquisitionPercentageOfVotingInterestsAcquired contextRef =" e39" decimals =" 2" id =" ixv- 14028" unitRef =" pure" > 1 < / us- gaap: BusinessAcquisitionPercentageOfVotingInterestsAcquired > < us- gaap: SignificantAccountingPoliciesTextBlock contextRef =" c0" id =" ixv- 6385" > & lt; table cellpadding =" 0" cellspacing =" 0" style =" font: 10pt Times New Roman, Times, Serif; margin- top: 0pt; margin- bottom: 0pt; width: 100 %" & gt; & lt; tr style =" vertical- align: top; text- align: justify" & gt; & lt; td style =" width: 0 %" & gt; & lt; / td & gt; & lt; td style =" width: 0. 5in; text- align: left" & gt; 2. & lt; / td & gt; & lt; td style =" text- align: justify" & gt; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES & lt; / td & gt; & lt; / tr & gt; & lt; / table & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; & # 160; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; & lt; i & gt; & lt; span style =" text- decoration: underline" & gt; Forward Stock Split & lt; / span & gt; & lt; / i & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; & # 160; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; On July 26, 2022, our Board of Directors approved the amendment to our Articles of Incorporation to effect a 7- for- 6 forward stock split (the & # x201c; Stock Split & # x201d;) of our outstanding common stock. The Company filed the amendment set forth in a Certificate of Change with the Secretary of State of Nevada on August 4, 2022. The 7: 6 forward stock split was effective for trading purposes on the Nasdaq Capital Market on August 12, 2022. Each shareholder of record as of the August 15, 2022 record date received one (1) additional share for each six (6) shares held as of the record date. No fractional shares of common stock were issued in connection with the Stock Split. Instead, all shares were rounded up to the next whole share. In connection with the Stock Split, which did not require shareholder approval under the Nevada corporation law, the number of shares of common stock of the Company was increased in the same ratio as the shares of outstanding common stock were increased in the Stock Split, from 250, 000, 000 authorized shares to 291, 666, 666 authorized shares. & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; & # 160; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; All share and per share information in these financial statements retroactively reflect the forward stock split. & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; & # 160; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; & lt; i & gt; & lt; span style =" text- decoration: underline" & gt; Going Concern Assessment & lt; / span & gt; & lt; / i & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; & lt; i & gt; & # 160; & lt; / i & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; Management assesses liquidity and going concern uncertainty in the Company & # x2019; s condensed financial statements to determine whether there is sufficient cash on hand and working capital, including available borrowings on loans, to operate for a period of at least one year from the date the consolidated financial statements are issued or available to be issued, which is referred to as the & # x201c; look- forward period & # x201d;, as defined in GAAP. As part of this assessment, based on conditions that are known and reasonably knowable to management, management will consider various scenarios, forecasts, projections, estimates and will make certain key assumptions, including timing and nature of projected cash expenditures or programs, its ability to delay or curtail expenditures or programs and its ability to raise additional capital, if necessary, among other factors. Based on this assessment, as necessary or applicable, management makes certain assumptions around implementing curtailments or delays in the nature and timing of programs and expenditures to the extent it deems probable those implementations can be achieved and management has the proper authority to execute them within the look- forward period. & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; & # 160; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; As of January 31, 2024, the Company had cash and cash equivalents of $ 492, 942 and working capital of $ 22, 770. For the year ended January 31, 2024, the Company incurred a loss from operations of $ 4, 871, 926 and used cash flow from operations of $ 3, 527, 509. The Company has generated operating losses since its inception and has relied on sales of securities and issuance of third- party and related- party debt to support cash flow from operations. In October 2021, the Company consummated a public offering and received net proceeds of $ 5, 836, 230. The Company has also received to date $ 3, 239, 845 in proceeds from the exercise of warrants. The Company has used these proceeds to fund operations and will continue to use the funds as needed. In March 2023, the Company entered into a three- year $ 2, 000, 000 Credit Line Note facility with a related party, amended on July 13, 2023, to $ 5, 000, 000, which will permit the Company to draw down on the credit line to fund the Company & # x2019; s research and development of its Aversa product. The Company was advanced $ 2, 000, 000, all of which was settled by the issuance of common stock during the year ended January 31, 2024. The $ 2, 000, 000 debt and accrued interest was converted into 1, 026, 720 shares of the Company & # x2019; s common stock. On April 19, 2024, the Company received proceeds of $ 8, 400, 000 from a private placement of its common stock. & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; & # 160; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; Management has prepared estimates of operations for the next twelve months and believes that sufficient funds will be generated from operations to fund its operations for one year from the date of the filing of these condensed consolidated financial statements, which indicates improved operations and the Company & # x2019; s ability to continue operations as a going concern. & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; & # 160; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; Management believes the substantial doubt about the ability of the Company to continue as a going concern is alleviated by the above assessment. & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; & # 160; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; & lt; i & gt; & lt; span style =" text- decoration: underline" & gt; Principles of Consolidation & lt; / span & gt; & lt; / i & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; & lt; i & gt; & # 160; & lt; / i & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; The consolidated financial statements of the Company include the Company and its wholly owned subsidiaries. All material intercompany balances and transactions have been eliminated. The operations of 4P Therapeutics are included in the Company & # x2019; s financial statements from the date of acquisition of August 1, 2018, and the operations of Pocono and Active Intelligence are included in the Company & # x2019; s financial statements from the date of acquisition of September 1, 2020 under Pocono Pharmaceuticals Inc. The wholly owned subsidiaries are as follows: & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; & # 160; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0. 5in; text- align: justify; background- color: white; text- indent: 1in" & gt; Nutriband Ltd. & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0. 5in; text- align: justify; background- color: white; text- indent: 1in" & gt; 4P Therapeutics LLC & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0. 5in; text- align: justify; background- color: white; text- indent: 1in" & gt; Pocono Pharmaceuticals Inc. & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white; text- indent: 1. 5in" & gt; & # 160; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; & lt; i & gt; & lt; span style =" text- decoration: underline" & gt; Use of Estimates & lt; / span & gt; & lt; / i & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align:

justify; background- color: white" & gt; & lt; i & gt; & # 160; & lt; / i & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires the Company to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an ongoing basis, the Company evaluates its estimates including, but not limited to, those related to such items as income tax exposures, accruals, depreciable / useful lives, allowance for doubtful accounts and valuation allowances. The Company bases its estimates on historical experience and on other various assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates. & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; & # 160; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; & lt; i & gt; & lt; span style =" text- decoration: underline" & gt; Revenue Recognition & lt; / span & gt; & lt; / i & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; & # 160; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; In May 2014, the FASB issued ASU No. 2014- 09, & # x201c; Revenue from Contracts with Customers (Topic 606) (& # x201c; ASU 2014- 09 & # x201d;), which amends the accounting standards for revenue recognition. ASU 2014- 09 is based on principles that govern the recognition of revenue at an amount an entity expects to be entitled when products are transferred to a customer. The Company recognizes revenue based on the five criteria for revenue recognition established under Topic 606: 1) identify the contract, 2) identify separate performance obligations, 3) determine the transaction price, 4) allocate the transaction price among the performance obligations, and 5) recognize revenue as the performance obligations are satisfied. & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; & # 160; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; background- color: white; text- indent: 0. 5in" & gt; & lt; i & gt; & lt; span style =" text- decoration: underline" & gt; Revenue Types - **Type** & lt; / span & gt; & lt; / i & gt; & lt; / p & gt; & lt; p style =" font - **na** 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; background- color: white; text- indent: 0. 5in" & gt; & # 160; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif; font- size: 10pt" & gt; The following is a description of the Company & # x2019; s revenue types, which include professional services and sale of goods: & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif; font- size: 10pt" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; table cellpadding =" 0" cellspacing =" 0" style =" font: 10pt Times New Roman, Times, Serif; margin- top: 0pt; margin- bottom: 0pt; width: 100 %" & gt; & lt; tr style =" font: 10pt Times New Roman, Times, Serif; vertical- align: top" & gt; & lt; td style =" font: 10pt Times New Roman, Times, Serif; width: 0. 5in" & gt; & lt; / td & gt; & lt; td style =" font: 10pt Times New Roman, Times, Serif; width: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif; font- size: 10pt" & gt; & # x25cf; & lt; / span & gt; & lt; / td & gt; & lt; td style =" font: 10pt Times New Roman, Times, Serif; text- align: justify" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif; font- size: 10pt" & gt; Contract development and manufacturing services for consumer health transdermal, topical and tape products with revenues listed under sale of goods & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; / table & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text- align: justify; text- indent: - 0. 25in; background- color: white" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif; font- size: 10pt" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; table cellpadding =" 0" cellspacing =" 0" style =" font: 10pt Times New Roman, Times, Serif; margin- top: 0pt; margin- bottom: 0pt; width: 100 %" & gt; & lt; tr style =" font: 10pt Times New Roman, Times, Serif; vertical- align: top" & gt; & lt; td style =" font: 10pt Times New Roman, Times, Serif; width: 0. 5in" & gt; & lt; / td & gt; & lt; td style =" font: 10pt Times New Roman, Times, Serif; width: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif; font- size: 10pt" & gt; & # x25cf; & lt; / span & gt; & lt; / td & gt; & lt; td style =" font: 10pt Times New Roman, Times, Serif; text- align: justify" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif; font- size: 10pt" & gt; Product revenues derived from the sale of the Company & # x2019; s consumer transdermal, topical and tape products with sales listed under sale of goods & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; / table & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text- align: justify; text- indent: - 0. 25in; background- color: white" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif; font- size: 10pt" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; table cellpadding =" 0" cellspacing =" 0" style =" font: 10pt Times New Roman, Times, Serif; margin- top: 0pt; margin- bottom: 0pt; width: 100 %" & gt; & lt; tr style =" font: 10pt Times New Roman, Times, Serif; vertical- align: top" & gt; & lt; td style =" font: 10pt Times New Roman, Times, Serif; width: 0. 5in" & gt; & lt; / td & gt; & lt; td style =" font: 10pt Times New Roman, Times, Serif; width: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif; font- size: 10pt" & gt; & # x25cf; & lt; / span & gt; & lt; / td & gt; & lt; td style =" font: 10pt Times New Roman, Times, Serif; text- align: justify" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif; font- size: 10pt" & gt; Contract research and development services for pharmaceuticals and medical devices for life sciences customers with revenues listed under services & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; / table & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif; font- size: 10pt" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- indent: 0. 5in" & gt; & lt; i & gt; & lt; span style =" text- decoration: underline" & gt; Contracts with Customers & lt; / span & gt; & lt; / i & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in" & gt; & # 160; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify" & gt; A contract with a customer exists when (i) we enter into an enforceable contract with a customer that defines each party & # x2019; s rights regarding the goods or services to be transferred and identifies the payment terms related to these goods or services, (ii) the contract has commercial substance and, (iii) we determine that collection of substantially all consideration for services that are transferred is probable based on the customer & # x2019; s intent and ability to pay the promised consideration. & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify" & gt; & # 160; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- indent: 0. 5in" & gt; & lt; i & gt; & lt; span style =" text- decoration: underline" & gt; Contract Liabilities & lt; / span & gt; & lt; / i & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- indent: 2. 25pt" & gt; & # 160; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify" & gt; Deferred revenue is a liability related to a revenue producing activity for which revenue has not been recognized. The Company records deferred revenue when it receives consideration from a contract before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 75in; text- align: justify; background- color: white" & gt; & lt; i & gt; & # 160; & lt; / i & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- indent: 0. 5in" & gt; & lt; i & gt; & lt; span style =" text- decoration: underline" & gt; Performance Obligations & lt; / span & gt; & lt; / i & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text- align: justify; background- color: white" & gt; & # 160; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify" & gt; A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in the new revenue standard. The contract transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. For the Company & # x2019; s different revenue service types, the performance obligation is satisfied at different times. The Company & # x2019; s performance obligations include providing products and professional services in the area of research. The Company recognizes product revenue performance obligations in most cases when the product has shipped to the customer. When we perform professional service work, we recognize revenue when we have the right to invoice the customer for the work completed, which typically occurs over time on a monthly basis for the work performed during that month. & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text- align: justify; background- color: white" & gt; & # 160; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; All revenue recognized in the income statement is considered to be revenue from contracts with customers. & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 75in; text- align: justify; background- color: white" & gt; & # 160; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- indent: 0. 5in" & gt; & lt; i & gt; & lt; span style =" text- decoration: underline" & gt; Disaggregation of Revenues & lt; / span & gt; & lt; / i & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in" & gt; & # 160; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; The Company disaggregates its revenue from contracts with customers by type and by geographical location. See the tables: & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; & # 160; & lt; / p & gt; & lt; table cellpadding =" 0" cellspacing =" 0" style =" font: 10pt Times New Roman, Times, Serif; border- collapse: collapse; width: 100 %" & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td colspan =" 6" style =" text- align: center" & gt; & lt; b & gt; Years Ended & lt; / b & gt; & lt; / td & gt; &

lt; td & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td colspan =" 6" style =" border- bottom: Black 1. 5pt solid; text- align: center" & gt; & lt; b & gt; January 31, & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" border- bottom: Black 1. 5pt solid; text- align: center" & gt; & lt; b & gt; 2024 & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" border- bottom: Black 1. 5pt solid; text- align: center" & gt; & lt; b & gt; 2023 & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td & gt; Revenue by type & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td colspan =" 2" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td colspan =" 2" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" width: 76 %" & gt; Sale of goods & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; 1, 920, 280 & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; 1, 785, 507 & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; Services & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; 165, 034 & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; 294, 102 & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" padding- bottom: 4pt" & gt; Total & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: right" & gt; 2, 085, 314 & lt; / td & gt; & lt; td style =" padding- bottom: 4pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: right" & gt; 2, 079, 609 & lt; / td & gt; & lt; td style =" padding- bottom: 4pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; / table & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" & gt; & # 160; & lt; / p & gt; & lt; table cellpadding =" 0" cellspacing =" 0" style =" font: 10pt Times New Roman, Times, Serif; border- collapse: collapse; width: 100 %" & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td colspan =" 6" style =" text- align: center" & gt; & lt; b & gt; Years Ended & lt; / b & gt; & lt; / td & gt; & lt; td & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td colspan =" 6" style =" border- bottom: Black 1. 5pt solid; text- align: center" & gt; & lt; b & gt; January 31, & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" border- bottom: Black 1. 5pt solid; text- align: center" & gt; & lt; b & gt; 2024 & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" border- bottom: Black 1. 5pt solid; text- align: center" & gt; & lt; b & gt; 2023 & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td style =" padding- left: 0in; text- align: left" & gt; Revenue by geographic location: & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td colspan =" 2" style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td colspan =" 2" style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" width: 76 %; text- align: left" & gt; United States & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; 2, 085, 314 & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; 2, 079, 609 & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; Foreign & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; div style ="- sec- ix- hidden: hidden- fact- 56" & gt;- & lt; / div & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; div style ="- sec- ix- hidden: hidden- fact- 57" & gt;- & lt; / div & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" padding- bottom: 4pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: right" & gt; 2, 085, 314 & lt; / td & gt; & lt; td style =" padding- bottom: 4pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: right" & gt; 2, 079, 609 & lt; / td & gt; & lt; td style =" padding- bottom: 4pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; / table & gt; & lt; p style =" margin- top: 0; margin- bottom: 0" & gt; & # 160; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in" & gt; & lt; i & gt; & lt; span style =" text- decoration: underline" & gt; Cash and cash equivalents. & lt; / span & gt; & lt; / i & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" & gt; & lt; i & gt; & # 160; & lt; / i & gt; & lt; / p & gt; & lt; p style =" text- align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in" & gt; Cash and cash equivalents include cash on hand, cash on deposit in money market accounts. The Company considers short- term highly liquid investments with an original maturity date of three months or less that are not part of an investment pool to be cash equivalents. As of January 31, 2024, the Company has no balances that exceed federally insured limits. & lt; / p & gt; & lt; p style =" margin- top: 0; margin- bottom: 0" & gt; & # 160; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; & lt; i & gt; & lt; span style =" text- decoration: underline" & gt; Accounts receivable & lt; / span & gt; & lt; / i & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; & lt; i & gt; & # 160; & lt; / i & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; Trade accounts receivables are recorded at the net invoice value and are not interest bearing. The Company maintains allowances for doubtful accounts for estimated losses from the inability of its customers to make the required payments. The Company determines its allowances by both the specific identification of customer accounts where appropriate and the application of historical loss to non- applicable accounts. For the years ended January 31, 2024, and 2023, the Company recorded bad debt expenses of $ 118, 364 and $- 0-, respectively, for doubtful accounts related to accounts receivable. During the year ended January 31, 2024, the Company entered into an accounts receivable sale agreement for one of its subsidiaries. The Company received $ 106, 528 in funds against an account receivable that is currently a claim in bankruptcy. The net accounts receivable remain on the books of the Company and a corresponding amount has been included as a secured borrowing liability under Notes payable. As of January 31, 2024, the receivable has been reserved in full. If the bankruptcy claim is not paid in full by the debtor, Company is obligated to pay any difference to the factor. The loan bears interest at 10 %. The Company adopted ASU 2016- 13 during 2023 and implemented the guidance on expected credit losses. & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; & # 160; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; & lt; i & gt; & lt; span style =" text- decoration: underline" & gt; Inventories & lt; / span & gt; & lt; / i & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; & lt; i & gt; & # 160; & lt; / i & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; Inventories are valued at the lower of cost and reasonable value determined using the first- in, first- out

(FIFO) method. Net realized value is the estimated selling price in the ordinary course of business, less applicable variable selling expenses. The cost of finished goods and work in process is comprised of material costs, direct labor costs and other direct costs and related production overheads (based on normal operating capacity). As of January 31, 2024, total inventory was $ 168, 605, consisting of work- in- process of $ 7, 466, finished goods of $ 8, 707 and raw materials of $ 134, 691. As of January 31, 2023, total inventory was $ 229, 335, consisting of work- in- process of $ 11, 021 and raw materials of $ 218, 334. & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; & # 160; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; & lt; i & gt; & lt; span style =" text- decoration: underline" & gt; Property, Plant and Equipment & lt; / span & gt; & lt; / i & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; & lt; i & gt; & # 160; & lt; / i & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; Property and equipment represent an important component of the Company & # x2019; s assets. The Company depreciates its plant and equipment on a straight- line basis over the estimated useful life of the assets. Property, plant and equipment is stated at historical cost. Expenditures for minor repairs, maintenance and replacement parts which do not increase the useful lives of the assets are charged to expense as incurred. All major additions and improvements are capitalized. Depreciation is computed using the straight- line method. The lives over which the fixed assets are depreciated range from 3 to 20 years as follows: & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; & # 160; & lt; / p & gt; & lt; table cellpadding =" 0" cellspacing =" 0" style =" font: 10pt Times New Roman, Times, Serif; border- collapse: collapse; width: 100 %" & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" width: 88 %; text- align: left" & gt; Lab Equipment & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 9 %; text- align: center" & gt; 5- 10 years & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" text- align: left" & gt; Furniture and fixtures & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: center" & gt; 3 years & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" text- align: left" & gt; Machinery and equipment & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: center" & gt; 10- 20 years & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; / table & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; & # 160; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; & lt; i & gt; & lt; span style =" text- decoration: underline" & gt; Intangible Assets & lt; / span & gt; & lt; / i & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; & lt; i & gt; & # 160; & lt; / i & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; Intangible assets include trademarks, intellectual property and customer base acquired through business combinations. The Company accounts for Other Intangible Assets under the guidance of ASC 350, & # x201c; Intangibles- Goodwill and Other. & # x201d; The Company capitalizes certain costs related to patent technology. A substantial component of the purchase price related to the Company & # x2019; s acquisitions have also been assigned to intellectual property and other intangibles. Under the guidance, other intangible assets with definite lives are amortized over their estimated useful lives. Intangible assets with indefinite lives are tested annually for impairment. Trademarks, intellectual property and customer base are being amortized over their estimated useful lives of ten years. & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; & # 160; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; & lt; i & gt; & lt; span style =" text- decoration: underline" & gt; Goodwill & lt; / span & gt; & lt; / i & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; & lt; i & gt; & # 160; & lt; / i & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; Goodwill represents the difference between the total purchase price and the fair value of assets (tangible and intangible) and liabilities at the date of acquisition. Goodwill is reviewed for impairment annually on January 31, and more frequently as circumstances warrant, and written down only in the period in which the recorded value of such assets exceeds their fair value. The Company does not amortize goodwill in accordance with ASC 350. In connection with the Company & # x2019; s acquisition of 4P Therapeutics LLC in 2018, the Company recorded Goodwill of $ 1, 719, 235. On August 31, 2020, in connection with the Company & # x2019; s acquisition of Pocono Coated Products LLC and Active Intelligence LLC, the Company recorded Goodwill of $ 5, 810, 640. During the years ended January 31, 2024, and 2023, the Company recorded an impairment charge of $- 0- and $ 327, 326, respectively, reducing the Active Intelligence LLC Goodwill to $ 3, 302, 478. As of January 31, 2024, and 2023, Goodwill amounted to $ 5, 021, 713 and $ 5, 021, 713, respectively. & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; & # 160; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; & lt; i & gt; & lt; span style =" text- decoration: underline" & gt; Long- lived Assets & lt; / span & gt; & lt; / i & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; & lt; i & gt; & # 160; & lt; / i & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; Management reviews long- lived assets for potential impairment whenever significant events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An impairment exists when the carrying amount of the long- lived asset is not recoverable and exceeds its fair value. The carrying amount of a long- lived asset is not recoverable if it exceeds the sum of the estimated undiscounted cash flows expected to result from the use and eventual disposition of the asset. If an impairment exists, the resulting write- down would be the difference between the fair market value of the long- lived asset and the related book value. & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; & lt; i & gt; & # 160; & lt; / i & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; & lt; i & gt; & lt; span style =" text- decoration: underline" & gt; Earnings per Share & lt; / span & gt; & lt; / i & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; & # 160; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; Basic earnings per share of common stock is computed by dividing net earnings by the weighted average number of shares of common stock outstanding during the period. & # 160; & # 160; Diluted earnings per share is computed by dividing net earnings by the weighted average number of shares of common stock and potential shares of common stock outstanding during the period. & # 160; Potential shares of common stock consist of shares issuable upon the exercise of outstanding options and common stock purchase warrants. As of January 31, 2024, and 2023, there were 2, 157, 873 and 1, 778, 006 common stock equivalents outstanding, that were not included in the calculation of dilutive earnings per share as their effect would be anti- dilutive. & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; & lt; i & gt; & # 160; & lt; / i & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; & lt; i & gt; & lt; span style =" text- decoration: underline" & gt; Stock- Based Compensation & lt; / span & gt; & lt; / i & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; & lt; i & gt; & # 160; & lt; / i & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; ASC 718, & # x201c; Compensation- Stock Compensation, & # x201d; prescribes accounting and reporting standards for all share- based payment transactions in which employee services, and, since February 1, 2019, non- employees, are acquired. Transactions include incurring liabilities, or issuing or offering to issue shares, options and other equity instruments such as employee stock ownership plans and stock appreciation rights. Share- based payments to employees, including grants of employee stock options, are recognized as compensation expense in the financial statements based on their fair values. That expense is recognized over the period during which an employee is required to provide services in exchange for the award, known as the requisite service period (usually the vesting period). As of February 1, 2019, pursuant to ASC 2018- 07, ASC 718 was applied to stock- based compensation for both employees and non- employees. & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; & lt; i & gt; & # 160; & lt; / i & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; & lt; i & gt; & lt; span style =" text- decoration: underline" & gt; Business Combinations & lt; / span & gt; & lt; / i & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; & # 160; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; The Company recognizes the assets acquired, the liabilities assumed, and any non- controlling interest in the acquired entity at the acquisition date, measured at their fair values as of that date, with limited exceptions specified in the accounting literature. In accordance with this guidance, acquisition- related costs, including restructuring costs, must be recognized separately from the acquisition and will generally be expensed as incurred. That replaces the cost- allocation

process detailed in previous accounting literature, which required the cost of an acquisition to be allocated to the individual assets acquired and liabilities assumed based on their estimated fair value. & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; & lt; i & gt; & # 160; & lt; / i & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; & lt; i & gt; & lt; span style =" text- decoration: underline" & gt; Leases & lt; / span & gt; & lt; / i & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; & lt; i & gt; & # 160; & lt; / i & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: # FDFDFD" & gt; & lt; span style =" background- color: # FDFDFD" & gt; In February 2016, the FASB issued ASU 2016- 02, & # x201c; Leases & # x201d; (Topic 842), to provide a new comprehensive model for lease accounting under this guidance, lessees and lessors should apply a & # x201c; right- of- use & # x201d; model in accounting for all leases (including subleases) and eliminate the concept of operating leases and off- balance **Balance** - sheet leases. Recognition, measurement and presentation of expenses will depend on classification as a finance or operating lease. Similar modifications have been made to lessor accounting in- line with revenue recognition guidance. & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: # FDFDFD" & gt; & # 160; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: # FDFDFD" & gt; & lt; span style =" background- color: # FDFDFD" & gt; The Company applies guidance for right- of- use accounting for all leases and records the operating lease liabilities on its balance sheet. The Company completed the necessary changes to its accounting policies, processes, disclosure and internal control over financial reporting. & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; & lt; i & gt; & # 160; & lt; / i & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; & lt; i & gt; & lt; span style =" text- decoration: underline" & gt; Research and Development Expenses & lt; / span & gt; & lt; / i & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; & lt; i & gt; & # 160; & lt; / i & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; Research and development costs are expensed as incurred. & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; & lt; i & gt; & # 160; & lt; / i & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; & lt; i & gt; & lt; span style =" text- decoration: underline" & gt; Income Taxes & lt; / span & gt; & lt; / i & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; & # 160; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; Taxes are calculated in accordance with taxation principles currently effective in the United States and Ireland. & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; & # 160; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. & # 160; & # 160; Under this method, deferred tax assets and liabilities are determined based on the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. & # 160; & # 160; The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; & # 160; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; The Company records net deferred tax assets to the extent they believe these assets will more- likely- than- not be realized. & # 160; & # 160; In making such determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax planning strategies and recent financial operations. & # 160; & # 160; In the event the Company was to determine that it would be able to realize its deferred income tax assets in the future in excess of its net recorded amount, the Company would make an adjustment to the valuation allowance which would reduce the provision for income taxes. & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; & # 160; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 25in; text- align: justify; text- indent: 0. 25in; background- color: # FDFDFD" & gt; & lt; span style =" background- color: # FDFDFD" & gt; & lt; i & gt; & lt; span style =" text- decoration: underline" & gt; Fair Value Measurements & lt; / span & gt; & lt; / i & gt; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 25in; text- align: justify; background- color: # FDFDFD" & gt; & # 160; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: # FDFDFD" & gt; FASB ASC 820, & # x201c; Fair Value Measurements and Disclosure & # x201d; (& # x201c; ASC 820 & # x201d;), defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between participants on the measurement date. ASC 820 also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value. & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 25in; text- align: justify; background- color: # FDFDFD" & gt; & # 160; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: # FDFDFD" & gt; The Company utilizes the accounting guidance for fair value measurements and disclosures for all financial assets and liabilities and nonfinancial assets and liabilities that are recognized or disclosed at fair value in the consolidated financial statements on a recurring basis during the reporting period. The fair value is an exit price, representing the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants based upon the best use of the asset or liability at the measurement date. The Company utilizes market data or assumptions that market participants would use in pricing the asset or liability. ASC 820 establishes a three- tier value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers are defined as follows: & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 25in; text- align: justify; background- color: # FDFDFD" & gt; & # 160; & lt; / p & gt; & lt; table cellpadding =" 0" cellspacing =" 0" style =" font: 10pt Times New Roman, Times, Serif; width: 100 %" & gt; & lt; tr style =" vertical- align: top" & gt; & lt; td style =" width: 0. 5in" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 0. 45in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif; font- size: 10pt" & gt; Level 1 & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif; font- size: 10pt" & gt;- Observable inputs such as quoted market prices in active markets. & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: top" & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: top" & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; span style =" font- family: Times New Roman, Times, Serif; font- size: 10pt" & gt; Level 2 & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif; font- size: 10pt" & gt;- Inputs other than quoted prices in active markets that are either directly or indirectly observable. & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: top" & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: top" & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif; font- size: 10pt" & gt; Level 3 & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif; font- size: 10pt" & gt;- Unobservable inputs about which little or no market data exists, therefore requiring an entity to develop its own assumptions. & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; / table & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 25in; text- align: justify; text- indent: 0. 75in; background- color: # FDFDFD" & gt; & # 160; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: # FDFDFD" & gt; The carrying value of the Company & # x2019; s financial instruments, including accounts receivable, prepaid expenses, accounts payable and accrued expenses, and deferred revenue approximate their fair value due to the short maturities of these financial instruments. & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: # FDFDFD" & gt; & # 160; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: # FDFDFD" & gt; & lt; i & gt; & lt; span style =" text- decoration: underline" & gt; Recent Accounting Standards & lt; / span & gt; & lt; / i & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: # FDFDFD" & gt; & # 160; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: # FDFDFD" & gt; In June 2016, the FASB issued ASU 2016- 13, Financial Instruments- Credit Losses (Topic 326), The ASU introduces a new credit loss methodology. Current Expected Credit Loss (& # x201c; CECL & # x201d;), which requires earlier recognition of credit losses, which also provides additional transparency about credit risk. Since its original issuance in 2016, the FASB has issued several updates to the original ASU. The Company adopted ASU 2016- 13 during the year ended January 31, 2024. The adoption of ASU 2016- 13 did not have a material impact on the Company & # x2019; s balance sheet or statement of operations. & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify;

background- color: # FDFDFD" & gt; & # 160; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: # FDFDFD" & gt; The Company has reviewed all other FASB- issued ASU accounting pronouncements and interpretations thereof that have effective dates during the period reported and in future periods. The Company has carefully considered the new pronouncements that alter previous GAAP and does not believe that any new or modified principles will have a material impact on the Company & # x2019; s reported financial position or operations in the near term. The applicability of any standard is subject to the formal review of the Company & # x2019; s financial management and certain standards are under consideration. & lt; / p & gt; < / us- gaap: SignificantAccountingPoliciesTextBlock > < ntrb: ForwardStockSplitPolicyTextBlock contextRef =" c0" id =" ixv- 6392" > & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; & lt; i & gt; & lt; span style =" text- decoration: underline" & gt; Forward Stock Split & lt; / span & gt; & lt; / i & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; On July 26, 2022, our Board of Directors approved the amendment to our Articles of Incorporation to effect a 7- for- 6 forward stock split (the & # x201c; Stock Split & # x201d;) of our outstanding common stock. The Company filed the amendment set forth in a Certificate of Change with the Secretary of State of Nevada on August 4, 2022. The 7: 6 forward stock split was effective for trading purposes on the Nasdaq Capital Market on August 12, 2022. Each shareholder of record as of the August 15, 2022 record date received one (1) additional share for each six (6) shares held as of the record date. No fractional shares of common stock were issued in connection with the Stock Split. Instead, all shares were rounded up to the next whole share. In connection with the Stock Split, which did not require shareholder approval under the Nevada corporation law, the number of shares of common stock of the Company was increased in the same ratio as the shares of outstanding common stock were increased in the Stock Split, from 250, 000, 000 authorized shares to 291, 666, 666 authorized shares. & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; All share and per share information in these financial statements retroactively reflect the forward stock split. & lt; / p & gt; < / ntrb: ForwardStockSplitPolicyTextBlock > < us- gaap: StockholdersEquityNoteStockSplit contextRef =" c0" id =" ixv- 14029" > The 7: 6 forward stock split was effective for trading purposes on the Nasdaq Capital Market on August 12, 2022. < / us- gaap: StockholdersEquityNoteStockSplit > < us- gaap: ExcessStockSharesAuthorized contextRef =" c40" decimals =" 0" id =" ixv- 14030" unitRef =" shares" > 250000000 < / us- gaap: ExcessStockSharesAuthorized > < us- gaap: ExcessStockSharesAuthorized contextRef =" c41" decimals =" 0" id =" ixv- 14031" unitRef =" shares" > 291666666 < / us- gaap: ExcessStockSharesAuthorized > < ntrb: GoingConcernPolicyTextBlock contextRef =" c0" id =" ixv- 6403" > & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; & lt; i & gt; & lt; span style =" text- decoration: underline" & gt; Going Concern Assessment & lt; / span & gt; & lt; / i & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; Management assesses liquidity and going concern uncertainty in the Company & # x2019; s condensed financial statements to determine whether there is sufficient cash on hand and working capital, including available borrowings on loans, to operate for a period of at least one year from the date the consolidated financial statements are issued or available to be issued, which is referred to as the & # x201c; look- forward period & # x201d;, as defined in GAAP. As part of this assessment, based on conditions that are known and reasonably knowable to management, management will consider various scenarios, forecasts, projections, estimates and will make certain key assumptions, including timing and nature of projected cash expenditures or programs, its ability to delay or curtail expenditures or programs and its ability to raise additional capital, if necessary, among other factors. Based on this assessment, as necessary or applicable, management makes certain assumptions around implementing curtailments or delays in the nature and timing of programs and expenditures to the extent it deems probable those implementations can be achieved and management has the proper authority to execute them within the look- forward period. & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; As of January 31, 2024, the Company had cash and cash equivalents of $ 492, 942 and working capital of $ 22, 770. For the year ended January 31, 2024, the Company incurred a loss from operations of $ 4, 871, 926 and used cash flow from operations of $ 3, 527, 509. The Company has generated operating losses since its inception and has relied on sales of securities and issuance of third- party and related- party debt to support cash flow from operations. In October 2021, the Company consummated a public offering and received net proceeds of $ 5, 836, 230. The Company has also received to date $ 3, 239, 845 in proceeds from the exercise of warrants. The Company has used these proceeds to fund operations and will continue to use the funds as needed. In March 2023, the Company entered into a three- year $ 2, 000, 000 Credit Line Note facility with a related party, amended on July 13, 2023, to $ 5, 000, 000, which will permit the Company to draw down on the credit line to fund the Company & # x2019; s research and development of its Aversa product. The Company was advanced $ 2, 000, 000, all of which was settled by the issuance of common stock during the year ended January 31, 2024. The $ 2, 000, 000 debt and accrued interest was converted into 1, 026, 720 shares of the Company & # x2019; s common stock. On April 19, 2024, the Company received proceeds of $ 8, 400, 000 from a private placement of its common stock. & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; Management has prepared estimates of operations for the next twelve months and believes that sufficient funds will be generated from operations to fund its operations for one year from the date of the filing of these condensed consolidated financial statements, which indicates improved operations and the Company & # x2019; s ability to continue operations as a going concern. & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; Management believes the substantial doubt about the ability of the Company to continue as a going concern is alleviated by the above assessment. & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; & # 160; & lt; / p & gt; < / ntrb: GoingConcernPolicyTextBlock > < us- gaap: OtherCashEquivalentsAtCarryingValue contextRef =" c5" decimals =" 0" id =" ixv- 14032" unitRef =" usd" > 492942 < / us- gaap: OtherCashEquivalentsAtCarryingValue > < ntrb: WorkingCapital contextRef =" c0" decimals =" 0" id =" ixv- 14033" unitRef =" usd" > 22770 < / ntrb: WorkingCapital > < us- gaap: OperatingIncomeLoss contextRef =" c0" decimals =" 0" id =" ixv- 14034" unitRef =" usd" > - 4871926 < / us- gaap: OperatingIncomeLoss > < us- gaap: NetCashProvidedByUsedInOperatingActivities contextRef =" c0" decimals =" 0" id =" ixv- 14035" unitRef =" usd" > - 3527509 < / us- gaap: NetCashProvidedByUsedInOperatingActivities > < ntrb: ProceedsFromIssuancesInitialPublicOffering contextRef =" c42" decimals =" 0" id =" ixv- 14036" unitRef =" usd" > 5836230 < / ntrb: ProceedsFromIssuancesInitialPublicOffering > < ntrb: ProceedsFromWarrantsExercises contextRef =" c42" decimals =" 0" id =" ixv- 14037" unitRef =" usd" > 3239845 < / ntrb: ProceedsFromWarrantsExercises > < us- gaap: LinesOfCreditCurrent contextRef =" c43" decimals =" 0" id =" ixv- 14038" unitRef =" usd" > 2000000 < / us- gaap: LinesOfCreditCurrent > < us- gaap: SeparateAccountLiabilityWithdrawal contextRef =" c44" decimals =" 0" id =" ixv- 14039" unitRef =" usd" > 5000000 < / us- gaap: SeparateAccountLiabilityWithdrawal > < us- gaap: RepaymentsOfAdvancesForConstruction contextRef =" c0" decimals =" 0" id =" ixv- 14040" unitRef =" usd" > 2000000 < / us- gaap: RepaymentsOfAdvancesForConstruction > < us- gaap: DebtCurrent contextRef =" c5" decimals =" 0" id =" ixv- 14041" unitRef =" usd" > 2000000 < / us- gaap: DebtCurrent > < us- gaap: DepositLiabilitiesAccruedInterest contextRef =" c5" decimals =" 0" id =" ixv- 14042" unitRef =" usd" > 1026720 < / us- gaap: DepositLiabilitiesAccruedInterest > < us- gaap: ProceedsFromIssuanceOfPrivatePlacement contextRef =" c45" decimals =" 0" id =" ixv- 14043" unitRef =" usd" > 8400000 < / us- gaap: ProceedsFromIssuanceOfPrivatePlacement > < us- gaap: ConsolidationPolicyTextBlock contextRef =" c0" id =" ixv- 6436" > & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; & lt; i & gt; & lt; span style =" text- decoration: underline" & gt; Principles of Consolidation & lt; / span & gt; & lt; / i & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; The consolidated financial statements of the Company include the Company and its wholly owned subsidiaries. All material intercompany balances and transactions have been eliminated. The operations of 4P Therapeutics are included in the Company & # x2019; s financial statements from the date of acquisition of August 1, 2018, and the operations of Pocono and Active Intelligence are included in the Company & # x2019; s financial statements from the date of acquisition of September 1, 2020 under Pocono Pharmaceuticals Inc. The wholly owned subsidiaries are as follows: & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0. 5in; text- align: justify; background- color: white; text- indent: 1in" & gt; Nutriband Ltd. & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0. 5in; text- align: justify; background- color: white; text- indent: 1in" & gt; 4P Therapeutics LLC & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0. 5in; text- align: justify; background- color: white; text- indent: 1in" & gt; Pocono Pharmaceuticals Inc. & lt; / p & gt; < / us- gaap: ConsolidationPolicyTextBlock > < us- gaap: UseOfEstimates contextRef =" c0" id =" ixv- 6452" > & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; & lt; i & gt; & lt; span style =" text- decoration: underline" & gt; Use of Estimates & lt; / span & gt; & lt; / i & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires the Company to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an ongoing basis, the Company evaluates its estimates including, but not limited to, those related to such items as income tax exposures, accruals, depreciable / useful lives, allowance for doubtful accounts and valuation allowances. The Company bases its estimates on historical experience and on other various assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the

carrying value of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates. & lt; / p & gt; < / us- gaap: UseOfEstimates > < us- gaap: RevenueRecognitionDeferredRevenue contextRef =" c0" id =" ixv- 6461" > & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; & lt; i & gt; & lt; span style =" text- decoration: underline" & gt; Revenue Recognition & lt; / span & gt; & lt; / i & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; In May 2014, the FASB issued ASU No. 2014- 09, & # x201c; Revenue from Contracts with Customers (Topic 606) (& # x201c; ASU 2014- 09 & # x201d;), which amends the accounting standards for revenue recognition. ASU 2014- 09 is based on principles that govern the recognition of revenue at an amount an entity expects to be entitled when products are transferred to a customer. The Company recognizes revenue based on the five criteria for revenue recognition established under Topic 606: 1) identify the contract, 2) identify separate performance obligations, 3) determine the transaction price, 4) allocate the transaction price among the performance obligations, and 5) recognize revenue as the performance obligations are satisfied. & lt; / p & gt; < / us- gaap: RevenueRecognitionDeferredRevenue > < us- gaap: RevenueRecognitionPolicyTextBlock contextRef =" c0" id =" ixv- 6469" > & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; background- color: white; text- indent: 0. 5in" & gt; & lt; i & gt; & lt; span style =" text- decoration: underline" & gt; Revenue Types - **Type** & lt; / span & gt; & lt; / i & gt; & lt; / p & gt; & lt; p style =" font - 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif; font- size: 10pt" & gt; The following is a description of the Company & # x2019; s revenue types, which include professional services and sale of goods: & lt; / span & gt; & lt; / p & gt; & lt; table cellpadding =" 0" cellspacing =" 0" style =" font: 10pt Times New Roman, Times, Serif; margin- top: 0pt; margin- bottom: 0pt; width: 100 %" & gt; & lt; tr style =" font: 10pt Times New Roman, Times, Serif; vertical- align: top" & gt; & lt; td style =" font: 10pt Times New Roman, Times, Serif; width: 0. 5in" & gt; & lt; / td & gt; & lt; td style =" font: 10pt Times New Roman, Times, Serif; width: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif; font- size: 10pt" & gt; & # x25ef; & lt; / span & gt; & lt; / td & gt; & lt; td style =" font: 10pt Times New Roman, Times, Serif; text- align: justify" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif; font- size: 10pt" & gt; Contract development and manufacturing services for consumer health transdermal, topical and tape products with revenues listed under sale of goods & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; / table & gt; & lt; table cellpadding =" 0" cellspacing =" 0" style =" font: 10pt Times New Roman, Times, Serif; margin- top: 0pt; margin- bottom: 0pt; width: 100 %" & gt; & lt; tr style =" font: 10pt Times New Roman, Times, Serif; vertical- align: top" & gt; & lt; td style =" font: 10pt Times New Roman, Times, Serif; width: 0. 5in" & gt; & lt; / td & gt; & lt; td style =" font: 10pt Times New Roman, Times, Serif; width: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif; font- size: 10pt" & gt; & # x25ef; & lt; / span & gt; & lt; / td & gt; & lt; td style =" font: 10pt Times New Roman, Times, Serif; text- align: justify" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif; font- size: 10pt" & gt; Product revenues derived from the sale of the Company & # x2019; s consumer transdermal, topical and tape products with sales listed under sale of goods & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; / table & gt; & lt; table cellpadding =" 0" cellspacing =" 0" style =" font: 10pt Times New Roman, Times, Serif; margin- top: 0pt; margin- bottom: 0pt; width: 100 %" & gt; & lt; tr style =" font: 10pt Times New Roman, Times, Serif; vertical- align: top" & gt; & lt; td style =" font: 10pt Times New Roman, Times, Serif; width: 0. 5in" & gt; & lt; / td & gt; & lt; td style =" font: 10pt Times New Roman, Times, Serif; width: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif; font- size: 10pt" & gt; & # x25ef; & lt; / span & gt; & lt; / td & gt; & lt; td style =" font: 10pt Times New Roman, Times, Serif; text- align: justify" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif; font- size: 10pt" & gt; Contract research and development services for pharmaceuticals and medical devices for life sciences customers with revenues listed under services & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; / table & gt; < / us- gaap: RevenueRecognitionPolicyTextBlock > < us- gaap: RevenueFromContractWithCustomerPolicyTextBlock contextRef =" c0" id =" ixv- 6509" > & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- indent: 0. 5in" & gt; & lt; i & gt; & lt; span style =" text- decoration: underline" & gt; Contracts with Customers & lt; / span & gt; & lt; / i & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify" & gt; A contract with a customer exists when (i) we enter into an enforceable contract with a customer that defines each party & # x2019; s rights regarding the goods or services to be transferred and identifies the payment terms related to these goods or services, (ii) the contract has commercial substance and, (iii) we determine that collection of substantially all consideration for services that are transferred is probable based on the customer & # x2019; s intent and ability to pay the promised consideration. & lt; / p & gt; < / us- gaap: RevenueFromContractWithCustomerPolicyTextBlock > < ntrb: ContractLiabilitiesPolicyTextBlock contextRef =" c0" id =" ixv- 6517" > & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- indent: 0. 5in" & gt; & lt; i & gt; & lt; span style =" text- decoration: underline" & gt; Contract Liabilities & lt; / span & gt; & lt; / i & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify" & gt; Deferred revenue is a liability related to a revenue producing activity for which revenue has not been recognized. The Company records deferred revenue when it receives consideration from a contract before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 75in; text- align: justify; background- color: white" & gt; & lt; i & gt; & # 160; & lt; / i & gt; & lt; / p & gt; < / ntrb: ContractLiabilitiesPolicyTextBlock > < ntrb: PerformanceObligationsPolicyTextBlock contextRef =" c0" id =" ixv- 6542" > & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- indent: 0. 5in" & gt; & lt; i & gt; & lt; span style =" text- decoration: underline" & gt; Performance Obligations & lt; / span & gt; & lt; / i & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify" & gt; A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in the new revenue standard. The contract transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. For the Company & # x2019; s different revenue service types, the performance obligation is satisfied at different times. The Company & # x2019; s performance obligations include providing products and professional services in the area of research. The Company recognizes product revenue performance obligations in most cases when the product has shipped to the customer. When we perform professional service work, we recognize revenue when we have the right to invoice the customer for the work completed, which typically occurs over time on a monthly basis for the work performed during that month. & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; All revenue recognized in the income statement is considered to be revenue from contracts with customers. & lt; / p & gt; < / ntrb: PerformanceObligationsPolicyTextBlock > < ntrb: DisaggregationOfRevenuesPolicyTextBlock contextRef =" c0" id =" ixv- 6553" > & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- indent: 0. 5in" & gt; & lt; i & gt; & lt; span style =" text- decoration: underline" & gt; Disaggregation of Revenues & lt; / span & gt; & lt; / i & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; The Company disaggregates its revenue from contracts with customers by type and by geographical location. See the tables: & lt; / p & gt; & lt; table cellpadding =" 0" cellspacing =" 0" style =" font: 10pt Times New Roman, Times, Serif; border- collapse: collapse; width: 100 %" & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td colspan =" 6" style =" text- align: center" & gt; & lt; b & gt; Years Ended & lt; / b & gt; & lt; / td & gt; & lt; td & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td colspan =" 6" style =" border- bottom: Black 1. 5pt solid; text- align: center" & gt; & lt; b & gt; January 31, & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" border- bottom: Black 1. 5pt solid; text- align: center" & gt; & lt; b & gt; 2024 & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" border- bottom: Black 1. 5pt solid; text- align: center" & gt; & lt; b & gt; 2023 & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td & gt; Revenue by type & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td colspan =" 2" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td colspan =" 2" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" width: 76 %" & gt; Sale of goods & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; 1, 920, 280 & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; 1, 785, 507 & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; Services & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; 165, 034 & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td style ="

border- bottom: Black 1. 5pt solid; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; 294, 102 & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" padding- bottom: 4pt" & gt; Total & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: right" & gt; 2, 085, 314 & lt; / td & gt; & lt; td style =" padding- bottom: 4pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: right" & gt; 2, 079, 609 & lt; / td & gt; & lt; td style =" padding- bottom: 4pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; / table & gt; & lt; table cellpadding =" 0" cellspacing =" 0" style =" font: 10pt Times New Roman, Times, Serif; border- collapse: collapse; width: 100 %" & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td colspan =" 6" style =" text- align: center" & gt; & lt; b & gt; Years Ended & lt; / b & gt; & lt; / td & gt; & lt; td & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td colspan =" 6" style =" border- bottom: Black 1. 5pt solid; text- align: center" & gt; & lt; b & gt; January 31, & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" border- bottom: Black 1. 5pt solid; text- align: center" & gt; & lt; b & gt; 2024 & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" border- bottom: Black 1. 5pt solid; text- align: center" & gt; & lt; b & gt; 2023 & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td style =" padding- left: 0in; text- align: left" & gt; Revenue by geographic location: & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td colspan =" 2" style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td colspan =" 2" style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" width: 76 %; text- align: left" & gt; United States & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; 2, 085, 314 & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; 2, 079, 609 & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; Foreign & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; div style ="- sec- ix- hidden: hidden- fact- 56" & gt;- & lt; / div & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; div style ="- sec- ix- hidden: hidden- fact- 57" & gt;- & lt; / div & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" padding- bottom: 4pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: right" & gt; 2, 085, 314 & lt; / td & gt; & lt; td style =" padding- bottom: 4pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: right" & gt; 2, 079, 609 & lt; / td & gt; & lt; td style =" padding- bottom: 4pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; / table & gt; < / ntrb: DisaggregationOfRevenuesPolicyTextBlock > < us- gaap: ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock contextRef =" c0" id =" ixv- 14044" > The Company disaggregates its revenue from contracts with customers by type and by geographical location. See the tables: & lt; table cellpadding =" 0" cellspacing =" 0" style =" font: 10pt Times New Roman, Times, Serif; border- collapse: collapse; width: 100 %" & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td colspan =" 6" style =" text- align: center" & gt; & lt; b & gt; Years Ended & lt; / b & gt; & lt; / td & gt; & lt; td & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td colspan =" 6" style =" border- bottom: Black 1. 5pt solid; text- align: center" & gt; & lt; b & gt; January 31, & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" border- bottom: Black 1. 5pt solid; text- align: center" & gt; & lt; b & gt; 2024 & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" border- bottom: Black 1. 5pt solid; text- align: center" & gt; & lt; b & gt; 2023 & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td & gt; Revenue by type & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td colspan =" 2" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td colspan =" 2" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" width: 76 %" & gt; Sale of goods & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; 1, 920, 280 & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; 1, 785, 507 & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; Services & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; 165, 034 & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; 294, 102 & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" padding- bottom: 4pt" & gt; Total & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: right" & gt; 2, 085, 314 & lt; / td & gt; & lt; td style =" padding- bottom: 4pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: right" & gt; 2, 079, 609 & lt; / td & gt; & lt; td style =" padding- bottom: 4pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; / table & gt; < / us- gaap: ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock > < us- gaap: CostOfGoodsAndServicesSold contextRef =" c0" decimals =" 0" id =" ixv- 14045" unitRef =" usd" > 1920280 < / us- gaap: CostOfGoodsAndServicesSold > < us- gaap: CostOfGoodsAndServicesSold contextRef =" c9" decimals =" 0" id =" ixv- 14046" unitRef =" usd" > 1785507 < / us- gaap: CostOfGoodsAndServicesSold > < us- gaap: CostOfServicesCatering contextRef =" c0" decimals =" 0" id =" ixv- 14047" unitRef =" usd" > 165034 < / us- gaap: CostOfServicesCatering > < us- gaap: CostOfServicesCatering contextRef =" c9" decimals =" 0" id =" ixv- 14048" unitRef =" usd" > 294102 < / us- gaap: CostOfServicesCatering > < us- gaap: Revenues contextRef =" c0" decimals =" 0" id =" ixv- 14049" unitRef =" usd" > 2085314 < / us- gaap: Revenues > < us- gaap: Revenues contextRef =" c9" decimals =" 0" id =" ixv- 14050" unitRef =" usd" > 2079609 < / us- gaap: Revenues > < us- gaap: RevenueFromExternalCustomersByGeographicAreasTableTextBlock contextRef =" c0" id =" ixv- 6636" > & lt; table cellpadding =" 0" cellspacing =" 0" style =" font: 10pt Times New Roman, Times, Serif; border- collapse: collapse; width: 100 %" & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td colspan =" 6" style =" text- align: center" & gt; & lt; b & gt; Years Ended & lt; / b & gt; & lt; / td & gt; & lt; td & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td colspan =" 6" style =" border- bottom: Black 1. 5pt solid;

text- align: center" & gt; & lt; b & gt; January 31, & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" border- bottom: Black 1. 5pt solid; text- align: center" & gt; & lt; b & gt; 2024 & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" border- bottom: Black 1. 5pt solid; text- align: center" & gt; & lt; b & gt; 2023 & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td style =" padding- left: 0in; text- align: left" & gt; Revenue by geographic location: & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td colspan =" 2" style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td colspan =" 2" style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" width: 76 %; text- align: left" & gt; United States & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; 2, 085, 314 & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; 2, 079, 609 & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; Foreign & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; div style ="- sec- ix- hidden: hidden- fact- 56" & gt;- & lt; / div & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; div style ="- sec- ix- hidden: hidden- fact- 57" & gt;- & lt; / div & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" padding- bottom: 4pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: right" & gt; 2, 085, 314 & lt; / td & gt; & lt; td style =" padding- bottom: 4pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: right" & gt; 2, 079, 609 & lt; / td & gt; & lt; td style =" padding- bottom: 4pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; / table & gt; < / us- gaap: RevenueFromExternalCustomersByGeographicAreasTableTextBlock > < us- gaap: Revenues contextRef =" c54" decimals =" 0" id =" ixv- 14051" unitRef =" usd" > 2085314 < / us- gaap: Revenues > < us- gaap: Revenues contextRef =" c55" decimals =" 0" id =" ixv- 14052" unitRef =" usd" > 2079609 < / us- gaap: Revenues > < us- gaap: Revenues contextRef =" c0" decimals =" 0" id =" ixv- 14053" unitRef =" usd" > 2085314 < / us- gaap: Revenues > < us- gaap: Revenues contextRef =" c9" decimals =" 0" id =" ixv- 14054" unitRef =" usd" > 2079609 < / us- gaap: Revenues > < us- gaap: CashAndCashEquivalentsPolicyTextBlock contextRef =" c0" id =" ixv- 6713" > & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in" & gt; & lt; i & gt; & lt; span style =" text- decoration: underline" & gt; Cash and cash equivalents. & lt; / span & gt; & lt; / i & gt; & lt; / p & gt; & lt; p style =" text- align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in" & gt; Cash and cash equivalents include cash on hand, cash on deposit in money market accounts. The Company considers short- term highly liquid investments with an original maturity date of three months or less that are not part of an investment pool to be cash equivalents. As of January 31, 2024, the Company has no balances that exceed federally insured limits. & lt; / p & gt; < / us- gaap: CashAndCashEquivalentsPolicyTextBlock > < us- gaap: ReceivablesPolicyTextBlock contextRef =" c0" id =" ixv- 6722" > & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; & lt; i & gt; & lt; span style =" text- decoration: underline" & gt; Accounts receivable & lt; / span & gt; & lt; / i & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; Trade accounts receivables are recorded at the net invoice value and are not interest bearing. The Company maintains allowances for doubtful accounts for estimated losses from the inability of its customers to make the required payments. The Company determines its allowances by both the specific identification of customer accounts where appropriate and the application of historical loss to non- applicable accounts. For the years ended January 31, 2024, and 2023, the Company recorded bad debt expenses of $ 118, 364 and $- 0-, respectively, for doubtful accounts related to accounts receivable. During the year ended January 31, 2024, the Company entered into an accounts receivable sale agreement for one of its subsidiaries. The Company received $ 106, 528 in funds against an account receivable that is currently a claim in bankruptcy. The net accounts receivable remain on the books of the Company and a corresponding amount has been included as a secured borrowing liability under Notes payable. As of January 31, 2024, the receivable has been reserved in full. If the bankruptcy claim is not paid in full by the debtor, Company is obligated to pay any difference to the factor. The loan bears interest at 10 %. The Company adopted ASU 2016- 13 during 2023 and implemented the guidance on expected credit losses. & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; & # 160; & lt; / p & gt; < / us- gaap: ReceivablesPolicyTextBlock > < ntrb: BadDebt contextRef =" c46" decimals =" 0" id =" ixv- 14055" unitRef =" usd" > 118364 < / ntrb: BadDebt > < ntrb: BadDebt contextRef =" c47" decimals =" 0" id =" ixv- 14056" unitRef =" usd" > 0 < / ntrb: BadDebt > < us- gaap: AccountsReceivableFairValueDisclosure contextRef =" c5" decimals =" 0" id =" ixv- 14057" unitRef =" usd" > 106528 < / us- gaap: AccountsReceivableFairValueDisclosure > < ntrb: LoanBearsInterestPercentage contextRef =" c0" decimals =" 2" id =" ixv- 14058" unitRef =" pure" > 0. 10 < / ntrb: LoanBearsInterestPercentage > < us- gaap: InventoryPolicyTextBlock contextRef =" c0" id =" ixv- 6746" > & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; & lt; i & gt; & lt; span style =" text- decoration: underline" & gt; Inventories & lt; / span & gt; & lt; / i & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; Inventories are valued at the lower of cost and reasonable value determined using the first- in, first- out (FIFO) method. Net realized value is the estimated selling price in the ordinary course of business, less applicable variable selling expenses. The cost of finished goods and work in process is comprised of material costs, direct labor costs and other direct costs and related production overheads (based on normal operating capacity). As of January 31, 2024, total inventory was $ 168, 605, consisting of work- in- process of $ 7, 466, finished goods of $ 8, 707 and raw materials of $ 134, 691. As of January 31, 2023, total inventory was $ 229, 335, consisting of work- in- process of $ 11, 021 and raw materials of $ 218, 334. & lt; / p & gt; < / us- gaap: InventoryPolicyTextBlock > < us- gaap: OtherInventory contextRef =" c5" decimals =" 0" id =" ixv- 14059" unitRef =" usd" > 168605 < / us- gaap: OtherInventory > < us- gaap: InventoryWorkInProcess contextRef =" c48" decimals =" 0" id =" ixv- 14060" unitRef =" usd" > 7466 < / us- gaap: InventoryWorkInProcess > < us- gaap: InventoryFinishedGoods contextRef =" c5" decimals =" 0" id =" ixv- 14061" unitRef =" usd" > 8707 < / us- gaap: InventoryFinishedGoods > < us- gaap: InventoryRawMaterials contextRef =" c5" decimals =" 0" id =" ixv- 14062" unitRef =" usd" > 134691 < / us- gaap: InventoryRawMaterials > < us- gaap: OtherInventory contextRef =" c6" decimals =" 0" id =" ixv- 14063" unitRef =" usd" > 229335 < / us- gaap: OtherInventory > < us- gaap: InventoryWorkInProcess contextRef =" c6" decimals =" 0" id =" ixv- 14064" unitRef =" usd" > 11021 < / us- gaap: InventoryWorkInProcess > < us- gaap: InventoryRawMaterials contextRef =" c6" decimals =" 0" id =" ixv- 14065" unitRef =" usd" > 218334 < / us- gaap: InventoryRawMaterials > < us- gaap: PropertyPlantAndEquipmentPolicyTextBlock contextRef =" c0" id =" ixv- 6755" > & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; & lt; i & gt; & lt; span style =" text- decoration: underline" & gt; Property, Plant and Equipment & lt; / span & gt; & lt; / i & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; Property and equipment represent an important component of the Company & # x2019; s assets. The Company depreciates its plant and equipment on a straight- line basis over the estimated useful life of the assets. Property, plant and equipment is stated at historical cost. Expenditures for minor repairs, maintenance and replacement parts which do not increase the useful lives of the assets are charged to expense as incurred. All major additions and improvements are capitalized. Depreciation is computed using the straight- line method. The lives over which the fixed assets are depreciated range from 3 to 20 years as follows: & lt; / p & gt; & lt; table cellpadding =" 0" cellspacing =" 0" style =" font: 10pt Times New Roman, Times, Serif; border- collapse: collapse; width: 100 %" & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" width: 88 %; text- align: left" & gt; Lab Equipment & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 9 %; text- align: center" & gt; 5- 10 years & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" text- align: left" & gt; Furniture and fixtures & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: center" & gt; 3 years & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" text- align: left" & gt; Machinery and equipment & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text-

align: center" & gt; 10- 20 years & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; / table & gt; < / us- gaap: PropertyPlantAndEquipmentPolicyTextBlock > < us- gaap: ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock contextRef =" c0" id =" ixv- 14066" > The lives over which the fixed assets are depreciated range from 3 to 20 years as follows: & lt; table cellpadding =" 0" cellspacing =" 0" style =" font: 10pt Times New Roman, Times, Serif; border- collapse: collapse; width: 100 %" & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" width: 88 %; text- align: left" & gt; Lab Equipment & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 9 %; text- align: center" & gt; 5- 10 years & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" text- align: left" & gt; Furniture and fixtures & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: center" & gt; 3 years & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" text- align: left" & gt; Machinery and equipment & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: center" & gt; 10- 20 years & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; / table & gt; < / us- gaap: ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock > < ntrb: AssetDepreciatedRange contextRef =" c49" id =" ixv- 14067" > P3Y < / ntrb: AssetDepreciatedRange > < ntrb: AssetDepreciatedRange contextRef =" c50" id =" ixv- 14068" > P20Y < / ntrb: AssetDepreciatedRange > < us- gaap: PropertyPlantAndEquipmentUsefulLife contextRef =" c58" id =" ixv- 14069" > P5Y < / us- gaap: PropertyPlantAndEquipmentUsefulLife > < us- gaap: PropertyPlantAndEquipmentUsefulLife contextRef =" c59" id =" ixv- 14070" > P10Y < / us- gaap: PropertyPlantAndEquipmentUsefulLife > < us- gaap: PropertyPlantAndEquipmentUsefulLife contextRef =" c60" id =" ixv- 14071" > P3Y < / us- gaap: PropertyPlantAndEquipmentUsefulLife > < us- gaap: PropertyPlantAndEquipmentUsefulLife contextRef =" c61" id =" ixv- 14072" > P10Y < / us- gaap: PropertyPlantAndEquipmentUsefulLife > < us- gaap: PropertyPlantAndEquipmentUsefulLife contextRef =" c62" id =" ixv- 14073" > P20Y < / us- gaap: PropertyPlantAndEquipmentUsefulLife > < us- gaap: IntangibleAssetsFiniteLivedPolicy contextRef =" c0" id =" ixv- 6786" > & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; & lt; i & gt; & lt; span style =" text- decoration: underline" & gt; Intangible Assets & lt; / span & gt; & lt; / i & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; Intangible assets include trademarks, intellectual property and customer base acquired through business combinations. The Company accounts for Other Intangible Assets under the guidance of ASC 350, & # x201c; Intangibles- Goodwill and Other. & # x201d; The Company capitalizes certain costs related to patent technology. A substantial component of the purchase price related to the Company & # x2019; s acquisitions have also been assigned to intellectual property and other intangibles. Under the guidance, other intangible assets with definite lives are amortized over their estimated useful lives. Intangible assets with indefinite lives are tested annually for impairment. Trademarks, intellectual property and customer base are being amortized over their estimated useful lives of ten years. & lt; / p & gt; < / us- gaap: IntangibleAssetsFiniteLivedPolicy > < ntrb: EstimatedUsefulLive contextRef =" c0" id =" ixv- 14074" > P10Y < / ntrb: EstimatedUsefulLive > < us- gaap: GoodwillAndIntangibleAssetsPolicyTextBlock contextRef =" c0" id =" ixv- 6795" > & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; & lt; i & gt; & lt; span style =" text- decoration: underline" & gt; Goodwill & lt; / span & gt; & lt; / i & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; Goodwill represents the difference between the total purchase price and the fair value of assets (tangible and intangible) and liabilities at the date of acquisition. Goodwill is reviewed for impairment annually on January 31, and more frequently as circumstances warrant, and written down only in the period **Period** in which the recorded value of such assets exceeds their fair value. The Company does not amortize goodwill in accordance with ASC 350. In connection with the Company & # x2019; s acquisition of 4P Therapeutics LLC in 2018, the Company recorded Goodwill of $ 1, 719, 235. On August 31, 2020, in connection with the Company & # x2019; s acquisition of Pocono Coated Products LLC and Active Intelligence LLC, the Company recorded Goodwill of $ 5, 810, 640. During the years ended January 31, 2024, and 2023, the Company recorded an impairment charge of $- 0- and $ 327, 326, respectively, reducing the Active Intelligence LLC Goodwill to $ 3, 302, 478. As of January 31, 2024, and 2023, Goodwill amounted to $ 5, 021, 713 and $ 5, 021, 713, respectively. & lt; / p & gt; < / us- gaap: GoodwillAndIntangibleAssetsPolicyTextBlock > < ntrb: GoodwillValue contextRef =" c5" decimals =" 0" id =" ixv- 14075" unitRef =" usd" > 1719235 < / ntrb: GoodwillValue > < ntrb: GoodwillValue contextRef =" c51" decimals =" 0" id =" ixv- 14076" unitRef =" usd" > 5810640 < / ntrb: GoodwillValue > < us- gaap: OtherAssetImpairmentCharges contextRef =" c52" decimals =" 0" id =" ixv- 14077" unitRef =" usd" > 0 < / us- gaap: OtherAssetImpairmentCharges > < us- gaap: OtherAssetImpairmentCharges contextRef =" c53" decimals =" 0" id =" ixv- 14078" unitRef =" usd" > 327326 < / us- gaap: OtherAssetImpairmentCharges > < us- gaap: GoodwillImpairedAccumulatedImpairmentLoss contextRef =" c5" decimals =" 0" id =" ixv- 14079" unitRef =" usd" > 3302478 < / us- gaap: GoodwillImpairedAccumulatedImpairmentLoss > < us- gaap: GoodwillOtherIncreaseDecrease contextRef =" c0" decimals =" 0" id =" ixv- 14080" unitRef =" usd" > 5021713 < / us- gaap: GoodwillOtherIncreaseDecrease > < us- gaap: GoodwillOtherIncreaseDecrease contextRef =" c9" decimals =" 0" id =" ixv- 14081" unitRef =" usd" > 5021713 < / us- gaap: GoodwillOtherIncreaseDecrease > < us- gaap: ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef =" c0" id =" ixv- 6804" > & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; & lt; i & gt; & lt; span style =" text- decoration: underline" & gt; Long- lived Assets & lt; / span & gt; & lt; / i & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; Management reviews long- lived assets for potential impairment whenever significant events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An impairment exists when the carrying amount of the long- lived asset is not recoverable and exceeds its fair value. The carrying amount of a long- lived asset is not recoverable if it exceeds the sum of the estimated undiscounted cash flows expected to result from the use and eventual disposition of the asset. If an impairment exists, the resulting write- down would be the difference between the fair market value of the long- lived asset and the related book value. & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; & lt; i & gt; & # 160; & lt; / i & gt; & lt; / p & gt; < / us- gaap: ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock > < us- gaap: EarningsPerSharePolicyTextBlock contextRef =" c0" id =" ixv- 6830" > & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; & lt; i & gt; & lt; span style =" text- decoration: underline" & gt; Earnings per Share & lt; / span & gt; & lt; / i & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; Basic earnings per share of common stock is computed by dividing net earnings by the weighted average number of shares of common stock outstanding during the period. & # 160; & # 160; Diluted earnings per share is computed by dividing net earnings by the weighted average number of shares of common stock and potential shares of common stock outstanding during the period. & # 160; Potential shares of common stock consist of shares issuable upon the exercise of outstanding options and common stock purchase warrants. As of January 31, 2024, and 2023, there were 2, 157, 873 and 1, 778, 006 common stock equivalents outstanding, that were not included in the calculation of dilutive earnings per share as their effect would be anti- dilutive. & lt; / p & gt; < / us- gaap: EarningsPerSharePolicyTextBlock > < us- gaap: CommonStockOtherSharesOutstanding contextRef =" c5" decimals =" 0" id =" ixv- 14082" unitRef =" shares" > 2157873 < / us- gaap: CommonStockOtherSharesOutstanding > < us- gaap: CommonStockOtherSharesOutstanding contextRef =" c6" decimals =" 0" id =" ixv- 14083" unitRef =" shares" > 1778006 < / us- gaap: CommonStockOtherSharesOutstanding > < us- gaap: ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef =" c0" id =" ixv- 6839" > & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; & lt; i & gt; & lt; span style =" text- decoration: underline" & gt; Stock- Based Compensation & lt; / span & gt; & lt; / i & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; ASC 718, & # x201c; Compensation- Stock Compensation, & # x201d; prescribes accounting and reporting standards for all share- based payment transactions in which employee services, and, since February 1, 2019, non- employees, are acquired. Transactions include incurring liabilities, or issuing or offering to issue shares, options and other equity instruments such as employee stock ownership plans and stock appreciation rights. Share- based payments to employees, including grants of employee stock options, are recognized as compensation expense in the financial statements based on their fair values. That expense is recognized over the period during which an employee is required to provide services in exchange for the award, known as the requisite service period (usually the vesting period). As of February 1, 2019, pursuant to ASC 2018- 07, ASC 718 was applied to stock- based compensation for both employees and non- employees. & lt; / p & gt; < / us- gaap: ShareBasedCompensationOptionAndIncentivePlansPolicy > < us- gaap: BusinessCombinationsPolicy contextRef =" c0" id =" ixv- 6849" > & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; & lt; i & gt; & lt; span style =" text- decoration: underline" & gt; Business Combinations & lt; / span & gt; & lt; / i & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; The Company recognizes the assets acquired, the liabilities assumed, and any non- controlling interest in the acquired entity at the acquisition date, measured at their fair values as of that date, with limited exceptions specified in the accounting literature. In accordance with this guidance, acquisition- related costs, including restructuring costs, must be recognized separately from the acquisition and will generally be expensed as

incurred. That replaces the cost- allocation process detailed in previous accounting literature, which required the cost of an acquisition to be allocated to the individual assets acquired and liabilities assumed based on their estimated fair value. & lt; / p & gt; < / us- gaap: BusinessCombinationsPolicy > < us- gaap: LesseeLeasesPolicyTextBlock contextRef =" c0" id =" ixv- 6858" > & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; & lt; i & gt; & lt; span style =" text- decoration: underline" & gt; Leases & lt; / span & gt; & lt; / i & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: # FDFDFD" & gt; & lt; span style =" background- color: # FDFDFD" & gt; In February 2016, the FASB issued ASU 2016- 02, & # x201c; Leases & # x201d; (Topic 842), to provide a new comprehensive model for lease accounting under this guidance, lessees and lessors should apply a & # x201c; right- of- use & # x201d; model in accounting for all leases (including subleases) and eliminate the concept of operating leases and off- balance- sheet leases. Recognition, measurement and presentation of expenses will depend on classification as a finance or operating lease. Similar modifications have been made to lessor accounting in- line with revenue recognition guidance. & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: # FDFDFD" & gt; & lt; span style =" background- color: # FDFDFD" & gt; The Company applies guidance for right- of- use accounting for all leases and records the operating lease liabilities on its balance sheet. The Company completed the necessary changes to its accounting policies, processes, disclosure and internal control over financial reporting. & lt; / span & gt; & lt; / p & gt; < / us- gaap: LesseeLeasesPolicyTextBlock > < us- gaap: ResearchAndDevelopmentExpensePolicy contextRef =" c0" id =" ixv- 6873" > & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; & lt; i & gt; & lt; span style =" text- decoration: underline" & gt; Research and Development Expenses & lt; / span & gt; & lt; / i & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; Research and development costs are expensed as incurred. & lt; / p & gt; < / us- gaap: ResearchAndDevelopmentExpensePolicy > < us- gaap: IncomeTaxPolicyTextBlock contextRef =" c0" id =" ixv- 6883" > & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; & lt; i & gt; & lt; span style =" text- decoration: underline" & gt; Income Taxes & lt; / span & gt; & lt; / i & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; Taxes are calculated in accordance with taxation principles currently effective in the United States and Ireland. & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; & # 160; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. & # 160; & # 160; Under this method, deferred tax assets and liabilities are determined based on the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. & # 160; & # 160; The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; The Company records net deferred tax assets to the extent they believe these assets will more- likely- than- not be realized. & # 160; & # 160; In making such determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax planning strategies and recent financial operations. & # 160; & # 160; In the event the Company was to determine that it would be able to realize its deferred income tax assets in the future in excess of its net recorded amount, the Company would make an adjustment to the valuation allowance which would reduce the provision for income taxes. & lt; / p & gt; < / us- gaap: IncomeTaxPolicyTextBlock > < us- gaap: FairValueMeasurementPolicyPolicyTextBlock contextRef =" c0" id =" ixv- 6912" > & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 25in; text- align: justify; text- indent: 0. 25in; background- color: # FDFDFD" & gt; & lt; span style =" background- color: # FDFDFD" & gt; & lt; i & gt; & lt; span style =" text- decoration: underline" & gt; Fair Value Measurements & lt; / span & gt; & lt; / i & gt; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: # FDFDFD" & gt; FASB ASC 820, & # x201c; Fair Value Measurements and Disclosure & # x201d; (& # x201c; ASC 820 & # x201d;), defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between participants on the measurement date. ASC 820 also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value. & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: # FDFDFD" & gt; The Company utilizes the accounting guidance for fair value measurements and disclosures for all financial assets and liabilities and nonfinancial assets and liabilities that are recognized or disclosed at fair value in the consolidated financial statements on a recurring basis during the reporting period. The fair value is an exit price, representing the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants based upon the best use of the asset or liability at the measurement date. The Company utilizes market data or assumptions that market participants would use in pricing the asset or liability. ASC 820 establishes a three- tier value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers are defined as follows: & lt; / p & gt; & lt; table cellpadding =" 0" cellspacing =" 0" style =" font: 10pt Times New Roman, Times, Serif; width: 100 %" & gt; & lt; tr style =" vertical- align: top" & gt; & lt; td style =" width: 0. 5in" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 0. 45in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif; font- size: 10pt" & gt; Level 1 & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif; font- size: 10pt" & gt;- Observable inputs such as quoted market prices in active markets. & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: top" & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: top" & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif; font- size: 10pt" & gt; Level 2 & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif; font- size: 10pt" & gt;- Inputs other than quoted prices in active markets that are either directly or indirectly observable. & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: top" & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: top" & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif; font- size: 10pt" & gt; Level 3 & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif; font- size: 10pt" & gt;- Unobservable inputs about which little or no market data exists, therefore requiring an entity to develop its own assumptions. & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; / table & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: # FDFDFD" & gt; The carrying value of the Company & # x2019; s financial instruments, including accounts receivable, prepaid expenses, accounts payable and accrued expenses, and deferred revenue approximate their fair value due to the short maturities of these financial instruments. & lt; / p & gt; < / us- gaap: FairValueMeasurementPolicyPolicyTextBlock > < us- gaap: NewAccountingPronouncementsPolicyPolicyTextBlock contextRef =" c0" id =" ixv- 6956" > & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: # FDFDFD" & gt; & lt; i & gt; & lt; span style =" text- decoration: underline" & gt; Recent Accounting Standards & lt; / span & gt; & lt; / i & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: # FDFDFD" & gt; In June 2016, the FASB issued ASU 2016- 13, Financial Instruments- Credit Losses (Topic 326), The ASU introduces a new credit loss methodology. Current Expected Credit Loss (& # x201c; CECL & # x201d;), which requires earlier recognition of credit losses, which also provides additional transparency about credit risk. Since its original issuance in 2016, the FASB has issued several updates to the original ASU. The Company adopted ASU 2016- 13 during the year ended January 31, 2024. The adoption of ASU 2016- 13 did not have a material impact on the Company & # x2019; s balance sheet or statement of operations. & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: # FDFDFD" & gt; & # 160; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: # FDFDFD" & gt; The Company has reviewed all other FASB- issued ASU accounting pronouncements and interpretations thereof that have effective dates during the period reported and in future periods. The Company has carefully considered the new pronouncements that alter previous GAAP and does not believe that any new or modified principles will have a material impact on the Company & # x2019; s reported financial position or operations in the near term. The applicability of any standard is subject to the formal review of the Company & # x2019; s financial management and certain standards are under consideration. & lt; / p & gt; < / us- gaap: NewAccountingPronouncementsPolicyPolicyTextBlock > < us- gaap: PropertyPlantAndEquipmentDisclosureTextBlock contextRef =" c0" id =" ixv- 6984" > & lt; table cellpadding =" 0" cellspacing =" 0" style =" font: 10pt Times New Roman, Times, Serif; margin- top: 0pt; margin- bottom: 0pt; width: 100 %" & gt; & lt; tr style =" vertical- align: top; text- align: justify" & gt; & lt; td style =" width: 0. 5in; text- align: left" & gt; 3. & lt; / td & gt; & lt; td style =" text- align: justify" & gt; PROPERTY AND EQUIPMENT & lt; / td & gt; & lt; / tr & gt; & lt; / table & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; & # 160; & lt; / p & gt; & lt; table cellpadding =" 0" cellspacing =" 0" style =" font: 10pt Times New Roman, Times, Serif; border- collapse: collapse; width: 100 %" & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt;

& lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td colspan =" 6" style =" border- bottom: Black 1. 5pt solid; text- align: center" & gt; & lt; b & gt; January 31, & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" border- bottom: Black 1. 5pt solid; text- align: center" & gt; & lt; b & gt; 2024 & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" border- bottom: Black 1. 5pt solid; text- align: center" & gt; & lt; b & gt; 2023 & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" width: 76 %; text- align: left" & gt; Lab equipment & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; 144, 585 & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; 144, 585 & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; Machinery and equipment & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 1, 292, 389 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 1, 240, 628 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" text- align: left; padding- bottom: 1. 5pt" & gt; Furniture and fixtures & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; 19, 643 & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; 19, 643 & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 1, 456, 617 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 1, 404, 856 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" padding- left: 0. 125in; padding- bottom: 1. 5pt" & gt; Less: Accumulated depreciation & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; (681, 693 & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt;) & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; (507, 121 & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt;) & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" text- align: left; padding- bottom: 4pt" & gt; Net Property and Equipment & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: right" & gt; 774, 924 & lt; / td & gt; & lt; td style =" padding- bottom: 4pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: right" & gt; 897, 735 & lt; / td & gt; & lt; td style =" padding- bottom: 4pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; / table & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background- color: white" & gt; & # 160; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; text- align: justify; margin: 0pt 0 0pt 0. 5in" & gt; Depreciation expenses amounted to $ 174, 572 and $ 183, 660 for the years ended January 31, 2024, and 2023, respectively. During the years ended January 31, 2024, and 2023, depreciation expenses of $ 131, 360 and $ 139, 689, respectively, have been allocated to cost of goods sold. & lt; / p & gt; < / us- gaap: PropertyPlantAndEquipmentDisclosureTextBlock > < us- gaap: PropertyPlantAndEquipmentTextBlock contextRef =" c0" id =" ixv- 6990" > & lt; table cellpadding =" 0" cellspacing =" 0" style =" font: 10pt Times New Roman, Times, Serif; border- collapse: collapse; width: 100 %" & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td colspan =" 6" style =" border- bottom: Black 1. 5pt solid; text- align: center" & gt; & lt; b & gt; January 31, & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: right" & gt; 897, 735 & lt; / td & gt; & lt; td style =" padding- bottom: 4pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; / table & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background- color: white" & gt; & # 160; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; text- align: justify; margin: 0pt 0 0pt 0. 5in" & gt; Depreciation expenses amounted to $ 174, 572 and $ 183, 660 for the years ended January 31, 2024, and 2023, respectively. During the years ended January 31, 2024, and 2023, depreciation expenses of $ 131, 360 and $ 139, 689, respectively, have been allocated to cost of goods sold. & lt; / p & gt; < / us- gaap: PropertyPlantAndEquipmentDisclosureTextBlock > < us- gaap: PropertyPlantAndEquipmentTextBlock contextRef =" e63" decimals =" 0" id =" ixv- 14084" unitRef =" usd" > 144585 < / us- gaap: PropertyPlantAndEquipmentGross > < us- gaap: PropertyPlantAndEquipmentGross contextRef =" e64" decimals =" 0" id =" ixv- 14085" unitRef =" usd" > 144585 < / us- gaap:

PropertyPlantAndEquipmentGross > < us- gaap: PropertyPlantAndEquipmentGross contextRef =" c65" decimals =" 0" id =" ixv- 14086" unitRef =" usd" > 1292389 < / us- gaap: PropertyPlantAndEquipmentGross > < us- gaap: PropertyPlantAndEquipmentGross contextRef =" c66" decimals =" 0" id =" ixv- 14087" unitRef =" usd" > 1240628 < / us- gaap: PropertyPlantAndEquipmentGross > < us- gaap: PropertyPlantAndEquipmentGross contextRef =" c60" decimals =" 0" id =" ixv- 14088" unitRef =" usd" > 19643 < / us- gaap: PropertyPlantAndEquipmentGross > < us- gaap: PropertyPlantAndEquipmentGross contextRef =" c67" decimals =" 0" id =" ixv- 14089" unitRef =" usd" > 19643 < / us- gaap: PropertyPlantAndEquipmentGross > < us- gaap: PropertyPlantAndEquipmentGross contextRef =" c5" decimals =" 0" id =" ixv- 14090" unitRef =" usd" > 1456617 < / us- gaap: PropertyPlantAndEquipmentGross > < us- gaap: PropertyPlantAndEquipmentGross contextRef =" c6" decimals =" 0" id =" ixv- 14091" unitRef =" usd" > 1404856 < / us- gaap: PropertyPlantAndEquipmentGross > < us- gaap: PropertyPlantAndEquipmentOtherAccumulatedDepreciation contextRef =" c5" decimals =" 0" id =" ixv- 14092" unitRef =" usd" > 681693 < / us- gaap: PropertyPlantAndEquipmentOtherAccumulatedDepreciation > < us- gaap: PropertyPlantAndEquipmentOtherAccumulatedDepreciation contextRef =" c6" decimals =" 0" id =" ixv- 14093" unitRef =" usd" > 507121 < / us- gaap: PropertyPlantAndEquipmentOtherAccumulatedDepreciation > < us- gaap: PropertyPlantAndEquipmentNet contextRef =" c5" decimals =" 0" id =" ixv- 14094" unitRef =" usd" > 774924 < / us- gaap: PropertyPlantAndEquipmentNet > < us- gaap: PropertyPlantAndEquipmentNet contextRef =" c6" decimals =" 0" id =" ixv- 14095" unitRef =" usd" > 897735 < / us- gaap: PropertyPlantAndEquipmentNet > < us- gaap: Depreciation contextRef =" c0" decimals =" 0" id =" ixv- 14096" unitRef =" usd" > 174572 < / us- gaap: Depreciation > < us- gaap: Depreciation contextRef =" c9" decimals =" 0" id =" ixv- 14097" unitRef =" usd" > 183660 < / us- gaap: Depreciation > < us- gaap: OtherDepreciationAndAmortization contextRef =" c0" decimals =" 0" id =" ixv- 14098" unitRef =" usd" > 131360 < / us- gaap: OtherDepreciationAndAmortization > < us- gaap: OtherDepreciationAndAmortization contextRef =" c9" decimals =" 0" id =" ixv- 14099" unitRef =" usd" > 139689 < / us- gaap: OtherDepreciationAndAmortization > < us- gaap: IncomeTaxDisclosureTextBlock contextRef =" c0" id =" ixv- 7081" > & lt; table cellpadding =" 0" cellspacing =" 0" style =" font: 10pt Times New Roman, Times, Serif; margin- top: 0pt; margin- bottom: 0pt; width: 100 %" & gt; & lt; tr style =" vertical- align: top; text- align: justify" & gt; & lt; td style =" width: 0. 5in; text- align: left" & gt; 4. & lt; / td & gt; & lt; td style =" text- align: justify" & gt; INCOME TAXES & lt; / td & gt; & lt; / tr & gt; & lt; / table & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in" & gt; & # 160; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify" & gt; The Company adopted the provisions of ASC 740, & # x201c; Income Taxes, (& # x201c; ASC 740 & # x201d;). As a result of the implementation of ASC 740, the Company recognized no adjustment in the net liability for unrecognized income tax benefits. The Company believes there are no potential uncertain tax positions, and all tax returns are correct as filed. Should the Company recognize a liability for uncertain tax positions, the Company will separately recognize the liability for uncertain tax positions on its balance sheet. Included in any liability or uncertain tax positions, the Company will also set up a liability for interest and penalties. The Company & # x2019; s policy is to recognize interest and penalties related to uncertain tax positions as a component of the current & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in" & gt; provision for income taxes. & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in" & gt; & # 160; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify" & gt; There is no U. S. tax provision due to losses from U. S. operations for the years ended January 31, 2024 and 2023. Deferred income taxes are provided for the temporary differences between the financial reporting and tax basis of the Company & # x2019; s assets and liabilities. The principal item giving rise to deferred taxes is the net operating loss carryforward in the U. S. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. The Company has set up a valuation allowance for losses for certain carryforwards that it believes may not be realized. & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in" & gt; & # 160; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in" & gt; The provision for income taxes consists of the following: & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in" & gt; & # 160; & lt; / p & gt; & lt; table cellpadding =" 0" cellspacing =" 0" style =" font: 10pt Times New Roman, Times, Serif; border- collapse: collapse; width: 100 %" & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td colspan =" 5" style =" border- bottom: Black 1. 5pt solid; text- align: center" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif; font- size: 10pt" & gt; & lt; b & gt; Years Ended & lt; br / & gt; January 31, & lt; / b & gt; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: center" & gt; & lt; b & gt; 2024 & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: center" & gt; & lt; b & gt; 2023 & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td & gt; Current & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" padding- left: 0. 125in; width: 76 %" & gt; Federal & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; & lt; div style ="- sec- ix- hidden: hidden- fact- 58" & gt; & # 160; & # 160; & # 160; & # 160; & # 160; & # 160; & # 160; & # 160; & # x202f;- & lt; / div & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; & lt; div style ="- sec- ix- hidden: hidden- fact- 59" & gt; & # 160; & # 160; & # 160; & # 160; & # 160; & # 160; & # 160; & # 160; & # 160; & # 160;- & lt; / div & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" padding- left: 0. 125in; padding- bottom: 1. 5pt" & gt; Foreign & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; div style ="- sec- ix- hidden: hidden- fact- 60" & gt;- & lt; / div & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; div style ="- sec- ix- hidden: hidden- fact- 61" & gt;- & lt; / div & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td & gt; Deferred & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" padding- left: 0. 125in" & gt; Federal & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; div style ="- sec- ix- hidden: hidden- fact- 62" & gt;- & lt; / div & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; div style ="- sec- ix- hidden: hidden- fact- 63" & gt;- & lt; / div & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" padding- left: 0. 125in; padding- bottom: 1. 5pt" & gt; Foreign & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; div style ="- sec- ix- hidden: hidden- fact- 64" & gt;- & lt; / div & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; div style ="- sec- ix- hidden: hidden- fact- 65" & gt;- & lt; / div & gt; & lt; / td &

gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; / table & gt; & lt; p style =" margin- top: 0; margin- bottom: 0" & gt; & # 160; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in" & gt; A reconciliation of taxes on income computed at the federal statutory rate to amounts provided is as follows: & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in" & gt; & # 160; & lt; / p & gt; & lt; table cellpadding =" 0" cellspacing =" 0" style =" font: 10pt Times New Roman, Times, Serif; border- collapse: collapse; width: 100 %" & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td colspan =" 6" style =" border- bottom: Black 1. 5pt solid; text- align: center" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif; font- size: 10pt" & gt; & lt; b & gt; Years Ended & lt; / b & gt; & lt; / span & gt; & lt; b & gt; & lt; br / & gt; January 31, & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" border- bottom: Black 1. 5pt solid; text- align: center" & gt; & lt; b & gt; 2024 & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" border- bottom: Black 1. 5pt solid; text- align: center" & gt; & lt; b & gt; 2023 & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" width: 76 %; text- align: left" & gt; Book Income (loss from operations) & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; (1, 151, 916 & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt;) & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; (941, 530 & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt;) & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" text- align: left" & gt; Common stock issued for services & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 155, 966 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 168, 768 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" text- align: left" & gt; Impairment expense & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; div style ="- sec- ix- hidden: hidden- fact- 66" & gt;- & lt; / div & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 68, 738 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" text- align: left; padding- bottom: 1. 5pt" & gt; Unused operating losses & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; 995, 950 & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; 704, 024 & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" text- align: left; padding- bottom: 4pt" & gt; Income tax expense & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: right" & gt; & lt; div style ="- sec- ix- hidden: hidden- fact- 67" & gt;- & lt; / div & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: right" & gt; & lt; div style ="- sec- ix- hidden: hidden- fact- 68" & gt;- & lt; / div & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; table & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" & gt; & # 160; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify" & gt; As of January 31, 2024, the Company recorded a deferred tax asset associated with a net operating loss (& # x201c; NOL & # x201d;) carryforward of approximately $ 15, 800, 000 that was fully offset by a valuation allowance due to the determination that it was more likely than not that the Company would be unable to utilize those benefits in the foreseeable future. The Company & # x2019; s NOL expires in 2041. The tax effect of the valuation allowance increased by approximately $ 1, 151, 916 during the year ended January 31, 2024. On December 22, 2017, the Tax Cuts and Jobs Act (the & # x201c; Tax Act & # x201d;) significantly revised U. S. corporate income tax law by, among other things, reducing the corporate rate from 34 % to 21 %. Because the Company recognizes a valuation allowance for the entire balance, there is no net impact on the Company & # x2019; s balance sheet or results of operations. & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in" & gt; & # 160; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify" & gt; The types of temporary differences between tax basis of assets and liabilities and their financial reporting amounts that give rise to the deferred tax liability and deferred tax asset and their approximate tax effects are as follows: & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in" & gt; & # 160; & lt; / p & gt; & lt; table cellpadding =" 0" cellspacing =" 0" style =" font: 10pt Times New Roman, Times, Serif; border- collapse: collapse; width: 100 %" & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td colspan =" 6" style =" border- bottom: Black 1. 5pt solid; text- align: center" & gt; & lt; b & gt; January 31, & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" border- bottom: Black 1. 5pt solid; text- align: center" & gt; & lt; b & gt; 2024 & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" border- bottom: Black 1. 5pt solid; text- align: center" & gt; & lt; b & gt; 2023 & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" width: 76 %; text- align: left" & gt; Net operating loss carryforward (expire through 2040) & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; (3, 312, 698 & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt;) & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; (2, 316, 748 & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt;) & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" text- align: left" & gt; Stock issued for services & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" text- align: right" & gt; (1, 455, 848 & lt; / td & gt; & lt; td style =" text- align: left" & gt;) & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; (1, 299, 882 & lt; / td & gt; & lt; td style =" text- align: left" & gt;) & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" text- align: left" & gt; Intangible impairment expense & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" text- align: right" & gt; (1, 051, 714 & lt; / td & gt; & lt; td style =" text- align: left" & gt;) & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; (1, 051, 714 & lt; / td & gt; & lt; td style =" text- align: left" & gt;) & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" text- align: left; padding- bottom: 1. 5pt" & gt; Valuation allowance & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; 5, 820, 260 & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; 4, 668, 344 & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" text- align: left; padding- bottom: 4pt" & gt; Net deferred taxes & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: right" & gt; & lt; div style ="- sec- ix- hidden: hidden- fact- 69" & gt;- & lt; / div & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: right" & gt; & lt; div style

=" sec- ix- hidden: hidden- fact- 70" & gt;- & lt; / div & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; / table & gt; < / us- gaap: IncomeTaxDisclosureTextBlock > < us- gaap: ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef =" c0" id =" ixv- 14100" > The provision for income taxes consists of the following: & lt; table cellpadding =" 0" cellspacing =" 0" style =" font: 10pt Times New Roman, Times, Serif; border- collapse: collapse; width: 100 %" & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td colspan =" 5" style =" border- bottom: Black 1. 5pt solid; text- align: center" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif; font- size: 10pt" & gt; & lt; b & gt; Years Ended & lt; br / & gt; January 31, & lt; / b & gt; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: center" & gt; & lt; b & gt; 2024 & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: center" & gt; & lt; b & gt; 2023 & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td & gt; Current & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" padding- left: 0. 125in; width: 76 %" & gt; Federal & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; & lt; div style =" sec- ix- hidden: hidden- fact- 58" & gt; & # 160; & # 160; & # 160; & # 160; & # 160; & # 160; & # 160; & # x202f;- & lt; / div & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; & lt; div style =" sec- ix- hidden: hidden- fact- 59" & gt; & # 160; & # 160; & # 160; & # 160; & # 160; & # 160; & # 160; & # 160; & # 160; & # 160; & # 160;- & lt; / div & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" padding- left: 0. 125in; padding- bottom: 1. 5pt" & gt; Foreign & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; div style =" sec- ix- hidden: hidden- fact- 60" & gt;- & lt; / div & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; div style =" sec- ix- hidden: hidden- fact- 61" & gt;- & lt; / div & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td & gt; Deferred & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" padding- left: 0. 125in" & gt; Federal & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; div style =" sec- ix- hidden: hidden- fact- 62" & gt;- & lt; / div & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; div style =" sec- ix- hidden: hidden- fact- 63" & gt;- & lt; / div & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" padding- left: 0. 125in; padding- bottom: 1. 5pt" & gt; Foreign & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; div style =" sec- ix- hidden: hidden- fact- 64" & gt;- & lt; / div & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; div style =" sec- ix- hidden: hidden- fact- 65" & gt;- & lt; / div & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; / table & gt; < / us- gaap: ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock > < us- gaap: ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef =" c0" id =" ixv- 14101" > A reconciliation of taxes on income computed at the federal statutory rate to amounts provided is as follows: & lt; table cellpadding =" 0" cellspacing =" 0" style =" font: 10pt Times New Roman, Times, Serif; border- collapse: collapse; width: 100 %" & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td colspan =" 6" style =" border- bottom: Black 1. 5pt solid; text- align: center" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif; font- size: 10pt" & gt; & lt; b & gt; Years Ended & lt; / b & gt; & lt; / span & gt; & lt; b & gt; & lt; br / & gt; January 31, & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" border- bottom: Black 1. 5pt solid; text- align: center" & gt; & lt; b & gt; 2024 & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" border- bottom: Black 1. 5pt solid; text- align: center" & gt; & lt; b & gt; 2023 & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" width: 76 %; text- align: left" & gt; Book Income (loss from operations) & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; (1, 151, 916 & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt;) & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; (941, 530 & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt;) & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" text- align: left" & gt; Common stock issued for services & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 155, 966 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 168, 768 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" text- align: left" & gt; Impairment expense & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; div style =" sec- ix- hidden: hidden- fact- 66" & gt;- & lt; / div & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 68, 738 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" text- align: left; padding- bottom: 1. 5pt" & gt; Unused operating losses & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; 995, 950 & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; 704, 024 & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" text-

align: left; padding- bottom: 4pt" & gt; Income tax expense & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: right" & gt; & lt; div style ="- sec- ix- hidden: hidden- fact- 67" & gt;- & lt; / div & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: right" & gt; & lt; div style ="- sec- ix- hidden: hidden- fact- 68" & gt;- & lt; / div & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; / table & gt; < / us- gaap: ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock > < us- gaap: IncomeLossFromContinuingOperations contextRef =" c0" decimals =" 0" id =" ixv- 14102" unitRef =" usd" >- 1151916 < / us- gaap: IncomeLossFromContinuingOperations > < us- gaap: IncomeLossFromContinuingOperations contextRef =" c9" decimals =" 0" id =" ixv- 14103" unitRef =" usd" >- 941530 < / us- gaap: IncomeLossFromContinuingOperations > < us- gaap: IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef =" c0" decimals =" 0" id =" ixv- 14104" unitRef =" usd" > 155966 < / us- gaap: IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost > < us- gaap: IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef =" c9" decimals =" 0" id =" ixv- 14105" unitRef =" usd" > 168768 < / us- gaap: IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost > < us- gaap: IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses contextRef =" c9" decimals =" 0" id =" ixv- 14106" unitRef =" usd" > 68738 < / us- gaap: IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses > < us- gaap: IncomeTaxReconciliationNondeductibleExpenseOther contextRef =" c0" decimals =" 0" id =" ixv- 14107" unitRef =" usd" > 995950 < / us- gaap: IncomeTaxReconciliationNondeductibleExpenseOther > < us- gaap: IncomeTaxReconciliationNondeductibleExpenseOther contextRef =" c9" decimals =" 0" id =" ixv- 14108" unitRef =" usd" > 704024 < / us- gaap: IncomeTaxReconciliationNondeductibleExpenseOther > < us- gaap: DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration contextRef =" e5" decimals =" 0" id =" ixv- 14109" unitRef =" usd" > 15800000 < / us- gaap: DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration > < us- gaap: IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef =" c0" decimals =" 0" id =" ixv- 14110" unitRef =" usd" > 1151916 < / us- gaap: IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance > < us- gaap: EffectiveIncomeTaxRateContinuingOperations contextRef =" c49" decimals =" 2" id =" ixv- 14111" unitRef =" pure" > 0. 34 < / us- gaap: EffectiveIncomeTaxRateContinuingOperations > < us- gaap: EffectiveIncomeTaxRateContinuingOperations contextRef =" c50" decimals =" 2" id =" ixv- 14112" unitRef =" pure" > 0. 21 < / us- gaap: EffectiveIncomeTaxRateContinuingOperations > < us- gaap: ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef =" c0" id =" ixv- 14113" > The types of temporary differences between tax basis of assets and liabilities and their financial reporting amounts that give rise to the deferred tax liability and deferred tax asset and their approximate tax effects are as follows: & lt; table cellpadding =" 0" cellspacing =" 0" style =" font: 10pt Times New Roman, Times, Serif; border- collapse: collapse; width: 100 %" & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td colspan =" 6" style =" border- bottom: Black 1. 5pt solid; text- align: center" & gt; & lt; b & gt; January 31, & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" border- bottom: Black 1. 5pt solid; text- align: center" & gt; & lt; b & gt; 2024 & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" border- bottom: Black 1. 5pt solid; text- align: center" & gt; & lt; b & gt; 2023 & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" width: 76 %; text- align: left" & gt; Net operating loss carryforward (expire through 2040) & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; (3, 312, 698 & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt;) & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; (2, 316, 748 & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt;) & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" text- align: left" & gt; Stock issued for services & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" text- align: right" & gt; (1, 455, 848 & lt; / td & gt; & lt; td style =" text- align: left" & gt;) & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; (1, 299, 882 & lt; / td & gt; & lt; td style =" text- align: left" & gt;) & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" text- align: left" & gt; Intangible impairment expense & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" text- align: right" & gt; (1, 051, 714 & lt; / td & gt; & lt; td style =" text- align: left" & gt;) & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; (1, 051, 714 & lt; / td & gt; & lt; td style =" text- align: left" & gt;) & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" text- align: left; padding- bottom: 1. 5pt" & gt; Valuation allowance & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; 5, 820, 260 & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; 4, 668, 344 & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" text- align: left; padding- bottom: 4pt" & gt; Net deferred taxes & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: right" & gt; & lt; div style ="- sec- ix- hidden: hidden- fact- 69" & gt;- & lt; / div & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: right" & gt; & lt; div style ="- sec- ix- hidden: hidden- fact- 70" & gt;- & lt; / div & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; / table & gt; < / us- gaap: ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock > < us- gaap: DeferredTaxAssetsOperatingLossCarryforwards contextRef =" c5" decimals =" 0" id =" ixv- 14114" unitRef =" usd" > 3312698 < / us- gaap: DeferredTaxAssetsOperatingLossCarryforwards > < us- gaap: DeferredTaxAssetsOperatingLossCarryforwards contextRef =" c6" decimals =" 0" id =" ixv- 14115" unitRef =" usd" > 2316748 < / us- gaap: DeferredTaxAssetsOperatingLossCarryforwards > < ntrb: StockIssuedForServices contextRef =" c0" decimals =" 0" id =" ixv- 14116" unitRef =" usd" >- 1455848 < / ntrb: StockIssuedForServices > < ntrb: StockIssuedForServices contextRef =" c9" decimals =" 0" id =" ixv- 14117" unitRef =" usd" >- 1299882 < / ntrb: StockIssuedForServices > < us- gaap: AssetImpairmentCharges contextRef =" c0" decimals =" 0" id =" ixv- 14118" unitRef =" usd" >- 1051714 < / us- gaap: AssetImpairmentCharges > < us- gaap: AssetImpairmentCharges contextRef =" c9" decimals =" 0" id =" ixv- 14119" unitRef =" usd" >- 1051714 < / us- gaap: AssetImpairmentCharges > < us- gaap: DeferredTaxAssetsValuationAllowance contextRef =" c5" decimals =" 0" id =" ixv- 14120" unitRef =" usd" > 5820260 < / us- gaap: DeferredTaxAssetsValuationAllowance > < us- gaap: DeferredTaxAssetsValuationAllowance contextRef =" c6" decimals =" 0" id =" ixv- 14121" unitRef =" usd" > 4668344 < / us- gaap: DeferredTaxAssetsValuationAllowance > < us- gaap: DebtDisclosureTextBlock contextRef =" c0" id =" ixv- 7407" > & lt; table cellpadding =" 0" cellspacing =" 0" style =" font: 10pt Times New Roman, Times, Serif; margin- top: 0pt; margin- bottom: 0pt; width: 100 %" & gt; & lt; tr style =" vertical- align: top; text- align: justify" & gt; & lt; td style =" width: 0. 5in; text- align: left" & gt; 5. & lt; / td & gt; & lt; td style =" text- align: justify" & gt; NOTES PAYABLE & lt; / td & gt; & lt; / tr & gt; & lt; / table & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in" & gt; & # 160; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- indent: 1in" & gt; & lt; span style =" text- decoration: underline" & gt; Notes Payable & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" & gt; & # 160; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; Active Intelligence, entered into an agreement with the Carolina Small Business Development Fund for a line of credit of $ 160, 000 due October 16, 2028, with interest of 5 % per year. The amount assumed was $ 139, 184. The loan requires monthly payments of principal and interest of $ 1, 697. During the year ended January 31, 2024, the Company made $ 15, 378 of principal payments. As of January 31, 2024, the amount due was $ 85, 249, of which $ 16, 129 is current. As of January 31, 2023, the amount due was $ 100, 627. & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; & # 160; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; On April 3, 2022, the Company entered into a retail installment agreement for the purchase of an automobile. The

contract price was $ 32, 274, of which $ 22, 795 was financed. The agreement is for five years bearing interest at 2. 95 % per annum with payments of $ 410 per month. The loan is secured by automobile. As of January 31, 2024, the amount due was $ 15, 232 of which $ 4, 456 is current. As of January 31, 2023, the amount due was $ 19, 610. & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; & # 160; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; & lt; span style =" text- decoration: underline" & gt; Note payable- related party. & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; & # 160; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; On July 17, 2023, the Company entered an amended Credit Line Note agreement, for an increased $ 5, 000, 000 credit line facility Note, with TII Jet Services LDA, a shareholder of the Company (replacing the $ 2, 000, 000 facility with the same lender that the Company entered on March 17, 2023). Outstanding advances under the Note bears interest at 7 % per annum. The promissory note is due and payable in full on March 19, 2026. Interest is payable annually on December 31 of each year during the term of the note. During the year ended January 31, 2024, the Company received $ 2, 000, 000 on the Note. In December 2023, the Company converted the balance of the credit facility of $ 2, 000, 000 and $ 53, 476 of accrued interest into 1, 026, 520 shares of common stock. The fair value of the common stock was $ 2, 554, 423 resulting in a $ 554, 423 loss on extinguishment. As of January 31, 2024, the balance due was $- 0-. The Company recorded interest expense of $ 60, 453 for the year ended January 31, 2024. & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white; text- indent: 0. 5in" & gt; & # 160; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; & lt; span style =" text- decoration: underline" & gt; Secured borrowing liability. & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; & # 160; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; The Company entered into an accounts receivable sale agreement for one of its subsidiaries in connection with a bankruptcy claim. The Company received $ 106, 528 and recorded the transaction as a secured loan payable against the account receivable. The sale of the account receivable balance was to an outside third party, whereby if the bankruptcy court does not pay the balance in full, the Company will owe back the unpaid portion. The loan is classified as a current liability as the Company expects the bankruptcy will be resolved in the next twelve months. The loan bears interest at 10 %. For the year ended January 31, 2024, the Company recorded interest expense of $ 5, 470. & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white; text- indent: 0. 25in" & gt; & # 160; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; Interest expenses for the year ended January 31, 2024, and 2023, were $ 75, 815 and $ 6, 289, respectively. & lt; / p & gt; < / us- gaap: DebtDisclosureTextBlock > < us- gaap: LineOfCreditFacilityIncreaseAccruedInterest contextRef =" c68" decimals =" 0" id =" ixv- 14122" unitRef =" usd" > 160000 < / us- gaap: LineOfCreditFacilityIncreaseAccruedInterest > < us- gaap: LineOfCreditFacilityExpirationDate1 contextRef =" c0" id =" ixv- 14123" > 2028- 10- 16 < / us- gaap: LineOfCreditFacilityExpirationDate1 > < us- gaap: LineOfCreditFacilityInterestRateDuringPeriod contextRef =" c0" decimals =" 2" id =" ixv- 14124" unitRef =" pure" > 0. 05 < / us- gaap: LineOfCreditFacilityInterestRateDuringPeriod > < us- gaap: DebtDefaultLongtermDebtAmount contextRef =" c69" decimals =" 0" id =" ixv- 14125" unitRef =" usd" > 139184 < / us- gaap: DebtDefaultLongtermDebtAmount > < us- gaap: DebtInstrumentPeriodicPayment contextRef =" c68" decimals =" 0" id =" ixv- 14126" unitRef =" usd" > 1697 < / us- gaap: DebtInstrumentPeriodicPayment > < us- gaap: DebtInstrumentPeriodicPaymentInterest contextRef =" c68" decimals =" 0" id =" ixv- 14127" unitRef =" usd" > 15378 < / us- gaap: DebtInstrumentPeriodicPaymentInterest > < ntrb: DueBalanceAmount contextRef =" c0" decimals =" 0" id =" ixv- 14128" unitRef =" usd" > 85249 < / ntrb: DueBalanceAmount > < us- gaap: ConvertibleNotesPayableCurrent contextRef =" c5" decimals =" 0" id =" ixv- 14129" unitRef =" usd" > 16129 < / us- gaap: ConvertibleNotesPayableCurrent > < us- gaap: LineOfCreditFacilityAverageOutstandingAmount contextRef =" c9" decimals =" 0" id =" ixv- 14130" unitRef =" usd" > 100627 < / us- gaap: LineOfCreditFacilityAverageOutstandingAmount > < us- gaap: LineOfCredit contextRef =" c70" decimals =" 0" id =" ixv- 14131" unitRef =" usd" > 32274 < / us- gaap: LineOfCredit > < us- gaap: LineOfCreditFacilityMaximumBorrowingCapacity contextRef =" c70" decimals =" 0" id =" ixv- 14132" unitRef =" usd" > 22795 < / us- gaap: LineOfCreditFacilityMaximumBorrowingCapacity > < us- gaap: LineOfCreditFacilityInterestRateDuringPeriod contextRef =" c71" decimals =" 4" id =" ixv- 14133" unitRef =" pure" > 0. 0295 < / us- gaap: LineOfCreditFacilityInterestRateDuringPeriod > < us- gaap: LineOfCreditFacilityPeriodicPayment contextRef =" c71" decimals =" 0" id =" ixv- 14134" unitRef =" usd" > 410 < / us- gaap: LineOfCreditFacilityPeriodicPayment > < us- gaap: LineOfCreditFacilityAverageOutstandingAmount contextRef =" c71" decimals =" 0" id =" ixv- 14135" unitRef =" usd" > 15232 < / us- gaap: LineOfCreditFacilityAverageOutstandingAmount > < us- gaap: LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod contextRef =" c71" decimals =" 0" id =" ixv- 14136" unitRef =" usd" > 4456 < / us- gaap: LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod > < us- gaap: LineOfCreditFacilityAverageOutstandingAmount contextRef =" c72" decimals =" 0" id =" ixv- 14137" unitRef =" usd" > 19610 < / us- gaap: LineOfCreditFacilityAverageOutstandingAmount > < us- gaap: LineOfCreditFacilityCapacityAvailableForTradePurchases contextRef =" c73" decimals =" 0" id =" ixv- 14138" unitRef =" usd" > 5000000 < / us- gaap: LineOfCreditFacilityCapacityAvailableForTradePurchases > < us- gaap: LineOfCreditFacilityCapacityAvailableForTradePurchases contextRef =" c74" decimals =" 0" id =" ixv- 14139" unitRef =" usd" > 2000000 < / us- gaap: LineOfCreditFacilityCapacityAvailableForTradePurchases > < us- gaap: LongTermDebtPercentageBearingFixedInterestRate contextRef =" c5" decimals =" 2" id =" ixv- 14140" unitRef =" pure" > 0. 07 < / us- gaap: LongTermDebtPercentageBearingFixedInterestRate > < ntrb: AdvancesAmount contextRef =" c69" decimals =" 0" id =" ixv- 14141" unitRef =" usd" > 2000000 < / ntrb: AdvancesAmount > < ntrb: LineOfCreditFacilityConverted contextRef =" c6" decimals =" 0" id =" ixv- 14142" unitRef =" usd" > 2000000 < / ntrb: LineOfCreditFacilityConverted > < us- gaap: LineOfCreditFacilityIncreaseAccruedInterest contextRef =" c9" decimals =" 0" id =" ixv- 14143" unitRef =" usd" > 53476 < / us- gaap: LineOfCreditFacilityIncreaseAccruedInterest > < ntrb: LineOfCreditFacilityCommonStock contextRef =" c9" decimals =" 0" id =" ixv- 14144" unitRef =" shares" > 1026520 < / ntrb: LineOfCreditFacilityCommonStock > < ntrb: FairValueOfCommonStock contextRef =" c9" decimals =" 0" id =" ixv- 14145" unitRef =" usd" > 2554423 < / ntrb: FairValueOfCommonStock > < us- gaap: GainsLossesOnExtinguishmentOfDebt contextRef =" c72" decimals =" 0" id =" ixv- 14146" unitRef =" usd" > 554423 < / us- gaap: GainsLossesOnExtinguishmentOfDebt > < us- gaap: LineOfCreditFacilityAverageOutstandingAmount contextRef =" c0" decimals =" 0" id =" ixv- 14147" unitRef =" usd" > 0 < / us- gaap: LineOfCreditFacilityAverageOutstandingAmount > < us- gaap: InterestExpenseDebt contextRef =" c68" decimals =" 0" id =" ixv- 14148" unitRef =" usd" > 60453 < / us- gaap: InterestExpenseDebt > < us- gaap: NotesAndLoansPayable contextRef =" c5" decimals =" 0" id =" ixv- 14149" unitRef =" usd" > 106528 < / us- gaap: NotesAndLoansPayable > < us- gaap: LongTermDebtPercentageBearingVariableInterestRate contextRef =" c5" decimals =" 2" id =" ixv- 14150" unitRef =" pure" > 0. 10 < / us- gaap: LongTermDebtPercentageBearingVariableInterestRate > < us- gaap: InterestExpenseDebt contextRef =" c0" decimals =" 0" id =" ixv- 14151" unitRef =" usd" > 5470 < / us- gaap: InterestExpenseDebt > < us- gaap: InterestExpenseDebt contextRef =" c75" decimals =" 0" id =" ixv- 14152" unitRef =" usd" > 75815 < / us- gaap: InterestExpenseDebt > < us- gaap: InterestExpenseDebt contextRef =" c76" decimals =" 0" id =" ixv- 14153" unitRef =" usd" > 6289 < / us- gaap: InterestExpenseDebt > < us- gaap: IntangibleAssetsDisclosureTextBlock contextRef =" c0" id =" ixv- 7446" > & lt; table cellpadding =" 0" cellspacing =" 0" style =" font: 10pt Times New Roman, Times, Serif; margin- top: 0pt; margin- bottom: 0pt; width: 100 %" & gt; & lt; tr style =" vertical- align: top" & gt; & lt; td style =" width: 0. 5in" & gt; 6. & lt; / td & gt; & lt; td & gt; INTANGIBLE ASSETS & lt; / td & gt; & lt; / tr & gt; & lt; / table & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; background- color: white" & gt; & # 160; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; background- color: white" & gt; As of January 31, 2024, and 2023, intangible assets consisted of intellectual property and trademarks, customer base, and license agreement, net of amortization, as follows: & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; background- color: white" & gt; & # 160; & lt; / p & gt; & lt; table cellpadding =" 0" cellspacing =" 0" style =" font: 10pt Times New Roman, Times, Serif; border- collapse: collapse; width: 100 %" & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td colspan =" 6" style =" border- bottom: Black 1. 5pt solid; text- align: center" & gt; & lt; b & gt; January 31, & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" border- bottom: Black 1. 5pt solid; text- align: center" & gt; & lt; b & gt; 2024 & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" border- bottom: Black 1. 5pt solid; text- align: center" & gt; & lt; b & gt; 2023 & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" width: 76 %; text- align: left" & gt; Customer base & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; 314, 100 & lt; / td & gt; & lt; td style =" width: 1 %;

text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; 314, 100 & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; Intellectual property and trademarks & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; 817, 400 & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; 817, 400 & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td & gt; Total & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 1, 131, 500 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 1, 131, 500 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; Less: Accumulated amortization & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; (464, 220 & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt;) & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; (351, 070 & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt;) & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" text- align: left; padding- bottom: 4pt" & gt; Net Intangible Assets & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: right" & gt; 667, 280 & lt; / td & gt; & lt; td style =" padding- bottom: 4pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: right" & gt; 780, 430 & lt; / td & gt; & lt; td style =" padding- bottom: 4pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; / table & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" & gt; & # 160; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; In February 2021, the Company acquired an IP license from Rambam Med- Tech Ltd. for $ 50, 000. The value of the intangible assets, consisting of intellectual property, license agreement and customer base has been recorded at their fair value by the Company and are being amortized over a period of three to ten years. The Company terminated the license agreement in October 2022. The Company issued 25, 000 shares of its common stock from its treasury shares held by the Company and warrants to purchase 25, 000 shares at an exercise price of $ 7. 50 per share as part of the termination agreement. The Company recorded a termination expense of $ 174, 025 during the year ended January 31, 2023. Which is included in selling, general and administrative expenses. The Company expensed the balance of the agreement of $ 33, 334 during the year ended January 31, 2023, which is included in selling, general and administrative expenses. Amortization expenses for the years ended January 31, 2024, and 2023 amounted to $ 113, 150 and $ 146, 483, respectively. & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; & # 160; & lt; / p & gt; & lt; table cellpadding =" 0" cellspacing =" 0" style =" font: 10pt Times New Roman, Times, Serif; border- collapse: collapse; width: 100 %" & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; Year Ended January 31, & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td colspan =" 2" style =" padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" width: 88 %; text- align: left" & gt; 2025 & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; 113, 109 & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" text- align: left" & gt; 2026 & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 113, 109 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" text- align: left" & gt; 2027 & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 113, 109 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" text- align: left" & gt; 2028 & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 113, 109 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" text- align: left" & gt; 2029 & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 113, 109 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" text- align: left; padding- bottom: 1. 5pt" & gt; 2030 and thereafter & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; 101, 735 & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" text- align: left; padding- bottom: 4pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: right" & gt; 667, 280 & lt; / td & gt; & lt; td style =" padding- bottom: 4pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; / table & gt; < / us- gaap: IntangibleAssetsDisclosureTextBlock > < us- gaap: ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock contextRef =" c0" id =" ixv- 14154" > As of January 31, 2024, and 2023, intangible assets consisted of intellectual property and trademarks, customer base, and license agreement, net of amortization, as follows: & lt; table cellpadding =" 0" cellspacing =" 0" style =" font: 10pt Times New Roman, Times, Serif; border- collapse: collapse; width: 100 %" & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td colspan =" 6" style =" border- bottom: Black 1. 5pt solid; text- align: center" & gt; & lt; b & gt; January 31, & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" border- bottom: Black 1. 5pt solid; text- align: center" & gt; & lt; b & gt; 2024 & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" border- bottom: Black 1. 5pt solid; text- align: center" & gt; & lt; b & gt; 2023 & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" width: 76 %; text- align: left" & gt; Customer base & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & # 160; & lt; / td & gt; & lt; td style =" width:

1 %; text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; 314, 100 & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; 314, 100 & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; Intellectual property and trademarks & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; 817, 400 & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; 817, 400 & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td & gt; Total & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 1, 131, 500 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 1, 131, 500 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; Less: Accumulated amortization & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; (464, 220 & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt;) & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; (351, 070 & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt;) & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" text- align: left; padding- bottom: 4pt" & gt; Net Intangible Assets & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: right" & gt; 667, 280 & lt; / td & gt; & lt; td style =" padding- bottom: 4pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: right" & gt; 780, 430 & lt; / td & gt; & lt; td style =" padding- bottom: 4pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; / table & gt; < / us- gaap: ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock > < us- gaap: FiniteLivedIntangibleAssetsGross contextRef =" c79" decimals =" 0" id =" ixv- 14155" unitRef =" usd" > 314100 < / us- gaap: FiniteLivedIntangibleAssetsGross > < us- gaap: FiniteLivedIntangibleAssetsGross contextRef =" c80" decimals =" 0" id =" ixv- 14156" unitRef =" usd" > 314100 < / us- gaap: FiniteLivedIntangibleAssetsGross > < us- gaap: FiniteLivedIntangibleAssetsGross contextRef =" c81" decimals =" 0" id =" ixv- 14157" unitRef =" usd" > 817400 < / us- gaap: FiniteLivedIntangibleAssetsGross > < us- gaap: FiniteLivedIntangibleAssetsGross contextRef =" c82" decimals =" 0" id =" ixv- 14158" unitRef =" usd" > 817400 < / us- gaap: FiniteLivedIntangibleAssetsGross > < us- gaap: FiniteLivedIntangibleAssetsGross contextRef =" c5" decimals =" 0" id =" ixv- 14159" unitRef =" usd" > 1131500 < / us- gaap: FiniteLivedIntangibleAssetsGross > < us- gaap: FiniteLivedIntangibleAssetsGross contextRef =" c6" decimals =" 0" id =" ixv- 14160" unitRef =" usd" > 1131500 < / us- gaap: FiniteLivedIntangibleAssetsGross > < us- gaap: FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef =" c5" decimals =" 0" id =" ixv- 14161" unitRef =" usd" > 464220 < / us- gaap: FiniteLivedIntangibleAssetsAccumulatedAmortization > < us- gaap: FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef =" c6" decimals =" 0" id =" ixv- 14162" unitRef =" usd" > 351070 < / us- gaap: FiniteLivedIntangibleAssetsAccumulatedAmortization > < us- gaap: FiniteLivedIntangibleAssetsNet contextRef =" c5" decimals =" 0" id =" ixv- 14163" unitRef =" usd" > 667280 < / us- gaap: FiniteLivedIntangibleAssetsNet > < us- gaap: FiniteLivedIntangibleAssetsNet contextRef =" c6" decimals =" 0" id =" ixv- 14164" unitRef =" usd" > 780430 < / us- gaap: FiniteLivedIntangibleAssetsNet > < us- gaap: InvestmentCompanyCommittedCapital contextRef =" c77" decimals =" 0" id =" ixv- 14165" unitRef =" usd" > 50000 < / us- gaap: InvestmentCompanyCommittedCapital > < ntrb: amortizedOverPeriod contextRef =" c49" id =" ixv- 14166" > P3Y < / ntrb: amortizedOverPeriod > < ntrb: amortizedOverPeriod contextRef =" c50" id =" ixv- 14167" > P10Y < / ntrb: amortizedOverPeriod > < us- gaap: ExcessStockSharesIssued contextRef =" c5" decimals =" 0" id =" ixv- 14169" unitRef =" shares" > 25000 < / us- gaap: ExcessStockSharesIssued > < ntrb: WarrantsToPurchase contextRef =" c0" decimals =" 0" id =" ixv- 14170" unitRef =" shares" > 25000 < / ntrb: WarrantsToPurchase > < us- gaap: ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef =" c5" decimals =" 2" id =" ixv- 14171" unitRef =" usdPershares" > 7. 5 < / us- gaap: ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 > < us- gaap: OtherExpenses contextRef =" c78" decimals =" 0" id =" ixv- 14172" unitRef =" usd" > 174025 < / us- gaap: OtherExpenses > < us- gaap: InterestExpenseDeposits contextRef =" c9" decimals =" 0" id =" ixv- 14173" unitRef =" usd" > 33334 < / us- gaap: InterestExpenseDeposits > < us- gaap: ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef =" c0" id =" ixv- 14174" > Amortization expenses for the years ended January 31, 2024, and 2023 amounted to $ 113, 150 and $ 146, 483, respectively. & lt; table cellpadding =" 0" cellspacing =" 0" style =" font: 10pt Times New Roman, Times, Serif; border- collapse: collapse; width: 100 %" & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; Year Ended January 31, & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td colspan =" 2" style =" padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" width: 88 %; text- align: left" & gt; 2025 & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; 113, 109 & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" text- align: left" & gt; 2026 & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 113, 109 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" text- align: left" & gt; 2027 & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 113, 109 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" text- align: left" & gt; 2028 & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 113, 109 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" text- align: left" & gt; 2029 & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 113, 109 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" text- align: left; padding- bottom: 1. 5pt" & gt; 2030 and thereafter & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; 101, 735 & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" text- align: left; padding- bottom: 4pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: right" &

gt; 667, 280 & lt; / td & gt; & lt; td style =" padding- bottom: 4pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; / table & gt; < / us- gaap: ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock > < us- gaap: AmortizationOfIntangibleAssets contextRef =" c0" decimals =" 0" id =" ixv- 14175" unitRef =" usd" > 113150 < / us- gaap: AmortizationOfIntangibleAssets > < us- gaap: AmortizationOfIntangibleAssets contextRef =" c9" decimals =" 0" id =" ixv- 14176" unitRef =" usd" > 146483 < / us- gaap: AmortizationOfIntangibleAssets > < us- gaap: FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths contextRef =" c5" decimals =" 0" id =" ixv- 14177" unitRef =" usd" > 113109 < / us- gaap: FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths > < us- gaap: FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef =" c5" decimals =" 0" id =" ixv- 14178" unitRef =" usd" > 113109 < / us- gaap: FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo > < us- gaap: FiniteLivedIntangibleAssetsAmortizationExpenseYearThree contextRef =" c5" decimals =" 0" id =" ixv- 14179" unitRef =" usd" > 113109 < / us- gaap: FiniteLivedIntangibleAssetsAmortizationExpenseYearThree > < us- gaap: FiniteLivedIntangibleAssetsAmortizationExpenseYearFour contextRef =" c5" decimals =" 0" id =" ixv- 14180" unitRef =" usd" > 113109 < / us- gaap: FiniteLivedIntangibleAssetsAmortizationExpenseYearFour > < us- gaap: FiniteLivedIntangibleAssetsAmortizationExpenseYearFive contextRef =" c5" decimals =" 0" id =" ixv- 14181" unitRef =" usd" > 113109 < / us- gaap: FiniteLivedIntangibleAssetsAmortizationExpenseYearFive > < us- gaap: FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive contextRef =" c5" decimals =" 0" id =" ixv- 14182" unitRef =" usd" > 101735 < / us- gaap: FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive > < us- gaap: FiniteLivedIntangibleAssetsNet contextRef =" c5" decimals =" 0" id =" ixv- 14183" unitRef =" usd" > 667280 < / us- gaap: FiniteLivedIntangibleAssetsNet > < us- gaap: RelatedPartyTransactionsDisclosureTextBlock contextRef =" c0" id =" ixv- 7615" > & lt; table cellpadding =" 0" cellspacing =" 0" style =" font: 10pt Times New Roman, Times, Serif; margin- top: 0pt; margin- bottom: 0pt; width: 100 %" & gt; & lt; tr style =" vertical- align: top" & gt; & lt; td style =" width: 0. 5in" & gt; 7. & lt; / td & gt; & lt; td style =" text- align: justify" & gt; RELATED PARTY TRANSACTIONS & lt; / td & gt; & lt; / tr & gt; & lt; / table & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify" & gt; & # 160; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in" & gt; Activity during the year ended January 31, 2024 & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in" & gt; & # 160; & lt; / p & gt; & lt; table cellpadding =" 0" cellspacing =" 0" style =" font: 10pt Times New Roman, Times, Serif; margin- top: 0pt; margin- bottom: 0pt" width =" 100 %" & gt; & lt; tr style =" vertical- align: top" & gt; & lt; td style =" width: 0. 5in" & gt; & lt; / td & gt; & lt; td style =" width: 0. 25in" & gt; a) & lt; / td & gt; & lt; td style =" text- align: justify" & gt; On February 1, 2023, options to purchase 30, 000 shares of the Company & # x2019; s common stock were issued to an executive of the Company at a price of $ 3. 975 per share. The options vest immediately and expire in three years. The fair value of the options issued for services amounted to $ 75, 030 and was expensed during the year ended January 31, 2024. & lt; / td & gt; & lt; / tr & gt; & lt; / table & gt; & lt; p style =" margin- top: 0; margin- bottom: 0" & gt; & # 160; & lt; / p & gt; & lt; table cellpadding =" 0" cellspacing =" 0" style =" font: 10pt Times New Roman, Times, Serif; margin- top: 0pt; margin- bottom: 0pt" width =" 100 %" & gt; & lt; tr style =" vertical- align: top" & gt; & lt; td style =" width: 0. 5in" & gt; & lt; / td & gt; & lt; td style =" width: 0. 25in" & gt; b) & lt; / td & gt; & lt; td style =" text- align: justify" & gt; In September and October 2023, options to purchase 374, 500 shares of common stock to executives and directors of the Company at a price of $ 1. 93, $ 2. 12 and $ 2. 65 per share. The options vest immediately and expire in three years. The fair value of the options issued amounted to $ 424, 826 and was expensed during the year ended January 31, 2024. & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: top" & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: justify" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; / table & gt; & lt; table cellpadding =" 0" cellspacing =" 0" style =" font: 10pt Times New Roman, Times, Serif; margin- top: 0pt; margin- bottom: 0pt" width =" 100 %" & gt; & lt; tr style =" vertical- align: top" & gt; & lt; td style =" width: 0. 5in" & gt; & lt; / td & gt; & lt; td style =" width: 0. 25in" & gt; c) & lt; / td & gt; & lt; td style =" text- align: justify" & gt; On October 26, 2023, warrants to purchase 87, 500 shares of the Company & # x2019; s common stock were issued to the Chief Financial Officer at a price of $ 1. 93 per share. The warrant expires in three years. The fair value of the warrants issued amounted to $ 93, 450 and was expensed during the year ended January 31, 2024. & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: top" & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: justify" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; / table & gt; & lt; table cellpadding =" 0" cellspacing =" 0" style =" font: 10pt Times New Roman, Times, Serif; margin- top: 0pt; margin- bottom: 0pt" width =" 100 %" & gt; & lt; tr style =" vertical- align: top" & gt; & lt; td style =" width: 0. 5in" & gt; & lt; / td & gt; & lt; td style =" width: 0. 25in" & gt; d) & lt; / td & gt; & lt; td style =" text- align: justify" & gt; On July 17, 2023, the Company entered an amended Credit Line Note facility with TII Jet Services LDA, a shareholder of the Company, for a credit facility of $ 5 million (replacing the $ 2, 000, 000 facility with the same lender that the Company entered on March 17, 2023). See Note 5 for further information. TII Jet Services LDA is owned 100 % by a shareholder of the Company. During the year ended January 31, 2024, the Company received $ 2, 000, 000 from the credit facility. In December 2023, TII Jet Services LDA converted the balance of the credit facility of $ 2, 000, 000 and $ 53, 436 of accrued interest into 1, 026, 520 shares of the Company & # x2019; s common stock. & lt; / td & gt; & lt; / tr & gt; & lt; / table & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 75in; text- align: justify" & gt; & # 160; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 25in; text- align: justify; text- indent: 0. 75in" & gt; Activity during the year ended January 31, 2023 & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify" & gt; & # 160; & lt; / p & gt; & lt; table cellpadding =" 0" cellspacing =" 0" style =" font: 10pt Times New Roman, Times, Serif; margin- top: 0pt; margin- bottom: 0pt" width =" 100 %" & gt; & lt; tr style =" vertical- align: top" & gt; & lt; td style =" width: 0. 5in" & gt; & lt; / td & gt; & lt; td style =" width: 0. 25in" & gt; a) & lt; / td & gt; & lt; td style =" text- align: justify" & gt; In May 2022, the Company issued stock awards to the Company & # x2019; s CEO and the independent members of the Board of Directors. The CEO received 11, 667 shares and the four directors received 1, 167 shares each. The Company recorded a compensation expense of $ 53, 200 in connection with the issuance of the shares. & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: top" & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: justify" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; / table & gt; & lt; table cellpadding =" 0" cellspacing =" 0" style =" font: 10pt Times New Roman, Times, Serif; margin- top: 0pt; margin- bottom: 0pt" width =" 100 %" & gt; & lt; tr style =" vertical- align: top" & gt; & lt; td style =" width: 0. 5in" & gt; & lt; / td & gt; & lt; td style =" width: 0. 25in" & gt; b) & lt; / td & gt; & lt; td style =" text- align: justify" & gt; On August 2, 2022, 137, 084 options to purchase shares of the Company & # x2019; s common stock were issued to executives of the Company at prices of $ 4. 09 and $ 4. 50 per share. The options vest immediately and expire in three years. The fair value of the options issued for services amounted to $ 399, 075 and was expensed during the year ended January 31, 2023. & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: top" & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: justify" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; / table & gt; & lt; table cellpadding =" 0" cellspacing =" 0" style =" font: 10pt Times New Roman, Times, Serif; margin- top: 0pt; margin- bottom: 0pt" width =" 100 %" & gt; & lt; tr style =" vertical- align: top" & gt; & lt; td style =" width: 0. 5in" & gt; & lt; / td & gt; & lt; td style =" width: 0. 25in" & gt; c) & lt; / td & gt; & lt; td style =" text- align: justify" & gt; On September 30, 2022, 35, 000 options to purchase shares of the Company & # x2019; s common stock were issued to the independent directors of the Company at a price of $ 3. 59 per share. The options vest immediately and expire in five years. The fair value of the options issued for services amounted to $ 85, 995 and was expensed during the year ended January 31, 2023 & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: top" & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: justify" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; / table & gt; & lt; table cellpadding =" 0" cellspacing =" 0" style =" font: 10pt Times New Roman, Times, Serif; margin- top: 0pt; margin- bottom: 0pt" width =" 100 %" & gt; & lt; tr style =" vertical- align: top" & gt; & lt; td style =" width: 0. 5in" & gt; & lt; / td & gt; & lt; td style =" width: 0. 25in" & gt; d) & lt; / td & gt; & lt; td style =" text- align: justify" & gt; On December 7, 2022, options to purchase 107, 500 shares of the Company & # x2019; s common stock were issued to executives of the Company at prices of $ 3. 53 and $ 3. 88 per share. The options vest immediately and expire in three years. The fair value of the options issued amounted to $ 245, 170 and was expensed during the year ended January 31, 2023. & lt; / td & gt; & lt; / tr & gt; & lt; / table & gt; < / us- gaap: RelatedPartyTransactionsDisclosureTextBlock > < us- gaap: StockIssuedDuringPeriodSharesPurchaseOfAssets contextRef =" c83" decimals =" 0" id =" ixv- 14184" unitRef =" shares" > 30000 < / us- gaap: StockIssuedDuringPeriodSharesPurchaseOfAssets > < us- gaap: SaleOfStockPricePerShare contextRef =" c84" decimals =" 3" id =" ixv- 14185" unitRef =" usdPershares" > 3. 975 < / us- gaap: SaleOfStockPricePerShare > < us- gaap: SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef =" c83" id =" ixv- 14186" > P3Y < / us- gaap: SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod > < us- gaap: RelatedPartyTransactionAmountsOfTransaction contextRef =" c85" decimals =" 0" id =" ixv- 14187" unitRef =" usd" > 75030 < / us- gaap: RelatedPartyTransactionAmountsOfTransaction > < us- gaap: StockIssuedDuringPeriodSharesPurchaseOfAssets contextRef =" c86" decimals =" 0" id =" ixv- 14188" unitRef =" shares" > 374500 < / us- gaap: StockIssuedDuringPeriodSharesPurchaseOfAssets > < us- gaap: StockIssuedDuringPeriodSharesPurchaseOfAssets contextRef =" c87" decimals =" 0" id =" ixv- 14189" unitRef =" shares" > 374500 < / us- gaap: StockIssuedDuringPeriodSharesPurchaseOfAssets > < us- gaap: SaleOfStockPricePerShare contextRef =" c88" decimals =" 2" id =" ixv- 14190" unitRef =" usdPershares" > 1. 93 < / us- gaap: SaleOfStockPricePerShare > < us- gaap: SaleOfStockPricePerShare contextRef =" c89" decimals =" 2" id =" ixv- 14191" unitRef =" usdPershares" > 1. 93 < / us- gaap: SaleOfStockPricePerShare > < us- gaap: SaleOfStockPricePerShare contextRef =" c90" decimals =" 2" id =" ixv- 14192" unitRef =" usdPershares" > 2. 12 < / us- gaap: SaleOfStockPricePerShare > < us- gaap:

SaleOfStockPricePerShare contextRef =" c91" decimals =" 2" id =" ixv- 14193" unitRef =" usdPershares" > 2. 12 < / us- gaap: SaleOfStockPricePerShare > < us- gaap: SaleOfStockPricePerShare contextRef =" c92" decimals =" 2" id =" ixv- 14194" unitRef =" usdPershares" > 2. 65 < / us- gaap: SaleOfStockPricePerShare > < us- gaap: SaleOfStockPricePerShare contextRef =" c93" decimals =" 2" id =" ixv- 14195" unitRef =" usdPershares" > 2. 65 < / us- gaap: SaleOfStockPricePerShare > < us- gaap: SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef =" c87" id =" ixv- 14196" > P3Y < / us- gaap: SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod > < us- gaap: RelatedPartyTransactionAmountsOfTransaction contextRef =" c0" decimals =" 0" id =" ixv- 14197" unitRef =" usd" > 424826 < / us- gaap: RelatedPartyTransactionAmountsOfTransaction > < us- gaap: StockIssuedDuringPeriodSharesPurchaseOfAssets contextRef =" c94" decimals =" 0" id =" ixv- 14198" unitRef =" shares" > 87500 < / us- gaap: StockIssuedDuringPeriodSharesPurchaseOfAssets > < us- gaap: SaleOfStockPricePerShare contextRef =" c95" decimals =" 2" id =" ixv- 14199" unitRef =" usdPershares" > 1. 93 < / us- gaap: SaleOfStockPricePerShare > < us- gaap: SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef =" c96" id =" ixv- 14200" > P3Y < / us- gaap: SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod > < us- gaap: RelatedPartyTransactionAmountsOfTransaction contextRef =" c97" decimals =" 0" id =" ixv- 14201" unitRef =" usd" > 93450 < / us- gaap: RelatedPartyTransactionAmountsOfTransaction > < us- gaap: RelatedPartyTransactionAmountsOfTransaction contextRef =" c98" decimals =" - 6" id =" ixv- 14202" unitRef =" usd" > 5000000 < / us- gaap: RelatedPartyTransactionAmountsOfTransaction > < us- gaap: RelatedPartyTransactionAmountsOfTransaction contextRef =" c99" decimals =" 0" id =" ixv- 14203" unitRef =" usd" > 2000000 < / us- gaap: RelatedPartyTransactionAmountsOfTransaction > < ntrb: PurchaseShare contextRef =" c98" decimals =" 2" id =" ixv- 14204" unitRef =" pure" > 1 < / ntrb: PurchaseShare > < us- gaap: DerivativeCashReceivedOnHedge contextRef =" c0" decimals =" 0" id =" ixv- 14205" unitRef =" usd" > 2000000 < / us- gaap: DerivativeCashReceivedOnHedge > < ntrb: LineOfCreditFacility contextRef =" c100" decimals =" 0" id =" ixv- 14206" unitRef =" usd" > 2000000 < / ntrb: LineOfCreditFacility > < us- gaap: LineOfCreditFacilityIncreaseAccruedInterest contextRef =" c31" decimals =" 0" id =" ixv- 14207" unitRef =" usd" > 53436 < / us- gaap: LineOfCreditFacilityIncreaseAccruedInterest > < us- gaap: CommonStockSharesAuthorized contextRef =" c10" decimals =" 0" id =" ixv- 14208" unitRef =" shares" > 1026520 < / us- gaap: CommonStockSharesAuthorized > < us- gaap: StockIssuedDuringPeriodSharesOther contextRef =" c101" decimals =" 0" id =" ixv- 14209" unitRef =" shares" > 11667 < / us- gaap: StockIssuedDuringPeriodSharesOther > < us- gaap: StockIssuedDuringPeriodSharesOther contextRef =" c102" decimals =" 0" id =" ixv- 14210" unitRef =" shares" > 1167 < / us- gaap: StockIssuedDuringPeriodSharesOther > < us- gaap: DeferredCompensationArrangementWithIndividualCompensationExpense contextRef =" c102" decimals =" 0" id =" ixv- 14211" unitRef =" usd" > 53200 < / us- gaap: DeferredCompensationArrangementWithIndividualCompensationExpense > < us- gaap: StockIssuedDuringPeriodSharesPurchaseOfAssets contextRef =" c103" decimals =" 0" id =" ixv- 14212" unitRef =" shares" > 137084 < / us- gaap: StockIssuedDuringPeriodSharesPurchaseOfAssets > < us- gaap: SaleOfStockPricePerShare contextRef =" c104" decimals =" 2" id =" ixv- 14213" unitRef =" usdPershares" > 4. 09 < / us- gaap: SaleOfStockPricePerShare > < us- gaap: SaleOfStockPricePerShare contextRef =" c105" decimals =" 2" id =" ixv- 14214" unitRef =" usdPershares" > 4. 5 < / us- gaap: SaleOfStockPricePerShare > < us- gaap: SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef =" c103" id =" ixv- 14215" > P3Y < / us- gaap: SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod > < us- gaap: RelatedPartyTransactionAmountsOfTransaction contextRef =" c103" decimals =" 0" id =" ixv- 14216" unitRef =" usd" > 399075 < / us- gaap: RelatedPartyTransactionAmountsOfTransaction > < us- gaap: StockIssuedDuringPeriodSharesPurchaseOfAssets contextRef =" c106" decimals =" 0" id =" ixv- 14217" unitRef =" shares" > 35000 < / us- gaap: StockIssuedDuringPeriodSharesPurchaseOfAssets > < us- gaap: SaleOfStockPricePerShare contextRef =" c107" decimals =" 2" id =" ixv- 14218" unitRef =" usdPershares" > 3. 59 < / us- gaap: SaleOfStockPricePerShare > < us- gaap: SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef =" c106" id =" ixv- 14219" > P5Y < / us- gaap: SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod > < us- gaap: RelatedPartyTransactionAmountsOfTransaction contextRef =" c106" decimals =" 0" id =" ixv- 14220" unitRef =" usd" > 85995 < / us- gaap: RelatedPartyTransactionAmountsOfTransaction > < us- gaap: StockIssuedDuringPeriodSharesPurchaseOfAssets contextRef =" c108" decimals =" 0" id =" ixv- 14221" unitRef =" shares" > 107500 < / us- gaap: StockIssuedDuringPeriodSharesPurchaseOfAssets > < us- gaap: SaleOfStockPricePerShare contextRef =" c109" decimals =" 2" id =" ixv- 14222" unitRef =" usdPershares" > 3. 53 < / us- gaap: SaleOfStockPricePerShare > < us- gaap: SaleOfStockPricePerShare contextRef =" c110" decimals =" 2" id =" ixv- 14223" unitRef =" usdPershares" > 3. 88 < / us- gaap: SaleOfStockPricePerShare > < us- gaap: SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef =" c108" id =" ixv- 14224" > P3Y < / us- gaap: SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod > < us- gaap: RelatedPartyTransactionAmountsOfTransaction contextRef =" c108" decimals =" 0" id =" ixv- 14225" unitRef =" usd" > 245170 < / us- gaap: RelatedPartyTransactionAmountsOfTransaction > < us- gaap: StockholdersEquityNoteDisclosureTextBlock contextRef =" c0" id =" ixv- 7705" > & lt; table cellpadding =" 0" cellspacing =" 0" style =" font: 10pt Times New Roman, Times, Serif; margin- top: 0pt; margin- bottom: 0pt; width: 100 %" & gt; & lt; tr style =" vertical- align: top" & gt; & lt; td style =" width: 0. 5in" & gt; 8. & lt; / td & gt; & lt; td style =" text- align: justify" & gt; STOCKHOLDERS & # x2019; EQUITY & lt; / td & gt; & lt; / tr & gt; & lt; / table & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify" & gt; & # 160; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in" & gt; & lt; span style =" text- decoration: underline" & gt; Preferred Stock & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in" & gt; & # 160; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; text- align: justify; margin: 0pt 0 0pt 0. 5in" & gt; On January 15, 2016, the board of directors of the Company approved a certificate of amendment to the articles of incorporation and changed the authorized capital stock of the Company to include and authorize 10, 000, 000 shares of Preferred Stock, par value $ 0. 001 per share. & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; text- align: justify; margin: 0pt 0 0pt 0. 5in" & gt; & # 160; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; text- align: justify; margin: 0pt 0 0pt 0. 5in" & gt; On May 24, 2019, the board of directors created a series of preferred stock consisting of 2, 500, 000 shares designated as the Series A Convertible Preferred Stock (& # x201c; Series A Preferred Stock & # x201d;). On June 20, 2019, the Series A preferred Stock was terminated, and the 2, 500, 000 shares were restored to the status of authorized but unissued shares of Preferred Stock, without designation as to series, until such stock is once more designated as part of a particular series by the board of directors. & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; text- align: justify; margin: 0pt 0 0pt 0. 5in" & gt; & # 160; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; text- align: justify; margin: 0pt 0 0pt 0. 5in" & gt; & lt; span style =" text- decoration: underline" & gt; Common Stock & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; text- align: justify; margin: 0pt 0 0pt 0. 5in" & gt; & # 160; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; text- align: justify; margin: 0pt 0 0pt 0. 5in" & gt; On June 25, 2019, the Company effected a one- for- four reverse stock split, pursuant to which each outstanding share of common stock was changed into 0. 25 shares of common stock, and the Company decreased its authorized common stock in the same ratio from 100, 000, 000 to 25, 000, 000 shares. & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; text- align: justify; margin: 0pt 0 0pt 0. 5in" & gt; & # 160; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; text- align: justify; margin: 0pt 0 0pt 0. 5in" & gt; On January 27, 2020, the Company amended its Articles of Incorporation to increase its authorized common shares from 25, 000, 000 authorized shares to 250, 000, 000 authorized shares. & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; text- align: justify; margin: 0pt 0 0pt 0. 5in" & gt; & # 160; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; text- align: justify; margin: 0pt 0 0pt 0. 5in" & gt; On July 26, 2022, the Board of Directors of the Company approved a 7- for- 6 forward stock split, effective for trading purposes as of August 12, 2022, pursuant to which each shareholder as of the August 15, 2022 record date received one (1) additional share for each six (6) shares held as of the record date. Pursuant to the operation of the amendment providing for the forward stock split filed with the Secretary of State of Nevada on August 4, 2022, the authorized common stock of the Company was increased from 250, 000, 000 shares to 291, 666, 666 shares in connection with the forward split. & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; text- align: justify; margin: 0pt 0 0pt 0. 5in" & gt; & # 160; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 25in; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" text- decoration: underline" & gt; Activity during the Year Ended January 31, 2024 & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; text- align: justify; margin: 0pt 0 0pt 0. 5in" & gt; & # 160; & lt; / p & gt; & lt; table cellpadding =" 0" cellspacing =" 0" style =" font: 10pt Times New Roman, Times, Serif; margin- top: 0pt; margin- bottom: 0pt" width =" 100 %" & gt; & lt; tr style =" vertical- align: top" & gt; & lt; td style =" text- align: justify; width: 38. 4pt" & gt; & lt; / td & gt; & lt; td style =" text- align: justify; width: 18pt" & gt; (a) & lt; / td & gt; & lt; td style =" text- align: justify" & gt; As of January 31, 2024, the Company holds 10, 000 of its shares comprising $ 32, 641 of treasury stock. There was no activity during the year ended January 31, 2024. & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: top" & gt; & lt; td style =" text- align: justify" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: justify" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: justify" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; / table & gt; & lt; table cellpadding =" 0" cellspacing =" 0" style =" font: 10pt Times New Roman, Times, Serif; margin- top: 0pt; margin- bottom: 0pt" width =" 100 %" & gt; & lt; tr style =" vertical- align: top" & gt; & lt; td style =" text- align: justify; width: 38. 4pt" & gt; & lt; / td & gt; & lt; td style =" text- align: justify; width: 18pt" & gt; (b)

& lt; / td & gt; & lt; td style =" text- align: justify" & gt; In December 2024, TII Jet Services LDA converted $ 2, 000, 000 of its outstanding credit facility and $ 53, 436 of accrued interest into 1, 026, 720 shares of the Company & # x2019; s common stock. The fair value of the common stock at the date of issuance was $ 2, 554, 423, resulting in a $ 554, 423 loss on extinguishment. & lt; / td & gt; & lt; / tr & gt; & lt; / table & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56. 4pt" & gt; & # 160; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify" & gt; & lt; span style =" text- decoration: underline" & gt; Activity during the Year Ended January 31, 2023 & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 75in; text- align: justify" & gt; & # 160; & lt; / p & gt; & lt; table cellpadding =" 0" cellspacing =" 0" style =" font: 10pt Times New Roman, Times, Serif; margin- top: 0pt; margin- bottom: 0pt" width =" 100 %" & gt; & lt; tr style =" vertical- align: top" & gt; & lt; td style =" width: 37. 8pt" & gt; & lt; / td & gt; & lt; td style =" width: 18pt" & gt; (a) & lt; / td & gt; & lt; td style =" text- align: justify" & gt; In March and May 2022, the Company purchased 35, 584 shares of its common stock for $ 119, 006 and recorded the purchase as Treasury Stock. In May and December 2022, the Company issued 33, 397 shares of stock awards to management, directors and employees from the treasury shares and recorded compensation expense of $ 113, 155 In December 2022, the Company issued 25, 000 shares from the treasury shares to non- employees in connection of the termination of the Rambam license agreement. As of January 31, 2023, the Company held 10, 000 of its shares comprising $ 32, 641 of treasury stock. & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: top" & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: justify" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; / table & gt; & lt; table cellpadding =" 0" cellspacing =" 0" style =" font: 10pt Times New Roman, Times, Serif; margin- top: 0pt; margin- bottom: 0pt" width =" 100 %" & gt; & lt; tr style =" vertical- align: top" & gt; & lt; td style =" width: 37. 8pt" & gt; & lt; / td & gt; & lt; td style =" width: 18pt" & gt; (b) & lt; / td & gt; & lt; td style =" text- align: justify" & gt; On July 29, 2022, the Company received proceeds of $ 296, 875 from the exercise of warrants and issued 55, 417 shares of common stock. & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: top" & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: justify" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; / table & gt; & lt; table cellpadding =" 0" cellspacing =" 0" style =" font: 10pt Times New Roman, Times, Serif; margin- top: 0pt; margin- bottom: 0pt" width =" 100 %" & gt; & lt; tr style =" vertical- align: top" & gt; & lt; td style =" width: 37. 8pt" & gt; & lt; / td & gt; & lt; td style =" width: 18pt" & gt; (c) & lt; / td & gt; & lt; td style =" text- align: justify" & gt; In July 2022, the Company cancelled 1, 400, 000 shares received in connection with the settlement of a lawsuit. See Note 11 for further information. & lt; / td & gt; & lt; / tr & gt; & lt; / table & gt; < / us- gaap: StockholdersEquityNoteDisclosureTextBlock > < us- gaap: PreferredStockSharesAuthorized contextRef =" c111" decimals =" 0" id =" ixv- 14226" unitRef =" shares" > 10000000 < / us- gaap: PreferredStockSharesAuthorized > < us- gaap: PreferredStockParOrStatedValuePerShare contextRef =" c111" decimals =" 3" id =" ixv- 14227" unitRef =" usdPershares" > 0. 001 < / us- gaap: PreferredStockParOrStatedValuePerShare > < ntrb: DesignatedSharesOfPreferredStocks contextRef =" c112" decimals =" 0" id =" ixv- 14228" unitRef =" shares" > 2500000 < / ntrb: DesignatedSharesOfPreferredStocks > < ntrb: DesignatedSharesOfPreferredStocks contextRef =" c113" decimals =" 0" id =" ixv- 14229" unitRef =" shares" > 2500000 < / ntrb: DesignatedSharesOfPreferredStocks > < ntrb: CommonStockOfDescription contextRef =" c0" id =" ixv- 14230" > the Company effected a one- for- four reverse stock split, pursuant to which each outstanding share of common stock was changed into 0. 25 shares of common stock, and the Company decreased its authorized common stock in the same ratio from 100, 000, 000 to 25, 000, 000 shares. < / ntrb: CommonStockOfDescription > < ntrb: IncreaseDecreasedInAuthorizedCommonStock contextRef =" c114" decimals =" 0" id =" ixv- 14231" unitRef =" shares" > 25000000 < / ntrb: IncreaseDecreasedInAuthorizedCommonStock > < ntrb: IncreaseDecreasedInAuthorizedCommonStock contextRef =" c115" decimals =" 0" id =" ixv- 14232" unitRef =" shares" > 250000000 < / ntrb: IncreaseDecreasedInAuthorizedCommonStock > < ntrb: StockholderEquityNoteStockSplit contextRef =" c0" id =" ixv- 14233" > the Company approved a 7- for- 6 forward stock split, effective for trading purposes as of August 12, 2022, pursuant to which each shareholder as of the August 15, 2022 record date received one (1) additional share for each six (6) shares held as of the record date. < / ntrb: StockholderEquityNoteStockSplit > < ntrb: IncreaseDecreasedInAuthorizedCommonStock contextRef =" c116" decimals =" 0" id =" ixv- 14234" unitRef =" shares" > 250000000 < / ntrb: IncreaseDecreasedInAuthorizedCommonStock > < ntrb: IncreaseDecreasedInAuthorizedCommonStock contextRef =" c117" decimals =" 0" id =" ixv- 14235" unitRef =" shares" > 291666666 < / ntrb: IncreaseDecreasedInAuthorizedCommonStock > < us- gaap: OptionIndexedToIssuersEquityShares contextRef =" c0" decimals =" 0" id =" ixv- 14236" unitRef =" shares" > 10000 < / us- gaap: OptionIndexedToIssuersEquityShares > < us- gaap: RedeemableNoncontrollingInterestEquityOtherCarryingAmount contextRef =" c5" decimals =" 0" id =" ixv- 14237" unitRef =" usd" > 32641 < / us- gaap: RedeemableNoncontrollingInterestEquityOtherCarryingAmount > < us- gaap: ConversionOfStockSharesConverted1 contextRef =" c118" decimals =" 0" id =" ixv- 14238" unitRef =" shares" > 2000000 < / us- gaap: ConversionOfStockSharesConverted1 > < us- gaap: LineOfCreditFacilityCommitmentFeeAmount contextRef =" c119" decimals =" 0" id =" ixv- 14239" unitRef =" usd" > 53436 < / us- gaap: LineOfCreditFacilityCommitmentFeeAmount > < us- gaap: CommonStockSharesOutstanding contextRef =" c120" decimals =" 0" id =" ixv- 14240" unitRef =" shares" > 1026720 < / us- gaap: CommonStockSharesOutstanding > < us- gaap: CommonUnitIssuanceValue contextRef =" c121" decimals =" 0" id =" ixv- 14241" unitRef =" usd" > 2554423 < / us- gaap: CommonUnitIssuanceValue > < ntrb: LossOnExtinguishment contextRef =" c119" decimals =" 0" id =" ixv- 14242" unitRef =" usd" > 554423 < / ntrb: LossOnExtinguishment > < us- gaap: SaleOfStockNumberOfSharesIssuedInTransaction contextRef =" c122" decimals =" 0" id =" ixv- 14243" unitRef =" shares" > 35584 < / us- gaap: SaleOfStockNumberOfSharesIssuedInTransaction > < us- gaap: SaleOfStockNumberOfSharesIssuedInTransaction contextRef =" c123" decimals =" 0" id =" ixv- 14244" unitRef =" shares" > 35584 < / us- gaap: SaleOfStockNumberOfSharesIssuedInTransaction > < ntrb: TreasuryStockPurchase contextRef =" c122" decimals =" 0" id =" ixv- 14245" unitRef =" usd" > 119006 < / ntrb: TreasuryStockPurchase > < ntrb: TreasuryStockPurchase contextRef =" c123" decimals =" 0" id =" ixv- 14246" unitRef =" usd" > 119006 < / ntrb: TreasuryStockPurchase > < ntrb: IssuanceOfCommonStock contextRef =" c123" decimals =" 0" id =" ixv- 14247" unitRef =" shares" > 33397 < / ntrb: IssuanceOfCommonStock > < ntrb: IssuanceOfCommonStock contextRef =" c124" decimals =" 0" id =" ixv- 14248" unitRef =" shares" > 33397 < / ntrb: IssuanceOfCommonStock > < ntrb: TreasurySharesAndRecordedCompensationExpense contextRef =" c123" decimals =" 0" id =" ixv- 14249" unitRef =" usd" > 113155 < / ntrb: TreasurySharesAndRecordedCompensationExpense > < ntrb: IssuanceOfCommonStock contextRef =" c125" decimals =" 0" id =" ixv- 14250" unitRef =" shares" > 25000 < / ntrb: IssuanceOfCommonStock > < us- gaap: OptionIndexedToIssuersEquityShares contextRef =" c9" decimals =" 0" id =" ixv- 14251" unitRef =" shares" > 10000 < / us- gaap: OptionIndexedToIssuersEquityShares > < us- gaap: RedeemableNoncontrollingInterestEquityOtherCarryingAmount contextRef =" c6" decimals =" 0" id =" ixv- 14252" unitRef =" usd" > 32641 < / us- gaap: RedeemableNoncontrollingInterestEquityOtherCarryingAmount > < us- gaap: ProceedsFromWarrantExercises contextRef =" c126" decimals =" 0" id =" ixv- 14253" unitRef =" usd" > 296875 < / us- gaap: ProceedsFromWarrantExercises > < ntrb: IssuanceOfCommonStock contextRef =" c126" decimals =" 0" id =" ixv- 14254" unitRef =" shares" > 55417 < / ntrb: IssuanceOfCommonStock > < ntrb: CancelledShares contextRef =" c127" decimals =" 0" id =" ixv- 14255" unitRef =" shares" > 1400000 < / ntrb: CancelledShares > < ntrb: OptionsAndWarrantsTextBlock contextRef =" c0" id =" ixv- 7799" > & lt; table cellpadding =" 0" cellspacing =" 0" style =" font: 10pt Times New Roman, Times, Serif; margin- top: 0pt; margin- bottom: 0pt; width: 100 %" & gt; & lt; tr style =" vertical- align: top" & gt; & lt; td style =" width: 0. 5in" & gt; 9. & lt; / td & gt; & lt; td style =" text- align: justify" & gt; OPTIONS and WARRANTS & lt; / td & gt; & lt; / tr & gt; & lt; / table & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify" & gt; & # 160; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 25in; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" text- decoration: underline" & gt; Warrants & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify" & gt; & # 160; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify" & gt; The following table summarizes the changes in warrants outstanding and the related price of the shares of the Company & # x2019; s common stock issued to non- employees of the Company during the year ended January 31, 2024. On March 7, 2023, the Company issued 30, 000 warrants to purchase the Company & # x2019; s common shares to Barandnic Holdings Ltd. for services provided. The warrants are exercisable at a price of $ 4. 00 per share and expire five years from the date of issuance. On October 27, 2023, the Company issued 145, 833 warrants to purchase the Company & # x2019; s common shares to management (87, 500 warrants were issued to the Chief Financial Officer) and non- employees of the Company. The warrants are exercisable at a price of $ 1. 93 per share and expire in three years from the date of issuance. These warrants replace previously issued warrants that have now been cancelled. The Company used the Black- Scholes valuation model to record the fair value. The valuation model used a dividend rate of 0 %; expected term of 1. 5 years; volatility rates of 152. 10- 174. 45 %; and a risk- free rate of 4. 31 %- 4. 84 %. Non- cash compensation for the year ended January 31, 2024, amounted to $ 242, 840. & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: center" & gt; & # 160; & lt; / p & gt; & lt; table cellpadding =" 0" cellspacing =" 0" style =" font: 10pt Times New Roman, Times, Serif; border- collapse: collapse; width: 100 %" & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td colspan =" 2" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" text- align: center" & gt; & lt; b & gt; Exercise & lt; / b & gt; & lt; / td & gt; & lt; td & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" text- align: center" & gt; & lt; b & gt; Remaining & lt; / b & gt; & lt; /

td & gt; & lt; td & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" text- align: center" & gt; & lt; b & gt; Intrinsic & lt; / b & gt; & lt; / td & gt; & lt; td & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" border- bottom: Black 1. 5pt solid; text- align: center" & gt; & lt; b & gt; Shares & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" border- bottom: Black 1. 5pt solid; text- align: center" & gt; & lt; b & gt; Price & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" border- bottom: Black 1. 5pt solid; text- align: center" & gt; & lt; b & gt; Life & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" border- bottom: Black 1. 5pt solid; text- align: center" & gt; & lt; b & gt; Value & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" width: 52 %" & gt; Outstanding, January 31, 2022 & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; 1, 435, 622 & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; 6. 91 & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif; font- size: 10pt" & gt; & # 160; 3. 93 years & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; & lt; div style ="- sec- ix- hidden: hidden- fact- 71" & gt;- & lt; / div & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td & gt; Granted & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 25, 000 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 7. 50 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif; font- size: 10pt" & gt; & # 160; 5. 00 years & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; div style ="- sec- ix- hidden: hidden- fact- 72" & gt;- & lt; / div & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left"

align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td & gt; Granted & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 175, 833 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 2. 28 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif; font- size: 10pt" & gt; 2. 97 years & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; div style =" - sec- ix- hidden: hidden- fact- 78" & gt; - & lt; / div & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; div style =" - sec- ix- hidden: hidden- fact- 79" & gt; - & lt; / div & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; div style =" - sec- ix- hidden: hidden- fact- 80" & gt; - & lt; / div & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; div style =" - sec- ix- hidden: hidden- fact- 81" & gt; - & lt; / div & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: right" & gt; & lt; div style =" - sec- ix- hidden: hidden- fact- 82" & gt; - & lt; / div & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; div style =" - sec- ix- hidden: hidden- fact- 83" & gt; - & lt; / div & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: right" & gt; & lt; div style =" - sec- ix- hidden: hidden- fact- 84" & gt; - & lt; / div & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td & gt; Expired / Cancelled & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; (200, 466 & lt; / td & gt; & lt; td style =" text- align: left" & gt;) & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 6. 33 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; div style =" - sec- ix- hidden: hidden- fact- 86" & gt; - & lt; / div & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right"

=" vertical- align: bottom" & gt; & lt; td colspan =" 2" style =" border- bottom: Black 1. 5pt solid; text- align: center" & gt; & lt; b & gt; Range of Exercise & lt; br / & gt; Prices & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: center" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: center" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" border- bottom: Black 1. 5pt solid; text- align: center" & gt; & lt; b & gt; Number & lt; br / & gt; Outstanding & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: center" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: center" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" border- bottom: Black 1. 5pt solid; text- align: center" & gt; & lt; b & gt; Weighted Average & lt; br / & gt; Remaining & lt; br / & gt; Contractual & lt; br / & gt; Life (Years) & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: center" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: center" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" border- bottom: Black 1. 5pt solid; text- align: center" & gt; & lt; b & gt; Weighted Average & lt; br / & gt; Exercise Price for & lt; br / & gt; Shares & lt; br / & gt; Outstanding & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: center" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: center" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" border- bottom: Black 1. 5pt solid; text- align: center" & gt; & lt; b & gt; Number & lt; br / & gt; Exercisable & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: center" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" border- bottom: Black 1. 5pt solid; text- align: center" & gt; & lt; b & gt; Weighted & # 160; Average & lt; br / & gt; Exercise Price for & lt; br / & gt; Shares & lt; br / & gt; Exercisable & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: center" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: center" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" border- bottom: Black 1. 5pt solid; text- align: center" & gt; & lt; b & gt; Intrinsic & lt; br / & gt; Value & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: center" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" width: 1 %; text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" width: 12 %; text- align: right" & gt; 4. 00 & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 12 %; text- align: right" & gt; 30, 000 & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 12 %; text- align: right" & gt; 4. 10 & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" width: 11 %; text- align: right" & gt; 4. 00 & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 11 %; text- align: right" & gt; 30, 000 & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" width: 11 %; text- align: right" & gt; 4. 00 & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" width: 11 %; text- align: right" & gt; & lt; div style ="- sec- ix- hidden: hidden- fact- 85" & gt;- & lt; / div & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" text- align: right" & gt; 6. 43 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 1, 082, 205 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 2. 68 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" text- align: right" & gt; 6. 43 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 1, 082, 205

of $ 1. 93- $ 3. 975 per share. The options vest immediately and expire three years from the date of issuance. The fair value of the options issued for services amounted to $ 499, 856 and was recorded during the year ended January 31, 2024. The Company used the Black- Scholes valuation model to record the fair value. The valuation model used a dividend rate of 0 %; expected term of 1. 5 years; volatility rates of 121. 52- 143. 54 %; and a risk- free rate of 3. 00- 4. 5 %. & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify" & gt; & # 160; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify" & gt; During the year ended January 31, 2023, 279, 584 options to purchase shares of the Company & # x2019; s common stock were issued to executive officers and directors of the Company at prices of $ 3. 59 to $ 4. 50 per share. The options vest immediately and expire three years from the date of issuance. The fair value of the options issued for services amounted to $ 732, 130 and was recorded during the year ended January 31, 2023. The Company used the Black- Scholes valuation model to record the fair value. The valuation model used a dividend rate of 0 %; expected term of 1. 5 years; volatility rate of 152. 10- 174. 45 %; and a risk- free rate of 3 %. & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify" & gt; & # 160; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify" & gt; The following table summarizes additional information relating to the options outstanding as of January 31, 2024. & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify" & gt; & # 160; & lt; / p & gt; & lt; table cellpadding =" 0" cellspacing =" 0" style =" font: 10pt Times New Roman, Times, Serif; border- collapse: collapse; width: 100 %" & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td style =" text- align: center" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td style =" text- align: center; padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" border- bottom: Black 1. 5pt solid; text- align: center" & gt; & lt; b & gt; Shares & lt; / b & gt; & lt; / td & gt; & lt; td style =" text- align: center; padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td style =" text- align: center; padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" border- bottom: Black 1. 5pt solid; text- align: center" & gt; & lt; b & gt; Exercise & lt; br / & gt; Price & lt; / b & gt; & lt; / td & gt; & lt; td style =" text- align: center; padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td style =" text- align: center; padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" border- bottom: Black 1. 5pt solid; text- align: center" & gt; & lt; b & gt; Remaining & lt; br / & gt; Life & lt; / b & gt; & lt; / td & gt; & lt; td style =" text- align: center; padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td style =" text- align: center; padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" border- bottom: Black 1. 5pt solid; text- align: center" & gt; & lt; b & gt; Intrinsic & lt; br / & gt; Value & lt; / b & gt; & lt; / td & gt; & lt; td style =" text- align: center; padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" width: 52 %" & gt; Outstanding, January 31, 2022 & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; 190, 751 & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; 4. 26 & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif; font- size: 10pt" & gt; & # 160; 2. 97 years & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; & lt; div style ="- sec- ix- hidden: hidden- fact- 88" & gt; & # 160; & lt; / div & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td & gt; Granted & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 279, 584 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 3. 93 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; div style ="- sec- ix- hidden: hidden- fact- 89" & gt;- & lt; / div & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td & gt; Expired / Cancelled & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; div style ="- sec- ix- hidden: hidden- fact- 90" & gt;- & lt; / div & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; div style ="- sec- ix- hidden: hidden- fact- 91" & gt;- & lt; / div & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; div style ="- sec- ix- hidden: hidden- fact- 92" & gt;- & lt; / div & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; div style ="- sec- ix- hidden: hidden- fact- 93" & gt; & # 160; & lt; / div & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; Exercised & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; div style ="- sec- ix- hidden: hidden- fact- 94" & gt;- & lt; / div & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: right" & gt; & lt; div style ="- sec- ix- hidden: hidden- fact- 95" & gt;- & lt; / div & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; div style ="- sec- ix- hidden: hidden- fact- 96" & gt;- & lt; / div & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: right" & gt; & lt; div style ="- sec- ix- hidden: hidden- fact- 97" & gt; & # 160; & lt; / div & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" &

gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td & gt; Outstanding, January 31, 2023 & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 470, 335 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 4. 13 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif; font- size: 10pt" & gt; & # 160; 2. 53 years & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; div style ="- sec- ix- hidden: hidden- fact- 98" & gt; & # 160; & lt; / div & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right"

gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" padding- bottom: 4pt" & gt; Exercisable- January 31, 2024 & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: right" & gt; 874, 835 & lt; / td & gt; & lt; td style =" padding- bottom: 4pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: right" & gt; 3. 23 & lt; / td & gt; & lt; td style =" padding- bottom: 4pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif; font- size: 10pt" & gt; 2. 31 years & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: right" & gt; 214, 460 & lt; / td & gt; & lt; td style =" padding- bottom: 4pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; / table & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" & gt; & # 160; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify" & gt; The following table summarizes additional information relating to the options outstanding as of January 31, 2024: & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify" & gt; & # 160; & lt; / p & gt; & lt; table cellpadding =" 0" cellspacing =" 0" style =" font: 10pt Times New Roman, Times, Serif; border- collapse: collapse; width: 100 %" & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td colspan =" 2" style =" border- bottom: Black 1. 5pt solid; text- align: center" & gt; & lt; b & gt; Prices & lt; / b & gt; & lt; / td & gt; & lt; td style =" text- align: center; padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td style =" text- align: center; border- bottom: Black 1. 5pt solid" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" border- bottom: Black 1. 5pt solid; text- align: center" & gt; & lt; b & gt; Outstanding & lt; / b & gt; & lt; / td & gt; & lt; td style =" text- align: center; padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td style =" text- align: center; border- bottom: Black 1. 5pt solid" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" border- bottom: Black 1. 5pt solid; text- align: center" & gt; & lt; b & gt; Life (Years) & lt; / b & gt; & lt; / td & gt; & lt; td style =" text- align: center; padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td style =" text- align: center; border- bottom: Black 1. 5pt solid" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" border- bottom: Black 1. 5pt solid; text- align: center" & gt; & lt; b & gt; Shares Outstanding & lt; / b & gt; & lt; / td & gt; & lt; td style =" text- align: center; padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td style =" text- align: center; border- bottom: Black 1. 5pt solid" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" border- bottom: Black 1. 5pt solid; text- align: center" & gt; & lt; b & gt; Exercisable & lt; / b & gt; & lt; / td & gt; & lt; td style =" text- align: center; padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td style =" text- align: center; border- bottom: Black 1. 5pt solid" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" border- bottom: Black 1. 5pt solid; text- align: center" & gt; & lt; b & gt; Shares Exercisable & lt; / b & gt; & lt; / td & gt; & lt; td style =" text- align: center; padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td style =" text- align: center; border- bottom: Black 1. 5pt solid" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" border- bottom: Black 1. 5pt solid; text- align: center" & gt; & lt; b & gt; Value & lt; / b & gt; & lt; / td & gt; & lt; td style =" text- align: center; padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td colspan =" 2" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td colspan =" 2" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td colspan =" 2" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td colspan =" 2" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td colspan =" 2" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td colspan =" 2" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td colspan =" 2" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" width: 1 %; text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" width: 12 %; text- align: right" & gt; 1. 93 & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 12 %; text- align: right" & gt; 214, 500 & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 12 %; text- align: right" & gt; 2. 74 & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" width: 11 %; text- align: right" & gt; 1. 93 & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 11 %; text- align: right" & gt; 214, 500 & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" width: 11 %; text- align: right" & gt; 1. 93 & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 11 %; text- align: right" & gt; 145, 860 & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" text- align: right" & gt; 2. 12 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 140, 000 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 2. 74 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" text- align: right" & gt; 2. 12 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 140, 000 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" text- align: right" & gt; 2. 12 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" text- align: right" & gt; 68, 600 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" text- align: right" & gt; 2. 65 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 20, 000 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 2. 63 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" text- align: right" & gt; 2. 65 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 20, 000 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" text- align: right" & gt; 2. 65 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 35, 000 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 3. 67 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" text- align: right" & gt; 3. 59 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 35, 000 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" text- align: right" & gt; 3. 59 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; div style ="- sec- ix- hidden: hidden- fact- 109" & gt;- & lt; / div & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" text- align:

right" & gt; 3. 75 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 57, 500 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 1. 85 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" text- align: right" & gt; 3. 75 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 57, 500 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" text- align: right" & gt; 3. 75 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; div style ="- sec- ix- hidden: hidden- fact- 110" & gt;- & lt; / div & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" text- align: right" & gt; 3. 98 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 30, 000 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 2. 01 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" text- align: right" & gt; 3. 98 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 30, 000 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" text- align: right" & gt; 3. 98 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; div style ="- sec- ix- hidden: hidden- fact- 111" & gt;- & lt; / div & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" text- align: right" & gt; 4. 09 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 78, 750 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 1. 50 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" text- align: right" & gt; 4. 09 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 78, 750 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" text- align: right" & gt; 4. 09 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; div style ="- sec- ix- hidden: hidden- fact- 112" & gt;- & lt; / div & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" text- align: right" & gt; 4. 12 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 50, 000 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 1. 85 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" text- align: right" & gt; 4. 12 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 50, 000 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 4. 12 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 144, 083 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 0. 97 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" text- align: right" & gt; 4. 16 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 144, 083 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" text- align: right" & gt; 4. 16 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; div style ="- sec- ix- hidden: hidden- fact- 113" & gt;- & lt; / div & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" text- align: right" & gt; 4. 16 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 144, 083 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" text- align: right" & gt; 4. 16 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; div style ="- sec- ix- hidden: hidden- fact- 114" & gt;- & lt; / div & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" text- align: right" & gt; 4. 50 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 58, 334 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 1. 50 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" text- align: right" & gt; 4. 50 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 58, 334 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" text- align: right" & gt; 4. 50 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; div style ="- sec- ix- hidden: hidden- fact- 115" & gt;- & lt; / div & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" text- align: right" & gt; 4. 58 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 46, 668 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 0. 97 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" text- align: right" & gt; 4. 58 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 46, 668 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" text- align: right" & gt; 4. 58 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; div style ="- sec- ix- hidden: hidden- fact- 116" & gt;- & lt; / div & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td

lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 874, 835 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 2. 06 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" text- align: right" & gt; 3. 23 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 874, 835 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 3. 23 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" text- align: right" & gt; 214, 460 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; / table & gt; < / ntrb: OptionsAndWarrantsTextBlock > < us- gaap: TemporaryEquitySharesIssued contextRef =" c128" decimals =" 0" id =" ixv- 14256" unitRef =" shares" > 30000 < / us- gaap: TemporaryEquitySharesIssued > < us- gaap: WarrantExercisePriceIncrease contextRef =" c129" decimals =" 2" id =" ixv- 14257" unitRef =" usdPershares" > 4 < / us- gaap: WarrantExercisePriceIncrease > < ntrb: OptionsVestExpireYear contextRef =" c0" id =" ixv- 14258" > P5Y < / ntrb: OptionsVestExpireYear > < us- gaap: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef =" c130" decimals =" 0" id =" ixv- 14259" unitRef =" shares" > 145833 < / us- gaap: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions > < us- gaap: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef =" c131" decimals =" 0" id =" ixv- 14260" unitRef =" shares" > 87500 < / us- gaap: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions > < us- gaap: WarrantExercisePriceIncrease contextRef =" c0" decimals =" 2" id =" ixv- 14261" unitRef =" usdPershares" > 1. 93 < / us- gaap: WarrantExercisePriceIncrease > < ntrb: ExpireYear contextRef =" c97" id =" ixv- 14262" > P3Y < / ntrb: ExpireYear > < us- gaap: ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef =" c97" id =" ixv- 14263" > The valuation model used a dividend rate of 0 %; expected term of 1. 5 years; volatility rates of 152. 10- 174. 45 %; and a risk- free rate of 4. 31 %- 4. 84 %. Non- cash compensation for the year ended January 31, 2024, amounted to $ 242, 840. & lt; table cellpadding =" 0" cellspacing =" 0" style =" font: 10pt Times New Roman, Times, Serif; border- collapse: collapse; width: 100 %" & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td colspan =" 2" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" text- align: center" & gt; & lt; b & gt; Exercise & lt; / b & gt; & lt; / td & gt; & lt; td & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" text- align: center" & gt; & lt; b & gt; Remaining & lt; / b & gt; & lt; / td & gt; & lt; td & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" text- align: center" & gt; & lt; b & gt; Intrinsic & lt; / b & gt; & lt; / td & gt; & lt; td & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" border- bottom: Black 1. 5pt solid; text- align: center" & gt; & lt; b & gt; Shares & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" border- bottom: Black 1. 5pt solid; text- align: center" & gt; & lt; b & gt; Price & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" border- bottom: Black 1. 5pt solid; text- align: center" & gt; & lt; b & gt; Life & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" border- bottom: Black 1. 5pt solid; text- align: center" & gt; & lt; b & gt; Value & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" width: 52 %" & gt; Outstanding, January 31, 2022 & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; 1, 435, 622 & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; 6. 91 & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif; font- size: 10pt" & gt; & # 160; 3. 93 years & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; & lt; div style ="- sec- ix- hidden: hidden- fact- 71" & gt;- & lt; / div & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left

160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; Exercised & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; (55, 417 & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt;) & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: right" & gt; 5. 36 & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; div style ="- sec- ix- hidden: hidden- fact- 75" & gt;- & lt; / div & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: right" & gt; & lt; div style ="- sec- ix- hidden: hidden- fact- 76" & gt;- & lt; / div & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; td & gt; Outstanding, January 31, 2023 & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 1, 307, 671 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 6. 43 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif; font- size: 10pt" & gt; 3. 34 years & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; div style ="- sec- ix- hidden: hidden- fact- 77" & gt;- & lt; / div & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td & gt; Granted & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 175, 833 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 2. 28 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif; font- size: 10pt" & gt; 2. 97 years & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; div style ="- sec- ix- hidden: hidden- fact- 78" & gt;- & lt; / div & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td & gt; Expired / Cancelled & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; (200, 466 & lt; / td & gt; & lt; td style =" text- align: left" & gt;) & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 6. 33 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; div style ="- sec- ix- hidden: hidden- fact- 79" & gt;- & lt; / div & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; div style ="- sec- ix- hidden: hidden- fact- 80" & gt;- & lt; / div & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" padding- bottom: 4pt" & gt; Outstanding- January 31, 2024 & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: right" & gt; 1, 283, 038 & lt; / td & gt; & lt; td style =" padding- bottom: 4pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & # 160; & lt; /

td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: right" & gt; 5. 88 & lt; / td & gt; & lt; td style =" padding- bottom: 4pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif; font- size: 10pt" & gt; & # 160; 2. 97 years & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: right" & gt; 99, 166 & lt; / td & gt; & lt; td style =" padding- bottom: 4pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" padding- bottom: 4pt" & gt; Exercisable- January 31, 2024 & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: right" & gt; 1, 283, 038 & lt; / td & gt; & lt; td style =" padding- bottom: 4pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: right" & gt; 5. 88 & lt; / td & gt; & lt; td style =" padding- bottom: 4pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif; font- size: 10pt" & gt; & # 160; 2. 97 years & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: right" & gt; 99, 166 & lt; / td & gt; & lt; td style =" padding- bottom: 4pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; / table & gt; < / us- gaap:
ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock > < us- gaap:
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef =" c132" decimals =" 2" id =" ixv- 14264" unitRef =" pure" > 0 < / us- gaap: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate > < us- gaap: SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef =" c132" id =" ixv- 14265" > P1Y6M < / us- gaap: SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 > < us- gaap:
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef =" c133" decimals =" 4" id =" ixv- 14266" unitRef =" pure" > 1. 521 < / us- gaap: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate > < us- gaap: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef =" c134" decimals =" 4" id =" ixv- 14267" unitRef =" pure" > 1. 7445 < / us- gaap:
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate > < us- gaap:
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef =" c133" decimals =" 4" id =" ixv- 14268" unitRef =" pure" > 0. 0431 < / us- gaap: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate > < us- gaap: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef =" c134" decimals =" 4" id =" ixv- 14269" unitRef =" pure" > 0. 0484 < / us- gaap:
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate > < us- gaap:
AllocatedShareBasedCompensationExpense contextRef =" c0" decimals =" 0" id =" ixv- 14270" unitRef =" usd" > 242840 < / us- gaap:
AllocatedShareBasedCompensationExpense > < ntrb: ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOutstandingNumber1 contextRef =" c147" decimals =" INF" id =" ixv- 14271" unitRef =" shares" > 1435622 < / ntrb:
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOutstandingNumber1 > < us- gaap:
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef =" c147" decimals =" 2" id =" ixv- 14272" unitRef =" usdPershares" > 6. 91 < / us- gaap:
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice > < ntrb:
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm contextRef =" c144" id =" ixv- 14273" > P3Y11M4D < / ntrb:
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm > < us- gaap:
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef =" c144" decimals =" INF" id =" ixv- 14274" unitRef =" shares" > 25000 < / us- gaap: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross > < us- gaap:
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef =" c144" decimals =" 2" id =" ixv- 14275" unitRef =" usdPershares" > 7. 5 < / us- gaap:
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice > < ntrb:
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsRemainingLifeRemainingLifeGranted contextRef =" c144" id =" ixv- 14276" > P5Y < / ntrb: ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsRemainingLifeRemainingLifeGranted > < us- gaap:
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod contextRef =" c144" decimals =" INF" id =" ixv- 14277" unitRef =" shares" > 97534 < / us- gaap: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod > < us- gaap:
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice contextRef =" c144" decimals =" 2" id =" ixv- 14278" unitRef =" usdPershares" > 5. 36 < / us- gaap:
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice > < ntrb:
StockIssuedDuringPeriodSharesStockOptionsSharesExercised contextRef =" c144" decimals =" INF" id =" ixv- 14279" unitRef =" shares" > - 55417 < / ntrb:
StockIssuedDuringPeriodSharesStockOptionsSharesExercised > < us- gaap:
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef =" c144" decimals =" 2" id =" ixv- 14280" unitRef =" usdPershares" > 5. 36 < / us- gaap:
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice > < ntrb:
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOutstandingNumber1 contextRef =" c148" decimals =" INF" id =" ixv- 14281" unitRef =" shares" > 1307671 < / ntrb: ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOutstandingNumber1 > < us- gaap:
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef =" c148" decimals =" 2" id =" ixv- 14282" unitRef =" usdPershares" > 6. 43 < / us- gaap:
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice > < ntrb:
SharebasedCompensationArrangementsBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm contextRef =" c144" id =" ixv- 14283" > P3Y4M2D < / ntrb:
SharebasedCompensationArrangementsBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm > < us- gaap:
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef =" c97" decimals =" INF" id =" ixv- 14284" unitRef =" shares" > 175833 < / us- gaap: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross > < us- gaap:
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef =" c97" decimals =" 2" id =" ixv- 14285" unitRef =" usdPershares" > 2. 28 < / us- gaap:
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice > < ntrb:
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsRemainingLifeRemainingLifeGranted contextRef =" c97" id =" ixv- 14286" >

P2Y11M19D < / ntrb: ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsRemainingLifeRemainingLifeGranted > < us- gaap: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod contextRef =" e97" decimals =" INF" id =" ixv- 14287" unitRef =" shares" > 200466 < / us- gaap: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod > < us- gaap: ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice contextRef =" e97" decimals =" 2" id =" ixv- 14288" unitRef =" usdPershares" > 6. 33 < / us- gaap: ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice > < ntrb: ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOutstandingNumber1 contextRef =" e149" decimals =" INF" id =" ixv- 14289" unitRef =" shares" > 1283038 < / ntrb: ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOutstandingNumber1 > < us- gaap: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef =" e149" decimals =" 2" id =" ixv- 14290" unitRef =" usdPershares" > 5. 88 < / us- gaap: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice > < ntrb: SharebasedCompensationArrangementsBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm contextRef =" e97" id =" ixv- 14291" > P2Y11M19D < / ntrb: SharebasedCompensationArrangementsBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm > < us- gaap: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef =" e149" decimals =" 0" id =" ixv- 14292" unitRef =" usd" > 99166 < / us- gaap: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue > < us- gaap: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef =" e149" decimals =" INF" id =" ixv- 14293" unitRef =" shares" > 1283038 < / us- gaap: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber > < us- gaap: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef =" e149" decimals =" 2" id =" ixv- 14294" unitRef =" usdPershares" > 5. 88 < / us- gaap: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice > < us- gaap: SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef =" e97" id =" ixv- 14295" > P2Y11M19D < / us- gaap: SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 > < us- gaap: SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef =" e149" decimals =" 0" id =" ixv- 14296" unitRef =" usd" > 99166 < / us- gaap: SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 > < ntrb: ScheduleOfAdditionalRelatingWarrantsOutstanding contextRef =" e0" id =" ixv- 14297" > The following table summarizes additional information relating to the warrants outstanding as of January 31, 2024: & lt; table cellpadding =" 0" cellspacing =" 0" style =" border- collapse: collapse; width: 100 %; font: 10pt Times New Roman, Times, Serif" & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td colspan =" 2" style =" border- bottom: Black 1. 5pt solid; text- align: center" & gt; & lt; b & gt; Range of Exercise & lt; br / & gt; Prices & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: center" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: center" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" border- bottom: Black 1. 5pt solid; text- align: center" & gt; & lt; b & gt; Number & lt; br / & gt; Outstanding & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: center" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: center" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" border- bottom: Black 1. 5pt solid; text- align: center" & gt; & lt; b & gt; Weighted Average & lt; br / & gt; Remaining & lt; br / & gt; Contractual & lt; br / & gt; Life (Years) & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: center" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: center" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" border- bottom: Black 1. 5pt solid; text- align: center" & gt; & lt; b & gt; Weighted Average & lt; br / & gt; Exercise Price for & lt; br / & gt; Shares & lt; br / & gt; Outstanding & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: center" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: center" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" border- bottom: Black 1. 5pt solid; text- align: center" & gt; & lt; b & gt; Number & lt; br / & gt; Exercisable & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: center" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: center" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" border- bottom: Black 1. 5pt solid; text- align: center" & gt; & lt; b & gt; Weighted & # 160; Average & lt; br / & gt; Exercise Price for & lt; br / & gt; Shares & lt; br / & gt; Exercisable & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: center" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: center" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" border- bottom: Black 1. 5pt solid; text- align: center" & gt; & lt; b & gt; Intrinsic & lt; br / & gt; Value & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: center" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" width: 1 %; text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" width: 12 %; text- align: right" & gt; 4. 00 & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 12 %; text- align: right" & gt; 30, 000 & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 12 %; text- align: right" & gt; 4. 10 & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" width: 11 %; text- align: right" & gt; 4. 00 & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 11 %; text- align: right" & gt; 30, 000 & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" width: 11 %; text- align: right" & gt; 4. 00 & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" width: 11 %; text- align: right" & gt; & lt; div style ="- sec- ix- hidden: hidden- fact- 85" & gt;- & lt; / div & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" text- align: right" & gt; 6. 43 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 1, 082, 205 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 2. 68 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" text- align: right" & gt; 6. 43 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 1, 082, 205 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" text- align: right" & gt; 6. 43 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; div style ="- sec- ix- hidden: hidden- fact- 86" & gt;- & lt; / div & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" text- align: right" & gt; 1. 93 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 145, 833 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 2. 74 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" text- align: right" & gt; 1. 93 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" text- align: right" & gt; 145, 833 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" text- align: right" & gt; 1. 93 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" text- align: right" & gt; 99, 166 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" text- align: right" & gt; 7.

50 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 25, 000 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 3. 77 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" text- align: right" & gt; 7. 50 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 25, 000 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" text- align: right" & gt; 7. 50 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; div style ="- sec- ix- hidden: hidden- fact- 87" & gt;- & lt; / div & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; / table & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; background- color: white" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / p & gt; < / ntrb: ScheduleOfAdditionalRelatingWarrantsOutstanding > < us- gaap: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit contextRef =" c150" decimals =" 2" id =" ixv- 14298" unitRef =" usdPershares" > 4 < / us- gaap: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit > < ntrb: WarrantsNumberOutstandinginShares contextRef =" c151" decimals =" INF" id =" ixv- 14299" unitRef =" shares" > 30000 < / ntrb: WarrantsNumberOutstandinginShares > < us- gaap: SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef =" c150" id =" ixv- 14300" > P4Y1M6D < / us- gaap: SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 > < us- gaap: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice contextRef =" c150" decimals =" 2" id =" ixv- 14301" unitRef =" usdPershares" > 4 < / us- gaap: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice > < ntrb: WarrantsNumberExercisableinShares contextRef =" c151" decimals =" INF" id =" ixv- 14302" unitRef =" shares" > 30000 < / ntrb: WarrantsNumberExercisableinShares > < us- gaap: SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 contextRef =" c151" decimals =" 2" id =" ixv- 14303" unitRef =" usdPershares" > 4 < / us- gaap: SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 > < us- gaap: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit contextRef =" c152" decimals =" 2" id =" ixv- 14304" unitRef =" usdPershares" > 6. 43 < / us- gaap: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit > < ntrb: WarrantsNumberOutstandinginShares contextRef =" c153" decimals =" INF" id =" ixv- 14305" unitRef =" shares" > 1082205 < / ntrb: WarrantsNumberOutstandinginShares > < us- gaap: SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef =" c152" id =" ixv- 14306" > P2Y8M4D < / us- gaap: SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 > < us- gaap: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice contextRef =" c152" decimals =" 2" id =" ixv- 14307" unitRef =" usdPershares" > 6. 43 < / us- gaap: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice > < ntrb: WarrantsNumberExercisableinShares contextRef =" c153" decimals =" INF" id =" ixv- 14308" unitRef =" shares" > 1082205 < / ntrb: WarrantsNumberExercisableinShares > < us- gaap: SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 contextRef =" c153" decimals =" 2" id =" ixv- 14309" unitRef =" usdPershares" > 6. 43 < / us- gaap: SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 > < us- gaap: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit contextRef =" c154" decimals =" 2" id =" ixv- 14310" unitRef =" usdPershares" > 1. 93 < / us- gaap: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit > < ntrb: WarrantsNumberOutstandinginShares contextRef =" c155" decimals =" INF" id =" ixv- 14311" unitRef =" shares" > 145833 < / ntrb: WarrantsNumberOutstandinginShares > < us- gaap: SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef =" c154" id =" ixv- 14312" > P2Y8M26D < / us- gaap: SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 > < us- gaap: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice contextRef =" c154" decimals =" 2" id =" ixv- 14313" unitRef =" usdPershares" > 1. 93 < / us- gaap: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice > < ntrb: WarrantsNumberExercisableinShares contextRef =" c155" decimals =" INF" id =" ixv- 14314" unitRef =" shares" > 145833 < / ntrb: WarrantsNumberExercisableinShares > < us- gaap: SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 contextRef =" c155" decimals =" 2" id =" ixv- 14315" unitRef =" usdPershares" > 1. 93 < / us- gaap: SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 > < ntrb: IntrinsicValue contextRef =" c155" decimals =" 0" id =" ixv- 14316" unitRef =" usd" > 99166 < / ntrb: IntrinsicValue > < us- gaap: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit contextRef =" c156" decimals =" 2" id =" ixv- 14317" unitRef =" usdPershares" > 7. 5 < / us- gaap: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit > < ntrb: WarrantsNumberOutstandinginShares contextRef =" c157" decimals =" INF" id =" ixv- 14318" unitRef =" shares" > 25000 < / ntrb: WarrantsNumberOutstandinginShares > < us- gaap: SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef =" c156" id =" ixv- 14319" > P3Y9M7D < / us- gaap: SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 > < us- gaap: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice contextRef =" c156" decimals =" 2" id =" ixv- 14320" unitRef =" usdPershares" > 7. 5 < / us- gaap: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice > < ntrb: WarrantsNumberExercisableinShares contextRef =" c157" decimals =" INF" id =" ixv- 14321" unitRef =" shares" > 25000 < / ntrb: WarrantsNumberExercisableinShares > < us- gaap: SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 contextRef =" c157" decimals =" 2" id =" ixv- 14322" unitRef =" usdPershares" > 7. 5 < / us- gaap: SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 > < us- gaap: SharesIssued contextRef =" c135" decimals =" 0" id =" ixv- 14323" unitRef =" shares" > 408333 < / us- gaap: SharesIssued > < ntrb: AdditionalShare contextRef =" c136" decimals =" 0" id =" ixv- 14324" unitRef =" shares" > 233333 < / ntrb: AdditionalShare > < ntrb: AdditionalShare contextRef =" c137" decimals =" 0" id =" ixv- 14325" unitRef =" shares" > 233333 < / ntrb: AdditionalShare > < ntrb: CommonStockReserved contextRef =" c138" decimals =" 0" id =" ixv- 14326" unitRef =" shares" > 408333 < / ntrb: CommonStockReserved > < us- gaap: InvestmentOwnedBalanceShares contextRef =" c5" decimals =" 0" id =" ixv- 14327" unitRef =" shares" > 166 < / us- gaap: InvestmentOwnedBalanceShares > < us- gaap: SharesIssued contextRef =" c139" decimals =" 0" id =" ixv- 14328" unitRef =" shares" > 404500 < / us- gaap: SharesIssued > < us- gaap: SharePrice contextRef =" c140" decimals =" 2" id =" ixv- 14329" unitRef =" usdPershares" > 1. 93 < / us- gaap: SharePrice > < us- gaap: SharePrice contextRef =" c141" decimals =" 3" id =" ixv- 14330" unitRef =" usdPershares" > 3. 975 < / us- gaap: SharePrice > < ntrb: ExpireYear contextRef =" c132" id =" ixv- 14331" > P3Y < / ntrb: ExpireYear > < us- gaap: FairValueOptionIneligibleItemsAggregateCarryingAmount

contextRef =" c5" decimals =" 0" id =" ixv- 14332" unitRef =" usd" > 499856 < / us- gaap: FairValueOptionIneligibleItemsAggregateCarryingAmount > < us- gaap: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef =" c0" decimals =" 2" id =" ixv- 14333" unitRef =" pure" > 0 < / us- gaap: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate > < us- gaap: SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef =" c0" id =" ixv- 14334" > P1Y6M < / us- gaap: SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 > < us- gaap: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef =" c49" decimals =" 4" id =" ixv- 14335" unitRef =" pure" > 1. 2152 < / us- gaap: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate > < us- gaap: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef =" c50" decimals =" 4" id =" ixv- 14336" unitRef =" pure" > 1. 4354 < / us- gaap: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate > < us- gaap: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef =" c49" decimals =" 4" id =" ixv- 14337" unitRef =" pure" > 0. 03 < / us- gaap: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate > < us- gaap: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef =" c50" decimals =" 3" id =" ixv- 14338" unitRef =" pure" > 0. 045 < / us- gaap: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate > < ntrb: PurchaseShares contextRef =" c9" decimals =" 0" id =" ixv- 14339" unitRef =" shares" > 279584 < / ntrb: PurchaseShares > < us- gaap: SharePrice contextRef =" c142" decimals =" 2" id =" ixv- 14340" unitRef =" usdPershares" > 3. 59 < / us- gaap: SharePrice > < us- gaap: SharePrice contextRef =" c143" decimals =" 2" id =" ixv- 14341" unitRef =" usdPershares" > 4. 5 < / us- gaap: SharePrice > < ntrb: FairValueOptionsServiceAmount contextRef =" c9" decimals =" 0" id =" ixv- 14342" unitRef =" usd" > 732130 < / ntrb: FairValueOptionsServiceAmount > < us- gaap: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef =" c144" decimals =" 2" id =" ixv- 14343" unitRef =" pure" > 0 < / us- gaap: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate > < us- gaap: SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef =" c144" id =" ixv- 14344" > P1Y6M < / us- gaap: SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 > < us- gaap: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef =" c145" decimals =" 4" id =" ixv- 14345" unitRef =" pure" > 1. 521 < / us- gaap: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate > < us- gaap: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef =" c146" decimals =" 4" id =" ixv- 14346" unitRef =" pure" > 1. 7445 < / us- gaap: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate > < us- gaap: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef =" c9" decimals =" 2" id =" ixv- 14347" unitRef =" pure" > 0. 03 < / us- gaap: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate > < us- gaap: ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef =" c85" id =" ixv- 14348" > The following table summarizes additional information relating to the options outstanding as of January 31, 2024. & lt; table cellpadding =" 0" cellspacing =" 0" style =" font: 10pt Times New Roman, Times, Serif; border- collapse: collapse; width: 100 %" & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td style =" text- align: center" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td style =" text- align: center; padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" border- bottom: Black 1. 5pt solid; text- align: center" & gt; & lt; b & gt; Shares & lt; / b & gt; & lt; / td & gt; & lt; td style =" text- align: center; padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td style =" text- align: center; padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" border- bottom: Black 1. 5pt solid; text- align: center" & gt; & lt; b & gt; Exercise & lt; br / & gt; Price & lt; / b & gt; & lt; / td & gt; & lt; td style =" text- align: center; padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td style =" text- align: center; padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" border- bottom: Black 1. 5pt solid; text- align: center" & gt; & lt; b & gt; Remaining & lt; br / & gt; Life & lt; / b & gt; & lt; / td & gt; & lt; td style =" text- align: center; padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td style =" text- align: center; padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" border- bottom: Black 1. 5pt solid; text- align: center" & gt; & lt; b & gt; Intrinsic & lt; br / & gt; Value & lt; / b & gt; & lt; / td & gt; & lt; td style =" text- align: center; padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" width: 52 %" & gt; Outstanding, January 31, 2022 & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; 190, 751 & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; 4. 26 & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif; font- size: 10pt" & gt; & # 160; 2. 97 years & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; & lt; div style ="- sec- ix- hidden: hidden- fact- 88" & gt; & # 160; & lt; / div & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td & gt; Granted & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 279, 584 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 3. 93 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif; font- size: 10pt" & gt; & # 160; 3. 00 years & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; div style ="- sec- ix- hidden: hidden- fact- 89" & gt;- & lt; / div & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td & gt; Expired / Cancelled & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; div style ="- sec- ix- hidden: hidden- fact- 90" & gt;- & lt; / div & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; div style ="- sec- ix- hidden: hidden- fact- 91" & gt;- & lt; / div & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; div style ="- sec- ix- hidden: hidden- fact- 92" & gt;- & lt; / div & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; &

lt; td style =" text- align: right" & gt; & lt; div style ="- sec- ix- hidden: hidden- fact- 93" & gt; & # 160; & lt; / div & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; Exercised & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; div style ="- sec- ix- hidden: hidden- fact- 94" & gt;- & lt; / div & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: right" & gt; & lt; div style ="- sec- ix- hidden: hidden- fact- 95" & gt;- & lt; / div & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; div style ="- sec- ix- hidden: hidden- fact- 96" & gt;- & lt; / div & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: right" & gt; & lt; div style ="- sec- ix- hidden: hidden- fact- 97" & gt; & # 160; & lt; / div & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td & gt; Outstanding, January 31, 2023 & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 470, 335 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 4. 13 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif; font- size: 10pt" & gt; & # 160; 2. 53 years & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; div style ="- sec- ix- hidden: hidden- fact- 98" & gt; & # 160; & lt; / div & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td & gt; Granted & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 404, 500 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 2. 18 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif; font- size: 10pt" & gt; & # 160; 2. 68 years & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; div style ="- sec- ix- hidden: hidden- fact- 99" & gt;- & lt; / div & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td & gt; Expired / Cancelled & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; div style ="- sec- ix- hidden: hidden- fact- 100" & gt;- & lt; / div & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; div style ="- sec- ix- hidden: hidden- fact- 101" & gt;- & lt; / div & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; div style ="- sec- ix- hidden: hidden- fact- 102" & gt;- & lt; / div & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; div style ="- sec- ix- hidden: hidden- fact- 103" & gt; & # 160; & lt; / div & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; Exercised & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; div style ="- sec- ix- hidden: hidden- fact- 104" & gt;- & lt; / div & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: right" & gt; & lt; div style ="- sec- ix- hidden: hidden- fact- 105" & gt;- & lt; / div & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; div style ="- sec- ix- hidden: hidden- fact- 106" & gt;- & lt; / div & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: right" & gt; & lt; div style ="- sec- ix- hidden: hidden- fact- 107" & gt; & # 160; & lt; / div & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; &

# 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" padding- bottom: 4pt" & gt; Outstanding- January 31, 2024 & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: right" & gt; 874, 835 & lt; / td & gt; & lt; td style =" padding- bottom: 4pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: right" & gt; 3. 23 & lt; / td & gt; & lt; td style =" padding- bottom: 4pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif; font- size: 10pt" & gt; 2. 31 years & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: right" & gt; 214, 460 & lt; / td & gt; & lt; td style =" padding- bottom: 4pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" padding- bottom: 4pt" & gt; Exercisable- January 31, 2024 & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: right" & gt; 874, 835 & lt; / td & gt; & lt; td style =" padding- bottom: 4pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: right" & gt; 3. 23 & lt; / td & gt; & lt; td style =" padding- bottom: 4pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif; font- size: 10pt" & gt; 2. 31 years & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: right" & gt; 214, 460 & lt; / td & gt; & lt; td style =" padding- bottom: 4pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; / table & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" & gt; & # 160; & lt; / p & gt; < / us- gaap:
ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock > < us- gaap:
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef =" c158" decimals =" INF" id =" ixv- 14349" unitRef =" shares" > 190751 < / us- gaap: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber > < ntrb:
ExercisePriceOutstanding contextRef =" c158" decimals =" 2" id =" ixv- 14350" unitRef =" usdPershares" > 4. 26 < / ntrb: ExercisePriceOutstanding > < us- gaap:
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef =" c159" id =" ixv- 14351" > P2Y11M19D < / us- gaap:
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 > < us- gaap:
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef =" c159" decimals =" INF" id =" ixv- 14352" unitRef =" shares" > 279584 < / us- gaap: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross > < us- gaap:
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef =" c159" decimals =" 2" id =" ixv- 14353" unitRef =" usdPershares" > 3. 93 < / us- gaap:
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice > < ntrb:
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAveragesRemainingContractualTerm2Granted contextRef =" c159" id =" ixv- 14354" > P3Y < / ntrb:
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAveragesRemainingContractualTerm2Granted > < us- gaap:
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef =" c160" decimals =" INF" id =" ixv- 14355" unitRef =" shares" > 470335 < / us- gaap: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber > < ntrb:
ExercisePriceOutstanding contextRef =" c160" decimals =" 2" id =" ixv- 14356" unitRef =" usdPershares" > 4. 13 < / ntrb: ExercisePriceOutstanding > < ntrb:
SharebasedCompensationArrangementsBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef =" c159" id =" ixv- 14357" > P2Y6M10D < / ntrb:
SharebasedCompensationArrangementsBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 > < us- gaap:
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef =" c85" decimals =" INF" id =" ixv- 14358" unitRef =" shares" > 404500 < / us- gaap: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross > < us- gaap:
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef =" c85" decimals =" 2" id =" ixv- 14359" unitRef =" usdPershares" > 2. 18 < / us- gaap:
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice > < ntrb:
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAveragesRemainingContractualTerm2Granted contextRef =" c85" id =" ixv- 14360" > P2Y8M4D < / ntrb:
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAveragesRemainingContractualTerm2Granted > < us- gaap:
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef =" c161" decimals =" INF" id =" ixv- 14361" unitRef =" shares" > 874835 < / us- gaap: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber > < ntrb:
ExercisePriceOutstanding contextRef =" c161" decimals =" 2" id =" ixv- 14362" unitRef =" usdPershares" > 3. 23 < / ntrb: ExercisePriceOutstanding > < ntrb:
SharebasedCompensationArrangementsBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef =" c85" id =" ixv- 14363" > P2Y3M21D < / ntrb:
SharebasedCompensationArrangementsBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 > < us- gaap:
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef =" c161" decimals =" INF" id =" ixv- 14364" unitRef =" usd" > 214460 < / us- gaap: SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 > < ntrb:
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableNumber contextRef =" c161" decimals =" INF" id =" ixv- 14365" unitRef =" shares" > 874835 < / ntrb: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableNumber > < us- gaap:
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef =" c161" decimals =" 2" id =" ixv- 14366" unitRef =" usdPershares" > 3. 23 < / us- gaap:
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice > < us- gaap:
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef =" c85" id =" ixv- 14367" > P2Y3M21D < / us- gaap:
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 > < ntrb:
SharebasedCompensationArrangementsBySharebasedPaymentAwardOptionExercisableIntrinsicValue1 contextRef =" c161" decimals =" INF" id =" ixv- 14368" unitRef =" usd" > 214460 < / ntrb: SharebasedCompensationArrangementsBySharebasedPaymentAwardOptionExercisableIntrinsicValue1 > < ntrb:

ScheduleOfSummarizesAdditionalInformationRelatingToTheOptionsOutstandingTableTextBlock contextRef =" c0" id =" ixv- 14369" > The following table summarizes additional information relating to the options outstanding as of January 31, 2024: & lt; table cellpadding =" 0" cellspacing =" 0" style =" font: 10pt Times New Roman, Times, Serif; border- collapse: collapse; width: 100 %" & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td colspan =" 2" style =" border- bottom: Black 1. 5pt solid; text- align: center" & gt; & lt; b & gt; Prices & lt; / b & gt; & lt; / td & gt; & lt; td style =" text- align: center; padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td style =" text- align: center; border- bottom: Black 1. 5pt solid" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" border- bottom: Black 1. 5pt solid; text- align: center" & gt; & lt; b & gt; Outstanding & lt; / b & gt; & lt; / td & gt; & lt; td style =" text- align: center; padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td style =" text- align: center; border- bottom: Black 1. 5pt solid" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" border- bottom: Black 1. 5pt solid; text- align: center" & gt; & lt; b & gt; Life (Years) & lt; / b & gt; & lt; / td & gt; & lt; td style =" text- align: center; padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td style =" text- align: center; border- bottom: Black 1. 5pt solid" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" border- bottom: Black 1. 5pt solid; text- align: center" & gt; & lt; b & gt; Shares Outstanding & lt; / b & gt; & lt; / td & gt; & lt; td style =" text- align: center; padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td style =" text- align: center; border- bottom: Black 1. 5pt solid" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" border- bottom: Black 1. 5pt solid; text- align: center" & gt; & lt; b & gt; Shares Exercisable & lt; / b & gt; & lt; / td & gt; & lt; td style =" text- align: center; padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td style =" text- align: center; border- bottom: Black 1. 5pt solid" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" border- bottom: Black 1. 5pt solid; text- align: center" & gt; & lt; b & gt; Value & lt; / b & gt; & lt; / td & gt; & lt; td style =" text- align: center; padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td colspan =" 2" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td colspan =" 2" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td colspan =" 2" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td colspan =" 2" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td colspan =" 2" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td colspan =" 2" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" width: 1 %; text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" width: 12 %; text- align: right" & gt; 1. 93 & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 12 %; text- align: right" & gt; 214, 500 & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 12 %; text- align: right" & gt; 2. 74 & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" width: 11 %; text- align: right" & gt; 1. 93 & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 11 %; text- align: right" & gt; 214, 500 & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" width: 11 %; text- align: right" & gt; 1. 93 & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 11 %; text- align: right" & gt; 145, 860 & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" text- align: right" & gt; 2. 12 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 140, 000 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 2. 74 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" text- align: right" & gt; 2. 12 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 140, 000 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" text- align: right" & gt; 2. 12 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" text- align: right" & gt; 68, 600 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" text- align: right" & gt; 2. 65 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 20, 000 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 2. 63 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" text- align: right" & gt; 2. 65 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 20, 000 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" text- align: right" & gt; 2. 65 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; div style ="- sec- ix- hidden: hidden- fact- 108" & gt;- & lt; / div & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" text- align: right" & gt; 3. 59 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 35, 000 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 3. 67 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" text- align: right" & gt; 3. 59 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 35, 000 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" text- align: right" & gt; 3. 59 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; div style ="- sec- ix- hidden: hidden- fact- 109" & gt;- & lt; / div & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" text- align: right" & gt; 3. 75 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 57, 500 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 1. 85 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" text- align: right" & gt; 3. 75 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 57, 500 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" text- align: right" & gt; 3. 75 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; div style ="- sec- ix- hidden: hidden- fact- 110" & gt;- & lt; / div & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" text- align: right" & gt; 3. 98 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 30, 000 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td &

gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 2. 01 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" text- align: right" & gt; 3. 98 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 30, 000 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" text- align: right" & gt; 3. 98 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; div style ="- sec- ix- hidden: hidden- fact- 111" & gt;- & lt; / div & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" text- align: right" & gt; 4. 09 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 78, 750 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 1. 50 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" text- align: right" & gt; 4. 09 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 78, 750 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" text- align: right" & gt; 4. 09 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; div style ="- sec- ix- hidden: hidden- fact- 112" & gt;- & lt; / div & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" text- align: right" & gt; 4. 12 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 50, 000 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 1. 85 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" text- align: right" & gt; 4. 12 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 50, 000 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" text- align: right" & gt; 4. 12 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; div style ="- sec- ix- hidden: hidden- fact- 113" & gt;- & lt; / div & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" text- align: right" & gt; 4. 16 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 144, 083 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 0. 97 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" text- align: right" & gt; 4. 16 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 144, 083 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" text- align: right" & gt; 4. 16 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; div style ="- sec- ix- hidden: hidden- fact- 114" & gt;- & lt; / div & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" text- align: right" & gt; 4. 50 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 58, 334 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 1. 50 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" text- align: right" & gt; 4. 50 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" text- align: right" & gt; 4. 50 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; div style ="- sec- ix- hidden: hidden- fact- 115" & gt;- & lt; / div & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" text- align: right" & gt; 4. 58 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 46, 668 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 0. 97 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" text- align: right" & gt; 4. 58 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 46, 668 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" text- align: right" & gt; 4. 58 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; div style ="- sec- ix- hidden: hidden- fact- 116" & gt;- & lt; / div & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td

usdPershares"> 1. 93 </ ntrb: ShareBasedCompensationArrangementByShareBasedPaymentAwardRangeOfExercisePrices > < ntrb: ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingNumber contextRef =" c163" decimals =" INF" id =" ixv- 14371" unitRef =" shares"> 214500 </ ntrb: ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingNumber > < ntrb: SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsOutstandingWeightedAverageRemainingContractualTerm2 contextRef =" c162" id =" ixv- 14372"> P2Y8M26D </ ntrb:
SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsOutstandingWeightedAverageRemainingContractualTerm2 > < ntrb: ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice contextRef =" c162" decimals =" 2" id =" ixv- 14373" unitRef =" usdPershares"> 1. 93 </ ntrb:
ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice > < ntrb: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumbers contextRef =" c163" decimals =" INF" id =" ixv- 14374" unitRef =" shares"> 214500 </ ntrb: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumbers > < ntrb:
ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableWeightedAverageExercisePrice contextRef =" c163" decimals =" 2" id =" ixv- 14375" unitRef =" usdPershares"> 1. 93 </ ntrb:
ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableWeightedAverageExercisePrice > < ntrb:
ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsIntrinsicValue contextRef =" c163" decimals =" 0" id =" ixv- 14376" unitRef =" usd"> 145860 </ ntrb: ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsIntrinsicValue > < ntrb:
ShareBasedCompensationArrangementByShareBasedPaymentAwardRangeOfExercisePrices contextRef =" c164" decimals =" 2" id =" ixv- 14377" unitRef =" usdPershares"> 2. 12 </ ntrb: ShareBasedCompensationArrangementByShareBasedPaymentAwardRangeOfExercisePrices > < ntrb:
ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingNumber contextRef =" c165" decimals =" INF" id =" ixv- 14378" unitRef =" shares"> 140000 </ ntrb: ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingNumber > < ntrb:
SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsOutstandingWeightedAverageRemainingContractualTerm2 contextRef =" c164" id =" ixv- 14379"> P2Y8M26D </ ntrb:
SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsOutstandingWeightedAverageRemainingContractualTerm2 > < ntrb:
ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice contextRef =" c164" decimals =" 2" id =" ixv- 14380" unitRef =" usdPershares"> 2. 12 </ ntrb:
ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice > < ntrb:
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumbers contextRef =" c165" decimals =" INF" id =" ixv- 14381" unitRef =" shares"> 140000 </ ntrb: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumbers > < ntrb:
ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableWeightedAverageExercisePrice contextRef =" c165" decimals =" 2" id =" ixv- 14382" unitRef =" usdPershares"> 2. 12 </ ntrb:
ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableWeightedAverageExercisePrice > < ntrb:
ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsIntrinsicValue contextRef =" c165" decimals =" 0" id =" ixv- 14383" unitRef =" usd"> 68600 </ ntrb: ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsIntrinsicValue > < ntrb:
ShareBasedCompensationArrangementByShareBasedPaymentAwardRangeOfExercisePrices contextRef =" c166" decimals =" 2" id =" ixv- 14384" unitRef =" usdPershares"> 2. 65 </ ntrb: ShareBasedCompensationArrangementByShareBasedPaymentAwardRangeOfExercisePrices > < ntrb:
ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingNumber contextRef =" c167" decimals =" INF" id =" ixv- 14385" unitRef =" shares"> 20000 </ ntrb: ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingNumber > < ntrb:
SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsOutstandingWeightedAverageRemainingContractualTerm2 contextRef =" c166" id =" ixv- 14386"> P2Y7M17D </ ntrb:
SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsOutstandingWeightedAverageRemainingContractualTerm2 > < ntrb:
ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice contextRef =" c166" decimals =" 2" id =" ixv- 14387" unitRef =" usdPershares"> 2. 65 </ ntrb:
ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice > < ntrb:
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumbers contextRef =" c167" decimals =" INF" id =" ixv- 14388" unitRef =" shares"> 20000 </ ntrb: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumbers > < ntrb:
ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableWeightedAverageExercisePrice contextRef =" c167" decimals =" 2" id =" ixv- 14389" unitRef =" usdPershares"> 2. 65 </ ntrb:
ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableWeightedAverageExercisePrice > < ntrb:
ShareBasedCompensationArrangementByShareBasedPaymentAwardRangeOfExercisePrices contextRef =" c168" decimals =" 2" id =" ixv- 14390" unitRef =" usdPershares"> 3. 59 </ ntrb: ShareBasedCompensationArrangementByShareBasedPaymentAwardRangeOfExercisePrices > < ntrb:
ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingNumber contextRef =" c169" decimals =" INF" id =" ixv- 14391" unitRef =" shares"> 35000 </ ntrb: ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingNumber > < ntrb:
SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsOutstandingWeightedAverageRemainingContractualTerm2 contextRef =" c168" id =" ixv- 14392"> P3Y8M1D </ ntrb:
SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsOutstandingWeightedAverageRemainingContractualTerm2 > < ntrb:
ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice contextRef =" c168" decimals =" 2" id =" ixv- 14393" unitRef =" usdPershares"> 3. 59 </ ntrb:
ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice > < ntrb:
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumbers contextRef =" c169" decimals =" INF" id =" ixv- 14394" unitRef =" shares"> 35000 </ ntrb: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumbers > < ntrb:
ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableWeightedAverageExercisePrice contextRef =" c169" decimals =" 2" id =" ixv- 14395" unitRef =" usdPershares"> 3. 59 </ ntrb:
ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableWeightedAverageExercisePrice > < ntrb:
ShareBasedCompensationArrangementByShareBasedPaymentAwardRangeOfExercisePrices contextRef =" c170" decimals =" 2" id =" ixv- 14396" unitRef =" usdPershares"> 3. 75 </ ntrb: ShareBasedCompensationArrangementByShareBasedPaymentAwardRangeOfExercisePrices > < ntrb:
ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingNumber contextRef =" c171" decimals =" INF" id =" ixv- 14397" unitRef =" shares"> 57500 </ ntrb: ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingNumber > < ntrb:
SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsOutstandingWeightedAverageRemainingContractualTerm2 contextRef =" c170" id =" ixv- 14398"> P1Y10M6D </ ntrb:
SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsOutstandingWeightedAverageRemainingContractualTerm2 > < ntrb:
ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice contextRef =" c170" decimals =" 2" id =" ixv- 14399" unitRef =" usdPershares"> 3. 75 </ ntrb:
ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice > < ntrb:
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumbers contextRef =" c171" decimals =" INF" id =" ixv- 14400" unitRef =" shares"> 57500 </ ntrb: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumbers > < ntrb:
ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableWeightedAverageExercisePrice contextRef =" c171" decimals =" 2" id =" ixv- 14401" unitRef =" usdPershares"> 3. 75 </ ntrb:
ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableWeightedAverageExercisePrice > < ntrb:
ShareBasedCompensationArrangementByShareBasedPaymentAwardRangeOfExercisePrices contextRef =" c172" decimals =" 2" id =" ixv- 14402" unitRef =" usdPershares"> 3. 98 </ ntrb: ShareBasedCompensationArrangementByShareBasedPaymentAwardRangeOfExercisePrices > < ntrb:

ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingNumber contextRef =" c173" decimals =" INF" id =" ixv- 14403" unitRef =" shares" > 30000 < / ntrb: ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingNumber > < ntrb:
SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsOutstandingWeightedAverageRemainingContractualTerm2 contextRef =" c172" id =" ixv- 14404" > P2Y3D < / ntrb:
SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsOutstandingWeightedAverageRemainingContractualTerm2 > < ntrb:
ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice contextRef =" c172" decimals =" 2" id =" ixv- 14405" unitRef =" usdPershares" > 3. 98 < / ntrb:
ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice > < ntrb:
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumbers contextRef =" c173" decimals =" INF" id =" ixv- 14406" unitRef =" shares" > 30000 < / ntrb: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumbers > < ntrb:
ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableWeightedAverageExercisePrice contextRef =" c173" decimals =" 2" id =" ixv- 14407" unitRef =" usdPershares" > 3. 98 < / ntrb:
ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableWeightedAverageExercisePrice > < ntrb:
ShareBasedCompensationArrangementByShareBasedPaymentAwardRangeOfExercisePrices contextRef =" c174" decimals =" 2" id =" ixv- 14408" unitRef =" usdPershares" > 4. 09 < / ntrb: ShareBasedCompensationArrangementByShareBasedPaymentAwardRangeOfExercisePrices > < ntrb:
ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingNumber contextRef =" c175" decimals =" INF" id =" ixv- 14409" unitRef =" shares" > 78750 < / ntrb: ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingNumber > < ntrb:
SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsOutstandingWeightedAverageRemainingContractualTerm2 contextRef =" c174" id =" ixv- 14410" > P1Y6M < / ntrb:
SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsOutstandingWeightedAverageRemainingContractualTerm2 > < ntrb:
ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice contextRef =" c174" decimals =" 2" id =" ixv- 14411" unitRef =" usdPershares" > 4. 09 < / ntrb:
ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice > < ntrb:
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumbers contextRef =" c175" decimals =" INF" id =" ixv- 14412" unitRef =" shares" > 78750 < / ntrb: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumbers > < ntrb:
ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableWeightedAverageExercisePrice contextRef =" c175" decimals =" 2" id =" ixv- 14413" unitRef =" usdPershares" > 4. 09 < / ntrb:
ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableWeightedAverageExercisePrice > < ntrb:
ShareBasedCompensationArrangementByShareBasedPaymentAwardRangeOfExercisePrices contextRef =" c176" decimals =" 2" id =" ixv- 14414" unitRef =" usdPershares" > 4. 12 < / ntrb: ShareBasedCompensationArrangementByShareBasedPaymentAwardRangeOfExercisePrices > < ntrb:
ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingNumber contextRef =" c177" decimals =" INF" id =" ixv- 14415" unitRef =" shares" > 50000 < / ntrb: ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingNumber > < ntrb:
SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsOutstandingWeightedAverageRemainingContractualTerm2 contextRef =" c176" id =" ixv- 14416" > P1Y10M6D < / ntrb:
SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsOutstandingWeightedAverageRemainingContractualTerm2 > < ntrb:
ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice contextRef =" c176" decimals =" 2" id =" ixv- 14417" unitRef =" usdPershares" > 4. 12 < / ntrb:
ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice > < ntrb:
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumbers contextRef =" c177" decimals =" INF" id =" ixv- 14418" unitRef =" shares" > 50000 < / ntrb: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumbers > < ntrb:
ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableWeightedAverageExercisePrice contextRef =" c177" decimals =" 2" id =" ixv- 14419" unitRef =" usdPershares" > 4. 12 < / ntrb:
ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableWeightedAverageExercisePrice > < ntrb:
ShareBasedCompensationArrangementByShareBasedPaymentAwardRangeOfExercisePrices contextRef =" c178" decimals =" 2" id =" ixv- 14420" unitRef =" usdPershares" > 4. 16 < / ntrb: ShareBasedCompensationArrangementByShareBasedPaymentAwardRangeOfExercisePrices > < ntrb:
ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingNumber contextRef =" c179" decimals =" INF" id =" ixv- 14421" unitRef =" shares" > 144083 < / ntrb: ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingNumber > < ntrb:
SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsOutstandingWeightedAverageRemainingContractualTerm2 contextRef =" c178" id =" ixv- 14422" > P0Y11M19D < / ntrb:
SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsOutstandingWeightedAverageRemainingContractualTerm2 > < ntrb:
ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice contextRef =" c178" decimals =" 2" id =" ixv- 14423" unitRef =" usdPershares" > 4. 16 < / ntrb:
ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice > < ntrb:
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumbers contextRef =" c179" decimals =" INF" id =" ixv- 14424" unitRef =" shares" > 144083 < / ntrb: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumbers > < ntrb:
ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableWeightedAverageExercisePrice contextRef =" c179" decimals =" 2" id =" ixv- 14425" unitRef =" usdPershares" > 4. 16 < / ntrb:
ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableWeightedAverageExercisePrice > < ntrb:
ShareBasedCompensationArrangementByShareBasedPaymentAwardRangeOfExercisePrices contextRef =" c180" decimals =" 2" id =" ixv- 14426" unitRef =" usdPershares" > 4. 5 < / ntrb: ShareBasedCompensationArrangementByShareBasedPaymentAwardRangeOfExercisePrices > < ntrb:
ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingNumber contextRef =" c181" decimals =" INF" id =" ixv- 14427" unitRef =" shares" > 58334 < / ntrb: ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingNumber > < ntrb:
SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsOutstandingWeightedAverageRemainingContractualTerm2 contextRef =" c180" id =" ixv- 14428" > P1Y6M < / ntrb:
SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsOutstandingWeightedAverageRemainingContractualTerm2 > < ntrb:
ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice contextRef =" c180" decimals =" 2" id =" ixv- 14429" unitRef =" usdPershares" > 4. 5 < / ntrb:
ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice > < ntrb:
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumbers contextRef =" c181" decimals =" INF" id =" ixv- 14430" unitRef =" shares" > 58334 < / ntrb: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumbers > < ntrb:
ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableWeightedAverageExercisePrice contextRef =" c181" decimals =" 2" id =" ixv- 14431" unitRef =" usdPershares" > 4. 5 < / ntrb:
ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableWeightedAverageExercisePrice > < ntrb:
ShareBasedCompensationArrangementByShareBasedPaymentAwardRangeOfExercisePrices contextRef =" c182" decimals =" 2" id =" ixv- 14432" unitRef =" usdPershares" > 4. 58 < / ntrb: ShareBasedCompensationArrangementByShareBasedPaymentAwardRangeOfExercisePrices > < ntrb:
ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingNumber contextRef =" c183" decimals =" INF" id =" ixv- 14433" unitRef =" shares" > 46668 < / ntrb: ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingNumber > < ntrb:
SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsOutstandingWeightedAverageRemainingContractualTerm2 contextRef =" c182" id =" ixv- 14434" > P0Y11M19D < / ntrb:
SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsOutstandingWeightedAverageRemainingContractualTerm2 > < ntrb:

ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingPeriodIncreaseDecreaseWeightedAverageExcercisePrice contextRef =" c182" decimals =" 2" id =" ixv- 14435" unitRef =" usdPershares" > 4. 58 < / ntrb:
ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingPeriodIncreaseDecreaseWeightedAverageExcercisePrice > < ntrb:
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExcercisableNumbers contextRef =" c183" decimals =" INF" id =" ixv- 14436" unitRef =" shares" > 46668 < / ntrb: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExcercisableNumbers > < ntrb:
ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExcercisableWeightedAverageExcercisePrice contextRef =" c183" decimals =" 2" id =" ixv- 14437" unitRef =" usdPershares" > 4. 58 < / ntrb:
ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExcercisableWeightedAverageExcercisePrice > < ntrb:
ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingNumber contextRef =" c161" decimals =" INF" id =" ixv- 14438" unitRef =" shares" > 874835 < / ntrb: ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingNumber > < ntrb:
SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsOutstandingWeightedAverageRemainingContractualTerm2 contextRef =" c85" id =" ixv- 14439" > P2Y21D < / ntrb:
SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsOutstandingWeightedAverageRemainingContractualTerm2 > < ntrb:
ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingPeriodIncreaseDecreaseWeightedAverageExcercisePrice contextRef =" c85" decimals =" 2" id =" ixv- 14440" unitRef =" usdPershares" > 3. 23 < / ntrb:
ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingPeriodIncreaseDecreaseWeightedAverageExcercisePrice > < ntrb:
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExcercisableNumbers contextRef =" c161" decimals =" INF" id =" ixv- 14441" unitRef =" shares" > 874835 < / ntrb: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExcercisableNumbers > < ntrb:
ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExcercisableWeightedAverageExcercisePrice contextRef =" c161" decimals =" 2" id =" ixv- 14442" unitRef =" usdPershares" > 3. 23 < / ntrb:
ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExcercisableWeightedAverageExcercisePrice > < ntrb:
ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsIntrinsicValue contextRef =" c161" decimals =" 0" id =" ixv- 14443" unitRef =" usd" > 214460 < / ntrb: ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsIntrinsicValue > < us- gaap:
SegmentReportingDisclosureTextBlock contextRef =" c0" id =" ixv- 9288" > & lt; table cellpadding =" 0" cellspacing =" 0" style =" font: 10pt Times New Roman, Times, Serif; margin- top: 0pt; margin- bottom: 0pt; width: 100 %" & gt; & lt; tr style =" vertical- align: top" & gt; & lt; td style =" width: 0. 5in" & gt; 10. & lt; / td & gt; & lt; td style =" text- align: justify" & gt; SEGMENT REPORTING & lt; / td & gt; & lt; / tr & gt; & lt; / table & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 25in; text- align: justify" & gt; & # 160; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify" & gt; We organize and manage our business by the following two segments which meet the definition of reportable segments under ASC280- 10, Segment Reporting: Sales of Goods and Services. These segments are based on the type **Type** of products or services provided and are the same as our business units. Separate financial information is available and regularly reviewed by our chief officer decision maker, in making resource allocation decisions for our segments. Our chief officer decision maker evaluates segment performance to the GAAP measure of gross profit. & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify" & gt; & # 160; & lt; / p & gt; & lt; table cellpadding =" 0" cellspacing =" 0" style =" border- collapse: collapse; width: 100 %; font: 10pt Times New Roman, Times, Serif" & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td style =" text- align: center" & gt; & # 160; & lt; / td & gt; & lt; td style =" font- weight: bold; padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td colspan =" 6" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" & gt; Years Ended January 31, & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; font- weight: bold" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td style =" text- align: center" & gt; & # 160; & lt; / td & gt; & lt; td style =" font- weight: bold; padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" & gt; 2024 & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; font- weight: bold" & gt; & # 160; & lt; / td & gt; & lt; td style =" font- weight: bold; padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" & gt; 2023 & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; font- weight: bold" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td & gt; Net sales & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td colspan =" 2" style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td colspan =" 2" style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" width: 76 %; text- align: left; padding- left: 9pt" & gt; Pocono Pharmaceuticals & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; 1, 920, 280 & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; 1, 785, 597 & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" padding- bottom: 1. 5pt; padding- left: 9pt" & gt; 4P Therapeutics & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; 165, 034 & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; 294, 102 & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; 2, 085, 314 & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; 2, 079, 699 & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" text- align: left" & gt; Gross profit & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" text- align: left; padding- left: 9pt" & gt; Pocono Pharmaceuticals & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 744, 391 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 726, 702 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" padding- bottom: 1. 5pt; padding- left: 9pt" & gt; 4P Therapeutics & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; 117, 714 & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; 23, 702 & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; 862, 105 & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; 750, 404 & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" text- align: left" & gt; Operating expenses & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & #

160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" text- align: left; padding- left: 9pt" & gt; Selling, general and administrative- Pocono Pharmaceuticals & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 606, 275 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 577, 930 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" text- align: left; padding- left: 9pt" & gt; Selling, general and administrative- 4P Therapeutics & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 236, 953 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 103, 181 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" text- align: left; padding- left: 9pt" & gt; Selling, general and administrative- Corporate & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 2, 930, 378 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 3, 234, 930 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" text- align: left; padding- left: 9pt" & gt; Research and development- 4P Therapeutics & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 1, 960, 425 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 982, 227 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" text- align: left; padding- bottom: 1. 5pt; padding- left: 9pt" & gt; Goodwill impairment- Pocono Pharmaceuticals & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; div style ="- sec- ix- hidden: hidden- fact- 117" & gt;- & lt; / div & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; 327, 326 & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; 5, 734, 031 & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; 5, 225, 594 & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" text- align: left" & gt; Depreciation and Amortization & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" text- align: left; padding- left: 9pt" & gt; Pocono Pharmaceuticals & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" text- align: right" & gt; 222, 159 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" text- align: right" & gt; 264, 156 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" padding- left: 9pt" & gt; Corporate & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 13, 986 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; div style ="- sec- ix- hidden: hidden- fact- 118" & gt;- & lt; / div & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" padding- bottom: 1. 5pt; padding- left: 9pt" & gt; 4P Therapeutics & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; 51, 577 & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; 65, 987 & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" padding- bottom: 4pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: right" & gt; 287, 722 & lt; / td & gt; & lt; td style =" padding- bottom: 4pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: right" & gt; 330, 143 & lt; / td & gt; & lt; td style =" padding- bottom: 4pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; / table & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify" & gt; & # 160; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify" & gt; The following table presents information about net sales and property and equipment, net of accumulated depreciation, in the United States and elsewhere. & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify" & gt; & # 160; & lt; / p & gt; & lt; table cellpadding =" 0" cellspacing =" 0" style =" font: 10pt Times New Roman, Times, Serif; border- collapse: collapse; width: 100 %" & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: center" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: center" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td colspan =" 6" style =" border- bottom: Black 1. 5pt solid; text- align: center" & gt; & lt; b & gt; Years Ended & lt; br / & gt; January 31, & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: center" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td style =" text- align: center" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td style =" text- align: center; padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" border- bottom: Black 1. 5pt solid; text- align: center" & gt; & lt; b & gt; 2024 & lt; / b & gt; & lt; / td & gt; & lt; td style =" text- align: center; padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td style =" text- align: center; padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" border- bottom: Black 1. 5pt solid; text- align: center" & gt; & lt; b & gt; 2023 & lt; / b & gt; & lt; / td & gt; & lt; td style =" text- align: center; padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td & gt; Net sales & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td colspan =" 2" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" padding- left: 0. 125in; width: 76 %; text- align: left" & gt; United States & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; 2, 085, 314 & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; 2, 079, 699 & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" padding- left: 0. 125in; text- align: left; padding- bottom: 1. 5pt" & gt; Outside the United States & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; div style ="- sec- ix- hidden: hidden- fact- 119" & gt;- & lt; / div & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; div style ="- sec- ix- hidden: hidden- fact- 120" & gt;- & lt; / div & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" padding- bottom: 4pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double;

text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: right" & gt; 2, 085, 314 & lt; / td & gt; & lt; td style =" padding- bottom: 4pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: right" & gt; 2, 079, 699 & lt; / td & gt; & lt; td style =" padding- bottom: 4pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; / table & gt; & lt; p style =" margin: 0" & gt; & # 160; & lt; / p & gt; & lt; table cellpadding =" 0" cellspacing =" 0" style =" font: 10pt Times New Roman, Times, Serif; border- collapse: collapse; width: 100 %" & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td style =" width: 76 %" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td style =" text- align: left; width: 1 %" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td style =" text- align: center; width: 9 %" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif; font- size: 10pt" & gt; & lt; b & gt; January 31, & lt; / b & gt; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left; width: 1 %" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td style =" text- align: left; width: 1 %" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td style =" text- align: center; width: 9 %" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif; font- size: 10pt" & gt; & lt; b & gt; January 31, & lt; / b & gt; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left; width: 1 %" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: center" & gt; & lt; b & gt; 2024 & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td style =" text- align: left" & gt; Property and equipment, net of accumulated depreciation & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" padding- left: 0. 125in; text- align: left" & gt; United States & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" text- align: right" & gt; 774, 924 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" text- align: right" & gt; 897, 735 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" padding- left: 0. 125in; text- align: left; padding- bottom: 1. 5pt" & gt; Outside the United States & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; div style ="- sec- ix- hidden: hidden- fact- 121" & gt;- & lt; / div & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; div style ="- sec- ix- hidden: hidden- fact- 122" & gt;- & lt; / div & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" padding- bottom: 4pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: right" & gt; 774, 924 & lt; / td & gt; & lt; td style =" padding- bottom: 4pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: right" & gt; 897, 735 & lt; / td & gt; & lt; td style =" padding- bottom: 4pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td & gt; Assets & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" padding- left: 0. 125in" & gt; Corporate & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" text- align: right" & gt; 344, 192 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" text- align: right" & gt; 1, 745, 731 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" padding- left: 0. 125in; text- align: left" & gt; Pocono Pharmaceuticals & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 5, 079, 293 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 5, 400, 814 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" padding- left: 0. 125in; padding- bottom: 1. 5pt" & gt; 4P Therapeutics & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; 2, 093, 369 & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; 2, 309, 832 & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" padding- bottom: 4pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: right" & gt; 7, 516, 854 & lt; / td & gt; & lt; td style =" padding- bottom: 4pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: right" & gt; 9, 456, 377 & lt; / td & gt; & lt; td style =" padding- bottom: 4pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; / table & gt; < / us- gaap: SegmentReportingDisclosureTextBlock > < us- gaap: ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef =" c0" id =" ixv- 14444" > Our chief officer decision maker evaluates segment performance to the GAAP measure of gross profit. & lt; table cellpadding =" 0" cellspacing =" 0" style =" border- collapse: collapse; width: 100 %; font: 10pt Times New Roman, Times, Serif" & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td style =" text- align: center" & gt; & # 160; & lt; / td & gt; & lt; td style =" font- weight: bold; padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td colspan =" 6" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" & gt; Years Ended January 31, & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; font- weight: bold" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td style =" text- align: center" & gt; & # 160; & lt; / td & gt; & lt; td style =" font- weight: bold; padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" & gt; 2024 & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; font- weight: bold" & gt; & # 160; & lt; / td & gt; & lt; td style =" font- weight: bold; padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" & gt; 2023 & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; font- weight: bold" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td & gt; Net sales & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td colspan =" 2" style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td colspan =" 2" style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" width: 76 %; text- align: left; padding- left: 9pt" & gt; Pocono Pharmaceuticals & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; 1, 920, 280 & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; 1, 785, 597 & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" padding- bottom: 1. 5pt; padding- left: 9pt" & gt; 4P Therapeutics & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; 165, 034 & lt; / td & gt;

& lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; 294, 102 & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; 2, 085, 314 & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; 2, 079, 699 & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" text- align: left" & gt; Gross profit & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left; padding- left: 9pt" & gt; Pocono Pharmaceuticals & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 744, 391 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 726, 702 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" padding- bottom: 1. 5pt; padding- left: 9pt" & gt; 4P Therapeutics & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; 117, 714 & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; 23, 702 & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; 862, 105 & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; 750, 404 & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" text- align: left" & gt; Operating expenses & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" text- align: left; padding- left: 9pt" & gt; Selling, general and administrative- Pocono Pharmaceuticals & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 606, 275 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 577, 930 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" text- align: left; padding- left: 9pt" & gt; Selling, general and administrative- 4P Therapeutics & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 236, 953 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 103, 181 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" text- align: left; padding- left: 9pt" & gt; Selling, general and administrative- Corporate & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 2, 930, 378 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 3, 234, 930 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" text- align: left; padding- left: 9pt" & gt; Research and development- 4P Therapeutics & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 1, 960, 425 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 982, 227 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" text- align: left; padding- bottom: 1. 5pt; padding- left: 9pt" & gt; Goodwill impairment- Pocono Pharmaceuticals & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; div style ="- sec- ix- hidden: hidden- fact- 117" & gt;- & lt; / div & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; 327, 326 & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; 5, 734, 031 & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; 5, 225, 594 & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" text- align: left" & gt; Depreciation and Amortization & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" text- align: left; padding- left: 9pt" & gt; Pocono Pharmaceuticals & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" text- align: right" & gt; 222, 159 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" text- align: right" & gt; 264, 156 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" padding- left: 9pt" & gt; Corporate & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 13, 986 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; div style ="- sec- ix- hidden: hidden- fact- 118" & gt;- & lt; / div & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" padding- bottom: 1. 5pt; padding- left: 9pt" & gt; 4P Therapeutics & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; 51, 577 & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; 65, 987 & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" padding- bottom: 4pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: right" & gt; 287, 722 & lt; / td & gt; & lt; td style =" padding- bottom: 4pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text-

align: left" & gt; $ & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: right" & gt; 330, 143 & lt; / td & gt; & lt; td style =" padding- bottom: 4pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; / table & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify" & gt; & # 160; & lt; / p & gt; < / us- gaap: ScheduleOfSegmentReportingInformationBySegmentTextBlock > < us- gaap: GainLossOnSalesOfLoansNet contextRef =" c184" decimals =" 0" id =" ixv- 14445" unitRef =" usd" > 1920280 < / us- gaap: GainLossOnSalesOfLoansNet > < us- gaap: GainLossOnSalesOfLoansNet contextRef =" c185" decimals =" 0" id =" ixv- 14446" unitRef =" usd" > 1785597 < / us- gaap: GainLossOnSalesOfLoansNet > < us- gaap: GainLossOnSalesOfLoansNet contextRef =" c186" decimals =" 0" id =" ixv- 14447" unitRef =" usd" > 165034 < / us- gaap: GainLossOnSalesOfLoansNet > < us- gaap: GainLossOnSalesOfLoansNet contextRef =" c187" decimals =" 0" id =" ixv- 14448" unitRef =" usd" > 294102 < / us- gaap: GainLossOnSalesOfLoansNet > < us- gaap: GainLossOnSalesOfLoansNet contextRef =" c0" decimals =" 0" id =" ixv- 14449" unitRef =" usd" > 2085314 < / us- gaap: GainLossOnSalesOfLoansNet > < us- gaap: GainLossOnSalesOfLoansNet contextRef =" c9" decimals =" 0" id =" ixv- 14450" unitRef =" usd" > 2079699 < / us- gaap: GainLossOnSalesOfLoansNet > < us- gaap: DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss contextRef =" c184" decimals =" 0" id =" ixv- 14451" unitRef =" usd" > 744391 < / us- gaap: DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss > < us- gaap: DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss contextRef =" c185" decimals =" 0" id =" ixv- 14452" unitRef =" usd" > 726702 < / us- gaap: DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss > < us- gaap: DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss contextRef =" c186" decimals =" 0" id =" ixv- 14453" unitRef =" usd" > 117714 < / us- gaap: DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss > < us- gaap: DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss contextRef =" c187" decimals =" 0" id =" ixv- 14454" unitRef =" usd" > 23702 < / us- gaap: DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss > < us- gaap: DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss contextRef =" c0" decimals =" 0" id =" ixv- 14455" unitRef =" usd" > 862105 < / us- gaap: DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss > < us- gaap: DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss contextRef =" c9" decimals =" 0" id =" ixv- 14456" unitRef =" usd" > 750404 < / us- gaap: DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss > < us- gaap: OtherCostAndExpenseOperating contextRef =" c184" decimals =" 0" id =" ixv- 14457" unitRef =" usd" > 606275 < / us- gaap: OtherCostAndExpenseOperating > < us- gaap: OtherCostAndExpenseOperating contextRef =" c185" decimals =" 0" id =" ixv- 14458" unitRef =" usd" > 577930 < / us- gaap: OtherCostAndExpenseOperating > < us- gaap: OtherCostAndExpenseOperating contextRef =" c186" decimals =" 0" id =" ixv- 14459" unitRef =" usd" > 236953 < / us- gaap: OtherCostAndExpenseOperating > < us- gaap: OtherCostAndExpenseOperating contextRef =" c187" decimals =" 0" id =" ixv- 14460" unitRef =" usd" > 103181 < / us- gaap: OtherCostAndExpenseOperating > < us- gaap: OtherCostAndExpenseOperating contextRef =" c188" decimals =" 0" id =" ixv- 14461" unitRef =" usd" > 2930378 < / us- gaap: OtherCostAndExpenseOperating > < us- gaap: OtherCostAndExpenseOperating contextRef =" c189" decimals =" 0" id =" ixv- 14462" unitRef =" usd" > 3234930 < / us- gaap: OtherCostAndExpenseOperating > < us- gaap: OtherCostAndExpenseOperating contextRef =" c190" decimals =" 0" id =" ixv- 14463" unitRef =" usd" > 1960425 < / us- gaap: OtherCostAndExpenseOperating > < us- gaap: OtherCostAndExpenseOperating contextRef =" c191" decimals =" 0" id =" ixv- 14464" unitRef =" usd" > 982227 < / us- gaap: OtherCostAndExpenseOperating > < us- gaap: OtherCostAndExpenseOperating contextRef =" c193" decimals =" 0" id =" ixv- 14465" unitRef =" usd" > 327326 < / us- gaap: OtherCostAndExpenseOperating > < us- gaap: OtherCostAndExpenseOperating contextRef =" c0" decimals =" 0" id =" ixv- 14466" unitRef =" usd" > 5734031 < / us- gaap: OtherCostAndExpenseOperating > < us- gaap: OtherCostAndExpenseOperating contextRef =" c9" decimals =" 0" id =" ixv- 14467" unitRef =" usd" > 5225594 < / us- gaap: OtherCostAndExpenseOperating > < us- gaap: CostOfGoodsAndServicesSoldDepreciationAndAmortization contextRef =" c184" decimals =" 0" id =" ixv- 14468" unitRef =" usd" > 222159 < / us- gaap: CostOfGoodsAndServicesSoldDepreciationAndAmortization > < us- gaap: CostOfGoodsAndServicesSoldDepreciationAndAmortization contextRef =" c185" decimals =" 0" id =" ixv- 14469" unitRef =" usd" > 264156 < / us- gaap: CostOfGoodsAndServicesSoldDepreciationAndAmortization > < us- gaap: CostOfGoodsAndServicesSoldDepreciationAndAmortization contextRef =" c188" decimals =" 0" id =" ixv- 14470" unitRef =" usd" > 13986 < / us- gaap: CostOfGoodsAndServicesSoldDepreciationAndAmortization > < us- gaap: CostOfGoodsAndServicesSoldDepreciationAndAmortization contextRef =" c186" decimals =" 0" id =" ixv- 14471" unitRef =" usd" > 51577 < / us- gaap: CostOfGoodsAndServicesSoldDepreciationAndAmortization > < us- gaap: CostOfGoodsAndServicesSoldDepreciationAndAmortization contextRef =" c187" decimals =" 0" id =" ixv- 14472" unitRef =" usd" > 65987 < / us- gaap: CostOfGoodsAndServicesSoldDepreciationAndAmortization > < us- gaap: CostOfGoodsAndServicesSoldDepreciationAndAmortization contextRef =" c0" decimals =" 0" id =" ixv- 14473" unitRef =" usd" > 287722 < / us- gaap: CostOfGoodsAndServicesSoldDepreciationAndAmortization > < us- gaap: CostOfGoodsAndServicesSoldDepreciationAndAmortization contextRef =" c9" decimals =" 0" id =" ixv- 14474" unitRef =" usd" > 330143 < / us- gaap: CostOfGoodsAndServicesSoldDepreciationAndAmortization > < us- gaap: ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock contextRef =" c0" id =" ixv- 14475" > The following table presents information about net sales and property and equipment, net of accumulated depreciation, in the United States and elsewhere. & lt; table cellpadding =" 0" cellspacing =" 0" style =" font: 10pt Times New Roman, Times, Serif; border- collapse: collapse; width: 100 %" & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: center" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: center" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td colspan =" 6" style =" border- bottom: Black 1. 5pt solid; text- align: center" & gt; & lt; b & gt; Years Ended & lt; br / & gt; January 31, & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: center" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td style =" text- align: center" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td style =" text- align: center; padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" border- bottom: Black 1. 5pt solid; text- align: center" & gt; & lt; b & gt; 2024 & lt; / b & gt; & lt; / td & gt; & lt; td style =" text- align: center; padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td style =" text- align: center; padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" border- bottom: Black 1. 5pt solid; text- align: center" & gt; & lt; b & gt; 2023 & lt; / b & gt; & lt; / td & gt; & lt; td style =" text- align: center; padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td & gt; Net sales & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td colspan =" 2" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; td colspan =" 2" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" padding- left: 0. 125in; width: 76 %; text- align: left" & gt; United States & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; 2, 085, 314 & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; 2, 079, 699 & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" padding- left: 0. 125in; text- align: left; padding- bottom: 1. 5pt" & gt; Outside the United States & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; div style ="- sec- ix- hidden: hidden- fact- 119" & gt;- & lt; / div & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; div style ="- sec- ix- hidden: hidden- fact- 120" & gt;- & lt; / div & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" padding- bottom: 4pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: right" & gt; 2, 085, 314 & lt; / td & gt; & lt; td style =" padding- bottom: 4pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: right" & gt; 2, 079, 699 & lt; / td & gt; & lt; td style =" padding- bottom: 4pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; / table & gt; & lt; table cellpadding =" 0" cellspacing =" 0" style =" font: 10pt Times New Roman, Times, Serif; border- collapse: collapse; width: 100 %" & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td style =" width: 76 %" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td style =" text- align: left; width: 1 %" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td style =" text- align: center; width: 9 %" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif; font- size: 10pt" & gt; & lt; b & gt; January 31, & lt; / b & gt; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left; width: 1 %" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td style =" text- align: left; width: 1 %" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td style =" text- align: center; width: 9 %" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif; font- size: 10pt" & gt; & lt; b & gt; January 31, & lt; / b & gt; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left; width: 1 %" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td

style =" padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: center" & gt; & lt; b & gt; 2024 & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: center" & gt; & lt; b & gt; 2023 & lt; / b & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td style =" text- align: left" & gt; Property and equipment, net of accumulated depreciation & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" padding- left: 0. 125in; text- align: left" & gt; United States & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" text- align: right" & gt; 774, 924 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" text- align: right" & gt; 897, 735 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" padding- left: 0. 125in; text- align: left; padding- bottom: 1. 5pt" & gt; Outside the United States & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; div style ="- sec- ix- hidden: hidden- fact- 121" & gt;- & lt; / div & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; div style ="- sec- ix- hidden: hidden- fact- 122" & gt;- & lt; / div & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" padding- bottom: 4pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: right" & gt; 774, 924 & lt; / td & gt; & lt; td style =" padding- bottom: 4pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: right" & gt; 897, 735 & lt; / td & gt; & lt; td style =" padding- bottom: 4pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td & gt; Assets & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" padding- left: 0. 125in" & gt; Corporate & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" text- align: right" & gt; 344, 192 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" text- align: right" & gt; 1, 745, 731 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" padding- left: 0. 125in; text- align: left" & gt; Pocono Pharmaceuticals & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 5, 079, 293 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 5, 400, 814 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" padding- left: 0. 125in; padding- bottom: 1. 5pt" & gt; 4P Therapeutics & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; 2, 093, 369 & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; 2, 309, 832 & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" padding- bottom: 4pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: right" & gt; 7, 516, 854 & lt; / td & gt; & lt; td style =" padding- bottom: 4pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: right" & gt; 9, 456, 377 & lt; / td & gt; & lt; td style =" padding- bottom: 4pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; / table & gt; < / us- gaap: ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock > < us- gaap: RevenueFromContractWithCustomerIncludingAssessedTax contextRef =" c54" decimals =" 0" id =" ixv- 14476" unitRef =" usd" > 2085314 < / us- gaap: RevenueFromContractWithCustomerIncludingAssessedTax > < us- gaap: RevenueFromContractWithCustomerIncludingAssessedTax contextRef =" c55" decimals =" 0" id =" ixv- 14477" unitRef =" usd" > 2079699 < / us- gaap: RevenueFromContractWithCustomerIncludingAssessedTax > < us- gaap: RevenueFromContractWithCustomerIncludingAssessedTax contextRef =" c0" decimals =" 0" id =" ixv- 14478" unitRef =" usd" > 2085314 < / us- gaap: RevenueFromContractWithCustomerIncludingAssessedTax > < us- gaap: RevenueFromContractWithCustomerIncludingAssessedTax contextRef =" c9" decimals =" 0" id =" ixv- 14479" unitRef =" usd" > 2079699 < / us- gaap: RevenueFromContractWithCustomerIncludingAssessedTax > < us- gaap: PropertyPlantAndEquipmentOwnedAccumulatedDepreciation contextRef =" c196" decimals =" 0" id =" ixv- 14480" unitRef =" usd" > 774924 < / us- gaap: PropertyPlantAndEquipmentOwnedAccumulatedDepreciation > < us- gaap: PropertyPlantAndEquipmentOwnedAccumulatedDepreciation contextRef =" c197" decimals =" 0" id =" ixv- 14481" unitRef =" usd" > 897735 < / us- gaap: PropertyPlantAndEquipmentOwnedAccumulatedDepreciation > < us- gaap: PropertyPlantAndEquipmentOwnedAccumulatedDepreciation contextRef =" c5" decimals =" 0" id =" ixv- 14482" unitRef =" usd" > 774924 < / us- gaap: PropertyPlantAndEquipmentOwnedAccumulatedDepreciation > < us- gaap: PropertyPlantAndEquipmentOwnedAccumulatedDepreciation contextRef =" c6" decimals =" 0" id =" ixv- 14483" unitRef =" usd" > 897735 < / us- gaap: PropertyPlantAndEquipmentOwnedAccumulatedDepreciation > < us- gaap: OtherAssets contextRef =" c200" decimals =" 0" id =" ixv- 14484" unitRef =" usd" > 344192 < / us- gaap: OtherAssets > < us- gaap: OtherAssets contextRef =" c201" decimals =" 0" id =" ixv- 14485" unitRef =" usd" > 1745731 < / us- gaap: OtherAssets > < us- gaap: OtherAssets contextRef =" c202" decimals =" 0" id =" ixv- 14486" unitRef =" usd" > 5079293 < / us- gaap: OtherAssets > < us- gaap: OtherAssets contextRef =" c203" decimals =" 0" id =" ixv- 14487" unitRef =" usd" > 5400814 < / us- gaap: OtherAssets > < us- gaap: OtherAssets contextRef =" c204" decimals =" 0" id =" ixv- 14488" unitRef =" usd" > 2093369 < / us- gaap: OtherAssets > < us- gaap: OtherAssets contextRef =" c205" decimals =" 0" id =" ixv- 14489" unitRef =" usd" > 2309832 < / us- gaap: OtherAssets > < us- gaap: OtherAssets contextRef =" c5" decimals =" 0" id =" ixv- 14490" unitRef =" usd" > 7516854 < / us- gaap: OtherAssets > < us- gaap: OtherAssets contextRef =" c6" decimals =" 0" id =" ixv- 14491" unitRef =" usd" > 9456377 < / us- gaap: OtherAssets > < us- gaap: CommitmentsAndContingenciesDisclosureTextBlock contextRef =" c0" id =" ixv- 9734" > & lt; table cellpadding =" 0" cellspacing =" 0" style =" font: 10pt Times New Roman, Times, Serif; margin- top: 0pt; margin- bottom: 0pt; width: 100 %" & gt; & lt; tr style =" vertical- align: top" & gt; & lt; td style =" width: 0. 5in" & gt; 11. & lt; / td & gt; & lt; td & gt; COMMITMENTS AND CONTIGENCIES & lt; / td & gt; & lt; / tr & gt; & lt; / table & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31. 5pt" & gt; & # 160; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 25in; text- align: justify; text- indent: 0. 25in" & gt; & lt; i & gt; Employment Agreements & lt; / i & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 25in; text- align: justify" & gt; & # 160; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify" & gt; The Company entered into three- year employment agreements with Gareth Sheridan, our CEO, and Serguei Melnik, our President, effective February 1, 2022. The agreement also provides that the executives will continue as directors and officers of the Company for the respective terms thereof. The agreement provides for an initial term, commencing on the effective date of the agreement and ending on January 31, 2025, and continuing on a year- to- year basis thereafter unless terminated by either party on not less than 30 days & # x2019; notice given prior to the expiration of the initial term or any one- year extension. For their services to the Company during the term of the agreement, Mr. Sheridan and Mr. Melnik will receive an annual salary of $ 250, 000 per annum, commencing on the effective date of the agreement. Mr. Sheridan and Mr. Melnik will also receive a performance bonus of 3. 5 % of net income before income taxes. As of July 31, 2022, the Company and Mr. Sheridan and Mr. Melnik mutually agreed to reduce their annual salary to $ 150,

000. & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify" & gt; & # 160; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify" & gt; The Company entered into a three- year employment agreement with Gerald Goodman, our CFO, effective February 1, 2022. The agreement provides for an initial term, commencing on the effective date of the agreement and ending on January 31, 2025, and continuing on a year- to- year basis thereafter unless terminated by either party on not less than 30 days & # x2019; notice given prior to the expiration of the initial term or any one- year extension. For his services to the Company during the term of the agreement, Mr. Goodman will receive an annual salary of $ 210, 000 per annum, commencing on the effective date of the agreement. As of July 31, 2022, the Company and Mr. Goodman mutually agreed to reduce his annual salary to $ 110, 000. & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 47. 4pt; text- align: justify" & gt; & # 160; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 5in" & gt; & lt; i & gt; Kindeva Drug Delivery Agreement & lt; / i & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 75in" & gt; & # 160; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify" & gt; On January 4, 2022, the Company signed a feasibility agreement with Kindeva Drug Delivery, L. P. (& # x201c; Kindeva & # x201d;) to develop Nutriband & # x2019; s lead product, AVERSA Fentanyl, based on its proprietary AVERSA abuse deterrent transdermal technology and Kindeva & # x2019; s FDA- approved transdermal fentanyl patch (fentanyl transdermal system). The feasibility agreement provides for adapting Kindeva & # x2019; s commercial transdermal manufacturing process to incorporate AVERSA technology in the fentanyl transdermal system. & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify" & gt; & # 160; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify" & gt; The agreement will remain in force until the earlier of: (1) the completion of the work and deliverables under the Workplan; or (2) two (2) years after the Effective Date, after which time the agreement will expire. The feasibility Workplan was completed in February 2024. & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify" & gt; & # 160; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify" & gt; The estimated cost to complete the feasibility Workplan was approximately $ 2. 5 million. Nutriband made an advance deposit of $ 250, 000 in January 2022, to be applied against the final invoices. As of January 31, 2024, Nutriband has incurred expenses of $ 2, 369, 508 and the net deposit of $ 138, 250 after application to final invoices is included in prepaid expenses. & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify" & gt; & # 160; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify" & gt; In January 2024, Nutriband signed a commercial development and clinical supply agreement with Kindeva Drug Delivery for development of AVERSA Fentanyl using Kindeva & # x2019; s FDA- approved fentanyl patch. Kindeva will perform commercial manufacturing process development and clinical supplies manufacturing for the human abuse potential clinical study required by the FDA in support of a New Drug Application. The agreement replaces the previous feasibility agreement between the two companies which was focused on adapting Kindeva & # x2019; s commercial transdermal manufacturing process to incorporate AVERSA abuse deterrent transdermal technology. The estimated cost to complete the commercial process development and clinical supplies manufacturing is approximately $ 8. 1 million and the expected timing of FDA submission is twelve to eighteen months. & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify" & gt; & # 160; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify" & gt; & lt; i & gt; & lt; span style =" text- decoration: underline" & gt; Lease Agreement & lt; / span & gt; & lt; / i & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify" & gt; & # 160; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34. 8pt; text- align: justify" & gt; On February 1, 2022, Pocono Pharmaceuticals entered into a lease agreement with Geometric Group, LLC for 12, 000 square feet of warehouse space currently occupied by Active Intelligence. The monthly rental is $ 3, 000 and the lease expires on January 31, 2025. The lease can be extended for an additional three years at the same monthly rental. The Company recorded a Right of Use asset in the amount of $ 94, 134 in connection with the valuation. & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34. 8pt; text- align: justify" & gt; & # 160; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34. 8pt; text- align: justify" & gt; & lt; i & gt; & lt; span style =" text- decoration: underline" & gt; MDM Worldwide Agreement & lt; / span & gt; & lt; / i & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34. 8pt; text- align: justify" & gt; & # 160; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34. 8pt; text- align: justify" & gt; In September 2022, the Company entered into a public relations agreement with MDM Worldwide. In connection with the agreement, the Company agreed to issue 20, 000 options to MDM Worldwide. In October 2023, the contract was mutually terminated, and no options were issued. For the year ended January 31, 2024, the Company paid MDM Worldwide $ 190, 000. & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34. 8pt; text- align: justify" & gt; & # 160; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34. 8pt; text- align: justify" & gt; & lt; i & gt; & lt; span style =" text- decoration: underline" & gt; Money Channel Agreement & lt; / span & gt; & lt; / i & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34. 8pt; text- align: justify" & gt; & lt; i & gt; & # 160; & lt; / i & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34. 8pt; text- align: justify" & gt; On March 13, 2023, the Company entered into a media advertising agreement with Money Channel Inc. The Company will pay a monthly fee and after ninety days can cancel the agreement. The Company, after 90 days, will also issue options to purchase 50, 000 shares of common stock to Money Channel Inc. at an exercise price of $ 4. 00 per share. In June 2023, the parties agreed to terminate the agreement by mutual consent. No options were issued. For the year ended January 31, 2024, the Company paid the Money Channel $ 100, 000. & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34. 8pt; text- align: justify" & gt; & # 160; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34. 8pt; text- align: justify" & gt; & lt; i & gt; & lt; span style =" text- decoration: underline" & gt; Sorrento Therapeutics, Inc. Agreement & lt; / span & gt; & lt; / i & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34. 8pt; text- align: justify" & gt; & lt; i & gt; & # 160; & lt; / i & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34. 8pt; text- align: justify" & gt; 4P Therapeutics had unpaid account receivables related to a contract clinical research services agreement in place with Sorrento Therapeutics. On February 13, 2023, Sorrento declared Chapter 11 bankruptcy. On July 25, 2023, 4P Therapeutics assigned its claim under the bankruptcy proceedings from Sorrento Therapeutics Inc. and received proceeds of $ 106, 528. The amount due under the claim was $ 118, 675 and 4P Therapeutics recorded a reserve for bad debts of $ 118, 675 during the year ended January 31, 2024. Under the agreement with the buyer of the claim, 4P Therapeutics will make proportional restitution and / or repayment of the purchase amount to the extent the claim is disallowed, reduced or not paid at the same time or distribution rate as other general unsecured claims against the Debtor are paid. The Company has recorded the amount of the proceeds as a secured loan payable to the factor as of January 31, 2024. & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34. 8pt; text- align: justify" & gt; & # 160; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34. 8pt; text- align: justify" & gt; & lt; i & gt; & lt; span style =" text- decoration: underline" & gt; Upstream Termination & lt; / span & gt; & lt; / i & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34. 8pt; text- align: justify" & gt; & lt; i & gt; & # 160; & lt; / i & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34. 8pt; text- align: justify" & gt; On May 24, 2023, the Company sent notice of the termination of the Securities Facility Services Agreement, dated January 3, 2023, by and between MERJ DEP Ltd. And the Company (& # x201c; Agreement & # x201d;), which provided for the dual listing of the Company & # x2019; s common stock on the MERJ Upstream exchange (& # x201c; Upstream & # x201d;), which is operated as a fully registered and licensed integrated securities exchange, clearing system and depository for digital and non- digital securities under the Seychelles security laws. The termination was effective May 31, 2023. & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34. 8pt; text- align: justify" & gt; & # 160; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34. 8pt; text- align: justify" & gt; & lt; i & gt; & lt; span style =" text- decoration: underline" & gt; Legal Proceedings & lt; / span & gt; & lt; / i & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34. 8pt; text- align: justify" & gt; & lt; i & gt; & # 160; & lt; / i & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34. 8pt; text- align: justify" & gt; The Company is currently a defendant in a lawsuit initiated by Joseph Gunnar, LLC (& # x201c; Gunnar & # x201d;) and Lucosky Brookman LLP (& # x201c; LB & # x201d;) in the Supreme Court of the State of New York, New York County, under Index No. 654633 / 2023. The lawsuit alleges multiple allegations such as breach of contract, fraudulent activities, and tortious interference and seeks damages following the Company & # x2019; s termination of an engagement letter for assistance with a public stock offering. Gunnar is seeking over $ 500, 000 in damages plus punitive damages, while LB is demanding reimbursement of legal fees. & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34. 8pt; text- align: justify" & gt; & # 160; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34. 8pt; text- align: justify" & gt; In response, the Company denies all allegations, alleging that the engagement letter was unenforceable, and its termination was legally justified. The Company has also initiated counterclaims against Joseph Gunnar & amp; amp; Co., accusing them of intentional interference and breach of fiduciary duty, and is seeking $ 1, 000, 000 for each claim along with a declaratory judgment affirming the legality and justification of the termination. The plaintiffs have denied these counterclaims. & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34. 8pt; text- align: justify" & gt; & # 160; & lt; / p & gt; & lt; p style =" font: 10pt Times

New Roman, Times, Serif; margin: 0pt 0 0pt 34. 8pt; text- align: justify" & gt; Currently, there are no pending hearings or motions as both parties are engaged in discovery and are attempting to resolve the matter amicably. & lt; / p & gt; < / us- gaap: CommitmentsAndContingenciesDisclosureTextBlock > < us- gaap: StockholdersEquityReverseStockSplit contextRef =" c0" id =" ixv- 14492" > The Company entered into three- year employment agreements with Gareth Sheridan, our CEO, and Serguei Melnik, our President, effective February 1, 2022 < / us- gaap: StockholdersEquityReverseStockSplit > < us- gaap: DebtInstrumentMaturityDate contextRef =" c206" id =" ixv- 14493" > 2025- 01- 31 < / us- gaap: DebtInstrumentMaturityDate > < us- gaap: SalariesWagesAndOfficersCompensation contextRef =" c207" decimals =" 0" id =" ixv- 14494" unitRef =" usd" > 250000 < / us- gaap: SalariesWagesAndOfficersCompensation > < ntrb: PercentageOfNetIncome contextRef =" c0" decimals =" 3" id =" ixv- 14495" unitRef =" pure" > 0. 035 < / ntrb: PercentageOfNetIncome > < ntrb: AgreedToAnnualSalary contextRef =" c208" decimals =" 0" id =" ixv- 14496" unitRef =" usd" > 150000 < / ntrb: AgreedToAnnualSalary > < us- gaap: SalariesWagesAndOfficersCompensation contextRef =" c209" decimals =" 0" id =" ixv- 14497" unitRef =" usd" > 210000 < / us- gaap: SalariesWagesAndOfficersCompensation > < ntrb: AgreedToAnnualSalary contextRef =" c210" decimals =" 0" id =" ixv- 14498" unitRef =" usd" > 110000 < / ntrb: AgreedToAnnualSalary > < us- gaap: OtherCommitmentsDescription contextRef =" c0" id =" ixv- 14499" > the Company signed a feasibility agreement with Kindeva Drug Delivery, L. P. (& # x201c; Kindeva & # x201d;) to develop Nutriband & # x2019; s lead product, AVERSA Fentanyl, based on its proprietary AVERSA abuse deterrent transdermal technology and Kindeva & # x2019; s FDA- approved transdermal fentanyl patch (fentanyl transdermal system). < / us- gaap: OtherCommitmentsDescription > < srt: PreviouslyEstimatedDevelopmentCostsIncurred contextRef =" c0" decimals =" - 5" id =" ixv- 14500" unitRef =" usd" > 2500000 < / srt: PreviouslyEstimatedDevelopmentCostsIncurred > < us- gaap: DepositAssets contextRef =" c211" decimals =" 0" id =" ixv- 14501" unitRef =" usd" > 250000 < / us- gaap: DepositAssets > < us- gaap: LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1 contextRef =" c0" decimals =" 0" id =" ixv- 14502" unitRef =" usd" > 2369508 < / us- gaap: LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1 > < us- gaap: PrepaidExpenseCurrentAndNoncurrent contextRef =" c5" decimals =" 0" id =" ixv- 14503" unitRef =" usd" > 138250 < / us- gaap: PrepaidExpenseCurrentAndNoncurrent > < ntrb: EstimatedCost contextRef =" c0" decimals =" - 5" id =" ixv- 14504" unitRef =" usd" > 8100000 < / ntrb: EstimatedCost > < ntrb: WarehouseSpace contextRef =" c136" decimals =" 0" id =" ixv- 14505" unitRef =" pure" > 12000 < / ntrb: WarehouseSpace > < us- gaap: LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef =" c212" decimals =" 0" id =" ixv- 14506" unitRef =" usd" > 3000 < / us- gaap: LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths > < us- gaap: DebtInstrumentMaturityDate contextRef =" c213" id =" ixv- 14507" > 2025- 01- 31 < / us- gaap: DebtInstrumentMaturityDate > < us- gaap: OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef =" c212" id =" ixv- 14508" > P3Y < / us- gaap: OperatingLeaseWeightedAverageRemainingLeaseTerm1 > < us- gaap: OperatingLeaseRightOfUseAssetAmortizationExpense contextRef =" c136" decimals =" 0" id =" ixv- 14509" unitRef =" usd" > 94134 < / us- gaap: OperatingLeaseRightOfUseAssetAmortizationExpense > < us- gaap: NotesIssued1 contextRef =" c106" decimals =" 0" id =" ixv- 14510" unitRef =" usd" > 20000 < / us- gaap: NotesIssued1 > < us- gaap: PurchaseObligationDueInThirdYear contextRef =" c214" decimals =" 0" id =" ixv- 14511" unitRef =" usd" > 190000 < / us- gaap: PurchaseObligationDueInThirdYear > < ntrb: PaymentsForRepurchaseOfWarrant contextRef =" c215" decimals =" 0" id =" ixv- 14512" unitRef =" shares" > 50000 < / ntrb: PaymentsForRepurchaseOfWarrant > < us- gaap: WarrantExercisePriceIncrease contextRef =" c216" decimals =" 2" id =" ixv- 14513" unitRef =" usdPershares" > 4 < / us- gaap: WarrantExercisePriceIncrease > < us- gaap: PurchaseObligationDueInThirdYear contextRef =" c217" decimals =" 0" id =" ixv- 14514" unitRef =" usd" > 100000 < / us- gaap: PurchaseObligationDueInThirdYear > < us- gaap: ProceedsFromFeesReceived contextRef =" c218" decimals =" 0" id =" ixv- 14515" unitRef =" usd" > 106528 < / us- gaap: ProceedsFromFeesReceived > < us- gaap: CashAndDueFromBanks contextRef =" c219" decimals =" 0" id =" ixv- 14516" unitRef =" usd" > 118675 < / us- gaap: CashAndDueFromBanks > < us- gaap: DebtInstrumentFeeAmount contextRef =" c220" decimals =" 0" id =" ixv- 14517" unitRef =" usd" > 118675 < / us- gaap: DebtInstrumentFeeAmount > < us- gaap: LegalFees contextRef =" c0" decimals =" 0" id =" ixv- 14518" unitRef =" usd" > 500000 < / us- gaap: LegalFees > < us- gaap: Cash contextRef =" c5" decimals =" 0" id =" ixv- 14519" unitRef =" usd" > 1000000 < / us- gaap: Cash > < us- gaap: SubsequentEventsTextBlock contextRef =" c0" id =" ixv- 9834" > & lt; table cellpadding =" 0" cellspacing =" 0" style =" font: 10pt Times New Roman, Times, Serif; margin- top: 0pt; margin- bottom: 0pt; width: 100 %" & gt; & lt; tr style =" vertical- align: top" & gt; & lt; td style =" width: 0. 5in" & gt; 12. & lt; / td & gt; & lt; td style =" text- align: justify" & gt; SUBSEQUENT EVENTS & lt; / td & gt; & lt; / tr & gt; & lt; / table & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify" & gt; & # 160; & lt; / p & gt; & lt; table cellpadding =" 0" cellspacing =" 0" style =" font: 10pt Times New Roman, Times, Serif; margin- top: 0pt; margin- bottom: 0pt" width =" 100 %" & gt; & lt; tr style =" vertical- align: top" & gt; & lt; td style =" width: 0. 5in" & gt; & lt; / td & gt; & lt; td style =" width: 0. 25in" & gt; (a) & lt; / td & gt; & lt; td style =" text- align: justify" & gt; In February and April 2024, the Company received proceeds of $ 300, 000 from its Credit Line Facility. & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: top" & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: justify" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; / table & gt; & lt; table cellpadding =" 0" cellspacing =" 0" style =" font: 10pt Times New Roman, Times, Serif; margin- top: 0pt; margin- bottom: 0pt" width =" 100 %" & gt; & lt; tr style =" vertical- align: top" & gt; & lt; td style =" width: 0. 5in" & gt; & lt; / td & gt; & lt; td style =" width: 0. 25in" & gt; (b) & lt; / td & gt; & lt; td style =" text- align: justify" & gt; On March 20, 2024, 390, 000 options to purchase shares of the Company & # x2019; s common stock were issued to executive officers and employees at prices of $ 2. 37- $ 2. 61 per share. The options vest immediately and expire three years from the date of issuance. The fair value of the options issued amounted to $ 450, 000. & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: top" & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: justify" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; / table & gt; & lt; table cellpadding =" 0" cellspacing =" 0" style =" font: 10pt Times New Roman, Times, Serif; margin- top: 0pt; margin- bottom: 0pt" width =" 100 %" & gt; & lt; tr style =" vertical- align: top" & gt; & lt; td style =" width: 0. 5in" & gt; & lt; / td & gt; & lt; td style =" width: 0. 25in" & gt; (c) & lt; / td & gt; & lt; td style =" text- align: justify" & gt; On March 20, 2024, our Board of Directors adopted an amendment to the Company & # x2019; s Employee Stock Option Plan (the & # x201c; Plan & # x201d;) increasing the number of shares of common stock subject to the Plan (as of March 20, 2024, 875, 000 shares) to 1, 400, 000 shares (the & # x201c; Amendment & # x201d;). The Company will submit the Amendment to the Plan to our stockholders for adoption and approval at the 2025 Annual Meeting. If the Amendment is not approved by stockholders within one year of adoption, the increase in shares subject to the Plan will be void, together with any options issued following March 20, 2024, in the period pending approval of the Plan by our stockholders. & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: top" & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: justify" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; / table & gt; & lt; table cellpadding =" 0" cellspacing =" 0" style =" font: 10pt Times New Roman, Times, Serif; margin- top: 0pt; margin- bottom: 0pt" width =" 100 %" & gt; & lt; tr style =" vertical- align: top" & gt; & lt; td style =" width: 0. 5in" & gt; & lt; / td & gt; & lt; td style =" width: 0. 25in" & gt; (d) & lt; / td & gt; & lt; td style =" text- align: justify" & gt; On April 19, 2024, the Company completed an $ 8, 400, 000 equity financing with European investors (the & # x201c; Offering & # x201d;) of 2, 100, 000 units (& # x201c; Units & # x201d;), at a price of $ 4. 00 per Unit, each Unit consisting of one share of common stock (& # x201c; Shares & # x201d;) and a Warrant to purchase two Shares of common stock, the Warrants having an initial exercise price of $ 6. 43, are exercisable by payment of the exercise price in cash only and expire April 19, 2029, five years from the date of issuance (& # x201c; Warrants & # x201d;). The Offering was made solely to investors residing outside the United States and was not registered under the Security Act of 1933, as amended, (the & # x201c; Security Act & # x201d;), or the securities law of any jurisdiction, including outside the United States, but was made privately by the Company pursuant to the exemptions from registration provided in the SEC & # x2019; s Regulation S and other exemptions under the Securities Act. & lt; / td & gt; & lt; / tr & gt; & lt; / table & gt; < / us- gaap: SubsequentEventsTextBlock > < us- gaap: ProceedsFromInterestReceived contextRef =" c221" decimals =" 0" id =" ixv- 14520" unitRef =" usd" > 300000 < / us- gaap: ProceedsFromInterestReceived > < us- gaap: StockRepurchasedDuringPeriodShares contextRef =" c222" decimals =" 0" id =" ixv- 14521" unitRef =" shares" > 390000 < / us- gaap: StockRepurchasedDuringPeriodShares > < us- gaap: SharesIssuedPricePerShare contextRef =" c223" decimals =" 2" id =" ixv- 14522" unitRef =" usdPershares" > 2. 37 < / us- gaap: SharesIssuedPricePerShare > < us- gaap: SharesIssuedPricePerShare contextRef =" c224" decimals =" 2" id =" ixv- 14523" unitRef =" usdPershares" > 2. 61 < / us- gaap: SharesIssuedPricePerShare > < ntrb: DateOfIssuance contextRef =" c222" id =" ixv- 14524" > P3Y < / ntrb: DateOfIssuance > < us- gaap: SharesIssued contextRef =" c225" decimals =" 0" id =" ixv- 14525" unitRef =" shares" > 450000 < / us- gaap: SharesIssued > < us- gaap: SharesIssued contextRef =" c226" decimals =" 0" id =" ixv- 14526" unitRef =" shares" > 875000 < / us- gaap: SharesIssued > < us- gaap: SharesIssued contextRef =" c227" decimals =" 0" id =" ixv- 14527" unitRef =" shares" > 1400000 < / us- gaap: SharesIssued > < ntrb: DateDoAdoption contextRef =" c222" id =" ixv- 14528" > P1Y < / ntrb: DateDoAdoption > < us- gaap: EquityMethodInvestmentSoldCarryingAmount contextRef =" c228" decimals =" 0" id =" ixv- 14529" unitRef =" usd" > 8400000 < / us- gaap: EquityMethodInvestmentSoldCarryingAmount > < us- gaap: ExcessStockSharesIssued contextRef =" c229" decimals =" 0" id =" ixv- 14530" unitRef =" shares" > 2100000 < / us- gaap: ExcessStockSharesIssued > < us- gaap: SharesIssuedPricePerShare contextRef =" c230" decimals =" 2" id =" ixv- 14531" unitRef =" usdPershares" > 4 < / us- gaap: SharesIssuedPricePerShare > < ntrb: NumberOfShares contextRef =" c228" decimals =" 0" id =" ixv- 14532" unitRef =" shares" > 1 < / ntrb: NumberOfShares > < ntrb: NumberOfShares contextRef =" c231" decimals =" 0" id =" ixv- 14533" unitRef =" shares" > 2 < / ntrb: NumberOfShares > < us- gaap: SaleOfStockPricePerShare contextRef =" c230" decimals =" 2" id =" ixv- 14534" unitRef =" usdPershares" > 6. 43 < / us- gaap:

SaleOfStockPricePerShare><us-gaap:WarrantsAndRightsOutstandingMaturityDate contextRef="c230" id="ixv-14535">2029-04-19</us-gaap:WarrantsAndRightsOutstandingMaturityDate><ntrb:DateOfIssuance contextRef="c228" id="ixv-14536">P5Y</ntrb:DateOfIssuance><ecd:NonRule10b51ArrTrmntdFlag contextRef="c232" id="ixv-14537">false</ecd:NonRule10b51ArrTrmntdFlag><ecd:Rule10b51ArrTrmntdFlag contextRef="c232" id="ixv-14538">false</ecd:Rule10b51ArrTrmntdFlag><ecd:NonRule10b51ArrAdoptedFlag contextRef="c232" id="ixv-14539">false</ecd:NonRule10b51ArrAdoptedFlag><ecd:Rule10b51ArrAdoptedFlag contextRef="c232" id="ixv-14540">false</ecd:Rule10b51ArrAdoptedFlag><dei:EntityVoluntaryFilers contextRef="c0" id="hidden-fact-0">No</dei:EntityVoluntaryFilers><us-gaap:OtherLiabilities contextRef="c7" id="hidden-fact-1" unitRef="usd" xsi:nil="true" /><us-gaap:OtherLiabilities contextRef="c8" id="hidden-fact-2" unitRef="usd" xsi:nil="true" /><us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c5" id="hidden-fact-3" unitRef="usd" xsi:nil="true" /><us-gaap:CommitmentsAndContingencies contextRef="c5" id="hidden-fact-4" unitRef="usd" xsi:nil="true" /><us-gaap:CommitmentsAndContingencies contextRef="c6" id="hidden-fact-5" unitRef="usd" xsi:nil="true" /><us-gaap:PreferredStockValue contextRef="c5" id="hidden-fact-6" unitRef="usd" xsi:nil="true" /><us-gaap:PreferredStockValue contextRef="c6" id="hidden-fact-7" unitRef="usd" xsi:nil="true" /><us-gaap:GoodwillImpairmentLoss contextRef="c0" id="hidden-fact-8" unitRef="usd" xsi:nil="true" /><us-gaap:InterestIncomeOther contextRef="c9" id="hidden-fact-9" unitRef="usd" xsi:nil="true" /><us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c9" id="hidden-fact-10" unitRef="usd" xsi:nil="true" /><us-gaap:IncomeTaxExpenseBenefit contextRef="c0" id="hidden-fact-11" unitRef="usd" xsi:nil="true" /><us-gaap:IncomeTaxExpenseBenefit contextRef="c9" id="hidden-fact-12" unitRef="usd" xsi:nil="true" /><us-gaap:EarningsPerShareDiluted contextRef="c9" decimals="2" id="hidden-fact-13" unitRef="usdPershares">-0.53</us-gaap:EarningsPerShareDiluted><us-gaap:EarningsPerShareDiluted contextRef="c0" decimals="2" id="hidden-fact-14" unitRef="usdPershares">-0.69</us-gaap:EarningsPerShareDiluted><us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c0" decimals="INF" id="hidden-fact-15" unitRef="shares">7954105</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding><us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c9" decimals="INF" id="hidden-fact-16" unitRef="shares">8459547</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding><us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="c16" id="hidden-fact-17" unitRef="usd" xsi:nil="true" /><us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="c17" id="hidden-fact-18" unitRef="usd" xsi:nil="true" /><us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="c18" id="hidden-fact-19" unitRef="usd" xsi:nil="true" /><us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="c19" id="hidden-fact-20" unitRef="usd" xsi:nil="true" /><us-gaap:NetIncomeLoss contextRef="c16" id="hidden-fact-21" unitRef="usd" xsi:nil="true" /><us-gaap:NetIncomeLoss contextRef="c15" id="hidden-fact-22" unitRef="usd" xsi:nil="true" /><us-gaap:NetIncomeLoss contextRef="c17" id="hidden-fact-23" unitRef="usd" xsi:nil="true" /><us-gaap:NetIncomeLoss contextRef="c19" id="hidden-fact-24" unitRef="usd" xsi:nil="true" /><us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c33" id="hidden-fact-25" unitRef="usd" xsi:nil="true" /><us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c34" id="hidden-fact-26" unitRef="usd" xsi:nil="true" /><us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c35" id="hidden-fact-27" unitRef="usd" xsi:nil="true" /><ntrb:StockIssuedDuringPeriodValueReturnedInSettlement contextRef="c9" id="hidden-fact-28" unitRef="usd" xsi:nil="true" /><ntrb:StockIssuedDuringPeriodValueReturnedInSettlement contextRef="c33" id="hidden-fact-29" unitRef="usd" xsi:nil="true" /><ntrb:StockIssuedDuringPeriodValueReturnedInSettlement contextRef="c34" id="hidden-fact-30" unitRef="usd" xsi:nil="true" /><ntrb:StockIssuedDuringPeriodValueReturnedInSettlement contextRef="c35" id="hidden-fact-31" unitRef="usd" xsi:nil="true" /><ntrb:StockIssuedDuringPeriodValueTreasuryStockIssuedForServices contextRef="c33" id="hidden-fact-32" unitRef="usd" xsi:nil="true" /><ntrb:StockIssuedDuringPeriodValueTreasuryStockIssuedForServices contextRef="c34" id="hidden-fact-33" unitRef="usd" xsi:nil="true" /><ntrb:StockIssuedDuringPeriodValueTreasuryStockRepurchased contextRef="c33" id="hidden-fact-34" unitRef="usd" xsi:nil="true" /><ntrb:StockIssuedDuringPeriodValueTreasuryStockRepurchased contextRef="c34" id="hidden-fact-35" unitRef="usd" xsi:nil="true" /><us-gaap:NetIncomeLoss contextRef="c31" id="hidden-fact-36" unitRef="usd" xsi:nil="true" /><us-gaap:NetIncomeLoss contextRef="c32" id="hidden-fact-37" unitRef="usd" xsi:nil="true" /><us-gaap:NetIncomeLoss contextRef="c33" id="hidden-fact-38" unitRef="usd" xsi:nil="true" /><us-gaap:NetIncomeLoss contextRef="c35" id="hidden-fact-39" unitRef="usd" xsi:nil="true" /><us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c9" id="hidden-fact-40" unitRef="usd" xsi:nil="true" /><us-gaap:ProvisionForDoubtfulAccounts contextRef="c9" id="hidden-fact-41" unitRef="usd" xsi:nil="true" /><us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="c0" id="hidden-fact-42" unitRef="usd" xsi:nil="true" /><ntrb:TreasuryStockIssuedForTerminationAgreement contextRef="c0" id="hidden-fact-43" unitRef="usd" xsi:nil="true" /><us-gaap:GoodwillImpairmentLoss contextRef="c0" id="hidden-fact-44" unitRef="usd" xsi:nil="true" /><ntrb:StockbasedCompensationwarrants contextRef="c9" id="hidden-fact-45" unitRef="usd" xsi:nil="true" /><us-gaap:ProceedsFromRelatedPartyDebt contextRef="c9" id="hidden-fact-46" unitRef="usd" xsi:nil="true" /><us-gaap:ProceedsFromIssuanceOfDebt contextRef="c9" id="hidden-fact-47" unitRef="usd" xsi:nil="true" /><us-gaap:ProceedsFromWarrantExercises contextRef="c0" id="hidden-fact-48" unitRef="usd" xsi:nil="true" /><ntrb:PurchaseOfTreasuryStock contextRef="c0" id="hidden-fact-49" unitRef="usd" xsi:nil="true" /><us-gaap:IncomeTaxesPaid contextRef="c0" id="hidden-fact-50" unitRef="usd" xsi:nil="true" /><us-gaap:IncomeTaxesPaid contextRef="c9" id="hidden-fact-51" unitRef="usd" xsi:nil="true" /><ntrb:AdoptionofOperatingLeaseAssetandLiability contextRef="c0" id="hidden-fact-52" unitRef="usd" xsi:nil="true" /><ntrb:PromissoryNoteOnEquipmentPurchase contextRef="c0" id="hidden-fact-53" unitRef="usd" xsi:nil="true" /><us-gaap:ConversionOfStockAmountIssued1 contextRef="c0" id="hidden-fact-54" unitRef="usd" xsi:nil="true" /><us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="c9" id="hidden-fact-55" unitRef="usd" xsi:nil="true" /><us-gaap:Revenues contextRef="c56" id="hidden-fact-56" unitRef="usd" xsi:nil="true" /><us-gaap:Revenues contextRef="c57" id="hidden-fact-57" unitRef="usd" xsi:nil="true" /><us-gaap:CurrentFederalTaxExpenseBenefit contextRef="c0" id="hidden-fact-58" unitRef="usd" xsi:nil="true" /><us-gaap:CurrentFederalTaxExpenseBenefit contextRef="c9" id="hidden-fact-59" unitRef="usd" xsi:nil="true" /><us-gaap:CurrentForeignTaxExpenseBenefit contextRef="c0" id="hidden-fact-60" unitRef="usd" xsi:nil="true" /><us-gaap:CurrentForeignTaxExpenseBenefit contextRef="c9" id="hidden-fact-61" unitRef="usd" xsi:nil="true" /><us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="c0" id="hidden-fact-62" unitRef="usd" xsi:nil="true" /><us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="c9" id="hidden-fact-63" unitRef="usd" xsi:nil="true" /><us-gaap:DeferredForeignIncomeTaxExpenseBenefit contextRef="c0" id="hidden-fact-64" unitRef="usd" xsi:nil="true" /><us-gaap:DeferredForeignIncomeTaxExpenseBenefit contextRef="c9" id="hidden-fact-65" unitRef="usd" xsi:nil="true" /><us-gaap:IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses contextRef="c0" id="hidden-fact-66" unitRef="usd" xsi:nil="true" /><us-gaap:IncomeTaxExpenseBenefit contextRef="c0" id="hidden-fact-67" unitRef="usd" xsi:nil="true" /><us-gaap:IncomeTaxExpenseBenefit contextRef="c9" id="hidden-fact-68" unitRef="usd" xsi:nil="true" /><us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="c5" id="hidden-fact-69" unitRef="usd" xsi:nil="true" /><us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="c6" id="hidden-fact-70" unitRef="usd" xsi:nil="true" /><us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c147" id="hidden-fact-71" unitRef="usd" xsi:nil="true" /><ntrb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodGrantDateIntrinsicValue contextRef="c144" id="hidden-fact-72" unitRef="usd" xsi:nil="true" /><ntrb:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsRemainingLifeExpiredCancelled contextRef="c144" id="hidden-fact-73" xsi:nil="true" /><ntrb:ShareBasedPaymentArrangementIntrinsicValueExpiredCancelled contextRef="c144" id="hidden-fact-74" unitRef="usd" xsi:nil="true" /><ntrb:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInRemainingLifeExercised contextRef="c144" id="hidden-fact-75" xsi:nil="true" /><us-gaap:StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense contextRef="c144" id="hidden-fact-76" unitRef="usd" xsi:nil="true" /><us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c148" id="hidden-fact-77" unitRef="usd" xsi:nil="true" /><ntrb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodGrantDateIntrinsicValue contextRef="c97" id="hidden-fact-78" unitRef="usd" xsi:nil="true" /><ntrb:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsRemainingLifeExpiredCancelled contextRef="c97" id="hidden-fact-79" xsi:nil="true" /><ntrb:ShareBasedPaymentArrangementIntrinsicValueExpiredCancelled contextRef="c97" id="hidden-fact-80" unitRef="usd" xsi:nil="true" /><ntrb:StockIssuedDuringPeriodSharesStockOptionsSharesExercised contextRef="c97" id="hidden-fact-81" unitRef="shares" xsi:nil="true" /><us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="c97" id="hidden-fact-82" unitRef="usdPershares" xsi:nil="true" /><ntrb:

ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInRemainingLifeExercised contextRef =" c97" id =" hidden- fact- 83" xsi: nil =" true" /> < us- gaap: StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense contextRef =" c97" id =" hidden- fact- 84" unitRef =" usd" xsi: nil =" true" /> < ntrb: IntrinsicValue contextRef =" c151" id =" hidden- fact- 85" unitRef =" usd" xsi: nil =" true" /> < ntrb: IntrinsicValue contextRef =" c153" id =" hidden- fact- 86" unitRef =" usd" xsi: nil =" true" /> < ntrb: IntrinsicValue contextRef =" c157" id =" hidden- fact- 87" unitRef =" usd" xsi: nil =" true" /> < us- gaap: SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef =" c158" id =" hidden- fact- 88" unitRef =" usd" xsi: nil =" true" /> < ntrb: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodGrantDateIntrinsicValue contextRef =" c159" id =" hidden- fact- 89" unitRef =" usd" xsi: nil =" true" /> < us- gaap: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod contextRef =" c159" id =" hidden- fact- 90" unitRef =" shares" xsi: nil =" true" /> < us- gaap: ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice contextRef =" c159" id =" hidden- fact- 91" unitRef =" usdPershares" xsi: nil =" true" /> < ntrb: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrices contextRef =" c159" id =" hidden- fact- 92" xsi: nil =" true" /> < ntrb: ShareBasedIntrinsicValueExpiredCancelled contextRef =" c159" id =" hidden- fact- 93" unitRef =" usd" xsi: nil =" true" /> < ntrb: StockIssuedDuringPeriodSharesStockOptionsSharesExercised contextRef =" c159" id =" hidden- fact- 94" unitRef =" shares" xsi: nil =" true" /> < us- gaap: ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef =" c159" id =" hidden- fact- 95" unitRef =" usdPershares" xsi: nil =" true" /> < ntrb: ShareBasedCompensationArrangementsByShareBasedPaymentRemainingLifeExercised contextRef =" c159" id =" hidden- fact- 96" xsi: nil =" true" /> < ntrb: ShareBasedIntrinsicValueExercised contextRef =" c159" id =" hidden- fact- 97" unitRef =" usd" xsi: nil =" true" /> < us- gaap: SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef =" c160" id =" hidden- fact- 98" unitRef =" usd" xsi: nil =" true" /> < ntrb: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodGrantDateIntrinsicValue contextRef =" e85" id =" hidden- fact- 99" unitRef =" usd" xsi: nil =" true" /> < us- gaap: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod contextRef =" e85" id =" hidden- fact- 100" unitRef =" shares" xsi: nil =" true" /> < us- gaap: ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice contextRef =" e85" id =" hidden- fact- 101" unitRef =" usdPershares" xsi: nil =" true" /> < ntrb: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrices contextRef =" e85" id =" hidden- fact- 102" xsi: nil =" true" /> < ntrb: ShareBasedIntrinsicValueExpiredCancelled contextRef =" e85" id =" hidden- fact- 103" unitRef =" usd" xsi: nil =" true" /> < ntrb: StockIssuedDuringPeriodSharesStockOptionsSharesExercised contextRef =" e85" id =" hidden- fact- 104" unitRef =" shares" xsi: nil =" true" /> < us- gaap: ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef =" e85" id =" hidden- fact- 105" unitRef =" usdPershares" xsi: nil =" true" /> < ntrb: ShareBasedCompensationArrangementsByShareBasedPaymentRemainingLifeExercised contextRef =" e85" id =" hidden- fact- 106" xsi: nil =" true" /> < ntrb: ShareBasedIntrinsicValueExercised contextRef =" e85" id =" hidden- fact- 107" unitRef =" usd" xsi: nil =" true" /> < ntrb: ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsIntrinsicValue contextRef =" e167" id =" hidden- fact- 108" unitRef =" usd" xsi: nil =" true" /> < ntrb: ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsIntrinsicValue contextRef =" e169" id =" hidden- fact- 109" unitRef =" usd" xsi: nil =" true" /> < ntrb: ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsIntrinsicValue contextRef =" e171" id =" hidden- fact- 110" unitRef =" usd" xsi: nil =" true" /> < ntrb: ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsIntrinsicValue contextRef =" e173" id =" hidden- fact- 111" unitRef =" usd" xsi: nil =" true" /> < ntrb: ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsIntrinsicValue contextRef =" e175" id =" hidden- fact- 112" unitRef =" usd" xsi: nil =" true" /> < ntrb: ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsIntrinsicValue contextRef =" e177" id =" hidden- fact- 113" unitRef =" usd" xsi: nil =" true" /> < ntrb: ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsIntrinsicValue contextRef =" e179" id =" hidden- fact- 114" unitRef =" usd" xsi: nil =" true" /> < ntrb: ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsIntrinsicValue contextRef =" e181" id =" hidden- fact- 115" unitRef =" usd" xsi: nil =" true" /> < ntrb: ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsIntrinsicValue contextRef =" e183" id =" hidden- fact- 116" unitRef =" usd" xsi: nil =" true" /> < us- gaap: OtherCostAndExpenseOperating contextRef =" e192" id =" hidden- fact- 117" unitRef =" usd" xsi: nil =" true" /> < us- gaap: CostOfGoodsAndServicesSoldDepreciationAndAmortization contextRef =" e189" id =" hidden- fact- 118" unitRef =" usd" xsi: nil =" true" /> < us- gaap: RevenueFromContractWithCustomerIncludingAssessedTax contextRef =" e194" id =" hidden- fact- 119" unitRef =" usd" xsi: nil =" true" /> < us- gaap: RevenueFromContractWithCustomerIncludingAssessedTax contextRef =" e195" id =" hidden- fact- 120" unitRef =" usd" xsi: nil =" true" /> < us- gaap: PropertyPlantAndEquipmentOwnedAccumulatedDepreciation contextRef =" e198" id =" hidden- fact- 121" unitRef =" usd" xsi: nil =" true" /> < us- gaap: PropertyPlantAndEquipmentOwnedAccumulatedDepreciation contextRef =" e199" id =" hidden- fact- 122" unitRef =" usd" xsi: nil =" true" /> < dei: AmendmentFlag contextRef =" c0" id =" ixv- 14666" > false < / dei: AmendmentFlag > < dei: DocumentFiscalPeriodFocus contextRef =" c0" id =" ixv- 14667" > FY < / dei: DocumentFiscalPeriodFocus > < dei: EntityCentralIndexKey contextRef =" c0" id =" ixv- 14668" > 0001676047 < / dei: EntityCentralIndexKey > < / xbrl > < / XML > < / TEXT > < / DOCUMENT > < / SEC- DOCUMENT >